<SEC-DOCUMENT>0000950170-25-043486.txt : 20250324
<SEC-HEADER>0000950170-25-043486.hdr.sgml : 20250324
<ACCEPTANCE-DATETIME>20250324070312
ACCESSION NUMBER:		0000950170-25-043486
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		109
CONFORMED PERIOD OF REPORT:	20241231
FILED AS OF DATE:		20250324
DATE AS OF CHANGE:		20250324

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Lexeo Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001907108
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				854012572
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41855
		FILM NUMBER:		25762197

	BUSINESS ADDRESS:	
		STREET 1:		345 PARK AVENUE SOUTH
		STREET 2:		FLOOR 6
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10010
		BUSINESS PHONE:		(212) 547-9879

	MAIL ADDRESS:	
		STREET 1:		345 PARK AVENUE SOUTH
		STREET 2:		FLOOR 6
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10010
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>lxeo-20241231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-03-24T06:04:06.7929+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:lxeo="http://www.lexeotx.com/20241231" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16">
 <head>
  <title>10-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_8681bb52-9d5a-4513-8709-0ab847ac8ff1" name="dei:DocumentFiscalPeriodFocus" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801">FY</ix:nonNumeric><ix:nonNumeric id="F_66538079-9108-4dff-a6db-e27e0ebc3aa7" name="dei:AmendmentFlag" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonNumeric id="F_97033277-f81a-4c26-b472-4238834ddd37" name="dei:EntityCentralIndexKey" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"> 0001907108</ix:nonNumeric><ix:nonFraction id="F_95c520d2-e3a3-4e2b-91f0-f9045a6f3c7f" name="us-gaap:CommitmentsAndContingencies" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_9891b892-ff8e-44a6-bc0c-e6f1514a27a8" name="us-gaap:CommitmentsAndContingencies" contextRef="C_28144b67-7dfd-494d-8133-75abcc735058" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_3797e8b8-b7a6-4ad2-8b98-c0c8d90f246c" name="us-gaap:NumberOfOperatingSegments" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" unitRef="U_Segment" decimals="INF" format="ixt:num-dot-decimal">1</ix:nonFraction><ix:nonNumeric id="F_73289f60-fe2f-4884-94cc-6b3d31ad5380" name="us-gaap:AccountingStandardsUpdateExtensibleList" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801">http://fasb.org/us-gaap/2024#AccountingStandardsUpdate202307Member</ix:nonNumeric><ix:nonNumeric id="F_995b2506-e09a-426b-8450-5340620be7de" name="us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" contextRef="C_ff8a14ec-2414-4dce-963c-ac378e45b5e3">http://fasb.org/us-gaap/2024#GainLossOnFairValueHedgesRecognizedInEarnings</ix:nonNumeric><ix:nonNumeric id="F_bb5c5ee6-6dc1-4359-ae05-87adfaa76496" name="us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801">http://fasb.org/srt/2024#ChiefExecutiveOfficerMember</ix:nonNumeric><ix:nonFraction id="F_e4a8210a-7701-4cf1-bb55-d8e020f66db8" name="us-gaap:NumberOfReportableSegments" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" unitRef="U_Segment" decimals="0" format="ixt-sec:numwordsen">One</ix:nonFraction><ix:nonFraction id="F_b4f1e989-f912-4b9a-9a96-f56301d549bc" name="us-gaap:NumberOfOperatingSegments" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" unitRef="U_Segment" decimals="0" format="ixt-sec:numwordsen">One</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="lxeo-20241231.xsd"/></ix:references><ix:resources><xbrli:context id="C_818a9569-5179-4332-bce6-97002fa8dd65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_81b19c2d-22eb-4f90-b119-49d130c596ae"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lxeo:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8821cec2-12fd-4f69-a047-478fca32226c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandTwentyThreeEmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_889faa80-3bbf-40d1-b770-591485567a8d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandAndTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8b7e354c-42e5-475d-87f9-4bfd1355ccaf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lxeo:AdverumBiotechnologiesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:AdverumLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8c6b7b14-2521-4983-80fe-50cd39b26715"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">lxeo:OfficeFacilityAndLaboratorySpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2029-08-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8ca9fee4-3e70-406e-b516-57586deaa558"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandTwentyOneAndTwoThousandTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8d26cf86-cfdb-467b-8eab-522b18243eda"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-02-17</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8e099335-d590-43f9-972a-d06c24fef007"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lxeo:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-07</xbrli:startDate><xbrli:endDate>2023-11-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8e396f66-88d9-4bb5-8412-da93d2388896"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lxeo:CommissionsAndOfferingCostsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8fa4e334-c5fa-44d9-8bc4-866b04e010d4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-07</xbrli:startDate><xbrli:endDate>2023-11-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_90a370bc-c9ba-46da-a45b-b1abd87d6810"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_90b3b8b5-08ff-4ed8-b03a-36a19e205081"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lxeo:SimpleAgreementForFutureEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-02</xbrli:startDate><xbrli:endDate>2023-11-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_90de349f-5edf-4ccd-81d6-310075c43d96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:AmendedFirstUcsdAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_931de80a-517d-4a40-8171-722f60ac7671"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lxeo:SeriesALiquidationPreferenceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_933a22df-2af6-4858-8d9e-d0defe7f6576"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_93e60cc0-c98a-4905-a0ae-b6c3266b5a78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_940cc76e-9af2-46e6-b22a-05a05af066b0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lxeo:CornellUniversityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:CornellLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-28</xbrli:startDate><xbrli:endDate>2020-05-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_948b5c1c-c12b-4ae5-a807-364c74cca6f3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_95dc5b03-a8d3-46ba-9c0f-f641f5341cf5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">lxeo:ConvertibleSimpleAgreementForFutureEquityNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_98130704-057d-4280-9bc9-5ebe7b7bf561"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lxeo:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-07</xbrli:startDate><xbrli:endDate>2023-11-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_982e832a-cdf3-4671-8548-8f56b1f3f254"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lxeo:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_98679350-4c2b-4d25-9968-d21e18f72506"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lxeo:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_98dbb090-8617-48e2-9f19-11212333ce32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandAndTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_99fa4607-5a6b-4035-bcda-41e63ec19b9d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9a05326c-b178-412f-9312-a4d581f2c9d7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandTwentyOneAndTwoThousandTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9a3288c8-11b0-411a-aef1-05a44eec67ca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9a32dff6-03c5-465f-846c-9b718f20e0b9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lxeo:SimpleAgreementForFutureEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9aca8f8c-d11a-4b96-bb2f-8028f5d80ed0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lxeo:AdverumBiotechnologiesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:AdverumLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9d082257-9ef3-44bf-b671-47a3b444bcf4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9d573f03-b8a1-43e3-9828-e04c95b23d8a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lxeo:SteliosTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9e79f7b3-b991-4a2c-abc3-1a0ef29ab5b5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a20a05b8-9d12-490a-93f2-114ea8e35fca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a398e430-4b76-4f00-9eb3-273c39d2e6fd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a42efdd6-1a5f-4930-9ba0-797305fcec72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">lxeo:OfficeFacilityAndLaboratorySpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a5546360-23ec-45e5-ba9d-ee679b197414"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-07</xbrli:startDate><xbrli:endDate>2023-11-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a65a8fba-bdff-47f7-a790-76ebb3dcb9f8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandAndTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-08</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a6bbca2b-aa76-4540-b619-c2e288370970"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:TwoThousandTwentyThreeEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a6d4ba66-86df-4d4a-b4e0-034d42abb2dc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">lxeo:OfficeFacilityAndLaboratorySpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a70f9bd2-aceb-4c0d-b0fa-5353c3dece2a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lxeo:CornellUniversityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:CornellLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a8c2e316-6ad2-4b74-acd6-08e9897fd12e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:ThirdUcsdLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lxeo:SteliosTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-04</xbrli:startDate><xbrli:endDate>2021-10-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a9ce9707-98f9-43cc-9660-650bbf29c98a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a9cf5f12-f6ff-4e48-8365-fa92cda8cd46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_aa9ff400-2f57-4dd1-8623-e1ed88b5664f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lxeo:UnderwritingDiscountsCommissionsAndOfferingCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_aaf7b4cc-4609-41bc-a23c-cf54d6116e53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ab7f0058-11d6-4f3c-b66e-25878efcc5c2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lxeo:CornellUniversityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:ThirdCornellLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_abb5ce74-a0ec-41a2-a9d1-032861f25e44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lxeo:SeriesAAndBConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_adf39fa9-e13e-4660-a6b0-e64e383d673a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ae668a8e-dcdc-48f6-9c7d-cd99b945d79a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandAndTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-08</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_afe980af-4f26-4fd3-8f3e-e44a3e233ab1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandAndTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b15d25c2-ef2b-415e-98f5-5721bc068283"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lxeo:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">lxeo:AntidilutiveSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b1a96dae-b4d3-465e-8d90-5f13defcc31f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:TwoThousandTwentyOneAndTwoThousandTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b4755659-dbea-42a4-911b-aaf4e5f99a6a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lxeo:SteliosTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:FirstUcsdLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-23</xbrli:startDate><xbrli:endDate>2020-04-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b4989bb1-3d29-41aa-910d-bd20c1974008"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandAndTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b520844c-238f-400e-8a4f-68368cd0badd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b7af60cb-baf3-4dbb-af94-8473e08ee442"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">lxeo:BlackScholesModelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b8320cf7-1637-4a5a-b0b7-b67e5100600a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b8ce5a83-8a3f-4019-b952-412e72e2157f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b8e13f0d-e121-406d-b1a0-0b776194fbaa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ba4a9d48-b7a3-4350-9c16-becc8f228a5a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-10</xbrli:startDate><xbrli:endDate>2023-11-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bba6b31e-5617-48b1-9ad1-7cf7f1501cf3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">lxeo:BlackScholesModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bc4e18d1-8708-4fa6-8c8b-10f077d3382c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bf7a1f3a-c205-45ba-9483-a2ad719c16b4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c25f5aa6-70c3-4c5e-b41f-0a034c1996d8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c5950291-be83-459b-b80e-1f0bffbf88e7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c679f25f-cc6a-43c7-8227-e208b67e0722"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-16</xbrli:startDate><xbrli:endDate>2023-11-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c6a9a2e2-eebe-4569-82e3-6437a6ce2366"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c6dd71d6-5140-472d-b5c8-2940a8c82dd8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">lxeo:OfficeFacilityAndLaboratorySpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c7d3289f-7fe7-4f19-ac48-22a403b83a4c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:ThirdCornellLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lxeo:CornellUniversityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-21</xbrli:startDate><xbrli:endDate>2024-04-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c96098bc-a151-4b74-aeae-a01a9db7efbb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cb661ff1-5311-4097-b67b-ccc8f26e5c71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lxeo:SteliosTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:FirstUcsdLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-23</xbrli:startDate><xbrli:endDate>2020-04-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cc906741-ea91-4e6d-8943-e5456da6d798"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lxeo:SimpleAgreementForFutureEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-01</xbrli:startDate><xbrli:endDate>2023-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cfef4556-754f-4351-9370-c51c9711c2f4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d00c7be3-f867-4469-ac2a-406521627abf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d1ca60e9-37da-42d1-8e5d-0809de6840b2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lxeo:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-10</xbrli:startDate><xbrli:endDate>2023-11-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d210b17b-f2c2-4a07-9b34-0371db6164dd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d4ba692f-b7d0-4af9-9603-697859726ab1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d54dc3c6-3447-4e53-b661-49e8beab972a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandTwentyThreeEmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-07</xbrli:startDate><xbrli:endDate>2023-11-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d58c59cb-9db1-486e-a4ba-83018b4264e1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d6e454da-2fb0-4d82-ae44-abd1e7e3c994"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-20</xbrli:startDate><xbrli:endDate>2023-11-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d965f156-2881-4f62-9e05-2ce8f77a88cb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:TwoThousandTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_db4d6fe7-17ff-4f4e-803b-2c15cda55624"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_db61ba99-c7c7-4e9a-a944-9cc82209837d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_db7527be-0d81-4c4d-82cd-9708fd4feeaa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lxeo:AdverumBiotechnologiesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:AdverumLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-25</xbrli:startDate><xbrli:endDate>2021-01-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dee9c396-7be8-4764-a1e9-de37e72c1b20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lxeo:SteliosTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-16</xbrli:startDate><xbrli:endDate>2021-07-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_df27e94d-4502-4904-99fe-3d1d46216d3e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lxeo:ThirdPartiesForPharmaceuticalManufacturingAndResearchActivitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dfaf0a7f-a734-4cd4-9b33-a8172ac5f59e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lxeo:CornellUniversityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:CornellLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dfb1adde-bdce-4971-8572-0c77f2a15437"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lxeo:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e226ab34-462b-4baf-bdb6-41d1da52235b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e30bab05-7cc4-4f13-aa74-111c8d09ef0d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:SecondUcsdLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lxeo:SteliosTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-06</xbrli:startDate><xbrli:endDate>2020-08-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e4562be4-fed1-4c76-8ee0-9ebb81409e47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e5969e3b-4f0f-4598-ab16-63cb541f8395"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lxeo:CornellUniversityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:CornellFirstLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e83f79f6-f924-4728-9c7c-5f1eb49397fe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e84f1a1e-8d42-4df6-8795-f518a72c03e0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lxeo:SimpleAgreementForFutureEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lxeo:SareptaTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ea417d17-7d7e-449f-9280-8a0a3bc657d1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_eb04d3ca-9afb-4d97-9a7e-b5be9da963d6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:ThirdUcsdLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lxeo:SteliosTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-04</xbrli:startDate><xbrli:endDate>2021-10-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ec3ec1bb-68cc-4820-9297-a6c0c881028e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-11</xbrli:startDate><xbrli:endDate>2024-03-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_edfd0d26-83c7-4293-8b0c-e99852a72a86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lxeo:SimpleAgreementForFutureEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_eef711a6-19ec-48b9-9c42-54e797d52952"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lxeo:CornellUniversityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:CornellSecondLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ef41b0f5-e670-47fb-a4ba-1fb722c72adf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:LeerinkAtTheMarketSalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-03-24</xbrli:startDate><xbrli:endDate>2025-03-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f04bbf56-d3c8-4272-a5ff-e1a1e02029b4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f13110bd-68e9-4c8f-869d-c3f80a05ef1a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f2189c8d-e1b8-45de-8953-73622e2e8923"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f22d9e2e-1a87-48b1-bd28-4d0a0a5afdfb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f579df17-1e2e-4b2c-ab33-2703e6c475a7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f5b88d17-128c-461e-aaa6-463ec8135b2a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lxeo:SteliosTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f6b1ccbb-21c3-4469-9c9a-20c3e22a9b8c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lxeo:ThirdPartiesForPharmaceuticalManufacturingAndResearchActivitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f6d073df-b45c-4611-a81b-0bd39b099fbf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandAndTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-08</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f8619687-73fe-4744-9482-f214f5f1a619"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lxeo:CornellUniversityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">lxeo:ThirdPortfolioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:CornellSecondLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f8c50f85-2ed2-437f-90c9-8336f5967e8e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fc82fec8-4701-4ddd-a632-831d62d00aa5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fcb1173a-0535-4c9d-91c0-398680f70ecb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherComprehensiveIncomeLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fd20e119-f9e2-4c0e-9735-4934b480df35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lxeo:SteliosTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fe2a112e-35b6-427a-9cf1-e602c55b5ef9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_feb46e5d-6816-4e22-a41b-42317def0254"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:UcsdSponsoredResearchAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lxeo:SteliosTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ff876ac5-7ddc-447a-ba80-cd3fc5d96d6b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lxeo:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">lxeo:AntidilutiveSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-07</xbrli:startDate><xbrli:endDate>2023-11-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ff8a14ec-2414-4dce-963c-ac378e45b5e3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">lxeo:ConvertibleSimpleAgreementForFutureEquityNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_002aeebf-8141-46fe-833a-b448a9ed53f3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lxeo:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_00b1026d-c1b5-4b98-bee1-f1aa2360eb94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_01ae7cc9-95ef-4205-a1f8-4bc92563980e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lxeo:SimpleAgreementForFutureEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lxeo:SareptaTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_03d0654e-3872-4474-936c-dc6ff5ca1f8d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:ResearchCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lxeo:WeillCornellMedicalCollegeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_05465aab-2ef4-47b5-84ef-3eacb2ef4089"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:ThirdUcsdLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-13</xbrli:startDate><xbrli:endDate>2024-04-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_057f47b0-3a28-481e-917c-c1c45349ef35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">lxeo:OfficeFacilityAndLaboratorySpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2029-08-01</xbrli:startDate><xbrli:endDate>2034-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_07376bba-ebc9-44c0-bc4a-e98679fa21ad"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lxeo:SteliosTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-16</xbrli:startDate><xbrli:endDate>2021-07-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_09b75305-e3e0-435b-b2a6-50f4050afab2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-07</xbrli:startDate><xbrli:endDate>2023-11-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0ed26320-f07c-4528-a9ac-162b961bf030"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0f4466dd-9ea9-4c34-a1ae-2fdff5adc7ed"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandTwentyThreeEmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_10dc49c3-ff40-493f-b51b-be28cd103318"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">lxeo:TwoPortfoliosMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lxeo:CornellUniversityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:CornellSecondLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_11aac366-2c9d-4773-bc55-7994d2ee9dd0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_17a6e9db-02db-43c5-9308-865a99b44dc2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandTwentyOneAndTwoThousandTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_181d6e2d-a650-47fe-a4ba-e4e8ee97c169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_186c2b13-b928-42dd-8bd4-f169393b3424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lxeo:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_18e0f1c1-de91-4bc1-b5ce-39772b43d1e3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_19581a58-f4b4-41e4-85f3-1dff41c48718"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:TwoThousandTwentyOneAndTwoThousandTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1c8074fe-d719-4d7e-8aa3-6e8936dddc3f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">lxeo:BlackScholesModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1e2a8137-62de-4a72-83f0-d154bc7a5841"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1e595beb-6e63-4729-9f01-fa8aaad38108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lxeo:CornellUniversityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lxeo:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:CornellLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1fd0f357-c2ff-41e2-bd80-50ac05612394"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:UcsdSponsoredResearchAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lxeo:SteliosTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-03</xbrli:startDate><xbrli:endDate>2021-12-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_202838fb-c603-44c3-ac57-cbb400921fd7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">lxeo:BlackScholesModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_202992e1-90d4-413d-b703-e8197a8dc6e3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lxeo:CornellUniversityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:ThirdCornellLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_222f24e5-787e-4d77-8748-8b551ff8243a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_23e9fdcf-7d72-4c30-b945-044420610762"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:TwoThousandTwentyOneAndTwoThousandTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2409277c-21f9-4adb-af62-46fdf50d9ce6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_240d6e00-2133-41ba-92ce-0078e7bbcbca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-13</xbrli:startDate><xbrli:endDate>2023-10-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2611b746-5276-4a2d-b18c-32e1fcba87aa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lxeo:SteliosTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:FirstUcsdLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_266f5c3d-d979-4718-851c-88a44ef02c23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-20</xbrli:startDate><xbrli:endDate>2023-11-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_27a6defd-2f97-4391-b27e-7d7b4574d1b7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:LeerinkAtTheMarketSalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-03-24</xbrli:startDate><xbrli:endDate>2025-03-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_28144b67-7dfd-494d-8133-75abcc735058"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2911d34b-7821-4985-b38e-577d63cb332d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:UcsdSponsoredResearchAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lxeo:SteliosTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_29a86653-566e-428b-a98b-7f3277fd7d90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_29bfd3ef-606a-4b0e-a5fa-8ba6f8566146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lxeo:CornellUniversityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:CornellLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2a226df6-55ca-4590-b4f4-0e51d8f169f6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandTwentyThreeEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2b151cd0-5507-43d4-aa4e-3c68accbaec1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lxeo:CornellUniversityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:ThirdCornellLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-21</xbrli:startDate><xbrli:endDate>2024-04-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2c640ac0-f0e4-4b44-953f-372c68c1666b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandAndTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2cce3246-207a-4da6-b759-efc03a70940c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2d31726b-58bc-4b55-8b8d-242c0b620bca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:ThirdUcsdLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2db6ae14-94d8-4061-8201-63bc8341dd14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandAndTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-07</xbrli:startDate><xbrli:endDate>2023-11-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2e7387e7-73ad-47fb-a0de-5ceccb4a2a0f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2f31b66a-0232-462f-8ba1-c31ab4b8824f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:ThirdUcsdLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lxeo:SteliosTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3283c13a-3e8c-4395-9d0b-cffabf13a351"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherComprehensiveIncomeLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3393a748-8c4c-4d41-87d8-1deb8ed9aa5a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lxeo:AdverumBiotechnologiesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:AdverumLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_34e9355d-4428-4f62-b1ae-10943dbb5161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lxeo:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3579d9a8-e7bf-4c6d-ac06-1c8021fed3eb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">lxeo:ConvertibleSimpleAgreementForFutureEquityNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_35a86fc1-0afe-4e3c-96ee-81097e533438"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:ResearchCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lxeo:WeillCornellMedicalCollegeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_36d77a3a-fda6-41cd-8ab5-65f7367582d3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_386c356b-4350-4ef6-bbc7-35471297e6b0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandTwentyThreeEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-07</xbrli:startDate><xbrli:endDate>2023-11-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3a1be116-5c64-4576-af28-6c9bb1f6ae39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-07</xbrli:startDate><xbrli:endDate>2023-11-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3b4c1dc7-9d04-44ef-97e9-98e10c0a6e4e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3bc3fa7e-440b-44ad-b57d-4fc9f9165d8a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3c3cff29-78d2-4481-b497-e743fdeb998d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3cbe0ed1-2f36-42ec-8001-032a59884f91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3d6eac78-9474-4e08-bcae-13f2246c0568"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:SecondUcsdLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lxeo:SteliosTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3df569eb-97ac-4247-ae8a-b4800fbcc697"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lxeo:SimpleAgreementForFutureEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-02</xbrli:startDate><xbrli:endDate>2023-11-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3eb26141-df5c-4391-985c-b5a244216bc1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3f598951-fd6b-41a3-b5a9-de413e56d5cb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4013d4d1-c4c9-4765-acc9-a1659c4750bf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:UcsdSponsoredResearchAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lxeo:SteliosTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_41123b72-f984-46ee-9547-e92bc56bb833"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4270dba9-ca70-4680-8947-60179d11e241"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4416291a-8898-4d40-bf16-c20112811638"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:SecondUcsdLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lxeo:SteliosTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-06</xbrli:startDate><xbrli:endDate>2020-08-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_44325f11-2b42-4650-93e1-0c060ce8130d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandTwentyThreeEmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_44dd3996-14be-4820-b581-6281744e49e6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-07</xbrli:startDate><xbrli:endDate>2023-11-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_44f34368-c2ff-4b64-9e18-4ee6525fb195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandTwentyThreeEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4591c456-caa6-4a3e-acb5-b25d3fb9ee55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">lxeo:BlackScholesModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_460d7490-ff50-4c44-98f4-b0211c51d98c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandAndTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-08</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_465c4136-b851-42be-84ee-27ed04fe8539"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_47a049b7-455a-448b-84ea-5e98846bad51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-11-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4a2b7157-1380-497a-a4ef-750dda612b33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">lxeo:BlackScholesModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4d1f9c2e-11bc-48e8-b628-60da7528906f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4d93aa08-044d-4a0a-8ae0-08a443ffa6ea"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-11</xbrli:startDate><xbrli:endDate>2024-03-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_500ad48d-4ad0-4259-8d4a-c15b843c549a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_55a64f42-6349-45b1-a852-990c1f09b912"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:ThirdUcsdLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lxeo:SteliosTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_55e7577e-8daf-46eb-b39f-2063a2405357"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:TwoThousandTwentyThreeEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_56bb5356-0f0e-409e-b6a4-c7cb72c011e1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_57207e39-81bb-4c7e-8c54-bf6e68c2462d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_57731d15-0745-4645-b184-c42a52a8959a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lxeo:SimpleAgreementForFutureEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5af5a379-1acd-457b-ba86-c64e18c5164a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lxeo:SteliosTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5b2a51f7-c997-4cda-9d61-3d1f32f1e815"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5b737ad7-5e23-417d-9cd9-c6d69e60d8a1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">lxeo:OfficeFacilityAndLaboratorySpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2029-07-01</xbrli:startDate><xbrli:endDate>2029-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5bca7169-3f0e-45f0-a257-63b105b31fcd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:ThirdUcsdLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lxeo:SteliosTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5d7d637d-2f7f-4be3-acba-58d6df49a889"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">lxeo:ConvertibleSimpleAgreementForFutureEquityNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5e1419ce-c719-45db-9032-ac6f99fec990"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5e727241-61dd-4591-9807-d7d2fe303dba"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lxeo:CornellUniversityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:CornellLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5efa4994-b1a0-45ae-b914-b6133056586b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5efc3a16-a0b9-4c5b-b4a7-4e7f9939e813"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lxeo:SeriesBLiquidationPreferenceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_61a2446f-5269-4a91-8e68-185d4038b801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_63208a9b-1a99-4da2-85ef-0801d8013b63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandTwentyThreeEmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_637f42f6-8969-4386-b873-8c291d47795a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_63e8ef1c-8500-4aca-9829-40a638535f8d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandAndTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_642842bb-c457-4819-9738-9093909922ea"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_66ade898-e08e-4277-96a4-d86c2aa63e09"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_698516d7-c81c-4f0a-9a78-6d719461191d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6a7a8e57-c021-4d66-95a4-3d7c93e89b8b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6c352529-96a0-4c56-b6f7-beafae1427a8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-16</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6d391be5-485e-4203-9a45-2881c2767c0e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lxeo:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-10</xbrli:startDate><xbrli:endDate>2023-11-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6dc19a43-c74a-4bb9-a484-18d905a695b2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lxeo:SeriesAAndSeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6e00ad79-bc53-4f37-aa8a-ea9cb4e9ab24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6e382123-eceb-4534-ab45-5c3a9359605b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lxeo:AdverumBiotechnologiesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:AdverumLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6ef7a0b8-9327-4be8-b39d-869ac79fb879"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7042155d-e81e-427a-88f0-e247950d7a4c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandTwentyOneAndTwoThousandTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_728011d4-41ee-44fe-984c-9acd7fa9e5e1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_72ef9daf-8437-4cbb-9e5d-f507601fa64a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7381b4b3-de2c-4fd9-b6c4-d8e5a85475c9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:TwoThousandTwentyOneAndTwoThousandTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_73f22931-4674-407c-ac09-c2a140ebf868"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:AmendedFirstUcsdAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-19</xbrli:startDate><xbrli:endDate>2024-04-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_741d702e-ac99-41f0-a816-77782c40ec42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-03-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_74419331-e290-447a-86d3-c0fb520fc7bc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_749a5dff-19cd-41f6-b877-35e4f821f1fe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lxeo:SteliosTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:FirstUcsdLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-06</xbrli:startDate><xbrli:endDate>2020-08-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_754c742e-ae45-493f-9e9c-c876f6b36a1b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">lxeo:OfficeFacilityAndLaboratorySpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_75c654f9-7566-4300-8e93-f4d56b98a5b5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_78220819-138e-4d2f-ae70-819bfa7f0e94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_794eac83-f22b-40f0-ab3d-8bc9174bde90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandTwentyThreeEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7be3bda2-4be1-4d70-adee-fffeb575b241"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7c1f486a-7a1e-460e-b332-6ac6ec1ac145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lxeo:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-10</xbrli:startDate><xbrli:endDate>2023-11-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7c51062b-38dd-4251-995b-95b9d29f554e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lxeo:CornellUniversityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:ThirdCornellLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-21</xbrli:startDate><xbrli:endDate>2024-04-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7c6c7513-7f64-4c68-bcf5-17a805d1e6fe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lxeo:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-07</xbrli:startDate><xbrli:endDate>2023-11-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7d2537f3-c638-4060-a3bc-90ab8b609181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7d455504-a441-4ca1-b057-e166af9463cf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lxeo:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7e7948fb-137c-405e-8479-be843ae42290"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001907108</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:UcsdSponsoredResearchAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lxeo:SteliosTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-03</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="U_Segment"><xbrli:measure>lxeo:Segment</xbrli:measure></xbrli:unit><xbrli:unit id="U_Installment"><xbrli:measure>lxeo:Installment</xbrli:measure></xbrli:unit><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_Director"><xbrli:measure>lxeo:Director</xbrli:measure></xbrli:unit><xbrli:unit id="U_IntegerItem"><xbrli:measure>lxeo:IntegerItem</xbrli:measure></xbrli:unit><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="U_Employees"><xbrli:measure>lxeo:Employees</xbrli:measure></xbrli:unit></ix:resources></ix:header></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="border-top:2.25pt double;padding-top:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UNITED STATES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Washington, D.C. 20549</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;margin-right:40%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FORM </span><span style="font-size:16pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b35bdbbd-890f-4c62-ad23-fc07c9751dbb" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10-K</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (Mark One)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:4%;box-sizing:content-box;"/>
    <td style="width:96%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_574756b6-363d-418f-ba64-af4f8ada790b" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the fiscal year ended </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b39b7c2f-8bce-42ce-88a6-e197b7115892" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d9eb8737-354b-46f6-8a9c-6d8497f00b3c" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ad549a93-a75b-493f-972e-28fa9dfdb3e0" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="dei:DocumentFiscalYearFocus"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024</span></ix:nonNumeric></span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">OR</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:4%;box-sizing:content-box;"/>
    <td style="width:96%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_e36f4895-364e-4703-b764-ea7bbc6b7842" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM                      TO</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">                     </span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commission File Number: </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d79642da-96d8-4650-a83d-0148cebb2ffc" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">001-41855</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2a146f68-0ac8-4dab-8d8e-107324c8acf3" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LEXEO THERAPEUTICS, INC.</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Exact name of Registrant as specified in its Charter)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50%;box-sizing:content-box;"/>
    <td style="width:50%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_b906f70d-90d8-4775-b5e7-e36f64159ead" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_45fdeeeb-773e-4676-aae2-198c1ae3a2b6" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">85-4012572</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(State or other jurisdiction of</span></p><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">incorporation or organization)</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(I.R.S. Employer</span></p><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Identification No.)</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_8f4a3bfe-7e6b-4212-bee8-735915b6c0fe" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">345 Park Avenue South</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_ea651cdb-0b11-48f6-9c32-6f66d3e87e63" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="dei:EntityAddressAddressLine2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Floor 6</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_91f05269-01d2-4219-abe6-98c1f2580e3b" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">New York</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_1e0eafd2-0cec-47b6-ab3a-88ac41d255c8" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">New York</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_472882ce-0a9c-411d-a5f9-db6d438029f9" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">10010</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Address of principal executive offices)</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registrant&#8217;s telephone number, including area code: (</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3961df50-ce7d-4e05-ae66-48b14b7e7f3c" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">212</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1f0c2a92-1858-4cc4-85ab-c5e03e73128a" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">547-9879</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:39%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:20%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:39%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Title of each class</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Trading</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Symbol(s)</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8.5pt;"><ix:nonNumeric id="F_f57eb837-d73e-4340-8454-c178eeb91403" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock, par value $0.0001</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8.5pt;"><ix:nonNumeric id="F_ec7e391c-73d3-4377-a69b-5375a2fc31e5" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">LXEO</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8.5pt;"><ix:nonNumeric id="F_4a1b2303-8431-471b-87e7-6181e110e502" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">The Nasdaq Global Market</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities registered pursuant to Section 12(g) of the Act: </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes </span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span><span style="font-size:8.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_57f1d6b0-743d-4268-bf22-afe4100dc782" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="dei:EntityWellKnownSeasonedIssuer"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act.  Yes </span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:8.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_427aa037-5bb8-451c-8339-790e3fe3cde1" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="dei:EntityVoluntaryFilers"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  </span><span style="font-size:8.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_64f0acc1-7850-4c30-a619-1f962061b760" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="dei:EntityCurrentReportingStatus"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> No </span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files).  </span><span style="font-size:8.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_921ba213-762e-498f-a090-6dffc107be87" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="dei:EntityInteractiveDataCurrent"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> No </span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:18%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:58.34%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:19%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.66%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Large accelerated filer</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accelerated filer</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8.5pt;"><ix:nonNumeric id="F_c3d03229-7cba-4676-b4d6-c67984f07555" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-accelerated filer</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Smaller reporting company</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8.5pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_bf44f215-528f-4eab-9d3d-3b68b36367f3" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Emerging growth company</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8.5pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_f4536b9a-b286-4974-92e5-fd308aa6638e" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="font-size:8.5pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_2c2e3877-4966-47a2-a2f9-2a6379772777" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="font-size:8.5pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_6bda6fcd-10a0-47be-a2af-92339be66328" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><span style="font-size:8.5pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_f40f38a5-4f53-467d-a163-37f0c14dfd46" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). </span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes </span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> No </span><span style="font-size:8.5pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_6d2739a7-b36b-4f1b-8e46-53d51dba6ad7" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="dei:EntityShellCompany" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of June 30, 2024, the last day of the registrant&#8217;s most recently completed second fiscal quarter, the aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant was approximately $</span><span style="font-size:8.5pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ee91ee46-bc52-47f6-9c3d-5e32589ccc43" contextRef="C_d00c7be3-f867-4469-ac2a-406521627abf" name="dei:EntityPublicFloat" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">527.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The number of shares of Registrant&#8217;s common stock outstanding as of March 21, 2025 was </span><span style="font-size:8.5pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0305e06b-8476-4f4c-b9c5-14649b69b298" contextRef="C_741d702e-ac99-41f0-a816-77782c40ec42" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">33,196,997</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE</span></p>
  <div><ix:nonNumeric id="F_991825b9-c949-43f7-8558-d5ac899398b9" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="dei:DocumentsIncorporatedByReferenceTextBlock" escape="true"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Portions of the Registrant&#8217;s definitive Proxy Statement relating to the 2025 Annual Meeting of Stockholders are incorporated herein by reference in Part III of this Annual Report on Form 10-K to the extent stated herein. Such proxy statement will be filed with the Securities and Exchange Commission within 120 days of the registrant&#8217;s fiscal year ended December 31, 2024.</span></p></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="border-top:2.25pt double;padding-top:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="toc_page"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TABLE OF CO</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NTENTS</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:10.1%;box-sizing:content-box;"/>
    <td style="width:82.82%;box-sizing:content-box;"/>
    <td style="width:7.08%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Page</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">PART I</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1_business"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Business</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1A.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1a_risk_factors"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Risk Factors</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1B.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1b_unresolved_staff_comments"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Unresolved Staff Comments</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1C.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1c_cybersecurity"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Cybersecurity</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 2.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_2_properties"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Properties</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 3.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_3_legal_proceedings"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Legal Proceedings</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 4.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_4_mine_safety_disclosures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Reserved</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">PART II</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 5.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_5__market_for_registrants_common_eq"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 6.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_6_reserved"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Reserved</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 7.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_7_managements_discussion_analysis_f"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">102</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 7A.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_7a_reserved"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Reserved</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">111</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 8.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_8_financial_statements_and_supplem"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Financial Statements and Supplementary Data</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">112</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 9.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9_changes_in_and_disagreements_with"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">141</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 9A.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9a_controls_and_procedures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Controls and Procedures</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">141</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 9B.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9b_other_information"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Other Information</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">142</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 9C.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9c_disclosure_regarding_foreign"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Disclosure Regarding Foreign Jurisdiction that Prevent Inspections</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">142</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">PART III</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 10.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_10_directors_executive_officers_and"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Directors, Executive Officers and Corporate Governance</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">143</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 11.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_11_executive_compensation"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Executive Compensation</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">143</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 12.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_12_security_ownership_of_certain"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">143</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 13.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#certain_relationships_and_related_transa"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">143</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 14.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#principal_accounting_fees_and_service"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Principal Accounting Fees and Services</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">143</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">PART IV</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 15.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#exhibits_and_financial_statement_schedul"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Exhibits, Financial Statement Schedules</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">144</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">i</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Annual Report on Form 10-K, or Annual Report, contains forward-looking statements that involve risks and uncertainties. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical facts contained in this Annual Report, including statements regarding our future results of operations and financial position, business strategy, development plans, planned preclinical studies and clinical trials, future results of clinical trials, expected research and development costs, regulatory strategy, timing and likelihood of success, as well as plans and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;could,&#8221; &#8220;intend,&#8221; &#8220;target,&#8221; &#8220;project,&#8221; &#8220;estimate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential&#8221; or &#8220;continue&#8221; or the negative of these terms or other similar expressions intended to identify statements about the future. Forward-looking statements contained in this Annual Report include, without limitation, statements about:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing, progress and results of our preclinical studies and clinical trials of our product candidates, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available and our research and development programs;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing of our planned investigational new drug, or IND, submissions, initiation of planned clinical trials and timing of expected clinical results for LX2006 and LX2020, if applicable, and our other future product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing for receipt and announcement of data from our preclinical studies and clinical trials;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing of any submission of filings for regulatory approval of and our ability to obtain and maintain regulatory approvals for LX2006, LX2020 and any other product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the impact of public health crises and other adverse global economic conditions on our operations and the potential disruption in the operations and business of third-party manufacturers, contract research organizations, or CROs, other service providers, and collaborators with whom we conduct business; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to identify patients with the diseases treated by our product candidates, and to enroll patients in trials;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the beneficial characteristics, safety, efficacy and therapeutic effects of our product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the ability of our preclinical studies and clinical trials to demonstrate safety and efficacy of our product candidates, and other positive results;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our expectations regarding the size of the patient populations, market acceptance and opportunity for and clinical utility of our product candidates, if approved for commercial use;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our manufacturing capabilities and strategy, including the scalability and commercial viability of our manufacturing methods and processes;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our reliance on third party manufacturing partners to comply with significant regulations with respect to manufacturing our products;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our expectations regarding the scope of any approved indication for LX2006, LX2020 or any other product candidate;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to successfully commercialize our product candidates, if approved;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to leverage our platform to identify and develop future product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our estimates of our expenses, ongoing losses, future revenue, capital requirements and our need for or ability to obtain additional funding before we can expect to generate any revenue from product sales;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to establish or maintain collaborations or strategic relationships and any expected benefits related thereto;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to identify, recruit and retain key personnel;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our reliance upon intellectual property licensed from third parties and our ability to obtain such licenses on commercially reasonable terms or at all;</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to protect and enforce our intellectual property position for our product candidates, and the scope of such protection;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our financial performance;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our competitive position and the development of and projections relating to our competitors or our industry;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our estimates regarding future revenue, expenses and needs for additional financing;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the impact of laws and regulations; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our expectations regarding the time during which we will be an emerging growth company under the Jumpstart Our Business Startups Act of 2012, or JOBS Act.</span></div></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We caution you that the foregoing list does not contain all of the forward-looking statements made in this Annual Report. We have based these forward-looking statements largely on our current expectations and projections about our business, the industry in which we operate and financial trends that we believe may affect our business, financial condition, results of operations and prospects, and these forward-looking statements are not guarantees of future performance or development. These forward-looking statements speak only as of the date of this Annual Report and are subject to a number of risks, uncertainties and assumptions described in the section titled &#8220;Item 1A. Risk Factors&#8221; and elsewhere in this Annual Report. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. Although we believe that we have a reasonable basis for each forward-looking statement contained in this Annual Report, the events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events or otherwise. In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Annual Report, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to unduly rely upon these statements.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_i"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> I</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;" id="item_1_business"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1. B</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">usiness.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a clinical stage genetic medicine company dedicated to reshaping heart health by applying pioneering science to fundamentally change how cardiovascular diseases are treated. We are advancing a portfolio of therapeutic candidates that take aim at the underlying genetic causes of conditions, including Friedreich ataxia, or FA, cardiomyopathy, plakophilin-2, or PKP2, arrhythmogenic cardiomyopathy, and other devastating diseases with high unmet need.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our most advanced cardiovascular product candidate, LX2006 for the treatment of FA cardiomyopathy, is currently being evaluated in SUNRISE-FA, our ongoing Phase 1/2 clinical trial and in a Cornell investigator-initiated trial. In July 2024, we provided an interim clinical update, which included baseline characteristics from 11 treated participants across the two studies and data from 8 participants who had reached at least 6-months of follow-up as of that time. These data showed improvements in key cardiac biomarkers including left ventricular mass index, lateral wall thickness, and high-sensitivity troponin I. Additionally, in November 2024 we reported that we observed an increase in frataxin protein expression in the hearts of four patients that had undergone cardiac biopsies (cohort 1 (n=1), cohort 2 (n=3)) as measured by LCMS and immunohistochemistry. LX2006 has been generally well-tolerated across both trials to date. One year after dosing, one participant with multiple comorbidities and a history of flu-like symptoms presented with Grade 2 asymptomatic myocarditis. Six weeks later, a biopsy was negative for myocarditis and the participant remains asymptomatic. In November 2024 we announced alignment with the U.S. Food and Drug Administration, or the FDA, on key elements of a registrational development plan for LX2006, including an accelerated approval pathway with left ventricular mass index and frataxin protein expression as co-primary registrational endpoints. In February 2025, we reached further alignment with FDA that the frataxin protein expression co-primary endpoint will be evaluated for any increase from baseline in frataxin positive area as opposed to any specific numerical threshold. We expect to provide a further interim data update in mid-2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our second most advanced cardiovascular product candidate, LX2020 for the treatment of arrhythmogenic cardiomyopathy, or ACM, caused by mutations in the PKP2 gene, referred to as PKP2-ACM, is currently being evaluated in HEROIC-PKP2, an ongoing Phase 1/2 clinical trial. To date, six participants have been enrolled in this trial: three in cohort 1 and three in cohort 2. We have obtained post-treatment cardiac biopsies from two participants in cohort 1; the third cohort 1 participant elected to not undergo the post-treatment biopsy procedure. In the two participants with post-treatment samples, we observed an increase in PKP2 protein expression in the heart, quantified using western blot assay, showing a 71% and 115% increase in PKP2 protein expression versus pre-treatment baseline. In addition, the first participant to reach 6 months post-treatment experienced a 67% reduction in PVCs from baseline and normalization of QRS duration. Across all participants dosed, LX2020 has been generally well-tolerated with no treatment-related serious adverse events to date. We expect to provide an interim data readout focused on clinical efficacy biomarkers in the second half of 2025.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each of our gene therapy candidates utilizes the vector construct, dose and route of administration that we believe will result in the most favorable biodistribution and safety profile for our product candidate for each disease. Our most advanced programs use the AAVrh10 vector due to its high transduction efficiency in myocardial cells, potential for lower toxicity given the opportunity to utilize lower doses compared to other well-established AAV serotypes, and low pre-existing immunity.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our pipeline</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Utilizing a stepwise, capital-efficient development approach, we are leveraging early proof-of-concept functional and biomarker data to advance a deep and diverse pipeline of cardiovascular programs for larger-rare and prevalent indications. We retain exclusive worldwide development and commercialization rights to all of our product candidates and programs.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><img src="img34756086_0.jpg" alt="img34756086_0.jpg" style="width:689px;height:271px;"/></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are developing a number of disease-modifying gene therapy candidates to treat larger-rare cardiovascular diseases that have high unmet need and no approved treatments that address the underlying genetic cause of the disease. These programs include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">LX2006</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> is an AAVrh10-based gene therapy candidate designed to intravenously deliver a functional frataxin, or </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">FXN, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">gene</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">for the treatment of FA cardiomyopathy, which is the most common cause of mortality in patients with FA and affects approximately 5,000 patients in the United States. LX2006 is designed to promote the expression of the protein frataxin to restore normal mitochondrial function and energy production in myocardial cells. LX2006 has received Rare Pediatric Disease designation, Orphan Drug designation, Fast Track designation and Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA, and Orphan Medicinal Product designation from the European Commission. We expect to provide an interim data update in mid-2025.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">LX2020</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> is an AAVrh10-based gene therapy candidate designed to intravenously deliver a functional</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> PKP2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> gene to cardiac muscle for the treatment of PKP2-ACM. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">PKP2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> mutations are associated with approximately 75% of all genetic cases of ACM, and we estimate they affect approximately 60,000 patients in the United States. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">PKP2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> mutations can cause replacement of heart muscle with fibrotic tissue and fatty deposits and severe abnormal heart rhythms, or arrhythmias, that cause cardiac dysfunction and can result in sudden cardiac death. LX2020 is designed to increase desmosomal PKP2 protein levels, reassemble desmosomes and restore myocardial cell function. In our preclinical studies using a genetic mouse model of ACM harboring a </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">PKP2 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">mutation that recapitulates the phenotype of PKP2-ACM, LX2020 resulted in fewer arrhythmias and increased survival. LX2020 has received Fast Track and Orphan Drug designations from the FDA and Orphan Medicinal Product designation from the European Commission. Cohort 2 has completed enrollment, and we expect to provide an interim data update focused on clinical efficacy biomarkers in the second half of 2025.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">LX2021</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> is a gene therapy candidate we are developing to intravenously deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including ACM and certain forms of dilated cardiomyopathy. We believe restoring the Cx43 protein can potentially treat multiple genetic causes of ACM because the cardiac loss of Cx43 is a molecular deficit generally observed in all ACM patient populations. Our LX2021 program is initially targeting Desmoplakin, or DSP, cardiomyopathy, a distinct form of ACM as well as a certain form of dilated cardiomyopathy, with a prevalence that may be as high as 4% of all inherited dilated cardiomyopathies and 4% of all ACMs, impacting up to approximately 35,000 patients in the United States.</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">LX2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> is a gene therapy candidate we are developing to intravenously deliver a functional </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">TNNI3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> gene to myocardial cells to treat a distinct form of hypertrophic cardiomyopathy, or HCM, due to mutations in the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">TNNI3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> gene. Mutations in the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">TNNI3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> gene often result in left ventricular hypertrophy and restrictive cardiomyopathy, leading to arrhythmias and heart failure. With an estimated prevalence of 1 in 500 people in the United States, HCM is one of the most common forms of genetic cardiomyopathy and is caused by mutations that affect the cardiac sarcomere in approximately 75% of cases. It is estimated that as many as 25,000 patients in the United States and 34,000 patients in the European Union are affected by HCM caused by mutations in the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">TNNI3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> gene.</span></div></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, we are seeking business development opportunities for our portfolio of candidates targeting APOE4-associated Alzheimer's disease, including LX1001 which has completed a Phase 1/2 clinical trial.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our strategy</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our company is purpose built to amplify genetic medicine&#8217;s potential for empowering individuals by treating the underlying cause of genetic disease. The key elements of our strategy to achieve this vision are to:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Focus our AAV-based gene therapy candidates in areas of high unmet need and with substantial potential for societal impact and commercial opportunity.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Advance a deep and diverse pipeline that includes candidates that are designed to address both larger-rare and more prevalent patient populations, prioritizing conditions most likely to benefit from our therapies</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Pursue a staged, capital-efficient approach for advancing programs through clinical development and regulatory approval</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Utilize a unified, high-quality manufacturing platform that can quickly respond at scale to high impact opportunities.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Pursue next-generation genetic medicine technologies that can enhance our capabilities and expand our impact on patients</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leverage and expand upon our partnerships and exclusive licenses with world-class academic institutions</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Build a fully integrated genetic medicine company and selectively evaluate strategic opportunities to maximize the impact of our pipeline</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span></div></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our approach</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our technology approach</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our most advanced programs use the AAVrh10 vector due to its high transduction efficiency in myocardial cells, higher ratio of cardiac to liver biodistribution, potentially lower toxicity given the ability to utilize lower doses, compared to other well-established AAV serotypes, and lower pre-existing immunity. The AAVrh10 vector has been shown to be capable of transducing myocardial cells based on preclinical research and ongoing clinical studies. We believe these results demonstrate that among currently available, commonly used serotypes, AAVrh10 is an efficient vector for delivery and expression of transgenes for the treatment of the cardiovascular diseases that we are currently targeting. We have observed organ-specific biodistribution advantages for our AAVrh10 vector compared to AAV9, a well-known serotype that has been evaluated in several clinical trials, including one cardiovascular clinical trial. For example, we have observed vector distribution of AAVrh10 in cardiac tissue of non-human primates, or NHPs, that is two times greater than for AAV9. Additionally, our preliminary studies in Yucatan minipigs have shown that AAVrh10 has approximately 1.5 times greater biodistribution in the heart than AAV9. In addition, preclinical studies conducted by Weill Cornell Medical College, or Weill Cornell Medicine, have demonstrated that systemic administration of AAVrh10 promotes a ratio of cardiac-to-liver biodistribution that is more favorable than what is known of other commonly used vector serotypes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our disease area strategy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our cardiovascular gene therapy programs are designed to have the following characteristics:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Indications that may be effectively treated by gene therapy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> We select targets that correspond to populations with a specific genetic profile and clearly defined disease phenotype.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Indications with the potential to demonstrate early evidence of meaningful clinical benefit.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> We pursue clearly defined biomarkers and functional endpoints that can provide early proof-of-mechanism and inform clinical development decisions, including the potential to seek accelerated approval pathways.</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Present opportunity to address high unmet medical need</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. We are focused on genetically defined cardiovascular diseases where there are no currently approved treatments or where we believe our therapeutic candidates will have a meaningful improvement relative to existing standards of care.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Significant market opportunity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. We pursue indications with significant commercial opportunities beyond those typically associated with gene therapy companies targeting rare monogenic diseases. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Targets that have established proof-of-concept</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. We have leveraged our relationships with academic institutions to in-license product candidates with established proof-of-concept in relevant preclinical models that closely resemble the clinical phenotype we are pursuing.</span></div></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our manufacturing approach</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are developing gene therapy candidates for larger-rare and prevalent disease patient populations that require a high-quality process that can produce vectors in relatively large quantities while utilizing traditional biologics manufacturing infrastructure. We utilize a baculovirus/Sf9 expression system to manufacture our gene therapy candidates. Our manufacturing platform is designed to infect Sf9 cells at high densities in suspension cell culture with both an AAVrh10 and baculovirus containing the transgene. The output is coupled with a chromatography- based purification process which allows for efficient AAV purification, resulting in higher yields and fewer empty AAV capsids than traditional plasmid HEK adherent cell culture approaches.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe our manufacturing process enables us to efficiently pursue our goal of targeting larger-rare and prevalent patient populations. Historically, manufacturing challenges, largely driven by the quantity of vector required to pursue large commercial opportunities have limited the utility of gene therapy for large patient populations. We believe our proprietary Sf9 baculovirus process will allow us to produce vectors at the necessary scale to support the patient populations we are targeting at a cost-of-goods profile similar to what the pharmaceutical marketplace has seen with biologics. To date, we have developed a highly reproducible and scalable 200L GMP AAV production process using the Sf9-baculovirus system, which does not require costly plasmids. Purification is also a straightforward 2-column process. The overall process delivers over 1E15 vg/L of purified AAVrh.10 product that contains less than 25% empty capsids.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on our approach, we expect that our existing partnerships can supply material for all of our currently ongoing and planned clinical trials as well as potential commercial production of some of our programs. We will own the intellectual property created by our manufacturing process development activities or have the ability to license it and will maintain the option to transfer the process to other CDMOs in the future and/or to our own potential facility to ensure ongoing redundancy and reliability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our cardiovascular gene therapy programs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">LX2006 for the treatment of FA cardiomyopathy</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Overview of FA</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FA is a genetic, progressive, and degenerative multi-system disorder with a prevalence of 1:50,000 or approximately 5,000 people in the United States. It is estimated that approximately 80% of these patients will develop FA cardiomyopathy. FA is caused by a mutation in the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">FXN</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> gene that disrupts the normal production of the protein frataxin, which is critical to the function of mitochondria in a cell and to the maintenance of cardiac function. The most common FA phenotype presents with significantly reduced frataxin levels compared to healthy individuals, however levels of frataxin in the cardiac tissue of FA patients is unknown. The frataxin deficiency in the mitochondria of myocardial cells in FA patients causes disruption of normal iron-sulfur cluster biosynthesis leading to mitochondrial dysfunction and deficient energy production.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The neurologic disease and cardiac disease are two distinct manifestations of FA. The disease is inherited in an autosomal recessive manner, where both inherited genes are abnormal, and symptoms usually begin in childhood. Absence of fully functional frataxin leads to damage to peripheral nerves and the parts of the brain that control movement and balance, leading to neurological symptoms that include impaired muscle coordination, or ataxia, that worsen over time. Initial symptoms may include unsteady posture, frequent falling, and progressive difficulty in walking due to impaired ability to coordinate voluntary movements. Affected individuals often develop slurred speech, hearing loss, scoliosis, diabetes, characteristic foot deformities, and an irregular curvature of the spine. The typical age of onset of neurological symptoms is five to 15 years old. As the disease progresses, patients typically experience various heart conditions, including thickening of the heart muscle, or hypertrophic cardiomyopathy, and arrhythmias. Hypertrophic cardiomyopathy, fibrosis, heart failure and arrhythmias are the cause of death in approximately two-thirds of FA patients. Typical onset of the cardiac disease is at 15 to 30 years old.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">By the time the cardiac disease of FA emerges, the neurologic disease is generally significantly advanced and may not be amenable to gene therapy. There are currently no approved treatments for the cardiac manifestations of FA. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Skyclarys</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the only approved treatment for FA, is an Nrf2 activator which targets only the CNS component of the disease. As a result, patients with FA have significant unmet need for a therapy to treat cardiovascular complications associated with the disease.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:0;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our approach: LX2006</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are developing LX2006 as an AAVrh10-based gene therapy delivered intravenously for the treatment of FA cardiomyopathy. LX2006 is designed to deliver the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">FXN</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> gene under the transcriptional control of the CAG promoter, a strong synthetic promotor frequently used in viral vectors. LX2006 utilizes AAVrh10 based on its favorable cardiac affinity and vector distribution profile observed in preclinical studies, as compared to AAV9. LX2006 is designed to transfer the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">FXN</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> gene to myocardial cells and increase frataxin levels in the mitochondria. The increase in frataxin levels in the mitochondria is intended to restore mitochondrial function and energy production in cardiac myocytes.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:0;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Lexeo-sponsored LX2006 clinical development and trial design</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LX2006 is currently being evaluated in an ongoing, multi-site Phase 1/2 clinical trial, or SUNRISE-FA, in patients with FA cardiomyopathy. SUNRISE-FA is a first-in-human, 52-week, dose-ascending, open-label trial of LX2006 in patients who have FA cardiomyopathy. LX2006 is administered as a one-time intravenous infusion with prednisone utilized for immune suppression. The trial consists of three dose cohorts. The cohort 1 dose level is 1.8&#215;10</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> vg/kg, the cohort 2 dose level is 5.6&#215;10</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> vg/kg, and the cohort 3 dose level is 1.2&#215;10</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> vg/kg. There is a long-term follow-up for patients who receive LX2006 to monitor ongoing safety for a total of five years, per FDA requirement.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Regulatory alignment for future pivotal trial</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, we announced alignment with the FDA on key elements of a registrational development plan for LX2006, including accelerated approval pathway with left ventricular mass index and frataxin protein expression as co-primary registrational endpoints. For the imaging endpoint, a threshold target of a 10% reduction in LVMI as measured by cardiac MRI was discussed, and we expect that a future pivotal trial would enroll only patients with abnormal LVMI at baseline. In February 2025, we reached further alignment with FDA that the frataxin protein expression co-primary endpoint will be evaluated for any increase from baseline as opposed to any specific numerical threshold.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cardiac Biopsy Results from SUNRISE-FA Trial</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024 we reported that we observed an increase in frataxin protein expression in the hearts of four patients that had undergone cardiac biopsies (cohort 1 (n=1), cohort 2 (n=3)) as measured by LCMS and immunohistochemistry. To our knowledge, SUNRISE-FA is the first clinical trial to evaluate frataxin levels in the target organ of FA cardiomyopathy patients.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Additional ongoing clinical trial of AAVrh10.hFXN (LX2006 at Lexeo)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AAVrh10.hFXN, which we refer to as LX2006, is currently being evaluated in an additional ongoing investigator-initiated, single-site clinical trial conducted by Weill Cornell Medicine (NCT05302271). Both the Weill Cornell investigator-initiated clinical study and our SUNRISE-FA clinical study use drug product manufactured at Weill Cornell Medicine utilizing the same process with identical doses in each study&#8217;s cohort 1 and cohort 2. In April 2024 we announced a license agreement with Cornell University for intellectual property rights including current and future clinical data from the ongoing Weill Cornell Medicine investigator-initiated trial of LX2006.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cardiac biomarker data from ongoing clinical trials of LX2006</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In July 2024, we provided an interim clinical update from the ongoing Lexeo-sponsored SUNRISE-FA trial and Cornell investigator-initiated trial, providing baseline characteristics from 11 participants that had been treated and follow-up data from 8 participants that had reached at least 6-months of follow-up as of that time, showing improvements in key cardiac biomarkers including left ventricular mass index, lateral wall thickness, and high-sensitivity troponin I.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">LX2020 for the treatment of ACM caused by </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PKP2 </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">mutations</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Overview of ACM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ACM is a genetic heart disease primarily characterized by myocardial cell loss and the replacement of heart muscle with fibrotic tissue and fatty deposits. ACM can result from mutations in several desmosomal genes. These genetic mutations impair the structure and function of cardiac desmosomes, which are membrane protein complexes engaged in cell-to-cell adhesion and the structural integrity of the ventricular myocardium. Lack of functioning cardiac desmosomes can lead to myocardial cell death and fibrosis, heart dysfunction, rhythm abnormalities, and sudden death. Standard of care may include antiarrhythmics, implantable cardioverter-defibrillators, and ablation procedures; however, none of these therapies address the underlying cause of myocardial dysfunction and ACM.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:0;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We estimate that ACM has a prevalence of approximately 130,000 patients in the United States and estimate that over half of all ACM patients have a genetic form of the disease with five desmosomal genes accounting for nearly all of the identified genetic causes of ACM. We have initially targeted the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">PKP2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> gene because mutations in this gene are the most commonly known genetic cause of ACM. We believe that mutations in the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">PKP2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> gene are associated with approximately 75% of all genetic cases of ACM, resulting in approximately 60,000 patients affected by the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">PKP2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> mutation in the United States. Most familial cases of the disease have an autosomal dominant pattern of inheritance, meaning one copy of an altered gene in each cell is sufficient to cause the disorder. Since having only one functioning copy of the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">PKP2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> gene is insufficient to produce the wild-type phenotype, this results in a phenomenon in genetics known as haploinsufficiency.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Symptoms of the disease can include palpitations, dizziness, heart failure and sudden death. Abnormal function of the right ventricle, fatty or fibrotic infiltrates in the myocardium, abnormal electrocardiogram, or ECG, arrhythmias, or a family history of ACM can all lead physicians to diagnose the disease. No effective treatments for PKP2-ACM exist.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our approach: LX2020</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are developing LX2020 as an AAVrh10-based gene therapy candidate for the treatment of PKP2-ACM. LX2020 is designed to intravenously deliver a functional</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> PKP2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> gene to cardiac muscle to increase desmosomal PKP2 protein levels and restore myocardial cell function. We believe that by delivering a functional </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">PKP2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> gene, LX2020 has the potential to address the underlying cause of PKP2-ACM for many patients and have a significant effect on lifespan by reassembling the cardiac desmosomes, preventing cardiac arrhythmias and preventing or treating cardiac dysfunction.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:0;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Preclinical studies</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our preclinical murine studies of LX2020</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">demonstrated</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">improved cardiac structure and function, and the survival of mice harboring a pathologic human mutation in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">PKP2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The genetic mouse model we utilize in our preclinical studies is a CRISPR Cas9-edited model constitutively expressing a mutation in the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">PKP2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> gene found in humans with ACM. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">PKP2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> RNA splicing and protein levels are impacted in this model, which recapitulates all classic PKP2-ACM disease features. In a preclinical study of NHPs, LX2020 demonstrated a favorable safety profile with no safety signals.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Preclinical efficacy studies</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have completed preclinical studies demonstrating that delivery of LX2020 led to the reassembling of the cardiac desmosome, prevented arrhythmias and cardiac dysfunction, and increased survival in a genetic murine model of ACM harboring </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">PKP2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> patient genetics. Three dose levels were administered to approximately three-week-old homozygous </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">PKP2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> mice (a more severe disease murine model) with necropsy at twelve weeks post LX2020 treatment and eight-week-old </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">PKP2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> heterozygous mice (a less severe murine model) with necropsy at eight weeks post LX2020 treatment. In the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">PKP2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> homozygous mouse study, 12 mice (six males and six females) in each group were treated with one of three dose cohorts (6&#215;10</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:5.025pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> vg/kg, 2&#215;10</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:5.025pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> vg/kg, or 6&#215;10</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:5.025pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> vg/kg, which varied by approximately a half-log increase between each dose). As shown in the graphic below, within twelve weeks, approximately 90% of mice that received vehicle and 58% of mice that received 6&#215;10</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:5.025pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> vg/kg dose of LX2020 died. Conversely, 100% of mice that received the 2&#215;10</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:5.025pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> vg/kg dose and 83% of the mice that received the 6&#215;10</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:5.025pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> vg/kg dose survived until the 12-week necropsy time period. No PKP2 protein expression was found in the mice that died in the 6&#215;10</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:5.025pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> vg/kg dose cohort, whereas all mice that survived in this cohort expressed PKP2. This and other characteristics of the mice indicate the potential of a technical injection dosing error.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LX2020 significantly extended survival in severe murine model</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><img src="img34756086_1.jpg" alt="img34756086_1.jpg" style="width:396px;height:243px;"/></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also performed quantitative MRI analysis which showed dose-dependent improvement in cardiac function (end-diastolic volume, or EDV, end-systolic volume, or ESV, and ejection fraction, or EF) in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">PKP2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> homozygous mice, compared to vehicle-treated animals as shown in the graphic below.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Quantitative MRI analysis showed improvement in cardiac function in homozygous murine model</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><img src="img34756086_2.jpg" alt="img34756086_2.jpg" style="width:636px;height:215px;"/></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As shown in the graphic below, we also completed surface ECG analyses which showed a reduction in arrhythmias as measured by premature ventricular contractions in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">PKP2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> homozygous murine models.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LX2020 treatment reduced premature ventricular contractions</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><img src="img34756086_3.jpg" alt="img34756086_3.jpg" style="width:548px;height:237px;"/></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also observed an 18% reduction in the QRS interval at 6&#215;10</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:5.025pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> vg/kg in the PKP2 homozygous mouse model, indicating improvement in ventricular depolarization abnormalities. Additional dose-dependent improvements were detected through histological evaluations, revealing decreases in heart size, diminished right ventricular wall thinning, and reduced fibrosis and calcification.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Preclinical safety studies</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In a twelve week safety study of NHPs, three doses of LX2020 (2&#215;10</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:5.025pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> vg/kg, 6&#215;10</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:5.025pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> vg/kg, or 1&#215;10</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:5.025pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> vg/kg, which vary by approximately a half-log increase between each dose) were administered to four monkeys per group (two males and two females) and resulted in dose-dependent increases in LX2020 biodistribution (reported as vector copy number, or VCN) in various regions of the heart as shown below. The biodistribution assay utilized qPCR technique with LX2020 transgene-specific primers.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">VCN in various heart regions in NHPs</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><img src="img34756086_4.jpg" alt="img34756086_4.jpg" style="width:413px;height:261px;"/></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, in the NHP study, mRNA expression following LX2020 administration was assessed using an RT-qPCR assay with human </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">PKP2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> transgene-specific mRNA primers. Data is reported as copies per nanogram of cDNA input, as shown below, and demonstrates that administration of LX2020 showed a dose-dependent increase of human PKP2 mRNA in various regions of the heart.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">PKP2</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> mRNA expression (RT-qPCR) in NHPs</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><img src="img34756086_5.jpg" alt="img34756086_5.jpg" style="width:432px;height:255px;"/></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Human PKP2 protein expression was assessed in the NHP hearts using an electrochemiluminescence, or ECL, immunoassay. Notably, unlike the VCN and mRNA assays shown above, where LX2020-specific primers were synthesized to eliminate the detection of endogenous NHP DNA and mRNA, the commercially available antibodies used to detect human PKP2 protein expressed by LX2020 also detect endogenous NHP PKP2. Given the high level of amino acid sequence similarity between the human and NHP PKP2 proteins, generating anti-PKP2 antibodies specific to one of the two species is impossible. Thus, the PKP2 levels measured by the ECL assay represent the sum of endogenous NHP PKP2 and exogenous human PKP2 encoded by LX2020. Data are reported as ng of PKP2 protein per mg of total protein.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PKP2 protein expression in the right ventricle in NHPs</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><img src="img34756086_6.jpg" alt="img34756086_6.jpg" style="width:329px;height:267px;"/></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Whereas a dose-response level in DNA and RNA was observed in most heart regions in the NHPs treated with LX2020, protein levels did not correlate directly with dose. However, a dose-dependent increase in human PKP2 protein expression was seen in the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">PKP2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> homozygous mouse model as shown in the graphic below that translated well to cardiac activity. Three-week-old adult, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">PKP2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> homozygous mice were administered a single dose of LX2020 (6&#215;10</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:5.025pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> vg/kg, 2&#215;10</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:5.025pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> vg/kg, and 6&#215;10</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:5.025pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> vg/kg) or formulation buffer (vehicle) intravenously and sacrificed twelve weeks post dose. LX2020 administration resulted in a dose-dependent increase in hPKP2 expression which was sufficient to prevent the cardiac cell-cell junction deficits of the classic proteins that make up the desmosome, including DSP, desmoglein-2, or DSG2, plakoglobin, or JUP, and N-cadherin, or Ncad, that have all been implicated in human ACM along with the gap junction protein Cx43.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cardiac PKP2 expression in homozygous mouse model</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><img src="img34756086_7.jpg" alt="img34756086_7.jpg" style="width:527px;height:255px;"/></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Possible explanations for the differences seen in mice and primate models include the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Inhibited Translation/Intracellular Protein Degradation:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Desmosomal proteins such as PKP2 are tightly regulated within striated muscle to maintain intracellular homeostasis. Therefore, excessive protein levels, such as those in wild-type primates, will likely result in decreased RNA translation and PKP2 protein degradation. This has been observed in previous studies and may explain why this effect was only observed in the wild-type primates but not in the murine model of PKP2 deficiency.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interference from NHP endogenous PKP2 levels:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> PKP2 protein is abundant in NHP cardiac muscle and can fluctuate considerably. Furthermore, for the most part, antibodies cannot distinguish between human and primate PKP2. Hence, the different protein levels in primates may be due to fluctuations in basal primate PKP2, not human PKP2 transcribed from LX2020.</span></div></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Importantly, in the NHP safety study, all LX2020 doses (2&#215;10</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:5.025pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> vg/kg, 6&#215;10</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:5.025pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> vg/kg, and 1&#215;10</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:5.025pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> vg/kg) demonstrated favorable safety profiles, including no abnormal effects on clinical signs, body weight, clinical pathology, hematology, histopathology, ECHOs, cardiac biomarkers, or ECG. Collectively these data indicate LX2020 was generally well tolerated during the twelve-week duration of the study in NHPs. The maximum dose of 1&#215;10</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:5.025pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> vg/kg is thus recognized as the NOAEL (no observed adverse event level) in NHPs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Preclinical Vector Comparability Studies</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, we completed preclinical studies comparing AAVrh10 and AAV9 in head-to-head studies measuring cardiac function in a </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">PKP2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> homozygous mouse model administered with human </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">PKP2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Human </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">PKP2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was administered before disease onset on day two (neonatal administration) to five mice in each group, and cardiac function was measured by MRI. As shown in the graphic below, AAVrh10 demonstrated a trend of improvements in EF, EDV, and ESV compared to AAV9.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AAVrh10 showed greater trends of cardiac function improvement versus AAV9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in PKP2 mouse models</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><img src="img34756086_8.jpg" alt="img34756086_8.jpg" style="width:600px;height:220px;"/></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">LX2020 clinical development and trial design</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> LX2020 is currently being evaluated in HEROIC-PKP2, a first-in-human, 52-week, open-label, dose-ascending multicenter trial to determine the safety and tolerability of LX2020 in patients with PKP2-ACM. Preliminary efficacy measures include myocardial protein expression, biomarkers measuring cardiac structure and function, and arrhythmia burden. Key inclusion criteria include: patients aged 18-65 years with a confirmed diagnosis of ACM with either 2010 Task Force Criteria or 2020 International Criteria for ACM; documented PKP2 mutation; existing implantable cardioverter defibrillator (ICD) that is MRI compatible; and a minimum threshold of PVCs over a 24-hour period. LX2020 is administered as a one-time intravenous infusion to patients in at least two ascending-dose cohorts of three patients each, with the potential for cohort expansion. Prednisone and rapamycin are utilized for immune suppression. Cohort 1 utilized a dose of 2&#215;10</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:5.025pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> vg/kg, which was selected based on the dose-response seen in our preclinical studies. The second cohort is utilizing a dose of 6&#215;10</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:5.025pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> vg/kg. There is a long-term follow-up for patients who receive LX2020 to monitor ongoing safety for a total of five years, per FDA requirement.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To date, six participants have been enrolled in this trial: three in cohort 1 and three in cohort 2. We have obtained post-treatment cardiac biopsies from two participants in cohort 1; the third cohort 1 participant elected to not undergo the post-treatment biopsy procedure. In these two participants with post-treatment samples, we observed an increase in PKP2 protein expression in the heart quantified using western blot assay showing a 71% and 115% increase in PKP2 protein expression versus pre-treatment baseline. In addition, the first participant to reach 6 months post-treatment experienced a 67% reduction in PVCs from baseline and normalization of QRS duration. Across all participants dosed, LX2020 has been generally well-tolerated to date.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, we have initiated SNAPSHOT-PKP2, a natural history study designed to evaluate PKP2-ACM disease progression up to two years retrospectively and over twelve months prospectively. The study will enroll up to 20 patients in the United States.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">LX2021 for the treatment of DSP cardiomyopathy</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">LX2021 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">is a gene therapy candidate we are developing to intravenously deliver the coding sequence for the functional Cx43 protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including ACM and certain forms of dilated cardiomyopathy, which are typically due to abnormalities or deficits in cardiac desmosomes. Cx43 is an integral protein component of gap junctions and functionally allows small molecules and ions to flow directly between cells to allow for electrical synchronization of muscle contraction. In patients with heart disease, including heart failure, Cx43 is often relocalized in the lateral walls of myocardial cells. As a result, it is significantly reduced at cardiac muscle cell junctions, especially in ACM populations. Restoring Cx43 protein to cardiac muscle cell-cell junctions can potentially treat multiple genetic causes of ACM because the cardiac loss of Cx43 is a molecular deficit generally observed in all ACM patient populations. DSP is a structural protein critical for force transmission in heart muscle. Mutations in DSP cause a distinct form of ACM and a certain form of dilated cardiomyopathy, known as DSP cardiomyopathy. Unlike many forms of ACM that predominantly affect the right side of the heart, DSP cardiomyopathy frequently affects the left side of the heart. The prevalence of DSP cardiomyopathy is unknown but may be as high as 4% of all inherited dilated cardiomyopathies and 4% of ACM, impacting up to 35,000 individuals in the U.S. Given the role of Cx43 in other forms of heart failure, we are also evaluating LX2021 for the treatment of additional indications beyond DSP cardiomyopathy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have conducted a preclinical study in a cardiac-specific DSP loss-of-function mouse model, or DSP-cKO mice, which is a genetic model of ACM. DSP-cKO mice develop molecular, histological and physiological features of ACM and ultimately die prematurely from heart failure. In this study, we observed that severely diseased mice treated with AAV-based gene therapy expressing Cx43 display fewer arrhythmias, have improved cardiac mechanical function, and experience an almost two-fold increase in lifespan when compared to untreated DSP-cKO adult mice. A single dose of an AAV-based gene therapy candidate representing Cx43 was administered intravenously to the cardiac-specific DSP-cKO mice, at four to six weeks of age. DSP-cKO mice are a genetic model of ACM harboring severe structural disease and loss of Cx43. RNA analysis of the treated mice revealed that cardiac-specific Cx43 gene delivery increased Cx43 RNA levels. Additionally, the Cx43-treated DSP-cKO mice showed a re-expression of mechanical junction proteins in their hearts compared to controls. Essential basement membrane proteins, including N-cadherin, as well as desmosomal proteins, PKP2 and junction plakoglobin, were also restored to cell-cell junctions in Cx43-treated DSP-cKO hearts compared to end-stage untreated DSP-cKO hearts, which had limited localization of junctional proteins at cell-cell junctions. These findings further validate the ability of Cx43 to resurrect the cardiac mechanical muscle junction complex in diseased hearts.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">LX2022 for the treatment of HCM caused by TNNI3 mutations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LX2022 is a gene therapy candidate we are developing to intravenously deliver a functional </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">TNNI3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> gene to myocardial cells to treat a distinct form of HCM due to mutations in the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">TNNI3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> gene. With an estimated prevalence of 1 in 500 people in the United States, HCM is one of the most common forms of genetic cardiomyopathy caused by mutations that affect the cardiac sarcomere in approximately 75% of cases. It is estimated that as many as 25,000 patients in the United States are affected by HCM caused by mutations in the gene </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">TNNI3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">TNNI3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> gene encodes troponin I, an essential protein in the thin filament of the sarcomere, which is involved in cardiac contraction and relaxation. Mutations in the gene often result in left ventricular hypertrophy and restrictive cardiomyopathy, leading to arrhythmias and heart failure.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our preclinical data from an A157V </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">TNNI3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> murine model, a model which results in cardiac dysfunction, was generated to validate the delivery of an AAV-based therapy candidate expressing human </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">TNNI3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> regulated by a cardiac-specific promoter. At four weeks post injection, the level and specificity of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">TNNI3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> gene expression were evaluated in the liver, skeletal muscle, and heart tissue. As </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">TNNI3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was regulated by a cardiac-specific promoter, expression of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">TNNI3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was only detected in the heart tissue. Additionally, retro-orbital injection of AAV9-hTNNI3 expressing A157V mutation was performed on three- month-old mice euthanized four weeks later. The hearts were dissected and immunostained. Immunostaining revealed robust expression of human </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">TNNI3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in the cardiomyocyte after treatment with AAV-based </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">TNNI3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Moreover, high magnification imaging demonstrated the incorporation of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">TNNI3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> within the cardiac sarcomere. Based on these preclinical findings, we believe that AAV-based therapy expressing </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">TNNI3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> can be administered to achieve transgene expression in heart tissue.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Outside of Core Focus Area: APOE4-associated Alzheimer&#8217;s disease programs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to our cardiac gene therapy programs, we have a portfolio of approaches aimed at treating the genetics underlying Alzheimer&#8217;s disease. We believe precision therapies, particularly those focused on the underlying genetics of Alzheimer&#8217;s disease, may have a substantial impact on this treatment landscape. Importantly, we believe gene therapy allows for a unique approach to treating the genetics of Alzheimer&#8217;s disease by delivering a therapeutic which acts upstream of both the amyloid-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">b</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and tau-driven pathology of Alzheimer&#8217;s disease. This treatment strategy is designed to impact multiple pathways, as opposed to most other treatments in development which target a single mechanism of Alzheimer&#8217;s disease.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In our lead Alzheimer&#8217;s disease program, LX1001, we are initially targeting homozygous APOE4-associated Alzheimer&#8217;s disease patients by administering AAVrh10 containing the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">APOE2 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">gene. Our approach to treating Alzheimer&#8217;s disease is predicated on the belief that expressing the protective APOE2 in the CNS of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">APOE4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> homozygous patients will halt or slow the progression of Alzheimer&#8217;s disease. We believe these patients represent an ideal target for gene therapy because the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">APOE4 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">homozygous profile is the most common genetic driver of Alzheimer&#8217;s disease.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our current gene therapy programs for the treatment of Alzheimer&#8217;s disease are:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">LX1001: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a clinical-stage AAVrh10-based gene therapy candidate that is designed to express the protective APOE2 protein in the CNS of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">APOE4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> homozygous patients. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">LX1021: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">an early-stage AAVrh10-based gene therapy candidate that is designed to express the Christchurch-modified APOE2 protein in the CNS of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">APOE4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> homozygous patients. The Christchurch mutation has been observed to protect patients against Alzheimer&#8217;s disease even in the presence of significant amyloid pathology.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">LX1020: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">an early-stage AAVrh10-based gene therapy candidate that is designed to express the protective APOE2 protein in the CNS of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">APOE4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> homozygous patients, while concurrently delivering miRNA to suppress the expression of the APOE4 protein.</span></div></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LX1001 has been evaluated in an open-label, dose-ranging Phase 1/2 clinical trial in patients who are </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">APOE4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> homozygous patients with clinical diagnoses ranging from mild cognitive impairment to mild or moderate dementia due to Alzheimer&#8217;s disease. All participants had evidence of amyloid plaque by PET scan and/or CSF biomarkers consistent with Alzheimer&#8217;s disease at baseline. The trial evaluated four ascending dose cohorts (1.4&#215;10</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:5.025pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">vg/ml, 4.4&#215;10</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:5.025pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">vg/ml, 1.4&#215;10</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:5.025pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">vg/ml and 1.4&#215;10</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:5.025pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> total genomes), with the dose for each patient in the first three cohorts determined based on CSF volume measured by MRI and patients in the fourth cohort receiving a fixed dose. Fifteen patients were enrolled in the study across the four dose cohorts. The primary objective of the trial was to evaluate the safety of LX1001 administered to the CNS via injection between cervical vertebrae 1 and 2, or intracisternal injection, and to establish the maximum tolerated dose. The trial was also designed to evaluate the conversion of the CSF from the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">APOE4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> homozygous profile to an </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">APOE4/E2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> profile. Additional secondary endpoints included CSF biomarkers, including A&#223;42, total tau, and phosphorylated tau, amyloid PET scan, structural MRI imaging and cognitive tests. Corticosteroids were utilized for immune suppression. Participants will continue to be evaluated for ongoing safety in a long-term follow-up study, per FDA requirement.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have completed the Phase 1/2 trial of LX1001 and shared preliminary results across all four dose cohorts in a late-breaking oral presentation at the Clinical Trials on Alzheimer&#8217;s Disease Conference in October 2024. In January 2025 we announced that we are seeking partnering opportunities to continue development.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Competition</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The biotechnology and pharmaceutical industries are characterized by rapidly changing technologies, significant competition and a strong emphasis on intellectual property. This is also true for the development and commercialization of treatments for cardiovascular and neurodegenerative diseases such as FA and PKP2-ACM and broadly across gene therapies. While we believe that our management and scientific team&#8217;s deep expertise in gene therapy provides us with competitive advantages, we face competition from several sources, including large and small biopharmaceutical companies, government agencies and academic and private research institutions. Not only must we compete with other companies that are focused on gene therapy technology, but any product candidates that we successfully develop and commercialize will compete with existing therapies, to the extent applicable, and new therapies that may become available in the future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Drug development, particularly in the gene therapy field, is highly competitive and subject to rapid and significant technological advancements. A significant unmet medical need exists in each of the indications that we are targeting, and it is likely that additional drugs will become available in the future for the treatment of these diseases.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are aware that our competitors are developing product candidates for the treatment of diseases that our product candidates will target. With respect to LX2006, we are aware of</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> clinical stage gene therapy programs in development at Astellas Pharma Inc.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and Solid Biosciences Inc. and those being developed in collaborations between Voyager Therapeutics, Inc. and Neurocrine Biosciences, Inc. Additionally, we are aware that Prime Medicine, Inc. and Tune Therapeutics, Inc. have early-stage gene editing discovery efforts. Among other treatment modalities for FA, we are aware that Larimar Therapeutics, Inc. is developing a clinical stage product candidate, CTI-1601, that Design Therapeutics, Inc. is developing a product candidate, DT-216P2, and that PTC Therapeutics, Inc. has submitted a new drug application for vatiquinone to the FDA. Reata Pharmaceuticals, Inc.&#8217;s omaveloxolone (Skyclarys) was approved by the FDA in 2023, and Biogen Inc. acquired Reata Pharmaceuticals, Inc. for approximately $7.3 billion in the same year and is currently commercializing Skyclarys.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With respect to LX2020, both Rocket Pharmaceuticals Inc., or Rocket, and Tenaya Therapeutics Inc. are developing an AAV-based gene therapy candidate designed to deliver a functional </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">PKP2 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">gene to patients with PKP2-ACM.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many of our existing or potential competitors have substantially greater financial, technical and human resources than we do and significantly greater experience in the discovery and development of product candidates, as well as in obtaining regulatory approvals of those product candidates in the United States and in foreign countries.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will face competition from other drugs or from other non-drug products and treatments currently approved or that will be approved in the future in the cardiovascular and neurology field, including for the treatment of diseases and diseases in the therapeutic categories we intend to target. Therefore, our ability to compete successfully will depend largely on our ability to:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">develop, manufacture and commercialize drugs that are superior to other products in the market;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">demonstrate through our clinical trials that our product candidates are differentiated from existing and future therapies;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">attract qualified scientific, product development and commercial personnel;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtain patent or other proprietary protection for our medicines;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtain required regulatory approvals;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtain coverage and adequate reimbursement from, and negotiate competitive pricing with, third-party payors; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">successfully collaborate with pharmaceutical companies in the discovery, development and commercialization of new medicines.</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The availability of our competitors&#8217; products could limit the demand, and the price we are able to charge, for any product candidate we develop. The inability to compete with existing or subsequently introduced drugs would have an adverse impact on our business, financial condition and prospects. In addition, the reimbursement structure of currently approved or future gene therapies by other companies could impact the anticipated reimbursement structure of our gene therapies, if approved, and our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Established pharmaceutical companies may invest heavily to accelerate discovery and development of novel compounds or to in-license novel compounds that could make our product candidates less competitive. In addition, any new product that competes with an approved product must demonstrate compelling advantages in efficacy, convenience, tolerability and safety in order to overcome price competition and to be commercially successful. Accordingly, our competitors may succeed in obtaining patent protection, discovering, developing, receiving regulatory and marketing approval for, or commercializing, drugs before we do, which would have an adverse impact on our business and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intellectual property</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We actively seek to protect our proprietary technology, inventions, and other intellectual property that is commercially important to the development of our business by a variety of means, such as seeking, maintaining, and defending patent rights, whether developed internally or licensed from third parties. We also may rely on trade secrets and know-how relating to our proprietary technology platform, on continuing technological innovation and on in-licensing opportunities to develop, strengthen and maintain the strength of our position in the field of gene therapy that may be important for the development of our business. We also intend to seek patent protection or rely upon trade secret rights to protect other technologies that may be used to discover and validate targets, and that may be used to manufacture and develop novel gene therapy products. We are a party to license agreements that give us rights to use specific technologies in our gene therapy candidates and in manufacturing our products. Additional regulatory protection may also be afforded through data exclusivity, market exclusivity and patent term extensions where available.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, we in-licensed three U.S. patents, 14 pending U.S. non-provisional patent applications, one pending PCT application, six foreign patents and 76 pending foreign applications.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In regard to our LX2006 product candidate, we in-license from Cornell University and Adverum Biotechnologies, Inc., or Adverum, two U.S. patents, four pending U.S. non-provisional patent applications, five foreign patents granted in India, Mexico, South Africa, and New Zealand and ten pending foreign applications pending in such jurisdictions as Australia, Brazil, Canada, Eurasia, Europe, Hong Kong, Israel and Mexico. Not accounting for any patent term adjustment and assuming that all annuity and/or maintenance fees are paid timely, these patents, if granted, will expire in 2033. These patents and pending patent applications disclose and/or contain composition-of-matter claims to an AAV vector encoding </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">FXN</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, or a fragment thereof, and disclose and/or contain claims to methods of producing and methods of treatment using the AAV </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">FXN</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> vector. Cornell University co-owns these patents and patent applications with Institut National de la Sant&#233; et de la Recherche M&#233;dicale, Centre National de la Recherche Scientifique, Universit&#233; de Strasbourg, Universit&#233; Paris-Saclay and Assistance Publique-H&#244;pitaux de Paris.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have rights to additional patent applications that we co-own with Cornell University, and which also relate to our LX2006 cardiac FA program. We in-license Cornell University's interest in one pending U.S. non-provisional patent application and 13 pending foreign applications in such jurisdictions as Australia, Brazil, Canada, China, Eurasia, Europe, Israel, India, Japan, Korea, Mexico, New Zealand, and South Africa. Not accounting for any patent term adjustment and assuming that all annuity and/or maintenance fees are paid timely, if granted, patents issuing from these applications will expire in 2043. These pending applications disclose and/or contain composition-of-matter claims to a pharmaceutical dosage form of viral vectors encoding </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">FXN</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and disclose and/or contain claims to methods of producing and methods of treatment using the pharmaceutical dosage form.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In regard to our LX2020 product candidate, we in-license from The Regents of the University of California one pending U.S. non-provisional patent application and 16 pending foreign applications in such jurisdictions as Australia, Brazil, Canada, China, Colombia, Eurasia, Europe, Hong Kong, Israel, India, Japan, Korea, Mexico, New Zealand, Singapore and South Africa. Not accounting for any patent term adjustment and assuming that all annuity and/or maintenance fees are paid timely, if granted, patents issuing from these applications will expire in 2042. These pending applications disclose and/or contain composition-of-matter claims to a vector encoding human plakophilin-2 (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">PKP2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">), and disclose and/or contain claims to methods of producing and methods of treatment using the PKP2 vector.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In regard to our LX2021 product candidate, we in-license from The Regents of the University of California one U.S. patent, three pending U.S. non-provisional patent applications, one foreign patent granted in Europe, and six pending foreign applications pending in Australia, Canada, China, Europe, Israel, and Japan. Not accounting for any patent term adjustment and assuming that all annuity and/or maintenance fees are paid timely, if granted, these patents and patent applications will expire in 2038. These pending patent applications disclose and/or contain composition-of-matter claims to a vector encoding a human Cx43 polypeptide, and disclose and/or contain claims to methods of producing and methods of treatment using the Cx43 vector.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In regard to our LX2022 product candidate, we in-license from The Regents of the University of California one pending U.S. non-provisional patent application. Not accounting for any patent term adjustment and assuming that all annuity and/or maintenance fees are paid timely, if granted, patent applications claiming the priority to this patent application, will expire in 2040. This pending U.S. non-provisional patent application discloses and/or contains composition-of-matter claims to a vector encoding a human </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">TNNI3 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">gene, and discloses and/or contains claims to methods of producing and methods of treatment using the TNNI3 vector.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In regard to our LX1020 product candidate, we in-license from Cornell University one pending U.S. non-provisional application and 14 pending foreign applications pending in Australia, Brazil, Canada, China, Colombia, Europe, Hong Kong, Israel, Japan, Korea, Mexico, New Zealand, Singapore and South Africa. Not accounting for any patent term adjustment and assuming that all annuity and/or maintenance fees are paid timely, if granted, these patent applications will expire in 2040. The pending patent applications disclose and/or contain composition-of-matter claims to a vector encoding human APOE2 protein and encoding one or more RNAi nucleic acid sequences for inhibition of APOE4 mRNA, and disclose and/or contain claims to methods of producing and methods of treatment using the APOE2+/APOE4- vector.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In regard to our LX1021 product candidate, we in-license from Cornell University one pending U.S. non-provisional application and 13 pending foreign applications pending in Australia, Brazil, Canada, China, Europe, Hong Kong, Israel, Japan, Korea, Mexico, New Zealand, Singapore and South Africa. Not accounting for any patent term adjustment and assuming that all annuity and/or maintenance fees are paid timely, if granted, this patent application will expire in 2040. We also in-license from Cornell an additional pending PCT application related to our LX1021 product candidate. Not accounting for any patent term adjustment and assuming that all annuity and/or maintenance fees are paid timely, if granted, patents claiming priority to the pending PCT application will expire in 2044. The pending patent applications disclose and/or contain composition-of-matter claims to a vector encoding a mutated human apolipoprotein E protein, and disclose and/or contain claims to methods of producing and methods of treatment using the mutated human apolipoprotein E vector.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In regard to our LX1001 product candidate, we co-own with Cornell University one pending PCT application. Not accounting for any patent term adjustment and assuming that all annuity and/or maintenance fees are paid timely, if granted, patent applications claiming the benefit of this PCT application will expire in 2043. This pending patent application discloses and/or contains composition-of-matter claims to a pharmaceutical dosage form of viral vectors encoding human APOE2, and discloses and/or contains claims to methods of producing and methods of treatment using the pharmaceutical dosage form.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">License, research collaboration and sponsored research agreements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">First license agreement with Cornell University</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2020, we entered into a license agreement with Cornell University, or the Cornell First License Agreement, pursuant to which we obtained a sublicensable, worldwide license under certain patents to make, use, and sell products that are covered by a valid claim of a licensed patent, are based on the transferred IND from Cornell University, use any licensed materials, or are produced using a licensed method, and to practice certain licensed technology, in all cases, for all human and non-human prophylactic and therapeutic uses. In July 2022, we entered into Amendment No. 1 to the Cornell First License Agreement that updated fees and royalties payable by us under the Cornell First License Agreement. In September 2022, we entered into Amendment No. 2 to the Cornell First License Agreement that clarified patent prosecution and maintenance obligations and added certain inventions and patents to the list of inventions and patent rights covered under the Cornell First License Agreement. The technology under the license includes portfolios for APOE, Alzheimer&#8217;s disease, and Anti-Tau, although our license is not restricted by such indications. The license is exclusive with respect to certain patents and non-exclusive with respect to other patents. Additionally, under the Cornell First License Agreement, Cornell University assigned to us an IND for the use of AAVrh10.hAPOE2 vector to treat </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">APOE4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> homozygous patients who are at risk of having or have Alzheimer&#8217;s disease. Cornell University reserved the rights to publish and disseminate information about inventions included in the licensed technology and licensed patents, and to use, and allow other nonprofit institutions to use, the patents and technology for educational and research purposes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are obligated to diligently proceed with the development, manufacture, and sale of licensed products, to raise certain amounts within specified time frames, to achieve certain development milestones within specified time frames, to meet agreed minimum-spend requirements, and to meet other diligence obligations. If we fail to perform these obligations, Cornell University could terminate the Cornell First License Agreement in full or in part in specified circumstances, subject to certain rights for us to extend these time frames.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">17</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Cornell First License Agreement, we paid Cornell University an upfront payment of approximately $0.15 million and entered into a purchase agreement for approximately $0.6 million of convertible preferred securities. We are obligated to pay Cornell University an annual license maintenance fee ranging from the low four digits to the mid five digits, increasing annually until such time that we are commercially selling a licensed product. Under the Cornell First License Agreement, we are obligated to pay Cornell University up to $8.4 million for each portfolio upon the achievement of specific clinical and regulatory milestones. We are obligated to pay Cornell University a flat royalty in the mid-single-digits based on net sales of a licensed product in a country, which royalty rate increases by one percent if the licensed product is an orphan drug, subject to a reduction upon the expiration of valid claims in licensed patents and certain reductions for third-party licenses. In addition, in certain specific instances where sales are made by a sublicensee, the royalty rate increases by an amount in the low to mid-single digits. If the royalties are below certain agreed amounts, we are required to pay Cornell University minimum annual royalties ranging from low-six digits to low-seven digits. The royalty term continues for each licensed product on a country-by-country basis beginning on the first commercial sale of such licensed product and ending on the latest of (a) expiration or invalidation of the last valid claim in the licensed patent, (b) the expiration of regulatory exclusivity, and (c) the month of the first commercial launch of a generic equivalent in such country. We are also obligated to pay Cornell University a percentage of sublicensing fees in the low-double digits to mid-double digits.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may terminate the Cornell First License Agreement or any portfolio thereunder at any time upon ninety (90) days&#8217; advance written notice to Cornell University. Cornell University may terminate the Cornell First License Agreement if we commit a material breach and fail to cure such breach within a specified cure period after written notice or if we challenge the validity of a licensed patent. Upon expiration of the royalty term of a given licensed product in a country, the license becomes non-exclusive and royalty-free. Upon termination of the Cornell First License Agreement, all licenses and rights granted by either party will terminate, although we will have a period of time to sell off any remaining licensed product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Second license agreement with Cornell University</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2020, we entered into a second license agreement with Cornell University, or the Cornell Second License Agreement, pursuant to which we obtained a sublicensable, worldwide license under certain patents to make, use, and sell products that are covered by a valid claim of a licensed patent, are based on the transferred IND from Cornell University, use any licensed materials, or are produced using a licensed method, and to practice certain licensed technology, in all cases, for all human and non-human prophylactic and therapeutic uses. In January 2022, we entered into Amendment No. 1 to the Cornell Second License Agreement, whereby we paid Cornell a material transfer fee and a license fee totaling $30,000, and Cornell added certain materials to the list of original materials subject to the Cornell Second License Agreement. In July 2022, we entered into Amendment No. 2 to the Cornell Second License Agreement that updated fees and royalties payable by us under the Cornell Second License Agreement. The technology under the license includes a portfolio for FA, although our license is not restricted by such indications. The license is exclusive with respect to certain patents and non-exclusive with respect to other patents. Cornell University reserved the rights to publish and disseminate information about inventions included in the licensed technology and licensed patents, and to use, and allow other nonprofit institutions to use, the patents and technology for educational and research purposes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are obligated to diligently proceed with the development, manufacture, and sale of licensed products, to raise certain amounts within specified time frames, to achieve certain development milestones within specified time frames, to meet agreed minimum-spend requirements, and to meet other diligence obligations. If we fail to perform these obligations, Cornell University could terminate the Cornell Second License Agreement in full or in part in specified circumstances, subject to certain rights for us to extend these time frames.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Cornell Second License Agreement, we paid Cornell University an upfront payment of approximately $0.15 million and entered into a purchase agreement for approximately $0.6 million of convertible preferred securities. We are obligated to pay Cornell University an annual license maintenance fee ranging from the low four digits to the mid five digits, increasing annually until such time that we are commercially selling a licensed product. Under the Cornell Second License Agreement, we are obligated to pay Cornell University up to $4.3 million for two portfolios and up to $0.6 million for a third portfolio upon the achievement of specific clinical and regulatory milestones. Upon submitting our IND application for LX2006 to the FDA in the first quarter of 2022, we achieved the first clinical milestone under the Cornell Second License Agreement, and we paid $0.1 million to Cornell University in the second quarter of 2022 in connection with this milestone. We are obligated to pay Cornell University a flat royalty in the mid-single-digits based on net sales of a licensed product in a country, which royalty rate increases by one percent if the licensed product is an orphan drug, subject to a reduction upon the expiration of valid claims in licensed patents and certain reductions for third-party licenses. In addition, in certain specific instances where sales are made by a sublicensee, the royalty rate increases by an amount in the low to mid-single digits. If the royalties are below certain agreed amounts, we are required to pay Cornell University minimum annual royalties ranging from low six digits to low seven digits. The royalty term continues for each licensed product on a country-by-country basis beginning on the first commercial sale of such licensed product and ending on the latest of (a) expiration or invalidation of the last valid claim in the licensed patent, (b) the expiration of regulatory exclusivity, and (c) the month of the first commercial launch of a generic equivalent in such country. We are also obligated to pay Cornell University a percentage of sublicensing fees ranging in the low double digits.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may terminate the Cornell Second License Agreement or any portfolio thereunder at any time upon ninety (90) days&#8217; advance written notice to Cornell University. Cornell University may terminate the Cornell Second License Agreement if we commit a material breach and fail to cure such breach within a specified cure period after written notice or if we challenge the validity of a licensed patent. Upon expiration of the royalty term of a given licensed product in a country, the license becomes non-exclusive and royalty-free. Upon termination of the Cornell Second License Agreement, all licenses and rights granted by either party will terminate, although we will have a period of time to sell off any remaining licensed product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Third license agreement with Cornell University</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In April 2024, w</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">e entered into a third license agreement with </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cornell University, or the Cornell Third License Agreement,</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> pursuant to which we obtained certain rights for FA cardiomyopathy, including </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">an exclusive license to practice under certain patent rights generated in animal studies conducted by Cornell University on our behalf and a non-exclusive license to know-how concerning a gene therapy for FA cardiomyopathy and current and future data generated in an ongoing Cornell University investigator-initiated Phase 1A trial of </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a gene therapy candidate AAVrh10.hFXN, known as LX2006 at Lexeo, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to treat FA cardiomyopathy. Both licenses are worldwide and cover products with human and non-human prophylactic and therapeutic uses. Cornell University has also granted us a right of reference to its IND application for a gene therapy for FA cardiomyopathy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are obligated to diligently proceed with the development, manufacture, and sale of licensed products, to raise certain amounts within specified time frames, to achieve certain development milestones within specified time frames, to meet agreed minimum-spend requirements, and to meet other diligence obligations. If we fail to perform these obligations, Cornell University could terminate the Cornell Third License Agreement in full or in part in specified circumstances, subject to certain rights for us to extend these time frames.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Cornell Third License Agreement, we paid a license issue fee and an initial data transfer fee to Cornell University totaling $0.6 million. Additionally, we will be paying an annual data transfer fee of $50,000 until data is no longer being gathered. We have agreed to pay annual license maintenance fees ranging from $2,500 to $25,000 until such time we commercialize a licensed product. In addition, we will pay Cornell University up to an aggregate of $2.1 million in regulatory milestones and up to an aggregate of $100 million in commercial milestones, plus low single digit royalties on net sales.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Cornell Third License Agreement contains other customary license terms including terms related to sublicensing, development, commercialization, milestones, royalties, intellectual property, and termination. Upon expiration of the applicable royalty term for a product in a given country, we shall retain a non-exclusive, royalty free license to the data and know-how, including to continue selling such product in that country.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may terminate the Cornell Third License Agreement, in whole or in part with respect to the right of reference, or the licensed data, know-how, or patent rights, with 90 days&#8217; prior written notice to Cornell University. Cornell University may terminate the Cornell Third License Agreement if we commit a material breach and fail to cure such breach within a specified cure period after written notice, participate in any proceeding challenging the validity of the licensed patents, publish the licensed data without Cornell&#8217;s prior written consent, or do not reach certain milestones. Cornell University may also terminate the Cornell Third License Agreement in part on product-by-product basis if we do not diligently develop and sale a product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research collaboration agreement with Weill Cornell Medicine</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In February 2021, we entered into a Research Collaboration Agreement with Cornell University on behalf of Weill Cornell Medicine, or the Cornell Collaboration Agreement, in connection with the Cornell First License Agreement and the Cornell Second License Agreement entered into in May 2020, collectively, the May 2020 Cornell License Agreements. In February 2022, we entered into Amendment No. 1 to the Research Collaboration Agreement. The Cornell Collaboration Agreement, as amended, is referred to as the Amended Cornell Collaboration Agreement. Under the Amended Cornell Collaboration Agreement, we committed to fund scientific research at Weill Cornell Medicine related to the technology licensed to us pursuant to the May 2020 Cornell License Agreements. Cornell University reserved the rights to publish and disseminate information about the results, excluding any inventions, generated from Cornell University&#8217;s investigator&#8217;s conduct of the research.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">19</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the May 2020 Cornell License Agreements, we committed to provide funding for research projects at Cornell University for a three-year period, with a minimum annual funding commitment of $1.0 million. With respect to each Weill Cornell Medicine invention and joint invention and related joint results that is either an improvement to, or is dominated by, the patent rights under the May 2020 Cornell License Agreements or is specifically designed for a licensed product under the May 2020 Cornell License Agreements, or Improvement, and for which we have made an election to obtain such inventions, the May 2020 Cornell License Agreements will be amended to include license grants to such Improvements following payment of the relevant amendment fee in the low five digits. With respect to each Weill Cornell Medicine invention and joint invention, and related joint results that are not Improvements, we have the first option to negotiate for a royalty-bearing, worldwide license under such intellectual property to develop, make, have made, use, offer for sale, sell, have sold and import products on commercially reasonable terms.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Amended Cornell Collaboration Agreement expired in accordance with its terms in February 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">License agreement with Adverum</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In January 2021, we entered into a license agreement with Adverum, which we amended in February 2022 pursuant to the First Amendment to the Adverum Agreement, such agreement as amended, the Amended Adverum Agreement. Pursuant to the Amended Adverum Agreement, we obtained an exclusive, sublicensable, worldwide license under certain patents, know-how, and other intellectual property relating to viral vector technology for gene therapy applications for the treatment of FA cardiomyopathy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are responsible for the development, manufacture, and commercialization of gene therapy products that consist of a specific nucleic acid sequence that is delivered by a specific gene therapy, or the Products. We are obligated to use commercially reasonable efforts to develop, obtain regulatory approval for, and commercialize the Products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Amended Adverum Agreement, we paid Adverum a $7.5 million upfront payment. We are obligated to pay Adverum up to $17.5 million upon the achievement of specified development and regulatory milestones, including a $3.5 million development milestone that was achieved in the first quarter of 2023, and up to $49 million in commercialization and sales milestones for the Products. We are obligated to pay Adverum tiered royalties ranging from high single-digits to sub teens based on annual aggregate worldwide net sales of Products, subject to reductions upon the expiration of valid claims in licensed patents and third-party licenses. The royalty term continues for each Product on a country-by-country basis beginning on the first commercial sale of such Product and ending on the latest of (a) expiration of the last valid claim in the licensed patent that covers the manufacture, use, or sale of the Product in such country, (b) the expiration of all regulatory and data exclusivity in such country, and (c) ten years after the first commercial sale of such Product in such country.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Amended Adverum Agreement will expire, unless earlier terminated, on the expiration of the last royalty term for a Product in a particular country. We have the right to terminate the Amended Adverum Agreement at any time upon one-hundred twenty days&#8217; advance written notice to Adverum. In addition, subject to certain conditions, either we or Adverum may terminate the Amended Adverum Agreement upon the insolvency of the other or if the other party commits a material breach of the agreement and fails to cure such breach within a specified cure period after written notice is provided. Additionally, Adverum may terminate the Amended Adverum Agreement if we challenge the validity of any licensed patents. Upon expiration of the Amended Adverum Agreement, the license becomes royalty-free, irrevocable and perpetual. Upon termination of the Amended Adverum Agreement, all licenses, sublicenses, and rights granted by either party will terminate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">First license agreement with the Regents of University of California, San Diego</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stelios Therapeutics, Inc., or Stelios, which we acquired in August 2021, is successor-in-interest to ARVC Therapeutics, Inc., or ARVC Therapeutics, under a worldwide license agreement entered into by ARVC Therapeutics and The Regents of the University of California, on April 23, 2020, or the UCSD First License Agreement, pursuant to which they obtained a license to certain intellectual property related to gene therapies for ARVC. The UCSD First License Agreement relates to our development efforts for our LX2021 program. Pursuant to the UCSD First License Agreement, we obtained an exclusive, sublicensable, worldwide license under certain patents to make, use, sell, offer for sale and import services, methods, composition and products that incorporate or are developed using any licensed invention or licensed methods, or is covered by a valid claim of a licensed patent, or a Product, in all cases for all diagnostic and therapeutic uses. The Regents of University of California, San Diego, or UCSD, reserved the right to practice the relevant invention and licensed patents for educational and research purposes, to publish and disseminate information about the relevant invention and licensed patents, and to allow other nonprofit institutions to use, publish, or disseminate information about the relevant inventions and licensed patents for educational and research purposes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the UCSD First License Agreement, we are obligated to achieve certain development milestones within specified time frames, to use commercially reasonable efforts to diligently develop, manufacture, and sell Products, and to meet agreed minimum-spend requirements. If we fail to perform any of these obligations, UCSD could either terminate the UCSD First License Agreement or convert the exclusive license to a nonexclusive license, subject to certain rights for us to extend these time frames.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">20</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The UCSD First License Agreement required Stelios to pay one-time up-front non-refundable cash fees of $20,000. We are obligated to pay annual license maintenance fees in the mid-four digits to low-five digits, increasing until such time that we are commercially selling a Product. We are also obligated to pay up to $4.75 million upon the achievement of specific development and commercialization milestones for the first Product and low- to mid-single digit royalties based on aggregate net sales, subject to certain reductions for third-party licenses. The royalty term continues until the expiration of the UCSD First License Agreement. Under the UCSD First License Agreement, if the royalties are below certain agreed amounts, we are required to pay UCSD minimum annual royalties ranging from low- to mid-five digits. We are also obligated to pay UCSD a percentage of sublicensing fees ranging in the low double digits. In the event that we assign the UCSD First License Agreement, we will be obligated to pay an assignment fee that will be determined based on certain aspects of the assignment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The UCSD First License Agreement will expire, unless earlier terminated, on the expiration of the last claim of any licensed patent or patent applications in a particular country. We have the right to terminate the UCSD First License Agreement at any time upon sixty days&#8217; written notice to UCSD. UCSD may terminate the UCSD First License Agreement if we commit a material breach, if we fail to meet certain specified milestones within the prescribed time periods, if we are delinquent on any report or payment or provide an intentionally misleading report, if we fail to diligently develop and commercialize the licensed products, or if we challenge the validity of a licensed patent, in each case only if we fail to cure such problem within a specified cure period after written notice. Upon termination of the UCSD First License Agreement, all licenses and rights granted by UCSD to us will terminate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Second license agreement with the Regents of University of California, San Diego</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stelios, which we acquired in August 2021, entered into a worldwide license agreement in August 2020 with The Regents of the University of California, or the UCSD Second License Agreement, pursuant to which they obtained a license to certain intellectual property and materials related to gene therapies for HCM. The UCSD Second License Agreement relates to our development efforts for our LX2022 programs. Pursuant to the UCSD Second License Agreement, we obtained an exclusive, sublicensable, worldwide license under certain patents to make, use, sell, offer for sale and import services, methods, composition and products that incorporate or are developed using any licensed invention or licensed methods or is covered by a valid claim of a licensed patent, or a Product, and a non-exclusive license to use nonpublic technical information, or Technology, in all cases for all diagnostic and therapeutic uses. UCSD reserved the rights to practice the relevant invention, Technology and licensed patents for educational and research purposes, to publish and disseminate information about the relevant invention, Technology and licensed patents, and to allow other nonprofit institutions to use, publish, or disseminate information about the relevant invention, Technology and licensed patents for educational and research purposes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the UCSD Second License Agreement, we are obligated to achieve certain development milestones within specified time frames and to use commercially reasonable efforts to diligently develop, manufacture, and sell Products. If we fail to perform any of these obligations, UCSD could either terminate the UCSD Second License Agreement or convert the exclusive license to a nonexclusive license subject to certain rights for us to extend these time frames.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The UCSD Second License Agreement required Stelios to pay one-time up-front non-refundable cash fees of $20,000. We are obligated to pay annual license maintenance fees in the mid-four digits to low-five digits, increasing until such time that we are commercially selling a Product. We are also obligated to pay up to $2.4 million upon the achievement of certain development and commercialization milestones for the first Product and low-single digit royalties based on aggregate net sales, subject to certain reductions for third-party licenses. The royalty term continues until the expiration of the UCSD Second License Agreement. We are also obligated to pay UCSD a percentage of sublicensing fees ranging in the low double digits.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The UCSD Second License Agreement will expire, unless earlier terminated, on the expiration of the last claim of any licensed patent or patent applications in a particular country. We have the right to terminate the UCSD Second License Agreement at any time upon sixty days&#8217; written notice to UCSD. UCSD may terminate the UCSD Second License Agreement if we commit a breach, if we fail to meet certain specified milestones within the prescribed time periods, if we are delinquent on any report or payment, if we are not diligently developing or commercializing Products in accordance with our diligence obligations, if we provide any intentionally false report, or if we challenge the validity of a licensed patent, in each case only if we fail to cure such problem within a specified cure period after written notice. In the event that we assign the UCSD Second License Agreement, we will be obligated to pay an assignment fee that will be determined based on the acquisition price. Upon termination of the UCSD Second License Agreement, all licenses and rights granted by UCSD to us will terminate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">21</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Third license agreement with the Regents of University of California, San Diego</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2021, we entered into a worldwide license agreement with UCSD, or the UCSD Third License Agreement, and collectively with the UCSD First License Agreement and the UCSD Second License Agreement, The UCSD License Agreements, pursuant to which we obtained a license to materials and intellectual property related to a gene therapy for ARVC. The UCSD Third License Agreement relates to our development efforts for our LX2020 program. Pursuant to the UCSD Third License Agreement, we obtained an exclusive, sublicensable, worldwide license under certain patents to make, use, and sell, offer for sale and import services, methods, composition and products that incorporate or are developed using any licensed invention or licensed methods, or is covered by a valid claim of a licensed patent, or a Product, and an exclusive license to use nonpublic technical information, or Technology, in all cases for all diagnostic and therapeutic uses. UCSD reserved the rights to practice the relevant invention, Technology and licensed patents for educational and research purposes, to publish and disseminate information about the relevant invention, Technology and licensed patents, and to allow other nonprofit institutions to use, publish, or disseminate information about the relevant invention, Technology and licensed patents for educational and research purposes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the UCSD Third License Agreement, we are obligated to achieve certain development milestones within specified time frames, to use commercially reasonable efforts to diligently develop, manufacture, and sell licensed products, and to meet agreed minimum-spend requirements. If we fail to perform any of these obligations, UCSD could either terminate the UCSD Third License Agreement or convert the exclusive license to a nonexclusive license subject to certain rights for us to extend these time frames.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The UCSD Third License Agreement required us to pay a one-time up-front non-refundable cash fee of $20,000. We are obligated to pay annual license maintenance fees in the mid-four digits to low-five digits, increasing until such time that we are commercially selling a Product. We are also obligated to pay up to $4.0 million upon the achievement of specified development and commercialization milestones for the first Product and low- to mid-single digit royalties based on aggregate net sales, subject to certain reductions for third-party licenses. The royalty term continues until the expiration of the UCSD Third License Agreement. If the royalties are below certain agreed amounts, we are required to pay UCSD minimum annual royalties ranging from low- to mid-five digits. We are also obligated to pay UCSD a percentage of sublicensing fees ranging in the low double digits.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The UCSD Third License Agreement will expire, unless earlier terminated, on the expiration of the last claim of any licensed patent or patent applications in a particular country. We have the right to terminate the UCSD Third License Agreement at any time upon sixty days&#8217; written notice to the UCSD. UCSD may terminate the UCSD Third License Agreement if we commit a material breach, if we fail to meet certain specified milestones within the prescribed time periods, if we are delinquent on any report or payment, if we are not diligently developing or commercializing Products in accordance with our diligence obligations, if we provide any intentionally false report, or if we challenge the validity of a licensed patent, in each case only if we fail to cure such problem within a specified cure period after written notice. In the event that we assign the UCSD Third License Agreement or we undergo a change of control, we will be obligated to pay a flat low-six digit fee or a fee that will be determined based on the acquisition price. Upon termination of the UCSD Third License Agreement, all licenses and rights granted by The Regents of UCSD to us will terminate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Sponsored research agreements with the Regents of University of California, San Diego</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the UCSD License Agreements, on December 3, 2021, we entered into a sponsored research agreement with UCSD for our LX2020 and LX2021 programs, or First UCSD SRA which was subsequently amended on April 5, 2023 and August 31, 2023, and another sponsored research agreement with UCSD for our LX2022 program, or Second UCSD SRA, which was subsequently amended on April 19, 2023. We refer to these agreements, as amended, as the Amended UCSD SRAs. UCSD reserved the rights to publish and disseminate information about the results generated from UCSD&#8217;s investigator&#8217;s conduct of the research. The total costs to be invoiced to us under the terms of the Amended UCSD SRAs are approximately $5.6 million. Under the terms of the Amended UCSD SRAs, we have the first rights to obtain non-exclusive or exclusive, sublicensable, royalty-bearing, perpetual and transferable worldwide licenses to any inventions generated by UCSD or UCSD&#8217;s interest in any inventions generated jointly by The Regents of UCSD and us, and we retain the rights to any inventions generated solely by us.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 13, 2024, we entered into a third sponsored research agreement with UCSD, or the Third UCSD SRA, for our LX2022 program in connection with the UCSD Second License Agreement. Under the terms of the Third UCSD SRA, we have the first rights to obtain non-exclusive or exclusive, sublicensable, royalty-bearing, perpetual and transferable worldwide licenses in any resulting inventions owned by UCSD or resulting inventions jointly owned between us and UCSD, and we retain the rights to any resulting inventions owned by us. The Third UCSD SRA has a two-year term and may be terminated early by us at any time upon the giving of thirty (30) days&#8217; written notice to UCSD. The costs to be invoiced to us over the term of the Third UCSD SRA are $0.7 million, and we may incur additional costs of $0.6 million under the Third UCSD SRA if certain study objectives are met.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 13, 2024, we entered into another amendment to the Second UCSD SRA for our LX2022 program that extended the term of the Second UCSD SRA to December 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">22</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 19, 2024 and September 27, 2024, we entered into amendments, respectively, to the First UCSD SRA for our LX2021 program in connection with the UCSD First License Agreement. We refer to the First UCSD SRA, as amended, as the Amended First UCSD SRA. The Amended First UCSD SRA extends the term of the First UCSD SRA to December 2026 and provides for additional research and development studies and expenses. The total costs to be invoiced to us under the Amended First UCSD SRA are $0.7 million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Government regulation</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Government authorities in the United States at federal, state and local levels, as well as in foreign countries, extensively regulate, among other things, the research, development, testing, manufacture, quality control, import, export, safety, effectiveness, labeling, packaging, storage, distribution, record keeping, approval, advertising, promotion, marketing, post-approval monitoring and post-approval reporting of biologics, including gene therapies, such as those we are developing. Generally, before a new biologic can be marketed, considerable data demonstrating its quality, safety and efficacy must be obtained, organized into a format specific for each regulatory authority, submitted for review and approved, authorized, or cleared by the applicable regulatory authority. We, along with third-party contractors, will be required to navigate the various preclinical, clinical and commercial approval requirements of the governing regulatory agencies of the countries in which we wish to conduct studies or seek approval or licensure of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">U.S. biologics regulation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the United States, biological products are subject to regulation under the U.S. Federal Food, Drug, and Cosmetic Act, or FDCA, and the Public Health Service Act, or PHSA, and their implementing regulations and other federal, state, local and foreign statutes and regulations. Failure to comply with the applicable United States requirements at any time during the product development process, approval process or following approval may subject an applicant to administrative actions or judicial sanctions. These actions and sanctions could include, among other actions, the FDA&#8217;s refusal to approve pending applications, withdrawal of an approval, license revocation, a clinical hold, untitled or warning letters, voluntary or mandatory product recalls or market withdrawals, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement and civil or criminal fines or penalties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our product candidates must be approved by the FDA through the Biologics License Application, or BLA, the process which is required by the FDA before biological product candidates may be marketed in the United States and generally involves the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">completion of extensive preclinical laboratory tests and animal studies performed in accordance with applicable regulations, including the FDA&#8217;s good laboratory practices, or GLPs, regulations;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">submission to the FDA of an IND application, which must become effective before human clinical trials may begin;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">approval by an Institutional Review Board, or IRB, or ethics committee at each clinical site before the trial is commenced;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">performance of adequate and well-controlled human clinical trials in accordance with applicable IND regulations, the FDA&#8217;s current Good Clinical Practices, or cGCPs, and other clinical trial-related regulations to establish the safety, purity and potency of the proposed biological product candidate for its intended purpose;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">preparation of and submission to the FDA of a BLA that contains sufficient data to demonstrate substantial evidence of effectiveness;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a determination by the FDA within 60 days of its receipt of a BLA to file the application for review;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">payment of user fees for FDA review of the BLA;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">satisfactory completion of an FDA pre-license inspection of the manufacturing facility or facilities at which the proposed product will be produced to assess compliance with current good manufacturing practices, or cGMPs, and to assure that the facilities, methods and controls are adequate to ensure and preserve the biological product&#8217;s identity, strength, quality and purity, and of selected clinical investigation sites to assess compliance with the cGCPs;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">satisfactory completion of an FDA Advisory Committee review, if applicable; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FDA review and approval, or licensure, of a BLA to permit commercial marketing of the product for particular indications for use in the United States.</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">23</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Preclinical and clinical development</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prior to beginning the first clinical trial with a product candidate, the product candidate must undergo rigorous preclinical testing. Preclinical studies include laboratory evaluation of product chemistry and formulation, as well as </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and animal studies to assess safety and in some cases to establish a rationale for therapeutic use. The conduct of preclinical studies is subject to federal and state regulations and requirements, including GLP regulations for safety/toxicology studies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An IND sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and plans for clinical trials, among other things, to the FDA as part of an IND application to the FDA. An IND application is a request for authorization from the FDA to administer an IND product to humans. The central focus of an IND submission is on the general investigational plan and the protocol or protocols for preclinical studies and clinical trials. The IND application also includes results of animal and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vitro </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">studies assessing the toxicology, pharmacokinetics, pharmacology and pharmacodynamic characteristics of the product, chemistry, manufacturing and controls information, and any available human data or literature to support the use of the investigational product. An IND application must become effective before human clinical trials may begin. The IND application automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day period, raises concerns or questions about the proposed clinical trial. In such a case, the IND application may be placed on clinical hold and the IND sponsor and the FDA must resolve any outstanding concerns or questions before the clinical trial can begin. Submission of an IND application therefore may or may not result in FDA authorization to begin a clinical trial. Additionally, the review of information in an IND submission may prompt FDA to, among other things, scrutinize existing INDs and could generate requests for information or clinical holds on other product candidates or programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators, generally physicians not employed by or under the sponsor&#8217;s control, in accordance with cGCPs, which include the requirement that all research subjects provide their informed consent for their participation in any clinical study. Clinical trials are conducted under protocols detailing, among other things, the objectives of the trial, dosing procedures, subject selection and exclusion criteria and the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A separate submission to the existing IND application must be made for each successive clinical protocol conducted during product development and for any subsequent protocol amendments. Furthermore, an independent IRB for each site proposing to conduct the clinical trial must review and approve the plan for any clinical trial and its informed consent form before the clinical trial begins at that site, and must monitor the study until completed to ensure that the risks to individuals participating in the clinical trial are minimized and are reasonable in relation to anticipated benefits.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A sponsor who wishes to conduct a clinical trial outside of the United States may, but need not, obtain FDA authorization to conduct the clinical trial under an IND application. If a foreign clinical trial is not conducted under an IND application, the sponsor may submit data from the clinical trial to the FDA in support of a BLA. The FDA will accept a well-designed and well-conducted foreign clinical trial not conducted under an IND application if the foreign data are applicable to the United States population and medical practice, the trial was performed by clinical investigators of recognized competence, the trial was conducted in accordance with cGCP requirements, and the data may be considered valid without the need for an on-site inspection by the FDA or the FDA is able to validate the data through an onsite inspection if deemed necessary.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For purposes of BLA approval of a product candidate, human clinical trials are typically conducted in three sequential phases that may overlap or be combined:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Phase 1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. For gene therapies in general, the investigational product is initially introduced into patients with the target disease or condition. These studies are designed to test the safety, dosage tolerance, absorption, metabolism and distribution of the investigational product in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Phase 2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The investigational product is administered to a limited patient population to evaluate the preliminary efficacy, optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Phase 3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The investigational product is administered to an expanded patient population to further evaluate dosage, to provide statistically significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the investigational product and to provide an adequate basis for product approval.</span></div></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">When these phases overlap or are combined, the trials may be referred to as Phase 1/2 or Phase 2/3.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">24</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In some cases, the FDA may require, or companies may voluntarily pursue, additional clinical trials after a product is approved to gain more information about the product. These so-called Phase 4 studies may be made a condition to approval of the BLA. Concurrent with clinical trials, companies may complete additional animal studies and develop additional information about the characteristics of the product candidate, and must finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, must develop methods for testing the identity, strength, potency, quality and purity of the final product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During all phases of clinical development, regulatory agencies require extensive monitoring and auditing of all clinical activities, clinical data and clinical study investigators. Written IND safety reports must be promptly submitted to the FDA and the investigators for serious, unexpected and suspected adverse events, any findings from other studies, tests in laboratory animals or in vitro testing that suggest a significant risk for human subjects, or any clinically important increase in the rate of a serious, and unexpected suspected adverse reaction over that listed in the protocol or investigator brochure. The sponsor must submit an IND safety report within 15 calendar days after the sponsor determines that the information qualifies for reporting. The sponsor also must notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction within seven calendar days after the sponsor&#8217;s initial receipt of the information. The FDA or the sponsor may suspend a clinical study at any time on various grounds, including a finding that the research patients or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical study at its institution if the clinical study is not being conducted in accordance with the IRB&#8217;s requirements or if the biological product candidate has been associated with unexpected serious harm to patients. Some studies also include oversight by an independent group of qualified experts organized by the clinical study sponsor, known as a data safety monitoring board, which provides authorization for whether or not a study may move forward at designated checkpoints based on access to certain data from the study and may recommend halting the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy. There are also requirements governing the reporting of ongoing clinical trials and completed clinical trial results to public registries. Sponsors of clinical trials of FDA-regulated products, including biologics, are required to register and disclose certain clinical trial information, which is publicly available at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">www.clinicaltrials.gov</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">BLA submission and review</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development, preclinical studies and clinical trials are submitted to the FDA as part of a BLA requesting approval to market the product for one or more indications. FDA approval of a BLA must be obtained before a biologic may be marketed in the United States. The BLA must include all relevant data available from pertinent preclinical studies and clinical trials, including negative or ambiguous results as well as positive findings, together with detailed information relating to the product&#8217;s chemistry, manufacturing, controls and proposed labeling, among other things. The submission of a BLA requires payment of a substantial application user fee to the FDA, unless a waiver or exemption applies. No user fees are assessed on BLAs for products designated as orphan drugs, unless the product also includes a non-orphan indication. The FDA reviews all submitted BLAs before it accepts them for filing, and may request additional information rather than accepting the BLA for filing. The FDA has sixty days from the applicant&#8217;s submission of a BLA to either issue a refusal to file letter or accept the BLA for filing, indicating that it is sufficiently complete to permit substantive review.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Once a BLA has been accepted for filing, the FDA&#8217;s goal is to review standard applications within ten months after it accepts the application for filing, or, if the application qualifies for priority review, six months after the FDA accepts the application for filing. In both standard and priority reviews, the review process can be significantly extended by FDA requests for additional information or clarification. The FDA reviews a BLA to determine, among other things, whether a product is safe, pure and potent for its intended use, and whether the facility in which it is manufactured, processed, packed or held meets standards designed to ensure and preserve the product&#8217;s identity, safety, strength, quality, potency and purity. The FDA may convene an advisory committee, typically a panel that includes clinicians and other experts, to provide clinical insight on applications for novel products or products which present difficult questions of safety or efficacy. The advisory committee will provide a recommendation as to whether the application should be approved and under what conditions, if any. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations when making decisions on approval. Before approving a BLA, the FDA will typically inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving a BLA, the FDA will typically inspect one or more clinical sites to assure compliance with cGCPs. If the FDA determines that the application, manufacturing process or manufacturing facilities are not acceptable, it will outline the deficiencies in the submission and often will request additional testing or information. Notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">25</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">After the FDA evaluates a BLA and conducts inspections of manufacturing facilities where the investigational product and/or its drug substance will be manufactured, the FDA may issue an approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A Complete Response Letter indicates that the review cycle of the application is complete, and the application will not be approved in its present form. A Complete Response Letter will usually describe all of the deficiencies that the FDA has identified in the BLA, except that where the FDA determines that the data supporting the application are inadequate to support approval, the FDA may issue the Complete Response Letter without first conducting required inspections, testing submitted product lots and/or reviewing proposed labeling. In issuing the Complete Response Letter, the FDA may recommend actions that the applicant might take to place the BLA in condition for approval, including requests for additional information or clarification, which may include the potential requirement for additional preclinical studies or clinical trials or additional manufacturing activities. If a Complete Response Letter is issued, the applicant may either resubmit the BLA, addressing all of the deficiencies identified in the letter, or withdraw the application or request an opportunity for a hearing. The FDA may delay or refuse approval of a BLA if applicable regulatory criteria are not satisfied, require additional testing or information and/or require post-marketing testing and surveillance to monitor the safety or efficacy of a product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If regulatory approval of a product is granted, such approval will be granted for particular indications and may entail limitations on the indicated uses for which such product may be marketed. For example, the FDA may approve the BLA with a Risk Evaluation and Mitigation Strategy, or REMS, to ensure the benefits of the product outweigh its risks. A REMS is a safety strategy to manage a known or potential serious risk associated with a product and to enable patients to have continued access to such medicines by managing their safe use, and could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. The FDA also may condition approval on, among other things, changes to proposed labeling or the development of adequate controls and specifications. Once approved, the FDA may withdraw the product approval if compliance with pre- and post-marketing requirements is not maintained or if problems occur after the product reaches the marketplace. The FDA may require one or more Phase 4 post-market studies and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization, and may limit further marketing of the product based on the results of these post-marketing studies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expedited development and review programs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA offers a number of expedited development and reviews programs for qualifying product candidates. The Fast Track program is intended to expedite or facilitate the process for developing new products that meet certain criteria. Specifically, product candidates are eligible for Fast Track designation if they are intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. Fast Track designation applies to the combination of the product candidate and the specific indication for which it is being studied. The sponsor of a Fast Track designated product candidate has opportunities for frequent interactions with the FDA review team during product development and, once a BLA is submitted, the product candidate may be eligible for priority review. A Fast Track designated product candidate may also be eligible for rolling review, where the FDA may consider for review sections of the BLA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the BLA, the FDA agrees to accept sections of the BLA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the BLA. The sponsor can request the FDA to designate the product candidate for Fast Track status any time before receiving BLA approval, but ideally no later than the pre-BLA meeting.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A product candidate intended to treat a serious or life-threatening disease or condition may also be eligible for Breakthrough Therapy designation to expedite its development and review. A product candidate may receive Breakthrough Therapy designation if preliminary clinical evidence indicates that the product candidate, alone or in combination with one or more other drugs or biologics, may demonstrate substantial improvement over available therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation includes all of the Fast Track program features, as well as more intensive FDA interaction and guidance beginning as early as Phase 1 and an organizational commitment to expedite the development and review of the product candidate, including involvement of senior managers.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">26</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As part of the 21st Century Cures Act, Congress amended the FDCA to facilitate an efficient development program for, and expedite review of regenerative medicine therapies, which include cell therapies, therapeutic tissue engineering products, human cell and tissue products, and combination products using any such therapies or products. Gene therapies, including genetically modified cells that lead to a durable modification of cells or tissues may meet the definition of a &#8220;regenerative medicine therapy.&#8221; A product candidate may be eligible for regenerative medicine therapy, or RMAT, designation if it meets the following criteria: (1) it is a regenerative medicine therapy; (2) it is intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition; and (3) preliminary clinical evidence indicates that it has the potential to address unmet medical needs for such a disease or condition. A sponsor may request that the FDA designate a product candidate as an RMAT concurrently with or at any time after the submission of an IND. A BLA for a product candidate that has received RMAT designation may be eligible for priority review or accelerated approval through (1) surrogate or intermediate endpoints reasonably likely to predict long-term clinical benefit or (2) reliance upon data obtained from a meaningful number of sites. Benefits of such designation also include early interactions with FDA to discuss any potential surrogate or intermediate endpoint to be used to support accelerated approval. A product candidate with RMAT designation that is granted accelerated approval and is subject to post-approval requirements may fulfill such requirements through the submission of clinical evidence, clinical studies, patient registries, or other sources of real world evidence, such as electronic health records; the collection of larger confirmatory data sets; or post-approval monitoring of all patients treated with such therapy prior to its approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any marketing application for a biologic submitted to the FDA for approval, including a product with a Fast Track designation and/or Breakthrough Therapy designation, may be eligible for other types of FDA programs intended to expedite the FDA review and approval process, such as priority review. A product is eligible for priority review if it is designed to treat a serious or life threatening disease or condition and, if approved, would provide a significant improvement in safety and effectiveness compared to available therapies. For original BLAs, priority review designation means the FDA&#8217;s goal is to take action on the marketing application within six months of the 60-day filing date.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, a product candidate may be eligible for accelerated approval if it is designed to treat a serious or life-threatening disease or condition and demonstrates an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, or IMM, that is reasonably likely to predict an effect on IMM or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of accelerated approval, the FDA will generally require the sponsor to perform adequate and well-controlled post-marketing clinical studies with due diligence to verify and describe the anticipated effect on IMM or other clinical benefit. The FDA may withdraw approval of a product or indication approved under accelerated approval if, for example, the confirmatory trial fails to verify the predicted clinical benefit of the product. In addition, for products being considered for accelerated approval, the FDA generally requires, unless otherwise informed by the agency, pre-approval of all advertising and promotional materials intended for dissemination or publication, which could adversely impact the timing of the commercial launch of the product. The Food and Drug Omnibus Reform Act also made several changes to the FDA&#8217;s authorities and its regulatory framework, including, among other changes, reforms to the accelerated approval pathway, such as requiring the FDA to specify conditions for post-approval study requirements and setting forth procedures for the FDA to withdraw a product on an expedited basis for non-compliance with post-approval requirements.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fast Track designation, Breakthrough Therapy designation, RMAT designation, and priority review do not change the standards for approval but may expedite the development or approval process. Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Orphan Drug designation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Orphan Drug Act, the FDA may grant Orphan Drug designation to a product candidate intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States, or 200,000 or more individuals in the United States for which there is no reasonable expectation that the cost of developing and making available in the United States a drug or biologic for this type of disease or condition will be recovered from sales in the United States for that product candidate. Orphan Drug designation must be requested before submitting a BLA. After the FDA grants Orphan Drug designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. The Orphan Drug designation does not convey any advantage in, or shorten the duration of, the regulatory review or approval process.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">27</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If a product that has Orphan Drug designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan drug exclusive approval (or exclusivity), which means that the FDA may not approve any other applications, including a full BLA, to market the same product for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity by means of greater effectiveness, greater safety or providing a major contribution to patient care or if the holder of the orphan drug exclusivity cannot assure the availability of sufficient quantities of the orphan drug to meet the needs of patients with the disease or condition for which the product was designated. Orphan drug exclusivity does not prevent the FDA from approving a different drug or biologic for the same disease or condition, or the same drug or biologic for a different disease or condition. Among the other benefits of Orphan Drug designation are tax credits for certain research and a waiver of the BLA application fee.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received Orphan Drug designation. In addition, exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition. In view of the court decision in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Catalyst Pharms., Inc. v. Becerra</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, 14 F.4th 1299 (11th Cir. 2021), in January 2023, the FDA published a notice in the Federal Register to clarify that while the agency complies with the court&#8217;s order in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Catalyst</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, FDA intends to continue to apply its longstanding interpretation of the regulations to matters outside of the scope of the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Catalyst </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">order &#8211; that is, the agency will continue tying the scope of orphan-drug exclusivity to the uses or indications for which a drug is approved, which permits other sponsors to obtain approval of a drug for new uses or indications within the same orphan designated disease or condition that have not yet been approved. It is unclear how future litigation, legislation, agency decisions, and administrative actions will impact the scope of the orphan drug exclusivity.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In June 2024, the U.S. Supreme Court overruled the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Chevron </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">doctrine, which gives deference to regulatory agencies&#8217; statutory interpretations in litigation against federal government agencies, such as the FDA, where the law is ambiguous. This landmark Supreme Court decision may invite various stakeholders to bring lawsuits against the FDA to challenge longstanding decisions and policies, such as market exclusivities, which could lead to uncertainties in the industry. Further, changes in the leadership of the FDA and other federal agencies under the Trump administration may lead to new policies, changes in the regulations, or disruptions to the operations of federal agencies, any of which may impact our clinical development plans.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Rare Pediatric Disease designation and priority review vouchers</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the FDCA, as amended, the FDA incentivizes the development of product candidates that meet the definition of a &#8220;rare pediatric disease,&#8221; defined to mean a serious or life-threatening disease in which the serious or life-threatening manifestations primarily affect individuals aged from birth to 18 years and the disease affects fewer than 200,000 individuals in the United States or affects 200,000 or more in the United States and for which there is no reasonable expectation that the cost of developing and making in the United States a drug for such disease or condition will be received from sales in the United States of such drug. The sponsor of a product candidate for a rare pediatric disease may be eligible for a voucher that can be used to obtain a priority review for a subsequent human drug or biologic application after the date of approval of the rare pediatric disease drug product. A sponsor may request Rare Pediatric Disease designation from the FDA prior to the submission of its BLA. A Rare Pediatric Disease designation does not guarantee that a sponsor will receive a priority review voucher, or PRV, upon approval of its BLA. Moreover, a sponsor who chooses not to submit a Rare Pediatric Disease designation request may nonetheless receive a PRV upon approval of their marketing application if they request such a voucher in their original marketing application and meet all of the eligibility criteria. If a PRV is received, it may be sold or transferred an unlimited number of times. Congress has not extended the PRV program, which means the FDA began sunsetting the program as of December 20, 2024. Unless Congress extends the rare pediatric disease priority review program, companies with existing designations have until September 30, 2026, to obtain FDA approval in order to earn a voucher.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">28</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Pediatric information and pediatric exclusivity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Pediatric Research Equity Act, or PREA, certain BLAs and certain supplements to a BLA must contain data to assess the safety and efficacy of the product for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may grant deferrals for the submission of pediatric data or full or partial waivers. The Food and Drug Administration Safety and Innovation Act, or FDASIA, amended the FDCA to require that a sponsor who is planning to submit a marketing application for a product that includes a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration submit an initial Pediatric Study Plan, or PSP, within 60 days of an end-of-Phase 2 meeting or, if there is no such meeting, as early as practicable before the initiation of the Phase 3 or Phase 2/3 study. The initial PSP must include an outline of the pediatric study or studies that the sponsor plans to conduct, including study objectives and design, age groups, relevant endpoints and statistical approach, or a justification for not including such detailed information, and any request for a deferral of pediatric assessments or a full or partial waiver of the requirement to provide data from pediatric studies along with supporting information. The FDA and the sponsor must reach an agreement on the PSP. A sponsor can submit amendments to an agreed-upon initial PSP at any time if changes to the pediatric plan need to be considered based on data collected from preclinical studies, early phase clinical trials and/or other clinical development programs. A biological product can also obtain pediatric market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to existing exclusivity periods. This six-month exclusivity, which runs from the end of other exclusivity protection, may be granted based on the voluntary completion of a pediatric study in accordance with an FDA-issued &#8220;Written Request&#8221; for such a study.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Post-approval requirements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any products manufactured or distributed by us pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to record-keeping, reporting of adverse experiences, periodic reporting, product sampling and distribution, and advertising and promotion of the product. As part of the manufacturing process, the manufacturer is required to perform certain tests on each lot of the product before it is released for distribution. After a BLA is approved for a biological product, the product also may be subject to official lot release. If the product is subject to official release by the FDA, the manufacturer submits samples of each lot of product to the FDA together with a release protocol showing a summary of the history of manufacture of the lot and the results of all of the manufacturer&#8217;s tests performed on the lot. The FDA also may perform certain confirmatory tests on lots of some products before releasing the lots for distribution by the manufacturer. In addition, the FDA conducts laboratory research related to the regulatory standards on the safety, purity, potency and effectiveness of biologics. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing user fee requirements, under which the FDA assesses an annual program fee for each product identified in an approved BLA. Biologic manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMPs, which impose certain procedural and documentation requirements upon us and our third-party manufacturers. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMPs and impose reporting requirements upon us and any third-party manufacturers that we may decide to use. Manufacturers and other parties involved in the drug supply chain for prescription drug products must also comply with product tracking and tracing requirements and for notifying the FDA of counterfeit, diverted, stolen and intentionally adulterated products or products that are otherwise unfit for distribution in the United States. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMPs and other aspects of regulatory compliance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">restrictions on the marketing or manufacturing of a product, complete withdrawal of the product from the market or product recalls;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">fines, warning or untitled letters or holds on post-approval clinical studies;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of existing product approvals;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">product seizure or detention, or refusal of the FDA to permit the import or export of products;</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">29</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">consent decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">mandated modification of promotional materials and labeling and the issuance of corrective information;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the issuance of safety alerts, Dear Healthcare Provider letters, press releases and other communications containing warnings or other safety information about the product; or</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">injunctions or the imposition of civil or criminal penalties.</span></div></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA closely regulates the marketing, labeling, advertising and promotion of biologics. A company can make only those claims relating to safety and efficacy, purity and potency that are approved by the FDA and in accordance with the provisions of the approved label. However, companies may share truthful and not misleading information that is otherwise consistent with a product&#8217;s FDA-approved labeling. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties. Physicians may prescribe legally available products for uses that are not described in the product&#8217;s labeling and that differ from those tested by us and approved by the FDA. Such off-label uses are common across medical specialties. Physicians may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer&#8217;s communications on the subject of off-label use of their products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Biosimilars and reference product exclusivity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the ACA, includes a subtitle called the Biologics Price Competition and Innovation Act, or BPCIA, which created an abbreviated approval pathway for biologics that are biosimilar to or interchangeable with an FDA-approved reference biological product. To date, a number of biosimilars have been licensed under the BPCIA, and numerous biosimilars have been approved in Europe. The FDA has issued several guidance documents outlining an approach to review and approval of biosimilars.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Biosimilarity, which requires that there be no clinically meaningful differences between the biological product and the reference product in terms of safety, purity and potency, can be shown through analytical studies, animal studies and a clinical study or studies. Interchangeability requires that a product is biosimilar to the reference product and the product must demonstrate that it can be expected to produce the same clinical results as the reference product in any given patient and, for products that are administered multiple times to an individual, the biologic and the reference biologic may be alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic. Complexities associated with the larger, and often more complex, structures of biologics, as well as the processes by which such products are manufactured, pose significant hurdles to the implementation of the abbreviated approval pathway that are still being worked out by the FDA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing that applicant&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of its product. The BPCIA also created certain exclusivity periods for biosimilars approved as interchangeable products. At this juncture, it is unclear whether products deemed &#8220;interchangeable&#8221; by the FDA will, in fact, be readily substituted by pharmacies, which are governed by state pharmacy law.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The BPCIA is complex and continues to be interpreted and implemented by the FDA. In addition, government proposals have sought to reduce the 12-year reference product exclusivity period. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. As a result, the ultimate impact and implementation of the BPCIA are subject to significant uncertainty.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">30</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Regulation of companion diagnostics</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If an in vitro diagnostic, which is regulated by the FDA as a medical device, is essential to the safe and effective use of a therapeutic and is not available on the market, then the FDA generally will require approval or clearance of that diagnostic, known as a companion diagnostic, at the same time that the FDA approves the therapeutic product. In August 2014, the FDA issued final guidance clarifying the requirements that will apply to approval of therapeutic products and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> companion diagnostics. According to the guidance, an unapproved or uncleared companion diagnostic device used to make treatment decisions in clinical trials of a drug generally will be considered an investigational medical device unless it is employed for an intended use for which the device is already approved or cleared. If used to make critical treatment decisions, such as patient selection, the diagnostic device generally will be considered a significant risk device under the FDA&#8217;s Investigational Device Exemption, or IDE, regulations. The sponsor of the diagnostic device will be required to comply with the IDE regulations for clinical studies involving the investigational diagnostic device. According to the guidance, if a diagnostic device and a drug are to be studied together to support their respective approvals, both products can be studied in the same clinical trial, if the trial meets both the requirements of the IDE regulations and the IND regulations. The guidance provides that depending on the details of the clinical trial protocol, the investigational product(s), and subjects involved, a sponsor may seek to submit an IDE alone (e.g., if the drug has already been approved by FDA and is used consistent with its approved labeling), or both an IND and an IDE.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuing FDA approval/clearance of an in vitro companion diagnostic would require either a pre-market notification, also called 510(k) clearance, or a pre-market approval, or PMA, or a de novo classification for that diagnostic. The review of companion diagnostics involves coordination of review with the FDA&#8217;s Center for Devices and Radiological Health. Once cleared or approved, the companion diagnostic must adhere to post-marketing requirements including the requirements of FDA&#8217;s quality system regulation, medical device reporting, recalls and corrections along with product marketing requirements and limitations. Companion diagnostic manufacturers are subject to unannounced FDA inspections at any time during which the FDA will conduct an audit of the product(s) and the company&#8217;s facilities for compliance with its authorities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">510(k) clearance process</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To obtain 510(k) clearance, a pre-market notification is submitted to the FDA demonstrating that the proposed device is substantially equivalent to a previously cleared 510(k) device or a device that was in commercial distribution before May 28, 1976 for which the FDA has not yet required the submission of a PMA application. The FDA&#8217;s 510(k) clearance process may take three to 12 months from the date the application is submitted and filed with the FDA, but may take longer if FDA requests additional information, among other reasons. In some cases, the FDA may require clinical data to support substantial equivalence. In reviewing a pre-market notification submission, the FDA may request additional information, which may significantly prolong the review process. Notwithstanding compliance with all these requirements, clearance is never assured. After a device receives 510(k) clearance, any subsequent modification of the device that could significantly affect its safety or effectiveness, or that would constitute a major change in its intended use, will require a new 510(k) clearance or require a PMA. In addition, the FDA may make substantial changes to industry requirements, including which devices are eligible for 510(k) clearance, which may significantly affect the process.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">De novo classification process</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If a new medical device does not qualify for the 510(k) pre-market notification process because no predicate device to which it is substantially equivalent can be identified, the device is automatically classified into Class III. The Food and Drug Administration Modernization Act of 1997 established a different route to market for low to moderate risk medical devices that are automatically placed into Class III due to the absence of a predicate device, called the &#8220;Request for Evaluation of Automatic Class III Designation,&#8221; or the de novo classification process. This process allows a manufacturer whose novel device is automatically classified into Class III to request down-classification of its medical device into Class I or Class II on the basis that the device presents low or moderate risk, rather than requiring the submission and approval of a PMA. If the manufacturer seeks reclassification into Class II, the manufacturer must include a draft proposal for special controls that are necessary to provide a reasonable assurance of the safety and effectiveness of the medical device. The FDA may reject the reclassification petition if it identifies a legally marketed predicate device that would be appropriate for a 510(k) or determines that the device is not low to moderate risk and requires PMA or that general controls would be inadequate to control the risks and special controls cannot be developed. Obtaining FDA marketing authorization, de novo down-classification, or approval for medical devices is expensive and uncertain, and may take several years, and generally requires significant scientific and clinical data.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">31</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">PMA process</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The PMA process, including the gathering of clinical and nonclinical data and the submission to and review by the FDA, can take several years or longer. The applicant must prepare and provide the FDA with reasonable assurance of the device&#8217;s safety and effectiveness, including information about the device and its components regarding, among other things, device design, manufacturing, and labeling. PMA applications are subject to an application fee. In addition, PMAs for medical devices must generally include the results from extensive preclinical and adequate and well-controlled clinical trials to establish the safety and effectiveness of the device for each indication for which FDA approval is sought. In particular, for a diagnostic, the applicant must demonstrate that the diagnostic produces reproducible results. As part of the PMA review, the FDA will typically inspect the manufacturer&#8217;s facilities for compliance with the Quality System Regulation, which imposes extensive testing, control, documentation, and other quality assurance and GMP requirements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Foreign regulation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In order to market any product outside of the United States, we would need to comply with numerous and varying regulatory requirements of other countries and jurisdictions regarding quality, safety, and efficacy and governing, among other things, clinical trials, marketing authorization, commercial sales and distribution of our products. Whether or not we obtain FDA approval for a product, we would need to obtain the necessary approvals by the comparable foreign regulatory authorities before we can commence clinical trials or marketing of the product in foreign countries and jurisdictions. Although many of the issues discussed above with respect to the United States apply similarly in the context of the European Union, the approval process varies between countries and jurisdictions and can involve additional product testing and additional administrative review periods. The time required to obtain approval in other countries and jurisdictions might differ from and be longer than that required to obtain FDA approval. Regulatory approval in one country or jurisdiction does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country or jurisdiction may negatively impact the regulatory process in others.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other healthcare laws and compliance requirements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pharmaceutical companies are subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which they conduct their business, particularly once they have a commercialized product that is reimbursable by third-party payor programs. Such laws include, without limitation: the U.S. federal Anti-Kickback Statute, the civil False Claims Act, the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, and similar foreign, federal and state fraud and abuse, transparency and privacy laws.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The U.S. federal Anti-Kickback Statute prohibits, among other things, persons and entities from knowingly and willfully soliciting, receiving, offering or paying remuneration, to induce, or in return for, either the referral of an individual, or the purchase or recommendation of an item or service for which payment may be made under any federal healthcare program. The term remuneration has been interpreted broadly to include anything of value, including stock options. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution, but they are drawn narrowly, and practices that involve remuneration, such as consulting agreements, that may be alleged to be intended to induce prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an exception or safe harbor. Our practices may not in all cases meet all of the criteria for protection under a statutory exception or regulatory safe harbor. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. Violations are subject to civil and criminal fines and penalties for each violation, plus up to three times the remuneration involved, imprisonment, and exclusion from government healthcare programs. In addition, a claim including items or services resulting from a violation of the U.S. federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Civil and criminal false claims laws, and civil monetary penalty laws, including the civil False Claims Act, which can be enforced through civil whistleblower or qui tam actions, prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment to the federal government, including federal healthcare programs, that are false or fraudulent. For example, the civil False Claims Act prohibits any person or entity from knowingly presenting, or causing to be presented, a false claim for payment to the federal government or knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government.</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">32</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">HIPAA created additional federal civil and criminal liability for, among other things, knowingly and willfully executing a scheme to defraud any healthcare benefit program, or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private) and knowingly and willfully falsifying, concealing, or covering up by any trick or device a material fact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters. Similar to the U.S. federal Anti-Kickback Statute, a person or entity can be found guilty of violating HIPAA without actual knowledge of the statute or specific intent to violate it.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and their respective implementing regulations, impose certain requirements on HIPAA covered entities, which include certain healthcare providers, healthcare clearing houses and health plans, and individuals and entities that provide services on their behalf that involve individually identifiable health information, known as business associates, relating to the privacy, security and transmission of individually identifiable health information, as well as their covered subcontractors. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The U.S. federal Physician Payments Sunshine Act requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to annually report to the Centers for Medicare and Medicaid Services, or CMS, information related to payments and other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain other licensed healthcare professionals (such as physician assistants and nurse practitioners), and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members.</span></div></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may also be subject to additional similar U.S. state and foreign law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers, or that apply regardless of payor, state laws which require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, state and local laws which require pharmaceutical companies to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures, state laws which require the reporting of information related to product pricing, state and local laws requiring the registration of pharmaceutical sales representatives, and state and foreign laws governing the privacy and security of health information which, in some cases, differ from each other in significant ways, and may not have the same effect, thus complicating compliance efforts. If our operations are found to be in violation of any of such laws or any other governmental regulations that apply, we may be subject to penalties, including, without limitation, significant civil, criminal and administrative penalties, damages, fines, exclusion from government-funded healthcare programs, such as Medicare and Medicaid or similar programs in other countries or jurisdictions, integrity oversight and reporting obligations to resolve allegations of non-compliance, disgorgement, imprisonment, contractual damages, reputational harm, diminished profits and the curtailment or restructuring of our operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Coverage and reimbursement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Significant uncertainty exists as to the coverage and reimbursement status of any pharmaceutical or biological product for which we obtain regulatory approval in the future. Sales of any product, if approved, depend, in part, on the extent to which such product will be covered by third-party payors, such as federal, state and foreign government healthcare programs, commercial insurance and managed healthcare organizations, and the level of reimbursement, if any, for such product by third-party payors. Decisions regarding whether to cover any of our product candidates, if approved, the extent of coverage and amount of reimbursement to be provided are made on a plan-by-plan basis. Further, no uniform policy for coverage and reimbursement exists in the United States, and coverage and reimbursement can differ significantly from payor to payor.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement rates, but also have their own methods and approval process apart from Medicare determinations. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our product candidates to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, it is possible that one or more of our product candidates may not be considered medically necessary or cost effective. A decision by a third-party payor not to cover any product candidates we may develop could reduce physician utilization of such product candidates once approved and have a material adverse effect on our sales, results of operations and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">33</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself or the treatment or procedure in which the product is used may not be available, which may impact physician utilization.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the U.S. government, state legislatures and foreign governments have continued implementing cost-containment programs, including price controls, restrictions on coverage and reimbursement and requirements for substitution of generic products. Third-party payors are increasingly challenging the prices charged for medical products and services, examining the medical necessity and reviewing the cost-effectiveness of pharmaceutical or biologics, medical devices and medical services, in addition to questioning safety and efficacy. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit sales of any product that receives approval. Decreases in third-party reimbursement for any product or a decision by a third party not to cover a product could reduce physician usage and patient demand for the product. In addition, companion diagnostic tests require coverage and reimbursement separate and apart from the coverage and reimbursement for their companion pharmaceutical or biological products. Similar challenges to obtaining coverage and reimbursement, applicable to pharmaceutical or biological products, will apply to companion diagnostics.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Outside the United States, ensuring adequate coverage and payment for any biological candidates we may develop will face challenges. Pricing of prescription pharmaceuticals is subject to governmental control in many countries. Pricing negotiations with governmental authorities can extend well beyond the receipt of regulatory marketing approval for a product and may require us to conduct a clinical trial that compares the cost effectiveness of any product candidates we may develop to other available therapies. The conduct of such a clinical trial could be expensive and result in delays in our commercialization efforts. In the European Union, pricing and reimbursement schemes vary widely from country to country. Some countries provide that products may be marketed only after a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the cost-effectiveness of a particular product candidate to currently available therapies (so called health technology assessments) in order to obtain reimbursement or pricing approval. For example, the European Union provides options for its member states to restrict the range of products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. European Union member states may approve a specific price for a product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the product on the market. Other member states allow companies to fix their own prices for products but monitor and control prescription volumes and issue guidance to physicians to limit prescriptions. Recently, many countries in the European Union have increased the amount of discounts required on pharmaceuticals and these efforts could continue as countries attempt to manage healthcare expenditures, especially in light of the severe fiscal and debt crises experienced by many countries in the European Union. The downward pressure on healthcare costs in general, particularly prescription products, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various European Union member states, and parallel trade (arbitrage between low-priced and high-priced member states), can further reduce prices. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products, if approved in those countries.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Healthcare reform</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The United States and some foreign jurisdictions are considering or have enacted a number of reform proposals to change the healthcare system. There is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by federal and state legislative initiatives, including those designed to limit the pricing, coverage and reimbursement of pharmaceutical and biopharmaceutical products, especially under government-funded healthcare programs, and increased governmental control of drug pricing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The ACA, which was enacted in 2010, substantially changed the way healthcare is financed by both governmental and private insurers in the United States, and significantly affected the pharmaceutical industry. In addition, other legislative and regulatory changes have been proposed and adopted in the United States since the ACA was enacted:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Budget Control Act of 2011 and subsequent legislation, among other things, created measures for spending reductions by Congress that include aggregate reductions of Medicare payments to providers of 2% per fiscal year, which remain in effect through 2032. Due to the Statutory Pay-As-You-Go Act of 2010, estimated budget deficit increases resulting from the American Rescue Plan Act of 2021, and subsequent legislation, Medicare payments to providers will be further reduced starting in 2025 absent further legislation. The U.S. American Taxpayer Relief Act of 2012 further reduced Medicare payments to several types of providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">34</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 13, 2017, CMS published a final rule that gives states greater flexibility in setting benchmarks for insurers in the individual and small group marketplaces, which may have the effect of relaxing the essential health benefits required under the ACA for plans sold through such marketplaces.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On May 23, 2019, CMS published a final rule to allow Medicare Advantage Plans the option of using step therapy for Part B drugs beginning January 1, 2020.</span></div></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several U.S. presidential executive orders, Congressional inquiries and proposed and enacted federal legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, and review the relationship between pricing and manufacturer patient programs. The Inflation Reduction Act of 2022, or the IRA, includes several provisions that may impact our business to varying degrees, including provisions that reduce the out-of-pocket spending cap for Medicare Part D beneficiaries from $7,050 to $2,000 starting in 2025, thereby effectively eliminating the coverage gap; impose new manufacturer financial liability on certain drugs under Medicare Part D, allow the U.S. government to negotiate Medicare Part B and Part D price caps for certain high-cost drugs and biologics without generic or biosimilar competition; require companies to pay rebates to Medicare for certain drug prices that increase faster than inflation; and delay until January 1, 2032 the implementation of the U.S. Department of Health and Human Services, or the HHS, rebate rule that would have limited the fees that pharmacy benefit managers can charge. The IRA permits HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years. Only high-expenditure single-source drugs that have been approved for at least 7 years (11 years for single-source biologics) can qualify for negotiation, with the negotiated price taking effect two years after the selection year. For 2026, the first year in which negotiated prices become effective, CMS selected 10 high-cost Medicare Part D drugs in 2023, negotiations began in 2024, and the negotiated maximum fair price for each drug has been announced. CMS has selected 15 additional Medicare Part D drugs for negotiated maximum fair pricing in 2027. For 2028, up to an additional 15 drugs, which may be covered under either Medicare Part B or Part D, will be selected, and for 2029 and subsequent years, up to 20 additional Part B or Part D drugs will be selected. HHS has and will continue to issue and update guidance as these programs are implemented. Further, under the IRA, orphan drugs are exempted from the Medicare drug price negotiation program, but only if they have one rare disease designation and for which the only approved indication is for that disease or condition. If a product receives multiple rare disease designations or has multiple approved indications, it may not qualify for the orphan drug exemption. Various industry stakeholders, including certain pharmaceutical companies and the Pharmaceutical Research and Manufacturers of America, have initiated lawsuits against the federal government asserting that the price negotiation provisions of IRA are unconstitutional. It is currently unclear how these judicial challenges as well as other legislative, executive, and administrative actions, including how the IRA will be implemented, will impact the pharmaceutical industry. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our product candidates if approved.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Employees and human capital resources</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, we had 72 full-time employees. Of our 72 full-time employees, 50 are engaged in research and development activities. None of our employees are represented by labor unions or covered by collective bargaining agreements. We consider our relationship with our employees to be good.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our employees. We believe our success depends on our ability to attract, retain, develop and motivate highly skilled personnel. In particular, we depend upon the personal efforts and abilities of the principal members of our senior management to partner effectively as a team, and to provide strategic direction, develop our business, manage our operations and maintain a cohesive and stable work environment. We also rely on qualified managers and skilled employees, such as scientists, medical professionals, engineers and laboratory technicians, with technical expertise in operations, scientific knowledge, engineering skills and quality management experience in order to operate our business successfully.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our compensation program is designed to retain, motivate and, as needed, attract highly qualified employees. Accordingly, we use a mix of competitive base salary, performance-based equity compensation awards and other employee benefits.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">35</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Corporate Information</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In February 2017, we were formed as a Delaware limited liability company under the name LEXEO Therapeutics, LLC. In November 2020, we converted into a Delaware corporation and were renamed Lexeo Therapeutics, Inc. Our principal executive offices are located at 345 Park Avenue South, Floor 6, New York, New York 10010, and our telephone number is (212) 547-9879.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Available Information</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our website address is </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">www.lexeotx.com</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The information contained on, or accessible through, our website is not incorporated by reference into this Annual Report. Our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and amendments to reports filed pursuant to Sections 13(a) and 15(d) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, are filed with the SEC. Such reports and other information filed by us with the SEC are available free of charge on our website at ir.lexeotx.com when such reports are available on the SEC&#8217;s website. The SEC maintains an internet site that contains reports, proxy and information statements and other information regarding issuers that file electronically with the SEC at www.sec.gov. The information contained on the websites referenced in this Annual Report is not incorporated by reference into this filing. Further, our references to website URLs are intended to be inactive textual references only.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Channels of Distribution</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We announce material information to the public through filings with the SEC, the investor relations page on our website, press releases, public conference calls, our LinkedIn account and webcasts in order to achieve broad, non-exclusionary distribution of information to the public and for complying with our disclosure obligations under Regulation FD. We encourage investors, the media, and others to follow the channels listed above and to review the information disclosed through such channels. Any updates to the list of disclosure channels through which we will announce information will be posted on the investor relations page on our website.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">36</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1a_risk_factors"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1A. Ri</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sk Factors</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Investing in our common stock involves a high degree of risk. You should consider carefully the risks and uncertainties described below, together with all of the other information in this Annual Report, including the section titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and our financial statements and related notes included elsewhere in this Annual Report, before deciding whether to invest in our common stock. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties that we are unaware of, or that we currently believe are not material, may also become important factors that affect us. If any of the following risks are realized, our business, financial condition, results of operations and prospects could be materially and adversely affected. In that event, the price of our common stock could decline, and you could lose part or all of your investment. We cannot provide assurance that any of the events discussed below will not occur.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risk Factors Summary</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investing in our common stock involves a high degree of risk because our business is subject to numerous risks and uncertainties, as fully described below. The principal factors and uncertainties that make investing in our common stock risky include, among others:</span></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we have incurred significant losses since our inception, and we expect to incur significant net losses for the foreseeable future and may not be able to achieve or sustain revenue or profitability in the future;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we have a limited operating history, have not completed any clinical trials, and have no products approved for commercial sale;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">if we are unable to raise capital when needed, we could be forced to curtail our planned operations and the pursuit of our growth strategy;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our business is dependent on our ability to advance our current and future product candidates through preclinical studies and clinical trials, obtain marketing approval and ultimately commercialize them. If we are unable to or experience significant delays in doing so, our business will be materially harmed;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we are developing novel gene therapy product candidates, which makes it difficult to predict the time, cost and potential success of product candidate development;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">because gene therapy is novel and the regulatory landscape that governs any product candidates we may develop is rigorous, complex, uncertain and subject to change, we cannot predict with certainty the geographic areas in which we could obtain regulatory approval or the time and cost of obtaining regulatory approval, if we receive it at all, for any product candidates we may develop; </span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">preclinical studies and clinical trials are expensive, time-consuming, difficult to design and implement and involve an uncertain outcome. Further, we may encounter substantial delays in completing the development of our product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the regulatory approval processes of the FDA, EMA and comparable foreign authorities are lengthy, time-consuming and inherently unpredictable. If we are not able to obtain required regulatory approval for our product candidates, our business will be substantially harmed;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">success in preclinical studies or earlier clinical trials may not be indicative of results in future clinical trials;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">interim &#8220;top-line&#8221; and preliminary results from our clinical trials that we announce, publish or present from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our preclinical studies and clinical trials may fail to demonstrate the safety and efficacy of our product candidates, or serious adverse or unacceptable side effects may be identified during the development of our product candidates, which could prevent or delay regulatory approval and commercialization, increase our costs or necessitate the abandonment or limitation of the development of some of our product candidates. We may also identify safety and efficacy concerns after the approval of a product candidate which can result in negative consequences to our business and results of operations; </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">37</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">some of the diseases we initially seek to treat have low prevalence and it may be difficult to identify and enroll patients with these diseases. If we experience delays or difficulties in the enrollment and/or maintenance of patients in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented; </span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may seek Orphan Drug designation or Rare Pediatric Disease designation for some of our product candidates and we may be unsuccessful, or may be unable to maintain the benefits associated with Orphan Drug designation, including the potential for market exclusivity, for product candidates for which we obtain Orphan Drug designation;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fast Track, Breakthrough Therapy, or Regenerative Medicine Advanced Therapy designation that we may receive from the FDA may not actually lead to a faster development or regulatory review or approval process, and does not assure FDA approval of our product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we have received Rare Pediatric Disease designation from the FDA for LX2006 for the treatment of FA and we may seek such designation for future product candidates if Congress extends the rare pediatric disease priority review program. However, a marketing application for these product candidates, if approved, may not meet the eligibility criteria for a rare pediatric disease priority review voucher;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we and our contract manufacturers are subject to significant regulation with respect to manufacturing our products. The third-party manufacturing facilities on which we rely, and any manufacturing facility that we may have in the future, may have limited capacity or fail to meet the applicable stringent regulatory requirements; </span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">gene therapies are novel, complex and difficult to manufacture. We could experience manufacturing problems that result in delays in the development or commercialization of our product candidates or otherwise harm our business;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we depend on third-party suppliers for materials used in the manufacture of our product candidates, and the loss of these third-party suppliers or their inability to supply us with adequate materials could harm our business;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">even if any of our product candidates receive marketing approval, they may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success; </span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we rely on our collaborations with several leading academic institutions to conduct research and development for many of our pipeline programs, including conducting preclinical and IND-enabling studies for portions of our near-term future pipeline. Failure or delay of our academic partners to fulfill all or part of their respective obligations to us under our agreements, a breakdown in collaboration between the parties or a complete or partial loss of either of these relationships could materially harm our business;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we intend to continue to rely on third parties to conduct a significant portion of our existing clinical trials and potential future clinical trials for product candidates, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials; </span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">if we are unable to obtain or protect intellectual property rights related to any of our product candidates, we may not be able to compete effectively in our market; </span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in the FDA and other government agencies, regulatory actions and other actions under the new Trump administration could hinder their ability to hire and retain key leadership and other personnel, or otherwise prevent new products and services from being developed or commercialized in a timely manner, which could negatively impact our business;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we are currently subject to a lawsuit claiming, among other things, that we misappropriated the confidential information and trade secrets of Rocket, and which seeks unspecified damages and asks the court to enjoin us from competing and working in the market for gene therapy treatments targeting cardiac diseases. In the future, we may be subject to additional claims that we and our employees, consultants or independent contractors have wrongfully used or disclosed confidential information or trade secrets of third parties.</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">38</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks related to our financial position and capital needs</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have incurred significant losses since our inception. We expect to incur losses over the next several years and may never achieve or maintain profitability.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since our inception, we have incurred significant net losses, and we expect to continue to incur significant expenses and operating losses for the foreseeable future. For the fiscal years ended December 31, 2024 and 2023, we incurred net losses of $98.3 million and $66.4 million, respectively, and we had an accumulated deficit of $280.2 million as of December 31, 2024. We have primarily financed our operations with net proceeds raised in our initial public offering, or IPO, and the subsequent partial exercise of the underwriters&#8217; 30-day option to purchase additional shares of common stock, as well as net proceeds from the sale of our common stock in a private placement, or the Private Placement, sales of our convertible equity securities and the convertible SAFE Note. We have no products approved for commercialization and have never generated any revenue from product sales.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are still in the early clinical stages of development of our lead product candidates. We expect to continue to incur significant expenses and operating losses over the next several years. Our operating expenses and net losses may fluctuate significantly from quarter to quarter and year to year. We anticipate that our expenses will increase substantially as we:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">continue to advance the preclinical and clinical development of our product candidates and discovery programs;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">initiate and complete additional clinical trials of our current and future product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">seek regulatory approval for any product candidates that successfully complete clinical trials;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">continue to develop our gene therapy product candidate pipeline; </span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">scale up our clinical and regulatory capabilities; </span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">work with our third party manufacturing partners to produce material in accordance with cGMP for clinical trials or potential commercial sales; </span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establish, either alone or with a third party, a commercialization infrastructure and scale up manufacturing and distribution capabilities to commercialize any product candidates for which we may obtain regulatory approval; </span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adapt our regulatory compliance efforts to incorporate requirements applicable to marketed products; </span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">maintain, expand and protect our intellectual property portfolio and patent claims; </span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">hire additional clinical, quality control, regulatory, manufacturing, scientific and administrative personnel; </span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">add operational, financial and management information systems and personnel, including personnel to support our product development and planned future commercialization efforts; and</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">incur additional legal, accounting and other expenses in operating as a public company.</span></div></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To date, we have not generated any revenue from the commercialization of our product candidates. To become and remain profitable, we must succeed in developing and eventually commercializing product candidates that generate significant revenue. This will require us to be successful in a range of challenging activities, including completing preclinical testing and clinical trials of our product candidates, obtaining regulatory approval, and manufacturing, marketing and selling any product candidates for which we may obtain regulatory approval, as well as discovering and developing additional product candidates. We are only in the preliminary stages of most of these activities and all of our product candidates are in early clinical trials or preclinical development. We may never succeed in these activities and, even if we do, may never generate any revenue or revenue that is significant enough to achieve profitability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if we achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would depress the value of our company and could impair our ability to raise capital, expand our business, maintain our development efforts, obtain product approvals, diversify our offerings or continue our operations. A decline in the value of our company could also cause you to lose all or part of your investment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">39</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have a limited operating history and no history of commercializing products, which may make it difficult for an investor to evaluate the success of our business to date and to assess our future viability.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a clinical stage genetic medicine company with a limited operating history. We commenced substantive business operations in 2020, and our operations to date have been largely focused on organizing and staffing our company, business planning, raising capital, entering into collaboration and license agreements for conducting preclinical and clinical research and development activities for our product candidates and gene therapy pipeline, and conducting clinical trials for our product candidates through CROs and other third parties. To date, we have not yet demonstrated our ability to successfully complete pivotal clinical trials, manufacture a product on a commercial scale or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful commercialization. Consequently, any predictions you make about our future success or viability may not be as accurate as they could be if we had a longer operating history or a history of successfully developing and commercializing products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We will need substantial additional funding to meet our financial obligations and to pursue our business objectives. If we are unable to raise capital when needed, we could be forced to curtail our planned operations and the pursuit of our growth strategy.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will require substantial future capital in order to complete planned and future clinical development for our lead product candidates, preclinical development for our other product candidates, and potential commercialization of these product candidates, if any are approved. We expect our spending levels to significantly increase in connection with our planned clinical trials of our lead product candidates. In addition, if we obtain marketing approval for any of our product candidates, we expect to incur significant expenses related to product sales, medical affairs, marketing, manufacturing and distribution. We also expect to incur additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on acceptable terms, we would be forced to delay, reduce or eliminate certain of our clinical trials, our research and development programs or other operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, we had cash, cash equivalents, and investments of $128.5 million. We believe that our cash, cash equivalents, and investments balances will be sufficient to fund our operating expenses and capital requirements into 2027. This estimate is based on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we expect. Changes may occur beyond our control that would cause us to consume our available capital before that time, including changes in and progress of our development activities, acquisitions of additional product candidates, and changes in regulation. Our future capital requirements will depend on many factors, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs of and investment in ongoing and future development of our gene therapy product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the scope, progress, costs and results of discovery, preclinical development, laboratory testing and clinical trials for our product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the extent to which we develop, in-license or acquire other product candidates and technologies in our product candidate pipeline;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs and timing of process development and manufacturing scale-up activities associated with our product candidates and other programs as we advance them through preclinical and clinical development;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the number of, and development requirements for, product candidates that we may pursue;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs, timing and outcome of regulatory review of our product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our headcount growth and associated costs as we expand our research and development capabilities and establish a commercial infrastructure;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs of establishing and maintaining commercial-scale cGMP manufacturing capabilities, either internally or with third parties;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs and timing of future commercialization activities, including product manufacturing, marketing, sales and distribution, for any of our product candidates for which we receive marketing approval;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the revenue, if any, received from commercial sales of our product candidates for which we receive marketing approval;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to establish and maintain additional collaborations on favorable terms, if at all;</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">40</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the success of any collaborations that we may establish and our license agreements;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the outcome of any legal proceedings involving us;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the achievement of milestones or occurrence of other developments that trigger payments under our collaboration agreement or any additional collaboration agreements we may enter into; and</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs of operating as a public company.</span></div></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will require additional capital to achieve our business objectives. While the long-term economic impact of the ongoing geopolitical conflicts in Ukraine and the Middle East is difficult to assess or predict, each of these events has caused significant disruptions to the global financial markets and contributed to a general global economic slowdown. Furthermore, inflation rates, particularly in the United States, have increased recently to levels not seen in decades. Increased inflation may result in increased operating costs and may affect our operating budgets, specifically with respect to increased labor costs and associated difficulties in recruiting qualified personnel. In addition, the U.S. Federal Reserve has raised, and may further raise, interest rates in response to concerns about inflation. Increases in interest rates, especially if coupled with reduced government spending and volatility in financial markets, may further increase economic uncertainty and heighten these risks. If the disruptions and slowdown deepen or persist, we may not be able to access additional capital on favorable terms, or at all, which could in the future negatively affect our financial condition and we could be forced to curtail our planned operations and the pursuit of our growth strategy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Until such time, if ever, as we can generate substantial revenue, we may finance our cash needs through a combination of equity offerings, government or private party grants, debt financings and license and collaboration agreements. We do not currently have any committed external source of funds. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may be required to relinquish valuable rights to our technologies, future revenue streams or product candidates, grant licenses on terms that may not be favorable to us or commit to future payment streams. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks related to the development of our product candidates</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our business is dependent on our ability to advance our current and future product candidates through preclinical studies and clinical trials, obtain marketing approval and ultimately commercialize them. If we are unable to or experience significant delays in doing so, our business will be materially harmed.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have invested a significant portion of our time and financial resources in the development of our product candidates and technology platforms. Our business is dependent on our ability to successfully complete preclinical and clinical development of, obtain regulatory approval for, and, if approved, successfully commercialize LX2006, LX2020 and any other product candidates in a timely manner.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each of our product candidates and programs will require additional preclinical and/or clinical development, regulatory approval and significant marketing efforts, and we will be required to obtain manufacturing supply and expertise and to build a commercial organization or successfully outsource commercialization before we generate any revenue from product sales. We do not have any products that are approved for commercial sale, and we may never be able to develop or commercialize marketable products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our ability to generate revenue from our product candidates, which may not occur for several years, will depend heavily on the successful development, regulatory approval and eventual commercialization of our product candidates. The success of our lead product candidates, or any other product candidates that we develop or otherwise may acquire will depend on various factors, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">timely and successful completion of preclinical studies, including toxicology studies, biodistribution studies and minimally efficacious dose studies in animals, where applicable, under GLPs;</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">41</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the availability or development of suitable animal disease models for nonclinical studies to enable us to proceed into clinical development or support the submission of a marketing application; </span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">effective IND applications from the FDA or comparable foreign applications that allow commencement of our planned clinical trials or future clinical trials for our product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sufficiency of our financial and other resources to complete the necessary preclinical studies and clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">successful enrollment and completion of clinical trials, including under cGCPs;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establishment of our own manufacturing capabilities and/or arrangements with third-party manufacturers for our commercial manufacturing processes for any of our product candidates that receive regulatory approval;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">receipt of timely marketing approvals from applicable regulatory authorities;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">launch of commercial sales of products, if approved, whether alone or in collaboration with others;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">acceptance of the benefits and use of our products, including method of administration, if and when approved, by patients, the medical community and third-party payors, for their approved indications;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the prevalence and severity of adverse events experienced with any of our product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the availability, perceived advantages, cost, safety and efficacy of alternative therapies for any diseases for which we are developing our product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to produce our product candidates on a commercial scale;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">attainment and maintenance of patent, trademark and trade secret protection and regulatory exclusivity for our product candidates and otherwise protecting our rights in our intellectual property portfolio;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">maintenance of compliance with regulatory requirements such as cGMPs;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">attainment and maintenance of third-party coverage and adequate reimbursement for our product candidates and patients&#8217; willingness to pay out-of-pocket in the absence of such coverage and adequate reimbursement; and</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">maintenance of a continued acceptable safety, tolerability and efficacy profile of our products following approval. </span></div></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are not successful with respect to one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize the product candidates we develop, which would materially harm our business. If we do not receive marketing approvals for any product candidate we develop, we may not be able to continue our operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are developing novel gene therapy product candidates, which makes it difficult to predict the time, cost and potential success of product candidate development.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our future success depends on the successful development of a novel therapeutic approach. To date, very few products that utilize gene transfer have been approved in the United States or Europe. There have been a limited number of clinical trials using AAVrh10. Although gene therapies have been studied in human clinical trials for over 30 years, only a limited number of AAV-based gene therapy products have been approved by the FDA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">42</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot be certain that our AAVrh10-based gene therapy product candidates will successfully complete clinical trials or that any future product candidates utilizing this or other vector constructs will successfully complete preclinical studies or clinical trials. We may not be successful in developing product candidates that avoid triggering toxicities or other side effects in preclinical studies or clinical trials. Our intravenous and intrathecal routes of administration may cause unforeseen side effects or present other challenges. Any such results could impact our ability to develop a product candidate, including our ability to enroll patients in our clinical trials. As a result of these factors, it is more difficult for us to predict the time and cost of product candidate development, and we cannot predict whether the application of our approach to gene therapy, or any similar or competitive programs, will result in the identification, development, and regulatory approval of any product candidate, or that other gene therapy programs will not be considered better or more favorable. There can be no assurance that any development problems we experience in the future related to our current gene therapy product candidates or any of our research programs will not cause significant delays or unanticipated costs, or that such development problems can be solved. We may also experience delays and challenges in achieving sustainable, reproducible, and scalable production. Any of these factors may prevent us from completing our preclinical studies or clinical trials or commercializing any product candidates we may develop on a timely or profitable basis, if at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Because gene therapy is novel and the regulatory landscape that governs any product candidates we may develop is rigorous, complex, uncertain and subject to change, we cannot predict with certainty the geographic areas in which we could obtain regulatory approval nor the time and cost of obtaining regulatory approval, if we receive it at all, for any product candidates we may develop.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The regulatory requirements that will govern any novel gene therapy product candidates we develop are not entirely clear and are subject to change. The novel nature of our capsids makes it difficult to determine how long it will take or how much it will cost to obtain regulatory approvals for our product candidates in the United States, the European Union or other jurisdictions. Within the broader genetic medicine field, very few gene therapy products have received marketing authorization from the FDA or the European Medicines Agency, or EMA. Even with respect to gene therapies, the regulatory landscape is still developing. Regulatory requirements governing gene therapy products have changed frequently and will likely continue to change in the future, including with respect to those responsible for regulation of existing gene therapy products. For example, in 2016, the FDA established the Office of Tissues and Advanced Therapies, or OTAT, within the Center for Biologics Evaluation and Research, or CBER, to consolidate the review of gene therapy and related products, and to advise the CBER on its review. In March 2023, the FDA retitled the OTAT to the Office of Therapeutic Products, or OTP, and elevated OTP to a &#8220;Super Office&#8221; to meet its growing cell and gene therapy workload.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our product candidates will need to meet safety and efficacy standards applicable to any new biologic being pursued for a given disease under the regulatory framework administered by the FDA. Although the FDA decides whether individual gene therapy protocols may proceed, the review process and determinations of other reviewing bodies, including IRBs, can impede or delay the initiation of a clinical trial.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The same applies in the European Union. The EMA&#8217;s Committee for Advanced Therapies, or CAT, is responsible for assessing the quality, safety and efficacy of advanced-therapy medicinal products. Advanced-therapy medicinal products include gene therapy medicines, somatic-cell therapy medicines and tissue-engineered medicines. The role of the CAT is to prepare a draft opinion on an application for marketing authorization for a gene therapy medicinal candidate that is submitted to the EMA. In the European Union, the development and evaluation of a gene therapy product must be considered in the context of the relevant EU guidelines. The EMA may issue new guidelines concerning the development and marketing authorization for gene therapy products and require that we comply with these new guidelines. This could mean that any gene therapy product candidate we may develop in the future could be required to comply with additional and/or more stringent gene therapy guidelines in the European Union.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">43</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adverse developments in preclinical studies or clinical trials conducted by others in the field of gene therapy and gene regulation products may cause the FDA, the EMA and other regulatory bodies to revise the requirements for approval of any product candidates we may develop or limit the use of products utilizing gene regulation technologies, either of which could harm our business. In addition, the clinical trial requirements of the FDA, the EMA and other regulatory authorities and the criteria these regulators use to determine the safety and efficacy of a product candidate vary substantially according to the type, complexity, novelty, and intended use and market of the potential products. The regulatory approval process for product candidates such as ours can be more expensive and take longer than for other, better known, or more extensively studied pharmaceutical or other product candidates. Further, as we are developing novel potential treatments for diseases in which, in some cases, there is little clinical experience with potential new endpoints and methodologies, there is heightened risk that the FDA, the EMA or other regulatory bodies may not consider the clinical trial endpoints to provide clinically meaningful results, and the resulting clinical data and results may be more difficult to analyze. In addition, we may not be able to identify or develop appropriate animal disease models to enable or support planned clinical development. Any natural history studies that we may rely upon in our clinical development may not be accepted by the FDA, EMA or other regulatory authorities. Regulatory agencies administering existing or future regulations or legislation may not allow production and marketing of products utilizing gene regulation technology in a timely manner or under technically or commercially feasible conditions. In addition, regulatory action or private litigation could result in expenses, delays, or other impediments to our research programs or the commercialization of resulting products. Further, approvals by one regulatory agency may not be indicative of what other regulatory agencies may require for approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The regulatory review committees and advisory groups described above and any new guidelines they promulgate may lengthen the regulatory review process, require us to perform additional preclinical studies or clinical trials, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of these treatment product candidates, or lead to significant post-approval limitations or restrictions. As we advance our research programs and develop future product candidates, we will be required to consult with these regulatory and advisory groups and to comply with applicable guidelines. If we fail to do so, we may be required to delay or discontinue development of any product candidates we identify and develop. These additional processes may result in a review and approval process that is longer than we otherwise would have expected. Delays as a result of an increased or lengthier regulatory approval process or further restrictions on the development of our product candidates can be costly and could negatively impact our ability to complete clinical trials and commercialize our current and future product candidates in a timely manner, if at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Preclinical studies and clinical trials are expensive, time-consuming, difficult to design and implement and involve an uncertain outcome. Further, we may encounter substantial delays in completing the development of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All of our product candidates are in preclinical or early clinical development, and the risk of failure is high. The preclinical studies, clinical trials and manufacturing of our product candidates are, and the manufacturing and marketing of our products, if approved, will be, subject to extensive and rigorous review and regulation by numerous government authorities in the United States and in other countries where we may test and market our product candidates. Before obtaining regulatory approvals for the commercial sale of any of our product candidates, we must demonstrate through lengthy, complex and expensive preclinical testing and clinical trials that our product candidates are both safe and effective for use in each target disease. In particular, because our product candidates are subject to regulation as biologics, we will need to demonstrate that they are sufficiently safe and of sufficient purity and potency for use in their target diseases. Each product candidate must demonstrate an adequate risk-versus-benefit profile in its intended patient population and for its intended use.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clinical testing is expensive, can take many years to complete and is subject to uncertainty. We cannot guarantee that any clinical trials will be initiated on schedule, conducted as planned or completed on schedule, if at all. To date, we are sponsoring clinical trials of LX2006 and LX2020, but we have not successfully completed any clinical trial that we have internally sponsored. Failure can occur at any time during the clinical trial process. Even if our ongoing and future clinical trials are completed as planned, we cannot be certain that their results will support the safety and effectiveness of our product candidates for their targeted diseases or support continued clinical development of such product candidates. Our future clinical trial results may not be successful.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, even if such trials are successfully completed, we cannot guarantee that the FDA or foreign regulatory authorities will interpret the results as we do, and more trials could be required before we submit our product candidates for approval. This is particularly true for clinical trials in rare diseases, where the small patient populations make it difficult or impossible to conduct two traditional, adequate and well-controlled trials, and therefore the FDA or comparable foreign regulatory authorities are often required to exercise flexibility in approving therapies for such diseases. Moreover, results acceptable to support approval in one jurisdiction may be deemed inadequate by another regulatory authority to support regulatory approval in that other jurisdiction. To the extent that the results of the trials are not satisfactory to the FDA or foreign regulatory authorities for support of a marketing application, we may be required to expend significant resources, which may not be available to us, to conduct additional trials in support of potential approval of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">44</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may experience delays in initiating and conducting clinical trials of our lead product candidates and we do not know whether our clinical trials will begin on time, need to be redesigned, recruit and enroll patients on time or be completed on schedule, or at all. Events that may prevent successful or timely completion of clinical development include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">inability to generate sufficient preclinical, toxicology, or other </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vivo </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vitro </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">data to support the initiation of clinical trials;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in sufficiently developing, characterizing or controlling a manufacturing process suitable for advanced clinical trials;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in sourcing or qualifying ancillaries required for administration of our clinical drug product (such as vials, stoppers, or tubing);</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in developing suitable assays for screening patients for eligibility for trials with respect to certain product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in reaching agreement with the FDA, EMA or other regulatory authorities as to the design or implementation of our clinical trials;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure to obtain regulatory approval to commence a clinical trial;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure to reach an agreement on acceptable terms with clinical trial sites or prospective CROs, the terms of which can be subject to extensive negotiation and may vary significantly among different clinical trial sites;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">inability to obtain IRB approval for each clinical trial site;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">inability to recruit suitable patients to participate in a clinical trial in a timely manner;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure to have patients complete a clinical trial or return for post-treatment follow-up;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">deviations by clinical trial sites, CROs or other third parties from trial protocol;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure to perform our planned clinical trials in accordance with the FDA&#8217;s cGCP requirements, or applicable regulatory guidelines in other countries;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">inability to address patient-safety concerns that arise during the course of a trial, including occurrence of adverse events associated with the product candidate that are viewed to outweigh its potential benefits;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure to initiate a sufficient number of clinical trial sites; or</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in manufacturing sufficient quantities of a product candidate for use in clinical trials.</span></div></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent our ability to receive marketing approval or commercialize our product candidates or significantly increase the cost of such trials, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may experience changes in regulatory requirements or guidance, or receive feedback from regulatory authorities, that require us to modify the design of our clinical trials;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clinical trials of our product candidates may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials or halt development programs;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the number of patients required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate, or participants may drop out of these clinical trials at a higher rate than we anticipate;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we, our investigators or regulators may suspend or terminate clinical trials of our product candidates for various reasons, including non-compliance with regulatory requirements, a finding that our product candidates have undesirable side effects or other unexpected characteristics, or a finding that the participants are being exposed to unacceptable health risks;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of clinical trials of our product candidates may be greater than we anticipate, and we may not have funds to cover the costs;</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">45</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient or inadequate;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulators may revise the requirements for approving our product candidates, or such requirements may not be as we anticipate; and</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any future collaborators that conduct clinical trials may face any of the above issues and may conduct clinical trials in ways they view as advantageous to them but that are suboptimal for us.</span></div></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are required to conduct additional clinical trials or other testing of our product candidates beyond those that we currently contemplate, if we are unable to successfully initiate or complete clinical trials of our product candidates or other testing, if the results of these trials or tests are not positive or are only modestly positive or if there are safety concerns, we may:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">incur unplanned costs;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">be delayed in obtaining marketing approval for our product candidates or not obtain marketing approval at all;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtain marketing approval in some countries and not in others;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtain marketing approval for diseases or patient populations that are not as broad as intended or desired;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtain marketing approval with labeling that includes significant use or distribution restrictions or safety warnings, including boxed warnings or REMS;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">be subject to additional post-marketing testing requirements; or</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">have the product removed from the market after obtaining marketing approval.</span></div></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We could encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions in which such trials are being conducted, by the Data Safety Monitoring Board for such trial or by the FDA, EMA or other regulatory authorities. Such authorities may impose such a suspension or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA, EMA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All of our product candidates will require extensive clinical testing before we are prepared to submit a BLA or marketing authorization application, or MAA, for regulatory approval. We cannot predict with any certainty if or when we might complete the clinical development for our product candidates and submit a BLA or MAA for regulatory approval of any of our product candidates or whether any such BLA or MAA will be approved. We may also seek feedback from the FDA, EMA or other regulatory authorities on our clinical development program, and the FDA, EMA or such regulatory authorities may not provide such feedback on a timely basis, or such feedback may not be favorable, which could further delay our development programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot predict with any certainty whether or when we might complete a given clinical trial. If we experience delays in the commencement or completion of our clinical trials, or if we terminate a clinical trial prior to completion, the commercial prospects of our product candidates could be harmed, and our ability to generate revenues from our product candidates may be delayed or lost. In addition, any delays in our clinical trials could increase our costs, slow down the development and approval process and jeopardize our ability to commence product sales and generate revenues. Any of these occurrences may harm our business, financial condition and results of operations. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">46</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The regulatory approval processes of the FDA, EMA and comparable foreign authorities are lengthy, time-consuming and inherently unpredictable. If we are not able to obtain required regulatory approval for our product candidates, our business will be substantially harmed.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The time required to obtain approval or other marketing authorizations by the FDA, EMA and comparable foreign authorities is unpredictable, and it typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval policies, regulations, and the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions. We have not obtained regulatory approval for any product candidate, and it is possible that we may never obtain regulatory approval for any product candidates we may seek to develop in the future. Neither we nor any collaborator is permitted to market any of our biologic product candidates in the United States until we receive regulatory approval of a BLA from the FDA, and we cannot market any of our product candidates in the European Union until we receive approval for an MAA from the EMA, or other required regulatory approval in other countries.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prior to obtaining approval to commercialize any product candidate in the United States or abroad, we must demonstrate with substantial evidence from well-controlled clinical trials, and to the satisfaction of the FDA or foreign regulatory agencies, that such product candidates are safe, effective and of sufficient purity for their intended uses. Results from preclinical studies and clinical trials can be interpreted in different ways. Even if we believe the preclinical or clinical data for our product candidates meet regulatory standards, such data may not be sufficient to support approval by the FDA and other regulatory authorities. The FDA may also require us to conduct additional preclinical studies or clinical trials for our product candidates either prior to or after approval, or it may object to elements of our clinical development programs, or require changes to our manufacturing approaches.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Of the large number of products in development, only a small percentage successfully complete the FDA or foreign regulatory approval processes and are commercialized. The lengthy approval and marketing authorization process as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval and marketing authorization to market our product candidates, which would significantly harm our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have invested a significant portion of our time and financial resources in the development of our product candidates and technology platforms. Our business is dependent on our ability to successfully complete preclinical and clinical development of, obtain regulatory approval for, and, if approved, successfully commercialize LX2006, LX2020, and our other product candidates in a timely manner.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if we eventually complete clinical testing and receive approval of a BLA or foreign marketing application for any of our product candidates, the FDA, EMA or the applicable foreign regulatory agency may grant approval or other marketing authorization contingent on the performance of costly additional clinical trials, including post-marketing clinical trials. The FDA, EMA or the applicable foreign regulatory agency also may approve or authorize for marketing a product candidate for a more limited disease or patient population than we originally request, and the FDA, EMA or applicable foreign regulatory agency may not approve or authorize the labeling that we believe is necessary or desirable for the successful commercialization of a product candidate. Any delay in obtaining, or inability to obtain, applicable regulatory approval or other marketing authorization would delay or prevent commercialization of that product candidate and would materially adversely impact our business and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the FDA, EMA and other regulatory authorities may change their policies, issue additional regulations or revise existing regulations, or take other actions, which may prevent or delay approval of our future products under development on a timely basis. Such policy or regulatory changes could impose additional requirements upon us that could delay our ability to obtain approvals, increase the costs of compliance or restrict our ability to maintain any marketing authorizations we may have obtained. In June 2024, the Supreme Court overruled the</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> Chevron</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> doctrine, which had given deference to regulatory agencies&#8217; statutory interpretations of ambiguous regulations in litigation against federal government agencies, such as the FDA. The overruling of the </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Chevron </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">doctrine may significantly increase the number of challenges brought by companies and other stakeholders against federal agencies such as the FDA and its longstanding decisions and policies, including the FDA&#8217;s statutory interpretations of market exclusivities and the &#8220;substantial evidence&#8221; requirements for drug approvals, which could undermine the FDA&#8217;s authority, lead to uncertainties in the industry, and disrupt the FDA&#8217;s normal operations, any of which could delay the FDA&#8217;s review of our regulatory submissions. We cannot predict the full impact of this decision, future judicial challenges brought against the FDA, or the nature or extent of government regulation that may arise from future legislation or administrative action.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">47</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Success in preclinical studies or earlier clinical trials may not be indicative of results in future clinical trials.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Success in preclinical testing and early clinical trials does not ensure that later clinical trials will generate the same results or otherwise provide adequate data to demonstrate the efficacy and safety of a product candidate. Preclinical tests and Phase 1 and Phase 2 clinical trials are primarily designed to test safety, to study pharmacokinetics and pharmacodynamics and to understand the side effects of product candidates at various doses and schedules. Success in preclinical or animal studies and early clinical trials does not ensure that later larger-scale efficacy and safety trials will be successful, nor does it predict final results. For example, we may be unable to identify suitable animal disease models for our product candidates, which could delay or frustrate our ability to proceed into clinical trials or obtain marketing approval. In addition, the preclinical studies conducted by Stelios (an entity that we acquired in 2021) and The Regents of UCSD for our product candidates LX2021 and LX2022 employed an AAV9-based formulation and studies using this vector may not be predictive of future testing we intend to conduct using an AAVrh10-based formulation or other potential capsid serotypes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our product candidates may fail to show the desired safety and efficacy in clinical development despite positive results in preclinical studies or having successfully advanced through initial clinical trials. Furthermore, our currently ongoing and most future clinical trials involve or will involve a small patient population. Because of the small sample sizes studied in our trials thus far, the results of these trials may not be indicative of results of future clinical trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, some of our ongoing and planned clinical trials utilize, or may utilize, an &#8220;open-label&#8221; trial design. An &#8220;open-label&#8221; clinical trial is one where both the patient and investigator know whether the patient is receiving the investigational product candidate or either an existing approved drug or placebo. Most typically, open-label clinical trials test only the investigational product candidate and sometimes may do so at different dose levels. Open-label clinical trials are subject to various limitations that may exaggerate any therapeutic effect as patients in open-label clinical trials are aware when they are receiving treatment. Open-label clinical trials may be subject to a &#8220;patient bias&#8221; where patients perceive their symptoms to have improved merely due to their awareness of receiving an experimental treatment. In addition, open-label clinical trials may be subject to an &#8220;investigator bias&#8221; where those assessing and reviewing the physiological outcomes of the clinical trials are aware of which patients have received treatment and may interpret the information of the treated group more favorably given this knowledge. The results from an open-label trial may not be predictive of future clinical trial results when studied in a controlled environment with a placebo or active control.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical trials even after achieving promising results in preclinical testing and earlier-stage clinical trials. Data obtained from preclinical and clinical activities are subject to varying interpretations, which may delay, limit or prevent regulatory approval. In addition, we may experience regulatory delays or rejections as a result of many factors, including changes in regulatory policy during the period of our product candidate development. Any such delays could negatively impact our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interim &#8220;top-line&#8221; and preliminary results from our clinical trials that we announce, publish or present from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, we have and may continue to publish or present interim top-line or preliminary results from our clinical trials. Interim results from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Preliminary or top-line results also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, interim and preliminary data should be viewed with caution until the final data are available. Differences between preliminary or interim data and final data could significantly harm our business prospects and may cause the trading price of our common stock to fluctuate significantly.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">48</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our preclinical studies and clinical trials may fail to demonstrate the safety and efficacy of our product candidates, or serious adverse or unacceptable side effects may be identified during the development of our product candidates, which could prevent or delay regulatory approval and commercialization, increase our costs or necessitate the abandonment or limitation of the development of some of our product candidates. We may also identify safety and efficacy concerns after the approval of a product candidate which can result in negative consequences to our business and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Before obtaining regulatory approvals for the commercial sale of our product candidates, we must demonstrate through lengthy, complex and expensive preclinical testing and clinical trials that our product candidates are safe, effective and of sufficient purity for use in each target disease, and failures can occur at any stage of testing. Preclinical studies and clinical trials often fail to demonstrate safety or efficacy of the product candidate studied for the target disease. While we have developed our AAVrh10-mediated gene therapy product candidates to leverage the low seropositivity of AAVrh10, any gene therapy product based on viral vectors carries the risks of immunogenicity, elevated liver enzymes and insertional oncogenesis, which is the process whereby the insertion of a functional gene near a gene that is important in cell growth or division results in uncontrolled cell division, which could potentially enhance the risk of malignant transformation. In one of our preclinical studies of LX2006, we observed four cases of hepatocellular carcinoma, or HCC, in wild-type mice at 10 months post-treatment. Although data reported by the FDA Cellular, Tissue, and Gene Therapies Advisory Committee in September 2021 suggests that HCC observed in mice after AAV treatment is unlikely to translate to risks for humans, any future instances of HCC in our clinical trials could result in delays or the abandonment of our trials. Health authorities also ask that sponsors closely monitor the risk of elevated liver enzymes and abnormal liver ultrasound on a routine basis in patients participating in gene therapy clinical trials.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Possible adverse side effects that could occur with treatment with gene therapy products include an immunologic reaction early after administration, which, while not necessarily adverse to the patient&#8217;s health, could substantially limit the effectiveness of the treatment. For example, in previous third-party clinical trials involving AAV capsids for gene therapy, some subjects experienced the development of a T-cell antibody response, whereby after the vector is within the target cell types, the cellular immune response system triggers the removal of transduced cell types by activated T-cells. If any of our product candidates demonstrate a similar effect, we may decide or be required to perform additional preclinical studies or to halt or delay further clinical development of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to side effects caused by the product candidate, the administration process or related procedures also can cause adverse side effects. Our APOE-associated Alzheimer&#8217;s disease product candidates are designed to be delivered via intracisternal administration. While the intracisternal method of administration has been available for some years, its use for gene therapies is new and no gene therapy is currently approved for this method of administration. Intracisternal administration may have greater risk and/or be perceived as having greater risk than more common methods of administration, such as intravenous injection. Other gene therapy product candidates in clinical development utilizing intracisternal delivery could also generate data that could adversely affect the clinical, regulatory or commercial perception of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If adverse events occur, either as a result of the product candidate or administration process, our clinical trials could be suspended or terminated. If we cannot demonstrate that any adverse events were not caused by the drug or administration process or related procedures, the FDA, EMA or foreign regulatory authorities could order us to cease further development of, or deny approval of, our product candidates for any or all targeted diseases. Even if we are able to demonstrate that serious adverse events are not product-related, such occurrences could affect patient recruitment or the ability of enrolled patients to complete the trial. Moreover, if we elect, or are required, to not initiate, delay, suspend or terminate any future clinical trial of any of our product candidates, the commercial prospects of such product candidates may be harmed and our ability to generate product revenues from any of these product candidates may be delayed or eliminated. Any of these occurrences may harm our ability to develop other product candidates, and may harm our business, financial condition and prospects significantly. Furthermore, negative results in our development of LX2006 or LX2020 could be interpreted as a failure to achieve proof of concept for our technology and result in the abandonment of other development programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, gene therapy is still a relatively new approach to disease treatment and additional adverse side effects could develop. There also is the potential risk of delayed adverse events following exposure to gene therapy products due to persistent biologic activity of the genetic material or other components of products used to carry the genetic material. If our product candidates are associated with side effects in clinical trials or have characteristics that are unexpected, we may need to abandon their development or limit development to more narrow uses in which the side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. The FDA or an IRB may also require that we suspend, discontinue, or limit our clinical trials based on safety information, or that we conduct additional animal or human studies regarding the safety and efficacy of our product candidates which we have not planned or anticipated. Such findings could further result in regulatory authorities failing to provide marketing authorization for our product candidates or limiting the scope of the approved indication, if approved. Many product candidates that initially showed promise in early-stage testing have later been found to cause side effects that prevented further development of the product candidate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">49</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, if one or more of our product candidates receives marketing approval, and we or others identify undesirable side effects caused by such products or the administration procedure, a number of potentially significant negative consequences could result, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory authorities may withdraw approvals of such product;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory authorities may require additional warnings on the labels;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may be required to create a medication guide outlining the risks of such side effects for distribution to patients or other requirements subject to a REMS;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we could be sued and held liable for harm caused to patients;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may not be able to obtain or maintain third-party payor coverage and adequate reimbursement; and</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our reputation and physician or patient acceptance of our products may suffer.</span></div></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There can be no assurance that we will resolve any issues related to any product-related adverse events to the satisfaction of the FDA or foreign regulatory agency in a timely manner or at all. Moreover, any of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and could significantly harm our business, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Some of the diseases we initially seek to treat have low prevalence and it may be difficult to identify and enroll patients with these diseases. If we experience delays or difficulties in the enrollment and/or maintenance of patients in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Successful and timely completion of clinical trials will require that we enroll a sufficient number of patients. Patient enrollment, a significant factor in the timing of clinical trials, is affected by many factors, including the size and nature of the patient population and competition for patients with other trials. The rare genetic diseases which some of our product candidates are designed to target have low incidence and prevalence and may be difficult to diagnose. In particular, because we are focused on patients with specific genetic mutations, our ability to enroll eligible patients may be limited or enrollment may be slower than we anticipate. For example, we estimate that approximately 6,600 people in the United States have FA and that approximately 80% of these patients will develop the cardiac manifestation of FA, or FA cardiomyopathy, and accordingly it may be difficult for us to identify and timely recruit a sufficient number of eligible patients to conduct our clinical trials. While the patient population for LX2020, our program targeting PKP2-ACM, is significantly larger than FA, we may face challenges in identifying and recruiting eligible patients to conduct our clinical trial given competing clinical trials. Even for more prevalent conditions such as Alzheimer&#8217;s disease, it may be difficult to recruit patients to clinical trials due to the number of approved products, difficulty identifying patients with the specific genotype we are studying, and the number of clinical trials being conducted in this indication.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our trials may be subject to delays as a result of patient enrollment taking longer than anticipated or patient withdrawal. We may not be able to initiate or continue clinical trials for our product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA, EMA or other foreign regulatory authorities. We cannot predict how successful we will be at enrolling subjects in future clinical trials. Subject enrollment is affected by other factors including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the severity of the disease under investigation;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the eligibility criteria for the trial in question;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the size of the patient population and process for identifying patients;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the perceived risks and benefits of the product candidate under study;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the product candidate being studied in relation to other available therapies, including any new drugs that may be approved for the diseases we are investigating;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the availability of competing commercially available therapies and other competing therapeutic product candidates&#8217; clinical trials;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the efforts to facilitate timely enrollment in clinical trials;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the risk that patients enrolled in clinical trials will drop out of the clinical trials before completion of their treatment;</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">50</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the patient referral practices of physicians;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the ability to monitor patients adequately during and after treatment; and</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the proximity and availability of clinical trial sites for prospective patients.</span></div></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our inability to enroll a sufficient number of patients for clinical trials would result in significant delays and could require us to abandon one or more clinical trials altogether. Enrollment delays in these clinical trials may result in increased development costs for our product candidates, which would cause the value of our company to decline and limit our ability to obtain additional financing. Furthermore, we rely on CROs and clinical trial sites to help ensure the proper and timely conduct of our clinical trials and we may have limited influence over their performance. For additional information, see the risk factor in this section under the heading &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We intend to continue to rely on third parties to conduct a significant portion of our existing clinical trials and potential future clinical trials for product candidates, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, even if we are able to enroll a sufficient number of patients for our clinical trials, we may have difficulty maintaining enrollment of such patients in our clinical trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may seek Orphan Drug designation or Rare Pediatric Disease designation for some of our product candidates and we may be unsuccessful, or may be unable to maintain the benefits associated with Orphan Drug designation, including the potential for market exclusivity, for product candidates for which we obtain Orphan Drug designation.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Regulatory authorities in some jurisdictions, including the United States, may designate drugs or biologics intended to treat relatively small patient populations as orphan drug products. Under the Orphan Drug Act, the FDA may designate a drug or biologic as an orphan drug if it is intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals in the United States, or a patient population of 200,000 or more in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the United States, Orphan Drug designation entitles a party to potential financial incentives such as tax advantages and user fee waivers. Opportunities for grant funding toward clinical trial costs may also be available for clinical trials of drugs or biologics for rare diseases, regardless of whether the drugs or biologics are designated for the orphan use. In addition, if a drug or biologic with an Orphan Drug designation subsequently receives the first marketing approval for the disease for which it has such designation, the product is entitled to a seven-year period of marketing exclusivity, which precludes the FDA from approving another marketing application for the same drug and disease for that time period, except in limited circumstances. If our competitors are able to obtain orphan drug exclusivity prior to us, for products that constitute the &#8220;same drug&#8221; and treat the same diseases as our product candidates, we may not be able to have competing products approved by the applicable regulatory authority for a significant period of time.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Similarly, in the European Union, the European Commission, upon the recommendation of the EMA&#8217;s Committee for Orphan Medicinal Products, grants Orphan Drug designation to promote the development of drugs that are intended for the diagnosis, prevention or treatment of life-threatening or chronically debilitating conditions and either the prevalence of the condition is not more than 5 in 10,000 persons in the European Union, or, without incentives, it is unlikely that sales of the drug in the European Union would be sufficient to justify the necessary investment in developing the drug. In each case, there must be no satisfactory method of diagnosis, prevention or treatment of the condition that has been authorized, or, if such a method exists, the product in question must be of significant benefit to those affected by such condition. In the European Union, Orphan Drug designation entitles a party to financial incentives such as reduction of fees or fee waivers.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">51</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have obtained from the FDA Orphan Drug designation for LX2006 for the treatment of FA cardiomyopathy and for LX2020 for the treatment of PKP2-ACM. LX2006 and LX2020 have also received Orphan Medicinal Product designation from the European Commission. We may seek orphan designation for some or all of our product candidates in orphan indications in which there is a medically plausible basis for the use of these product candidates. However, we may be unsuccessful in obtaining Orphan Drug designation and may be unable to maintain the benefits associated with such designations. Even if we obtain orphan drug exclusivity for any of our product candidates, that exclusivity may not effectively protect those product candidates from competition because different drugs can be approved for the same condition, and orphan drug exclusivity does not prevent the FDA from approving the same or a different drug in another indication. Even after an orphan drug is granted orphan exclusivity and approved, the FDA can subsequently approve a later application for the same drug for the same condition before the expiration of the seven-year exclusivity period if the FDA concludes that the later drug is clinically superior in that it is shown to be safer in a substantial portion of the target populations, more effective or makes a major contribution to patient care. On August 3, 2017, Congress passed the FDA Reauthorization Act of 2017, or FDARA. FDARA, among other things, codified the FDA&#8217;s preexisting regulatory interpretation, to require that a drug sponsor demonstrate the clinical superiority of an orphan drug that is otherwise the same as a previously approved drug for the same rare disease in order to receive orphan drug exclusivity. The statute supplants prior precedent holding that the Orphan Drug Act unambiguously requires that the FDA recognize the orphan exclusivity period regardless of a showing of clinical superiority. Moreover, in the Consolidated Appropriations Act of 2021, Congress clarified that the interpretation of orphan drug exclusivity codified in FDARA would apply in cases where the FDA issued an orphan designation before the enactment of FDARA but where product approval came after the enactment of FDARA. In addition, a designated Orphan Drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the disease for which it received orphan designation. In </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Catalyst Pharms., Inc. v. Becerra</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, 14 F.4</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">th</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> 1299 (11th Cir. 2021), the court disagreed with the FDA&#8217;s longstanding position that orphan drug exclusivity only applies to the approved use or indication within an eligible disease. This decision created uncertainty in the application of orphan drug exclusivity. In January 2023, the FDA published a notice in the Federal Register to clarify that while the agency complies with the court&#8217;s order in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Catalyst</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the FDA intends to continue to apply its longstanding interpretation of the regulations to matters outside of the scope of the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Catalyst</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> order &#8211; that is, the agency will continue tying the scope of orphan-drug exclusivity to the uses or indications for which a drug is approved, which permits other sponsors to obtain approval of a drug for new uses or indications within the same orphan designated disease or condition that have not yet been approved. In view of the overturn of the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Chevron </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">doctrine in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Loper Bright Enterprises v. Raimondo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, this landmark Supreme Court decision may invite various stakeholders to bring lawsuits against the FDA to challenge longstanding decisions and policies, including regulatory exclusivities, which could lead to uncertainties in the industry. Further, changes in the leadership of the FDA and other federal agencies under the Trump administration may lead to new policies and changes in the regulations and operations of the FDA, which may impact our clinical development plans. We do not know if, when, or how the FDA, Congress, or future judicial challenges may change the orphan drug regulations and policies in the future, and it is uncertain how any changes might affect our business. Depending on what changes the FDA may make to its orphan drug regulations and policies, our business could be adversely impacted. Moreover, orphan drug-exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or if we are unable to manufacture sufficient quantities of the product to meet the needs of patients with the rare disease or condition. Orphan Drug designation neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fast Track, Breakthrough Therapy, or Regenerative Medicine Advanced Therapy designation that we may receive from the FDA may not actually lead to a faster development or regulatory review or approval process, and does not assure FDA approval of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may seek Fast Track, Breakthrough Therapy or RMAT designation from the FDA for some or all of our product candidates, but we may be unable to obtain such designations or to maintain the benefits associated with such designations. The FDA&#8217;s Fast Track, Breakthrough Therapy, and RMAT designation programs are intended to expedite the development of certain qualifying product candidates intended for the treatment of serious diseases and conditions. If a product candidate is intended for the treatment of a serious or life-threatening condition and preclinical or clinical data demonstrate the product&#8217;s potential to address an unmet medical need for this condition, the sponsor may apply for FDA Fast Track designation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A product candidate may be designated as a breakthrough therapy if it is intended, alone or in combination with one or more other drugs or biologics to treat a serious or life-threatening condition and preliminary clinical evidence indicates that the product candidate may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints. For product candidates that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Drugs and biologics designated as breakthrough therapies by the FDA may also be eligible for accelerated approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">52</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A product candidate may receive RMAT designation if it is a regenerative medicine therapy that is intended to treat, modify, reverse or cure a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the product candidate has the potential to address an unmet medical need for such condition. RMAT designation allows companies developing regenerative medicine therapies to work more closely and frequently with the FDA, and RMAT-designated product candidates may be eligible for priority review and accelerated approval. FDA has confirmed that gene therapies, including genetically modified cells, that lead to a sustained effect on cells or tissues may meet the definition of a regenerative medicine therapy. For product candidates that have received an RMAT designation, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have received Fast Track designation </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">for LX2006 for the treatment of FA cardiomyopathy,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and for LX2020 for the treatment of PKP2-ACM. We have also received RMAT designation for LX2006 for the treatment of FA cardiomyopathy. While we may seek Fast Track, Breakthrough Therapy and/or RMAT designation for some or all of our product candidates, there is no guarantee that we will be successful in obtaining any such designation. Even if we do obtain such designation, we may not experience a faster development process, review or approval compared to conventional FDA procedures. A Fast Track, Breakthrough Therapy, or RMAT designation does not ensure that the product candidate will receive marketing approval or that approval will be granted within any particular time frame. In addition, the FDA may withdraw Fast Track, Breakthrough Therapy, or RMAT designation if it believes that the designation is no longer supported by data from our clinical development program. Fast Track, Breakthrough Therapy and/or RMAT designation alone does not guarantee qualification for the FDA&#8217;s priority review procedures.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have received Rare Pediatric Disease designation from the FDA for LX2006 for the treatment of FA and we may seek such designation for future product candidates. However, a marketing application for these product candidates, if approved, may not meet the eligibility criteria for a rare pediatric disease priority review voucher.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have received Rare Pediatric Disease designation from the FDA for LX2006 for the treatment of FA and LX1004 for the treatment of CLN2 disease and we may seek Rare Pediatric Disease designation for future product candidates. The FDA defines &#8220;rare pediatric disease&#8221; as a (i) serious or life-threatening disease in which the serious or life-threatening manifestations primarily affect individuals aged from birth to 18 years, including age groups often called neonates, infants, children, and adolescents; and (ii) a rare disease or condition within the meaning of the Orphan Drug Act. Designation of a product candidate as a product for a rare pediatric disease does not guarantee that a marketing application for such product candidate will meet the eligibility criteria for a rare pediatric disease priority review voucher at the time the application is approved. Under the FDCA, we will need to request a rare pediatric disease priority review voucher in our original marketing application for our product candidates for which we have received Rare Pediatric Disease designation. The FDA may determine that a marketing application for any such product candidates, if approved, does not meet the eligibility criteria for a priority review voucher, including for the following reasons:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the rare pediatric disease that received such designation no longer meets the definition of a &#8220;rare pediatric disease&#8221;;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the marketing application contains an active ingredient (including any ester or salt of the active ingredient) that has been previously approved in a marketing application;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the marketing application is not deemed eligible for priority review;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the marketing application does not rely on clinical data derived from studies examining a pediatric population and dosages of the product intended for that population (that is, if the marketing application does not contain sufficient clinical data to allow for adequate labeling for use by the full range of affected pediatric patients); or</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the marketing application is approved for a different adult indication than the rare pediatric disease for which our product candidates are designated.</span></div></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the current statutory sunset provisions, after September 30, 2024, the FDA may only award a priority review voucher, or PRV, for an approved rare pediatric disease product application if the sponsor has Rare Pediatric Disease designation for the drug or biologic that is the subject of such application, and that designation was granted by September 30, 2024. After September 30, 2026, the FDA may not award any rare pediatric disease PRVs. However, it is possible the authority for FDA to award rare pediatric disease PRVs will be further extended by Congress. As such, if we do not obtain approval of a marketing application for LX2006 in patients with FA on or before September 30, 2026, and if the PRV program is not extended by Congressional action, we may not receive a PRV. Congress did not reauthorize the rare pediatric disease priority review program at the end of 2024, and it is unclear whether the Congress under the Trump administration will extend the program.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">53</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Where appropriate, we may seek approval from the FDA, EMA or comparable foreign regulatory authorities through the use of accelerated approval pathways. If we are unable to obtain such approval, we may be required to conduct additional preclinical studies or clinical trials beyond those that we contemplate, which could increase the expense of obtaining, and delay the receipt of, necessary marketing approvals. Even if we receive accelerated approval from the FDA, EMA or comparable regulatory authorities, if our confirmatory trials do not verify clinical benefit, or if we do not comply with rigorous post-marketing requirements, the FDA, EMA or such other regulatory authorities may seek to withdraw accelerated approval.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Where possible, we may pursue accelerated development strategies in areas of high medical need. We may seek an accelerated approval pathway for one or more of our therapeutic product candidates from the FDA, EMA or comparable foreign regulatory authorities. Under the accelerated approval provisions in the FDCA and the FDA&#8217;s implementing regulations, the FDA may grant accelerated approval to a therapeutic candidate that is designed to treat a serious or life-threatening condition, generally provides a meaningful therapeutic benefit over available therapies, and demonstrates an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, or IMM, that is reasonably likely to predict an effect on IMM or other clinical benefit. The FDA considers a clinical benefit to be a positive therapeutic effect that is clinically meaningful in the context of a given disease, such as IMM. For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign, or other measure that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. An intermediate clinical endpoint is a clinical endpoint that can be measured earlier than an effect on IMM that is reasonably likely to predict an effect on IMM or other clinical benefit. The accelerated approval pathway may be used in cases in which the advantage of a new product over available therapy may not be a direct therapeutic advantage, but is a clinically important improvement from a patient and public health perspective. If granted, accelerated approval is usually contingent on the sponsor&#8217;s agreement to conduct, in a diligent manner, additional post-approval confirmatory studies to verify and describe the product&#8217;s clinical benefit. If such post-approval studies fail to confirm the product&#8217;s clinical benefit, the FDA may withdraw its approval of the product. In addition, the FDA currently requires, unless otherwise informed by the agency, pre-approval of promotional materials for products receiving accelerated approval, which could adversely impact the timing of the commercial launch of the product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prior to seeking accelerated approval, we would seek feedback from the FDA, EMA or comparable foreign regulatory authorities and would otherwise evaluate our ability to seek and receive such accelerated approval. However, there can be no assurance that after our evaluation of the feedback and other factors we will decide to pursue or submit a BLA for accelerated approval or any other form of expedited development, review or approval for LX2006 or any other product candidate. Similarly, there can be no assurance that after subsequent feedback from the FDA, EMA or comparable foreign regulatory authorities, we will continue to pursue or apply for accelerated approval or any other form of expedited development, review or approval, even if we initially decide to do so. Furthermore, if we decide to submit an application for accelerated approval, there can be no assurance that such application will be accepted or that any approval will be granted on a timely basis, or at all. The FDA, EMA or other comparable foreign regulatory authorities could also require us to conduct further studies prior to considering our application or granting approval of any type, including, for example, if other products are approved via the accelerated pathway and subsequently converted by FDA to full approval. A failure to obtain accelerated approval or any other form of expedited development, review or approval for our therapeutic candidate would result in a longer time period to commercialization of such therapeutic candidate, could increase the cost of development of such therapeutic candidate and could harm our competitive position in the marketplace.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Priority review designation by the FDA may not lead to a faster regulatory review or approval process and, in any event, does not assure FDA approval of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the FDA determines that a product candidate is intended to treat a serious disease or condition and, if approved, would provide a significant improvement in the safety or effectiveness of the treatment, prevention, or diagnosis of such disease or condition, the FDA may designate the product candidate for priority review. A priority review designation means that the goal for the FDA to review a marketing application is six months from filing of the application, rather than the standard review period of ten months. We may request priority review for certain of our product candidates. The FDA has broad discretion with respect to whether or not to grant priority review status to a product candidate, so even if we believe a particular product candidate is eligible for such designation or status, the FDA may disagree and decide not to grant it. Moreover, a priority review designation does not necessarily mean a faster regulatory review process or necessarily confer any advantage with respect to approval compared to conventional FDA procedures. Receiving priority review from the FDA does not guarantee approval within the six-month review cycle or thereafter.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">54</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may expend our limited resources to pursue a particular product candidate and fail to capitalize on product candidates that may be more profitable or for which there is a greater likelihood of success.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because we have limited financial and management resources, we must focus on development programs and product candidates that we identify for specific diseases. As such, currently we are primarily focused on the development of our current pipeline of product candidates. As a result, we may forego or delay pursuit of opportunities with other product candidates. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future development programs and product candidates for specific diseases may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not be successful in our efforts to build a pipeline of additional product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our business model is centered on developing product candidates targeting patient populations that place significant burden on society and are most amenable to our genetic medicine approach. We are targeting diseases that have seen limited penetration of precision medicine and where we believe there is significant opportunity for gene therapy to play a role as a key therapeutic option. We aim to select, develop and advance product candidates that we believe will have a high probability of technical and regulatory success through development into commercialization. We may not be able to continue to identify and develop new product candidates. Even if we are successful in continuing to build our pipeline, the potential product candidates that we identify may not be suitable for clinical development. For example, they may be shown to have side effects or other characteristics that indicate that they are unlikely to be drugs that will receive marketing approval and achieve market acceptance. If we do not successfully develop and commercialize product candidates based upon our approach, we will not be able to obtain product revenue in future periods, which likely would result in significant harm to our financial position and adversely affect our stock price.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are unable to successfully validate, develop and obtain regulatory approval for companion diagnostic tests for our product candidates that require or would commercially benefit from such tests, or experience significant delays in doing so, we may not realize the full commercial potential of these product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the clinical development of our product candidates for certain indications, we intend to work with collaborators to develop or obtain access to </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> companion diagnostic tests to identify patient subsets within a disease category who may derive selective and meaningful benefit from our product candidates. To be successful, we or our collaborators will need to address a number of scientific, technical, regulatory and logistical challenges. The FDA and comparable foreign regulatory authorities regulate </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> companion diagnostics as medical devices and, under that regulatory framework, will likely require the conduct of clinical trials to demonstrate the safety and effectiveness of any diagnostics we may develop, which we expect will require separate regulatory clearance or approval prior to commercialization. The FDA generally will require approval or clearance of the diagnostic at the same time that the FDA approves the therapeutic product if the FDA determines that safe and effective use of a therapeutic product depends on an </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vitro </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">companion diagnostic. The clearance or approval of a companion diagnostic as part of the product label will also limit the use of the product candidate to patients who have met the screening criteria tested for by the companion diagnostic.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We intend to rely on third parties for the design, development and manufacture of companion diagnostic tests for our therapeutic product candidates that may require such tests. If we enter into such collaborative agreements, we will be dependent on the sustained cooperation and effort of our future collaborators in developing and obtaining approval for these companion diagnostics. It may be necessary to resolve issues such as selectivity/specificity, analytical validation, reproducibility, or clinical validation of companion diagnostics during the development and regulatory approval processes. Moreover, even if data from preclinical studies and early clinical trials appear to support development of a companion diagnostic for a product candidate, data generated in later clinical trials may fail to support the analytical and clinical validation of the companion diagnostic. We and our future collaborators may encounter difficulties in developing, obtaining regulatory approval for, manufacturing and commercializing companion diagnostics similar to those we face with respect to our therapeutic candidates themselves, including issues with achieving regulatory clearance or approval, production of sufficient quantities at commercial scale and with appropriate quality standards, and in gaining market acceptance. If we are unable to successfully develop companion diagnostics for these product candidates, or experience delays in doing so, the development of these product candidates may be adversely affected, these product candidates may not obtain marketing approval, and we may not realize the full commercial potential of any of these product candidates that obtain marketing approval. As a result, our business, results of operations and financial condition could be materially harmed. In addition, a diagnostic company with whom we contract may decide to discontinue selling or manufacturing the companion diagnostic test that we anticipate using in connection with development and commercialization of our product candidates or our relationship with such diagnostic company may otherwise terminate. We may not be able to enter into arrangements with another diagnostic company to obtain supplies of an alternative diagnostic test for use in connection with the development and commercialization of our product candidates or do so on commercially reasonable terms, which could adversely affect and/or delay the development or commercialization of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">55</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks related to the manufacturing of our product candidates</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We and our contract manufacturers are subject to significant regulation with respect to manufacturing our products. The third-party manufacturing facilities on which we rely, and any manufacturing facility that we may have in the future, may have limited capacity or fail to meet the applicable stringent regulatory requirements.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently have relationships with a limited number of suppliers for the manufacturing of all components of our product candidates. However, if we experience slowdowns or problems with our manufacturing partners and are unable to establish or scale our internal manufacturing capabilities, we will need to continue to contract with manufacturers that can produce the preclinical, clinical and commercial supply of our products. Each supplier may require licenses to manufacture such components if such processes are not owned by the supplier or in the public domain and we may be unable to license such intellectual property rights on reasonable commercial terms or to transfer or sublicense the intellectual property rights we may have with respect to such activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All entities involved in the preparation of therapeutics for clinical trials or commercial sale, including our existing contract manufacturers for components of our product candidates, are subject to extensive regulation. Components of a finished therapeutic product approved for commercial sale or used in late-stage clinical trials in the United States and European Union must be manufactured in accordance with cGMP. These regulations govern manufacturing processes and procedures (including recordkeeping) and the implementation and operation of quality systems to control and assure the quality of investigational products and products approved for sale. Poor control of production processes can lead to the introduction of adventitious agents or other contaminants, or to inadvertent changes in the properties or stability of our product candidates that may not be detectable in final product testing. We or our contract manufacturers must supply all necessary documentation in support of a BLA or an MAA on a timely basis. Our potential manufacturing facilities and quality systems and the facilities and quality systems of some or all of our third-party contractors must pass a pre-approval inspection for compliance with the applicable regulations as a condition of regulatory approval of our product candidates or any of our other potential products. In addition, the regulatory authorities may, at any time, audit or inspect a manufacturing facility involved with the preparation of our product candidates or our other potential products or the associated quality systems for compliance with the regulations applicable to the activities being conducted, and they could put a hold on one or more of our clinical trials if the facilities of our contract manufacturing organizations, or CMOs do not pass such audit or inspections. If these facilities do not pass a pre-approval plant inspection, FDA approval of the products will not be granted.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The regulatory authorities also may, at any time following approval of a product for sale, inspect or audit our manufacturing facilities or those of our third-party contractors. If any such inspection or audit identifies a failure to comply with applicable regulations or if a violation of our product specifications or applicable regulations occurs independent of such an inspection or audit, we or the relevant regulatory authority may require remedial measures that may be costly and/or time-consuming for us or a third party to implement and that may include the temporary or permanent suspension of a clinical trial or commercial sales or the temporary or permanent closure of a facility. Any such remedial measures imposed upon us or third parties with whom we contract could harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we or any of our third-party manufacturers fail to maintain regulatory compliance, the FDA can impose regulatory sanctions including, among other things, refusal to approve a pending application for a new drug product or biologic product, or revocation of a pre-existing approval. As a result, our business, financial condition and results of operations may be harmed. Additionally, if supply from one approved manufacturer is interrupted, there could be a significant disruption in commercial supply. An alternative manufacturer would need to be qualified through a BLA and/or an MAA supplement which could result in further delay. The regulatory agencies may also require additional studies if a new manufacturer is relied upon for commercial production. Switching manufacturers may involve substantial costs and is likely to result in a delay in our desired clinical and commercial timelines.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These factors could cause the delay of clinical trials, regulatory submissions, required approvals or commercialization of our product candidates, cause us to incur higher costs and prevent us from commercializing our products successfully, if approved. Furthermore, if our suppliers fail to meet contractual requirements, and we are unable to secure one or more replacement suppliers capable of production at a substantially equivalent cost, our clinical trials may be delayed, or we could lose potential revenue.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Gene therapies are novel, complex and difficult to manufacture. We could experience manufacturing problems that result in delays in the development or commercialization of our product candidates or otherwise harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The manufacture of gene therapy products is technically complex and necessitates substantial expertise and capital investment. Production difficulties caused by unforeseen events may delay the availability of material for our clinical studies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">56</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We rely on third-party manufacturers to manufacture our product candidates for preclinical studies and clinical trials. The manufacturers of pharmaceutical products must comply with strictly enforced cGMP requirements, state and federal regulations, as well as foreign requirements when applicable. Any failure of us or our CMOs to adhere to or document compliance to such regulatory requirements could lead to a delay or interruption in the availability of our product candidate materials for clinical trials or enforcement action from the FDA, EMA or foreign regulatory authorities. If we or our manufacturers fail to comply with the requirements of the FDA, EMA or other regulatory authority, sanctions could be imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There can be no assurances that our third-party manufacturers will be able to meet our timetable and requirements. If any third party with whom we contract fails to perform its obligations, we may be forced to either manufacture the materials ourselves, for which we may not have the capabilities or resources, or enter into an agreement with a different third-party manufacturer, which we may not be able to do on reasonable terms, if at all. In either scenario, our clinical trials and future commercial supply could be delayed significantly as we establish alternative supply sources. In some cases, the technical skills required to manufacture our product candidates may be unique or proprietary to the original third-party manufacturer and we may have difficulty, or there may be contractual restrictions prohibiting us from, transferring such skills to a back-up or alternate supplier, or we may be unable to transfer such skills at all. In addition, if we are required to change manufacturers for any reason, we will be required to verify that the new manufacturer maintains facilities and procedures that comply with quality standards and with all applicable regulations. We will also need to verify, such as through a manufacturing comparability study, that any new manufacturing process will produce our product candidates according to the specifications previously submitted to the FDA or another regulatory authority. The delays associated with the verification of a new manufacturer could negatively affect our ability to develop product candidates or commercialize our products, if approved, in a timely manner or within budget.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to arrange for alternative third-party manufacturing sources on commercially reasonable terms or in a timely manner, we may be delayed in the development of our product candidates. Our dependence upon others for the manufacture of our product candidates may also adversely affect our future profit margins and our ability to commercialize any product candidates that receive regulatory approval on a timely and competitive basis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our product candidates require processing steps that are more complex than those required for most chemical pharmaceuticals. Moreover, unlike chemical pharmaceuticals, the physical and chemical properties of a biologic such as our modified virus generally cannot be fully characterized. As a result, assays of the finished product may not be sufficient to ensure that the product will perform in the intended manner. Although we believe that the manufacture of our product candidates may be simplified due to their shared raw materials and other similarities, we cannot be certain that this will be the case and we may be required to develop manufacturing methods that ultimately differ significantly between product candidates, which would require that we invest substantial time and capital to develop suitable manufacturing methods. Our program materials are manufactured using technically complex processes requiring specialized equipment and facilities, highly specific raw materials, cell types and reagents, and other production constraints. Our production process also requires a number of highly specific raw materials, cell types and reagents with limited suppliers. Even though we aim to have backup supplies of raw materials, cell types and reagents whenever possible, we cannot be certain they will be sufficient if our primary sources are unavailable. A shortage of a critical raw material, cell line, or reagent, or a technical issue during manufacturing may lead to delays in clinical development or commercialization plans. We are particularly susceptible to any shortages, delays or our inability to obtain suitable raw materials for our lead product candidates. Any changes in the manufacturing of components of the raw materials we use could result in unanticipated or unfavorable effects in our manufacturing processes, resulting in delays.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, if any of our product candidates obtain approval, the FDA, EMA and other regulatory authorities may require us to submit samples of any lot of any approved product together with the protocols showing the results of applicable tests at any time. Under some circumstances, the FDA, EMA or other regulatory authorities may require that we not distribute a lot until the agency authorizes its release. Slight deviations in the manufacturing process, including those affecting quality attributes and stability, may result in unacceptable changes in the product that could result in lot failures or product recalls. Lot failures or product recalls could cause us to delay product launches or clinical trials, which could be costly to us and otherwise harm our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">57</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We depend on third-party suppliers for materials used in the manufacture of our product candidates, and the loss of these third-party suppliers or their inability to supply us with adequate materials could harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We rely on third-party suppliers for the materials and components required for the production of our product candidates. Our dependence on these third-party suppliers and the challenges we may face in obtaining adequate supplies of materials involve several risks, including limited control over pricing, availability, and delivery schedules. There is substantial demand and limited supply for certain of the raw materials used to manufacture gene therapy products. As a small company, our negotiation leverage is limited, and we may get lower priority than our competitors that are larger than we are. We cannot be certain that our suppliers will continue to provide us with the quantities of these raw materials within the timelines that we require or satisfy our anticipated specifications and quality requirements. Any supply interruption in limited or sole-sourced raw materials could materially harm our ability to manufacture our product candidates until a new source of supply, if any, could be identified and qualified. We may be unable to find a sufficient alternative supply channel in a reasonable time or on commercially reasonable terms. Any performance failure on the part of our suppliers could delay the development and potential commercialization of our product candidates, including limiting supplies necessary for clinical trials and regulatory approvals, which would have a material adverse effect on our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Any contamination or interruption in our manufacturing process, shortages of raw materials or failure of our suppliers of viruses to deliver necessary components could result in delays in our clinical development or marketing schedules.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Given the nature of gene therapy manufacturing, there is a risk of contamination occurring during the manufacturing process. Any contamination could adversely affect our ability to produce product candidates on schedule and could, therefore, harm our results of operations and cause reputational damage. Some of the raw materials required in our manufacturing process are derived from biologic sources. Such raw materials are difficult to procure and may be subject to contamination or recall. A material shortage, contamination, recall or restriction on the use of biologically derived substances in the manufacture of our product candidates could adversely impact or disrupt the commercial manufacturing or the production of clinical material, which could adversely affect our development timelines and our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Changes in methods of product candidate manufacturing or formulation may result in additional costs or delay.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As product candidates proceed through preclinical studies to late-stage clinical trials towards potential approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods and formulation, are altered along the way in an effort to optimize processes and product characteristics. Such changes carry the risk that they will not achieve our intended objectives. Any such changes could cause our product candidates to perform differently and affect the results of planned clinical trials or other future clinical trials conducted with the materials manufactured using altered processes. Such changes may also require additional testing, FDA notification or FDA approval. This could delay the initiation and completion of clinical trials, require the conduct of bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidates and jeopardize our ability to commence sales and generate revenue. In addition, we may be required to make significant changes to our upstream and downstream processes across our pipeline, which could delay the development of our future product candidates. Regulatory agencies, and in particular the FDA and EMA, have demonstrated increased caution in their regulation of gene therapies, including increased scrutiny related to chemistry, manufacturing and control, or CMC, issues. This increased regulatory scrutiny around gene therapy CMC may result in us being required to conduct additional preclinical studies or clinical trials with respect to any of our product candidates, which may result in delays and increased costs in the development or commercialization of our product candidates and ultimately could lead to the failure to obtain approval for any gene therapy product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks related to the commercialization of our product candidates</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Even if any of our product candidates receive marketing approval, they may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If any of our product candidates receive marketing approval, they may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors and others in the medical community. If our product candidates do not achieve an adequate level of acceptance, we may not generate significant revenue and we may not become profitable. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on a number of factors, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">their efficacy, safety and potential advantages compared to alternative treatments; </span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to offer our products for sale at competitive prices;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">their convenience and ease of administration compared to alternative treatments;</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">58</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">product labeling or product insert requirements of the FDA or foreign regulatory authorities, including any limitations or warnings contained in a product&#8217;s approved labeling, including any boxed warning or REMS;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the willingness of the target patient population to try new treatments, such as gene therapy as a novel modality for treatment of our target indications and of physicians to prescribe these treatments;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to hire and retain a sales force in the United States;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the strength of marketing and distribution support;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the availability of coverage and adequate reimbursement for our product candidates, once approved, from third-party payors and government authorities;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the prevalence and severity of any side effects; and</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any restrictions on the use of our products together with other medications.</span></div></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Negative public opinion of gene therapy and increased regulatory scrutiny of gene therapy and genetic research may adversely impact the development or commercial success of our current and future product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our product candidates involve introducing genetic material into a patient&#8217;s cells via intrathecal and intravenous administration. The clinical and commercial success of our potential products will depend in part on public acceptance of the use of gene therapy and gene regulation for the prevention or treatment of human diseases. Public attitudes may be influenced by claims that gene therapy and gene regulation are unsafe, unethical or immoral, and consequently, our products may not gain the acceptance of the public or the medical community. Adverse public attitudes may adversely impact our ability to enroll clinical trials. Moreover, our success will depend upon physicians prescribing, and their patients being willing to receive, treatments that involve the use of product candidates we may develop in lieu of, or in addition to, existing treatments with which they are already familiar and for which greater clinical data may be available.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">More restrictive government regulations or negative public opinion would have a negative effect on our business or financial condition and may delay or impair the development and commercialization of our product candidates or demand for any products once approved. In recent years, sponsors of other clinical trials involving gene therapies have announced imposition of clinical holds by the FDA to evaluate safety issues arising during the trials. Among the risks in any gene therapy product based on viral vectors are the risks of immunogenicity, elevated liver enzymes and insertional oncogenesis. If any of our vectors demonstrate a similar effect, we may decide or be required to halt or delay further clinical development of any product candidates that utilize that vector. Adverse events in our or others&#8217; clinical trials, even if not ultimately attributable to our product candidates, and the resulting publicity could result in increased governmental regulation, unfavorable public perception, potential regulatory delays in the testing or approval of our product candidates, stricter labeling requirements for those product candidates that are approved and a decrease in demand for any such product candidates. The risk of cancer remains a concern for gene therapy, and we cannot assure that it will not occur in any of our planned or future clinical trials or in any clinical trials conducted by other companies. In addition, there is the potential risk of delayed adverse events following exposure to gene therapy products due to persistent biological activity of the genetic material or other components of products used to carry the genetic material. In addition, for our regulated gene replacement therapy product candidates which require that the expression of a therapeutic transgene be tightly regulated, we may inadvertently cause overexpression, which could lead to numerous issues, including safety and toxicity concerns. Furthermore, one of our regulatory gene replacement therapy candidates, LX1020, requires the insertion of miRNA targets into the viral genome, which is a technology that to our knowledge is not present in any approved gene therapy products. If any such adverse events occur, commercialization of our product candidates or further advancement of our clinical trials could be halted or delayed, which would have a negative impact on our business and operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The affected populations for our other product candidates may be smaller than we or third parties currently project, which may affect the addressable markets for our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently focus our research and product development on several indications that are larger-rare diseases. However, our projections of the number of people who have the diseases we are seeking to treat, as well as the subset of people with these diseases who have the potential to benefit from treatment with our product candidates, are estimates based on our knowledge and understanding of these diseases. These estimates may prove to be incorrect and new studies may further reduce the estimated incidence or prevalence of this disease. The number of patients in the United States, the European Union and elsewhere may turn out to be lower than expected, may not be otherwise amenable to treatment with our product candidate or patients may become increasingly difficult to identify and access, all of which would adversely affect our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">59</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The total addressable market opportunity for our product candidates will ultimately depend upon a number of factors, including the diagnosis and treatment criteria included in the final label, if approved for sale in specified indications, acceptance by the medical community, patient access and product pricing and reimbursement. Incidence and prevalence estimates are frequently based on information and assumptions that are not exact and may not be accurate, and the methodology is forward-looking and potentially speculative. The process we have used in developing an estimated incidence and prevalence range for the indications we are targeting has involved collating limited data from multiple sources. Accordingly, the incidence and prevalence estimates included in this Annual Report on Form 10-K should be viewed in that context. Further, the data and statistical information used in this Annual Report, including estimates derived from them, may differ from information and estimates made by our competitors or from current or future studies conducted by independent sources.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We face significant competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Drug development, particularly in the gene therapy field, is highly competitive and subject to rapid and significant technological advancements. As a significant unmet medical need exists in the cardiovascular disease area, there are several large and small pharmaceutical companies focused on delivering therapeutics for the treatment of these diseases, including those that we are initially targeting. It is likely that additional drugs will become available in the future for the treatment of our target diseases.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are aware that our competitors are developing product candidates for the treatment of diseases that our product candidates will target. With respect to LX2006, we are aware of</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> clinical stage gene therapy programs in development at Astellas Pharma Inc. and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Solid Biosciences Inc., and those being developed in collaborations between Voyager Therapeutics, Inc. and Neurocrine Biosciences, Inc. Additionally, we are aware that Prime Medicine, Inc. and Tune Therapeutics, Inc. have early-stage gene editing discovery efforts. Among other treatment modalities for FA, we are aware that Larimar Therapeutics, Inc. is developing a clinical stage product candidate, CTI-1601, that Design Therapeutics, Inc. is developing a product candidate, DT-216P2, and that PTC Therapeutics, Inc. has submitted a new drug application for vatiquinone to the FDA. Reata Pharmaceuticals, Inc.&#8217;s omaveloxolone (Skyclarys) was approved by the FDA in 2023, and Biogen Inc. acquired Reata Pharmaceuticals, Inc. for approximately $7.3 billion in the same year and is currently commercializing Skyclarys.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With respect to LX2020, both Rocket and Tenaya Therapeutics Inc. are developing an AAV-based gene therapy candidate designed to deliver a functional </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">PKP2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> gene to patients with PKP2-ACM.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many of our existing or potential competitors have substantially greater financial, technical and human resources than we do and significantly greater experience in the discovery and development of product candidates, as well as in obtaining regulatory approvals of those product candidates in the United States and in foreign countries. Our current and potential future competitors may also have significantly more experience commercializing drugs, particularly gene therapy and other biologics, that have been approved for marketing. Mergers and acquisitions in the pharmaceutical and biotechnology industries could result in even more resources being concentrated among a small number of our competitors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will face competition from other drugs or from other non-drug products currently approved or that will be approved in the future in the cardiac and neurology fields, including for the treatment of diseases and diseases in the therapeutic categories we intend to target. Therefore, our ability to compete successfully will depend largely on our ability to:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">develop and commercialize drugs that are advantageous as compared to other products in the market;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">demonstrate through our clinical trials that our product candidates are differentiated from existing and future therapies;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">attract qualified scientific, product development and commercial personnel;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtain patent or other proprietary protection for our product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtain required regulatory approvals;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtain coverage and adequate reimbursement from, and negotiate competitive pricing with, third-party payors; and</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">successfully collaborate with other pharmaceutical companies in the discovery, development and commercialization of new medicines.</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">60</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The availability of our competitors&#8217; products could limit the demand, and the price we are able to charge, for any product candidate we develop. The inability to compete with existing or subsequently introduced drugs would have an adverse impact on our business, financial condition and prospects. In addition, the reimbursement structure of approved gene therapies by other companies could impact the anticipated reimbursement structure of our gene therapies, if approved, and our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Established pharmaceutical companies may invest heavily to accelerate discovery and development of novel compounds or to in-license novel compounds that could make our product candidates less competitive. In addition, any new product that competes with an approved product must demonstrate compelling advantages in efficacy, convenience, tolerability and safety in order to overcome price competition and to be commercially successful. Accordingly, our competitors may succeed in obtaining patent protection, discovering, developing, receiving regulatory and marketing approval for, or commercializing, drugs before we do, which would have an adverse impact on our business and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Any product candidates for which we intend to seek approval as biologic products may face competition sooner than anticipated.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The ACA includes a subtitle called the Biologics Price Competition and Innovation Act of 2009, or BPCIA, which created an abbreviated approval pathway for biologics that are biosimilar to or interchangeable with an FDA-licensed reference biological product. Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing the sponsor&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of its product. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation and meaning are subject to uncertainty. While it is uncertain when such processes intended to implement BPCIA may be fully adopted by the FDA, any such processes could have an adverse effect on the future commercial prospects for our biologics.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There is a risk that any of our product candidates approved as a biological product under a BLA would not qualify for the 12-year period of exclusivity or that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider our product candidates to be reference products for competing products, potentially creating the opportunity for generic competition sooner than anticipated. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of our reference products in a way that is similar to traditional generic substitution for non-biologics is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing. If competitors are able to obtain marketing approval for biosimilars referencing our product candidates, if approved, our products may become subject to competition from such biosimilars, with the attendant competitive pressure and potential adverse consequences.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The success of our product candidates will depend significantly on coverage and adequate reimbursement or the willingness of patients, commercial and government payors to pay for these procedures.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe our success depends on obtaining and maintaining coverage and adequate reimbursement for our product candidates, including LX2006 and LX2020, and the extent to which patients will be willing to pay out-of-pocket for such products, in the absence of reimbursement for all or part of the cost. In the United States and in other countries, patients who are provided medical treatment for their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. The availability of coverage and adequacy of reimbursement for our products by third-party payors, including government health care programs (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">e.g.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, Medicare, Medicaid, TRICARE), managed care providers, private health insurers, health maintenance organizations and other organizations is essential for most patients to be able to afford medical services and pharmaceutical products such as our product candidates. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own coverage and reimbursement policies. However, decisions regarding the extent of coverage and amount of reimbursement to be provided are made on a payor-by-payor basis. One payor&#8217;s determination to provide coverage for a drug product does not assure that other payors will also provide coverage, and adequate reimbursement. For more information, see the section titled &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Business &#8211; Government Regulation &#8211; Coverage and Reimbursement</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">61</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The principal decisions about reimbursement for new medicines are typically made by CMS, an agency within HHS. CMS decides whether and to what extent products will be covered and reimbursed under Medicare and private payors tend to follow CMS to a substantial degree. </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Most significantly, in August 2022, the Inflation Reduction Act of 2022, or IRA, was signed into law. Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare, with prices that can be negotiated subject to a cap (with resulting prices for the initial ten drugs first effective in 2026); imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023); redesigns the Medicare Part D benefit (beginning in 2024); and replaces the Part D coverage gap discount program with a new discounting program (beginning in 2025). The IRA permits the Secretary of the HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years. On August 29, 2023, HHS announced the list of the first ten drugs that will be subject to price negotiations. HHS has issued and will continue to issue and update guidance implementing the IRA, although the Medicare drug price negotiation program is currently subject to legal challenges. While the impact of the IRA on the pharmaceutical industry cannot yet be fully determined, it is likely to be significant. Only high-expenditure single-source drugs that have been approved for at least 7 years (11 years for single-source biologics) can qualify for negotiation, with the negotiated price taking effect two years after the selection year. For 2026, the first year in which negotiated prices become effective, CMS selected 10 high-cost Medicare Part D drugs in 2023, negotiations began in 2024, and the negotiated maximum fair price for each drug has been announced. CMS has selected 15 additional Medicare Part D drugs for negotiated maximum fair pricing in 2027. For 2028, up to an additional 15 drugs, which may be covered under either Medicare Part B or Part D, will be selected, and for 2029 and subsequent years, up to 20 additional Part B or Part D drugs will be selected.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Third-party payors determine which products and procedures they will cover and establish reimbursement levels. Even if a third-party payor covers a particular product or procedure, the resulting reimbursement payment rates may not be adequate. Patients who are treated in-office for a medical condition generally rely on third-party payors to reimburse all or part of the costs associated with the procedure, including costs associated with products used during the procedure, and may be unwilling to undergo such procedures in the absence of such coverage and adequate reimbursement. Physicians may be unlikely to offer procedures for such treatment if they are not covered by insurance and may be unlikely to purchase and use our product candidates, if approved, for our stated diseases unless coverage is provided and reimbursement is adequate. In addition, for products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. Further, coverage policies and third-party reimbursement rates may change at any time. Therefore, even if favorable coverage and reimbursement status is attained, less favorable coverage policies and reimbursement rates may be implemented in the future. In addition, companion diagnostic tests require coverage and reimbursement separate and apart from the coverage and reimbursement for their companion pharmaceutical or biological products. Similar challenges to obtaining coverage and reimbursement, applicable to pharmaceutical or biological products, will apply to companion diagnostics.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Reimbursement by a third-party payor may depend upon a number of factors, including the third-party payor&#8217;s determination that a procedure is a covered benefit under its health plan; safe, effective and medically necessary; appropriate for the specific patient; cost-effective; supported by peer-reviewed medical journals; included in clinical practice guidelines; and neither cosmetic, experimental, nor investigational. Further, increasing efforts by third-party payors in the United States and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide adequate payment for our product candidates. In order to secure coverage and reimbursement for any product that might be approved for sale, we may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of our products, in addition to the costs required to obtain FDA or comparable regulatory approvals. Additionally, we may also need to provide discounts to purchasers, private health plans or government healthcare programs. Our product candidates may nonetheless not be considered medically necessary or cost-effective. If third-party payors do not consider a product to be cost-effective compared to other available therapies, they may not cover the product after approval as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow a company to sell its products at a profit. We expect to experience pricing pressures from third-party payors in connection with the potential sale of any of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Foreign governments also have their own healthcare reimbursement systems, which vary significantly by country and region, and we cannot be sure that coverage and adequate reimbursement will be made available with respect to the treatments in which our products are used under any foreign reimbursement system.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There can be no assurance that LX2006, LX2020 or any other product candidates, if approved for sale in the United States or in other countries, will be considered medically reasonable and necessary, that it will be considered cost-effective by third-party payors, that coverage or an adequate level of reimbursement will be available or that reimbursement policies and practices in the United States and in foreign countries where our products are sold will not adversely affect our ability to sell our product candidates profitably, if they are approved for sale.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">62</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of any products that we may develop.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We face an inherent risk of product liability exposure related to the testing of our product candidates in human clinical trials and will face an even greater risk if we commercially sell any products that we may develop. If we cannot successfully defend ourselves against claims that our product candidates or drugs caused injuries, we will incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">decreased demand for any product candidates or drugs that we may develop;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">injury to our reputation and significant negative media attention;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">withdrawal of clinical trial participants;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">significant costs to defend the related litigation;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">substantial monetary awards paid to trial participants or patients;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">loss of revenue;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reduced resources of our management to pursue our business strategy; and </span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the inability to commercialize any products that we may develop. </span></div></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although we maintain product liability insurance coverage, such insurance may not be adequate to cover all liabilities that we may incur. We may need to increase our insurance coverage as we expand our clinical trials or if we commence commercialization of our product candidates. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks related to our dependence on third parties</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Currently, we rely on our collaborations with Cornell University and The Regents of UCSD to conduct research and development for many of our pipeline programs, including conducting preclinical and IND-enabling studies for portions of our near-term future pipeline. Failure or delay of Cornell University or The Regents of UCSD to fulfill all or part of their respective obligations to us under our agreements, a breakdown in collaboration between the parties or a complete or partial loss of either of these relationships could materially harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our collaboration with Cornell University is critical to our business and in May 2020, we entered into two separate license agreements with Cornell University </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">pursuant to which we obtained rights under certain patents, know-how and data to exploit products and technologies covered by such intellectual property. As part of our first license agreement, as amended, we assumed oversight for the conduct of the Phase 1/2 clinical trial of LX1001 that was initiated by Cornell University at the end of 2019. As part of our second license agreement with Cornell </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">University</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, as amended, we obtained certain rights to portfolios for infantile neuronal ceroid lipofuscinosis type 2 (also called CLN2 Batten disease) and FA cardiomyopathy, as well as an assignment of Cornell University&#8217;s IND to support the development of our LX1004 program. In February 2021, we further expanded our collaboration and entered into a research collaboration agreement with Cornell University to conduct preclinical research to develop the licensed technology, which expired pursuant to its terms in February 2024. We entered into a third license agreement with Cornell University in April 2024 pursuant to which we obtained certain rights for FA cardiomyopathy, including rights to current and future clinical data from an ongoing Cornell University investigator-initiated Phase 1A trial of a gene therapy candidate AAVrh10.hFXN, known as LX2006 at Lexeo. Pursuant to these license agreements, we are obligated to diligently proceed with the development, manufacture, and sale of licensed products. If Cornell University delays or fails to perform its obligations under the license agreements terminates any of the license agreements in accordance with its terms, or a dispute otherwise arises between the parties concerning the terms of the agreements or our respective rights to licensed technology, our pipeline of product candidates would be significantly adversely affected and our prospects may be materially harmed</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">63</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our collaboration with UCSD is also highly important to our business, as we have licensed from UCSD intellectual property rights related to our LX2020, LX2021 and LX2022 programs under three separate license agreements, and we have entered into sponsored research agreements with UCSD for preclinical research and development for these programs. If The Regents of UCSD delays or fails to perform its obligations under either of the sponsored research agreements or any of the license agreements, disagrees with our interpretation of the terms of the sponsored research agreements, license agreements or our discovery plans, or terminates any of our existing license agreements, our pipeline of product candidates would be significantly adversely affected and our prospects may be materially harmed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We intend to continue to rely on third parties to conduct a significant portion of our existing clinical trials and potential future clinical trials for product candidates, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We engage CROs to help conduct our ongoing clinical trials. We expect to continue to rely on third parties, including clinical data management organizations, medical institutions and clinical investigators, to conduct those clinical trials and any future clinical trials. Any of these third parties may terminate their engagements with us, some in the event of an uncured material breach and some at any time for convenience. If any of our relationships with these third parties terminate, we may not be able to timely enter into arrangements with alternative third parties or to do so on commercially reasonable terms, if at all. Switching or adding a CRO involves substantial cost and requires management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. Though we intend to carefully manage our relationships with our CROs, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, any third parties conducting our clinical trials will not be our employees, and except for remedies available to us under our agreements with such third parties, we cannot control whether or not they devote sufficient time and resources to our clinical programs. If these third parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. Consequently, our results of operations and the commercial prospects for our product candidates would be harmed, our costs could increase substantially and our ability to generate revenue could be delayed significantly.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We rely on these parties for execution of our preclinical studies and clinical trials, and generally do not control their activities. Our reliance on these third parties for research and development activities will reduce our control over these activities but will not relieve us of our responsibilities. For example, we will remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA requires us to comply with cGCP regulations, for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. We also are required to register ongoing clinical trials and post the results of completed clinical trials on a government-sponsored database, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">www.clinicaltrials.gov</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, within specified time frames. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions. If we or any of our CROs or other third parties, including trial sites, fail to comply with applicable cGCPs, or experience material protocol deviations, the clinical data generated in our clinical trials may be deemed unreliable and the FDA, EMA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. If the FDA or any regulatory authority determines that our clinical data are not reliable for any reason, or if we encounter any data integrity issues, the FDA or other regulatory authorities may require us to exclude such data, which may cause the trial to be underpowered and fail to meet the trial endpoints. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials complies with cGCP regulations. In addition, our clinical trials must be conducted with product produced under cGMP conditions. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA. The FDA may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the trial. The FDA may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA and may ultimately lead to the denial of marketing approval of LX2006, LX2020 or any other product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">64</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also expect to rely on other third parties to store and distribute product supplies for our clinical trials. Any performance failure on the part of our distributors could delay clinical development or marketing approval of our product candidates or commercialization of our products, producing additional losses and depriving us of potential revenue.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may seek collaborations with non-academic third parties for the development or commercialization of our product candidates. If those collaborations are not successful, we may not be able to capitalize on the market potential of these product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may seek third-party collaborators for the development and commercialization of our product candidates, including for the commercialization of any of our product candidates that are approved for marketing outside the United States. Our likely collaborators for any such arrangements include regional and national pharmaceutical companies and biotechnology companies. If we enter into any additional such arrangements with any third parties, we will likely have limited control over the amount and timing of resources that our collaborators dedicate to the development or commercialization of our product candidates. Our ability to generate revenue from these arrangements will depend on our collaborators&#8217; abilities to successfully perform the functions assigned to them in these arrangements. Collaborations involving our product candidates pose the following risks to us:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborators may not perform their obligations as expected;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborators may not pursue development and commercialization of any product candidates that achieve regulatory approval or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborators&#8217; strategic focus or available funding, or external factors, such as an acquisition, that divert resources or create competing priorities;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we could grant exclusive rights to our collaborators that would prevent us from collaborating with others; </span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">product candidates discovered in collaboration with us may be viewed by our collaborators as competitive with their own product candidates or drugs, which may cause collaborators to cease to devote resources to the commercialization of our product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a collaborator with marketing and distribution rights to one or more of our product candidates that achieve regulatory approval may not commit sufficient resources to the marketing and distribution of such products;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the preferred course of development, might cause delays or termination of the research, development or commercialization of product candidates, might lead to additional responsibilities for us with respect to product candidates, or might result in litigation or arbitration, any of which would be time-consuming and expensive;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborators may not properly maintain or defend our or their intellectual property rights or may use our or their proprietary information in such a way as to invite litigation that could jeopardize or invalidate such intellectual property or proprietary information or expose us to potential litigation;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability; and</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborations may be terminated for the convenience of the collaborator and, if terminated, we could be required to raise additional capital to pursue further development or commercialization of the applicable product candidates.</span></div></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Collaboration agreements may not lead to development or commercialization of product candidates in the most efficient manner or at all. If any future collaborator of ours were to be involved in a business combination, the continued pursuit and emphasis on our product development or commercialization program could be delayed, diminished or terminated.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">65</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We face significant competition in seeking appropriate collaborators. Whether we reach a definitive agreement for any collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA or similar regulatory authorities outside the United States, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge and industry and market conditions generally. The collaborator may also consider alternative product candidates or technologies for similar diseases that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our product candidate. Collaborations are complex and time-consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may not be able to negotiate additional collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of such product candidate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our product candidates or bring them to market and generate revenue.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks related to intellectual property</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are unable to obtain or protect intellectual property rights related to any of our product candidates, we may not be able to compete effectively in our market.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We rely upon a combination of patents, trade secret protection and confidentiality agreements to protect the intellectual property related to our product candidates, including LX2006, LX2020, LX2021, LX2022, LX1001, LX1020, LX1021, and other programs, their respective components, formulations, therapies, methods used to manufacture them and methods of treatment.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our success depends in large part on our ability to obtain and maintain patent and other intellectual property protection in the United States and in other countries with respect to our proprietary technology and product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot offer any assurances about which of our patent applications will issue, the breadth of any resulting patent or whether any of the issued patents will be found invalid and unenforceable or will be threatened by third parties. We cannot offer any assurances that the breadth of our granted patents will be sufficient to stop a competitor from developing and commercializing a product, including a biosimilar product that would be competitive with one or more of our product candidates. Furthermore, any successful challenge to these patents or any other patents owned by or licensed to us after patent issuance could deprive us of rights necessary for the successful commercialization of any of our product candidates. Further, if we encounter delays in regulatory approvals, the period of time during which we could market a product candidate under patent protection could be reduced.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">66</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The patent prosecution process is expensive and time-consuming. We may not be able to prepare, file and prosecute all necessary or desirable patent applications at a commercially reasonable cost or in a timely manner or in all jurisdictions. It is also possible that we may fail to identify patentable aspects of inventions made in the course of development and commercialization activities before it is too late to obtain patent protection on them. We may not be able to obtain or maintain patent applications and patents due to the subject matter claimed in such patent applications and patents being in the public domain. In some cases, the work of certain academic researchers in the gene therapy field has entered the public domain, which may preclude our ability to obtain patent protection for certain inventions relating to such work. Although we enter into nondisclosure and confidentiality agreements with parties who have access to confidential or patentable aspects of our research and development output, such as our employees, corporate collaborators, outside scientific collaborators, contract manufacturers, consultants, advisors and other third parties, any of these parties may breach these agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection. Consequently, we would not be able to prevent any third party from using any technology that is in the public domain to compete with our product candidates. </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, as the licensee of patents from Cornell University and UCSD, we have less control over the prosecution and enforcement of those patents than we would if we owned the patents. While we do have typical rights with respect to those patents under university license agreements, our ability to enforce those patents to maintain exclusivity in our markets may be limited by the terms of our agreements with Cornell University and UCSD. In addition, to the extent the federal government provided research funding to the licensor university for any technology licensed under the license agreements, then if the federal government elects to exercise any of its overriding rights which may apply as a result of provision of such funding, we may be subject to changes in market exclusivity or other material business requirements or constraints.</span><span style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, depending on the terms of any future in-licenses to which we may become a party, we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering technology in-licensed from third parties. Therefore, these patents and patent applications may not be prosecuted and enforced in a manner consistent with the best interests of our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has, in recent years, been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of any patent rights are highly uncertain. Our owned and licensed pending and future patent applications may not result in issued patents which protect our technology or product candidates, effectively prevent others from commercializing competitive technologies and product candidates or otherwise provide any competitive advantage. In fact, patent applications may not issue as patents at all. Even if patent applications we license or own currently or in the future issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors or other third parties from competing with us, or otherwise provide us with any competitive advantage. Any patents that we hold or in-license may be challenged, narrowed, circumvented, or invalidated by third parties. Consequently, we do not know whether any of our technologies and product candidates will be protectable or remain protected by valid and enforceable patents. In addition, our existing patents and any future patents we obtain may not be sufficiently broad to prevent others from using our technology or from developing competing technologies and products, and the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. Any failure to obtain, maintain or defend our patents and other intellectual property could have a material adverse effect on our business, financial conditions, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot be certain that we are the first to invent the inventions covered by pending patent applications and, if we are not, we may be subject to priority or entitlement disputes. We may be required to disclaim part or all of the term of certain patents or all of the term of certain patent applications. There may be prior art of which we are not aware that may affect the validity or enforceability of a patent claim. There also may be prior art of which we are aware, but which we do not believe affects the validity or enforceability of a claim, which may, nonetheless, ultimately be found to affect the validity or enforceability of a claim. Since patent applications in the United States and other countries are confidential for a period of time after filing, at any moment in time, we cannot be certain that we were in the past or will be in the future the first to file any patent application related to our product candidates. For example, some patent applications in the United States may be maintained in secrecy until the patents are issued. Further, publications in the scientific literature often lag behind actual discoveries. Consequently, we cannot be certain that others have not filed patent applications for technology covered by our owned and in-licensed issued patents or our pending applications, or that we or, if applicable, a licensor, were the first to invent or first to file an application for the technology.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It is possible that defects of form in the preparation or filing of our patents or patent applications may exist, or may arise in the future, for example, with respect to proper priority claims, inventorship, claim scope, or requests for patent term adjustments. If there are material defects in the form, preparation, prosecution, or enforcement of our patents or patent applications, such patents may be invalid and/or unenforceable, and such applications may never result in valid, enforceable patents. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">67</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to the protection provided by our patent estate, we rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not amenable to patent protection. Although we generally require all of our employees to assign their inventions to us, and all of our employees, consultants, advisors and any third parties who have access to our proprietary know-how, information, or technology to enter into confidentiality agreements, we cannot provide any assurances that all such agreements have been duly executed, or that our trade secrets and other confidential proprietary information will not be disclosed. In addition, while we have undertaken reasonable efforts to ensure such agreements are enforceable and that employees and third parties comply with their obligations thereunder, these agreements may be found insufficient by a court of law or may be breached, or we may not enter into sufficient agreements with such individuals in the first instance, in either case potentially resulting in the unauthorized use or disclosure of our trade secrets and other intellectual property, including to our competitors, which could cause us to lose any competitive advantage resulting from this intellectual property. Individuals not subject to invention assignment agreements may make adverse ownership claims to our current and future intellectual property. Moreover, our competitors may independently develop knowledge, methods and know-how equivalent to our trade secrets. Competitors could purchase our products, if approved, and replicate some or all of the competitive advantages we derive from our development efforts for technologies on which we do not have patent protection. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would be harmed. Enforcing a claim that a third-party entity illegally obtained and is using any of our trade secrets is expensive and time-consuming, and the outcome is unpredictable, and we may not be able to obtain adequate remedies for such breaches.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also seek to preserve the integrity and confidentiality of our data and trade secrets by working to maintain the physical security of our premises and physical and electronic security of our information technology systems. Our confidentiality agreements may, however, be breached, and we may not have adequate remedies for any breach. </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our and other applicable security measures may also not be able to prevent security breaches and other compromises of the security of our trade secrets or other data. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Also, if the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating the trade secret. In addition, others may independently discover our trade secrets and proprietary information. For example, the FDA is considering whether to make additional information publicly available on a routine basis, including information that we may consider to be trade secrets or other proprietary information, and it is not clear at the present time how the FDA&#8217;s disclosure policies may change in the future. If we are unable to prevent material disclosure of the non-patented intellectual property related to our technologies to third parties, and there is no guarantee that we will have any such enforceable trade secret protection, we may not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, results of operations and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Patent terms may be inadequate to protect our competitive position on our products for an adequate amount of time, and if we do not obtain protection under the Hatch-Waxman Amendments and similar non-United States legislation for extending the term of patents covering each of our product candidates, our business may be materially harmed.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such product candidates are commercialized. Depending upon the timing, duration and conditions of FDA marketing approval of our product candidates, one or more of our United States patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments, and similar legislation in the European Union. The Hatch-Waxman Amendments permit a patent term extension of up to five years for a patent covering an approved product as compensation for effective patent term lost during product development and the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval. Only one patent may be extended, and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. However, we may not receive an extension if we fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. Moreover, the length of the extension could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is less than we request, the period during which we can enforce our patent rights for that product will be shortened and our competitors may obtain approval to market competing products sooner. As a result, our revenue from applicable products could be reduced and could have a material adverse effect on our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">68</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We in-license key intellectual property necessary for the development of each of our current product candidates. If we fail to comply with our obligations in our current and future intellectual property licenses with third parties, resulting in the termination of such licenses, we could lose rights that are important to our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are heavily reliant upon licenses to certain patent rights and proprietary technology for the development of each of our current product candidates. In particular, we in-license key patents and patent applications from Adverum related to LX2006, we in-license patent applications and know-how from Cornell University related to our LX1001, LX1020 and LX1021 product candidates, and we in-license patent applications and know-how from UCSD, related to our LX2020, LX2021 and LX2022 product candidates. Our license agreements impose diligence and milestone and royalty payment obligations on us, and also contain certain development requirements. If we fail to comply with our obligations, our licensors may have the right to terminate our licenses, in which event we will not be able to develop, manufacture or market any product using the intellectual property under any such terminated agreement and may face other penalties. Such an occurrence would materially adversely affect our business prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain of our licenses may not provide us with exclusive rights to use the licensed intellectual property and technology, or may not provide us with exclusive rights to use such intellectual property and technology in all relevant fields of use and in all territories in which we may wish to develop or commercialize our technology and product candidates in the future. In addition, the intellectual property rights licensed to us by our licensors, including certain intellectual property licensed by Cornell University, UCSD, and Adverum, at least in some respects, may be used by such licensors or licensed to third parties, and such third parties may have certain enforcement rights with respect to such intellectual property. Thus, patents licensed to us could be put at risk of being invalidated or interpreted narrowly in litigation filed by or against our licensors or another licensee or in administrative proceedings brought by or against our licensors or another licensee in response to such litigation or for other reasons. As a result, we may not be able to prevent competitors or other third parties from developing and commercializing competitive products, including in territories covered by our licenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Licenses to additional third-party technology and materials that may be required for our development programs may not be available in the future or may not be available on commercially reasonable terms, or at all, which could have a material adverse effect on our business and financial condition. In such events, we may be required to expend significant time and resources to redesign our technology, product candidates, or the methods for manufacturing them or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis. If we are unable to do so, we may be unable to develop or commercialize the affected technology or product candidates. Even if we are able to obtain such additional licenses, they may be non-exclusive thereby giving our competitors and other third parties access to the same technology licensed to us.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we or our licensors fail to adequately protect our licensed intellectual property, our ability to commercialize our product candidates and technology could suffer. Although we have oversight rights, Cornell University and UCSD generally control the prosecution, maintenance and enforcement of our in-licensed patents and patent applications. Therefore, we cannot be certain that the prosecution, maintenance and enforcement of these patent rights will be in a manner consistent with the best interests of our business, or in compliance with applicable laws and regulations, or will result in valid and enforceable patents and other intellectual property rights. It is possible that our licensors&#8217; infringement proceedings or defense activities may be less vigorous than had we conducted them ourselves or may not be conducted in accordance with our best interests. If we or our licensors fail to maintain such patents or patent applications, or if we or our licensor lose rights to those patents or patent applications, the rights we have licensed may be reduced or eliminated and our right to develop and commercialize any of our product candidates that are the subject of such licensed rights could be adversely affected. In addition to the foregoing, the risks associated with patent rights that we license from third parties will also apply to patent rights we may own in the future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, if we fail to comply with our development obligations under our license agreements, we may lose our patent rights with respect to such agreement on a territory-by-territory basis, which would affect our patent rights worldwide. In spite of our efforts, our current and future licensors might conclude that we have materially breached our obligations under our license agreements and might therefore terminate such license agreements, thereby removing or limiting our ability to develop and commercialize products and technology covered by these license agreements. Disputes may also arise between us and our licensors regarding intellectual property subject to a license agreement, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the scope of rights granted under the license agreement and other interpretation-related issues;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our financial and other obligations under the license agreement;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our right to sublicense patent and other rights to third parties under collaborative development relationships;</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">69</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of our product candidates and what activities satisfy those diligence obligations;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the inventorship or ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the priority of invention of patented technology.</span></div></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected technology or product candidates. In addition, if any such disputes result in the termination of our intellectual property licenses, this could result in the loss of our ability to develop and commercialize our lead product candidates, or we could lose other significant rights, experience significant delays in the development and commercialization of our other product candidates, or incur liability for damages, any of which could have a material adverse effect on our business, financial condition, results of operations and prospects. In addition, we may seek to obtain additional licenses from our licensors and, in connection with obtaining such licenses, we may agree to amend our existing licenses in a manner that may be more favorable to the licensors, including by agreeing to terms that could enable third parties, including our competitors, to receive licenses to a portion of the intellectual property that is subject to our existing licenses and to compete with our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Some of our future agreements with certain of our third-party research partners may provide that improvements developed in the course of our relationship may be owned solely by either us or our third-party research partner. If we determine that rights to such improvements owned solely by a third-party research partner or other third party with whom we collaborate are necessary to commercialize our therapeutic product candidates or maintain our competitive advantage, we may need to obtain a license from such third party in order to use the improvements and continue developing, manufacturing or marketing our drug candidates. We may not be able to obtain such a license on an exclusive basis, on commercially reasonable terms, or at all, which could prevent us from commercializing our product candidates or allow our competitors or others the chance to access technology that is important to our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Termination of our current or any future license agreements would reduce or eliminate our rights under these agreements and may result in our having to negotiate new or reinstated agreements with less favorable terms or cause us to lose our rights under these agreements, including our rights to important intellectual property or technology. Any of the foregoing could prevent us from commercializing our other product candidates, which could have a material adverse effect on our operating results and overall financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, intellectual property rights that we in-license in the future may be sublicenses under intellectual property owned by third parties, in some cases through multiple tiers. The actions of our licensors may therefore affect our rights to use our sublicensed intellectual property, even if we are in compliance with all of the obligations under our license agreements. Should our licensors or any of the upstream licensors fail to comply with their obligations under the agreements pursuant to which they obtain the rights that are sublicensed to us, or should such agreements be terminated or amended, our ability to develop and commercialize our product candidates may be materially harmed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, a third party may in the future bring claims that our performance under our license agreements, including our sponsoring of clinical trials, interferes with such third party&#8217;s rights under its agreement with one of our licensors. If any such claim were successful, it may adversely affect our rights and ability to advance our product candidates as clinical candidates or subject us to liability for monetary damages, any of which would have an adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are generally also subject to all of the same risks with respect to protection of intellectual property that we license as we are for intellectual property that we own, which are described above and below. If we or our licensors fail to adequately protect this intellectual property, our ability to commercialize products could suffer. We may not be successful in obtaining or maintaining necessary rights to product components and processes for our development pipeline through acquisitions and in-licenses.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Presently, we have obtained rights to certain intellectual property rights through licenses from third parties to develop, manufacture and commercialize our lead product candidates and other potential product candidates in our pipeline. Because the commercialization of our product candidates may require the use of additional intellectual property rights held by third parties, the growth of our business likely will depend, in part, on our ability to acquire or license these intellectual property rights. Our product candidates also require specific formulations and manufacturing processes to work effectively and efficiently, and some of these rights are held by others.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">70</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may be unable to acquire or in-license any compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify as necessary, important or more expedient to further our business operations. In addition, even if we are able to obtain such licenses, we may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, which would harm our business. Were that to happen, we may need to cease use of the product candidates and technologies covered by those third-party intellectual property rights and may need to seek to develop alternative approaches that do not infringe, misappropriate or violate those intellectual property rights, which may entail additional costs and development delays if we are able to develop such alternatives, or which may not be feasible. Even if we are able to obtain a license, it may be non-exclusive, which means that our competitors may also receive access to the same technologies licensed to us. The licensing and acquisition of third-party intellectual property rights is a competitive practice, and companies that may be more established, or have greater resources than we do, may also be pursuing strategies to license or acquire third-party intellectual property rights that we may consider necessary or attractive in order to commercialize our product candidates. More established companies may have a competitive advantage over us due to their larger size and cash resources or greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. There can be no assurance that we will be able to successfully complete such negotiations and ultimately acquire the rights to the intellectual property surrounding the additional product candidates that we may seek to acquire. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to successfully obtain rights to required third-party intellectual property or maintain the existing intellectual property rights we have licensed, we may be required to expend significant time and resources to redesign our product candidates, or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis, and we may have to abandon development of our product candidates, any of which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our intellectual property licenses with third parties may be subject to disagreements over contract interpretation, which could narrow the scope of our rights to the relevant intellectual property or technology or increase our financial or other obligations to our licensors.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently depend, and will continue to depend, on our license agreements, including the license agreements with Cornell University and Adverum related to LX2006, with Cornell University related to our LX1001, LX1020 and LX1021 product candidates, and with UCSD, related to LX2020, LX2021 and LX2022 product candidates. The agreements under which we currently license intellectual property or technology from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If any of our licenses or material relationships or any in-licenses upon which our licenses are based are terminated or breached, we may:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">lose our rights to develop and market our products;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">lose patent protection for our products;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">experience significant delays in the development or commercialization of our products;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">not be able to obtain any other licenses on acceptable terms, if at all; or</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">incur liability for damages.</span></div></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These risks apply to any agreements that we may enter into in the future for our products or for any future product candidates. If we experience any of the foregoing, it could have a material adverse effect on our business, financial condition, results or operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">71</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We cannot be certain that any of our or licensed pending patent applications or our future owned or licensed patent applications will result in issued patent claims covering such aspects of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Composition-of-matter patents on the active pharmaceutical ingredient, or API, in prescription drug products are generally considered to be the strongest form of intellectual property protection for drug products because those types of patents provide protection without regard to any particular method of use or manufacture or formulation of the API used. Although we intend to file patent applications in the future that cover these product candidates, we cannot be certain that our future owned or licensed patent applications will cover our current or future product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Method-of-use patents protect the use of a product for the specified method and formulation patents cover formulations of the API. These types of patents do not prevent a competitor or other third party from developing or marketing an identical product for an indication that is outside the scope of the patented method or from developing a different formulation that is outside the scope of the patented formulation. Moreover, with respect to method-of-use patents, even if competitors or other third parties do not actively promote their product for our targeted indications or uses for which we may obtain patents, physicians may recommend that patients use these products off-label, or patients may do so themselves. Although off-label use may infringe or contribute to the infringement of method-of-use patents, the practice is common, and this type of infringement is difficult to prevent or prosecute. In addition, there are numerous publications and other prior art that may be relevant to our owned or in-licensed method-of-use patents and patent applications and may be used to challenge the validity of these owned or in-licensed patents and patent applications in litigation or other intellectual property-related proceedings. If these types of challenges are successful, our owned or in-licensed patents and patent applications may be narrowed or found to be invalid, and we may lose valuable intellectual property rights. Any of the foregoing could have a material adverse effect on our business, financial conditions, prospects and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The strength of patents in the biotechnology and pharmaceutical field involves complex legal and scientific questions and can be uncertain. The patent applications that we own or in-license may fail to result in issued patents with claims that cover our product candidates or uses thereof in the United States or in other countries. Even if patents do successfully issue, the issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability and third parties may challenge the validity, enforceability or scope of our owned and licensed patents in courts or patent offices in the United States and abroad, which may result in those patents being narrowed, invalidated or held unenforceable. Furthermore, even if they are unchallenged, our owned and licensed patents and pending patent applications, if issued, may not adequately protect our intellectual property or prevent competitors or others from designing around our patent claims to circumvent our owned or licensed patents by developing similar or alternative technologies or therapeutics in a non-infringing manner. If the breadth or strength of protection provided by the patents and patent applications we own or license with respect to our product candidates is not sufficient to impede such competition or is otherwise threatened, it could dissuade companies from collaborating with us to develop, and threaten our ability to commercialize, our product candidates. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may be involved in lawsuits to protect or enforce our patents, which could be expensive, time-consuming and unsuccessful.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Competitors may infringe the patents for which we have applied. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. If we initiate legal proceedings against a third party to enforce a patent covering one of our product candidates, the defendant could counterclaim that the patent covering our product or product candidate is invalid and/or unenforceable. In patent litigation in the United States, counterclaims alleging invalidity and/or unenforceability are common, and there are numerous grounds upon which a third party can assert invalidity or unenforceability of a patent. In an infringement proceeding, a court may decide that the patent claims we are asserting are invalid and/or unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patent claims do not cover the technology in question. Third parties may also raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination, post-grant review, inter partes review and equivalent proceedings in foreign jurisdictions (for example, opposition proceedings). Such proceedings could result in revocation of or amendment to our patents in such a way that they no longer cover our product candidates. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we, our patent counsel and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our product candidates. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated or interpreted narrowly, could put our patent applications at risk of not issuing and could have a material adverse impact on our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">72</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interference proceedings provoked by third parties or brought by us may be necessary to determine the priority of inventions with respect to our patent applications. An unfavorable outcome could require us to cease using the related technology or force us to take a license under the patent rights of the prevailing party, if available. Furthermore, our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Our defense of litigation or interference proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. We may not be able to prevent misappropriation of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the United States.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if we establish infringement of any of our patents by a competitive product, a court may decide not to grant an injunction against further infringing activity, thus allowing the competitive product to continue to be marketed by the competitor. It is difficult to obtain an injunction in U.S. litigation and a court could decide that the competitor should instead pay us a &#8220;reasonable royalty&#8221; as determined by the court, and/or other monetary damages. A reasonable royalty or other monetary damages may or may not be an adequate remedy. Loss of exclusivity and/or competition from a related product would have a material adverse impact on our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For certain of our in-licensed patent rights, such as patent rights in-licensed from Cornell University and Adverum, we may not have the right to file a lawsuit for infringement and may have to rely on a licensor to enforce these rights for us. If we are not able to directly assert our licensed patent rights against infringers or if a licensor does not vigorously prosecute any infringement claims on our behalf, we may have difficulty competing in certain markets where such potential infringers conduct their business, and our commercialization efforts may suffer as a result.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we or our licensors, as the case may be, may not be able to detect infringement against our owned or in-licensed patents, which may be especially difficult for manufacturing processes or formulation patents. Even if we or our licensors detect infringement by a third party of our owned or in-licensed patents, we or our licensors, as the case may be, may choose not to pursue litigation against or settlement with the third party. If we or our licensors later sue such third party for patent infringement, the third party may have certain legal defenses available to it that otherwise would not be available but for the delay between when the infringement was first detected and when the suit was brought. These legal defenses may make it impossible for us or our licensors to enforce our owned or in-licensed patents, as the case may be, against that third party.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions, or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As our current and future product candidates progress toward commercialization, the possibility of a patent infringement claim against us increases. We cannot provide any assurance that our current and future product candidates do not infringe other parties&#8217; patents or other proprietary rights, and competitors or other parties may assert that we infringe their proprietary rights in any event. We may become party to, or threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect to our current and future product candidates, including interference or derivation proceedings before the USPTO, or oppositions and other proceedings in foreign jurisdictions. We may be exposed to, or threatened with, future litigation by third parties having patent or other intellectual property rights alleging that our product candidates, manufacturing methods, formulations, administration methods and/or proprietary technologies infringe, misappropriate or otherwise violate their intellectual property rights.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Numerous issued patents and pending patent applications that are owned by third parties exist in the fields in which we are developing our product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may give rise to claims of infringement of the patent rights of others. Moreover, it is not always clear to industry participants, including us, the claim scope that may issue from pending patent applications owned by third parties or which patents cover various types of drugs, products or their methods of use or manufacture. Thus, because of the large number of patents issued and patent applications filed in our fields, there may be a risk that third parties, including our competitors, may allege they have patent rights encompassing our product candidates, technologies or methods and that we are employing their proprietary technology without authorization.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">73</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we were sued for patent infringement, we would need to demonstrate that the relevant product or methods of using the product either do not infringe the patent claims of the relevant patent or that the patent claims are invalid or unenforceable, and we may not be able to do this. In order to successfully challenge the validity of any such United States patent in federal court, we would need to overcome a presumption of validity. As this burden is high and requires us to present clear and convincing evidence as to the invalidity of any such United States patent claim, there is no assurance that a court of competent jurisdiction would agree with us and invalidate the claims of any such United States patent. Moreover, given the vast number of patents in our field of technology, we cannot be certain that we do not infringe existing patents or that we will not infringe patents that may be granted in the future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While we may decide to initiate proceedings to challenge the validity of these or other patents in the future, we may be unsuccessful, and courts or patent offices in the United States and abroad could uphold the validity of any such patent. Furthermore, because patent applications can take many years to issue and may be confidential for 18 months or more after filing, and because pending patent claims can be revised before issuance, there may be applications now pending which may later result in issued patents that may be infringed by the manufacture, use or sale of our product candidates. Regardless of when filed, we may fail to identify relevant third-party patents or patent applications, or we may incorrectly conclude that a third-party patent is invalid or not infringed by our product candidates or activities. If a patent holder believes that one of our product candidates infringes its patent, the patent holder may sue us even if we have received patent protection for our technology. Moreover, we may face patent infringement claims from non-practicing entities that have no relevant drug revenue and against whom our own patent portfolio may thus have no deterrent effect. If a patent infringement suit were threatened or brought against us, we could be forced to stop or delay research, development, manufacturing or sales of the drug or product candidate that is the subject of the actual or threatened suit.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If any third-party patents are held by a court of competent jurisdiction to be valid and enforceable and to cover any of our technology or product candidates, including the manufacturing process of our product candidates, constructs or molecules used in or formed during the manufacturing process, or any final product itself, we could be forced, including by court order, to cease developing, manufacturing or commercializing the infringing product. Alternatively, we may be required to obtain a license from such third party in order to use the infringing technology and continue developing, manufacturing or marketing the infringing product. If we were required to obtain a license to continue to manufacture or market the affected product, we may be required to pay substantial royalties or grant cross-licenses to our patents. We cannot, however, assure that any such license will be available on acceptable terms, if at all. Ultimately, we could be prevented from commercializing a product, or be forced to cease some aspect of our business operations as a result of claims of patent infringement or violation of other intellectual property rights. Further, the outcome of intellectual property litigation is subject to uncertainties that cannot be adequately quantified in advance, including the demeanor and credibility of witnesses and the identity of any adverse party. This is especially true in intellectual property cases that may turn on the testimony of experts as to technical facts upon which experts may reasonably disagree. Furthermore, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors access to the same technologies licensed to us; alternatively, or additionally, it could include terms that impede or destroy our ability to compete successfully in the commercial marketplace. In addition, we could be found liable for significant monetary damages, including treble damages and attorneys&#8217; fees if we are found to have willfully infringed a patent. A finding of infringement could prevent us from commercializing a product or force us to cease some of our business operations, which could harm our business. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or administrative proceedings, there is a risk that some of our confidential information could be compromised by disclosure. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have material adverse effect on our ability to raise additional funds or otherwise have a material adverse effect on our business, results of operations, financial condition and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The cost to us in defending or initiating any litigation or other proceeding relating to patent or other proprietary rights, even if resolved in our favor, could be substantial, and litigation would divert our management&#8217;s attention. Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could delay our research and development efforts and limit our ability to continue our operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">74</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are currently, and may in the future be, subject to claims that we and our employees, consultants, or independent contractors have wrongfully used or disclosed confidential information or trade secrets of third parties.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We employ individuals who were previously employed at other biotechnology or biopharmaceutical companies. Although we require, evidenced by written agreements, that all of our employees, consultants and advisors not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or our employees, consultants, or independent contractors have inadvertently or otherwise used or disclosed confidential information of our employees&#8217; former employers or other third parties. We may also be subject to claims that former employers or other third parties have an ownership interest in our future patents. Litigation may be necessary to defend against these claims. There is no guarantee of success in defending these claims, and even if we are successful, litigation can have an adverse impact on us due to defense and settlement costs, diversion of management resources, harm to our reputation and other factors. For example, on October 12, 2023, Rocket filed a lawsuit against us and two former employees claiming, among other things, misappropriation of confidential information and trade secrets. The complaint alleges the individual defendants downloaded confidential Rocket company documents and other proprietary materials prior to leaving Rocket in 2021 and that we used this information to advance our programs after they became employed by Lexeo. The complaint seeks unspecified damages and asks the court to enjoin us from competing and working in the market for gene therapy treatments targeting cardiac diseases. In August 2024, we asserted counterclaims against Rocket and Spacecraft Seven LLC, a wholly owned subsidiary of Rocket, for misappropriation of trade secrets, correction of inventorship of certain patents, breach of contract, and tortious interference with contract. The case is currently in the discovery phase. It is not possible to predict the outcome with certainty and an estimate of the possible loss cannot be made. For additional information regarding this litigation, see Item 3: Legal Proceedings.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if we are successful in defending against these types of claims, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and, if securities analysts or investors perceive these results to be negative, that perception could have a substantial adverse effect on the price of our common stock. This type of litigation or proceeding could substantially increase our operating losses and reduce our resources available for development activities. Some of our competitors may be able to sustain the costs of this type of litigation or proceedings more effectively than we can because of their substantially greater financial resources. Uncertainties resulting from the initiation and continuation of intellectual property litigation or other intellectual property related proceedings could adversely affect our ability to compete in the marketplace.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may be subject to claims challenging the inventorship or ownership of our future patents and other intellectual property.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may also be subject to claims that former employees, collaborators, or other third parties have an ownership interest in our patent applications, our future patents, or other intellectual property. We may be subject to ownership disputes in the future arising, for example, from conflicting obligations of consultants or others who are involved in developing our product candidates and platform discovery. Although it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own, and we cannot be certain that our agreements with such parties will be upheld in the face of a potential challenge, or that they will not be breached, for which we may not have an adequate remedy. The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">75</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we rely on third parties to manufacture or commercialize our product candidates, or if we collaborate with additional third parties for the development of such product candidates, we must, at times, share trade secrets with them. We may also conduct joint research and development programs that may require us to share trade secrets under the terms of our research and development partnerships or similar agreements. We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, consulting agreements or other similar agreements with our advisors, employees, third-party contractors and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, including our trade secrets. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor&#8217;s discovery of our trade secrets or other unauthorized use or disclosure could have an adverse effect on our business and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, these agreements typically restrict the ability of our advisors, employees, third-party contractors and consultants to publish data potentially relating to our trade secrets. Despite our efforts to protect our trade secrets, we may not be able to prevent the unauthorized disclosure or use of our technical know-how or other trade secrets by the parties to these agreements. Moreover, we cannot guarantee that we have entered into such agreements with each party that may have or have had access to our confidential information or proprietary technology and processes. Monitoring unauthorized uses and disclosures is difficult, and we do not know whether the steps we have taken to protect our proprietary technologies will be effective. If any of the collaborators, scientific advisors, employees, contractors and consultants who are parties to these agreements breaches or violates the terms of any of these agreements, we may not have adequate remedies for any such breach or violation, and we could lose our trade secrets as a result. Moreover, if confidential information that is licensed or disclosed to us by our partners, collaborators, or others is inadvertently disclosed or subject to a breach or violation, we may be exposed to liability to the owner of that confidential information. Enforcing a claim that a third party illegally obtained and is using our trade secrets, like patent litigation, is expensive and time consuming, and the outcome is unpredictable. In addition, courts outside the United States are sometimes less willing to protect trade secrets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Intellectual property rights do not necessarily address all potential threats to our competitive advantage.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business, or permit us to maintain our competitive advantage. The following examples are illustrative:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">others may be able to make or use capsids, nucleic acids and vectors that are similar to the biological compositions of our products that are the same as or similar to our product candidates but that are not covered by the claims of owned or in-licensed patents;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">others may independently develop similar or alternative technologies or duplicate any of our technologies;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">it is possible that others may circumvent our owned or in-licensed patents;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">others, including inventors or developers of our owned or in-licensed patented technologies who may become involved with competitors, may independently develop similar technologies that function as alternatives or replacements for any of our technologies without infringing our intellectual property rights;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">it is possible that our owned or in-licensed patents or patent applications omit individual(s) who should be listed as inventor(s) or include individual(s) who should not be listed as inventor(s), which may cause these patents or patents issuing from these patent applications to be held invalid or unenforceable;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we or our licensors or our other collaboration partners might not have been the first to conceive and reduce to practice the inventions covered by the patents or patent applications that we own, license or will own or license;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we or our licensors or our other collaboration partners might not have been the first to file patent applications covering certain of the patents or patent applications that we or they own or have obtained a license, or will own or will have obtained a license;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we or our licensors may fail to meet obligations to the U.S. government with respect to in-licensed patents and patent applications funded by U.S. government grants, leading to the loss of patent rights;</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">76</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">it is possible that our pending patent applications will not result in issued patents;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may not be able to generate sufficient data to support full patent applications that protect the entire breadth of developments in one or more of our programs;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">no patent protection may be available with regard to formulation or method of use;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the claims of our owned or in-licensed issued patents or patent applications, if and when issued, may not cover our product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">it is possible that there are prior public disclosures that could invalidate our or our licensors&#8217; patents;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">it is possible that there are unpublished applications or patent applications maintained in secrecy that may later issue with claims covering our products or technology similar to ours;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">issued patents that we own or exclusively license may not provide us with any competitive advantage, or may be held invalid or unenforceable, as a result of legal challenges by our competitors;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may not exclusively license our patents and, therefore, may not have a competitive advantage if such patents are licensed to others;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our competitors might conduct research and development activities in countries where we do not have patent rights, or in countries where research and development safe harbor laws exist, and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the laws of other countries may not protect our or our licensors&#8217;, as the case may be, proprietary rights to the same extent as the laws of the United States;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">there may be significant pressure on the U.S. government and international governmental bodies to limit the scope of patent protection both inside and outside the United States for disease treatments that prove successful, as a matter of public policy regarding worldwide health concerns;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">countries other than the United States may, under certain circumstances, force us or our licensors to grant a license under our patents to a competitor, thus allowing the competitor to compete with us in that jurisdiction or forcing us to lower the price of our drug in that jurisdiction;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we have engaged in scientific collaborations in the past and will continue to do so in the future and our collaborators may develop adjacent or competing products that are outside the scope of our patents;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may not successfully commercialize the product candidates, if approved, before our relevant patents expire;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may not develop additional proprietary technologies for which we can obtain patent protection;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">it is possible that product candidates or technologies we develop may be covered by third parties&#8217; patents or other exclusive rights;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ownership, validity or enforceability of our or our licensors&#8217; patents or patent applications may be challenged by third parties; and</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the patents of third parties or pending or future applications of third parties, if issued, may have an adverse effect on our business.</span></div></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may have limited geographical protection with respect to certain patents and we may not be able to protect our intellectual property rights throughout the world.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Filing and prosecuting patent applications and defending patents covering our product candidates in all countries throughout the world would be prohibitively expensive. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection, but enforcement rights are not as strong as that in the United States or Europe. These products may compete with our product candidates, and our future patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">77</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we may decide to abandon national and regional patent applications before they are granted. The examination of each national or regional patent application is an independent proceeding. As a result, patent applications in the same family may issue as patents in some jurisdictions, such as in the United States, but may issue as patents with claims of different scope or may even be refused in other jurisdictions. It is also quite common that depending on the country, the scope of patent protection may vary for the same product candidate or technology.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While we intend to protect our intellectual property rights in our expected significant markets, we cannot ensure that we will be able to initiate or maintain similar efforts in all jurisdictions in which we may wish to market our product candidates. Accordingly, our efforts to protect our intellectual property rights in such countries may be inadequate, which may have an adverse effect on our ability to successfully commercialize our product candidates in all of our expected significant foreign markets. If we encounter difficulties in protecting, or are otherwise precluded from effectively protecting, the intellectual property rights important for our business in such jurisdictions, the value of these rights may be diminished, and we may face additional competition from others in those jurisdictions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The laws of some jurisdictions do not protect intellectual property rights to the same extent as the laws or rules and regulations in the United States and Europe and many companies have encountered significant difficulties in protecting and defending such rights in such jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property rights, which could make it difficult for us to stop the infringement of our future patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in other jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our future patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing as patents, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Some countries also have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, some countries limit the enforceability of patents against government agencies or government contractors. In those countries, the patent owner may have limited remedies, which could materially diminish the value of such patents. If we are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Periodic maintenance fees, renewal fees, annuity fees and various other government fees on patents and/or applications will be due to be paid to the USPTO and various government patent agencies outside of the United States over the lifetime of our patents and/or applications and any patent rights we may obtain in the future. Furthermore, the USPTO and various non-United States government patent agencies require compliance with several procedural, documentary, fee payment and other similar provisions during the patent application process. In many cases, an inadvertent lapse of a patent or patent application can be cured by payment of a late fee or by other means in accordance with the applicable rules. There are situations, however, in which non-compliance can result in abandonment or lapse of the patents or patent applications, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, potential competitors might be able to enter the market, which could have a material adverse effect on our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Changes in patent laws or patent jurisprudence could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As is the case with other biotechnology companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biotechnology and genetic medicine industries involve both technological and legal complexity. Therefore, obtaining and enforcing biotechnology and genetic medicine patents is costly, time-consuming and inherently uncertain. In addition, the Leahy-Smith America Invents Act, or the AIA, which was passed in September 2011, resulted in significant changes to the U.S. patent system.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">78</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An important change introduced by the AIA is that, as of March 16, 2013, the United States transitioned from a &#8220;first-to-invent&#8221; to a &#8220;first-to-file&#8221; system for deciding which party should be granted a patent when two or more patent applications are filed by different parties claiming the same invention. Under a &#8220;first-to-file&#8221; system, assuming the other requirements for patentability are met, the first inventor to file a patent application generally will be entitled to a patent on the invention regardless of whether another inventor had made the invention earlier. A third party that files a patent application in the USPTO after that date but before us could therefore be awarded a patent covering an invention of ours even if we made the invention before it was made by the third party. This will require us to be cognizant going forward of the time from invention to filing of a patent application and be diligent in filing patent applications, but circumstances could prevent us from promptly filing patent applications on our inventions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Among some of the other changes introduced by the AIA are changes that limit where a patentee may file a patent infringement suit and providing opportunities for third parties to challenge any issued patent in the USPTO. This applies to all of our U.S. patents, even those issued before March 16, 2013. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in U.S. federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. It is not clear what, if any, impact the AIA will have on the operation of our business. However, the AIA and its implementation could increase the uncertainties and costs surrounding the prosecution of our or our licensors&#8217; patent applications and the enforcement or defense of our or our licensors&#8217; issued patents.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may become involved in opposition, interference, derivation, inter partes review or other proceedings challenging our or our licensors&#8217; patent rights, and the outcome of any proceedings are highly uncertain. An adverse determination in any such proceeding could reduce the scope of, or invalidate, our owned or in-licensed patent rights, allow third parties to commercialize our technology or products and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the United States federal government retains certain rights in inventions produced with its financial assistance under the Bayh-Dole Act. The federal government retains a &#8220;nonexclusive, nontransferable, irrevocable, paid-up license&#8221; for its own benefit. The Bayh-Dole Act also provides federal agencies with &#8220;march-in rights.&#8221; March-in rights allow the government, in specified circumstances, to require the contractor or successors in title to the patent to grant a &#8220;nonexclusive, partially exclusive, or exclusive license&#8221; to a &#8220;responsible applicant or applicants.&#8221; If the patent owner refuses to do so, the government may grant the license itself. Some of our licensed patents are subject to the provisions of the Bayh-Dole Act. If our licensors fail to comply with the regulations of the Bayh-Dole Act, they could lose title to any patents subject to such regulations, which could affect our license rights under the patents and our ability to stop others from using or commercializing similar or identical technology and products, or limit patent protection for our technology and products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, the U.S. Supreme Court has ruled on several patent cases in recent years either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations, and there are other open questions under patent law that courts have yet to decisively address. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents once obtained. Depending on decisions by Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways and could weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. In addition, the European patent system is relatively stringent in the type of amendments that are allowed during prosecution, but the complexity and uncertainty of European patent laws has also increased in recent years. Complying with these laws and regulations could limit our ability to obtain new patents in the future that may be important for our business.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">79</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our current or future trademarks or trade names may be challenged, infringed, circumvented or declared generic or descriptive or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these names, which we need for name recognition by potential partners or customers in our markets of interest. During trademark registration proceedings, we may receive rejections of our applications by the USPTO or in other foreign jurisdictions. Although we would be given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings. If we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively and our business may be adversely affected. We may license our trademarks and trade names to third parties, such as distributors. Although these license agreements may provide guidelines for how our trademarks and trade names may be used, a breach of these agreements or misuse of our trademarks and tradenames by our licensees may jeopardize our rights in or diminish the goodwill associated with our trademarks and trade names.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, any name we have proposed to use with our product candidate in the United States must be approved by the FDA, regardless of whether we have registered it, or applied to register it, as a trademark. Similar requirements exist in Europe. The FDA typically conducts a review of proposed product names, including an evaluation of potential for confusion with other product names. If the FDA (or an equivalent administrative body in a foreign jurisdiction) objects to any of our proposed proprietary product names, we may be required to expend significant additional resources in an effort to identify a suitable substitute name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA. Furthermore, in many countries, owning and maintaining a trademark registration may not provide an adequate defense against a subsequent infringement claim asserted by the owner of a senior trademark. At times, competitors or other third parties may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. If we assert trademark infringement claims, a court may determine that the marks we have asserted are invalid or unenforceable, or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of such trademarks.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">80</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks related to legal and regulatory compliance matters</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our current and future relationships with customers, healthcare providers, including physicians, and third-party payors may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws, health information privacy and security laws and other healthcare laws and regulations. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are currently or will in the future be subject to healthcare regulation and enforcement by the U.S. federal government and the states in which we will conduct our business once our product candidates are approved by the FDA and commercialized in the United States. In addition to the FDA&#8217;s restrictions on marketing of pharmaceutical products, the U.S. healthcare laws and regulations that may affect our ability to operate include: the federal fraud and abuse laws, including the federal anti-kickback and false claims laws; federal data privacy and security laws; and federal transparency laws related to payments and/or other transfers of value made to physicians and other healthcare professionals and teaching hospitals. For more information, see the section titled </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#8220;Business &#8211; Government Regulation &#8211; Other Healthcare Laws and Compliance Requirements.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Many states have similar laws and regulations that may differ from each other and federal law in significant ways, thus complicating compliance efforts. For example, states have anti-kickback and false claims laws that may be broader in scope than analogous federal laws and may apply regardless of payor. In addition, state laws regarding the privacy and security of health information may differ from each other and may not be preempted by federal law. Moreover, several states have enacted legislation requiring pharmaceutical manufacturers to, among other things, establish marketing compliance programs, file periodic reports with the state, make periodic public disclosures on sales and marketing activities, report information related to drug pricing, require the registration of sales representatives, and prohibit certain other sales and marketing practices. These laws may adversely affect our sales, marketing and other activities with respect to any product candidate for which we receive approval to market in the United States by imposing administrative and compliance burdens on us. It is possible that governmental authorities will conclude that our current or future business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant penalties, including, without limitation, civil, criminal and administrative penalties, damages, fines, disgorgement, individual imprisonment, exclusion from participating in federal and state funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, contractual damages, diminished profits and future earnings, reputational harm and the curtailment or restructuring of our operations, any of which could harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The risk of being found in violation of these laws is increased by the fact that many of them have not been fully interpreted by the regulatory authorities or the courts, and their provisions are open to a variety of interpretations. Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. The shifting compliance environment and the need to build and maintain robust and expandable systems to comply with multiple jurisdictions with different compliance and/or reporting requirements increases the possibility that a healthcare company may run afoul of one or more of the requirements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Even if we obtain FDA or EMA approval for any of our product candidates in the United States or European Union, we may never obtain approval for or commercialize any of them in any other jurisdiction, which would limit our ability to realize their full market potential.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In order to market any products in any particular jurisdiction, we must establish and comply with numerous and varying regulatory requirements on a country-by-country basis regarding safety and efficacy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Approval by the FDA in the United States or the EMA in the European Union does not ensure approval by regulatory authorities in other countries or jurisdictions. However, the failure to obtain approval in one jurisdiction may negatively impact our ability to obtain approval elsewhere. In addition, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not guarantee regulatory approval in any other country.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Approval processes vary among countries and can involve additional product testing and validation and additional administrative review periods. Seeking foreign regulatory approval could result in difficulties and increased costs for us and require additional preclinical studies or clinical trials which could be costly and time consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our products in those countries. We do not have any product candidates approved for sale in any jurisdiction, including in international markets. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, or if regulatory approvals in international markets are delayed, our target market will be reduced and our ability to realize the full market potential of any product we develop will be unrealized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">81</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Even if we receive regulatory approval of our product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense, and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any product candidate for which we obtain marketing approval will be subject to ongoing regulatory requirements for, among other things, manufacturing processes, submission of post-approval clinical data and safety information, labeling, packaging, distribution, adverse event reporting, storage, recordkeeping, export, import, advertising, promotional activities and product tracking and tracing. These requirements include submissions of safety and other post-marketing information and reports, establishment registration and drug listing requirements, applicable tracking and tracing requirements, continued compliance with cGMP requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, requirements regarding the distribution of samples to physicians and recordkeeping and cGCP requirements for any clinical trials that we conduct post-approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any regulatory approvals that we receive for our product candidates or any future product candidates may also be subject to a REMS, limitations on the approved indicated uses for which the product may be marketed or to the conditions of approval, or requirements that we conduct potentially costly post-marketing testing, including Phase 4 trials and surveillance to monitor the quality, safety and efficacy of the product. An unsuccessful post-marketing study or failure to complete such a study could result in the withdrawal of marketing approval. We will further be required to immediately report any serious and unexpected adverse events and certain quality or production problems with our products to regulatory authorities along with other periodic reports.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA and EMA closely regulate the post-approval marketing and promotion of genetic therapy medicines to ensure they are marketed only for the approved indications and in accordance with the provisions of the approved labeling. However, companies may share truthful and not misleading information that is otherwise consistent with a product&#8217;s FDA approved labeling. The FDA imposes stringent restrictions on manufacturers&#8217; communications regarding off-label use and if we market our products for uses beyond their approved diseases, we may be subject to enforcement action for off-label marketing. Violations of the FDCA, relating to the promotion of prescription drugs for unapproved uses may lead to enforcement actions and investigations alleging violations of federal and state health care fraud and abuse laws, as well as state consumer protection laws. The holder of an approved BLA must submit new or supplemental applications and obtain prior approval for certain changes to the approved product, product labeling, or manufacturing process. A company that is found to have improperly promoted off-label uses of their products may be subject to significant civil, criminal and administrative penalties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, later discovery of previously unknown adverse events or other problems with our products, manufacturers or manufacturing processes, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may yield various results, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">restrictions on manufacturing such products;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">restrictions on the labeling or marketing of a product;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">restrictions on product distribution or use;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">refusal to allow entry into supply contracts, including government contracts;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">requirements to conduct post-marketing studies or clinical trials;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">warning or untitled letters, or holds on clinical trials;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">withdrawal of the products from the market;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">refusal to approve pending applications or supplements to approved applications that we submit;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">recall of products;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">fines, restitution or disgorgement of profits or revenues;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">suspension or withdrawal of marketing approvals;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">refusal to permit the import or export of our products;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">product seizure or detention; or</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">82</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">injunctions or the imposition of administrative, civil or criminal penalties or monetary fines.</span></div></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA&#8217;s policies, and the policies of foreign regulatory agencies, may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. For example, executive orders or other actions could impose significant burdens on, or otherwise materially delay, the FDA&#8217;s ability to engage in routine oversight activities such as implementing statutes through rulemaking, issuance of guidance, and review and approval of marketing applications. If such executive actions were to impose restrictions on the FDA&#8217;s ability to engage in oversight and implementation activities in the normal course, our business could be negatively impacted. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained which would adversely affect our business, prospects and ability to achieve or sustain profitability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. The occurrence of any event or penalty described above may inhibit our ability to commercialize our current product candidates or any future product candidates and harm our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Enacted and future healthcare legislation may increase the difficulty and cost for us to progress our clinical programs and obtain marketing approval of and commercialize our product candidates and may affect the prices we may set.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the United States, the European Union and other jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes and proposed changes to the healthcare system that could affect our future results of operations. In particular, there have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs and improve the quality of healthcare. For more information, see the below section titled &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Business&#8212;Government Regulation&#8212;Healthcare Reform</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The continuing efforts of the government, insurance companies, managed care organizations and other payers of healthcare services to contain or reduce costs of healthcare may adversely affect:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the demand for any of our product candidates, if approved;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the ability to set a price that we believe is fair for any of our product candidates, if approved;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to generate revenues and achieve or maintain profitability;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the level of taxes that we are required to pay; and</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the availability of capital.</span></div></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical and biologic products. We cannot be sure whether additional legislative changes will be enacted, or whether FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our product candidates, if any, may be. In addition, increased scrutiny by Congress of the FDA&#8217;s approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing testing and other requirements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. For example, CMS may develop new payment and delivery models, such as bundled payment models. In addition, recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several U.S. presidential executive orders, Congressional inquiries and proposed and enacted federal legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, and review the relationship between pricing and manufacturer patient programs. We expect that additional U.S. federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that the U.S. federal government will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures and could negatively affect our customers and accordingly, our financial operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">83</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Individual states in the United States have also increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, results of operations, financial condition and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate demand for our product candidates or put pressure on our product pricing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the European Union, similar political, economic and regulatory developments may affect our ability to profitably commercialize our product candidates, if approved. In addition to continuing pressure on prices and cost containment measures, legislative developments at the European Union or member state level may result in significant additional requirements or obstacles that may increase our operating costs. The delivery of healthcare in the European Union, including the establishment and operation of health services and the pricing and reimbursement of medicines, is almost exclusively a matter for national, rather than European Union, law and policy. National governments and health service providers have different priorities and approaches to the delivery of health care and the pricing and reimbursement of products in that context. In general, however, the healthcare budgetary constraints in most European Union member states have resulted in restrictions on the pricing and reimbursement of medicines by relevant health service providers. Coupled with ever-increasing European Union and national regulatory burdens on those wishing to develop and market products, this could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to commercialize our product candidates, if approved.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In markets outside of the United States and the European Union, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action in the United States, the European Union or any other jurisdiction. If we or any third parties we may engage are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or such third parties are not able to maintain regulatory compliance, our product candidates may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Changes in funding for the FDA and other government agencies could hinder their ability to hire and retain key leadership and other personnel, or otherwise prevent new products and services from being developed or commercialized in a timely manner, which could negatively impact our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel, accept the payment of user fees, and statutory, regulatory and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. Changes in the leadership of the FDA and other federal agencies under the Trump administration, including return-to-office policy, hiring freeze, layoffs, and other policies implemented by the Department of Government Efficiency, may lead to changes in the operations of the FDA, which may have a material impact on the industry and our clinical development plans.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. Additionally, changes in the FDA leadership, regulatory actions and other actions under the new Trump administration, may result in delays in regulatory approval. Our business depends upon the ability of the FDA to accept and review our potential regulatory filings. If a prolonged government shutdown occurs or if a significant number of federal employees are laid off or leave federal agencies, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our ability to advance clinical development of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">84</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are unable to establish sales, marketing and distribution capabilities either on our own or in collaboration with third parties, we may not be successful in commercializing our product candidates or realizing the synergies in the target diseases of our programs, even if they are approved.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not have any infrastructure for the sales, marketing or distribution of our products, and the cost of establishing and maintaining such an organization may exceed the cost-effectiveness of doing so. We expect to build a focused sales, distribution and marketing infrastructure to market our product candidates in the United States and European Union, if approved. There are significant expenses and risks involved with establishing our own sales, marketing and distribution capabilities, including our ability to hire, retain and appropriately incentivize qualified individuals, generate sufficient sales leads, provide adequate training to sales and marketing personnel, and effectively manage a geographically dispersed sales and marketing team. Any failure or delay in the development of our internal sales, marketing and distribution capabilities could delay any product launch, which would adversely impact the commercialization of our product candidates. Additionally, if the commercial launch of our product candidates for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may not have the resources in the foreseeable future to allocate to the sales and marketing of our product candidates in certain international markets. Therefore, our future sales in these markets will largely depend on our ability to enter into and maintain collaborative relationships for such capabilities, the collaborator&#8217;s strategic interest in the product and such collaborator&#8217;s ability to successfully market and sell the product. We may pursue collaborative arrangements regarding the sale and marketing of LX2006 or LX2020, if approved, for certain markets overseas; however, we cannot assure that we will be able to establish or maintain such collaborative arrangements, or if able to do so, that they will have effective sales forces.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to build our own sales force or negotiate a collaborative relationship for the commercialization of LX2006, or LX2020, or any of our other product candidates, if approved, we may be forced to delay the potential commercialization of LX2006, or LX2020 or any of our other product candidates or reduce the scope of our sales or marketing activities for LX2006 or LX2020 or any of our other product candidates. If we elect to increase our expenditures to fund commercialization activities internationally, we will need to obtain additional capital, which may not be available to us on acceptable terms, or at all. We could enter into arrangements with collaborative partners at an earlier stage than otherwise would be ideal and we may be required to relinquish rights to LX2006, or LX2020 or any of our other product candidates or otherwise agree to terms unfavorable to us, any of which may have an adverse effect on our business, operating results and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to establish adequate sales, marketing and distribution capabilities, either on our own or in collaboration with third parties, we will not be successful in commercializing LX2006, or LX2020 or any of our other product candidates, if approved, and may not become profitable and may incur significant additional losses. We will be competing with many companies that currently have extensive and well-funded marketing and sales operations. Without an internal team or the support of a third party to perform marketing and sales functions, we may be unable to compete successfully against these more established companies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we obtain approval to commercialize any products outside of the United States or the European Union, a variety of risks associated with international operations could adversely affect our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If LX2006, LX2020 or any of our other product candidates are approved for commercialization, we may seek to enter into agreements with third parties to market them in certain jurisdictions outside the United States and the European Union. We expect that we would be subject to additional risks related to international pharmaceutical operations, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">different regulatory requirements for drug and biologic approvals and rules governing drug and biologic commercialization in foreign countries;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reduced protection for intellectual property rights;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">foreign reimbursement, pricing and insurance regimes;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">unexpected changes in tariffs, trade barriers and regulatory requirements;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">economic weakness, including inflation, or political instability in particular foreign economies and markets;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other obligations incident to doing business in another country;</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">85</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">business interruptions resulting from geopolitical actions, including war and terrorism or natural disasters including earthquakes, typhoons, floods and fires, or from economic or political instability;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">greater difficulty with enforcing our contracts;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">potential noncompliance with the U.S. Foreign Corrupt Practices Act, or the FCPA, the U.K. Bribery Act 2010 and similar anti-bribery and anticorruption laws in other jurisdictions; and</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad.</span></div></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, there are complex regulatory, tax, labor and other legal requirements imposed by individual countries in Europe with which we will need to comply. If we are unable to successfully manage the challenges of international expansion and operations, our business and operating results could be harmed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. From time to time and in the future, our operations may involve the use of hazardous and flammable materials, including chemicals and biological materials, and may also produce hazardous waste products. Even if we contract with third parties for the disposal of these materials and waste products, we cannot completely eliminate the risk of contamination or injury resulting from these materials. In the event of contamination or injury resulting from the use or disposal of our hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees, but this insurance may not provide adequate coverage against potential liabilities. However, we do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. Environmental laws and regulations may impair our research, development or production efforts. In addition, failure to comply with these laws and regulations may result in substantial fines, penalties or other sanctions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are subject to a variety of privacy, data protection, and cybersecurity laws, rules, regulations, policies, industry standards and contractual obligations, and our failure to comply with them could harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We maintain and otherwise process a large quantity of sensitive information, including confidential business and personal information in connection with the conduct of our clinical trials and related to our employees and others, and we are subject to laws and regulations governing the privacy and security of such information. In the United States, numerous federal and state privacy and cybersecurity laws and regulations govern the collection, use, disclosure and protection of personal information, including federal and state health information privacy laws, federal and state security breach notification laws and federal and state consumer protection laws. The legislative and regulatory landscape for privacy, data protection and cybersecurity continues to evolve, and there has been an increasing focus on privacy, data protection and cybersecurity issues, which may affect our business and is expected to increase our compliance costs and exposure to liability. In the United States, numerous federal and state laws and regulations could apply to our operations or the operations of our partners, including state and federal data breach notification laws, state health information privacy and cybersecurity laws and federal and state consumer protection laws and regulations that govern the collection, use, disclosure and protection of health-related and other personal information. Among these regulations are: Section 5 of the Federal Trade Commission Act, which prohibits unfair or deceptive commercial practices; new rules adopted by the SEC in July 2023, which require public companies to disclose material cybersecurity incidents they experience and to disclose on an annual basis material information regarding their cybersecurity risk management, strategy, and governance; and </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the HIPAA</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, as amended by HITECH, and the regulations promulgated thereunder. We may obtain health and other data from third parties, including research institutions from which we obtain clinical trial data, that are subject to privacy and security requirements under HIPAA, and depending on the facts and circumstances, we could be subject to significant penalties if we obtain, use or disclose individually identifiable health information in a manner that is not authorized or permitted by HIPAA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">86</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the European Economic Area, or the EEA, and the United Kingdom, or the UK, the collection, use, disclosure, transfer or other processing of personal data, including clinical trial data, of individuals is governed by the General Data Protection Regulation, or the European Union GDPR (with regard to the EEA), and UK GDPR (with regard to the UK), as well as applicable national data protection legislation and requirements. In this document, &#8220;GDPR&#8221; refers to both the European Union GDPR and the UK GDPR, unless specified otherwise. The GDPR is wide-ranging in scope and imposes numerous requirements on companies that process personal data, including requirements relating to processing health and other sensitive data, obtaining consent of the individuals to whom the personal data relates, providing information to individuals regarding data processing activities, implementing safeguards to protect the security and confidentiality of personal data, providing notification of data breaches, and taking certain measures when engaging third-party processors. The GDPR imposes substantial fines for breaches and violations (up to the greater of &#8364;20 million (&#163;17.5 million for the UK) or 4% of our consolidated annual worldwide gross revenue), and confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies and obtain compensation for damages resulting from violations of the GDPR.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The GDPR also includes restrictions on cross-border data transfers of personal data to countries outside the EEA and the UK that are not considered by the European Commission or UK government as providing &#8220;adequate&#8221; protection to personal data, or third countries, including the United States, unless a valid GDPR transfer mechanism (for example, the European Commission-approved Standard Contractual Clauses, or SCCs, and the UK International Data Transfer Agreement/Addendum, or UK IDTA) has been put in place. Where relying on the SCCs or UK IDTA for data transfers, we may also be required to carry out transfer impact assessments to assess whether the recipient is subject to local laws which allow public authority access to personal data. The international transfer obligations under the EEA and UK data protection regimes require significant effort and cost, and may result in us needing to make strategic considerations around where EEA and UK personal data is transferred and which service providers we can utilize for processing EEA and UK personal data.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The UK government has also introduced a Data Protection and Digital Information Bill, or the UK Bill, into the UK legislative process. The aim of the UK Bill is to reform the UK&#8217;s data protection regime following Brexit. If passed, the final version of the UK Bill may reduce the similarities between the UK and EEA data protection regime and threaten the European Commission's determination that the UK provides "adequate" protection to personal data. </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, this adequacy determination is subject to renewal in 2025. Any loss by the UK of its adequacy determination by the European Commission</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> may lead to additional compliance costs and could increase our overall risk. The respective provisions and enforcement of the European Union GDPR and UK GDPR may further diverge in the future and create additional regulatory challenges and uncertainties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compliance with these and any other applicable privacy, data protection and cybersecurity laws and regulations is a rigorous and time-intensive process, and we may be required to put in place additional mechanisms ensuring compliance with new and evolving laws and regulations. </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, many privacy, data protection, and cybersecurity regimes are evolving and are inconsistent across jurisdictions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> If we fail, or are alleged to fail, to comply with any such laws or regulations, we may face regulatory inquiries, </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">investigations, and other proceedings, private claims and litigation, and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">significant fines and penalties that could adversely affect our business, financial condition and results of operations. In addition, states are constantly adopting new laws or amending existing laws, requiring attention to frequently changing regulatory requirements. For example, California enacted the California Consumer Privacy Act, or CCPA, which took effect on January 1, 2020, became enforceable on July 1, 2020 and has been dubbed the first &#8220;GDPR-like&#8221; law in the United States. The CCPA gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing and receive detailed information about how their personal information is used by requiring covered companies to provide new disclosures to California consumers (as that term is broadly defined) and provide such consumers new ways to opt out of certain sales of personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. Further, the California Privacy Rights Act, or CPRA, which became effective as of January 1, 2023, amended the CCPA and imposes additional privacy obligations on companies doing business in California, including additional consumer rights processes, limitations on data uses, new audit requirements for higher risk data and opt-outs for certain uses of sensitive data. The amendments introduced by the CPRA also created a new California Privacy Protection Agency to implement and enforce this legislation, and it is anticipated that this development could result in increased privacy and information security enforcement. Although the CCPA, as amended by the CPRA, currently exempts certain health-related information, including clinical trial data, the CCPA may increase our compliance costs and potential liability if we expand our operations into California. Similar broad consumer privacy laws have been enacted in Colorado, Connecticut, </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Delaware, Florida, Indiana, Iowa, Kentucky, Maryland, Minnesota, Montana, Nebraska, New Hampshire, New Jersey, Oregon, Rhode Island, Tennessee, Texas, Utah, and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Virginia and have been proposed in numerous other states and at the federal level. If passed, these bills may provide for various requirements that would make compliance challenging</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, particularly in light of certain conflicting and otherwise various requirements in the state privacy laws that have been enacted</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">87</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to these consumer privacy laws, the state of Washington has enacted health-focused privacy legislation, the My Health, My Data Act, which became effective in March 2024. This law imposes strict requirements on the collection, use and processing of certain health-related information that is not subject to HIPAA. </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This law also provides for a private right of action. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other states are considering bills with similar requirements. The Washington law and, if passed, the other state bills, will add additional complexity to our compliance obligations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With the GDPR, CCPA and other laws, regulations and other obligations relating to privacy and data protection imposing new and relatively burdensome obligations, and with substantial uncertainty over the interpretation and application of these and other obligations, we may face challenges in addressing their requirements and making necessary changes to our policies and practices and may incur significant costs and expenses in an effort to do so. </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not currently have formal data privacy policies and procedures in place and have not completed formal assessments of whether we are in compliance with all applicable data privacy laws and regulations. I</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t is possible that both existing and new laws, regulations, and other actual or asserted obligations to which we are or may be subject may be interpreted and applied in manners inconsistent with our existing or future privacy, data protection and cybersecurity practices. Any failure or perceived failure by us to comply with our current or future obligations relating to privacy, data protection or cybersecurity, or any actual or perceived failure by any third party with which we work, such as third-party CMOs, CROs, manufacturers, contractors, consultants, collaborators, vendors, or service providers, to comply with our applicable policies or other applicable obligations, may result in governmental investigations, enforcement actions, or other proceedings, litigation, claims, or public statements against us and could result in significant liability, cause harm to our brand and reputation, and otherwise materially and adversely affect our reputation and business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may be subject to various governmental export control and trade sanctions laws and regulations that could impair our ability to compete in international markets or subject us to liability if we violate these controls.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our product candidates may be subject to export control and import laws and regulations, including the U.S. Export Administration Regulations administered by the U.S. Department of Commerce and U.S. Customs laws and regulations and our product candidates and activities may be subject to various economic and trade sanctions regulations administered by the U.S. Treasury Department&#8217;s Office of Foreign Assets Controls, or collectively, Trade Controls. As such, a license may be required to export or re-export our product candidate, or provide related services, to certain countries and end-users, and for certain end-uses. The process for obtaining necessary licenses may be time-consuming or unsuccessful, potentially causing delays in sales or losses of sales opportunities and these licenses may not be issued. Compliance with applicable regulatory requirements regarding the export or import of our product candidates may create delays in the introduction of our product candidates in international markets or, in some cases, prevent the export of our product candidates to some countries altogether. Furthermore, U.S. export control laws and economic sanctions prohibit the shipment of certain product candidates and services to countries, territories, governments and persons targeted by U.S. sanctions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Trade Controls are complex and dynamic regimes and monitoring and ensuring compliance can be challenging. Although we have procedures in place designed to ensure our compliance with Trade Controls, any failure to comply could subject us to both civil and criminal penalties, including substantial fines, possible incarceration of responsible individuals for willful violations, possible loss of our export or import privileges, and reputational harm. Although we have no knowledge that our activities have resulted in violations of Trade Controls, there is no certainty that all of our employees, agents, suppliers, manufacturers, contractors or collaborators, or those of our affiliates, will comply with all applicable export and import control and sanctions laws and regulations, particularly given the high level of complexity of these laws. Any failure by us or our partners to comply with applicable laws and regulations could have negative consequences for us, including reputational harm, government investigations, penalties, fines, settlements, investigations, criminal sanctions against us, our officers, or our employees, the closing down of facilities, including those of our suppliers and manufacturers, requirements to obtain export licenses, cessation of business activities in sanctioned countries, implementation of additional compliance programs, and prohibitions on the conduct of our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are subject to U.S. and certain foreign anti-corruption laws and regulations. We could face liability and other serious consequences for violations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are subject to anti-corruption laws and regulations, including the FCPA, the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act and will be subject to local and national anti-bribery laws in the countries in which we may conduct activities in the future. Anti-corruption laws are interpreted broadly and generally prohibit companies and their employees, agents, representatives, contractors and other third- party intermediaries from offering, promising, giving, or authorizing others to give anything of value, either directly or indirectly through third parties, to any person in the public or private sector to obtain or retain business. The FCPA also requires public companies to make and keep books and records that accurately and fairly reflect the transactions of the corporation and to devise and maintain an adequate system of internal accounting controls.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">88</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our business is heavily regulated and therefore involves significant interaction with public officials, including officials of non-United States governments. Additionally, in many other countries, the healthcare providers who prescribe pharmaceuticals are employed by their government, and therefore will be considered foreign officials for purposes of the FCPA. We also expect to rely on third parties for research, preclinical studies and clinical trials and/or to obtain necessary permits, licenses, patent registrations and other marketing approvals on our behalf outside of the United States. We can be held liable for the corrupt or other illegal activities of our employees, agents, representatives, CROs, contractors and other third-party intermediaries, even if we do not explicitly authorize or have actual knowledge of such activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There is no certainty that all of our employees, agents, representatives, contractors or third-party intermediaries will comply with all applicable anti-corruption laws. Allegations concerning or violations of these laws and regulations could result in whistleblower complaints, fines, settlements, investigations, criminal or civil sanctions, adverse media coverage or suspension or debarment from government contracts, all of which could damage our reputation, our brand, our international expansion efforts, our ability to attract and retain employees, and our business, prospects, operating results and financial condition. Responding to any investigation or action will likely result in a materially significant diversion of management&#8217;s attention and resources and significant defense costs and other professional fees.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks related to employee matters and managing our growth</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our future success depends on our ability to attract and retain key executives and advisors and to attract, retain and motivate qualified personnel.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are highly dependent on the management, development, clinical, financial and business development expertise of our executive officers, particularly R. Nolan Townsend, our Chief Executive Officer and a member of our board of directors, Eric Adler, M.D., our Chief Medical Officer and Head of Research, Jose Manuel Otero, our Chief Technical Officer, Kyle Rasbach, our Chief Financial Officer, Jenny R. Robertson, our Chief Legal Officer, Sandi See Tai, M.D., our Chief Development Officer, as well as on the scientific expertise of our founder, Ronald G. Crystal, M.D., Professor and Chairman of Weill Cornell Medicine&#8217;s Department of Genetic Medicine. Each of our executive officers may currently terminate their employment with us at any time and we do not have an employment contract with Dr. Crystal. We do not maintain &#8220;key person&#8221; insurance for any of our executives or employees.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recruiting and retaining qualified executives, scientists and clinical personnel and, if we progress the development of our product pipeline toward scaling up for commercialization, manufacturing and sales and marketing personnel, will also be critical to our success. The loss of the services of our executive officers or other key employees, or our inability to recruit certain executives, could impede the achievement of our development and commercialization objectives and seriously harm our ability to successfully implement our business strategy. Furthermore, recruiting executive officers, or replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain regulatory approval of and commercialize gene therapy products. Competition to hire from this limited pool is intense, and we have experienced and may continue to experience challenges filling certain executive roles. We may be unable to hire, train, retain or motivate key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our development and commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. If we are unable to continue to attract and retain high quality personnel, our ability to pursue our growth strategy will be limited.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We expect to expand our clinical development, manufacturing and regulatory capabilities and potentially implement sales, marketing and distribution capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, we had 72 full-time employees. As our development progresses, we expect to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of clinical product development, regulatory affairs and, if any of our product candidates receives marketing approval, sales, marketing and distribution. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. Our choice to focus on multiple therapeutic areas may negatively affect our ability to develop adequately the specialized capability and expertise necessary for operations. The expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">89</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our employees, independent contractors, consultants, collaborators, principal investigators, CROs, suppliers and vendors may be improperly classified and may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We endeavor to properly classify our employees as exempt or non-exempt with respect to wage and hour laws (including, but not limited to, for purposes of minimum wage, overtime and applicable meal and rest periods), and we monitor and evaluate such classifications. Although there are no current, pending, or threatened claims or investigations against us asserting that any employees have been incorrectly classified as exempt, the possibility nevertheless exists that certain job roles could be deemed to have been incorrectly classified as exempt. In addition, we endeavor to classify our workforce properly, and we monitor and evaluate such classifications. Although there are no current, pending, or threatened claims or investigations against us asserting that any independent contractors have been incorrectly classified, the possibility nevertheless exists that certain contractors could be deemed to be employees.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are exposed to the risk that our employees, independent contractors, consultants, collaborators, principal investigators, CROs, suppliers and vendors may engage in fraudulent conduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct that violates FDA regulations, including those laws requiring the reporting of true, complete and accurate information to the FDA, manufacturing standards, federal and state healthcare laws and regulations, and laws that require the true, complete and accurate reporting of financial information or data. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Misconduct by these parties could also involve the improper use of individually identifiable information, including, without limitation, information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. Although we have adopted a code of business conduct and ethics, it is not always possible to identify and deter misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant civil, criminal and administrative penalties, including, without limitation, damages, fines, disgorgement, imprisonment, exclusion from participation in government healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, and the curtailment or restructuring of our operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The administrator of the 2023 Plan is authorized to exercise its discretion to reprice stock options and stock appreciation rights, and if a repricing occurs, there may be adverse consequences to our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The administrator of the 2023 Plan, which is our compensation committee, is authorized, subject to the consent of any award holder whose award is materially impaired by such action, to reduce the exercise price of a stock option or stock appreciation right; to cancel a stock option or stock appreciation right in exchange for a different award, cash or other consideration; or to take any other action that is treated as a repricing under generally accepted accounting principles, or each such action, a repricing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have no current expectation that a repricing will occur. However, if the administrator were to implement a repricing without seeking prior stockholder approval, certain proxy advisory firms and/or institutional investors may express a lack of support for the repricing, and proxy advisory firms may recommend an &#8220;against&#8221; or &#8220;withhold&#8221; vote for members of our compensation committee or our board of directors. In addition, if we are required to hold an advisory vote on named executive officer compensation (known as a &#8220;say on pay&#8221; vote) at the time of, or subsequent to, any such repricing, it is likely, based on their current policies, that proxy advisory firms would issue an &#8220;against&#8221; recommendation on our say on pay proposal. Defending against negative recommendations with respect to our directors and/or say on pay proposal would require management attention, and could be costly and time-consuming.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If our stockholders agree with proxy advisory firms&#8217; recommendations, we may need to make changes to our compensation and corporate governance practices, and perhaps the composition of our board of directors and its committees, potentially leading to business disruptions and a negative impact on our stock price. Even absent negative reactions from proxy advisory firms and institutional investors, we may be required to recognize a compensation expense and the repricing will require management&#8217;s time and attention and the payment of administrative costs and attorney and accounting firm fees. As such, a repricing could cause a negative impact on our stock price, and adverse consequences to our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">90</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks related to ownership of our common stock and our status as a public company</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The trading price of the shares of our common stock may be volatile, and purchasers of our common stock could incur substantial losses.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The trading price of our common stock is likely to be highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control, including limited trading volume. The stock market in general and the market for biopharmaceutical companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, investors may not be able to sell their common stock at or above the price paid for the shares. The trading price for our common stock may be influenced by many factors, including those discussed in this &#8220;Risk Factors&#8221; section and elsewhere in this Annual Report on Form 10-K and:</span></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the reporting of unfavorable preclinical and clinical results;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the commencement, enrollment or results of our clinical trials of LX2006, LX2020 or any future clinical trials we may conduct, or changes in the development status of our product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any delay in our regulatory filings for LX2006, LX2020 or any other product candidate we may develop, and any adverse development or perceived adverse development with respect to the applicable regulatory authority&#8217;s review of such filings, including without limitation the FDA&#8217;s issuance of a &#8220;refusal to file&#8221; letter or a request for additional information;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adverse results from, delays in or termination of clinical trials;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adverse regulatory decisions, including failure to receive regulatory approval of our product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">unanticipated serious safety concerns related to the use of LX2006, LX2020 or any other product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in financial estimates by us or by any equity research analysts who might cover our stock; </span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">conditions or trends in our industry;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in the market valuations of similar companies;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">stock trading price and volume fluctuations of comparable companies and, in particular, those that operate in the biopharmaceutical industry;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">publication of research reports about us or our industry or positive or negative recommendations or withdrawal of research coverage by securities analysts;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">announcements by us or our competitors of significant acquisitions, strategic partnerships or divestitures; </span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our relationships with our collaborators; </span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">announcements of investigations or regulatory scrutiny of our operations or lawsuits filed against us; </span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">investors&#8217; general perception of our company and our business;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">recruitment or departure of key personnel;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">overall performance of the equity markets;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">trading volume of our common stock;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">significant lawsuits, including patent or stockholder litigation or employee or independent contractor litigation; </span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in the structure of healthcare payment systems; </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">91</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">unfavorable geopolitical and economic conditions; and</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">other events or factors, many of which are beyond our control.</span></div></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The global economy, including credit and financial markets and the banking sector, has experienced extreme volatility and disruptions, including, among other things, severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates, supply chain shortages, increases in inflation rates, bank failures, higher interest rates, changing foreign trade policies and uncertainty about economic stability. For example, the ongoing wars in Ukraine and Israel have created volatility in the global capital markets and may have further global economic consequences, including disruptions of the global supply chain and energy markets. Any such volatility and disruptions may have adverse consequences on us or the third parties on whom we rely. If the equity and credit markets continue to deteriorate, it may make any necessary debt or equity financings more difficult to obtain in a timely manner or on favorable terms, more costly or more dilutive. Increased inflation rates can adversely affect us by increasing our costs, including labor and employee benefit costs. In addition, higher inflation and macro turmoil and uncertainty could also adversely affect our buyers and sellers, which could reduce demand for our products. These factors may negatively affect the trading price of our common stock, regardless of our actual operating performance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, in the past, stockholders have initiated class action lawsuits against pharmaceutical and biotechnology companies following periods of volatility in the trading prices of these companies&#8217; stock. This risk is especially relevant for us because biopharmaceutical companies have experienced significant stock price volatility in recent years. Such litigation, if instituted against us, could cause us to incur substantial costs and divert management&#8217;s attention and resources, which could harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business or our market, our stock price and trading volume could decline.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The trading market for our common stock is influenced by the research and reports that equity research analysts publish about us and our business. As a newly public company, we have only limited research coverage by equity research analysts. Equity research analysts may elect not to provide research coverage of our common stock, and such lack of research coverage may adversely affect the trading price of our common stock. While we currently have equity research analyst coverage, we will not have any control over the analysts or the content and opinions included in their reports. The price of our stock could decline if one or more equity research analysts downgrade our stock or issue other unfavorable commentary or research. If one or more equity research analysts cease coverage of our company or fail to publish reports on us regularly, demand for our stock could decrease, which in turn could cause our stock price or trading volume to decline.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">92</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are an &#8220;emerging growth company&#8221; and a &#8220;smaller reporting company&#8221; and, as a result of the reduced disclosure and governance requirements applicable to emerging growth companies and smaller reporting companies, our common stock may be less attractive to investors.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are an &#8220;emerging growth company&#8221; as defined in the JOBS Act, and we intend to take advantage of some of the exemptions from reporting requirements that are applicable to other public companies that are not emerging growth companies, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">not being required to comply with the auditor attestation requirements in the assessment of our internal control over financial reporting; </span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the audit and the financial statements;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reduced disclosure obligations regarding executive compensation in our periodic reports, proxy statements and registration statements; and</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">not being required to hold a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.</span></div></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot predict if investors will find our common stock less attractive because we will rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile. We may take advantage of these reporting exemptions until we are no longer an emerging growth company. We will remain an emerging growth company until the last day of the fiscal year ending after the fifth anniversary of our IPO, or, if earlier, (i) the last day of the fiscal year in which we have total annual gross revenue of at least $1.235 billion, (ii) the date on which we are deemed to be a large accelerated filer, which means the market value of our common stock that is held by non-affiliates exceeds $700 million as of the prior June 30, or (iii) the date on which we have issued more than $1.0 billion in non-convertible debt during the prior three-year period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we have elected to take advantage of the extended transition period to comply with new or revised accounting standards and to adopt certain of the reduced disclosure requirements available to emerging growth companies. As a result of the accounting standards election, we will not be subject to the same implementation timing for new or revised accounting standards as other public companies that are not emerging growth companies, which may make comparison of our financials to those of other public companies more difficult. As a result of these elections, the information that we provide in this Annual Report on Form 10-K may be different than the information investors may receive from other public companies in which they hold equity interests. In addition, it is possible that some investors will find our common stock less attractive as a result of these elections, which may result in a less active trading market for our common stock and higher volatility in our trading price.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even after we no longer qualify as an emerging growth company, we may, under certain circumstances, still qualify as a &#8220;smaller reporting company,&#8221; which would allow us to take advantage of many of the same exemptions from disclosure requirements, including reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Because we do not anticipate paying any cash dividends on our common stock in the foreseeable future, capital appreciation, if any, will be your sole source of gains and you may never receive a return on your investment.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You should not rely on an investment in our common stock to provide dividend income. We have not declared or paid cash dividends on our common stock to date. We currently intend to retain our future earnings, if any, to fund the development and growth of our business. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future. Investors seeking cash dividends should not purchase our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">93</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware and the federal district courts of the United States of America will be the exclusive forums for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware is the exclusive forum for the following types of actions or proceedings under Delaware statutory or common law:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any derivative action or proceeding brought on our behalf;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any action asserting a breach of fiduciary duty;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any action asserting a claim against us arising under the Delaware General Corporation Law, or DGCL, our amended and restated certificate of incorporation, or our amended and restated bylaws;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any claim or cause of action seeking to interpret, apply, enforce or determine the validity of our restated certificate or our amended and restated bylaws;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any claim or cause of action as to which the DGCL confers jurisdiction on the Court of Chancery of the state of Delaware; and</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any action asserting a claim against us that is governed by the internal-affairs doctrine.</span></div></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This provision would not apply to suits brought to enforce a duty or liability created by the Exchange Act. Furthermore, Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims. To prevent having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, our amended and restated certificate of incorporation further provides that the federal district courts of the United States will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions. In such instance, we would expect to vigorously assert the validity and enforceability of the exclusive forum provisions of our amended and restated certificate of incorporation. This may require significant additional costs associated with resolving such action in other jurisdictions and there can be no assurance that the provisions will be enforced by a court in those other jurisdictions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These exclusive forum provisions may result in increased costs for investors to bring a claim. Further, these exclusive forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, or other employees, which may discourage lawsuits against us and our directors, officers and other employees. If a court were to find either exclusive forum provision in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur further significant additional costs associated with resolving the dispute in other jurisdictions, all of which could seriously harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Provisions in our corporate charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Provisions in our certificate of incorporation and our bylaws may discourage, delay, or prevent a merger, acquisition, or other change in control of our company that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the trading price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions:</span></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establish a classified board of directors such that only a portion of our directors stand for election at any given annual stockholder meeting;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">allow the authorized number of our directors to be changed from time to time by our shareholders or our board of directors;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">limit the manner in which stockholders can remove directors from our board of directors;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establish requirements for stockholder proposals that can be acted on at stockholder meetings;</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">94</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">require that stockholder actions must be effected at a duly called stockholder meeting and allow actions by our stockholders by written consent, with certain requirements;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">limit who may call stockholder meetings; and</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">authorize our board of directors to issue preferred stock without stockholder approval, which could be used to institute a &#8220;poison pill&#8221; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our board of directors.</span></div></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the DGCL, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General risks</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Unstable market and economic conditions may have serious adverse consequences on our business and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The global economy, including credit and financial markets, has experienced extreme volatility and disruptions recently, including, among other things, diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, supply chain shortages, increases in inflation rates, higher interest rates, and uncertainty about economic stability. The Federal Reserve has raised interest rates multiple times in response to concerns about inflation and it may raise them again. Higher interest rates, coupled with reduced government spending and volatility in financial markets, may increase economic uncertainty and affect consumer spending. Similarly, the ongoing military conflicts in Ukraine and the Middle East and increasing tensions between China and Taiwan have created extreme volatility in the global capital markets and may have further global economic consequences, including disruptions of the global supply chain. Any such volatility and disruptions may adversely affect our business or the third parties on whom we rely. If the equity and credit markets deteriorate, including as a result of political unrest or war, it may make any necessary debt or equity financing more difficult to complete, more costly, and more dilutive. Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our growth strategy, financial performance and share price and could require us to delay or abandon development or commercialization plans. In addition, there is a risk that one or more of our service providers, manufacturers or other partners would not survive or be able to meet their commitments to us under such circumstances, which could directly affect our ability to attain our operating goals on schedule and on budget. We have experienced and may in the future experience disruptions as a result of such macroeconomic conditions, including delays or difficulties in initiating or expanding clinical trials and manufacturing sufficient quantities of materials. Any one or a combination of these events could have a material and adverse effect on our results of operations and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we fail to maintain proper and effective internal controls, our ability to produce accurate financial statements on a timely basis could be impaired.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, and the rules and regulations of Nasdaq Stock Market. The Sarbanes-Oxley Act requires, among other things, that we maintain effective disclosure controls and procedures and internal control over financial reporting. In addition, Section 404 of the Sarbanes-Oxley Act requires our management and independent registered public accounting firm to report on the effectiveness of our internal control over financial reporting. We are also required to disclose changes made in our internal controls and procedures on a quarterly basis. However, for so long as we remain an emerging growth company as defined in the JOBS Act, we intend to take advantage of certain exemptions from various reporting requirements that are applicable companies that are not emerging growth companies, including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act. Once we are no longer an emerging growth company or, if prior to such date we opt to no longer take advantage of the applicable exemption, we will be required to include an opinion from our independent registered public accounting firm on the effectiveness of our internal control over financial reporting. An independent assessment of the effectiveness of our internal controls over financial reporting could detect problems that our management&#8217;s assessment might not.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The requirements of these rules and regulations are difficult, time-consuming and costly, and place significant strain on our personnel, systems and resources. Effective internal controls over financial reporting are necessary for us to provide reliable financial reports and, together with adequate disclosure controls and procedures, are designed to prevent fraud. In order to maintain and improve the effectiveness of our disclosure controls and procedures and internal control over financial reporting, we have expended and anticipate we will continue to expend significant resources, including accounting-related costs, and provide significant management oversight. Any failure to implement required new or improved controls, or difficulties encountered in their implementation could cause us to fail to meet our reporting obligations. In addition, if we are unable to continue to meet these requirements, we may not be able to remain listed on the Nasdaq Global Market.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">95</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may identify weaknesses in our system of internal financial and accounting controls and procedures that could result in a material misstatement of our financial statements. Our internal control over financial reporting will not prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud will be detected. If we fail to identify material weaknesses, in our internal control over financial reporting, if we are not able to comply with the requirements of Section 404 of the Sarbanes-Oxley Act in a timely manner, or if we are unable to maintain proper and effective internal controls, we may not be able to produce timely and accurate financial statements. If that were to happen, the trading price of our stock could decline and we could be subject to sanctions or investigations by the stock exchange on which our common stock is listed, the Securities and Exchange Commission, or the SEC, or other regulatory authorities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our ability to utilize our net operating loss carryforwards and research tax credits to offset future taxable income may be subject to limitations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, we had approximately $106.4 million of U.S. federal net operating loss carryforwards, or NOLs, $212.7 million of U.S. state and local NOLs, and $10.7 million of federal tax credits. U.S. federal NOLs generated in taxable years beginning after December 31, 2017, do not expire and may be carried forward indefinitely, but the deductibility of such NOLs is limited to no more than 80% of current year taxable income. Our U.S. state and local NOLs begin to expire in 2040 and our federal research tax credits begin to expire in 2040.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, or the Code, if a corporation undergoes an &#8220;ownership change,&#8221; which is generally defined as a greater than 50% change, by value, in its equity ownership by certain stockholders over a rolling three-year period, the corporation&#8217;s ability to use its pre-change NOLs and certain other pre-change tax attributes (such as research tax credits) to offset its post-change taxable income or taxes may be limited. If we undergo an ownership change, and our ability to use our pre-change NOLs and other pre-change tax attributes (such as tax credits) to offset our post-change income or taxes is limited, it may harm our future results of operations by effectively increasing our future tax obligations. U.S. state and local NOLs may be similarly limited. In addition, at the U.S. state and local level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase U.S. state and local taxes owed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Irrespective of the above, our ability to utilize our NOLs and research tax credits to offset future taxable income or taxes is conditioned on our attaining profitability and generating taxable income. We do not know if and when we will generate sufficient taxable income to utilize our NOLs and research tax credits.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Changes in tax laws or regulations that are applied adversely to us or our customers may materially harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">New tax laws, statutes, rules, regulations, or ordinances could be enacted at any time. Further, existing tax laws, statutes, rules, regulations, or ordinances could be interpreted differently, changed, repealed, or modified at any time. Any such enactment, interpretation, change, repeal, or modification could adversely affect us, possibly with retroactive effect. For example, the IRA enacted a 15% minimum tax on the adjusted financial statement income of certain large U.S. corporations for taxable years beginning after December 31, 2022, as well as a 1% excise tax on stock repurchases made by public corporations after December 31, 2022. Further, the Tax Cuts and Jobs Act of 2017, or the Tax Act, enacted many significant changes in U.S. federal tax laws, some of which were further modified by the Coronavirus Aid, Relief, and Economic Security Act, or the CARES Act, and may be modified in the future by the current or a future presidential administration. Among other changes, the Tax Act amended the Code to require that certain research and experimental expenditures be capitalized and amortized over five years if incurred in the United States or fifteen years if incurred in foreign jurisdictions for taxable years beginning after December 31, 2021. If the capitalization and amortization requirement is not deferred, repealed, or otherwise modified, it may increase our cash taxes and effective tax rate. In addition, it is uncertain if and to what extent various states will conform to the IRA, the Tax Act, the CARES Act, or any future U.S. federal tax laws. Changes in corporate tax rates, the realization of net deferred tax assets relating to our operations, the taxation of foreign earnings, and the deductibility of expenses could have a material impact on the value of our deferred tax assets, result in significant one-time charges, and increase our future U.S. tax expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our business and operations would suffer in the event of system failures, cyberattacks or a deficiency in our or our CMOs&#8217;, CROs&#8217;, manufacturers&#8217;, contractors&#8217;, consultants&#8217; or collaborators&#8217; cybersecurity.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the ordinary course of our business, we and third parties with whom we conduct business, including third-party CMOs, CROs, manufacturers, contractors (including sites performing our clinical trials), consultants, and collaborators, collect and store sensitive data, including intellectual property, clinical trial data, proprietary and confidential business information, and personal data and personal information of our clinical trial subjects, employees, and others. The secure maintenance, transmission, and other processing of this information is critical to our operations.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">96</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Despite the implementation of security measures, our internal systems, as well as those of third parties on which we rely, are vulnerable to damage from, among other things, computer viruses, ransomware and other forms of malware, unauthorized access, natural disasters, terrorism, war, telecommunication and electrical failures, system malfunctions, cyberattacks or cyber-intrusions, email attachment compromise, denial of service attacks, phishing attacks, and unauthorized or otherwise improper acts or omissions by persons inside our organization, or persons with access to systems inside our organization. Any such event could lead to the prevention of access to, loss, destruction, alteration, disclosure, or dissemination of, or damage or unauthorized access to or other processing of, our data (including trade secrets or other confidential information, intellectual property, proprietary business information and personal data) or other data that is processed or maintained on our behalf, and cause disruptions to our operations, which could lead to a material disruption of our product candidate development programs. For example, the loss, corruption or unavailability of preclinical study or clinical trial data from completed, ongoing or planned trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">More generally, despite the implementation of security measures </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in an effort to protect our systems and data</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, we cannot ensure that our information technology and infrastructure or any of our relevant policies or measures will prevent breakdowns or disruptions of, or breaches or incidents impacting, our systems or those of third parties on which we rely, or other cybersecurity incidents that lead to loss, destruction, unavailability, or unauthorized alteration, dissemination or other processing of, or damage or unauthorized access to, our data, including personal data, our other assets, or other data processed or maintained on our behalf, that could </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delay clinical development of our product candidates and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">have a material adverse effect upon our reputation, business, operations or financial condition. To our knowledge, we have not experienced any security breach to date </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that has had a material impact on our business or operations, but we and the third parties with whom we conduct business have faced, and we anticipate continuing to face, cybersecurity risks, including risks of security breaches and incidents</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks of security breaches and incidents and other types of system disruptions, particularly through cyberattacks or cyber intrusions, including by hackers, foreign governments, cyber terrorists, and associated actors, have increased generally as the number, intensity, and sophistication of attempted attacks and intrusions from around the world have increased. Geopolitical conflicts and tensions may also increase such risks.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any security breach or incident resulting in any loss</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, destruction, unavailability, alteration, disclosure, dissemination, or other processing</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of, or damage or unauthorized access to, our data, systems or applications, or inappropriate disclosure or other processing of confidential or proprietary information or personal data, </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, or any other event resulting in unauthorized access to, or disclosure or processing of, such information, or for it to be believed or reported that any of the foregoing has occurred, could lead to us facing regulatory inquiries and proceedings, incurring material legal claims and proceedings, and incurring material damage to our reputation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Any such event could also </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">disrupt our operations, lead to delays in the further development of our product candidates, cause a loss of confidence in us and our ability to conduct clinical trials,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> compel us to comply with federal and state breach notification laws and foreign law equivalents, subject us to mandatory corrective action, and subject us to material liability under applicable laws, rules, regulations and standards, which could result in significant legal and financial exposure and reputational damage that could have a material adverse effect on our business</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, operations, and financial condition</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notifications and follow-up actions related to a security breach or other security incident could impact our reputation and cause us to incur significant costs, including significant legal expenses and remediation costs. We expect to incur significant costs in an effort to detect and prevent security incidents, and we may face increased costs and requirements to expend substantial resources in the event of an actual or perceived security incident. However, we cannot guarantee that we will be able to detect or prevent any such incidents, or that we can remediate any such incidents in an effective or timely manner. Our efforts to improve security and protect data from compromise may also identify previously undiscovered instances of data breaches or other cybersecurity incidents. Any security breach or incident resulting in any loss, destruction, or alteration of, damage or unauthorized access to, or unauthorized or otherwise inappropriate disclosure, dissemination, or other processing of, our data, including personal data, or other information that is processed or maintained on our behalf</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, any significant damage to or disruption of our systems, or any perception that any of these has occurred,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> could expose us to litigation and governmental investigations and inquiries, lead to delays in further development and commercialization of our product candidates, and subject us to significant fines, penalties and other liabilities.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our insurance policies may not be adequate to compensate us for the potential losses arising from any failure or other disruption of, security breach of, or incident impacting, our systems or third-party systems where information important to our business operations is stored or otherwise processed, or any other unauthorized disclosure of information. In addition, such insurance may not be available to us in the future on economically reasonable terms, or at all. Further, our insurance may not cover all claims made against us and could have high deductibles in any event, and defending a suit, regardless of its merit, could be costly and divert management attention.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">97</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We incur increased costs and demands upon management as a result of being a public company.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a public company listed in the United States, we incur significant additional legal, accounting and other expenses that we did not incur as a private company, including the cost of director and officer liability insurance. These additional costs could negatively affect our financial results. In addition, changing laws, regulations and standards relating to corporate governance and public disclosure, including regulations implemented by the SEC and the Nasdaq Stock Market, may increase legal and financial compliance costs and make some activities more time-consuming. These laws, regulations and standards are subject to varying interpretations and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. We intend to invest resources to comply with evolving laws, regulations and standards, and this investment may result in increased general and administrative expenses and a diversion of management&#8217;s time and attention from revenue-generating activities to compliance activities. If notwithstanding our efforts to comply with new laws, regulations and standards, we fail to comply, regulatory authorities may initiate legal proceedings against us and our business may be harmed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Failure to comply with these rules might also make it more difficult for us to obtain some types of insurance, including director and officer liability insurance, and we might be forced to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. The impact of these events could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, on committees of our board of directors or as members of senior management.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are subject to certain reporting requirements of the Exchange Act. Our disclosure controls and procedures are designed to reasonably assure that information required to be disclosed by us in reports we file or submit under the Exchange Act is accumulated and communicated to management, recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements or insufficient disclosures due to error or fraud may occur and not be detected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1b_unresolved_staff_comments"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1B.    Unresolve</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">d Staff Comments.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span></p>
  <div><ix:nonNumeric id="F_22002f0b-3642-4aa8-a282-356a27febc28" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" escape="true" continuedAt="F_22002f0b-3642-4aa8-a282-356a27febc28_1"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1c_cybersecurity"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">em 1C.    Cybersecurity</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risk Management and Strategy</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7bd46ff9-4352-4c7e-99e1-5da34fce3666" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="cyd:CybersecurityRiskRoleOfManagementTextBlock" escape="true"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have established policies and processes for assessing, identifying, and managing risk from cybersecurity threats. We periodically assess risks from cybersecurity threats, including any potential unauthorized occurrence on or conducted through our information systems that may result in adverse effects on the confidentiality, integrity, or availability of our information systems or any information residing therein. Following these risk assessments, we evaluate how to reasonably address any identified gaps in existing safeguards and monitor the effectiveness of our safeguards. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d523653a-7813-4dae-9be4-3c52144b127e" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock" escape="true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We devote resources and designate high-level personnel, including our Chief Legal Officer, who reports to our Chief Executive Officer, to manage the risk assessment and mitigation process in a manner that is consistent and </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0e27eed5-5cd6-44e9-8380-2d3a6a848c87" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">integrated</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> with our overall risk management processes. </span></ix:nonNumeric></span><span style="font-size:10pt;font-family:Times New Roman;"></span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As part of our overall risk management system, we monitor and test our safeguards and train our employees on these safeguards, including our cybersecurity safeguards, in collaboration with human resources, IT, and management. Personnel at all levels and departments receive periodic trainings on cybersecurity best practices and threats. For example, we conduct e-mail phishing campaigns with our employees and contractors which send phishing-style e-mails, monitor user responses, and automatically assign further training, as needed, and also provide convenient solutions for our employees to report suspicious messages.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4b9391e1-0f5c-485f-90d4-08a3b1a7078c" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">engage</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> specialized third parties in connection with our risk assessment processes. These </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e603fbe3-db09-475d-97cf-1fcd84a100bf" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">third parties assist </span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">us in designing and implementing our cybersecurity policies and procedures, as well as in monitoring and testing our safeguards.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also conduct IT security assessments on our key third-party service providers and require them to implement and maintain reasonable security measures in connection with their work with us, and to promptly report any suspected breach of their security measures that may affect our company.</span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">98</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_22002f0b-3642-4aa8-a282-356a27febc28_1"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have not previously experienced any cybersecurity risk or cybersecurity incident which has been determined to be </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f4124969-6bbb-4f48-844a-0b7d2da46760" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">material</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. For additional information regarding whether any risks from cybersecurity threats are reasonably likely to materially affect our company, including our business strategy, results of operations, or financial condition, please refer to Item 1A, &#8220;Risk Factors&#8221; in this Annual Report on Form 10-K, including the risk factor entitled &#8220;Our business and operations would suffer in the event of system failures, cyberattacks or a deficiency in our or our CMOs&#8217;, CROs&#8217;, manufacturers&#8217;, contractors&#8217;, consultants&#8217; or collaborators&#8217; cybersecurity&#8221;.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Governance</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_11338233-5dc5-4c6b-84e0-f48f40f846c0" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock" escape="true"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">One of the key functions of our board of directors is informed oversight of our risk management process, including risks from cybersecurity threats. Our board of directors is responsible for monitoring and assessing strategic risk exposure, and our executive officers are responsible for the day-to-day management of the material risks we face. Our board of directors administers its cybersecurity risk oversight function directly as a whole, as well as through our audit committee.</span></p><div><ix:nonNumeric id="F_db5866f1-9d9e-4bdb-916b-99d74bbcb049" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" escape="true"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Chief Legal Officer and our security governance steering committee, which includes our Vice President and Corporate Controller, Vice President of Human Resources, Senior Vice President of Development Operations, and Director of Information Technology and Cybersecurity, are primarily responsible for assessing and managing our risks from cybersecurity threats. Our Chief Legal Officer has more than a decade of operational experience overseeing and advising on risk management in the highly regulated biopharmaceutical industry, and leads a wide range of business functions, including IT/IS. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7655f1e6-f7f3-461c-9755-cfed650d67d3" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" escape="true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Director of Information Technology and Cybersecurity has nearly 20 years of experience with IT, having had leadership roles in strategic technology development and information security, and holds several industry-recognized certifications such as the Certified Information Security Manager (CISM) and CompTIA Network+. They and other members of our security governance steering committee engage in training and education relating to cybersecurity risk.</span></ix:nonNumeric></span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_dffd865c-bbff-4607-8887-e43160f40b34" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" escape="true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Chief Legal Officer and our security governance steering committee oversee our cybersecurity policies and processes, including those described in &#8220;Risk Management and Strategy&#8221; above.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_de753e8d-20e9-4b2e-8a7f-5e2caaa68361" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" escape="true"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_41cd2f14-97d4-436c-ac94-a67d34964807" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Chief Legal Officer and our management committee</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> on cybersecurity are informed about and monitor the prevention, detection, mitigation, and remediation of cybersecurity incidents through their work overseeing, working with, and delegating daily operations to the IT/IS team, as well as their work developing and implementing information security policies, consistent with the IT/IS processes.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> These policies are reviewed at least annually with updates authorized and approved by the security governance steering committee.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b91906aa-5d48-41a7-9cb0-19ca64a6027c" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" escape="true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Chief Legal Officer and representatives from our security governance steering committee provide quarterly briefings to the audit committee regarding our company&#8217;s cybersecurity risks and activities, including any recent cybersecurity incidents and related responses, cybersecurity systems testing, activities of third parties</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and the like. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d3b75bda-5e83-422f-9490-93326f79207e" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our audit committee provides regular updates to the board of directors on such reports</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In addition, our Chief Legal Officer and representatives from our security governance steering committee provide annual briefings to the board of directors on cybersecurity risks and activities.</span></p></ix:nonNumeric></div></ix:continuation></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_2_properties"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 2.    Pro</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">perties.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our corporate headquarters is located at 345 Park Avenue South, 6</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">th</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Floor, New York, NY 10010, where we lease a total of approximately 15,839 square feet of office and laboratory space used for our research and development activities, general and administrative activities and other activities. This lease agreement began in April 2022 and expires in July 2029 with an additional five-year option to extend at the then-prevailing effective market rental rate. We also lease up to 3,000 square feet of laboratory and related office space used for our research and development activities at BioLabs San Diego, 9276 Scranton Road, Suite 500, San Diego, CA 92121. This lease agreement began in September 2024 and expires in September 2026 and is terminable by either party with 30 days' notice.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe that our current facilities are sufficient to meet our current and near term needs and that suitable additional or substitute space will be available at commercially reasonable terms as and when needed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">99</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_3_legal_proceedings"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 3.    Legal </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Proceedings.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, we may become involved in legal proceedings arising in the ordinary course of our business. On October 12, 2023, Rocket filed a lawsuit in the U.S. District Court for the Southern District of New York against Lexeo and two former employees claiming, among other things, misappropriation of confidential information and trade secrets. The complaint alleges that while employees of Rocket, the individual defendants downloaded confidential Rocket company documents and other proprietary materials and that Lexeo used this information to advance its programs after the individuals became employed by Lexeo. The complaint seeks unspecified damages and injunctive relief. </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In August 2024, we asserted counterclaims against Rocket and Spacecraft Seven LLC, a wholly owned subsidiary of Rocket, for misappropriation of trade secrets, correction of inventorship of certain PKP2-ACM patents, breach of contract, and tortious interference with contract in connection with their diligence of a PKP2-ACM program at UCSD that was later licensed by Lexeo. Our counterclaims seek equitable relief, damages, attorneys' fees and costs from Rocket and Spacecraft Seven LLC. The case is currently in the discovery phase.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> While it is not possible to predict the outcome with certainty and an estimate of the possible loss cannot be made, we currently do not expect the final outcome will have a material adverse effect on our timelines for development of our product candidates. Regardless of the final outcome, litigation can have an adverse impact on us due to defense and settlement costs, diversion of management resources, harm to our reputation and other factors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_4_mine_safety_disclosures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 4.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   Reserved.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">100</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_ii"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART II</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_5__market_for_registrants_common_eq"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 5.    Market for Registrant&#8217;s Common Equity, Related Sto</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ckholder Matters and Issuer Purchases of Equity Securities.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Market Information</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our common stock has been listed on the Nasdaq Global Market under the symbol &#8220;LXEO&#8221; since November 3, 2023. Prior to that date there was no public trading market for our common stock.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Holders</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of March 20, 2025, there were approximately 18 registered holders of record of our common stock. We believe a greater number of holders of our common stock are &#8220;street name&#8221; or beneficial holders, whose shares of record are held by banks, brokers and other financial institutions.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dividend Policy</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have never declared or paid, and do not anticipate declaring or paying, in the foreseeable future, any cash dividends on our capital stock. We currently intend to retain all available funds and any future earnings to support our operations and finance the growth and development of our business. Any future determination related to our dividend policy will be made at the discretion of our board of directors and will depend upon, among other factors, our results of operations, financial condition, capital requirements, contractual restrictions, business prospects and other factors our board of directors may deem relevant.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recent Sales of Unregistered Securities; Use of Proceeds</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There have been no unregistered sales of securities other than previously disclosed by us in our Current Report on Form 8-K, as filed with the SEC on March 11, 2024.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Purchases of Equity Securities by the Issuer and Affiliated Purchases</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:24.83%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:15.986%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:2.941%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:14.886%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:15.366%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:15.986%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Period</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total Number of Shares (or Units) Purchased</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Average Price Paid per Share (or Unit)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total Number of Shares (or Units) Purchased as Part of Publicly Announced Plans or Programs</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Maximum Number (or Approximate Dollar Value) of Shares (or Units) that May Yet Be Purchased Under the Plans or Programs</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">October 1, 2024 to October 31, 2024</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">November 1, 2024 to November 30, 2024</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">836</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.87</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 1, 2024 to December 31, 2024</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">836</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;(1)</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,074</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) We repurchased shares of our common stock that were previously issued upon the early exercise of employee stock options in connection with the exercise of our repurchase right upon cessation of service of certain of our employees.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_6_reserved"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 6. R</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">eserved</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">101</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_7_managements_discussion_analysis_f"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 7. Management&#8217;s Discussion and Analysis of </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial Condition and Results of Operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">You should read the following discussion and analysis of our financial condition and results of operations together with the financial statements and related notes included elsewhere in this Annual Report on Form 10-K. This discussion contains forward-looking statements based upon current expectations that involve risks and uncertainties. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of various factors, including those discussed in &#8220;Item 1A. Risk Factors&#8221; and in other parts of this Annual Report on Form 10-K.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Overview</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a clinical stage genetic medicine company dedicated to reshaping heart health by applying pioneering science to fundamentally change how cardiovascular diseases are treated. We are advancing a portfolio of therapeutic candidates that take aim at the underlying genetic causes of conditions, including FA cardiomyopathy, PKP2 arrhythmogenic cardiomyopathy, and other devastating diseases with high unmet need.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our most advanced cardiovascular product candidate, LX2006 for the treatment of FA cardiomyopathy, is currently being evaluated in SUNRISE-FA, our ongoing Phase 1/2 clinical trial and in a Cornell investigator-initiated trial. In July 2024, we provided an interim clinical update, which included baseline characteristics from the 11 treated participants across the two studies and data from the 8 participants who had reached at least 6-months of follow-up as of that time. These data showed improvements in key cardiac biomarkers including left ventricular mass index, lateral wall thickness, and high-sensitivity troponin I. Additionally, in November 2024 we reported that we observed an increase in frataxin protein expression in the hearts of four patients that had undergone cardiac biopsies (cohort 1 (n=1), cohort 2 (n=3)) as measured by LCMS and immunohistochemistry. LX2006 has been generally well-tolerated across both trials to date. One year after dosing, one participant with multiple comorbidities and a history of flu-like symptoms presented with Grade 2 asymptomatic myocarditis. Six weeks later, a biopsy was negative for myocarditis and the participant remains asymptomatic. In November 2024 we announced alignment with the FDA on key elements of a registrational development plan for LX2006, including an accelerated approval pathway with left ventricular mass index and frataxin protein expression as co-primary registrational endpoints. In February 2025, we reached further alignment with FDA that the frataxin protein expression co-primary endpoint would be evaluated for any increase from baseline in frataxin positive area as measured by immunohistochemistry as opposed to any specific numerical threshold. We expect to provide a further interim data update in mid-2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our second most advanced cardiovascular product candidate, LX2020 for the treatment of ACM caused by mutations in the PKP2 gene, referred to as PKP2-ACM, is currently being evaluated in HEROIC-PKP2, an ongoing Phase 1/2 clinical trial. To date, six participants have been enrolled in this trial: three in cohort 1 and three in cohort 2. We have obtained post-treatment cardiac biopsies from two participants in cohort 1; the third cohort 1 participant elected to not undergo the post-treatment biopsy procedure. In these two participants with post-treatment samples, we have observed an increase in PKP2 protein expression in the heart quantified using western blot assay showing a 71% and 115% increase in PKP2 protein expression versus pre-treatment baseline. In addition, the first participant to reach 6 months post-treatment experienced a 67% reduction in PVCs from baseline and normalization of QRS duration. Across all participants dosed, LX2020 has been generally well-tolerated with no treatment-related serious adverse events to date. We expect to provide an interim data readout focused on clinical efficacy biomarkers in the second half of 2025.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each of our gene therapy candidates utilizes the vector construct, dose and route of administration that we believe will result in the most favorable biodistribution and safety profile for our product candidate for each disease. Our most advanced programs use the AAVrh10 vector due to its high transduction efficiency in myocardial cells, potential for lower toxicity given the opportunity to utilize lower doses compared to other well-established AAV serotypes, and low pre-existing immunity.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To date, we have funded our operations primarily through proceeds from the sale of shares of our convertible preferred stock and common stock, including our Private Placement, IPO and the subsequent partial exercise of the underwriters&#8217; 30-day option to purchase additional shares of common stock. As of December 31, 2024, we had $128.5 million of cash, cash equivalents, and investments. We have incurred significant operating losses since the commencement of our operations. Our ability to generate product revenue sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of one or more of our current gene therapy candidates or any future gene therapy candidates. Our net losses for the years ended December 31, 2024 and December 31, 2023 were $98.3 million and $66.4 million, respectively, and our accumulated deficit was $280.2 million at December 31, 2024. We expect to continue to incur significant losses for the foreseeable future as we advance our current and future product candidates through preclinical and clinical development, continue to build our operations and operate as a public company.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">102</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect to continue to incur net operating losses for at least the next several years, and we expect our research and development expenses, general and administrative expenses, and capital expenditures to continue to increase. We expect our expenses and capital requirements will increase significantly in connection with our ongoing activities as we:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">continue our ongoing and planned clinical trials as well as research and development of our FA cardiomyopathy (LX2006) and arrhythmogenic cardiomyopathy caused by mutations in the PKP2 gene, or PKP2-ACM (LX2020) programs and other product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">initiate preclinical studies and clinical trials for any additional product candidates that we may pursue in the future;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">seek to discover and develop additional product candidates and further expand our clinical product pipeline;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">seek regulatory approvals for any product candidates that successfully complete clinical trials;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">invest in capital equipment in order to expand our research and development and manufacturing activities;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">attract, hire and retain additional clinical, scientific, quality control, regulatory, and manufacturing management and administrative personnel;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">add clinical, operational, financial and management information systems and personnel, including personnel to support our product development;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">develop, maintain, expand, protect and enforce our intellectual property portfolio, including patents, trade secrets and know-how;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">acquire or in-license other product candidates and technologies;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">expand our operations in the United States and to other geographies;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">incur additional legal, accounting, investor relations and other general and administrative expenses associated with operating as a public company; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establish a sales, marketing and distribution infrastructure, either ourselves or in partnership with others, to commercialize any product candidates, if approved, and related additional commercial manufacturing costs.</span></div></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Summary of key factors impacting the comparability of our performance</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Components of our results of operations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To date, we have not generated any revenue from product sales. If our development efforts for LX2006 and LX2020 or any future product candidates, are successful and result in regulatory approval, or if we enter into collaboration or license agreements with third parties, we may generate revenue in the future from product sales, royalties or payments from such collaboration or license agreements, or a combination of product sales and payments from such agreements.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">103</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Operating expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and development</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expenses consist of costs incurred for our research activities, including our discovery efforts and the preclinical and clinical development of our programs. These expenses include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">employee-related expenses, including salaries, benefits, and stock-based compensation expense for employees engaged in research and development functions;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">expenses incurred under agreements with third parties, such as consultants, clinical investigators, contractors and CROs that assist with (i) identification of potential product candidates in discovery platforms and (ii) the preclinical and clinical studies of our product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of developing and scaling our manufacturing process and manufacturing product candidates for use in our research, preclinical studies and clinical trials, including under agreements with third parties, such as consultants, contractors and CMOs;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">costs to maintain compliance with FDA and other regulatory requirements;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">laboratory supplies and research materials;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">facilities, depreciation, and other expenses, which include direct and allocated expenses for rent and maintenance of facilities;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">payments made under our licensing agreements with third parties, including milestone payments; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">other expenses incurred as a result of research and development activities.</span></div></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expense research and development costs as incurred. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. When third-party service providers&#8217; billing terms do not coincide with our period-end, we are required to make estimates of our obligations to those third parties incurred in a given accounting period and record accruals at the end of the period. We base these estimates on our knowledge of the research and development programs, services performed for the period, past history for related activities and the expected duration of the third-party service contract, where applicable. If timelines or contracts are modified based upon changes in the scope of work to be performed, we modify our estimates of accrued expenses accordingly on a prospective basis; therefore, actual results could differ from our estimates. Upfront payments under license agreements are expensed upon receipt of the license, and annual maintenance fees under license agreements are expensed in the period in which they are incurred. Milestone payments under license agreements are accrued, with a corresponding expense being recognized, in the period in which the milestone is determined to be probable of achievement and the related amount is reasonably estimable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our direct research and development expenses are tracked on a program-by-program basis and consist primarily of external costs, such as fees paid to CROs, CMOs, central laboratories and certain outside consultants in connection with our research and discovery, preclinical development, process development, manufacturing, clinical development, clinical trials, regulatory and quality assurance activities. We do not allocate professional services costs and licensing fees and other similar costs to specific programs because these costs are deployed across multiple programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">104</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development activities are central to our business model and account for a significant portion of our operating expenses. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. As a result, we expect our research and development expenses to increase for the foreseeable future as we further advance LX2006 and LX2020, and any other future product candidates that we may develop, into and through preclinical studies and clinical trials and pursue regulatory approvals. We cannot determine with certainty the timing of initiation, the duration or the completion costs of current or future preclinical studies and clinical trials of our product candidates due to the inherently unpredictable nature of preclinical and clinical development. Clinical and preclinical development timelines, the probability of success and development costs can differ materially from expectations. We anticipate that we will make determinations as to which product candidates to pursue and how much funding to direct to each product candidate on an ongoing basis in response to the results of ongoing and future research, preclinical studies and clinical trials, regulatory developments and our assessments as to each product candidate&#8217;s commercial potential. In addition, we cannot forecast whether any of our current or future product candidates will be subject to future collaborations, when such arrangements will be secured, if at all, and to what degree such arrangements would affect our development plans and capital requirements. We are also unable to predict when, if ever, we will generate revenue from our product candidates to offset our expenses.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">General and administrative</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General and administrative expenses consist primarily of personnel expenses, including salaries, benefits and stock-based compensation expense, for personnel in executive, accounting, business development, legal, human resources and administrative functions. General and administrative expenses also include corporate facility costs not otherwise included in research and development expenses, depreciation, and other expenses, which include direct or allocated expenses for rent and maintenance of facilities and insurance, not otherwise included in research and development expenses, as well as professional fees for legal, consulting, investor and public relations, accounting and audit services.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect that our general and administrative expenses will increase in the future as we incur additional expenses to support the continued research and development of our programs and the growth of our business, including increasing our general and administrative headcount, as well as additional costs associated with operating as a large public company, including increased expenses for audit, legal, regulatory, investor relations and tax-related services associated with maintaining compliance with the rules and regulations of the Securities and Exchange Commission, or SEC, and standards applicable to companies listed on a national securities exchange.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Loss on fair value adjustment to convertible SAFE Note</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Loss on fair value adjustment to convertible SAFE Note consists of losses on the estimated fair value of the convertible SAFE Note.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other income (expense), net</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other income (expense), net includes net foreign exchange gains and (losses).</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interest expense</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interest expense is primarily associated with our finance right of use asset equipment leases.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interest income</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interest income is primarily related to interest earned from our investment in a U.S. government money market fund and interest earned from our investments in U.S. Treasury securities, as well as interest earned on interest-bearing demand deposit cash accounts.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income taxes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Provision for income taxes consists of U.S. federal and state income taxes in the jurisdictions where we conduct business. Since our inception, we have not recorded any income tax benefits for the net losses we have incurred in each year or for our research and development tax credits, as we believe, based upon the weight of available evidence, that it is more likely than not that all of our net operating loss, or NOL, carryforwards and tax credits will not be realized. Accordingly, we have recorded a full valuation allowance against our net deferred tax assets at December 31, 2024 and December 31, 2023. As of December 31, 2024 and December 31, 2023, we had no unrecognized tax benefits.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Accretion of discount on investments</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accretion of discount on investments consists of accretion of discount on our investments in U.S. Treasury securities.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">105</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Results of operations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Comparison of the Years Ended December 31, 2024 and 2023</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes our results of operations for the years ended December 31, 2024 and 2023 (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:57.4%;box-sizing:content-box;"/>
    <td style="width:1.42%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.780000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.42%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.780000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.42%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.780000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating expenses</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">74,091</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53,130</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,961</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31,675</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,383</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,292</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">105,766</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">68,513</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37,253</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating loss</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(105,766</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(68,513</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(37,253</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income and expense</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss on fair value adjustment to convertible SAFE Note</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(530</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">530</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income (expense), net</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(9</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(13</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest expense</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(137</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(205</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">68</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest income</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,556</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,867</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,689</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accretion of discount on investments</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total other income and expense</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,433</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,119</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,314</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from operations before income taxes</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(98,333</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(66,394</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(31,939</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Income taxes</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net Loss</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(98,333</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(66,394</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(31,939</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and development expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes our research and development expenses incurred for the years ended December 31, 2024 and 2023 (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:57.4%;box-sizing:content-box;"/>
    <td style="width:1.42%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.780000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.42%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.780000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.42%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.780000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Direct external research and development expenses by program:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">LX2020</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,451</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,192</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,259</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">LX2006</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,256</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,537</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,719</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">LX1001</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,501</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,936</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(5,435</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other programs</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,424</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,535</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">889</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total direct external research and development expenses by program</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45,632</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34,200</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,432</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unallocated research and development expenses:</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Employee and stock-based compensation expenses</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,011</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,499</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,512</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lab-related costs and supplies</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,356</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,160</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">196</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Professional fees</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,030</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,707</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">323</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other unallocated costs, including facilities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,062</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,564</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">498</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total unallocated research and development expenses:</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28,459</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,930</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,529</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total research and development expenses</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">74,091</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53,130</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,961</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The net increase of $21.0 million in total research and development expenses for the year ended December 31, 2024 compared to the year ended December 31, 2023 was primarily due to increases in (i) clinical trial costs of $8.7 million excluding an adjustment reducing estimated accrued clinical trial expenses by $2.2 million for our LX1001 program recorded during the year ended December 31, 2024, (ii) employee compensation and stock-based compensation expenses of $8.5 million primarily due to increased headcount and equity awards granted since December 31, 2023, (iii) chemistry, manufacturing and controls, or CMC, expenses of $3.8 million, (iv) net milestone expense of $2.6 million, including a $6.0 million development milestone for our LX2020 program that was achieved and paid to the selling shareholders of Stelios during the year ended December 31, 2024, which was partially offset by a $3.5 million development milestone for our LX2006 program that was achieved and paid to Adverum during the year ended December 31, 2023, (v) quality assurance and program and portfolio management expenses of $1.0 million, and (vi) license fees of $0.7 million primarily related to the Third Cornell License Agreement. These increases were partially offset by decreases in (i) non-clinical and preclinical expenses of $2.5 million primarily related to our early stage cardiovascular and CNS disease programs, and (ii) estimated accrued clinical trial expenses of $2.2 million resulting from an adjustment recorded during the year ended December 31, 2024 for our LX1001 program.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">106</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">General and administrative expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The net increase of $16.3 million in general and administrative expenses for the year ended December 31, 2024 compared to the year ended December 31, 2023 was primarily due to increases in (i) employee compensation and stock-based compensation expenses of $7.3 million primarily due to increased headcount and equity awards granted since December 31, 2023, (ii) third-party legal fees and associated costs of $6.4 million, (iii) third-party audit, tax, investor relations, public relations and other professional service provider fees, as well as insurance expenses, of $1.2 million primarily due to our becoming a publicly traded company in November 2023, (iv) travel, software, office supplies, and dues and subscription expenses of $0.6 million, and (v) capital tax expense of $0.3 million.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interest income</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We recognized interest income of $7.6 million and $2.9 million for the years ended December 31, 2024 and December 31, 2023, respectively, primarily related to interest earned on our investment in a U.S. government money market fund and our investments in U.S Treasury securities with an increased average invested balance in 2024 primarily due to the net proceeds received from our IPO and the subsequent partial exercise of the underwriters' option to purchase additional shares in November 2023, as well as the net proceeds received from our Private Placement offering in March 2024.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Liquidity and capital resources</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Sources of liquidity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since our inception, we have not generated any revenue from product sales and have incurred significant operating losses and negative cash flows from our operations. We expect to incur significant expenses and operating losses for the foreseeable future as we advance the clinical development of our product candidates. Since our inception through December 31, 2024, we funded our operations primarily with total net proceeds from sales of our common stock, convertible SAFE Note and convertible equity securities of $377.9 million. As of December 31, 2024 and December 31, 2023, we had cash, cash equivalents, and investments of $128.5 million and $121.5 million, respectively.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe that our cash, cash equivalents, and investments balances will be sufficient to fund our planned operating expenses and capital expenditure requirements into 2027. Our total future capital requirements will depend on many factors and is subject to the risks and uncertainties set forth in &#8220;Item 1A. Risk Factors.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash flows</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes our sources and uses of cash for the years ended December 31, 2024 and December 31, 2023 (in thousands):</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.993%;box-sizing:content-box;"/>
    <td style="width:1.62%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.883000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.62%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.883000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash used in operating activities</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(81,151</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(59,496</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash used in investing activities</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(94,077</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(165</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">88,776</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">103,791</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net increase (decrease) in cash</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(86,452</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44,130</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Operating activities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2024, net cash used in operating activities consisted primarily of our net loss of $98.3 million, which was partially offset by (i) $12.5 million of stock-based compensation expense, (ii) $2.7 million of net cash provided by changes in operating assets and liabilities, and (iii) $1.7 million of amortization of our right-of-use assets for our operating and finance leases.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2023, net cash used in operating activities consisted primarily of our net loss of $66.4 million, which was partially offset by (i) $3.0 million of stock-based compensation expense, (ii) $1.6 million of amortization of our right-of-use assets for our operating and finance leases, and (iii) $1.5 million of net cash provided by changes in operating assets and liabilities.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Investing activities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2024, net cash used in investing activities was $94.1 million and consisted primarily of the purchase of investments in U.S. Treasury securities and lab equipment.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2023, net cash used in investing activities was $0.2 million and consisted primarily of the purchase of lab equipment and internal use software.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">107</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Financing activities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2024, net cash provided by financing activities consisted primarily of the net proceeds received from the Private Placement offering of $88.7 million, as well as $0.5 million of proceeds received from the exercise of stock options, which were partially offset by $0.4 million of principal payments made on equipment finance leases.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2023, net cash provided by financing activities consisted primarily of the net proceeds received from the IPO of $100.3 million, as well as net proceeds received from the issuance of the convertible SAFE Note of $3.9 million, which were partially offset by $0.4 million of principal payments made on equipment finance leases.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Funding requirements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect our expenses and capital requirements to increase significantly in connection with our ongoing activities, particularly as we advance our lead product candidates and other development programs. Accordingly, we will continue to require substantial additional funding to support our continuing operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The timing and amount of our future operating and capital requirements will largely depend on many factors, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the initiation, scope, progress, timing, results and costs of product discovery, preclinical studies and clinical trials for our product candidates or any future candidates we may develop;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to maintain our relationships with Weill Cornell Medicine, Adverum, The Regents of UCSD, and any other key licensors or collaborators;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the scope, prioritization and number of our research and development programs; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs, timing and outcome of seeking and obtaining regulatory approvals from the FDA and comparable foreign regulatory authorities, including the potential for such authorities to require that we perform more preclinical studies or clinical trials than those that we currently expect or change their requirements on studies that had previously been agreed to;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to establish and maintain collaborations on favorable terms, if at all;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the achievement of milestones or occurrence of other developments that trigger payments under any collaboration agreements we have or may enter into;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the extent to which we are obligated to reimburse, or entitled to reimbursement of, clinical trial costs under collaboration agreements, if any;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs to establish, maintain, expand, enforce and defend the scope of our intellectual property portfolio, including preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the extent to which we acquire or in-license other product candidates and technologies;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs of securing manufacturing arrangements for commercial production;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs of establishing or contracting for sales and marketing capabilities if we obtain regulatory approvals to market our product candidates; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our need to implement additional internal systems and infrastructure. </span></div></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may be unable to raise additional funds or enter into potential collaborations, strategic partnerships or marketing, distribution, licensing or other similar agreements or arrangements on favorable terms, or at all. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted. If we fail to raise capital or enter into such agreements or arrangements as, and when, needed, we may have to significantly delay, scale back or discontinue the development or commercialization of our product candidates or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">108</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Critical accounting policies and significant judgments and estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management&#8217;s discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles, or U.S. GAAP. The preparation of our financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, expenses, and the disclosure of our contingent liabilities in our financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While our significant accounting policies are described in more detail in Note 2 to our audited financial statements included elsewhere in this Annual Report, we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our audited financial statements.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and development</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As part of the process of preparing our financial statements, we are required to estimate our accrued research and development expenses. This process involves estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of actual costs. The majority of our service providers invoice us in arrears for services performed on a pre-determined schedule or when contractual milestones are met; however, some require advance payments. We make estimates of our accrued expenses as of each balance sheet date in the financial statements based on facts and circumstances known to us at that time. At each period end, we corroborate the accuracy of these estimates with the service providers and make adjustments, if necessary. Examples of estimated accrued research and development expenses include those related to fees paid to:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">vendors in connection with discovery and preclinical development activities;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CROs in connection with preclinical studies and testing; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CMOs in connection with the process development and scale up activities and the production of materials.</span></div></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We record the expense and accrual related to contract research and manufacturing based on our estimates of the services received and efforts expended considering a number of factors, including our knowledge of the progress towards completion of the research, development, and manufacturing activities; invoicing to date under contracts; communication from the CROs, CMOs, and other companies of any actual costs incurred during the period that have not yet been invoiced; and the costs included in the contracts and purchase orders. The financial terms of these agreements are subject to negotiation, vary from contract to contract, and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the expense. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, we adjust the accrual or the amount of prepaid expense accordingly. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low in any particular period. To date, there have not been any material adjustments to our prior estimates of accrued research and development expenses; however, we cannot guarantee that such adjustments will not be made in the future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Determination of fair value of common stock</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Following the closing of our IPO, the fair value of our common stock is determined based on the quoted market price of our common stock on the date of grant.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock option awards</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We recognize share-based compensation expense related to stock option awards granted based on the estimated fair value of the awards on the date of grant using a Black-Scholes option pricing model. The grant date fair value of the share-based awards is recognized on an accelerated basis under the graded vesting method over the requisite service period of the award, which is the vesting period of the respective awards. Share-based payments to non-employees issued in exchange for services are based upon the fair value of the equity instruments issued. Compensation expense for stock options issued to non-employees is calculated using the Black-Scholes option pricing model and is recorded over the requisite service performance period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Black-Scholes option-pricing model requires the use of highly subjective assumptions, which are used to determine the fair value stock option awards granted. These assumptions include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">109</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expected Term</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The expected term represents the period that our stock option awards granted are expected to be outstanding and is determined using the simplified method (based on the mid-point between the vesting date and the end of the contractual term).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expected Volatility</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Because we did not have any trading history for our shares of common stock prior to the IPO, the expected volatility for stock options granted prior to the IPO was estimated entirely using averages of the historical volatility of our peer group of companies, and the expected stock price volatility was primarily based on the historical volatility of a publicly traded set of peer companies for stock options granted since the IPO, each for a period equal to the expected life of the stock options granted, and we expect to continue to do so until such time as we have adequate historical data regarding the volatility of our own traded stock price. Our peer group of publicly traded companies was chosen based on their similar size, stage in the life cycle or area of specialty.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risk-Free Interest Rate</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The risk-free interest rate is based on the interest rates paid on securities issued by the U.S. Treasury with a term approximating the expected life of stock options granted.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expected Dividend</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. We have never paid, and do not anticipate paying, cash dividends on our shares of common stock. Therefore, the expected dividend yield was assumed to be zero.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair Value of Common Stock</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Since our IPO, the fair value of shares of our common stock is measured by the stock price on the date of grant.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Emerging growth company and smaller reporting company status</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The JOBS Act permits an &#8220;emerging growth company&#8221; such as us to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. We have elected not to &#8220;opt out&#8221; of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, we will adopt the new or revised standard at the time private companies adopt the new or revised standard and will do so until such time that we either (i) irrevocably elect to &#8220;opt out&#8221; of such extended transition period or (ii) no longer qualify as an emerging growth company. There are other exemptions and reduced reporting requirements provided by the JOBS Act that we are currently evaluating. For example, as an &#8220;emerging growth company,&#8221; we are exempt from Sections 14A(a) and (b) of the Exchange Act, which would otherwise require us to (1) submit certain executive compensation matters to shareholder advisory votes, such as &#8220;say-on-pay,&#8221; &#8220;say-on-frequency,&#8221; and &#8220;golden parachutes;&#8221; and (2) disclose certain executive compensation related items such as the correlation between executive compensation and performance and comparisons of our chief executive officer&#8217;s compensation to our median employee compensation. We also rely on an exemption from the rule requiring us to provide an auditor&#8217;s attestation report on our internal controls over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act. We will continue to remain an &#8220;emerging growth company&#8221; until the earliest of the following: (1) the last day of the fiscal year following the fifth anniversary of the date of the completion of our IPO; (2) the last day of the fiscal year in which our total annual gross revenue is equal to or more than $1.235 billion; (3) the date on which we have issued more than $1.0 billion in nonconvertible debt during the previous three years; or (4) the date on which we are deemed to be a large accelerated filer under the rules of the SEC.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are also a &#8220;smaller reporting company,&#8221; meaning that the market value of our stock held by non-affiliates was less than $700.0 million as of June 30, 2024 and our annual revenue was less than $100.0 million during the most recently completed fiscal year. We may continue to be a smaller reporting company if either (1) the market value of our stock held by non-affiliates is less than $250.0 million or (2) our annual revenue is less than $100.0 million during the most recently completed fiscal year and the market value of our stock held by non-affiliates is less than $700.0 million as of June 30 of such year. If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal years of audited consolidated financial statements in our Annual Report on Form 10-K and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recently issued accounting pronouncements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A description of recently issued accounting pronouncements that may potentially impact our financial position, results of operations and cash flows is disclosed in Note 2 to our audited financial statements included elsewhere in this Annual Report.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Qualitative and quantitative disclosures about market risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interest rate risk</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a smaller reporting company, as defined by Rule 12b-2 under the Exchange Act and are not required to provide the information under this item.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">110</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_7a_reserved"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ite</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">m 7A.    Reserved</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">111</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_8_financial_statements_and_supplem"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ite</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">m 8.    Financial Statements and Supplementary Data.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LEXEO THERAPEUTICS, INC.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INDEX TO FINANCIAL STATEMENTS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:92.92%;box-sizing:content-box;"/>
    <td style="width:7.08%;box-sizing:content-box;"/>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#report_of_independent_registered_public"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Report of Independent Registered Public Accounting Firm (</span><span><ix:nonNumeric id="F_465d32ab-ac34-4768-a849-de577eb44e5e" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="dei:AuditorName"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">KPMG LLP</span></ix:nonNumeric></span><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_c3f1162f-306f-415e-84f1-65edc3f1794f" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="dei:AuditorLocation"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">New York, NY</span></ix:nonNumeric></span><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">, Auditor Firm ID: </span><span><ix:nonNumeric id="F_83d2b853-29ee-4d78-9d2b-e7273551c317" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="dei:AuditorFirmId"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">185</span></ix:nonNumeric></span><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">)</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">113</span></p></td>
   </tr>
   <tr style="height:6pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#condensed_consolidated_balance_sheets"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Balance Sheets</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">114</span></p></td>
   </tr>
   <tr style="height:6pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#comprehensive_loss"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Statements of Operations and Comprehensive Loss</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">115</span></p></td>
   </tr>
   <tr style="height:6pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#stockholders_deficit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Statements of Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit)</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">116</span></p></td>
   </tr>
   <tr style="height:6pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#cash_flows"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Statements of Cash Flows</span></a><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">117</span></p></td>
   </tr>
   <tr style="height:6pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#notes_to_condensed_consolidated_fin"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Notes to Financial Statements</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">118</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">112</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <table style="border-spacing:0;table-layout:auto;width:50.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:28%;box-sizing:content-box;"/>
    <td style="width:72%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img34756086_9.jpg" alt="img34756086_9.jpg" style="width:90px;height:43px;"/></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">KPMG LLP</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">345 Park Avenue</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">New York, NY 10154-0102</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="report_of_independent_registered_public"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Report of Independent Registered Public Accounting Firm</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the Stockholders and Board of Directors</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lexeo Therapeutics, Inc.:</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_09d10cbc-df2b-4f9a-8f0a-eefc90cdbf38" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="dei:AuditorOpinionTextBlock" escape="true"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Opinion on the Financial Statements</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have audited the accompanying balance sheets of Lexeo Therapeutics, Inc. (the Company) as of December 31, 2024 and 2023, the related statements of operations and comprehensive loss, convertible preferred stock and stockholders&#8217; equity (deficit), and cash flows for the years then ended, and the related notes (collectively, the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for the years then ended, in conformity with U.S. generally accepted accounting principles.</span></p></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basis for Opinion</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on these financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img34756086_10.jpg" alt="img34756086_10.jpg" style="width:129px;height:31px;"/></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have served as the Company&#8217;s auditor since 2021.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">New York, New York</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 24, 2025</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">KPMG LLP, a Delaware limited liability partnership and a member firm of</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the KPMG global organization of independent member firms affiliated with</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">KPMG International Limited, a private English company limited by guarantee.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">113</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lexeo Therapeutics, Inc.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="condensed_consolidated_balance_sheets"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Balance Sheets</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">(In thousands, except share and per share amounts)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.993%;box-sizing:content-box;"/>
    <td style="width:1.62%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.883000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.62%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.883000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Assets</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current assets:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0b4fd9b1-9cac-48b5-b9dc-02e3707053ab" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,014</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0d271bfa-3663-4cfc-81dd-7749fb0ff5b9" contextRef="C_28144b67-7dfd-494d-8133-75abcc735058" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">121,466</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Investments</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_60e85897-3047-4edd-b5a2-41edbe7ba6a0" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">86,504</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_328d931b-434c-420c-aa4f-6dd64a9ed771" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,603</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8dd292fc-a122-48f4-88ea-61f6ba69bd10" contextRef="C_28144b67-7dfd-494d-8133-75abcc735058" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,828</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total current assets</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7d612836-1b77-444b-b947-a11e2c5234e9" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">126,121</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b9ce66f1-f6c7-43e0-a264-186862eeee67" contextRef="C_28144b67-7dfd-494d-8133-75abcc735058" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">124,294</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted cash</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c1eb0996-db8a-47d8-a7d2-2283579976b7" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,252</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e419bfa2-d2d0-48f4-ad7e-e97de2dae10c" contextRef="C_28144b67-7dfd-494d-8133-75abcc735058" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,252</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Investments</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bc1bab9e-14d5-41b4-be80-f3eb49b02cc6" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="us-gaap:LongTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,012</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment, net</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9061a874-1f1e-4ee2-b9fa-b25f3dde1d89" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,028</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_07f903ea-8a8c-4e47-8fbd-9f91e6354c02" contextRef="C_28144b67-7dfd-494d-8133-75abcc735058" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,056</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease right-of-use assets - finance, net</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4188bab5-5b86-46d2-827f-13bf953cfeeb" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="us-gaap:FinanceLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,460</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d007e499-1c98-4112-9b28-6e24faab6219" contextRef="C_28144b67-7dfd-494d-8133-75abcc735058" name="us-gaap:FinanceLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,763</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease right-of-use assets - operating</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_34bd0bbb-2f69-4253-b79a-93c9c9b29224" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,069</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_47b3dbac-da52-4cbb-ae52-a4d8045525dd" contextRef="C_28144b67-7dfd-494d-8133-75abcc735058" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,442</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total assets</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_821167c4-2e75-4f2f-b60a-b92dd72085f7" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">146,942</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_606e7a15-5c9e-4884-9b41-7ba2911c146b" contextRef="C_28144b67-7dfd-494d-8133-75abcc735058" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">139,807</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Liabilities and Stockholders' equity</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current liabilities:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0daa4963-8d8c-4c7b-a9ba-98ea3a611982" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,417</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_43a2966d-d5a2-4b7d-994a-698668d20232" contextRef="C_28144b67-7dfd-494d-8133-75abcc735058" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,794</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued expenses and other current liabilities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fc6db418-111d-4630-8108-cc524560f54c" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="lxeo:AccruedLiabilitiesAndOtherLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,759</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_17963d74-f81f-4663-98cb-1d68364b8042" contextRef="C_28144b67-7dfd-494d-8133-75abcc735058" name="lxeo:AccruedLiabilitiesAndOtherLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,840</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current portion of lease liabilities - finance</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f22f0731-a6ac-4e31-a4c3-85c0c4c28e45" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="us-gaap:FinanceLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">570</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b0551b63-6c35-4c8a-af94-b6e51f1e8313" contextRef="C_28144b67-7dfd-494d-8133-75abcc735058" name="us-gaap:FinanceLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">518</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current portion of lease liabilities - operating</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7fbd935c-acb3-4f99-bcfc-a0f5f09c57f8" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,100</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0f879c49-e864-4af5-99a7-3b2af1471f37" contextRef="C_28144b67-7dfd-494d-8133-75abcc735058" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,087</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total current liabilities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a9840f44-2f3c-45b0-bfaa-11d5ff37c1df" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,846</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c9abf934-dd77-42f9-a5f3-2f6cc2217049" contextRef="C_28144b67-7dfd-494d-8133-75abcc735058" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,239</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-current liabilities</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-current portion of lease liabilities - finance</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_46eb5e8f-9ed0-41ee-90e7-30129acfb39f" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="us-gaap:FinanceLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">817</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0363413f-19c0-4e1d-be6a-38a4d645dcda" contextRef="C_28144b67-7dfd-494d-8133-75abcc735058" name="us-gaap:FinanceLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,247</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-current portion of lease liabilities - operating</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9bec8af9-f732-4d1b-a778-dfa06aefcafe" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,437</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ff1a54d2-f560-4735-9799-84a054712629" contextRef="C_28144b67-7dfd-494d-8133-75abcc735058" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,786</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total liabilities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_432530a9-d511-425f-b74b-0970c1e8efad" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,100</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3010171e-04ca-480e-aac1-5a0e2fa3f43d" contextRef="C_28144b67-7dfd-494d-8133-75abcc735058" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,272</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_95c520d2-e3a3-4e2b-91f0-f9045a6f3c7f;"><span style="-sec-ix-hidden:F_9891b892-ff8e-44a6-bc0c-e6f1514a27a8;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commitments and contingencies (Note 12)</span></span></span></span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stockholders' equity:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock, $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_51d4bbd9-ff2a-417d-ab77-7258c12f4498" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_390b56ff-1225-409c-a92d-2d234c739516" contextRef="C_28144b67-7dfd-494d-8133-75abcc735058" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;par value, </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3428772a-c35b-45b3-890a-18a9475d61ce" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">500,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares authorized as of December 31, 2024; </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0199ce48-7229-4f7b-8474-bb048ebbeda1" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">33,079,209</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares issued and </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_65cc649e-1c1b-4391-a0be-57fa430a5d1c" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">33,071,261</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares outstanding as of December 31, 2024; </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7b908d1c-5aef-4ddb-a06a-eb6129cd9225" contextRef="C_28144b67-7dfd-494d-8133-75abcc735058" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">500,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares authorized as of December 31, 2023; </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ff8eda1e-58e5-4d2e-b73f-6f330f90fe07" contextRef="C_28144b67-7dfd-494d-8133-75abcc735058" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">26,668,485</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares issued and </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_36490d19-e9ae-43c0-b9ca-76b6714a2e9b" contextRef="C_28144b67-7dfd-494d-8133-75abcc735058" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">26,646,378</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares outstanding as of December 31, 2023</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c61fd279-f2f4-4a97-8f67-97a8802d3e37" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5e4a5a03-396e-480e-8e0c-e3c519fa063c" contextRef="C_28144b67-7dfd-494d-8133-75abcc735058" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Treasury stock, at cost, </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_37c10cd3-77ba-47ce-9ada-d8f7b90a671f" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="us-gaap:TreasuryStockCommonShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,827</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;common shares at December 31, 2024 and </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4bd0b785-174e-4a16-b048-b3cea1017980" contextRef="C_28144b67-7dfd-494d-8133-75abcc735058" name="us-gaap:TreasuryStockCommonShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;common shares at December 31, 2023</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3ad95da6-d400-477a-bed1-68fb666f9557" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="us-gaap:TreasuryStockCommonValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additional paid-in capital</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_98db8bfb-8c7d-41a6-b64a-1b24b0fa7dfe" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">397,132</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_317d3fce-63ff-4634-9687-99a1767c102e" contextRef="C_28144b67-7dfd-494d-8133-75abcc735058" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">295,372</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accumulated other comprehensive loss</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_12a8e2be-e51e-4d0b-aab4-fa5d2bc9e947" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">103</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accumulated deficit</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_477b4bff-13a6-4f7c-9914-cd9fdd3ba01c" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">280,173</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bc488715-a893-4360-a796-6516883a96fd" contextRef="C_28144b67-7dfd-494d-8133-75abcc735058" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">181,840</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total stockholders' equity</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d3edce55-3c97-4dbb-9894-594854ea163c" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">116,842</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9aef0872-c827-440f-b242-fc7bfa8dccf6" contextRef="C_28144b67-7dfd-494d-8133-75abcc735058" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">113,535</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total liabilities and stockholders' equity</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5aa44c6d-85d7-4211-af16-a949bdc3eea3" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">146,942</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7c2b41b0-9773-4ce6-86ba-013ee9e2d6d0" contextRef="C_28144b67-7dfd-494d-8133-75abcc735058" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">139,807</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these financial statements.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">114</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lexeo Therapeutics, Inc.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="comprehensive_loss"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Statements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of Operations and Comprehensive Loss</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">(In thousands, except share and per share amounts)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:63.32%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:15.56%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.56%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:15.56%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating expenses</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_73fdcc1f-0f65-48a4-911d-d3c6a6a73021" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">74,091</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_edd40730-64db-47ea-b463-78df4289093f" contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">53,130</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_428653c4-6d75-4ab0-8db4-bd4361c5c25b" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31,675</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ce40f303-82a4-45a8-b74a-3333748d9749" contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,383</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_833fe65b-6e61-4e63-bc41-8776d50acd67" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">105,766</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c944e571-be9f-46be-8216-48a8bde71e8f" contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">68,513</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating loss</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_65df310b-6bdb-4cff-a840-883aa58d0574" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">105,766</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b6fd411a-2aea-4a3d-a390-a73e8876ca2f" contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">68,513</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income and expense</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss on fair value adjustment to convertible SAFE Note</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b203c694-ecc4-4742-a8bf-1c944cd52b46" contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca" name="us-gaap:GainLossOnFairValueHedgesRecognizedInEarnings" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">530</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income (expense), net</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_81ccf843-8e1f-425e-ab18-3be920312a3d" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">9</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8ef508b1-b68b-4127-95eb-12bde16e1064" contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">13</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest expense</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_502ace51-eab6-4984-8c29-09ecdc645c2e" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:InterestExpenseNonoperating" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">137</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e6d9fe84-a948-43d4-b23d-9f99f865304b" contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca" name="us-gaap:InterestExpenseNonoperating" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">205</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest income</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a6642ae1-909c-41bf-9e26-7e666558c869" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,556</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f6ea862c-9d63-4cbf-8f83-6cdf202d6fe3" contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,867</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accretion of discount on investments</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9e068a54-af3e-4141-929f-10af7c1ec324" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:InvestmentIncomeAmortizationOfDiscount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total other income and expense</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b241ecf7-093d-49dc-8d22-b78b0b271d44" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,433</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ab97ae53-c7d8-425e-be54-ef92c60473e7" contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,119</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from operations before income taxes</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1aaaff0a-d14c-4006-b313-6ea0ca9857bc" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">98,333</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c713e5a8-5515-4aec-bcf5-983e781b948c" contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">66,394</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Income taxes</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c3229343-28e0-4bfb-86fe-720e1a921905" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">98,333</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_113f576b-d848-4485-bb92-1c332306ec7e" contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">66,394</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other comprehensive loss</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net unrealized loss on investments</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_42737d83-89e2-4418-81be-bad3d7dbf837" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:UnrealizedGainLossOnInvestments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">103</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total other comprehensive loss</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a17953d8-e455-4cad-a2da-e5b0e08d1947" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">103</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Comprehensive loss</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7079d20e-accd-4a19-aa2d-b604f1198c98" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">98,436</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5e3fdc5b-e23b-44ef-ac2e-c96a7e9e01c7" contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">66,394</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per common share, basic and diluted</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_42af735b-0873-4591-8538-5a27299d0eff" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_1eb85904-a51c-4ac0-b5c2-db4e7d9de094" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">3.09</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6b464957-2b1c-4a23-b8eb-46765dc0933b" contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_087b04dd-88df-47af-94cb-0508e79609b1" contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">12.40</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average number of shares outstanding used in computation of net loss per common share, basic and diluted</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_988bb475-15a4-45c5-80d7-906c15c21565" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_50b5c16e-001e-4ded-8a71-c57247f10c43" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">31,787,491</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0090fa9e-fb1a-4c30-9736-a526bcb79679" contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_16ca339d-b270-4fad-bc98-ed61012d7be7" contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">5,354,368</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these financial statements.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">115</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lexeo Therapeutics, Inc.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="stockholders_deficit"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stateme</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">nts of Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">(In thousands, except share amounts)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:27.289%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:5.818%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:4.418%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:5.818%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:4.838%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:4.838%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:4.838%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:7.777%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:4.838%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:5.538%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="5" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Convertible</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="5" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Additional</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Other</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="5" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Preferred Stock</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="5" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Common Stock</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Treasury</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Paid-in</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Comprehensive</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Stockholders'</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Stock</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Capital</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Loss</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Deficit</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Equity (Deficit)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balances at December 31, 2022</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fd401cc6-f10a-4226-b7ea-42ffa8758072" contextRef="C_b8ce5a83-8a3f-4019-b952-412e72e2157f" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">143,653,545</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_471669fd-d099-4f91-bdeb-4b8b67cd75db" contextRef="C_b8ce5a83-8a3f-4019-b952-412e72e2157f" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">185,033</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_887f21a4-892b-4670-a426-0639a517d6fe" contextRef="C_d58c59cb-9db1-486e-a4ba-83018b4264e1" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,607,185</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9f9a314a-0d43-42f7-b1ed-92608980beaa" contextRef="C_5efa4994-b1a0-45ae-b914-b6133056586b" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,492</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_26c2ea6c-8ce8-47fd-864e-6a0814e1c65c" contextRef="C_4d1f9c2e-11bc-48e8-b628-60da7528906f" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">115,446</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ff645ec8-1152-4014-bdf9-7cbde4476bef" contextRef="C_e83f79f6-f924-4728-9c7c-5f1eb49397fe" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">112,954</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercise of stock options</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aad99da5-97a2-4050-a394-3ad6b7724d52" contextRef="C_728011d4-41ee-44fe-984c-9acd7fa9e5e1" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">11,916</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a646cae6-a3e4-4b24-9ccb-34db2398d9c7" contextRef="C_c5950291-be83-459b-b80e-1f0bffbf88e7" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">51</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7e670300-c297-461d-9588-6b8775e19898" contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">51</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amounts reclassified from deposit liabilities upon the vesting of early-exercised stock options previously subject to repurchase</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_39dbc0a4-655e-4f70-a8bc-d293e08ec299" contextRef="C_728011d4-41ee-44fe-984c-9acd7fa9e5e1" name="lxeo:AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsShare" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">19,442</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b2a021fd-05b6-47d5-b115-5c90a1624ff9" contextRef="C_c5950291-be83-459b-b80e-1f0bffbf88e7" name="lxeo:AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">87</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_44969d59-6d41-406d-b62b-c1d741232dd4" contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca" name="lxeo:AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">87</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">Conversion of SAFE Note into common stock in connection with initial public offering, net of issuance costs of $</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b7cd95ba-7c93-4966-905a-f6be05d1d804" contextRef="C_edfd0d26-83c7-4293-8b0c-e99852a72a86" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">113</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3316a44a-f64c-476d-bd6c-e9d2438bf016" contextRef="C_728011d4-41ee-44fe-984c-9acd7fa9e5e1" name="lxeo:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtShare" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">411,815</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a4c64611-72e4-4821-bd0c-988a73417c93" contextRef="C_c5950291-be83-459b-b80e-1f0bffbf88e7" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,417</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_98f09e82-03fa-4339-ab98-599247dbcbc5" contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,417</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">Issuance of common stock upon initial public offering and subsequent partial exercise of underwriters' option to purchase additional shares, net of underwriting discounts, commissions and offering costs of $</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a353942b-1894-47f1-b28e-7b3d1c6f98b4" contextRef="C_aa9ff400-2f57-4dd1-8623-e1ed88b5664f" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,285</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4781f99c-c9bb-41d2-8de6-edf6c85e0ccd" contextRef="C_90a370bc-c9ba-46da-a45b-b1abd87d6810" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">10,139,656</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fa9f0ace-1c51-4cfa-a1d3-9a103309cace" contextRef="C_90a370bc-c9ba-46da-a45b-b1abd87d6810" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_25e8db4b-c87c-4c59-928f-248c9ef1a7e7" contextRef="C_f04bbf56-d3c8-4272-a5ff-e1a1e02029b4" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">100,250</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_77a66d5b-008d-41cb-ae89-dde1c182bef2" contextRef="C_c6a9a2e2-eebe-4569-82e3-6437a6ce2366" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">100,251</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">Conversion of convertible preferred stock into common stock in connection with initial public offering, net of issuance costs of $</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6a893262-e988-4939-8384-8e2a53d3fe29" contextRef="C_f579df17-1e2e-4b2c-ab33-2703e6c475a7" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">519</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cda58fa9-f71a-49de-92cd-5712daa75ff8" contextRef="C_29a86653-566e-428b-a98b-7f3277fd7d90" name="lxeo:TemporaryEquityConversionOfStockInInitialPublicOfferingShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">143,653,545</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d35f59fa-e54b-4c46-8f29-9c86520a2f28" contextRef="C_29a86653-566e-428b-a98b-7f3277fd7d90" name="lxeo:TemporaryEquityConversionOfStockInInitialPublicOfferingValue" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">185,033</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bdad7a87-0db1-4e8c-a851-47471e9a5b94" contextRef="C_728011d4-41ee-44fe-984c-9acd7fa9e5e1" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">14,456,364</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a61169c8-55d6-4a8d-a436-a572e353fff7" contextRef="C_728011d4-41ee-44fe-984c-9acd7fa9e5e1" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2b0935d2-9d7e-4d30-8290-59673afe8148" contextRef="C_c5950291-be83-459b-b80e-1f0bffbf88e7" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">185,032</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_340c19b2-1948-4fad-8d47-38f4512044c8" contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">185,034</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation expense</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_febd0f89-18f9-49be-a952-8f89bc2fcacb" contextRef="C_c5950291-be83-459b-b80e-1f0bffbf88e7" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,043</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_61871af4-53fe-4232-8fb3-abd31db1355e" contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,043</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_84ecb6f3-b7c3-4bf2-8fec-1220ca118d4c" contextRef="C_948b5c1c-c12b-4ae5-a807-364c74cca6f3" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">66,394</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9b9a9b2e-a205-4f6a-86e7-dcf47816ef4d" contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">66,394</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balances at December 31, 2023</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a4095834-74f9-41ec-98a7-c0b48825c143" contextRef="C_933a22df-2af6-4858-8d9e-d0defe7f6576" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">26,646,378</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_28e02e59-4bf5-4b40-8adb-ef2be2e7a200" contextRef="C_933a22df-2af6-4858-8d9e-d0defe7f6576" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_24aad368-7897-4f12-a3f9-86a3f9573083" contextRef="C_e4562be4-fed1-4c76-8ee0-9ebb81409e47" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">295,372</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f725909c-c310-48b7-b65d-c63b296e8035" contextRef="C_1e2a8137-62de-4a72-83f0-d154bc7a5841" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">181,840</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e2e9c909-d7c7-4211-b5bb-6bfd04910e69" contextRef="C_28144b67-7dfd-494d-8133-75abcc735058" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">113,535</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercise of stock options</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_62f4c58e-1e63-4ce0-9079-30febe4cb6d8" contextRef="C_2cce3246-207a-4da6-b759-efc03a70940c" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">135,646</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5e4340e1-f52a-49af-9f88-c8d300bb1392" contextRef="C_3c3cff29-78d2-4481-b497-e743fdeb998d" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">491</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6a82ced1-68d2-4b92-a4b1-a119fb298c8a" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">491</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amounts reclassified from deposit liabilities upon the vesting of early-exercised stock options previously subject to repurchase</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7aa20353-6c8a-4d9c-9b63-6e572dfcad62" contextRef="C_2cce3246-207a-4da6-b759-efc03a70940c" name="lxeo:AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsShare" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">14,159</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6bac568d-68c1-45cc-9961-14cab1e74324" contextRef="C_3c3cff29-78d2-4481-b497-e743fdeb998d" name="lxeo:AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">59</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_18df30b1-86cc-4744-8275-1601b008826c" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="lxeo:AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">59</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">Issuance of common stock upon private placement offering, net of commissions and offering costs of $</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_814ae46c-a06a-4f55-8b85-0567e42c4ccc" contextRef="C_8e396f66-88d9-4bb5-8412-da93d2388896" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,288</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8b762c6d-f5e0-4276-b020-0f1bcbb6fa96" contextRef="C_f2189c8d-e1b8-45de-8953-73622e2e8923" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">6,278,905</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9bc456e0-aad1-4bd5-b88e-c3a4d99374c5" contextRef="C_b520844c-238f-400e-8a4f-68368cd0badd" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">88,712</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_975a5325-d855-4893-907a-17215ed8c061" contextRef="C_a9cf5f12-f6ff-4e48-8365-fa92cda8cd46" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">88,712</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additional issuance costs incurred for SAFE Note</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e5d6df29-4b9e-4d86-a5f8-357e9032da3a" contextRef="C_3c3cff29-78d2-4481-b497-e743fdeb998d" name="lxeo:StockIssuedDuringPeriodValueNewIssuesAdditionalOfferingCostsIncurred" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1345e201-38a3-4218-9a05-c3445cc810af" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="lxeo:StockIssuedDuringPeriodValueNewIssuesAdditionalOfferingCostsIncurred" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Treasury stock repurchases</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c7759e05-6667-4818-9079-3815fb2ac610" contextRef="C_2cce3246-207a-4da6-b759-efc03a70940c" name="us-gaap:StockRepurchasedDuringPeriodShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,827</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e4983e1f-7f8d-47be-9dc9-17658ac576ff" contextRef="C_698516d7-c81c-4f0a-9a78-6d719461191d" name="us-gaap:StockRepurchasedDuringPeriodValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2ae168f7-0388-41bc-bc72-a016720053bc" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:StockRepurchasedDuringPeriodValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unrealized comprehensive loss on investments</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_95498bb3-1292-40e6-ad1e-042b8e85a72a" contextRef="C_fcb1173a-0535-4c9d-91c0-398680f70ecb" name="us-gaap:UnrealizedGainLossOnInvestments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">103</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d117744d-3dd0-4392-bdf0-e54e9b9efe65" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:UnrealizedGainLossOnInvestments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">103</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation expense</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fb478d66-62b4-44ae-94e4-0cd70d193d5d" contextRef="C_3c3cff29-78d2-4481-b497-e743fdeb998d" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,474</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e015922e-b69e-4d79-89d4-90dc1f96d932" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,474</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_91b15811-ffc2-4b87-8b36-e5d136d98f93" contextRef="C_db61ba99-c7c7-4e9a-a944-9cc82209837d" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">98,333</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ebe9d4da-b78c-4330-a86c-de1452d80865" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">98,333</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balances at December 31, 2024</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_91cb2c9d-0c95-4d24-b2ee-3fb913e33819" contextRef="C_7be3bda2-4be1-4d70-adee-fffeb575b241" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">33,071,261</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fa4fa378-c96c-4f95-b5b8-ea07979de9f4" contextRef="C_7be3bda2-4be1-4d70-adee-fffeb575b241" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dba74b03-a6a9-4332-be80-a1784de5020e" contextRef="C_4270dba9-ca70-4680-8947-60179d11e241" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">17</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a9a197b2-9fac-4605-ac89-eaf0f82bf20a" contextRef="C_0ed26320-f07c-4528-a9ac-162b961bf030" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">397,132</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4dbdd29e-de6d-4f03-9998-608d29990fa4" contextRef="C_3283c13a-3e8c-4395-9d0b-cffabf13a351" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">103</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b3521589-83ee-4ee7-b58d-36bb63845122" contextRef="C_9e79f7b3-b991-4a2c-abc3-1a0ef29ab5b5" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">280,173</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f5d46319-3919-4c8c-b75b-9c212975958c" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">116,842</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these financial statements.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">116</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lexeo Therapeutics, Inc.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="cash_flows"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Statements of Cash Flows</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">(In thousands)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.887%;box-sizing:content-box;"/>
    <td style="width:1.62%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.937%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.62%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.937%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash flows from operating activities:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1a4e76cb-875c-46d4-8e7b-11f054ffe169" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">98,333</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_40c3b074-cf86-40d4-9251-d61dd6b6b5bb" contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">66,394</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adjustments to reconcile net loss to net cash used in operating activities:</span></p></td>
    <td style="padding-top:0.01in;text-indent:10pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Reduction in the carrying amount of ROU assets, operating</span></p></td>
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8ccc6703-696e-4eba-b4e8-479363e94e94" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,373</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4e7bbb7b-59b8-4b80-8b2d-dc788e9c64d9" contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,266</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Reduction in the carrying amount of ROU assets, finance</span></p></td>
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4fba9135-5414-47de-beb6-747be8da0745" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">325</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_55d8cfba-e4bc-4b61-b804-359aa954300e" contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">306</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock based compensation expense</span></p></td>
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a7a1ed63-bf5b-4a5f-b7dc-41f20124ab92" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,474</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_51a9ba6b-5398-4207-8490-d2e0362d05bc" contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,043</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciation and amortization expense</span></p></td>
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ca148a76-6f36-49bd-a48c-b9a187eaa597" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">304</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c638f5b3-3f95-4b5a-a0e7-e98e426dbfe9" contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">271</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in fair value of convertible SAFE Note liability</span></p></td>
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b3b178c5-822e-4c2c-bc43-ce7859ba6b93" contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca" name="us-gaap:IncreaseDecreaseInDerivativeAssetsAndLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">530</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accretion of discount on investments</span></p></td>
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b7b731e6-b25d-441b-a86c-5e99e9b35a06" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Changes in operating assets and liabilities:</span></p></td>
    <td style="padding-top:0.01in;text-indent:10pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_770600bb-bf13-4c2b-bae0-5b363c66dbaf" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,690</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_10aa9fd6-87cd-4bea-9ba1-7e9a1e486172" contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">990</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_25ee229d-f9ef-4834-80de-31d91dc9e782" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,378</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_15f5ea7a-0f51-4099-8b1c-dc238ca5df68" contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">180</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued expenses and other current liabilities</span></p></td>
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_231b63dc-6060-4bdb-bcd8-84e4e66a81c0" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,367</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dee4aa49-5682-4888-87f5-f5dc93c8c7e7" contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,091</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease liabilities, operating</span></p></td>
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ef9bd871-7889-4547-9620-b6640c3ec9ee" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,336</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_083e0d3d-46dc-450f-b314-e61ee75de12a" contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,414</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease liabilities, finance</span></p></td>
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_be9134ff-5b2b-4509-bf25-5afa9db24b7f" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="lxeo:IncreaseDecreaseInFinanceLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ba00382f-5238-4ef8-89ab-dbce162cc910" contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca" name="lxeo:IncreaseDecreaseInFinanceLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">5</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash used in operating activities</span></p></td>
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9c8e7279-40e3-49cf-b0e9-589a2394c43f" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">81,151</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bed0f94f-93ab-4022-a321-2ee7efd26254" contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">59,496</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash flows from investing activities:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchase of internal use software</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e1cfd58f-eab6-46fc-bbfa-2eb78dab5fdf" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:PaymentsToAcquireSoftware" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6fa2fabf-23ab-43e3-9107-2cbd757f35c3" contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca" name="us-gaap:PaymentsToAcquireSoftware" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">50</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchase of property and equipment</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_77766342-7ce0-4a4a-8e07-73e8ddc19580" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">481</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9c4887b7-a802-432c-ade7-42e2d34eb238" contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">115</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchases of investments</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_069b134e-7806-4485-9081-277eb2995d38" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:PaymentsToAcquireInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">93,596</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash used in investing activities</span></p></td>
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4f899f37-c584-4710-8a5a-2d2675624acb" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">94,077</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_843c72a8-9063-47f5-b34f-7dada7a20e4f" contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">165</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash flows from financing activities:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from exercise of stock options</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cdfe0d04-9808-4ab7-b687-4d761d36cc3e" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">491</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c5f15e7d-8f11-45bb-8c5f-4c8cde67b0c9" contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">51</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Payments on finance leases</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0351ec0a-b3b5-4bb2-8dff-a2ef8efe0cc7" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:FinanceLeasePrincipalPayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">410</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b89a306d-4414-4687-afe5-56ddba0dadac" contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca" name="us-gaap:FinanceLeasePrincipalPayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">425</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Treasury stock repurchases</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e987d413-40f1-4186-8e9e-961d7637b2f3" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="lxeo:TreasuryStockRepurchase" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Payments of issuance costs on convertible SAFE Note</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8b1dff7a-91bd-453b-a40b-93c85859603e" contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca" name="us-gaap:PaymentsOfDebtIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">86</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from issuance of convertible SAFE Note</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ff01a92e-b840-42da-ba91-c93e9e66d671" contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca" name="us-gaap:ProceedsFromConvertibleDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,000</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from issuance of common stock upon private placement offering, net of commissions and offering costs</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_44181701-3820-4aa0-9f65-dc2d85080db9" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">88,712</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from issuance of common stock upon initial public offering, net of underwriters' discounts, commissions and other offering costs</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_16440035-1db6-4505-96a6-e588f3f7d2a9" contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">100,251</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fe8341dd-8e3b-4b2f-84d5-6622ffc3814c" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">88,776</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_90423f01-78d8-466f-8911-5e0100ac9e39" contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">103,791</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net change in cash, cash equivalents and restricted cash</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1b6b40d5-2da0-4fed-a402-51d38d018ab0" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">86,452</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0a82ab25-cb54-4f54-a87e-396d35ccd12b" contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">44,130</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash, cash equivalents and restricted cash at beginning of period</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c37600ec-8549-42af-94f2-cfd5e5849a82" contextRef="C_28144b67-7dfd-494d-8133-75abcc735058" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">124,718</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8030339f-f12f-475d-812d-475bc9fe363a" contextRef="C_e83f79f6-f924-4728-9c7c-5f1eb49397fe" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">80,588</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash, cash equivalents and restricted cash at end of period</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_71bf30a1-52e8-4fac-b8d3-c3464096f01a" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">38,266</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_31043c81-0e04-435a-88e3-5452e3887a88" contextRef="C_28144b67-7dfd-494d-8133-75abcc735058" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">124,718</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Supplemental disclosures of cash flow information</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest paid</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_40d7fcd4-0672-40ea-b94f-b66fae84e8f6" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">127</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3ace30de-0377-4ac2-a63b-42078fa139d0" contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">176</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Supplemental disclosure of non-cash activities</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred offering costs included in accounts payable and accrued expenses</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bce135aa-29a1-46fb-a45c-1c942ca13e1e" contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca" name="lxeo:DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,105</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unrealized loss on investments</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c7be950d-b972-45ee-b1d8-8f362f03453d" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:UnrealizedGainLossOnInvestments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">103</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Reclassification of internal use software into prepaid expenses</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_467e8b0c-8cdb-4610-9c21-7c1d5e84e142" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="lxeo:ReclassificationOfInternalUseSoftwareIntoPrepaidExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">98</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance costs related to convertible debt included in accounts payable and accrued expenses</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_955ff2b0-3eea-4bd0-bd26-ed9d064b0575" contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca" name="us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">50</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Property and equipment purchased in the prior period and paid in the current period), net of property and equipment purchased in the current period included in accounts payable</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bceef92e-fe69-440f-b4bf-e3697c736c81" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="lxeo:CapitalExpendituresIncurredButNotYetPaidNetOfPaidAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">120</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_576824a6-a7ba-4e3e-80ba-d751e9d4987a" contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca" name="lxeo:CapitalExpendituresIncurredButNotYetPaidNetOfPaidAmount" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">141</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Finance lease right-of use assets and finance lease liabilities recognized</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_18154b28-9949-4c58-bd50-278501b3c52e" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="lxeo:FinanceLeaseRightOfUseAssetsAndFinanceLeaseLiabilitiesRecognized" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Conversion of convertible preferred stock into common stock in connection with initial public offering, net of issuance costs</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_41e85b2e-969f-4d64-9e32-eaaf96ab479c" contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca" name="us-gaap:ConversionOfStockAmountIssued1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">185,032</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Conversion of SAFE Note into common stock in connection with initial public offering, net of issuance costs</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_868b586a-af8a-4aa4-9064-8e375b8722e5" contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca" name="us-gaap:DebtConversionConvertedInstrumentAmount1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,417</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amounts reclassified from deposit liabilities upon the vesting of early-exercised stock options previously subject to repurchase, net of proceeds received from early exercise of unvested stock options subject to repurchase and recorded as deposit liabilities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8cf2cef8-a073-4cf1-8972-af7439adc392" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="lxeo:AmountsReclassifiedFromDepositLiabilitiesUponTheVestingOfEarlyExercisedStockOptionsPreviouslySubjectToRepurchaseNetOfProceedsReceivedFromEarlyExerciseOfUnvestedStockOptionsSubjectToRepurchaseAndRecord" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">59</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e2b0f135-cff5-4b77-a05e-0d3599126367" contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca" name="lxeo:AmountsReclassifiedFromDepositLiabilitiesUponTheVestingOfEarlyExercisedStockOptionsPreviouslySubjectToRepurchaseNetOfProceedsReceivedFromEarlyExerciseOfUnvestedStockOptionsSubjectToRepurchaseAndRecord" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">87</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these financial statements.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">117</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lexeo Therapeutics, Inc.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="notes_to_condensed_consolidated_fin"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">N</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">otes to Financial Statements</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">(Table amounts in thousands, except share and per share amounts)</span></p>
  <div><ix:nonNumeric id="F_8972b225-efc3-4da7-8be9-028d13d3a9db" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" escape="true" continuedAt="F_8972b225-efc3-4da7-8be9-028d13d3a9db_1"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1. Description of Business and Basis of Presentation</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Description of Business</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Lexeo Therapeutics, Inc. (the &#8220;Company&#8221;) is a clinical stage genetic medicine company with a focus on hereditary and acquired diseases of high unmet need. The Company&#8217;s investigational therapies have the potential to offer gene therapy-based treatments to address many diseases that have eluded today&#8217;s existing drug delivery platforms. The Company utilizes adeno-associated viruses (&#8220;AAV&#8221;) that have been engineered to transfer genes to patients. The Company&#8217;s therapeutic investigational treatments include gene therapies primarily in the early clinical and late pre-clinical stages of research and development.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is located in New York, NY and was first formed on February 17, 2017, as an LLC under the laws of the State of Delaware under the legal name Lexeo Therapeutics, LLC. The Company filed and executed a certificate of conversion to corporation on November 20, 2020, to convert the LLC to Lexeo Therapeutics, Inc, a Delaware corporation. All of the Company&#8217;s tangible assets are held in the United States (&#8220;U.S.&#8221;).</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basis of Presentation and Principles of Consolidation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;The accompanying financial statements and these notes reflect the operations of the Company that have been prepared in conformity with generally accepted accounting principles in the United States of America (&#8220;GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;). The Company has no unconsolidated subsidiaries. Certain prior period balances have been reclassified to conform to the current period presentation.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_41d9f36b-6ccd-4502-86e3-94e91fe76dff" contextRef="C_240d6e00-2133-41ba-92ce-0078e7bbcbca" name="us-gaap:StockholdersEquityReverseStockSplit"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10.594230-for-1</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> reverse share split of the Company&#8217;s series A convertible preferred stock, series B convertible preferred stock, common stock, and options to purchase common stock under the Company&#8217;s 2021 Equity Incentive Plan (the "2021 Plan"), as well as corresponding adjustments in the respective conversion prices of the series A convertible preferred stock and series B convertible preferred stock, was effected on October 13, 2023 as approved by the Company&#8217;s board of directors (the "Board of Directors") and its shareholders (the &#8220;Stock Split&#8221;). The Stock Split reduced the number of shares of the Company&#8217;s authorized, issued and outstanding common stock, as well as the numbers of shares reserved and available for future issuance and underlying outstanding options to purchase common stock under its 2021 Equity Incentive Plan, on a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_aeaac8fe-8255-473b-85b4-23e2a40109c8" contextRef="C_240d6e00-2133-41ba-92ce-0078e7bbcbca" name="us-gaap:StockholdersEquityReverseStockSplit"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10.594230-for-1</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> basis. As such, all references to series A convertible preferred stock and series B convertible preferred stock conversion ratios, conversion share and per share amounts, and post- conversion share and per share amounts, as well as common stock option, option per common share, common share and common per share amounts, in these financial statements and accompanying notes have been retroactively restated to reflect the Stock Split and the Stock Split&#8217;s effect on the respective series A convertible preferred stock and series B convertible preferred stock conversion ratios for each series of convertible preferred stock. The Stock Split did not affect the par values per share.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Need for Additional Capital</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Since inception, the Company has incurred net losses and negative cash flows from operations, including net losses of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b3dda6db-8f76-4870-9759-192a39486e56" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">98.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_853cdea5-ca82-4b74-9036-0a634e4df4f4" contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">66.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million during the years ended December 31, 2024 and December 31, 2023, respectively. As of December 31, 2024, the Company had cash, cash equivalents, and investments of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_01ca010e-ee6f-4eb8-b30f-d1cb8862aa41" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">128.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and an accumulated deficit of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bd444f6a-4ce8-4a40-ae4c-49ef383b760a" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">280.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and expects to incur substantial operating losses and negative cash flows from operations for the foreseeable future. During the years ended December 31, 2021 and December 31, 2020, the Company raised aggregate total net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_389e5093-aec4-4d3b-8120-c1027e896819" contextRef="C_6dc19a43-c74a-4bb9-a484-18d905a695b2" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">185.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in connection with the issuance of series A and series B convertible preferred stock. During the year ended December 31, 2023 the Company raised $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7d76c4b4-c6bd-405a-b160-a2000659a2eb" contextRef="C_8fa4e334-c5fa-44d9-8bc4-866b04e010d4" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">100.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of total net proceeds in connection with the closing of its initial public offering ("IPO") on November 7, 2023 and subsequent partial exercise of the underwriters' option to purchase additional shares, as well $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e7a4195a-3f09-4fb7-9870-ccc7fcd920f9" contextRef="C_cc906741-ea91-4e6d-8943-e5456da6d798" name="us-gaap:ProceedsFromNotesPayable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of net proceeds from the issuance of a convertible Simple Agreement for Future Equity (&#8220;SAFE&#8221;) note (the "convertible SAFE Note") in August 2023. During the year ended December 31, 2024, the Company received total net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a3a37707-e8a7-4ed2-a0e5-a9816b54a8bc" contextRef="C_a9cf5f12-f6ff-4e48-8365-fa92cda8cd46" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">88.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million after deducting underwriting commissions and offering expenses in a private placement offering of its common stock (see Note 8). Management estimates that the Company's current cash, cash equivalents, and investments balances are sufficient to fund its operations for at least 12 months from the issuance date of these financial statements.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the Company is unable to obtain additional funding before achieving sufficient profitability and positive cash flows from operations, if ever, the Company will be forced to delay, reduce or eliminate some or all of its research and development programs, which could adversely affect its business prospects, or the Company may be unable to continue operations. Although management continues to pursue plans to obtain additional funding before achieving sufficient profitability and positive cash flows from operations, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations, if at all.</span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">118</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_8972b225-efc3-4da7-8be9-028d13d3a9db_1"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks and Uncertainties</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;The Company is subject to risks and uncertainties common to early-stage companies in the biopharmaceutical industry, including, but not limited to, successful discovery and development of its product candidates, development by competitors of new technological innovations, dependence on key personnel, the ability to attract and retain qualified employees, protection of proprietary technology, compliance with governmental regulations, the ability to secure additional capital to fund operations, and commercial success of its product candidates. Any of the Company&#8217;s current product candidates and future product candidates that it may develop will require extensive non-clinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel, infrastructure, and extensive compliance- reporting capabilities. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.</span></p></ix:continuation></div>
  <div><ix:nonNumeric id="F_73be07b6-3428-4d7c-9ed9-55c01408fd60" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:SignificantAccountingPoliciesTextBlock" escape="true" continuedAt="F_73be07b6-3428-4d7c-9ed9-55c01408fd60_1"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2. Summary of Significant Accounting Policies</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_406f6f3c-a715-454f-b7d1-57da3384aaea" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:UseOfEstimates" escape="true"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;The preparation of the financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of income and expense during the reporting period. The most significant estimates relate to the accruals of research and development costs, including accruals of research contract costs, and assumptions used to estimate the fair value of the Company&#8217;s stock option awards and, prior to its IPO, to determine the fair value of its common stock. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when facts and circumstances dictate. These estimates are based on information available as of the date of the financial statements; therefore, actual results could differ from those estimates.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_178c054d-cd8b-4f96-950c-c4172e30de9c" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" escape="true"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash and Cash Equivalents and Restricted Cash</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;The Company considers all highly liquid investments with a remaining maturity when purchased of three months or less to be cash equivalents. Cash equivalents are reported at carrying values, which approximated their fair values and are based on quoted prices in active markets for identical securities. At December 31, 2024 and December 31, 2023, the Company&#8217;s cash equivalents were held in a money market fund. As of December 31, 2024 and 2023, cash consists of cash on deposit with U.S. banks denominated in U.S. dollars, and restricted cash consists of cash on deposit with U.S. banks denominated in U.S. dollars for which its use is restricted and is classified as non-current in the Company&#8217;s balance sheet according to the timing of maturity, and is associated with collateral for letters of credit issued in connection with its operating lease right-of-use and finance lease right-of-use assets and corresponding lease liabilities. Cash is stated at its historical carrying amount, which approximates fair value due to its short-term nature. Restricted cash is stated at its historical carrying amount, which approximates fair value. The Company regularly maintains cash and cash equivalents and restricted cash balances with financial institutions that exceed Federal Deposit Insurance Corporation insurance limits.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d3bd3b38-21c5-4514-b4c1-830d90529230" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:InvestmentPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investments</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Investments consist primarily of U.S. Treasury securities. Management determines the appropriate classification of these securities at the time they are acquired and evaluates the appropriateness of such classifications at each balance sheet date, including the determination of current and non-current classifications based on the contractual maturity dates of the underlying investments. Investments may be sold by the Company prior to contractual maturity. The Company classifies its investments as available-for-sale pursuant to ASC Topic 320, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Investments&#8212;Debt and Equity Securities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Investments are recorded at fair value, with unrealized gains and losses included as a component of accumulated other comprehensive income (loss) in stockholders&#8217; equity and a component of total comprehensive loss in the statements of comprehensive loss, until realized. The Company's current and non-current investments are presented net of discounts of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_904cd445-e17f-4b0d-82bb-0107283c0956" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="lxeo:InvestmentCurrent" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">49,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_896a838a-b928-4fc0-9b43-071e697a7323" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="lxeo:InvestmentNonCurrent" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">55,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively, at December 31, 2024.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9031150b-5b62-4c0b-84eb-3cb147cbe0da" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:InternalUseSoftwarePolicy" escape="true"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deferred Software Costs</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;We capitalize certain costs related to hosting arrangements that are service contracts (cloud computing arrangements). Capitalized costs are included in Other Current Assets and are amortized on a straight-line basis over the estimated useful life. For the year ended December 31, 2024, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d5d366ed-d68c-4492-9c4e-9c1ece836a40" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="us-gaap:CapitalizedComputerSoftwareGross" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of deferred software costs were capitalized related to cloud computing arrangements.</span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_e71c5b31-ae91-4917-a3cc-4509d52a90aa" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:EarningsPerSharePolicyTextBlock" escape="true" continuedAt="F_e71c5b31-ae91-4917-a3cc-4509d52a90aa_1"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net Loss per Share&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Company follows the two-class method when computing net income (loss) per common share as the Company has issued shares that meet the definition of participating securities. The two-class method determines net income (loss) per common share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income (loss) available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed. The Company also considers the shares issued upon the early exercise of stock options that are subject to repurchase to be participating securities because holders of such shares have non-forfeitable dividend rights in the event a dividend is paid on common stock. There is no allocation required under the two-class method during periods of loss since the participating securities do not have a contractual obligation to share in the losses of the Company.</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">119</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_73be07b6-3428-4d7c-9ed9-55c01408fd60_1" continuedAt="F_73be07b6-3428-4d7c-9ed9-55c01408fd60_2"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_e71c5b31-ae91-4917-a3cc-4509d52a90aa_1"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic net income (loss) per common share is computed by dividing the net income (loss) per common share by the weighted-average number of common shares outstanding for the period. Diluted net income (loss) per common share is computed by adjusting net income (loss) to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net loss per common share is computed by dividing the diluted net loss by the weighted-average number of common shares outstanding for the period, including potential dilutive common shares.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In periods in which the Company reported a net loss, diluted net loss per common share was the same as basic net loss per common share since dilutive common shares were not assumed to have been issued if their effect was anti-dilutive. During (i) the year ended December 31, 2023, potential common shares related to the conversion of the convertible SAFE Note, which converted into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b6ec1366-44d2-4893-bae8-fe76cbf546e6" contextRef="C_90b3b8b5-08ff-4ed8-b03a-36a19e205081" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">411,815</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> common shares in connection with the Company&#8217;s IPO on November 2, 2023 (see Note 6), and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dd0b43ea-6fd5-4dd8-a784-90c17d6d8be0" contextRef="C_982e832a-cdf3-4671-8548-8f56b1f3f254" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">8,070,027</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> potential common shares related to the conversion of series A convertible preferred stock and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1f9ff97a-7997-4425-940f-3a3f35b43799" contextRef="C_98679350-4c2b-4d25-9968-d21e18f72506" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,489,573</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> potential common shares related to the conversion of series B convertible preferred stock, which converted into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1793b359-e698-475f-8dd1-dec26a32778b" contextRef="C_98130704-057d-4280-9bc9-5ebe7b7bf561" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">8,070,027</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> common shares and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_96df45c5-b0ea-4ab1-bec5-d2e6931c37aa" contextRef="C_7c6c7513-7f64-4c68-bcf5-17a805d1e6fe" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">6,386,337</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> common shares, respectively, in connection with the Company&#8217;s IPO on November 7, 2023 (see Note 7), and (ii) the years ended December 31, 2024 and December 31, 2023, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cbf82ba8-fb53-420d-8d43-b1ce8ae3fa54" contextRef="C_6e00ad79-bc53-4f37-aa8a-ea9cb4e9ab24" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,724,218</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_10434e37-9303-4f77-a36d-b5e5f3880409" contextRef="C_222f24e5-787e-4d77-8748-8b551ff8243a" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,415,740</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> potential common shares, respectively, related to the exercise of outstanding stock options and settlement of outstanding Restricted Stock Units ("RSUs") (see Note 9), were excluded from the computation of diluted net loss per common share because including them would have had an anti-dilutive effect as the Company reported net losses for those periods.</span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a7db4365-2d02-4296-a318-c891e50598f3" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:DeferredChargesPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deferred Offering Costs</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;The Company capitalizes certain legal, accounting and other third-party fees that are directly associated with equity financings as deferred offering costs until such financings are consummated. After consummation of the equity financing, these costs are recorded as a reduction of the proceeds from the offering, either as a reduction of the carrying value of preferred stock or in stockholders&#8217; equity (deficit) as a reduction of additional capital generated as a result of the offering. Should the equity financing be abandoned, the deferred offering costs would be expensed immediately as a charge to operating expenses in the statement of operations and comprehensive loss. The Company had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d15a925d-9c6e-47e2-800f-f133efad6ff9" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="us-gaap:DeferredCostsCurrentAndNoncurrent" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_1275f940-de14-4dc3-864f-44597632ffc4" contextRef="C_28144b67-7dfd-494d-8133-75abcc735058" name="us-gaap:DeferredCostsCurrentAndNoncurrent" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> deferred offering costs recorded as of December 31, 2024 or December 31, 2023.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6e919e10-b39a-40b6-9deb-350bf5acf88b" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and Development</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred to discover, research, and develop drug candidates, including personnel expenses, allocated facility-related and depreciation expenses, and third-party license fees. Costs incurred to obtain technology licenses are charged immediately to research and development expense if the technology licensed has not reached technological feasibility and has no alternative future use.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_196a168a-718c-492b-af10-27d94d2df755" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="lxeo:GeneralAndAdministrativeExpensesPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General and Administrative&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General and administrative expenses consist primarily of the cost of employees to engage in corporate functions, such as finance and accounting, information technology, human resources, and legal and executive management. General and administrative expenses also include rent occupancy costs, office expenses, depreciation and amortization, other general overhead costs, insurance premiums, professional service fees, and costs related to regulatory and litigation matters.</span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_f16239d9-394b-4109-9a07-0881b76dad71" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" escape="true" continuedAt="F_f16239d9-394b-4109-9a07-0881b76dad71_1"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock Based Compensation Expense&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for stock-based payment awards granted to employees and non-employees, as well as shares issued to its employees under the Company's 2023 Employee Stock Purchase Plan (the "2023 ESPP"), as stock-based compensation expense at fair value. The Company issues stock-based awards to employees and non-employees in the form of stock options and also issues stock-based awards to employees in the form of restricted stock units (&#8220;RSUs&#8221;). The measurement date for employee stock option and RSU awards is the date of grant, and stock-based compensation costs are recognized as expense over the employees&#8217; requisite service period, which is the vesting period, on an accelerated basis. The measurement date for non-employee awards is the date of grant without changes in the fair value of the award. The measurement date for shares issued under the 2023 ESPP is the first date of each employee stock purchase plan offering period, and stock-based compensation costs are recognized as expense over the offering period on a straight-line basis. Stock-based compensation costs for non-employees are recognized as expense over the vesting period on an accelerated basis. Stock-based compensation expense is classified in the accompanying statement of operations based on the function to which the related services are provided. As the Company is permitted to repurchase shares legally issued for unvested stock options exercised at their exercise price under the 2021 Plan, (i) cash received for unvested stock options exercised under the 2021 Plan is recorded as a deposit liability as a reclassification from additional paid-in capital in the Company&#8217;s balance sheet, which is relieved to additional paid-in capital as such awards vest, (ii) stock based compensation expense is recognized over the requisite service period for each such award, and (iii) the amount and number of shares of common stock outstanding in the Company&#8217;s balance sheet and statement of convertible preferred stock and stockholders&#8217; equity (deficit) are reduced until such awards vest. Forfeitures are recorded as they occur.</span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">120</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_73be07b6-3428-4d7c-9ed9-55c01408fd60_2" continuedAt="F_73be07b6-3428-4d7c-9ed9-55c01408fd60_3"><div><ix:continuation id="F_f16239d9-394b-4109-9a07-0881b76dad71_1"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value of each stock option grant and shares issued under the 2023 ESPP are estimated on the date of grant or on the first date of each employee stock purchase plan offering period, respectively, using the Black-Scholes option-pricing model, while the fair value of each RSU granted is equal to the closing price of the Company's common stock on the date of the grant. Prior to its IPO on November 3, 2023, the Company was a private company and lacked company-specific historical and implied volatility information for stock options granted. Therefore, the Company estimated its expected stock volatility entirely based on the historical volatility of a publicly traded set of peer companies for stock options granted prior to its IPO, and estimates its expected stock price volatility primarily based on the historical volatility of a publicly traded set of peer companies for stock options granted since its IPO, each for a period equal to the expected life of the stock options granted, and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. The expected term of the Company&#8217;s stock options granted has been determined utilizing the &#8220;simplified&#8221; method for awards that qualify as &#8220;plain-vanilla&#8221; options and expects to continue to do so until such time as it has adequate historical data regarding the expected term of its own stock options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The expected dividend yield is zero as the Company has never paid cash dividends on its common stock and does not expect to pay any cash dividends in the foreseeable future.</span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_20006a9e-7b5c-458e-a606-064a289abae4" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Prior to November 20, 2020, the Company was an LLC entity and elected to be treated under the Partnership provisions of the Internal Revenue Code. Accordingly, the LLC entity was not viewed as a tax-paying entity in any jurisdiction and all income and deductions of the LLC entity flowed through to the individual members and therefore no income taxes were recorded by the Company. On November 20, 2020, the Company converted to a C Corporation.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for income taxes under the asset and liability method pursuant to ASC Topic 740, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">("ASC 740"). Under this method, the Company recognizes deferred tax assets and liabilities for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recorded for deferred tax assets if it is more likely than not that some portion or all of the deferred tax assets will not be realized based on all available positive and negative evidence. Under the Tax Cuts and Jobs Act of 2017, the Company is required to capitalize, and subsequently amortize, research and development expenses over five years for research activities conducted in the U.S. and over fifteen years for research activities conducted outside of the U.S commencing in 2022. The capitalization of research and development expenses during the year resulted in a decrease to the Company's operating loss generation during the years ended December 31, 2024 and December 31, 2023 as compared to prior periods (see Note 11). As of December 31, 2024 and December 31, 2023, the Company continues to maintain a full valuation allowance against its deferred tax assets.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognizes a tax benefit only if it is more likely than not the tax position will be sustained on examination by the local taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such positions are then measured based on the largest benefit greater than 50% likelihood of being realized upon settlement with the related tax authority. The changes in recognition or measurement are reflected in the period in which the change in judgment occurs. As of December 31, 2024 and December 31, 2023, the Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_107c753c-16cd-40fe-b097-67d0298843a9" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_77892856-cefc-430b-9696-ebe34582eb13" contextRef="C_28144b67-7dfd-494d-8133-75abcc735058" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t identified any uncertain tax positions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company records interest and penalties related to uncertain tax positions in the provision for income taxes.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_24afb23b-e7f9-4c67-a91b-be61083bde99" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fair Value Measurements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The three levels of inputs that may be used to measure fair value are as follows:</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Level 1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Level 2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Level 3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Inputs are unobservable inputs for the asset or liability.</span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">121</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_73be07b6-3428-4d7c-9ed9-55c01408fd60_3" continuedAt="F_73be07b6-3428-4d7c-9ed9-55c01408fd60_4"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3b52618b-72cb-4a2a-9f08-868beb746861" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:ConcentrationRiskCreditRisk" escape="true"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Concentrations of Credit Risk</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, cash equivalents, restricted cash, and investments. The Company&#8217;s cash and restricted cash balances exceed Federal Deposit Insurance Corporation insurance limits. The Company&#8217;s cash equivalents consist of investments in a U.S. government money market fund, and the Company's investments primarily consist of U.S. Treasury securities. The Company&#8217;s cash, cash equivalents, restricted cash, and investments are held with large financial institutions that management believes to be of high credit quality. To date, the Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3b8d32d1-2091-4245-9671-4e144befc30f" contextRef="C_8d26cf86-cfdb-467b-8eab-522b18243eda" name="lxeo:LossRecognizedFromUninsuredBalances" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t recognized any losses caused by uninsured balances.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9bd25b73-9a13-4394-a5cc-065e8069e281" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Segment Information</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;The Company manages its operations as a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_3797e8b8-b7a6-4ad2-8b98-c0c8d90f246c;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">single</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> segment for the purposes of assessing performance and allocating resources. The Company is focused on preclinical and clinical stage gene therapies, and specifically on hereditary and acquired diseases of high unmet need. The Company&#8217;s Chief Operating Decision Maker ("CODM") is its Chief Executive Officer ("CEO") and its senior leadership team. The CODM reviews the Company&#8217;s financial information on an aggregated basis for purposes of assessing performance and allocating resources. All assets are held in the United States. The Company has not earned any product revenue through December 31, 2024.</span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_e9f456a2-1309-4d3f-8362-bc858c3d148c" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and Equipment</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization are recognized using the straight-line method over the estimated useful life of each asset. Such costs are periodically reviewed for recoverability when impairment indicators are present. Such indicators include, among other factors, unused capacity, market value declines, and obsolescence of technology. Recorded values of asset groups of equipment that are not expected to be recovered through undiscounted future net cash flows are written down to current fair value, which generally is determined from estimated discounted future net cash flows (assets held for use) or net realizable value (assets held for sale).</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Costs for capital assets not yet placed into service are capitalized as construction-in-progress and depreciated once placed into service. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation and amortization are removed from the accounts and any resulting gain or loss is included in loss from operations. Expenditures for repairs and maintenance that do not improve or extend the life of the respective assets are charged to expense in the period incurred. See Note 5 for information regarding the Company&#8217;s capitalized operating and finance lease right-of-use assets.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c82f6d39-f798-4c10-a825-1845407ad04e" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:PropertyPlantAndEquipmentTextBlock" escape="true" continuedAt="F_c82f6d39-f798-4c10-a825-1845407ad04e_1"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following is the summary of property and equipment and related accumulated depreciation as of December 31, 2024, and December 31, 2023 (years not stated in thousands):</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:58.884%;box-sizing:content-box;"/>
          <td style="width:1.421%;box-sizing:content-box;"/>
          <td style="width:13.085%;box-sizing:content-box;"/>
          <td style="width:1.421%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:9.884%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1.421%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:9.884%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Useful Life</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Internal use software</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_190c6e8b-a80c-4c48-b7f5-9a1cf0b07235" contextRef="C_7d2537f3-c638-4060-a3bc-90ab8b609181" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3 </span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">years</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f22c46ff-017c-4ac9-a184-c719d349c6c7" contextRef="C_7d2537f3-c638-4060-a3bc-90ab8b609181" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_71d9a6f1-a055-47d0-9d13-df2bf7ba0880" contextRef="C_e226ab34-462b-4baf-bdb6-41d1da52235b" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">296</ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Furniture and fixtures</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_d6df4c2e-6825-4273-bbd9-f8e379e3dec5" contextRef="C_181d6e2d-a650-47fe-a4ba-e4e8ee97c169" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5 </span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">years</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dac06f1b-d823-4855-b8e4-cd7b0038a80d" contextRef="C_181d6e2d-a650-47fe-a4ba-e4e8ee97c169" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">386</ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fb900f26-51a9-4c36-a2aa-ec470562099d" contextRef="C_41123b72-f984-46ee-9547-e92bc56bb833" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">380</ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lab equipment</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_2b47fc44-1c6e-4e9b-b3e4-1db79cc78725" contextRef="C_c25f5aa6-70c3-4c5e-b41f-0a034c1996d8" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7 </span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">years</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_941f9949-6750-4070-a659-4d058dacbb43" contextRef="C_c25f5aa6-70c3-4c5e-b41f-0a034c1996d8" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">844</ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f5d16bd9-ec76-4d77-a247-b298a9884d4e" contextRef="C_ea417d17-7d7e-449f-9280-8a0a3bc657d1" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">514</ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_33f33880-b5d6-41bc-8594-7d948c3c4245" contextRef="C_00b1026d-c1b5-4b98-bee1-f1aa2360eb94" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7 </span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">years</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6922291f-129b-46b8-a773-349a8751bd54" contextRef="C_00b1026d-c1b5-4b98-bee1-f1aa2360eb94" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">272</ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_96cf09f2-c852-4073-8f70-6862731ed108" contextRef="C_a9ce9707-98f9-43cc-9660-650bbf29c98a" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">247</ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total property and equipment</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b0350604-8696-414f-94f1-69fbe543032a" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,502</ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dfabf5f8-4fdd-4ba8-b0fc-16ce23727751" contextRef="C_28144b67-7dfd-494d-8133-75abcc735058" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,437</ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: accumulated depreciation and amortization</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_873383da-c3ea-440b-80b5-e39759ac4f9a" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">474</ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b6d7c7cc-6b2b-493e-82ef-b0b60e9ed704" contextRef="C_28144b67-7dfd-494d-8133-75abcc735058" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">381</ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total property and equipment, net</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_52e627c0-cfaf-4c6e-881a-3f39b39e1222" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,028</ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_93d9d69b-010c-41f4-b16d-322d9e157175" contextRef="C_28144b67-7dfd-494d-8133-75abcc735058" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,056</ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></ix:nonNumeric></div></ix:nonNumeric></div><div><ix:continuation id="F_c82f6d39-f798-4c10-a825-1845407ad04e_1"></ix:continuation></div><div><ix:nonNumeric id="F_0adc84c5-141d-4eac-8505-52a34478923e" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:LesseeLeasesPolicyTextBlock" escape="true" continuedAt="F_0adc84c5-141d-4eac-8505-52a34478923e_1"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;In accordance with ASC Topic 842, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">("ASC 842"), the Company determines if an arrangement is or contains a lease at inception. A contract is or contains a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. The Company classifies leases at the lease commencement date as operating or finance leases and records a right-of-use asset and a lease liability on the balance sheet for all leases with an initial lease term of greater than 12 months. Leases with an initial term of 12 months or less are not recorded in the balance sheet, but payments are recognized as expense on a straight-line basis over the lease term. The Company has elected not to recognize leases with terms of 12 months or less.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A lease qualifies as a finance lease if any of the following criteria are met at the inception of the lease: (i) there is a transfer of ownership of the leased asset to the Company by the end of the lease term, (ii) the Company holds an option to purchase the leased asset that it is reasonably certain to exercise, (iii) the lease term is for a major part of the remaining economic life of the leased asset, (iv) the present value of the sum of lease payments equals or exceeds substantially all of the fair value of the leased asset, or (v) the nature of the leased asset is specialized to the point that it is expected to provide the lessor no alternative use at the end of the lease term. All other leases are recorded as operating leases.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company enters into contracts that contain both lease and non-lease components. Non-lease components may include maintenance, utilities, and other operating costs. The Company combines the lease and non-lease components of fixed costs in its lease arrangements as a single lease component. Variable costs, such as utilities or maintenance costs, are not included in the measurement of right-of-use assets and lease liabilities but rather are expensed when the event determining the amount of variable consideration to be paid occurs.</span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">122</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_73be07b6-3428-4d7c-9ed9-55c01408fd60_4"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_0adc84c5-141d-4eac-8505-52a34478923e_1"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating lease right-of-use assets and lease liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term using the discount rate implicit in the lease. If the implicit rate is not readily determinable, the Company utilizes an estimate of its incremental borrowing rate based upon the available information at the operating lease commencement date. Operating lease right-of-use assets are further adjusted for prepaid or accrued lease payments. Operating lease payments are expensed using the straight-line method as an operating expense over the lease term. The Company&#8217;s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Finance lease right-of-use assets and lease liabilities are recognized upon receipt of the assets based on their fair values and are amortized to depreciation expense using the straight-line method over the estimated useful lives of the related assets. Finance lease liability payments are bifurcated into (i) a portion that is recorded as interest expense and (ii) a portion that reduces the finance liability associated with the lease, according to the interest rates implicit in the leases.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain of the Company&#8217;s leases include options to extend or terminate the lease. The amounts determined for the Company&#8217;s right-of-use assets and lease liabilities generally do not assume that renewal options or early-termination provisions, if any, are exercised, unless it is reasonably certain that the Company will exercise such options.</span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c93cf723-5cca-44b0-86ba-0ef99785d98e" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recent Accounting Pronouncements Adopted</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;In November 2023, the FASB issued ASU No. 2023-07, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Segment Reporting - Improving Reportable Segment Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (Topic 280) ("ASU 2023-07"). </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_73289f60-fe2f-4884-94cc-6b3d31ad5380;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ASU 2023-07</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> requires disclosures to include significant segment expenses that are regularly provided to the CODM, a description of other segment items by reportable segment, and any additional measures of a segment's profit or loss used by the CODM when deciding how to allocate resources. ASU 2023-07 also requires all annual disclosures currently required by Topic 280 to be included in interim periods. This update is effective for fiscal years beginning after December 15, 2023, and is to be applied retrospectively to all periods presented in the financial statements. The Company's </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_981b3ae7-f300-468e-b441-94964a43c71c" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adoption</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of ASU 2023-07 resulted in a new footnote disclosure for segment reporting.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recent Accounting Pronouncements Not Yet Adopted&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, the FASB issued ASU No. 2023-09, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (Topic 740) ("ASU No. 2023-09"). ASU No. 2023-09 requires disaggregation of the effective tax rate reconciliation into standard categories, enhances disclosure of income taxes paid, and modifies other income tax-related disclosures. ASU No. 2023-09 became effective for the Company on January 1, 2025. The adoption of this guidance will not have a material impact on the Company's financial statements.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the FASB issued ASU No. 2024-03, I</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ncome Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (Subtopic 220-40) ("ASU No. 2024-03"). ASU No. 2024-03 requires disclosure, in the notes to financial statements, of specified information about certain costs and expenses. ASU No. 2024-03 will be effective for the Company starting in annual periods in 2027, with early adoption permitted. The Company is currently assessing the impact of adopting this guidance on its financial statements.</span></p></ix:nonNumeric></div></ix:continuation></div>
  <div><ix:nonNumeric id="F_df15aa06-fcc5-4c7d-b3d0-ed445c3392a4" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:FairValueDisclosuresTextBlock" escape="true" continuedAt="F_df15aa06-fcc5-4c7d-b3d0-ed445c3392a4_1"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3. Fair Value Measurements</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s cash equivalents consist of investments in a U.S. government money market fund stated at carrying value, which approximates fair value and is based on quoted prices in active markets for identical securities. Cash is stated at carrying value, which approximates fair value due to its short-term nature. The Company classifies its investments, primarily in U.S. Treasury securities as Level 2 assets as these assets are not traded in an active market and have been valued through a third-party pricing service based on quoted prices for similar assets. The carrying values of the Company&#8217;s prepaid expenses, other current assets, accounts payable and accrued expenses approximate their fair values due to their short-term nature.</span></p><div><ix:nonNumeric id="F_be1b0fa5-123e-4c74-b57f-1aaaee3ab7a7" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" escape="true" continuedAt="F_be1b0fa5-123e-4c74-b57f-1aaaee3ab7a7_1"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents information about the Company&#8217;s financial assets, financial liabilities, and investments measured at fair value on a recurring basis and indicates the level of the fair value hierarchy utilized to determine such fair values:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:32.32%;box-sizing:content-box;"/>
        <td style="width:1.78%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.14%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.78%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.14%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.78%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.14%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.78%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.14%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31, 2024:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Assets:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents (money market)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0c6be6ca-fe8a-4988-b85e-10949e233537" contextRef="C_b8e13f0d-e121-406d-b1a0-0b776194fbaa" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,636</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b46b969c-f24d-4904-8d18-9f2bf28b356d" contextRef="C_36d77a3a-fda6-41cd-8ab5-65f7367582d3" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,636</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_41a76624-f54e-4ed9-9b86-c8520e5362ca" contextRef="C_2409277c-21f9-4adb-af62-46fdf50d9ce6" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">86,504</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cb27bb2a-4205-4f1a-8f39-3b6084c16032" contextRef="C_c96098bc-a151-4b74-aeae-a01a9db7efbb" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">86,504</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Investments:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3f827fdf-6b22-430c-82b7-de1de6407a27" contextRef="C_2409277c-21f9-4adb-af62-46fdf50d9ce6" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,012</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ca0c0aa8-cf9d-4bb1-b776-9726bb2fa1f5" contextRef="C_c96098bc-a151-4b74-aeae-a01a9db7efbb" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,012</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_407980b4-0016-4f5d-9c79-67b88b29e86c" contextRef="C_2e7387e7-73ad-47fb-a0de-5ceccb4a2a0f" name="us-gaap:FairValueNetAssetLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,636</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e6f4ca44-7943-42be-a00a-095d37970529" contextRef="C_fc82fec8-4701-4ddd-a632-831d62d00aa5" name="us-gaap:FairValueNetAssetLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">93,516</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f06b3d04-b279-41e0-b4de-a28fdf1aec58" contextRef="C_6ef7a0b8-9327-4be8-b39d-869ac79fb879" name="us-gaap:FairValueNetAssetLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">111,152</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">123</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_df15aa06-fcc5-4c7d-b3d0-ed445c3392a4_1" continuedAt="F_df15aa06-fcc5-4c7d-b3d0-ed445c3392a4_2"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_be1b0fa5-123e-4c74-b57f-1aaaee3ab7a7_1">
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:32.32%;box-sizing:content-box;"/>
        <td style="width:1.78%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.14%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.78%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.14%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.78%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.14%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.78%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.14%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31, 2023:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Assets:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents (money market)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4ea09a13-d06e-45f7-a7fd-943d17f0bb25" contextRef="C_3eb26141-df5c-4391-985c-b5a244216bc1" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">102,484</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1ec5fce6-0f30-4d54-be4d-fceb899cca37" contextRef="C_a20a05b8-9d12-490a-93f2-114ea8e35fca" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">102,484</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Investments:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a7925312-7c84-4ecb-9364-277271db83cd" contextRef="C_3f598951-fd6b-41a3-b5a9-de413e56d5cb" name="us-gaap:FairValueNetAssetLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">102,484</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d1b38864-aab4-4c96-8b6e-4db24afbee0b" contextRef="C_57207e39-81bb-4c7e-8c54-bf6e68c2462d" name="us-gaap:FairValueNetAssetLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">102,484</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_28715e2a-7f11-47b4-93a9-afcbfe67d7c4" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investments, which are classified as available-for-sale securities, consisted of the following as of December 31, 2024 and December 31, 2023:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:23.745%;box-sizing:content-box;"/>
        <td style="width:1.3%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:15.763%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.3%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:15.763%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.3%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:15.763%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.3%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:15.763%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31, 2024:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized Cost Basis</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross Unrealized Gains</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross Unrealized Losses</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Available-for-sale securities:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a487dc7a-ca6e-4457-8ba5-d81ad237e189" contextRef="C_b8320cf7-1637-4a5a-b0b7-b67e5100600a" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">93,619</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8b4aa70c-af86-43dd-9f4b-f5502efc2e73" contextRef="C_b8320cf7-1637-4a5a-b0b7-b67e5100600a" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">103</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8d483756-0fa0-4067-a12f-f358180702dc" contextRef="C_b8320cf7-1637-4a5a-b0b7-b67e5100600a" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">93,516</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_601b07f3-ffcf-46f5-b7f6-dd7dc77499a5" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">93,619</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0239a1e9-d347-48cd-9e89-032e5ee36f83" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">103</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_26458d95-4a3e-4f7b-bb28-bfaceceb2578" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">93,516</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31, 2023:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized Cost Basis</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross Unrealized Gains</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross Unrealized Losses</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Available-for-sale securities:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All investments classified as available-for-sale securities held as of December 31, 2024 and December 31, 2023 had contractual maturities of less than two years. There have been no material realized gains or losses on investments classified as available-for-sale securities for the periods presented.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2a40baa8-fe06-429f-9646-40ed21ca047d" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Aggregate fair values of investments classified as available-for-sale securities with unrealized losses and gains were as follows as of December 31, 2024 and December 31, 2023:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:38.36%;box-sizing:content-box;"/>
        <td style="width:2.12%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:26.7%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:2.12%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:26.7%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Available-for-sale securities:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Due within one year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e5d878a0-9a00-423a-83fb-0248a0d1d99d" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">86,504</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Due after one year through five years</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bf9e2d19-464f-4f89-9245-119e4ba5448a" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,012</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1cb9b75c-7454-41b0-87e1-acb378682707" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">93,516</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8c1b0d59-f757-4466-9145-6c6c01121e4e" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" escape="true"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth a roll forward of changes in the fair value of financial liabilities, gross of unamortized discount, classified as Level 3 in the fair value hierarchy:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:77.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:53.567%;box-sizing:content-box;"/>
        <td style="width:4.73%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:39.705%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Convertible<br/>SAFE Note,<br/>gross</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Beginning balance at December 31, 2022</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Convertible SAFE Note issuance at August 24, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6b84ecf6-7871-44d9-b80a-20c6fdfba158" contextRef="C_ff8a14ec-2414-4dce-963c-ac378e45b5e3" name="lxeo:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConvertibleNoteIssuance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,000</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_995b2506-e09a-426b-8450-5340620be7de;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in estimated fair value since issuance</span></span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_40b2dcce-b05a-47fa-a363-e2c3754235b3" contextRef="C_ff8a14ec-2414-4dce-963c-ac378e45b5e3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">530</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Conversion of SAFE Note into common stock in connection with initial public offering</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5a36fa4b-5687-4a8b-971b-d58aa95772ae" contextRef="C_ff8a14ec-2414-4dce-963c-ac378e45b5e3" name="lxeo:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversionOfNotesIntoCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,530</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ending balance at December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">124</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_df15aa06-fcc5-4c7d-b3d0-ed445c3392a4_2"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The valuation models used to estimate the fair value of the Company&#8217;s convertible SAFE Note considered the estimated probabilities of each of qualified equity financing, public offering, and change of control events, together with corresponding estimated periods of time from each valuation date until the achievements of each such event. Future values were converted to present value using a discount rate appropriate for probability-adjusted cash flows. </span><span><ix:nonNumeric id="F_1d3d22e4-ed62-41a3-95c3-a53335a84607" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="lxeo:ScheduleOfSignificantUnobservableInputsUsedInValuationModelToEstimateFairValueTableTextBlock" escape="true" continuedAt="F_1d3d22e4-ed62-41a3-95c3-a53335a84607_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The ranges of the significant unobservable inputs used in the valuation model to estimate the fair value of the Company&#8217;s convertible SAFE Note that was categorized within Level 3 of the fair value hierarchy as of August 24, 2023 (issuance) until November 2, 2023 (settlement) were as follows (not stated in thousands):</span></ix:nonNumeric></span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_1d3d22e4-ed62-41a3-95c3-a53335a84607_1">
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:77.86%;box-sizing:content-box;"/>
        <td style="width:1.92%;box-sizing:content-box;"/>
        <td style="width:20.22%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Probability of meeting qualified equity financing event</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a4beffc4-e0a8-484a-9914-4caa743c3c3e" contextRef="C_3579d9a8-e7bf-4c6d-ac06-1c8021fed3eb" name="lxeo:FairValueProbabilityOfMeetingQualifiedEquityFinancingEvent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">10.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a0fcd1eb-0ce5-4422-8f6e-f522640c3890" contextRef="C_95dc5b03-a8d3-46ba-9c0f-f641f5341cf5" name="lxeo:FairValueProbabilityOfMeetingQualifiedEquityFinancingEvent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">20.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Probability of meeting public offering event</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6beae816-1b08-44e0-9610-33b6d8ff8b15" contextRef="C_3579d9a8-e7bf-4c6d-ac06-1c8021fed3eb" name="lxeo:FairValueProbabilityOfMeetingPublicOfferingEvent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">75.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0ff9e128-47a0-4380-8261-b827f0d0cc83" contextRef="C_95dc5b03-a8d3-46ba-9c0f-f641f5341cf5" name="lxeo:FairValueProbabilityOfMeetingPublicOfferingEvent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">85.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Probability of meeting change in control event</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bb7becdf-8b4c-410f-8f5d-fdb7f7f9b872" contextRef="C_5d7d637d-2f7f-4be3-acba-58d6df49a889" name="lxeo:FairValueProbabilityOfMeetingChangeInControlEvent" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Time until qualified equity financing event (in years)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_b4fccadb-2146-4447-a662-be938ae79f9f" contextRef="C_3579d9a8-e7bf-4c6d-ac06-1c8021fed3eb" name="lxeo:FairValueTimeUntilQualifiedEquityFinancingEvent" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.17</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span><ix:nonNumeric id="F_a5608f1c-ff36-4f51-b35c-d57ebefbe403" contextRef="C_95dc5b03-a8d3-46ba-9c0f-f641f5341cf5" name="lxeo:FairValueTimeUntilQualifiedEquityFinancingEvent" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.27</span></ix:nonNumeric></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Time until public offering event (in years)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_27a502d3-f52d-4c75-879b-c183527a7c7e" contextRef="C_3579d9a8-e7bf-4c6d-ac06-1c8021fed3eb" name="lxeo:FairValueTimeUntilPublicOfferingEvent" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.08</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span><ix:nonNumeric id="F_008a2b38-01db-4513-86c8-168f45f33e70" contextRef="C_95dc5b03-a8d3-46ba-9c0f-f641f5341cf5" name="lxeo:FairValueTimeUntilPublicOfferingEvent" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.19</span></ix:nonNumeric></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Time until change in control event (in years)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_8fd1a4f9-2a18-4c86-b64a-3f68f2d9d436" contextRef="C_3579d9a8-e7bf-4c6d-ac06-1c8021fed3eb" name="lxeo:FairValueTimeUntilChangeInControlEvent" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.50</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span><ix:nonNumeric id="F_055749cd-66d8-4e3d-97e7-ea47933005f9" contextRef="C_95dc5b03-a8d3-46ba-9c0f-f641f5341cf5" name="lxeo:FairValueTimeUntilChangeInControlEvent" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.60</span></ix:nonNumeric></span></p></td>
       </tr>
      </table></ix:continuation></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the closing of the Company&#8217;s IPO on November 7, 2023, the underwriters of the IPO were granted an option for a period of 30 days to purchase up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_303224c0-cdf9-4d34-8024-1dd25f05d6fa" contextRef="C_a5546360-23ec-45e5-ba9d-ee679b197414" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,363,636</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> additional shares from the Company at the public offering price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0b37db10-0918-4d4f-831a-73a8e98f3691" contextRef="C_74419331-e290-447a-86d3-c0fb520fc7bc" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">11.00</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share less the underwriting discount, of which </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d837c73a-7d3d-41c9-bf75-b25bba3e89d7" contextRef="C_09b75305-e3e0-435b-b2a6-50f4050afab2" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,048,746</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares were exercised (see Note 8). </span><span><ix:nonNumeric id="F_e0e68581-61dc-47fc-8674-60dca9d89dcc" contextRef="C_99fa4607-5a6b-4035-bcda-41e63ec19b9d" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" escape="true" continuedAt="F_e0e68581-61dc-47fc-8674-60dca9d89dcc_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The total grant date fair value of this option of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e6b39a72-5cf0-4de3-b61e-c0cadb4b9ac7" contextRef="C_47a049b7-455a-448b-84ea-5e98846bad51" name="lxeo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, or $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fa3dc1e9-05de-41e9-a399-9a24fd09c7d0" contextRef="C_44dd3996-14be-4820-b581-6281744e49e6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.85</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, was recorded as an offset to additional paid-in capital and was estimated using a Black-Scholes model incorporating the following assumptions (not stated in thousands):</span></ix:nonNumeric></span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_e0e68581-61dc-47fc-8674-60dca9d89dcc_1" continuedAt="F_e0e68581-61dc-47fc-8674-60dca9d89dcc_2">
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:77.86%;box-sizing:content-box;"/>
        <td style="width:1.92%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:18.22%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock price</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a5a92941-c788-4617-b56d-a558eba68935" contextRef="C_4591c456-caa6-4a3e-acb5-b25d3fb9ee55" name="us-gaap:AlternativeInvestmentMeasurementInput" unitRef="U_USD" scale="2" decimals="0" format="ixt:num-dot-decimal">11.00</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercise price</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d3867ff0-f184-4dfc-877b-79be306d55c6" contextRef="C_202838fb-c603-44c3-ac57-cbb400921fd7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">11.00</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average risk-free interest rate</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9be41146-0951-4325-89a3-e3e8b51f4efb" contextRef="C_bba6b31e-5617-48b1-9ad1-7cf7f1501cf3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">5.53</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_1d7eee1b-dff7-4aa6-89c7-b8b7bcc0410e" contextRef="C_b7af60cb-baf3-4dbb-af94-8473e08ee442" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.08</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3232e8aa-44ce-4645-9785-6ff88933975f" contextRef="C_1c8074fe-d719-4d7e-8aa3-6e8936dddc3f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">65.88</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_589501c1-c5e5-4fc0-87f4-ab11f76bc6ba" contextRef="C_4a2b7157-1380-497a-a4ef-750dda612b33" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">0.00</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div></ix:continuation></div>
  <div><ix:continuation id="F_e0e68581-61dc-47fc-8674-60dca9d89dcc_2"></ix:continuation></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_5bc4c2ab-890b-4665-8ae1-0691c0378b88" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" escape="true"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4. Accrued Expenses and Other Current Liabilities</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d66c071d-c4f3-42c6-a49b-2235cc9c5681" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" escape="true" continuedAt="F_d66c071d-c4f3-42c6-a49b-2235cc9c5681_1"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued expenses and other current liabilities consisted of the following</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:88.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:72.793%;box-sizing:content-box;"/>
        <td style="width:1.274%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.693000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.274%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.965%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued research and development expenses</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0198fafb-6214-498b-866d-99341ac29344" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="lxeo:AccruedResearchAndDevelopmentExpenseCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,696</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_82eae3c2-6db0-4db9-b1e4-502f3f3ac8b1" contextRef="C_28144b67-7dfd-494d-8133-75abcc735058" name="lxeo:AccruedResearchAndDevelopmentExpenseCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,384</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued bonus expenses</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6470db6b-f670-4e71-8bff-4815ddc49d22" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="us-gaap:AccruedBonusesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,718</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ec806e56-8785-4cd5-aded-b71f3dca3704" contextRef="C_28144b67-7dfd-494d-8133-75abcc735058" name="us-gaap:AccruedBonusesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,810</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued general and administrative expenses and other professional fees</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6edd41cb-2c6d-473e-b6c8-ef7d563db1e2" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="lxeo:AccruedGeneralAndAdministrativeExpensesAndOtherProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,406</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7c9cd471-6bc2-4717-afb7-b6dae104a41d" contextRef="C_28144b67-7dfd-494d-8133-75abcc735058" name="lxeo:AccruedGeneralAndAdministrativeExpensesAndOtherProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,092</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other current liabilities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_47024422-60bb-483f-95e5-e448bf77a1ef" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">939</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_853a8532-1926-40a6-ad61-4cd03ca034fd" contextRef="C_28144b67-7dfd-494d-8133-75abcc735058" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">554</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total accrued expenses and other current liabilities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ca1d07fb-c0c3-4e1c-a388-9e5022433d84" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="lxeo:AccruedLiabilitiesAndOtherLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,759</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_71ddc285-be68-41e6-81bb-86e7b342c705" contextRef="C_28144b67-7dfd-494d-8133-75abcc735058" name="lxeo:AccruedLiabilitiesAndOtherLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,840</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <div><ix:continuation id="F_d66c071d-c4f3-42c6-a49b-2235cc9c5681_1"></ix:continuation></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_5a77f444-e834-4995-a369-77f78a6189d3" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="lxeo:LesseeOperatingAndFinancingLeasesDisclosureTextBlock" escape="true" continuedAt="F_5a77f444-e834-4995-a369-77f78a6189d3_1"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5. Leases</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Operating Lease Right-of-Use Asset</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1573e534-5b72-4bf8-8dcf-e90dab0baf7b" contextRef="C_754c742e-ae45-493f-9e9c-c876f6b36a1b" name="lxeo:OperatingLeaseAgreementEnteredDate" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">January 2022</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company entered into a lease agreement for an office facility and laboratory space in New York, New York that commenced in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_055cfa16-f41e-4f7a-81f6-2a76bc14f01f" contextRef="C_3bc3fa7e-440b-44ad-b57d-4fc9f9165d8a" name="lxeo:OperatingLeaseCommencementDate" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">April 2022</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and ends in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_19f0992f-1cdb-4691-b887-eb53e7321e56" contextRef="C_5b737ad7-5e23-417d-9cd9-c6d69e60d8a1" name="lxeo:OperatingLeaseEndDate" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">July 2029</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> with an </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_89538aac-eb2c-43ee-89f2-d6ed42e8fb9c" contextRef="C_c6dd71d6-5140-472d-b5c8-2940a8c82dd8" name="us-gaap:LesseeOperatingLeaseOptionToExtend"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">additional </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_962c68ad-534d-4100-ba30-d08379faf8b7" contextRef="C_8c6b7b14-2521-4983-80fe-50cd39b26715" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">five-year</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_82f51493-cfe7-4f9d-960a-1c873124a239" contextRef="C_057f47b0-3a28-481e-917c-c1c45349ef35" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">option to extend the lease beyond July 2029 </span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">at the then-prevailing effective market rental rate</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Upon commencement of this lease, the Company recorded operating lease right-of-use assets and operating lease liabilities of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dc250255-564b-46d7-aca8-0b30a81cf225" contextRef="C_a6d4ba66-86df-4d4a-b4e0-034d42abb2dc" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_4f8a0f10-0f5c-45c7-a022-4a10e4e01ecf" contextRef="C_a6d4ba66-86df-4d4a-b4e0-034d42abb2dc" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">11.6</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million based on the present value of payments over the lease term using an estimated incremental borrowing rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d6687662-39db-4e11-8580-755918b04c89" contextRef="C_a6d4ba66-86df-4d4a-b4e0-034d42abb2dc" name="us-gaap:LesseeOperatingLeaseDiscountRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">8.53</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% in accordance with the provisions of ASC 842. In connection with the Company&#8217;s lease of office space and laboratory space, the Company provided a security deposit to the landlord in the form of a letter of credit totaling $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ea717c9b-ae36-4060-8955-2ad60d5e7e07" contextRef="C_a42efdd6-1a5f-4930-9ba0-797305fcec72" name="us-gaap:SecurityDeposit" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The cash collateralizing the letter of credit was included in long-term restricted cash in the Company&#8217;s balance sheets as of December 31, 2024, and December 31, 2023. This lease was classified as an operating lease in accordance with the provisions of ASC 842. The Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aef2c22c-25e8-411a-8e06-f895954914f1" contextRef="C_8c6b7b14-2521-4983-80fe-50cd39b26715" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_5cbdf731-1688-47f5-b889-191fc1a4e251" contextRef="C_8c6b7b14-2521-4983-80fe-50cd39b26715" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t recognize any right-of-use assets and lease liabilities associated with the potential option to renew or extend. The Company&#8217;s operating lease agreement does not contain any significant residual value guarantees or restrictive covenants.</span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">125</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_5a77f444-e834-4995-a369-77f78a6189d3_1" continuedAt="F_5a77f444-e834-4995-a369-77f78a6189d3_2"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The remaining lease terms and payment terms as of December 31, 2024 and December 31, 2023 were </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9e19e77b-02e5-4421-b187-2512a62d8816" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><ix:nonNumeric id="F_c06f706a-1e62-45d6-a90f-cc040a1d5be4" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="lxeo:OperatingLeaseWeightedAverageRemainingPaymentTerm" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4.6</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years and </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1ea720f1-922e-46c0-9b7d-a3109bb33e35" contextRef="C_28144b67-7dfd-494d-8133-75abcc735058" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><ix:nonNumeric id="F_8c5e47e9-5450-4f21-b811-45e7dfdc23f8" contextRef="C_28144b67-7dfd-494d-8133-75abcc735058" name="lxeo:OperatingLeaseWeightedAverageRemainingPaymentTerm" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.6</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years, respectively. </span><span><ix:nonNumeric id="F_487abefb-62c4-4cf5-b938-e3d0d7397523" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="lxeo:ComponentsOfOperatingLeaseTableTextBlock" escape="true" continuedAt="F_487abefb-62c4-4cf5-b938-e3d0d7397523_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The components of this operating lease were as follows:</span></ix:nonNumeric></span></p><div style="font-size:11pt;font-family:Times New Roman;"><ix:continuation id="F_487abefb-62c4-4cf5-b938-e3d0d7397523_1">
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.64%;box-sizing:content-box;"/>
        <td style="width:2.08%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:17.099999999999998%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:2.08%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:17.099999999999998%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease expense</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d60d58cb-c5b9-49a0-b4eb-fe32effd2c5e" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,147</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_be38c6fb-1012-48bb-aa65-8b3fcb35146b" contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,147</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Variable lease expense</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4b9c9aa4-3221-4eee-b774-191d7af32cf3" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:VariableLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">459</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_72122d69-55bc-4223-a1bb-e5063c04b544" contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca" name="us-gaap:VariableLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">355</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating lease expense</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_22cd6715-48ab-4c0c-ba13-80bb68341015" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,606</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c3dfacde-b6b2-4a11-9072-4479e083c57a" contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,502</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash paid for amounts included in the measurement of lease liabilities, included in operating cash flows</span></p></td>
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d5fe241e-ef44-4ee4-bc4c-1c657ae04bc1" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,110</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1b3c03a8-e9c8-4c03-b81c-c0b9058dd8da" contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,294</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><div style="font-size:11pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fd7d7985-2638-4f72-8eaf-33ee9984829a" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table provides a reconciliation of the Company&#8217;s remaining undiscounted contractual rent obligations due within each year ended December 31 to the operating lease liabilities recognized as of December 31, 2024:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:73.02%;box-sizing:content-box;"/>
        <td style="width:2.7%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:22.279999999999998%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Year ended December 31</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Operating<br/>Leases</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c44af2fe-ce8b-4d8a-be15-02d640a9f1ae" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,152</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ed99035a-a853-4b88-ba9c-dc9fddd1d5f4" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,206</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e9ec2c35-a81a-4d70-94f6-5a66d7e366d2" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,261</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_26ee9081-3326-4da4-9ad4-2c26aa59e3d5" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,318</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f701011d-aa3f-4449-b1d6-8ff14b265228" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,372</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Thereafter</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1b31bd74-26a8-4796-aac6-f4b5cf22bbc5" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total lease payments</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_731606be-8082-4b2f-a274-468c67bed127" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,309</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: present value adjustment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_19e9a9e0-18a6-467f-834c-6dcef3eed152" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,772</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating lease liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_29c7e4a8-a11e-4e97-ba23-c333a49e0243" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,537</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Included in the balance sheet:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current portion of lease liabilities - operating</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1045e883-ee9f-4e44-98ac-f8a4fe99dfcb" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,100</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-current portion of lease liabilities - operating</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3847e248-f6b7-44eb-b811-0587add57b8e" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,437</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating lease liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b292e42d-f767-40e7-a5e4-3786eefa0da0" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,537</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Equipment Finance Leases</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commencing in April 2022, the Company leases certain laboratory equipment under financing arrangements accounted for as finance leases in accordance with the provisions of ASC 842 that are classified in the Company&#8217;s balance sheet as finance lease liabilities with related right-of-use assets recorded and depreciated on a straight-line basis over the estimated useful life of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e9236bca-7d4d-467a-a8bf-f23f979320c1" contextRef="C_c25f5aa6-70c3-4c5e-b41f-0a034c1996d8" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years. In connection with the Company&#8217;s leases of laboratory equipment, the Company provided a security deposit to the lessor in the form of a letter of credit totaling $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ae181e96-5086-4363-97e8-4ee20c8cc72e" contextRef="C_75c654f9-7566-4300-8e93-f4d56b98a5b5" name="us-gaap:SecurityDeposit" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and assigned all rights and interests in the equipment to the lessor. The cash collateralizing the letter of credit is included in long-term restricted cash in the Company&#8217;s balance sheet as of December 31, 2024. The total gross, accumulated amortization, and net book values of equipment finance lease right-of-use assets capitalized under such finance lease arrangements at December 31, 2024 were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c71ab003-697a-4400-9a45-140142e0d07f" contextRef="C_c25f5aa6-70c3-4c5e-b41f-0a034c1996d8" name="us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f19b63d3-20d4-4a33-8764-f36a0f5b055a" contextRef="C_c25f5aa6-70c3-4c5e-b41f-0a034c1996d8" name="us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9594ece5-b42b-42c3-8a2b-2450b7f8be1f" contextRef="C_c25f5aa6-70c3-4c5e-b41f-0a034c1996d8" name="us-gaap:FinanceLeaseRightOfUseAsset" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively. Under the terms of the equipment finance lease agreements executed through the issuance of these financial statements, the principal balances plus interest for the equipment are to be repaid in full after </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fdd2ae30-d71c-43f3-9f3b-cb1878fc9520" contextRef="C_bc4e18d1-8708-4fa6-8c8b-10f077d3382c" name="lxeo:NumberOfMonthlyInstallmentsLease" unitRef="U_Installment" decimals="INF" format="ixt:num-dot-decimal">60</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> monthly installments following lease commencement, with lease commencement dates ranging from </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_799db80f-fb82-4f33-8edb-eed883a2c60c" contextRef="C_3cbe0ed1-2f36-42ec-8001-032a59884f91" name="lxeo:LesseeFinanceLeaseCommencementDateRangeStart" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">April 1, 2022</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5802a426-603e-4cfa-bdc4-596e1738138d" contextRef="C_a398e430-4b76-4f00-9eb3-273c39d2e6fd" name="lxeo:LesseeFinanceLeaseCommencementDateRangeEnd" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">April 1, 2023</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, annual imputed interest rates ranging from </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_96a11173-5a31-492a-b8b3-bd37a6174fa9" contextRef="C_93e60cc0-c98a-4905-a0ae-b6c3266b5a78" name="us-gaap:LesseeFinanceLeaseDiscountRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">7.90</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4447d356-c024-4a73-8637-d6845b6abca5" contextRef="C_78220819-138e-4d2f-ae70-819bfa7f0e94" name="us-gaap:LesseeFinanceLeaseDiscountRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">9.30</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%, and monthly installment payment amounts ranging from $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9245f3f4-a898-496b-8589-01d876f54199" contextRef="C_93e60cc0-c98a-4905-a0ae-b6c3266b5a78" name="lxeo:FinanceLeaseMonthlyInstallmentPaymentAmounts" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">4,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e6522759-b249-49e5-9b95-5fda609660f8" contextRef="C_78220819-138e-4d2f-ae70-819bfa7f0e94" name="lxeo:FinanceLeaseMonthlyInstallmentPaymentAmounts" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">18,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The total aggregate monthly installment payment amount is $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_07fb4d4d-6880-4337-a1db-7a83b3d78a75" contextRef="C_c25f5aa6-70c3-4c5e-b41f-0a034c1996d8" name="lxeo:FinanceLeaseAggregateMonthlyInstallmentPaymentAmounts" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">49,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for the Company's equipment finance lease agreements.</span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">126</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_5a77f444-e834-4995-a369-77f78a6189d3_2"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The weighted-average remaining lease payment term, weighted-average remaining amortization term, and weighted-average effective interest rate for the Company's equipment finance lease agreements as of December 30, 2024 were </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4dd75619-1d0f-4456-a70a-a353773674b8" contextRef="C_f13110bd-68e9-4c8f-869d-c3f80a05ef1a" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.7</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_82415951-a465-468a-a4ea-08a9c545615e" contextRef="C_9a3288c8-11b0-411a-aef1-05a44eec67ca" name="lxeo:FinanceLeaseWeightedAverageRemainingAmortizationTerm" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4.8</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years, and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6f3c9632-087a-4951-a69a-cdd7bee162bf" contextRef="C_f13110bd-68e9-4c8f-869d-c3f80a05ef1a" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">8.59</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%, respectively. The weighted-average remaining lease payment term, weighted-average remaining amortization term, and weighted-average effective interest rate for the Company's equipment finance lease agreements as of December 31, 2023 were </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_99454693-bc98-408a-a2c1-4414f08938a8" contextRef="C_28144b67-7dfd-494d-8133-75abcc735058" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.7</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3d7858f2-9c42-43e1-82b1-6a8d700ba31d" contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca" name="lxeo:FinanceLeaseWeightedAverageRemainingAmortizationTerm" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.7</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years, and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f29e4845-a201-42c9-9129-7298bd806333" contextRef="C_28144b67-7dfd-494d-8133-75abcc735058" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">8.59</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%, respectively. </span><span><ix:nonNumeric id="F_9a8f27e8-b058-40c1-b68f-498fbe01881f" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="lxeo:ComponentsOfEquipmentFinanceLeaseTableTextBlock" escape="true" continuedAt="F_9a8f27e8-b058-40c1-b68f-498fbe01881f_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The components of the equipment finance leases were as follows:</span></ix:nonNumeric></span></p><div style="font-size:11pt;font-family:Times New Roman;"><ix:continuation id="F_9a8f27e8-b058-40c1-b68f-498fbe01881f_1">
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:62.34%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:15.860000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.94%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:15.860000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Reduction in the carrying amount of ROU assets, finance</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_77fd4978-0d66-4496-8e89-46cc9073f73c" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">325</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_98f2f87a-5910-43fa-a416-33535bacfa98" contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">306</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest on finance lease liabilities</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_396a4383-5f1d-48ee-83b2-09c9288998e2" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:FinanceLeaseInterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">127</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5b199938-6410-45cb-b982-202244dd2fe1" contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca" name="us-gaap:FinanceLeaseInterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">176</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total finance lease expense</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_426b5663-fc3e-4eb2-a9f2-ae2b1f1e2c5f" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="lxeo:FinanceLeaseExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">452</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1f4627d2-6826-4865-bf16-7aee36d7f48f" contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca" name="lxeo:FinanceLeaseExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">482</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash paid for amounts included in the measurement of lease liabilities, included in financing cash flows</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e1f26958-4eb2-4a89-91e0-2847b09465f3" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:FinanceLeasePrincipalPayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">410</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ed12f960-b37f-48a4-a2b3-53dc51e53822" contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca" name="us-gaap:FinanceLeasePrincipalPayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">425</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><div style="font-size:11pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c06becc4-0d45-4d75-afcb-4598ea0c592f" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock" escape="true" continuedAt="F_c06becc4-0d45-4d75-afcb-4598ea0c592f_1"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table provides a reconciliation of the Company&#8217;s remaining equipment finance lease obligations due within each year ending December 31 to the equipment finance lease liabilities recognized at December 31, 2024:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:77.7%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:20.299999999999997%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Year ended December 31</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Equipment Finance Leases</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_60078e7b-8f5e-47e0-b6a5-4ad1340e558a" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">587</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0e0ee3d0-8e9c-497c-9602-a81752931458" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">587</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a2a9e783-03c9-4b58-a227-852d52750e33" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">359</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2ef64039-4f2a-445a-b283-a9e18bef2340" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1e0352f6-cacc-4cce-9e8c-0b651afb2d6f" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Thereafter</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cc5e8958-b1cf-419d-80a9-27c02915ce58" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total lease payments</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d2ad9ded-4e09-4904-8907-1fc5a21ea28f" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,544</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: imputed interest</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5c2921b7-08c2-43ef-a368-2e9db0e76edd" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">157</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total finance lease liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0c64f65d-a7ad-49a2-9f67-1447c43b1a21" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="us-gaap:FinanceLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,387</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Included in the balance sheet:</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current portion of lease liabilities - finance</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e6a4888e-8978-46bd-bb6d-1fe78677dcf8" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="us-gaap:FinanceLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">570</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-current portion of lease liabilities - finance</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4aee5403-79bd-4ea5-8d88-13e12ba14148" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="us-gaap:FinanceLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">817</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total finance lease liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3d2bde62-f3bd-4bac-81ea-67f657583d8e" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="us-gaap:FinanceLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,387</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:continuation></div>
  <div><ix:continuation id="F_c06becc4-0d45-4d75-afcb-4598ea0c592f_1"></ix:continuation></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_3f7f5262-0a5a-483f-83bf-bcdd6efaa409" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:DebtDisclosureTextBlock" escape="true" continuedAt="F_3f7f5262-0a5a-483f-83bf-bcdd6efaa409_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6. Convertible SAFE Note</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On August 24, 2023, the Company entered into the convertible SAFE Note with Sarepta Therapeutics, Inc. (the "Investor") in a principal amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_64d498e3-f0ca-4d61-9590-83339d0c7047" contextRef="C_e84f1a1e-8d42-4df6-8795-f518a72c03e0" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million bearing simple interest at an annual rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_baa95010-7fb9-4ab9-a2b3-6e855e217f04" contextRef="C_e84f1a1e-8d42-4df6-8795-f518a72c03e0" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">10</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% to be repaid after one year (the "Cash Out Amount") in the absence of the occurrence of certain settlement events, including upon a qualified preferred stock equity financing, a public offering or a Special Purpose Acquisition Company ("SPAC" transaction, a change of control, or dissolution. The convertible SAFE Note was accounted for as a liability in accordance with the provisions of ASC Topic 480, Distinguishing Liabilities from Equity, which was initially and subsequently measured at fair value with changes in fair value recognized in earnings (see Note 3). </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9155180a-d408-4416-b73d-7020f0aa98f6" contextRef="C_01ae7cc9-95ef-4205-a1f8-4bc92563980e" name="us-gaap:DebtInstrumentDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upon a qualified equity financing event, the convertible SAFE Note would have automatically converted into a number of shares of corresponding preferred stock based on a certain discount to the price of such preferred stock issued to the other investors applied to the then-current Cash-Out Amount. Upon the effective date of an IPO or a direct listing, or immediately prior to the closing of a SPAC transaction, the convertible SAFE Note would have automatically converted, and did automatically convert upon the effectiveness of the Company's IPO registration statement on November 2, 2023, into a number of shares of common stock based on a certain discount to the public offering price of such common stock applied to the then-current Cash-Out Amount (see Note 8). Upon a change of control, the Investor would have been entitled to receive the greater of (i) an amount equal to a certain premium applied to the then-current Cash-Out Amount, or (ii) the amount that would have been payable on the number of shares of the senior-most series of the Company&#8217;s preferred stock after applying a certain discount to the original issue price of such senior-most preferred stock together with a certain premium applied to the then-current Cash-Out Amount (the greater of (i) and (ii), the &#8220;Conversion Amount&#8221;). Upon the one-year maturity of the convertible SAFE Note, or upon dissolution of the Company, the Investor was to be paid an amount equal to the Cash-Out Amount. Upon the event of a change of control or dissolution, the Investor&#8217;s right to receive its Cash-Out Amount or its Conversion Amount would have been junior to payment of outstanding indebtedness and creditor claims, on par with payments for the Company&#8217;s most senior series of preferred stock or other SAFE note holders, if any, and senior to payments for the Company&#8217;s common stock and any other series or class of stock. The convertible SAFE Note did not maintain any voting rights. </span></ix:nonNumeric></span><span style="font-size:10pt;font-family:Times New Roman;"></span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">127</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_3f7f5262-0a5a-483f-83bf-bcdd6efaa409_1"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the convertible SAFE Note, the Company incurred issuance costs of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d3d129ac-aabd-4766-aac1-2c83f9fb0ef8" contextRef="C_9a32dff6-03c5-465f-846c-9b718f20e0b9" name="us-gaap:DeferredFinanceCostsNet" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million that were recorded as a discount to the liability balance and amortized to interest expense over the term of the convertible SAFE Note. As of November 2, 2023, the estimated fair value of the convertible SAFE Note, gross of unamortized discount, increased by $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_50c72b92-9b28-440c-a33e-0c47e69e2659" contextRef="C_3df569eb-97ac-4247-ae8a-b4800fbcc697" name="lxeo:IncreaseDecreaseInFairValueOfSafeInstrument" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fc94790d-62d2-490d-b22a-1732658b79f8" contextRef="C_57731d15-0745-4645-b184-c42a52a8959a" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million (see Note 3), and the corresponding carrying value was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_55c00670-3cd9-4908-ae0a-3e9d63aee7ba" contextRef="C_57731d15-0745-4645-b184-c42a52a8959a" name="us-gaap:ConvertibleNotesPayableCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, net of unamortized discount, which automatically converted into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1481de7a-3825-46d3-a493-aa81a020cfd1" contextRef="C_90b3b8b5-08ff-4ed8-b03a-36a19e205081" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">411,815</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company&#8217;s common stock upon the declaration of effectiveness of the Company's IPO registration statement on November 2, 2023 (see Note 8).</span></p></ix:continuation></div>
  <div><ix:nonNumeric id="F_ef9a575c-8906-4a9f-a622-4c2b7af57840" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:PreferredStockTextBlock" escape="true" continuedAt="F_ef9a575c-8906-4a9f-a622-4c2b7af57840_1"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7. Convertible Preferred Stock</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2022 and until the closing of the Company's IPO on November 7, 2023, the Company&#8217;s certificate of incorporation authorized the Company to issue </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_427d96b3-96a0-4c0c-9643-59fc2923cd92" contextRef="C_abb5ce74-a0ec-41a2-a9d1-032861f25e44" name="us-gaap:TemporaryEquitySharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">143,653,546</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of series A and series B convertible preferred stock each with a par value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_31dc9345-3c33-496b-b523-255736f0453d" contextRef="C_abb5ce74-a0ec-41a2-a9d1-032861f25e44" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. Upon the closing of the Company's IPO on November 7, 2023, all </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dd31c88a-6abd-46cf-8938-45b714b8af63" contextRef="C_dfb1adde-bdce-4971-8572-0c77f2a15437" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">85,495,722</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> outstanding shares of the Company&#8217;s series A convertible preferred stock and all </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9f1b771b-840a-4a93-9075-73a5ebb1e31e" contextRef="C_7d455504-a441-4ca1-b057-e166af9463cf" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">58,157,823</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> outstanding shares of the Company&#8217;s series B convertible preferred stock converted into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_237dd7c5-d22d-4a88-9818-192305263372" contextRef="C_dfb1adde-bdce-4971-8572-0c77f2a15437" name="us-gaap:PreferredStockConvertibleSharesIssuable" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">8,070,027</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ee43b7a7-dbea-408a-ad1a-a2625f72f305" contextRef="C_b15d25c2-ef2b-415e-98f5-5721bc068283" name="us-gaap:PreferredStockConvertibleSharesIssuable" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">6,386,337</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock, respectively, including </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_87629bf6-e0aa-4b17-891f-ba97bc777fbc" contextRef="C_ff876ac5-7ddc-447a-ba80-cd3fc5d96d6b" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">896,764</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock issued as a result of series B convertible preferred stock antidilution provisions (see Note 8).</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e0d8b6bb-0c91-42dc-8ffb-b2d68ecd328b" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:TemporaryEquityTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2022 and until the closing of the Company's IPO on November 7, 2023, convertible preferred stock consisted of the following:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:26.9%;box-sizing:content-box;"/>
        <td style="width:1.1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.6%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.6%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.56%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.440000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.56%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.440000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.6%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Convertible</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Convertible</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Preferred</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Preferred</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Stock</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Common Stock</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Stock</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Issued and</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Proceeds</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Liquidation</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Issuable Upon</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Authorized</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Outstanding</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Received</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Preference</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Conversion</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Series A convertible preferred stock</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d0838c56-3adf-4c36-ac2a-cc101ade67cf" contextRef="C_dfb1adde-bdce-4971-8572-0c77f2a15437" name="us-gaap:TemporaryEquitySharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_3432366d-47f3-4c4c-8bee-598ecacb7c6d" contextRef="C_34e9355d-4428-4f62-b1ae-10943dbb5161" name="us-gaap:TemporaryEquitySharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">85,495,722</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0f66bd94-e2da-4d2f-bf7d-87b9fe6c5dd9" contextRef="C_dfb1adde-bdce-4971-8572-0c77f2a15437" name="us-gaap:TemporaryEquitySharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_074c2f67-b89e-43b7-89fc-16b264474474" contextRef="C_dfb1adde-bdce-4971-8572-0c77f2a15437" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_760cd3b8-e316-4ec4-9126-05f5d343916c" contextRef="C_34e9355d-4428-4f62-b1ae-10943dbb5161" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_00765210-006f-4308-8056-94c0f6962b3d" contextRef="C_34e9355d-4428-4f62-b1ae-10943dbb5161" name="us-gaap:TemporaryEquitySharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">85,495,722</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_86d37996-91da-4025-8e94-6e4e7a7de7e3" contextRef="C_7c1f486a-7a1e-460e-b332-6ac6ec1ac145" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal"><ix:nonFraction id="F_7238fa9a-12ac-436a-a8be-338d0f114e27" contextRef="C_81b19c2d-22eb-4f90-b119-49d130c596ae" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">85,496</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7d6a13b2-0490-4131-95c9-103e206bed61" contextRef="C_dfb1adde-bdce-4971-8572-0c77f2a15437" name="us-gaap:TemporaryEquityLiquidationPreference" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal"><ix:nonFraction id="F_3dc783fa-3723-49ef-826a-f5d6b41f718a" contextRef="C_34e9355d-4428-4f62-b1ae-10943dbb5161" name="us-gaap:TemporaryEquityLiquidationPreference" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">85,496</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_20f9fc07-be3c-41c1-ad6f-480c8a60be75" contextRef="C_dfb1adde-bdce-4971-8572-0c77f2a15437" name="us-gaap:PreferredStockConvertibleSharesIssuable" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_6f6b2ea5-fd77-4882-9873-a5ad326c11ef" contextRef="C_34e9355d-4428-4f62-b1ae-10943dbb5161" name="us-gaap:PreferredStockConvertibleSharesIssuable" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">8,070,027</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Series B convertible preferred stock</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e3ddf0fb-b10d-47f4-b87f-eba7f31fbf33" contextRef="C_7d455504-a441-4ca1-b057-e166af9463cf" name="us-gaap:TemporaryEquitySharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_d9e38357-fddc-4835-9996-6be9563e2de5" contextRef="C_186c2b13-b928-42dd-8bd4-f169393b3424" name="us-gaap:TemporaryEquitySharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">58,157,824</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eb34a0fd-a3d7-411d-b089-a233a553bdae" contextRef="C_7d455504-a441-4ca1-b057-e166af9463cf" name="us-gaap:TemporaryEquitySharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_accd0682-45f2-45bc-aed7-524dbeebce6d" contextRef="C_7d455504-a441-4ca1-b057-e166af9463cf" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_98c214aa-dbbb-44c6-8e80-a11157260fb3" contextRef="C_186c2b13-b928-42dd-8bd4-f169393b3424" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_10848c46-2b23-44f4-8de3-c02e18803086" contextRef="C_186c2b13-b928-42dd-8bd4-f169393b3424" name="us-gaap:TemporaryEquitySharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">58,157,823</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_19ce5292-c883-41c0-9c5f-229ae7c6a749" contextRef="C_d1ca60e9-37da-42d1-8e5d-0809de6840b2" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal"><ix:nonFraction id="F_0a314790-4e22-4467-bb19-fe17cd2ff7c1" contextRef="C_002aeebf-8141-46fe-833a-b448a9ed53f3" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">100,060</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d9ae343f-ecd0-482c-a4ff-3b4a99752550" contextRef="C_7d455504-a441-4ca1-b057-e166af9463cf" name="us-gaap:TemporaryEquityLiquidationPreference" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal"><ix:nonFraction id="F_c8cbe552-e5fa-476d-ad1f-cc470753e5f6" contextRef="C_186c2b13-b928-42dd-8bd4-f169393b3424" name="us-gaap:TemporaryEquityLiquidationPreference" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">100,060</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7bbcbc88-c778-425e-906e-35f2629e3fdb" contextRef="C_7d455504-a441-4ca1-b057-e166af9463cf" name="us-gaap:PreferredStockConvertibleSharesIssuable" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_444d6f5c-ef95-4b84-bf43-bd740721bc15" contextRef="C_186c2b13-b928-42dd-8bd4-f169393b3424" name="us-gaap:PreferredStockConvertibleSharesIssuable" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,489,573</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5d2f38c1-eec2-47b4-b7a6-666e1ab29f72" contextRef="C_47a049b7-455a-448b-84ea-5e98846bad51" name="us-gaap:TemporaryEquitySharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_98c7c9ea-9d92-4594-bd45-b41120f86aa5" contextRef="C_e83f79f6-f924-4728-9c7c-5f1eb49397fe" name="us-gaap:TemporaryEquitySharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">143,653,546</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1d4506ab-2291-4b4a-9857-9fa82590d4fd" contextRef="C_47a049b7-455a-448b-84ea-5e98846bad51" name="us-gaap:TemporaryEquitySharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_9ebeeb2b-4a44-456e-9fb0-856843ad74ae" contextRef="C_47a049b7-455a-448b-84ea-5e98846bad51" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_4fd8d436-3e07-4a80-87e5-473f6234327d" contextRef="C_e83f79f6-f924-4728-9c7c-5f1eb49397fe" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_524c9c48-0d46-42a3-89f8-25f082fe19d9" contextRef="C_e83f79f6-f924-4728-9c7c-5f1eb49397fe" name="us-gaap:TemporaryEquitySharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">143,653,545</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9cd1b5b1-2a2e-4baf-8595-ba8a5433554c" contextRef="C_cfef4556-754f-4351-9370-c51c9711c2f4" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal"><ix:nonFraction id="F_3eed4896-30f2-4812-a957-469c3e93a13f" contextRef="C_ba4a9d48-b7a3-4350-9c16-becc8f228a5a" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">185,556</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_352ec02c-c16b-4e60-a6a0-a8c90a8fdc76" contextRef="C_47a049b7-455a-448b-84ea-5e98846bad51" name="us-gaap:TemporaryEquityLiquidationPreference" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal"><ix:nonFraction id="F_4b9f03c8-c0ec-4f14-94e2-fcfaf68ad4ad" contextRef="C_e83f79f6-f924-4728-9c7c-5f1eb49397fe" name="us-gaap:TemporaryEquityLiquidationPreference" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">185,556</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_03a06c1d-78dd-49bb-a78f-4e1132ccc54f" contextRef="C_47a049b7-455a-448b-84ea-5e98846bad51" name="us-gaap:PreferredStockConvertibleSharesIssuable" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_2050811b-6fae-4757-bfd5-9151f39378fd" contextRef="C_e83f79f6-f924-4728-9c7c-5f1eb49397fe" name="us-gaap:PreferredStockConvertibleSharesIssuable" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">13,559,600</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2022 and until the closing of the Company's IPO on November 7, 2023, the rights and privileges of the holders of the convertible preferred stock were as follows:</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Voting</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Holders of preferred stock were to vote together with the holders of common stock as a single class and on an as converted to common stock basis.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Dividends</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;The holders of shares of series B convertible preferred stock were entitled to receive, as declared by the Company&#8217;s Board of Directors, dividends per share at the rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d70710e6-df4d-4b33-aac7-b00ad5073c0c" contextRef="C_d1ca60e9-37da-42d1-8e5d-0809de6840b2" name="us-gaap:PreferredStockDividendRatePercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the issue price per share of series B convertible preferred stock, prior and in preference to any declaration or payment of any other dividend (other than dividends on shares of common stock payable in shares of common stock). After payment of dividends to the holders of shares of series B convertible preferred stock, the holders of shares of series A convertible preferred stock were entitled to receive, as declared by the Company&#8217;s Board of Directors, dividends per share at the rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fb5dc939-fa06-4bea-abf1-aea8c9252bcf" contextRef="C_7c1f486a-7a1e-460e-b332-6ac6ec1ac145" name="us-gaap:PreferredStockDividendRatePercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the issue price per share of series A convertible preferred stock, prior and in preference to any declaration or payment of any other dividend (other than dividends on shares of common stock payable in shares of common stock).</span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">128</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_ef9a575c-8906-4a9f-a622-4c2b7af57840_1" continuedAt="F_ef9a575c-8906-4a9f-a622-4c2b7af57840_2"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Deemed Liquidation Event</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Each of the following events was to be considered a &#8220;Deemed Liquidation Event&#8221; unless the holders of a majority of the outstanding shares of preferred stock and the holders of at least </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0c359780-11f1-4657-8c03-a5c8c60d1333" contextRef="C_6d391be5-485e-4203-9a45-2881c2767c0e" name="lxeo:PercentageOfOutstandingSharesForDeemedLiquidation" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">64</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the outstanding shares of series B convertible preferred stock elected otherwise by written notice to be sent to the Company at least five business days prior to the effective date of any such event; (a) a merger or consolidation in which the Company is a constituent party or a subsidiary of the Company was a constituent party and the Company issued shares of its capital stock pursuant to such merger or consolidation, except: any such merger or consolidation involving the Company or a subsidiary in which the shares of capital stock of the Company outstanding immediately prior to such merger or consolidation continued to represent, or were converted into or exchanged for shares of capital stock that represented, immediately following such merger or consolidation, at least a majority by voting power of the capital stock of (1) the surviving or resulting company; or (2) if the surviving or resulting company was a wholly owned subsidiary of another company immediately following such merger or consolidation, the parent company of such surviving or resulting corporation; (b) (1) the sale, lease, transfer, exclusive license or other disposition, in a single transaction or series of related transactions, by the Company or any subsidiary of the Company of all or substantially all the assets of the Company and its subsidiaries taken as a whole, or (2) the sale or disposition (whether by merger, consolidation or otherwise, and whether in a single transaction or a series of related transactions) of one or more subsidiaries of the Company if substantially all of the assets of the Company and its subsidiaries taken as a whole were held by such subsidiary or subsidiaries, except where such sale, lease, transfer, exclusive license or other disposition was to a wholly owned subsidiary of the Company; or (c) the Corporation&#8217;s completion of (1) a reverse merger into a public shell, or (2) a merger or consolidation with a special purpose acquisition company or its subsidiary in which the common stock (or similar securities) of the surviving or parent entity were publicly traded in a public offering pursuant to an effective registration statement under the 1933 Securities Act, as amended.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Liquidation Preference</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;In the event of any voluntary or involuntary liquidation, dissolution, or winding up of the Company, the holders of shares of series B convertible preferred stock were entitled to be paid out of the assets of the Company or, in the case of a Deemed Liquidation Event, out of the consideration payable to stockholders or the available proceeds, before any payment would be made to the holders of common stock or series A convertible preferred stock, an amount per share equal to the series B convertible preferred stock issue price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c16240dd-70cf-4d3d-a47a-186850086548" contextRef="C_7d455504-a441-4ca1-b057-e166af9463cf" name="us-gaap:TemporaryEquityLiquidationPreferencePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="6" format="ixt:num-dot-decimal">18.227267</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share (subject to adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization), plus any dividends declared but unpaid. If upon any such liquidation, dissolution or winding up of the Company or Deemed Liquidation Event, the assets of the Company available for distribution to its stockholders was insufficient to pay the holders of shares of series B convertible preferred stock the full amount to which they were entitled, the holders of shares of series B convertible preferred stock would have shared ratably in any distribution of the assets available for distribution in proportion to the respective amounts which would otherwise be payable in respect of the shares held by them upon such distribution if all amounts payable on or with respect to such shares were paid in full (the &#8220;Series B Liquidation Preference&#8221;).</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the event of any voluntary or involuntary liquidation, dissolution, or winding up of the Company, after payment of the Series B Liquidation Preference, the holders of shares of series A convertible preferred stock were entitled to be paid out of the assets of the Company or, in the case of a Deemed Liquidation Event, out of the consideration payable to stockholders or the available proceeds, before any payment shall be made to the holders of common stock or series A convertible preferred stock, an amount per share equal to the series A convertible preferred stock issue price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_618a14ab-9848-47c1-bcab-6adce4ccbf4d" contextRef="C_dfb1adde-bdce-4971-8572-0c77f2a15437" name="us-gaap:TemporaryEquityLiquidationPreferencePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="6" format="ixt:num-dot-decimal">10.594230</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share (subject to adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization), plus any dividends declared but unpaid. If upon any such liquidation, dissolution or winding up of the Company or Deemed Liquidation Event, the assets of the Company available for distribution to its stockholders was insufficient to pay the holders of shares of series A convertible preferred stock the full amount to which they were entitled, the holders of shares of series A convertible preferred stock would have shared ratably in any distribution of the assets available for distribution in proportion to the respective amounts which would otherwise be payable in respect of the shares held by them upon such distribution if all amounts payable on or with respect to such shares were paid in full (the &#8220;Series A Liquidation Preference&#8221;).</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the event that there were additional assets to be distributed after payment of the Series A Liquidation Preference and the Series B Liquidation Preference, the holders of the series A convertible preferred stock and series B convertible preferred stock would have shared in the distribution along with common stockholders as if the shares of the series A convertible preferred stock and series B convertible preferred stock had converted to common stock immediately prior to the distribution, up to an amount, (a) taken together with the Series A Liquidation Preference, not to exceed $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5b921a9a-bf5f-4c80-8be0-776000d60a17" contextRef="C_931de80a-517d-4a40-8171-722f60ac7671" name="us-gaap:TemporaryEquityLiquidationPreferencePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="6" format="ixt:num-dot-decimal">31.782691</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share with respect to the series A convertible preferred stockholders; and (b) taken together with the Series B Liquidation Preference, not to exceed $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_76b21a89-0f9f-4121-884f-e3fc120a181d" contextRef="C_5efc3a16-a0b9-4c5b-b4a7-4e7f9939e813" name="us-gaap:TemporaryEquityLiquidationPreferencePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="6" format="ixt:num-dot-decimal">54.681802</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share with respect to the series B convertible preferred stockholders.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Redemption</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;The preferred stock did not contain a mandatory redemption provision. Upon a deemed liquidation event, the holders would have been paid their preference amounts according to their priority. Remeasurement to redemption value would only have been required if a deemed liquidation event was probable.</span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">129</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_ef9a575c-8906-4a9f-a622-4c2b7af57840_2"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Conversion</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Upon either (a) the closing of the sale of shares of common stock to the public at a price of at least $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_adc6ec09-a3a4-45c4-b28c-ce723566646c" contextRef="C_bf7a1f3a-c205-45ba-9483-a2ad719c16b4" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="6" format="ixt:num-dot-decimal">22.784057</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the common stock), in a firm-commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended, resulting in at least $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f15f5439-cb4e-46ee-92a8-e63cb02b12cb" contextRef="C_266f5c3d-d979-4718-851c-88a44ef02c23" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">75,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of gross proceeds to the Company and in connection with the offering of the common stock listed for trading on the Nasdaq Stock Market&#8217;s National Market, the New York Stock Exchange or another exchange or marketplace approved by the Company&#8217;s Board of Directors, including the approval of at least </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2e7b5a7a-428f-4466-9114-b55b02e7b4f3" contextRef="C_d6e454da-2fb0-4d82-ae44-abd1e7e3c994" name="lxeo:QualifiedIpoMinimumNumberOfDirectorsApprovalRequired" unitRef="U_Director" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (2) preferred directors (a &#8220;Qualified IPO&#8221;), which occurred on November 7, 2023, or (b) the date and time, or the occurrence of an event specified by vote or written consent of the Noteholders, then (i) all outstanding shares of convertible preferred stock were to automatically be converted into shares of common stock, at the then effective conversion rate.</span></p></ix:continuation></div>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9b0fadde-3883-4e43-b5ab-b89bca749e5a" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8. Capital Stock</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024 and December 31, 2023, the Company&#8217;s amended and restated certificate of incorporation provided that the authorized capital stock of the Company was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2dec0de7-d2c4-4a9f-8b63-e396297c3751" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="us-gaap:CapitalUnitsAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_eb8c1b11-09c2-48d9-a08c-088c077df3c1" contextRef="C_28144b67-7dfd-494d-8133-75abcc735058" name="us-gaap:CapitalUnitsAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">510,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares consisting of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c9713f8c-ee39-4ec6-b254-6a5c790f338e" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_953153b6-752a-4c11-b9b0-bd87bf57878a" contextRef="C_28144b67-7dfd-494d-8133-75abcc735058" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">500,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5970e92f-5a91-4827-8d63-b55fa6de1612" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_c00257fd-06e2-4829-8f69-fa5c2fafc337" contextRef="C_28144b67-7dfd-494d-8133-75abcc735058" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">10,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of undesignated preferred stock, both with a par value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6c11d0c8-ba3b-4f3e-b58c-a689e4a0c715" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. As of December 31, 2024 and December 31, 2023, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_92a160cd-dc28-4ba3-91fa-1da70d038be1" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">33,079,209</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_229fa49d-967c-4ce3-adf0-d950dd01bac7" contextRef="C_28144b67-7dfd-494d-8133-75abcc735058" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">26,668,485</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares, respectively, of the Company's common stock authorized were issued, including </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c7ed91a2-3d34-4835-aef2-c12d81277fd6" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="lxeo:CommonStockSharesIssuedOnEarlyExerciseOfUnvestedStockOptions" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">7,948</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fde6dd5c-002c-4cf0-89d9-c6673a642034" contextRef="C_28144b67-7dfd-494d-8133-75abcc735058" name="lxeo:CommonStockSharesIssuedOnEarlyExerciseOfUnvestedStockOptions" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">22,107</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares, respectively, that were legally issued upon the early exercise of unvested stock options and that are excluded from the number of shares outstanding until the right to repurchase subsequently lapses upon vesting. Until the closing of the Company&#8217;s IPO on November 7, 2023, the voting, dividend and liquidation rights of the holders of the Company&#8217;s common shares were subject to and qualified by the rights, powers and preferences of the holders of the convertible preferred stock set forth in Note 7. The Company repurchased a total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f4cbd2fe-aa06-4202-978d-933bd4009907" contextRef="C_9d082257-9ef3-44bf-b671-47a3b444bcf4" name="us-gaap:StockRepurchasedDuringPeriodShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,827</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock issued pursuant to the early exercise of stock options granted under the 2021 Plan for a total of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c9ef02d4-64d9-46f0-9a4f-1cad6353e6f7" contextRef="C_9d082257-9ef3-44bf-b671-47a3b444bcf4" name="us-gaap:StockRepurchasedDuringPeriodValue" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">17,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> during the year ended December 31, 2024, which was recorded to treasury stock in the Company's balance sheet (see Note 9). Each common share entitles the holder to one vote on all matters submitted to a vote of the Company&#8217;s stockholders. Common stockholders are entitled to receive dividends, if any, as may be declared by the Company&#8217;s Board of Directors and were subject to the preferential dividend rights of the convertible preferred stock until the closing of the Company's IPO. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_42650972-aa78-444a-b9c2-db1fba0de3e0" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:DividendsCommonStockCash" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> cash dividends have been declared or paid by the Company.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upon the declaration of effectiveness of the Company&#8217;s IPO registration statement on November 2, 2023, the Company's then outstanding convertible SAFE Note automatically converted into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6c6fb810-f021-4b79-b21e-0c064238c93c" contextRef="C_90b3b8b5-08ff-4ed8-b03a-36a19e205081" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">411,815</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock (see Note 6). Upon the closing of the Company's IPO on November 7, 2023, the Company issued and sold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4a61475a-372a-4ac2-8614-fad1fd90e43b" contextRef="C_3a1be116-5c64-4576-af28-6c9bb1f6ae39" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">9,090,910</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of its common stock, and subsequently, the underwriters partially exercised their associated 30-day option to purchase additional shares of common stock with </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0e6f8dff-2d32-44d7-852c-a027d137b6d7" contextRef="C_09b75305-e3e0-435b-b2a6-50f4050afab2" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,048,746</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> additional shares issued. The net proceeds to the Company from the IPO and subsequent partial exercise of the underwriters&#8217; 30-day option to purchase additional shares were approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8442b192-46e4-4a8e-877a-cfe60e67c19c" contextRef="C_44dd3996-14be-4820-b581-6281744e49e6" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">100.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million based on the initial offering price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a1855e99-1ef9-4ec5-81e3-701e251aa2bb" contextRef="C_74419331-e290-447a-86d3-c0fb520fc7bc" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">11.00</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, after deducting underwriting discounts, commissions and offering expenses totaling $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0f3a1470-5db7-4679-b2f2-8cc55ee10530" contextRef="C_3a1be116-5c64-4576-af28-6c9bb1f6ae39" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">11.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. Also upon the closing of the Company's IPO on November 7, 2023, all </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2552f638-c422-48ca-b867-46ea07c8d410" contextRef="C_dfb1adde-bdce-4971-8572-0c77f2a15437" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">85,495,722</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> then outstanding shares of the Company&#8217;s series A convertible preferred stock and all </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6d03292c-50d3-4a21-a9df-0d9701422778" contextRef="C_7d455504-a441-4ca1-b057-e166af9463cf" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">58,157,823</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> then outstanding shares of the Company&#8217;s series B convertible preferred stock converted into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_35266470-1c0b-42a5-a802-8a8032bcb060" contextRef="C_8e099335-d590-43f9-972a-d06c24fef007" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">8,070,027</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d71dea99-795c-41db-8d62-d900b90f22ae" contextRef="C_7c6c7513-7f64-4c68-bcf5-17a805d1e6fe" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">6,386,337</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock, respectively, including </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ee26de8b-3ec8-4222-bc2e-5bf73e481cec" contextRef="C_ff876ac5-7ddc-447a-ba80-cd3fc5d96d6b" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">896,764</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock issued as a result of series B convertible preferred stock antidilution provisions. On March 11, 2024, the Company entered into a common stock purchase agreement to issue and sell an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_65f44f6a-db40-4d0c-ab36-3ec12b51ef51" contextRef="C_ec3ec1bb-68cc-4820-9297-a6c0c881028e" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">6,278,905</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of its common stock at a price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4557c4da-8455-4557-9de5-7641ba598c2a" contextRef="C_11aac366-2c9d-4773-bc55-7994d2ee9dd0" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">15.13</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, in a private placement that closed on March 13, 2024 (the "Private Placement"). The gross and net proceeds received from the Private Placement were approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4a4cd17a-9958-480f-87c1-d9b410fbd0ee" contextRef="C_4d93aa08-044d-4a0a-8ae0-08a443ffa6ea" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">95.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fa3580e7-f8a6-4732-9a0f-14f2b468c832" contextRef="C_4d93aa08-044d-4a0a-8ae0-08a443ffa6ea" name="lxeo:NetProceedsReceivedFromPrivatePlacement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">88.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, after deducting approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0d4378d6-8adb-46cc-a0e7-804c2333b669" contextRef="C_4d93aa08-044d-4a0a-8ae0-08a443ffa6ea" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of commissions and other offering costs.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6c8156cd-272e-496f-b66b-7579df06cfa4" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:ScheduleOfStockholdersEquityTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company had reserved the following number of shares of common stock for the exercise of outstanding stock options, settlement of outstanding RSUs, and future issuance of stock-based awards:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:86.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:62.12%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:15.92%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:15.96%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options to purchase shares of common stock under the 2021 Plan and 2023 Plan</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7ec077b5-2c43-4e57-824b-ba08636ae120" contextRef="C_b1a96dae-b4d3-465e-8d90-5f13defcc31f" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,457,918</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_242aee94-bf9b-4858-a7e7-7668684341c1" contextRef="C_7381b4b3-de2c-4fd9-b6c4-d8e5a85475c9" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,415,740</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">RSUs subject to settlement in shares of common stock under the 2023 Plan</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5ad3ce9e-dbcd-4d7f-9b54-b94f8c77ac21" contextRef="C_d965f156-2881-4f62-9e05-2ce8f77a88cb" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">266,300</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares available for issuance under the 2023 Plan</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e5caa94f-a02d-4e5c-8b23-63db21f80ada" contextRef="C_19581a58-f4b4-41e4-85f3-1dff41c48718" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,185,328</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1c2b3431-3fb6-4581-846c-ab7b6446b8c9" contextRef="C_23e9fdcf-7d72-4c30-b945-044420610762" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,293,816</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares available for issuance under the 2023 ESPP</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4db58a96-b830-4f56-b057-619f4b148c10" contextRef="C_a6bbca2b-aa76-4540-b619-c2e288370970" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">505,284</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5dd4ce48-6dea-4bc2-971e-f00c11b9fca5" contextRef="C_55e7577e-8daf-46eb-b39f-2063a2405357" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">238,600</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total shares of common stock reserved for future issuance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_658c1d6a-3303-4566-a7a6-2eafde94e0e6" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">6,414,830</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3bc4d8db-4a86-4fe0-b97c-86ac4a5a2e27" contextRef="C_28144b67-7dfd-494d-8133-75abcc735058" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">4,948,156</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">130</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:nonNumeric id="F_3d539449-7dcc-4f1f-9b92-feac14ab54a5" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true" continuedAt="F_3d539449-7dcc-4f1f-9b92-feac14ab54a5_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9. Stock-based Compensation</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In February 2021, the Company adopted the 2021 Plan for the issuance of stock options granted to the Company&#8217;s key directors, officers, employees and consultants, as a means to secure the benefits arising from capital stock ownership. In connection with the Company&#8217;s IPO in November 2023, the Company adopted the 2023 Equity Incentive Plan (the &#8220;2023 Plan&#8221;) and the 2023 ESPP (together with the 2021 Plan and 2023 Plan, the &#8220;Plans&#8221;) for the issuance of equity awards granted to the Company's key directors, officers, employees, and consultants, and for the issuance of shares purchased under the 2023 ESPP to the Company's employees, respectively, as a means to secure the benefits arising from capital stock ownership. The purposes of the Plans are to promote the alignment of the interests of key directors, officers, employees, and consultants with the success of the Company and to provide compensation opportunities to attract, retain and motivate directors, officers, employees, and consultants of the Company.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s Board of Directors adopted the 2023 Plan and the 2023 ESPP in October 2023, and the Company&#8217;s stockholders approved the 2023 Plan and the 2023 ESPP in October 2023. In connection with the IPO, the Company&#8217;s 2023 Equity Incentive Plan (the &#8220;2023 Plan&#8221;) and its 2023 Employee Stock Purchase Plan (the &#8220;2023 ESPP&#8221;) became effective. Upon the effectiveness of the 2023 Plan and the 2023 ESPP:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dd7b85bd-5f7e-42ab-a718-da88af99a59b" contextRef="C_5e1419ce-c719-45db-9032-ac6f99fec990" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">582,699</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock reserved for future issuance under the 2021 Plan ceased to be available for issuance and were added to, and became available for issuance under, the 2023 Plan, and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a842d8ab-13d5-4927-89c4-1d823abf27bb" contextRef="C_5b2a51f7-c997-4cda-9d61-3d1f32f1e815" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> further grants will be made under the 2021 Plan; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_12052bd2-4d44-483d-a3f3-18621d284711" contextRef="C_2c640ac0-f0e4-4b44-953f-372c68c1666b" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,803,980</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock were reserved for future issuance under the 2023 Plan, in addition to the shares of common stock reserved for issuance under the 2021 Plan that were added to the shares reserved under the 2023 Plan; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_825fdebb-2d1d-42bc-b02d-5acd19aba4c7" contextRef="C_44f34368-c2ff-4b64-9e18-4ee6525fb195" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">238,600</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock were reserved for future issuance under the 2023 ESPP.</span></div></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upon adoption, the maximum number of shares of common stock that may be issued under the 2023 Plan was initially </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7a093fdb-e8bd-431d-835a-745c311c1115" contextRef="C_2c640ac0-f0e4-4b44-953f-372c68c1666b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">4,737,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares, which was approximately the sum of (i) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e3adfe3c-d6cf-403b-a686-5234b41fa799" contextRef="C_2c640ac0-f0e4-4b44-953f-372c68c1666b" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,803,980</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> new shares, plus (ii) the 2021 Plan&#8217;s available reserve, plus (iii) the number of returning shares, if any, upon the cancellation or forfeiture of equity awards that are outstanding under the 2021 Plan. In addition, the number of shares of common stock reserved for issuance under the 2023 Plan will automatically increase on January 1 of each year, beginning on January 1, 2024, and continuing through and including January 1, 2033, by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7732807f-5b70-472b-8df2-a2c8f607a982" contextRef="C_2db6ae14-94d8-4061-8201-63bc8341dd14" name="lxeo:PercentageOfAutomaticallyIncreaseInAvailableSharesOfCommonStockOnBeginningOfCachCalendarYear" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the total number of shares of common stock outstanding on December 31 of the immediately preceding calendar year, or a lesser number of shares determined by the Company&#8217;s Board of Directors prior to the applicable January 1. Upon adoption, the maximum number of shares of common stock that may be issued under the 2023 ESPP was initially </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c130a77a-c4b6-4b51-8afd-fa8e52575ed9" contextRef="C_44f34368-c2ff-4b64-9e18-4ee6525fb195" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">238,600</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares. The number of shares of common stock reserved for issuance under the 2023 ESPP will automatically increase on January 1 of each calendar year, beginning on January 1, 2024 and continuing through and including January 1, 2033, by the lesser of (i) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_264ad72c-82ab-48a8-b9b6-b4a811c100d1" contextRef="C_d54dc3c6-3447-4e53-b661-49e8beab972a" name="lxeo:PercentageOfAutomaticallyIncreaseInAvailableSharesOfCommonStockOnBeginningOfCachCalendarYear" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the total number of shares of capital stock outstanding on December 31 of the preceding calendar year, (ii) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_963ad2f4-ece8-47e0-8a91-43f22d167ea9" contextRef="C_386c356b-4350-4ef6-bbc7-35471297e6b0" name="lxeo:NumberOfSharesAutomaticallyIncreaseInAvailableSharesOfCommonStockUnderPlan" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">477,200</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares and (iii) a number of shares determined by the Company&#8217;s Board of Directors. Shares subject to purchase rights granted under the 2023 ESPP that terminate without having been exercised in full will not reduce the number of shares available for issuance under the 2023 ESPP.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On January 1, 2024, the number of shares of common stock reserved for issuance under the 2023 Plan and the 2023 ESPP automatically increased by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1f3fbf41-c79b-4ae3-93a3-b22d80c9180a" contextRef="C_889faa80-3bbf-40d1-b770-591485567a8d" name="lxeo:IncreaseInCommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,333,424</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dff8c546-8c4b-478c-93e3-0e401b8c7be5" contextRef="C_2a226df6-55ca-4590-b4f4-0e51d8f169f6" name="lxeo:IncreaseInCommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">266,684</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares, respectively, to totals of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c7257481-b21e-404d-977c-758952348994" contextRef="C_889faa80-3bbf-40d1-b770-591485567a8d" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">6,070,424</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_92aebde3-3ce1-4138-bf8e-0d3209d6c8d0" contextRef="C_2a226df6-55ca-4590-b4f4-0e51d8f169f6" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">505,284</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares, respectively. On January 1, 2025, the number of shares of common stock reserved for issuance under the 2023 Plan and the 2023 ESPP automatically increased by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0ea8af13-de5d-4761-b344-294543d65142" contextRef="C_b4989bb1-3d29-41aa-910d-bd20c1974008" name="lxeo:IncreaseInCommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,653,960</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ff72825b-5a3a-41ca-af89-92dd1ad9c922" contextRef="C_0f4466dd-9ea9-4c34-a1ae-2fdff5adc7ed" name="lxeo:IncreaseInCommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">330,792</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares, respectively, to totals of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b24e6010-3e2f-4d34-bebe-392b1b416ef1" contextRef="C_b4989bb1-3d29-41aa-910d-bd20c1974008" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">7,724,384</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_976426a3-d244-4bbe-a44f-b6ac207f1635" contextRef="C_0f4466dd-9ea9-4c34-a1ae-2fdff5adc7ed" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">836,076</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares, respectively. As of December 31, 2024, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_67e4def3-c251-4180-ab89-9abdcd47d29e" contextRef="C_63e8ef1c-8500-4aca-9829-40a638535f8d" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,185,328</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_055ae26e-c672-416b-a509-3824f40bf7de" contextRef="C_794eac83-f22b-40f0-ab3d-8bc9174bde90" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">505,284</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares were available for future issuance under the 2023 Plan and 2023 ESPP, respectively. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2293e07a-be0c-4327-96aa-103ae647666e" contextRef="C_794eac83-f22b-40f0-ab3d-8bc9174bde90" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares have been issued under the 2023 ESPP through December 31, 2024.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock option activity</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock options granted under the 2021 Plan are issued from new shares upon exercise, have a contractual term of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_71ee80bf-ce06-4bb1-9516-1dca932cf4e4" contextRef="C_6c352529-96a0-4c56-b6f7-beafae1427a8" name="lxeo:ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualTermGrantDate" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10 years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from grant date, and generally (i) are subject to requisite service requirements, (ii) </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9cb6e0ca-2a11-4d86-89f7-a97b2b6dcb21" contextRef="C_c679f25f-cc6a-43c7-8227-e208b67e0722" name="lxeo:ShareBasedCompensationPaymentDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">vest over a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_dbb5911a-0173-49d7-8bbe-72b5e7774fbd" contextRef="C_6c352529-96a0-4c56-b6f7-beafae1427a8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">four-year</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> period with </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a75d0835-2f10-40fe-bcb4-dfbcb9acb87c" contextRef="C_6c352529-96a0-4c56-b6f7-beafae1427a8" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">25</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the options granted vesting after one year and the remainder vesting in equal monthly installments over the following 36 months</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and (iii) allow for early exercise subject to repurchase. Stock options granted under the 2021 Plan to certain of the Company&#8217;s non-employees vest in equal monthly installments over a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e70bfffb-6e57-4d42-ab0c-c483c339deac" contextRef="C_6c352529-96a0-4c56-b6f7-beafae1427a8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">four-year </span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">period or vested upon the achievement of a certain milestone event. The Company repurchased a total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_106b2a78-cfbb-448e-9c1d-e91db6f0d62c" contextRef="C_9d082257-9ef3-44bf-b671-47a3b444bcf4" name="us-gaap:StockRepurchasedDuringPeriodShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,827</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock issued pursuant to the early exercise of stock options granted under the 2021 Plan for a total of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_09f3a5ab-764b-45e8-9482-28475322d14a" contextRef="C_aaf7b4cc-4609-41bc-a23c-cf54d6116e53" name="us-gaap:StockRepurchasedDuringPeriodValue" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">17,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> during the year ended December 31, 2024, which was recorded to treasury stock in the Company's balance sheet (see Note 8).</span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">131</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_3d539449-7dcc-4f1f-9b92-feac14ab54a5_1" continuedAt="F_3d539449-7dcc-4f1f-9b92-feac14ab54a5_2"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock options granted under the 2023 Plan through December 31, 2024 are issued from new shares upon exercise, have a contractual term of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_22f57384-6a70-451a-9229-c748a7c89c54" contextRef="C_ae668a8e-dcdc-48f6-9c7d-cd99b945d79a" name="lxeo:ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualTermGrantDate" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10 years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from grant date, and generally (i) are subject to requisite service requirements, and (ii) </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0d22ccb1-03ce-4c77-88f6-ad2437c1549f" contextRef="C_ae668a8e-dcdc-48f6-9c7d-cd99b945d79a" name="lxeo:ShareBasedCompensationPaymentDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">vest over a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3de0020c-2638-4261-a4bd-d1b6140cac8b" contextRef="C_ae668a8e-dcdc-48f6-9c7d-cd99b945d79a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">four-year</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> period with </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eb1de0a8-4ff6-4831-93d5-1bb9f6e973a4" contextRef="C_ae668a8e-dcdc-48f6-9c7d-cd99b945d79a" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">25</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the options granted vesting after one year and the remainder vesting in equal monthly installments over the following 36 months</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Stock options granted under the 2023 Plan to certain of the Company's non-employee directors vest in equal annual installments over a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6898b935-4e92-4bac-ba66-32b6283bb499" contextRef="C_460d7490-ff50-4c44-98f4-b0211c51d98c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three-year</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> period or over a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bba13ef2-e359-4987-ad65-602bd0872114" contextRef="C_a65a8fba-bdff-47f7-a790-76ebb3dcb9f8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">one-year</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> period.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6df3d892-aa6b-437c-bd04-1b6669102044" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the stock option activity under the 2021 Plan and the 2023 Plan for the years ended December 31, 2024 and December 31, 2023 (weighted-average remaining contractual term (in years) is not stated in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:44.791%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.878%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.38%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.298%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.878%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.38%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.398%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>Average<br/>Exercise Price</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate<br/>Intrinsic</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(per share)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in years)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding as of December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f8becc96-2daa-44cd-93f1-88a5bc4f7c23" contextRef="C_9a05326c-b178-412f-9312-a4d581f2c9d7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,415,740</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2aee35c7-eba1-49b6-96cc-b970c8582a84" contextRef="C_9a05326c-b178-412f-9312-a4d581f2c9d7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">8.32</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_b5094625-4dd4-4b90-b5b6-d199fbc055dc" contextRef="C_7042155d-e81e-427a-88f0-e247950d7a4c" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.83</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_89ceb185-041a-406a-bccc-78e7e3228461" contextRef="C_9a05326c-b178-412f-9312-a4d581f2c9d7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,689</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2844795f-14ac-4317-9b87-a9f38679e304" contextRef="C_8ca9fee4-3e70-406e-b516-57586deaa558" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,520,330</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7f49589f-a3cc-4566-8d1d-083a0f26f31f" contextRef="C_8ca9fee4-3e70-406e-b516-57586deaa558" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">15.60</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a557552b-a892-4d46-872e-b26be4c94d8e" contextRef="C_8ca9fee4-3e70-406e-b516-57586deaa558" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">135,646</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7284f39d-edca-4dfe-8493-f0c642755666" contextRef="C_8ca9fee4-3e70-406e-b516-57586deaa558" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">3.62</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2f65ab54-a251-4e56-aa1d-22408c345d75" contextRef="C_8ca9fee4-3e70-406e-b516-57586deaa558" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,288</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_12e588d6-2bf5-4d3b-bbde-b6111b850264" contextRef="C_8ca9fee4-3e70-406e-b516-57586deaa558" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">272,276</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_92bca7e5-0530-4222-bc5f-733924449d1b" contextRef="C_8ca9fee4-3e70-406e-b516-57586deaa558" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">11.40</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expired</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f3d7e8b6-1aa2-41e4-87a8-efcdc8affc57" contextRef="C_8ca9fee4-3e70-406e-b516-57586deaa558" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">70,230</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aff59ccf-873a-4024-a4e3-cc58ad3adf96" contextRef="C_8ca9fee4-3e70-406e-b516-57586deaa558" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">12.94</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding as of December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cf69608a-2459-490b-bb8b-193d26ef79e8" contextRef="C_17a6e9db-02db-43c5-9308-865a99b44dc2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,457,918</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_accfd193-64e4-45ff-98b7-6fedb2b2e3f0" contextRef="C_17a6e9db-02db-43c5-9308-865a99b44dc2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">11.37</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_c993d7d5-91c5-48b1-ba67-c0d96ec34ef5" contextRef="C_8ca9fee4-3e70-406e-b516-57586deaa558" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.18</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3f1fc462-52e9-462c-b83e-bf3b3615b2fa" contextRef="C_17a6e9db-02db-43c5-9308-865a99b44dc2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,851</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options exercisable at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ebbc96f4-d827-4cb9-b674-82ff0851dceb" contextRef="C_17a6e9db-02db-43c5-9308-865a99b44dc2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,954,937</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a3b81aba-9448-493d-abf0-a828b50edb0d" contextRef="C_17a6e9db-02db-43c5-9308-865a99b44dc2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">8.16</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_a571cd17-9d3c-4a8c-959c-230832b349ed" contextRef="C_8ca9fee4-3e70-406e-b516-57586deaa558" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.38</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3c6f4f10-763c-4df4-8446-634f67133ca3" contextRef="C_17a6e9db-02db-43c5-9308-865a99b44dc2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,851</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The weighted average grant date fair value of options granted during the years ended December 31, 2024 and 2023 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1f4d6fe7-c66e-4256-93d6-4c803bf8f300" contextRef="C_d210b17b-f2c2-4a07-9b34-0371db6164dd" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">11.58</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a026973f-ae13-44c0-8b8d-d0817d34a03d" contextRef="C_d4ba692f-b7d0-4af9-9603-697859726ab1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">9.89</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, respectively.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#8217;s common stock for those stock options that had exercise prices lower than the fair value of the Company&#8217;s common stock. The total intrinsic value of stock options exercised during the year ended December 31, 2023 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9c062f66-2765-4a69-83c6-95341ffa71cd" contextRef="C_d4ba692f-b7d0-4af9-9603-697859726ab1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The total grant date fair values of stock options vested during the years ended December 31, 2024 and December 31, 2023 were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d26c6341-9dbc-4c01-bcd5-648e6701c0cc" contextRef="C_d210b17b-f2c2-4a07-9b34-0371db6164dd" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_984c6220-cc39-4dae-8b94-94eaf1e663b1" contextRef="C_d4ba692f-b7d0-4af9-9603-697859726ab1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_02462a73-0e6c-43a3-b078-90557295626d" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company estimated the fair value of options granted using a Black-Scholes option pricing model with the following assumptions presented on a weighted average basis during the year ended December 31, 2024 (not stated in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:61.96%;box-sizing:content-box;"/>
        <td style="width:1.44%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:15.58%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.44%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:15.58%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dc0b5a8f-e23b-40ca-a1a3-839d2779e259" contextRef="C_d210b17b-f2c2-4a07-9b34-0371db6164dd" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.14</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7faf58d3-c847-4ffa-8483-f034171ef31f" contextRef="C_d4ba692f-b7d0-4af9-9603-697859726ab1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">3.43</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_2793de8a-3380-4039-93f0-3873aedbccd0" contextRef="C_d210b17b-f2c2-4a07-9b34-0371db6164dd" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.02</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_f0a22b2b-41d4-49d5-aaf2-e9caec59f884" contextRef="C_d4ba692f-b7d0-4af9-9603-697859726ab1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.78</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_77491c10-e5ab-427c-8d31-ef1bada6358b" contextRef="C_d210b17b-f2c2-4a07-9b34-0371db6164dd" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">85.85</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5a8122a2-6d17-423c-843d-b0c8d0f5b82c" contextRef="C_d4ba692f-b7d0-4af9-9603-697859726ab1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">67.59</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d11736e2-55aa-471f-bb7b-d751aa02a3e2" contextRef="C_d210b17b-f2c2-4a07-9b34-0371db6164dd" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">0.00</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d8f98218-f3b8-4feb-8d8f-d3d89540c18a" contextRef="C_d4ba692f-b7d0-4af9-9603-697859726ab1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">0.00</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The expected dividend yields are </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2bbb0485-74a7-4696-916f-f22591aa7c27" contextRef="C_d210b17b-f2c2-4a07-9b34-0371db6164dd" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">0.00</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% as the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024 there was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ee223627-6d22-48cf-8abb-3aa72cdd1e4f" contextRef="C_642842bb-c457-4819-9738-9093909922ea" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">13.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of unrecognized stock-based compensation expense related to stock options estimated to be recognized over a weighted-average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f22895cc-cead-42d8-aa09-f57b17efacfd" contextRef="C_d210b17b-f2c2-4a07-9b34-0371db6164dd" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.62</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">RSU activity</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RSUs granted under the 2023 Plan through December 31, 2024 generally (i) are subject to requisite service requirements, and (ii) </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9ebb737d-74b3-404f-bc09-2d7063c0db79" contextRef="C_f6d073df-b45c-4611-a81b-0bd39b099fbf" name="lxeo:ShareBasedCompensationPaymentDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">vest over a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ef35818b-f96f-473f-80e9-184ac37ed57f" contextRef="C_f6d073df-b45c-4611-a81b-0bd39b099fbf" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">four-year</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> period with </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2ddbed77-3cbf-4409-985f-d029d8317223" contextRef="C_f6d073df-b45c-4611-a81b-0bd39b099fbf" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">25</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the RSUs vesting after approximately one year and the remainder vesting in equal quarterly installments over the following 12 quarters</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">132</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_3d539449-7dcc-4f1f-9b92-feac14ab54a5_2"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_15e40e10-4717-4293-bbb0-a248b5a617fd" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the RSU activity under the 2023 Plan for the year ended December 31, 2024:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:61.96%;box-sizing:content-box;"/>
        <td style="width:1.44%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:15.58%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.9%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:15.120000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>Average<br/>Grant Date Fair Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(per share)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested as of December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2af97535-5136-4c3e-ae50-2188c3bb393e" contextRef="C_afe980af-4f26-4fd3-8f3e-e44a3e233ab1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">287,078</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a7825116-4c85-46cc-8882-02a4c414bccb" contextRef="C_afe980af-4f26-4fd3-8f3e-e44a3e233ab1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">15.52</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fa02c6c1-e6b7-4e7c-9024-19cd4b729da0" contextRef="C_afe980af-4f26-4fd3-8f3e-e44a3e233ab1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">20,778</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d4ee3518-ce82-4834-b13c-d4b1f4f63b02" contextRef="C_afe980af-4f26-4fd3-8f3e-e44a3e233ab1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">14.65</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested as of December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1a2a8801-b2eb-453c-87aa-a81a10f15a03" contextRef="C_98dbb090-8617-48e2-9f19-11212333ce32" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">266,300</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_22015f1a-fbff-4714-ba28-d9d99e1244ad" contextRef="C_98dbb090-8617-48e2-9f19-11212333ce32" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">15.59</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024 there was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b7feb7aa-ff60-4b2c-88b1-2da1773622b5" contextRef="C_818a9569-5179-4332-bce6-97002fa8dd65" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of unrecognized stock-based compensation expense related to RSUs estimated to be recognized over a weighted-average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_87370e41-cf07-40e3-ac3d-fda61826df7a" contextRef="C_465c4136-b851-42be-84ee-27ed04fe8539" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.28 </span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">years.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Employee Stock Purchase Plan</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the 2023 ESPP, eligible employees may purchase shares of the Company's common stock through payroll deductions at a price equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7c7ca657-751a-4846-a350-4072639bc4b0" contextRef="C_8821cec2-12fd-4f69-a047-478fca32226c" name="lxeo:PayrollDeductionsAtPrice" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">85</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the lower of the fair market values of the stock as of the beginning or the end of six-month offering periods. Employees may not purchase more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eef80bbf-c4bc-4012-a26d-6d69cbcdc5dd" contextRef="C_63208a9b-1a99-4da2-85ef-0801d8013b63" name="lxeo:CommonStockDuringOfferingPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">6,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company's common stock during any offering period. As of and during the years ended December 31, 2024 and December 31, 2023, stock-based compensation expense and the fair value of unearned employee stock ownership plans related to the 2023 ESPP was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9002bbdd-f7fb-412c-b76b-6690726e5a02" contextRef="C_8821cec2-12fd-4f69-a047-478fca32226c" name="lxeo:FairValueOfUnearnedEmployeeStockOwnershipPlans" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_58c2cac4-6fb2-4325-a81a-8889af0ebe0d" contextRef="C_44325f11-2b42-4650-93e1-0c060ce8130d" name="lxeo:FairValueOfUnearnedEmployeeStockOwnershipPlans" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t material.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock-based compensation expense</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f5be0796-0b80-4dd7-bc64-d517c69c3816" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-based compensation expense was classified as follows in the Company&#8217;s statements of operations and comprehensive loss:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:62.072%;box-sizing:content-box;"/>
        <td style="width:1.86%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:15.103%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.86%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:15.103%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development expense</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c9c3043a-274d-4f48-b758-ab302ccb1219" contextRef="C_db4d6fe7-17ff-4f4e-803b-2c15cda55624" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,001</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a3ecbc8e-6af7-4e2c-98b4-ee9aaea411b6" contextRef="C_18e0f1c1-de91-4bc1-b5ce-39772b43d1e3" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,751</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative expense</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_01da58d8-7c4d-49c8-9d51-83c6bbda97ad" contextRef="C_f22d9e2e-1a87-48b1-bd28-4d0a0a5afdfb" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,473</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f2ec6d86-5515-4e0b-bf00-565658871f0b" contextRef="C_3b4c1dc7-9d04-44ef-97e9-98e10c0a6e4e" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,292</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total stock-based compensation expense</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_06132283-3e01-47a7-b655-8769d72766be" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,474</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0634fc32-2a15-4b0e-aa1d-10d662ce84d7" contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,043</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:continuation></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_001dca8e-608b-4e55-a7d1-03cac0b67b51" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:EarningsPerShareTextBlock" escape="true"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10. Net Loss per Share</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_48ea2ae8-d38d-4744-9b07-1774363f928f" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic and diluted net loss per common share attributable to common stockholders was calculated as follows:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:63.247%;box-sizing:content-box;"/>
        <td style="width:1.84%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:14.537%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.84%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:14.537%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Numerator:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss attributable to common stockholders</span></p></td>
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ec1f79cc-f567-49fb-b651-ee525602b4b2" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">98,333</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f623000c-a438-4ab6-a662-b318c655e8f0" contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">66,394</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Denominator:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average common shares outstanding, basic and diluted</span></p></td>
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bd5b8c5b-9841-4fbc-8336-7b31b2b71b3c" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_82febfcf-87f2-449b-ab72-e4bd69508291" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">31,787,491</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f092e840-046e-41d4-9eb5-e0acc859d9fb" contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_8c464008-5127-42ef-af30-141ad7a24f46" contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">5,354,368</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per share attributable to common stockholders, basic and diluted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cac7f9d2-5d06-41d5-859e-fc4c7ac0eb32" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_456675f1-8db4-40f1-babe-9670b7596317" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">3.09</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ff862a2c-e160-43af-afaa-0b7265449c23" contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_15e9be39-3237-40d4-9d00-1de0bc494c9b" contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">12.40</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">133</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:nonNumeric id="F_3b6333a7-4e1f-4e36-b65d-7f79e390ba07" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true" continuedAt="F_3b6333a7-4e1f-4e36-b65d-7f79e390ba07_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11. Income Taxes</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c332914d-d577-4d7b-b5c1-27928be876b1" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A reconciliation of the Company's statutory income tax rate to the Company&#8217;s effective income tax rate is as follows for the years ended December 31, 2024, and December 31, 2023:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:91.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.357%;box-sizing:content-box;"/>
        <td style="width:2.03%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:17.435000000000002%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:2.03%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:17.148%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Federal statutory rate</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e398e903-a766-45a1-91ec-d62bd638567c" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">21.00</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_34d47b1a-6711-4b7a-8204-88817fe7148f" contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">21.00</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State Taxes, net of federal benefit</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e6fec0f5-afe5-4df6-af8f-8b2d6e2eca58" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">10.72</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_13a543f5-7cf6-468c-8c54-807f562e9d5b" contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">10.80</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e0d56f88-7de3-43f4-bb9e-06fb667b4e24" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="4" sign="-" format="ixt:num-dot-decimal">33.98</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6feae12c-fdfc-4f21-b426-8ee205d66d4e" contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="4" sign="-" format="ixt:num-dot-decimal">36.12</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Permanent differences</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0c0591de-981c-4f0b-a892-f48d42514963" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" unitRef="U_pure" scale="-2" decimals="4" sign="-" format="ixt:num-dot-decimal">0.51</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1e22dfd9-2f03-42ac-88ff-cc54e970d5d5" contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" unitRef="U_pure" scale="-2" decimals="4" sign="-" format="ixt:num-dot-decimal">0.36</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax credits</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_61756e3d-86fc-4e6e-8dc2-53716eaca317" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" unitRef="U_pure" scale="-2" decimals="4" sign="-" format="ixt:num-dot-decimal">3.73</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_03fc9d1e-0120-4ecc-b64d-5b3f09d1e389" contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" unitRef="U_pure" scale="-2" decimals="4" sign="-" format="ixt:num-dot-decimal">4.80</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a197c325-65c5-4a89-b9f1-edd8177a5c78" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" unitRef="U_pure" scale="-2" decimals="4" sign="-" format="ixt:num-dot-decimal">0.96</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eb53aee9-231d-4767-b511-463406bd66ee" contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" unitRef="U_pure" scale="-2" decimals="4" sign="-" format="ixt:num-dot-decimal">0.12</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Effective income tax rate</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_82d3a3d7-e829-4e60-9ae1-fe1e3f05fb87" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">0.00</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6932a1c5-1bfa-4e11-a013-ddd11e6386db" contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">0.00</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_895193cc-0f01-47ba-9880-64f51829bdcc" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The principal components of the Company's deferred tax assets and liabilities at December 31, 2024 and December 31, 2023 are as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.688%;box-sizing:content-box;"/>
        <td style="width:2.063%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:17.259%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:2.063%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:16.926%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e5a244d0-e0e7-483d-8e51-59ac89a7cc04" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,295</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_88bdd709-6147-4a06-8960-b3deb80bc13f" contextRef="C_28144b67-7dfd-494d-8133-75abcc735058" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,904</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax credits</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_206b128d-54e1-4f20-b3a8-a27bfe76903e" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,743</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e161a92c-4972-4b3e-bf70-730d2ab040df" contextRef="C_28144b67-7dfd-494d-8133-75abcc735058" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,070</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Intangibles</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_39c83b88-3691-4c00-8d66-95afcec5318e" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="lxeo:DeferredTaxAssetsIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,918</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1b5a2a51-642a-49ef-b261-d353ef15693c" contextRef="C_28144b67-7dfd-494d-8133-75abcc735058" name="lxeo:DeferredTaxAssetsIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,241</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Capitalized R&amp;D expenses</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_934ac133-11f2-4fcc-8e56-e17944d58c18" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39,338</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_675be89e-82de-4ab8-86a8-c796688ce8b8" contextRef="C_28144b67-7dfd-494d-8133-75abcc735058" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,127</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease liabilities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_876602ae-c2b8-457f-9854-285d22f9f4f1" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="lxeo:DeferredTaxAssetsLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,818</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_298fc5e7-5079-422e-b1b7-d072b5d1bb7f" contextRef="C_28144b67-7dfd-494d-8133-75abcc735058" name="lxeo:DeferredTaxAssetsLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,244</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other deferred tax assets</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b82852ed-06a9-40ca-94de-5de3e5e47676" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,292</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8bd045b9-3aaf-4b8b-a687-5b6027cbdf09" contextRef="C_28144b67-7dfd-494d-8133-75abcc735058" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,753</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_39a559f3-4c66-414d-b743-a07838490d62" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">98,404</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_52d1eef0-890c-4c51-b8d9-435c0b6a394c" contextRef="C_28144b67-7dfd-494d-8133-75abcc735058" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">65,339</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f1ce16f8-5d6f-4add-bf18-1539ed97bcf3" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">95,426</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7452e813-3b0d-4188-aa18-0a0670ff1483" contextRef="C_28144b67-7dfd-494d-8133-75abcc735058" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">61,974</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_51970f40-dc1a-418c-b7ff-d21a4971e1b7" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,978</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_84af31c1-861f-4f2d-903a-5fe339017ce7" contextRef="C_28144b67-7dfd-494d-8133-75abcc735058" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,365</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.688%;box-sizing:content-box;"/>
        <td style="width:2.063%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:17.259%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:2.063%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:16.926%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Right of use asset</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a64b88fc-86b0-447b-afb0-a167c09a7eee" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,663</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e7f59281-2810-402b-b6e0-702af78e1c68" contextRef="C_28144b67-7dfd-494d-8133-75abcc735058" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,102</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other deferred tax liabilities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d894c368-3900-43e2-8069-3a5caedc6f16" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="us-gaap:DeferredTaxLiabilitiesOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">315</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_320f03d0-6679-4d9f-a2f6-5055799c46d0" contextRef="C_28144b67-7dfd-494d-8133-75abcc735058" name="us-gaap:DeferredTaxLiabilitiesOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">263</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_554edf10-61c2-466c-9627-221c65ae8514" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,978</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7b7df12d-59d9-4f5d-befd-99996d22f6f8" contextRef="C_28144b67-7dfd-494d-8133-75abcc735058" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,365</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net deferred tax assets (liabilities)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bb57bdb7-8e16-40d3-a518-dd46008c2320" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9a8c4eb4-d82d-4e1e-ba7f-97a0d7694a9f" contextRef="C_28144b67-7dfd-494d-8133-75abcc735058" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024 and 2023, the Company had federal net operating loss ("NOL") carryforwards of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_538e21c9-3579-4776-823f-4dba8a6fda93" contextRef="C_fe2a112e-35b6-427a-9cf1-e602c55b5ef9" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">106.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7e1eb0f4-c611-4cce-ab3a-f7d1089e561a" contextRef="C_6a7a8e57-c021-4d66-95a4-3d7c93e89b8b" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">70.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, which can be carried forward indefinitely. As of December 31, 2024 and December 31, 2023, the Company had state and local net operating loss carryforwards of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6014dc24-60bb-49dd-b32e-b810d91c807f" contextRef="C_66ade898-e08e-4277-96a4-d86c2aa63e09" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">212.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_43c4cb49-c56f-4334-9a60-1c25f337fc28" contextRef="C_adf39fa9-e13e-4660-a6b0-e64e383d673a" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">139.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, which begin to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4c662304-38a0-4051-ab64-d5f17f1d552d" contextRef="C_56bb5356-0f0e-409e-b6a4-c7cb72c011e1" name="lxeo:OperatingLossCarryForwardsExpirationYear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2040</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024 and December 31, 2023, the Company had federal tax credits of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_14f80352-9ca6-4d07-90c3-2bceaaba2d74" contextRef="C_fe2a112e-35b6-427a-9cf1-e602c55b5ef9" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e4419583-9196-49d8-96a4-e5a80a4df052" contextRef="C_6a7a8e57-c021-4d66-95a4-3d7c93e89b8b" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, which begin to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_73b1003d-aff9-4917-8fe2-c83f0a154bdd" contextRef="C_500ad48d-4ad0-4259-8d4a-c15b843c549a" name="lxeo:TaxCreditCarryForwardExpirationYear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2040</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Future realization of the tax benefits of existing temporary differences and net operating loss carryforwards ultimately depends on the existence of sufficient taxable income within the carryforward period. As of December 31, 2024 and December 31, 2023, the Company performed an evaluation to determine whether a valuation allowance was needed. The Company considered all available evidence, both positive and negative, which included the results of operations for the current and preceding years. The Company determined that it was not possible to reasonably quantify future taxable income and determined that it is more likely than not that all of the deferred tax assets will not be realized. Accordingly, the Company maintained a full valuation allowance as of December 31, 2024 and December 31, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">134</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_3b6333a7-4e1f-4e36-b65d-7f79e390ba07_1"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The utilization of NOLs and tax credit carryforwards to offset future taxable income may be subject to an annual limitation as a result of ownership changes that have occurred previously or may occur in the future. Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, (the &#8220;IRC&#8221;), a corporation that undergoes an ownership change may be subject to limitations on its ability to utilize its pre-change NOLs and other tax attributes otherwise available to offset future taxable income and/or tax liability. An ownership change is defined as a cumulative change of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ed2b5f45-a16a-465e-85fb-798789cb60d9" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="lxeo:PercentageOfCumulativeOwnershipChange" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% or more in the ownership positions of certain stockholders during a rolling three-year period.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company conducted an ownership analysis under IRC Section 382 as of September 30, 2024 and determined the Company experienced an ownership change associated with the closing of the Company's IPO on November 7, 2023 that limits the Company&#8217;s NOLs and tax credits. As a result of the ownership change, the Company is limited to a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_37108c59-4aff-45b8-a7eb-98cd4ec7399e" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="lxeo:AnnualLimitationAbilityToUtilize" unitRef="U_USD" decimals="INF" format="ixt:num-dot-decimal">1,689,195</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> annual limitation on its ability to utilize its NOLs and tax credits recognized prior to the ownership change. Due to this limitation, no federal NOLs are expected to expire unutilized and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1bf64344-3411-47e4-ba61-92682c28906f" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:IncomeTaxReconciliationTaxCreditsForeign" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of federal tax credits that had been available to offset future tax liabilities, prior to the date of the ownership change, will expire unutilized. As a result, during the year ended December 31, 2024, the Company reduced its deferred tax assets related to the federal tax credits, which was offset by a corresponding decrease in the valuation allowance.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The calculation of the Company's tax liabilities involves dealing with uncertainties in the application of complex tax laws and regulations for both federal taxes and the many states in which it operates or does business in. ASC 740 states that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, on the basis of the technical merits.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company records uncertain tax positions as liabilities in accordance with ASC 740 and adjusts these liabilities when its judgment changes as a result of the evaluation of new information not previously available. Because of the complexity of some of these uncertainties, the ultimate resolution may result in a payment that is materially different from the Company's current estimate of the unrecognized tax benefit liabilities. These differences will be reflected as increases or decreases to income tax expense in the period in which new information is available. As of December 31, 2024 and December 31, 2023, the Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4ee90a60-1287-4e41-99c1-b4c748386249" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_0c0339ce-a235-47c9-9b34-513ca46e0731" contextRef="C_28144b67-7dfd-494d-8133-75abcc735058" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t recorded any uncertain tax positions in its financial statements.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognizes interest and penalties related to uncertain tax positions on the income tax expense line in the accompanying statements of operations. As of December 31, 2024 and December 31, 2023, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_67014513-4325-4d60-8b88-2ec5b04f627a" contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_897458ed-8f48-4c59-bc73-205e7169a8a9" contextRef="C_28144b67-7dfd-494d-8133-75abcc735058" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> accrued interest or penalties are included on the related tax liability line in the balance sheet.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company files tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. The resolution of tax matters is not expected to have a material effect on the Company's financial statements.</span></p></ix:continuation></div>
  <div><ix:nonNumeric id="F_b81ae0e3-a98a-4b72-98ca-a66f33ad6d9d" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true" continuedAt="F_b81ae0e3-a98a-4b72-98ca-a66f33ad6d9d_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12. Commitments and Contingencies</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;As of December 31, 2024, the Company had entered into commitments under lease agreements to rent laboratory and office space and finance equipment (see Note 5).</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commitments</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;As of December 31, 2024, the Company had entered into commitments under license, acquisition, research collaboration and sponsored research agreements with third parties (see Note 13). In addition, the Company has entered into services agreements with third parties for pharmaceutical manufacturing and research activities in the normal course of business, which can generally be terminated by the Company with </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5ee059ae-39f2-49fd-9b1f-831ee7a23452" contextRef="C_f6b1ccbb-21c3-4469-9c9a-20c3e22a9b8c" name="lxeo:LicenseAgreementTerminationNoticePeriod" format="ixt-sec:durday"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">30</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">- to </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_65a0215d-8cf7-4f10-93c4-14b11f325bc2" contextRef="C_df27e94d-4502-4904-99fe-3d1d46216d3e" name="lxeo:LicenseAgreementTerminationNoticePeriod" format="ixt-sec:durday"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">60</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-days&#8217; written notice, unless otherwise indicated. Further, certain of the Company&#8217;s manufacturing agreements could require early termination and wind-down payments due from the Company upon either the termination of its clinical trials or if the Company terminates such agreements for convenience.</span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">135</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_b81ae0e3-a98a-4b72-98ca-a66f33ad6d9d_1"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Contingencies</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of business. The Company recognizes any associated legal fees as incurred and accrues a liability for such contingent liability matters when it is probable that future expenditures will be made, and such expenditures can be reasonably estimated. For all periods presented, the Company was not a party to any pending material litigation or other material legal proceedings, except that on October 12, 2023, Rocket Pharmaceuticals, Inc. (&#8220;Rocket&#8221;) filed a lawsuit in the U.S. District Court for the Southern District of New York against the Company and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4687dfc6-6b94-4901-b21b-efa37114f36b" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="lxeo:NumberOfFormerEmployees" unitRef="U_Employees" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> former employees claiming, among other things, misappropriation of confidential information and trade secrets. The complaint alleges the individual defendants downloaded confidential Rocket company documents and other proprietary materials prior to leaving Rocket in 2021 and that the Company used this information to advance its programs after they became employed at Lexeo. The complaint seeks unspecified damages and asks the court to enjoin the Company from competing and working in the market for gene therapy treatments targeting cardiac diseases. In August 2024, the Company asserted counterclaims against Rocket and Spacecraft Seven LLC, a wholly owned subsidiary of Rocket, for misappropriation of trade secrets, correction of inventorship of certain patents, breach of contract, and tortious interference with contract. </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our counterclaims seek equitable relief, damages, attorneys' fees and costs from Rocket and Spacecraft Seven LLC. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The case is currently in the discovery phase. While it is not possible to predict the outcome with certainty and an estimate of the possible loss cannot be made, the Company currently does not expect the final outcome will have a material adverse effect on its timelines for development of its product candidates.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indemnification Agreements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its Board of Directors and executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. For all periods presented, the Company has not incurred any material costs as a result of such indemnifications.</span></p></ix:continuation></div>
  <div><ix:nonNumeric id="F_09f69824-f1f7-4d75-915d-77645f54b2e3" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="lxeo:LicenseAndAcquisitionAndResearchCollaborationAndSponsoredResearchAgreementsDisclosureTextBlock" escape="true" continuedAt="F_09f69824-f1f7-4d75-915d-77645f54b2e3_1"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13. License, Acquisition, Research and Collaboration and Sponsored Research Agreements</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adverum Biotechnologies</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;On January 25, 2021, the Company entered into an exclusive license agreement with Adverum Biotechnologies Inc. (&#8220;Adverum&#8221;) to in-license materials and technology related to the treatment of cardiomyopathy due to Friedreich ataxia ("FA") (the &#8220;Adverum Agreement&#8221;). In connection with the Adverum Agreement, the Company gained access to a portfolio of inventions, patent rights, technology, and licensed methods that the Company continues to develop, and the Company will assume all development and commercialization activities worldwide. Pursuant to the Adverum Agreement, the Company paid a one-time up-front non-refundable fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d5d7f32d-b413-463e-b7e9-5fd68340d46d" contextRef="C_db7527be-0d81-4c4d-82cd-9708fd4feeaa" name="lxeo:PaymentOfOneTimeUpFrontNonRefundableFee" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, and is obligated to pay aggregate development and regulatory milestones of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_22981da6-cfe4-4b30-be23-90773b10107d" contextRef="C_9aca8f8c-d11a-4b96-bb2f-8028f5d80ed0" name="lxeo:DevelopmentAndRegulatoryMilestonesDue" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">17.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million including a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_82465fd3-7fe0-4f99-9e29-03c74782350c" contextRef="C_6e382123-eceb-4534-ab45-5c3a9359605b" name="lxeo:PaymentOfDevelopmentMilestone" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million development milestone that was achieved and paid in the first quarter of 2023, and aggregate sales event and commercialization milestones of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9e4aa8a2-f08b-4273-bf99-660ce54ea7b2" contextRef="C_9aca8f8c-d11a-4b96-bb2f-8028f5d80ed0" name="lxeo:CommercializationMilestonesDue" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">49.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b6cc7fec-658a-4a10-9574-fead4359abd4" contextRef="C_3393a748-8c4c-4d41-87d8-1deb8ed9aa5a" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is obligated to pay Adverum tiered royalties ranging from high single-digits to sub teens based on annual aggregate worldwide net sales of Products (as defined in the Adverum Agreement).</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> As of December 31, 2024, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_324616f1-c518-41fc-aa83-07e18e8f741a" contextRef="C_8b7e354c-42e5-475d-87f9-4bfd1355ccaf" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> research and development expenses recorded by the Company or payments made to Adverum under the terms of the Adverum Agreement other than the one-time up-front non-refundable fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_75ba5dcd-9572-4360-bbef-ae3ba1738fd5" contextRef="C_6e382123-eceb-4534-ab45-5c3a9359605b" name="lxeo:PaymentOfOneTimeUpFrontNonRefundableFee" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5f9a46e0-3a5d-429a-adfe-54b89b37b18b" contextRef="C_6e382123-eceb-4534-ab45-5c3a9359605b" name="lxeo:PaymentOfDevelopmentMilestone" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million development milestone that was achieved and paid in the first quarter of 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Adverum Agreement remains in effect until termination at the date of the last royalty term to expire. The Company can terminate the Adverum Agreement with </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4646a18c-3d75-426f-848c-fd7d8caf8116" contextRef="C_db7527be-0d81-4c4d-82cd-9708fd4feeaa" name="lxeo:LicenseAgreementTerminationNoticePeriod" format="ixt-sec:durday"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">120</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> days&#8217; written notice. The Adverum Agreement can also be terminated as a result of a patent challenge, material breach of contractual terms, or insolvency by either party.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cornell University</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;On May 28, 2020, the Company entered into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_368fac61-629d-4032-be8e-afad9b1b166e" contextRef="C_dfaf0a7f-a734-4cd4-9b33-a8172ac5f59e" name="lxeo:NumberOfLicenseAgreements" unitRef="U_IntegerItem" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> exclusive license agreements with Cornell University (&#8220;Cornell&#8221;) (the &#8220;First Cornell License Agreement&#8221; and the &#8220;Second Cornell License Agreement,&#8221; collectively the &#8220;May 2020 Cornell License Agreements&#8221;). The First Cornell License Agreement is for the in-license of technology related to portfolios for APOE-associated Alzheimer&#8217;s disease and Anti-Tau, although the Company&#8217;s license is not restricted by such indications and it includes assignment to the Company of Cornell&#8217;s IND for the use of AAVrh10.hAPOE2 vector to treat APOE4 homozygous patients who are at risk for or have Alzheimer&#8217;s disease to support development of the Company&#8217;s LX1001 program. The Second Cornell License Agreement is for the in-license of technology related to a portfolio for FA although the Company&#8217;s license is not restricted by such indications, and it includes assignment to the Company of Cornell&#8217;s IND for the use of AAVrh.10cUhCLN2 to treat children with CLN2 Batten disease to support development of the Company&#8217;s LX1004 program. Through the May 2020 Cornell License Agreements, the Company gains access to a portfolio of inventions, patent rights, technology, and licensed methods that the Company continues to develop. Under the terms of the May 2020 Cornell License Agreements, the Company has assumed all development and commercialization activities worldwide with respect to the licensed technology.</span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">136</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_09f69824-f1f7-4d75-915d-77645f54b2e3_1" continuedAt="F_09f69824-f1f7-4d75-915d-77645f54b2e3_2"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As initial consideration for the May 2020 Cornell License Agreements, the Company paid Cornell an upfront payment in cash of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_870bf19e-24a8-4c26-8a8b-de71b7e4d65d" contextRef="C_940cc76e-9af2-46e6-b22a-05a05af066b0" name="lxeo:UpfrontCashPayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and issued $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3704754d-077f-4115-b510-40abcc469931" contextRef="C_940cc76e-9af2-46e6-b22a-05a05af066b0" name="us-gaap:NotesIssued1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of notes (the &#8220;Cornell Notes&#8221;). In November 2020, the Cornell Notes with outstanding principal of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0e5d477a-8ce4-48e6-944e-bab14c713dc6" contextRef="C_5e727241-61dd-4591-9807-d7d2fe303dba" name="us-gaap:DebtConversionOriginalDebtAmount1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million were cancelled in exchange for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b65bae23-d239-4cc7-95e1-c64a949b9127" contextRef="C_1e595beb-6e63-4729-9f01-fa8aaad38108" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,337,610</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of series A convertible preferred stock, which converted into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_954fa7fe-b540-4266-b10f-7a0531485641" contextRef="C_a70f9bd2-aceb-4c0d-b0fa-5353c3dece2a" name="us-gaap:PreferredStockConvertibleSharesIssuable" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">126,258</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock upon the closing of the Company's IPO on November 7, 2023. As additional consideration, the Company is required to pay Cornell up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ba12c9d9-f7e4-4bea-b828-6714aa93a7c1" contextRef="C_e5969e3b-4f0f-4598-ab16-63cb541f8395" name="lxeo:SpecificClinicalAndRegulatoryMilestonesDue" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">8.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upon the achievement of specific clinical and regulatory milestones under the First Cornell License Agreement and up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3d0a43ff-28bf-4f19-b8ee-2558cd32246b" contextRef="C_10dc49c3-ff40-493f-b51b-be28cd103318" name="lxeo:SpecificClinicalAndRegulatoryMilestonesDue" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">4.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in two portfolios and up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_86b50a80-f3d4-4781-9bf2-25c6e5b2b3b2" contextRef="C_f8619687-73fe-4744-9482-f214f5f1a619" name="lxeo:SpecificClinicalAndRegulatoryMilestonesDue" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">0.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for a third portfolio upon the achievement of specific clinical and regulatory milestones under the Second Cornell License Agreement. In the second quarter of 2022, a clinical and regulatory milestone of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dd09dc39-c277-4a41-9040-d4ddd94b2a12" contextRef="C_eef711a6-19ec-48b9-9c42-54e797d52952" name="lxeo:PaymentOfClinicalAndRegulatoryMilestone" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million was recognized and paid to Cornell in connection with the Second Cornell License Agreement. The Company is also required to pay Cornell a flat royalty in the mid-single-digits based on net sales of the products covered by the licenses, subject to certain adjustments.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upon expiration of the royalty term of a given licensed product in a country, the respective license becomes non-exclusive and royalty-free. In addition, each of the May 2020 Cornell License Agreements may be terminated by the Company for any reason upon ninety (</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_95363cd0-7520-465f-9028-0dbdd979579a" contextRef="C_940cc76e-9af2-46e6-b22a-05a05af066b0" name="lxeo:LicenseAgreementTerminationNoticePeriod" format="ixt-sec:durday"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">90</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) days&#8217; advance notice to Cornell and by Cornell upon the Company&#8217;s material uncured breach, and all licenses and rights granted by either party under such agreement will concurrently terminate.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 21, 2024, the Company entered into the Third License Agreement (the &#8220;Third Cornell License Agreement,&#8221; together with the May 2020 Cornell License Agreements, the &#8220;Cornell License Agreements&#8221;) with Cornell. Pursuant to the Third Cornell License Agreement, Cornell has granted the Company an exclusive license to practice under certain patent rights generated in animal studies conducted by Cornell on behalf of the Company and a non-exclusive license to know-how concerning a gene therapy for FA cardiomyopathy and current and future data generated in an ongoing investigator-initiated Phase 1A trial of AAVrh.10hFXN to treat FA cardiomyopathy. Both licenses are worldwide and cover products with human and non-human prophylactic and therapeutic uses. Cornell has also granted the Company a right of reference to Cornell&#8217;s Investigation New Drug application for a gene therapy for FA cardiomyopathy.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Third Cornell License Agreement, the Company paid a license issue fee and an initial data transfer fee to Cornell totaling $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5febd073-d045-46b8-b8ee-9874af37cbd5" contextRef="C_2b151cd0-5507-43d4-aa4e-3c68accbaec1" name="lxeo:PaymentOfLicenseIssueFeeAndInitialDataTransferFee" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. Additionally, the Company will be paying an annual data transfer fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d9da4499-d29a-4216-969a-e841824857f3" contextRef="C_2b151cd0-5507-43d4-aa4e-3c68accbaec1" name="lxeo:PaymentOfAnnualDataTransferFee" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">50,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> until data is no longer being gathered. The Company has agreed to pay annual license maintenance fees ranging from $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5d09922a-b72f-4e3c-b2a6-29615612f071" contextRef="C_c7d3289f-7fe7-4f19-ac48-22a403b83a4c" name="lxeo:PaymentOfAnnualLicenseMaintenanceFees" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">2,500</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c6f32d83-7846-4800-a653-e56876f0e67f" contextRef="C_7c51062b-38dd-4251-995b-95b9d29f554e" name="lxeo:PaymentOfAnnualLicenseMaintenanceFees" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">25,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> until such time the Company commercializes a licensed product. In addition, the Company will pay Cornell up to an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ed777e55-a48a-40c2-b1db-b31d0f3f669c" contextRef="C_7c51062b-38dd-4251-995b-95b9d29f554e" name="lxeo:PaymentOfRegulatoryMilestones" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in regulatory milestones and up to an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1c2e939e-42f6-4e81-920a-5ebd9d3a71ce" contextRef="C_202992e1-90d4-413d-b703-e8197a8dc6e3" name="lxeo:CommercializationMilestonesDue" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">100</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in commercial milestones, plus low single digit royalties on net sales.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Third Cornell License Agreement contains other customary license terms including terms related to sublicensing, development, commercialization, milestones, royalties, intellectual property, and termination. Upon expiration of the applicable royalty term for a product in a given country, the Company shall retain a non-exclusive, royalty free license to the data and know-how, including to continue selling such product in that country.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cornell may terminate the Third Cornell License Agreement if the Company (i) breaches the Third Cornell License Agreement (subject to a cure period), (ii) participates in any proceeding challenging the validity of the licensed patents, (iii) publishes the licensed data without Cornell&#8217;s prior written consent, or (iv) does not reach certain milestones. Cornell may also terminate the Third Cornell License Agreement in part on product-by-product basis if the Company does not diligently develop and sale a product. The Company may terminate the Third Cornell License Agreement, in whole or in part with respect to the right of reference, or the licensed data, know-how, or patent rights, with </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cf2e2df8-9ac8-4da2-94e8-dc58601a3461" contextRef="C_2b151cd0-5507-43d4-aa4e-3c68accbaec1" name="lxeo:LicenseAgreementTerminationNoticePeriod" format="ixt-sec:durday"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">90</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> days&#8217; prior written notice to Cornell.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2023, the Company incurred and paid $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bf797626-5495-4800-a965-80474b924c41" contextRef="C_ab7f0058-11d6-4f3c-b66e-25878efcc5c2" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">10,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in connection with the Cornell License Agreements. During the year ended December 31, 2024, the Company incurred and paid $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6ee3b74e-5bc2-44ca-9e9a-dff3be036a75" contextRef="C_29bfd3ef-606a-4b0e-a5fa-8ba6f8566146" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in connection with the Cornell License Agreements.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stelios Therapeutics, Inc.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Stelios Therapeutics, Inc. (&#8220;Stelios&#8221;) was an early-stage company developing novel adeno-associated AAV-based gene therapies for rare cardiac conditions including arrhythmogenic cardiomyopathy and TNNI3-associated hypertrophic cardiomyopathy. On </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f6aa761c-003e-4c43-a7de-2d17ddaa3054" contextRef="C_dee9c396-7be8-4764-a1e9-de37e72c1b20" name="us-gaap:BusinessAcquisitionEffectiveDateOfAcquisition1" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">July 16, 2021</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company acquired </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7349d891-add7-4529-b24c-3752212bba68" contextRef="C_fd20e119-f9e2-4c0e-9735-4934b480df35" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">100</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the outstanding stock of Stelios that was accounted for as an asset acquisition pursuant FASB ASC 805, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Business Combinations</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company is required to pay up to a remaining aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d7792ce5-8a6e-42f8-b850-a044587c32b9" contextRef="C_07376bba-ebc9-44c0-bc4a-e98679fa21ad" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">12.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to the selling shareholders of Stelios upon the achievement of certain development milestones, excluding a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8221db4a-139d-4dd9-8ca0-ade772f9f192" contextRef="C_9d573f03-b8a1-43e3-9828-e04c95b23d8a" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million development milestone that was achieved in the third quarter of 2024 and paid in the fourth quarter of 2024. Dr. Eric Adler, the Company's Chief Medical Officer and Head of Research, was a co-founder of Stelios and a selling shareholder. Of the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5e0fb416-ff72-4a19-991c-ae8d89f3ea19" contextRef="C_f5b88d17-128c-461e-aaa6-463ec8135b2a" name="lxeo:PaymentOfDevelopmentMilestone" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million development milestone payment, Dr. Adler received approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1ebd571e-aa0f-4fd6-a74c-e668d2517567" contextRef="C_5af5a379-1acd-457b-ba86-c64e18c5164a" name="lxeo:MilestoneReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. Stelios was merged into the Company on December 15, 2022 and ceased to exist.</span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">137</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_09f69824-f1f7-4d75-915d-77645f54b2e3_2" continuedAt="F_09f69824-f1f7-4d75-915d-77645f54b2e3_3"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Regents of the University of California, San Diego</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Stelios entered into exclusive worldwide license agreements on April 23, 2020, and August 6, 2020 (the &#8220;First UCSD Agreement&#8221; and the &#8220;Second UCSD Agreement,&#8221; respectively) with the Regents of UCSD to in-license materials and intellectual property related to gene therapies for arrhythmogenic right ventricular cardiomyopathy and hypertrophic cardiomyopathy, respectively. The First UCSD Agreement and the Second UCSD Agreement relate to the Company&#8217;s development efforts for its LX2021 and LX2022 programs, respectively. In connection with the First UCSD Agreement and the Second UCSD Agreement, the Company gained access to inventions, patent rights, technology, and licensed methods that it continues to develop, and it has assumed all worldwide development and commercialization activities with respect to the licensed technologies. The First UCSD Agreement and Second UCSD Agreement required Stelios to pay one-time up-front non-refundable cash fees of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4cc350a9-842a-4f0a-89c5-ac053f6ba15c" contextRef="C_b4755659-dbea-42a4-911b-aaf4e5f99a6a" name="lxeo:PaymentOfOneTimeUpFrontNonRefundableFee" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_7bf29203-635a-487b-9834-00178cc55082" contextRef="C_749a5dff-19cd-41f6-b877-35e4f821f1fe" name="lxeo:PaymentOfOneTimeUpFrontNonRefundableFee" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">20,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for each agreement and requires the Company to pay aggregate development and commercialization milestones of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_812fba38-08b5-47b4-b69c-b7adb050516d" contextRef="C_2611b746-5276-4a2d-b18c-32e1fcba87aa" name="lxeo:DevelopmentAndCommercializationMilestonesDue" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">4.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5dc135d5-8e88-4d68-b522-0707756d404e" contextRef="C_3d6eac78-9474-4e08-bcae-13f2246c0568" name="lxeo:DevelopmentAndCommercializationMilestonesDue" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">2.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, and low- to mid-single digit royalties and low-single digit royalties, respectively, based on aggregate net sales. The only research and development expenses incurred by Stelios or the Company and payments made to the Regents of UCSD through December 31, 2024 under the terms of the First UCSD Agreement and the Second UCSD Agreement were the one-time up-front non-refundable cash fees of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f4ecd601-6187-4e33-9e87-4b5fafb02a2e" contextRef="C_cb661ff1-5311-4097-b67b-ccc8f26e5c71" name="lxeo:OneTimeUpFrontNonRefundableFees" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_4ac888b1-5748-4561-a064-ca90a6183412" contextRef="C_4416291a-8898-4d40-bf16-c20112811638" name="lxeo:OneTimeUpFrontNonRefundableFees" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">20,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for each agreement. The Company has the right to terminate the First UCSD Agreement and the Second UCSD Agreement at any time upon sixty (</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b6b7d64c-a14a-4900-b95f-0a34633454c7" contextRef="C_b4755659-dbea-42a4-911b-aaf4e5f99a6a" name="lxeo:LicenseAgreementTerminationNoticePeriod" format="ixt-sec:durday"><ix:nonNumeric id="F_40db76a4-248c-4db2-a642-f8d49ccd5046" contextRef="C_e30bab05-7cc4-4f13-aa74-111c8d09ef0d" name="lxeo:LicenseAgreementTerminationNoticePeriod" format="ixt-sec:durday"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">60</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">)-days&#8217; written notice to the Regents of UCSD.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On October 4, 2021, the Company entered into an exclusive worldwide license agreement (the &#8220;Third UCSD Agreement&#8221; and collectively with the First UCSD Agreement and the Second UCSD Agreement, the &#8220;UCSD Agreements&#8221;) with the Regents of UCSD to in-license materials and intellectual property related to LX2020, a gene therapy for arrhythmogenic right ventricular cardiomyopathy. The Third UCSD Agreement relates to the Company&#8217;s development efforts for its LX2020 program. In connection with the Third UCSD Agreement, the Company gained access to inventions, patent rights, technology, and licensed methods that it continues to develop, and it has assumed all worldwide development and commercialization activities with respect to the licensed technology. The Third UCSD Agreement required the Company to pay a one-time up-front non-refundable cash fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_07d026a2-e8fc-479b-ba87-72166ea9659a" contextRef="C_a8c2e316-6ad2-4b74-acd6-08e9897fd12e" name="lxeo:PaymentOfOneTimeUpFrontNonRefundableFee" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">20,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and requires </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f892c825-1832-41b6-b76b-1696d80da1b8" contextRef="C_2f31b66a-0232-462f-8ba1-c31ab4b8824f" name="lxeo:AggregateDevelopmentAndCommercializationMilestonesDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Company to pay aggregate development and commercialization milestones of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_662a6313-a90f-4ebf-a2cd-2e5f0c9dda67" contextRef="C_55a64f42-6349-45b1-a852-990c1f09b912" name="lxeo:DevelopmentAndCommercializationMilestonesDue" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">4.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, and low- to mid-single digit royalties based on aggregate net sales.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Research and development expenses incurred by the Company and payments made to the Regents of UCSD under the terms of the Third UCSD Agreement were the one-time up-front non-refundable cash fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6b152640-2dc9-48c1-8d89-613771cad81c" contextRef="C_eb04d3ca-9afb-4d97-9a7e-b5be9da963d6" name="lxeo:OneTimeUpFrontNonRefundableFees" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">20,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> as well as a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ee7451a0-8885-4926-8ac7-1b6711ccc487" contextRef="C_5bca7169-3f0e-45f0-a257-63b105b31fcd" name="lxeo:PaymentOfDevelopmentMilestone" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million development milestone that was achieved during the third quarter of 2024. The Company has the right to terminate the Third UCSD Agreement at any time upon sixty (</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ff710b60-4af1-4767-b796-5c7f9fcd1bbb" contextRef="C_a8c2e316-6ad2-4b74-acd6-08e9897fd12e" name="lxeo:LicenseAgreementTerminationNoticePeriod" format="ixt-sec:durday"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">60</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">)-days&#8217; written notice to the Regents of UCSD.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On December 3, 2021, the Company entered into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b1365a90-b658-4bae-891f-cdb22bd25cef" contextRef="C_2911d34b-7821-4985-b38e-577d63cb332d" name="lxeo:NumberOfResearchAgreements" unitRef="U_IntegerItem" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> sponsored research agreements with the Regents of UCSD (the "First UCSD SRA", the "Second UCSD SRA", and collectively, the &#8220;UCSD SRAs&#8221;) for the Company&#8217;s LX2020, LX2021 and LX2022 programs in connection with the UCSD Agreements. Under the terms of the UCSD SRAs, the Company has the first rights to obtain non-exclusive or exclusive, sublicensable, royalty-bearing, perpetual and transferable worldwide licenses in any resulting inventions owned by the Regents of UCSD or resulting inventions jointly owned between the Company and the Regents of UCSD, and the Company retains the rights to any resulting inventions owned by the Company. The UCSD SRAs each have a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fd213912-5b80-49cb-b01c-374818ad37ef" contextRef="C_1fd0f357-c2ff-41e2-bd80-50ac05612394" name="lxeo:ResearchAgreementsTerm" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">two-year</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> term and may be terminated early by the Company at any time upon the giving of thirty (</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_272a787e-9c7e-4e10-984a-ca2bc43ccd2c" contextRef="C_1fd0f357-c2ff-41e2-bd80-50ac05612394" name="lxeo:ResearchAgreementTerminationNoticePeriod" format="ixt-sec:durday"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">30</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) days&#8217; written notice to the Regents of UCSD. The total costs to be invoiced to the Company over the terms of the UCSD SRAs are $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7bf1a830-033b-4422-9ea7-d251b47e4c8c" contextRef="C_1fd0f357-c2ff-41e2-bd80-50ac05612394" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, of which the Company incurred $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c073a4f5-5651-4486-89d4-266410f89953" contextRef="C_4013d4d1-c4c9-4765-acc9-a1659c4750bf" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of research and development expenses during the year ended December 31, 2023. The Company paid $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d61ea2fc-06f2-4a1e-8641-7d9366b63cac" contextRef="C_4013d4d1-c4c9-4765-acc9-a1659c4750bf" name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to the Regents of UCSD in connection with the UCSD SRAs during the year ended December 31, 2023. The Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f9892128-3e9c-46c2-9920-160f5fa494eb" contextRef="C_feb46e5d-6816-4e22-a41b-42317def0254" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t incur any research and development expenses in connection with the UCSD SRAs during the year ended December 31, 2024. The Company paid $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c9ef88fc-0e4f-4da0-b830-4217bc81f5cb" contextRef="C_feb46e5d-6816-4e22-a41b-42317def0254" name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to the Regents of UCSD in connection with the UCSD SRAs during the year ended December 31, 2024. The Company has paid a cumulative total of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c47b37e5-f852-45f9-8824-f8975db7e8c6" contextRef="C_7e7948fb-137c-405e-8479-be843ae42290" name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to the Regents of UCSD as of December 31, 2024, in connection with the UCSD SRAs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 13, 2024, the Company entered into a third sponsored research agreement with the Regents of UCSD (the &#8220;Third UCSD SRA&#8221;) for the Company&#8217;s LX2022 program in connection with the Second UCSD Agreement. Under the terms of the Third UCSD SRA, the Company has the first rights to obtain non-exclusive or exclusive, sublicensable, royalty-bearing, perpetual and transferable worldwide licenses in any resulting inventions owned by the Regents of UCSD or resulting inventions jointly owned between the Company and the Regents of UCSD, and the Company retains the rights to any resulting inventions owned by the Company. The Third UCSD SRA has a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_037c6ae9-c1fa-40b6-8e9e-a1c40be08070" contextRef="C_05465aab-2ef4-47b5-84ef-3eacb2ef4089" name="lxeo:ResearchAgreementsTerm" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">two-year</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> term and may be terminated early by the Company at any time upon the giving of thirty (</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_442342f2-f01b-4e66-b067-8765709132a2" contextRef="C_05465aab-2ef4-47b5-84ef-3eacb2ef4089" name="lxeo:ResearchAgreementTerminationNoticePeriod" format="ixt-sec:durday"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">30</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) days&#8217; written notice to the Regents of UCSD. The costs to be invoiced to the Company over the term of the Third UCSD SRA are $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_56ab5b59-7024-4204-afc8-b17d1ac9de81" contextRef="C_05465aab-2ef4-47b5-84ef-3eacb2ef4089" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, and the Company may incur additional costs of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dbc2cfb2-56d7-46e3-b1d6-145c764041ee" contextRef="C_05465aab-2ef4-47b5-84ef-3eacb2ef4089" name="lxeo:ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalCostsIncurred" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million under the Third UCSD SRA if certain study objectives are met.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 13, 2024, the Company also entered into an amendment to the Second UCSD SRA for the Company&#8217;s LX2022 program that extended the term of the Second UCSD SRA to December 2024. The Company incurred $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_113f16eb-ddf3-48bf-8671-d431072d24c9" contextRef="C_2d31726b-58bc-4b55-8b8d-242c0b620bca" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of research and development costs during the year ended December 31, 2024, and paid $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_310dea35-b494-453f-afe8-04f313f4798d" contextRef="C_2d31726b-58bc-4b55-8b8d-242c0b620bca" name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million during the year ended December 31, 2024, to the Regents of UCSD in connection with the Third UCSD SRA.</span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">138</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_09f69824-f1f7-4d75-915d-77645f54b2e3_3"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 19, 2024, the Company entered into an amendment to the First UCSD SRA (as amended, the "Amended First UCSD SRA") for the Company&#8217;s LX2021 program in connection with the First UCSD Agreement. The Amended First UCSD SRA extends the term of the First UCSD SRA to December 2026 and provides for additional research and development studies and expenses. The total costs to be invoiced to the Company under the Amended First UCSD SRA are $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aaab8794-6396-4d33-9100-126a62489aa4" contextRef="C_73f22931-4674-407c-ac09-c2a140ebf868" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The Company incurred $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d6096990-d41b-42df-a501-3b7d18dcc2a7" contextRef="C_90de349f-5edf-4ccd-81d6-310075c43d96" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of research and development costs during the year ended December 31, 2024, and paid $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1d4a9d25-79e0-4ee1-8f79-b421e7deb0de" contextRef="C_90de349f-5edf-4ccd-81d6-310075c43d96" name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million during the year ended December 31, 2024 to the Regents of UCSD in connection with the Amended First UCSD SRA.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Weill Cornell Medical College</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;On February 2, 2021, the Company entered into a Research Collaboration Agreement with Weill Cornell Medical College (&#8220;WCM&#8221; and the &#8220;WCM Agreement&#8221;) in connection with the Cornell License Agreements entered on May 28, 2020. The Company committed to fund scientific research at WCM to investigate further and potentially enhance the technology licensed to the Company pursuant to the License Agreements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the terms of the WCM Agreement (as amended on February 1, 2022), each WCM invention, joint invention, and related joint results for which an Improvement, as defined in the WCM Agreement, applies and the Company has made an election to amend the Cornell License Agreements, the Company has the first option to negotiate in good faith with WCM for royalty- bearing, worldwide license, under Cornell patent rights, Cornell rights, and Cornell&#8217;s interest in joint patent rights, to develop, make, have made, use, offer for sale, sell, have sold, and import derived products in the field. During the year ended December 31, 2023 the Company incurred $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1057e437-c789-49f9-9f6a-39bc661afb3a" contextRef="C_03d0654e-3872-4474-936c-dc6ff5ca1f8d" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of research and development costs and paid $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a706fa2f-4799-4c7d-8ee5-89aeab73f96a" contextRef="C_03d0654e-3872-4474-936c-dc6ff5ca1f8d" name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to Cornell in connection with the WCM Agreement. During the year ended December 31, 2024 the Company incurred $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_529cfd15-ccef-4aba-ae3b-c4bbd12b6812" contextRef="C_35a86fc1-0afe-4e3c-96ee-81097e533438" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and paid $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_530c779a-314d-4250-8075-ad853f8aad4a" contextRef="C_35a86fc1-0afe-4e3c-96ee-81097e533438" name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of research and development costs to Cornell in connection with the WCM Agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The WCM Agreement expired in accordance with its terms in February 2024.</span></p></ix:continuation></div>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b98e6b79-b2f5-4f5a-aac0-a01efaff0cd5" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:SegmentReportingDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14. Segment Information</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b9dddd81-7ad3-4b17-809b-851a9dbf5054" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:SegmentReportingExpenseInformationUsedByCodmDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company's CODM is its </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_bb5c5ee6-6dc1-4359-ae05-87adfaa76496;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CEO and senior leadership team</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. All of the Company&#8217;s operating results are reviewed by the Company&#8217;s CODM within the same statement of operations and comprehensive loss whether research and development (by program) or general and administrative in nature. Accordingly, the Company has determined that it has a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_e4a8210a-7701-4cf1-bb55-d8e020f66db8;"><span style="-sec-ix-hidden:F_b4f1e989-f912-4b9a-9a96-f56301d549bc;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">single</span></span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> reportable segment and operating segment structure. The Company's CODM regularly reviews total expenses and expenses by significant areas such as departments and programs to make decisions when evaluating the Company's financial performance. The Company does not evaluate performance or allocate resources based on segment asset data and therefore such information is not presented. All long-lived assets are located in the United States.</span></ix:nonNumeric></span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4cf0a330-2d6e-4be1-bb41-bcfe2543bad7" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" escape="true"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table contains additional information on the Company's net loss, including significant segment expenses for the years ended December 31, 2024 and December 31, 2023:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.887%;box-sizing:content-box;"/>
        <td style="width:1.66%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.897%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.66%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.897%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development expense</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">LX2020</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1d686e06-d165-46bf-bea9-31b7b32705c3" contextRef="C_637f42f6-8969-4386-b873-8c291d47795a" name="lxeo:ResearchAndDevelopmentExpenseLX2020" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,451</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9b31930d-9359-4d1a-b17e-532dbb3ddfa0" contextRef="C_f8c50f85-2ed2-437f-90c9-8336f5967e8e" name="lxeo:ResearchAndDevelopmentExpenseLX2020" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,192</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">LX2006</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7397ac48-24b9-4f1a-8c05-6f3a709cf018" contextRef="C_637f42f6-8969-4386-b873-8c291d47795a" name="lxeo:ResearchAndDevelopmentExpenseLX2006" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,256</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ee61f246-fe92-4988-a22f-ced649cfdd12" contextRef="C_f8c50f85-2ed2-437f-90c9-8336f5967e8e" name="lxeo:ResearchAndDevelopmentExpenseLX2006" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,537</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">LX1001</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5c6c7e62-90fd-4536-a86c-ec6c43435b43" contextRef="C_637f42f6-8969-4386-b873-8c291d47795a" name="lxeo:ResearchAndDevelopmentExpenseLX1001" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,501</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_49904193-6dad-4fee-bc53-4204ded52638" contextRef="C_f8c50f85-2ed2-437f-90c9-8336f5967e8e" name="lxeo:ResearchAndDevelopmentExpenseLX1001" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,936</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other programs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c2fa02d1-6e73-4c01-bc06-caece2c75da2" contextRef="C_637f42f6-8969-4386-b873-8c291d47795a" name="lxeo:ResearchAndDevelopmentExpenseOtherPrograms" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,424</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dffea6f9-dd1b-4f68-bd0b-b9a3604899a7" contextRef="C_f8c50f85-2ed2-437f-90c9-8336f5967e8e" name="lxeo:ResearchAndDevelopmentExpenseOtherPrograms" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,535</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Employee compensation expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a7bf18c3-6f49-4cb8-a727-905b6c3bb28a" contextRef="C_637f42f6-8969-4386-b873-8c291d47795a" name="lxeo:ResearchAndDevelopmentExpenseEmployeeCompensationExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,010</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e17c1992-7698-480e-8295-dfa25c281693" contextRef="C_f8c50f85-2ed2-437f-90c9-8336f5967e8e" name="lxeo:ResearchAndDevelopmentExpenseEmployeeCompensationExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,748</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lab-related costs and supplies</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7ddd0854-90fe-400a-b4e9-c392835d7dce" contextRef="C_637f42f6-8969-4386-b873-8c291d47795a" name="us-gaap:LaborAndRelatedExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,356</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0b4f2103-6a41-4683-961c-017d20de6abc" contextRef="C_f8c50f85-2ed2-437f-90c9-8336f5967e8e" name="us-gaap:LaborAndRelatedExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,160</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">All other research and development expense</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7fe2ea78-5f84-4892-b355-c9dad1967402" contextRef="C_637f42f6-8969-4386-b873-8c291d47795a" name="us-gaap:OtherResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,093</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_78272df8-7416-4e8a-a568-fa2db41d252d" contextRef="C_f8c50f85-2ed2-437f-90c9-8336f5967e8e" name="us-gaap:OtherResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,022</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative expense</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Employee compensation expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_50692c79-ce7f-4496-b439-b482f71a0d41" contextRef="C_637f42f6-8969-4386-b873-8c291d47795a" name="lxeo:GeneralAndAdministrativeExpenseEmployeeCompensationExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,158</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_57b0df72-41a4-4ad2-a02b-4410c95b9b01" contextRef="C_f8c50f85-2ed2-437f-90c9-8336f5967e8e" name="lxeo:GeneralAndAdministrativeExpenseEmployeeCompensationExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,872</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">All other general and administrative expense</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_54fdbb5b-8751-4f6f-8deb-8b68f8e2a2e6" contextRef="C_637f42f6-8969-4386-b873-8c291d47795a" name="us-gaap:OtherGeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,517</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c5140dac-3fc7-4383-b519-aa854abf0ede" contextRef="C_f8c50f85-2ed2-437f-90c9-8336f5967e8e" name="us-gaap:OtherGeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,511</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income and expense, net</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2d83cf76-33e8-4acf-baff-7ab586111022" contextRef="C_637f42f6-8969-4386-b873-8c291d47795a" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,433</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4ee8c1c3-62d0-4fe9-ba10-14183b48f10d" contextRef="C_f8c50f85-2ed2-437f-90c9-8336f5967e8e" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,119</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net Loss</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bccee535-63f3-47ad-8370-51ec556c507f" contextRef="C_637f42f6-8969-4386-b873-8c291d47795a" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">98,333</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_39021236-46e0-4067-b322-c0529e1f3e04" contextRef="C_f8c50f85-2ed2-437f-90c9-8336f5967e8e" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">66,394</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_a275bb75-b950-41cf-af87-0d363a051b56" contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801" name="us-gaap:SubsequentEventsTextBlock" escape="true" continuedAt="F_a275bb75-b950-41cf-af87-0d363a051b56_1"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15. Subsequent Events</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subsequent events have been evaluated through March 24, 2025, which is the date that these financial statements were issued and were available to be issued.</span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">139</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_a275bb75-b950-41cf-af87-0d363a051b56_1"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 24, 2025, the Company entered into a sales agreement with Leerink Partners LLC ("Leerink") to sell shares of the Company's common stock having an aggregate offering price of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ca96207a-576e-4a2b-8ff0-0bc7d0d9ae0d" contextRef="C_27a6defd-2f97-4391-b27e-7d7b4574d1b7" name="lxeo:StockOfferingValueSharesAuthorizedToBeSold" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">75.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million from time to time through an at-the-market equity offering program under which Leerink is acting as the Company's agent. Leerink is entitled to compensation for its services in an amount equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_591cc955-f4ca-4e62-bb34-02fab867c3d2" contextRef="C_ef41b0f5-e670-47fb-a4ba-1fb722c72adf" name="lxeo:StockOfferingGrossProceedsPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the gross proceeds of any of the shares of the Company's common stock sold under the sales agreement.</span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">140</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9_changes_in_and_disagreements_with"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">em 9.    Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9a_controls_and_procedures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ite</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">m 9A.    Controls and Procedures.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Evaluation of Disclosure Controls and Procedures</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management, with the participation of our principal executive officer and principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act), as of December 31, 2024. Based on such evaluation, our principal executive officer and principal financial officer have concluded that, as of such date, the design and operation of our disclosure controls and procedures were effective at a reasonable assurance level.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Management&#8217;s Report on Internal Control Over Financial Reporting</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rule 13a-15(f) promulgated under the Exchange Act. Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, our management assessed and conducted an evaluation of the effectiveness of our internal control over financial reporting based on the Internal Control&#8212;Integrated Framework (2013 framework) issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on this assessment, our management concluded that our internal control over financial reporting was effective as of December 31, 2024.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Attestation Report of the Registered Public Accounting Firm</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Annual Report on Form 10-K does not include an attestation report of our registered public accounting firm regarding the effectiveness of internal control over financial reporting a required by Section 404(b) of the Sarbanes-Oxley Act of 2002. Management&#8217;s report was not subject to attestation by our registered public account firm pursuant to rules of the SEC related to emerging growth and smaller reporting companies.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Changes in Internal Control Over Financial Reporting</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There were no changes in our internal control over financial reporting identified in management&#8217;s evaluation pursuant to Rules 13a-15(d) or 15d-15(d) of the Exchange Act during the fourth quarter of the year ended December 31, 2024, that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Limitations on Effectiveness of Controls and Procedures</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management, including our principal executive officer and principal financial officer, do not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of the controls. The design of any system of controls is also based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Due to inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">141</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9b_other_information"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ite</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">m 9B.    Other Information.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ATM Offering</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 24, 2025, we entered into a Sales Agreement with Leerink Partners LLC, as the Sales Agent, pursuant to which we may, from time to time, sell up to an aggregate amount of $75.0 million of our common stock through the Sales Agent in an &#8220;at-the-market&#8221; offering, or the ATM Offering. We will pay the Sales Agent a commission equal to 3% of the aggregate gross proceeds we receive from all sales of our common stock under the Sales Agreement. We have also provided the Sales Agent with customary indemnification rights. The Sales Agreement remains in effect until the earlier of selling all shares available under the Sales Agreement or until such agreement is terminated by written notice from either of the parties pursuant to the terms thereof. We are not obligated to make any sales of our common stock under the Sales Agreement, and no sales have been made under the Sales Agreement as of the filing of this Annual Report.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The ATM Offering is being made under a prospectus supplement to be dated March 24, 2025 and filed with the Securities and Exchange Commission on March 24, 2025, and the related prospectus contained in our shelf registration statement on Form S-3 (Registration No. 333- 283781) filed on December 13, 2024, and declared effective by the Securities and Exchange Commission on December 19, 2024.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A copy of the Sales Agreement is filed as Exhibit 10.32 to this Annual Report. The foregoing description of the Sales Agreement does not purport to be complete and is qualified in its entirety by reference to Exhibit 10.32. A copy of the opinion of Wilson Sonsini Goodrich &amp; Rosati, P.C. relating to the validity of the securities issued in the ATM Offering is filed as Exhibit 5.1 to this Annual Report.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Securities Trading Plans of Directors and Executive Officers</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c18758b8-047d-483d-8b52-ac48fc38a043" contextRef="C_72ef9daf-8437-4cbb-9e5d-f507601fa64a" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_6ef0a5ea-0f5b-4417-93a3-09fac310e112" contextRef="C_72ef9daf-8437-4cbb-9e5d-f507601fa64a" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_1d5d7ebf-b412-4756-ab19-a0ef3bb72399" contextRef="C_72ef9daf-8437-4cbb-9e5d-f507601fa64a" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_b9d81b97-7ed9-450b-81d1-9be662f8566d" contextRef="C_72ef9daf-8437-4cbb-9e5d-f507601fa64a" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No</span></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> officers, as defined in Rule 16a-1(f), or directors adopted or terminated a &#8220;Rule 10b5-1 trading arrangement&#8221; or a &#8220;non-Rule 10b5-1 trading arrangement,&#8221; as defined in Regulation S-K Item 408, during the last fiscal quarter.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9c_disclosure_regarding_foreign"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">em 9C.    Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">142</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_iii"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PA</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RT III</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_10_directors_executive_officers_and"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ite</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">m 10.    Directors, Executive Officers and Corporate Governance.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by this item will be included in our definitive proxy statement for the annual meeting of stockholders to be held in June 2025 to be filed with the SEC on or before April 30, 2025, or the Proxy Statement, and is incorporated herein by reference.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_11_executive_compensation"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">em 11.    Executive Compensation.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by this item will be included in the Proxy Statement and is incorporated herein by reference.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_12_security_ownership_of_certain"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ite</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">m 12.    Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by this item will be included in the Proxy Statement and is incorporated herein by reference.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="certain_relationships_and_related_transa"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> 13.    Certain Relationships and Related Transactions, and Director Independence.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by this item will be included in the Proxy Statement and is incorporated herein by reference.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="principal_accounting_fees_and_service"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ite</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">m 14.    Principal Accounting Fees and Services.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by this item will be included in the Proxy Statement and is incorporated herein by reference.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">143</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART IV</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="exhibits_and_financial_statement_schedul"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ite</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">m 15.    Exhibits and Financial Statement Schedules.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EXHIBIT INDEX</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:8%;box-sizing:content-box;"/>
    <td style="width:1.02%;box-sizing:content-box;"/>
    <td style="width:46%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:6%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:11%;box-sizing:content-box;"/>
    <td style="width:2%;box-sizing:content-box;"/>
    <td style="width:7%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:14.98%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Description</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Form</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">File No.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Filing Date</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;3.1</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1907108/000119312523272430/d576843dex31.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated Certificate of Incorporation of the Registrant (as amended and currently in effect)</span></a><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-41855</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">November 7, 2023</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;3.2</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1907108/000119312523272430/d576843dex32.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated Bylaws of the Registrant (as amended and currently in effect)</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-41855</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.2</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">November 7, 2023</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;4.1&#165;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1907108/000119312523247367/d287237dex41.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated Investors&#8217; Rights Agreement, dated August 10, 2021, by and among the Registrant and certain of its stockholders</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-274777</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">September 29, 2023</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;4.2</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1907108/000119312523265646/d287237dex42.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Common Stock Certificate of the Registrant</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1/A</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-274777</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.2</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">October 30, 2023</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;4.3</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1907108/000095017024028941/lxeo-ex4_3.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Description of Securities of the Registrant</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-41855</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.3</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 11, 2024</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.9pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0200000000000005pt;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;5.1*</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="lxeo-ex5_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Opinion of Wilson Sonsini Goodrich &amp; Rosati, P.C.</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-kerning:none;min-width:fit-content;">10.1</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">+</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1907108/000095017024095057/lxeo-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">2021 Equity Incentive Plan, as amended from time to time and Form of Stock Option Agreement, Early Exercise Notice and Restricted Stock Purchase Agreement, and Exercise Notice</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-41855</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">August 12, 2024</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0200000000000005pt;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-kerning:none;min-width:fit-content;">10.2</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">+</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001907108/000119312523265646/d287237dex102.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">2023 Equity Incentive Plan and Forms of Option Grant Notice and Agreement, Exercise Notice and Restricted Stock Unit Award Notice</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1/A</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-274777</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">October 30, 2023</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-kerning:none;min-width:fit-content;">10.3</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">+</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1907108/000119312523265646/d287237dex103.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">2023 Employee Stock Purchase Plan</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1/A</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-274777</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.3</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">October 30, 2023</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-kerning:none;min-width:fit-content;">10.4</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">+</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1907108/000119312523247367/d287237dex104.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Indemnification Agreement with Executive Officers and Directors</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-274777</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.4</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">September 29, 2023</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-kerning:none;min-width:fit-content;">10.5</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">+</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1907108/000119312523247367/d287237dex105.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated Employment Agreement, dated September 28, 2023, by and between the Company and R. Nolan Townsend</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-274777</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.5</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">September 29, 2023</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-kerning:none;min-width:fit-content;">10.6</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">+</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001907108/000119312523247367/d287237dex106.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated Employment Agreement, dated September 28, 2023, by and between the Company and Jenny R. Robertson</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-274777</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.6</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">September 29, 2023</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-kerning:none;min-width:fit-content;">10.7</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">+</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-kerning:none;min-width:fit-content;">&#134;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1907108/000119312523247367/d287237dex108.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consulting Agreement, dated October 9, 2020, between LEXEO Therapeutics, LLC and Ronald G. Crystal, M.D.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-274777</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.8</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">September 29, 2023</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-kerning:none;min-width:fit-content;">10.8</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">+</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-kerning:none;min-width:fit-content;">&#134;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001907108/000119312523247367/d287237dex109.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consulting Agreement, dated July 16, 2021, between LEXEO Therapeutics, LLC and Eric Adler, M.D.</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-274777</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.9</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">September 29, 2023</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.9&#165;&#134;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1907108/000119312523247367/d287237dex1010.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Stock Purchase Agreement, dated July 16, 2021, by and among LEXEO Therapeutics, Inc., Stelios Therapeutics, Inc., The Cystinosis Research Foundation, Eric Adler, M.D., Farah Sheikh, Ph.D., Jeffrey M. Ostrove, Ph.D., and Stephanie Cherqui, Ph.D., and Jeffery M. Ostrove, Ph.D., as Stockholders&#8217; Representative</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-274777</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.10</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">September 29, 2023</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.10&#165;&#134;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1907108/000119312523247367/d287237dex1011.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">License Agreement, dated October 4, 2021, by and between LEXEO Therapeutics, Inc. and the Regents of the University of California</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-274777</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.11</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">September 29, 2023</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">144</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:8%;box-sizing:content-box;"/>
    <td style="width:1.02%;box-sizing:content-box;"/>
    <td style="width:46%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:6%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:11%;box-sizing:content-box;"/>
    <td style="width:2%;box-sizing:content-box;"/>
    <td style="width:7%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:14.98%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.11&#165;&#134;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001907108/000119312523247367/d287237dex1012.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">License Agreement, dated April 23, 2020, by and between Stelios Therapeutics, Inc. (as successor-in-interest to ARVC Therapeutics, Inc.) and the Regents of the University of California</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-274777</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.12</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">September 29, 2023</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.12&#165;&#134;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1907108/000119312523247367/d287237dex1013.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">License Agreement, dated August 6, 2020, by and between Stelios Therapeutics, Inc. and the Regents of the University of California</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-274777</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.13</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">September 29, 2023</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.13&#165;&#134;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1907108/000119312523247367/d287237dex1014.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">ARVC Research Agreement, dated December 3, 2021, between LEXEO Therapeutics, Inc. and the Regents of the University of California, as amended by Amendment No. 1, dated April 5, 2023</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-274777</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.14</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">September 29, 2023</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.14&#165;&#134;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001907108/000119312523247367/d287237dex1015.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">TNNI3 Research Agreement, dated December 3, 2021, between LEXEO Therapeutics, Inc. and the Regents of the University of California, as amended by Amendment No. 1, dated April 19, 2023</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-274777</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.15</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">September 29, 2023</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.15&#165;&#134;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1907108/000119312523247367/d287237dex1016.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">First License Agreement, dated May 28, 2020, between LEXEO Therapeutics, LLC and Cornell University</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-274777</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.16</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">September 29, 2023</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.16&#165;&#134;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1907108/000119312523247367/d287237dex1017.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Second License Agreement, dated May 28, 2020, between LEXEO Therapeutics, LLC and Cornell University</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-274777</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.17</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">September 29, 2023</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.17&#134;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001907108/000119312523247367/d287237dex1018.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment No. 1, dated January 13, 2022, to the Second License Agreement, dated May 28, 2020, by and between LEXEO Therapeutics, Inc. and Cornell University</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-274777</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.18</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">September 29, 2023</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.18&#134;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1907108/000119312523247367/d287237dex1019.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment No. 1, dated July 4, 2022, to the First License Agreement, dated May 28, 2020, by and between LEXEO Therapeutics, Inc. and Cornell University and Amendment No. 2, dated July 1, 2022, to the Second License Agreement, dated May 28, 2020 (as amended by Amendment No. 1 to the Second License Agreement, dated January 13, 2022)</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-274777</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.19</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">September 29, 2023</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.19&#134;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1907108/000119312523247367/d287237dex1020.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment No. 2, dated September 28, 2022, to the First License Agreement, dated May 28, 2020, by and between LEXEO Therapeutics, Inc. and Cornell University (as amended by Amendment No. 1 to the First License Agreement, dated July 4, 2022)</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-274777</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.20</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">September 29, 2023</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.20&#165;&#134;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001907108/000119312523247367/d287237dex1022.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">License Agreement, dated January 19, 2021, between Adverum Biotechnologies, Inc. and LEXEO Therapeutics, Inc., as amended by the First Amendment, dated February 28, 2022</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-274777</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.22</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">September 29, 2023</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.21</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1907108/000119312524090233/d759703dex1021.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment No. 3, dated February 11, 2024, to the First License Agreement, dated May 28, 2020, by and between Lexeo Therapeutics, Inc. and Cornell University (as amended by Amendment No. 1 to the First License Agreement, dated July 4, 2022 and Amendment No. 2 to the First License Agreement, dated September 28, 2022)</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-278566</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.21</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">April 9, 2024</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.22+</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1907108/000095017024095057/lxeo-ex10_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Employment Agreement, dated April 10, 2024, by and between the Company and Jose Manuel Otero</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-41855</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">August 12, 2024</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.23&#165;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1907108/000095017024095057/lxeo-ex10_3.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Third License Agreement, dated April 21, 2024, by and between Cornell University and the Company</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-41855</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.3</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">August 12, 2024</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.24+*</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="lxeo-ex10_24.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Employment Agreement, dated December 18, 2024, by and between the Company and Kyle Rasbach</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.25+</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1907108/000119312524090233/d759703dex108.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Employment Agreement, dated February 3, 2024, by and between the Company and Eric Adler, M.D.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-278566</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.8</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">April 9, 2024</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">145</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:8%;box-sizing:content-box;"/>
    <td style="width:1.02%;box-sizing:content-box;"/>
    <td style="width:46%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:6%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:11%;box-sizing:content-box;"/>
    <td style="width:2%;box-sizing:content-box;"/>
    <td style="width:7%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:14.98%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.26+</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1907108/000119312524090233/d759703dex109.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Employment Agreement, dated February 2, 2024, by and between the Company and Sandi See Tai, M.D.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-278566</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.9</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">April 9, 2024</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.27*</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="lxeo-ex10_27.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Third Sponsored Research Agreement, dated April 13, 2024, by and between the Company and the Regents of University of California, San Diego</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.28*</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="lxeo-ex10_28.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment No. 2, dated April 13, 2024, to the TNNI3 Research Agreement, dated December 3, 2021, between LEXEO Therapeutics, Inc. and the Regents of the University of California, as amended</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.29*</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="lxeo-ex10_29.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment No. 2, dated August 31, 2023, to the ARVC Research Agreement, dated December 3, 2021, between LEXEO Therapeutics, Inc. and the Regents of the University of California, as amended</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.30*</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="lxeo-ex10_30.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment No. 3, dated April 19, 2024, to the ARVC Research Agreement, dated December 3, 2021, between LEXEO Therapeutics, Inc. and the Regents of the University of California, as amended</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.31*</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="lxeo-ex10_31.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment No. 4, dated September 27, 2024 to the ARVC Research Agreement, dated December 3, 2021, between LEXEO Therapeutics, Inc. and the Regents of the University of California, as amended</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.32*</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="lxeo-ex10_32.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Sales Agreement, dated as of March 24, 2025, by and between Lexeo Therapeutics, Inc. and Leerink Partners LLC</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.1</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1907108/000095017024028941/lxeo-ex14_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Code of Ethics</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-41855</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 11, 2024</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0200000000000005pt;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19.1*</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="lxeo-ex19_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Insider Trading and Window Period Policy</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23.1*</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="lxeo-ex23_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consent of KPMG LLP, independent registered public accounting firm.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23.2*</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="lxeo-ex5_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consent of Wilson Sonsini Goodrich &amp; Rosati, P.C. (included in Exhibit 5.1)</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24.1*</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#power_of_attorney"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Power of Attorney (contained in the signature page to this Annual Report on Form 10-K).</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31.1*</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="lxeo-ex31_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31.2*</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="lxeo-ex31_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32.1*#</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="lxeo-ex32_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32.2*#</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="lxeo-ex32_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">97.1</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1907108/000095017024028941/lxeo-ex97_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Policy Relating to Recovery of Erroneously Awarded Compensation</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-41855</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">97.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 11, 2024</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">146</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:8%;box-sizing:content-box;"/>
    <td style="width:1.02%;box-sizing:content-box;"/>
    <td style="width:46%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:6%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:11%;box-sizing:content-box;"/>
    <td style="width:2%;box-sizing:content-box;"/>
    <td style="width:7%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:14.98%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.INS</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Instance Document-the Instance Document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.SCH</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Taxonomy Extension Schema Document</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.CAL</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.DEF</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.LAB</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Taxonomy Extension Label Linkbase Document</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.PRE</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:73.333%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">* Filed herewith.</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">+ Indicates management contract or compensatory plan.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#165; Schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Registrant undertakes to furnish supplemental copies of any of the omitted schedules upon request by the SEC.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#134; Portions of this exhibit (indicated by [***]) have been omitted because the registrant has determined that the information is both not material and is the type that the Registrant treats as private or confidential.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"># The certification attached as Exhibit 32.1 that accompanies this Annual Report on Form 10-K is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Annual Report on Form 10-K, irrespective of any general incorporation language contained in such filing.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 16.    Form 10-K Summary</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has elected not to include summary information.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">147</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SIGNATURES</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Annual Report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50%;box-sizing:content-box;"/>
    <td style="width:4%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:45%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="3" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">LEXEO THERAPEUTICS, INC.</span></p></td>
   </tr>
   <tr style="height:7.9pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;border-bottom:0.5pt solid;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ R. Nolan Townsend</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">R. Nolan Townsend</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Chief Executive Officer</span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.4%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="power_of_attorney"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">POWER OF ATTORNEY</span></p>
  <p style="text-indent:6.507%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints R. Nolan Townsend, Kyle Rasbach and Jenny R. Robertson as his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place, and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming that the attorney-in-fact and agent, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report on Form 10-K has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated:</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:24.84%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:46.16%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:27%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Signature</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Title</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Date</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ R. Nolan Townsend</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">R. Nolan Townsend</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Executive Officer and Director</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Principal Executive Officer</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 24, 2025</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Kyle Rasbach</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td rowspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Financial Officer</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Principal Financial and Accounting Officer</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td rowspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td rowspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 24, 2025</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Kyle Rasbach</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Mette Kirstine Agger</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Mette Kirstine Agger</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 24, 2025</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Steven Altschuler</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Steven Altschuler, M.D.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 24, 2025</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Paula HJ Cholmondeley</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Paula HJ Cholmondeley</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 24, 2025</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Brenda Cooperstone</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Brenda Cooperstone, M.D.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 24, 2025</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Reinaldo Diaz</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Reinaldo Diaz</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 24, 2025</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Tolga Tanguler</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tolga Tanguler</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 24, 2025</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Tim Van Hauwermeiren</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tim Van Hauwermeiren</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 24, 2025</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">148</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>lxeo-ex5_1.htm
<DESCRIPTION>EX-5.1
<TEXT>
<html>
 <head>
  <title>EX-5.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 5.1</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:15.52%;box-sizing:content-box;"></td>
    <td style="width:15.5%;box-sizing:content-box;"></td>
    <td style="width:34.86%;box-sizing:content-box;"></td>
    <td style="width:1%;box-sizing:content-box;"></td>
    <td style="width:19.22%;box-sizing:content-box;"></td>
    <td style="width:13.9%;box-sizing:content-box;"></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.014in;vertical-align:middle;padding-bottom:0.01in;padding-right:0.014in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;padding-left:0.014in;vertical-align:middle;padding-bottom:0.01in;padding-right:0.014in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;padding-left:0.014in;vertical-align:middle;padding-bottom:0.01in;padding-right:0.014in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;padding-left:0.014in;vertical-align:middle;padding-bottom:0.01in;padding-right:0.014in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;padding-left:0.014in;vertical-align:middle;padding-bottom:0.01in;padding-right:0.014in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;padding-left:0.014in;vertical-align:middle;padding-bottom:0.01in;padding-right:0.014in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="3" style="padding-top:0in;padding-left:0.017in;vertical-align:middle;padding-bottom:0in;padding-right:0.017in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img155268912_0.jpg" alt="img155268912_0.jpg" style="width:142px;height:54px;"></p></td>
    <td colspan="3" style="padding-top:0.021in;padding-left:0.017in;vertical-align:top;padding-bottom:0.021in;padding-right:0.017in;"><p style="font-size:7.5pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Georgia',serif;font-kerning:none;min-width:fit-content;">Wilson Sonsini Goodrich &amp; Rosati<br>Professional Corporation</font></p><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#023f50;white-space:pre-wrap;font-family:'Georgia',serif;font-kerning:none;min-width:fit-content;">1301 Avenue of the Americas</font><font style="color:#000000;white-space:pre-wrap;font-family:'Georgia',serif;font-kerning:none;min-width:fit-content;"><br></font><font style="color:#023f50;white-space:pre-wrap;font-family:'Georgia',serif;font-kerning:none;min-width:fit-content;">New York, NY 10019</font></p><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Georgia',serif;font-kerning:none;min-width:fit-content;">o: (</font><font style="color:#023f50;white-space:pre-wrap;font-family:'Georgia',serif;font-kerning:none;min-width:fit-content;">212) 999-5800</font><font style="color:#000000;white-space:pre-wrap;font-family:'Georgia',serif;font-kerning:none;min-width:fit-content;"><br>f: (</font><font style="color:#023f50;white-space:pre-wrap;font-family:'Georgia',serif;font-kerning:none;min-width:fit-content;">212) 999-5801</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 24, 2025</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lexeo Therapeutics, Inc.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">345 Park Avenue South, Floor 6</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">New York, New York 10010</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Re:</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registration Statement on Form S-3</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ladies and Gentlemen:</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have acted as counsel to Lexeo Therapeutics, Inc., a Delaware corporation (the &#x201c;Company&#x201d;), in connection with the registration of the proposed offer and sale of up to $75,000,000 of shares (the &#x201c;Shares&#x201d;) of the Company&#x2019;s common stock, $0.0001 par value per share, pursuant to the Company&#x2019;s Registration Statement on Form S-3 (File No. 333- 283781) (the &#x201c;Registration Statement&#x201d;) including the prospectus dated December 19, 2024 included therein (the &#x201c;Base Prospectus&#x201d;), filed by the Company with the Securities and Exchange Commission (the &#x201c;Commission&#x201d;) in connection with the registration pursuant to the Securities Act of 1933, as amended (the &#x201c;Act&#x201d;), of the Shares.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The offering and sale of the Shares are being made pursuant to the Sales Agreement, dated as of March 24, 2025 (the &#x201c;Sales Agreement&#x201d;), by and between the Company and Leerink Partners LLC.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have examined copies of the Sales Agreement, the Registration Statement, the Base Prospectus, and the prospectus supplement thereto related to the offering of the Shares, which prospectus supplement is dated as of March 24, 2025, and will be filed by the Company in accordance with Rule 424(b) promulgated under the Act (the &#x201c;Prospectus Supplement&#x201d; and together with the Base Prospectus, the &#x201c;Prospectus&#x201d;). We have also examined instruments, documents and records which we deemed relevant and necessary for the basis of our opinion hereinafter expressed.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In such examination, we have assumed (a) the authenticity of original documents and the genuineness of all signatures; (b) the conformity to the originals of all documents submitted to us as copies; (c) the truth, accuracy and completeness of the information, representations and warranties contained in the instruments, documents, certificates and records we have reviewed; (d) that the Registration Statement, and any amendments thereto (including post-effective amendments), will have become effective under the Act; (e) that the Prospectus Supplement will have been filed with the Commission describing the Shares offered thereby; (f) that the Shares will be sold in compliance with applicable U.S. federal and state securities laws and in the manner stated in the Registration Statement and the Prospectus; and (g) the legal capacity of all natural persons. As to any facts material to the opinions expressed herein that were not independently established or verified, we have relied upon oral or written statements and representations of officers and other representatives of the Company.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img155268912_1.jpg" alt="img155268912_1.jpg" style="width:84px;height:32px;"></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lexeo Therapeutics, Inc.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 24, 2025</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Page 2</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on and subject to the foregoing, we are of the opinion that the Shares have been duly authorized by the Company and, when issued and delivered by the Company against payment therefor in accordance with the terms of the Sales Agreement, will be validly issued, fully paid and nonassessable.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We express no opinion as to the laws of any other jurisdiction other than the federal laws of the United States of America and the General Corporation Law of the State of Delaware.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">* * *</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We hereby consent to the use of this opinion as an exhibit to the Company&#x2019;s Annual Report on Form 10-K, filed on or about March 24, 2025, for incorporation by reference into the Registration Statement and the Prospectus. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Act or the rules and regulations of the Commission thereunder.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sincerely,</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:28.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/s/ Wilson Sonsini Goodrich &amp; Rosati, P.C.</font></p>
  <p style="margin-left:28.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:28.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WILSON SONSINI GOODRICH &amp; ROSATI<br>Professional Corporation</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.24
<SEQUENCE>3
<FILENAME>lxeo-ex10_24.htm
<DESCRIPTION>EX-10.24
<TEXT>
<html>
 <head>
  <title>EX-10.24</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:0.94in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.24</font></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EMPLOYMENT AGREEMENT</font></p>
  <p style="margin-left:0.04%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">for</font></p>
  <p style="margin-left:0.04%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">KYLE RASBACH</font></p>
  <p style="font-size:10pt;margin-top:0.15pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:6.804%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.093%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Employment Agreement (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) is made between Lexeo Therapeutics, Inc. (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) and Kyle Rasbach (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Executive</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) (collectively, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Parties</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).</font></p>
  <p style="margin-left:0.92%;text-indent:6.809%;font-size:10pt;margin-top:11.85pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.167%;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Whereas</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company desires for Executive to provide services to the Company, and wishes to provide Executive with certain compensation and benefits in return for such employment services; and</font></p>
  <p style="margin-left:0.92%;text-indent:6.81%;font-size:10pt;margin-top:11.7pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.185%;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Whereas</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, Executive wishes to be employed by the Company and to provide personal services to the Company in return for certain compensation and benefits;</font></p>
  <p style="margin-left:0.92%;text-indent:6.809%;font-size:10pt;margin-top:11.95pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.167%;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Now, Therefore</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, in consideration of the mutual promises and covenants contained herein and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties hereto agree as follows:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:0.935%;text-indent:6.812%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.204%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.4788270327562714%;">1.</font><div style="width:100%;display:inline;" id="x__employment_by_the_company_"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Employment by the Company.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:0.935%;text-indent:13.605%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.9014788270327565%;">1.1</font><div style="width:100%;display:inline;" id="position___beginning_may_20__2024__execu"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Position. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Beginning December 18, 2024, Executive shall serve as the Company&#x2019;s Chief Financial Officer. During the term of Executive&#x2019;s employment with the Company, Executive will devote Executive&#x2019;s best efforts and substantially all of Executive&#x2019;s business time and attention to the business of the Company, except for approved time off permitted by the Company&#x2019;s general employment policies.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:0.935%;text-indent:13.605%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.9014788270327565%;">1.2</font><div style="width:100%;display:inline;" id="x_1_duties_and_location___executive_shal"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Duties and Location. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Executive shall perform such duties incident to the position(s) held by Executive, including without limitation such duties and responsibilities as may be assigned to Executive by the Chief Executive Officer (&#x201c;CEO&#x201d;), to whom Executive will report. Executive shall work in the Company&#x2019;s New York City office as needed and requested by the Company, and Executive will be permitted to work remotely from his home office in North Carolina when not in the New York City office. The Company reserves the right, at the Board&#x2019;s discretion, to reasonably require Executive to perform Executive&#x2019;s duties at places other than Executive&#x2019;s primary office location from time to time, and to require reasonable business travel. The Company may modify Executive&#x2019;s job title and duties as it deems necessary and appropriate in light of the Company&#x2019;s needs and interests from time to time.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:0.935%;text-indent:13.605%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.9014788270327565%;">1.3</font><div style="width:100%;display:inline;" id="x_2_policies_and_procedures___the_employ"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Policies and Procedures. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The employment relationship between the Parties shall be governed by the general employment policies and practices of the Company, except that when the terms of this Agreement differ from or are in conflict with the Company&#x2019;s general employment policies or practices, this Agreement shall control.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:0.935%;text-indent:13.625%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.204%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.9014788270327565%;">1.4</font><div style="width:100%;display:inline;" id="x_3_indemnification__the_executive_shall"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indemnification. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Executive shall be provided indemnification coverage under the Company&#x2019;s D&amp;O liability insurance policies to the same extent as directors and other executive officers of the Company.</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.19in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:0.94in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:0.935%;text-indent:6.812%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.204%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.4788270327562714%;">2.</font><div style="width:100%;display:inline;" id="x__compensation_"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compensation.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:0.935%;text-indent:13.605%;font-size:0;margin-top:11.95pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.9014788270327565%;">2.1</font><div style="width:100%;display:inline;" id="x_1_salary___for_services_to_be_rendered"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Salary. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For services to be rendered hereunder, Executive shall receive a base salary at the rate of $480,000</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">per year (the &#x201c;Base Salary&#x201d;), subject to standard payroll deductions and withholdings and payable in accordance with the Company&#x2019;s regular payroll schedule. The Base Salary is subject to periodic review and modification by the CEO and the Board (or the Compensation Committee of the Board), from time to time, at their sole discretion.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:0.935%;text-indent:13.605%;font-size:0;margin-top:11.95pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.9014788270327565%;">2.2</font><div style="width:100%;display:inline;" id="annual_cash_bonus___executive_will_be_el"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Annual Cash Bonus. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Executive will be eligible for an annual discretionary cash bonus of up to Forty Percent (40%) of Executive&#x2019;s Base Salary (the &#x201c;Annual Bonus&#x201d;). Whether Executive receives an Annual Bonus for any given year, and the amount of any such Annual Bonus, will be determined by the CEO and the Board (or the Compensation Committee of the Board) in their sole discretion based upon the Company&#x2019;s performance and Executive&#x2019;s achievement of individual objectives and milestones to be determined on an annual basis. Any Annual Bonus that is awarded will be paid within the first ninety (90) days of the calendar year following the applicable bonus year. Executive will not be eligible for, and will not earn, any Annual Bonus if Executive&#x2019;s employment terminates for any reason, or if Executive or the Company has given notice of the termination of Executive&#x2019;s employment, before the payment date, except as expressly provided for in Section 5.5 herein. For clarity, Executive will not be eligible for any Annual Bonus for performance in 2024.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:0.935%;text-indent:13.605%;font-size:0;margin-top:12.25pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.9014788270327565%;">2.3</font><div style="width:100%;display:inline;" id="x_2_equity_awards__subject_to_the_approv"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Equity Awards</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subject to the approval of the Compensation Committee of the Board of Directors (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Committee</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), Executive will be granted a mix of equity awards as follows:</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.602%;display:flex;margin-top:11.85pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.731%;min-width:3.333%;text-align:left;"><font style="color:#232323;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.607220935518085%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An option to purchase 245,250 shares of the Company&#x2019;s Common Stock (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Option</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). The Option will vest and become exercisable over 4 years at the rate of 25% of the total number of Option shares on the 1-year anniversary of Executive&#x2019;s start date of employment with the Company and 1/48th of the total number of Option shares on each monthly anniversary thereafter, subject to Executive&#x2019;s continuous service with the Company through each vesting date. The exercise price per share of the Option will be equal to the fair market value per share of the Company&#x2019;s Common Stock on the date the Option is granted, as determined by the Committee in good faith. There is no guarantee that the Internal Revenue Service will agree with this value.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.602%;display:flex;margin-top:11.85pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.731%;min-width:3.333%;text-align:left;"><font style="color:#232323;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.607220935518085%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">40,875 restricted stock units of the Company&#x2019;s Common Stock (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RSUs</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). The RSUs will vest over a period of approximately 4 years. RSUs for the Company will generally vest on specific dates each quarter for the entire Company. The vesting start date of Executive&#x2019;s RSUs will be the next Company RSU vesting date that occurs after Executive&#x2019;s start date. The RSUs will vest as to 25% of the total number of RSUs on the 1-year anniversary of Executive&#x2019;s RSU vesting start date and 1/16th of the total number of RSU shares on each quarterly date 3-months thereafter, subject to Executive&#x2019;s continuous service with the Company through each vesting date.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:0.935%;text-indent:6.812%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.204%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.4788270327562714%;">3.</font><div style="width:100%;display:inline;" id="x__standard_company_benefits___executive"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Standard Company Benefits. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Executive shall be entitled to participate in all employee benefit programs for which Executive is eligible under the terms and conditions of the benefit plans that may be in effect from time to time and provided by the Company to its employees, subject to the eligibility criteria, rules, plan provisions and regulations applicable to such plans, except to the extent that participation in such plans or programs would result in duplication of benefits provided hereunder. The Company reserves the right to cancel or change the benefit plans or programs it offers to its employees at any time, in its sole discretion.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:0.935%;text-indent:6.812%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.204%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.4788270327562714%;">4.</font><div style="width:100%;display:inline;" id="x__expenses___the_company_will_reimburse"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Expenses. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company will reimburse Executive for reasonable travel, entertainment or other expenses incurred by Executive in furtherance or in connection with the performance of Executive&#x2019;s duties hereunder, subject to, and in accordance with, the Company&#x2019;s expense reimbursement policy as in effect from time to time.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:0.935%;text-indent:6.812%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.204%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.4788270327562714%;">5.</font><div style="width:100%;display:inline;" id="x__termination_of_employment__severance"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Termination of Employment; Severance</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:0.935%;text-indent:13.605%;font-size:0;margin-top:11.95pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.9014788270327565%;">5.1</font><div style="width:100%;display:inline;" id="x_1_at_will_employment___executive_s_emp"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At-Will Employment. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Executive&#x2019;s employment relationship is at-will. Either Executive or the Company may terminate the employment relationship at any time, with or without cause or advance notice.</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.19in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:0.94in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:0.935%;text-indent:13.605%;font-size:0;margin-top:11.85pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.9014788270327565%;">5.2</font><div style="width:100%;display:inline;" id="x_2_termination_based_on_death_or_disabi"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Termination Based on Death or Disability</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In the event of the Executive&#x2019;s death, the Executive&#x2019;s employment with the Company shall terminate automatically. The Company, in its discretion, shall have the right to terminate the Executive&#x2019;s employment because of the Executive&#x2019;s Disability during the Employment Period, subject to applicable law. For purposes of this Agreement, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disability</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means that the Executive has been unable, for 60 consecutive days, or for any period aggregating 90 business days in any consecutive 180 day period, as the case may be, to perform a substantial portion of the Executive&#x2019;s duties under this Agreement, as a result of physical or mental impairment, illness or injury, as determined by a medical doctor reasonably selected by the Company and approved by the Executive, such approval not to be unreasonably withheld, delayed or conditioned. Such determination shall be deemed to be conclusive for all purposes of this Section 5.2. In connection with the foregoing, the Executive shall cooperate with such medical doctor, including without limitation, by submitting to such medical tests and examinations as may be requested by the medical doctor. A termination of the Executive&#x2019;s employment by the Company for Disability shall be communicated to the Executive by written notice upon the expiration of the applicable period and shall be effective on the 30th day after receipt of such notice by the Executive (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disability Effective Date</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), unless the Executive returns to satisfactory full-time performance of the Executive&#x2019;s previous duties before the Disability Effective Date. In the event the Executive&#x2019;s employment is terminated due to death or Disability, the Company shall have no further obligations to the Executive hereunder, except the Company shall pay to the Executive (or, in the event of death, to the Executive&#x2019;s estate) any (i) Base Salary earned or payable but unpaid to the Executive through the Date of Termination, (ii) reimbursable business expenses incurred but unpaid through the Date of Termination (subject to Company&#x2019;s applicable expense policies, including submission of all required documentation), and (iii) any other amounts or benefits required by applicable law.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:0.935%;text-indent:13.605%;font-size:0;margin-top:11.95pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.9014788270327565%;">5.3</font><div style="width:100%;display:inline;" id="x_3_termination_without_cause__resignati"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Termination Without Cause; Resignation for Good Reason.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:0.935%;text-indent:20.437%;font-size:0;margin-top:11.95pt;justify-content:flex-start;margin-bottom:0;margin-right:1.204%;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:1.747337606621915%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company may terminate Executive&#x2019;s employment with the Company at any time without Cause (as defined below). Further, Executive may resign at any time for Good Reason (as defined below).</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:0.935%;text-indent:20.408%;font-size:0;margin-top:11.7pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:1.747337606621915%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="width:100%;display:inline;" id="xii__in_the_event_executive_s_employment"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the event Executive&#x2019;s employment with the Company is terminated by the Company without Cause, or Executive resigns for Good Reason, then provided such termination constitutes a &#x201c;separation from service&#x201d; (as defined under Treasury Regulation Section 1.409A-1(h), without regard to any alternative definition thereunder, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Separation from Service</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), and provided that Executive remains in compliance with the terms of this Agreement, the Company shall provide Executive with the following severance benefits:</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:0.935%;text-indent:27.211%;font-size:0;margin-top:11.95pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:26.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.169989400898401%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;" id="xa__the_company_shall_pay_executive__as_"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company shall pay Executive, as severance, twelve (12) months of Executive&#x2019;s base salary in effect as of the date of Executive&#x2019;s employment termination, subject to standard payroll deductions and withholdings (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Severance</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). The Severance will be paid in a single lump sum on or about the Company&#x2019;s first regular payroll date following the 60</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> day after Executive&#x2019;s Separation from Service.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:0.935%;text-indent:27.211%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:26.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.169989400898401%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;" id="xb__provided_executive_timely_elects_con"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Provided Executive timely elects continued coverage under COBRA, the Company shall pay Executive&#x2019;s COBRA premiums to continue Executive&#x2019;s coverage (including coverage for eligible dependents, if applicable) (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">COBRA Premiums</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) through the period (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">COBRA Premium Period</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) starting on Executive&#x2019;s Separation from Service and ending on the earliest to occur of: (i) twelve (12) months following Executive&#x2019;s Separation from Service; (ii) the date Executive becomes eligible for group health insurance coverage through a new employer; or (iii) the date Executive ceases to be eligible for COBRA continuation coverage for any reason, including plan termination. In the event Executive becomes covered under another employer&#x2019;s group health plan or otherwise ceases to be eligible for COBRA during the COBRA Premium Period, Executive must immediately notify the Company of such event. Notwithstanding the foregoing, if the Company determines, in its sole discretion, that it cannot pay the COBRA Premiums without a substantial risk of violating applicable law (including, without limitation, Section 2716 of the Public Health Service Act), the Company instead shall pay to Executive, on the first day of each calendar month, a fully taxable cash payment equal to the applicable COBRA premiums for that month (including premiums for Executive and Executive&#x2019;s eligible dependents who have elected and remain enrolled in such COBRA coverage), subject to applicable tax withholdings (such amount, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Special Cash Payment</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), for the remainder of the COBRA Premium Period. Executive may, but is not obligated to, use such Special Cash Payments toward the cost of COBRA premiums.</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.19in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:0.94in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:0.935%;text-indent:27.211%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:26.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.169989400898401%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If, at the time of Executive&#x2019;s Separation from Service, he has completed an equity financing of at least $120,000,000 million, then any portion of the Option and RSUs described in Section 2.3 that are then unvested and outstanding shall be permitted to continue to vest for a period of twenty-four (24) months or such shorter time as may cause them to be fully vested (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Post-Employment Partial Vesting Period</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). If, during the Post-Employment Partial Vesting Period a Change in Control (as defined herein) occurs, the portion of the Options and RSUs that would have vested by the end of the Post-Employment Vesting Period will vest immediately as of the date of the Change in Control (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Post-Employment Partial Vesting Acceleration</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). Executive shall only be entitled to the post-employment vesting set forth in this provision if Executive cooperates fully with the Company in connection with the transition of Executive&#x2019;s responsibilities as well as any actual or contemplated defense, prosecution, or investigation of any claims or demands by or against third parties, or other matters arising from events, acts, or failures to act that occurred during the period of Executive&#x2019;s employment by the Company. Such cooperation includes, without limitation, being available to the Company upon reasonable notice, without subpoena, to provide complete, truthful and accurate information in witness interviews, depositions, and trial testimony, as well as in response to any inquiries from regulatory bodies or agencies.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:0.935%;text-indent:13.605%;font-size:0;margin-top:11.95pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.9014788270327565%;">5.4</font><div style="width:100%;display:inline;" id="x_4_termination_for_cause__resignation_w"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Termination for Cause; Resignation Without Good Reason; Death or Disability.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:0.935%;text-indent:20.408%;font-size:0;margin-top:4pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:1.747337606621915%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;" id="xi__the_company_may_terminate_executive_"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company may terminate Executive&#x2019;s employment with the Company at any time for Cause. Further, Executive may resign at any time without Good Reason. Executive&#x2019;s employment with the Company may also be terminated due to Executive&#x2019;s death or disability.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:0.935%;text-indent:20.408%;font-size:0;margin-top:4pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:1.747337606621915%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="width:100%;display:inline;" id="xii__if_executive_resigns_without_good_r"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If Executive resigns without Good Reason, or the Company terminates Executive&#x2019;s employment for Cause, or upon Executive&#x2019;s death or disability, then (i) Executive will no longer vest in the Option and any other stock options held by the Executive, (ii) all payments of compensation by the Company to Executive hereunder will terminate immediately (except as to amounts already earned), and (c) Executive will not be entitled to any severance benefits, including (without limitation) the Severance, COBRA Premiums, Special Cash Payments, unless required by law.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:0.935%;text-indent:13.605%;font-size:0;margin-top:11.9pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.9014788270327565%;">5.5</font><div style="width:100%;display:inline;" id="x_5_termination_in_connection_with_chang"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Termination in Connection with Change in Control</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. If the Company terminates Executive&#x2019;s employment no more than three (3) months prior to a Change in Control (as defined herein) or within twelve (12) months after a Change in Control, Executive shall be entitled to receive the following severance benefits:</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:0.935%;text-indent:20.408%;font-size:0;margin-top:12.1pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:1.747337606621915%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company shall pay Executive, as severance, twelve (12) months of Executive&#x2019;s base salary in effect as of the date of Executive&#x2019;s employment termination, subject to standard payroll deductions and withholdings (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CIC Severance</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). The CIC Severance will be paid in a single lump sum on or about the Company&#x2019;s first regular payroll date following the 60</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> day after Executive&#x2019;s Separation from Service.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:0.935%;text-indent:20.408%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:1.747337606621915%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Provided Executive timely elects continued coverage under COBRA, the Company shall pay Executive&#x2019;s COBRA premiums to continue Executive&#x2019;s coverage (including coverage for eligible dependents, if applicable) (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CIC COBRA Premiums</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) through the period (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CIC COBRA Premium Period</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) starting on Executive&#x2019;s Separation from Service and ending on the earliest to occur of: (i) twelve (12) months following Executive&#x2019;s Separation from Service; (ii) the date Executive becomes eligible for group health insurance coverage through a new employer; or (iii) the date Executive ceases to be eligible for COBRA continuation coverage for any reason, including plan termination. In the event Executive becomes covered under another employer&#x2019;s group health plan or otherwise ceases to be eligible for COBRA during the CIC COBRA Premium Period, Executive must immediately notify the Company of such event. Notwithstanding the foregoing, if the Company determines, in its sole discretion, that it cannot pay the CIC COBRA Premiums without a substantial risk of violating applicable law (including, without limitation, Section 2716 of the Public Health Service Act), the Company instead shall pay to Executive, on the first day of each calendar month, a fully taxable cash payment equal to the applicable COBRA premiums for that month (including premiums for Executive and Executive&#x2019;s eligible dependents who have elected and remain enrolled in such COBRA coverage), subject to applicable tax withholdings (such amount, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CIC Special Cash Payment</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), for the remainder of the CIC COBRA Premium Period. Executive may, but is not obligated to, use such CIC Special Cash Payments toward the cost of COBRA premiums.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:0.935%;text-indent:20.892%;font-size:0;margin-top:12.2pt;justify-content:flex-start;margin-bottom:0;margin-right:3.333%;min-width:20%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:1.747337606621915%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(iii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company shall pay Executive, as further severance, a lump sum amount equal to Executive&#x2019;s full bonus target for the calendar year in which the Change in Control occurs (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CIC Bonus Payment</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), to be paid no later than thirty (30) days following Executive&#x2019;s Separation from Service.</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.19in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:0.94in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:0.935%;text-indent:20.408%;font-size:0;margin-top:12.2pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:1.747337606621915%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(iv)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company shall accelerate the vesting of any shares, options, or other equity grants then unvested and outstanding as of the Executive&#x2019;s Separation from Service, such that Executive will thereafter be 100% vested in any shares, options, or other equity grants awarded by the Company to Executive during Executive&#x2019;s employment with the Company (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Vesting Acceleration</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:0.935%;text-indent:6.812%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.204%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.4788270327562714%;">6.</font><div style="width:100%;display:inline;" id="x__conditions_to_receipt_of_severance__c"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Conditions to Receipt of Severance, COBRA Premiums, and Special Cash Payments. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The receipt of the Severance, CIC Severance, COBRA Premiums, CIC COBRA Premiums, Special Cash Payments, CIC Special Cash Payments, CIC Bonus Payment, and Vesting Acceleration (collectively, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Severance Benefits</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) will be subject to Executive signing and not revoking a separation agreement and release of claims in a form satisfactory to the Company (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Separation Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) within a time period specified by the Company, in its sole discretion. No Severance Benefits will be paid or provided until the Separation Agreement becomes effective. Executive shall also resign from all positions and terminate any relationships as an employee, advisor, officer or director with the Company and any of its affiliates, each effective on the date of termination.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:0.935%;text-indent:6.812%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.204%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.4788270327562714%;">7.</font><div style="width:100%;display:inline;" id="x__section_409a___it_is_intended_that_al"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 409A. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It is intended that all of the severance benefits and other payments payable under this Agreement satisfy, to the greatest extent possible, the exemptions from the application of Code Section 409A provided under Treasury Regulations 1.409A-1(b)(4), 1.409A-1(b)(5) and 1.409A-1(b)(9), and this Agreement will be construed to the greatest extent possible as consistent with those provisions, and to the extent not so exempt, this Agreement (and any definitions hereunder) will be construed in a manner that complies with Section 409A. For purposes of Code Section 409A (including, without limitation, for purposes of Treasury Regulation Section 1.409A-2(b)(2)(iii)), Executive&#x2019;s right to receive any installment payments under this Agreement (whether severance payments, reimbursements or otherwise) shall be treated as a right to receive a series of separate payments and, accordingly, each installment payment hereunder shall at all times be considered a separate and distinct payment. Notwithstanding any provision to the contrary in this Agreement, if Executive is deemed by the Company at the time of Executive&#x2019;s Separation from Service to be a &#x201c;specified employee&#x201d; for purposes of Code Section 409A(a)(2)(B)(i), and if any of the payments upon Separation from Service set forth herein and/or under any other agreement with the Company are deemed to be &#x201c;deferred compensation&#x201d;, then to the extent delayed commencement of any portion of such payments is required in order to avoid a prohibited distribution under Code Section 409A(a)(2)(B)(i) and the related adverse taxation under Section 409A, such payments shall not be provided to Executive prior to the earliest of (i) the expiration of the six-month period measured from the date of Executive&#x2019;s Separation from Service with the Company, (ii) the date of Executive&#x2019;s death or (iii) such earlier date as permitted under Section 409A without the imposition of adverse taxation. Upon the first business day following the expiration of such applicable Code Section 409A(a)(2)(B)(i) period, all payments deferred pursuant to this Paragraph shall be paid in a lump sum to Executive, and any remaining payments due shall be paid as otherwise provided herein or in the applicable agreement. No interest shall be due on any amounts so deferred.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:0.935%;text-indent:6.812%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.204%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.4788270327562714%;">8.</font><div style="width:100%;display:inline;" id="x__definitions_"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Definitions.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:0.935%;text-indent:13.605%;font-size:0;margin-top:11.95pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.9014788270327565%;">(i)</font><div style="width:100%;display:inline;" id="xi__cause___for_purposes_of_this_agreeme"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cause. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For purposes of this Agreement, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cause</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; for termination will mean: (a) Executive&#x2019;s conviction for, or entry of a guilty plea or plea of nolo contendere for, any felony or crime involving dishonesty; (b) Executive&#x2019;s participation in any fraud against the Company; (c) material breach of Executive&#x2019;s duties to the Company; (d) persistent unsatisfactory performance of Executive&#x2019;s job duties after written notice from the Board and a reasonable opportunity to cure (if deemed curable); (e) Executive&#x2019;s intentional damage to any property of the Company; (f) Executive&#x2019;s misconduct, or other violation of Company policy that causes harm; (g) Executive&#x2019;s breach of any written agreement with the Company; and (h) conduct by Executive which in the good faith and reasonable determination of the Board demonstrates gross unfitness to serve, including but not limited to conduct involving moral turpitude, corruption, dishonesty, or other conduct that harms the Company&#x2019;s reputation or prospects.</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.19in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:0.94in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:0.935%;text-indent:13.605%;font-size:0;margin-top:11.95pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.9014788270327565%;">(ii)</font><div style="width:100%;display:inline;" id="xii__good_reason___for_purposes_of_this_"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Good Reason. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For purposes of this Agreement, Executive shall have &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Good Reason</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; for resignation from employment with the Company if any of the following actions are taken by the Company without Executive&#x2019;s prior written consent: (a) a material reduction in Executive&#x2019;s base salary as Chief Financial Officer, which the parties agree is a reduction of at least 10% of Executive&#x2019;s base salary (unless pursuant to a salary reduction program applicable generally to the Company&#x2019;s similarly situated executive employees); (b) a material reduction in Executive&#x2019;s duties as Chief Financial Officer (including responsibilities and/or authorities), </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided, however, </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that a change in job position to a different executive role shall not be deemed a &#x201c;material reduction&#x201d; in and of itself; or (c) relocation of Executive&#x2019;s principal place of employment to a place that increases Executive&#x2019;s one-way commute by more than sixty (60) miles as compared to Executive&#x2019;s then-current principal place of employment immediately prior to such relocation. In order to resign for Good Reason, Executive must provide written notice to the Board within 30 days after the first occurrence of the event giving rise to Good Reason setting forth the basis for Executive&#x2019;s resignation, allow the Company at least 30 days from receipt of such written notice to cure such event, and if such event is not reasonably cured within such period, Executive must resign from all positions Executive then holds with the Company not later than 90 days after the expiration of the cure period.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:0.935%;text-indent:13.605%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.9014788270327565%;">(iii)</font><div style="width:100%;display:inline;" id="xiii__change_in_control___for_purposes_o"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Change in Control</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. For purposes of this Agreement, &#x201c;Change in Control&#x201d; shall have the meaning set forth in the Lexeo Therapeutics, Inc. 2023 Equity Incentive Plan.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:0.935%;text-indent:6.812%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.204%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.4788270327562714%;">9.</font><div style="width:100%;display:inline;" id="x__proprietary_information_obligations_"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Proprietary Information Obligations.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:0.935%;text-indent:13.605%;font-size:0;margin-top:11.95pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.9014788270327565%;">9.1</font><div style="width:100%;display:inline;" id="x_1_confidential_information_agreement__"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Confidential Information Agreement. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a condition of employment, Executive shall execute and abide by the Company&#x2019;s standard form of Employee Confidential Information And Inventions Assignment Agreement (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Confidentiality Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:0.935%;text-indent:13.605%;font-size:0;margin-top:12.15pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.9014788270327565%;">9.2</font><div style="width:100%;display:inline;" id="x_2_third_party_agreements_and_informati"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Third-Party Agreements and Information. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Executive represents and warrants that Executive&#x2019;s employment by the Company does not conflict with any prior employment or consulting agreement or other agreement with any third party, and that Executive will perform Executive&#x2019;s duties to the Company without violating any such agreement. Executive represents and warrants that Executive does not possess confidential information arising out of prior employment, consulting, or other third party relationships, that would be used in connection with Executive&#x2019;s employment by the Company, except as expressly authorized by that third party. During Executive&#x2019;s employment by the Company, Executive will use in the performance of Executive&#x2019;s duties only information which is generally known and used by persons with training and experience comparable to Executive&#x2019;s own, common knowledge in the industry, otherwise legally in the public domain, or obtained or developed by the Company or by Executive in the course of Executive&#x2019;s work for the Company. Executive expressly acknowledges that she will not use any confidential or proprietary information of a third-party in connection with the performance of his duties to the Company.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:0.935%;text-indent:6.812%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.204%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.4788270327562714%;">10.</font><div style="width:100%;display:inline;" id="x0__outside_activities_during_employment"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Outside Activities During Employment.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:0.935%;text-indent:13.605%;font-size:0;margin-top:11.95pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.9014788270327565%;">10.1</font><div style="width:100%;display:inline;" id="x0_1_non_company_business__except_with_t"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Non-Company Business. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Except with the prior written consent of the Board, Executive will not during the term of Executive&#x2019;s employment with the Company undertake or engage in any other employment, occupation or business enterprise, other than ones in which Executive is a passive investor. In any event, Executive may: (i) engage in civic and not- for-profit activities; (ii) engage in activities in connection with personal investments; (iii) serve, following receiving consent from the Board (which shall not unreasonably be withheld), on board of directors positions for up to two (2) organizations, and (iv) serve as an advisor, or as a member of an advisory board, following receiving consent from the Board (which shall not unreasonably be withheld), on up to two (2) organizations; so long as such activities do not materially interfere with the performance of Executive&#x2019;s duties hereunder.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:0.935%;text-indent:13.605%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.9014788270327565%;">10.2</font><div style="width:100%;display:inline;" id="x0_2_no_adverse_interests__executive_agr"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Adverse Interests. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Executive agrees not to acquire, assume or participate in, directly or indirectly, any position, investment or interest known to be adverse or antagonistic to the Company, its business or prospects, financial or otherwise. This does not prohibit the Executive from purchasing any publicly listed securities or funds which hold publicly listed securities.</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.19in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:0.94in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:0.935%;text-indent:6.803%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:6pt;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:1.4788270327562714%;">11.</font><div style="width:100%;display:inline;" id="x1__dispute_resolution___to_ensure_the_t"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dispute Resolution. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To ensure the timely and economical resolution of disputes that may arise in connection with Executive&#x2019;s employment with the Company, Executive and the Company agree that any and all disputes, claims, or causes of action arising from or relating to the enforcement, breach, performance, negotiation, execution, or interpretation of this Agreement, the Confidential Information Agreement, or Executive&#x2019;s employment, or the termination of Executive&#x2019;s employment, including but not limited to all statutory claims, with the exception of discrimination and harassment claims, will be resolved pursuant to the Federal Arbitration Act, 9 U.S.C. &#167;1-16 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FAA</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), and to the fullest extent permitted by law, by final, binding and confidential arbitration by a single arbitrator conducted in New York, New York by Judicial Arbitration and Mediation Services Inc. (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">JAMS</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) under the then applicable JAMS rules appropriate to the relief being sought (the applicable rules are available at the following web addresses: (i) </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">https://www.jamsadr.com/rules-employment-arbitration/</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and (ii) </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">https://www.jamsadr.com/rules-comprehensive-arbitration/</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">); provided, however, this arbitration provision not apply to any action or claim that cannot be subject to mandatory arbitration as a matter of law, including, without limitation, claims involving allegations of sexual harassment and discrimination, to the extent such claims are not permitted by applicable law(s) to be submitted to mandatory arbitration and the applicable law(s) are not preempted by the FAA or otherwise invalid (collectively, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Excluded Claims</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). A hard copy of the rules will be provided to Executive upon request. A hard copy of the rules will be provided to Executive upon request. </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">By agreeing to this arbitration procedure, both Executive and the Company waive the right to resolve any such dispute through a trial by jury or judge or administrative proceeding. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, all claims, disputes, or causes of action under this section, whether by Executive or the Company, must be brought in an individual capacity, and shall not be brought as a plaintiff (or claimant) or class member in any purported class or representative proceeding, nor joined or consolidated with the claims of any other person or entity. The Arbitrator may not consolidate the claims of more than one person or entity, and may not preside over any form of representative or class proceeding.</font><font style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the extent that the preceding sentences regarding class claims or proceedings are found to violate applicable law or are otherwise found unenforceable, any claim(s) alleged or brought on behalf of a class shall proceed in a court of law rather than by arbitration. The Company acknowledges that Executive will have the right to be represented by legal counsel at any arbitration proceeding. Questions of whether a claim is subject to arbitration under this Agreement) shall be decided by a federal court in the State of New York. However, procedural questions which grow out of the dispute and bear on the final disposition are matters for the arbitrator. The arbitrator shall: (a) have the authority to compel adequate discovery for the resolution of the dispute and to award such relief as would otherwise be permitted by law; (b) issue a written arbitration decision, to include the arbitrator&#x2019;s essential findings and conclusions and a statement of the award; and (c) be authorized to award any or all remedies that Executive or the Company would be entitled to seek in a court of law. Executive and the Company shall equally share all JAMS&#x2019; arbitration fees. To the extent JAMS does not collect or Executive otherwise does not pay to JAMS an equal share of all JAMS&#x2019; arbitration fees for any reason, and the Company pays JAMS Executive&#x2019;s share, Executive acknowledges and agrees that the Company shall be entitled to recover from Executive half of the JAMS arbitration fees invoiced to the parties (less any amounts Executive paid to JAMS) in a federal or state court of competent jurisdiction. Except as modified in the Confidential Information Agreement, each party is responsible for its own attorneys&#x2019; fees. Nothing in this Agreement is intended to prevent either Executive or the Company from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any such arbitration. Any awards or orders in such arbitrations may be entered and enforced as judgments in the federal and state courts of any competent jurisdiction. To the extent a New York federal court determines that any applicable law prohibits mandatory arbitration of Excluded Claims, if Executive intends to bring multiple claims, including one or more Excluded Claims, the Excluded Claim(s) may be publicly filed with a court, while any other claims will remain subject to mandatory arbitration.</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.19in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:0.94in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:0.935%;text-indent:6.812%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.204%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.4788270327562714%;">12.</font><div style="width:100%;display:inline;" id="x2__section_280g_matters_"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 280G Matters.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:0.935%;text-indent:13.605%;font-size:0;margin-top:11.95pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.9014788270327565%;">12.1</font><div style="width:100%;display:inline;" id="x2_1_if_any_payment_or_benefit_executive"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If any payment or benefit Executive will or may receive from the Company or otherwise (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">280G Payment</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) would (i) constitute a &#x201c;parachute payment&#x201d; within the meaning of Section 280G of the Code, and (ii) but for this Section, be subject to the excise tax imposed by Section 4999 of the Code (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Excise Tax</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), then any such 280G Payment provided pursuant to this Agreement (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Payment</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) shall be equal to the Reduced Amount. The &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Reduced Amount</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall be either (x) the largest portion of the Payment that would result in no portion of the Payment (after reduction) being subject to the Excise Tax, or (y) the largest portion, up to and including the total, of the Payment, whichever amount (i.e., the amount determined by clause (x) or by clause (y)), after taking into account all applicable federal, state, and local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in Executive&#x2019;s receipt, on an after-tax basis, of the greater economic benefit notwithstanding that all or some portion of the Payment may be subject to the Excise Tax. If a reduction in a Payment is required pursuant to the preceding sentence and the Reduced Amount is determined pursuant to clause (x) of the preceding sentence, the reduction shall occur in the manner (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Reduction Method</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) that results in the greatest economic benefit for Executive. If more than one method of reduction will result in the same economic benefit, the items so reduced will be reduced pro rata (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pro Rata Reduction Method</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:0.935%;text-indent:13.605%;font-size:0;margin-top:4pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.9014788270327565%;">12.2</font><div style="width:100%;display:inline;" id="x2_2_notwithstanding_any_provision_of_th"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notwithstanding any provision of this Section 12 to the contrary, if the Reduction Method or the Pro Rata Reduction Method would result in any portion of the Payment being subject to taxes pursuant to Section 409A that would not otherwise be subject to taxes pursuant to Section 409A, then the Reduction Method and/or the Pro Rata Reduction Method, as the case may be, shall be modified so as to avoid the imposition of taxes pursuant to Section 409A as follows: (A) as a first priority, the modification shall preserve to the greatest extent possible, the greatest economic benefit for Executive as determined on an after-tax basis; (B) as a second priority, Payments that are contingent on future events (e.g., being terminated without Cause), shall be reduced (or eliminated) before Payments that are not contingent on future events; and (C) as a third priority, Payments that are &#x201c;deferred compensation&#x201d; within the meaning of Section 409A shall be reduced (or eliminated) before Payments that are not deferred compensation within the meaning of Section 409A.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:0.935%;text-indent:13.605%;font-size:0;margin-top:11.95pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.9014788270327565%;">12.3</font><div style="width:100%;display:inline;" id="x2_3_the_company_shall_appoint_a_nationa"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company shall appoint a nationally-recognized accounting, consulting or law firm to make the determinations required by this Section 12. The Company shall bear all expenses with respect to the determinations by such firm required to be made hereunder.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:0.935%;text-indent:13.605%;font-size:0;margin-top:11.7pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.9014788270327565%;">12.4</font><div style="width:100%;display:inline;" id="x2_4_if_executive_receives_a_payment_for"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If Executive receives a Payment for which the Reduced Amount was determined pursuant to clause (x) of and the Internal Revenue Service determines thereafter that some portion of the Payment is subject to the Excise Tax, Executive agrees to promptly return to the Company a sufficient amount of the Payment (after reduction pursuant to clause (x) of Section 12(i)) so that no portion of the remaining Payment is subject to the Excise Tax. For the avoidance of doubt, if the Reduced Amount was determined pursuant to clause (y) of Section 12(i), Executive shall have no obligation to return any portion of the Payment pursuant to the preceding sentence.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:0.935%;text-indent:6.812%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.204%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.4788270327562714%;">13.</font><div style="width:100%;display:inline;" id="x3__general_provisions_"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General Provisions.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:0.935%;text-indent:13.605%;font-size:0;margin-top:11.95pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.9014788270327565%;">13.1</font><div style="width:100%;display:inline;" id="x3_1_notices___any_notices_provided_must"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notices. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any notices provided must be in writing and will be deemed effective upon the earlier of personal delivery (including personal delivery by fax) or the next day after sending by overnight carrier, to the Company at its primary office location and to Executive at the address as listed on the Company payroll.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:0.935%;text-indent:13.605%;font-size:0;margin-top:12.1pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.9014788270327565%;">13.2</font><div style="width:100%;display:inline;" id="x3_2_severability___whenever_possible__e"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Severability. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Whenever possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability will not affect any other provision or any other jurisdiction, but this Agreement will be reformed, construed and enforced in such jurisdiction to the extent possible in keeping with the intent of the parties.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:0.935%;text-indent:13.625%;font-size:0;margin-top:11.95pt;justify-content:flex-start;margin-bottom:0;margin-right:1.204%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.9014788270327565%;">13.3</font><div style="width:100%;display:inline;" id="x3_3_waiver___any_waiver_of_any_breach_o"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Waiver. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any waiver of any breach of any provisions of this Agreement must be in writing to be effective, and it shall not thereby be deemed to have waived any preceding or succeeding breach of the same or any other provision of this Agreement.</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.19in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:0.94in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:0.935%;text-indent:13.605%;font-size:0;margin-top:11.7pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.9014788270327565%;">13.4</font><div style="width:100%;display:inline;" id="x3_4_complete_agreement___this_agreement"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Complete Agreement. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Agreement, together with the Confidentiality Agreement, constitutes the entire agreement between Executive and the Company with regard to this subject matter and is the complete, final, and exclusive embodiment of the Parties&#x2019; agreement with regard to this subject matter. This Agreement is entered into without reliance on any promise or representation, written or oral, other than those expressly contained herein, and it supersedes any other such promises, warranties or representations. It is entered into without reliance on any promise or representation other than those expressly contained herein, and it cannot be modified or amended except in a writing signed by a duly authorized officer of the Company.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:0.935%;text-indent:13.605%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.9014788270327565%;">13.5</font><div style="width:100%;display:inline;" id="x3_5_amendments_and_waivers___this_agree"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amendments and Waivers</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This Agreement cannot be changed, modified or amended, and no provision or requirement hereof may be waived, without the consent in writing of the Executive and the Company. The failure of a party at any time or times to require performance of any provision hereof shall in no manner affect the right of such party at a later time to enforce the same. No waiver by a party of the breach of any term or covenant contained in this Agreement, whether by conduct or otherwise, in any one or more instances, shall be deemed to be, or construed as, a further or continuing waiver of any such breach, or a waiver of the breach of any other term or covenant in this Agreement.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:0.935%;text-indent:13.625%;font-size:0;margin-top:11.9pt;justify-content:flex-start;margin-bottom:0;margin-right:1.204%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.9014788270327565%;">13.6</font><div style="width:100%;display:inline;" id="x3_6_counterparts___this_agreement_may_b"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Counterparts. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Agreement may be executed in separate counterparts, any one of which need not contain signatures of more than one party, but all of which taken together will constitute one and the same Agreement.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:0.935%;text-indent:13.625%;font-size:0;margin-top:11.7pt;justify-content:flex-start;margin-bottom:0;margin-right:1.204%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.9014788270327565%;">13.7</font><div style="width:100%;display:inline;" id="x3_7_headings___the_headings_of_the_para"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Headings. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The headings of the paragraphs hereof are inserted for convenience only and shall not be deemed to constitute a part hereof nor to affect the meaning thereof.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:0.935%;text-indent:13.625%;font-size:0;margin-top:12.1pt;justify-content:flex-start;margin-bottom:0;margin-right:1.204%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.9014788270327565%;">13.8</font><div style="width:100%;display:inline;" id="x3_8_successors_and_assigns___this_agree"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Successors and Assigns. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Agreement is intended to bind and inure to the benefit of and be enforceable by Executive and the Company, and their respective successors, assigns, heirs, executors and administrators, except that Executive may not assign any of his duties hereunder and he may not assign any of his rights hereunder without the written consent of the Company, which shall not be withheld unreasonably.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:0.935%;text-indent:13.625%;font-size:0;margin-top:11.8pt;justify-content:flex-start;margin-bottom:0;margin-right:1.204%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.9014788270327565%;">13.9</font><div style="width:100%;display:inline;" id="x3_9_tax_withholding_and_indemnification"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tax Withholding and Indemnification. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All payments and awards contemplated or made pursuant to this Agreement will be subject to withholdings of applicable taxes in compliance with all relevant laws and regulations of all appropriate government authorities. Executive acknowledges and agrees that the Company has neither made any assurances nor any guarantees concerning the tax treatment of any payments or awards contemplated by or made pursuant to this Agreement. Executive has had the opportunity to retain a tax and financial advisor and fully understands the tax and economic consequences of all payments and awards made pursuant to the Agreement.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:0.935%;text-indent:13.605%;font-size:0;margin-top:12.15pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.9014788270327565%;">13.10</font><div style="width:100%;display:inline;" id="x3_10_choice_of_law___all_questions_conc"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Choice of Law. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All questions concerning the construction, validity and interpretation of this Agreement will be governed by the laws of the State of New York.</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.19in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:0.94in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:0.92%;text-indent:6.729%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In Witness Whereof</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Parties have executed this Agreement on the day and year written below.</font></p>
  <p style="margin-left:0.92%;text-indent:6.729%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:37.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:16.22%;box-sizing:content-box;"></td>
    <td style="width:83.78%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">LEXEO THERAPEUTICS, INC.</font></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ R. Nolan Townsend</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">R. Nolan Townsend</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Executive Officer</font></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Date:</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12/18/2024</font></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">KYLE RASBACH</font></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Kyle Rasbach</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Financial Officer</font></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td colspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Date:</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12/18/2024</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.19in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.27
<SEQUENCE>4
<FILENAME>lxeo-ex10_27.htm
<DESCRIPTION>EX-10.27
<TEXT>
<html>
 <head>
  <title>EX-10.27</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.13in;z-index:-3;min-height:0.93in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:31.84%;font-size:10pt;margin-top:5.3pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.27</font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:31.84%;font-size:10pt;margin-top:5.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid #000000;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RESEARCH AGREEMENT</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:8.389%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Agreement is made by and between Lexeo Therapeutics, Inc. (&#x201c;Company&#x201d;) with offices at 345 Park Avenue South, Sixth Floor, New York, NY 10010, and The Regents of the University of California on behalf of its San Diego campus, having its office at 9500 Gilman Drive, La Jolla, CA 92093-0934, (&#x201c;University&#x201d;), (each may be individually referred to as a &#x201c;Party&#x201d; and collectively, as the &#x201c;Parties&#x201d;), effective as of the date of last signature below (&#x201c;Effective Date&#x201d;).</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:8.389%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WHEREAS, it is in the mutual interest of Company and University that research be conducted on a project entitled [***];</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:8.389%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WHEREAS, Company desires to financially support said Project at University;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:8.389%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOW, THEREFORE, the Parties agree as follows:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:10.537%;text-align:left;" id="x__schedule___the_project_shall_be_condu">&#160;</p>
  <div class="item-list-element-wrapper" style="margin-left:1.065%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:10.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.5063425481376655%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SCHEDULE </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">- The Project shall be conducted in accordance with the scope of work attached hereto as Exhibit A (the &#x201c;Scope of Work&#x201d; or &#x201c;SOW&#x201d;), which SOW is incorporated into this Agreement by this reference for the purpose of describing the scope and timing of work to be performed under this Agreement. Such SOW may also include budget and payment terms as mutually agreed upon by the Parties. The term of this Agreement shall be for two years from the Effective Date (the &#x201c;Term&#x201d;), unless sooner terminated as herein provided. The Term may be extended or renewed by the parties&#x2019; formal Amendment to this Agreement, as signed by an officer or designated authorized representative of both Parties, in accordance with Section 18(h) of this Agreement.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:1.065%;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:8.13%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.5063425481376655%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;" id="x__budget___company_shall_support_the_pr"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">BUDGET </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x2013; Company shall support the Project by a grant of [***] (the &#x201c;Total Budget Amount&#x201d;). The grant amount shall cover all direct and indirect costs of the Project, as set forth in the budget (the &#x201c;Budget&#x201d;) attached hereto as part of Exhibit A and incorporated into this fixed-cost Agreement. If at any time the Project Working Group has reason to believe that the cost of the Project will be greater than the Total Budget Amount, University shall notify Company immediately in writing to that effect, and shall provide a revised budget of the cost of completion of the Project, together with its justification for such increase, with such notice. Sponsor shall not be obligated to reimburse University for the costs incurred in excess of the Total Budget Amount unless and until Sponsor has notified University in writing that the revised budget is accepted via formal Amendment to this Agreement (the &#x201c;Revised Total Budget Amount&#x201d;). Upon expenditure of the Total Budget Amount or the Revised Total Budget Amount, as applicable, University&#x2019;s obligation to continue performance of the Project shall cease and the Project shall be deemed to be terminated as of the date that University ceases performance of the Project.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:1.065%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:8.796%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.5063425481376655%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;" id="x__payment___unless_otherwise_stated_in_"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PAYMENT </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x2013; Unless otherwise stated in a SOW, payments to University shall be made in accordance with this Section 3. Upon execution of this Agreement, the University will submit an advance payment invoice to Company for the advancement to University of University&#x2019;s estimated expenses, shown by major categories, to be incurred by the University to perform the Project during [***] (the &#x201c;Initial Payment&#x201d;). The Initial Payment shall be due within [***] after Company&#x2019;s receipt of the applicable invoice.</font></div></div>
  <p style="margin-left:7.773%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:8.389%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Payment shall be made to &#x201c;The Regents of the University of California&#x201d; and sent to the following address if by mail:</font></p>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:12.05pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="margin-left:7.773%;text-indent:-9.047%;padding-left:6.68%;font-size:10pt;margin-top:0.15pt;font-family:Times New Roman;margin-bottom:0;margin-right:11.713%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Checks being delivered via courier (e.g., FedEx) shall be sent to the following address:</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.53in;min-height:0.67in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.187%;font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.13in;z-index:-3;min-height:0.93in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:7.773%;text-indent:-18.714%;padding-left:6.68%;font-size:10pt;margin-top:0.1pt;font-family:Times New Roman;margin-bottom:0;margin-right:49.852%;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:13.373%;text-indent:-2.987%;padding-left:1.067%;font-size:10pt;margin-top:0.1pt;font-family:Times New Roman;margin-bottom:0;margin-right:49.852%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="margin-left:7.773%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">University shall forward invoices to Company at the following address:</font></p>
  <p style="margin-left:14.44%;font-size:10pt;margin-top:12.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:49.852%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="margin-left:7.773%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:8.194%;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:7.773%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:8.194%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At least [***] , the University will submit an advance payment invoice to Company to request that the University be advanced the estimated costs shown by major cost categories for the ensuing [***]. Company will make the payment to the University within [***] of receipt of the invoice. The total amount requested in any advance payment invoice will not, together with amounts already paid by Company pursuant to prior advance payment invoices, exceed the Total Budget Amount or the Revised Total Budget Amount, as applicable.</font></p>
  <p style="margin-left:7.773%;font-size:10pt;margin-top:12.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:8.194%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From the Effective Date until [***]  after the completion of the Project, Company may at any time request that University provide a formal report of expenditures shown by major cost categories in accordance with the budget justification in Exhibit A (&#x201c;Budget Justification&#x201d;). In addition, University shall provide Company with supporting documentation for the expenditures set forth in the most recent Budget Justification provided by University within [***] after (a) the [***]; and (b) notice of termination of this Agreement is given by either Party or on the date of expiration of this Agreement, as applicable.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:1.065%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:8.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.5063425481376655%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;" id="x__principal_investigators___the_researc"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PRINCIPAL INVESTIGATORS</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">- The research is to be conducted by University under the direction of [***]  (&#34;Principal Investigators&#34;) who will be responsible for the direction of the Project, including all budgeting, in accordance with applicable University policies. If both of the Principal Investigators become unable to continue to conduct the Study for reasons beyond the Principal Investigators&#x2019; reasonable control, or if both of the Principal Investigators leave the employment of the University, and the University and Company do not agree on at least one qualified replacement principal investigator, either Party may terminate this Agreement with [***]&#x2019; written notice to the other Party pursuant to Section 17.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:1.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:6.7387678778996305%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;" id="x__project_working_group"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PROJECT WORKING GROUP</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.731%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:8.537%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.225612069058946%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">a.</font><div style="width:100%;display:inline;" id="a__specific_responsibilities__the_projec"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Specific Responsibilities</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Project Working Group will be comprised of representatives of University and Company (&#x201c;PWG&#x201d;) and will meet to discuss the Project at least [***] (or as otherwise agreed to by the PWG) and at Company&#x2019;s additional expense, if in person, to (i) coordinate activities relating to the Project between University and Weill Cornell, (ii) review and discuss the Project activities and any Research Results (defined below), (iii) review any proposed changes to the scope of work for the Project, the timeline for the Project and/or the Project budget, including approving the updated budget for the subsequent year on or prior to [***], (iv) ensure the Parties are working in good faith together on the Project and communicating on a regular basis; (v) subject each milestone to verification of acceptability by Company to ensure that such milestone was performed pursuant to the requirements set forth in the Scope of Work, (vi) determine whether any adjustments to the Total Budget Amount or the Revised Total Budget Amount as applicable are necessary based on progress to date on the Project, and (vii) perform such other functions as appropriate, to further the purposes of this Agreement, in each case as may be assigned to the Parties pursuant to this Agreement or as may be agreed to in writing by all of the Parties by formal Amendment of this Agreement. Each Party will determine on a PWC meeting-by-PWC meeting basis which of its representatives will attend.</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.53in;min-height:0.67in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.187%;font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.13in;z-index:-3;min-height:0.93in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:1.065%;display:flex;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:6.7387678778996305%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">6.</font><div style="width:100%;display:inline;" id="x__confidentiality"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CONFIDENTIALITY</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.731%;display:flex;margin-top:11.9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:8.398%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.225612069058946%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">a.</font><div style="width:100%;display:inline;" id="a__confidential_information___confidenti"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Confidential Information</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. &#x201c;Confidential Information&#x201d; means any information which is disclosed by or on behalf of one Party (&#x201c;Disclosing Party&#x201d;) to the other Party (&#x201c;Receiving Party&#x201d;) in the performance of the Project under this Agreement and which is marked as &#x201c;Confidential&#x201d; at the time of disclosure, or (i) in the case of oral disclosures, identified at the time of such oral disclosure as confidential and reduced to writing and marked as &#x201c;Confidential&#x201d; within [***] of oral disclosure; (ii) if not marked, information is regarded as &#x201c;Confidential&#x201d; if a reasonable person in the relevant field would consider such information to be the Institution&#x2019;s confidential information given its content and the circumstances of the disclosure. The confidentiality obligations set forth in this Section 6 do not apply to any information that: (a) was known to the Receiving Party prior to its receipt from Disclosing Party as shown by contemporaneous evidence, (b) is independently developed by the Receiving Party without use of or reference to the Confidential Information of Disclosing Party, (c) becomes known generally to the public at any time through no fault of Receiving Party, or (d) was disclosed to Receiving Party by a third party whom Receiving Party reasonably believed to have a right to disclose the information. The Receiving Party will use the Disclosing Party&#x2019;s Confidential Information solely for the purposes of the Project.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.731%;display:flex;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:9.602%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.225612069058946%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">b.</font><div style="width:100%;display:inline;" id="b__duty_to_safeguard_confidential_inform"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Duty to Safeguard Confidential Information</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Receiving Party will maintain the Disclosing Party&#x2019;s Confidential Information in confidence, except that Receiving Party may disclose or permit disclosure of any of the Disclosing Party&#x2019;s Confidential Information to its directors, officers, employees, and agents who need to know such Confidential Information to conduct the Project and who are subject to confidentiality obligations with respect to the Confidential Information no less restrictive than those set forth herein as a condition of their employment. Receiving Party will promptly, upon discovery of any disclosure or use of Disclosing Party&#x2019;s Confidential Information not authorized hereunder, notify Disclosing Party and take reasonable steps to prevent any further unauthorized disclosure or unauthorized use of Disclosing Party&#x2019;s Confidential Information. Notwithstanding the foregoing, Receiving Party may disclose Disclosing Party&#x2019;s Confidential Information pursuant to an order of a court or other governmental authority of competent jurisdiction, provided that the Receiving Party (a) promptly notifies Disclosing Party of such order, (b) gives Disclosing Party an opportunity to oppose such disclosure, and (iii) takes reasonable efforts to minimize the disclosure of such Confidential Information.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.731%;display:flex;margin-top:4pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:8.13%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.225612069058946%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">c.</font><div style="width:100%;display:inline;" id="c__company_materials__company_may__from_"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company Materials</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Company may, from time to time, provide, or request a third party to provide, University with biological, chemical or physical materials for use in the Project, (the &#x201c;Materials&#x201d;). The Materials will be deemed to be confidential and proprietary to Company for purposes of this Agreement and shall be held securely by University. Accordingly, University will not (a) transfer or permit the transfer of the Materials to any third party or (b) modify or create derivatives or improvements or permit the modification of or creation of derivatives of, or improvements on, the Materials without Company&#x2019;s prior written consent, and will use the Materials solely for purposes of conducting the Project as described in the SOW.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.731%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:8.269%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.225612069058946%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">d.</font><div style="width:100%;display:inline;" id="d__rights_in_confidential_information_an"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rights in Confidential Information and Materials</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. As between the Parties, Disclosing Party is and will remain the exclusive owner of its Confidential Information. Company, or the applicable owner, is and will remain the exclusive owner of the Company&#x2019;s Confidential Information disclosed by or on behalf of Company and the Materials provided by or on behalf of Company to University under this Agreement and all preexisting intellectual property rights therein prior to the Effective Date, and all intellectual property rights in which any of the foregoing obtains on or after the Effective Date but separate and apart from the Project. No option, license, or conveyance of such rights to University or any third party regarding the Confidential Information or Materials is granted or implied under this Agreement.</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.53in;min-height:0.67in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.187%;font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.13in;z-index:-3;min-height:0.93in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:1.065%;display:flex;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:6.7387678778996305%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">7.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid #000000;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RIGHTS IN DATA AND REPORTING</font></div></div>
  <p style="margin-left:7.773%;font-size:10pt;margin-top:12.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:8.296%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subject to Paragraph 6 (&#x201c;Confidentiality&#x201d;) of this Agreement, University shall have the right to copyright , publish, disclose, disseminate and use, in whole and in part, any data and information developed by University. University will deliver to Company reports of data from the Project in a format and frequency as mutually agreed to between the Principal Investigators and the Company (&#x201c;Research Results&#x201d;) no less frequently than once every [***]. The Principal Investigators will submit written reports summarizing the research conducted under the Project to Company once each calendar quarter during the Term and will submit a comprehensive final report summarizing key supporting data and additional analyses for the preceding studies (collectively, the &#x201c;Research Reporting&#x201d;) to Company within [***] of the earlier of (a) completion of the Project and (b) the expiration or termination of this Agreement. Subject to University&#x2019;s first right to publish in accordance with Section 9 of this Agreement, University hereby grants to Company an exclusive, worldwide, perpetual, sublicensable, irrevocable, transferable, fully paid-up, royalty-free license under University&#x2019;s interest in the Research Results and Research Reporting to use, reproduce, modify, adapt, translate, distribute, perform and display the Research Results and Research Reporting for any purposes.</font></p>
  <p style="margin-left:7.773%;font-size:10pt;margin-top:11.95pt;font-family:Times New Roman;margin-bottom:0;margin-right:8.389%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ALL INFORMATION, DATA AND REPORTS ARE PROVIDED &#x201c;AS IS&#x201d; AND WITHOUT ANY REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:1.065%;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.5063425481376655%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">8.</font><div style="width:100%;display:inline;" id="x__use_of_name_publicity___it_is_agreed_"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">USE OF NAME/PUBLICITY</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">- It is agreed by each Party that it will not under any circumstance use the name of the other Party or its employees in any advertisement, press release or publicity with reference to this Agreement, without prior written approval of the other Party.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:1.065%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:13.065%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.5063425481376655%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">9.</font><div style="width:100%;display:inline;" id="x__publication___university_shall_have_t"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PUBLICATION</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">- University shall have the first right to publish the results of the work conducted by University under this Agreement to the extent such results do not contain Confidential Information of Company, provided, Company has the opportunity to review and comment on any proposed manuscripts, abstracts, presentations, or other publications (a &#x201c;Publication&#x201d;) describing said work at least [***] prior to the intended date of submission for publication. University agrees to reasonably consider Company&#x2019;s comments prior to publication, provided that, if Company notifies University within such [***] period that such proposed Publication contains Confidential Information of Company, University will delete such Confidential Information prior to publication. Notwithstanding the foregoing, if the proposed Publication contains patentable information, University will, if requested by Company, (a) withhold publication for up to an additional [***] to allow for the filing of patent applications in accordance with Section 10 or (b) at University&#x2019;s option, delete such information and publish as set forth herein.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:1.065%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:13.065%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.5063425481376655%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">10.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PATENT RIGHTS </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">- Inventorship of inventions, developments or discoveries arising from research conducted under this Agreement shall be determined in accordance with inventorship under United States Patent Law, Title 35 United States Code. Ownership shall follow inventorship.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.731%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:8.935%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.225612069058946%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">a.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company Inventions</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#x2013; All rights to inventions or discoveries made, developed, created, conceived, reduced to practice or invented hereunder solely by Company&#x2019;s or its Affiliates employees or agents or representatives (each, a &#x201c;Company Invention&#x201d;) without use of the University employees or facilities shall belong to Company. Notwithstanding the foregoing and anything to the contrary set forth herein, if Company provides any Materials to University that are proprietary to Company and/or any third party (&#x201c;Proprietary Materials&#x201d;), Company and University hereby agree to use best efforts to determine an appropriate and fair allocation of ownership of inventions or discoveries using or incorporating such Proprietary Materials upon disclosure of such inventions or discoveries to the University, taking into consideration factors such as whether the contribution or use of such Proprietary Materials or Confidential Information of Company results in a new vector construct or materially increases the functionality or activity of a vector construct developed by the Principal Investigators prior to receipt of such Proprietary Materials or Confidential Information.</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.53in;min-height:0.67in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.187%;font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.13in;z-index:-3;min-height:0.93in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:7.731%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:12%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.225612069058946%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">b.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">University Inventions</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> - All rights to inventions made or invented hereunder solely by University&#x2019;s employees or agents (each, a &#x201c;University Invention&#x201d;) shall belong to the University and shall be disposed of in accordance with University policy.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.731%;display:flex;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:10%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.225612069058946%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">c.</font><div style="width:100%;display:inline;" id="c__joint_inventions___all_rights_to_inve"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Joint Inventions</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> - All rights to inventions made or invented hereunder jointly by or on behalf of employees or agents from both University and Company whether or not at the University facility (each, a &#x201c;Joint Invention&#x201d;) shall be jointly-owned by Company and University.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.731%;display:flex;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.225612069058946%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">d.</font><div style="width:100%;display:inline;" id="d__procedures"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Procedures</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:14.398%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:10.935%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.788369430620779%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">i.</font><div style="width:100%;display:inline;" id="i__university_will_make_prompt_written_d"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">University will make prompt written disclosure to Company of all University Inventions and Joint Inventions. Company shall treat disclosures of University Inventions as Confidential Information of University in accordance with the obligations set forth in Section 6.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:14.398%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:12.667%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.788369430620779%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">ii.</font><div style="width:100%;display:inline;" id="ii__to_the_extent_legally_able__universi"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the extent legally able, University shall grant to Company a royalty-free license to develop, make, use, sell, offer for sale, import, commercialize and otherwise exploit University&#x2019;s interest in any University Inventions or Joint Inventions that necessarily use or necessarily incorporate Materials or Confidential Information.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:14.398%;display:flex;margin-top:4pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:9.602%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.788369430620779%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">iii.</font><div style="width:100%;display:inline;" id="iii__upon_such_written_disclosure__durin"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upon such written disclosure, during the Negotiation Period set forth in Section 10(e) or if Company has exercised its Option under Section 10(e) of this Agreement and University does not intend to file a patent for protection of University Invention(s), then upon Company&#x2019;s request and expense, University agrees to file the necessary papers for obtaining patent protection for such University Invention in any and all countries of the world which Company determines are of sufficient interest to merit such filing, provided that Company shall bear all costs for such filing and reimburse University of its reasonable costs related thereto.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:14.398%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:10.13%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.788369430620779%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">iv.</font><div style="width:100%;display:inline;" id="iv__unless_otherwise_agreed_to_by_the_pa"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unless otherwise agreed to by the Parties, patent applications relating to a Joint Invention will be filed, prosecuted and maintained by Company, [***]. University and Company will together select independent patent counsel satisfactory to both parties to prepare and prosecute any such applications.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:14.398%;display:flex;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:8.537%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.788369430620779%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">v.</font><div style="width:100%;display:inline;" id="v__patent_applications_relating_to_a_com"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Patent applications relating to a Company Invention will be filed, prosecuted and maintained by Company, [***], using patent counsel acceptable to Company in its sole discretion.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:14.398%;display:flex;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:8.269%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.788369430620779%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">vi.</font><div style="width:100%;display:inline;" id="vi__with_respect_to_patent_applications_"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With respect to patent applications filed pursuant to Section 10(d)(iii), both parties will have the right to review and comment upon applications and correspondence with the relevant patent office and will be provided with drafts thereof sufficiently in advance to reasonably allow for such review and comment.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:14.398%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:10.667%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.788369430620779%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">vii.</font><div style="width:100%;display:inline;" id="vii__university_agrees_that_it_will_caus"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">University agrees that it will cause to be signed by concerned University personnel all documents of assignment or other documents necessary to obtain patent protection as set forth herein, and that University will do whatever Company reasonably requests to obtain and maintain such patent rights as required by this Agreement, at the reasonable expense of Company.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:14.398%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:8.537%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.788369430620779%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">viii.</font><div style="width:100%;display:inline;" id="viii__if_company_elects_not_to_have_a_pa"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If Company elects not to have a patent application filed in any country with respect to a particular Joint Invention, Company will advise University of such fact within [***] from the date such invention was disclosed to Company by University. University may then, at its own expense, file and prosecute a patent application claiming such invention, and such patent application and any patents issuing therefrom will not be included within the license option granted to Company pursuant to Section 10(e), and University will be free to license its rights in such patent application and any resulting patent to any party upon prior written notice to Company.</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.53in;min-height:0.67in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.187%;font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.13in;z-index:-3;min-height:0.93in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:7.731%;display:flex;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:8.13%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.225612069058946%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">e.</font><div style="width:100%;display:inline;" id="e__license__option__to_the_extent_legall"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">License; Option</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. To the extent legally able, the University hereby grants Company a first right to obtain a non-exclusive or exclusive (at the election of Company in its sole discretion), royalty-bearing, perpetual and transferable worldwide license, with the right to grant sublicenses through multiple tiers, to University&#x2019;s interest in any University Invention or in any Joint Invention (&#x201c;Option&#x201d;). Company shall advise University in writing within [***] of any disclosure made to the Company pursuant to Section 10(d)(i) of a University Invention or Joint Invention whether or not it wishes to exercise the Option. During such Option period, in the event University does not intend to file a patent for protection of the University Invention, then upon Company&#x2019;s request, University agrees to file patent application(s) of such University Invention provided that Company shall bear all costs for such filing and reimburse University for its reasonable costs related thereto. The Parties will have [***] from the date of election to negotiate and conclude an exclusive license agreement (as may be extended as set forth in this Section 10(e), the &#x201c;Negotiation Period&#x201d;). Such period may be further extended by mutual written agreement of the parties. Such license shall contain reasonable terms and shall require diligent performance by Company for the timely commercial development and early marketing of such inventions, and include Company&#x2019;s continuing obligation to pay patent costs. If the license has not been concluded within the period described above, rights to the University Inventions and Joint Inventions disclosed hereunder shall be disposed of in accordance with University policies, with no further obligation to Company; provided that University will not enter into an agreement with a third party regarding the sale or license of such University Inventions on terms that are materially more favorable to the third party than those terms last offered to Company for one year after the negotiations between Company and University are terminated. For clarity, during and before the Negotiation Period described above, with respect to a particular University Invention, to the extent legally able, University shall not grant to any third party any rights in or otherwise encumber such University Invention in any manner that would prevent University from granting to Company an exclusive license as contemplated hereunder.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:1.065%;display:flex;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:6.7387678778996305%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">11.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid #000000;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INDEMNIFICATION</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.731%;display:flex;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:9.065%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.225612069058946%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">a.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company shall defend, indemnify and hold University, its directors, officers, agents, and employees harmless from and against any and all liability, loss, expense (including reasonable attorneys&#x2019; fees), or claims for injury or damages brought by a third party arising out of the performance of this Agreement by Company, but only in proportion to and to the extent such liability, loss, expense, attorneys&#x2019; fees, or claims for injury or damages are caused by or result from the negligent or intentional acts or omissions of, or a material breach of this Agreement by, Company, its directors, officers, agents or employees.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.731%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:8.796%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.225612069058946%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">b.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">University shall defend, indemnify and hold Company, its directors, officers, agents and, employees harmless from and against any and all liability, loss, expense (including reasonable attorneys&#x2019; fees), or claims for injury or damages brought by a third party arising out of the performance of this Agreement by University, but only in proportion to and to the extent such liability, loss, expense, attorneys&#x2019; fees, or claims for injury or damages are caused by or result from the negligent or intentional acts or omissions of, or a material breach of this Agreement by, University, its directors, officers, agents, or employees.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:1.065%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:8.935%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.5063425481376655%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">12.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INDEMNIFICATION PROCEDURE </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">- The Parties&#x2019; indemnification obligations set forth in Section 11 are conditioned upon the Party claiming indemnification thereunder (the &#x201c;Indemnified Party&#x201d;) (a) promptly notifying the other Party (the &#x201c;Indemnifying Party&#x201d;) of a claim (provided, however, that failure to provide such notice will relieve the Indemnifying Party from its liability or obligation hereunder only to the extent of any material prejudice as a direct result of such failure); (b) promptly giving the Indemnifying Party the right to control and direct the investigation, preparation, defense and settlement of such claim with counsel of the Indemnifying Party&#x2019;s own choosing; and (c) giving assistance and full cooperation for the defense of same. Without limiting the foregoing, the Indemnified Party will have the right to reasonably participate, at its own expense, in the defense or settlement of any claim.</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.53in;min-height:0.67in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.187%;font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.13in;z-index:-3;min-height:0.93in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:1.065%;margin-top:4pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:8.13%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.5063425481376655%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">13.</font><div style="width:100%;display:inline;" id="x3__limit_of_liability___except_for_each"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LIMIT OF LIABILITY </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">- EXCEPT FOR EACH PARTY&#x2019;S INDEMNIFICATION OBLIGATIONS AND DAMAGES AND LIABILITIES ARISING OUT A BREACH OF A PARTY&#x2019;S CONFIDENTIALITY OBLIGATIONS OR INTELLECTUAL PROPERTY OBLIGATIONS, IN NO EVENT WILL EITHER PARTY, EMPLOYEES, OFFICERS, AGENTS OR REPRESENTATIVES BE LIABLE TO THE OTHER PARTY FOR SPECIAL, PUNITIVE, INCIDENTAL OR CONSEQUENTIAL DAMAGES OF ANY KIND, INCLUDING ECONOMIC DAMAGES OR LOST PROFITS, REGARDLESS OF WHETHER THE PARTY WAS ADVISED, HAD OTHER REASON TO KNOW OR IN FACT KNEW OF THE POSSIBILITY OF THE FOREGOING.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:1.065%;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:9.602%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.5063425481376655%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">14.</font><div style="width:100%;display:inline;" id="x4__supplies_and_equipment___in_the_even"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SUPPLIES AND EQUIPMENT</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">- In the event that University purchases equipment hereunder, title to such equipment shall vest in University.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:1.065%;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:8.269%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.5063425481376655%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">15.</font><div style="width:100%;display:inline;" id="x5__excusable_delays___in_the_event_of_a"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EXCUSABLE DELAYS</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">- In the event of a delay caused by inclement weather, fire, flood, strike or other labor dispute, act of God, act of governmental officials or agencies, or any other cause beyond the reasonable control of a Party, such Party shall be excused from performance hereunder for the period of time attributable to such delay as set forth in this Section 15, which may extend beyond the time lost due to one or more of the causes mentioned above. In the event of any such delay, this Agreement may be revised by changing the Budget, performance period and other provisions, as appropriate, by mutual agreement of the parties.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:1.065%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:9.87%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.5063425481376655%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">16.</font><div style="width:100%;display:inline;" id="x6__notice___notices_shall_be_deemed_giv"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTICE</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">- Notices shall be deemed given when: (a) sent by email; (b) delivered personally; (b) sent by confirmed facsimile; or (c) three (3) days after having been sent by registered or certified mail, return receipt requested, postage prepaid. Whenever any notice is to be given hereunder, it shall be in writing and sent to the following address:</font></div></div>
  <p style="margin-left:7.773%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">University:	  [***]</font></p>
  <p style="margin-left:7.773%;font-size:10pt;margin-top:12.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company:	  [***]</font></p>
  <p style="margin-left:7.773%;font-size:10pt;margin-top:12.65pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">with a copy to (which shall not constitute notice):</font></p>
  <p style="margin-left:21.107%;font-size:10pt;margin-top:11.9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font></p>
  <div class="item-list-element-wrapper" style="margin-left:1.065%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:9.87%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.5063425481376655%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">17.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TERMINATION</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">- This Agreement may be terminated early by Company at any time upon the giving of [***] prior written notice to University. Written notice of early termination shall be directed to the individual named in Section 16 of this Agreement. Upon the giving of notice of early termination by Company, as of the effective termination date, University shall exert its best efforts to terminate any outstanding commitments. Should University have costs incurred by it for all work performed through the effective early termination date, including outstanding obligations which cannot be canceled and that are not covered by the payments already received in accordance with Exhibit A, Company shall reimburse University for all remaining costs. University shall furnish, within [***] of the effective date of early termination, a final invoice for settlement of all remaining costs to be reimbursed or if the final Budget Justification and supporting document delivered by University pursuant to Section 3 indicates that University has not utilized all of the advance payment made by Company during the Term, then University shall promptly refund to Company such amounts. Upon the giving of notice of termination by University, as of the effective termination date Company shall have no additional liability for any costs or obligations. If this fixed-cost Agreement expires in accordance with Section 1, the obligations in this Section 17 do not apply to either Company or University. Each Party&#x2019;s obligations of confidentiality with respect to the other&#x2019;s Party&#x2019;s Confidential Information will survive for a period of [***] following the termination or expiration of this Agreement. Upon termination of this Agreement, Receiving Party shall, at Disclosing Party&#x2019;s option and expense, either return or destroy any Materials in University&#x2019;s possession and the other Party&#x2019;s Confidential Information provided, however, that the Receiving Party may retain one copy of Confidential Information in a secure location for purposes of compliance with this Agreement and Applicable Law.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:1.065%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:9.87%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.5063425481376655%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">18.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">MISCELLANEOUS</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.731%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:8.796%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.225612069058946%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">a.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Severability.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> In the event that any provision of this Agreement is found to be unenforceable, such provision shall be reformed only to the extent necessary to make it enforceable, as mutually negotiated in good faith between the Parties, and the remainder shall continue in effect, to the extent consistent with the intent of the Parties as of the Effective Date.</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.53in;min-height:0.67in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.187%;font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.13in;z-index:-3;min-height:0.93in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:7.731%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:8.796%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.225612069058946%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">b.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Relationship of the Parties.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Nothing in this Agreement shall be construed to place the parties in an agency, employment, franchise, joint venture, or partnership relationship. Neither Party shall have the authority to obligate or bind the other in any manner, and, with the exception of third party Indemnified Parties, nothing herein contained shall give rise or is intended to give rise to any rights of any kind to any third parties. Neither Party shall represent to the contrary, either expressly, implicitly or otherwise.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.731%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:8.796%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.225612069058946%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">c.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Governing Law.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> All disputes, claims or controversies arising out of this Agreement, or the negotiation, validity or performance of this Agreement, or the transactions contemplated hereby shall be governed by and construed in accordance with the laws of the State of California without regard to its rules of conflict of laws.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.731%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:8.796%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.225612069058946%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">d.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Assignment; Binding Effect.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Neither Party may assign this Agreement in whole or in part without the prior written consent of the other Party, except that a Party may make such an assignment without the other Party&#x2019;s consent to its Affiliates or to a third party successor of, or transferee to, assets of such Party to which this Agreement relates, whether in a merger, sale of stock, sale of assets or other transaction.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.731%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:8.796%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.225612069058946%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">e.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Waiver.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Failure by either Party to enforce any provision of this Agreement shall not be deemed a waiver of future enforcement of that or any other provision.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.731%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:8.796%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.225612069058946%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">f.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Counterparts.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which shall constitute one and the same instrument.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.731%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:8.796%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.225612069058946%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">g.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Construction.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> This Agreement has been negotiated by each of the Parties and each of their respective counsel. This Agreement shall be fairly interpreted in accordance with its terms and without any strict construction in favor of or against either Party. All notices, communications and discussions pertaining to this Agreement, whether oral or written, shall be conducted in the English language, including any enforcement proceedings.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.731%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:8.796%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.225612069058946%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">h.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Complete Agreement.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> This Agreement, including the exhibits hereto, which are hereby incorporated into this Agreement by this reference, constitutes the entire agreement between the parties with respect to the subject matter hereof. It supersedes and replaces all prior or contemporaneous understandings or agreements, written or oral, regarding such subject matter, and prevails over any conflicting terms or conditions contained on printed forms submitted with purchase orders, sales acknowledgments or quotations, except for agreements UC reference # [***], [***] and clarification purposes. Nothing in this Agreement will affect the rights already granted in prior License Agreements UC reference # [***], [***]. For clarity purposes, royalties and any licensing terms included those License Agreements shall still apply.. This Agreement may not be modified or waived, in whole or part, except in writing and signed by an officer or duly authorized representative of both Parties.</font></div></div>
  <p style="margin-left:9.813%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:9.889%;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.53in;min-height:0.67in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.187%;font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.13in;z-index:-3;min-height:0.93in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:9.813%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:9.889%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IN WITNESS WHEREOF, the Parties, intending to be legally bound hereby, have each caused its duly authorized representative to execute and deliver this Agreement as of the Effective Date.</font></p>
  <p style="margin-left:9.813%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:9.889%;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:11.579%;box-sizing:content-box;"></td>
    <td style="width:34.737%;box-sizing:content-box;"></td>
    <td style="width:11.579%;box-sizing:content-box;"></td>
    <td style="width:11.579%;box-sizing:content-box;"></td>
    <td style="width:30.526%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">THE REGENTS OF THE UNIVERSITY OF CALIFORNIA ON BEHALF OF ITS SAN DIEGO CAMPUS</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">LEXEO THERAPEUTICS, INC.</font></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;/s/ Leah Williams</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;/s/ R. Nolan Townsend</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(signature)</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(signature)</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Name:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;Leah Williams</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Name:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;R. Nolan Townsend</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Title:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;Principal Contract Officer</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Title:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;CEO</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;4/10/2024</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;4/13/2024</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.53in;min-height:0.67in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.187%;font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.13in;z-index:-3;min-height:0.93in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:26.413%;font-size:10pt;margin-top:4.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit A: Scope of Work and Budget</font></p>
  <p style="margin-left:26.413%;font-size:10pt;margin-top:4.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.53in;min-height:0.67in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.187%;font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.28
<SEQUENCE>5
<FILENAME>lxeo-ex10_28.htm
<DESCRIPTION>EX-10.28
<TEXT>
<html>
 <head>
  <title>EX-10.28</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.13in;z-index:-3;min-height:0.47in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:9.9pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.28</font></p>
  <p style="margin-left:12.787%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:12.759%;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:12.787%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:12.759%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></p>
  <p style="margin-left:12.787%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:12.759%;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:12.787%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:12.759%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECOND AMENDMENT TO THE RESEARCH AGREEMENT BETWEEN LEXEO THERAPEUTICS, INC.</font></p>
  <p style="margin-left:12.787%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:12.787%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AND</font></p>
  <p style="margin-left:7.76%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:7.75%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">THE REGENTS OF THE UNIVERSITY OF CALIFORNIA ON BEHALF OF ITS SAN DIEGO CAMPUS</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:9.813%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:9.889%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Second Amendment (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Second Amendment</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) by and between </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lexeo Therapeutics, Inc. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">located at 345 Park Avenue South, Sixth Floor, New York, NY 10010 (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sponsor</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) and </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Regents of the University of California on behalf of its San Diego Campus</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, located at 9500 Gilman Drive #0934, La Jolla, CA 92093-0934 (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Institution</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) is made and effective as of the last date of signature (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Effective Date</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:9.813%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:9.889%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WHEREAS, Sponsor and Institution entered into the Research Agreement, effective on December 3, 2021 (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), as amended on April 19, 2023 (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">First Amendment</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), to conduct a research project entitled [***] (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Project</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;);</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:9.813%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WHEREAS, Sponsor and Institution mutually desire to amend the Agreement as set forth below;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:9.813%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:9.889%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOW THEREFORE, in consideration of the premises and mutual covenants herein, the parties agree as follows:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:16.537%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:18.935%;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.9933862909313116%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	Section 1, Scheduling, Sentence 2 shall be deleted and replaced with the following:</font></div></div>
  <p style="margin-left:23.147%;font-size:10pt;margin-top:13.75pt;font-family:Times New Roman;margin-bottom:0;margin-right:9.889%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The term of this Agreement shall be for three years from the Effective Date (the &#x201c;Term&#x201d;), unless sooner terminated as herein provided.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:16.537%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:11.87%;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.9933862909313116%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	Capitalized terms used herein that are not otherwise defined shall have the same meanings ascribed to such terms in the Agreement;</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:16.537%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:10.398%;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.9933862909313116%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	If the terms of the Agreement or First Amendment in any way conflict with or are otherwise inconsistent with the terms of this Second Amendment, the terms of this Second Amendment shall govern and control.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:16.537%;display:flex;margin-top:0.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:12%;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.9933862909313116%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	Except as modified herein, the above-referenced Agreement shall remain in full force and effect and is hereby incorporated by references. The Agreement, as amended and modified, constitutes the entire agreement and understanding between the parties.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:16.537%;display:flex;margin-top:13.8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:11.065%;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.9933862909313116%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	This Second Amendment may be executed in two or more counterparts, each of which shall be deemed an original, but all of which shall constitute one and the same instrument.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:9.9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:1in;min-height:1.31in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.13in;z-index:-3;min-height:0.47in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:9.813%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:9.889%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IN WITNESS WHEREOF, the parties have caused this Second Amendment to be executed by their duly authorized representatives as of the Effective Date.</font></p>
  <p style="margin-left:9.813%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:9.889%;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:11.579%;box-sizing:content-box;"></td>
    <td style="width:34.737%;box-sizing:content-box;"></td>
    <td style="width:11.579%;box-sizing:content-box;"></td>
    <td style="width:11.579%;box-sizing:content-box;"></td>
    <td style="width:30.526%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, on behalf of its San Diego Campus</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">LEXEO THERAPEUTICS, INC.</font></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;/s/ Leah Williams</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;/s/ R. Nolan Townsend</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Name:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;Leah Williams</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Name:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;R. Nolan Townsend</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Title:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;Principal Contract Officer</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Title:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;Chief Executive Officer</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;4/12/2024</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;4/13/2024</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:1in;min-height:1.31in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.29
<SEQUENCE>6
<FILENAME>lxeo-ex10_29.htm
<DESCRIPTION>EX-10.29
<TEXT>
<html>
 <head>
  <title>EX-10.29</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.13in;z-index:-3;min-height:0.93in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:4.28%;font-size:10pt;margin-top:4.2pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.88%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.29</font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:4.28%;font-size:10pt;margin-top:4.2pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.88%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECOND AMENDMENT TO THE RESEARCH AGREEMENT BETWEEN LEXEO THERAPEUTICS, INC.</font></p>
  <p style="margin-left:4.267%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:4%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AND</font></p>
  <p style="margin-left:14.387%;font-size:10pt;margin-top:1.1pt;font-family:Times New Roman;margin-bottom:0;margin-right:14.019%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">THE REGENTS OF THE UNIVERSITY OF CALIFORNIA ON BEHALF OF ITS SAN DIEGO CAMPUS</font></p>
  <p style="font-size:10pt;margin-top:0.9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.25%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Second Amendment (&#x201c;Amendment&#x201d;) by and between LEXEO Therapeutics, Inc. located at 345 Park Avenue South, Sixth Floor, New York, NY 10010 (&#x201c;Sponsor&#x201d;) and The Regents of the University of California on behalf of its San Diego Campus, located at 9500 Gilman Drive #0934, La Jolla, CA 92093-0934 (&#x201c;Institution&#x201d;) is made and effective as of the last date of signature (&#x201c;Effective Date&#x201d;).</font></p>
  <p style="font-size:10pt;margin-top:0.95pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.25%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WHEREAS, </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sponsor and Institution entered into the Research Agreement, effective on December 3, 2021 (&#x201c;Agreement&#x201d;), to conduct a research project entitled [***] (&#x201c;Project&#x201d;);</font></p>
  <p style="font-size:10pt;margin-top:1.1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.25%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WHEREAS, </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sponsor and Institution subsequently entered into a First Amendment to the Agreement, effective on April 5, 2023 (&#x201c;First Amendment&#x201d;);</font></p>
  <p style="font-size:10pt;margin-top:1.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.25%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WHEREAS, </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sponsor and Institution mutually desire to further amend the First Amendment as set forth below;</font></p>
  <p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.25%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOW THEREFORE, </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in consideration of the premises and mutual covenants herein, the parties agree as follows:</font></p>
  <p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:4.398%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:5.87%;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4863287378925123%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Exhibit A: Updated Scope of Work and Budget&#x201d; of the First Amendment shall be amended to incorporate the &#x201c;Revised Scope of Work and Budget&#x201d; attached herein as </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit A</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div>
  <p style="font-size:10pt;margin-top:1.15pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:4.398%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:9.463%;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4863287378925123%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Capitalized terms used herein that are not otherwise defined shall have the same meanings ascribed to such terms in the Agreement.</font></div></div>
  <p style="font-size:10pt;margin-top:1.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:4.398%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.731%;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4863287378925123%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the terms of the Agreement in any way conflict with or are otherwise inconsistent with the terms of this Amendment, the terms of this Amendment shall govern and control.</font></div></div>
  <p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:4.398%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2.13%;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4863287378925123%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Except as modified herein, the above-referenced Agreement and First Amendment shall remain in full force and effect and is hereby incorporated by references. The Agreement, as amended and modified, constitutes the entire agreement and understanding between the parties.</font></div></div>
  <p style="font-size:10pt;margin-top:1.1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:4.398%;display:flex;margin-top:0.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:3.602%;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4863287378925123%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Amendment may be executed in two or more counterparts, each of which shall be deemed an original, but all of which shall constitute one and the same instrument.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.13in;z-index:-3;min-height:0.93in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:4.713%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IN WITNESS WHEREOF, </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the parties have caused this Amendment to be executed by their duly authorized representatives as of the Effective Date.</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:4.713%;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:95.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:11.579%;box-sizing:content-box;"></td>
    <td style="width:34.737%;box-sizing:content-box;"></td>
    <td style="width:11.579%;box-sizing:content-box;"></td>
    <td style="width:11.579%;box-sizing:content-box;"></td>
    <td style="width:30.526%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, on behalf of its San Diego Campus</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">LEXEO THERAPEUTICS, INC.</font></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;/s/ Samantha Friedman</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;/s/ R. Nolan Townsend</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Print Name:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;Samantha Friedman</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Print Name:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;R. Nolan Townsend</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Title:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;Principal Contract and Grant Analyst</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Title:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;Chief Executive Officer</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.13in;z-index:-3;min-height:0.93in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:4.28%;font-size:10pt;margin-top:4.2pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.898%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid #000000;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit A: Revised Scope of Work and Budget</font></p>
  <p style="font-size:10pt;margin-top:2.15pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:2.15pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.30
<SEQUENCE>7
<FILENAME>lxeo-ex10_30.htm
<DESCRIPTION>EX-10.30
<TEXT>
<html>
 <head>
  <title>EX-10.30</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="z-index:-3;min-height:0.96in;position:relative;"></div>
  <p style="margin-left:5.467%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;margin-right:5.083%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.30</font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:5.467%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;margin-right:5.083%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">THIRD AMENDMENT TO THE RESEARCH AGREEMENT BETWEEN LEXEO THERAPEUTICS, INC.</font></p>
  <p style="margin-left:5.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:5.12%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AND</font></p>
  <p style="margin-left:14.587%;font-size:10pt;margin-top:1.15pt;font-family:Times New Roman;margin-bottom:0;margin-right:14.213%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">THE REGENTS OF THE UNIVERSITY OF CALIFORNIA ON BEHALF OF ITS SAN DIEGO CAMPUS</font></p>
  <p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.293%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.565%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Third Amendment (&#x201c;Amendment&#x201d;) by and between Lexeo Therapeutics, Inc. located at 345 Park Avenue South, Sixth Floor, New York, NY 10010 (&#x201c;Sponsor&#x201d;) and The Regents of the University of California on behalf of its San Diego Campus, located at 9500 Gilman Drive #0934, La Jolla, CA 92093-0934 (&#x201c;Institution&#x201d;) is made and effective as of the last date of signature (&#x201c;Effective Date&#x201d;).</font></p>
  <p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.293%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.565%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WHEREAS, </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sponsor and Institution entered into the Research Agreement, effective on December 3, 2021 (&#x201c;Agreement&#x201d;), to conduct a research project entitled [***];</font></p>
  <p style="font-size:10pt;margin-top:1.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.293%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.565%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WHEREAS, </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sponsor and Institution subsequently entered into a First Amendment to the Agreement, effective on April 5, 2023 (&#x201c;First Amendment&#x201d;);</font></p>
  <p style="font-size:10pt;margin-top:1.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.293%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.565%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WHEREAS, </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sponsor and Institution further entered into a Second Amendment to the Agreement, effective on August 31, 2023 (&#x201c;Second Amendment&#x201d;);</font></p>
  <p style="font-size:10pt;margin-top:1.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.293%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.12%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WHEREAS, </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sponsor and Institution mutually desire to further amend the Agreement as set forth below;</font></p>
  <p style="font-size:10pt;margin-top:1.1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.293%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.565%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOW THEREFORE, </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in consideration of the premises and mutual covenants herein, the parties agree as follows:</font></p>
  <p style="font-size:10pt;margin-top:1.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:5.602%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Exhibit A: Revised Scope of Work and Budget&#x201d; of the Second Amendment shall be deleted and replaced with the attached &#x201c;Further Revised Scope of Work and Budget&#x201d; attached herein as </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit A</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div>
  <p style="font-size:10pt;margin-top:1.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 1, Scheduling, Sentence 2 shall be deleted and replaced with the following:</font></div></div>
  <p style="font-size:10pt;margin-top:10.2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:7.96%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.565%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The term of this Agreement shall be for five years from the Effective Date (the &#x201c;Term&#x201d;), unless sooner terminated as herein provided.</font></p>
  <p style="font-size:10pt;margin-top:1.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:9.731%;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Capitalized terms used herein that are not otherwise defined shall have the same meanings ascribed to such terms in the Agreement.</font></div></div>
  <p style="font-size:10pt;margin-top:1.1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the terms of the Agreement in any way conflict with or are otherwise inconsistent with the terms of this Amendment, the terms of this Amendment shall govern and control.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:3pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:3.731%;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Except as modified herein, the above-referenced Agreement, and the subsequent Amendments shall remain in full force and effect and is hereby incorporated by references. The Agreement, as amended and modified, constitutes the entire agreement and understanding between the parties.</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.19in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.96in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:1.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:3.87%;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">6.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Amendment may be executed in two or more counterparts, each of which shall be deemed an original, but all of which shall constitute one and the same instrument.</font></div></div>
  <p style="font-size:10pt;margin-top:1.1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.19in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.96in;position:relative;"></div>
  <p style="margin-left:1.293%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.565%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IN WITNESS WHEREOF, </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the parties have caused this Amendment to be executed by their duly authorized representatives as of the Effective Date.</font></p>
  <p style="margin-left:1.293%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.565%;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:13.75%;box-sizing:content-box;"></td>
    <td style="width:32.575%;box-sizing:content-box;"></td>
    <td style="width:11.575%;box-sizing:content-box;"></td>
    <td style="width:13.75%;box-sizing:content-box;"></td>
    <td style="width:28.35%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, on behalf of its San Diego Campus</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">LEXEO THERAPEUTICS, INC.</font></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;/s/ Elaine Tom</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;/s/ R. Nolan Townsend</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Print Name:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;Elaine Tom</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Print Name:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;R. Nolan Townsend</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Title:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;Principal Contract Officer</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Title:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;Chief Executive Officer</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;4/18/24</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;4/19/2024</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.19in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:0.96in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:5.467%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;margin-right:5.111%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid #000000;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit A: Further Revised Scope of Work and Budget</font></p>
  <p style="font-size:10pt;margin-top:2.15pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font></p>
  <p style="font-size:10pt;margin-top:1.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.19in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:0.94in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.19in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.31
<SEQUENCE>8
<FILENAME>lxeo-ex10_31.htm
<DESCRIPTION>EX-10.31
<TEXT>
<html>
 <head>
  <title>EX-10.31</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.13in;z-index:-3;min-height:0.47in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:9.9pt;font-family:Times New Roman;margin-bottom:6pt;margin-right:11.333%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.31</font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></p>
  <p style="margin-left:12.893%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:12.87%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FOURTH AMENDMENT TO THE RESEARCH AGREEMENT BETWEEN LEXEO THERAPEUTICS, INC.</font></p>
  <p style="margin-left:12.893%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:12.889%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AND</font></p>
  <p style="margin-left:23.107%;font-size:10pt;margin-top:1.15pt;font-family:Times New Roman;margin-bottom:0;margin-right:23.102%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">THE REGENTS OF THE UNIVERSITY OF CALIFORNIA ON BEHALF OF ITS SAN DIEGO CAMPUS</font></p>
  <p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:9.813%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:10.454%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Fourth Amendment (&#x201c;Amendment&#x201d;) by and between LEXEO Therapeutics, Inc. located at 345 Park Avenue South, Sixth Floor, New York, NY 10010 (&#x201c;Sponsor&#x201d;) and The Regents of the University of California on behalf of its San Diego Campus, located at 9500 Gilman Drive #0934, La Jolla, CA 92093-0934 (&#x201c;Institution&#x201d;) is made and effective as of the last date of signature (&#x201c;Effective Date&#x201d;).</font></p>
  <p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:9.813%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:10.454%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WHEREAS, </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sponsor and Institution entered into the Research Agreement, effective on December 3, 2021 (&#x201c;Agreement&#x201d;), to conduct a research project entitled [***] (&#x201c;Project&#x201d;);</font></p>
  <p style="font-size:10pt;margin-top:1.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:9.813%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:10.454%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WHEREAS, </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sponsor and Institution subsequently entered into a First Amendment to the Agreement, effective on April 5, 2023 (&#x201c;First Amendment&#x201d;);</font></p>
  <p style="font-size:10pt;margin-top:1.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:9.813%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:10.454%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WHEREAS, </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sponsor and Institution further entered into a Second Amendment to the Agreement, effective on August 31, 2023 (&#x201c;Second Amendment&#x201d;);</font></p>
  <p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:9.813%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:10.454%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WHEREAS, </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sponsor and Institution further entered into a Third Amendment to the Agreement, effective on April 19, 2024 (&#x201c;Third Amendment&#x201d;);</font></p>
  <p style="margin-left:9.8%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;margin-right:10.843%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WHEREAS, </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sponsor and Institution mutually desire to further amend the Agreement as set forth below;</font></p>
  <p style="font-size:10pt;margin-top:1.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:9.8%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:10.454%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOW THEREFORE, </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in consideration of the premises and mutual covenants herein, the parties agree as follows:</font></p>
  <p style="font-size:10pt;margin-top:1.1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:13.204%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:12%;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.8400387114613586%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Exhibit A: Further Revised Scope of Work and Budget&#x201d; of the Third Amendment shall be deleted and replaced with the attached &#x201c;Scope of Work and Budget Extension&#x201d; attached herein as </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit A</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div>
  <p style="font-size:10pt;margin-top:1.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:13.204%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:18.537%;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.8400387114613586%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Capitalized terms used herein that are not otherwise defined shall have the same meanings ascribed to such terms in the Agreement.</font></div></div>
  <p style="font-size:10pt;margin-top:1.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:13.204%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:10.935%;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.8400387114613586%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the terms of the Agreement in any way conflict with or are otherwise inconsistent with the terms of this Amendment, the terms of this Amendment shall govern and control.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.204%;display:flex;margin-top:9.9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:10.398%;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.8400387114613586%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Except as modified herein, the above-referenced Agreement, and the subsequent Amendments shall remain in full force and effect and is hereby incorporated by references. The Agreement, as amended and modified, constitutes the entire agreement and understanding between the parties.</font></div></div>
  <p style="font-size:10pt;margin-top:1.1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:13.204%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:12.667%;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.8400387114613586%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Amendment may be executed in two or more counterparts, each of which shall be deemed an original, but all of which shall constitute one and the same instrument.</font></div></div>
  <p style="font-size:10pt;margin-top:1.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:0.2in;justify-content:flex-end;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:18pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.13in;z-index:-3;min-height:0.47in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:9.813%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:10.454%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IN WITNESS WHEREOF, </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the parties have caused this Amendment to be executed by their duly authorized representatives as of the Effective Date.<br></font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:11.579%;box-sizing:content-box;"></td>
    <td style="width:34.737%;box-sizing:content-box;"></td>
    <td style="width:11.579%;box-sizing:content-box;"></td>
    <td style="width:11.579%;box-sizing:content-box;"></td>
    <td style="width:30.526%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, on behalf of its San Diego Campus</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">LEXEO THERAPEUTICS, INC.</font></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;/s/ Leah Williams</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;/s/ Jenny Robertson</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Print Name:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;Leah Williams</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Print Name:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;Jenny Robertson</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Title:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;Principal Contract Officer</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Title:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;Chief Business &amp; Legal Officer</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;9/23/2024</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;9/27/2024</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:0.2in;justify-content:flex-end;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:18pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.13in;z-index:-3;min-height:0.47in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:12.893%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:12.889%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit A: Scope of Work and Budget Extension</font></p>
  <p style="font-size:10pt;margin-top:9.75pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font></p>
  <p style="margin-left:9.813%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:0.2in;justify-content:flex-end;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:18pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.13in;z-index:-3;min-height:0.47in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:18pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.32
<SEQUENCE>9
<FILENAME>lxeo-ex10_32.htm
<DESCRIPTION>EX-10.32
<TEXT>
<html>
 <head>
  <title>EX-10.32</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.32</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LEXEO THERAPEUTICS, INC.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Shares of Common Stock</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">($0.0001 par value per share)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SALES AGREEMENT</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 24, 2025</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LEERINK PARTNERS LLC</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1301 Avenue of the Americas, 5</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Floor</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">New York, New York 10019</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ladies and Gentlemen:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lexeo Therapeutics, Inc., a Delaware corporation (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), confirms its agreement (this &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) with Leerink Partners LLC (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Agent</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), as follows:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Issuance and Sale of Shares</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Company agrees that, from time to time during the term of this Agreement, on the terms and subject to the conditions set forth herein, it may issue and sell through the Agent up to $75,000,000 of shares of common stock, $0.0001 par value per share, of the Company (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Common Stock</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), subject to the limitations set forth in Section 5(c) (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Placement Shares</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). Notwithstanding anything to the contrary contained herein, the parties hereto agree that compliance with the limitation set forth in this Section 1 on the aggregate gross sales price of Placement Shares that may be issued and sold under this Agreement from time to time shall be the sole responsibility of the Company, and that the Agent shall have no obligation in connection with such compliance.  The issuance and sale of Placement Shares through the Agent will be effected pursuant to the Registration Statement (as defined below) filed by the Company with the Securities and Exchange Commission (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commission</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) on December 13, 2024 and declared effective by the Commission on December 19, 2024, although nothing in this Agreement shall be construed as requiring the Company to issue any Placement Shares.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has prepared and filed, in accordance with the provisions of the Securities Act of 1933, as amended, and the rules and regulations thereunder (collectively, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities Act</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), with the Commission a registration statement on Form S-3 (File No. 333-283781), including a base prospectus (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Base Prospectus</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), relating to certain securities of the Company, including the Common Stock, to be issued from time to time by the Company, and which incorporates by reference documents that the Company has filed and will file in accordance with the provisions of the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder (collectively, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exchange Act</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).  The Company has prepared and will file a prospectus supplement to the Base Prospectus, which prospectus supplement specifically relates to the Placement Shares to be issued from time to time pursuant to this Agreement (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prospectus Supplement</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).  The Company will furnish to the Agent, for use by the Agent, copies of the Base Prospectus, as supplemented by the Prospectus Supplement.  Except where the context otherwise requires, such registration statement, including all documents filed as part thereof or incorporated by reference therein, and including any information contained in a Prospectus (as defined below) subsequently filed with the Commission pursuant to Rule 424(b) under the Securities Act or deemed to be a part of such registration statement pursuant to Rule 430B or Rule 462(b) under the Securities Act, is herein called the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registration Statement</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.&#x201d;  The Base Prospectus, including all documents incorporated therein by reference, included in the Registration Statement, as supplemented by the Prospectus Supplement, in the form in which such prospectus and/or the Prospectus Supplement have most recently been filed by the Company with the Commission pursuant to Rule 424(b) under the Securities Act, together with any &#x201c;issuer free writing prospectus&#x201d; (as defined in Rule 433 under the Securities Act (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rule 433</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;)), relating to the Placement Shares that (i) is required to be filed with the Commission by the Company or (ii) is exempt from filing pursuant to Rule 433(d)(5)(i), in each case, in the form filed or required to be filed with the Commission or, if not required to be filed, in the form retained in the Company&#x2019;s records pursuant to Rule 433(g), is herein called the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prospectus</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.&#x201d;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any reference herein to the Registration Statement, the Prospectus Supplement, the Prospectus or any issuer free writing prospectus shall be deemed to refer to and include the documents, if any, that are or are deemed to be incorporated by reference therein (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Incorporated Documents</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), including, unless the context otherwise requires, the documents, if any, filed as exhibits to such Incorporated Documents. Any reference herein to the terms &#x201c;amend,&#x201d; &#x201c;amendment&#x201d; or &#x201c;supplement&#x201d; with respect to the Registration Statement, the Prospectus Supplement, the Prospectus or any issuer free writing prospectus shall be deemed to refer to and include the filing after the date hereof of any document with the Commission deemed to be incorporated therein by reference.  For purposes of this Agreement, all references to the Registration Statement, the Prospectus or any amendment or supplement thereto shall be deemed to include the most recent copy filed with the Commission pursuant to its Electronic Data Gathering Analysis and Retrieval System or, if applicable, the Interactive Data Electronic Application system when used by the Commission (collectively, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EDGAR</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Placements</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Each time that the Company wishes to issue and sell any Placement Shares through the Agent hereunder (each, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Placement</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), it will notify the Agent by email notice (or other method mutually agreed to in writing by the parties) (each such notice, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Placement Notice</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) containing the parameters in accordance with which it desires such Placement Shares to be sold, which at a minimum shall include the maximum number or dollar amount of Placement Shares to be sold, the time period during which sales are requested to be made, any limitation on the number or dollar amount of Placement Shares that may be sold in any one Trading Day (as defined in Section 3) and any minimum price below which sales may not be made, a form of which containing such minimum sales parameters is attached hereto as </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 1</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Placement Notice must originate from one of the individuals authorized to act on behalf of the Company and set forth on </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 2</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (with a copy to each of the other individuals from the Company listed on such </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 2</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">), and shall be addressed to each of the recipients from the Agent set forth on </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 2</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, as such </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 2</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> may be updated by either party from time to time by sending a written notice containing a revised </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 2</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to the other party in the manner provided in Section 12 (including by email correspondence to each of the individuals of the Company set forth on </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 2</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, if receipt of such correspondence is actually acknowledged by any of the individuals to whom the notice is sent, other than via auto-reply).  The Placement Notice shall be effective upon receipt by the Agent unless and until (i) in accordance with the notice requirements set forth in Section 4, the Agent declines to accept the terms contained therein for any reason, in its sole discretion, within two Trading Days of the date the Agent receives the Placement Notice, (ii) in accordance with the notice requirements set forth in Section 4, the Agent suspends sales under the Placement Notice for any reason in its sole discretion, (iii) the entire amount of the Placement Shares has been sold pursuant to this Agreement, (iv) in accordance with the notice requirements set forth in Section 4, the Company suspends sales under or terminates the Placement Notice for any reason in its sole discretion, (v) the Company issues a subsequent Placement Notice and explicitly indicates that its parameters supersede those contained in the earlier dated Placement Notice or (vi) this Agreement has been terminated pursuant to the provisions of Section 11.  The amount of any discount, commission or other compensation to be paid by the Company to the Agent in connection with the sale of the Placement Shares effected through the Agent shall be calculated in accordance with the terms set forth in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 3</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  It is expressly acknowledged and agreed that neither the Company nor the Agent will have any obligation whatsoever with respect to a Placement or any Placement Shares unless and until the Company delivers a Placement Notice to the Agent and the Agent does not decline such Placement Notice pursuant to the terms set forth above, and then only upon the terms specified therein and herein. In the event of a conflict between the terms of this Agreement and the terms of a Placement Notice, the terms of the Placement Notice will control with respect to the matters covered thereby.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sale of Placement Shares by the Agent</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  On the basis of the representations and warranties herein contained and subject to the terms and conditions herein set forth, including Section 5(c), upon the Agent&#x2019;s acceptance of the terms of a Placement Notice as provided in Section 2, and unless the sale of the Placement Shares described therein has been declined, suspended or otherwise terminated in accordance with the terms of this Agreement, the Agent, for the period specified in the Placement Notice, will use its commercially reasonable efforts consistent with its normal trading and sales practices and applicable state and federal laws, rules and regulations and the rules of the Nasdaq Global Market (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nasdaq</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) to sell such Placement Shares up to the number or amount specified in, and otherwise in accordance with the terms of, such Placement Notice.  The Agent will provide written confirmation to the Company (including by email correspondence to each of the individuals of the Company set forth on </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 2</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, if receipt of such correspondence is actually acknowledged by any of the individuals to whom the notice is sent, other than via auto-reply) no later than the opening of the Trading Day (as defined below) immediately following the Trading Day on which it has made sales of Placement Shares hereunder setting forth the number or amount of Placement Shares sold on such Trading Day, the volume-weighted average price of the Placement Shares sold and the Net Proceeds (as defined below) payable to the Company.  Unless otherwise specified by the Company in a Placement Notice, the Agent may sell Placement Shares by any method permitted by law deemed to be an &#x201c;at the market offering&#x201d; as defined in Rule 415 of the Securities Act, including sales made directly on or through Nasdaq, on or through any other existing trading market for the Common Stock or to or through a market maker.  If expressly authorized by the Company (including in a Placement Notice), the Agent may also sell Placement Shares in negotiated transactions. Notwithstanding the provisions of Section 6(zz), except as may be otherwise agreed by the Company and the Agent, the Agent shall not purchase Placement Shares on a principal basis pursuant to this Agreement unless the Company and the Agent enter into a separate written agreement setting forth the terms of such sale.  The Company acknowledges and agrees that (i) there can be no assurance that the Agent will be successful in selling Placement Shares, (ii) the Agent will incur no liability or obligation to the Company or any other person or entity if it does not sell Placement Shares for any reason other than a failure by the Agent to use its commercially reasonable efforts consistent with its normal trading and sales practices and applicable state and federal laws, rules and regulations and the rules of Nasdaq to sell such Placement Shares as required under this Agreement and (iii) the Agent shall be under no obligation to purchase Placement Shares on a principal basis pursuant to this Agreement unless the Company and the Agent enter into a separate written agreement setting forth the terms of such sale.  For the purposes hereof, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Trading Day</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any day on which the Common Stock is purchased and sold on Nasdaq.</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Suspension of Sales</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:7.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	The Company or the Agent may, upon notice to the other party in writing (including by email correspondence to each of the individuals of the other party set forth on </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 2</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, if receipt of such correspondence is actually acknowledged by any of the individuals to whom the notice is sent, other than via auto-reply) or by telephone (confirmed immediately by email correspondence to each of the individuals of the other party set forth on </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 2</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">), suspend any sale of Placement Shares; </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">however</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that such suspension shall not affect or impair either party&#x2019;s obligations with respect to any Placement Shares sold hereunder prior to the receipt of such notice.  While a suspension pursuant to this Section 4(a) is in effect, any obligation under Sections 7(m), 7(n), 7(o), and 7(p) with respect to the delivery of certificates, opinions, or comfort letters to the Agent, shall be waived; provided, that upon delivery of a Placement Notice following a Representation Date, the Company shall be subject to the obligations set forth in Sections 7(m), 7(n), 7(o), and 7(p) as applicable. Each of the parties agrees that no such notice under this Section 4 shall be effective against the other party unless such notice is sent by one of the individuals named on </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 2</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> hereto to the other party in writing (including by email correspondence to each of the individuals of the other party set forth on </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 2</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, if receipt of such correspondence is actually acknowledged by any of the individuals to whom the notice is sent, other than via auto-reply).</font></p>
  <p style="text-indent:7.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	Notwithstanding any other provision of this Agreement, during any period in which the Company is, or could be deemed to be, in possession of material non-public information, the Company and the Agent agree that (i) no sale of Placement Shares will take place, (ii) the Company shall not request the sale of any Placement Shares and shall cancel any effective Placement Notices instructing the Agent to make any sales and (iii) the Agent shall not be obligated to sell or offer to sell any Placement Shares.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Settlement and Delivery of the Placement Shares</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:7.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Settlement of Placement Shares</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Unless otherwise specified in the applicable Placement Notice, settlement for sales of Placement Shares will occur on the first Trading Day following the date on which such sales are made (each, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Settlement Date</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).  The amount of proceeds to be delivered to the Company on a Settlement Date against receipt of the Placement Shares sold (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net Proceeds</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) will be equal to the aggregate gross sales price received by the Agent at which such Placement Shares were sold, after deduction of (i) the Agent&#x2019;s commission, discount or other compensation for such sales payable by the Company pursuant to Section 2 hereof, (ii) any other amounts due and payable by the Company to the Agent hereunder pursuant to Section 7(g) hereof and (iii) any transaction fees imposed by any governmental or self-regulatory organization in respect of such sales.</font></p>
  <p style="text-indent:7.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Delivery of Placement Shares</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  On or before each Settlement Date, the Company will issue the Placement Shares being sold on such date and will, or will cause its transfer agent to, electronically transfer such Placement Shares by crediting the Agent&#x2019;s or its designee&#x2019;s account (provided the Agent shall have given the Company written notice of such designee prior to the Settlement Date) at The Depository Trust Company through its Deposit and Withdrawal at Custodian System (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">DWAC</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) or by such other means of delivery as may be mutually agreed upon by the parties hereto, which in all cases shall be duly authorized, freely tradeable, transferable, registered shares of Common Stock in good deliverable form.  On each Settlement Date, the Agent will deliver the related Net Proceeds in same day funds to an account designated by the Company on or prior to the Settlement Date.  The Agent shall be responsible for providing DWAC instructions or other instructions for delivery by other means with regard to the transfer of the Placement Shares being sold.  In addition to and in no way limiting the rights and obligations set forth in Section 9(a) hereto, the Company agrees that if the Company or its transfer agent (if applicable), defaults in its obligation to deliver duly authorized, freely tradeable, transferable, registered Placement Shares in good deliverable form by 2:30 P.M., New York City time, on a Settlement Date (other than as a result of a failure by the Agent to provide instructions for delivery), the Company will (i) take all necessary action to cause the full amount of any Net Proceeds that were delivered to the Company&#x2019;s account with respect to such settlement, together with any costs incurred by the Agent and/or its clearing firm in connection with recovering such Net Proceeds, to be immediately returned to the Agent or its clearing firm no later than 5:00 P.M., New York City time, on such Settlement Date, by wire transfer of immediately available funds to an account designated by the Agent or its clearing firm, (ii) indemnify and hold the Agent and its clearing firm harmless against any loss, claim, damage, or expense (including reasonable legal fees and expenses), as incurred, arising out of or in connection with such default by the Company or its transfer agent (if applicable) and (iii) pay to the Agent any commission, discount or other compensation to which it would otherwise have been entitled absent such default. Certificates for the Placement Shares, if any, shall be in such denominations and registered in such names as the Agent may request in writing one Business Day (as defined below) before the applicable Settlement Date.  Certificates for the Placement Shares, if any, will be made available by the Company for examination and packaging by the Agent in New York City not later than 12:00 P.M., New York City time, on the Business Day prior to the applicable Settlement Date.</font></p>
  <p style="text-indent:7.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Limitations on Offering Size</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Under no circumstances shall the Company cause or request the offer or sale of any Placement Shares if, after giving effect to the sale of such Placement Shares, the aggregate number or gross sales proceeds of Placement Shares sold pursuant to this Agreement would exceed the lesser of: (i) the number or dollar amount of shares of Common Stock registered pursuant to, and available for offer and sale under, the Registration Statement pursuant to which the offering of Placement Shares is being made, (ii) the number of authorized but unissued shares of Common Stock of the Company (less shares of Common Stock issuable upon exercise, conversion or exchange of any outstanding securities of the Company or otherwise reserved from the Company&#x2019;s authorized capital stock), (iii) the number or dollar amount of shares of Common Stock permitted to be offered and sold by the Company under Form S-3 (including General Instruction I.B.6. thereof, if such instruction is applicable), (iv) the number or dollar amount of shares of Common Stock that the Company&#x2019;s board of directors or a duly authorized committee thereof is authorized to issue and sell from time to time, and notified to the Agent in writing, or (v) the dollar amount of shares of Common Stock for which the Company has filed the Prospectus Supplement.  Under no circumstances shall the Company cause or request the offer or sale of any Placement Shares pursuant to this Agreement at a price lower than the minimum price authorized from time to time by the Company&#x2019;s board of directors or a duly authorized committee thereof, and notified to the Agent in writing. Notwithstanding anything to the contrary contained herein, the parties hereto acknowledge and agree that compliance with the limitations set forth in this Section 5(c) on the number or dollar amount of Placement Shares that may be issued and sold under this Agreement from time to time shall be the sole responsibility of the Company, and that the Agent shall have no obligation in connection with such compliance.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Representations and Warranties of the Company</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Company represents and warrants to, and agrees with, the Agent that as of the date of this Agreement, and as of (i) each Representation Date (as defined in Section 7(m)) for which no waiver is in effect, (ii) each date on which a Placement Notice is given, (iii) the date and time of each sale of any Placement Shares pursuant to this Agreement and (iv) each Settlement Date (each such time or date referred to in clauses (i) through (iv), an &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Applicable Time</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;):</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	The Company and the transactions contemplated by this Agreement meet the requirements for and comply with the conditions for the use of Form S-3 (including General Instructions I.A and I.B.1.) under the Securities Act.  The Registration Statement has been filed with the Commission and has been declared effective by the Commission under the Securities Act prior to the issuance of any Placement Notices by the Company.  At the time the Registration Statement was declared effective and, subsequent thereto, at the time the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2024, was filed with the Commission, the Company met the then-applicable requirements for use of Form S-3 (including General Instructions I.A and I.B.1.) under the Securities Act.  The Registration Statement meets, and the offering and sale of Placement Shares as contemplated hereby comply with, the requirements of Rule 415(a)(1)(x) under the Securities Act.  The Agent is named as the agent engaged by the Company in the section entitled &#x201c;Plan of Distribution&#x201d; in the Prospectus Supplement. The Company has not received, and has no notice from the Commission of, any notice pursuant to Rule 401(g)(1) under the Securities Act objecting to the use of the shelf registration statement form.  No stop order of the Commission preventing or suspending the use of the Base Prospectus, the Prospectus Supplement or the Prospectus, or the effectiveness of the Registration Statement, has been issued, and no proceedings for such purpose are pending before or, to the knowledge of the Company, threatened by the Commission.  At the time of the initial filing of the Registration Statement, the Company paid the required Commission filing fees relating to the securities covered by the Registration Statement, including the Placement Shares that may be sold pursuant to this Agreement, in accordance with Rule 457(o) under the Securities Act.  Copies of the Registration Statement, the Prospectus, any such amendments or supplements to any of the foregoing and all Incorporated Documents that were filed with the Commission on or prior to the date of this Agreement have been delivered, or are available through EDGAR, to the Agent and its counsel.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	Each of the Registration Statement and any post-effective amendment thereto, at the time it became or becomes effective, at each deemed effective date with respect to the Agent pursuant to Rule 430B(f)(2) under the Securities Act and as of each Applicable Time, complied, complies and will comply in all material respects with the requirements of the Securities Act and did not, does not and will not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading, except that the representations and warranties set forth in this sentence do not apply to Agent&#x2019;s Information (as defined below).  The Prospectus and any amendment or supplement thereto, when so filed with the Commission under Rule 424(b) under the Securities Act, complied, complies and as of each Applicable Time will comply in all material respects with the requirements of the Securities Act, and the Prospectus Supplement, Prospectus or issuer free writing prospectus (or any amendments or supplements to any of the foregoing) furnished to the Agent for use in connection with the offering of the Placement Shares was identical to the electronically transmitted copies thereof filed with the Commission pursuant to EDGAR, except to the extent permitted by Regulation S-T.  Neither the Prospectus nor any amendment or supplement thereto, as of its date and as of each Applicable Time, included, includes or will include an untrue statement of a material fact or omitted, omits or will omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading, except that the representations and warranties set forth in this sentence do not apply to Agent&#x2019;s Information. Each Incorporated Document heretofore filed, when it was filed (or, if any amendment with respect to any such document was filed, when such amendment was filed), conformed in all material respects with the requirements of the Exchange Act and was filed on a timely basis with the Commission, and any further Incorporated Documents so filed and incorporated into the Prospectus after the date of this Agreement will be filed on a timely basis and, when so filed, will conform in all material respects with the requirements of the Exchange Act; no such Incorporated Document when it was filed (or, if an amendment with respect to any such document was filed, when such amendment was filed), contained an untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; and any further Incorporated Document, when filed, will not contain an untrue statement of a material fact or will omit to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	(i) At the time of filing the Registration Statement and (ii) at the time of the execution of this Agreement (with such date being used as the determination date for purposes of this clause (ii)), the Company was not and is not an &#x201c;ineligible issuer&#x201d; (as defined in Rule 405 under the Securities Act (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rule 405</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;)), without taking account of any determination by the Commission pursuant to Rule 405 that it is not necessary that the Company be considered an ineligible issuer.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	The Company is an &#x201c;emerging growth company,&#x201d; as defined in Section 2(a) of the Securities Act (an &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Emerging Growth Company</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e)	Each issuer free writing prospectus, as of its issue date and as of each Applicable Time, did not, does not and will not include any information that conflicted, conflicts or will conflict with the information contained in the Registration Statement or the Prospectus, including any Incorporated Document deemed to be a part thereof that has not been superseded or modified. Each issuer free writing prospectus that the Company has filed, or is required to file, pursuant to Rule 433 or that was prepared by or on behalf of or used by the Company complies or will comply in all material respects with the requirements of the Securities Act.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(f)	The Company has not distributed and, prior to the later to occur of each Settlement Date and completion of the Agent&#x2019;s distribution of the Placement Shares under this Agreement, will not distribute any offering material in connection with the offering and sale of the Placement Shares other than the Registration Statement, the Prospectus or any Permitted Free Writing Prospectus (as defined below).</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(g)	The Company is subject to and in compliance in all material respects with the reporting requirements of Section 13 or Section 15(d) of the Exchange Act.  The Common Stock is registered pursuant to Section 12(b) of the Exchange Act and is listed on Nasdaq, and the Company has taken no action designed to, or reasonably likely to have the effect of, terminating the registration of the Common Stock under the Exchange Act or delisting the Common Stock from Nasdaq, nor has the Company received any notification that the Commission or Nasdaq is contemplating terminating such registration or listing. The Company is in compliance with the current listing standards of Nasdaq.  The Company has filed a Notification of Listing of Additional Shares with Nasdaq with respect to the Placement Shares.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(h)	The Company is not a party to any other agreement with an agent or underwriter for any other &#x201c;at the market&#x201d; or continuous equity transaction.  No person (as such term is defined in Rule 1-02 of Regulation S-X promulgated under the Securities Act) has the right to act as an underwriter or as a financial advisor to the Company in connection with the offer and sale of the Placement Shares hereunder, whether as a result of the filing or effectiveness of the Registration Statement or the sale of the Placement Shares as contemplated hereby or otherwise.  Except for the Agent, there is no broker, finder or other party that is entitled to receive from the Company any brokerage or finder&#x2019;s fee or other fee or commission as a result of any transactions contemplated by this Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i)	The financial statements (including the related notes thereto) of the Company included or incorporated by reference in the Registration Statement and the Prospectus comply in all material respects with the applicable requirements of the Securities Act and the Exchange Act, as applicable, and present fairly in all material respects the financial position of the Company as of the dates indicated and the results of operations and the changes in cash flows for the periods specified; such financial statements have been prepared in conformity with generally accepted accounting principles (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">GAAP</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) in the United States applied on a consistent basis throughout the periods covered thereby, except for any normal year-end adjustments in any unaudited interim financial statements, which do not contain certain related notes as permitted by the applicable rules of the Commission, and any supporting schedules included or incorporated by reference in the Registration Statement present fairly in all material respects the information required to be stated therein; the other financial information included or incorporated by reference in the Registration Statement and the Prospectus has been derived from the accounting records of the Company and presents fairly in all material respects the information shown thereby; and any disclosures included or incorporated by reference in the Registration Statement and the Prospectus regarding &#x201c;non-GAAP financial measures&#x201d; (as such term is defined by the rules and regulations of Commission), if any, comply with Regulation G of the Exchange Act and Item 10 of Regulation S-K of the Securities Act, to the extent applicable.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(j)	Since the date of the most recent financial statements of the Company included or incorporated by reference in the Registration Statement and the Prospectus, (i) there has not been any material change in the capital stock of the Company (other than the issuance of shares of Common Stock upon exercise of stock options described as outstanding in, and the grant of options and awards under existing equity incentive plans described in, the Registration Statement and the Prospectus), short-term debt or long-term debt of the Company (in each case, except as otherwise disclosed in the Registration Statement and the Prospectus), or any dividend or distribution of any kind declared, set aside for payment, paid or made by the Company on any class of capital stock, or any material adverse change, or any development that would reasonably be expected to result in a prospective material adverse change, in or affecting the business, property, management, financial position, stockholders&#x2019; equity, results of operations or prospects of the Company ; (ii) the Company has not entered into any transaction or agreement (whether or not in the ordinary course of business) that is material to the Company or incurred any liability or obligation, direct or contingent, that is material to the Company ; and (iii) the Company has not sustained any loss or interference with its business that is material to the Company and that is either from fire, explosion, flood or other calamity, whether or not covered by insurance, or from any labor disturbance or dispute or any action, order or decree of any court or arbitrator or governmental or regulatory authority, except in each case as otherwise disclosed in the Registration Statement and the Prospectus.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(k)	The Company has been duly organized and is validly existing and in good standing under the laws of the State of Delaware, is duly qualified to do business and is in good standing in each jurisdiction in which its ownership or lease of property or the conduct of its business requires such qualification, and has all power and authority necessary to own or hold its property and to conduct the business in which it is engaged, except where the failure to be so qualified or in good standing or have such power or authority would not, individually or in the aggregate, have a material adverse effect on the business, property, management, financial position, stockholders&#x2019; equity, results of operations or prospects of the Company or on the performance by the Company of its obligations under this Agreement (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Material Adverse Effect</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).  The Company does not own or control, directly or indirectly, any corporation, association or other entity.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(l)	The Company has the authorized and outstanding capitalization as set forth in the Company&#x2019;s Annual Report on Form 10-K for the most recent fiscal year or, if later, the Company&#x2019;s Quarterly Report on Form 10-Q for the most recent fiscal quarter, as of the dates referred to therein (subject, in each case, to the issuance of Placement Shares under this Agreement, the issuance of shares of Common Stock upon exercise of options and warrants and/or the settlement of restricted stock units disclosed as outstanding as of the date hereof in the Registration Statement and the Prospectus and the grant of options and restricted stock units under existing Company Stock Plans (as defined below) described in the Registration Statement and the Prospectus); all the outstanding shares of capital stock of the Company have been duly and validly authorized and issued and are fully paid and non-assessable and are not subject to any pre-emptive or similar rights that have not been duly waived or satisfied; except as described in or expressly contemplated by the Registration Statement and the Prospectus, there are no outstanding rights (including, without limitation, pre-emptive rights that have not been duly waived or satisfied), warrants or options to acquire, or instruments convertible into or exchangeable for, any shares of capital stock or other equity interest in the Company, or any contract, commitment, agreement, understanding or arrangement of any kind relating to the issuance of any capital stock of the Company, any such convertible or exchangeable securities or any such rights, warrants or options; and the capital stock of the Company conforms in all material respects to the description thereof contained in the Registration Statement and the Prospectus.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(m)	With respect to the stock options (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock Options</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) granted pursuant to the stock-based compensation plans of the Company (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company Stock Plans</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), (i) each Stock Option intended to qualify as an &#x201c;incentive stock option&#x201d; under Section 422 of the Internal Revenue Code of 1986, as amended (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Code</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) so qualifies, (ii) each grant of a Stock Option was duly authorized no later than the date on which the grant of such Stock Option was by its terms to be effective by all necessary corporate action, including, as applicable, approval by the board of directors of the Company (or a duly constituted and authorized committee thereof) and any required stockholder approval by the necessary number of votes or written consents, and, to the knowledge of the Company (other than with respect to due execution and delivery by the Company), the award agreement governing such grant (if any) was duly executed and delivered by each party thereto, (iii) each such grant was made in accordance with the terms of the Company Stock Plans, the Exchange Act and all other applicable laws and regulatory rules or requirements, including the rules of Nasdaq and any other exchange on which Company securities are traded, in all material respects, and (iv) each such grant was properly accounted for in accordance with GAAP in the financial statements (including the related notes) of the Company and disclosed in the Company&#x2019;s filings with the Commission in accordance with the Exchange Act and all other applicable laws in all material respects.  The Company has not knowingly granted, and there is no and has been no policy or practice of the Company of granting, Stock Options prior to, or otherwise coordinating the grant of Stock Options with, the release or other public announcement of material information regarding the Company or its results of operations or prospects.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(n)	The Company has full right, power and authority to execute and deliver this Agreement and to perform its obligations hereunder; and all action required to be taken for the due and proper authorization, execution and delivery by it of this Agreement and the consummation by it of the transactions contemplated hereby has been duly and validly taken.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(o)	This Agreement has been duly authorized, executed and delivered by the Company.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(p)	The Placement Shares to be issued and sold by the Company hereunder have been duly authorized by the Company and, when issued and delivered and paid for as provided herein, will be duly and validly issued, will be fully paid and nonassessable and will conform in all material respects to the descriptions thereof in the Registration Statement and the Prospectus; and the issuance of the Placement Shares is not subject to any preemptive or similar rights that have not been duly waived or satisfied.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(q)	This Agreement conforms in all material respects to the description thereof contained in the Registration Statement and the Prospectus.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(r) 	The Company is not (i) in violation of its charter or by-laws; (ii) in default, and no event has occurred that, with notice or lapse of time or both, would constitute such a default, in the due performance or observance of any term, covenant or condition contained in any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which the Company is a party or by which the Company or is bound or to which any property or asset of the Company is subject; or (iii) in violation of any law or statute or any judgment, order, rule or regulation of any court or arbitrator or governmental or regulatory authority having jurisdiction over the Company, except, in the case of clauses (ii) and (iii) above, for any such default or violation that would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(s)	The execution, delivery and performance by the Company of this Agreement, the issuance and sale of the Placement Shares and the consummation of the transactions contemplated by this Agreement or the Prospectus will not (i) conflict with or result in a breach or violation of any of the terms or provisions of, or constitute a default under, result in the termination, modification or acceleration of, or result in the creation or imposition of any lien, charge or encumbrance upon any property, right or asset of the Company pursuant to, any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which the Company is a party or by which the Company is bound or to which any property, right or asset of the Company is subject, (ii) result in any violation of the provisions of the charter or by-laws of the Company or (iii) result in the violation of any law or statute or any judgment, order, rule or regulation of any court or arbitrator or governmental or regulatory authority having jurisdiction over the Company, except, in the case of clauses (i) and (iii) above, for any such conflict, breach, violation, default, lien, charge or encumbrance that would not, individually or in the aggregate, reasonably be excepted to have a Material Adverse Effect.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(t)	No consent, approval, authorization, order, registration or qualification of or with any court or arbitrator or governmental or regulatory authority is required for the execution, delivery and performance by the Company of this Agreement, the issuance and sale of the Placement Shares and the consummation of the transactions contemplated by this Agreement, except for the registration of the Placement Shares under the Securities Act and such consents, approvals, authorizations, orders and registrations or qualifications as may be required by the Financial Industry Regulatory Authority, Inc. (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FINRA</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), Nasdaq and under applicable state securities laws in connection with the consummation of the transactions contemplated hereby or by the Registration Statement and the Prospectus .</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(u)	Except as described in the Registration Statement and the Prospectus, there are no legal, governmental or regulatory investigations, actions, demands, claims, suits, arbitrations, inquiries or proceedings (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Actions</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) pending to which the Company is or may reasonably be expected to become a party or to which any property of the Company is or may reasonably be expected to become the subject that, individually or in the aggregate, if determined adversely to the Company, could reasonably be expected to have a Material Adverse Effect; to the knowledge of the Company, no such Actions are threatened or contemplated by any governmental or regulatory authority or, except as described in the Registration Statement and the Prospectus, threatened by others; and (i) there are no current or pending Actions that are required under the Securities Act to be described in the Registration Statement or the Prospectus that are not so described in the Registration Statement and the Prospectus and (ii) there are no statutes, regulations or contracts or other documents that are required under the Securities Act to be filed as exhibits to the Registration Statement or described in the Registration Statement or the Prospectus that are not so filed as exhibits to the Registration Statement or described in the Registration Statement and the Prospectus.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(v) 	KPMG LLP, who have certified certain financial statements of the Company, is an independent registered public accounting firm with respect to the Company within the applicable rules and regulations adopted by the Commission and the Public Company Accounting Oversight Board (United States) and as required by the Securities Act.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(w)	The Company has good and marketable title in fee simple to, or has valid rights to lease or otherwise use, all items of real and personal property that are material to the business of the Company, in each case free and clear of all liens, encumbrances, claims and defects and imperfections of title except those that (i) do not materially interfere with the use made and proposed to be made of such property by the Company or (ii) could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(x)	(i) The Company owns or possesses or has the right to use all patents, patent applications, software and software developments, trademarks, service marks, trade names, trademark registrations, service mark registrations, domain names and other source indicators, copyrights, authors&#x2019; rights and copyrightable works, know-how, trade secrets, systems, procedures, inventions, licenses, technology, proprietary or confidential information and all other worldwide intellectual property, industrial property and proprietary rights (collectively, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intellectual Property</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) necessary to carry on the business now operated by them, or as proposed to be conducted; (ii) except as described in the Registration Statement and the Prospectus, there is no pending or, to the knowledge of the Company, threatened action, suit, proceeding or claim by others challenging the Company&#x2019;s rights</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in or to any such Intellectual Property, and the Company is unaware of any facts which would form a reasonable basis for any such action, suit, proceeding or claim; (iii) there is no pending or, to the knowledge of the Company, threatened action, suit, proceeding or claim by others challenging the validity or scope of any such Intellectual Property, and the Company is unaware of any facts which would form a reasonable basis for any such claim; (iv) the Intellectual Property has not been adjudged by a court of competent jurisdiction invalid or unenforceable, in whole or in part; (v) there is no prior art</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of which the Company is aware that may render any patent held by the Company invalid or any patent application held by the Company un-patentable which has not been disclosed to the U.S. Patent and Trademark Office; (vi) to the knowledge of the Company, the Company&#x2019;s conduct of its business does not infringe, misappropriate or otherwise violate any Intellectual Property of any person and the Company is unaware of any facts which would form a reasonable basis for any such claim; (vii) the Company has not received any written notice of any claim of ownership or inventorship with respect to the Company&#x2019;s owned Intellectual Property; (viii) the Company has taken reasonable steps in accordance with normal industry practice to maintain the confidentiality of all Intellectual Property of the Company where the value to the Company is contingent upon maintaining the confidentiality thereof and no such Intellectual Property has been disclosed other than to employees, representatives and agents of the Company, all of whom are bound by written confidentiality agreements; and (ix) to the knowledge of the Company, the Intellectual Property of the Company is not being infringed, misappropriated or otherwise violated by any person. Each patent application owned, or purported to be owned by the Company is being diligently prosecuted and each issued patent owned or purported to be owned by the Company is being diligently maintained.  Except as disclosed in the Registration Statement and the Prospectus, all Intellectual Property rights described in the Registration Statement as owned by the Company are owned solely by the Company.  All Intellectual Property rights owned or purported to be owned by the Company are owned free and clear of all material liens, encumbrances, defects or other restrictions.  The Company is not aware of any specific facts that would form a reasonable basis for a finding that any of the issued or granted patents owned by the Company is invalid or unenforceable and, to the knowledge of the Company, all such issued or granted patents are valid and enforceable.  The Company is not subject to any judgment, order, writ, injunction or decree of any court or any federal, state, local, foreign or other governmental department, commission, board, bureau, agency or instrumentality, domestic or foreign, or any arbitrator, nor has it entered into or is it a party to any agreement made in settlement of any pending or threatened litigation, which restricts or impairs its use of any Intellectual Property rights, except as would not reasonably be expected, singly or in the aggregate, to have a material adverse effect on the Company.  All of the Company&#x2019;s employment agreements and consulting agreements contain, to the extent permitted by applicable law, provisions requiring the disclosure of any inventions and effecting the automatic transfer to the Company of all rights, titles and interests in intellectual property, including intellectual property rights in and to any creation, made by such employees and consultants from the beginning of their employment.  All payments in connection with such transfers have been duly made to the Company&#x2019;s employees and consultants in accordance with applicable law, employment agreements and consulting agreements.  To the knowledge of the Company, no current or former employee or consultant of the Company is in violation of the confidential information and invention disclosure and assignment provisions included in their respective employment agreement or consultant agreement.  All employees and consultants have executed an employment agreement or consulting agreement, as applicable, with the Company.  All of the Company&#x2019;s sub-contractor agreements contain the provisions necessary to ensure, to the extent permitted by applicable law, the transfer to the Company of all material Intellectual Property rights with respect to the work performed on behalf of the Company, except with respect to background intellectual property belonging to such sub-contractors.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(y)	No relationship, direct or indirect, exists between or among the Company, on the one hand, and the directors, officers, stockholders, customers, suppliers or other affiliates of the Company, on the other, that is required by the Securities Act to be described in each of the Registration Statement and the Prospectus and that is not so described in such documents.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(z)	The Company is not and, after giving effect to the offering and sale of the Placement Shares and the application of the proceeds thereof as described in the Prospectus, will not be required to register as an &#x201c;investment company&#x201d; or an entity &#x201c;controlled&#x201d; by an &#x201c;investment company&#x201d; within the meaning of the Investment Company Act of 1940, as amended, and the rules and regulations of the Commission thereunder (collectively, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investment Company Act</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(aa) 	The Company has paid all federal, state, local and foreign taxes and filed all tax returns required to be paid or filed through the date hereof (except where the failure to pay or file would not, individually or in the aggregate, have a Material Adverse Effect); and except as otherwise disclosed in each of the Registration Statement and the Prospectus, there is no tax deficiency that has been, or could reasonably be expected to be, asserted in writing against the Company or any of its property or assets and that could, individually or in the aggregate, have a Material Adverse Effect.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(bb) 	The Company possesses all licenses, sub-licenses, certificates, permits and other authorizations issued by, and have made all declarations and filings with, the appropriate federal, state, local or foreign governmental or regulatory authorities that are necessary for the ownership or lease of its property or the conduct of its business as described in each of the Registration Statement and the Prospectus, except where the failure to possess or make the same would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect; and except as described in each of the Registration Statement and the Prospectus, the Company has not received notice of any revocation or modification of any such license, sub-license, certificate, permit or authorization or has any reason to believe that any such license, sub-license, certificate, permit or authorization will not be renewed in the ordinary course.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(cc)	No labor disturbance by or dispute with employees of the Company exists or, to the knowledge of the Company, is contemplated or threatened, and the Company is not aware of any existing or imminent labor disturbance by, or dispute with, the employees of any of its principal suppliers, contractors or customers, except as would not reasonably be expected to have a Material Adverse Effect.  The Company has not received any notice of cancellation or termination with respect to any collective bargaining agreement to which it is a party.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(dd)	(i) The Company (x) is in compliance with all, and has not violated any, applicable federal, state, local and foreign laws (including common law), rules, regulations, requirements, decisions, judgments, decrees, orders and other legally enforceable requirements relating to pollution or the protection of human health or safety, the environment, natural resources, hazardous or toxic substances or wastes, pollutants or contaminants (collectively, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Environmental Laws</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;); (y) has received and is in compliance with all, and have not violated any, permits, licenses, certificates or other authorizations or approvals required of them under any Environmental Laws to conduct its business; and (z) has not received notice of any actual or potential liability or obligation under or relating to, or any actual or potential violation of, any Environmental Laws, including for the investigation or remediation of any disposal or release of hazardous or toxic substances or wastes, pollutants or contaminants, and has no knowledge of any event or condition that would reasonably be expected to result in any such notice; (ii) there are no costs or liabilities associated with Environmental Laws of or relating to the Company, except in the case of each of (i) and (ii) above, for any such matter as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect; and (iii) except as described in the Prospectus, (x) there is no proceeding that is pending, or that is known to be contemplated, against the Company under any Environmental Laws in which a governmental entity is also a party, other than such proceeding regarding which it is reasonably believed no monetary sanctions of $100,000 or more will be imposed, (y) the Company is not aware of any facts or issues regarding compliance with Environmental Laws, or liabilities or other obligations under Environmental Laws or concerning hazardous or toxic substances or wastes, pollutants or contaminants, that could reasonably be expected to have a material effect on the capital expenditures, earnings or competitive position of the Company, and (z) the Company does not anticipate material capital expenditures relating to any Environmental Laws.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ee) 	(i) Each employee benefit plan, within the meaning of Section 3(3) of the Employee Retirement Income Security Act of 1974, as amended (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ERISA</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), for which the Company or any member of its &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Controlled Group</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; (defined as any entity, whether or not incorporated, that is under common control with the Company within the meaning of Section 4001(a)(14) of ERISA or any entity that would be regarded as a single employer with the Company under Section 414(b),(c),(m) or (o) of the Code) would have any liability (each, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) has been maintained in compliance with its terms and the requirements of any applicable statutes, orders, rules and regulations, including but not limited to ERISA and the Code, except for non-compliance that would not reasonably be expected to result in a material liability to the Company; (ii) no prohibited transaction, within the meaning of Section 406 of ERISA or Section 4975 of the Code, has occurred with respect to any Plan, excluding transactions effected pursuant to a statutory or administrative exemption; (iii) for each Plan that is subject to the funding rules of Section 412 of the Code or Section 302 of ERISA, no Plan has failed (whether or not waived), or is reasonably expected to fail, to satisfy the minimum funding standards (within the meaning of Section 302 of ERISA or Section 412 of the Code) applicable to such Plan; (iv) no Plan is, or is reasonably expected to be, in &#x201c;at risk status&#x201d; (within the meaning of Section 303(i) of ERISA) and no Plan that is a &#x201c;multiemployer plan&#x201d; within the meaning of Section 4001(a)(3) of ERISA is in &#x201c;endangered status&#x201d; or &#x201c;critical status&#x201d; (within the meaning of Sections 304 and 305 of ERISA) (v) the fair market value of the assets of each Plan exceeds the present value of all benefits accrued under such Plan (determined based on those assumptions used to fund such Plan); (vi) no &#x201c;reportable event&#x201d; (within the meaning of Section 4043(c) of ERISA and the regulations promulgated thereunder) has occurred or is reasonably expected to occur; (vii) each Plan that is intended to be qualified under Section 401(a) of the Code is so qualified, and, to the knowledge of the Company, nothing has occurred, whether by action or by failure to act, which would cause the loss of such qualification; (viii) neither the Company nor any member of the Controlled Group has incurred, nor reasonably expects to incur, any liability under Title IV of ERISA (other than contributions to the Plan or premiums to the Pension Benefit Guarantee Corporation, in the ordinary course and without default) in respect of a Plan (including a &#x201c;multiemployer plan&#x201d; within the meaning of Section 4001(a)(3) of ERISA); and (ix) none of the following events has occurred or is reasonably likely to occur: (A) a material increase in the aggregate amount of contributions required to be made to all Plans by the Company or its Controlled Group affiliates in the current fiscal year of the Company and its Controlled Group affiliates compared to the amount of such contributions made in the Company&#x2019;s and its Controlled Group affiliates&#x2019; most recently completed fiscal year; or (B) a material increase in the Company&#x2019;s &#x201c;accumulated post-retirement benefit obligations&#x201d; (within the meaning of Accounting Standards Codification Topic 715-60) compared to the amount of such obligations in the Company&#x2019;s most recently completed fiscal year, except in each case with respect to the events or conditions set forth in (i) through (ix) hereof, as would not, individually or in the aggregate, have a Material Adverse Effect.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ff)	The Company maintains an effective system of &#x201c;disclosure controls and procedures&#x201d; (as defined in Rule 13a-15(e) of the Exchange Act) that complies with the applicable requirements of the Exchange Act and that has been designed to ensure that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Commission&#x2019;s rules and forms, including controls and procedures designed to ensure that such information is accumulated and communicated to the Company&#x2019;s management as appropriate to allow timely decisions regarding required disclosure.  The Company has carried out evaluations of the effectiveness of its disclosure controls and procedures as required by Rule 13a-15 of the Exchange Act.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(gg)	The Company maintains a system of &#x201c;internal control over financial reporting&#x201d; (as defined in Rule 13a-15(f) of the Exchange Act) that is designed to comply with the applicable requirements of the Exchange Act and has been designed by, or under the supervision of, its principal executive and principal financial officers, or persons performing similar functions, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP.  The Company maintains internal accounting controls sufficient to provide reasonable assurance that (i) transactions are executed in accordance with management&#x2019;s general or specific authorizations; (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability; (iii) access to assets is permitted only in accordance with management&#x2019;s general or specific authorization; (iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences; and (v) interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement and the Prospectus fairly presents the information called for in all material respects and is prepared in accordance with the Commission&#x2019;s rules and guidelines applicable thereto.  Based on the Company&#x2019;s most recent evaluation of its internal controls over financial reporting pursuant to Rule 13a-15(c) of the Exchange Act, there are no material weaknesses in the Company&#x2019;s internal controls.  The Company&#x2019;s auditors and the Audit Committee of the Board of Directors of the Company have been advised of:  (i) all significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting known to the Company which have adversely affected or are reasonably likely to adversely affect the Company&#x2019;s ability to record, process, summarize and report financial information; and (ii) any fraud known to the Company, whether or not material, that involves management or other employees who have a significant role in the Company&#x2019;s internal controls over financial reporting.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(hh)	The Company has insurance covering its property, operations, personnel and business, including business interruption insurance, which insurance is in amounts and insures against such losses and risks as are reasonably adequate to protect the Company and its business; and the Company has not (i) received notice from any insurer or agent of such insurer that capital improvements or other expenditures are required or necessary to be made in order to continue such insurance or (ii) any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage at reasonable cost from similar insurers as may be necessary to continue its business.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii) 	The Company&#x2019;s information technology assets and equipment, computers, systems, networks, hardware, software, websites, applications, and databases (including all data of employees, suppliers, vendors and any third-party data under the control of and maintained by the Company) (collectively, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IT Systems</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) are adequate for, and operate and perform in all material respects as required in connection with the operation of the business of the Company as currently conducted, in each case, to the knowledge of the Company, free and clear of all material bugs, errors, defects, Trojan horses, time bombs, malware and other corruptants.  The Company implements and maintains commercially reasonable controls, policies, procedures, and safeguards designed to maintain and protect its material confidential information and the integrity, continuous operation, redundancy and security of all IT Systems and personal, personally identifiable, or regulated data comprising personal data (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Personal Data</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) collected, used or otherwise processed in connection with its business, and, to the knowledge of the Company, there have been no breaches, violations, outages or unauthorized uses of or accesses to same, except for those that have been remedied without material cost or liability or the duty to notify any other person, nor any incidents under internal review or investigations relating to the same.   The Company is presently in material compliance with all applicable laws or statutes and all judgments, orders, rules and regulations of any court or arbitrator or governmental or regulatory authority, approved and released internal policies and contractual obligations relating to the privacy and security of IT Systems and Personal Data and to the protection of such IT Systems and Personal Data from unauthorized use, access, misappropriation or modification.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(jj)	Neither the Company nor any director, officer or employee of the Company nor, to the knowledge of the Company, any agent, affiliate or other person associated with or acting on behalf of the Company has (i) used any corporate funds for any unlawful contribution, gift, entertainment or other unlawful expense relating to political activity; (ii) made or taken an act in furtherance of an offer, promise or authorization of any direct or indirect unlawful payment or benefit to any foreign or domestic government official or employee, including of any government-owned or controlled entity or of a public international organization, or any person acting in an official capacity for or on behalf of any of the foregoing, or any political party or party official or candidate for political office; (iii) violated or is in violation of any provision of the Foreign Corrupt Practices Act of 1977, as amended, or any applicable law or regulation implementing the OECD Convention on Combating Bribery of Foreign Public Officials in International Business Transactions, or committed an offence under the Bribery Act 2010 of the United Kingdom or any other applicable anti-bribery or anti-corruption law; or (iv) made, offered, agreed, requested or taken an act in furtherance of any unlawful bribe or other unlawful benefit, including, without limitation, any rebate, payoff, influence payment, kickback or other unlawful or improper payment or benefit.  The Company has instituted, maintain and enforce, and will continue to maintain and enforce policies and procedures designed to promote and ensure compliance with all applicable anti-bribery and anti-corruption laws.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(kk)	The operations of the Company are and have been conducted at all times in compliance with applicable financial recordkeeping and reporting requirements, including those of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the applicable money laundering statutes of all jurisdictions where the Company conducts business, the rules and regulations thereunder and any related or similar rules, regulations or guidelines issued, administered or enforced by any governmental agency (collectively, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Anti-Money Laundering Laws</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company with respect to the Anti-Money Laundering Laws is pending or, to the knowledge of the Company, threatened.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ll)	Neither the Company nor any of its directors, officers, or employees, nor, to the knowledge of the Company, any agent, affiliate or other person associated with or acting on behalf of the Company is currently the subject or the target of any sanctions administered or enforced by the U.S. government, (including, without limitation, the Office of Foreign Assets Control of the U.S. Department of the Treasury (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">OFAC</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) or the U.S. Department of State and including, without limitation, the designation as a &#x201c;specially designated national&#x201d; or &#x201c;blocked person&#x201d;), the United Nations Security Council (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UNSC</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), the European Union, His Majesty&#x2019;s Treasury (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">HMT</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), the Special Economic Measures Act (Canada) or other relevant sanctions authority (collectively, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sanctions</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), nor is the Company located, organized or resident in a country or territory that is the subject or target of Sanctions, including, without limitation, the so-called Donetsk People&#x2019;s Republic, the so-called Luhansk People&#x2019;s Republic, the Crimea Region of Ukraine, the non-government controlled areas of the Zaporizhzhia and Kherson Regions of Ukraine (or any other Covered Region of Ukraine identified pursuant to Executive Order 14065), Cuba, Iran, North Korea and Syria (each, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sanctioned Territory</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;); and the Company will not directly or indirectly use the proceeds of the offering of the Placement Shares hereunder, or lend, contribute or otherwise make available such proceeds to any joint venture partner or other person or entity (i) to fund or facilitate any activities of or business with any person that, at the time of such funding or facilitation, is the subject or target of Sanctions, (ii) to fund or facilitate any activities of or business in any Sanctioned Territory or (iii) in any other manner that will result in a violation by any person (including any person participating in the transaction, whether as underwriter, advisor, investor or otherwise) of Sanctions.  During the applicable statute of limitations period, the Company has not knowingly engaged in and is not now knowingly engaged in any dealings or transactions with any person that at the time of the dealing or transaction is or was the subject or the target of Sanctions or with any Sanctioned Territory.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(mm)	[Reserved.]</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(nn)	The Company is not a party to any contract, agreement or understanding with any person (other than this Agreement) that would give rise to a valid claim against any of them or the Agent for a brokerage commission, finder&#x2019;s fee or like payment in connection with the offering and sale of the Placement Shares.	</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(oo)	No person has the right to require the Company to register any securities for sale under the Securities Act by reason of the filing of the Registration Statement or Prospectus with the Commission or the issuance and sale of the Placement Shares, except for such rights that have been validly waived.	</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(pp)	Neither the Company nor any of its affiliates has taken, directly or indirectly, any action designed to or that could reasonably be expected to cause or result in any stabilization or manipulation of the price of the Placement Shares.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(qq)	Neither the issuance, sale and delivery of the Placement Shares nor the application of the proceeds thereof by the Company as described in each of the Registration Statement and the Prospectus will violate Regulation T, U or X of the Board of Governors of the Federal Reserve System or any other regulation of such Board of Governors.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(rr)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No forward-looking statement (within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act) included or incorporated by reference in the Registration Statement or the Prospectus has been made or reaffirmed without a reasonable basis or has been disclosed other than in good faith.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ss)	Nothing has come to the attention of the Company that has caused the Company to believe that the statistical and market-related data included or incorporated by reference in each of the Registration Statement and the Prospectus is not based on or derived from sources that are reliable and accurate in all material respects.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(tt)	There is and has been no failure on the part of the Company or any of the Company&#x2019;s directors or officers, in their capacities as such, to comply with any provision of the Sarbanes-Oxley Act of 2002, as amended and the rules and regulations promulgated in connection therewith (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sarbanes-Oxley Act</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), including Section 402 related to loans and Sections 302 and 906 related to certifications.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(uu)	(i) Except as described in the Registration Statement and the Prospectus, the clinical trials, preclinical studies and tests (collectively, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Studies</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) conducted by or on behalf of or sponsored by the Company, or in which the Company has participated or in which Company product candidates have been studied, that are described in the Registration Statement and the Prospectus, or the results of which are referred to in the Registration Statement and the Prospectus, as applicable, were, and if still pending are, being conducted in all material respects in accordance with the protocols, procedures and controls designed and approved for such studies, standard medical and scientific research procedures and all applicable statutes, rules and regulations, including good clinical practice and good laboratory practice requirements, of the applicable regulatory agencies to which they are subject, including the U.S. Food and Drug Administration (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FDA</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), the Centers for Medicare and Medicaid Services, the European Medicines Agency, or any foreign, federal, state or local governmental body exercising comparable authority (collectively, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Regulatory Authorities</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;); (ii) the descriptions in the Registration Statement and the Prospectus of the results of such Studies are accurate and complete descriptions in all material respects and fairly present the data derived therefrom; (iii) the Company does not have knowledge of any other Studies not described in the Registration Statement and the Prospectus, the results of which are inconsistent with or call into question the results described or referred to in the Registration Statement and the Prospectus; (iv) the Company has operated at all times and is currently in compliance in all material respects with all applicable statutes, rules and regulations of the Regulatory Authorities; (v) the Company has provided the Agent with all substantive written notices, correspondence and summaries of all communications from the Regulatory Authorities and reports of Studies; (vi) the Company nor has not received any notices, correspondence or other communications from the Regulatory Authorities, any other governmental authority or any Institutional Review Board or ethics committee or similar body requiring or threatening the termination, material modification, suspension or clinical hold of any Studies or that call into question the studies that are described in the Registration Statement and the Prospectus or the results of which are referred to in the Registration Statement and the Prospectus, other than ordinary course communications with respect to modifications in connection with the design and implementation of such Studies conducted or proposed to be conducted by or on behalf of the Company, and, to the knowledge of the Company, there are no reasonable grounds for the same; (vii) the Company is not a party to any corporate integrity agreements, deferred prosecution agreements, monitoring agreements, consent decrees, plans of correction, settlement orders, or similar agreements with or imposed by any governmental or Regulatory Authority; (viii) none of the Studies described in the Registration Statement and the Prospectus or the results of which are referred to in the Registration Statement and the Prospectus involved any investigator who has been disqualified as a clinical investigator or has been found by the FDA or other Regulatory Authority to have engaged in scientific misconduct and no such proceedings are pending; and (ix) the manufacturing facilities and operations of the Company and its suppliers, are and have been operated in compliance in all material respects with all applicable statutes, rules, regulations and policies of the Regulatory Authorities.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(vv)	The Company has not failed to file with the Regulatory Authorities any required filing, declaration, listing, registration, report or submission or failed to obtain any required approval or authorization with respect to the product candidates of the Company that are described or referred to in the Registration Statement and the Prospectus; all such filings, declarations, listings, registrations, reports or submissions, as applicable, were in material compliance with applicable laws when filed; and no deficiencies have been asserted by any applicable Regulatory Authority with respect to any such filings, declarations, listings, registrations, reports or submissions.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ww) 	The Company is, and at all times has been, in compliance in all material respects with all applicable Health Care Laws.  For purposes of this Agreement, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Health Care Laws</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; in all material respects means: (i) the Federal Food, Drug, and Cosmetic Act (21 U.S.C. Section 301 et seq.), the Public Health Service Act (42 U.S.C. Section 201 et seq.), and the regulations promulgated thereunder; (ii) all applicable U.S. federal, state, local and non-U.S. health care fraud and abuse laws, including, without limitation, the Anti-Kickback Statute (42 U.S.C. Section 1320a-7b(b)), the Civil False Claims Act (31 U.S.C.  Section 3729 et seq.), the criminal false statements law (42 U.S.C. Section 1320a-7b(a)), 18 U.S.C. Sections 286 and 287, the health care fraud criminal provisions under HIPAA,  the civil monetary penalties law (42 U.S.C. Section 1320a-7a), the exclusion law (42 U.S.C. Section 1320a-7), the Physician Payments Sunshine Act (42 U.S.C. Section 1320-7h), and applicable laws governing government funded or sponsored healthcare programs; (iii) HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (42 U.S.C. Section 17921 et seq.); (iv) the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010; (v) licensure, quality, safety and accreditation requirements under applicable U.S. federal, state, local or non-U.S. laws or regulatory bodies; (vi) all other local, state, U.S. federal, national, supranational and non-U.S. laws relating to the regulation of the Company, and (vii) the directives and regulations promulgated pursuant to such statutes, and any state or non-U.S. counterpart thereof.  The Company has not received any Form FDA 483, notice of adverse finding, warning letter, untitled letter or other adverse correspondence or notice from Regulatory Authorities, or notice of any deficiency, noncompliance, pending or threatened claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any court or arbitrator or governmental or Regulatory Authority or third party alleging that any product operation or activity is or potentially is in violation of any Health Care Laws nor, to the knowledge of the Company, is any such claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action threatened or pending.  The Company has filed, maintained or submitted all reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required by any Health Care Laws, and all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were complete and accurate on the date filed in all material respects (or were corrected or supplemented by a subsequent submission).  Additionally, neither the Company nor any of its employees, officers, directors, or their respective agents has been excluded, suspended, debarred or disqualified from participation in any U.S. federal health care program or human clinical research or is subject to a governmental inquiry, investigation, proceeding, or other similar action that could reasonably be expected to result in debarment, disqualification, suspension, or exclusion, has been convicted of any crime or engaged in any conduct that would reasonably be expected to result in debarment under 21 U.S.C. Section 335a or comparable foreign law or has been liable for a civil monetary penalty under 21 U.S.C. Section 335b or comparable foreign law.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(xx)	There are (and prior to the date hereof, have been) no debt securities, convertible securities or preferred stock issued or guaranteed by the Company that are rated by a &#x201c;nationally recognized statistical rating organization&#x201d;, as such term is defined in Section 3(a)(62) under the Exchange Act.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(yy)	The Company acknowledges and agrees that the Agent has informed the Company that the Agent may, to the extent permitted under the Securities Act and the Exchange Act, purchase and sell shares of Common Stock for its own account while this Agreement is in effect; </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that (i) no such purchase or sales shall take place while a Placement Notice is in effect (except to the extent the Agent may engage in sales of Placement Shares purchased or deemed purchased from the Company as a &#x201c;riskless principal&#x201d; or in a similar capacity) and (ii) the Company shall not be deemed to have authorized or consented to any such purchases or sales by the Agent, except as may be otherwise agreed by the Company and the Agent.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(zz)	Neither the Company nor, to the Company&#x2019;s knowledge, any of its affiliates (within the meaning of Rule 144 under the Securities Act) has, prior to the date hereof, made any offer or sale of any securities which could be &#x201c;integrated&#x201d; (within the meaning of the Securities Act) with the offer and sale of the Placement Shares hereunder.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any certificate signed by any officer of the Company and delivered to the Agent or its counsel in connection with the offering of the Placement Shares shall be deemed a representation and warranty by the Company, as to matters covered thereby, to the Agent.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Covenants of the Company</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Company covenants and agrees with the Agent that:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registration Statement Amendments</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  After the date of this Agreement and during any period in which the Prospectus relating to any Placement Shares is required to be delivered by the Agent under the Securities Act (including in circumstances where such requirement may be satisfied pursuant to Rule 172 under the Securities Act or a similar rule); (i) the Company will notify the Agent promptly of the time when any subsequent amendment to the Registration Statement, other than Incorporated Documents, has been filed with the Commission and/or has become effective or any subsequent supplement to the Prospectus, other than Incorporated Documents, has been filed and of any request by the Commission for any amendment or supplement to the Registration Statement or Prospectus or for additional information (in each case, insofar as it relates to the transactions contemplated hereby); (ii) the Company will prepare and file with the Commission, promptly upon the Agent&#x2019;s reasonable request, any amendments or supplements to the Registration Statement or Prospectus that, in the Agent&#x2019;s reasonable opinion, may be necessary or advisable in connection with the distribution of the Placement Shares by the Agent (provided, however, that the failure of the Agent to make such request shall not relieve the Company of any obligation or liability hereunder, or affect the Agent&#x2019;s right to rely on the representations and warranties made by the Company in this Agreement and provided, further, that the only remedy the Agent shall have with respect to the failure by the Company to make such filing (but without limiting the Agent&#x2019;s rights under Section 9 hereof) will be to cease making sales under this Agreement until such amendment or supplement is filed); (iii) the Company will not file any amendment or supplement to the Registration Statement or Prospectus, other than Incorporated Documents, relating to the Placement Shares or a security convertible into or exchangeable or exercisable for the Placement Shares unless a copy thereof has been submitted to the Agent within a reasonable period of time before the filing and the Agent has not reasonably objected thereto (provided, however, that the failure of the Agent to make such objection shall not relieve the Company of any obligation or liability hereunder, or affect the Agent&#x2019;s right to rely on the representations and warranties made by the Company in this Agreement and provided, further, that the only remedy the Agent shall have with respect to the Company&#x2019;s making such filing notwithstanding the Agent&#x2019;s objection (but without limiting the Agent&#x2019;s rights under Section 9 hereof) will be to cease making sales under this Agreement) and the Company will furnish to the Agent at the time of filing thereof a copy of any Incorporated Document, except for those documents available via EDGAR; and (iv) the Company will cause each amendment or supplement to the Prospectus, other than Incorporated Documents, to be filed with the Commission as required pursuant to the applicable paragraph of Rule 424(b) of the Securities Act and, in the case of any Incorporated Document, to be filed with the Commission as required pursuant to the Exchange Act, within the time period prescribed.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notice of Commission Stop Orders</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Company will advise the Agent, promptly after it receives notice or obtains knowledge thereof, of the issuance or threatened issuance by the Commission of any stop order suspending the effectiveness of the Registration Statement, of the suspension of the qualification of the Placement Shares for offering or sale in any jurisdiction or of the initiation or threatening of any proceeding for any such purpose; and it will promptly use its commercially reasonable efforts to prevent the issuance of any stop order or to obtain its withdrawal if such a stop order should be issued.  The Company will advise the Agent promptly after it receives any request by the Commission for any amendments to the Registration Statement or any amendment or supplements to the Prospectus or for additional information related to the offering of the Placement Shares or for additional information related to the Registration Statement or the Prospectus.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">17</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Delivery of Prospectus; Subsequent Changes</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  During any period in which the Prospectus relating to the Placement Shares is required to be delivered by the Agent under the Securities Act with respect to the offer and sale of the Placement Shares (including in circumstances where such requirement may be satisfied pursuant to Rule 172 under the Securities Act or a similar rule), the Company will comply with all requirements imposed upon it by the Securities Act, as from time to time in force, and will file on or before their respective due dates (taking into account any extensions available under the Exchange Act) all reports and any definitive proxy or information statements required to be filed by the Company with the Commission pursuant to Sections 13(a), 13(c), 14, 15(d) or any other provision of or under the Exchange Act.  If during such period any event occurs as a result of which the Prospectus as then amended or supplemented would include an untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances then existing, not misleading, or if during such period it is necessary to amend or supplement the Registration Statement or Prospectus to comply with the Securities Act, the Company will promptly notify the Agent to suspend the offering of Placement Shares during such period and the Company will promptly amend or supplement the Registration Statement or Prospectus (at the expense of the Company) so as to correct such statement or omission or effect such compliance.  If the Company has omitted any information from the Registration Statement pursuant to Rule 430B under the Securities Act, it will use its reasonable best efforts to comply with the provisions thereof and make all requisite filings with the Commission pursuant to said Rule 430B and to notify the Agent promptly of all such filings if not available on EDGAR.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Listing of Placement Shares</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  During any period in which the Prospectus relating to the Placement Shares is required to be delivered by the Agent under the Securities Act with respect to the offer and sale of the Placement Shares (including in circumstances where such requirement may be satisfied pursuant to Rule 172 under the Securities Act or a similar rule), the Company will use its commercially reasonable efforts to cause the Placement Shares to be listed on Nasdaq.  The Company will timely file with Nasdaq all material documents and notices required by Nasdaq of companies that have or will issue securities that are traded on Nasdaq.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Delivery of Registration Statement and Prospectus</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Company will furnish to the Agent and its counsel (at the expense of the Company) copies of the Registration Statement, the Prospectus (including all Incorporated Documents) and all amendments and supplements to the Registration Statement or Prospectus that are filed with the Commission during any period in which the Prospectus relating to the Placement Shares is required to be delivered under the Securities Act (including all Incorporated Documents filed with the Commission during such period), in each case as soon as reasonably practicable and in such quantities as the Agent may from time to time reasonably request and, at the Agent&#x2019;s request, will also furnish copies of the Prospectus to each exchange or market on which sales of the Placement Shares may be made; </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">however</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that the Company shall not be required to furnish any document (other than the Prospectus) to the Agent to the extent such document is available on EDGAR.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(f)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Earnings Statement</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Company will make generally available to its security holders and to the Agent as soon as practicable, but in any event not later than 15 months after the end of the Company&#x2019;s current fiscal quarter, an earnings statement covering a 12-month period that satisfies the provisions of Section 11(a) of and Rule 158 under the Securities Act, which requirement shall be satisfied by the timely filing with the Commission of the Company&#x2019;s annual report on Form 10-K.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(g)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Expenses</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Company, whether or not the transactions contemplated hereunder are consummated or this Agreement is terminated in accordance with the provisions of Section 11 hereunder, will pay all expenses incident to the performance of its obligations hereunder, including expenses relating to (i) the preparation, printing and filing of the Registration Statement and each amendment and supplement thereto, of the Prospectus and of each amendment and supplement thereto and of this Agreement and such other documents as may be required in connection with the offering, purchase, sale, issuance or delivery of the Placement Shares, (ii) the preparation, issuance, sale and delivery of the Placement Shares and any taxes due or payable in connection therewith, (iii) the qualification of the Placement Shares under securities laws in accordance with the provisions of Section 7(w) of this Agreement, including filing fees (provided, however, that any fees or disbursements of counsel for the Agent in connection therewith shall be paid by the Agent except as set forth in clauses (vii) and (viii) below), (iv) the printing and delivery to the Agent and its counsel of copies of the Prospectus and any amendments or supplements thereto, and of this Agreement, (v) the fees and expenses incurred in connection with the listing or qualification of the Placement Shares for trading on Nasdaq, (vi) the filing fees and expenses, if any, owed to the Commission or FINRA and the fees and expenses of any transfer agent or registrar for the Placement Shares, (vii) the fees and associated expenses of the Agent&#x2019;s outside legal counsel for filings with the FINRA Corporate Financing Department in an amount not to exceed $15,000 (excluding FINRA filing fees referred to in clause (vi) above and in addition to the fees and disbursements referred to in clause (viii) below), and (viii) the reasonable fees and disbursements of the Agent&#x2019;s outside legal counsel (A) in an amount not to exceed $75,000 arising out of executing this Agreement and the Company&#x2019;s delivery of the initial certificate pursuant to Section 7(m) and (B) in an  amount not to exceed $15,000 in connection with each Representation Date (as defined below) on which the Company is required to provide a certificate pursuant to Section 7(m) (in addition to the fees and associated expenses referred to in clause (vii) above).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(h)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Use of Proceeds</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Company will use the Net Proceeds as described in the Prospectus in the section entitled &#x201c;Use of Proceeds.&#x201d;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notice of Other Sales</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Without the prior written consent of the Agent, the Company will not, directly or indirectly, offer to sell, sell, contract to sell, grant any option to sell or otherwise dispose of any shares of Common Stock (other than the Placement Shares offered pursuant to this Agreement) or securities convertible into or exchangeable or exercisable for shares of Common Stock, warrants or any rights to purchase or acquire shares of Common Stock during the period beginning on the third Trading Day immediately prior to the date on which any Placement Notice is delivered to Agent hereunder and ending on the second Trading Day immediately following the final Settlement Date with respect to Placement Shares sold pursuant to such Placement Notice (or, if the Placement Notice has been terminated or suspended prior to the sale of all Placement Shares covered by a Placement Notice, the date of such suspension or termination); and will not directly or indirectly in any other &#x201c;at the market offering&#x201d; or continuous equity transaction offer to sell, sell, contract to sell, grant any option to sell or otherwise dispose of any shares of Common Stock (other than the Placement Shares offered pursuant to this Agreement) or securities convertible into or exchangeable or exercisable for shares of Common Stock, warrants or any rights to purchase or acquire, shares of Common Stock prior to the later of the termination of this Agreement and the thirtieth day immediately following the final Settlement Date with respect to Placement Shares sold pursuant to such Placement Notice; </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">however</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that such restrictions will not be required in connection with the Company&#x2019;s issuance, grant or sale of (i) shares of Common Stock, options to purchase shares of Common Stock, other securities under the Company&#x2019;s existing equity incentive plans, or shares of Common Stock issuable upon the exercise of options or other equity awards or vesting of other securities, pursuant to any employee or director stock option or benefits plan, stock ownership plan, dividend reinvestment plan (but not shares of Common Stock subject to a waiver to exceed plan limits in its dividend reinvestment plan), inducement award under Nasdaq rules or other compensation plan of the Company whether now in effect or hereafter implemented, (ii) shares of Common Stock issuable upon the exchange, conversion or redemption of securities or the exercise or vesting of warrants, options or other rights in effect or outstanding, and disclosed in filings by the Company available on EDGAR or otherwise in writing to the Agent and (iii) up to 5% of the Company&#x2019;s then-outstanding shares of Common Stock or securities convertible into or exchangeable for shares of Common Stock as consideration for mergers; acquisitions; other business combinations; joint ventures; collaborations; licensing arrangements; manufacturing, distribution, marketing, supply, sponsored research, technology transfer or development or third party service arrangements; or strategic alliances occurring after the date of this Agreement which are not issued for capital raising purposes.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">19</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(j)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Change of Circumstances</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Company will, at any time during a fiscal quarter in which the Company intends to tender a Placement Notice or sell Placement Shares, advise the Agent promptly after it shall have received notice or obtained knowledge of any information or fact that would alter or affect in any material respect any opinion, certificate, letter or other document provided or required to be provided to the Agent pursuant to this Agreement.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(k)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Due Diligence Cooperation</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  During the term of this Agreement, the Company will cooperate with any reasonable due diligence review conducted by the Agent, its affiliates agents and counsel from time to time in connection with the transactions contemplated hereby, including providing information and making available documents and senior corporate officers, during regular business hours and at the Company&#x2019;s principal offices, as the Agent may reasonably request.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(l)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Required Filings Relating to Placement of Placement Shares</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Company agrees that on or prior to such dates as the Securities Act shall require with respect to the Placement Shares, the Company will (i) file a prospectus supplement with the Commission under the applicable paragraph of Rule 424(b) under the Securities Act, which prospectus supplement will set forth, within the relevant period, the number or amount of Placement Shares sold through the Agent, the Net Proceeds to the Company and the compensation payable by the Company to the Agent with respect to such Placement Shares, and (ii) deliver such number of copies of each such prospectus supplement to each exchange or market on which such sales were effected as may be required by the rules or regulations of such exchange or market; </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that, unless a prospectus supplement containing such information is required to be filed under the Securities Act, the requirement of this Section 7(l) may be satisfied by Company&#x2019;s inclusion in the Company&#x2019;s Form 10-K or Form 10-Q, as applicable, of the number or amount of Placement Shares sold through the Agent, the Net Proceeds to the Company and the compensation payable by the Company to the Agent with respect to such Placement Shares during the relevant period.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(m)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Representation Dates; Certificate</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  On or prior to the date on which the Company first delivers a Placement Notice pursuant to this agreement (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">First Placement Notice Date</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) and each time the Company:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i)	amends or supplements the Registration Statement or the Prospectus relating to the Placement Shares (other than a prospectus supplement filed in accordance with Section 7(l) of this Agreement) by means of a post-effective amendment, sticker or supplement but not by means of incorporation of document(s) by reference into the Registration Statement or the Prospectus relating to the Placement Shares;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii)	files an annual report on Form 10-K under the Exchange Act (including any Form 10-K/A containing amended financial information or a material amendment to the previously filed Form 10-K);</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iii)	files a quarterly report on Form 10-Q under the Exchange Act; or</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iv)	files a current report on Form 8-K containing amended financial information (other than an earnings release that is &#x201c;furnished&#x201d; pursuant to Item 2.02 or Item 7.01 of Form 8-K) under the Exchange Act (each date of filing of one or more of the documents referred to in clauses (i) through (iv) shall be a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Representation Date</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;),</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Company shall furnish the Agent (but in the case of clause (iv) above only if (1) a Placement Notice is pending or in effect and (2) the Agent requests such certificate within three Business Days after the filing of such Form 8-K with the Commission) with a certificate, in the form attached hereto as </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 7(m)</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(modified, as necessary, to relate to the Registration Statement and the Prospectus as then amended or supplemented), within two Trading Days of any Representation Date.  The requirement to provide a certificate under this Section 7(m) shall be waived for any Representation Date occurring at a time at which no Placement Notice is pending or in effect, which waiver shall continue until the earlier to occur of (1) the date the Company delivers a Placement Notice hereunder (which for such calendar quarter shall be considered a Representation Date) and (2) the next occurring Representation Date.  Notwithstanding the foregoing, if the Company subsequently decides to sell Placement Shares following a Representation Date on which the Company relied on the waiver referred to in the previous sentence and did not provide the Agent with a certificate under this Section 7(m), then before the Company delivers a Placement Notice or the Agent sells any Placement Shares pursuant thereto, the Company shall provide the Agent with a certificate, in the form attached hereto as </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 7(m)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, dated the date of such Placement Notice. Within two Trading Days of each Representation Date, the Company shall have furnished to the Agent such further information, certificates and documents as the Agent may reasonably request.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">20</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(n)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Legal Opinions</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  On or prior to the First Placement Notice Date and on any date which the Company is obligated to deliver a certificate pursuant to Section 7(m) for which no waiver is applicable, the Company shall cause to be furnished to the Agent the written opinion and negative assurance letter of Wilson Sonsini Goodrich &amp; Rosati, P.C., counsel to the Company, or such other counsel satisfactory to the Agent (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company Counsel</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), in form and substance satisfactory to the Agent and its counsel, dated the date that the opinion and negative assurance letter are required to be delivered, modified, as necessary, to relate to the Registration Statement and the Prospectus as then amended or supplemented; </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">however</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that in lieu of such opinion and negative assurance letter for subsequent Representation Dates, Company Counsel may furnish the Agent with a letter to the effect that the Agent may rely on a prior opinion or negative assurance letter delivered by such counsel under this Section 7(n) to the same extent as if it were dated the date of such letter (except that statements in such prior opinion or negative assurance letter shall be deemed to relate to the Registration Statement and the Prospectus as amended or supplemented at such Representation Date).</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(o)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intellectual Property Opinion</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. On or prior to the First Placement Notice Date and on any date which the Company is obligated to deliver a certificate pursuant to Section 7(m) for which no waiver is applicable, the Company shall cause to be furnished to the Agent the written opinion of Cooley LLP, counsel for the Company with respect to intellectual property matters, or such other intellectual property counsel satisfactory to the Agent (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intellectual Property Counsel</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), in form and substance satisfactory to the Agent and its counsel, dated the date that the opinion letter is required to be delivered, modified, as necessary, to relate to the Registration Statement and the Prospectus as then amended or supplemented; </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">however</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that in lieu of such written opinion for subsequent Representation Dates, Intellectual Property Counsel may furnish the Agent with a letter to the effect that the Agent may rely on a prior opinion letter delivered by such counsel under this Section 7(o) to the same extent as if it were dated the date of such opinion letter (except that statements in such prior opinion letter shall be deemed to relate to the Registration Statement and the Prospectus as amended or supplemented at such Representation Date).</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(p)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Comfort Letter</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  On or prior to the First Placement Notice Date and on any date which the Company is obligated to deliver a certificate pursuant to Section 7(m) for which no waiver is applicable, the Company shall cause its independent registered public accounting firm (and any other independent accountants whose report is included in the Registration Statement or the Prospectus) to furnish the Agent letters (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Comfort Letters</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), dated the date the Comfort Letter is delivered, which shall meet the requirements set forth in this Section 7(p); </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that if requested by the Agent, the Company shall cause a Comfort Letter to be furnished to the Agent within 10 Trading Days of the occurrence of any material transaction or event that necessitates the filing of additional, pro forma, amended or revised financial statements (including any restatement of previously issued financial statements).  Each Comfort Letter shall be in form and substance satisfactory to the Agent and each Comfort Letter from the Company&#x2019;s independent registered public accounting firm shall (i) confirm that they are an independent registered public accounting firm within the meaning of the Securities Act and the PCAOB, (ii) state, as of such date, the conclusions and findings of such firm with respect to the financial information and other matters ordinarily covered by accountants&#x2019; &#x201c;comfort letters&#x201d; to underwriters in connection with registered public offerings (the first such letter, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Initial Comfort Letter</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) and (iii) update the Initial Comfort Letter with any information that would have been included in the Initial Comfort Letter had it been given on such date and modified as necessary to relate to the Registration Statement and the Prospectus, as amended and supplemented to the date of such letter.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(q)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Market Activities</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Company will not, directly or indirectly, (i) take any action designed to cause or result in, or that constitutes or might reasonably be expected to constitute, the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of shares of Common Stock or (ii) sell, bid for, or purchase shares of Common Stock in violation of Regulation M, or pay anyone any compensation for soliciting purchases of the Placement Shares other than the Agent; </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">however</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that the Company may bid for and purchase shares of Common Stock in accordance with Rule 10b-18 under the Exchange Act.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(r)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Insurance</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Company shall maintain, or cause to be maintained, insurance in such amounts and covering such risks as is reasonable and customary for the business for which it is engaged.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(s)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compliance with Laws</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Company shall maintain, or cause to be maintained, all material environmental certificates, authorizations or permits required by federal, state and local law in order to conduct its business as described in the Prospectus (collectively, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Permits</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), and the Company shall conduct its business, or cause its business to be conducted, in substantial compliance with such Permits and with applicable Environmental Laws, except where the failure to maintain or be in compliance with such Permits could not reasonably be expected to result in a Material Adverse Effect.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">21</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(t)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investment Company Act</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Company will conduct its affairs in such a manner so as to reasonably ensure that it will not be or become, at any time prior to the termination of this Agreement, an &#x201c;investment company,&#x201d; as such term is defined in the Investment Company Act.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(u)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities Act and Exchange Act</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Company will use its best efforts to comply with all requirements imposed upon it by the Securities Act and the Exchange Act as from time to time in force, so far as necessary to permit the sales of, or dealings in, the Placement Shares as contemplated by the provisions hereof and the Prospectus.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(v)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Offer to Sell</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Other than a free writing prospectus (as defined in Rule 405) approved in advance by the Company and the Agent, neither the Agent nor the Company (including its agents and representatives, other than the Agent in its capacity as agent) will make, use, prepare, authorize, approve or refer to any written communication (as defined in Rule 405), required to be filed with the Commission, that constitutes an offer to sell or solicitation of an offer to buy Placement Shares hereunder.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(w)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Blue Sky and Other Qualifications</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company will use its commercially reasonable efforts, in cooperation with the Agent, to qualify the Placement Shares for offering and sale, or to obtain an exemption for the Placement Shares to be offered and sold, under the applicable securities laws of such states and other jurisdictions (domestic or foreign) as the Agent may designate and to maintain such qualifications and exemptions in effect for so long as required for the distribution of the Placement Shares (but in no event for less than one year from the date of this Agreement); </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided, however</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that the Company shall not be obligated to file any general consent to service of process or to qualify as a foreign corporation or as a dealer in securities in any jurisdiction in which it is not so qualified or to subject itself to taxation in respect of doing business in any jurisdiction in which it is not otherwise so subject. In each jurisdiction in which the Placement Shares have been so qualified or exempt, the Company will file such statements and reports as may be required by the laws of such jurisdiction to continue such qualification or exemption, as the case may be, in effect for so long as required for the distribution of the Placement Shares (but in no event for less than one year from the date of this Agreement).</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(x)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sarbanes-Oxley Act</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Company will maintain and keep accurate books and records reflecting its assets and maintain internal accounting controls in a manner designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP and including those policies and procedures that (i) pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the Company, (ii) provide reasonable assurance that transactions are recorded as necessary to permit the preparation of the Company&#x2019;s financial statements in accordance with GAAP, (iii) that receipts and expenditures of the Company are being made only in accordance with management&#x2019;s and the Company&#x2019;s directors&#x2019; authorization, and (iv) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company&#x2019;s assets that could have a material effect on its financial statements.  The Company will maintain such controls and other procedures, including, without limitation, those required by Sections 302 and 906 of the Sarbanes-Oxley Act, and the applicable regulations thereunder that are designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission&#x2019;s rules and forms, including, without limitation, controls and procedures designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the Company&#x2019;s management, including its principal executive officer and principal financial officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure and to ensure that material information relating to the Company is made known to it by others within the Company, particularly during the period in which such periodic reports are being prepared.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(y)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Emerging Growth Company</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Company will promptly notify the Agent if the Company ceases to be an Emerging Growth Company at any time prior to the completion of the Agent&#x2019;s distribution of the Placement Shares pursuant to this Agreement.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">22</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(z)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Renewal of Registration Statement.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  If, immediately prior to the third anniversary of the initial effective date of the Registration Statement (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Renewal Date</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), any of the Placement Shares remain unsold and this Agreement has not been terminated, the Company will, prior to the Renewal Date, file a new shelf registration statement or, if applicable, an automatic shelf registration statement relating to the Common Stock that may be offered and sold pursuant to this Agreement (which shall include a prospectus reflecting the number or amount of Placement Shares that may be offered and sold pursuant to this Agreement), in a form satisfactory to the Agent and its counsel, and, if such registration statement is not an automatic shelf registration statement, will use its reasonable best efforts to cause such registration statement to be declared effective within 180 days after the Renewal Date.  The Company will take all other reasonable actions necessary or appropriate to permit the public offer and sale of the Placement Shares to continue as contemplated in the expired registration statement and this Agreement. From and after the effective date thereof, references herein to the &#x201c;Registration Statement&#x201d; shall include such new shelf registration statement or such new automatic shelf registration statement, as the case may be.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(aa)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General Instruction I.B.6. of Form S-3</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  If, from and after the date of this Agreement, the Company is no longer eligible to use Form S-3 (including pursuant to General Instruction I.B.6.) at the time it files with the Commission an annual report on Form 10-K or any post-effective amendment to the Registration Statement, then it shall promptly notify the Agent and, within two Business Days after the date of filing of such annual report on Form 10-K or amendment to the Registration Statement, the Company shall file a new prospectus supplement with the Commission reflecting the number of shares of Common Stock available to be offered and sold by the Company under this Agreement pursuant to General Instruction I.B.6. of Form S-3; </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">however</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that the Company may delay the filing of any such prospectus supplement for up to 30 days if, in the reasonable judgment of the Company, it is in the best interest of the Company to do so, provided that no Placement Notice is in effect or pending during such time. Until such time as the Company shall have corrected such misstatement or omission or effected such compliance, the Company shall not notify the Agent to resume the offering of Placement Shares.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(bb)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Transfer Agent</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company has engaged and will maintain, at its sole expense, a transfer agent and registrar for the Common Stock.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Conditions to the Agent&#x2019;s Obligations</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The obligations of the Agent hereunder with respect to a Placement will be subject to the continuing accuracy and completeness of the representations and warranties made by the Company herein, to the due performance by the Company of its obligations hereunder, to the completion by the Agent of a due diligence review satisfactory to the Agent in its reasonable judgment, and to the continuing satisfaction (or waiver by the Agent in its sole discretion) of the following additional conditions:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registration Statement Effective</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Registration Statement shall be effective and shall be available for all offers and sales of Placement Shares (i) that have been issued pursuant to all prior Placement Notices and (ii) that will be issued pursuant to any Placement Notice.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prospectus Supplement</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company shall have filed with the Commission the Prospectus Supplement with respect to the Placement Shares pursuant to Rule 424(b) under the Securities Act not later than the Commission&#x2019;s close of business on the second Business Day following the date of this Agreement.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Material Notices</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  None of the following events shall have occurred and be continuing: (i) receipt by the Company of any request for additional information from the Commission or any other federal or state governmental authority during the period of effectiveness of the Registration Statement, the response to which would require any post-effective amendments or supplements to the Registration Statement or the Prospectus; (ii) the issuance by the Commission or any other federal or state governmental authority of any stop order suspending the effectiveness of the Registration Statement or the initiation of any proceedings for that purpose; (iii) receipt by the Company of any notification with respect to the suspension of the qualification or exemption from qualification of any of the Placement Shares for sale in any jurisdiction or the initiation or threatening of any proceeding for such purpose; or (iv) the occurrence of any event that makes any material statement made in the Registration Statement or the Prospectus or any material Incorporated Document untrue in any material respect or that requires the making of any changes in the Registration Statement, the Prospectus or Incorporated Documents so that, in the case of the Registration Statement, it will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein not misleading and, in the case of the Prospectus, so that it will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">23</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Misstatement or Material Omission</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Agent shall not have advised the Company that the Registration Statement or Prospectus, or any amendment or supplement thereto, contains an untrue statement of fact that in the Agent&#x2019;s opinion is material, or omits to state a fact that in the Agent&#x2019;s opinion is material and is required to be stated therein or is necessary to make the statements therein not misleading.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Material Changes</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Except as contemplated in the Prospectus, or disclosed in the Company&#x2019;s reports filed with the Commission, there shall not have been any material adverse change, on a consolidated basis, in the authorized capital stock of the Company or any Material Adverse Effect or any development that could reasonably be expected to result in a Material Adverse Effect, or any downgrading in or withdrawal of the rating assigned to any of the Company&#x2019;s securities (other than asset backed securities), if any, by any rating organization or a public announcement by any rating organization that it has under surveillance or review its rating of any of the Company&#x2019;s securities (other than asset backed securities), if any, the effect of which, in the judgment of the Agent (without relieving the Company of any obligation or liability it may otherwise have), is so material as to make it impracticable or inadvisable to proceed with the offering of the Placement Shares on the terms and in the manner contemplated in the Prospectus.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(f)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company Counsel Legal Opinions</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Agent shall have received the opinions and negative assurance letters, as applicable, of Company Counsel and Intellectual Property Counsel required to be delivered pursuant to Section 7(n) and Section 7(o), as applicable, on or before the date on which such delivery of such opinions and negative assurance letters are required pursuant to Section 7(n) and Section 7(o), as applicable.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(g)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Agent&#x2019;s Counsel Legal Opinion</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Agent shall have received from Paul Hastings LLP, counsel for the Agent, such opinion or opinions, on or before the date on which the delivery of the Company Counsel legal opinion is required pursuant to Section 7(n), with respect to such matters as the Agent may reasonably require, and the Company shall have furnished to such counsel such documents as they may request to enable them to pass upon such matters.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(h)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Comfort Letter</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Agent shall have received the Comfort Letter required to be delivered pursuant to Section 7(p) on or before the date on which such delivery of such Comfort Letter is required pursuant to Section 7(p).</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Representation Certificate</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Agent shall have received the certificate required to be delivered pursuant to Section 7(m) on or before the date on which delivery of such certificate is required pursuant to Section 7(m).</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(j)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Secretary&#x2019;s Certificate</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. On or prior to the First Placement Notice Date, the Agent shall have received a certificate, signed on behalf of the Company by the Secretary of the Company and attested to by an executive officer of the Company, dated as of such date and in form and substance satisfactory to the Agent and its counsel, certifying as to (i) the amended and restated certificate of incorporation of the Company, (ii) the amended and restated bylaws of the Company, (iii) the resolutions of the board of directors of the Company or duly authorized committee thereof authorizing the execution, delivery and performance of this Agreement and the issuance and sale of the Placement Shares and (iv) the incumbency of the officers of the Company duly authorized to execute this Agreement and the other documents contemplated by this Agreement (including each of the officers set forth on </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 2</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">).</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(k)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Suspension</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Common Stock shall be duly listed, and admitted and authorized for trading, subject to official notice of issuance, on Nasdaq. Trading in the Common Stock shall not have been suspended on, and the Common Stock shall not have been delisted from, Nasdaq.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(l)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other Materials</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  On each date on which the Company is required to deliver a certificate pursuant to Section 7(m), the Company shall have furnished to the Agent such appropriate further information, opinions, certificates, letters and other documents as the Agent may have reasonably requested.  All such information, opinions, certificates, letters and other documents shall have been in compliance with the provisions hereof.  The Company shall have furnished the Agent with conformed copies of such opinions, certificates, letters and other documents as the Agent may have reasonably requested.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">24</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(m)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities Act Filings Made</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  All filings with the Commission required by Rule 424(b) or Rule 433 under the Securities Act to have been filed prior to the issuance of any Placement Notice hereunder shall have been made within the applicable time period prescribed for such filing by Rule 424(b) (without reliance on Rule 424(b)(8) of the Securities Act) or Rule 433, as applicable.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(n)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Approval for Listing</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Either (i) the Placement Shares shall have been approved for listing on Nasdaq, subject only to notice of issuance, or (ii) the Company shall have filed an application for listing of the Placement Shares on Nasdaq at, or prior to, the First Placement Notice Date and Nasdaq shall have reviewed such application and not provided any objections thereto.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(o)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FINRA</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  FINRA shall have raised no objection to the terms of the offering contemplated hereby and the amount of compensation allowable or payable to the Agent as described in the Prospectus.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(p)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Termination Event</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  There shall not have occurred any event that would permit the Agent to terminate this Agreement pursuant to Section 11(a).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indemnification and Contribution</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company Indemnification</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Company agrees to indemnify and hold harmless the Agent, its affiliates and their respective partners, members, directors, officers, employees and agents, and each person, if any, who (i) controls the Agent within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act or (ii) is controlled by or is under common control with the Agent, in each case from and against any and all losses, claims, liabilities, expenses and damages (including any and all investigative, legal and other expenses reasonably incurred in connection with, and any and all amounts paid in settlement (in accordance with this Section 9), any action, suit, investigation or proceeding between any of the indemnified parties and any indemnifying parties or between any indemnified party and any third party (including any governmental or self-regulatory authority, or otherwise, or any claim asserted or threatened), as and when incurred, to which the Agent, or any such other person may become subject under the Securities Act, the Exchange Act or other federal or state statutory law or regulation, at common law or otherwise, insofar as such losses, claims, liabilities, expenses or damages arise out of or are based, directly or indirectly, on (x) any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement or the Prospectus (or any amendment or supplement to the Registration Statement or the Prospectus) or in any free writing prospectus or in any application or other document executed by or on behalf of the Company or based on written information furnished by or on behalf of the Company filed in any jurisdiction in order to qualify the Common Stock under the securities laws thereof or filed with the Commission, (y) the omission or alleged omission to state in any such document a material fact required to be stated therein or necessary to make the statements therein (solely with respect to the Prospectus, in light of the circumstances under which they were made) not misleading or (z) any breach by any of the indemnifying parties of any of their respective representations, warranties or agreements contained in this Agreement; </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">however</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that this indemnity agreement shall not apply to the extent that such loss, claim, liability, expense or damage arises from the sale of the Placement Shares pursuant to this Agreement and is caused, directly or indirectly, by an untrue statement or omission, or alleged untrue statement or omission, made in reliance upon and in conformity with the Agent&#x2019;s Information.  This indemnity agreement will be in addition to any liability that the Company might otherwise have.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Agent Indemnification</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Agent agrees to indemnify and hold harmless the Company and its directors and each officer of the Company who signed the Registration Statement, and each person, if any, who (i) controls the Company within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act or (ii) is controlled by or is under common control with the Company against any and all loss, liability, claim, damage and expense described in the indemnity contained in Section 9(a), as incurred, but only with respect to untrue statements or omissions, or alleged untrue statements or omissions, made in the Registration Statement (or any amendments thereto) or the Prospectus (or any amendment or supplement thereto) in reliance upon and in conformity with the Agent&#x2019;s Information.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">25</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Procedure</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Any party that proposes to assert the right to be indemnified under this Section 9 will, promptly after receipt of notice of commencement of any action against such party in respect of which a claim is to be made against an indemnifying party or parties under this Section 9, notify each such indemnifying party of the commencement of such action, enclosing a copy of all papers served, but the omission so to notify such indemnifying party will not relieve the indemnifying party from (i) any liability that it might have to any indemnified party otherwise than under this Section 9 and (ii) any liability that it may have to any indemnified party under the foregoing provision of this Section 9 unless, and only to the extent that, such omission results in the forfeiture of substantive rights or defenses by the indemnifying party.  If any such action is brought against any indemnified party and it notifies the indemnifying party of its commencement, the indemnifying party will be entitled to participate in and, to the extent that it elects by delivering written notice to the indemnified party promptly after receiving notice of the commencement of the action from the indemnified party, jointly with any other indemnifying party similarly notified, to assume the defense of the action, with counsel reasonably satisfactory to the indemnified party, and after notice from the indemnifying party to the indemnified party of its election to assume the defense, the indemnifying party will not be liable to the indemnified party for any other legal expenses except as provided below and except for the reasonable documented costs of investigation subsequently incurred by the indemnified party in connection with the defense.  The indemnified party will have the right to employ its own counsel in any such action, but the fees, expenses and other charges of such counsel will be at the expense of such indemnified party unless (1) the employment of counsel by the indemnified party has been authorized in writing by the indemnifying party, (2) the indemnified party has reasonably concluded (based on advice of counsel) that there may be legal defenses available to it or other indemnified parties that are different from or in addition to those available to the indemnifying party, (3) a conflict or potential conflict exists (based on advice of counsel to the indemnified party) between the indemnified party and the indemnifying party (in which case the indemnifying party will not have the right to direct the defense of such action on behalf of the indemnified party) or (4) the indemnifying party has not in fact employed counsel reasonably satisfactory to the indemnified party to assume the defense of such action within a reasonable time after receiving notice of the commencement of the action, in each of which cases the reasonable fees, disbursements and other charges of counsel will be at the expense of the indemnifying party or parties.  It is understood that the indemnifying party or parties shall not, in connection with any proceeding or related proceedings in the same jurisdiction, be liable for the reasonable fees, disbursements and other charges of more than one separate firm (plus local counsel) admitted to practice in such jurisdiction at any one time for all such indemnified party or parties.  All such fees, disbursements and other charges will be reimbursed by the indemnifying party promptly after the indemnifying party receives a written invoice relating to such fees, disbursements and other charges in reasonable detail. An indemnifying party will not, in any event, be liable for any settlement of any action or claim effected without its written consent.  No indemnifying party shall, without the prior written consent of each indemnified party, settle or compromise or consent to the entry of any judgment in any pending or threatened claim, action or proceeding relating to the matters contemplated by this Section 9 (whether or not any indemnified party is a party thereto), unless such settlement, compromise or consent (1) includes an unconditional release of each indemnified party, in form and substance reasonably satisfactory to such indemnified party, from all liability arising out of such claim, action or proceeding and (2) does not include a statement as to or an admission of fault, culpability or a failure to act by or on behalf of any indemnified party.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Settlement Without Consent if Failure to Reimburse</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> If an indemnified party shall have requested an indemnifying party to reimburse the indemnified party for reasonable fees and expenses of counsel for which it is entitled to be reimbursed under this Section 9, such indemnifying party agrees that it shall be liable for any settlement of the nature contemplated by Section 9(a) effected without its written consent if (i) such settlement is entered into more than 45 days after receipt by such indemnifying party of the aforesaid request, (ii) such indemnifying party shall have received notice of the terms of such settlement at least 30 days prior to such settlement being entered into and (iii) such indemnifying party shall not have reimbursed such indemnified party in accordance with such request prior to the date of such settlement.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">26</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Contribution</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  In order to provide for just and equitable contribution in circumstances in which the indemnification provided for in the foregoing paragraphs of this Section 9 is applicable in accordance with its terms but for any reason is held to be unavailable or insufficient from the Company or the Agent, the Company and the Agent will contribute to the total losses, claims, liabilities, expenses and damages (including any documented investigative, legal and other expenses reasonably incurred in connection with, and any amount paid in settlement of, any action, suit, investigation or proceeding or any claim asserted, but after deducting any contribution received by the Company from persons other than the Agent, such as persons who control the Company within the meaning of the Securities Act, officers of the Company who signed the Registration Statement and directors of the Company, who also may be liable for contribution) to which the Company and the Agent may be subject in such proportion as shall be appropriate to reflect the relative benefits received by the Company on the one hand and the Agent on the other hand. The relative benefits received by the Company on the one hand and the Agent on the other hand shall be deemed to be in the same proportion as the total Net Proceeds from the sale of the Placement Shares (before deducting expenses) received by the Company bear to the total compensation received by the Agent from the sale of Placement Shares on behalf of the Company.  If, but only if, the allocation provided by the foregoing sentence is not permitted by applicable law, the allocation of contribution shall be made in such proportion as is appropriate to reflect not only the relative benefits referred to in the foregoing sentence but also the relative fault of the Company, on the one hand, and the Agent, on the other hand, with respect to the statements or omission that resulted in such loss, claim, liability, expense or damage, or action, suit, investigation or proceeding in respect thereof, as well as any other relevant equitable considerations with respect to such offering. Such relative fault shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or omission or alleged omission to state a material fact relates to information supplied by the Company or the Agent, the intent of the parties and their relative knowledge, access to information and opportunity to correct or prevent such statement or omission.  The Company and the Agent agree that it would not be just and equitable if contributions pursuant to this Section 9(e) were to be determined by</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> pro rata</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> allocation or by any other method of allocation that does not take into account the equitable considerations referred to herein. The amount paid or payable by an indemnified party as a result of the loss, claim, liability, expense or damage, or action, suit, investigation or proceeding in respect thereof, referred to above in this Section 9(e) shall be deemed to include, for the purpose of this Section 9(e), any legal or other expenses reasonably incurred by such indemnified party in connection with investigating or defending any such action, suit, investigation, proceeding or claim to the extent consistent with this Section 9.  Notwithstanding the foregoing provisions of this Section 9(e), the Agent shall not be required to contribute any amount in excess of the commissions received by it under this Agreement and no person found guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) will be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. For purposes of this Section 9(e), any person who controls a party to this Agreement within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act, any affiliates of the Agent, any partners, members, directors, officers, employees and agents of the Agent and each person that is controlled by or under common control with the Agent will have the same rights to contribution as that party, and each officer of the Company who signed the Registration Statement will have the same rights to contribution as the Company, subject in each case to the provisions hereof.  Any party entitled to contribution, promptly after receipt of notice of commencement of any action against such party in respect of which a claim for contribution may be made under this Section 9(e), will notify any such party or parties from whom contribution may be sought, but the omission to so notify will not relieve that party or parties from whom contribution may be sought from any other obligation it or they may have under this Section 9(e) except to the extent that the failure to so notify such other party materially prejudiced the substantive rights or defenses of the party from whom contribution is sought.  Except for a settlement entered into pursuant to the last sentence of Section 9(c) hereof or pursuant to Section 9(d) hereof, no party will be liable for contribution with respect to any action or claim settled without its written consent if such consent is required pursuant to Section 9(c) hereof.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Representations and Agreements to Survive Delivery</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The indemnity and contribution agreements contained in Section 9 of this Agreement and all representations and warranties of the Company herein or in certificates delivered pursuant hereto shall survive, as of their respective dates, regardless of (i) any investigation made by or on behalf of the Agent, any controlling persons, or the Company (or any of their respective officers, directors, employees or controlling persons), (ii) delivery and acceptance of the Placement Shares and payment therefor or (iii) any termination of this Agreement.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">27</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Termination</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	The Agent shall have the right, by giving notice as hereinafter specified, at any time to terminate this Agreement if (i) any Material Adverse Effect, or any development that could reasonably be expected to result in a Material Adverse Effect, has occurred that, in the judgment of the Agent, may materially impair the ability of the Agent to sell the Placement Shares hereunder, (ii) the Company shall have failed, refused or been unable to perform any agreement on its part to be performed hereunder; </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">however</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, in the case of any failure of the Company to deliver (or cause another person to deliver) any certification, opinion or letter required under Section 7(m), Section 7(n), Section 7(o) or Section 7(p), the Agent&#x2019;s right to terminate shall not arise unless such failure to deliver (or cause to be delivered) continues for more than 30 calendar days from the date such delivery was required, (iii) any other condition of the Agent&#x2019;s obligations hereunder is not fulfilled, (iv) any suspension or limitation of trading in the Placement Shares or in securities generally on Nasdaq shall have occurred, (v) a general banking moratorium shall have been declared by any of United States federal or New York authorities, or (vi) there shall have occurred any outbreak or escalation of national or international hostilities or any crisis or calamity, or any change in the United States or international financial markets, or any substantial change or development involving a prospective substantial change in United States or international political, financial or economic conditions that, in the judgment of the Agent, may materially impair the ability of the Agent to sell the Placement Shares hereunder or to enforce contracts for the sale of securities.  Any such termination shall be without liability of any party to any other party except that the provisions of Section 7(g), Section 9, Section 10, Section 16 and Section 17 hereof shall remain in full force and effect notwithstanding such termination. If the Agent elects to terminate this Agreement as provided in this Section 11(a), the Agent shall provide the required notice as specified in Section 12.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	The Company shall have the right, by giving 10 days&#x2019; prior notice as hereinafter specified, to terminate this Agreement in its sole discretion at any time after the date of this Agreement.  Any such termination shall be without liability of any party to any other party except that the provisions of Section 7(g), Section 9, Section 10, Section 11(f), Section 16 and Section 17 hereof shall remain in full force and effect notwithstanding such termination.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	The Agent shall have the right, by giving 10 days&#x2019; prior notice as hereinafter specified, to terminate this Agreement in its sole discretion at any time after the date of this Agreement.  Any such termination shall be without liability of any party to any other party except that the provisions of Section 7(g), Section 9, Section 10, Section 11(f), Section 16 and Section 17 hereof shall remain in full force and effect notwithstanding such termination.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	Unless earlier terminated pursuant to this Section 11, this Agreement shall automatically terminate upon the issuance and sale of all of the Placement Shares through the Agent on the terms and subject to the conditions set forth herein; </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that the provisions of Section 7(g), Section 9, Section 10, Section 11(f), Section 16 and Section 17 hereof shall remain in full force and effect notwithstanding such termination.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e)	This Agreement shall remain in full force and effect unless terminated pursuant to Sections 11(a), (b), (c), or (d) above or otherwise by mutual agreement of the parties; </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">however</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that any such termination by mutual agreement shall in all cases be deemed to provide that Section 7(g), Section 9, Section 10, Section 11(f), Section 16 and Section 17 shall remain in full force and effect.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(f)	Any termination of this Agreement shall be effective on the date specified in such notice of termination; </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided, however</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that such termination shall not be effective until the close of business on the date of receipt of such notice by the Agent or the Company, as the case may be. If such termination shall occur prior to the Settlement Date for any sale of Placement Shares, such Placement Shares shall settle in accordance with the provisions of this Agreement. Upon termination of this Agreement, the Company shall not be required to pay to the Agent any discount or commission with respect to any Placement Shares not otherwise sold by the Agent under this Agreement; </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">however</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that the Company shall remain obligated to reimburse the Agent&#x2019;s expenses pursuant to Section 7(g).</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notices</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  All notices or other communications required or permitted to be given by any party to any other party pursuant to the terms of this Agreement shall be in writing, unless otherwise specified in this Agreement, and if sent to the Agent, shall be delivered to:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:5.867%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Leerink Partners LLC</font></p>
  <p style="margin-left:5.867%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1301 Avenue of the Americas, 5</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Floor</font></p>
  <p style="margin-left:5.867%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">New York, New York 10019</font></p>
  <p style="margin-left:5.867%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Attention: Peter M. Fry</font></p>
  <p style="margin-left:5.84%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">E-mail: peter.fry@leerink.com</font></p>
  <p style="margin-left:5.84%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">with a copy (which shall not constitute notice) to:</font></p>
  <p style="margin-left:5.84%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:5.84%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Leerink Partners LLC</font></p>
  <p style="margin-left:5.84%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1301 Avenue of the Americas, 5</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Floor</font></p>
  <p style="margin-left:5.84%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">New York, New York 10019</font></p>
  <p style="margin-left:5.84%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Attention: Stuart R. Nayman, Esq.</font></p>
  <p style="margin-left:5.84%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">E-mail: stuart.nayman@leerink.com</font></p>
  <p style="margin-left:5.84%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">with copies (which shall not constitute notice) to:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:5.84%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Paul Hastings LLP</font></p>
  <p style="margin-left:5.84%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Attention: William A. Magioncalda</font></p>
  <p style="margin-left:5.84%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">E-mail: willmagioncalda@paulhastings.com</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and if to the Company, shall be delivered to:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:5.84%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lexeo Therapeutics, Inc.</font></p>
  <p style="margin-left:5.84%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Attention: R. Nolan Townsend</font></p>
  <p style="margin-left:5.84%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">E-mail: rntownsend@lexeotx.com</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">with copies (which shall not constitute notice) to:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:5.84%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Wilson Sonsini Goodrich &amp; Rosati, P.C.</font></p>
  <p style="margin-left:5.84%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Attention: Megan Baier</font></p>
  <p style="margin-left:5.84%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">E-mail: mbaier@wsgr.com</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each party to this Agreement may change such address for notices by sending to the parties to this Agreement written notice of a new address for such purpose.  Each such notice or other communication shall be deemed given (i) when delivered personally on or before 4:30 P.M., New York City time, on a Business Day, or, if such day is not a Business Day, on the next succeeding Business Day, (ii) by Electronic Notice as set forth in the next paragraph, (iii) on the next Business Day after timely delivery to a nationally-recognized overnight courier or (iv) on the Business Day actually received if deposited in the U.S. mail (certified or registered mail, return receipt requested, postage prepaid). For purposes of this Agreement, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Business Day</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall mean any day on which the Nasdaq and commercial banks in the City of New York are open for business.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An electronic communication (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Electronic Notice</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) shall be deemed written notice for purposes of this Section 12 if sent to the electronic mail address specified by the receiving party in Section 12. Electronic Notice shall be deemed received at the time the party sending Electronic Notice receives actual acknowledgment of receipt from the person whom the notice is sent, other than via auto-reply.  Any party receiving Electronic Notice may request and shall be entitled to receive the notice on paper, in a nonelectronic form (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nonelectronic Notice</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), which shall be sent to the requesting party within 10 days of receipt of the written request for Nonelectronic Notice.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">29</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Successors and Assigns</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  This Agreement shall inure to the benefit of and be binding upon the Company and the Agent and their respective successors and the affiliates, controlling persons, officers, directors and other persons referred to in Section 9 hereof. References to any of the parties contained in this Agreement shall be deemed to include the successors and permitted assigns of each such party. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto, the persons referred to in the preceding sentence and their respective successors and permitted assigns any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement.  Neither party may assign its rights or obligations under this Agreement without the prior written consent of the other party; </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided, however</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that the Agent may assign its rights and obligations hereunder to an affiliate of the Agent without obtaining the Company&#x2019;s consent, so long as such affiliate is a registered broker-dealer.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adjustments for Share Splits</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The parties acknowledge and agree that all share-related numbers contained in this Agreement shall be adjusted to take into account any share split, share dividend or similar event effected with respect to the Common Stock.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Entire Agreement; Amendment; Severability; Waiver</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  This Agreement (including all schedules (as amended pursuant to this Agreement) and exhibits attached hereto and Placement Notices issued pursuant hereto) constitutes the entire agreement and supersedes all other prior and contemporaneous agreements and undertakings, both written and oral, among the parties hereto with regard to the subject matter hereof.  Neither this Agreement nor any term hereof may be amended except pursuant to a written instrument executed by the Company and the Agent; </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">however</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 2</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of this Agreement may be amended by either party from time to time by sending a notice containing a revised </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 2</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to the other party in the manner provided in Section 12 and, upon such amendment, all references herein to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 2</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shall automatically be deemed to refer to such amended </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 2</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  In the event that any one or more of the provisions contained herein, or the application thereof in any circumstance, is held invalid, illegal or unenforceable as written by a court of competent jurisdiction, then such provision shall be given full force and effect to the fullest possible extent that it is valid, legal and enforceable, and the remainder of the terms and provisions herein shall be construed as if such invalid, illegal or unenforceable term or provision was not contained herein, but only to the extent that giving effect to such provision and the remainder of the terms and provisions hereof shall be in accordance with the intent of the parties as reflected in this Agreement.  No implied waiver by a party shall arise in the absence of a waiver in writing signed by such party.  No failure or delay in exercising any right, power, or privilege hereunder shall operate as a waiver thereof, nor shall any single or partial exercise thereof preclude any other or further exercise thereof or the exercise of any right, power, or privilege hereunder.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">GOVERNING LAW AND TIME; WAIVER OF JURY TRIAL</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK WITHOUT REGARD TO THE PRINCIPLES OF CONFLICTS OF LAWS. SPECIFIED TIMES OF DAY REFER TO NEW YORK CITY TIME. EACH PARTY HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">17.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consent to Jurisdiction</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, Borough of Manhattan,</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">for the adjudication of any dispute hereunder or in connection with any of the transactions contemplated hereby, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is brought in an inconvenient forum, or that the venue of such suit, action or proceeding is improper.  Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy (certified or registered mail, return receipt requested) to such party at the address in effect for notices under Section 12 of this Agreement and agrees that such service shall constitute good and sufficient notice of process and notice thereof.  Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">30</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Construction</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	The section and exhibit headings herein are for convenience only and shall not affect the construction hereof.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	Words defined in the singular shall have a comparable meaning when used in the plural, and vice versa.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	The words &#x201c;hereof,&#x201d; &#x201c;hereto,&#x201d; &#x201c;herein&#x201d; and &#x201c;hereunder&#x201d; and words of similar import, when used in this Agreement, shall refer to this Agreement as a whole and not to any particular provision of this Agreement.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	Wherever the word &#x201c;include,&#x201d; &#x201c;includes&#x201d; or &#x201c;including&#x201d; is used in this Agreement, it shall be deemed to be followed by the words &#x201c;without limitation.&#x201d;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e)	References herein to any gender shall include each other gender.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(f)	References herein to any law, statute, ordinance, code, regulation, rule or other requirement of any governmental authority shall be deemed to refer to such law, statute, ordinance, code, regulation, rule or other requirement of any governmental authority as amended, reenacted, supplemented or superseded in whole or in part and in effect from time to time and also to all rules and regulations promulgated thereunder.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">19.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Permitted Free Writing Prospectuses</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Each of the Company and the Agent represents, warrants and agrees that, unless it obtains the prior written consent of the other party, which consent shall not be unreasonably withheld, conditioned or delayed, it has not made and will not make any offer relating to the Placement Shares that would constitute an issuer free writing prospectus, or that would otherwise constitute a free writing prospectus (as defined in Rule 405), required to be filed with the Commission.  Any such free writing prospectus consented to by the Agent or by the Company, as the case may be, is hereinafter referred to as a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Permitted Free Writing Prospectus</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.&#x201d;  The Company represents and warrants that it has treated and agrees that it will treat each Permitted Free Writing Prospectus as an issuer free writing prospectus, and that it has complied and will comply with the requirements of Rule 433 applicable to any Permitted Free Writing Prospectus, including timely filing with the Commission where required, legending and record keeping.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">20.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Absence of Fiduciary Relationship</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Company acknowledges and agrees that:</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	the Agent has been retained to act as sales agent in connection with the sale of the Placement Shares, the Agent has acted at arms&#x2019; length and no fiduciary or advisory relationship between the Company or any of its respective affiliates, stockholders (or other equity holders), creditors or employees or any other party, on the one hand, and the Agent, on the other hand, has been or will be created in respect of any of the transactions contemplated by this Agreement, irrespective of whether the Agent has advised or is advising the Company on other matters and the Agent has no duties or obligations to the Company with respect to the transactions contemplated by this Agreement except the obligations expressly set forth herein;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	the Company is capable of evaluating, and understanding and understands and accepts, the terms, risks and conditions of the transactions contemplated by this Agreement;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	neither the Agent nor its affiliates have provided any legal, accounting, regulatory or tax advice with respect to the transactions contemplated by this Agreement and it has consulted its own legal, accounting, regulatory and tax advisors to the extent it has deemed appropriate;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	the Company has been advised and is aware that the Agent and its affiliates are engaged in a broad range of transactions which may involve interests that differ from those of the Company and that the Agent and its affiliates have no obligation to disclose such interests and transactions to the Company by virtue of any fiduciary, advisory or agency relationship or otherwise; and</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">31</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e)	the Company waives, to the fullest extent permitted by law, any claims it may have against the Agent or its affiliates for breach of fiduciary duty or alleged breach of fiduciary duty in connection with the transactions contemplated by this Agreement and agrees that the Agent and its affiliates shall have no liability (whether direct or indirect) to the Company in respect of such a fiduciary claim or to any person asserting a fiduciary duty claim on behalf of or in right of the Company, including stockholders (or other equity holders), creditors or employees of the Company.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">21.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recognition of the U.S. Special Resolution Regimes</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  In the event that the Agent is a Covered Entity and becomes subject to a proceeding under a U.S. Special Resolution Regime, the transfer from the Agent of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution Regime if this Agreement, and any such interest and obligation, were governed by the laws of the United States or a state of the United States.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the event that the Agent is a Covered Entity and the Agent or a BHC Act Affiliate of the Agent becomes subject to a proceeding under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against the Agent are permitted to be exercised to no greater extent than such Default Rights could be exercised under the U.S. Special Resolution Regime if this Agreement were governed by the laws of the United States or a state of the United States.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For purposes of this Agreement, (A) &#x201c;BHC Act Affiliate&#x201d; has the meaning assigned to the term &#x201c;affiliate&#x201d; in, and shall be interpreted in accordance with, 12 U.S.C. &#167; 1841(k); (B) &#x201c;Covered Entity&#x201d; means any of the following: (i) a &#x201c;covered entity&#x201d; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 252.82(b); (ii) a &#x201c;covered bank&#x201d; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 47.3(b); or (iii) a &#x201c;covered FSI&#x201d; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 382.2(b); (C) &#x201c;Default Right&#x201d; has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. &#167;&#167; 252.81, 47.2 or 382.1, as applicable; and (D) &#x201c;U.S. Special Resolution Regime&#x201d; means each of (i) the Federal Deposit Insurance Act and the regulations promulgated thereunder and (ii) Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">22.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Counterparts</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Delivery of an executed Agreement by one party to the other may be made by facsimile or electronic transmission. Counterparts may be delivered via facsimile, electronic mail (including any electronic signature covered by the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act, the Electronic Signatures and Records Act or other applicable law, e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">23.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Use of Information</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.	The Agent may not provide any information gained in connection with this Agreement and the transactions contemplated by this Agreement, including due diligence, to any third party other than its legal counsel advising it on this Agreement and the transactions contemplated by this Agreement unless expressly approved by the Company in writing.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">24.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Agent&#x2019;s Information</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. As used in this Agreement, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Agent&#x2019;s Information</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means solely the following information in the Registration Statement and the Prospectus: the last sentence of the eighth paragraph under the heading &#x201c;Plan of Distribution&#x201d; in the Prospectus Supplement.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All references in this Agreement to the Registration Statement, the Prospectus or any amendment or supplement to any of the foregoing shall be deemed to include the copy filed with the Commission pursuant to EDGAR.  All references in this Agreement to financial statements and schedules and other information that is &#x201c;contained,&#x201d; &#x201c;included&#x201d; or &#x201c;stated&#x201d; in the Registration Statement or the Prospectus (and all other references of like import) shall be deemed to mean and include all such financial statements and schedules and other information that is incorporated by reference in the Registration Statement or the Prospectus, as the case may be.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All references in this Agreement to &#x201c;supplements&#x201d; to the Prospectus shall include any supplements, &#x201c;wrappers&#x201d; or similar materials prepared in connection with any offering, sale or private placement of any Placement Shares by the Agent outside of the United States.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[Remainder of Page Intentionally Blank]</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">32</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the foregoing correctly sets forth the understanding between the Company and the Agent, please so indicate in the space provided below for that purpose, whereupon this letter shall constitute a binding agreement between the Company and the Agent.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:37.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:10.811%;box-sizing:content-box;"></td>
    <td style="width:18.919%;box-sizing:content-box;"></td>
    <td style="width:70.27%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Very truly yours,</font></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">LEXEO THERAPEUTICS, INC.</font></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ R. Nolan Townsend</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Name:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">R. Nolan Townsend</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Title:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Executive Officer</font></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">ACCEPTED as of the date</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">first-above written:</font></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">LEERINK PARTNERS LLC</font></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Peter Fry</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Name:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Peter Fry</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Title:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Head of Alternative Equities</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">33</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SCHEDULE 1</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FORM OF PLACEMENT NOTICE</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From:	[			]</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">		[TITLE]</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">		Lexeo Therapeutics, Inc.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cc:		[			]</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To:		Leerink Partners LLC</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subject:	Leerink Partners &#x2014;At the Market Offering&#x2014;Placement Notice</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ladies and Gentlemen:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the terms and subject to the conditions contained in the Sales Agreement, dated March 24, 2025 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), by and between Lexeo Therapeutics, Inc., a Delaware corporation (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), and Leerink Partners LLC (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Leerink Partners</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), I hereby request on behalf of the Company that Leerink Partners sell up to [  ] shares of common stock, $0.0001 par value per share, of the Company (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Shares</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), at a minimum market price of $      per share[; </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that no more than [  ] Shares shall be sold in any one Trading Day (as such term is defined in Section 3 of the Agreement)].  Sales should begin [on the date of this Placement Notice] and end on [DATE] [until all Shares that are the subject of this Placement Notice are sold].</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">34</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SCHEDULE 2</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">R. Nolan Townsend</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Kyle Rasbach</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Jenny R. Robertson</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Leerink Partners</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Anurag Jindal</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[   ]</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">35</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SCHEDULE 3</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compensation</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company shall pay Leerink Partners compensation in cash equal to 3.0% of the gross proceeds from the sales of Placement Shares pursuant to the terms of the Sales Agreement of which this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 3</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> forms a part.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">36</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 7(m)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">OFFICERS&#x2019; CERTIFICATE</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each of R. Nolan Townsend, the duly qualified and elected Chief Executive Officer of Lexeo Therapeutics, Inc., a Delaware corporation (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), and Kyle Rasbach, the duly qualified and elected Chief Financial Officer of the Company, does hereby certify in his respective capacity and on behalf of the Company, pursuant to Section 7(m) of the Sales Agreement, dated March 24, 2025 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sales Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), by and between the Company and Leerink Partners LLC, that, after due inquiry, to the best of the knowledge of the undersigned:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i)	The representations and warranties of the Company in Section 6 of the Sales Agreement (A) to the extent such representations and warranties are subject to qualifications and exceptions contained therein relating to materiality or Material Adverse Effect, are true and correct on and as of the date hereof with the same force and effect as if expressly made on and as of the date hereof, and (B) to the extent such representations and warranties are not subject to any qualifications or exceptions relating to materiality or Material Adverse Effect, are true and correct in all material respects as of the date hereof as if made on and as of the date hereof with the same force and effect as if expressly made on and as of the date hereof.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii)	The Company has complied with all agreements and satisfied all conditions on its part to be performed or satisfied pursuant to the Sales Agreement at or prior to the date hereof.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iii)	As of the date hereof, (A) the Registration Statement complies in all material respects with the requirements of the Securities Act and does not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein not misleading, (B) the Prospectus complies in all material respects with the requirements of the Securities Act does not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading and (C) no event has occurred as a result of which it is necessary to amend or supplement the Registration Statement or the Prospectus in order to make the statements therein not untrue or misleading or for clauses (A) and (B) above, to be true and correct.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iv)	There has been no material adverse change, or any development that could reasonably be expected to result in a material adverse change, in the condition (financial or otherwise), earnings, results of operations, business, property, operations, assets, liabilities or prospects of the Company, whether or not arising from transactions in the ordinary course of business, since the date as of which information is given in the Prospectus, as amended or supplemented to the date hereof.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(v)	The Company does not possess any material non-public information.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(vi)	The maximum amount of Placement Shares that may be sold pursuant to the Sales Agreement has been duly authorized by the Company&#x2019;s board of directors or a duly authorized committee thereof pursuant to a resolution or unanimous written consent in accordance with the Company&#x2019;s amended and restated articles of incorporation, amended and restated bylaws and applicable law.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Sales Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each of Wilson Sonsini Goodrich &amp; Rosati, P.C. and Paul Hasting LLP are entitled to rely on this certificate in connection with the respective opinions such firms are rendering pursuant to the Sales Agreement.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IN WITNESS WHEREOF, each of the undersigned, in such individual&#x2019;s respective capacity as Chief Executive Officer or Chief Financial Officer of the Company, has executed this Officers&#x2019; Certificate on behalf of the Company.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">37</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:37.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:10.811%;box-sizing:content-box;"></td>
    <td style="width:18.919%;box-sizing:content-box;"></td>
    <td style="width:70.27%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Name:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">R. Nolan Townsend</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Title:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Executive Officer</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Name:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Kyle Rasbach</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Title:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Financial Officer</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Company Signature Page to Officers&#x2019; Certificate</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">]</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">38</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-19.1
<SEQUENCE>10
<FILENAME>lxeo-ex19_1.htm
<DESCRIPTION>EX-19.1
<TEXT>
<html>
 <head>
  <title>EX-19.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="z-index:-3;min-height:0.94in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:3.95pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.167%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 19.1</font></p>
  <p style="font-size:10pt;margin-top:3.95pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.167%;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:3.95pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.167%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LEXEO THERAPEUTICS, INC.</font></p>
  <p style="margin-left:0.013%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.167%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INSIDER TRADING AND WINDOW PERIOD POLICY</font></p>
  <p style="font-size:10pt;margin-top:9.65pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:3.55pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:0.935%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:6.729924796850553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">I.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Introduction</font></div></div>
  <p style="font-size:10pt;margin-top:1.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:6.805%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.111%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This policy determines acceptable transactions in the securities of Lexeo Therapeutics, Inc. (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) by our employees, directors and consultants. During the course of your employment, directorship or consultancy with the Company, you may receive important information that is not yet publicly available about the Company or about other publicly-traded companies with which the Company has business dealings (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">inside information</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). Because of your access to this inside information, you may be in a position to profit financially by buying or selling, or in some other way dealing, in the Company&#x2019;s stock, or stock of another publicly-traded company, or to disclose such information to a third party who does so profit (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">tippee</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).</font></p>
  <div class="item-list-element-wrapper" style="margin-left:0.935%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:6.729924796850553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">II.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Insider Trading Policy</font></div></div>
  <p style="font-size:10pt;margin-top:1.1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:0.935%;text-indent:6.803%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.4788270327562714%;">A.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities Transactions. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Use of inside information by someone for personal gain, or to pass on, or &#x201c;tip,&#x201d; the inside information to someone who uses it for personal gain, is illegal, regardless of the quantity of shares, and is therefore prohibited. You can be held liable both for your own transactions and for transactions effected by a tippee, or even a tippee of a tippee. Furthermore, it is important that the appearance of insider trading in securities be avoided. The only exception is that transactions directly with the Company, </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">e.g., </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">option exercises for cash or purchases under the Company&#x2019;s employee stock purchase plan, are permitted. However, the subsequent sale (including the sale of shares in a cashless exercise program) or other disposition of such stock </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">is </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">fully subject to these restrictions.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:0.935%;text-indent:6.803%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.4788270327562714%;">B.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Inside Information. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a practical matter, it is sometimes difficult to determine whether you possess inside information. The key to determining whether nonpublic information you possess about a public company is inside information is whether dissemination of the information would likely affect the market price of the company&#x2019;s stock or would likely be considered important, or &#x201c;material,&#x201d; by investors who are considering trading in that company&#x2019;s stock. Certainly, if the information makes </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">you </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">want to trade, it would probably have the same effect on others. Remember, both positive and negative information can be material. If you possess inside information, you may not trade in a company&#x2019;s stock, advise anyone else to do so or communicate the information to anyone else until you know that the information has been publicly disseminated. This means that in some circumstances, you may have to forego a proposed transaction in a company&#x2019;s securities even if you planned to execute the transaction prior to learning of the inside information and even though you believe you may suffer an economic loss or sacrifice an anticipated profit by waiting. &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Trading</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; includes engaging in short sales, transactions in put or call options, hedging transactions and other inherently speculative transactions.</font></div></div>
  <p style="margin-left:0.92%;text-indent:6.812%;font-size:10pt;margin-top:12.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.213%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although by no means an all-inclusive list, information about the following items may be inside information until it is publicly disseminated:</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.54in;min-height:0.67in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">May 9, 2024</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.94in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:12.667%;display:flex;margin-top:3.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:8.269%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:9.468356749453243%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">financial results or forecasts;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:12.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:8.269%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:9.468356749453243%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">communications with government agencies, such as the FDA;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:12.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:8.269%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:9.468356749453243%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">strategic plans;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:12.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:8.269%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:9.468356749453243%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">discovery and development of new product candidates and new technology;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:12.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:8.269%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:9.468356749453243%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">details or results of clinical trials of the Company&#x2019;s product candidates;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:12.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:8.269%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:9.468356749453243%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">6.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">significant changes or developments in suppliers;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:12.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:8.269%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:9.468356749453243%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">7.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">acquisitions or dispositions of assets, divisions, companies, etc.;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:12.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:8.269%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:9.468356749453243%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">8.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">pending public or private sales of debt or equity securities;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:12.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:8.269%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:9.468356749453243%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">9.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">declaration of stock splits, dividends or changes in dividend policy;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:11.472%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:9.463%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:10.689273450207843%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">10.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">major contract awards or cancellations;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:11.472%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:9.463%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:10.689273450207843%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">11.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">significant regulatory or legislative developments;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:11.472%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.204%;min-width:9.463%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:10.689273450207843%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">12.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">major new drugs, processes or services, or many developments related to the same;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:11.472%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:9.463%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:10.689273450207843%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">13.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">top management or control changes;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:11.472%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:9.463%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:10.689273450207843%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">14.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">possible tender offers or proxy fights;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:11.472%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:9.463%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:10.689273450207843%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">15.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">significant writeoffs;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:11.472%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:9.463%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:10.689273450207843%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">16.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">actual or threatened significant litigation, or the resolution of such litigation;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:11.472%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:9.463%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:10.689273450207843%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">17.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">impending bankruptcy of the Company or its key collaborators or partners;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:11.472%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:9.463%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:10.689273450207843%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">18.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">gain or loss of significant partners, customers or suppliers;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:11.472%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:9.463%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:10.689273450207843%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">19.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">pricing changes or discount policies;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:11.472%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.204%;min-width:9.463%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:10.689273450207843%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">20.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establishment of or developments related to corporate partner relationships, strategic partnerships, joint ventures or other collaborations;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:11.472%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:9.463%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:10.689273450207843%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">21.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">cybersecurity and data security incidents; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:11.472%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:9.463%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:10.689273450207843%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">22.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">notice of issuance of patents.</font></div></div>
  <p style="margin-left:0.92%;text-indent:6.811%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.194%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For information to be considered publicly disseminated, it must be widely disclosed through a press release or SEC filing, and a sufficient amount of time must have passed to allow the information to be fully disclosed. Generally speaking, information will be considered publicly disseminated after two full trading days have elapsed since the date of public disclosure of the information. For example, if an announcement of inside information of which you were aware was made prior to trading on Wednesday, then you may execute a transaction in the Company&#x2019;s securities on Friday.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.55in;min-height:0.68in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">May 9, 2024</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.94in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:0.935%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:6.729924796850553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">III.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock Trading by Directors, Officers and Other Employees</font></div></div>
  <p style="font-size:10pt;margin-top:1.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:6.81%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.185%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because the employees, officers and directors of the Company are the most visible to the public and are most likely, in the view of the public, to possess inside information about the Company, we require them to do more than refrain from insider trading and require that they notify, and receive approval from, a Clearing Officer (as defined in III.D. below) prior to engaging in transactions in the Company&#x2019;s stock and observe other restrictions designed to minimize the risk of perceived or actual insider trading.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:0.935%;text-indent:6.812%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.204%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.4788270327562714%;">A.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Covered Insiders. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The provisions outlined in this stock trading policy apply to all directors, officers and employees of the Company. Generally, any entities or family members whose trading activities are controlled or influenced by any of such persons should be considered to be subject to the same restrictions.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:0.935%;text-indent:6.803%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.4788270327562714%;">B.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Window Period. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Generally, except as set forth in this paragraph B and in paragraphs C, D, G and F of this policy, directors, officers and employees may buy or sell securities of the Company only during a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">window period</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; that opens after two full trading days have elapsed after the public dissemination of the Company&#x2019;s annual or quarterly financial results and closes on the last trading day one week before the end of the quarter. This window period may be closed early or may not open if, in the judgment of the Company&#x2019;s Chief Executive Officer or Chief Legal Officer, there exists undisclosed information that would make trades inappropriate. It is important to note that the fact that the window period has closed early or has not opened should be considered inside information. An employee or director who believes that special circumstances require him or her to trade outside the window period should consult with a Clearing Officer. Permission to trade outside the window period will be granted only where the circumstances are extenuating and there appears to be no significant risk that the trade may subsequently be questioned.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.602%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.2155241455442765%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">C.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exceptions to Window Period.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:0.935%;text-indent:13.605%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.9014788270327565%;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Option Exercises</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Directors, officers and employees may exercise options for cash granted under the Company&#x2019;s stock option plans without restriction to any particular period. However, the subsequent </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sale </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of the stock (including sales of stock in a cashless exercise) acquired upon the exercise of options is subject to all provisions of this policy.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:0.935%;text-indent:13.605%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.9014788270327565%;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">10b5-1 Automatic Trading Programs</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, purchases or sales of the Company&#x2019;s securities made pursuant to, and in compliance with, a written plan established by a director or employee (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Trading Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) that meets the requirements of Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Exchange Act</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) may be made without restriction to any particular period provided that (i) the Trading Plan was established in good faith, in compliance with the requirements of Rule 10b5-1, at the time when such individual was not in possession of inside information about the Company and the Company had not imposed any trading blackout period, (ii) the Trading Plan was reviewed by the Company&#x2019;s Chief Business and Legal Officer or their designee (each, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Clearing Officer</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) prior to establishment, solely to confirm compliance with this policy and the securities laws and (iii) the Trading Plan allows for the cancellation of a transaction and/or suspension of such Trading Plan upon notice and request by the Company to the individual if any proposed trade (a) fails to comply with applicable laws (</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">e.g.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, exceeding the number of shares that may be sold under Rule 144) or (b) would create material adverse consequences for the Company. The Clearing Officer must be notified in writing of the establishment of any such Trading Plan, any amendments to such Trading Plan and the termination of such Trading Plan.</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.55in;min-height:0.68in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">May 9, 2024</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.94in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:0.935%;text-indent:6.803%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.4788270327562714%;">D.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pre-Clearance and Advance Notice of Transactions. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to the requirements of paragraph B above, employees, officers and directors may not engage in any transaction in the Company&#x2019;s securities, including any purchase or sale in the open market, loan, or other transfer of beneficial ownership without first obtaining pre-clearance of the transaction from the Clearing Officer at least two business days in advance of the proposed transaction. The Clearing Officer will then determine whether the transaction may proceed and, if so, will direct the Compliance Coordinator (as identified in the Company&#x2019;s Section 16 Compliance Program) to assist in complying with the reporting requirements under Section 16(a) of the Exchange Act, if any. Pre-cleared transactions not completed within ten business days shall require new pre- clearance under the provisions of this paragraph. The Clearing Officer may, at their discretion, shorten such period of time. Advance notice of gifts or an intent to exercise an outstanding stock option shall be given to a Clearing Officer. To the extent possible, advance notice of upcoming transactions to be effected pursuant to an established Trading Plan under Section III.C.2 above shall also be given to a Clearing Officer. Upon completion of any transaction, the officer or director or other member of management must immediately notify the Compliance Coordinator and any other individuals identified in Section 3 of the Company&#x2019;s Section 16 Compliance Program so that the Company may assist in any Section 16 reporting obligations.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:0.935%;text-indent:6.803%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.4788270327562714%;">E.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prohibition of Speculative or Short-term Trading. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No employee or director may engage in short sales, transactions in put or call options, hedging transactions, margin accounts or other inherently speculative transactions with respect to the Company&#x2019;s stock at any time.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:0.935%;text-indent:6.803%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.4788270327562714%;">F.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Short-Swing Trading/Control Stock/Section 16 Reports. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Officers and directors subject to the reporting obligations under Section 16 of the Exchange Act should take care not to violate the prohibition on short-swing trading (Section 16(b) of the Exchange Act) and the restrictions on sales by control persons (Rule 144 under the Securities Act of 1933, as amended), and should file all appropriate Section 16(a) reports (Forms 3, 4 and 5), which are enumerated and described in the Company&#x2019;s Section 16 Compliance Program, and any notices of sale required by Rule 144.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:0.935%;text-indent:6.803%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.4788270327562714%;">G.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Special Blackout Periods. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, the Company may prohibit directors, officers, employees and agents from engaging in transactions involving the Company&#x2019;s securities when, in the judgment of the Clearing Officer, a trading blackout is warranted. The Company will generally impose special blackout periods when there are material developments known to the Company that have not yet been disclosed to the public. For example, the Company may impose a special blackout period in anticipation of announcing material clinical data, interim earnings guidance, or a significant transaction or business development. However, special blackout periods may be declared for any reason. The Company will notify those persons subject to a special blackout period. Each person who has been so identified and notified by the Company may not engage in any transaction involving the Company&#x2019;s securities until instructed otherwise by the Clearing Officer, and should not disclose to others the fact of such suspension of trading.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:0.935%;text-indent:6.803%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.4788270327562714%;">H.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prohibition of Trading During Pension Fund Blackouts. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In accordance with Regulation BTR under the Exchange Act, no director or executive officer of the Company shall, directly or indirectly, purchase, sell or otherwise acquire or transfer any equity security of the Company (other than an exempt security) during any &#x201c;blackout period&#x201d; (as defined in Regulation BTR) with respect to such equity security, if such director or executive officer acquires or previously acquired such equity security in connection with his or her service or employment as a director or executive officer. This prohibition shall not apply to any transactions that are specifically exempted from Section 306(a)(1) of the Sarbanes-Oxley Act of 2002 (as set forth in Regulation BTR), including but not limited to, purchases or sales of the Company&#x2019;s securities made pursuant to, and in compliance with, a Trading Plan; compensatory grants or awards of equity securities pursuant to a plan that, by its terms, permits executive officers and directors to receive automatic grants or awards and specifies the terms of the grants and awards; acquisitions or dispositions of equity securities involving a bona fide gift or by will or the laws of descent or pursuant to a domestic relations order; etc. The Company shall timely notify each director and executive officer of any blackout periods in accordance with the provisions of Regulation BTR.</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.55in;min-height:0.68in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">May 9, 2024</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.94in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:0.935%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:6.729924796850553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">IV.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Duration of Policy&#x2019;s Applicability</font></div></div>
  <p style="font-size:10pt;margin-top:1.1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:6.809%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.167%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This policy continues to apply to your transactions in the Company&#x2019;s stock or the stock of other public companies engaged in business transactions with the Company even after your employment or directorship with the Company has terminated. If you are in possession of inside information when your relationship with the Company concludes, you may not trade in the Company&#x2019;s stock or the stock of such other company until the information has been publicly disseminated or is no longer material.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:0.935%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:6.729924796850553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">V.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Penalties</font></div></div>
  <p style="font-size:10pt;margin-top:1.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:6.809%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.167%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Anyone who effects transactions in the Company&#x2019;s stock or the stock of other public companies engaged in business transactions with the Company (or provides information to enable others to do so) on the basis of inside information is subject to both civil liability and criminal penalties, as well as disciplinary action by the Company. An employee, director or consultant who has questions about this policy should contact his or her own attorney or the Clearing Officer of the Company.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.167%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">* * *</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.55in;min-height:0.68in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">May 9, 2024</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>11
<FILENAME>lxeo-ex23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html>
 <head>
  <title>EX-23.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="z-index:-3;min-height:1in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br>Exhibit 23.1</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:auto;width:50.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:34%;box-sizing:content-box;"></td>
    <td style="width:66%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img238985936_0.jpg" alt="img238985936_0.jpg" style="width:93px;height:38px;"></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">KPMG LLP</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">345 Park Avenue</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">New York, NY 10154-0102</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:24pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consent of Independent Registered Public Accounting Firm</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We consent to the incorporation by reference in the registration statements (No. 333-275374, and 333-277816) on Form S-8 and (No. 333-283781) on Form S-3 of our report dated March 24, 2025, with respect to the financial statements of Lexeo Therapeutics, Inc..</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/s/ KPMG LLP</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">New York, New York</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 24, 2025</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">KPMG LLP, a Delaware limited liability partnership and a member firm of</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the KPMG global organization of independent member firms affiliated with</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">KPMG International Limited, a private English company limited by guarantee.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>12
<FILENAME>lxeo-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 31.1</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EXCHANGE ACT RULES 13a-14(a) AND 15d-14(a),</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AS ADOPTED PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I, R. Nolan Townsend certify that:</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K of Lexeo Therapeutics, Inc.;</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant&#x2019;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant&#x2019;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:45.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Dated: March 24, 2025</font></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ R. Nolan Townsend</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By: R. Nolan Townsend</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Executive Officer (Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>13
<FILENAME>lxeo-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31.2</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 31.2</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EXCHANGE ACT RULES 13a-14(a) AND 15d-14(a),</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AS ADOPTED PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I, Kyle Rasbach certify that:</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K of Lexeo Therapeutics, Inc.;</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant&#x2019;s other certifying officer and I are  responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant&#x2019;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:45.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Dated: March 24, 2025</font></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Kyle Rasbach</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By: Kyle Rasbach</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Financial Officer (Principal Financial and Accounting Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>14
<FILENAME>lxeo-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 32.1</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18 U.S.C. SECTION 1350,</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AS ADOPTED PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the Annual Report of Lexeo Therapeutics, Inc. (the &#x201c;Company&#x201d;) on Form 10-K for the period ended December 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Report fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:45.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Dated: March 24, 2025</font></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ R. Nolan Townsend</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">R. Nolan Townsend</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Executive Officer (Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>15
<FILENAME>lxeo-ex32_2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html>
 <head>
  <title>EX-32.2</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 32.2</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION OF THE CHIEF FINANCIAL OFFICER</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18 U.S.C. SECTION 1350,</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AS ADOPTED PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the Annual Report of Lexeo Therapeutics, Inc. (the &#x201c;Company&#x201d;) on Form 10-K for the period ended December 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Report fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:45.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Dated: March 24, 2025</font></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Kyle Rasbach</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Kyle Rasbach</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Financial Officer (Principal Financial and Accounting Officer)</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>img34756086_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img34756086_0.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" )2!>8# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M'/C/^?&&_P#"NK_\Q'T)17SW_P ,K? 7_H1/_+H\9_\ S14?\,K? 7_H1/\
MRZ/&?_S14<N'_P"?M;_P1#_YH#GQG_/C#?\ A75_^8CZ$HKY[_X96^ O_0B?
M^71XS_\ FBH_X96^ O\ T(G_ )='C/\ ^:*CEP__ #]K?^"(?_- <^,_Y\8;
M_P *ZO\ \Q'T)17SW_PRM\!?^A$_\NCQG_\ -%1_PRM\!?\ H1/_ "Z/&?\
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M%_Z$3_RZ/&?_ ,T57RX?_G[6_P#!$/\ YH,^?&?\^,-_X5U?_F(^A**^>_\
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MX.TG3?$]]I.H:E+X/L+'P5IVN:?>"?1K46TNL^(=?BBCDG5H)"\;1>:?#?\
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M=#\>>#_A=X@U][#3O WAO3(K6U\#R6.EQRWNN:GJ6HZAJ5C=67FG_!O[\._
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M_9C^!FH_#C]C[_@NMX^?]IK]E?X\/\0_@J=2\8Z/^R5JWC[5OASX6\7ZO/\
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M&_$OBS5_$%QXCN='NK#2=$N++2_$T]Z]O#)H<0E+I^-__!?GX ?"KX,^!O\
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MK:[.]K;:>IE5I^T]GK;DJPJ;7OR.]MU:_?6W9A1114&H4444 %%%% !1110
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M /PLP_\ \L\U]Y]<45\C_P##?_[!_P#T>Q^R/_XDC\&__FSH_P"&_P#]@_\
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MCK.A/#9I*BZTINK*JZ3@X.HZC=1SY>9S;FWS-LF-?AV%55X5LEC64%25:-3
MQJJG&"IQIJHFIJ"ARP4+\JA:*5K(ZK]E[]DC]GC]C#X=ZA\*/V:/AS;?#'P#
MJOBS4_'6I:%;^(?%WBAKWQ7K.G:-I&HZQ<ZOXW\0>)=<DFGTOP]HM@D#:E]C
MMK73;:&UMX$4AOHZOD?_ (;_ /V#_P#H]C]D?_Q)'X-__-G1_P -_P#[!_\
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M)J>FZ+<^'K.>+5O!'BGPUK=W$FCWEQ926>H:E=V5RK)-<V\UQ##-'7_X;_\
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M[/\ _H1YQ_X;,;_\H#^ULK_Z&67_ /A9A_\ Y9YK[SZXHKY'_P"&_P#]@_\
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MGFOO/KBBOD?_ (;_ /V#_P#H]C]D?_Q)'X-__-G1_P -_P#[!_\ T>Q^R/\
M^)(_!O\ ^;.C_5[/_P#H1YQ_X;,;_P#* _M;*_\ H99?_P"%F'_^6>:^\^N*
M*^1_^&__ -@__H]C]D?_ ,21^#?_ ,V='_#?_P"P?_T>Q^R/_P")(_!O_P";
M.C_5[/\ _H1YQ_X;,;_\H#^ULK_Z&67_ /A9A_\ Y9YK[SZXHKY'_P"&_P#]
M@_\ Z/8_9'_\21^#?_S9T?\ #?\ ^P?_ -'L?LC_ /B2/P;_ /FSH_U>S_\
MZ$><?^&S&_\ R@/[6RO_ *&67_\ A9A__EGFOO/KBN)^(OPV^'WQ>\&ZY\._
MBGX)\+?$3P)XFM19Z_X0\9Z'IWB+P]JUNDB3Q+>Z5JEO<VDLEM<Q0W5I.8A/
M9WD,%W:R0W,,4J?/O_#?_P"P?_T>Q^R/_P")(_!O_P";.C_AO_\ 8/\ ^CV/
MV1__ !)'X-__ #9U4<@XBA*,X9+G4)Q:E&4<MQT91DG=2C)44TT]4TTT]4*6
M:93.+C+,<NE&2:E&6+PSC)/1IIU&FFG9IZ._F?)"?\$)/^"3R>(CXH7]D#PX
M=2-P+K[,_P 2?C;)X=\U550O_"(2?$MO"8M\*";,:)]D9BSM 7=V;[[\0?LQ
M_L\^*?@C%^S;X@^#'PYU+X"V^C6>@6?PGF\+:7'X)T[2]-D$^FQZ7HT%O%!I
M=UIUVJW^GZGIWV;4['4P-3M;R+4!]IKSO_AO_P#8/_Z/8_9'_P#$D?@W_P#-
MG1_PW_\ L'_]'L?LC_\ B2/P;_\ FSKLKX+C+$NE+$X3B;$.A)3H.OA\UJNC
M./PSI.I"3IRCTE#E:Z,Y:-;AR@JBH5<DHJM%QJJC/ 4U5C+>-10<5.+NKJ5T
M[ZGSO\+/^",/_!,;X,?$#2?BA\/OV3O"5CXUT'6;/Q%H6I>(/%_Q0\>6&BZY
MIU\NI:;JFD^&_'OCGQ-X8TZ\TV_2*[TZ6ST>$V$\%N]GY)MH/+^G+;]BW]F>
MT_:FU#]M2W^&:1_M-:IX:3P???$S_A+O'CM/X>CT.R\-I8?\(>_BAO ,3C1-
M.L[#[=#X6CU$QP^8;LSR2ROE_P##?_[!_P#T>Q^R/_XDC\&__FSH_P"&_P#]
M@_\ Z/8_9'_\21^#?_S9TZN"XRKRE.OA.)ZTYT)X:<ZN'S6I*>&J-.>'E*<&
MY4)N,7.DVZ<G%-Q;2"G6X<HQC"C5R2E"-6->$:<\!",:\$U"M&,6DJL5)J-1
M)32DTFKEW3OV(_V7M)_:JU[]MK3_ (6P6_[3WB;08?#.N?$\>+/'<DE_HUOX
M9T;P;#;MX0E\42> H)T\,>']'T?^T;7PM!J1MK)2UV9IKB6;PGX]?\$A_P#@
MG%^TSX_U7XI?&7]ESPEX@\?Z_=G4/$'B7P_XF^(OPXO/$6I/DSZKXAA^&?C+
MP?9:]JUVQ+WVJZO:WFH7\F)+RYGD 8>T_P##?_[!_P#T>Q^R/_XDC\&__FSH
M_P"&_P#]@_\ Z/8_9'_\21^#?_S9TJ>!XQHU(5J.#XFI5:="&&IU:>'S2%2G
MAJ?\/#PG&"E"A3^Q2BU3C]F*'.OP[5A*G4K9+4IU*LJ\Z<ZF!G"=>?QUI0DW
M&56=_>J-.<KZR=RYI'[#W[*'A[]G+Q/^R3X>^"?A7P[^SQXTL]1LO%?PV\/S
M:WH=EKRZL;(ZC>ZCKFE:M:>*I]9NSING^;KYUT:X?L-F%U "VA">G_ ?X#_"
M;]F3X3>$/@;\#?"$'@/X5^ X-4MO"GA2VU37=;CTN/6]=U3Q-J[-J_B;5-:U
M[4)]0U[6M5U2ZNM4U6]NI;J]F9IMNU5\D_X;_P#V#_\ H]C]D?\ \21^#?\
M\V='_#?_ .P?_P!'L?LC_P#B2/P;_P#FSK&IE/%56$Z=7+.(*M.I7^LU*=3!
M9C.%3$\KA]8G&5)QG7Y&X>UDG4Y6X\UFT:0QN1TY0G3Q>4TYPI>PISA7P<90
MH<RE[&$HS3C2YE&7LTU#F2?+=)GUQ17R/_PW_P#L'_\ 1['[(_\ XDC\&_\
MYLZ/^&__ -@__H]C]D?_ ,21^#?_ ,V=<_\ J]G_ /T(\X_\-F-_^4&W]K97
M_P!#++__  LP_P#\L\U]Y]<45\C_ /#?_P"P?_T>Q^R/_P")(_!O_P";.C_A
MO_\ 8/\ ^CV/V1__ !)'X-__ #9T?ZO9_P#]"/./_#9C?_E ?VME?_0RR_\
M\+,/_P#+/-?>?7%%?(__  W_ /L'_P#1['[(_P#XDC\&_P#YLZEM_P!OC]A:
MZGAM;7]M+]DRYN;F6.WM[>W_ &C/@]-///,ZQPPPPQ^,6DEEED94CC16=W95
M52Q H?#V?I-O(\X26K;RS&V2[O\ <#_M7*_^AE@/_"S#^7_3SS7WH^LZ***\
M<[PHHHH _,OX\?\ !'/_ ()O_M,_%CQ=\</C7^S;:^+OBAX[GTRZ\6>);3XI
M?&WP?'K%UI&BZ;X>LKJ30? _Q*\-^&K:Z&E:3817=Q8Z/;3:C<Q2ZCJ+W>I7
M=W=S^W?LS?\ !/O]C+]CJYO-1_9O_9\\"_#77=0LH],O/%4":OXF\:S:;&H5
MM._X3?QIJGB/Q:EA<%4DOK./6DMM0GCBN;Z*XN(8I$^QJ*[ZF:YI5P\<)5S+
M'U,)&$*<<+4QF(GAXTZ:480C1E4=-0@DE"*CRQ22222..&79?3K/$T\#@Z>(
ME*4Y5X8:A&LYS;<YNK&"FY2;;E)RO)MMMMGRW<_L6_LSW?[4UA^VI<?#-)/V
MFM+\-/X/L?B9_P )=X\1H/#TFAWOAM[#_A#T\4+X!E<Z)J-Y8?;IO"TFHB.;
MS!=B>.*5/EB^_P""*'_!+?4OB%<_$^__ &0? ]WXKO-5N-;NXY_$_P 2W\(7
M6HW5W)?7$MQ\.#XW_P"%=SP37,LCR6,GA5K!HV\@VWV<+$/U+HHI9KF=&WL<
MQQ]*U"&&7LL9B*=L-3<G3PZY*BM0IN<W"E_#@YR<8KF=RIE^ J_Q<#@ZEZLZ
M[]IAJ,[UZBBIUO>@_P![-1BIU/CDHQNW96^;/VA/V/OV9?VJ_AUI/PG^/_P:
M\(?$3P!X>FMY_#.A7D%[HDGA2:UL3ID#^$M9\+WFAZ]X4,>FD:?CP[JFF!K%
M4M'#01I&O ?LR_\ !.[]B[]CJR\76/[.GP#\+> 8_'NEMH7C.YNM3\5^.=4\
M2Z"\DLLF@ZOK7Q$\0>+=8N]"D>>4RZ,]]_9DH8+):LJ(%^TJ*SCC\=##2P<<
M;BXX2<N>>%CB*RPTI\RESRH*:I2ES)2YG%OF2=[HT>#PDJ\<3+"X=XF,>6.(
M="DZ\8VY>6-5Q]HHV;5E*UG:UC\I[C_@A_\ \$J[GQN?B#)^QUX%77FU$ZH;
M"#Q3\3[7P1]I,K3&(?#.U\<P_#==.WL0-'7PH-)$6V 60A58Q^COB3X8?#WQ
M=\--;^#>O^#]"O/A9XB\$W_PXU;P'%8QZ=X;F\":EHDGANZ\+6^G:9]CBT[1
M_P"PI7TNVM=-^R"QM!''8FW\F(IW=%.OF.88IT7BL=C,2\/;V#KXJO6=&UFO
M8NI.3IV<4UR<MK+LB:."P>'518?"86@JW\54</2I*KHU^\4(1Y]&U[U]&^Y\
M8_LF_P#!/7]CO]AN?QK=_LM_!BQ^&%[\1(M%M_%^H-XO^(7C?4M5M?#SZC+I
M-E'J7Q&\6^+K[2K&";5;V>:QT>XT^TO[AK>?4(;J:RLGM^=_:<_X)C?L(?MC
M>*8O'/[1?[.?A/Q[XVCLK73I?&-EK/C3P%XJU&QL(TAL+;6O$/PW\3>$-7UZ
M+3[>-+6P76[R_P#L5FBV=J8;51"/O"BFLSS)8J6.688U8V2498Q8NNL5**C&
M"C+$*I[5I1C&*3FURQBMDD)X# O#K"/!X1X6+O'#/#T?JZ;;DVJ/)[--RE*5
MU&]VWNV?%7P^_P""=/[%?PI^!OQ,_9O^'/P"\+^$/@[\9-%F\/?%+PWH^J^+
M8-5\<Z3-8W.F^1X@\<OXBD\?WD]O97EW#87_ /PE":AIOVJXET^ZMIII)&]R
M^ 'P ^$?[+GPC\(_ GX$^$1X%^%7@4:XOA7PJNN>)?$HTL>)?$NL^+];_P")
MWXOUGQ!XCOC?>(_$&KZDS:EJ]XT+7AMK8PV<-O;P^QT5%;&XS$1J0KXO%5X5
M:RQ%6-;$5:D:F(C3=*->I&<Y*=:-)NFJLDYJFW!2Y78TIX7"T90E1PU"E*G2
M="G*G1IPE"C*:J.C!QBG&DYI3=.+4'-*35TF?RL_\%'?V2/BA^VS_P %L_V/
MM#@_9L^(</P#^#_AWX?7/Q<_:#NOASXHA^&_C#2?#7B+Q#\7]4\&7/Q&>Q3P
MA>6261L_ VE6$&H_VU!XI\5^(;1HI5BMUM_ZIJ**ZLPS6MF&'RS"RA&E1RO!
M_5:,8RG+GE*I*I6KR<V[3JR<4XQM",81C%61S8++Z>#KX_$1FZE7,,3]8JR<
M8QY8Q@J=*E%16L::4FI/WI2G)O5A1117EGH!7/6T6H#Q7K4TFJ6\NE2>'O#$
M5GHJS;KNPU"+4O%S:EJDUOY8\JWU>VFTFTM9O-?SY-$NT\N/[-NEZ&N2LCH_
M_"=^)! +S^WQX2\%'4V?9_9YT<ZSX_&ABUP?,^V+>CQ";[>H3R&T[RR6\T+2
MVG_A[7^U'[O5>FS)EO#_ !/JU?W)].O>SLNNZ2.MHHHJ2CROXW?!+X7_ +1W
MPK\9?!/XT>%H_&OPP^(&GV^E^+?"\NJZYH:ZM96FI66KVL8U?PSJ>C:]I\EO
MJ6G65Y#<Z7JEE=1S6Z%9@NY6I_ /X!_"3]F#X2>$?@7\"_",?@3X5>!(]8B\
M*^%(M8\0^(%TM?$'B'5O%>LDZSXKU;7?$-_)?^(==U;4YIM3U:]F$UZ\<;I;
MI##'[!16WUBO[#ZK[>M]6]M]8^K>TG[#V_)[/V_L>;V?MO9MT_:<O/R>[S<N
MAG[&C[;ZQ[*G[?V?L?;\D?;>QYN?V7M+<_L^=*?)S<O-[UKZGRW^TC^Q;^S/
M^UU?_"W4_P!H?X9I\0[WX+>);CQA\,YG\7>//"W_  C7B&[FT:XN;\Q>"O%'
MAN'64FF\/Z0[V/B"/5=./V-5%H%FN%F]R^(/P\\"?%CP7XC^'/Q-\(>'O'O@
M/Q=ISZ3XF\(^*]*L];T#6]/=XYOL^H:;?Q36TPBN(8+JVD*":TO+>WO+62&Z
MMX9D[*BAXG$.-"#Q%9PPKE+#0=6HXX:4Y^TFZ$>:U%SJ)5).FHN4US.\M1*A
M14JTU1I*>(457DJ<.:LHQY(JM*UZBC!N$5-R2B^566A^5G@S_@B/_P $L_ /
MC2S\?^'/V0_!X\1Z??1:E9#7O&7Q5\8>'K:]MYH[B">+P9XO\>Z[X-4P311R
M0Q_V!Y43+^[102#],_M3_L&?LB_MKVGA^U_:>^"/AKXI2^%4NHO#FL7.H>)O
M"WBC1K6]DBFO+"P\7>!]<\,^*8-,NIX(IY]+76/[.EG03O:F7+GZZHKJGFV:
MU*U+$U,SS">(H*2H8B>-Q,JU%25I*E5E4=2FI+22A))K1F$<NR^%*I0A@<'"
MA6:=6C'"T(TJK3NG4IJ"A-IZIR3L]C\][#_@E5_P3_TG]GKQ7^ROI/[.6@:5
M\#/'6O>'?$_C'PCIGBWXD:?J?B;7_"=U;WGAW5-:\>V?C.'XB:A<Z5/:Q&W-
MQXL=&B,]M,DEM=7,4W:?$W_@G=^QS\8_!W[.?@#XC_!R/Q'X1_9,L]!L/V?M
M'/COXFZ0OP_L_#&E^&=%T2W%[H7C33-1\4QV>F>#O#=JP\:WGB,W8TQ9;TW,
M]U>RW/VI14_VIF;FJCS''.HJM2NI_6\1SJO5I*A5K*7M.95:E%*C4J7YYTDJ
M<FX*P_J& 47!8+"*#IPI.'U:CRNE3J.K3I./)9TZ=5NI"%N6-1N<4I.Y\MW/
M[%O[,]W^U-8?MJ7'PS23]IK2_#3^#['XF?\ "7>/$:#P])H=[X;>P_X0]/%"
M^ 97.B:C>6'VZ;PM)J(CF\P78GCBE2$_L2?LOG]JE?VV3\+8/^&GET#_ (1@
M?$\>+/':R'13X:;P?]F;P@/% \!//_PC+'2/[1?PLVI"V"D7GG*LH^JJ*S^O
M8U;8S%+_ &5X'_>*W^Y-W>#^/_=6]7A_X-_L%_5,+_T#8?\ WCZW_!I_[TML
M3\/^\?\ 3[^)_>/ECX,?L4?LQ_L]_%+XY?&GX0_#"'PG\2_VD]?OO%'QK\1O
MXL\=^(E\:ZYJ?B#7?%.H7CZ)XJ\4:YX=\/I=Z]XFUN_FLO"NDZ'8,;W[/]E%
MI;6=O;_+>I?\$4/^"6NK?$"Y^)M]^Q[X!D\3W>H2:I<VL/B#XBV?@J6\FG:X
ME8_#*S\9V_PV%O)*[,UBOA-;$J?+-OY8"#]2Z*UAFN9TJE2K3S+'TZM:%.E5
MJ0QF(A4JTZ4%"E3J3C44IPIP2A3A)N,()1BDDD9SR_ 5(0ISP.#G3ISG4IPG
MAJ,H4ZE27/4G"+@XQG4FW*<HI2E)\TFWJ? '[2'_  2T_8%_:X^(D7Q9_:"_
M9Q\,^._B,D&FVUUXNM_$?C[P7JNM0:/;V]EI<?B=O 'BWPM!XL6PL+2UTVU_
MX2:'5C#IEM;Z:A%A#';KT/PH_P""<'[%'P-'QN3X2? G1? EK^T7X+A^'?Q@
MTW0_$_CV/1_$W@N#1]2T"+P_I^BW'BNXTGP;:+I.KZC:E_ UEX;NF-Q]H>=K
MJ&">+[>HI?VIF;H1PKS''?5H1C"&'^MXCV$(0G"I"$:7M/9QC&I3ISC%12C.
M$))*48M/^S\![66(^I83V\I2E*M]6H^UE*490E*53DYW*4)SC)N3;C.46[2:
M?@/[-7[+OP)_9 ^&%M\&OV=? J_#OX;6>M:OXBM_#@\2>+_%A36=>EBFU6];
M6?''B#Q+K\K73P1'R9M5DMH%C6.VAAC&VO?J**Y:M6K7J3K5ZE2M6JR<ZE6K
M.52I4G)WE.<YMRG*3U<I-MO5LZ*=.G1A"E2IPI4J<5&%.G&,(0BE91A"*48Q
M2T2222V04445F6%%%% '/:U%J$FI>$6L]4M["VA\0W,NK6DTWE2:WIY\*>)X
M8]+M$\M_M-Q%JLNFZTT.Z+;::1=7'F'R/*DZ&N2\2'1QK/@ :F+PWI\6WH\/
M&UV>0NL?\()XU,YU'>0WV/\ L :XJ>4&?^T&L<CR_,8=;5/:'^%]+?:E]_J_
M39$1^*IY375NW[NF]G\/>RT=^;>3"BBBI+"BBB@#Y*MOV%OV5;/]J_4/VX+;
MX3VT?[4>JZ6FC7_Q2_X2WQZ\L^GQ^#+'X>HG_"'R>*F\ 17*^#--LM ^WP^%
M8]0-I#O-T;F26>3ZUHHK6KB*]?V?MZU6M[&E##T?:U)U/94*2:IT:?/*7)2I
MIM0IQM"";Y8JYG3HT://[&E3I>UJ3K5?9PC#VE:I;GJSY4N>I.RYYRO*5E=N
MQ\M_LQ?L6_LS_L:V'CS3/V;?AFGPVLOB;XEC\8>.(5\7>//%O]M^(8H9K>*_
M\WQUXH\3S:8D<-Q,B6.CR:?IR^8S"T#88<;\#_\ @G3^Q9^SG\,OBK\&OA'\
M!O#N@_"WXWS23_%3P/KFN>,_B!H7C'S-.DTDV]_;?$7Q+XL:UL$L)7A@TW3)
M+'3[=V^T6]M%<@3#[6HK:688^;K2GC<7*6)E1GB)2Q-:3Q$\.[X>=9N;=65!
MZT95.9TG\#B9+!X2*I*.%PT50C5C12H4DJ,:^E:-)*-J<:RTJJ%E4^VF?DW9
M?\$,O^"4]AI?C+1[;]D3PT++QY;VUKX@:;XA_&:ZU"*WM?$.E>)X8_#.KW7Q
M'FU;P,#JVBV F;P1>^'FN=*%WX>N6F\/ZGJ6EW?L'QV_X)7_ + G[2^F_#;2
M_C9^SMHGC2+X1?#[P]\*OAY?+XQ^)7AG7O#_ ,._":2IX<\)'Q-X0\::!XBU
M?2M)\^ZDM8]=U34Y1<7M_=/*]Q?WDL_Z"45T/.LXE4A5EFV9RJTG*5.H\?BG
M4IRG"-.;A-U>:#E3C&$G%IRA&,7>*26*RO+(PG3678!4ZBC&<%@\.H3C&3G%
M3BJ?+)1G*4HIII2;DK-MGSO\$/V2_P!FO]F_X7ZE\%_@G\&/ O@/X8:ZNHIX
ME\)66D+J=GXN&KV9TW5&\9W>O2:KJ?C*2_TL_P!E74OBF^U>6;25CTMW-A%'
M;I\3R_\ !#?_ ()3S>+CXW?]CSP:-9-Z]^;*+QI\68/"/GO(\AC'P_@\?Q^
MEL@SD)IR^&QI\<82)+58HT1?U@HK.EFN9T*E:K1S''T:N)=\14I8S$4ZF(>N
MM:<*BE5>KUJ.6[-*F7X"K"E3JX+"5:=!6HPJ8:C.%%::4HR@XTUHM();+L96
MA:'HWAC1-'\->'-+L-#\/>'M*T_0]"T32K6&QTO1]&TFTAL-+TO3;*W2.WL[
M#3[&W@M+.U@C2&WMX8X8D5$51^=/[0?_  2 _P""=7[5'Q;\4_'7X\?L[)XY
M^*OC5-"3Q1XJ7XK_ !P\*MJR^&?#FD^$M#,FB^"_B7X<\.V[V/AW0M)TT26>
MD6\EQ'9)-=M/=/+/)^E=%98;&XW!595\'B\5A*TXRA.MAL15H59PE*,Y0E4I
M3A.493A&4HMM.48R:NDU=?"X7%4XTL3AL/B*49*4:5>C3K4XRBG&,HPJ1E%2
M492BFE=*32=FS\(_VD/^"67P[_9A_8X_:K\-?\$L/V7Y-/\ VA_VC?AYIWP5
MU*&+XU^)GDN/ /B+7;>V\:7']K?'GXLS>'=*%GX2N_$(@&EZAIVIWFHW5@#]
MKBM_+3[?_P""7_[),_[$W[#_ ,#?@-K6GV>G^/=+\.R>*?BL+.[M]123XG>-
M+F3Q#XMMFU.SDEL]330+F\A\*65_9226=SI?A^P>VEFAV32??M%=F(SK,,7@
M98'$UI8B-3&1QM;$UZE:MC*]6%!8:C"M7JU9\U&A3YO8P45RRG)N4O=4>:AE
M6"PV+6+H4HT90PKPE*A2A2I8:E3G6=>I.G2ITX\M6K.WM)\SYE&*26K?YO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?JM.FZ9$,/1YJMZ:_B*UVFK>RI[):Q5[Z2]Z]Y+W7$V/[;N_^>=O_P!\2?\
MQVC^V[O_ )YV_P#WQ)_\=K'HJ2_J]'_GW'\?\S8_MN[_ .>=O_WQ)_\ ':/[
M;N_^>=O_ -\2?_':QZ* ^KT?^?<?Q_S-C^V[O_GG;_\ ?$G_ ,=H_MN[_P">
M=O\ ]\2?_':QZ* ^KT?^?<?Q_P S8_MN[_YYV_\ WQ)_\=H_MN[_ .>=O_WQ
M)_\ ':QZ* ^KT?\ GW'\?\S8_MN[_P">=O\ ]\2?_':/[;N_^>=O_P!\2?\
MQVL>B@/J]'_GW'\?\S8_MN[_ .>=O_WQ)_\ ':/[;N_^>=O_ -\2?_':QZ*
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M^)/_ ([1_;=W_P \[?\ [XD_^.UCT4!]7H_\^X_C_F;']MW?_/.W_P"^)/\
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M%XQUNRNXR;?QIJ\#+)HEJR)<>%]+<7,S+KFHM;Z'_0O6L8VU:U_+_@_UW/\
M);Z8_P!*'_6:OF'A+X>Y@GPYA:TL-QAQ!@JUXY_BZ$[5,CR^O3E:62X2K&V8
M8B#E'-<33]A2E_9U"<\R****L_SH"BBB@ HHHH **** "BBB@ HHHH ****
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MOV:__#Z?"_\ ^:FC_ALW]C[_ *.N_9K_ /#Z?"__ .:FO\_.BCVC[+^OZ?\
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M_P ->5?_ "1_H&?\-F_L??\ 1UW[-?\ X?3X7_\ S4T?\-F_L??]'7?LU_\
MA]/A?_\ -37^?G11[1]E_7]/^EJ?\4]N#?\ HX?$W_AKRK_Y(_T#/^&S?V/O
M^CKOV:__  ^GPO\ _FIH_P"&S?V/O^CKOV:__#Z?"_\ ^:FO\_.BCVC[+^OZ
M?]+4_P"*>W!O_1P^)O\ PUY5_P#)'^@9_P -F_L??]'7?LU_^'T^%_\ \U-'
M_#9O['W_ $==^S7_ .'T^%__ ,U-?Y^=%'M'V7]?T_Z6I_Q3VX-_Z.'Q-_X:
M\J_^2/\ 0,_X;-_8^_Z.N_9K_P##Z?"__P":FO9_!/C_ ,"?$O08O%/PY\:^
M$O'_ (8N+BYM(/$?@GQ)H_BK09KNSD\J\M8M7T*]O]/DN+67]W<PI<-)!)\D
MJHW%?YQE?=O["7[=OQ%_8H^(HU72C=>)OA7XFNK6/XC_  XDNO+MM6MH]L*Z
M_H#3-Y&E^+]+@S]AOL)!J4"?V3JV^T>">R:GKJM/Z_K_ (;7Y/C?Z ,<!PUF
M..X%XPS'.N),'3^L8/)\XP>!P>&S2-).5;!4L91J16%QM6'^YU*Z>%G7C&AB
M)X>G5>*H?W9T5Y?\&_C)\.OC[\.O#OQ3^%GB.U\3>#O$UJ)[.\@/EW-G<QX6
M]T?6+)B9]+UO2Y]UKJ>F72I/:SH00\3Q2R>H5H?YOX[ XW+,;B\NS'"8C X_
M XBMA,;@L71J8?%83%8>I*E7P^(H58QJ4:U&I&5.I3J1C.$XN,DF@HHHH.4*
M*** "BBB@ KF+273F\9Z_!%8RQZM'X8\(RWNI&:1H;O3IM5\;)I=C' 7,4<N
MG7,&KW$TR1I),FJ0I*\BV\*Q=/6/!_;']OZF)Q%_PC_]CZ'_ &81Y7GG6#>^
M(?[<$F#YWE"R'A[R?, BWF?RB7\[%+:7^'O;[4>GVO3_ +>^R1->]2TVFV_=
M4K?NZBNV]8:NW,KMMJ&TVS8HHHJ2PHHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ K\[_P#@KK_RC4_:0_Z^/A)_ZO/X55^B%?G?_P %=?\
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M'GQG:^ -,\1:]J&KW5MX3\"01^'H?#VA75\LNG)KUW% DICOEM/U3^)?Q+\
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MOC*[T[XE^ /$>I^*8/ T)TS5/"T7CSPIH?@;Q'XF\1:!I5N^D>+H[SP3XO\
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M;G>$X>X=HU,97PU?&X66$Q%/'8R-' U\#[>+YL5+%48PI1Y._P#^"?T^C_\
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MX6DZ:N=MI5/BW6X1I'DO'X=\+RMKVU\:DLNI^+T72-QB6(_V(87O=J3R.O\
MPD ,D4*M$\]+:>_PJ]K?SQWONK]M;V>R9G.W-2O;^([74F[^RJ_#;1.U]9^[
MRW2]YQ.BHHHJ30**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH *_._\ X*Z_\HU/VD/^OCX2?^KS^%5?HA7YW_\ !77_ )1J?M(?]?'PD_\
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M^JW?A/P[''HVCOI.I:H^I:KXINXX+2TUC0H8C_-=15<VM^57]7Y?\'\.VO\
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M4ZK=:M4KSYIJ,5+WZLDGRWY;<SE*\F4445YYV!1110 5\M_MQ?\ )E_[6O\
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M#4M>U[46EU*UTB2&"2 >2\L\R0?DM14WW\_^'/O\[X!X;S_,N"LSQ^&K1J<
M9C4S3AO"X6L\+@<-C)Y=4RNG*MA:45"M3PN$J3CA:5XTZ,GS*+22/5/@;\5M
M6^!GQD^%_P 8]$M%U#4OAGXZ\,^,X=+>Z-E%K,6@ZM:W]YH<]X+>[:TMM;LH
M;C2;FY2VGD@M[R26.)W15/\ 0SK?_!7[_@GS<_'?PE^TE8_LG_%#4?C6MAIW
MA;Q+\1_$%IX2DU;PKX1M+3489YO ^BK\1KW0=6\4/;7LWAZ+6I[?P3JYT+4+
MB&\UV[TVQB\.WW\R5%-2:_/\O\CYCQ#\%.!O$[,<'FO$M+.J>/PF2YEP[*OD
MF?YID<L?D>:RA5Q659FLNQ%&.89?]8A'$K!XA3P]2K>.)IUZ,G2?[':=_P %
M+/ MC_P5&US]N"[\&^.=<^%^I6<GAK2_"]\-$A\=:!X9/PUT_P #PW&F6!UR
M]\.6FHIJ%G<:K/ID'B&.RNH]5U0-J4=W>S3MWOC#]O[]A>\_;X^"O[6/@3X(
M?%_PKX?\+:O\2O&_QEOI[/P_J7C[XD^/?%7A#_A'O"=Q8:!J/Q3U+PMHND^&
M-0@@U)UT_P 0:3#(UYJ4L.C"]E-Q+^&E%',_+>_ST_R_%GEUOH^^'E3$8+$T
M8<08">"\-9>$ZAE_$&88/#XO@[^S,;E-/"9AA:4UAL=BL/ALPQ%;#XK$4INE
MCU0S",/KF%P]:E^WGPG_ ."LN@?#G]OK]HO]I74? /BGQ%\&OVA+:P\/ZIX6
M+Z)9^.=)T3PGINCZ/X'U@6CW]UH-YJMGI.D3:=J6@_\ "006#Q:W<RQ:W-)I
MMNMYSWQU_:O_ ."6#?"3XJ^&_P!F+]B;Q/H?Q0^).E7^F6'C+XI6NCW5AX&N
MM8E*WFO>$X+SXE?%!] OM-MI)I-#L?#%EX;M+2[-N(9;.WMEC?\ &2BCF?D]
M]TGOK_7_  UG#Z/_ (?8?.<JSO+I<4Y-7RS+.%,HKX+).+<]RG*L]P/!.'HX
M3AJEQ'EV!QE'#YPLNPE"EAHK$1Y*E&+A5A-3J<WZL?&S]N?X3>)_^"<'P&_8
MG^$V@?$C0/$G@O7]%\0?%;5?$6D^%K;PGXBF0>+_ !'X@L]!O]/\5:UK=Y;W
M?Q#\2V>MV3W^AZ',MGI%NDC1 O92K^U-^W7\*/B]^P=^RO\ LC_#;PO\0-%U
MOX.'P;JWQ$U7Q+IWAW3?#>K>(?#_ (&UK0M3/AF31O%6MZAJ=E?>(_$^MZI'
M<:SI6B7#0+:SR6L=U-+!!^4U%%W^%OEI_EK\SU,#X+<#8#$9/BJ6'S&I7R7C
MS/O$G#5*^8U:DL1Q=Q'3Q-/,,QQ[Y4\8HPQ=2.%IU';#J-*,7*,$G^\O[6?_
M  4L_8R_:I_9B\+>#?%/[.GQ'O/VA/ /PYO/"OPVUG5+[3K7X>_#SQ'XETOP
MQI'BG7-,U+0_'=G?>(;>&/PY97FC0:_\/WW7.F6$?D:4+B\F'HO@/_@I7_P2
MZ^$/B;3_ (Z?"C]B;XC^#/V@]&\'W/A_3(O#T_A[POX!$EYI4MC>6LW]C?$(
MZ!B_,LEK>^*3\(Y]?FMW-T]N\Z);C^=6BGS.]]+Z=%T_K_(^3_XEE\-XY!3X
M6HXSCS#<.T\9GN(>3X3C_B?"Y?5P7$D\-5SG(JV&H9A"E4R'&5L.\14R^4;2
MQ.*Q^)E4E7QN(J5/4/C9\5_$/QU^+GQ&^,7BN*TMM?\ B1XOUOQ;J-GI\8BL
M-.;5KV2XM]+L@%5WM-+M#!IUM-<>9=W$-LD][-<7<DT\GE]%%2?O> P.$RS
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M/_HT?]F/_P ,)\*__F4KT[X=?!/X,_!_^U?^%2?"/X8_"W^W?LG]M_\ "NO
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M&+^%_P#\RU'_  QE^Q]_T:C^S7_X8OX7_P#S+5]*44679?U_PR^X/]=>,O\
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M\U.W%O$]N=WMG^9I->SJ;WQ=VKV=HZW2?PIGAG_#&7['W_1J/[-?_AB_A?\
M_,M1_P ,9?L??]&H_LU_^&+^%_\ \RU?2E%39=E_7_#+[B_]=>,O^BMXF_\
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M_#+[@_UUXR_Z*WB;_P /V:__ #6?-?\ PQE^Q]_T:C^S7_X8OX7_ /S+4?\
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MUY8PWV@V-EJ&JWFOW=UJ-B-.TVUM]0M3YEO'?W<K.PALI%CD9?>J_/O]O_\
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M .>=1_PFGB3_ *)'\0O_  9?"G_YYU>A44<T?^?</OJ?_+ ]G+_G]5^ZC_\
M*OZN_*WGO_":>)/^B1_$+_P9?"G_ .>=1_PFGB3_ *)'\0O_  9?"G_YYU>A
M44<T?^?</OJ?_+ ]G+_G]5^ZC_\ *OZN_*WGO_":>)/^B1_$+_P9?"G_ .>=
M1_PFGB3_ *)'\0O_  9?"G_YYU>A44<T?^?</OJ?_+ ]G+_G]5^ZC_\ *OZN
M_*WGO_":>)/^B1_$+_P9?"G_ .>=1_PFGB3_ *)'\0O_  9?"G_YYU>A44<T
M?^?</OJ?_+ ]G+_G]5^ZC_\ *OZN_*WGO_":>)/^B1_$+_P9?"G_ .>=1_PF
MGB3_ *)'\0O_  9?"G_YYU>A44<T?^?</OJ?_+ ]G+_G]5^ZC_\ *OZN_*WG
MO_":>)/^B1_$+_P9?"G_ .>=1_PFGB3_ *)'\0O_  9?"G_YYU>A44<T?^?<
M/OJ?_+ ]G+_G]5^ZC_\ *OZN_*WGO_":>)/^B1_$+_P9?"G_ .>=1_PFGB3_
M *)'\0O_  9?"G_YYU>A44<T?^?</OJ?_+ ]G+_G]5^ZC_\ *OZN_*WGO_":
M>)/^B1_$+_P9?"G_ .>=1_PFGB3_ *)'\0O_  9?"G_YYU>A44<T?^?</OJ?
M_+ ]G+_G]5^ZC_\ *OZN_*WGO_":>)/^B1_$+_P9?"G_ .>=1_PFGB3_ *)'
M\0O_  9?"G_YYU>A44<T?^?</OJ?_+ ]G+_G]5^ZC_\ *OZN_*WGO_":>)/^
MB1_$+_P9?"G_ .>=1_PFGB3_ *)'\0O_  9?"G_YYU>A44<T?^?</OJ?_+ ]
MG+_G]5^ZC_\ *OZN_*WGO_":>)/^B1_$+_P9?"G_ .>=1_PFGB3_ *)'\0O_
M  9?"G_YYU>A44<T?^?</OJ?_+ ]G+_G]5^ZC_\ *OZN_*WGO_":>)/^B1_$
M+_P9?"G_ .>=1_PFGB3_ *)'\0O_  9?"G_YYU>A44<T?^?</OJ?_+ ]G+_G
M]5^ZC_\ *OZN_*WGO_":>)/^B1_$+_P9?"G_ .>=1_PFGB3_ *)'\0O_  9?
M"G_YYU>A44<T?^?</OJ?_+ ]G+_G]5^ZC_\ *OZN_*WGO_":>)/^B1_$+_P9
M?"G_ .>=1_PFGB3_ *)'\0O_  9?"G_YYU>A44<T?^?</OJ?_+ ]G+_G]5^Z
MC_\ *OZN_*WGO_":>)/^B1_$+_P9?"G_ .>=1_PFGB3_ *)'\0O_  9?"G_Y
MYU>A44<T?^?</OJ?_+ ]G+_G]5^ZC_\ *OZN_*WGO_":>)/^B1_$+_P9?"G_
M .>=1_PFGB3_ *)'\0O_  9?"G_YYU>A44<T?^?</OJ?_+ ]G+_G]5^ZC_\
M*OZN_*WGO_":>)/^B1_$+_P9?"G_ .>=1_PFGB3_ *)'\0O_  9?"G_YYU>A
M44<T?^?</OJ?_+ ]G+_G]5^ZC_\ *OZN_*WGO_":>)/^B1_$+_P9?"G_ .>=
M1_PFGB3_ *)'\0O_  9?"G_YYU>A44<T?^?</OJ?_+ ]G+_G]5^ZC_\ *OZN
M_*WGO_":>)/^B1_$+_P9?"G_ .>=1_PFGB3_ *)'\0O_  9?"G_YYU>A44<T
M?^?</OJ?_+ ]G+_G]5^ZC_\ *OZN_*WGO_":>)/^B1_$+_P9?"G_ .>=1_PF
MGB3_ *)'\0O_  9?"G_YYU>A44<T?^?</OJ?_+ ]G+_G]5^ZC_\ *OZN_*WG
MO_":>)/^B1_$+_P9?"G_ .>=1_PFGB3_ *)'\0O_  9?"G_YYU>A44<T?^?<
M/OJ?_+ ]G+_G]5^ZC_\ *OZN_*WGO_":>)/^B1_$+_P9?"G_ .>=1_PFGB3_
M *)'\0O_  9?"G_YYU>A44<T?^?</OJ?_+ ]G+_G]5^ZC_\ *OZN_*WGO_":
M>)/^B1_$+_P9?"G_ .>=1_PFGB3_ *)'\0O_  9?"G_YYU>A44<T?^?</OJ?
M_+ ]G+_G]5^ZC_\ *OZN_*WGO_":>)/^B1_$+_P9?"G_ .>=1_PFGB3_ *)'
M\0O_  9?"G_YYU>A44<T?^?</OJ?_+ ]G+_G]5^ZC_\ *OZN_*WGO_":>)/^
MB1_$+_P9?"G_ .>=1_PFGB3_ *)'\0O_  9?"G_YYU>A44<T?^?</OJ?_+ ]
MG+_G]5^ZC_\ *OZN_*WGO_":>)/^B1_$+_P9?"G_ .>=1_PFGB3_ *)'\0O_
M  9?"G_YYU>A44<T?^?</OJ?_+ ]G+_G]5^ZC_\ *OZN_*WGO_":>)/^B1_$
M+_P9?"G_ .>=1_PFGB3_ *)'\0O_  9?"G_YYU>A44<T?^?</OJ?_+ ]G+_G
M]5^ZC_\ *OZN_*WGO_":>)/^B1_$+_P9?"G_ .>=1_PFGB3_ *)'\0O_  9?
M"G_YYU>A44<T?^?</OJ?_+ ]G+_G]5^ZC_\ *OZN_*WGO_":>)/^B1_$+_P9
M?"G_ .>=1_PFGB3_ *)'\0O_  9?"G_YYU>A44<T?^?</OJ?_+ ]G+_G]5^Z
MC_\ *OZN_*WGO_":>)/^B1_$+_P9?"G_ .>=1_PFGB3_ *)'\0O_  9?"G_Y
MYU>A44<T?^?</OJ?_+ ]G+_G]5^ZC_\ *OZN_*WGO_":>)/^B1_$+_P9?"G_
M .>=5'4O&7B-K*93\)OB!&#Y>7?4OA65&)8SR$^);MST&%/)&<#)'J%9^J_\
M>$__ &R_]'1T<T?^?</OJ?\ RPTI4Y^UI?OZO\2&MJ/\R_Z<V_X?TMXK_P )
M=K__ $2[QU_X,/AG_P#/$H_X2[7_ /HEWCK_ ,&'PS_^>)7=44<T?^?</OJ?
M_+#V_95/^@FO_P" X;_YG_J[\K<+_P )=K__ $2[QU_X,/AG_P#/$H_X2[7_
M /HEWCK_ ,&'PS_^>)7=44<T?^?</OJ?_+ ]E4_Z":__ (#AO_F?^KORMPO_
M  EVO_\ 1+O'7_@P^&?_ ,\2C_A+M?\ ^B7>.O\ P8?#/_YXE=U11S1_Y]P^
M^I_\L#V53_H)K_\ @.&_^9_ZN_*W"_\ "7:__P!$N\=?^##X9_\ SQ*/^$NU
M_P#Z)=XZ_P#!A\,__GB5W5%'-'_GW#[ZG_RP/95/^@FO_P" X;_YG_J[\K<+
M_P )=K__ $2[QU_X,/AG_P#/$H_X2[7_ /HEWCK_ ,&'PS_^>)7=44<T?^?<
M/OJ?_+ ]E4_Z":__ (#AO_F?^KORMPO_  EVO_\ 1+O'7_@P^&?_ ,\2C_A+
MM?\ ^B7>.O\ P8?#/_YXE=U11S1_Y]P^^I_\L#V53_H)K_\ @.&_^9_ZN_*W
M"_\ "7:__P!$N\=?^##X9_\ SQ*/^$NU_P#Z)=XZ_P#!A\,__GB5W5%'-'_G
MW#[ZG_RP/95/^@FO_P" X;_YG_J[\K<+_P )=K__ $2[QU_X,/AG_P#/$H_X
M2[7_ /HEWCK_ ,&'PS_^>)7=44<T?^?</OJ?_+ ]E4_Z":__ (#AO_F?^KOR
MMPO_  EVO_\ 1+O'7_@P^&?_ ,\2C_A+M?\ ^B7>.O\ P8?#/_YXE=U11S1_
MY]P^^I_\L#V53_H)K_\ @.&_^9_ZN_*W"_\ "7:__P!$N\=?^##X9_\ SQ*/
M^$NU_P#Z)=XZ_P#!A\,__GB5W5%'-'_GW#[ZG_RP/95/^@FO_P" X;_YG_J[
M\K<+_P )=K__ $2[QU_X,/AG_P#/$KGK;Q;<?\)7K1A^%_CG^WO^$>\,C4O^
M)E\/B?[(&I>+?[$RC_$ 6*C[:?$&&MYI+MSD7D4,*6#S^MUCP-K!\0:FD\<0
M\/KH^A-IDH,7G/K#7OB(:['( YG$4=DGAUH3)&L1>6?R7D<3K'2G&TOW</A_
MFJ*_O1Z<_O=[>7-T(E2J<U/_ &BN_?>OL\-+E_=SUO[!<E_AYK._,X67.G'G
M?^$NU_\ Z)=XZ_\ !A\,_P#YXE'_  EVO_\ 1+O'7_@P^&?_ ,\2NZHJ>:/_
M #[A]]3_ .6%^RJ?]!-?_P !PW_S/_5WY6X7_A+M?_Z)=XZ_\&'PS_\ GB4?
M\)=K_P#T2[QU_P"##X9__/$KNJ*.:/\ S[A]]3_Y8'LJG_037_\  <-_\S_U
M=^5N%_X2[7_^B7>.O_!A\,__ )XE'_"7:_\ ]$N\=?\ @P^&?_SQ*[JBCFC_
M ,^X??4_^6![*I_T$U__  '#?_,_]7?E;A?^$NU__HEWCK_P8?#/_P">)1_P
MEVO_ /1+O'7_ (,/AG_\\2NZHHYH_P#/N'WU/_E@>RJ?]!-?_P !PW_S/_5W
MY6X7_A+M?_Z)=XZ_\&'PS_\ GB4?\)=K_P#T2[QU_P"##X9__/$KNJ*.:/\
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M  EVO_\ 1+O'7_@P^&?_ ,\2NZHHYH_\^X??4_\ E@>RJ?\ 037_ / <-_\
M,_\ 5WY6X7_A+M?_ .B7>.O_  8?#/\ ^>)1_P )=K__ $2[QU_X,/AG_P#/
M$KNJ*.:/_/N'WU/_ )8'LJG_ $$U_P#P'#?_ #/_ %=^5N%_X2[7_P#HEWCK
M_P &'PS_ /GB4?\ "7:__P!$N\=?^##X9_\ SQ*[JBCFC_S[A]]3_P"6![*I
M_P!!-?\ \!PW_P S_P!7?E;A?^$NU_\ Z)=XZ_\ !A\,_P#YXE'_  EVO_\
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M/AG_ //$H_X2[7_^B7>.O_!A\,__ )XE=U11S1_Y]P^^I_\ + ]E4_Z":_\
MX#AO_F?^KORMPO\ PEVO_P#1+O'7_@P^&?\ \\2C_A+M?_Z)=XZ_\&'PS_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M9?\ A-A?\_7^EJ?\2_9/_P!%#F?_ (2X7_/U_I:_W<?\->_LF_\ 1T'[._\
MX>OX:_\ S34?\->_LF_]'0?L[_\ AZ_AK_\ --7\(]%'_$!<H_Z'^9?^$V%_
MS]?Z6I_Q+]D__10YG_X2X7_/U_I:_P!W'_#7O[)O_1T'[.__ (>OX:__ #34
M?\->_LF_]'0?L[_^'K^&O_S35_"/11_Q 7*/^A_F7_A-A?\ /U_I:G_$OV3_
M /10YG_X2X7_ #]?Z6O]W'_#7O[)O_1T'[.__AZ_AK_\TU'_  U[^R;_ -'0
M?L[_ /AZ_AK_ /--7\(]%'_$!<H_Z'^9?^$V%_S]?Z6I_P 2_9/_ -%#F?\
MX2X7_/U_I:_W<?\ #7O[)O\ T=!^SO\ ^'K^&O\ \TU'_#7O[)O_ $=!^SO_
M .'K^&O_ ,TU?PCT4?\ $!<H_P"A_F7_ (387_/U_I:G_$OV3_\ 10YG_P"$
MN%_S]?Z6O]W'_#7O[)O_ $=!^SO_ .'K^&O_ ,TU'_#7O[)O_1T'[.__ (>O
MX:__ #35_"/11_Q 7*/^A_F7_A-A?\_7^EJ?\2_9/_T4.9_^$N%_S]?Z6O\
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M /#U_#7_ .::C_AKW]DW_HZ#]G?_ ,/7\-?_ )IJ_A'HH_X@+E'_ $/\R_\
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M HHHH **** "BBB@ HHHH *_._\ X*Z_\HU/VD/^OCX2?^KS^%5?HA7YW_\
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M-=UC3KWP5XK\316-P_@B?43H&M:#XG34=,O=0M]162SO=+EMQ\1_M]ZO;?\
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MR;Q#8ZMJNA)XIT^_L+J1S=WDG>_\%7?"G_!07]K3Q1\&OAQ^SM^S;??M"?\
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MA"G5J?S14445^GGZX%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MA\>^/[+6='76-$OK;6/"GA?3?%T\ \47]O>:)JNK^'_#FBVT%MJ,V@>$]/\
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M\1*K@Y4<73P*Q>!BJ*P^#Q*PM:$\7A\+2]O5E5_>!1117Z*?J(4444 %%%%
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M:_6Q$_BI;_&[VM_S[J;WUM>WPZWM]GF-^BBBI+"BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N-^(GA/0/'O
M@3Q?X&\66']J^%O&?AW5O"?B72_M5[8_VEH'B*SET?6;#[;IMS9ZC9_;-.O+
MFW^U6%W:WMOYGG6MS!.D<J]E6?JO_'A/_P!LO_1T=5"<Z<X5*<Y4ZE.49TZD
M).$X3@U*,X2BU*,HR2<9)III---&V&G.EB,/4ISE3J4ZU*=.I"3A.$X5(RC.
M$HM2C*,DI1E%IQ:3331^7_\ PZB_8$_Z(+_YE+XT?_/%H_X=1?L"?]$%_P#,
MI?&C_P">+7Z(45]#_KCQ=_T5/$?_ (?,S_\ FH^__P!<^,/^BLXE_P##[FG_
M ,U'YW_\.HOV!/\ H@O_ )E+XT?_ #Q:/^'47[ G_1!?_,I?&C_YXM?HA11_
MKCQ=_P!%3Q'_ .'S,_\ YJ#_ %SXP_Z*SB7_ ,/N:?\ S4?G?_PZB_8$_P"B
M"_\ F4OC1_\ /%H_X=1?L"?]$%_\RE\:/_GBU^B%%'^N/%W_ $5/$?\ X?,S
M_P#FH/\ 7/C#_HK.)?\ P^YI_P#-1^=__#J+]@3_ *(+_P"92^-'_P \6C_A
MU%^P)_T07_S*7QH_^>+7Z(44?ZX\7?\ 14\1_P#A\S/_ .:@_P!<^,/^BLXE
M_P##[FG_ ,U'YW_\.HOV!/\ H@O_ )E+XT?_ #Q:/^'47[ G_1!?_,I?&C_Y
MXM?HA11_KCQ=_P!%3Q'_ .'S,_\ YJ#_ %SXP_Z*SB7_ ,/N:?\ S4?G?_PZ
MB_8$_P"B"_\ F4OC1_\ /%H_X=1?L"?]$%_\RE\:/_GBU^B%%'^N/%W_ $5/
M$?\ X?,S_P#FH/\ 7/C#_HK.)?\ P^YI_P#-1^=__#J+]@3_ *(+_P"92^-'
M_P \6C_AU%^P)_T07_S*7QH_^>+7Z(44?ZX\7?\ 14\1_P#A\S/_ .:@_P!<
M^,/^BLXE_P##[FG_ ,U'YW_\.HOV!/\ H@O_ )E+XT?_ #Q:/^'47[ G_1!?
M_,I?&C_YXM?HA11_KCQ=_P!%3Q'_ .'S,_\ YJ#_ %SXP_Z*SB7_ ,/N:?\
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M )E+XT?_ #Q:/^'47[ G_1!?_,I?&C_YXM?HA11_KCQ=_P!%3Q'_ .'S,_\
MYJ#_ %SXP_Z*SB7_ ,/N:?\ S4?G?_PZB_8$_P"B"_\ F4OC1_\ /%H_X=1?
ML"?]$%_\RE\:/_GBU^B%%'^N/%W_ $5/$?\ X?,S_P#FH/\ 7/C#_HK.)?\
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M6?\ X,C_ /*PM6_Y^4O_  5+_P"7>O\ 2U\]_P"%G>&_^@;\0O\ PT?Q6_\
MF+H_X6=X;_Z!OQ"_\-'\5O\ YBZ]"HHO3_EG_P"#(_\ RL+5O^?E+_P5+_Y=
MZ_TM?/?^%G>&_P#H&_$+_P -'\5O_F+H_P"%G>&_^@;\0O\ PT?Q6_\ F+KT
M*BB]/^6?_@R/_P K"U;_ )^4O_!4O_EWK_2U\]_X6=X;_P"@;\0O_#1_%;_Y
MBZ/^%G>&_P#H&_$+_P -'\5O_F+KT*BB]/\ EG_X,C_\K"U;_GY2_P#!4O\
MY=Z_TM?/?^%G>&_^@;\0O_#1_%;_ .8NC_A9WAO_ *!OQ"_\-'\5O_F+KT*B
MB]/^6?\ X,C_ /*PM6_Y^4O_  5+_P"7>O\ 2U\]_P"%G>&_^@;\0O\ PT?Q
M6_\ F+H_X6=X;_Z!OQ"_\-'\5O\ YBZ]"HHO3_EG_P"#(_\ RL+5O^?E+_P5
M+_Y=Z_TM?/?^%G>&_P#H&_$+_P -'\5O_F+H_P"%G>&_^@;\0O\ PT?Q6_\
MF+KT*BB]/^6?_@R/_P K"U;_ )^4O_!4O_EWK_2U\]_X6=X;_P"@;\0O_#1_
M%;_YBZ/^%G>&_P#H&_$+_P -'\5O_F+KT*BB]/\ EG_X,C_\K"U;_GY2_P#!
M4O\ Y=Z_TM?/?^%G>&_^@;\0O_#1_%;_ .8NC_A9WAO_ *!OQ"_\-'\5O_F+
MKT*BB]/^6?\ X,C_ /*PM6_Y^4O_  5+_P"7>O\ 2U\]_P"%G>&_^@;\0O\
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MO^?E+_P5+_Y=Z_TM?/?^%G>&_P#H&_$+_P -'\5O_F+H_P"%G>&_^@;\0O\
MPT?Q6_\ F+KT*BB]/^6?_@R/_P K"U;_ )^4O_!4O_EWK_2U\]_X6=X;_P"@
M;\0O_#1_%;_YBZ/^%G>&_P#H&_$+_P -'\5O_F+KT*BB]/\ EG_X,C_\K"U;
M_GY2_P#!4O\ Y=Z_TM?/?^%G>&_^@;\0O_#1_%;_ .8NC_A9WAO_ *!OQ"_\
M-'\5O_F+KT*BB]/^6?\ X,C_ /*PM6_Y^4O_  5+_P"7>O\ 2U\]_P"%G>&_
M^@;\0O\ PT?Q6_\ F+H_X6=X;_Z!OQ"_\-'\5O\ YBZ]"HHO3_EG_P"#(_\
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M\]_X6=X;_P"@;\0O_#1_%;_YBZ/^%G>&_P#H&_$+_P -'\5O_F+KT*BB]/\
MEG_X,C_\K"U;_GY2_P#!4O\ Y=Z_TM?/?^%G>&_^@;\0O_#1_%;_ .8NC_A9
MWAO_ *!OQ"_\-'\5O_F+KT*BB]/^6?\ X,C_ /*PM6_Y^4O_  5+_P"7>O\
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M_P"7>O\ 2U\]_P"%G>&_^@;\0O\ PT?Q6_\ F+H_X6=X;_Z!OQ"_\-'\5O\
MYBZ]"HHO3_EG_P"#(_\ RL+5O^?E+_P5+_Y=Z_TM?/?^%G>&_P#H&_$+_P -
M'\5O_F+H_P"%G>&_^@;\0O\ PT?Q6_\ F+KT*BB]/^6?_@R/_P K"U;_ )^4
MO_!4O_EWK_2U\]_X6=X;_P"@;\0O_#1_%;_YBZHZE\2_#CV4RC3?B "?+P7^
M$WQ4C7B6,\N_@U5'3C+#)P!DD"O4*S]5_P"/"?\ [9?^CHZ+T_Y9_P#@R/\
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M8F@?] _QU_X:[XF?_,C7=447I_RS_P#!D?\ Y6'+B?\ G[0_\)ZG_P T^O\
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MY9_^#(__ "L.7$_\_:'_ (3U/_FGU_I:\+_PL30/^@?XZ_\ #7?$S_YD:/\
MA8F@?] _QU_X:[XF?_,C7=447I_RS_\ !D?_ )6'+B?^?M#_ ,)ZG_S3Z_TM
M>%_X6)H'_0/\=?\ AKOB9_\ ,C1_PL30/^@?XZ_\-=\3/_F1KNJ*+T_Y9_\
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M&1_^5ARXG_G[0_\ ">I_\T^O]+7A?^%B:!_T#_'7_AKOB9_\R-'_  L30/\
MH'^.O_#7?$S_ .9&NZHHO3_EG_X,C_\ *PY<3_S]H?\ A/4_^:?7^EKPO_"Q
M- _Z!_CK_P -=\3/_F1H_P"%B:!_T#_'7_AKOB9_\R-=U11>G_+/_P &1_\
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M[_&7_P .?XW_ /EY7C5%']G9?_T 8+_PEH?_ "OR7W!_9>6?]"[ ?^$F'_\
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MI_\ 15/_ "Q_B/\ _,A2_P!7.(?^A%G/_AKQW_R@O_5SB'_H19S_ .&O'?\
MR@^NJ*^1?^&[OV4_^BJ?^6/\1_\ YD*/^&[OV4_^BJ?^6/\ $?\ ^9"C_5SB
M'_H19S_X:\=_\H#_ %<XA_Z$6<_^&O'?_*#ZZHK)T+7=&\3Z-IOB'P]J5GK&
MB:Q9PW^F:G83+<6E[:7"AXIH94)!!!PRG#QN&CD5)$91K5Y$HRA*4)QE"<9.
M,HR3C*,HNTHRB[-233332::L]3R)1E"4H3C*$XR<91DG&491=I1E%V:DFFFF
MDTU9ZA1114DA1110 4444 %%%% !1110 4444 %%%% !1110!C:HNKM?>'#I
ML\,-DFM3MX@CD$.^ZT@^'M>2&"W\V*1Q,NO/HETQMW@F\BVG#2FW,\$VS7+Z
M_'I;ZMX(;4+BXANX?%%W)H<<*!H[O5#X+\7PS6]VQC?R[==%EU>[5PT)-W;6
ML?F$2&*7J*I[1_P]K?:EU^UZ_P#;OV3.#]ZKK>U1+X^:W[JD[*-OW>]^36[;
MJ7]^R****DT"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
ML:!=7'B'5'FGA;06T705TVU40^?#JZ7WB,ZW/(5B%QY-S9/X?C@$L\D(>UN/
M(BA<W#S[-<O:1Z6/&FOS0W%PVM/X7\(1ZA:,@%I#I<6K>-VTBXAD\L%KBYNY
MM<CND,KB..TM&$<7F%IJ6T_*/:_VH]?L^O\ V[U(F_>I:[S:^+EO^[J.S7V]
MK\NEFE/[%CJ****DL**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M5'S5:LD_98:A%I5,16DEI3IIK1>].;C3@G.<4_(_V_?VS?[:DU;X$?"G5O\
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MS\/:(GB#Q'J.D:[>IX:T'3V73]_]H7VK:-I>HR74$NKZ1;3VFGZ1?3I/J=N
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M(_"GPZT"?5KQ?)DU/49=]OHF@6<SLBW^NZH8WAL+7Y)#$A$EW>-%)#I]K=W
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M2J1OQX+BK(,=@,/F,,UP5##8FK4P])XO%8?#5/;TVN:A*%6JG&OR3IU?8O\
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MIJ>(;>PUJUL-1L)8K&%8XKPP7,5I<)<?O)^QGXH@\:_LH_L]>+8-9\:^(?\
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M6W]"/[7?[.?[2_[0=W9^$_!OB?X6^$?@_HB6;:?X;NM>\5V6HZYJ%O$FV_\
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MT^M5HNZ<GJL/2DFIS3G-.G!QGU/@'P%X5^&7A+1O!'@O28-&\.Z%:K:V5I"
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MA<OI8FE3S&-2>,I9G*K44*^,53%7^K2E.&(Q%=SLTG559<D?-P&08VV%I8W
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M+5%T#Q)J5W_9*>//$E]XVT7Q?+J%IKT4<2V\BR%_W)_98_X)2>%_V>OV@/\
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MT\+AZ&&I*U/#T:=&"V]VG!03?FTKON[L****YC<**** "BBB@ HHHH ****
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MEAS?1?P$_:M_::^#%IX(_9X\/?!?1M4N=/O;DV?AO7O"GC32?'NJP^(M?O\
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M0_Z^/A)_ZO/X54I;/T?Y'Z-X.?\ )XO"+_LZ7A]_ZUF4GZH4444S\9"BBB@
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M&?\ H!SW_P )LO\ _GF?S0T5_2]_P[\_9$_Z))_Y?OQ-_P#FTH_X=^?LB?\
M1)/_ "_?B;_\VE'_ !%3A[_H#SG_ ,)\#_\ /$/^(P\,_P#0#GO_ (39?_\
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M_P#@T_>?^(M_]4__ .97_P#!I_(O17]=%%'_ !%O_JG_ /S*_P#X-#_B+?\
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MG33W;T=2HUS5)>]*R48Q****\8\4**** "BBB@ HHHH **** "BBB@ HHHH
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ME_\ +O7^EKY[_P +<^%/_13OA[_X6GAO_P"65'_"W/A3_P!%.^'O_A:>&_\
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M5%%Z?\L__!D?_E86K?\ /RE_X*E_\N]?Z6OGO_"W/A3_ -%.^'O_ (6GAO\
M^65'_"W/A3_T4[X>_P#A:>&__EE7H5%%Z?\ +/\ \&1_^5A:M_S\I?\ @J7_
M ,N]?Z6OGO\ PMSX4_\ 13OA[_X6GAO_ .65'_"W/A3_ -%.^'O_ (6GAO\
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M"_\ "T?AG_T43P+_ .%=H'_RPH_X6C\,_P#HHG@7_P *[0/_ )85W5%%Z?\
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M^%H_#/\ Z*)X%_\ "NT#_P"6%'_"T?AG_P!%$\"_^%=H'_RPKNJ*+T_Y9_\
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MQ_G2^U);^S][U7IT,X+$\U7]]1=JB7\*<K?NJ3MRK$_N]V^1W;O[3::1PO\
MPM'X9_\ 11/ O_A7:!_\L*/^%H_#/_HHG@7_ ,*[0/\ Y85W5%3>G_+/_P &
M1_\ E9IRXG_G[0_\)ZG_ ,T^O]+7A?\ A:/PS_Z*)X%_\*[0/_EA1_PM'X9_
M]%$\"_\ A7:!_P#+"NZHHO3_ )9_^#(__*PY<3_S]H?^$]3_ .:?7^EKPO\
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M8<N)_P"?M#_PGJ?_ #3Z_P!+7A?^%H_#/_HHG@7_ ,*[0/\ Y84?\+1^&?\
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M_P#"NT#_ .6%=U11>G_+/_P9'_Y6'+B?^?M#_P )ZG_S3Z_TM>%_X6C\,_\
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M%% !1110 4444 %%%% !1110 4444 %9^J_\>$__ &R_]'1UH5GZK_QX3_\
M;+_T='0:4?XM+_KY#_TI''T444'N!1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !7/6TC'Q7K41T<0(GA[PS(OB#R74ZFTNI>+5?1S<&(1R
MC0Q"EZ(5GD> ^(B\D4*W$;S]#6%;QWP\3:O+)J,$NFOH7AV.TTE9=US8WT6H
M>*&U#49H-@\N#5()M,MK>7S&\Z31[I-D?V?=)2VG_A\_YH]OUT^=B)_%2W^-
MWLD_^7=3>^J5^L=;V7PN1NT445)84444 %%%% !1110 4444 %%%% !1110
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MX3=GT>I\*_\ #S?X"_\ 0I?%W_P0^#?_ )OJ/^'F_P !?^A2^+O_ ((?!O\
M\WU?A=10?Z)_\2X^&?\ T"YQ_P"':K_\K/W1_P"'F_P%_P"A2^+O_@A\&_\
MS?4?\/-_@+_T*7Q=_P#!#X-_^;ZOPNHH#_B7'PS_ .@7./\ P[5?_E9^Z/\
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M?!O_ ,WU?A=10'_$N/AG_P! N<?^':K_ /*S]T?^'F_P%_Z%+XN_^"'P;_\
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M*U/6-8M+9_$&GR+XH\.Q:;9VMTTEQI&G[X8)[RW'P7^T9_R<)\=_^RR_$_\
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M1OTM+?Q!I\VIZ%KEI<:U++K-K%<+$VG:EIVIRSSVM]+9JI@9KB)>]^'>F_\
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M5XZ_9D^%>L^,M?\  7PS^$FJ?V#J_P 0-0T35?%UW_PF?[/GPZ^(&J?VO?\
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M/5OC1:$-#=6DKV>L:'JD P6BDEL[^U=E)EMY6#]%_P '-6CZ1X?OO^";VO\
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M.C."K5U-^TMR-\KJ1:;@KV/P0_9(^#?_  5Q_P""P7@[Q-^V!XE_X*,_$?\
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M4==LM"TZ_P!2CT74=8TB^N[2RO;FVCDM[.[EA_%?XM_M>_&3]EG]E+_@B_\
MLY:/HOP(^%GQ4^(?P>TC7T_:=_:<\ :'XQ7]GGPQXGU_1M(TB[\//XLT?5;?
MP/%;^')](U;QKJ5QIMU);Z/I?A^P-O9K:2W4/S3\!_%WQ#\4?\%^_P!DW5/B
M3^UU\)?VTO&L%VFDZM\<?@;H'@_PYX&O(T^'?Q+0>%[>;X?^'_#?ACQ#>Z59
MW1&HZ]I]O?)?1:E'I\VIW7V$PP887A++WEF-J8BE5=:CALXQ6'Q<,;4?UB.6
MXBO2IM86G@)X:G0JQI1C-U<?]8<I2G2I<CBXZU^(\:L?A(4ITU2JU\LP];#2
MPM->QECJ%"I43Q$\9'$5*M-U7**IX/V*BE&=3F3O]1?LZ_\ !R9<-^VQ\;-5
M^--_\;O&'[(7CQDT7]FOX4^'OA1\![3QWX!UO4O$?AN#2;GQAJ=GXC\-:E=V
MJ:2NO6]Z)OB+XY?[5>VK06DI1);6?XJ_MB_!O]AO_@XM_;8^._QWUC7]/\#:
M7\"/ OA^VT_PUI%QK_B#Q%XAU?X _LT2:/X=T33$FM+)[Z[-M?74<VK:CI6D
M6L=O<W%[J5JHW-Z)^QK\>?@O^SU_P7T_X*=ZE\=/B?X+^$6F>*M"\6:3X;U/
MXAZ]8^%--US6/^$T^%^N6^BZ9J&L2VMG=ZWJ6E037FBZ-#,VIZ['&R:-:WTH
M\NNQ^'7@KPAXS_X.G_VG3XN\,Z'XF'A3X,^#_%WAM-=TRTU2+1?%%A^SA^SA
MIUAK^GPWD4T5OJUA9ZMJ,5C?(@N+-KIYK9XIPDB>C*EE6'Q>82I915PF#GP.
M\175"M&"QD*CR>HJ=*;PL:<*U*[AB,4HUI5JE3VTZ<)I1?"JF85L-@HSS*GB
M<3#BU4*3JTI2>%G!9E#GJ1^L2G*E.RG1P[E2C3A'V<9RB^9?I-\$/^"['[%G
M[07P4_:"^,WP]T/XY2W'[-/@-_B?\1?A+JO@OPG9_%:X^'\&I1Z9?^*O"]E;
M_$&]\#:WI>D22I<ZTQ\>6D^D6<D$NHP6[W=G%<?5WPJ_X*+?LZ_%W]A_6?V_
M_#]QXMTKX(>'/!_Q"\8>(-+\1:9HMI\0M&'PUN]9L-<\-WN@Z=XCU71O^$IO
M[K1Q%X>TVW\2SVVL?VOH;PWZ1ZE&Z?SR_LK^!O"FH_\ !Q[^W_\ "]]$L;3P
M#X^^#'Q<\+^+_"VF0IIFCZ[H7C/PW\'+[Q1IU_8V2PV]Q!K6HWEQJE\DD;+/
MJCC4) UVJRC\>/&WQ:^+W['GP6_;L_X(S6D6M:KXF\??MA?#O1? SV@8C5_"
MC:E<C6V@N+F.VEM!\1D\)_ *[TJ"W@LSJ.EZUX@2\5+>>>";@7"65XZLL/@?
M;T*LZ>19LX5L1&HZ>49BN3'TU+D@IRP4^6LJS2;A-0:>YV_ZR9AA*3K8OV-6
M$9YOEO-2HN"GF6!?/@YM<TG&.*A>E[)/2<7)-7L?WS?L7_M=> /VY?@!X7_:
M0^%OA/XD>$/ ?C'4_$VFZ!8_%+0]#T'Q)?)X5UV]\-ZCJ<-KX<\3>+]'GTF7
M6--U"SM+NUURX,DUE=0SQ6\\$D*_55> _LK? C1?V8?V;O@C^S]H MFL?A)\
M-?"G@RXO+0S&#5];TO2X%\2^( ;A(Y3+XC\1OJNO7&Z&W7[1J,NRVMH]L$?O
MU?G6,>&>+Q7U.,HX3ZQ6^JQG)RFL/[27L>>32;E[/E<G9:WT1]MA?;_5L/\
M6G&6)]C2^L.*48NMR1]KRQ6BCS\UEVL%%%%<QN%%%% !7PE^U9^PO_PU3XO\
M-^+O^&Q?V[?V</\ A'/#9\.?\(Q^RG^T)_PI_P (:]G4[W4_[>\2:+_PB/B+
M^U/$@^V_V>-4^TP?\2RTLK3R/W'F/]VT5OAL37PE55L//V=6*DE+EA.RDK-<
MLXRCJG;5:=#&O0I8FFZ5:'/3;BW'FE'6+NG>#C+1J^^O4_E-_P""7G['7Q,_
M;2^#/Q4^)7Q3_P""F'_!570]<\ _M.?%OX-Z19> _P!LOQ!IFC7?A?X?/X=.
MC7NJVWB/PQXJO+C7+O\ M:Y&JW%K?V>G3A(1:Z79;9/,\X_:M_;._:Z_9G_X
M*\?M:_&W0OB3\5_&O[)/[)_BC]D+2OC?^SY%XM\2ZGX T7X-_'KX&^$[#Q5X
MZT+P#)>2^&[#6O#GCBYM==M=2L+*SU&Y\4:_9?;[IM'NM99/TH_X( _\FK?M
M&?\ 9^O[2W_H7@FN(^ GP\\'_%O_ (+$?\%MOA=\0-%M/$?@?XA?!;]D/P=X
MLT.]C62VU/0?$/[/'A?3-3M'#*VQY+6YD\F= );:<1W$+)-$CK^A3QT(9UQ)
M]=H4L5@L!ETXQPKHT8J%#$9GDM#$JBXPCR5I4*E14JMW*E-J46M;_%QPDI95
MD/U6K4P^*Q>-IREB%4J2<JU#+LSK4'54IR4J2JP@ZE.RC.*<6MK>K_\ !4'X
M\^,-'\2_\$C]?^"/Q8\6>'_!7QO_ ."AG[-.DZ[?_#[Q=KGA_1_BA\*O&U[8
M79T+Q$NC7MC'XH\%>)M(U"*>ZT+6$N](U&WGB:ZLI"J;?C#_ (+5_%#]M?P_
M^VW^R]X._8\^+WQ,\(^(M!_9X^+?QY3X8^%/&'B+2?!WQ2O_ (.ZG>>-];T'
MQ?X-TO4;;2?'4FJ^#?"VK:5IFB:Q9:@VH7<D&D620R:E(S?G7XJ\1_$/]GG]
MH/\ 8#_X)8?&:]U/6?$'[(__  5B_9B\:?L^^,[^W79X^_95^(_C9;SP=<+>
MPH4GO?!VLW,FDZBLTNW3GUB#PEIP>'P?=16G[A_M)?\ *>K_ ()Q?]FQ?M+?
M^H]XWITL)2RBMELE2P^-IT,HXCQU"I4I1G2QV'5.OB,'5J)Q]Y5*#IJ2U=)N
M=--2@PJ8FIF5+')SKX6=7-,CPM:$*DHU,)6=2A0Q5.#35G3K*=I*RJ)1G9J2
M#]LG]N%_CU_P0\^*7[9?[.OC?Q1\-_$?B7X7^"=4L]:\#^*-3\->-/AQXT3X
MI^"_#/CKPQ;>(O#]]9ZQI6IZ)J9UWP_+=VEW;2:AICK=PLUAJ432\Y^W'\:?
MC#X2\&?\$0+OPK\5/B)X9NOB[^V1^QIX9^*UQX>\9^(=%G^)?AOQ5I'AYO$_
MAWQ[+INHVS^+M!\1/>7,FN:-KYO]-U665I;ZVGD"L/R8_P""HVB:G_P38T;]
MO/\ 96M;._A_9%_X*)^%;3XY?LZP6=K,^@?##]HOPQ\1_ .K?%WX=1$)'!IF
MGZ]X=TP:M8PP[K.TTR+X=:'I\7FP:U/%^C7_  4$_P"1$_X-_/\ L^/]A;_T
MS^%:FAEV%H1RFI0A"K@L=F.=XO!3J1C.;PD\EPLH4*LFGS5,%B(UL-43T6(H
MU)Q2YDW5;&XBL\PA6G*GB\)@\JP^*C"4HQ6)AFM52K4TFK0Q5&5.O!K7V-6,
M)-N+1^J7[1O[&WQ%_:3^)5OKFI_MK?M0?!'X0Z7X4TW3-)^$7[,/B?3/@MJE
MUXPAU#4[G5_&/BWXM6%CK7C7Q#:ZC8W6EV%EX4L1X=TS2FT5+EKG4%U+4[:Y
M^"O^"07QC^..J_'W_@H!^S%XH^.7C;]JOX!?LQ_$CPEX=^#'[0GQ%U>V\6>,
M[VYUFVUL^(O FO?$*UB2/QYJ.@KIUD+_ %)WDEM=1M[V\5+/3M?TS3K/]"OV
MFOV5/V,?VZ]6LOAI\?;#3?B;XF^#MOJMQ_PAGAWXT>//!7B7P7;_ !$T_0Y+
MFY\4>'?A=X_\+:A+;Z]IVEZ)<:6/&5A?69M0)M+C2#4KPW?Y5?\ !,2*^_9@
M_P""EG[8O_!.;X+_ ! UKXC_ +&_PG^$FA_%?PS8Z_?V/B:_^"/Q8US6? EK
MJOPO_P"$OLK>&:[-_!XD\4W$NF:I))?:?%X4LM/N$_M?2]>O+_Q,'.&)R+-,
M/*?M<3AL#0Q$</7P&'PU#"T:>-PZ>*PN-I.=:OBJM*I"#C6IX558UZMZN(E&
MFI^KBHRH9OE]=+V="OBZM"5:EC*]>KB*D\+5MAZ^%J*-*CAZ=2$IITIU_9RH
MTVJ=%2FX_P!%]%%%?)'T85XE^TM_R;O\=?\ LD7Q$_\ 43U:O;:\2_:6_P"3
M=_CK_P!DB^(G_J)ZM0>YPQ_R4O#W_8\RG_U/PY_,/\)OAUJ?Q:^)'@WX;Z1=
M0V-[XNUNUTH7\Z>=#IUJV^?4-1>#S8#<C3]/@NKP6J31271@%O'(CRJP_1[Q
MO_P3[^''B;0O%%I^S+\3-2\=_$;X<^*(O"_CSPMXIU708;:&_&([^UM;FWT3
M0ETVZL)3*Y>XN=5L+B2PU;28[U=7TZXMU_+/1-=UOPUJMEKOAS6-5\/ZWILI
MFT[6=$U"[TK5;"9HWB::RU"PF@N[64Q221F2":-S&[H3M9@=[1?B/\0_#>M:
MKXD\.^//&>@^(M=DN9M;U_1?%&N:7K6L37EP]W>2ZKJEC?07VH275U))<W+W
M<\S3W$CS2EY&9B'^HO%>0\:YGF6%Q_#7%U/(:.786E+#Y96P$,9@,RS&6-YL
M5_;4?<Q%; 3RZ,</AZ>$Q&&KX?$RGB(U&[(^Y?%WP8_9%^!O[16K^"?B7XO\
M9Z[X#\+?#G3M4O\ 28YY-1U[5_B3J5VK_P#".?;?">BZ/'IVF6_AZ6'5A'>7
M.E7"W,UK%-JSQO) WT!K?[./[(?Q<_9:\=_&WX,>#?%7@&Z\,>&O&6MZ=<:Q
MKNOW&HMJ7@G3[G4KC2M4TW5O%'BK1I;75%M5MEGTVZ\Q/M<;Q3QSPR6P^(_V
M<OV6/'O[2>N7OBK6=1G\._#FRU"[OO&_Q+UZ<R27,R-]NU6'3)[^3.K:Y/YK
M3WVH7<HT_3A)+?:I=23B"QOO=/VJ/VH/ 6F?#VU_9;_9J3[#\,M#5=.\3>*K
M*;=%XI2&<WMUIFD7NYKF_P!.U#57DOO$.ON87\0W:RV]KYN@W$\NJA^39U@L
M^Q?$O"G#?#''/%V<\6Y/B,DJ<:8_#YI4PW"F595@8RGF$LVR["QC@ZF:9U6E
MS8;*\35QF+G3@X5I4<*H.<7[.GPF_9WT3]E_Q5^T'^T7X U[QC91^/5T#P_!
MH.MZWI^I3:3_ ,272D;3[+3_ !;X2T^Z9M=O-6-Y)?WQECMM+D-MEE\J?PS]
MH#QE^Q_XA\*Z19?L\?";QUX%\5Q>((;K6=9\6:IJ%W:W'AZ/3M1AETRUM[GX
MC>,X#<3ZE/IUTTWV&UECCLF2.[V32PR>V_ 3]JW]IKX,6G@C]GCP]\%]%U2Y
MT^^N39^&]>\*>--*\>ZK#XB\07VL7$EQ<2:[965C'Y^HSV]OJ]SX>%A86%O#
M+>K.EM/,_P!/_MC?#'PGXK_:M_90TG1M*T>S\7>+M<DN_'\=LD2/?>&?#NL>
M']2MKK4(X(U:[N%TVS\7VMK=W-O&]Y':0VDDZV]JHM0Q6=9ID/B5B*G%>*S^
MM@LUK\6<2\-5\IX_Q-;A^EP[P]ED\5AZ&:<)T5]6H8:OA,+4K1Q=2K.CB,=7
M]E&A-T*TX^.?'K]B?P_83_LX?";X/^"[B/XG>+](OM0^)?BR?6=?O;*SL-#L
M?#%GJWB+7+&_U*ZTK1[ ZKJM_=(NEVFGF6>"/2+""ZN[NSM3X#^U[X/_ &</
MA)%X=^#WPKTF[UOXH>%I;-OB;\29-;UJ6TN;F/39XI_#R:+/JEWH,>H75Y<P
M:IJ)TJSMDT+[';:.+J[NYM6ALOVFU'X@:-\1?B#^T!\#_">J_P#"*_%?PS\/
M=%M-/\6VR1)J,$7B/1+J_L9;*5]\TL?A;5-<T^ZOWMXU2!]>M4BG6^C<VW\Q
MOB#3-9T77M;T;Q'!<VOB'2=7U+3-=MKR037EOK-A>SVNJ074PDE$MS%?13QS
MR"60/*KL)'!W$(\%<UXHXNQ6%AQ+G^;X>7"N!PV<_P!DSS#&K%\2U.+UB,VP
M&;YI7E6?UG(<!E^(HX+*LHI2GAJ=2G3K8J--JEAG]K?L!_ 3P9\=?B?XHM?B
M-H3>(/!?A?P;-J%S9#5=8T</KNH:II]IHPDN]#O],OQ&MG'K=P46\2-I+:,2
MI(I('S1;^&/#_CCXXP>#/!Z/IWA7QA\5HO#'A9()I[V2P\/^(/%ZZ5HB0W%]
M)<W-V]KIUW:K'->37$\[()+B261W9OTO_P""?5A>>'/V:OVG_B+X9T^YU;QD
M]MJ^EZ3IME'-<WUW=>$O U[K.B6MI:PK)-)+=ZGXFF016L;W-V\4<4<<TL<$
M=?-__!/CX2^*/%W[1/A3Q6^@Z@OA/X>R:UK.N:Q<V-U%IT&J6VE7>GZ3I4=Y
M)"+5M9&LZA87?]G^:+I+.SO;KRPMLQ ?35.,<1@<_P#&[/L5FU:&6<'Y3E.6
M9-EM?'2AA8YE2R7%9ABJE+ U*DJ,,7CLRK8?!X?$1H\^)4(T_P!YR<D?=/BG
M^QY\*/$G[7G@CX#?#33IOA_X5@^'*>-?B!?6NMZUKNISQKJNJQR0:4/$U]K2
MVVIW%K'HUK#*TGV&V749=0DTVY-C]FU!GQ"T;_@FQX.U_P <_"G6/!_Q'\.^
M+/"$.J:9+XQ6]\;7,%SXAL8)D%GIR/KVJPR7+W:QK#>7W@N#P_<%HKF*ZET]
M_.;QKXO_ !G^)^A_M8_$W]HSX4V.LZCH/A7Q3-X)7Q%)HFJZIX&N+3P_H>G>
M'+_1-4O;3RM/_L_4!9?VJELNH6EPWVJTUBW>&Z>&Y'U_\9+'X??M5_LB>)?V
MC/%'PW/PR^(OAK2;NYTK7+C;'<ZJNCW%H;*WM]4DBTQ_$OAGQ)%>C3M(.HVI
MFL=5N)H]*^T- LVHA\%B)\498O#:IQ3Q-QC+AS,\FX?R/$XOAWBB>$SO+..<
MXK0QM:7$.'KNMCLXHNG7AA>2K+$0PF'I22PD9RI4\1^']?LCXG^#_P"Q3^SK
M\*?@AJ/QZ^%GBCQ#XT^('AO3Y=6N?#OB3Q8]RNLP:3H]_P");V\T^+Q]X8L;
M;3--N]:M[1%TJREG93$%LY92[M^5?PK\)CQY\3?A[X*:&:>+Q7XU\,>'[F.#
M>)!9ZMK-G97L@>/#Q)#:3332SAE$$4;S,Z)&S#]Q/VN/C=^R?X,^)OA7P]\:
MOA;XL^(OB_P/H*:UX:&FPV5WX6TJW\0RLC6.H:7?>-=%TZ_N95T>TN98]3\.
MZM!#!]AD@D,FY(@^Z\7<WS6?$_ _#65?ZX5Z5?#\0YUG6"X(S*>59UBL+A<+
M1P>50^MQQN"A#!_VGB'/%RJU)1A3I\].E6JJ,#XF_;?_ &4/ OPMN?A7KOP2
MT[61:?$VYN=%MO!?VG4]>O)=4\K3KK29="%Z;S6)FU"/4#:W%E<W5U(EREI]
MF \^5$\,G_85_:NMVTE9?A!J>=:N!:V9C\1>"YEBE-O+<C^U'A\22+H<1CA=
M!<:TVGVYN6BLQ*;N>""3]+OV8?C'-^UE^T#XN^+&MZ#;Z3H7P3\%?V5\,?".
M8-0N=,N_'%W<QZQXFGU P0RR>(+_ $SPX=)=;6..PL["[CLH$>9)[^_J_L,>
M._VA/BG\0?BW\8/BAXA\3VWPQDL+VST[PYJS7,7AFTUZ'5O,6W\+6%U''!96
MWA#2K#4M*UF>PA@FOKR[M3K,][J5M,T0?"T?$;Q)X,X:S#+,PJ\/XO-N!<HR
MS$\2XCBK%8_,,SQV:<4XO%8GA_(<OK9?BL.L9B\'E3H/'8RI/$1KUXSH1G"E
M3>.?Q?\ LQ?L(^+/BEXZ\3Z?\6=)\1>$_ O@Z[\0^&-<UCP[KWA ZB/'VB2:
M2K>';1Y3XB2Z@AAU*6>ZU6RTN^T@R6<M@FIQWH>-#P7\ ?C%\!OVMO#-MHGP
M>N_'CZ7JGC'Q9X!\*:SXT\#VEWXC\$:5+JNC:5KVK>(8+BZT31+^S6ZTW4"]
M_86$QU:.&.VTV"26*./ZE_8S^(7B:/X5?MC?'R_UC6KG2/[6\8^*M \*R7]W
M+I^CZ[!I7B+QQK=U9637+V%M>ZO+KVA6]W<V]M [_P!G*]S/.FP0<7_P3GU+
MQ5XF^(?QD^,/Q.\4>+/$^I_#SX;Z?X9_M'QEK6K:U?V>F:QJ>H>(Y[47NMW%
MU=V\5FOA:ZDBMED6&'^TKN;R@UPS,'7GG&/'%*?BUCLWQ&0X[(.'\ERKANKD
M$<-F].AB\VS[ 4*4Z.$J8;-J&*P]2&,S>EA,TKQQ,JDZ2IT\!5P\XK%OXW^+
M=A\7/VH/VEOB&=#^%UY;^.Y-6.CZUX,T*[L=:@\-3>#;&U\)WB:MXJACL-&F
MCBN=&,<VO7EQ;:?<W4L5O9W#0O8Q-Q'Q1_9@^/'P8T>#Q!\2/AYJ'A_0Y[J.
MR75H=3\/Z_I\-U,&,$-Y=>&]7UB&P><HRP?;FMUGD'E1%Y"%/ZV?LQ:EX(\&
M_LE^)?C=X]\6:SX U/XU>,?&&N^-/B+X/T.?5?$>D7<WB_6-$M(=/6V\->,I
M;"Q@DT^^GM9K[2+NWTVXUJ[N4FM[NX@N1Y!^T5\<?!FM? 7PO^SK\+[KXO?$
MEOBYK^@Z=HOQ5^+L'BJ./5%LO%F@ZS)-9^(O%.D:?J7B6Z.I'1K62VTG28M,
MTG2]5#QRQ$66FW >KDWB3Q11XER[@_AWA3!T^$^&\YPG!>8XF6"SJ5+#8?(<
M)&CG^.PN?8C&1RRA2RBGAZDL+EV)>9YIC<-0]M6J0G6@Y?!.C_LA?M'>((?!
M5SHOPPU+4;7XA>'CXK\*7=OK'AAK2\\/>1I-RFI:A=-KBV_AZ.>#7-,>UB\1
MR:3<WGVAUM89GMKM8,\_LK_'Q/B=:_!V;X>7T'Q"O=(D\06VBS:KX>2UET.$
M2^=JT>O_ -KGP[)8Q/!+;M-'JK@WJ'3T#7[+;-^JW[9OQA\=>$?B'\!OV9_A
M/XGU/P4_B-O!L>M:UX>;[%KGV'4_$<7A+PQIECJ"DFTMXGT[4;N_M(Q_IJM8
M6]P[6#W-M=Z?QUUW5_$?_!0?]F_P%H.LZMH2Z)X;;5M;N]#U.ZTRZU2R:ZU[
MQ=JOAK4WL9();O1-0T[P5IB7]A<RRVMY!?3QR6VT;I0PR[Q?X^Q>%R_,<5EO
M">#P&=<(\;\4X%*CG%3&9?@N&8U*F Q^9P>.C2J8;'+V5!X/"R5:KRRQBQ6%
MC6CA*7QC^V!^PT/@3X=TOQG\-H/%_B+P7I.FI+\1/$WBCQ!X-DATG4M1UG2=
M#T*VTG2;*TT#7)8[N^ORMQY6GZND*7-HSW4*07CCP>U_8I_:CO/#*^+H?A!K
M@T9]/_M15GU/PU::T;/R!<[O^$7NM;A\3B<PD,MD='^VLW[M;<R_)7T[^UI\
M6OBOJ7[7][X:T)/'GBWP5X&\2^!+NW^%NAW?B*YT'Q0W@?3O#OCS7?M'ANR2
M]TV\NXKF6XN;O4'TF[>QT]+*]G!A@B:OK3XH>-[KXX_"'QM^TE^SY\9_B?X#
MU/P#X1UG3/%?P_UF&5/"<B:1IKZQKNE7OA;4K6[T>#Q<FGWICA\5:+<:K")8
MH+)+F&6*2XM RP/'OB7P[POX?QS*OP]F-3B:GA\7B.)<UP><XRC@:6>?4ZN0
MY7G4,JQ:Q&$QV+KXC&X>.;+#?V="%##X6&#G5PV*KS_ FBBB@_J0*^E?V:OV
ME?%?[/'BL7MD9]8\%:Q/"GBWPD\VV&^A7$8U/3#(?*LM>LHL_9KG"Q7<2_8;
M[= T<EO\U5+!!/=3PVUM#+<7-Q+'!;V\$;S3SSS.(XH88HPTDLLLC*D<:*SN
M[!5!8@4'EYUD^5Y_E>,RC.<)1QN6XVC*EB</77NN'Q*I&::E2JTI*-6C7IRA
M5HU81JTYQG%27]6/@#Q_X4^)_A32?&G@O5H-8T#6(!+;W$1VS6\RX%Q87]N3
MYMEJ-E+F&\LY@LL,JGAD9';LJ^#_ -AG]G3QA\$_"6J:_P"-M7U*TUKQO%9W
M+^ EN,Z5X>@A&^WNM2@PRMXIGB8171@9$L+3;83FYN%;[+]X4'^7/&.69-DW
M$N;Y9P_FRSO*,)BYTL'F"C;VL$DY4W.*5/$/#U'+#O%T$L/B_9?6*$8TJD8H
MHHHH/F0HHHH **** "BBB@ HHHH **** "BBB@#G=:B$FI>$'.K_ -F^3XBN
M919;W7_A(2?"?BB'^R-J2QK)Y E.O[)$G0?V'Y@B62..>'HJYC7Y=.CU7P2E
M[8RW=S/XGNXM(N(YI(TTO45\&>+IY;Z=$=%N(I-)AU331#,LL:S:C#.$$L,4
MD?3U3VAO\+M>W\\MK;J_?6]ULD9PMS5K6_B*]G)N_L:6ZEHG:VD+QM9OWW)(
MHHHJ30**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *YVVB
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M HHHH **** "BBB@ HHHH *:[I$CR2.L<<:L\DCL$1$0%G=V8A555!9F8@*
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MM4:M&>,P]&G[M"555?:5%'_E[3I3ING[-(^\?BCX_P#V =5\ ^)M/^%?P/\
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M^(G[)?@NX\7:M>SZEJU_X1\3?$GX966K:E=S"YO-1U30/ACXU\'^'M2U"]N
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M,FTEHAK+<"\-AL)5PN'Q%'"4Z=*C'$4:5905.$8*252$DI-17-))-O4_#_\
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M+2PFM;.VEE>;[.\C.6Y?_AG[X]?]$2^+O_AMO&7_ ,I:/^&?OCU_T1+XN_\
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M8]3TK59GU"'^V9=;OHKVYT/25NXGUQ5:"R2*'R!+<&;S'_AG[X]?]$2^+O\
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MN4YSDW*4I-RE)MMML****" HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH *S]5_P"/"?\ [9?^CHZT*S]5_P"/"?\ [9?^CHZ#2C_%I?\ 7R'_
M *4CCZ***#W HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MD;C$L1_L0PO>[4GD=?\ A( 9(H5:)Y^BK#MTU$>)-6DEO[:327T/P\EEI:R
MW=GJ,=_XF;5+^>+R5*6VI6TNCV]K(;B42RZ5>*(8/)+W%+:?^'NU]J/;?T>G
M7=(B=^:EO\;OI%Z>SJ;MZQ5[:Q]Z]HOW7(W****DL**** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ K\U?VVO%WBCXT^-? ?\ P3]^$&KWFF>+_C?9
M3>(/CMXPT=[>6X^%7[.&FW45MXKO+A)"1%K'CUI#X8T*WFQ%=QRW-A=B"/6[
M"ZK['^/_ ,;_  9^SE\(/'/QD\>W(A\/^"M&GU#[&DT4-[KNK28MM$\-Z49?
MD?5?$&JRVFEV(8&..:Y%Q<%+6&>5/%_^"?WP(\9>#_"GC#]HOXYPM+^TG^U#
MJ5KX\\?I=QHTW@'PDL)3X>_";2F=?/L]-\(^'7M%OK)BDT>J2G3KPW1T2SN2
MGKI]_IV^>MOGV/TW@J%#A3*L?XH9G1I57DN*_LO@; XF$:E+-^.I488FAC)T
M)J4<1EO!N$JTN(,Q4XSH5,RJ<.Y7B83P^;U>3[>\!^!O"WPR\%>%?A[X(TBU
MT'PCX+T'3/#?AW2+-%2"QTK2;6.TM(L@ RS-'&)+FYDW3W=R\US</)/-([=;
M113/QC$8BOB\17Q6*K5<1B<36JXC$8BO.56M7KUIRJ5JU:K-RG4JU:DI3J3F
MW*<Y.4FVVPHHHH,0HHHH **** "BBB@ HHHH **** "BOA7XR?MS?\*=^)'B
M/X<?\,>?MU?%/_A'/[(_XKSX-_L^_P#"<?#?7?[7T'2]=_XISQ1_PEVE_P!J
M?V7_ &I_8VL?Z#!]BU[3M4T[][]D\Z3S'_AYE_UC\_X*<?\ B*7_ .'M*Z_K
MY?YH_1L#X2^(.98+!YC@N'_;8/'X7#XW"5O[5R2G[7#8JE"O0J^SJYE3JT_:
M4JD)\E6$*D;\LX1DFE^G%%?F/_P\R_ZQ^?\ !3C_ ,12_P#P]H_X>9?]8_/^
M"G'_ (BE_P#A[1==_P"M/\T=7_$&/$K_ *)O_P S&0?_ #T/TXHK\Q_^'F7_
M %C\_P""G'_B*7_X>T?\/,O^L?G_  4X_P#$4O\ \/:+KO\ UI_F@_X@QXE?
M]$W_ .9C(/\ YZ'Z<45^8_\ P\R_ZQ^?\%./_$4O_P /:/\ AYE_UC\_X*<?
M^(I?_A[1==_ZT_S0?\08\2O^B;_\S&0?_/0_3BBOS'_X>9?]8_/^"G'_ (BE
M_P#A[1_P\R_ZQ^?\%./_ !%+_P##VBZ[_P!:?YH/^(,>)7_1-_\ F8R#_P">
MA^G%%?F/_P /,O\ K'Y_P4X_\12__#VC_AYE_P!8_/\ @IQ_XBE_^'M%UW_K
M3_-!_P 08\2O^B;_ /,QD'_ST/TXHK\Q_P#AYE_UC\_X*<?^(I?_ (>T?\/,
MO^L?G_!3C_Q%+_\ #VBZ[_UI_F@_X@QXE?\ 1-_^9C(/_GH?IQ17YC_\/,O^
ML?G_  4X_P#$4O\ \/:/^'F7_6/S_@IQ_P"(I?\ X>T77?\ K3_-!_Q!CQ*_
MZ)O_ ,S&0?\ ST/TXHK\Q_\ AYE_UC\_X*<?^(I?_A[1_P /,O\ K'Y_P4X_
M\12__#VBZ[_UI_F@_P"(,>)7_1-_^9C(/_GH?IQ17YC_ /#S+_K'Y_P4X_\
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M)7_1-_\ F8R#_P">A^G%%?F/_P /,O\ K'Y_P4X_\12__#VC_AYE_P!8_/\
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M^9C(/_GH?IQ17YC_ /#S+_K'Y_P4X_\ $4O_ ,/:/^'F7_6/S_@IQ_XBE_\
MA[1==_ZT_P T'_$&/$K_ *)O_P S&0?_ #T/TXHK\Q_^'F7_ %C\_P""G'_B
M*7_X>T?\/,O^L?G_  4X_P#$4O\ \/:+KO\ UI_F@_X@QXE?]$W_ .9C(/\
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M4O\ \/:/^'F7_6/S_@IQ_P"(I?\ X>T77?\ K3_-!_Q!CQ*_Z)O_ ,S&0?\
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M&0?_ #T/TXHK\Q_^'F7_ %C\_P""G'_B*7_X>T?\/,O^L?G_  4X_P#$4O\
M\/:+KO\ UI_F@_X@QXE?]$W_ .9C(/\ YZ'Z<5GZK_QX3_\ ;+_T='7YK_\
M#S+_ *Q^?\%./_$4O_P]J.7_ (*6QSQM%+_P3Z_X*<,C8W+_ ,,ILN=K!ARO
MCX$8(!X(Z8/%%UW_ *T_S1</!KQ)C.$GPV[1G&3MG&07LFF[?\*JU/ORBOSW
M_P"'CUA_TCT_X*<?^(K3?_/!H_X>/6'_ $CT_P""G'_B*TW_ ,\&BZ[_ -:?
MYH]'_B$WB+_T3-3_ ,._#W_SW/T(HK\]_P#AX]8?](]/^"G'_B*TW_SP:/\
MAX]8?](]/^"G'_B*TW_SP:+KO_6G^:#_ (A-XB_]$S4_\._#W_SW/T(HK\]_
M^'CUA_TCT_X*<?\ B*TW_P \&C_AX]8?](]/^"G'_B*TW_SP:+KO_6G^:#_B
M$WB+_P!$S4_\._#W_P ]S]"**_/?_AX]8?\ 2/3_ (*<?^(K3?\ SP:/^'CU
MA_TCT_X*<?\ B*TW_P \&BZ[_P!:?YH/^(3>(O\ T3-3_P ._#W_ ,]S]"**
M_/?_ (>/6'_2/3_@IQ_XBM-_\\&C_AX]8?\ 2/3_ (*<?^(K3?\ SP:+KO\
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M_@IQ_P"(K3?_ #P:+KO_ %I_F@_XA-XB_P#1,U/_  [\/?\ SW/T(HK\]_\
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M:;_YX-%UW_K3_-!_Q";Q%_Z)FI_X=^'O_GN?H117Y[_\/'K#_I'I_P %./\
MQ%:;_P">#1_P\>L/^D>G_!3C_P 16F_^>#1==_ZT_P T'_$)O$7_ *)FI_X=
M^'O_ )[GZ$45^>__  \>L/\ I'I_P4X_\16F_P#G@T?\/'K#_I'I_P %./\
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M'11]2I?S5/OC_P#(!]=J_P M/[I?_)G>?VUIG_/S_P"0;C_XU1_;6F?\_/\
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MF_Y]-OT/6?[:TS_GY_\ (-Q_\:H_MK3/^?G_ ,@W'_QJN#HH^I4OYJGWQ_\
MD!_7:O\ +3^Z7_R9WG]M:9_S\_\ D&X_^-4?VUIG_/S_ .0;C_XU7!T4?4J7
M\U3[X_\ R ?7:O\ +3^Z7_R9WG]M:9_S\_\ D&X_^-4?VUIG_/S_ .0;C_XU
M7!T4?4J7\U3[X_\ R ?7:O\ +3^Z7_R9WG]M:9_S\_\ D&X_^-4?VUIG_/S_
M .0;C_XU7!T4?4J7\U3[X_\ R ?7:O\ +3^Z7_R9WG]M:9_S\_\ D&X_^-4?
MVUIG_/S_ .0;C_XU7!T4?4J7\U3[X_\ R ?7:O\ +3^Z7_R9WG]M:9_S\_\
MD&X_^-4?VUIG_/S_ .0;C_XU7!T4?4J7\U3[X_\ R ?7:O\ +3^Z7_R9WG]M
M:9_S\_\ D&X_^-4?VUIG_/S_ .0;C_XU7!T4?4J7\U3[X_\ R ?7:O\ +3^Z
M7_R9WG]M:9_S\_\ D&X_^-4?VUIG_/S_ .0;C_XU7!T4?4J7\U3[X_\ R ?7
M:O\ +3^Z7_R9WG]M:9_S\_\ D&X_^-4?VUIG_/S_ .0;C_XU7!T4?4J7\U3[
MX_\ R ?7:O\ +3^Z7_R9WG]M:9_S\_\ D&X_^-4?VUIG_/S_ .0;C_XU7!T4
M?4J7\U3[X_\ R ?7:O\ +3^Z7_R9WG]M:9_S\_\ D&X_^-4?VUIG_/S_ .0;
MC_XU7!T4?4J7\U3[X_\ R ?7:O\ +3^Z7_R9U5]XOT+3KK1K2XNI!-KNI2Z5
M8;+:X93=PZ/JNN.)F\L>7']AT:](?#9E$4>/WFY=+^VM,_Y^?_(-Q_\ &J\F
MU>2X34/"RPZ7#J$<NNW$=W=R0>:^AVX\,^(Y5U2WDP?LTTUW';:(T^1N@UB>
MVS_I&#NT?4J6GO5/_ H]W_<T_I]1+'5KR]VGH[+W9K[,7_/KJWJO3='>?VUI
MG_/S_P"0;C_XU1_;6F?\_/\ Y!N/_C5<'11]2I?S5/OC_P#(#^NU?Y:?W2_^
M3.\_MK3/^?G_ ,@W'_QJC^VM,_Y^?_(-Q_\ &JX.BCZE2_FJ??'_ .0#Z[5_
MEI_=+_Y,[S^VM,_Y^?\ R#<?_&J/[:TS_GY_\@W'_P :K@Z*/J5+^:I]\?\
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MC^VM,_Y^?_(-Q_\ &JX.BCZE2_FJ??'_ .0#Z[5_EI_=+_Y,[S^VM,_Y^?\
MR#<?_&J/[:TS_GY_\@W'_P :K@Z*/J5+^:I]\?\ Y /KM7^6G]TO_DSO/[:T
MS_GY_P#(-Q_\:H_MK3/^?G_R#<?_ !JN#HH^I4OYJGWQ_P#D ^NU?Y:?W2_^
M3.\_MK3/^?G_ ,@W'_QJLV+Q?H4VL7VAI=2?;M.TW2M5N ;:X$0M-9NM9M+(
MI)Y?S2&;0K_S4VCRU$+9;S,+RM85O)<'Q-J\3:7##:)H7AR2'6U@VSZA<2:A
MXI6YTN2YQ^]AT>.*TNX(,G[.^N7$F!]IR3ZE2U]ZI_X%'NO[FO\ 3Z">.K77
MNT]7K[LNS?\ /IM^AZS_ &UIG_/S_P"0;C_XU1_;6F?\_/\ Y!N/_C5<'11]
M2I?S5/OC_P#(#^NU?Y:?W2_^3.\_MK3/^?G_ ,@W'_QJC^VM,_Y^?_(-Q_\
M&JX.BCZE2_FJ??'_ .0#Z[5_EI_=+_Y,[S^VM,_Y^?\ R#<?_&J/[:TS_GY_
M\@W'_P :K@Z*/J5+^:I]\?\ Y /KM7^6G]TO_DSO/[:TS_GY_P#(-Q_\:H_M
MK3/^?G_R#<?_ !JN#HH^I4OYJGWQ_P#D ^NU?Y:?W2_^3.\_MK3/^?G_ ,@W
M'_QJC^VM,_Y^?_(-Q_\ &JX.BCZE2_FJ??'_ .0#Z[5_EI_=+_Y,[S^VM,_Y
M^?\ R#<?_&J/[:TS_GY_\@W'_P :K@Z*/J5+^:I]\?\ Y /KM7^6G]TO_DSO
M/[:TS_GY_P#(-Q_\:H_MK3/^?G_R#<?_ !JN#HH^I4OYJGWQ_P#D ^NU?Y:?
MW2_^3.\_MK3/^?G_ ,@W'_QJC^VM,_Y^?_(-Q_\ &JX.BCZE2_FJ??'_ .0#
MZ[5_EI_=+_Y,[S^VM,_Y^?\ R#<?_&J/[:TS_GY_\@W'_P :K@Z*/J5+^:I]
M\?\ Y /KM7^6G]TO_DSO/[:TS_GY_P#(-Q_\:H_MK3/^?G_R#<?_ !JN#HH^
MI4OYJGWQ_P#D ^NU?Y:?W2_^3.\_MK3/^?G_ ,@W'_QJOQZ_X+]W4%W_ ,$B
M/VMI+=_,17^ Z%MKIAA^TS\%V(PZJ>C*<@8YZY!K]2:_)_\ X+Q?\H?OVNO^
MOKX$_P#K2OP2KTLEPU.EG>1SBYM_VSE:]YQ:UQM'M%?F<69XFI5RK-H24$O[
M+S!^ZI)Z82KWD_R/VPHHHKYD^A"BBB@ HHHH ^._V@?C%^PW^S58S^(?VAO$
MOP$^'4EV7O1;>)],\,7'BS67N#//)<:;X6L=-U#Q=X@FF:*>1WTO2+^61U=F
MRYY_)N?_ (*<:9^TEXMU7X7_ /!-?_@GK#^T!XKTW3-)U?4/B#\7/#G@CX1_
M#;1-$UNYOK;2_%)TW5'M==UKP[?-92+92:AJO@F_O9(+^.SM;B2TB2\\W\/?
M\$P?VC?V*OBUXM^-OA?]GW]FK_@IE8:[XGNO%=Q??%J^UOPE^TKH41G:Y$/A
M2X^(VO>,?A&;JQ@FE-MJ4-E-XHOKJU@%H(6DM[1-7]GO_@H-\&_!'_!2/]I7
MXD?M3^&_'W[$TGQ:^"GP-\#^$_"/[0_A#6?"[2>(/AL=9A\116VOV&G7GAI?
M#RVVIZ;>Z+XAO[W2-.U6PNX)+<([+"?Z!ROAG(:& S/'9%#%^(V)P&3QS#"U
M/[5GAL)4QL<9EU&6#J<'95BH<5J%'#XG%8F6(QF+PV'J4\#*^&=-U'#\LQN<
MYG4Q.#PV92H<)4<5F#PM:'U&-7$1PSH8FI'$0X@QM&61\TZM&A15+#T*U6$L
M1&U524.;^@;X&Q?%&#X._#.'XV:?X*TGXM0^"] B^(.E?#F.YB\#:9XGCT^%
M-2T_PQ%=RSRQZ592C[-!&L\UNAB=;.62T$#GU6L7PYXD\.^,-!TCQ3X2U[1?
M%/ACQ!I]MJV@^(_#FJ6.MZ#K>EWL2S6>I:1J^F3W6GZEI]W"RS6UY9W$UM/$
MRR12.A!.U7X+BIRJXG$5)T88>=2O6G/#TZ<J5.A*=24I4:=*3<J<*3;A"G)N
M4(Q46VU<_3J,8PHTH1J2JQC2IQC5G)3G4C&*2J2FDE.4TN:4DDI-MI),****
MP-0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQ('BN;,+)*4986NOI^J_K3\KB>\?7S[/;O\ /2UWO8Z:BBBD,**** "BBB@
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MS^N#_B*;_P"K%?\ S9W_ /)ZH_XBF_\ JQ7_ ,V=_P#R>J_D?HH_X@)X3?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MK/R/_B*'"G_/['?^$4__ )+^K/RO_;-17\3/_$2/^W'_ -$J_91_\(;XO?\
MS]*/^(D?]N/_ *)5^RC_ .$-\7O_ )^E'_$OOB+_ - V4_\ ATI?_*P_XBAP
MI_S^QW_A%/\ ^2_JS\K_ -LU%?Q,_P#$2/\ MQ_]$J_91_\ "&^+W_S]*/\
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M_91_\(;XO?\ S]*/^(D?]N/_ *)5^RC_ .$-\7O_ )^E'_$OOB+_ - V4_\
MATI?_*P_XBAPI_S^QW_A%/\ ^2_JS\K_ -LU%?Q,_P#$2/\ MQ_]$J_91_\
M"&^+W_S]*/\ B)'_ &X_^B5?LH_^$-\7O_GZ4?\ $OOB+_T#93_X=*7_ ,K#
M_B*'"G_/['?^$4__ )+^K/RO_;-17\3/_$2/^W'_ -$J_91_\(;XO?\ S]*/
M^(D?]N/_ *)5^RC_ .$-\7O_ )^E'_$OOB+_ - V4_\ ATI?_*P_XBAPI_S^
MQW_A%/\ ^2_JS\K_ -LU8\#:L?$&II-;PKH:Z/H3:==KY7VB?5GO?$0UFWE
ME:?R;6S3098/,@CBWW=SY,LSB=+?^+'_ (B1_P!N/_HE7[*/_A#?%[_Y^E9T
M7_!QI^V_%J]]K ^&7[+;37^FZ5IDEJ_@OXN&QABTFZUBZBN+> ?' /'=W+ZU
M-'>2M*ZS0VE@BQQF!VE?_$OOB+K_ +-E.W_0TI=U_<T$_%#A6\?WV.WU_P!C
MFM+/?WM5=[=U?IK_ &[T5_$S_P 1(_[<?_1*OV4?_"&^+W_S]*/^(D?]N/\
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M *)5^RC_ .$-\7O_ )^E'_$OOB+_ - V4_\ ATI?_*P_XBAPI_S^QW_A%/\
M^2_JS\K_ -LU%?Q,_P#$2/\ MQ_]$J_91_\ "&^+W_S]*/\ B)'_ &X_^B5?
MLH_^$-\7O_GZ4?\ $OOB+_T#93_X=*7_ ,K#_B*'"G_/['?^$4__ )+^K/RO
M_;-17\3/_$2/^W'_ -$J_91_\(;XO?\ S]*/^(D?]N/_ *)5^RC_ .$-\7O_
M )^E'_$OOB+_ - V4_\ ATI?_*P_XBAPI_S^QW_A%/\ ^2_JS\K_ -LU%?Q,
M_P#$2/\ MQ_]$J_91_\ "&^+W_S]*/\ B)'_ &X_^B5?LH_^$-\7O_GZ4?\
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M_P##I2_^5C_XBAPI_P _L=_X13_^2_JS\K_VS45_$S_Q$C_MQ_\ 1*OV4?\
MPAOB]_\ /TH_XB1_VX_^B5?LH_\ A#?%[_Y^E'_$OOB+_P! V4_^'2E_\K#_
M (BAPI_S^QW_ (13_P#DOZL_*_\ ;-17\3/_ !$C_MQ_]$J_91_\(;XO?_/T
MH_XB1_VX_P#HE7[*/_A#?%[_ .?I1_Q+[XB_] V4_P#ATI?_ "L/^(H<*?\
M/['?^$4__DOZL_*_]LU%?Q,_\1(_[<?_ $2K]E'_ ,(;XO?_ #]*/^(D?]N/
M_HE7[*/_ (0WQ>_^?I1_Q+[XB_\ 0-E/_ATI?_*P_P"(H<*?\_L=_P"$4_\
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MB*M3'8>.6TJ-2GCL91=)4Z>&Q<JKPT)<ZYL3'W&US0A]UT445^=GZ %?D_\
M\%XO^4/W[77_ %]? G_UI7X)5^L%?D__ ,%XO^4/W[77_7U\"?\ UI7X)5W9
M3_R.<C_['65?^IU$YL?_ ,BS-O\ L59C_P"HE4_;"BBBOD3ZD**** "BBB@#
M\I/B5_P3L\4_"WQIXD^/'_!.;XHK^S+\5?$%]-KWC7X-:Q#=ZW^RK\:M5>7S
M)%\8?#R,SKX$UBX22ZAM_%W@*U@N=,%S<?8=)MKB^O-0/S1\%/B-^T3\:/\
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M[I6F2>)O#>IWGA:'X8^ +27QKXEM1]DC?XB/-X=NM1\V^T7RO&O^",_[*?\
MP3N\01_!SXE?M.>./"OQB^/OQH\>^+O WPB_98U"WT[Q'HN@#PU%J9O?%GQ(
M\&Q-J/\ :,-QI.E:EJNDS^/$TGP>MG/;QZ?H_B7Q))I,]CXT_%7+(Y)Q#Q%2
MRC-\9E.3YMBLFR^O@**QDL_Q.!H5J^-Q."A2]W#Y7AHT*TJN98FI##*E1K34
MN>G[*7HQX(QKS+*<IGC\!0QV88"AF&*IXFHZ"RNCBJE.GAZ.(<[.KC:SJTXP
MP=&,JSG4IQY>67.OYM**_;'_ (+Z?"?X6_!O]NZV\(_"'X;> OA7X3D^"'P]
MUA_"_P ./"'A_P $>'#JU[JWC""\U/\ L/PUI^F:8+^[BL[6.ZNUM1/<+;P^
M<[^6N/U)\8?![]A#_@C3^QA\!?%_Q[_9+^'_ .UU^TO\<QI+:_I7Q(MO#>M6
M<>K1:+8Z]XY70KKQSX2\6Z7X6\)_#Z'7+'0;#^QO!']M>*-4O-'DU^>V%S)?
MZ1K7\3<)'(^#\RP62YCF6:\<1B\BX?PM7!PQ=3DPZQ6*GB,7BJU#"4*&#H.,
MJ]>4^6+G!M*G[2I3SI<&UWF6?X/$YC@\'@N&W;,\UK0Q$J$.:K[&A&E0HTZE
M>K5Q%1-4J2C=\LDFY\D)_P @M%?U+?\ !57]@O\ 9Y^+/[*O[,G[>'[$?PAL
M?A6_QCU3X6>'M;^&'AK2],\-:+>Z=\9H!!X.N9_#&B&;P[HOB[0?&EUIO@W5
MCX=DBTO5#K*S.UV=,MKF?Z'_ &C] _X)L_\ !%OX=_L[?"7QY^Q9X$_; ^)_
MQ/MKO5/B#XW^(.A>!]>UJ'3-#DT/3_%OC&QE^(/ASQ?%8/=ZAJ+P^!/A]H%E
MX=T6XM=)U$:WXITK4O.U76O.H^,&78[!9*LHR#.,TX@SK'9QET.&:<\!A\=@
ML5P_&-3-UCL5B,3#!4*>'ISI3HS=5O$JK!0A&:JQI]D^ <7AL1F+Q^:8#!95
MEV&P&+EG,XXJKAL11S27)@/JU&E1EB*DZLE.-2/LTJ3IR<I.+A*?\<5%?T=?
M\%V/V#?@#\%_#GP&_; _9=\,Z9X"^&GQU-IH/B+P5H,7]G^%(=8U3PHGC+P-
MXF\*Z#'$]KX>7Q!X9M-:A\0Z58W-OI"76E:7?:;I<-Y?ZY=W7[&?\$V_V&O^
M"3NGVOQ7^"GPZTKX2_ML_%'X0VOP^E^.?Q=^(7@?PI\3_"__  D'CN+Q<VD:
M-\/;G6;#7?!NDV%B?"6N"]L?!=QJ=S8!K#3_ !/XHUO7;6YCT_+,_&G(<!P=
MEW&%+*,\QM''RQ,*F HX1*KED\!C<-EV._M7%.4L)@H4<;B\+AJ$IU'/%U<3
M0C0IM2JNC6#\.\SQ7$&+R">/RW#5,*J,HXJI7;AC(XK#5<7AOJ-!)5\1*IAJ
M%:M448*.'A1JNK--053^#FBBBOV0_/PHHHH *^EOV2?V4_BQ^V;\</"GP+^$
M&E?;->U^;[7K>M70*Z'X*\)6<]NNO>,O$=SN00:1HL$Z-Y*,;W5+^:RT72H;
MK5M2L;6;R_X1_"7XA?';XD^#_A'\*?#.H>,/'_CO6;?0_#>@::@::ZNYMTDM
MQ<3.5M[#3-.M8Y]1U?5;R2&PTK3+6[U&_N(+.VFF3_1>_P"":O\ P3K^''_!
M/?X*6_A/25L?$OQ?\70V>I_&#XFBW(N?$6M1HS0Z%HC3H+G3O!?AWS'MM%TT
M>6UW,;G6]10ZEJ$PB_(_%KQ0P7AWDW)AW2Q/$N94JD<HP$FIQHK6$LSQL$TX
MX2A*ZIP=I8S$+V-.T(8FK0^[X$X+Q'%F8<U53HY/@YP>/Q*O%U'I)8/#RLT\
M15CK*6JH4G[27O2I4ZON'[&?['_PH_8C^!GAGX)?"G3D\C3H8[_Q?XLNK:WB
MU_Q_XQGMX8]8\6>()X4'F7-V\2P:?9!GM]'TF"RTFT/D6@=_JRBBO\YL?C\9
MFF-Q68YAB:N+QV-KU,3BL37DYU:U:K)RG.<GU;>B5HQ248I122_K7"X7#X+#
M4,)A*,*&&PU*%&A1IQ484Z<$HQC%+LEJW=MW;;;;9117\9?_  6,\)^._P#@
MIO\ \%$?'7[)GPLU*XG\/?L%_L??%3XOZQ::;,-0@UKXKWGA?2?%A\/VWEQ-
M:0:EKNI:K\(? DUOMO+VTN+/Q# 9+*=+K^S>[(\I6<8R="IBHX+#4,/5Q6*Q
MDJ7MHT*-/EA%NG[2ESN=:I2I)>TC9U.;6UGR9MF+RW#1K0P[Q=>K6IX?#X:-
M3V3K5)WE)<_)4Y5"E"I4;Y):0MI>Z_LTHK\9_P#@@O\ M22?M._\$Y?A,-:U
M%K_QQ\"9[WX!>,)+B\:ZO9U\"VFG3^"=0G\YFNR+OX=ZOX4@ENKAI!=ZI8ZJ
M8YG,4B1?RO?\$M?^";GP(_X*.>)O^"@'C?\ :*^,_P 2_A1J?P*\4>"_$6A?
M$#PYXG\&:1HEIJ7Q(UOXV7WB'Q-\1KCQMX;U>74;73;SP)I%_%+8>)?"$R_:
M-6:\U5Y+BUN+'T\-PQ!U,^CF.83P%/(:^&H5JE/ RQDJ[Q6*GA:,X4HXBC)0
ME)0FK.HW"HFEIKY]?/YJ&3O X*.+GG%&O6I0GBXX6-%8?#PQ%2,ZDJ-6+E&+
MG%W4$I0:OKI_H<T5_#G_ ,$X?^"GG[0'[-'_  39_P""CFNZQ\0M0^+]M^S=
MXK^$/@O]E3Q;XR_M/Q#;'Q9\:=8\=^$[F*RN/$%U)=7?A'PM:>&-$^)-AX0O
M+IX=/BN]0LS L&KK;GW#]C7_ ((;-_P45_9[\)?MC_MU?M9?M#^*?BK\=M'U
M'QSX)M?#/B#0;B#PAHFL7ER?#USKMYXY\.>+I-4&I);P:[)X=\*0^"=+TNPN
MK/1K"Z#6OVT;XGA*GEL\=/-LVA@\'A<92P-#$4L'5Q5;%UJN%I8U<F%52BZ4
M:>'K4Y5I5*MH5'*DN>25\J'$<\='"0RW+IXK%8C"U,75HU,53P]/#4J>(GA7
MSXAPJ*;G6IS5-0IWG!*I[L6[?V.45_)7_P $D?C!^T=^QE_P4X^.'_!)#XX_
M%C7OC3X!TC1]6U;X5:UK^HW.I7/A^_T_P=X?^*7AN\T=M1O-6O=#T3Q=\*M9
M:[USP<FK7.G:%XFM;8:>(YFU:;4/Y[OV.?AU_P $R_BK\1_VG[W_ (*6?M*?
M&SX&7ECXVTFZ^$MW\+M)UKQ#<^-KG6-=^(LOQ+N/%$]A\"_C=*L^D2V?@B73
MYKQ_#DEU)K>J.K:VT<ITKHH<$NI4Q_/F%6IA\+A,LQV$JY?EE;,*V883-)58
MT:M+"1KT:T'#V<G4C^\<8J<[\D.9X5N*U"&#Y<%3A6Q&)Q^$Q%/&X^E@J6#Q
M&7JFZT*F)E2JTI*7M$J<O<YFXQMS2Y5_IRT5^(OP>^)O[$O_  2E_P""4!^-
M?P%^(_CKXM?L[FW\0^//@YJ7Q)NXK7QK\5/'/Q"U"XB\.^#]/LV\#?#FZTV'
M4M>L72>WD\%6-_H.@6.O>(]1MKJ'3KVX;^7#X9?#+]H/PY_P5/\ ^"9W[0W[
M3>N7=Y\:?VU_BU\./VF]=TJ:WNM-N/"WASQI\8-2T+PIH,MA/A]*BN/#FBPZ
MC8>'X66S\/>&-4T3PT(()=+NX1QY=PJ\P>9S^NRPV&P4L73PM3$8*4*^/KX.
ME4KUJ/U65>,L,Z5*">(E*I4]A.I3IN,Y2TZ\;Q#]3^H0^J1KU\5'#5,3"CBH
MRHX.CBJM.C2J?6(TI*NJE6=J*C"'M80J5$XQCK_HDT45^&'_  <(?M'ZC\%O
MV ]<^%_@^623XE?M6^,= ^ _A73[*1AJLNA:K*=9\=W-I ,">"]T'3$\$W +
MH8[CQO8NN6P!\]EF!J9GF&$P%)\L\77IT>=KF5.,G^\JRC>-XTJ:E4DN97C!
MZH]G'XN& P>)QE1<T</2G4Y$[.I)*T*<79VE4FXTXNS]Z2T9^Y]%?R!?\$8]
M&\8?\$VO^"GW[0W_  3,^).L7.I:5\5_AKX0^(/@/4I&A^P:UXZ\)^"+/QO-
M=:+$'2);74/!VN>/[#5KJR\V62]^'FGV5S',MDUU:?IO^V__ ,%H7_9F_:<N
M_P!C[]GS]C[XO?MH_'SP[X9TKQ5XY\(_#._U73SX8L-:T?3O$=C;PVOA?X??
M%/Q/J]W!X;UC1M<U:5?"]AI6FV6M:2&U2>>XGBM/7Q?#.,AF:R_+9K,Z=3 T
M<RPV+2I8.E6P-:$']8G]8K^SH0A4E*BW4K_'%*ZE)17FX;/L-/ /&8Z+P,X8
MNK@*^&?M,34IXNG.4?815&C[2M.4$JB4*5^5MVM%R/W&HK\/?'7_  7"^%7P
MR_80^'W[8OC[X$?%#PUXX^)?Q$\2_"/PU^S9?75G!XU;XA^$-3U6R\0VFH:[
M>:=9OIWAS3;?2Q<W&L7?A:+61<ZEI6FKX6:YO%9?0OV O^"H_P 0?VN?B;X^
M^$OQV_8C^+_[$_BSP7\-)_BU:2?%O4M;;1]?\&V>M:%HE]>PW/C'X:?"C4K5
MK:;7[2\:>/2-0TH6$<T\VIP-Y44G'4X?SBEAL1BZF#<,/A:M6C6G*OAD_:4*
MBI5E2I^V]IB(TZDE"=3#PJTTWK.R9TPSG+:E>AAH8E2K8BG3JTH*E7:Y*T'4
MI>TG[+DHRJ03E&%:5.;2^$_8"BOYF/''_!QNNL^,?B%#^R+^P!\?/VLO@_\
M"V[N(/&GQK\/ZIK_ (;T'3[*TE*2^(FTOP[\)/B>FE>&KV**YO=&O_&.M^$K
MV]L%MY[W2]+>::&U_0WX$_\ !8?]DOXT_L0?$3]N:ZO_ !!X"\"_!L3:9\6?
M!&N06-YXV\,^,MNG1Z-X0TF*TO(]-\2W?C>_UG1]/\!ZA%>:?9:U<ZK;0ZH?
M#]U:ZS:Z5IB.&<]PE*G6KY=5C"K5HT(QC.C5JQK8BRH4JU"E5G7H5*K:4(5Z
M=.4I-12YFDXH9]E&)J5*5'&TY2ITZM:3E&K3INE1_BU*=:K3A2JPII-RE2G-
M**<F[)M?JU7RM\(?VV_V6_CS\:OC#^SM\)?BWI?C#XS? .^U33?BQX(M]!\7
MZ7=>%KS0]?/A;6XH]6UWP]I?A_Q$NC>(P-%U:?PMJVMP:;J+Q6M[+!)+$'_&
MS]GW_@O[XN^.'Q3^#.C:C_P3E_:!\!?L_P#QY^+?@WX/?#W]I2]UW5=6\&W/
MB#QUXSTKP+HUQJ!E^%.B>"Q!:ZYJL<6LVVB?$W7;NQ\F6*WBOKD>0.L_86^.
M?[)"?\%&/^"I5E\-_P!CA?@[\6/A!<?$#7_C-\<M%^*OB_XD:S\;X]+^(.I7
MGBV?3?ACK&EV6B_#Z]\0^(+$>)IM'\)7UU%K>K/"EZSW$$$[=+X;QF$HYB\Q
MP>*A7P^$A7P_U;$Y=5I4YO%TL-/ZY;$3FXIU/9^QH7Q$*LH.I"--2:P6>87$
MU<$L%B</*C6Q,Z-?V]#&TZDXK#5*\/JUZ,()M0Y_:UK4)4E)0FY\J?\ 0A17
M\N.O_P#!Q]\1=+\/GXO67_!*[]I:3]F#[;:Q+\?=?\1:[X?\/FRO;A+>UG-Q
M%\%=9^'HO;IY[6.UL!\4S%<W%PD$=^28WE\)_P""X_\ P5,^-'B3]F?]E?7?
MV1-'_:)^$OP?^-NG?#CX[6G[8/P_\:^//AG:)K6JZ9\;?"^J_LH^(;WP?I=C
MI_\ PF6GOHT'C?7]-'Q+G69O#$,UCX9U;3K.'Q)!KAN#<[JXS"86O0IX6.+J
MSI+$3Q.$K4Z<Z</:3A45#$3E&M&%G]7=J\E=QIOEE;.OQ1E-/#8G$4:T\1+#
M4X5'1C0Q%*<X3FH1G!U:,%*FY.SK*]*+:4IKF5_[!**_"KX9_P#!8F^^'_["
M?C#]J[]MG]E3XS?LN/X$\4^%?A5\/_ _C-_$FJ>.?VB/$>K>"K/7=)UOP@WC
M;X>?"U(;37?L^N7UYJ<RZIHUGIVA:YJ(UV_NK7^SI?"?@[_P<0VFL?$_X3^%
M_P!J+]A?XW?LE_"SX[ZG8Z=\)?CCXNUC6=<\)^)(-7NH+72O$,MOKOPK^'%M
M-X48ZAI,FJ:]X0UWQI;Z1#J"W4T<VGQ&]?CCPOGDUB73P+JQPM2I2J2IXC"S
M4YTJ:JU(X;EKMXN4*;4IQPJK2CJI)232Z7Q!E,70C4Q:IRQ$(5(1G1Q$7"%2
M;IPE7;HI8:,IIQB\0Z2EHTVFF_Z2Z\P3XV_!B7XHS? Z/XN_#"3XU6^DC7KC
MX0)X^\*/\48-#:UBOEUF;X?KJQ\61:2;*>&\&HOI*V9M9HK@3>3(CG\E?^"@
M?_!:/P[^QU^T!X7_ &3_ (-?LW?$+]L+]H_6=*LM8UKX:_#W6-0T.X\/Q:Q9
M+JV@Z/ =&\"?$CQ#XB\4:EH"R^))=%TCPJ\6GZ%+IE]<:B6OWAL_QX_8/_:A
MTW]L7_@X8O/CO8?#_P 9?"FZU_X!:WH/B+X<>/[86OBOP9XL\%?"3P_X3\3:
M'J2>5;/*MKJ^D736=Q/9:;>3V4EO)?:5I=ZUQI]MTX'A;'5\!C,RQ=*IAL'2
MRG$9CA:G-0<L1*DX>QC*C[1UZ=&M%U)0K2I1C45/]W*2=S#%\082CB\-@</4
MA7Q53,:&!Q%/EJJ-*-2_M'&KR>QG5I/D4Z<:DI1<K3C%[?V@445_GO?\%$M'
M^)W_  4 ^/'_  4H_;X^&VNZE'X _8$\7?![X9_#:719F9K[1- \9WGA'4/$
MWAR]7;=)!I>K:3KGQ7N+BV6)[&Q\26UP\@BM@&Y^'LB6>8BM3J8R. P]"%'G
MQ4Z+KQ]OBL32PF$P_(JM+WJ]:K92Y[1C"4FFD;YUF_\ 9-&E.&&EC*U657EP
M\:GLI>QP]"IB,36YG3J>[1IT[M<MY2E%)JY_H0T5^2?BO]I>/]JG_@B3\9/V
MF-'N7L=6^(?_  3V^/WB#6)-.E%LVC?$+1/@MX[T+QS9Z=/9R PKH7C[1-?L
M;&>(V\ZI90RM#:3[H(OYH_\ @D1_P1,^ /\ P4$_8X\0_'[Q9\7_ (Y?##XO
MZ=\6O&?@#PS?^!M3\%S>"-+MO#VA>#=3T[5=1\-:EX.;Q1J=ZTWB'4([Q-/^
M(.@1S0I:"!K1HYWN>C!</8>>#S'&9IF4\LCEV80RZK"& EC9>WESJ7,H8FA*
M,82IRC*T:CT;2O9/'%9S7CB<%ALOP,<?+&X.>.IREC(X1*C%PM;FH58R<HU(
MM7E!=+]5_=IKFMZ3X:T36/$>O7T&EZ'X?TO4-;UG4[IBMMIVDZ5:37^HWUPR
MAF6"TLX)KB9@K$1QL0"1BOB#]D']N?1?VE/V.W_;5^(?@F#]GKX4W#?$OQ%I
MDGB7QG'XG8?"CX=ZWK&C#XA^(+F'PWX=;09-7'A_6+[_ (1N.SU62UM(+66R
MU;68]0M96_FL_90_::_:I^$_A/\ X*X_\$H_VC?B/K/Q=\2_ []CC]K'7_@G
MX_U.YU;6M=CF\)?#74-.70;'6]8GN]8?PWXE\/\ BGP_XR\(:;KSR#PP+'4]
M&BU$1WFFZ<GJ?COQ?\2=9_X)B?\ !)']G?PG^SK^U+\:?V8?B7X%\+^-?VO[
MW]DOX1>(/BEXNU'P-\-)M*U2V^#D2:->Z7H^EGXF^.KJY?Q?<:[K>AW-OIOA
M^6XTA]:D_M727]!\*QH-X:M5I595\?@O88^G-PIRRN67XK'U:U"G4E"$JV)A
M"$*5.M=^VH^RINU1S?$N(95DJ]*G4IQI8/%*M@ZD5*:S".-PV#ITJTX1G-4J
M$YRE4G2M^ZJ>TFO=45^S7Q+_ ."M'P)7]B?XA_MU?LM63_M4?";X0_$CP_X#
M^)D%C)XT^$&J:#;WNI>#+7Q1JFGV7Q ^&RZSK5]X3TSX@>%=>?2UT.RTW5=-
MO;EH_$EDVGW>S]0/#OB#1O%OA_0O%7AV_BU7P_XFT;3/$&A:I;K*L&I:-K-E
M!J.EW\*S)%,L5Y8W,%Q&LL4<H211(B,"H_C(_9$^*VC^)O\ @DO_ ,%Q?!?_
M  J;XH> -*7XT_M+?%+3]4\<^ [7PKX(TMO'_ASP'HVB_");[^T;BVLOC'\/
M[OPI93>,O ,%KGPI;^(O!<EIJ%[+JT45M_4G_P $^?M__#!'[$/]J_;/[4_X
M9"_9J_M+^T/.^W_;_P#A3/@O[9]N^T_Z1]L^T>9]I^T?OO.W^;^\W5PY]D^%
MRRC55"%6,\/F];"<]:JJE2KAJF P6*H*IR*%'GHRG5]^E2I\\:J4XMPC;KR?
M,\1CZE-U94Y0K9;2Q#C2ING3IUX8O$X>JX<[E5Y:L8T[1J3J<KIMPDE)W^O:
M***^5/H0HHHH **** "BBB@ HHHH **** "BBB@ HHKR_P"-OQ:\*_ 7X/?%
M#XU^-[A+;PE\*? 7BKQ_K[--'!)/I_A71;S6);&T:0$2:CJ1M%T_3+9$EGO-
M0NK6TMX9KB:*)ZA"=2<*=.+G.I*,(0BKRE.;48Q2ZN3:27=DSG&G&4YR480C
M*<Y/11C%-RDWT22;?D>H45_(3^P;H?Q9_8U_:Q_8>_:W^,NKZ[)%_P %B?#G
MQ4TGX]6=^9#I?A;XV^//'%]\6OV?EAMM2QJ-A)KOACQ!X5\*:3ITDSM8/+XJ
M5$6)8H&^\O\ @MU\/O!_Q>^,G_!)SX2_$;1D\3_#KXB?MKV7AGQIX6N;S4;*
MQU_0]4L-$TZ^L;J;2[NQOHO.LKV\MUN;2ZM[N".YF^SSQ-(Q/TE3AZ%/-<+@
M%CU5PV)HXJJL=1P_.E+ K%1Q=.%&6(@IRIU\'5ITVZ]-5:<J5?W(U%%>'3SJ
M4\OKXQX-TZ]&MAJ3PE2ORNV,>&>&J3JJC)P4Z.*IU)I4IN$XU*2YG!R?] E%
M?S ?M"? 3X/_ /!-[_@H1_P39T3_ ()\3:O\*?%/[1/QMB^'?[0/[/7ASXC>
M)O%GA/QA\#+S4/#</BGQ_P"(? 'B_7_$DND2^'M#DUS4-.U^!M/M6NO#YU+3
M8&U?1;Z\/I?B3P?XB_X*W_\ !0_]JOX#?$WXD?$?PM^PU^PL/!G@+5?A)\-O
M%][X)C^.'QI\6VNI7&J:AX_UG0Y8=5U#0_#%QH/B/3XM)CG62P:PT*XTV[TF
MXU7Q FH3_8-)PI8Q8Z<,LG@)YA4Q-;!^SQ5*G3QBR]4U@H8FK"I4K8J4(8=Q
MQ?LJD7*<ZE)4YJ+_ +8J*53#/"1ECXXR&"A0I8GGP]2<\+]<=1XJ5"G*%.EA
MU.5;FPSJ0E%1C";G!O\ HTHK^7;]OK]A+PM_P24^%5M^W[_P3:U7XB_!6X^"
M?CGX?W7QH^!9^*'CWQA\(_C#\+_$GBO1/"6I:3XCT3QKKGB;6;BY_M[5]#,]
MPVJW5OINE7NL:SIUKIVKZ3H^JZ;U7_!79/@#\??VKO\ @B='\>SX>/[-_P 5
M;K]I[Q-XTM/'OB67P7X6D\.:M\./@;KV@R>(]=&K: =(:WNKRQ6*X;4[&2.Y
MF-JLH%S)#+5#(,/BZF"GA<?6JX'%PS2]9X&,<91KY5@)8^MAYX)8R=.52K2=
M)4'#&N$_:W<HN#@*MG%;#PQ4,1@Z=/%X:67VI?6V\+5I9CBXX.E7ABGAHS4*
M=3VGM5+"J4?9V2:DI']+]%?EQ^QM^Q__ ,$H_A?\4;SXC_L2Z#\")OBGH/AR
M_P!+U'5_A5\:M0^)6K:1X:\0R06]ZNH:4/B)XKM+*RU&:UA@6\NM/C8RQ^7;
MW"N74^!_M7?\$;OV(/&'@G]HCX]?&K7_ (Z>,/BE%H'Q+^*=A\=/'_Q^\>3Z
MY\'CI]GK'C!$\$Z;8ZCI'@#1O!_A**UBL]+TC5_".L0:;X>TNUMA.9K<7M<,
M,%EKQ?U>KC<QH4VJ482J913^LRJU96M+"K,^6-**<9>T6(E4FI6A0;2OV2Q6
M.6']M3PN"JS3J.489C/V"IPBG=5W@.:523YH\GL(P5DY54F[?N'17Y$?\$+_
M (E_&OXL_P#!-+X#^+_CMJNN>(O$QG\;Z'X<\4>)YM0N_$GB7P!X<\7ZMHOA
M/4]:OM2C6ZU*:&TLYM(L=4DENWU/1M,TR_GO;JYN)Y3^N]<6/PDL!CL9@9SA
M4G@\36PTJE._).5&I*FY1OJDW&]GJMGJCIP>)CC,)AL7",H1Q-"E7C"?Q156
M$9J,K:-I2M=:/=:,*^/?^"A?_)A/[:W_ &:C^T'_ .JH\5U]A5\>_P#!0O\
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MWI3%'"VVEZ-\;-&TNV,EUXG\,6L8AM+'QE8VD+WGC+P;9I'"T,=SXJ\*VRZ
MNLZ-X._<&O\ *I\-^)/$'@_Q!HGBSPIK>J^&_$_AO5;'7/#_ (@T._N=+UG1
M-9TNYCO-.U32]1LY(;NQO[&[ABN+6ZMY8YH)HTDC=64&O[E?^"2W_!6GP_\
MMG>'[#X*_&J_TKPW^U)X;TIBCA;;2]&^-FC:7;&2Z\3^&+6,0VECXRL;2%[S
MQEX-LTCA:&.Y\5>%;9= 76=&\'?QAXQ>#LL@EB.*>%L-*>1SE*KF>648N4LG
ME)KFQ&&@KREEDI-N<%=X!N_^Y_[M^_\  ?'BS)4LFSFJHYC%*G@\9-I+'I)*
M-&J]EC$OAD],2O\ I_\ QOW!HHHK^<#]8"BBB@ HHKC?B'XXT?X;>"?$GCK7
MO-.E>&]-DO[B*  SW,F](+.R@S\HGOKV:WLX6<B-99U:1EC#,-:%"MBJ]'#8
M>G*K7Q%6G0H4H*\ZM:K-4Z=."ZRG.48Q75M&5>M2PU&MB*]2-*A0I5*U:K-V
MA3I4H.=2I)](PA%RD^B3.RHKX)/QM_:ON?AW)\:K+X;?"N+X?G3Y/$L'A:ZO
M_%4OC^3P@D#7ZZTMU%<0:(]N^F@7<<@M4NY;<?;(])-O)&&^F_ WQJ\">,_!
M'@KQI-KFD>&8_'&DZIJ>EZ5X@UK3+"^=_#JS_P#"506JW-Q;G48_#CVMT^IW
M=K&8K>SB%]<K;0O\ON9CPQFN7457FL+BZ<<75P%9Y=BZ./>%QU&C/$5<)B(X
M>4W"K&C3JU.9*5*4:-9QJ25.5O$R_B;*\PJ^P@\5A*DL+3QU%9CA:V!6)P5:
MK3H4\5AY8B,(SIRK5:-/E;C5C.M2C*G%U(W];HKD-/\ B%X!U;1M2\1Z5XX\
M(:EX>T82'6->T_Q+HMYHVE")/,E.I:I;7LEC8B./YY#=3Q!$^9L+S4=A\1_A
MYJFKVN@:9X\\&:CKU[;1WEEHEAXHT.[U>[M);<7<5U:Z;;WTEY<6TMH1=1SQ
M0O$]N1,K&,[J\AX+&KVM\)BE[#F=:^'J_N5",9S=7W/W?)&492Y[<L91D[)I
MGKK&X-^RMB\,_;<OL;5Z3]KSR<8>R]_]YSRC*,>2_-*+2NTT=G7!_$[P%9?$
M_P  ^*/ .HZA?:5:>)M--C)J.G%!=6CI/#=6\JI)\D\(N+>(7=JS1K>6AGM3
M+#YWFI<\1?$/P!X0NH++Q9XY\'^%[VY19+:T\1>)M%T2ZN(V8HLD%OJ5[;2R
MHS*RJ\:,I92H.015K4/&O@W2+?2KO5?%OAC3+370YT.ZU#7M*LK?61'!]JD.
ME37-W%'J(2V(N7-HTP6 ^<V(_FK7#4\QPM;!XS#4,53K1K0Q&!K1P\Y<U7#2
M5:-2CS0E"JZ3@JCLIQ2BW)<J9EB:F7XFCB\'B:V&J4I4I8?&T9UX+EI8F+HR
MIUDIJ5-55/V:NXMN247=H^5?#/[)FN6_B#X::E\0/C+J?CW1/A#<V-WX$\-P
M>"M$\*1:=+I3VTNEI>ZE97^H7>IQ6LUC9.WVE?M$JVRQBYCC=U/VA7SQXK_:
ME^"_A/7_  1H,_C#1]97QS<WT$&N>'M?\*ZEX>\.0V,UK;G4/%FIMX@M_P"R
M-.NI[B:&SNTANTFETW5$(1K-P?9-.\8^$=7U3^P])\5>&]4UK^R;;7_['T[7
M-,O=4_L*]6V>SUK^S[:ZEN_[)NTO;-K;4?)^QSK=VS13.)XB_KY[/B;'QP>,
MSK"XB-)T,3/!N.6X?+\/&C'%U?K=2.'P6&PU"FY8R526(JSI1J5*LU.I*7/&
M3\G)(<-X&6+PF3XFA*K[?#QQ:EF-?'XB5:6$I?5*<L1C,3B*U11P<:<</3A5
ME3ITX\E.,>645T=%<9'\1OA[-I<>N1>//!DNBRZPOAV+6(_%&AOI<GB!P"FA
M1Z@M\;1]8<$%=,68WK @B Y%6M!\=>"?%5W>V'ACQCX5\1WVFC=J-EH/B'2-
M8N[!=XCW7MMI]Y<36H\PA,SI&-Y"_>(%>%+!8R$*E2>$Q,84FXU9RH58PI23
M46JDG!*#4I134FFFTMVCVXXS"3E3A'%8:4ZJ3I0C7I2E433DG3BI-S3BFTXI
MII-[)G4T5\;Z/^U)_P (A\)KKXA?&U/"*ZL?&>I>'=,T'X3^(_"_BF74;*T&
MF@26G_%;7]K=7VGM?&76X4U:&ZL+22SN+G3+,W"1OVFM_&K5=1\6_!I/AKJ/
MPPU_P%X^U+4++Q)JNH>,] 77[>2SCTV5].\,Z>GBBQ?4]8LDOT74;+3;+Q)=
M6MQ+;P7=E8I)%/<>U/A7.*=6<)T:4:$*F848X]UZ?]G5JV6X:6*Q5*AC+^RJ
MS]G'EI*+_?57[.G>2DH^/#BC)ZE.$H5JCK2IX"K+ ^QG]?HTLQQ,,+AJE;"6
M]K3A[2:E5<E^YI_O*G+%Q;^E**XW5OB-\/= U>+P_KOCOP;HNO3&$0Z)JWBC
M1-.U>4W 5H!%IMY?0WDAG5T:'9"?,#*4W!AFQXA\=^"/",UI;>+/&7A7PQ<:
MA_QX6_B'Q#I&BS7V7,8^R1:E>6TESEP4_<J_S@KUXKQ5@L9)THQPF)D\1!U*
M"5"JW6IQ5Y3I)0O4@EJY0YHI:MGL/&82*JREBL-&-":IUVZ])*C.3M&%5N5J
M<Y/11G9MZ)7.JHK*U+7=$T;29]?U?6=*TK0K:".ZN=:U+4+2QTFWM92BQ7,^
MHW4T5G%!(TL8CFDF6-S(@5B77/Q=^RE\9?&/Q0M/%_Q ^('Q6\)MHUO)JL9^
M'"Z?X;T>X\$64-WI\NF^(+O6(IXM8;2;JW?4;!3KBO"TD"7$>H3R>;'!Z&"R
M/&X[+,SS6FZ=/"Y74PE&K[2&)=2OB,;*I&CA\,J&'K0=6U*<JCKSH4H)TXNI
M[2M2A/@QF=X/!9EEN5U%4J8K,X8JM2]G+#*G0P^#C2=;$8AUL11DJ;=:$::H
M0KU:C524:?LZ56</N:BN1\-_$#P'XRFN;;PAXV\(^*KBSC\V[@\-^)-&UR:U
MBWK'YES%IE[=/!'O=$WRJJ[V5<Y8 QZ5\1OA[KM_9:5HGCOP;K&IZDE[)IVG
M:5XHT34+^_33FF34'LK.TOIKBZ2P>WG2]:".06K03+.8S$X7@E@L9!U8RPF*
MC*A%2K1EAZJ=&+A*HI54X)TXNG"<TYV3A"4D^6+:[XXW!S5*4,7AI1K2<:,H
MUZ4E5DIQ@XTFIM5)*<X0:A=J<XQ>LDGYW_PI-?\ AH'_ (7M_P )*V?^$+_X
M1'_A%O['&-V_/]H_VW_:>=NSY?L7]DYW?/\ ;,?)7NU%%5C,?B\?]5^MUO:_
M4L'0P&&]RG#V6$P_-[&C^[A#GY.>7OU.:I*_O3E96G"8#"8'ZS]5I>R^N8NM
MC\3[]2?M,7B.7VU7]Y.?)S\D?<ARTXV]V$;NY1117&=85^3_ /P7B_Y0_?M=
M?]?7P)_]:5^"5?K!7Y/_ /!>+_E#]^UU_P!?7P)_]:5^"5=V4_\ (YR/_L=9
M5_ZG43FQ_P#R+,V_[%68_P#J)5/VPHHHKY$^I"BBB@ HHHH _F1_:"_X)^?\
M$ROV24;PI\8O^"E7[8OP,TWQ+)KNJV'PFTG]HKPRL,&F>)M4O]2U0Z?\-?#'
MP7UO6K?PYJ&H:EJ!>[N]*DM-1GFO#=7M[=M>2-QG[/?[&'_!*G]H&>V^#WP"
M_P""JW[:>O7$6F'1=(^&%O\ M&:'X(:]TA+<6[Z/X:\'>*_@5X9&M6$=I(8I
M=,T#3KV&*U\U9(%ACEV_2G_!)S]F+X(?M,>&?C-^W'^T3\._"/QF_:!^+O[1
M'Q@MKZ_^)>BZ7XRL_AWHOACQ =!T?PCX>\-ZW8SZ1H,VGV5OB.[&F1ZK#H\^
MFZ=;36FF0QVK?2W_  4E_P""?/[*_CW]ECXV?$;0_A1\//A)\6_@[\-_&7Q>
M^'WQ>^'/A30_ ?BWP_XE^&>@7OC/3?[0UOPQ;:-<ZEH]S)H0L;F'5I;R+2XK
MJ75=+2UU2VM[E/Z/Q'%CR_.5PCF'%_&KSF&,H9?C\ZH4<AGE&'SF<H4:E2&5
M5,#+,,=A,)B*DZ<\4\SHXO$4X3KTJ"<XTI?D=+(_K67_ -NX3(.'5ESP]3%X
M7+:M3-(X^KE\8NI",L=#$K"8;$5J4(SC0^I5:%*<HTJE5J,JB_1[X$?!KPI^
MSQ\&_AK\#O USK=[X0^%GA#1_!GAZ\\27=I?Z_=Z;HMLMM!=:Q>:?I^DV%QJ
M-P%,UU)9:9I]H97;[/9VT(2)/6:^6_V(?BMXB^.7['_[-/Q<\8;F\6^/O@M\
M/O$'BBY8K_Q,/$5SX=L8];U952*%(H]8U.*ZU2*W5-MM'>) LDPC$K_4E?@.
M;TL90S;-*.85/;8^CF.-I8ZMS<_M<93Q-6&)J<]ES>TK*<N:RYKWLKGZC@)X
M>I@<%4PD/9X6IA,-/#4[<O)AYT82HPY=>7EIN,;7=K6"BBBO..L***Y7QQXX
M\(?#3P?XE^('C_Q%I/A'P5X/T:^\0>)_$NN7<=CI.BZ/IL#7%Y?7MS(0J1Q1
M(=J*'FFD*001RSR1QM=.G4JU(4J4)U:M6<:=.G3C*=2I4G)1A"$(IRG.<FHQ
MC%.4I-))MDSE&$93G*,(0BY3G-J,8QBFY2E)M*,8I-MMI))MNQP'[0O[0/PM
M_9>^$7C+XV?&+Q):^&?!'@O3);V[FEDB.H:QJ!1QI?AKP]922Q/JWB37[M4T
M_1M+@;S+J[E4NT-O'/<0_P"<=_P4"_;M^)W[??QWU?XK>-WFT7PEIGVC1/A7
M\.H;IIM+\!^#$NI);2SRH2*_\1ZF2M_XHUYHUEU/4G\FW6UT>QTG3;#Z _X*
MN_\ !3?Q=_P4"^+AL/#L^K>'/V</AWJ%W;_"_P $SRR6[Z[=*9+6X^)'BVS7
M8LOB36[<LFEV5P)5\*Z)+_9=H5OKW7KW5/R9K^_?!+PCAP5@8\09[0A/BK,:
M%HTIJ,UDF#JI-X2F]5]>K1M]>K1?N+_9*4O9QKSQ'\M^(W'<N(\2\KRRI*.2
M82I=SC>+S+$0=O;SZ_5J;O\ 5J;MS/\ ?U%S.G&B4445_0!^6A7]%'_!LO\
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M[K5KJYU.^VW>N>)=<:PTI->UQK?3K>]32-,ALM(TNUM(K8?L-\*?^#AKX#_
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M-GKOB>9[YWO7DUN_OG:[=KEF,S%SY\L\RBB\U^I9?C%'-:,%6AB\52K+VO\
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MC2PM:IAZJJ5IWQ$ZE6#3E"K3C3I.FM)*+<KZ'\4O_!+WXO\ B3P-_P $Z/\
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MMU'#W7)RNVUON];GKT%4C2IQJJE&I&*4HT%)4E;1*FI>\HJ-DD]NF@5\>_\
M!0O_ ),)_;6_[-1_:#_]51XKK["KX]_X*%_\F$_MK?\ 9J/[0?\ ZJCQ77J<
M-_\ )19!_P!CK*O_ %.H''G'_(IS3_L78W_U&JG^8#1117^LQ_# 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MX=@U&6[OM"MKW7=7\;VEE!J$5O#;7I?QAIFEM#+9&]\/^(8%U33)O'OV5O\
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MX _Z+G@__P 2;)?_ )M/Q#_53BG_ *)K/_\ PSYC_P#,Q^1]%?KA_P .)_\
M@JI_T:S_ .9O_9R_^>]1_P .)_\ @JI_T:S_ .9O_9R_^>]1_P 1#X _Z+G@
M_P#\2;)?_FT/]5.*?^B:S_\ \,^8_P#S,?D?17ZX?\.)_P#@JI_T:S_YF_\
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MKI9=@HJ4]*F+Q4HJ-7&8EQ2G6G:[C%?#1I<S5*FE%.4N:<BBBBOBSZ(****
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MO^C8O_,T_L]?_/9K_04HH_XF3XZ_Z%7"?_A#G'_S]#_B$O#G_0;G?_A3@/\
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MC:M!\U&ECZN&JT(54TX5O9T<)0<JE-J]/GE*$9>_R.<82B4445^,'WX4444
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M\,:-J.A_"GQ3XS^&\_PWM+RUN-/MI;6R^(5I_:5SIUA<DO%;-;W>BP"1<H1
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M;^>VRUZ[)G14444AA1110 4444 %%%% !1110 4444 >5_&SX9#XQ_#'Q/\
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M?^'.O_64[_@LE_XF_P#_ (L*/^'.O_64[_@LE_XF_P#_ (L*/J64_P#0Z_\
M,=B?_DP^M9E_T*O_ "^H>7]WS?W>9^R5%?C;_P .=?\ K*=_P62_\3?_ /Q8
M4?\ #G7_ *RG?\%DO_$W_P#\6%'U+*?^AU_YCL3_ /)A]:S+_H5?^7U#R_N^
M;^[S/V2HK\;?^'.O_64[_@LE_P")O_\ XL*/^'.O_64[_@LE_P")O_\ XL*/
MJ64_]#K_ ,QV)_\ DP^M9E_T*O\ R^H>7]WS?W>9^R5%?C;_ ,.=?^LIW_!9
M+_Q-_P#_ !84?\.=?^LIW_!9+_Q-_P#_ !84?4LI_P"AU_YCL3_\F'UK,O\
MH5?^7U#R_N^;^[S/V2HK\;?^'.O_ %E._P""R7_B;_\ ^+"C_ASK_P!93O\
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M?_\ Q84?\.=?^LIW_!9+_P 3?_\ Q84?4LI_Z'7_ )CL3_\ )A]:S+_H5?\
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M /\ %A1]2RG_ *'7_F.Q/_R8?6LR_P"A5_Y?4/+^[YO[O,_9*BOQM_X<Z_\
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M (L*/J64_P#0Z_\ ,=B?_DP^M9E_T*O_ "^H>7]WS?W>9^R5%?C;_P .=?\
MK*=_P62_\3?_ /Q84?\ #G7_ *RG?\%DO_$W_P#\6%'U+*?^AU_YCL3_ /)A
M]:S+_H5?^7U#R_N^;^[S/V2HK\;?^'.O_64[_@LE_P")O_\ XL*/^'.O_64[
M_@LE_P")O_\ XL*/J64_]#K_ ,QV)_\ DP^M9E_T*O\ R^H>7]WS?W>9^R5%
M?C;_ ,.=?^LIW_!9+_Q-_P#_ !84?\.=?^LIW_!9+_Q-_P#_ !84?4LI_P"A
MU_YCL3_\F'UK,O\ H5?^7U#R_N^;^[S/V2HK\;?^'.O_ %E._P""R7_B;_\
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MW_D:W_\ CM']BZG_ ,^W_D:W_P#CM?E3_P .=?\ K*=_P62_\3?_ /Q84?\
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M+O\ H<4__#9B_P#Y:')C/^A94_\ "_#>7_3KS?W>9^JW]BZG_P ^W_D:W_\
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M8_RV_P"'.O\ UE._X+)?^)O_ /XL*/\ ASK_ -93O^"R7_B;_P#^+"B^7?\
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MRI_X<Z_]93O^"R7_ (F__P#BPH_X<Z_]93O^"R7_ (F__P#BPHOEW_0XI_\
MALQ?_P M#DQG_0LJ?^%^&\O^G7F_N\S]5O[%U/\ Y]O_ "-;_P#QVC^Q=3_Y
M]O\ R-;_ /QVORI_X<Z_]93O^"R7_B;_ /\ BPH_X<Z_]93O^"R7_B;_ /\
MBPHOEW_0XI_^&S%__+0Y,9_T+*G_ (7X;R_Z=>;^[S/U6_L74_\ GV_\C6__
M ,=H_L74_P#GV_\ (UO_ /':_*G_ (<Z_P#64[_@LE_XF_\ _BPH_P"'.O\
MUE._X+)?^)O_ /XL*+Y=_P!#BG_X;,7_ /+0Y,9_T+*G_A?AO+_IUYO[O,_5
M;^Q=3_Y]O_(UO_\ ':/[%U/_ )]O_(UO_P#':_*G_ASK_P!93O\ @LE_XF__
M /BPH_X<Z_\ 64[_ (+)?^)O_P#XL*+Y=_T.*?\ X;,7_P#+0Y,9_P!"RI_X
M7X;R_P"G7F_N\S]5O[%U/_GV_P#(UO\ _':/[%U/_GV_\C6__P =K\J?^'.O
M_64[_@LE_P")O_\ XL*/^'.O_64[_@LE_P")O_\ XL*+Y=_T.*?_ (;,7_\
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M'.O_ %E._P""R7_B;_\ ^+"B^7?]#BG_ .&S%_\ RT.3&?\ 0LJ?^%^&\O\
MIUYO[O,_4FZ\*37L^FW-UIXEGT>]DU'3I#<QJ;:]ETZ_TF2<*EPJR%M/U2_M
MMDRR1@7!D"":.*1+O]BZG_S[?^1K?_X[7Y4_\.=?^LIW_!9+_P 3?_\ Q84?
M\.=?^LIW_!9+_P 3?_\ Q847R[_H<4__  V8O_Y:"IXS_H65%?5_[?A=[)7?
M[K6RT](^A^JW]BZG_P ^W_D:W_\ CM']BZG_ ,^W_D:W_P#CM?E3_P .=?\
MK*=_P62_\3?_ /Q84?\ #G7_ *RG?\%DO_$W_P#\6%%\N_Z'%/\ \-F+_P#E
MH<F,_P"A94_\+\-Y?].O-_=YGZK?V+J?_/M_Y&M__CM']BZG_P ^W_D:W_\
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M?].O-_=YGZK?V+J?_/M_Y&M__CM']BZG_P ^W_D:W_\ CM?E3_PYU_ZRG?\
M!9+_ ,3?_P#Q84?\.=?^LIW_  62_P#$W_\ \6%%\N_Z'%/_ ,-F+_\ EH<F
M,_Z%E3_POPWE_P!.O-_=YGZK?V+J?_/M_P"1K?\ ^.U2C\*31:C=:M'IX74+
MVRL-.NKG[3&3+9:7/J5S80&,W!A46\^L:C('2-9)#<E97=8X5C_+;_ASK_UE
M._X+)?\ B;__ .+"C_ASK_UE._X+)?\ B;__ .+"B^7?]#BG_P"&S%__ "T/
M9XS3_A,J?^%^%TV_Z=>;^[S/U6_L74_^?;_R-;__ !VC^Q=3_P"?;_R-;_\
MQVORI_X<Z_\ 64[_ (+)?^)O_P#XL*/^'.O_ %E._P""R7_B;_\ ^+"B^7?]
M#BG_ .&S%_\ RT.3&?\ 0LJ?^%^&\O\ IUYO[O,_5;^Q=3_Y]O\ R-;_ /QV
MC^Q=3_Y]O_(UO_\ ':_*G_ASK_UE._X+)?\ B;__ .+"C_ASK_UE._X+)?\
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M4_\ GV_\C6__ ,=H_L74_P#GV_\ (UO_ /':_*G_ (<Z_P#64[_@LE_XF_\
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M'QL\0V7A?X?:WX8^%,/C'X7V'Q1\.Z1J'_"._$[6?%'Q)\5:C:75[X3C\)_
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M)O!_ACPO8VOB/6Y/@WX;^#FOZG=3Z#I7@N:73]<TE;/P_=66FZ99P1K:\8^
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M--SA#7ZM>U.$E"+?U3#W<8IOV>OQ3YOSV^,W[!__  MSPY_P4#\/_P#"U/\
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M66L9RIVY.51_-*3]@3Q?*/%OAI_CCX;'PRU;]NOX?_MT>%M!C^#FJ+XV\/\
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M-%:K,ZR</=I6]C0H5_W=)U*]+#JG3A3]NZ;KTH.A1HTI1IU%%\DI6_>33S>
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M<TY2<7=2?+S)\D.7\]O@K^P?_P *?\1_LQ>(/^%J?\)%_P ,X_\ #9W^B?\
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M ,,_C%=^./#5GH'P[^(>J^&-,T7Q!J,GPV^(=Y=6V@:Y;^#O%OANYOKDZ?\
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MHJI[Y2RW!QCR*E)0M37(J]=0?LJWMZ;E#VO+*4:OO*<DYV]QR</=/SE\$_\
M!/\ _P"$.TSXFZ=_PMK^T?\ A8W[!GP1_8C\[_A _LG]C?\ "G/#/Q6\._\
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M]JW-U_9^$;3E"I-IIKVF(Q-2\HII5)<]67-54'[-597J*E^Z4O9I1/S9U_\
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M,?CKXD?$W1?COK.C?$.XGTP76L>.O#>@>!/AGIWC7Q9+:ZM87G@_3K(:'/\
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M?V,[WX-_$[5?"/A3P?\ %;QEX?\ AO\ LH_!/X>?"FV\6_L]_MK_ +3'@/\
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6BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>img34756086_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img34756086_1.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" )X! 0# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MKPS5_'OQKL]6U.STKX _VSI=KJ-[;:;J_P#PM3PGIW]JV$%S+%9ZE_9]S9M<
M6/VZW6.Z^QSLTUMYOD2L71B<[_A8WQZ_Z-P_\S!X,_\ D&ME0FU?FHZZZXB@
MG\TZEUZ/4YGBJ2;7+B=';3!XMK3LU0::\TVGT/H2BOGO_A8WQZ_Z-P_\S!X,
M_P#D&C_A8WQZ_P"C</\ S,'@S_Y!H]A/^:C_ .%&'_\ EH?6Z7\F)_\ "+&?
M_*#Z$HKY[_X6-\>O^C</_,P>#/\ Y!H_X6-\>O\ HW#_ ,S!X,_^0:/83_FH
M_P#A1A__ ):'UNE_)B?_  BQG_R@^A**^>_^%C?'K_HW#_S,'@S_ .0:/^%C
M?'K_ *-P_P#,P>#/_D&CV$_YJ/\ X48?_P"6A];I?R8G_P (L9_\H/H2BOGO
M_A8WQZ_Z-P_\S!X,_P#D&C_A8WQZ_P"C</\ S,'@S_Y!H]A/^:C_ .%&'_\
MEH?6Z7\F)_\ "+&?_*#Z$HKY[_X6-\>O^C</_,P>#/\ Y!H_X6-\>O\ HW#_
M ,S!X,_^0:/83_FH_P#A1A__ ):'UNE_)B?_  BQG_R@^A**^>_^%C?'K_HW
M#_S,'@S_ .0:/^%C?'K_ *-P_P#,P>#/_D&CV$_YJ/\ X48?_P"6A];I?R8G
M_P (L9_\H/H2BOGO_A8WQZ_Z-P_\S!X,_P#D&C_A8WQZ_P"C</\ S,'@S_Y!
MH]A/^:C_ .%&'_\ EH?6Z7\F)_\ "+&?_*#Z$HKY[_X6-\>O^C</_,P>#/\
MY!H_X6-\>O\ HW#_ ,S!X,_^0:/83_FH_P#A1A__ ):'UNE_)B?_  BQG_R@
M^A**^>_^%C?'K_HW#_S,'@S_ .0:/^%C?'K_ *-P_P#,P>#/_D&CV$_YJ/\
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MS!X,_P#D&C_A8WQZ_P"C</\ S,'@S_Y!H]A/^:C_ .%&'_\ EH?6Z7\F)_\
M"+&?_*#Z$HKY[_X6-\>O^C</_,P>#/\ Y!H_X6-\>O\ HW#_ ,S!X,_^0:/8
M3_FH_P#A1A__ ):'UNE_)B?_  BQG_R@^A**^>_^%C?'K_HW#_S,'@S_ .0:
M/^%C?'K_ *-P_P#,P>#/_D&CV$_YJ/\ X48?_P"6A];I?R8G_P (L9_\H/H2
MBOGO_A8WQZ_Z-P_\S!X,_P#D&C_A8WQZ_P"C</\ S,'@S_Y!H]A/^:C_ .%&
M'_\ EH?6Z7\F)_\ "+&?_*#Z$HKY[_X6-\>O^C</_,P>#/\ Y!H_X6-\>O\
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MA];I?R8G_P (L9_\H/H2BOGO_A8WQZ_Z-P_\S!X,_P#D&C_A8WQZ_P"C</\
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M_A8WQZ_Z-P_\S!X,_P#D&C_A8WQZ_P"C</\ S,'@S_Y!H]A/^:C_ .%&'_\
MEH?6Z7\F)_\ "+&?_*#Z$HKY[_X6-\>O^C</_,P>#/\ Y!H_X6-\>O\ HW#_
M ,S!X,_^0:/83_FH_P#A1A__ ):'UNE_)B?_  BQG_R@^A**^>_^%C?'K_HW
M#_S,'@S_ .0:/^%C?'K_ *-P_P#,P>#/_D&CV$_YJ/\ X48?_P"6A];I?R8G
M_P (L9_\H/H2BOGO_A8WQZ_Z-P_\S!X,_P#D&C_A8WQZ_P"C</\ S,'@S_Y!
MH]A/^:C_ .%&'_\ EH?6Z7\F)_\ "+&?_*#Z$HKY[_X6-\>O^C</_,P>#/\
MY!H_X6-\>O\ HW#_ ,S!X,_^0:/83_FH_P#A1A__ ):'UNE_)B?_  BQG_R@
M^A**^>_^%C?'K_HW#_S,'@S_ .0:/^%C?'K_ *-P_P#,P>#/_D&CV$_YJ/\
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MS!X,_P#D&C_A8WQZ_P"C</\ S,'@S_Y!H]A/^:C_ .%&'_\ EH?6Z7\F)_\
M"+&?_*#Z$HKY[_X6-\>O^C</_,P>#/\ Y!H_X6-\>O\ HW#_ ,S!X,_^0:/8
M3_FH_P#A1A__ ):'UNE_)B?_  BQG_R@^A**^>_^%C?'K_HW#_S,'@S_ .0:
M/^%C?'K_ *-P_P#,P>#/_D&CV$_YJ/\ X48?_P"6A];I?R8G_P (L9_\H/H2
MBOGO_A8WQZ_Z-P_\S!X,_P#D&C_A8WQZ_P"C</\ S,'@S_Y!H]A/^:C_ .%&
M'_\ EH?6Z7\F)_\ "+&?_*#Z$HKY[_X6-\>O^C</_,P>#/\ Y!KT+X5>//\
MA9O@+0?&_P#97]B?VW_:G_$L^W?VE]E_LW6=1TC_ (_?L=AYWG?8/M'_ !Z1
M>7YOE?O/+\UU*C.$>=\CCS*+<*M*I9R4FDU"<FKJ,K-I+1E4\12J3]G'VJFX
MRFE4H5Z-XQ<8R:=6G!2Y7.":3;7,M+'H5%%%9&X4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_@W=_P"4+W[ W_9)=4_]6#XRH _:2BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ KY[_96_P"2"^ _^YH_]3/Q%7T)7SW^RM_R07P'
M_P!S1_ZF?B*MH_[O5_Z_4/\ TC$'-/\ WRA_V#8O_P!.X(^A****Q.D****
M"BBB@ HHHH **** "BBB@ HHHH **** /Y*O^#R[_E%1X$_[.W^%_P#Z@_Q2
MK],?^#=W_E"]^P-_V275/_5@^,J_,[_@\N_Y14>!/^SM_A?_ .H/\4J_3'_@
MW=_Y0O?L#?\ 9)=4_P#5@^,J /VDHHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH ****+KN 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !7SW^RM_R07P'_P!S1_ZF?B*OH2OGO]E;_D@O
M@/\ [FC_ -3/Q%6T?]WJ_P#7ZA_Z1B#FG_OE#_L&Q?\ Z=P1]"4445B=(444
M4 %%%% !1110 4444 <5\2?%MUX!^'WC;QO8^'=4\7WOA+PKKOB*S\*Z(C2:
MQXDN](TVYOK;0]+1(IW>_P!5F@2RM%6&9C/,FV*0X0_Q>_ ;]N__ (*??&[_
M (. /V1O#7[6WA77?V4?A/\ $SX->.O%GPX_9'L-<G=]-\ PZ5XD32-<^+ML
MZQSZEX_U;5K*YU&Y74+:P?3+:.QLK;2M.AAV3?V[U_)?^U797K_\'6G[!-ZE
ME=O91?LD^+8Y;Q+6=K2.1H_'V$DN5C,*,<CY6<'+*,99<@&=_P %#/B%^V!_
MP4,_X++:!_P2J_9]_:M\=?L>?!GX,_LZ7?QU^*7CGX8Q(GB_QKXKU&>"WT[1
M[B66:VE>TTMKK3$L%29]/2*?5)[BTFNVM98/CGX9?\%H?VOOV5?^"6W_  58
M\ ?&+XG-\6_VKO\ @GK^T5=_LI_#/XYZ_IT5UJOB$>.O&>M^"/#/BG7H82%U
M74O"-]HVLW.GW-Z2RP-HEM?7%]'9%I?;_P!MCXV:3_P27_X.&%_;R_:.\%?$
MO4?V5OVEOV29_AAI7Q$^'WA&X\7OH/Q"T*ZL[F[T;4-/M;BT"11C3;)2OVB2
M_DCU2*[@M)+6VNY8/S"T#]A_X\_MT?\ !*W_ (+>_M@^ ?AGXXTBR_; _;('
M[37P"\ :SH<UCXV\7_#GX7_$WQ-XVUNXM]$E9Y+B6ZMO$%Q9V:6DDWVF[T+4
MHK*6[Q$90#[3\*^)?^"BG_!(O]H+_@E?\9OC1^WG\1?VKOA%_P %#_$-MX$_
M:+^&WQ+2&ZT;P?XF\3Z?X9UO3-3\"LT\DL<MK#XAN!9:@ALS:3:9<6]Q;W=G
MJ\4%E_79^T!^WO\ L4?LI>)](\%_M+_M5_ 7X#^+M?T1?$FB>&_BM\3O"G@C
M6M5T![VZTY=9L-/U[4K*YNM-:_LKNS6[BC:$W%M/$'WQN!_%CX^_;%\*_P#!
M;'XX?\$3/V5/V8?A7\8[77_V8/&>D_%+]J;6_&O@J\\-Z)\*++P9H_@W0KFS
M&I233PZO&9]'U>6:[ L^6T6UM(;NZU"[AT[]^_\ @K9_P;V_ ?\ X*Y?&_X?
M?''XJ?'GXL_"O6?A[\,X?AE8:+X!TCPCJ&F7^G0^)-<\2KJ5W+X@L[FZ2]-Q
MKL]L8X6$'DPQ-C>6) /QQ_X.M/\ @H-^PS^U+_P3<\&?#G]F_P#:W_9\^.7C
MZU_:=^'7B.Y\&_"WXI^$O&OB2'0+#P?\1K.]UF72-!U.]O$TVTNM1L+>>[:(
M0QS7EO&6W2J#^Z'_  ;S>,?"%E_P1Z_8-\,7?BOPU;>);7X4ZW#=>'I]>TJ+
M7+6>U\=^-;BY@N=)>[6_MYK:"*2>XAFMTDAA1I9%6-2P_C._X+D?\&Z7P"_X
M)(_LB>%/VHOA1^T'\7_B=XLO?CIX)^':>'O'FA^#+/0H;+6M#\7:]+J@FT&S
MMKUKVUN?#%I%#"S-;RQ7-QY@#)'G]Y/^"(G_  1)_81^//[,G[*O_!3GX@^&
M_B5<_M7_ !=T7XD?$_QEXATOXE:QI?A&;QCX\UWXB^%M>OM.\&6T TNQM&TS
M5KHVNFYFLH[D(TT5Q!OMW /Z]]3\4>&=$M[&[UGQ%H6D6NIS1V^FW.IZOI]A
M;ZC<3 -#!8S75Q%'=S2J0T<5NTCR @JI!I=-\3^&]8;4ETCQ#H>JMHSB/5UT
MW5K"^;2I")2$U(6MQ*;%R()R%NO*;$,IQ^[?'YZ_M/?\$HOV0_VNK+]F>W^,
M>A^.+V\_9*OK/4/@UJ^@^-;[1KS3;BRM;"UB_MRS6WN="U]6&FVDSF^T<R+,
MC&&2*-S'3OV8/^"4G[(G[(D?[52?!_0_'-J_[9>O:?XF^.-QK_C?4-6FU;6M
M,D\5SVEWH12&RC\/(MSXSURXDM;&/[),\T4<L#V\1A<T_I=/O_#\0/O/4/B)
M\/\ 2;L6&J^.O!VF7[1VTHLM0\3Z)979BO(HYK206US?1S&.ZAEBEMG";9XI
M(Y(BR.I/517-M<0+=07$$ULRLZW$4L<D#(A(9EF1FC*J58,P; *D$C!K\$_B
M9_P;7_\ !+[XL?':']I#Q5X.^+Y^*\6H>#M7.LV'Q<UJ+3I=8\#Z=I.FZ-J<
MN@W5G>:096BT6QDN[-+5-*>576WT^UMBMNG[.>'/@QX)\,_"2#X*646J7'@B
M'0]1\/F.[U*5=6FL-4GN[J\:34[!;&2.Y>>]GD26V2W$9*JB!%VDT_I=/O\
MP_$#I?\ A8OP^_M%-'_X3OP;_:\ES'9II?\ PD^B?VB]W,RI#:I8_;OM+7,K
MNBQP"(RNSJJJ2P!UM1\3^&M(TL:WJWB'0]+T4R+$-7U'5K"RTLRLSHL8O[FX
MBM#(SHZ*@EW%D=0"5('X2ZG_ ,&U?_!+[6_VC[3]JS6/"'QBU#XPVGQ&\/?%
M0:JWQ@UVSTB;Q?X8U#3=3TJZDT33+2QLTM8[O2;)Y;6U%NL@1OF5G9J^U/VE
M_P#@E/\ LB?M;?L\?#;]F3XU:%XWUKX<?";QS'\1?!$ND^-M0T'Q#I_BA-2U
M356N;N]TZ&/3=6M9+G5[M7L=3TBZMA"(XXTC_>M* ?H+IWBCPSK%_=:7I/B+
M0M4U.RA2XO-.T[5]/O;^T@DV>7/=6=M<2W%O"_FQ[))8T1O,3:QWKG-U3X@^
M M#DABUKQOX0T>6YMS=V\>J>)=&T^2>U$\]L;F%+N]A:6W%S;7-N9D#1B>WG
MBW>9%(J_ ?[-W_!)W]D+]E?X]_'']I3X7:-X[_X6K^T3\/[7X9_%#5/$/C>\
MU'3=4\*V?]C+%!INDV=KIEKHEZ8]!TV-[_31!<;82R,DCF2OD/\ :-_X-O?^
M"8G[5'Q$T7XJ?%SP=\7=1\;Z%X>L/#5KJFD?%W7](@FT[2]=UO7]--UI<5O+
MI;36ESKMU;@V]G;P7%K# ;V"YO6O+R[ /W=LK^QU*W2[TZ\M+^TE ,=U97$-
MU;R @,"DT#R1N"K*P*L<@@]"*YB]^(OP^TR].FZEXZ\&Z?J(9%-A>^)]$M+T
M-+@1J;6>^CG#2$C8#'E\C;G-<1\&/@+X"^!/PRM_A+X*76)?"4 OE(UK45NM
M2F74+>.UN%>\L;;35C'V>&.*(VT%NT04,C"3YZ_''X]?\&UG_!+[]I/XR7?Q
MW^*_A'XQ:O\ $&\;0?.N].^+^N:-IQA\-1P0:/;#3M/M(HVCM[:V@MI)I7DO
M+F-/,N;J6X9IF-/\M/\ @Z?B!^\%UKVAV6GW>KWNM:3::58,R7VIW6HV=OI]
MDZND;+=WLLR6ULRR21QLLTJ$/(BD;F4&CI_C/P?JU[;Z;I7BOPUJ>HW=DNHV
MNGZ?KNEWM[<Z>Z"5+^WM;:ZDGFLGC82+=1QM R$.)"I!KX>^-G_!,G]E3]H3
M]EGQO^QW\4M"\8ZU\%O'WC*#QYK%C9^-=6T;Q#;^(K2ZT^ZLI['7]+^S7)M[
M0Z;;PI:ZC'J,4T9>2\%S=>7<1^8_L_\ _!'#]BW]FO\ ::\(?M<_#C1_B&?C
M3X'^#D?P(T#5M>\<S7^B0?#N'28M$AT^?P[::;IVF3W\6GQ+$FIF);G)9V+$
MC#T\_+3_ (.GX@?I7J_C?P7X?\H:]XO\+Z(9Y;F"#^U]?TG3?.FLC"+R&+[9
M=P^9+:&XMQ<QIN> SP^:$\U-VMI6LZ1KEI'?Z)JNFZQ8RJCQ7FE7UKJ%I(DB
MAXWCN+26:%U="'1E<AE(9200:_%?]K7_ (-\?^";W[:^O>'?$OQW\'_%75M8
M\+3>)WT>YT#XM^)- 6&V\5W>FWM]82V]L)+>XM[:YTR.2RN)8VU0BXN$O]0O
MT6T6U_2']E7]DSX3?L<?#.R^$WP<C\0Q>$=/@TFTLX_$NJP:O?PVNAZ3:Z+I
MMN+J"PTY&2"PM(D+/ TLLF^221F;@T\_+3_@Z?B![9JWC_P)H%U]AUWQKX2T
M6]"EC9ZMXDT?3;H*':,M]GO+V&7:'1T)V8#JRYRI VDUO1I+.YU"/5],>PLH
M#=7E\E_:M9VEJ(#<FYN;E93#! +8&X,TKI&( 92WEC=7XC?M>_\ !N]_P3:_
M;A^)T?Q;^/?A7XM:MXNM]+GT2RD\/?%C6O#UA9:7<:UJWB%K2.VM;626X":K
MK>I7$<VH7-Y<JLX@,QABBC3[57_@FQ^RV?V9OBI^R-<Z#XNO?@C\8?!FB> O
M%VAW'C35TU@>'/#NBVNAZ1;Z7XEM&M=:M)[:VLH)GN)[J[:YG5DNA-92/9E
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MLC^LVO4M[3ZM?EC_ #/E_<F>YM[6%[FYGAM[>-0TEQ/*D,,:D@!GED94522
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M(!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M=GN7U%A\5FN68O*,-@J>$R_#4,GQ.$Q])T(T*6'JXO'3SC%4,2HT:=2-6%+
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *^>_P!E;_D@O@/_ +FC_P!3
M/Q%7T)7SW^RM_P D%\!_]S1_ZF?B*MH_[O5_Z_4/_2,0<T_]\H?]@V+_ /3N
M"/H2BBBL3I"BBB@ HHHH XGXF0>-;GX<?$"V^&K:,GQ%N/!'BN#P"_B)!)X?
M3QK+H-_'X5;74,-R'T9==:P.J(;><-9"<&&4'8W\/%S^T_X*_8M^%?Q-_8P_
MX++?\$3;CX1_L^?&GXF:C\2?&7Q:_9>\/V?Q'^!7B'XAWS6=I_PL.QLM$U::
M#P?J+VVF)JBQ^&]=L=;TI3)'%X3MWO?L[_W$_$CQ/JO@GX=^/?&>A^&-1\;:
MWX1\%^*?$^C^#-'+#5O%VJZ#H=]JNG^&-+*0W##4=>N[2'2K(K!.WVF[BQ#*
M<(W\I/C+X*_\'"'_  5TL=5\*?'#4OA'_P $N_V1_$HDL]3^'>DZ%:?$CXX^
M+?#TLTD4UCXA?6)=1%A)J.F21.Q6?1HK2^C.+#RW=8P#]9O^"..H?\$D8_@1
MK.A_\$G-8^&=[X >]T[Q'\0K/PN-:M_B(FL:G;20:5=?$[3_ !C:6'CFTU'[
M+;2V>G1^(+."..*WFCLEV^:S?L)7Y&?\$H_^"-7[,O\ P20\'^-M'^!OB#XB
M>-O&'Q2A\/?\+*\<_$#5K*:77[KPVM[]@DTKP_I5C9:7X>M1)J%T[VUN;J1R
MR^9<N$%?KG0 4444 %%%% !1110!_)5_P>7?\HJ/ G_9V_PO_P#4'^*5?IC_
M ,&[O_*%[]@;_LDNJ?\ JP?&5?F=_P 'EW_**CP)_P!G;_"__P!0?XI5^F/_
M  ;N_P#*%[]@;_LDNJ?^K!\94 ?M)1110 4444 %%%% !1110 4444 %%%%
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MZ?V!1117VQ^B!1110 4444 %%%% !1110 4444 %%%% !1110 5\VZ?^U?\
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M44 %%%% !1110 4444 %?/?[*W_)!? ?_<T?^IGXBKZ$KY[_ &5O^2"^ _\
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ML:V?P1-MJOPE\,?#2RN/B=KS/(T%MIULNN-)H/V-1#*M[;K':7'VR56@4R;
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MUE!U+3FMHHM+O=.NMUI&(;BY-[#BXD\E@$;[%HHIY1.GFU3-7F^<U%4C*/\
M9E3%4'E,(NG&FO9X586,X2BXJHIJNYNHY.4I*4HM8SQ&H8OP_P 'P#'PZ\-<
M)/!U*59<<X/(<SI^(.)J4\75Q<WC,_J9]5PU>G75:>$JX:65K"QP:I4Z%&C4
MH4*M/\2?BW>_\%VKWXG>.+GX0:+^R-H?PM/B348O >F:[J<VKZVGA>VF-MI=
MSJU_/:VLKZEJ=M"NIWL!@"6-S>26,+RPVT<K_IKXPU;]H_\ X9QOM6\%^$?A
M\/VGI_ 6GR67A'5/$EVWPYL/B'=V]G'JELWB/^STN[W1-'GFOKJRF?3[=M4^
MQV]O,MJMT\D7T#148/))X.ICZO\ ;>>XMX^-1<F-Q>'KTL%*<IR53+Z:P=..
M'E3<VJ<7[2DHQIQE3DH1.KB7Q.PW$F"X1P2\,/"OA^/"57"S>(X:X?SC+,;Q
M11PU+"49X7B[%SXCQ57.*6+6$C4Q5:#PF.E6KXJI1QE"6(J7_&_]G:\_X+8V
MGQC\#M^TEH_[*^L?!2?4_LGCV/P;J4FE^*+'2+F&2)M8T:2&UN3=WVERM'=Q
M::RQ1:B4-K+<6R2&9/J?]M^[_;]CT7P#9_L':3\&I]9N-2UVX^(NM_%W49HD
MT[3K2WTR/P]IN@Z4MN\%ZVK7%WJ]QJ5]+<Q2Z<-(L8(89UU*9[?[IHK*AD$Z
M&6XK+?[>XAK/%5(S685\=0J9GADG2YJ>$Q+P:C2IS5-Q:E2J2BJE1TY0G)2C
MW9KXN8?->-L@XT?A-X.Y='(L+4PTN$,JX6S;!<$YY*4<8J6+S_)(\23JXW%8
M>>,56G.AC\)2JRPF#ABZ.)H4IT:OP+^Q#>?\%$&B\=6/[=^C?!-&1]+N_ &O
M_"34Y6FG$HGAU?2-9T;[*L$45KY5O>6FIK>/+.UU-:O;(ENDLGSS^TO>_P#!
M:&Y^,_BS_AE_1?V7-+^"%I+9VG@[_A.-3EU#Q5JUO%;1O>:OJYEMH/[.N;R[
MDFB73HO/AM8;>)DGE:5VK]@**=7()U<KP^6?V]Q#3="M[5YC2QV'AFE=7JM4
M<1BOJ;C.BO:V48TH3:I4E.<E&7.L!XMX? <=YOQS_P 0G\'L;'-LOC@(\&8_
MA;-<1P'E4U' 0GF.49"N(X5<+F%58&3G4JYAB</"6/Q\J&%HRK4G0\.\':Y^
MT!?? N77?&_@/P#H/[0?_"+>)+F'P%HOBZ_U;P!_PEULFI?\(MIDGB^;2[:^
M&E:F\6E'5;]=+,E@+JZ$,5Q]G1I/S&^$^L?\%T-,^).AWOQ;\'?LC>*?AI/J
M:6^OZ'HOB6Z\/ZM8Z3>W<<<NHV.JVVGWMQ=W6B6;RW-O9/!&FJ30I!--")"X
M_:JBM<;DU3&?V>_[;SS"2P$4G+!8G"45CIKV5ZF84W@:E+$.7L[N$:=*C^\J
M<M)*5EY_#7B7@^&X\74WX7^%O$-'BVI4<:7$V2\09D^%L/-XSEPG"&*I\4X3
M'Y33I+&<M/%5\7C\S:PN#E4Q]2I1<ZGR3^V5=_MC6_PMT^']B32?AA?_ !7O
M/%6GPZG??%;4);30=%\(QV6HW.HWME:)!*FJ:K<7\.F:;%;32P1P6M[=7JM)
M);)&WCO[%VK?\%,AKVMZ-^W!X2^ 3^&GLKS4-#\;?"OQ%=)K,&HJVEP6/ARY
M\*C3S9S6,L9U:_GUMM22XBD%M9BS=&,R_HQ15U<IG5S2EFBS?.**I1C#^S:6
M)P\<JJQBI)^UPL\).<Y3YFY5%7C434>2<%%(Y<O\0L-@> \PX%GX=^'&83Q]
M>MB?]=LPR;-ZG'N"JU9T94UE^>4.(,-A</0PL:,:=#!O*ZF"E"=9XK#XFI6J
M3E^67[8EY_P5IF^*L5M^Q;H_[.5E\(K/P_IZMJ?Q,U*6[\4:UXAGWS:G++8R
M6T<6E6E@Q2SLXH9;E;N-3=2NCOY,?V3^S?JW[2>I_"/3Y_VGO"/P^\+_ !DL
MS-8W]A\._$EUKWA?6H[*PLX[;7OMESI]FVEW&N7XO;BXTB"*Z@TF)HH8KFY"
MEJ^A**>&RF>'S+%9B\WSC$1Q2DGEV)Q&'J9;0NXN/U7#K"PJ4734;1:KMR4I
M.K[23N+.?$'#9QP5D?!J\//#G*:N1RHRCQCDV39M@^-LV=.-55EGF;5,^Q&"
MS*.+E5]I6C4RJ$:,J=*. 6#I0=.7X@6FN?\ !>>U^(<FN7?@7]CK5?AZNNWU
MW'X"7Q9>Z?=RZ%))/]AT<^+TTR:_26WC:#?J?]F>=<-$Q:WB\TJGZ9_M)WO[
M34'P*UR7]E_1/A_??'^Z@T2#0[7X@:I-:^#=)FN;JU&OW\TZ6\CZD=,M#=MI
M]G*MO'?2B+S98QE6^C*XKXDZS?\ ASX=>/O$.E2K!JFA>"O%.LZ;,\<<RPW^
MEZ%?WUG*T4JM%*L=Q!&[1R*T;@%74J2#SX;)9X'#9C3EGN?XM8RG-^VQ>+PM
M:O@6X34JF7SC@:<:$[2O",XU:,)4Z;A3BU-S]?//$S#<4YWP7C*7A7X2\/RX
M9Q>%C_9W#V09]EV4<4TX8C!SHX3C'#5.)\9/-*#E0E#$5\-5P&88FCC,73Q.
M,KQ>'6'_ #H_9$U;_@K3:_$>/3/VR/"7[-NJ_"_4XIS<>*/ASXBNM.\3^%I;
M33-2EM4L] AT^>V\0+K&JG3+6Y-U>V/]FVJSW,)G<^2>Q_9,_8H\7_L[_M3?
MMJ?'[7O&OAOQ%H?[4/BSP[XB\.:!I%CJEMJWAB#19M>EFM];N+P"SNI9EU>%
M8VL"44PR%CAU \H_X)Q_MN:Y\</V+I_BE\>?BU\/_P#A;,?B3XO6'^FZCX-\
M)W*67AC7-5M/#:R:!#+IT2".TMK<++)9J;Q0)I&D#EC^=]W_ ,%*OVOI_P#@
ME/9_M-Z;\0="7XTZC^U2_P *;7Q.?!WA672QX4GNO$-M:6IT8:6VD.5-G9.U
M\MH;IEC8K*?,;=\#'B#A;!Y?P[FV,Q7$6=/#Y9FW&655L=6PF)S'"8>C@,/@
M\7A\2J%7"PJ5I8?.''#T*_MXJ<ZO^T05*BH_UO5\(?'KB/C'QB\/N'<C\'/#
M.GG7''A[]&SQ RWA;+N(,FX/S[.<QXKS/B'A[-LE>:X#/<5A<MIYSX>4Z^;9
MKE2RJM4PV'P"648BICLQG4_J"HK^;_XG?'3_ (+#?L0>#]!_:3^/'C3X*_M"
M_ '3;_PO+\3?#_ACPII7AS7M"\,^(;ZPL_[1LKNQT_1+R.[674(+>*X"W]G%
M=/"MS;F*4M7]#/@GQ;I'C[P=X7\;^'YQ<Z'XNT#2?$>DW"D$3:=K%C!?VD@(
M)!#0SH<@X-?<Y'Q-AL[Q&*P3P&:Y3F&#HX;%5<!G&&I8;$RPF+=6&'QE%T,1
MBJ%;#U*E"O2<Z=9RIU:4H580;CS?RMXI>!^=^&&4</\ $T>+> O$'A#B3,<Z
MR/ <6^'.=X_.<FH<1</4LMQ.<<.YG#-LGR'-<MS?!X/.,LQT:&+RRG1Q6"QM
M'$X*OB(*K[/IZ***^D/Q4**** "BBB@ HHHH **** "BBB@ HHHH *0,I) 8
M$J<, 02IQG! Z'!!P>U+7,:%X7MM!U/Q+JD-_JEW-XGU*+4KJ"^O&GL[%X8/
M(2'2[<JJV<+)\TRJSF5PKDC   .7^,^MW^@_![XM:[H=\UEK.@_#CQQJFFWM
MNR&>PU/3O#&IWEE<IG<%FM[F&*9 X^\@)!%>7_L<>,?$?CW]GCP)XH\6ZQ<Z
M[XAU%O$?]H:E=NK7,_V7Q3K5G;"78% \JUMX8D&T?)&.O6O1="^#OA[28?B=
M9:CJ?B#Q1I?Q6OM4N/$.D^(-5GNK*VL=8MKNSOM'TE83!-8:?+:WLUOMAE$R
MQ"()*AB0BE\(/@;X2^"4?B2R\&7>NKHVOZFNHV^A:EJ<U_I>@*J,#9Z)#,"]
MK!++)+-.7DEDFD8.[EER7I9][JWXW_-?<![*KHS,JNK,A =58%D)&0& .5)'
M(!QQ3J\W\&?#6R\%^)/'GB6VU_Q)JT_CW5XM6NK#6M2:]T[1GB:[=;71+<HH
MLK7-Y(GEAGQ##;0@A8!GTBD!SOB[3-1UKPKXDTC2-3N]%U;4]"U6PTS5[%TC
MO=,U"ZL9X;*_M9'5T2>TN7CGC9E90R D5^)'_!+K]N#XAW?_  2]^,GQ0_:R
M\=7?C?XV_L0^)?VJ_AO^T'XNU18(=4USQ#^SYXD\8W$E_)%#;VT;B_T>QL;+
M272UC:\CAMPL;S,Q;]V:_B/_ ."@VJ:U\"?VG/\ @HS_ ,$V_"$OB#3[[_@K
M)\9OV-O%OPKBTN2.Q^Q:=\6/&'A_PA^TI>^%"\0$XTC2/"VNZ[XP2*.YV6^M
M33S QR * ?H-_P $(OVL_P!LKQO\5?C/\$OVZ_BQJOQ,\8?%GX)_!K]MS]G5
MM7TB+26\.?!?XI:IXT\.ZGX.@:*WMTE?1-3T?1I6L7$EW8Q3F6=MMRNWI?@;
M9_M;?\%+/C9_P47\0^#/VZ?CI^S7\%/A%^V$OP.^!Z_##1_"MY#)I_P9\,:K
MX4^)"V']OV,T5YH'B[Q5?Z;KXOUFEF^W:6(X_*5IXER_^"K'BC2O^"9_Q\_X
M)X_MW:):OIOP_P#A?\-?C!^Q_P#$N&W:WM- C\)Z]\/H?%'PPFUZ29D246/C
M/PA+I6A))+B*\\02A%8RG;^@G_!%3X$ZK\!?^";?[-VE^*;._L_B!\3?"]S\
M>?B5'J\K7&L1^._CAJ5W\2]?L]3NG'F7$^F7/B/^S$9V?9!:11J[*@) /QO^
M"/P*_;[^*'_!3+]N#]B'5/\ @KM^UOIW@K]EOX9_LW>-O"_BNS\.?#:37_$5
M]\:O"5YXAUFTUB"735M+>WTF>V6'3WMC(\L;'S@IP:_J'^ WPW\5_"/X3>#?
MAYXW^+/BWXY>*/#.F?8=7^*GCJVTVS\5^+[CS9)/[2UBWTA(].BN2KK$5MD6
M/;&I !K\6_V0O^5@S_@L!_V;_P#L#?\ JL=6K^@*@#\J?C[^T7\0_B1_P4(^
M G["'P-\57?A.#P3X=L_VH?VL_%VCRVK:G9?#+3]4EL/AY\)H!-#</9R?%7Q
M#97!URY\I6/A2SN8;2XBN+G>F]\7?^"Q_P#P3>^!'C#XI?#SXI_M->&?#'C[
MX->);#PCX_\ !/\ 8'C36?%.DZUJ.C_V_"D.B:#X<U._U#3HM)_TJ]UNSAFT
M6Q9H[:[U"&[EB@D^2?V*4C7_ (+C?\%<#XJ1!X[;X:_LHMX7:3YK@_" ^$'&
MD>4S[I%M3XI&N_)&RP^8"WEAR6/DW_!++X3_  R\4?\ !5?_ (+P>/\ Q+X#
M\*>(?&>E_M ? CP5IOB+7-#T_5M3T_PIJWPIO]7U70;.>^@G^S:?J6HV=I=W
MT$2J+J2V@\XLL:K0!^NA_P""A_['4_[+$?[:>B_&K1/%G[-4HM-OQ(\'Z3XD
M\3PK+>:FFCQVD_A[2-'N?%5IJ$.HR+;7FG7FB07]BY+7=O"@+5\>O_P7Y_X)
M:1HSM\?_ !"%16=C_P *0^.!PJ@DG ^'I)P > "3VKX&_P""5MO\8/ ?PQ_X
M+*>$_P!DWX4_#+X@>+/!7_!7#]J+1OAE\(?B+KC^$?AC::-%X]BM[RP6\@M[
MI-'M=.TR(SV-M;V_EO/!%&%!8M7U4_CC_@MQL?9_P3H_X)[L^UMJM\>;X*6P
M=H8_\(]]TG /MF@#EOVQOVEOVG_VM?VX_P!GG_@G?^Q1\?)OV7/"'C_]F'4/
MVR_BS^TKIGA*S\1?$2;X81:]H/AWPOX0^&_A[Q-%!:Z9J^M:EXFT2;6+K6X+
M>:UTRYO%C$-[9K&_H_[)_P 9_P!IC]F#_@H!=?\ !-#]J;X]S_M6:;\2OV?+
MO]I7]G7XY:[X8TWPG\2K31O#7BB?P?X_\ ?$^VT5ET/4KFSU!;34_">LZ8@G
MN]/FNH;^.*:W&[P#]N[PA%K/[>W[#^N?#+]H"T_8>_X*BZM^SKXKL/"^O:_X
M0B\<?LN_%SX=VIMM0^)7P \1WFKFWT[5=2T76XO^$B\+QZ4UMXC-GIEG>VP6
M1;*:T\!_94^&WQI\9?\ !P+IWCKXE_M,V'[6?C?X"_L->(/#_P"T!XS\!>&]
M \+_  :^#WB_XB^.&N/A]\'/ >B:$]V=/G;0+"^\1>(1K^L:GXINM1NQ>:HM
MG#-:6Z 'ZZ?L7?M$_$#2_P!J?]JO]@/X\>*]0\:?$?X+RZ/\:O@]XZUB&*+4
M_'G[.'Q3U"^7P_%JDMO#!:7.O_#O7K>X\)ZE+ K2W5D=-NYTB8MN_4^OP3\?
MFZ/_  <:_LZ_V%YIMQ_P3>^.P\??8,F-8S\3_AZ?")U_9P ;C[>-',_S;OM0
M@X\VOWLH **** "BBB@ HHHH **** "BBB@ HHHH **** "OGO\ 96_Y(+X#
M_P"YH_\ 4S\15]"5\]_LK?\ )!? ?_<T?^IGXBK:/^[U?^OU#_TC$'-/_?*'
M_8-B_P#T[@CZ$HHHK$Z0HHHH **** /"_P!J*"*Z_9G_ &B;:>?P]:P7'P*^
M+D$USXN\S_A$[>*7P!X@CDG\3^4KR_\ "/0HQDUKRT>3^S5N=BLV ?Y1?^"&
M/_!<#_@F9\(OV-=!^$_[1/Q6_9^_9N_:#\!>(/%?A[Q^GAOP%I?P]\%^-;6U
MUVZ?P_XC\,ZCX6TK^RM?L+G2VMXFG5TG-S;23S6Z&=))?ZY?C-JN@:%\'_BM
MK?BKPK=>.O"^C_#;QUJOB3P19:>FK7OC'0-/\+ZI=ZQX5M-*D_=ZE=>(=.AN
M-(M]/?Y+R6\2V;Y9#7\2%Y_P45_X(U6HNI[O_@WA_: CAMA/+<W4O[&/A58$
MCAW/-<22LX58E56D>1B %!8D &@#^O/]E/\ X* _L<_MP-XP7]E+X^>!?C:W
M@'^S/^$P'@V]N+O^P1K/GG3#>^?;6^P7GV6X\K;NR8GSC%?8M?SZ_P#!"_\
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M;A#]QE];"2HX2G%U8JI5QDW4C*;IPV:***^W/T4_ _\ X.3?VM/C_P#L6_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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METCP;9SVLDS6D"Z/I\TEO$]O#$\BL3*SMS7N]%% 'Y3?'[]F[XC?#[_@H?\
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M]'"9+@X8#!2CA:-Y5*_U6E2I5*]>I5J.%*E1IRIX6CA\/1****]H_,@HHHH
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M?C6X@O+&^.E6[0S+':K)/8SIJ-VUW:2S16CQ?=U &)XFL]7U#P[KMCX?U/\
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M/@3PAINB^ OCK\2/ ^B7-X;BZCTS3(;/PYX<TNWN;B2X59YXI+A\/*P'W'\
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MX?\ @II_P1#BAC2*)/VA?C*$CC14C0'X2:J2%10%7)Y. ,GF@#Z2_;J^(?\
MP44\3_'CX,_LK?L)Z)X8^%.C^-/!WB'XC?&?]LSXG^!;OXA^!_AEHND:M#HN
ME?#WPCX1BU'1K'7?B1XAE>?4O)U75;:VLM(^SWL)=XYXI/G_ /9-_:B_;?\
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M+N.XB:XMFU*POKNRMKW3KUK:^B^/OV+/V*?^"CG[$OA'_@HW_P %5/CK\-/
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M]Q:ZYY'AH?#CQ]K^G^)-?ANM#^QOY^LG4]-MFLM3^V)]F@,L7V>3S"P^JZ*
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M[VEQ';S6>FZKI4#Q;BQK]<Z;)(D2/+*Z1QQHTDDDC!$C1 6=W=B%5%4%F9B
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M]2N+Y!=/#' PGEW,\+AW#?IK7Y(?\%9/AUXY^(7A_P#9<C\$^"_$?C*3P_\
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MV-J%-Q<W?C3XO2S330L@,LMP[;W9U+2DACG(H _2+XN_\%";W0/@Q\ /CO\
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M]X*U_P >?\%5_#WCSP1HGBK0M5\7^"(?V0/!_AZ7Q=X:L-2M[G6O#<>O6_Q
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MO_7ZA_Z1B#FG_OE#_L&Q?_IW!'T)1116)TA1110 4444 %?E]^T-_P $7/\
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M/Z;;7>@>'[W1;*$Q7OB:XFNX)X[;4-;U#1]&1+*&>6V2_EU.93;6,R/]_P!
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M$>D:M8:A9Z3J+:!%-<6BQ6*116WD_P!:/PE\(:G\/OA;\./ >M:R?$>K^"_
MOA3PIJ>OE9%.LWWA_0['2KK4\3%IO]-FM'N!YQ,I#@R'>6K\6/\ @A]\)_\
M@D5\'/#GQP\/?\$P/C='\>M8UC6/#^O_ !R\<:Q\1)/B-XWNKJ5-1B\-+KNJ
M#3='M+:TPVIFTCM=.A:XG-S-=2SS#<O[T4 %%%% !1110 4444 ?R5?\'EW_
M "BH\"?]G;_"_P#]0?XI5^F/_!N[_P H7OV!O^R2ZI_ZL'QE7YG?\'EW_**C
MP)_V=O\ "_\ ]0?XI5^F/_!N[_RA>_8&_P"R2ZI_ZL'QE0!^TE%%% !1110
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M^('C"[F-PD'_  HGXG?'G5O@]\:([W[*RR3V]EX7\9?VO!#/FSAN[%+RX&V
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M9!-/TV"WLX/+M+>)&\J)=[ NV6)-?E#_ ,$J/V6?V,?V@_\ @DE\6?BI\<O
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MNUUK%SKE[9R3/I9TVV1KB[@O(8;F*'$C0[&4G\,O#O[-WP5^.O\ P<<_M/\
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M]2T&@?\ "J_^%'ZM/J?]I&07G_"0_P!O^?J-^8O(VV7V/:(MV^4$-M!K]4:
M"BBB@ HHHH **** /Y*O^#R[_E%1X$_[.W^%_P#Z@_Q2K],?^#=W_E"]^P-_
MV275/_5@^,J_,[_@\N_Y14>!/^SM_A?_ .H/\4J_3'_@W=_Y0O?L#?\ 9)=4
M_P#5@^,J /VDHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/Q9X4^'OC3Q-X6\,&9(I?$GB'0/#FI:IHNA1%F4[]6U*UMM/4CHUP#7\6O\
MP3X_X)8^,_\ @L!^SPG[??[8?_!2K]J2R^,7Q=\3^-Y%^''PK\?2>"_#/P$N
M/#?BO6-$@\,-H2ZO(MK>VZ6%KJ']F_9=*CM[&33V+3S337#?T=?\%'/^"6>A
M?\%$]6^&^KZS^U)^TU^SL?AOINL:?%;?L_\ Q#U'P/:^(EU:YCNGN?$26-S;
MK?36GE>7:O(&,4;.H(!(K^6G6O\ @ES_ ,$,?@+XF\?> ;W_ (+L?%SX=>)+
M_5KR+XEZ#H7[2&G6)UC6_.N([\>+&\-[['6M1\^2Z2[;4)KN?S9)UF;<[@@'
M[)_\&^WQ8_:4@\:_\%!OV+/B[\=M5_:O^%'[$7QRT_X6?!/]I#7O/O-;\4:5
M*NM'4?"NJZ_+<WR:_J/AE+&RM]1ECO\ 4/L.I?;(1>3VL]HY_I:K^</_ (('
M? #_ ()O?LX7G[1_@/\ X)\_MN^+OVNK*Y?P?KWQ'T[4]?EUWPMX#U'47U22
MPN])F@T[3]'_ +7\2;KF;5I[ W4\YM8Q>S">)HU_H\H **** "BBB@ HHHH
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MT33Q>7"ZCJ5I;2VVBVUW=RZ?H=C<7#XFUG5=/@E6"U>>\M_KFOP9_P""EW[
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M_!?BOQ>]JUZOACP]J^O-9JXC:Z72K&>],"N>$,HAV!CP"V37DX?/,KQ>+SG
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M:V4\*9'F7$&94LOH5:%"MC:F"RK#8K$PPE&MBL-2JXB5-4H5*]&$IJ52"?Z
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MFO:_&_\ :5\(Z3XLGF74/$5C,OBW4])LO$4UQ,$2]UFUD\O4FFF"K<7D>Z3
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M'B_4O!>M6?AJ:&102DL>LS63QN 2KJK $BO\W_\ 9[^ ?[#_ ,-?V)O^"?\
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M6@.MP^$/$7Q1\.:==B]MK.X%Y;6^IV$:Q>;-'';WD,DB*9(I&! /[,/V7/\
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MT2^O?#NI:9<ZOX5UI[2SDUGPSJ<ESH^I26=K)<VKO"C#VG]H;]D?]GG]J?\
M9Y\1?LK_ !O^&NB^+_@5XET#2O#EUX&_TC2;33M/\/\ V5O#DGAZ\TF:SO\
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M3YZOL:<I.%+VL_?J<D8\\_>E=ZA7X-_\$1_@QJWA3PO_ ,%"&^)_PQFT2_\
M$O\ P4__ &T?%?AU_&/A2.VN]:\):Y\6]<O="UW3'U6R$UYHFIVDBW.FWL)>
MUN8'$L#LCAC^\E%48GX3_'/X2>(8?^"]G_!/3XA^%OAW>V_P]\/?L;?M<Z+X
MI\7Z'X;^S^&=)US6-2\)_P!BZ;K.K6-K'96^HZ@D<W]GV]W*)YT23R%95?'Y
M">'OV0?VF=2_8[\<?%_X?_"#Q5XD^+O[(7_!:[XJ_MF^#/@GJD7_  C&K_&W
MP+8>(?%/AO6M-\+RZM;@7=_>^$?%NI>(/"IA4Q:I>Z;#;K)Y<Q)_M3KXW_;F
M_8S\*?MR?!!_A!XB\??$7X4:OI7BSPU\0/ 7Q0^%7B&Z\.>-O GCCPC?"^T3
M7-,N8)4M[Z%6,MM?:7J4=Q87MI/)'+#O$;H ?S0?\%)_^"@FJ?MG_$G_ ()2
M:)X0_96_:)^%'@+P]_P4I_9RU#QOX\^.W@Q_AXEA\16N=0BLOAMX8T:]DFOO
M%EU:VTFJW>MZ_8B/2+18=.2WDN6O7\C]:/V%OA]XX\/?\%9_^"M?C77?"/B#
M1_"7C6/]F\>$?$NHZ5=VFB^)3I/ASQ+%J0T749HEM]1_L^6:-+H6\DGD/*@?
M!89U_A=_P2;^)&K?';X,_'7]M_\ ;A^+G[:%Y^S9KX\6_ ?P!XD\+^$_A]\/
M?"OC6"%8=.^('B#0O"=O$/%WCC2-BOIVMZI(6A?YS$S &OVHH _#W_@E1\/_
M !SX/_;(_P""U.N^*_"7B'P[HOCS]M_P?KW@K5=:TF\TZP\5Z)!\$/"5C-JW
MA^ZNHHXM5TZ*\BDM)+NS:6!+F-X&<2HZ+6_X*Q_#?XW> OV@/V#_ /@H;\%_
MA)XF^/UC^R'XN^(^A?&;X0^"$CN?'FH_";XKZ%I^GZEXK\":;(535=>\+:II
M%G=7-BS!IM,DN$A!D;*?N710!_*KXO\ VB?B?^W1_P %<O\ @EI\6_AW^RI^
MT)\/OV;OA5)\=[?4_BG\7_A[J/@J[U3Q3KW@.>W>U3P_<O+?:)H6E-$U@=6U
M=88M7U.=([#]U#NFM?L:_'[XE?\ !&/0?CM^Q3\>_P!D?]ISXIZ+:?';XK?%
M?]F7XP? ;X>7'Q)\+_&WPC\5=:D\3VF@:O<Z=)#_ ,(7XTT?7I;[3-1BU<'3
M8[*XTV876^.YC7^J"B@#^2_X<?LV?M#?"C_@G5^T_P#&?]I#_@GKI_[3VJ?M
MQ_MIW_[3/[0G[$-[KJR>//AM\%O%6K);6.H>#(+?3+RSUGXM>!-.T_PYXCET
M%9-$%O<+JUQ#JT%S8QI<>&_L/_L\QS?MV_!5?^"87@+_ (*!?L\?L?7GAOXG
M6W[;/@S]IQO$>C_ ]+/7_#=QIGA;P_\ #GP_XX>^\0W/CVTUN:2=[ZWU&[TJ
MWL;:U^R2(!=)-_:%10!_ 5^SG^QS^RQ^Q'\,==_9;_;U_P""4G[5/QA_:0^%
MFM^)] ^&OQ3^!L7Q&\4_#K]JG09-6O;CP?XBTG5?#OBNRT/X>W^HVDT-KJNG
MZK;M9:8%0_:[R99TK^M[_@E7\$O^%%?L8_#OPY<?LP>'OV.=5\2ZCXG\>:Q^
MSWX=\>:U\2(_ EWXGUNZN+6'6?%6NV5A=77B;4M(BTW5/$=E#;BUTK5KNZTV
M*6X>VDN)?T7HH _!3QII4OP3_P"#A[X2_$O7_-A\,?M@_P#!/OQE\#/".H7$
M#M9)\0/@E\4-(^(VIZ/'?;A%;WFI>'==LYK.R<"6Y^R7C0^8 XBZ_P"!/P_\
M<:=_P7;_ &[/B+?^$O$%GX#\1?LK?LZZ-H/C&YTNZA\.ZQJVEV.G+J6FZ;JS
MQBTN[RQ92+JWAD:2$J=ZC!Q^@G[7G[)7AO\ :L\,?#M)?$%[X!^)GP7^)_AC
MXP_!KXHZ-9P7>N>!/&WAR62*:2WAG:-+O2?$6B76H^'_ !!IDDJP7^G7S"0&
M2&$K]9P"98(5N7CDN%BC$\D2&.*28(HE>.-F=HXV?<R(SN54A2S$9(!_/?\
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M'TBXA2YO+C7;:!8]'6.,K>2SPB,D/FOWIHH _A^^"?[9W@C]I#]I>?\ ;?\
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M $*WUBYTRZMV=VAN],?4387<;,66YMI00IRH^]:1555554*J@*JJ %50,!5
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M]0&H.S+ T?\ 0&"" 1R" 0?8\B@!:*** "BBB@ HHHH **** "BBB@ HHHH
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M[_E%1X$_[.W^%_\ Z@_Q2K],?^#=W_E"]^P-_P!DEU3_ -6#XRH _:2BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** /Y./\ @Z=\'?M%:EH'_!-_XE_!7]G[XI?M >$?@G^U
M+JGQ#^*&A?"+P;K/C7Q78-I5CX2OO"5NMCH%EJNI6-IKD>G>*K0ZD^E3Z;#=
MVUI'>W-J\MK'=?TD_LL_'BW_ &G/V>_A/\>;?X=_$?X2?\++\)VFOW7PS^+?
MAG4?"'Q%\$:F)9[#5O#GB?0=4MK.\M[O3=4L[N"VNVM8(-7L%M-8LXUL[^"O
M?J_%S_@D[_P4?^*W[?GQA_X*;>%OB!X2\'>#_"O['_[8OB#]G7X6V7AH:C<:
MM?>&?"5SXET&\UCQ;J]].(=4U;6=1\--J\8L-+TJWTR#4/[+V7QM!J%P ?M'
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !7SW^RM_R07P'_P!S1_ZF?B*OH2OGO]E;_D@O
M@/\ [FC_ -3/Q%6T?]WJ_P#7ZA_Z1B#FG_OE#_L&Q?\ Z=P1]"4445B=(444
M4 %%%% '\DW_  76\/>!?BE_P5V_X(>?!WXV)HNM? S6/B?XT\3^,/"GBZYM
M(?!>HWFA0SZC9S:^FH21:?-:27&DV%M<P7KFWN[;=92HZ7#QOY)XNM_V<?V:
M_P#@Z/\ V:]8_9\F^$GPS\$_&/\ 8_\ $\/Q77P!KWAGP_X%UG65N]?M+>^U
MFST;4+?P[!K,EIH^E1HDL4,UR+"SF6)Y8TE/[W?\%#/^"0'[&W_!3K7/AIXB
M_:CT?X@:AJWPFL=6T[P;=>!_'FI^"WL[?6KB.ZOOM#:;$[W$K2Q(8Y"Z-& 0
M.#7YP/\ \&F/_!(R2\34)/#?[04FH1H(X[]_CSXJ>]CC&["1W30F=$&]\(L@
M7YFXY.0#^CWPYXW\%^,/M0\(^+_"_BDV7E_;1X<U_2=;^R>;N\K[5_9EW=?9
M_,VMY?F[-^UMN<&NHK\T/^">_P#P2>_9,_X)E/\ $E_V8[7XD6S?%;^PAXK_
M .$_^(6L>.M__"/"[&G?V=_:J@V&/MLWGF(DS?(&XC4#]+Z "BBB@ HHHH *
M*** /Y*O^#R[_E%1X$_[.W^%_P#Z@_Q2K],?^#=W_E"]^P-_V275/_5@^,J_
M,[_@\N_Y14>!/^SM_A?_ .H/\4J_3'_@W=_Y0O?L#?\ 9)=4_P#5@^,J /VD
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ KX2_8Z_X)Y_ C]AWX@?M;^/_ ()3^,89OVQ_
MC=<_'WXCZ#XDUQ-;T?0_'>IQZA+KI\(236B:O9Z5K6KZOJNMW%CJNIZL+.[O
MFM-+DL=*M[2P@^[:_E>_X-[?CY\5?BI^V1_P7&\+_%#Q?XJ\;3>&_P!O7QS'
MX=OO%6NZEJ;>'O#?AOQCXZ\%>'O"^B:?>2/::1HNG>'])TFVM+?3X[:'R+*W
M!B<CS" ?U0T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 5\]_LK?\D%\!_]S1_ZF?B*OH2O
MGO\ 96_Y(+X#_P"YH_\ 4S\15M'_ '>K_P!?J'_I&(.:?^^4/^P;%_\ IW!'
MT)1116)TA1110 4444 %%%% !1110 4444 %%?D#_P %%_\ @MY^Q!_P3,\:
M>$?A;\<=9\=>+_B]XTTS^WM-^%GPB\+#QIXOT_P\WG^1KVOV0U"P72=.OOLE
MX-.9VFN+W['=/% (()9E]7_92_X*T_L/?MB?LL_$+]K_ .%?Q7AT[X1_!^PU
MF^^,1\<68\,^)OA8-"TR36+Z#QEH4EQ=26,DVFQFZTQK:>[BU5'2*RDENM]N
M@!^D]%?@M^QI_P ''7_!-O\ ;=_:$TC]FSX:>)?B5X0\>>,KBZM?AC>_%'P0
MOA#PW\3;FUGN+?[#X4U5M6OO/U*[>UF_LZQN((7O?+DBC<7,;05^]- '\E7_
M  >7?\HJ/ G_ &=O\+__ %!_BE7Z8_\ !N[_ ,H7OV!O^R2ZI_ZL'QE7YG?\
M'EW_ "BH\"?]G;_"_P#]0?XI5^F/_!N[_P H7OV!O^R2ZI_ZL'QE0!^TE%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %?SE>(?^"7'[<_[(-S^W=\=O^"9WQV^%]Q^TW^VK
M^TMX>^+=Q;?'GPW;1^ ?!'@=[WQ#>>+- MY(M'\2/J.IRMJ&FI87,VFJX2"X
MQ-"[AC_1K10!^)W_  3=\*_\%W-"^+WBFY_X*;?$_P#8[\9_!23P<T7AK3/@
MAH5_:>-8O&AOD:WN5N[?PMX6LH=,2R$J7ZZDVI"8/$ME!;3J\[4O^"CWA/\
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M#QMX%TZ^6'7-*TNZ\-&7Q#"?#NF27MU?Z'/J_P!$R_\ !7?]DJ/_ ()J6?\
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M5_\ E$C_ ,$Y/^S//@5_Z@>D5^G= !1110 4444 %%%% !1110 5\]_LK?\
M)!? ?_<T?^IGXBKZ$KY[_96_Y(+X#_[FC_U,_$5;1_W>K_U^H?\ I&(.:?\
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M7\9/^"*GPD_X6)\4OA)_PL7_ (*)Z5X2_P"%F_!+Q;_P@7Q=\"_VSX7BM/\
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MO^#R[_E%1X$_[.W^%_\ Z@_Q2K],?^#=W_E"]^P-_P!DEU3_ -6#XRK\SO\
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M-\'_ /P2?LO?_/9H _N<HK^&/_A?_P#P>G_]&S?!_P#\$G[+W_SV:/\ A?\
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M^R]_\]FC_A?_ /P>G_\ 1LWP?_\ !)^R]_\ /9H _N<HK^&/_A?_ /P>G_\
M1LWP?_\ !)^R]_\ /9H_X7__ ,'I_P#T;-\'_P#P2?LO?_/9H _N<HK^&/\
MX7__ ,'I_P#T;-\'_P#P2?LO?_/9H_X7_P#\'I__ $;-\'__  2?LO?_ #V:
M /[G**_AC_X7_P#\'I__ $;-\'__  2?LO?_ #V:/^%__P#!Z?\ ]&S?!_\
M\$G[+W_SV: /[G**_AC_ .%__P#!Z?\ ]&S?!_\ \$G[+W_SV:^6_P!KW_@J
MC_P==?L'?">/XX?M5_##X+_"OX7R^*-(\&)XGN? GP(\21MXDUV"_N-*TW^S
MO"'C[7]5#7<.F7SK<&Q%K'Y!$LT;-&& /]$"BO\ /X_9U_X*$?\ !W=^U?\
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M!<RR?;5CCC>6*=(P#_1XHK^&/_A?_P#P>G_]&S?!_P#\$G[+W_SV:/\ A?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MA?P-INFZ/X3TG3)YI;T0Z'IND1Q:;:V<T]S-=!;2-8I))Y)1DR%B =U1110
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MG% &S13(I8IXXYH9(YH9462*6)UDCDC<!D>-T)5T92"K*2K @@D&GT %%%%
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MSX"T"[\+,Z:/I.G:;;>7#;7'A/3#9V5AIKRKI=U=2Q0RK:%!N?L!>'/VL?\
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M!+97-Q::7I44\=Y>W%BDNL:F]E);VT+^:)HW_!1/_@E=I_\ P5!_X)W>!/\
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M_P#@XQ_:K_:]\<_'3P!^P=\-_P!GC]J3Q5^Q4;'PYXF_:]\7?LY>%-2?QO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !7SW^RM_R07P'_W-'_J9^(J^A*^>_P!E;_D@O@/_ +FC
M_P!3/Q%6T?\ =ZO_ %^H?^D8@YI_[Y0_[!L7_P"G<$?0E%%%8G2%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?R"?\'.GC35?VE_B_
M_P $X?\ @DEX$U4PZS^T_P#''2_B3\58X9GC&E_#WPYJ*^'-$N[_ &R1PS6+
M&[\<:I=V=U(I*Z%97$44K;&C\G_X([65C_P2U_X+G?MU?\$M1+'HWP._:)TS
M_A?O[,FFF^@GLHULX#KUAH\$PDXN8/"5YKFBV>G(CSK;>%A-/,Q9=W.>-_\
M@D9\?O\ @KQ_P6?_ &O_ (\?M;:9^TY^RU^SE\&?#'ASP%^S+\0/!MRO@'7_
M !M#I4]SI-I>>#M>OK/41%8+'#KVJ:V-.M(I;M-:TV62Z7S667R?]N#_ ((.
M?&W_ ()L_M!?L2_MW?\ !.G4?VN_VS/B=\-?CMHA^*NA^-/$5C\2/&UC\/K6
M!DN4TVZ33-+O8]$UK0[G7O"M^D\UQ#9IJJS+]G5C(H!]]_ME_P#!0C_@IO\
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M?0-3%W_8<UG;>+-'UZ]U6V*336GAV\9;6W-\4B^[_P#@I)_P5]^.-_\ L/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M10D:BOK&BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M3$LHI7$U_>2,USJ>K78!#7NJ7\N;B\N7+.V7810[V2VBAB(C&W)"EK4M*?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M9'K94KI/VM%75[.>J]=-SG>(LVO88AV=KJE=/;5/FVU_!GT)17SW_P 96_\
M5O?_ )D>C_C*W_JWO_S(]'L?^GM'_P #_P" +ZS_ -0^)_\ !7I_>\_P?8^A
M**^>_P#C*W_JWO\ \R/1_P 96_\ 5O?_ )D>CV/_ $]H_P#@?_ #ZS_U#XG_
M ,%>G][S_!]CZ$HKY[_XRM_ZM[_\R/1_QE;_ -6]_P#F1Z/8_P#3VC_X'_P
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M8_\ 3VC_ .!_\ /K/_4/B?\ P5Z?WO/\'V/H2BOGO_C*W_JWO_S(]'_&5O\
MU;W_ .9'H]C_ -/:/_@?_ #ZS_U#XG_P5Z?WO/\ !]CZ$HKY[_XRM_ZM[_\
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M , /K/\ U#XG_P %>G][S_!]CZ$HKY[_ .,K?^K>_P#S(]'_ !E;_P!6]_\
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MHKY[_P",K?\ JWO_ ,R/1_QE;_U;W_YD>CV/_3VC_P"!_P# #ZS_ -0^)_\
M!7I_>\_P?8^A**^>_P#C*W_JWO\ \R/1_P 96_\ 5O?_ )D>CV/_ $]H_P#@
M?_ #ZS_U#XG_ ,%>G][S_!]CZ$HKY[_XRM_ZM[_\R/1_QE;_ -6]_P#F1Z/8
M_P#3VC_X'_P ^L_]0^)_\%>G][S_  ?8^A**^>_^,K?^K>__ #(]'_&5O_5O
M?_F1Z/8_]/:/_@?_   ^L_\ 4/B?_!7I_>\_P?8^A**^>_\ C*W_ *M[_P#,
MCT?\96_]6]_^9'H]C_T]H_\ @?\ P ^L_P#4/B?_  5Z?WO/\'V/H2BOGO\
MXRM_ZM[_ /,CT?\ &5O_ %;W_P"9'H]C_P!/:/\ X'_P ^L_]0^)_P#!7I_>
M\_P?8^A**^>_^,K?^K>__,CT?\96_P#5O?\ YD>CV/\ T]H_^!_\ /K/_4/B
M?_!7I_>\_P 'V/H2BOGO_C*W_JWO_P R/1_QE;_U;W_YD>CV/_3VC_X'_P
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MZ*WDT'@7QW\9+B+5?BTT_A3P.EPEUI7PITJ[=+K485PT,WCG5[9XIIW.%?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
4B@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>img34756086_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img34756086_2.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" '>!84# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQ3X>TS1_A9\'O!D6HSCPAX+USPKH/B&ZT?P=*EMK<4G]JW8O;Z-'^L?V6?\
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MSM'_  U3\!?^A[_\M?QG_P#,[6OU?$?\^*W_ (*G_P#(G/\ 7<'_ -!>&_\
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MWUF2V\1?$6Q70I_#EA<Z/JTC7=AXV\40Z=8VCW%_J[VX6[EZYY#FU/+WF=3
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M "U_&?\ \SM'_#5/P%_Z'O\ \M?QG_\ ,[3^KXC_ )\5O_!4_P#Y$7UW!_\
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MZ5:KC,)3HUOX-6>(HPIU;[>RJ2FHU+_W&S]/J*_FP_:]_P""_G@']G__ (*
M?"S]GKP;XL^$NM_LW:+>-X>_:R^(FL?#SXSZSXU^&?BNRUWQ!8ZQIO@R\\/W
M>GZ9XAMM/TJV\/WJ7WAWP7\1-/NY[^ZBM=0E:-X;.?\ ;A@_8?\ VQ_VK/\
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MO_!4_P#Y$P^NX/\ Z"\-_P"#Z7_R9]"45\]_\-4_ 7_H>_\ RU_&?_S.T?\
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MS?L,_#W_ ()_^*?%'Q<LO@Y\-+#P!8>'?$^A>(?"5K\3I!\.E9-'N=3UB_\
M NI^%+FYOHY9X]7$/@NUMIEG=K"VTZ1(7BZI\78".,C5H8C&4Z,^+GFU=0A.
MG[3+G@L)A[5(QFO:2=2E4O1E=.-F]TCG7#>,EAG3JT<-.K'AI9;2<Y1GR8Y8
MK$5KPDXODBH5(6JJS3NEL?S"_P#!1?\ 8L_9>^#O_!"/]A3XT?#KX-^#?#?Q
M@\80_LS^+O%OQ2L]-B_X3_Q1J7QF^!^N>-O'5GXA\4L#JVLZ%<^('@N=&T'4
M+FXTKPU#8VEMH-KI\2SK/R?_  5@\7?$?XD?M+_\$>=#UKP'X8^-6@ZI^Q1^
MSKX[T'X5?$?QO:>!/A[\0_BAX[U75AXST+Q+XR\3>*- TW3+'Q##X8^']GJL
M^K^(=/\ M]O]FT^[U.X:^V5_5=^T1_P3'^ '[2_[&?PA_8:\<^)OBSH_PD^"
MFF_"C2_!^O>$?$'A.Q^(<UO\'?!4W@+PP^M:OK?@?Q!X=O9KS0[B5M<:V\*6
M*75\WVBQCTV-5@%;]IO_ ()4_LA?M;_ OX.? CXQ>&?$U]I?P"\)Z)X,^$_Q
M T+Q#'HOQ.\*Z+HV@Z+X;D@37X],GTG4XM;TWP_I3:YI^L>'K_1;J_M+?4K?
M2[2^M;2>WSP/%V"HSP53&3Q6)J4LPSV<ZLXU*M6AALSI1A0J4Y.M2G)QDG[2
ME3K4IQ@Y^SFI<M[Q7#6+J0Q4,-'#T(5,%D\(PBX0A6Q& J2G6A->RJ07,K<E
M2=*I&4U'G@XW/YYO@A^RG^VCIW_!6O\ 8U^/FL_L0_LU_P#!/W2E>ZT;Q#\/
M_@A\>?V<-)TWX@^%+/PSXYF\6^(="^$?A/XKWNO^(KV[\'W%W8ZY!X$\'7T$
MMAHB^(-6B1K'4]7B_LXK\8_V*_\ @A-^Q-^PQ\9_#_Q_^&FI_&[QQ\4/"":^
MGA#6_BGXZ\/ZE:^&_P#A)_"^K^#=;>RT?P-X'\ :7?/>>'M>UBQ#:[:ZO]G-
M\]Q;"&YAMI8/V<KYOB?-,/FF*P;PM2-:C@\##"QJK"U\)>U:O4Y>3$X_,:\X
MPC4BHSJ5TVW**@HQBY>[D&7UL!A\2L1!TZN)Q<L1*F\11Q%KT:-/FYJ&#P-&
M,I2IR;C"BU;E;G*3:11117S1[H4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% 'SW\1O\ DO7[-_\ W6#_ -0RQKZ$KY[^(W_)
M>OV;_P#NL'_J&6-?0E;5?@P__7F7_J17.:A_%QO_ &$P_P#4/"!1116)TA11
M10!_GP?\$P?^"97P&_X*5?M6?MU^&_CIXM^+GA2Q^%/C*]UOP[+\)M>\&Z%=
MWMWXH^(_CNPOX]:D\8> ?'<-Q;PPZ1;-9I8P:=)'(\YFEN%:-(OUQ_X+I_LV
M^!OV0O\ @B_\%?V</AKJOBS7/ _PM_:&\!:1X?U7QUJ&DZIXKO+;4]/^,OB.
MX?6+_0]#\-Z3<3)?:S=10&QT/3H8[..WA\EGC:63WSQS_P &Q7[ ?CWQMXQ\
M<W_Q2_:WTJ^\9^*?$'BR]TO1?B!\(ET?3;OQ%JUWK%S8:2NK? G5M473+.:\
M>WL%U+5=3U 6L<0O-0O;@27,GTJ?^"&7[)3?L2K^P8?B%^T4?A"GQO\ ^%^I
MXD/B_P"'!^)*^,CH+>'3IRZL?A-_PBR^&C8,S_81X-&H_:F:;^UL$H?U'&\3
MY;B,URK,%G&.J8/!XS 5WE,\O<:6']AA_8UJ\,1]8?/-OGDH*BK^UDE+2[_/
M\)D&.H9=F&">682&)Q.%Q=+^THXU2G6]K6]K2I3H^P7)!+ECS>U=O9IN.MC\
M)O\ @LY^P_\ LJ?LZ?\ !)O]B/XC_!KX+>#? WQ&U+X@?!C0/$?Q TK3U7QG
MXQL/'O[/_P 2/&OBK_A,?$<A?4_$LM_XH\,Z3JMH-4GG@T,QS66@0:7IL\ED
M>D_X*22:!\8O^"EG_!&3P/\ M-7MEJWP#\3_ +.7[/.O>*_^$OU/^S?#.M^*
M/'/C3Q''X[AUV[DN;>R@MO$C>'OA[8>(&VV2W5E<Q6]S=B!HC:_TF?MA?\$V
M?@/^VS^S-\,?V5?BMXC^*>@_#WX3:_X&\2>%M9^'^O\ A;2?&;ZA\/\ P-XB
M^'VC+JNH>(O!7BK0[NVN= \4:F=3BB\.VKS7_P!GN;62R2$P/SO[8'_!*3]D
MO]MSX3?"CX4_&32O&=H_P1T"Q\+_  T^)'@KQ!IVB?$OP_H5KI.EZ/=:9)JN
MH:!K?AW5[+5H-%TRYU"TUKPMJ%I'J%J+W3(-.FEN#+Q8'BO"0AEJQM?&U*U&
MMQ!"MBDI5<1A:6:4H0P]>A.I4C*4J<E*4H1G%QCS<MWRQ?5B^'<3*>.>$HX2
M%*I2R:5+#W5*CB*F75)3K4:T80:C&<;*,W&2D[)V5VOYZOVY?@?^R?\  O\
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M G@.TT#0YU^'?BK5[339-!O?! T;5](%YJGA7Q#8:[<IK'AY=9EUN%XO%O\
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M#X?\$?!1?B'<?L[> ?%&A?&U+;PS#\7M8_:*U&P\-7>N>%9O&,$D'B:]U/\
MX3.;5/#FK?#R2^N['1=,2^MCHX6QDN:_/#]N34/%NI_\&^7_  2IN?&LNH3:
MS%\7/B/I]D^I9^T#PEI&K_'#2O $4>>?[/@\"67AN#2>W]EQV>.,5^\>D?\
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M\0/#OC.ZL/!'BQ;_ $_5KGP!H&@?#_P_H:2:7JG]@:#?/<02VKQ6]T?Z!O\
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MI]EI6F_:+A[31?#VCZ)HZW,]Q?RV$NH7$]W)YI^RK_P26_93_9/_ &<_C?\
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M_P#%WB2\\6?$BU^/WQ!^)]QX?T?Q+\-WL/$NJV7A;3+;XDW6KZ=XE^%VEO\
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M,%.6$P&/E0I9CAJF$Q5>U&FL7B_;T\13F\/.$VX+DJQ]E"3@^6*7,^3\_?\
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M'GJ1QBKQPMY**E5M&5)--_NU&R^$_02BBBO@C[$**** "BBB@ HHHH ****
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M7SW\1O\ DO7[-_\ W6#_ -0RQKZ$K:K\&'_Z\R_]2*YS4/XN-_["8?\ J'A
MHHHK$Z0HHHH **** "BBB@ HHHH **** "BBB@ HHKY]_:I_:2\!_L@_L_\
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M<ZNOBB6SD>^BU-D[/_@CI_RD@_X+O_\ 9S7PQ_\ 4O\ VI*_0;X1_P#!(/\
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MZ/90)#!##'!'8^)G_!,3]A?XQ6'[/&E_$KX"Z=XIL?V4_"GAOP-\"(;KQO\
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M=0NM6T,7(N+%9[2 _9Y+=I5G_-+XY?L[^//@QKG[7&BR?M%>+OVO/A[^RO\
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M ,QE>]_Q@'_58?\ F%/,_P",I_ZD'_F1\O\ @_AYA_PW_P#L'_\ 1['[(_\
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M_FSH_P"&_P#]@_\ Z/8_9'_\21^#?_S9T?\ # '[!_\ T9/^R/\ ^(W?!O\
M^8RC_A@#]@__ *,G_9'_ /$;O@W_ /,91_Q@'_58?^84/^,I_P"I!_YD?+_@
M_AYA_P -_P#[!_\ T>Q^R/\ ^)(_!O\ ^;.C_AO_ /8/_P"CV/V1_P#Q)'X-
M_P#S9T?\, ?L'_\ 1D_[(_\ XC=\&_\ YC*/^& /V#_^C)_V1_\ Q&[X-_\
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MQW\0/ ?PM\*:KX[^)OC;PC\.O ^A?8?[;\9>._$FC>$?"FC_ -IZE9Z/IO\
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M_P#B2/P;_P#FSH_X;_\ V#_^CV/V1_\ Q)'X-_\ S9T?\, ?L'_]&3_LC_\
MB-WP;_\ F,H_X8 _8/\ ^C)_V1__ !&[X-__ #&4?\8!_P!5A_YA0_XRG_J0
M?^9'R_X/X>8?\-__ +!__1['[(__ (DC\&__ )LZ/^&__P!@_P#Z/8_9'_\
M$D?@W_\ -G1_PP!^P?\ ]&3_ +(__B-WP;_^8RC_ (8 _8/_ .C)_P!D?_Q&
M[X-__,91_P 8!_U6'_F%#_C*?^I!_P"9'R_X/X>8?\-__L'_ /1['[(__B2/
MP;_^;.C_ (;_ /V#_P#H]C]D?_Q)'X-__-G1_P , ?L'_P#1D_[(_P#XC=\&
M_P#YC*/^& /V#_\ HR?]D?\ \1N^#?\ \QE'_& ?]5A_YA0_XRG_ *D'_F1\
MO^#^'F'_  W_ /L'_P#1['[(_P#XDC\&_P#YLZ/^&_\ ]@__ */8_9'_ /$D
M?@W_ /-G1_PP!^P?_P!&3_LC_P#B-WP;_P#F,H_X8 _8/_Z,G_9'_P#$;O@W
M_P#,91_Q@'_58?\ F%#_ (RG_J0?^9'R_P"#^'F'_#?_ .P?_P!'L?LC_P#B
M2/P;_P#FSH_X;_\ V#_^CV/V1_\ Q)'X-_\ S9T?\, ?L'_]&3_LC_\ B-WP
M;_\ F,H_X8 _8/\ ^C)_V1__ !&[X-__ #&4?\8!_P!5A_YA0_XRG_J0?^9'
MR_X/X>8?\-__ +!__1['[(__ (DC\&__ )LZ/^&__P!@_P#Z/8_9'_\ $D?@
MW_\ -G1_PP!^P?\ ]&3_ +(__B-WP;_^8RC_ (8 _8/_ .C)_P!D?_Q&[X-_
M_,91_P 8!_U6'_F%#_C*?^I!_P"9'R_X/X>8?\-__L'_ /1['[(__B2/P;_^
M;.OHGP'\0? 7Q3\*Z9XZ^&/C?PA\1O!&MF^&C>,? ?B71O%_A75SIFH7>D:D
M-,\0^'[W4=(OSI^JV%]IE\+2\E-IJ%G=V4_EW-O-$GSM_P , ?L'_P#1D_[(
M_P#XC=\&_P#YC*^B? ?P^\!?"SPKIG@7X8^"/"'PY\$:(;XZ-X.\!^&M&\(>
M%=(.IZA=ZOJ1TSP]X?LM.TBP.H:K?WVIWQM+.(W>H7EW>S^9<W$TK^;FG^J_
MU>']B_V]];]M'G_M3^S_ *O]7Y*G/R?5/WGMO:>RY;^YR>TO[W*=>"_MKVLO
M[1_LOV'LWR_4OK?M?:\T.7F]O[GL^7VE[>]S<EM.8Z^BBBO!/4/GOXC?\EZ_
M9O\ ^ZP?^H98U]"5\]_$;_DO7[-__=8/_4,L:^A*VJ_!A_\ KS+_ -2*YS4/
MXN-_["8?^H>$"BBBL3I"BBB@ HHHH **** "BBB@ KSKXF_&#X2_!30;3Q5\
M9?BC\.OA)X8U#5[?P_8>(_B;XV\-> M!O=>NK._U&UT2TUCQ5J>E:?<ZO<Z?
MI6J7]OIL-P][-9Z;?W4<+06=P\?HM>=?$WX/_"7XUZ#:>%?C+\+OAU\6_#&G
MZO;^(+#PY\3?!/AKQ[H-EKUK9W^G6NMVFC^*M,U73[;5[;3]5U2PM]2AMTO8
M;/4K^UCF6"\N$DZ<']3^M4?[0^L_4^=?6/J?LOK7L[._L?;?NN>]K<_NVN8X
MCZQ[&I]5]C]8Y?W7UCG]CS77\3V?O\MK_#K>QX9_PW_^P?\ ]'L?LC_^)(_!
MO_YLZ/\ AO\ _8/_ .CV/V1__$D?@W_\V='_  P!^P?_ -&3_LC_ /B-WP;_
M /F,H_X8 _8/_P"C)_V1_P#Q&[X-_P#S&5]/_P 8!_U6'_F%/&_XRG_J0?\
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M1_Q@'_58?^84/^,I_P"I!_YD?+_@_AYA_P -_P#[!_\ T>Q^R/\ ^)(_!O\
M^;.C_AO_ /8/_P"CV/V1_P#Q)'X-_P#S9T?\, ?L'_\ 1D_[(_\ XC=\&_\
MYC*/^& /V#_^C)_V1_\ Q&[X-_\ S&4?\8!_U6'_ )A0_P",I_ZD'_F1\O\
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M8?\ #?\ ^P?_ -'L?LC_ /B2/P;_ /FSH_X;_P#V#_\ H]C]D?\ \21^#?\
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M !@'_58?^84/^,I_ZD'_ )D?+_@_AYA_PW_^P?\ ]'L?LC_^)(_!O_YLZ/\
MAO\ _8/_ .CV/V1__$D?@W_\V='_  P!^P?_ -&3_LC_ /B-WP;_ /F,H_X8
M _8/_P"C)_V1_P#Q&[X-_P#S&4?\8!_U6'_F%#_C*?\ J0?^9'R_X/X>8?\
M#?\ ^P?_ -'L?LC_ /B2/P;_ /FSH_X;_P#V#_\ H]C]D?\ \21^#?\ \V='
M_# '[!__ $9/^R/_ .(W?!O_ .8RC_A@#]@__HR?]D?_ ,1N^#?_ ,QE'_&
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M_P!@_P#Z/8_9'_\ $D?@W_\ -G1_PP!^P?\ ]&3_ +(__B-WP;_^8RC_ (8
M_8/_ .C)_P!D?_Q&[X-__,91_P 8!_U6'_F%#_C*?^I!_P"9'R_X/X>8?\-_
M_L'_ /1['[(__B2/P;_^;.C_ (;_ /V#_P#H]C]D?_Q)'X-__-G1_P , ?L'
M_P#1D_[(_P#XC=\&_P#YC*/^& /V#_\ HR?]D?\ \1N^#?\ \QE'_& ?]5A_
MYA0_XRG_ *D'_F1\O^#^'F'_  W_ /L'_P#1['[(_P#XDC\&_P#YLZ/^&_\
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M^T]E^[_B>TY>7[')?WN8/^&__P!@_P#Z/8_9'_\ $D?@W_\ -G1_PW_^P?\
M]'L?LC_^)(_!O_YLZ/\ A@#]@_\ Z,G_ &1__$;O@W_\QE'_  P!^P?_ -&3
M_LC_ /B-WP;_ /F,KL_XP#_JL/\ S"G/_P 93_U(/_,CY?\ !_#S#_AO_P#8
M/_Z/8_9'_P#$D?@W_P#-G1_PW_\ L'_]'L?LC_\ B2/P;_\ FSH_X8 _8/\
M^C)_V1__ !&[X-__ #&4?\, ?L'_ /1D_P"R/_XC=\&__F,H_P", _ZK#_S"
MA_QE/_4@_P#,CY?\'\/,/^&__P!@_P#Z/8_9'_\ $D?@W_\ -G1_PW_^P?\
M]'L?LC_^)(_!O_YLZ/\ A@#]@_\ Z,G_ &1__$;O@W_\QE'_  P!^P?_ -&3
M_LC_ /B-WP;_ /F,H_XP#_JL/_,*'_&4_P#4@_\ ,CY?\'\/,/\ AO\ _8/_
M .CV/V1__$D?@W_\V='_  W_ /L'_P#1['[(_P#XDC\&_P#YLZ/^& /V#_\
MHR?]D?\ \1N^#?\ \QE'_# '[!__ $9/^R/_ .(W?!O_ .8RC_C /^JP_P#,
M*'_&4_\ 4@_\R/E_P?P\P_X;_P#V#_\ H]C]D?\ \21^#?\ \V='_#?_ .P?
M_P!'L?LC_P#B2/P;_P#FSH_X8 _8/_Z,G_9'_P#$;O@W_P#,91_PP!^P?_T9
M/^R/_P"(W?!O_P"8RC_C /\ JL/_ #"A_P 93_U(/_,CY?\ !_#S#_AO_P#8
M/_Z/8_9'_P#$D?@W_P#-G1_PW_\ L'_]'L?LC_\ B2/P;_\ FSH_X8 _8/\
M^C)_V1__ !&[X-__ #&4?\, ?L'_ /1D_P"R/_XC=\&__F,H_P", _ZK#_S"
MA_QE/_4@_P#,CY?\'\/,/^&__P!@_P#Z/8_9'_\ $D?@W_\ -G1_PW_^P?\
M]'L?LC_^)(_!O_YLZ/\ A@#]@_\ Z,G_ &1__$;O@W_\QE'_  P!^P?_ -&3
M_LC_ /B-WP;_ /F,H_XP#_JL/_,*'_&4_P#4@_\ ,CY?\'\/,/\ AO\ _8/_
M .CV/V1__$D?@W_\V='_  W_ /L'_P#1['[(_P#XDC\&_P#YLZ/^& /V#_\
MHR?]D?\ \1N^#?\ \QE'_# '[!__ $9/^R/_ .(W?!O_ .8RC_C /^JP_P#,
M*'_&4_\ 4@_\R/E_P?P\P_X;_P#V#_\ H]C]D?\ \21^#?\ \V='_#?_ .P?
M_P!'L?LC_P#B2/P;_P#FSH_X8 _8/_Z,G_9'_P#$;O@W_P#,91_PP!^P?_T9
M/^R/_P"(W?!O_P"8RC_C /\ JL/_ #"A_P 93_U(/_,CY?\ !_#S/K<$, RD
M,K %6!!!!&001P01R"."*^?/B-_R7K]F_P#[K!_ZAEC7T& % 50%50 J@
M#   X  X ' %?/GQ&_Y+U^S?_P!U@_\ 4,L:^5H?'+_KSB/_ %'JGK8O^%#_
M +"<%_ZF4#Z$HHHK$Z0HHHH **** "BBB@ HHHH *^6?$/[:O[,OA77]<\+Z
M]\2_L&N^&]8U/0=:L?\ A#?B!=?8M6T>]GT[4;3[39>%;BSN/L]Y;S0^?:7$
M]M-L\R":6)D=OJ:OY9OVA/\ DOGQP_[*_P#$O_U--:K2G!3;3OHNEOU3 _=O
M_AO3]D__ **M_P"6-\2?_F/K8\/?MJ_LR^*M?T/POH/Q+^WZ[XDUC3-!T6Q_
MX0WX@6OVW5M8O8-.TZT^TWOA6WL[?[1>7$,/GW=Q!;0[_,GFBB5W7^:VO7_V
M>_\ DOGP/_[*_P##3_U--%K5T8)-WEHGU7^0']3-%<A\0=+\6:WX"\;Z+X"\
M2KX+\=:OX0\2Z7X+\8OI^GZLGA/Q9J&C7MIX<\2OI6K6&JZ5J:Z%K$UGJC:?
MJ>F:CI]Z+4VUY87EM));R?D[X<_X*!>*]7\'_"7XP>)[C6_#7@OX ?L>?%S]
MI3]O3PMX=\/^%-<U>?QYX+O?$?P5TSX/:*E[$9=.U";XS_"K]H_4]+GM-:\#
M&ZO/@]I^DZK?)I&H>)M.TK7"Y?7QD)3H.#Y)JG*+<E)3G3J3H1LHM-XF=*5"
MBDW>NX0GR*<9/DQ&,HX:<85>9.<7.+2C9PC4IPJRUDFE0C4C5JW6E)2E'F<7
M%?LC17XD>/?VX/VA?B=\(VN8/V=_B9\&/B'X1_:4_8/7P_!;2_M*_#3P9\6=
M-^)_[3'AGPUK_P *4^(/[1W[+O[*7B)-0%MH\FA_%;3=/^'WC#P+'X+^('AR
M6W\1>+IM1\2^%]"^D]-_;"\5:UJGPCLOB%X:NOA#XGTO]L?XK_LV_&/PY\/?
MB!H?Q'\ $?#S]D?XV?M*0ZROBKQ9\"=)\:>-?!NJ^&O!?A:^@T[PQX<^"OC?
M3O%&I)'=:[JFA^'=5\+^..B>2XZG3E.<(*4)5U5I^UI2G35'#T\3S\M.I.4X
MSA448RA&4%4M3E*,Y*)C'-<).2493<9JDZ<_95(PFZM:=!1YIPC&,HS@VXS<
M9.%YQBXIL_22BORC\5_M#_M"?$[X.?LY?%W5? .@? GP-\6OVD?V)M8^';^"
M/CUXF\9?$;Q/\,_BI\5O#5S?>'OB[X=LOA+\/?#'@Z75_!NIZ3;^(_"OAKXC
M?%WP]J$NJ:SH-SJ]WI^G0ZAK/7?LX?\ !0G6_P!HOXSV_@O1?V</B7I7P?\
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M\>&_AUXGUG]EZ#X;6WQ T:VTJYFUJ^\*:-H/[7/CWQ'XNTJRN?!NL:DIN/\
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M(4?]'S?^:S?MA_\ T/M'_$4=_P $*/\ H^;_ ,UF_;#_ /H?:_R!:*XCK/\
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M\0>+++7?!?ASZ-_8>_;,\7?M?S_$Z^N/ ?P4T[P+X /@?3]*^)7P*_:.U?\
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M8U'6?[6^)'PW\'Z'<?9]<\8>'+'^SK34Y]6F_M'[3!8RV=I?7%K^C5?YL/\
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M_@C'\#OBG\2_@I\4OVR?^$7^)OP?^('C+X6_$7PS_P ,\_M5ZW_PCOCOX?\
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M?XSTCPQXO\/;G[(G[,_Q-_9VC^(S_$C]H3Q)\;G\;WWAF?1-&OM1^/6H^%O
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M<7)1DHQC%?N^;V<;*$4G&*>_\TK_ , ?_$#'_P!91?\ S2;_ /*XH_X@8_\
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MO^91_P"$I_M;_A*?^$8_ZF?PY]@^P?\ ".?]/GVK[9_R[_9_W_Q3_P .>_\
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M\:7/[0/C#X9^+]6?5O%&B>*_VQ?VO_$>J:_'/H-]X:O/#FK>,=9^.M[XUO?
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M^&_AW[-XBDO9?#'@717U&[N;V>_EG^<_VB?^"=.G?$KQ/X=\;? KXDW'[/\
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M?LW_ /=8/_4,L:RH?'+_ *\XC_U'JBQ?\*'_ &$X+_U,H'T)1116)TA1110
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M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\]_M4_\
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MWB+3](\0:1_:_A_5]/U#^S-=TK3-8L/M'V74]/LKV*>VB] H **** "BBB@
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MER_]8\\$T ?O]1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %?/?Q&_Y+U^S?\ ]U@_]0RQKZ$KY[^(W_)>OV;_ /NL'_J&6-;4/CE_
MUYQ'_J/5.;%_PH?]A."_]3*!]"4445B=(4444 %%?$/Q8_X*%_LT?"OX@:Q\
M'K;6/'WQC^-7A_R!K_P=_9U^%'Q$^/'Q \/&XLQJ$2>*M/\ AOX=UW3/!TK6
M+1WH@\7ZOH4YLY%NQ&;99)DX'4?^"FOPE\**-1^*'P$_;=^$'A&/<;[X@>/O
MV0/C-_PA6C*I@59-=U7PAH'BVXT6WD><*EYJ5A;68,4S/<(D>X]\,JS&I&$X
M8+$M5(J5)>RDI58R2<94H-*=6,KKE=.,E+[+9QRS# P<HRQ5!.$G&H_:1<:<
MD[.-22;C3<7I)3<7'K8_1RBO-_A-\8?A9\>/ FC?$[X->/\ PK\3/ 'B!)6T
MCQ9X.UBTUK1[J2WD,-W:-<6DCFUU"PG5K;4=,O%M]0TZZ1[6^MK>X1XU](KB
MG"=.<J=2$H3A)QG"<7&<)1=I1E&23C)/1II-/1HZHRC.,9PE&<))2C*+4HRB
MU=2C)-IIK5--IK5!1114E!1110 4444 %?@#_P %#_\ E.O_ ,&ZO_>7+_UC
MSP37[_5^ /\ P4/_ .4Z_P#P;J_]Y<O_ %CSP30!^_U%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 ?/?Q&_Y+U^S?\ ]U@_]0RQKZ$K
MY[^(W_)>OV;_ /NL'_J&6-?0E;5?@P__ %YE_P"I%<YJ'\7&_P#83#_U#P@4
M445B=(4444 %%%% !1110 4444 %%%% !1110!^ /_!T=_R@H_;F_P"[9O\
MUL/]GVOW^K\ ?^#H[_E!1^W-_P!VS?\ K8?[/M?O]0 4444 %%%% !16!XF\
M4^'/!ND3:]XJUK3M T:WD@AFU+5+F.UM8Y;F58;>,RR$ O+*ZHBC+$DG& 2/
M,%_:3^ ;2/$OQ;\#M+$$,L:ZY:F2,2!C&70-N0.%8H6 #!6VYP:]/!Y)G.8T
MI5\ORC,\=0C-TY5L'@,5BJ49Q47*$JE"E."FE.#<7)-*<;KWE?@Q.:99@JBH
MXS,<!A*LHJ<:6)QF'H5'!\R4E"K4A)Q;C*TDK/EE9Z.WMU%5[2ZMKZUMKZRG
MBNK.\MX;JTN8'66"XMKB-9H)X9$)62*:)TDC=25=&#*2"*L5YK3BW&2<91;4
MHM---.S33U33T:>J9W)II----)IIW33U336C36J:W"BBBD,**** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH *^>_VJ?\ D@OCS_N5_P#U,_#M?0E?/?[5/_)!?'G_ '*__J9^':VP
M_P#O%#_K]2_]+B<V-_W/%_\ 8-7_ /34SZ$HHHK$Z0HHHH **** "BBB@ HH
MHH **** "BBB@ KX _X*Q?\ *++_ (*6?]F ?MD?^LZ_$:OO^O@#_@K%_P H
MLO\ @I9_V8!^V1_ZSK\1J #_ ()._P#*++_@FG_V8!^QO_ZSK\.:^_Z^ /\
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M#WAGPSX>T?Q]>:OKWB#7=7O+/2]&T;2[.ZU'5-1NK:QL;:>YGBB;_#FK[_\
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M5HQ5V[)+0****DH**** "BBB@#\ ?^#H[_E!1^W-_P!VS?\ K8?[/M?O]7X
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MB*%?EMS>QJTZG+?;FY)2M?I>US0HHHKG-PHHHH **** "O@#_@K%_P HLO\
M@I9_V8!^V1_ZSK\1J^_Z^ /^"L7_ "BR_P""EG_9@'[9'_K.OQ&H /\ @D[_
M ,HLO^":?_9@'[&__K.OPYK[_KX _P""3O\ RBR_X)I_]F ?L;_^LZ_#FOO^
M@ HHHH **** "BBB@ HHHH **** "O\ (%_X.CO^4Z_[<W_=LW_K'G[/M?Z_
M5?Y O_!T=_RG7_;F_P"[9O\ UCS]GV@#\ :^_P#_ ()._P#*4W_@FG_V?_\
ML;_^M%?#FO@"OO\ _P""3O\ RE-_X)I_]G__ +&__K17PYH _P!OFBBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ K\ O\ @Z-_Y04?MS?3]F?_ -;"_9^K
M]_:_ +_@Z-_Y04?MS?3]F?\ ];"_9^H _P @2BBB@#_3Z_X,J?\ E%G\??\
ML_[XI?\ K.O[*U?U_5_(#_P94_\ *+/X^_\ 9_WQ2_\ 6=?V5J_K^H ****
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MN[))79ZT(\D(PYI3Y8J//-WG*RMS2:2O)[MV5WT04445!04444 %%%% !7X
M_P#!0_\ Y3K_ /!NK_WER_\ 6//!-?O]7X _\%#_ /E.O_P;J_\ >7+_ -8\
M\$T ?O\ 4444 %%%% !117!^+_AQX>\;W-G=:SJ/CRREL8)+>%?"'Q4^)_P^
MMGCDD\QFO+/P%XO\-6>H3AN$N;^"YN8H_P!U%*D7R5T86.$G6C'&UL1A\.U+
MGJX7"T\96BU%N"C0JXO PDI2LI-XF#C%N24VE%XXB6(C2D\+2HUJUX\M/$5Y
MX:DTY+F<JU/#8N<6HW<4J$N:246XI\R[RBOEO]GCX?Z5<^!/A_X^U#Q'\5-8
M\33Z=->W,VO?&SXQ^(-(N[AYKZS+7OA?6O'=_P"%[U! 1L@N]&F@BF2.YCC2
MYBCF7ZDKNSO 87*\RQ>787%XC&/ XC$83$5J^#IX)?6<-B*M"JJ,*>-QWM*#
M]FI0JU)T:DN9J5"'+>7'E.,Q&88'#8VOAZ.%6+HT<30IT<5/%/V&(HTZT'5G
M/"X3DJKG<9TX1JP7*FJLN:T2BBBO)/2"BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Y[^
M(W_)>OV;_P#NL'_J&6-?0E?/?Q&_Y+U^S?\ ]U@_]0RQKZ$K:K\&'_Z\R_\
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MYI9^'%YX5^"7QHA^(8NQWWP%_;[_ &K?'?[4OP3^(.M?%"+4O@!^T'_P4O\
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M-_W;-_ZQY^S[0!^ -??_ /P2=_Y2F_\ !-/_ +/_ /V-_P#UHKX<U\ 5]_\
M_!)W_E*;_P $T_\ L_\ _8W_ /6BOAS0!_M\T444 %%%% !1110 4444 %%%
M% !1110 4444 %?@%_P=&_\ *"C]N;Z?LS_^MA?L_5^_M?@%_P '1O\ R@H_
M;F^G[,__ *V%^S]0!_D"4444 ?Z?7_!E3_RBS^/O_9_WQ2_]9U_96K^OZOY
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ME*%6G0P.+<(TZL'4C.=;"1JWG"524(5.3^FBBBBOC3Z<**** "BBB@ HHHH
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MZ4*/-4KYGB:#YDKU;8>/,_@Y%H?T@4445_%I_484444 %%%% !1110 4444
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MS_L__P#X*4_^O!?VF*]!KS[P/_R,W[3G_9__ /P4I_\ 7@O[3%>@UW0^"/\
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MUH7Q+^'/CC2!X@\+:IJ6KZ]X9U>PUG7=!U[PY(+BPU33OU<HH _GD\;_ /!
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M^J6_JUV _I[HK^83_AXE_P %3?\ HJ'[ '_B$G[17_TQVON[_@F3^VE^U/\
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M\9K>:3I.LWUU>WVL6FD:@EW^UE?SA_LOM^R)\3/^"@'[(WC+_@F7\%+WX6^
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M$\]:#C"#PV-JXG#Q=*&&KS4X-<]&+YYSI_T:4445\P>\%%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P"&O_"8_;/A/X<_X2=_^$.OO"O@VX^VZC_8>RZ_L]H _C&\#_\ (S?M.?\
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M?_UG7X<U%?['_;W_ +:!]_T445S@%%%% !1110 4444 %%%% !1110 4444
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M?:_U^J_R!?\ @Z._Y3K_ +<W_=LW_K'G[/M?\0Q_29^ -??_ /P2=_Y2F_\
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M:-=>(O"'AW4;_3HK:_DTJT6Y2,-)O9-^BO\ D!^UM%?B%_P^\\,_](\_V_\
M_P #?^"?7_T?==/\-?\ @LSX/^)/QK^!OP*3]AS]M_P?XF_: ^)'_"L_!FN>
M+)_V(7\*Z=JEEX*\9?$WQ+K7B:X\(?ML>+==LO#_ (1^&OPZ\=^.-9?2_#^L
MZU?Z=X8N=%\*Z)XD\9:IX=\,ZRW&2U<9)=VG_D!^RU%%%2 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110!\]_$;_DO7[-__ '6#_P!0RQKZ
M$KY[^(W_ "7K]F__ +K!_P"H98U]"5M5^##_ /7F7_J17.:A_%QO_83#_P!0
M\(%%%%8G2%%%% 'RU^VLWP63]E[XMR?M":MXXT+X2QZ1HTOB/5_AG<>,K3XB
MV&HQ>*M!D\&S>!9_A]%/XO7Q;_PG"^&T\/II$$WFZHUK#?Q2:9)>H?@/_@FS
MK7_!2&_\5:_%\7+/Q1JO[%RK+_PJ#Q-^V+9:1X2_;GNM,\N3^S&\2Z)\.3J>
MB:GIQD(>[O/BC:>&?'ES"8)"KJ66OU0^-/QB^%_P ^&/BKXP_&?Q19>"_AEX
M'@T[4?%/BC4+#4]3L]'AN]8T[2=.N9;+1K#5-3F+:SJ&G01&SL+B2*:6.=A'
M'&\J8GBG]HSX+>"O%7P1\$^*/'5EI'BG]HZZU6R^"FD3:;KL\WCNZT30[3Q+
MJD-C-::5<6NFM9Z'?6NH.==GTI7CE$<323I)$GL87$UH9=6P<, \5'%5:THU
MJM.=:%!T*-*K7G@HQ@G1Q5.BE/%5E5FOJWLU4I1C%3EYM>C2EC:6)GC%AW0I
MTU*E3G&E*JJM6=.E'%2E-JIAYU&X4*7LX/V_.X592ER+VRBBBO'/2"BBB@ H
MHHH **** /P!_P"#H[_E!1^W-_W;-_ZV'^S[7[_5^ /_  ='?\H*/VYO^[9O
M_6P_V?:_?Z@#^,;P/_R,W[3G_9__ /P4I_\ 7@O[3%>@UY]X'_Y&;]IS_L__
M /X*4_\ KP7]IBO0:[H?!'_#'\D!O? G_E(-_P $R_\ LZ#XR_\ KN7]NVOZ
MVJ_DE^!/_*0;_@F7_P!G0?&7_P!=R_MVU_6U7-6^-^B _@3_ &,O^3/OV4?^
MS:_@7_ZJ_P +5]*5\U_L9?\ )GW[*/\ V;7\"_\ U5_A:OI2O]KN%_\ DF>'
M?^Q%E'_JOPY_E;G_ /R/<Z_[&V8_^IE8]"_9A_Y2+?\ !-'_ +.4^-/_ *[L
M_;EK^Q:OXZ?V8?\ E(M_P31_[.4^-/\ Z[L_;EK^Q:O\W?I6?\G<QG_8BR3_
M -,53^X?H\_\FXPW_8WS7_T[3"BBBOYN/W$**** "BBB@ HHHH **** /YX_
M^"PO_)Z/[!'_ &:__P %#?\ U:__  3<KXCK[<_X+"_\GH_L$?\ 9K__  4-
M_P#5K_\ !-ROB.NNC\"]6 5^_/\ P2=_Y19?\$T_^S /V-__ %G7X<U^ U?O
MS_P2=_Y19?\ !-/_ +, _8W_ /6=?AS45_L?]O?^V@??]%%%<X!1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %?/?[5/_)!?'G_<K_\ J9^':^A*
M^>_VJ?\ D@OCS_N5_P#U,_#M;8?_ 'BA_P!?J7_I<3FQO^YXO_L&K_\ IJ9]
M"4445B=(4444 %?'O[??QF\1?L^?L@_&WXO>%%^$<^O>$=!T4V>F_'2#Q==_
M#'7XM>\7^'?#&H>%M=L? NFZOXFU'4?%FFZU=^&O".EV=B]GJ?C/5?#^GZW/
M9:%<ZE>V_P!A5\'?\%.+/X%7_P"PG^T+:?M+0_$ _!*;P[X;_P"$WU/X6Z3)
MKGCOPJB>/?"DGA_Q]H6FQG,Q^'7BI-#\=ZE,R3PV.C^'=0OI[2\@MI+6;MRV
M-.>8Y?"K3G5I2QN%C4I4X\]2I3E7IJ=.$+KGG.+<8QNN:32NKG+CI3C@L9*G
M.-.<<+B)0J3ER0A-4IN,YSL^6,6E*4K/E2;L['YN?L7>&?VBOV2/VO\ X*_"
M+XD_LG?\$ROV6]"_:N\$>/O$FI:E^S9:?%&'XF^*=1^&/@ZZ\2:A\)M'O;C3
M;GPPOBKP5J&K:#XF\0Z3?7T/P^O?!R>+-2\!^)_$FOZ3+9Q_T*5^6/[/_P"P
M)\4-+^.WPJ_:9_:?_;6\4?MC^(/@?X,\4^'/V;X&^%_@SX4^%_!.G_$;P_;^
M'/$_C;5SX1USQ"WQ'\=^)O"(_LB[\97MUIT-Y97DTZ::6:U:W_4ZNW/<30Q6
M*HU:56C7JK"QABZV'ABX4*F(C6K\OLECDL5)0PKPU.<JL8_O(3C!.FH-\N4T
M*N'P]6G4IU*5/V\I8>G6EAI58472HW]H\(WATY5U7G%4V_W<H.=JCDD4445X
MIZ@4444 %%%?F#_P5N_X*8>#O^"6'[)6M?M"ZMX-G^*WQ U/7+7PE\)/@WI^
MI7.DZC\0O$D>GZCXI\3S7.J6.D:_=Z!X4\"?#OP[XN\>>,/$[Z+>6&D:5H M
M[@QW6J:>LH!^GU? '_!6+_E%E_P4L_[, _;(_P#6=?B-7Q;^TU_P6;E^ 7Q
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MJ_Z._I8?\HL_25_[,!XR?^NZXC/R#(O^1YDW_8UR[_U+HG^R77^0+_P='?\
M*=?]N;_NV;_UCS]GVO\ 7ZK_ "!?^#H[_E.O^W-_W;-_ZQY^S[7_ !#'])GX
M U]__P#!)W_E*;_P33_[/_\ V-__ %HKX<U\ 5]__P#!)W_E*;_P33_[/_\
MV-__ %HKX<T ?[?-%%% !1110 4444 %%%% !1110 5^#_\ P<R?\H3OVQ/^
MPY^RA_ZVE^SM7[P5^#__  <R?\H3OVQ/^PY^RA_ZVE^SM7Z!X3?\G4\-/^S@
M<&_^M'EIRX[_ '+&?]@N(_\ 3,S_ "SZ***_[N#^83^VK_@S$_Y&?_@IM_V
M?V'O_3A^V57[4_\ !T;_ ,H*/VYOI^S/_P"MA?L_5^*W_!F)_P C/_P4V_[
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M_P"[9O\ UL/]GVOW^H _C&\#_P#(S?M.?]G_ /\ P4I_]>"_M,5Z#7GW@?\
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MX%ZL K]^?^"3O_*++_@FG_V8!^QO_P"LZ_#FOP&K]^?^"3O_ "BR_P"":?\
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MX)S_ /*1C_@G;_V?_P#L2_\ K4'PJKXZK[%_X)S_ /*1C_@G;_V?_P#L2_\
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MJ_&__LX'#W_K.3/Z9\2?]]RS_L%K?^GD%?Z)O_!GG_RCG_:6_P"S_P#XA?\
MK+_[(U?YV5?Z)O\ P9Y_\HY_VEO^S_\ XA?^LO\ [(U??_MJ?^46> ?^S_\
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M (*=?]GQ> /_ %VQ_P $]:_+N#?^2<\6?^S?Y;_Z]3PT/V?$?QL#_P!A4_\
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M117\+G]:!1110 4444 %%%% !1110 4444 %%%% !7SW^U3_ ,D%\>?]RO\
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M_LEU_D"_\'1W_*=?]N;_ +MF_P#6//V?:_U^J_R!?^#H[_E.O^W-_P!VS?\
MK'G[/M?\0Q_29^ -??\ _P $G?\ E*;_ ,$T_P#L_P#_ &-__6BOAS7P!7W_
M /\ !)W_ )2F_P#!-/\ [/\ _P!C?_UHKX<T ?[?-%%% !1110 4444 %%%?
MEA_P6B\4^,?!_P#P3T^(VJ>!/'7Q ^&WB#4/C?\ L1>$'\8?"WQ[XQ^%_CNQ
M\._$#]N?]F_P'XTT[0O'OP_UOPWXR\-_\))X-\2:_P"&=3N_#^NZ9?3:/K&H
M60N5ANI5;KP&#JYCCL%E]"5.%;'8O#8.C*JY1I1JXJM"A3E4E",YJFIS3FXP
MG)13<8R=D^?&8FG@L)BL954Y4L)AZ^)J1IJ+J2IT*4JLU!2E"+FXP:BI2C%R
MLG)+5?J?7B?[.G_)&_!W_<P_^I3KE?QU?V+X\_Z.G_;_ /\ Q9#^WW_]$E4L
MVD>-))6>U_:2_;?T2 [=FF>%OV_?VW/"&@VV% ;[#X=\+_M :1H6G^<X:XNO
ML.G6_P!KO);B^NO.O+FXGE_K6E]$GQ'AD^.R]YWP2ZV*S+*L93DLRSWV2I8'
M"YS0K1G)\-J:J2GF-!TU&$HN,*KE*#C!3_G*I]([@B>983&+*N*O94,#F&&G
M%X'*/:.IB\1EE6FXK^W'%PC'!55-N2DI2IJ,9)R</[?*_!__ (.9/^4)W[8G
M_8<_90_];2_9VKR__@B5XC^(#?M)?MR^ ?$OQD_: ^*'A+P]\#_V'O&'AO2?
MCI^T-\</V@/^$7\1>-?'O[=6B^+M1\+7WQN^('Q U+PU_P )+IG@#P5;:W::
M%>:?8ZE_PC.D375M)<6B2UZA_P ',G_*$[]L3_L.?LH?^MI?L[5^0<(\-X[@
M_P =N"N&<SJX2OC\F\2^#\'BJV!J5JN$J58\097-RP]3$4,+6G3M-6=3#TI7
MO[MK-_N669YA.)>%Z.?8&GB*6#S3+*V*P]/%PI4\3"G*G5BE6A1K5Z49WB[J
M%:I&UO>/\L^BBBO^Y<_GH_MJ_P"#,3_D9_\ @IM_V ?V'O\ TX?ME5^U/_!T
M;_R@H_;F^G[,_P#ZV%^S]7XK?\&8G_(S_P#!3;_L _L/?^G#]LJOVI_X.C?^
M4%'[<WT_9G_];"_9^K_C&^GY_P ID_2$_P"R_P 7_P"H& /Z)X6_Y)[*?^P2
M'_I4C_($HHHK^0#WS_3Z_P"#*G_E%G\??^S_ +XI?^LZ_LK5_7]7\@/_  94
M_P#*+/X^_P#9_P!\4O\ UG7]E:OZ_J "BBB@ HHHH **** "OGOXC?\ )>OV
M;_\ NL'_ *AEC7T)7SW\1O\ DO7[-_\ W6#_ -0RQK:A\<O^O.(_]1ZIS8O^
M%#_L)P7_ *F4#Z$HHHK$Z0HHHH ^'?\ @I9XCE\'_L$?M7>+(-*\8:S<>&?@
MYXGU^WL? ?B76O!WB8W&D117\%Y:^*/#C)KNB:?IDUNFI^(+[29;>^C\.V>J
MBWNK61A<1?B/\,_A3\#?@3^T-_P2AU_X5?M:_M#?M,^)/VAM7?\ X37P9=_M
M1^*O&VF7EO#\+&\<K\88_!EGK5_;67@OPOX@M)=,\2>%_$MOJVFS^'M9=#J-
MKKWAR34;S]VOV@_B+^UAX3\:66B_!/\ 97\*?M _#.]^$OCK5_$-[KGQD\+?
M#*]N?B7:ZGHECX1^&XA\16&LB/2/$^B7>O7>H:_+X?U?2X!:_9[V;3I(K>UU
MS\\OV/\ X6?%SX-_'G3_ !'X=_X(@_ #]E.T\>ZBVC?$/XW>!/VM_A%XOU[P
M=X7U&476IRZ+X0T;X6:3J,VE/=06DEUX4\*ZCH%E?-%;.\3?8X%3Z_*:\L+E
M6)@ZE)*I'%UO9PS3*J/MU7P<\+&E7H8G%T\72EAYQ^L06'HU:M=N--PBU2G'
MYO,:2KYC0DH5+PEAJ;J2R_,*OL72Q4,0YT:U'#3PU15HOV$W6JPIT4I5%)I5
M(/\ <VBBBOD#Z0**** "BBB@ HHK^5#PE_P4._:S_9E^"/[2WCO]LA?VKO G
M[8\O[(7[>_[8'[/7P5^-UE^S8_[,^M^%/A-\0_$UQX'\+^'=(^$MI=_%_0O$
M?P>\&:S\&H?$6C_%7Q1I=_XJT'7M;UFPFU*^,T&A@']5]?@#_P %#_\ E.O_
M ,&ZO_>7+_UCSP370_L<?M<?%+X)>._VN/"W[8W[2/B7XR_!KX%_L!?LD_\
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MU_R>C^WO_P!FO_\ !/+_ -6O_P %(Z^(Z^W/^"/7_)Z/[>__ &:__P $\O\
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M/_K8?[05 '[_ %%%% !7\8W@?_D9OVG/^S__ /@I3_Z\%_:8K^SFOXQO _\
MR,W[3G_9_P#_ ,%*?_7@O[3%;4/C?^%_F@/0:WO@3_RD&_X)E_\ 9T'QE_\
M7<O[=M8-;WP)_P"4@W_!,O\ [.@^,O\ Z[E_;MK>I\$O0#^MJOX$_P!C+_DS
M[]E'_LVOX%_^JO\ "U?WV5_ G^QE_P F??LH_P#9M?P+_P#57^%J_K[Z&O\
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M=PO_ ,DSP[_V(LH_]5^'/\K<_P#^1[G7_8VS'_U,K'H7[,/_ "D6_P"":/\
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MLI_[!(?^E2/\@2BBBOY /?/]/K_@RI_Y19_'W_L_[XI?^LZ_LK5_7]7\@/\
MP94_\HL_C[_V?]\4O_6=?V5J_K^H **** "BBB@ HHHH *^>_B-_R7K]F_\
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M_P!7X _\%#_^4Z__  ;J_P#>7+_UCSP30!]__P#!6+_E%E_P4L_[, _;(_\
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M^LO_ +(U??\ [:G_ )19X!_[/_PM_P"NZ\53D\.?^1YBO^Q57_\ 4O G"_\
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MH'\\>$__ "<?A#_L;TO_ $U5/[%Z_P 9_0O^"D/_  4>O=$T:\N?^"BO[?\
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M7XY?]XS_ /7/>'Q^Z<$_\DQEG_<[_P"K#%A1117\ GU04444 %%%% '\\?\
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MYIZ_I8_X).?\HL?^":?_ &8#^QQ_ZSM\.:_"_II?\VU_[O'_ -]4_6OHN?\
M-<_]VS_[\)]^32I!#+/)O\N&.263RXY)GV1J7;9%"DDLK[5.V.)'D=L*B,Q
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M?@X3>L</36ATQ4E%*;C*5ES2C%PBWU:BY3<5V3G)KNPHHHKE*"BBB@ HHHH
M**** "BBB@ KY[_:I_Y(+X\_[E?_ -3/P[7T)7SW^U3_ ,D%\>?]RO\ ^IGX
M=K;#_P"\4/\ K]2_]+B<V-_W/%_]@U?_ --3/H2BBBL3I"BBB@ KY(_;Q_X9
MM_X8^^/_ /PU[C_AG+_A KS_ (6;Y?VW^T/[/^W6/]B_\(__ &=_I_\ PEG_
M  E/]A?\(?\ 9/\ 2/\ A*?['\OYL5];U^<O_!23PS^SY^TK^S;\?OV+/B=^
MT'\,_@SXL\=?"30/B,;GQGXMT/19_"&A:+\5O#$7@+XBZ_I^IZQH\J^!IOC#
MHWAKPG=7KW=K;ZEJ-X= M9Y-2NX+:3NRR*EF&"YY8BG3CB\-.M6PL9RQ%"BJ
M]/VE>DH1E)5*46Y4VHM\ZC9-V3Y,?)QP>*Y8T:E26'KQI4L0XJC6JNE/DI5.
M9QBX5)6C--J\7+H?G/\ \$X_#_[,Z_%S]D3XQ?$3XN_M?_$[X]_%7X:_M-_"
MG]D'PG^US%X;;5/@KX/_ &8?'&I?#/XS^%57P%86WAF'XH:MI^GSS:K>ZCJ.
MNZV_A.PO+'4+JSN! =4_HRK^8#]COPI=6W[2_P %?CO^VE^V_P#\$\;?3/V5
M-=_;0\4_"7P]\%?VC/#&N7OCGXG_ +;'Q/\ '/CSXI^/_$MQKUQX6L=!\+P:
M7X]NO#WA;P[!:W.HD:/8WFHV.D3([7G]+/@[QKX-^(OAO3O&/P^\6^&/'7A#
M6/MG]D>*O!VO:5XG\-ZI_9]_=:5?_P!G:YHEW?:9??8=3L;W3KS[-=2_9K^S
MNK.;9<6\L:>OQ/!_785%4JUH^SG"4[-X6BWC,9/#X;#35&C3<(X)X:K448W>
M)J8B4VZCFSS<@DOJDH.$*4N>$E&Z5>K;"X6%>O7@ZE2:D\4J].#<K*A"@HI0
MY$=-1117S1[H4444 %%%?$?[4_[;VE_LLZI<:?>?LU?M8_&K3= ^%?BCXW_$
M7QM\%/A?X>N_AE\+OA7X+FGC\3:_XL^*'Q2\>_"KP!K'BC3K:TN]6A^#/PW\
M1>/?CSJ^@VLNO:'\+=3T@Q7D@!]N5\ ?\%8O^467_!2S_LP#]LC_ -9U^(U>
M/>/O^"RW['_@G7-(.FP_%+XC_"F#X7?LU_&GXL?M$_#WPQX<O?@M^SO\+_VP
MM731OV:?%_QGO/$GC/PO\0;2Q^*LC_VK96OP^^'GQ#U/PGX723Q?\0K'PAX6
MBDU=?8?^"L7_ "BR_P""EG_9@'[9'_K.OQ&H /\ @D[_ ,HLO^":?_9@'[&_
M_K.OPYK[_KX _P""3O\ RBR_X)I_]F ?L;_^LZ_#FOO^@ HHHH *_CI_:>_Y
M2+?\%+O^SE/@M_Z[L_8:K^Q:OXZ?VGO^4BW_  4N_P"SE/@M_P"N[/V&J_I'
MZ*?_ "=S!_\ 8BSO_P!,4C\/^D+_ ,FXQ7_8VRK_ -/3//:^:_VS?^3/OVKO
M^S:_CI_ZJ_Q37TI7S7^V;_R9]^U=_P!FU_'3_P!5?XIK_2+BC_DF>(O^Q%F_
M_JOQ!_#W#_\ R/LD_P"QOEO_ *FT3^^RO\I;_@XM_P"4V/[>G_8=_9O_ /6+
M/V:J_P!6FO\ *6_X.+?^4V/[>G_8=_9O_P#6+/V:J_"OV0__ "F1DO\ V;_C
MO_U!PA_H[Q]_R3M7_L*PO_I;/Q8K[%_X)S_\I&/^"=O_ &?_ /L2_P#K4'PJ
MKXZK[%_X)S_\I&/^"=O_ &?_ /L2_P#K4'PJK_H[^EA_RBS])7_LP'C)_P"N
MZXC/R#(O^1YDW_8UR[_U+HG^R77^0+_P='?\IU_VYO\ NV;_ -8\_9]K_7ZK
M_(%_X.CO^4Z_[<W_ ';-_P"L>?L^U_Q#'])GX U]_P#_  2=_P"4IO\ P33_
M .S_ /\ 8W_]:*^'-? %??\ _P $G?\ E*;_ ,$T_P#L_P#_ &-__6BOAS0!
M_M\T444 %%%% !1110 5^2O_  7 _P"4=/CC_LY3_@GC_P"O$_V5*_6JOR5_
MX+@?\HZ?''_9RG_!/'_UXG^RI7N\+_\ )3<._P#8]RC_ -6&'/)S_P#Y$6=?
M]BG,?_4.L?@C1117^V9_E:?HO_P12_Y/#_;\_P"S:O\ @GO_ .K1_P""C->P
M_P#!S)_RA._;$_[#G[*'_K:7[.U>/?\ !%+_ )/#_;\_[-J_X)[_ /JT?^"C
M->P_\',G_*$[]L3_ +#G[*'_ *VE^SM7^8V=?\I7X#_L[O"7_J\R8_T;\-/^
M35\.?]D]/\L0?Y9]%%%?]L)^2']M7_!F)_R,_P#P4V_[ /[#W_IP_;*K]J?^
M#HW_ )04?MS?3]F?_P!;"_9^K\5O^#,3_D9_^"FW_8!_8>_].'[95?M3_P '
M1O\ R@H_;F^G[,__ *V%^S]7_&-]/S_E,GZ0G_9?XO\ ]0, ?T3PM_R3V4_]
M@D/_ $J1_D"4445_(![Y_I]?\&5/_*+/X^_]G_?%+_UG7]E:OZ_J_D!_X,J?
M^46?Q]_[/^^*7_K.O[*U?U_4 %%%% !1110 4444 %?/?Q&_Y+U^S?\ ]U@_
M]0RQKZ$KY[^(W_)>OV;_ /NL'_J&6-;4/CE_UYQ'_J/5.;%_PH?]A."_]3*!
M]"4445B=(4444 ?B]^WYX;_;@^ OPY_:1_:P\-_\%+O'/@/X5?#SP]X@\?\
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M\!J_?G_@K%_RBR_X*6?]F ?MD?\ K.OQ&K\!JZ*'V_\ MW_VX K[<_X(]?\
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M_L15?_3] _GCPG_Y./PA_P!C>E_Z:JG]B]?X:?AC_D6O#W_8#TG_ -(+>O\
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M9'[17_SQJ_Y!3]^/];']F?\ :,_X*#_'JZUC6=4^!_[&OAOP+X'_ &@_B?\
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MWQU^T7\3/&O@'4O 4VI6.F(MB?"/@2TTM[W7;KP_/;S:[<Q7ITN6VF@EFNM
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M_P#LP#XV?^M%?L@5_I#U_P HO[4;_E.OQR_[QG_ZY[P^/W3@G_DF,L_[G?\
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MV3T_RQ!_EGT445_VPGY(?VU?\&8G_(S_ /!3;_L _L/?^G#]LJOVI_X.C?\
ME!1^W-]/V9__ %L+]GZOQ6_X,Q/^1G_X*;?]@']A[_TX?ME5^U/_  =&_P#*
M"C]N;Z?LS_\ K87[/U?\8WT_/^4R?I"?]E_B_P#U P!_1/"W_)/93_V"0_\
M2I'^0)1117\@'OG^GU_P94_\HL_C[_V?]\4O_6=?V5J_K^K^0'_@RI_Y19_'
MW_L_[XI?^LZ_LK5_7]0 4444 %%%% !1110 5\]_$;_DO7[-_P#W6#_U#+&O
MH2OGOXC?\EZ_9O\ ^ZP?^H98UM0^.7_7G$?^H]4YL7_"A_V$X+_U,H'T)111
M6)TA1110!^/?[7/[9/P$^,_[*?\ P4W\ :K%\8O".@?LKPS_  ?^.&NZ7X!^
M&/B[5M2/B*VL);VX^&7AGQ7XV;PSXML+G3;N2PGC\=/X1*BXFD2T9XH7/S7\
M/M!^(O[)?CC_ ()UV7C#_@HI^V7\7? /[2GB;PEX/^%WPOUWX7? ZXT2ZTN/
MP/8^)--T+XN>*9]>@\8Z;IBZ'=6=K=ZKX=U'QGK+:A;LC&ZAS=R]]\:_^".'
MQ5^)OB3]L5/!7[>OB;X5?"7]MOQH?&/QB^$=G^SI\,O&5M?R16]K;65A#XW\
M1Z[_ ,)?8I:1VD8%QX=O?#;3DDS0L<D]EX3_ ."6/[0DOQ1_9-\;_'#_ (*&
M>)OCEX._8\\7Z5XK^%_PWO/V9?@_\.K: :3X?B\,0Z=-XJ\":AIVO7"-HMM:
MVANM;;7W!MQ<-%)=2RSO]M2K9+A\'[&CFF&]C4C7K5\+5P.)KU_:U,IP]*$*
M-6OE-2%*LLRC6<IT\3"FL/R.-7FNCY6K2S2MB55J8"O[6#HTJ>(IXNA1H^SA
MF52I.=2G1S&G*I3^HR@HQG0G-UE-2I\K5_VHHHHKXD^J"BBB@ HHHH ****
M"OP!_P""A_\ RG7_ .#=7_O+E_ZQYX)K]_J_ '_@H?\ \IU_^#=7_O+E_P"L
M>>": /O_ /X*Q?\ *++_ (*6?]F ?MD?^LZ_$:OP&K]^?^"L7_*++_@I9_V8
M!^V1_P"LZ_$:OP&KHH?;_P"W?_;@"OMS_@CU_P GH_M[_P#9K_\ P3R_]6O_
M ,%(Z^(Z^W/^"/7_ ">C^WO_ -FO_P#!/+_U:_\ P4CJZWP/U0'UE_P7 _Y1
MT^./^SE/^">/_KQ/]E2OP1K][O\ @N!_RCI\<?\ 9RG_  3Q_P#7B?[*E?@C
M7]]?0U_Y)GC/_L>X#_U7R/XU^D[_ ,CWA?\ [%.-_P#4R(5^C'_!%+_D\']O
MW_LVO_@GM_ZM#_@HW7YSU^C'_!%+_D\']OW_ +-K_P"">W_JT/\ @HW7W7TK
M/^31XS_L>Y)_Z?JGR7T>?^3CX;_L49K_ .FJ9Z__ ,',O_*$[]L3_L._LG_^
MMI_LZU_EH5_J7_\ !S+_ ,H3OVQ/^P[^R?\ ^MI_LZU_EH5_?O[$3_DU?C?_
M -G X>_]9R9_3/B3_ON6?]@M;_T\@K_1-_X,\_\ E'/^TM_V?_\ $+_UE_\
M9&K_ #LJ_P!$W_@SS_Y1S_M+?]G_ /Q"_P#67_V1J^__ &U/_*+/ /\ V?\
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MC_UG7XC5_B"U_M]?\%8/^46?_!2O_LP']LC_ -9U^(U?X@M?\@I^_!7]_?\
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M[_P@6N_%'4_AE%_PE%E\0/%T']F0>#(M'T3^U_,\.Z?I$UAIDEE_9[7X _\
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M\%%:^4J^K?\ @I]_RE-^('_9@'[%W_K17_!16OE*O]5/HU?\F4X+_P"[C_\
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MV3T_RQ!_EGT445_VPGY(?VU?\&8G_(S_ /!3;_L _L/?^G#]LJOVI_X.C?\
ME!1^W-]/V9__ %L+]GZOQ6_X,Q/^1G_X*;?]@']A[_TX?ME5^U/_  =&_P#*
M"C]N;Z?LS_\ K87[/U?\8WT_/^4R?I"?]E_B_P#U P!_1/"W_)/93_V"0_\
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MW]D__P!;3_9UK_+0K^_?V(G_ ":OQO\ ^S@</?\ K.3/Z9\2?]]RS_L%K?\
MIY!7^B;_ ,&>?_*.?]I;_L__ .(7_K+_ .R-7^=E7^B;_P &>?\ RCG_ &EO
M^S__ (A?^LO_ +(U??\ [:G_ )19X!_[/_PM_P"NZ\53D\.?^1YBO^Q57_\
M4O G"_\ !ZM_RBR^ ?\ V?\ _"S_ -9U_:JK_,$K_3[_ .#U;_E%E\ _^S__
M (6?^LZ_M55_F"5_S"'[2%?Z_7_!KC_R@H_89_[N9_\ 6P_V@J_R!:_U^O\
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MTY_V?_\ \%*?_7@O[3%>@UY]X'_Y&;]IS_L__P#X*4_^O!?VF*]!KNA\$?\
M#'\D!O? G_E(-_P3+_[.@^,O_KN7]NVOZVJ_DE^!/_*0;_@F7_V=!\9?_7<O
M[=M?UM5S5OC?H@/X$_V,O^3/OV4?^S:_@7_ZJ_PM7TI7S7^QE_R9]^RC_P!F
MU_ O_P!5?X6KZ4K_ &NX7_Y)GAW_ +$64?\ JOPY_E;G_P#R/<Z_[&V8_P#J
M96/0OV8?^4BW_!-'_LY3XT_^N[/VY:_L6K^.G]F'_E(M_P $T?\ LY3XT_\
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M9U^'-?A)\=O^4@W_  4T_P"SH/@U_P"NY?V$J_=O_@D[_P HLO\ @FG_ -F
M?L;_ /K.OPYK\)/CM_RD&_X*:?\ 9T'P:_\ 7<O["5:T?C7HP,&OE_\ ;>_Y
M,N_:\_[-?^/W_JJ/%E?4%?+_ .V]_P F7?M>?]FO_'[_ -51XLKJEL_1_D!_
M<Q7\=/[3W_*1;_@I=_V<I\%O_7=G[#5?V+5_'3^T]_RD6_X*7?\ 9RGP6_\
M7=G[#5?T%]%/_D[F#_[$6=_^F*1^'_2%_P"3<8K_ +&V5?\ IZ9Y[7S7^V;_
M ,F??M7?]FU_'3_U5_BFOI2OFO\ ;-_Y,^_:N_[-K^.G_JK_ !37^D7%'_),
M\1?]B+-__5?B#^'N'_\ D?9)_P!C?+?_ %-HG]]E?Y2W_!Q;_P IL?V]/^P[
M^S?_ .L6?LU5_JTU_E+?\'%O_*;']O3_ +#O[-__ *Q9^S57X5^R'_Y3(R7_
M +-_QW_Z@X0_T=X^_P"2=J_]A6%_]+9^+%?8O_!.?_E(Q_P3M_[/_P#V)?\
MUJ#X55\=5]B_\$Y_^4C'_!.W_L__ /8E_P#6H/A57_1W]+#_ )19^DK_ -F
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M##GDY_\ \B+.O^Q3F/\ ZAUC\$:***_VP/\ *T_1?_@BE_R>'^WY_P!FU?\
M!/?_ -6C_P %&:]A_P"#F3_E"=^V)_V'/V4/_6TOV=J\>_X(I?\ )X?[?G_9
MM7_!/?\ ]6C_ ,%&:]A_X.9/^4)W[8G_ &'/V4/_ %M+]G:O\QLZ_P"4K\!_
MV=WA+_U>9,?Z-^&G_)J^'/\ LGI_EB#_ "SZ***_[83\D/[:O^#,3_D9_P#@
MIM_V ?V'O_3A^V57[4_\'1O_ "@H_;F^G[,__K87[/U?BM_P9B?\C/\ \%-O
M^P#^P]_Z</VRJ_:G_@Z-_P"4%'[<WT_9G_\ 6POV?J_XQOI^?\ID_2$_[+_%
M_P#J!@#^B>%O^2>RG_L$A_Z5(_R!****_D ]\_T^O^#*G_E%G\??^S_OBE_Z
MSK^RM7]?U?R _P#!E3_RBS^/O_9_WQ2_]9U_96K^OZ@ HHHH **** "BBB@
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MO_67_P!D:O\ .RK_ $3?^#//_E'/^TM_V?\ _$+_ -9?_9&K[_\ ;4_\HL\
M_P#9_P#A;_UW7BJ<GAS_ ,CS%?\ 8JK_ /J7@3A?^#U;_E%E\ _^S_\ X6?^
MLZ_M55_F"5_I]_\ !ZM_RBR^ ?\ V?\ _"S_ -9U_:JK_,$K_F$/VD*_U^O^
M#7'_ )04?L,_]W,_^MA_M!5_D"U_K]?\&N/_ "@H_89_[N9_];#_ &@J /W^
MHHHH *_C&\#_ /(S?M.?]G__ /!2G_UX+^TQ7]G-?QC>!_\ D9OVG/\ L_\
M_P""E/\ Z\%_:8K:A\;_ ,+_ #0'H-;WP)_Y2#?\$R_^SH/C+_Z[E_;MK!K>
M^!/_ "D&_P""9?\ V=!\9?\ UW+^W;6]3X)>@'];5?P)_L9?\F??LH_]FU_
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M_P#Y'N=?]C;,?_4RL>A?LP_\I%O^":/_ &<I\:?_ %W9^W+7]BU?QT_LP_\
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M ,I3?CY_V8!\4_\ UHK]E6O]/NO\P3_@RI_Y2F_'S_LP#XI_^M%?LJU_I]T
M%%%% '\\?_!87_D]']@C_LU__@H;_P"K7_X)N5\1U]N?\%A?^3T?V"/^S7_^
M"AO_ *M?_@FY7Q'771^!>K *_?G_ ()._P#*++_@FG_V8!^QO_ZSK\.:_ :O
MWY_X)._\HLO^":?_ &8!^QO_ .LZ_#FHK_8_[>_]M _%/_@I]_RE-^('_9@'
M[%W_ *T5_P %%:^4J^K?^"GW_*4WX@?]F ?L7?\ K17_  45KY2K_53Z-7_)
ME."_^[C_ /6MSX_SQ\<_^3I\4_\ =$_]9S* K^EC_@DY_P HL?\ @FG_ -F
M_L<?^L[?#FOYIZ_I8_X).?\ *+'_ ()I_P#9@/[''_K.WPYK\+^FE_S;7_N\
M?_?5/UKZ+G_-<_\ =L_^_"?P\_\ !W;_ ,I3/A/_ -F _!3_ -:*_:^K^76O
MZBO^#NW_ )2F?"?_ +,!^"G_ *T5^U]7\NM?]"7[+G_E!3P-_P"\F?\ KX?$
M$^VXV_Y*?,_^Y+_U7X0PO%'_ "+/B+_L!:O_ .F^XK_<L7H/H/Y5_AI^*/\
MD6?$7_8"U?\ ]-]Q7^Y8O0?0?RK_ #"_;=_\G2\#_P#L@.(O_6BIGVOAM_N.
M9?\ 872_],G^0/\ \'1W_*=?]N3Z?LS?^L>_L_5^ %?O_P#\'1W_ "G7_;D^
MG[,W_K'O[/U?@!7^(1^DGW]_P2?_ .4IG_!-3_L_[]C?_P!:*^'-?[?5?X@O
M_!)__E*9_P $U/\ L_[]C?\ ]:*^'-?[?5 !1110 4444 %%%% !7SW^U3_R
M07QY_P!RO_ZF?AVOH2OGO]JG_D@OCS_N5_\ U,_#M;8?_>*'_7ZE_P"EQ.;&
M_P"YXO\ [!J__IJ9]"4445B=(4444 %%%% !1110 4444 %%%% !1110 5\
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M]/3//:^:_P!LW_DS[]J[_LVOXZ?^JO\ %-?2E?-?[9O_ "9]^U=_V;7\=/\
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M^ _[.[PE_P"KS)C_ $;\-/\ DU?#G_9/3_+$'^6?1117_;"?DA_;5_P9B?\
M(S_\%-O^P#^P]_Z</VRJ_:G_ (.C?^4%'[<WT_9G_P#6POV?J_%;_@S$_P"1
MG_X*;?\ 8!_8>_\ 3A^V57[4_P#!T;_R@H_;F^G[,_\ ZV%^S]7_ !C?3\_Y
M3)^D)_V7^+_]0, ?T3PM_P D]E/_ &"0_P#2I'^0)1117\@'OG^GU_P94_\
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M_P!#I_P1L_\ "C_;:_\ G<5L>!/^"6G_  <,_#WXT? [XZ:+XP_X(R77BWX
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M1V.@WD][<:9:ZAH^J?HE_P =37_6 '_SHI7[_45+;;NW=^8'\1/PR_X(M_\
M!?;X4_#;X??"[P[X]_X(_7OA_P"&W@?PGX!T.\UKQ3^VA<:Q=Z/X.T&P\.Z9
M<ZM<6/PKTZRGU.>RTZ"6_FL]/L+66Z>5[>SM8F2!.W_X=,_\'!__ $.G_!&S
M_P */]MK_P"=Q7]G]%?J.'\:_%;"T*&%P_'.=TL/AJ-.A0I1JT>6G1HPC3I4
MXWHM\L(1C%7;=DM3X"MX6>'F(K5:];A/*JE:M4G6JU)4ZO-.I4DYSG*U5*\I
M-R>EKM]V?QL^!/\ @EI_P<,_#WXT? [XZ:+XP_X(R77BWX ^./%'C[P=IVJ>
M(/VWYO#FI:QXL^#'Q6^!FHVWB:TM/A[9:G>:9#X2^,'B74;*'2]7T:ZC\16.
MA7<]Y<Z9;:AI&I_I1_QU-?\ 6 '_ ,Z*5^_U%?$<0<29[Q5F,LWXBS/$YMF4
MZ5*A+&8N495I4:"<:5-N,8+EIIM1TZGU639'E/#V"CEN2X"AEV!C4J5HX;#J
M4::J56G4G:4I/FFTFW?H?YJ%A_P9_?\ !6[3K&RT^#XX?\$YWAL;2VLX6E^)
M?[3#2M%:PI!&TC)^S,B&0H@+E412Q)55& +?_$(5_P %<_\ HMW_  3C_P##
ME?M-?_0T5_I245_3&7?3K^EYE.7X'*\M\?..\'E^68/"Y?@,)1Q>!5+"X+!4
M:>&PN'I)X%M4Z%"E3I03;:C%)MZM\T^&,@J3E.>5864YR<Y2<97E*3O)OWMV
M]7ZONS^$[_@G-_P0:_X+N_\ !,;X^^(?VC/@+\1_^"27B[QMXE^#_BCX*7VE
M_%[Q?^V-KWA6+PKXM\:?#?QUJ6H6ECX,^#W@'5X_$$&K_"_0+>RNIM<GTZ/3
MKS6(9]*N;FXLKS3_ -4_VA?@I_P<X_M*? +XX?LY^.M0_P""$.D^"?C]\'_B
M7\%/&.J>$[K_ (*!V/BK3?"OQ4\%ZUX%\0ZAX9OM8TK7M(L_$%GI&NWEQHUU
MJFAZSIUOJ,=M-?:5J-LDMG-_2]17\^<>\?\ &7BAQ9FO'7B!Q#F'%7%V>?4?
M[7S_ #2=.IC\?_9F6X/)\![>=*G2@_JN69?@L%2Y81M1P]-.\DY/UL+A</@J
M%/"X2C"AAZ7-[.E!-1ASSE4E:[;]Z<Y2>N[9_F"?\05/_!4W_HOG[ '_ (=/
M]HK_ .A5H_X@J?\ @J;_ -%\_8 _\.G^T5_]"K7^GW17QYT'\$?_  2__P"#
M>G_@N5_P29^/OB_]HS]G/XG?\$H/&GC;QI\']?\ @IJFE_&OQI^U]XC\*V_A
M7Q'XT^'_ (ZOM0T^Q\"_!7X<:O%X@BU?X<:';VMU<:Y=:<FG76JPS:5/<SV=
MY8_N]_QU-?\ 6 '_ ,Z*5^_U% 'X _\ '4U_U@!_\Z*4?\=37_6 '_SHI7[_
M %% '\F_[27[#O\ P<A?M1_$[X1_%CX@>(?^"(FC^(O@QX#^,OP\\+V7@[5O
MV\-/T6_T7XX^(?@EXD\676OVVM>$O$%]=:II]]\!?!\7AV?3M1TJTM+34O$D
M>I66K37FESZ/Y9_P[!_X.'O^AN_X(P?^#_\ ;A_^8"O[&Z*I3E%64FD!_')_
MP[!_X.'O^AN_X(P?^#_]N'_Y@*^O?V>O@I_P<X_LU_ +X'_LY^!=0_X(0ZMX
M)^ /P?\ AI\%/!VJ>++K_@H'?>*M2\*_"OP7HO@7P]J'B:^T?2M!TB\\07FD
M:%9W&LW6EZ'HVG7&HR7,UCI6G6SQ6</]+U%#E*5KMNVUP/Y ?CO_ ,$X?^#B
MO]H7X^ZQ^T9XT\5?\$5M,\;:W\'_ (8_!2[TOPOKG[<UEX5C\*_"CQI\:/'7
MAW4+>QU;P-K6KIX@O=7^.GBVWUJZDUR73KG3M.\.0V.E:=<VFIWFK^??\.F?
M^#@__H=/^"-G_A1_MM?_ #N*_L_HK[_(_%;Q%X:RO"Y)D7%N;99E6"]O]5P.
M&J4HT*'UG$5L77Y%*E*2]KB:]:M*\G[]235EH?&9MX><%9YF&(S7-^',NQ^8
M8KV7UC%UX5)5:OL*-+#TN=QJ13]G0HTJ4;)>[!+O?^,#_ATS_P '!_\ T.G_
M  1L_P#"C_;:_P#G<5]P_L]?!3_@YQ_9J^ 7P/\ V<_ NH?\$(=6\$? +X0?
M#3X*^#M4\677_!0.^\5:EX5^%G@S1? WA[4/$U]H^E:#I%YX@O-)T*TN-9NM
M+T/1M.N-1DN9K'2M.MGBM(?Z7J*\KB?CGB[C3ZC_ *U9]C\[_LWZS]0^NSA/
MZK]<^K_6O9<D(6]M]5P_/>]_90M:SOZ.0<)<-\+_ %O_ %?RC"95]>]A];^J
MQG'ZQ]5]M]7]IS3E?V7UBMRVM_$E>]S^$_\ X*,_\$&O^"[O_!3KX^>'OVB_
MCU\1_P#@DEX1\;>&OA!X7^"MCI?PA\7_ +8V@>%9?"OA+QI\1_'6G:A=V/C/
MX/\ C[5Y/$$^K_$_7[>]NH=<@TZ33K/1X8-*MKFWO;S4/@O_ (A"O^"N?_1;
MO^"<?_AROVFO_H:*_P!*2BOV/@+Z7GTEO"_A/*N!?#_QCXPX5X1R/Z]_9&09
M7B<)3P& _M/,L9G&/]A"KA*LU]:S/,,;C:O-.5ZV)JM6B^5=6*R#)L;7J8K%
MY?AZ^(J\OM*M2,G*?)"-.%[22]V$(Q6FR];_ .:A?_\ !G]_P5NU&QO=/G^.
M'_!.=(;ZTN;.9HOB7^TPLJQ74+P2-&S_ +,SH) CDH61U# %E89!_JQ'_$4T
M !_QH!X_[2*5^_U%?!^*?C=XL>-N/RK-/%?CK/..LPR/!ULORG%YY5HU:N P
M6(K+$5\/0=&A12IU:Z562DI-R5[G5@<MP.6PG3P.%I86%62G4C232E)+E4G=
MO5+0_P \3]O7_@U__P""T/\ P42_:Q^*W[8OQK^+O_!,#PO\3?C!_P (-_PD
MNA?"WQ]^U;HG@2Q_X5_\-O!_PNT;^PM,\6? #QOX@MOM/A_P3I5YJ?\ :'B?
M4_.UBXU"XM?L5E+;:?:?'_\ Q!4_\%3?^B^?L ?^'3_:*_\ H5:_T^Z*_+#N
M/\V/]GO_ (-$_P#@KO\ LU_'SX'_ +1?@7XV_P#!.#5?&WP"^+_PT^-7@[2_
M%GQ)_:;OO"NI>*OA7XTT7QUX>T_Q+8Z/^S5H6KWGA^\U?0K2WUFUTO7-&U&X
MTZ2YAL=5TZY>*\A_J>_XZFO^L /_ )T4K]_J* /D#]BG_AOK_A5FO_\ #Q?_
M (8__P"%V?\ "P-5_P"$6_X8I_X71_PJS_A5G_".^%?[$_M__A>G_%6_\+ _
MX2W_ (3?^U?[._XIW_A'?^$5^R?\3/\ M>OK^BB@ HHHH **** "OGG]JN1$
M^ WCA7=%:5_#$<2LP4R./%^@2E(P2"[B..20JN2$C=\;58CWC4]3T_1=.O=6
MU:\M]/TW3K:6\OKVZD6*WMK:!"\LTLC<*JJ">Y8X506(!^;/#.GWOQY\36?Q
M"\36$]I\,/#=V\OPY\,7\9C/B74(BT9\;:Y:.,/;#YET:RE&S:-Y5H?M#ZGO
M07+*-9Z0HSA-O^:2DG&$>\I6_P"W8WD]%9\F+ESTY8:&M7$4YTXKI"$ER3JS
MMM""E?\ O2M!:NZ^H:***P.L**** "BBB@ HHHH **** "BHGG@CEBADFB2:
MX\SR(7D199O*4/+Y49(>3RT(:38&V*0S8'-2T %%%% '\2?_  55M?%>C?&[
M_@X<^"_BG5;,?%O]N+X._P#!'S3O^">7PR^U6\'Q!^-TG@[Q/K7@'Q#I'P;T
M8Q6NJ>*=9\$_'2ZO]4\2W&B-J+^!H-8TSQ3X@U'0]$@%WIW['?\ !2CX*?\
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M?\ ?^.IK_K #_P"=%*_G!_;U_P"#7[_@M#_P42_:Q^*W[8OQK^+O_!,#PO\
M$WXP?\(+_P )-H7PM\??M6Z)X$L?^%?_  V\'?"W1O["TSQ9\ /&WB"V^T^'
M_!.E7FI_VAXGU/SM8N-0N+7[%92VVGVG^AY17\L'N'^8)_Q!4_\ !4W_ *+Y
M^P!_X=/]HK_Z%6O8/V>O^#13_@KO^S7\??@?^T9X%^-O_!.#5O&WP!^,'PT^
M-?@[2_%GQ)_:;OO"NI>*OA7XTT7QUX>T_P 36.C_ +-6@ZO>>'[S5]"L[?6;
M72]<T;4;C3I+F&QU73KEXKR'_2;HH _ '_CJ:_ZP _\ G12C_CJ:_P"L /\
MYT4K]_J* /P!_P".IK_K #_YT4KQ_P#:%^"G_!SC^TI\ OCA^SGXZU#_ ((0
MZ3X)^/WP?^)?P4\8ZIX3NO\ @H'8^*M-\*_%3P7K7@7Q#J'AF^UC2M>TBS\0
M6>D:[>7&C76J:'K.G6^HQVTU]I6HVR2V<W]+U% '\<G_  [!_P"#A[_H;O\
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MW5_-N;B65;'1-%LQYFIZ_K$^5L]*TZ!5>22:>3'F2+&ZV\(>9E;:J/Q'PL\
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MC@5.M3>+H*6'INK73FDJ5-*#<IR^%656FVKW2J0;7OQO^AU%?F/^R]_P5:^
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M)@Y8N->C6;H5ZV'I*JHO$.@K2@I*,W!^TM2;E!\M22@XN;47_8S17Y!?!_\
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MYO\ 0+W3+$ZO?27-E*TOQY^SE\.OCE^WO_P4N_X*E?"SQI^WU^WY\&O!_P
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MKDTAM[2'PSX^D\37U]-;W5T8[=KJ]\.V,.F&5;C7&TJRBN;J#U7]HC_@KO\
MLT_LU_M%^)OV5/%O@?\ :$\:?&[1_!_A'Q7X8\&_"3X7V_Q%U3XIWGC.6/\
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M_P %R_V5/ GQ%^._PAL/A-^UG\3_ (I_L\^./&'A#QSX"^$7P:TWQ[KDVC^
M%<^,?B?ILFG^.(M)T_X8>'VC==0\0>,=3\)ZC&(Y9ET1K:&:>/\ 0G]DO]K#
MX-_MK? [PM^T#\"]8U#5? WBB34+$VVMZ>-(\2>'==T>X-IK/AKQ+I2W%Y%8
M:UI<^P3I;7M_875M-:ZCIFH7^FWEI>3SB<IS+!T(8K$X*O1P\W34:TX-0;JP
M=2EKK95(*4J;=E-1DHMN,DG0S' XFM*A0Q5*K6BIN5.,KR2IS4*FFE^232FE
M=QO&]E)-_2=%?RM?\%3OBCXCN_\ @LY^R7^S?X[_ &Y_CU^QA^ROXZ_93N/%
M'Q*\4?"G]I6X_9ST32?$=GJ'[4>H:+KNH>(M7O#X"M-5\1:_X'\">#WOO$FD
M7]QJ%H]IH6F26^HW5A-%[O\ M!^-=1_8@_X):_M5?'?]A3]N7XZ?MT:W=^(/
M!^C6_P :/BO^T/X6_:Z;X.&ZUSP_X9\6W7@[7O#.C#0=$ET/0?$<>KW^GZA'
M>QZ5J-[I7B/4HA:6RPS^HN'*CI92XXJ/M\XCA)8:F\/76'A];Q4\+"-;&6=*
M$XRIRG*"3FX\O*FY*_!_;4%4S!/#R]CELL1&O-5J3K2^KT(5Y.EAKJI*,E.,
M8RNH\U[M),_HNHK^=K_@D[X'TCXRVWP7_:)^'W_!6_\ ::_:4UP^ &O?VJ?V
M:OB?\6#XXT&+Q1XN^'^K:9>Z)HW@K49M#\;_  1@\#>/?$&GZGH?B2Q368M?
MD\)QVFE:NVG:G%=6,?\ P1'^.GQPT/XY_P#!0+]@3]IGXO?$CXQ?$K]G+XP7
M'B3P'XO^*WC;Q%X_\4ZU\-KN\D\'W,MGK_BR_OM;3PXD6E^!?%&F:=(\-I;R
M?$"ZN(K2TN+JZC?/$Y"Z$,T=+%QK5,IIX>IB:,L-B<-6Y:V)EA9N-/$0A*U&
M?L:DI6<)4L13DI*4:D(W0S=598!5,.Z4<QG6A0JQKT*]+FI4(UX)SHRE&]6/
MM81C=252C.+BXN$I?T4T5^ '_!(CXQ_&/]L+]K#_ (*/_M9ZW\6?B?K_ .SA
M:_&!O@/^SC\.-3\9>(;[X5Z=I?A66.]U7Q-X?\%RZC+X1T37[CPK9?#K49[W
M1=/%[+-XS\1->W]S)?RW%[^_]>;F> GEF+E@ZM2-2M3I8>=;D32I5:U"G7G0
M=]YT74]G4:TYXR2V.W XR..P\<3"$H4YU*T:7,TW4ITJLZ4:JMM&KR<\%OR.
M+ZA3))(XHWEE=(HHD:2221E2..-%+.[NQ"HB*"S,Q"JH)) %/KYA\7:U?_&W
MQ+>_"WP?=W%MX#T2X6+XI>,;)]HOF5LMX'T&Y *27%SM*:Q=1F1(8M\,@,2M
M;ZCR4X<[U?+"*O.;VC&]K^;;=HQWE)I>:VK552BK+GJ3?+2IIV=2;5TK](I>
M].;TA%.3Z)U9)9?VC?$K6D(GC^!WA/4A]LN5:2 ?$WQ%8R;EM8'4J[>%M+F5
M'ED7 O9@"CF9HGTSZDAAAMX8K>WBC@@@C2&""%%BAAAB4)'%%&@5(XXT541$
M4*B@*H  %4M(TC3- TNQT71K*#3M*TRVBL[&QMDV06UO"NU(T&2Q/5GD=FDE
MD9I97>1V8Z-%2:E:,4XTX:0C>[UWE)]9RWD_1+1)"HTG34IS:G6J6=6:5EI\
M,()ZQIPNU".^\I7E*3911169N%%%% !1110 4444 %?+G[8O[8OP(_84^!'B
MS]H3]H3Q9%X:\%^&HA;:=IUL(KKQ1XX\4744SZ)X'\#Z(\T$NO>*]>E@DCLK
M*.2*VM+:*\UC6+S3=#TW4]3L_J.OY-/^"XO_  2#_:/_ &E]*_: _;M^(G_!
M0F$>#OV4_@?\9OB[\%OV9]+_ &7T'@[PKHOPW\!:YXYF\/0^(]4^/^IVUSXT
M\9'PY;V?B7XI7W@JZU!KIK6XL/#MIHFC:+X9L?8R'"9;C<SPM#-L=/ 8&=6F
MJ]2EAZN)Q%2,JD8^RPU.$>3VL[Z2KU*-**NW4O9/AS*OB\/@ZU3 X:.)Q,82
M=.$ZL*-*+46^>K.3YN2-M53A4F]E%G\Z/[3W_!3G]N3]K7]JOPY^VE8_$SQ%
M\ ?$_P )-7N;S]EGX5^&-4DN/"OPE\,S2!;O3O%UG+ MGXUUWX@Z:D=C\3KS
M5M/>#7[&4Z+<:9%X;M-.\,:9_;9_P2,_X*Z?#3_@I9\-+O0=>M--^&/[6GPQ
MTVT3XU?!5[LJLRJ8;1?B3\-FNYI+K7?AQKMU)$05EO-0\(:A>0:'KD]S#<Z!
MK_B/_.I\'W]WJGA+PMJ=_+Y]]J/AS1+^]G\N.+SKN\TRUN+B7RH4CAC\R:1W
M\N*..-,[8T50%'[0_P#!%;_@DW\=_P!MF'Q#^WE\'_V]]1_9-^)/[-W[5/C[
MX-^![31OV>M-^)%U-9>$_"GP]\727&JZ_%\7/ALNK>'->T_XBR^&-:\$Z_H>
MMZ9?Z;8WIU"\OH==N;*U_J_QB\/N \FX*R+&86-7)<3AZ=+"9?C%0GB(8E58
M?6'3S2-&52JI5)3E-5J%.MR5)23BX-,_#^ .*N)\QXBS3#UW3S"C4G.OBJ'M
M%2E0<)*BI8)U%&#C%1473J3IN44FGS73_P!$*BL/PS;>(K/P[H5IXOU?2/$'
MBJUTC3[?Q)KN@:#=>%=#UG7(;6*/5-3TCPU?>(/%E[X?TV^O5FN;/1KKQ/XA
MN--MY([276=2>(W<O\G_ .SE\.OCE^WO_P %+O\ @J5\+/&G[?7[?GP:\'_
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M?X@ZCI]S/97^G^"/%=[8WEM(T-S:7EKH-_/;7-O*A#Q3P31I+%(A#)(BLI!
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M-=\4:?'IFHZC>11:%XEFT)+NXFO)((+C\SO^"=7P?^-'_!1/X]_\%&C\6O\
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M60UQ>74I6&VMT.Z25@,JH9EU=5U33M$TV]U?5[RWT_3--MI;R^O;J01P6UM
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MCY/VO_A-O[?W_P!C?\*Q_L;_ (JG_A,O[2_L+_A&_P#B;_VI_8__ !-J_P!
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MR5'#9AA?K$94L;5QE6D_8N,Z'UUU)5(SE[:2KJ$JGN-1HOE7+*[?,?P&7?\
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M^)/ 4-O#)9V?_"0^,?BII^KZW:Z;:_9);62RU+QAJ'Q4\!7$FDK))::7J-G
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M#G[9^E:9:6%C#LDOK_4=2U>V\FWB82WEQ=1@-OG#GZY_X-UOVF/A-XJ_8?\
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M7J6,JNGAG2HS5'!5,%2I4Z;Q%65*T:CJ2J2JU7*2Y5&*MR_S>_\ !N1;_9_
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MU)KXYK3W8P2****R.@**** "BBB@ HHHH **** "OAG_ (*?_P#*-+_@H?\
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MI6@ZN'EB*<_:4*E!QE"&(PTE:-1R353=*Z:N?RR_LJ?"GX[?\%!_VV/V^/\
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M=CX7\.:C-X8T_2O$$7P\\:ZH-<U.'1=.N);NTQ)%Q/[)7[??P%_8)_X*1_\
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MJ6'KQKT(THJ=*KB<3%5*<U[7VGO*3Y8J$''G?-^#?"/A[X?^$/"O@/PCI_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/?\ QE;_ -6]_P#F1Z/^,K?^K>__ #(]?0E%'MO^G5'_ , _X(?5O^HC$_\
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MUM=:Z?F14A[1)<\X6:=Z<N63M?1NST=]5Z'SW_QE;_U;W_YD>C_C*W_JWO\
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?R2DTK.5KV;2:4FF4445D= 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>img34756086_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img34756086_3.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" (U!1<# 2(  A$! Q$!_\0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MDVHJUZ-%TE5J1INO5C0I<SMSU91E*--/;FDH2<4[7M9:V1]OT445@:A1110
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MY:Z=KJ2ZM8C!^!W[&_[:?[4W_!2[P1_P49_;C^%GA#]F?PY\ OAW<>!_@?\
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M.KZ$HH]O/^6C_P"$^'_^5!]4I?SXG_PMQG_R\^>_^%<_'K_HX_\ \P_X,_\
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ME.>&Q"P]2M*5.C&->K"G*2C*JG-^L?L]?\%$?VF_A?\ \%.O@3^QUXQ_;T^
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M-IIWAO7H+/;))+<6./\ M&_\%*?CW\2_V_?B9^Q-\)OVX?V>?^"?'PR_9O\
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M6KYK6IX;)\3B$J4\5@XXK%T\=5^K8>O[:',ZTL-*,&JT56J*,:E2+2:/S/\
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M?:NVGV<HF$?_  [[_:X_XAT_^&$/^%4)_P -5[-W_"K?^$\^&VW=_P -Q_\
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MTBSM+V>T34;AAPF@?\$H/VK?%G_!!NW_ &)_$OA?2? W[3?A_P")^K_%+0_
M>J>,?!^IZ7J,MO\ %'4M7MM!U'QCX:UK7?"EE/K'A#5+^_TZX@UBXM8-5&EV
M.K7&GQRW\EGZ3\9/V&OVV?\ @H-_P2RT']E7XX_ ?PI^RG\9OV:I?@E=? RS
MU+XR^$_BCI'Q;U7X2_#'6OAWK&I>)-4^'C:GIO@"U\3Z+K^K6VC:7<W/B)M+
MUB:SFU&^EL$>^M^VMB\FK*EA)U<H_LG#<78]XBC3CE].2RZK5H2PM7#<D(XB
MIA95.:%6O@W+_98>RJS^KTX0CR4L-FE+VN)A3S+^T:_#>#5"K4EC9IXZG3JQ
MQ%.OSRE0AB(PM*G1Q2C_ +1+VE./MYSD_F,?\%0/VM/V4_B/^R%XO^)O_!1S
M]D3]OOX>_'[QGX;\&_'CX(?!O3/@-9^*/V>I_$[V DN_#>N_"?5#XG\16&B1
MZE<B/Q'XPM-.TRYU30ET&\TJ%]8MM7'MW_!4;4H_@S_P7 _X)$_&;P\[V/B+
MXD:GI_P-\0RV<*QR7WA_Q'\16^'@CO'\T)=1RZ?\;-:M)3)%YL%M#$RRRF*V
MCM^W_9]_9S_:AO?%GP-\*>/_ /@A7_P36^"\GA7Q?X!/Q@_:6U&;]FSQ1:ZM
MX:T/7M*D\8>*_A/\-/AIX5E\;>%?'UWH=GJ-]X,_M[Q%JFFZ?XLN-)N=2\G3
MK>Z@3BO^"AEHG[1__!>K_@F1\"/#%O'JMS^SQI%G\??'MY;^<8_#J:/XJOOB
M;;VFL31L4M94M/A?X6GLE>-(Y[KQCHEJTTSWZ0Q8T98%YK!T:.#IPI9)Q"\R
MJX*KE<Z%?"/"5U0=2EE,GA:;BY1IQ4N7$5%[)UX^T5WK4CBUE\O:U<5.53-L
ME^HT\53Q\:U+$+$4?;*%3,4L144^64W9RHTW[14GR-)?T_U\]_\ "N?CU_T<
M?_YA_P &?_)U?0E%?FD*DH7Y5!WM?GITZFU]O:1E;?6UKZ7O9'W%2E&K;F=5
M<M[>SK5J.]K\WLJD.;96YKVUM:[O\]_\*Y^/7_1Q_P#YA_P9_P#)U'_"N?CU
M_P!''_\ F'_!G_R=7T)15^WG_+1_\)\/_P#*C/ZI2_GQ/_A;C/\ Y>?/?_"N
M?CU_T<?_ .8?\&?_ "=1_P *Y^/7_1Q__F'_  9_\G5]"44>WG_+1_\ "?#_
M /RH/JE+^?$_^%N,_P#EY\]_\*Y^/7_1Q_\ YA_P9_\ )U'_  KGX]?]''_^
M8?\ !G_R=7T)11[>?\M'_P )\/\ _*@^J4OY\3_X6XS_ .7GSW_PKGX]?]''
M_P#F'_!G_P G4?\ "N?CU_T<?_YA_P &?_)U?0E%'MY_RT?_  GP_P#\J#ZI
M2_GQ/_A;C/\ Y>?/?_"N?CU_T<?_ .8?\&?_ "=1_P *Y^/7_1Q__F'_  9_
M\G5]"44>WG_+1_\ "?#_ /RH/JE+^?$_^%N,_P#EY\]_\*Y^/7_1Q_\ YA_P
M9_\ )U'_  KGX]?]''_^8?\ !G_R=7T)11[>?\M'_P )\/\ _*@^J4OY\3_X
M6XS_ .7GSW_PKGX]?]''_P#F'_!G_P G4?\ "N?CU_T<?_YA_P &?_)U?0E%
M'MY_RT?_  GP_P#\J#ZI2_GQ/_A;C/\ Y>?/?_"N?CU_T<?_ .8?\&?_ "=1
M_P *Y^/7_1Q__F'_  9_\G5]"44>WG_+1_\ "?#_ /RH/JE+^?$_^%N,_P#E
MY\]_\*Y^/7_1Q_\ YA_P9_\ )U'_  KGX]?]''_^8?\ !G_R=7T)11[>?\M'
M_P )\/\ _*@^J4OY\3_X6XS_ .7GSW_PKGX]?]''_P#F'_!G_P G4?\ "N?C
MU_T<?_YA_P &?_)U?0E%'MY_RT?_  GP_P#\J#ZI2_GQ/_A;C/\ Y>?/?_"N
M?CU_T<?_ .8?\&?_ "=1_P *Y^/7_1Q__F'_  9_\G5]"44>WG_+1_\ "?#_
M /RH/JE+^?$_^%N,_P#EY\]_\*Y^/7_1Q_\ YA_P9_\ )U'_  KGX]?]''_^
M8?\ !G_R=7T)11[>?\M'_P )\/\ _*@^J4OY\3_X6XS_ .7GSW_PKGX]?]''
M_P#F'_!G_P G5G^"-0^)FA?&RX^'GC/XB_\ ">:7)\+)?&=O)_PB/A_PO]FO
MW\6VFAQ)LTI)KB;R;>&Z;<]Z(9/MF&M0]O',?I2OGO\ YNM_[M[_ />D5<*C
MJ*JI1I65*<ERT:,&FK6:E"G&2^3,JM&-)T90G7NZ]*+YL5B:D7&3=TX5*LHM
M/S3/H2BBBN8[@HHHH **** "BBB@ HHHH **** "BBB@ JGJ-A;:KI]_I=X)
MS9ZE9W5A="UN[O3[DVUY ]O.+>_L)[:_LIS%(WE7=E<V]W;2;9K:>*9$D6Y1
M0FT[IV:U36Z?<-]SY?\ V5_V,?V9_P!BCP?XA\!_LQ_#"U^&7ACQ7XC;Q;XC
MM$\3>-/&%]K&OM86FEK>WFO>/O$GBG7WCAL;*"&VL%U1=.M";B:VM(9[R\EG
M^H***UK5ZV)JSKXBM5Q%>H^:I6K5)U:M25DKSJ5'*<G9)7DV[)+9&=*E2H4X
MTJ-.G1I05H4J4(TZ<%=NT802C%7;=DDKMA11161H%?-/Q#_8^_9R^*OQ[^$O
M[3_CKX;PZO\ 'CX&6=WIWPO^(EKXG\::!J7A[3KU]1>XTVZTWPYXCTG0/$^G
M%M8U?RK#Q9I.NVEL-6U1;:&%=1O!-]+45K2K5J$G.A5JT9RA4I2E2J2IRE3J
MQ<*M-R@TW"I"4H5(-\LXMQDFFT9U*5*JE&K3IU8QG"I&-2$9J-2G)3IS2DFE
M.$TI0DO>C)*46FDPHHHK(T"BBB@ HHHH **** "BBB@ K,UK1[#Q#HVK:!JL
M<TVEZYIE_H^I0V]Y>:?/+8:G:RV5Y'!?Z=<6FH6,TEO/(L=Y875M>6SE9K6X
MAG1)%TZ*:;333:::::=FFM4TUJFGLP:3335T]&GLUV9\^?LS?LK? +]CKX9I
M\'OV;OAY:?#3X=KK^K>*'T&VUOQ1XDFNO$.N"U34]6U#7O&6M^(O$>I7=Q!8
M6%HCZAJ]R+6PL;+3[18+*TM[>/Z#HHJZM6K7J3K5ZM2M6JR<ZE6K.52I4G)W
ME.=2;<IR;U<I-MO=D4Z=.C3A2HTX4J5.*C"G3A&%.$5M&$(I1C%=$DDNB"BB
MBLRPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KY[^
M(W_)>OV;_P#NL'_J&6-?0E?/?Q&_Y+U^S?\ ]U@_]0RQK:A\<O\ KSB/_4>J
M<V+_ (4/^PG!?^IE ^A****Q.D**** "BBB@ HHHH **** "BBB@ HHHH **
M** /E3X,_L2?LP_L^_&#XQ?'SX2_#$>&OC!\?=3U'5OBSXYO?&7Q \6:GXIO
M-6U^Y\3Z@([?QGXK\0Z9X=LKG7+I[UM,\+6.B:8@ALK6*S2RT[3[>V^JZ**U
MK5Z^(G[3$5JM>IRPA[2M4G5GR4XJ%.'--RERPA%0A&]HQ2C%))(SI4:5"/)1
MI4Z,.:4^2E"-.//.3E.7+!)<TY-RE*UY2;;;;;"BBBLC0*^:OVD?V/\ ]G/]
MKFQ\ Z?^T)\.(?'T7PN\8VWC_P  7,?B?QIX/U7POXLM(Q'#JFG:WX$\1^&-
M9*,$@>XTVYOY])NY[2QN;NQGN+"SE@^E:*UHUJV'J1K8>K5H5H7Y*M&I*E4A
MS1<7RS@XRC>+<79J\6T]&S.K2I5H2I5J=.K3E;FIU81J0E9J2YH23B[-)JZ=
MFD]T%%%%9&@4444 %%%% !7P=^T__P $QOV$OVRO%=KX[_:._9W\,^/_ !M:
MV%II?_"7V>O^.? 7B:]TZP$BV%GK&N?#?Q3X0U/7;>QCE>&RCUJYOQ:6^RWM
M_+ABBC3[QHK?#8K%8.JJV$Q-?"UDG%5<-6J4*JB]XJI2E&:3LKJ]G;4QKX>A
MB:;I8FA1Q%)M-TZ].%6FVMFX5(RBVNCM='S#^S%^QA^R[^QGX<U7PK^S-\&_
M"_PITK7Y;*;Q!/I4NL:QK_B&338YHM./B#Q9XIU/7?%6N+IZ7-U]ACU76;N.
MT:[NY+=8Y+JX:3Z>HHJ:U>MB:LZ^(K5:]:H[U*U:I.K5F[)7G4FY3D[)*\FW
M9)%4J5*A3C2HTZ=&E!6A3I0C3IP6]HP@E&*OK9)!11161H%%%% !1110!C>(
MO#^C^+/#^N^%?$-DFI:!XFT;4_#^N:=))/#'J&CZS93Z=J=D\UM+!<Q)=65S
M/ TEO-#.BR%HI8Y KCQ']F/]E+X _L;_  U;X0?LW?#^/X;?#N3Q%JOBR3P^
MGB3QAXK:7Q#K<-A;:GJ<VL^.?$'B;7YI+FWTS3X!#+JCVUO#:Q1VT$* @_0]
M%:QKUHT9X>-:K&A5G"I4H1J35&I.FI*G.=-/DG.FIR4)2BW%2DHM7=\W2I2J
M0K.G3=6G&4(57"+J0A-Q<X0FUS1C-QBY132DXQ;3LK%%%%9&@4444 %%%% !
M1110 4444 %%%% !7S5X0_9 _9T\"?M'_$K]KCPS\.8K3]HKXN^'[#PIX^^)
MM]XG\::[J6K>&],M?#EE9:+I^CZ_XCU/PSX8L([3PCX9MY(/"FB:(MS%HMBM
MUYPBY^E:*TIUJU)58TJM2E&M3=&LJ=24%5I.49NE546E4IN<(3<)WBY0C*UX
MIK.=*E4=-U*=.HZ4U5I.<(R=.HHRBJE-R3<)J,Y14XVDHRDKVDTRBBBLS0**
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH *^>_\ FZW_ +M[_P#>D5]"5\]_\W6_]V]_^](K:C_R]_Z\S_0YL3M0_P"P
MFC^;/H2BBBL3I"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OGOXC?\EZ_9O\ ^ZP?
M^H98U]"5\]_$;_DO7[-__=8/_4,L:VH?'+_KSB/_ %'JG-B_X4/^PG!?^IE
M^A****Q.D**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MV._&VI?L[^./!_[5O[57Q4^ _P ,_ OB']J7XA_LW_ .Q\=>%?A!%J_AVVU
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M]HS7/VF=9\6Z#9?M'_&+]L+X+7/PR^)GQHUCQ=X2\!_$C4]/UW0]9G%WX?\
M#-QX+O+.[\!1Q^ 5U_0-IUU_W(U+QUX(T:V\,WFL>,?"NE6GC74]*T7P;=:E
MXATBQMO%NLZ['YNAZ3X9GNKR*+7M3UF+]YI5AI37=UJ,?SVD4R\UU5>(OI.^
M)\N)<VXFAB.':>.SNK0IYWA,'D6%P&79AD6"\/JWA=D?"-7"Y=/"SPW"W#W
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M>)HO"JNJ5:EB:M/$..)FIXB-2K%J51591@Y.7O1<(.#BXIK^>KXR_P#!+/\
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M'JG-B_X4/^PG!?\ J90/H2BBBL3I"BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?/?_ #=;_P!V
M]_\ O2*^A*^>_P#FZW_NWO\ ]Z16U'_E[_UYG^AS8G:A_P!A-'\V?0E%%%8G
M2%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_$U_P<._\IS_ /@W
MX_[+S\+?_6J?A37]LM?Q-?\ !P[_ ,IS_P#@WX_[+S\+?_6J?A37]LM !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M);W6$TO7] TK4]2L;98]LTVE6E\$FDMX#B>ZMHY>3^'O[?O[)'Q5\9Z!\/O
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M]H'A?Q'HUQH]G=6UY=?VEI%JAL[B&ZB>2WD20_S8?\$Z/V#_ -KW]KCX1_\
M!+#XM?&SQ]^S;X4_95_9$U;0OC5\$O#_ ,,=$^(%]\?/&-]X>\7MX@TG2_BG
MJGBFVB\)Z6G_  D?AS3Q='PAJ4NG2:1)<@Z3)J9M[R#R']K#XB^.?^"??QO_
M ."I'[!WPUTN]6\_X*1?\*R^(O[(6E:1;/I%E'XP_:4\80?"?XS:/I+6P>WT
MJ>8ZUXITK04L_*CMX_ FCFU.E^>D%MZU;AK*<1C<1EN5XRO/&T'"4Z=7$4:]
M*E3IYD\'BW4K1P>$C*I##5*..E""2PU.EB83G7:4J?F4L]S&CA*&.S##48X2
MLI*,Z=&I1J5)U,"L5AU"E+%8EJ$L1"KA(SF[UYU*$XPHJ\9_TK77_!2;]B+3
MOV;?#?[7>L?'O0O#_P"SUXRU75=#\'>/?$WAKQYX9G\7ZMHFK:KHFIV'A7P9
MK_A33O'WB.>VU'0]8BVZ-X6O1-!IMY?6[2V$#W([O]E?]MK]ES]MGPYXB\5_
MLP?%O2OBIHWA'4+'2_%#6FB>+?#&J:#>ZI#=3Z9'JGA_QMX?\->(+./48K&]
M>PN9M,6UO!9W0MII#;S!/Y]/VT_A?\'?V(OVQ/\ @B)X>^/5M9+^P_\ L_\
MP^^(7PWOM>\2Z7/JWP[TWXT0^");?2?&7BBU\F:WL]2U;QZO@/QS?ZEJ<0MQ
M'HVJ:RT+6.A:JL7UM_P49_:K^"/Q)_9N^*5_^PG^V9\!OAI\6;SXN_ ?P?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /XFO^#AW_E.?_P;\?\
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M?![]IKXG?LW_ !E^+?PD\%?MA?'W0=;^ 5_\,?&E[XJ^&$_CN;PS/X8_:L\
M_#Q-';4O%UJ3;P17NN_V)JMC;V_@C3/['O+?4KK3]6T#PWQGXC^$>N?%;]J+
M6_V@-$^-<7[+Q_X*.?$+Q[XX\=?"W]E7P!\;_AS<7UKXIT6WL?#=]^V)J7Q
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M\2S:CK/BZTM["QTS1M"N;76[&--*T_6O1O@+^P7^TW??\$>OVF--N/@U\5_
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MFB>,[+2O$,^B>/OB1>67BRSF6UCL#J;>(]%BU34IM.N6M.8_X)X?M#?M?_\
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M!^S@!P!\!?A  /0#X>^'<5[S7@W[*_\ R;#^SC_V0;X0?^J]\.U[S0 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %?/?_-UO_=O?_O2*^A*^>_\ FZW_ +M[_P#>
MD5M1_P"7O_7F?Z'-B=J'_831_-GT)1116)TA1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 ?Q-?\ !P[_ ,IS_P#@WX_[+S\+?_6J?A37]LM?Q-?\
M'#O_ "G/_P"#?C_LO/PM_P#6J?A37]LM !1110 4444 %%%% !1110 4444
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M_@\9_P"41&G_ /9V/P6_]1OXG5_5?7\J'_!XS_RB(T__ +.Q^"W_ *C?Q.H
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M:O5__DFC_B+8_P""/W_0_P#Q:_\ #5ZO_P#)-?G?_P 0O_\ P2]_Z!WQT_\
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M/[./_9!OA!_ZKWP[7O->#?LK_P#)L/[./_9!OA!_ZKWP[7O- !1110 4444
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M)X4\4^'[V'4=%U_0M6MH[S3M3TV]MV:*XM;JWE21&4AER4D5)%9%ZNOY1O\
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M]OX6N-5M;N*&YMH;'Q(-*NKA98T)MXRPRC!C_&U\+/V_/V@/V//^"1_[7/\
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M:_K@K^1__@[D_P"3;?V0O^RW>.?_ %!(: /ZM/\ @@#_ ,H:O^"?'_9!=/\
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M,/\ 8Z_;G^&WPF_X+&?!7]C?XQ_L#_ CX6Z%\>/@M\$?'G[)?[1?A#X-^'/
MWBMOB)XL_9L\,>+/&^HV6L:9;?9-:\'>,_'4GQ(\.:3<V<D&K^&[Z?2] N$-
MB\BC^SR@ HHHH **** "BBB@ K^5#_@\9_Y1$:?_ -G8_!;_ -1OXG5_5?7\
MJ'_!XS_RB(T__L['X+?^HW\3J /Z-OV5_P#DV']G'_L@WP@_]5[X=KWFO!OV
M5_\ DV']G'_L@WP@_P#5>^':]YH **** "BBB@ HHHH **** "BBB@ HHHH
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M^S//VF?_ %2OC:O\^#_@T,_Y*I^W!_V3'X0_^IEXDK_0?_X*'_\ )@'[<O\
MV9Y^TS_ZI7QM7^?!_P &A?/Q4_;@_P"R8_"'_P!3+Q)0!_<6 3D\8 R22% &
M<=20,DD #J20 ":08;=M:-MG$FV1#Y;8!V288[)""I$;XD(92%PRY_FG_P""
MD?[>-AXI_:(^&7P]\&?M :'\(_A+^R5^V?\ LIZ3\;;1O$"Z'XF^,7CC7OB'
MI%[XPT$P,T5W_P *E^#O@CS+WQIJ/S6&K^(=8&FMYD.E3U4US3?VD]6^%_[#
M'[5]Y\?/$WAKX9_M)?\ !1#X5?%^Y^!^EV4UK>:]IW[1GQ)\9ZCX$C\6^*9I
M_MLGA/PU\"_#WPOT_0?!UE'%IXU2XUV^U".1[B/ !_3)@X!XYSCD9.,9(7.2
M 2 6Q@$@$Y(%?R/?\'<G_)MO[(7_ &6[QS_Z@D-?K/\ LX:-\=O"G_!5O]IO
M0_C/\<]1^+4?B+]CWP-X^\,^'++25\-> OAII%]\>]?T?1/"_A/P]%+())[/
M0[*V_MGQ'?;M4UG4[F^DE<6HMXD_)C_@[D_Y-M_9"_[+=XY_]02&@#^K3_@@
M#_RAJ_X)\?\ 9!=/_P#4D\15^PE?CW_P0!_Y0U?\$^/^R"Z?_P"I)XBK]A*
M/Q"_X.._^4+G[<W_ &3[PU_ZL7P?7\V'_!I7_P F<?M*_P#9QUE_ZK?PY7])
M_P#P<=_\H7/VYO\ LGWAK_U8O@^OYL/^#2O_ ),X_:5_[..LO_5;^'* /U)_
M:!_;B_:6^ OQU\*:5X@^%_P?L?A'XV_:/\#?L^?#7X::CXHU>7]J#XWZ#XMF
MT#2]:^//P\T:SD?PY#X*\'ZYJU\9-'OD%]=^'](N]2NVAG,*/Y;\:/\ @J'\
M:? /A#7/%_@#X!WGQ$\+ZY^V+JGP9\$?$R"S>S^&'A#X%^%_C1X4_9\U'QSX
MRUIITN-9\8>,_B,GC>7P-HVF1L)M&?1]1NB+&SF,G-?MY?LT_P#!1']H:T^)
MW@#PO\*/V<O%VK:3\6++XG_LG_M=77BZT\%?$KX'>#M OM(\6Z/\-T\.16LF
MMS>,8?$6CGP[+XJM+^/2->T75IKW5;5ELA&WTU\4_P!BOX@77_!.?X/?LE?#
M5M#OO'/@'6OV9]<UNXUK68]*TO5-2^'/Q1\'_$#XF:U+J<T<J7&IZE-I_B'4
M8&,?F:KJ$ZH&1KD$ '!>,O\ @H5\<M UOQ]\;],^''PQNOV*/AA^V"O['^OW
M-QJ?B$_'#7IH/'^D_"/7OC7H9C_XI*+PMH?Q/U&?1[?PU-_Q,+_0+"XU:65;
M@*E?SB_\'<\30_M.?LH0OC?%\#O%\38Z;H_B%=*V/;(-?T >*/V(OVIM3A^)
MW[).G>'OANW[)?Q(_;=?]JJ+XY3^-(T\;^'OAOJ_Q=TWXZ^)/A*?ABUM]LO_
M !:WCBWO-#TWQ(;U=);P[>-?21B[M45OP _X.Z)3-^T[^RC,0 9O@?XPE('0
M&3XAW;D#V!.* /\ 2A_9=_Y-F_9U_P"R%?"/_P!0#P_7NM>%?LN_\FS?LZ_]
MD*^$?_J >'Z]UH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "OGOXC?\EZ_9O_[K!_ZAEC7T)7SW\1O^2]?LW_\ =8/_ %#+&MJ'
MQR_Z\XC_ -1ZIS8O^%#_ +"<%_ZF4#Z$HHHK$Z0HHHH **** "BBB@ HHHH
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MSPC4=2G4C HHHKU#V0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%JB0B6]L-0EK_5(U9+Z32]233&5-2?3[Q-/=R%5+YK:06C,S J%6X,98L"
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M (.._P#E"Y^W-_V3[PU_ZL7P?7\V'_!I7_R9Q^TK_P!G'67_ *K?PY7])_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M7-?RE_\ $$]^U_\ ]'V? _\ \(OXE_\ R71_Q!/?M?\ _1]GP/\ _"+^)?\
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M^'2\%_\ RYK^4O\ X@GOVO\ _H^SX'_^$7\2_P#Y+H_X@GOVO_\ H^SX'_\
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M2?SX?M/_ +4?CS_@X*^*W_!(7]C/]GCX _%CPQJ'P!L_#$'[2/B;Q9X>NH-
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MU1_#">(_#VC2?VYX.^('A[2KN30M2FMT%IK5C86ETLTUM]EBM@#L_P!FL_\
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M\U_$-_P>\?\ )JG[$/\ V<'X_P#_ %7"T ?OK_P0!_Y0U?\ !/C_ +(+I_\
MZDGB*OV$K\>_^" /_*&K_@GQ_P!D%T__ -23Q%7["4 ?B%_P<=_\H7/VYO\
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MTA\)/VL?^"47Q!UR+PWX ^"\/@KX@?"3P[XUTVPU'Q9XDL?'7B7Q)'<M\/\
MQ.J^%O%UI?Z5JNG6,S375K>I_9X@+M"8RGX^?"S_ (.7?VB?V7_&&G^"?^"N
M/_!,/3(?%.D7+V-_\5/#_P )[/X=^,'NW9HKO43I/B71;KPMJ>^=2S?\(QJM
MK%<#*QL20]?TS_\ !5__ (+N_LD_\$E-7\*^ OC'H'Q&\?\ Q?\ 'G@UO'G@
M[X?>!M)MH[:]\-C6=2\/K?ZOXLU.=-,T82:KI-]!#";>\N)$MY)1"%"[OY.?
MC9_P6K_X*Z_\%FH]1^#?[$/_  3M\,P_#?Q#!/I;>(]8^%5G\5=3@TF[CD62
M[F^(WQ#LK;P+X5N[19/MB7VAB&^MD262W:1W! !_8A^P;_P6O_X)M?\ !0&;
M0/!G[.OQTT.P^).IV\B:;\$O&^G2^!/B&JV5I)=3V^EZ!>J-/U9+>VMKJ5(M
M!U"_D%K9S7#6\4"!C^M=?PB?\$3O^#7K]J[]DW]KKX&?MR?M5?%CX=^%-<^$
MGB#7/%MI\'/!(G\7:KJM]K_A3Q)X;$&M>*42QT33EA3Q$;R>#3[>\>.>W-LD
MI7]X/[NZ "LC5_#^@>((X(M>T/2-;BM93/:QZOIMEJ4=M.5V&:!+V"9892A*
MF2,*Y7Y<XXK7HH ;Y:;/*V)Y>SR_+VC9LQMV;,;=FWY=N,8XQBN;T+P5X-\+
MW-Y>>&O"7AGP[>:B2=0NM"T'2M)N;XL48F\GL+2WEN26CC8F=GR40GE5QTU%
M &-KOASP]XHL6TOQ-H.C>(M,=@[Z=KNEV.KV+.%90[6FH07%NS!7=0QC)"LP
MSAB#;TS2],T6QM],T?3K'2=-M$,=IIVF6EO86-JC.TC);VEK'%;PHTCNY6.-
M079F(W,2;U% !7\J'_!XS_RB(T__ +.Q^"W_ *C?Q.K^J^OY4/\ @\9_Y1$:
M?_V=C\%O_4;^)U ']&W[*_\ R;#^SC_V0;X0?^J]\.U[S7@W[*__ ";#^SC_
M -D&^$'_ *KWP[7O- !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %?$GB#_ )2)?#+_ +-$^*W_ *MGX95]MU\2>(/^4B7PR_[-$^*W_JV?AE7Q
M?&_^YY!_V6G"'_J]P9^>^(W^X<,?]G"X#_\ 6EP!]MT445]H?H04444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5\]_\W6_]V]_^](KZ$KY[_P";K?\ NWO_
M -Z16U'_ )>_]>9_H<V)VH?]A-'\V?0E%%%8G2%%%% !1110 4444 8MSXD\
M/V8UHW6MZ3 ?#=FVH^($?4+42Z)8I:&_:[U6(2F6PM_L(-V);E(D:V_?*3&0
MQ\:\*?M5?LV^.?A1XF^.O@[XX?#3Q-\&_!8U,^+?B9HOBS2K_P &^'/[%MK>
M\U8:QKD%P]E8'3K2[MKF[%Q(AAAN(9' 612?XR/^"X?[,'[(?Q)_;_\ VF?'
MFF_\%B;_ /8\_:M7X:^!I/%'[.'B.^\2^'_"VN+IGP.T*#PUIVCZMI>HV5A?
M#QCX3M-,FO[2Y2=5O=9E4V[DNQ_G1_8G\+?\%6S_ ,$?OVT/%/[,?Q4^&Q_8
M3D_X6K8?M,?"'6_$/A,>.(-)M?!'A63QOXOT/PYJ4+:Z%O\ P_-I%C;WVG31
MR32:=,MN"]N^ #_6L^''Q,^'OQ@\&Z/\0_A9XS\.?$#P-XACFFT/Q9X3U6TU
MK0=5CM[B6TN'LM1LI);><07,$UO*$<F.:-XV 92*[BO\\/\ X(<_\%8_^"DG
M[+7[,O[('P!/_!.'Q-\4_P!D#Q9XYM_!'@']H/PMI/BF%AIWC7XI7EGXE\1Z
MA>:;;:II-W;^&M7U;53<S74-BGV?3FADD4Q>:W^AY0 4444 %%!( ))P!R2>
M@'J:X:3XG_#2*22*7XA^!HI8G>*6*3Q;H"21R1L4DCD1M0#(Z."KHP#*P*L
M010!W-%4M.U/3=8LK?4M(U"RU33KM2]K?Z==P7UE<HKM&SV]U;22P3*'1T+1
MR, ZLI.5(%V@#^)K_@X=_P"4Y_\ P;\?]EY^%O\ ZU3\*:_MEK^)K_@X=_Y3
MG_\ !OQ_V7GX6_\ K5/PIK^V6@ K_+-_X+1?\K2GA?\ [.8_8-_E\'*_U,J_
MRS?^"T7_ "M*>%_^SF/V#?Y?!R@#_4RHHHH *^>/VN_^33OVG_\ LWCXU?\
MJMO$M?0]?/'[7?\ R:=^T_\ ]F\?&K_U6WB6@#_/A_X,F/\ D^?]L'_LU:U_
M]7!X(K_2EK_-:_X,F/\ D^?]L'_LU:U_]7!X(K_2EH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@#X\_P""A_\ R8!^W+_V9Y^TS_ZI7QM7\.G_
M  8^?\EK_;\_[);\$O\ U+/'%?W%_P#!0_\ Y, _;E_[,\_:9_\ 5*^-J_AT
M_P"#'S_DM?[?G_9+?@E_ZEGCB@#_ $3J*** "OXAO^#WC_DU3]B'_LX/Q_\
M^JX6O[>:_B&_X/>/^35/V(?^S@_'_P#ZKA: /WU_X( _\H:O^"?'_9!=/_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *^>_^;K?^[>__>D5]"5\]_\ -UO_ ';W_P"](K:C_P O
M?^O,_P!#FQ.U#_L)H_FSZ$HHHK$Z0HHHH **** "BBB@#\5O^"D/_!#O]@+]
MO:7XI_&[XI_ 637_ -H[5?A]J$&E^._"GB76?#/B?Q!X@\+^#9-&\!VNHO:7
M8L;\6*Z=HVEVL5S;B%[:VAAFW+N8_P 7/[.G_!KS^V)XJ_X)R?M _&'QI/\
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MI_\ 'Z /QD_X+-_M8?LU_M6_\%N?^"#.N_LW_&SX??&C2?"7[1/PBTKQ-?>
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M?%_@.VCN88+W3]5\-)K^O6>B7Y:ZT_Q':>'+KR98;TQQ3_O70 4444 %%%%
M!1110 5_*A_P>,_\HB-/_P"SL?@M_P"HW\3J_JOK^5#_ (/&?^41&G_]G8_!
M;_U&_B=0!_1M^RO_ ,FP_LX_]D&^$'_JO?#M>\UX-^RO_P FP_LX_P#9!OA!
M_P"J]\.U[S0 4444 %%%% !1110 4444 %?+W[6'[9O[-O[$7PW?XJ?M+?$_
M1/AQX7EGEL='COFEN]=\3ZK% UQ_9'AG0K-)=1UC4#&H++;PBWM_,B:\N+9)
M$<_1^M'5ET?5CH"V3ZZ-,OSHJ:D95TYM6%K*=.74# 1.+)KSR1=&$B40&0QG
M?BO\TO\ X.6]2_;NN_VG_@?;?MGV?P\TZSA^"B3_  UL_@S<>*+CX6M--XJU
MN/QE/;2>*'>]/C%IX=$CU]<[(](7PV8@%E8M_8OT(_HRY+]*7QHRK@+B3C+!
M\*\/TJ&-S/-\/A<=@Z/&&=83 8'$XR6"X5P.-HUZ.(K.5"*Q^-J4J\,LP4JN
M+>&Q$HPI2^>XDSJIDF75,51PTJ]5N,*;E&3P].4YQCS5YQ::5G[D4TYRM'F6
MK/[<_P!C#_@M!_P3Y_;Q\;2_#/X$_&*1/B0R7$NE> _'^@WO@CQ)XEMK.#[1
M>7'AFUU-GM]9%I%EYK:UNC?A%DE2T>&*61/U3K_%O_91N_BS8_M-? *Z^!)U
M'_A<</Q=\ 'X;#2S>B[?Q<WB73DTB)O[/!O/L<UPRQ:D(@0=->[$H,)DK_8$
M_9EN/VI[GP+J,G[6^G_!W3?B*/$-TNEP?!.Y\377A=O"XL=/-G)>R>*7>_&L
MG4#J2W"PG[*+9;4QC>9*_:OVB'T)>"?HG\0<)XSP]XUJ9CPWQ;EF*KQX7XLS
M7+Z_&> QF7XO#X7$8G QP6"P"S7)*\<52F\1+"4:N!KTL12J5,1"=)T_.X2X
MDQ.>TJ\<7AE"MAYQ3KX>$UAY1G%R2ESSGR55RO12:DFFE'6_T91117^:!]D%
M,\R,=73_ +Z7_&GU_%=X.\"_M&_M1?M8?%OX1_#+XF:Y8:S:^*OB?KL UKQM
MK^F:;%I>A^++BWD@CDAGG".@O($@A2$($0@;0M?CWBOXK5_#2KPGA,%PGCN+
MLQXNS'%Y9E^7X#'4\%B/K.&AA9QA!5,+BE6G7>)4817L^5P;;=]/P7QN\;,5
MX0UN",#EW!&8\=9MQUFN.R?*\KRS,J.78KZWA*>#G3ITU5P6,6(GB7C%"$%[
M+E<&W*7,K?VG>9'_ ,]$_P"^E_QKXF\0,O\ P\0^&3[EV']D7XK -D8)'Q9^
M&1(!S@D#KZ5^)7_#J/\ X*%_]%@TK_PZ7BC_ .1Z\GO?^"<_[;5K\<?#WPIG
M^*.G/X^U?X7^)O'6FZK_ ,+#\0M%;^%-$\3^'M#U33O[3:'[5%)<ZKK.F7(L
M8E-O,L)N)#O@&/R3B;QA\1\9A\IABO +C' 1H<2</8NE.KFN%FL1B<+FF&K8
M? P2R^/+5QM6*P]*?O*,YJ3C)*S_  SC#QZ\6L?A,DAC/HQ<>Y9##\7<*XZC
M4KYU@YQQ6+P>=8/$87+8)95#EK9A6C'"49MM0J34G&23B?US>9'_ ,]$_P"^
ME_QH\R/^^G_?2_XU_+C_ ,.H_P#@H7_T6#2O_#I>*/\ Y'KXI_:/^$G[4'[(
MOQ'\">#/B?\ %'5[S4/%-I9>(+$^'O'GB'4K<6(UB73F2X:6:V,<OGVLIV%&
M#)M;)#8KLSWZ1O&?"^7RS;B/P)XJR7*Z=;#X>KC\=G>%IX>E5Q56G0HQE)97
M)WJ59\D5;65D=_$GTLO$'@W*Y9YQ9]&KC3A_):6(PN%K9GF/$6#I86C6QM:%
M##0G-9-)J56M45."MK.T;JY_;/165H3,VB:.S,69M*T]F9B2S,;2$EF)R222
M223DGDUJU_5T)<\(3M;GC&5M[<R3M?K:Y_;=.?M*<*EK<\(SM>]N:*E:^E[7
MM>R"BBBJ+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ KY[_YNM_[M[_]Z17T)7SW_P W
M6_\ =O?_ +TBMJ/_ "]_Z\S_ $.;$[4/^PFC^;/H2BBBL3I"BBB@ HHHH **
M** "BBB@ HHHH **** ,O7-#T;Q-HNK^'/$6E:?KGA_7],OM&US1=6M(+_2]
M7TC4[:6RU'3-1L;E)+>\L;ZTFFMKJUGC>&>"5XI$9&(/\]&H_P#!J]_P1KU'
MXH7'Q-/P!\564=SK#:T?AWIWQ,\3VOPSAG:[%U]@MO#"S,T.B*H^RKI"W_V4
M6Q,8&?FK^BNB@#FO!O@SPG\._"?AWP)X$\.:/X1\&^$M(L= \,^&/#]A;Z7H
MFA:+ID"6UAINF:?:)';VMK;01K'''&@'!9BSLS'I:** /XFO^#AW_E.?_P &
M_'_9>?A;_P"M4_"FO[9:_B:_X.'?^4Y__!OQ_P!EY^%O_K5/PIK^V6@ K_+-
M_P""T7_*TIX7_P"SF/V#?Y?!RO\ 4RK_ "S?^"T7_*TIX7_[.8_8-_E\'* /
M])S]K3]D;X$_MM_!G6?@/^T/X2D\6> M6U+2->MOL&J7_A_Q'X:\3^'KH7N@
M>+?"'B;29K?5O#7B?1+K=+I>M:9<0W=JTD@1]LC _%'@[_@BC^P[X,^#_P"T
M5\(H=*^+'B9OVJ_"VD>!/C?\5/'GQ:\5>-/C3XK\!:)>V%[8^!8OB-KLUSJN
MD^$5-B8)-"TU+>RFAO;[S8Y);@R#];:* /A7]K[_ ()S?LO_ +;7A;X7>'/C
M#X<\2Z3J?P1U1=7^#WQ ^%OB_6/AK\2OAK<'3(]'NK?PEXR\-R6^I:;INI:9
M!;6>J:6/,L+^"UMXY[=EC KS&']B?]GK]A?]@?\ :S^&?[/?A.^T33O$OP?^
M/GC?QSXH\2Z[JGC#X@_$7QIJWPV\1K?>*_'WC?7I[K7/$^MR010VD=U?W#+;
MVL*16\40:4R?IQ7SQ^UW_P FG?M/_P#9O'QJ_P#5;>): /\ /A_X,F/^3Y_V
MP?\ LU:U_P#5P>"*_P!*6O\ -:_X,F/^3Y_VP?\ LU:U_P#5P>"*_P!*6@ H
MHHH **** "BBB@ HHHH SM8_Y!.J?]@Z]_\ 2:6O\K#_ (-ZO^4V/QZ_[$?]
MJ'_U9WABO]4_6/\ D$ZI_P!@Z]_])I:_RL/^#>K_ )38_'K_ +$?]J'_ -6=
MX8H _P! BBBB@ K^>K_@YW_Y18>(O^R\_!O_ -&>**_H5K^>K_@YW_Y18>(O
M^R\_!O\ ]&>** /N7_@T%_Y0Y>&?^SBOCG_Z7^'Z_J(K^7?_ (-!?^4.7AG_
M +.*^.?_ *7^'Z_J(H ^//\ @H?_ ,F ?MR_]F>?M,_^J5\;5_#I_P &/G_)
M:_V_/^R6_!+_ -2SQQ7]Q?\ P4/_ .3 /VY?^S//VF?_ %2OC:OX=/\ @Q\_
MY+7^WY_V2WX)?^I9XXH _P!$ZBBB@ K^(;_@]X_Y-4_8A_[.#\?_ /JN%K^W
MFOXAO^#WC_DU3]B'_LX/Q_\ ^JX6@#]]?^" /_*&K_@GQ_V073__ %)/$5?L
M)7X]_P#! '_E#5_P3X_[(+I__J2>(J_82@#\0O\ @X[_ .4+G[<W_9/O#7_J
MQ?!]?CQ_P9-?\F*_M7_]G36W_JK/!]?L/_P<=_\ *%S]N;_LGWAK_P!6+X/K
M\>/^#)K_ ),5_:O_ .SIK;_U5G@^@#^T2BBB@ K_ #=_^#W;_D[?]BC_ +-S
M\:?^K,NJ_P!(BO\ -W_X/=O^3M_V*/\ LW/QI_ZLRZH _P!!/]EW_DV;]G7_
M +(5\(__ % /#]>ZUX5^R[_R;-^SK_V0KX1_^H!X?KW6@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^>_B-_R7K]F__NL'_J&6
M-?0E?/?Q&_Y+U^S?_P!U@_\ 4,L:VH?'+_KSB/\ U'JG-B_X4/\ L)P7_J90
M/H2BBBL3I"BBB@ HHHH **** "BBB@"O=P?:K6YMO-D@^T6\T'G1';+#YT;1
M^;$W:2/=O0]F -?Y*W[3OCWXN_\ !+SX&_\ !5[_ ()9?M%_LPZJ_B7]JSXV
M^&?'OPV_::>T\IM3T#PI\5/#WB_3KO\ X2*\TYHO%?A'Q)H&@"^TZ'2;^"\T
M?Q+KNL1ZG#O>6)/];$]#CKVK_-8C_:Q_X.*?VZ?VFOVIO@;^S\GPU_:6\)?L
MZ_%WQIX,UOQ%>?#/X,>*_AGX52/Q'JT6A^'K3QEXPT-;2_U V%GY#6FG_:9V
M:PEEN1Y7E3S 'H7_  3U^*OQ4_X+.?\ !8'_ ()J_'?X3?LS:O\ !KX&_P#!
M.[X(^!?#OQ.^+UY9B2]\9R_#KP3=Z;&?$7BVSL;+3-6N_$OB=K'PUX5\-V\M
MW?Z9X8O-4NKV0Q"5$_T9:_S+OA5^W)_P<X>&_P!I_P 3_L*>"+?P;\//VA_!
M/@V[^)47P'NOA?\ !7P7_P )7X5MXDG?6O!-M%IMEX?\81SV8>ZA;3KV5I+:
MTOMS*^G7L5O_ %M?\&_'_!5?XL_\%.?V=_B_:_M(^#M+\&_M-?LN_%"+X4_%
MZ#0]/.C:7KDE]875QH^NOH9EE70=:.I:+XIT/7='MR+*WO-#$]H$CNC#$ ?O
MO1110 4444 %%%% !7\J'_!XS_RB(T__ +.Q^"W_ *C?Q.K^J^OY4/\ @\9_
MY1$:?_V=C\%O_4;^)U ']&W[*_\ R;#^SC_V0;X0?^J]\.U[S7@W[*__ ";#
M^SC_ -D&^$'_ *KWP[7O- !1110 4444 %%%% !1110 5\C_ +8O[#'[,?[>
M?PW@^%W[3GPUT_Q[X?TZ_&J^']06>XTGQ1X5U0A4FO\ PQXDL&BU+1Y[NW4V
MEZL$I@O+5VBN(9 $*?7%%>UP[Q'Q!PAG>6\2\*YWFO#G$.38F&-RG.\DQ^)R
MS-<NQ5--1KX/'8.K1Q.'J*,I0<J=2+E"4X2O"4HO.M1I8BE.C7I4ZU&I'EJ4
MJL(SISCVE"2<6KV>JW2>Y_,C_P &_7_!,C]CSX;_  -\-_M@:9\-%UW]H"?X
MH?M*>"M+\<>++^XUY_"NB_#OX_\ Q/\ A=H#>%-.NRUAHFJ/X2\,:?;:CK%M
M#_:-U/+=RB>/SL#^FZOR._X(>_\ */3P=_V7W]L__P!;"^.-?KC7[E]+3C#B
MOC/Z1?C!B^+>(\ZXDQ.4>(?&7#^55LZS'%9C/+,BRGB7-</EF3Y?]9JU%@\L
MP%%<F%P6'5/#T5*<HTU*<Y2\S(</0PV49?&A1IT8U,)AJLU3A&'/5J4*;G4G
M9+FG)_%)W;TN] HHHK^<SUPK^5W_ ()??\I/OC#_ ->OQW_]32SK^J*OY7?^
M"7W_ "D^^,/_ %Z_'?\ ]32SK^9O'/\ Y.-]'?\ [+_%?^DY2?R!](__ ).O
M]%7_ +.?C/\ TG)#^J%F5%9W9415+,S$*JJHRS,QP H )))  &3Q7Y/>*/VL
M_P!FVT_X*%^ KR?XR>"%L-)_9W^(7P]U+5%U/S=(L?&>L_$CP%JVF:#<:M%&
M^G1W5UIVE:A<B3[2;6-;9EFGCD*J?:_^"G/BWQIX*_8B^-VM^ Y[ZSUE]+T#
M1[O4--:1;W3_  _K_BG1=&\0W,#PD31;](OKJTEN(V1[2"YENPZ>1O'\1+22
M,Q=G8N<DMN.>>O/].E?)_25\=,?X=Y[PSPOE>1X7'UT\HXPQ6,S"K7A1E# Y
MQ6>#P&&A0<)<]6MEM5XK$3E-4Z=2G&G2E-RE#X?Z7?TD<S\*^).#^#,FX<P6
M9XB+R+CS&X_-*N*IX>5/+<^Q'U#+<'3PTJ4G.K7RBL\;B9SG&E2JTH4J,ZCG
M*G_HSVUS;7MM;WEG<07=I=P17-K=6TL<]M<VT\:RP7%O/$SQ3031.LD4L;-'
M)&RNC%2"?YAO^"X/_)S'P%_[$"S_ /4SU:OTP_X(Z>+_ !EXN_8L\/'Q?=WV
MH0^'?&OBSPSX4O;\N\K^%]..G3VUK%-(-]Q::=J=YJMA;/N98([<6"%4L@B_
MF?\ \%P?^3F/@+_V(%G_ .IGJU=GCYQ+3XQ^C=@N*J6%J8&&?U>"\T6#JR4Y
MX9XO,L'5G1=11BJL:<W*,*JA#VL%&IR0YN5=WTG.+J7'WT2<MXTH8*MEU/B>
MOX?9RL!7FJE3"2QV;8&M/#NJHP5:%*<I1I5U"FJ])0K*G#GY%_33H'_("T7_
M +!.G?\ I'#6M63H'_("T7_L$Z=_Z1PUK5_6E#^!1_Z]4_\ TB)_<>'_ -WH
M?]>:7_I$0HHHK4V"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KY[_P";K?\ NWO_ -Z1
M7T)7SW_S=;_W;W_[TBMJ/_+W_KS/]#FQ.U#_ +":/YL^A****Q.D**** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@#^)K_@X=_Y3G_\&_'_ &7GX6_^
MM4_"FO[9:_B:_P"#AW_E.?\ \&_'_9>?A;_ZU3\*:_MEH *_RS?^"T7_ "M*
M>%_^SF/V#?Y?!RO]3*O\LW_@M%_RM*>%_P#LYC]@W^7P<H _U,J*** "OGC]
MKO\ Y-._:?\ ^S>/C5_ZK;Q+7T/7SQ^UW_R:=^T__P!F\?&K_P!5MXEH _SX
M?^#)C_D^?]L'_LU:U_\ 5P>"*_TI:_S6O^#)C_D^?]L'_LU:U_\ 5P>"*_TI
M: "BBB@ HHHH **** "BBB@#.UC_ )!.J?\ 8.O?_2:6O\K#_@WJ_P"4V/QZ
M_P"Q'_:A_P#5G>&*_P!4_6/^03JG_8.O?_2:6O\ *P_X-ZO^4V/QZ_[$?]J'
M_P!6=X8H _T"**_+WX\_\%"OBAX-^/7Q$^ '[-'[&?Q(_:HU_P"!W@G1?'?Q
MS\1:7XDTOX?^'/"%EXALY]4T?P]X;O?$5NL?C3Q/=:3:W=W)9Z2\D-O+;26D
MDOG @;GBW_@I+\/9?V O!_[=?PC\*ZGX]L?BA-\./#GPO^&6H7":1XA\0?$?
MXD_$;1OACIW@2YD D6+4M,\0:G>37S0"0/IVDW5W#E"" #])J_GJ_P"#G?\
MY18>(O\ LO/P;_\ 1GBBOJ;7O^"C/[26O?&W]H?X1?LT_P#!/+X@_M-:)^S1
M\0K'X4^/_B=X9^*7A+PQX=E\=2^%M(\4W^F6%IK,9N7BL+;5XHWF+$90EMI(
M%?&G_!R)J^NZ_P#\$@+;7O%'ABX\$^)=;^*OP U;Q#X,N[VWU.Z\(ZYJ-AKU
MYJWAFYU*TQ:ZA<:#?33Z7->VW^CW4EJT\/[MUH _0K_@T%_Y0Y>&?^SBOCG_
M .E_A^OZB*_EW_X-!?\ E#EX9_[.*^.?_I?X?K^HB@#X\_X*'_\ )@'[<O\
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MW_JK/!]?L/\ \''?_*%S]N;_ +)]X:_]6+X/K\>/^#)K_DQ7]J__ +.FMO\
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M_B31=96\N+JST;Q3I_B;P7'>:IINKW6@G2M,\4>'->A5XM2TQIK?>G^DW/\
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M@ HHHH **** /R._X(>_\H]/!W_9??VS_P#UL+XXU^N-?D=_P0]_Y1Z>#O\
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M+_V"=._](X:UJ_I.A_ H_P#7JG_Z1$_KG#_[O0_Z\TO_ $B(4445J;!1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 5\]_\W6_]V]_^](KZ$KY[_YNM_[M[_\ >D5M1_Y>
M_P#7F?Z'-B=J'_831_-GT)1116)TA1110 4444 %%%% !1110 4444 %%%%
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MU;2)H+C2M4\4:%8W]MH7B"_L)[>.:&XU33[EI) S7(G+'/YD_P#!SC!!:_\
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M@_\ 4,L:VH?'+_KSB/\ U'JG-B_X4/\ L)P7_J90/H2BBBL3I"BBB@ HHHH
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M+#Q%_P!EY^#?_HSQ17]"F1ZC\Q7\]7_!SN0?^"6'B+!!_P"+\_!SO_TT\3T
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M=5_I$5_F[_\ ![M_R=O^Q1_V;GXT_P#5F75 '^@G^R[_ ,FS?LZ_]D*^$?\
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M"5\]_P#-UO\ W;W_ .](K:C_ ,O?^O,_T.;$[4/^PFC^;/H2BBBL3I"BBB@
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M=\?Z;M?Y5OAF1XO^#M7XA21.\<B?\%%_C>5>-BCJ?[3\9<JRD,#[@@T ;?\
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MQR_Z\XC_ -1ZIS8O^%#_ +"<%_ZF4#Z$HHHK$Z0HHHH **** "BBB@ HHHH
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MIRS_ + ,)_Z8IG^?-_P:W\_\%7_VMB>O_"E_B[_ZN[P)7^@]7^?#_P &M_\
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M+A/B+ANNZF;9IC\WQ*E+-<%3<(8G,<1B*T**5-2C0A-4HSE4G&"E4FY?S?\
M3"R3#Y#]'?/L)AL9G..A4XLX2Q+JYWG69Y[BHRGG67TG3IXO-<5B\13PZ5*,
MHX>%2-&-2=6I&"G5J2E_33H'_("T7_L$Z=_Z1PUK5DZ!_P @+1?^P3IW_I'#
M6M7]04/X%'_KU3_](B?V7A_]WH?]>:7_ *1$****U-@HHHH **** "BBB@ K
MS'XP?&7X9? /P#K7Q/\ B[XPTGP1X(T!(_M^M:O,8XVN)V*6MA96\:R76H:C
M>."EK86<,US-MD<1B**61/3J_ER_X.6V^(0\'_LQBV%W_P *L.O^._[6-N)_
MLG_"=?8=&.BKJA3]QYAT(:T='$WSX&L^3QYM?J_@?X=X/Q7\4^$N LPS6638
M#/<9BHXS'4E2>)6&P&7XO,ZV'P4:R=)X[&4\'+"X1U(U(4ZU:-65&M&FZ-3]
M%\)N"<+XB^(7#?!V-S"65X/.,3B%B<735-XA4,'@L3CZM'"*K>F\7B885X?#
MNI&<(5:L:DJ=50=*?ZD? [_@L5^PI\?/B):_##PI\2-6T#Q-JFHII7A]O'?A
MVX\+Z1XCU&622.WM-(U:>XN+4SW;1XM4OS8F=GBCCW2R+&?U%K_*BL/MWVZS
M_LS[5_:/VF#[!]A\[[;]L\U?LWV3[/\ O_M/G;#!Y/[WS=OE_-BO]/K]G;_A
M-S\ /@<?B7]J_P"%C'X0_#?_ (3W[;C[;_PF?_"':-_PDWVO;Q]J_MK[;]HQ
MQYN^OW_Z7?T;N$? M<'YIP=G.:8C <2U,SP6(RG/,3A<5C\/B<KI8*J\=A,1
MAL-@_:X2M'%JGB*=2A?#5U1<*U2&)5.A^R_24\#.&O"-<,X_AC,\PKX//9X_
M"5LNS>OA\1BZ-? 4\+4>+PU>AA\+[3#5(XA0K4YT6Z%7V7+5G&NH4O8Z***_
MBD_E4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O
MGO\ YNM_[M[_ />D5]"5\]_\W6_]V]_^](K:C_R]_P"O,_T.;$[4/^PFC^;/
MH2BBBL3I"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _B:_X.'?^
M4Y__  ;\?]EY^%O_ *U3\*:_MEK^)K_@X=_Y3G_\&_'_ &7GX6_^M4_"FO[9
M: "O\LW_ (+1?\K2GA?_ +.8_8-_E\'*_P!3*O\ +-_X+1?\K2GA?_LYC]@W
M^7P<H _U,J*** "OGC]KO_DT[]I__LWCXU?^JV\2U]#U\\?M=_\ )IW[3_\
MV;Q\:O\ U6WB6@#_ #X?^#)C_D^?]L'_ +-6M?\ U<'@BO\ 2EK_ #6O^#)C
M_D^?]L'_ +-6M?\ U<'@BO\ 2EH *_RJ_#G_ "MI?$/_ +2+?&__ -.?C&O]
M52O\JOPY_P K:7Q#_P"TBWQO_P#3GXQH _O\HKX"_;7_ &M_BY\!/$OP&^#/
M[.7P$'Q\_:"_:.U_Q3IO@K2O$FL:AX1^%7A#0/ ^FV6J>+?%WQ(\:V%I=-HM
MC9P:E8QZ99KLN-2E:Z>+?'92HW+_ +&G[<7Q$^,7Q5_:/_9J_:H^#WAWX ?M
M%_LN:=X*\7>/;#P5XOF\=?#'Q%\-/B!H]UKOA[QOX2\2WD4%\T,.GVC/J]I?
MQ1M UQ;F#*+-@ _26OS/_P""R?\ RBW_ &W_ /LA/B;_ -&6E?)W@?\ X*C_
M +77QOL/@;X._9R_9(\'_$+XQ_'SP_\ %OXUZ3?^._%NO^ O@CX#_9L\*?%+
MQ'X ^&?B?Q)XVMK*ZEU#QO\ $/3]#@UR#0[-A';PZC9,T;17]M*GG7[4?[9G
MB3]J_P#X)0?\%2_"OQ3^%,/P3_:#_9FT/QO\%_CE\.M,U_\ X2OPQ8>*;.ST
MK5;'5_"'B1E2;5/#NL6%R7LY+M$NT>VF,BB.2$D A_X,A?\ DV+]N+_LO'PZ
M_P#5?7-?W"5_#W_P9"_\FQ?MQ?\ 9>/AU_ZKZYK^X2@#.UC_ )!.J?\ 8.O?
M_2:6O\R/_@UF_P"4^'Q\_P"R5?M8_P#JUO!5?Z;FL?\ ()U3_L'7O_I-+7^9
M'_P:S?\ *?#X^?\ 9*OVL?\ U:W@J@#_ $)OVL/^"@/['W[#\?A,?M/_ !P\
M+?"_4?'<EY'X-\/WT6K:SXH\2+IZ,]]<Z7X:\.:=J^M36%H$99]0:R2Q213"
M;CS@8Z](^#G[4_[/7[07P3C_ &B_@Q\6?"'Q#^"KZ7K&L2>/] U#S='LK/P]
M!-<ZZ-46X2WO-)N]'AMYGU&PU.VM+VT5-TT"JR%OA']NN[_X)^?L3?$J_P#^
M"FG[3&D-KWQS;X4Q?LV_"[PZRR>-?%?CN'4/$,7B;2_AO\&_AE+%=_;/''B3
MQ!%%%/JFEVJSQ65Q<+J%U!932B3\9+3X2_'_ /9?_P""1'[:6J>,/!%A\"_V
MC/\ @LI^U_;>%?A)^S9H+QVUM\$;S]MGQ)X1^#NF>![<6!2UL?%NE_"T>+?B
M'XG&G1QQ6>MVEVBA'MW,8!^X?CG_ (+0?\$T_A=X9^#?BKXF?M0>%? 5A\?O
MA?IOQF^%5IXAT3Q<NL>)_AGK-]=Z=I7BQ-)TW0-1O+'3=0NK&Y6T;4([9YD0
M2HAC=&/XH_\ !SI^T7\%_P!JK_@A'<_&KX >.M.^(_PQ\1_M(_".TT7Q9I=I
MJEE97]QH^K>*M.U**.WUFQTZ_0VM[!+ YEM$5F0F,NA#'V#QW_P3?_X*':7^
MW[\5OB9^QQKW[%?A#X1?#S]D#]FO]ESX/7'[1?AY_C9K5KX:^$6DWMS>^%X/
M 6B26LOP[N/$NM/;2ZAX@U-Y3<Z?I]H]A!.S7"K^:G_!8_\ :\UO]L?_ (-Q
M?%/B[QQ\+?"_P:^+?PD_;HTC]G7XV> O [6[^"-/^+/P:\8>+/#'B_4/!\MM
M!;QR>']9NTCU&T#(9(I)YX&DE6))' /TV_X-!?\ E#EX9_[.*^.?_I?X?K^H
MBOY=_P#@T%_Y0Y>&?^SBOCG_ .E_A^OZB* /CS_@H?\ \F ?MR_]F>?M,_\
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M_@]V_P"3M_V*/^S<_&G_ *LRZK_2(K_-W_X/=O\ D[?]BC_LW/QI_P"K,NJ
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M]@W^7P<K_4RK_+/_ ."T:./^#I;PLI1PS_M+_L%E5VMN8.OP;*%5QE@X(*$
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M &0KX1_^H!X?KW6O"_V7@1^S/^SL"""/@7\) 01@@CP!X?!!!Y!!X(/2O=*
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M - :OR3_ ."'O_*/3P=_V7W]L_\ ];"^.-?K9/\ ZB;_ *Y2?^@-7RGTC/\
ME(7QN_[.YX@_^M;FIOE'_(IRS_L PG_IBF?Y\W_!K?\ \I7_ -K;_LB_Q=_]
M7=X#K_0>K_/A_P"#6_\ Y2O_ +6W_9%_B[_ZN[P'7^@]7]??M6_^4L:__9K_
M  T_]4<CY_@7_D0Q_P"PW&?^G0K^5W_@E]_RD^^,/_7K\=__ %-+.OZHJ_E=
M_P""7W_*3[XP_P#7K\=__4TLZ_P^\<_^3C?1W_[+_%?^DY2?SC](_P#Y.O\
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M5K#0] TJ.669+#3;-+0I;VRRS2R+&IP&D8]Z[G_AP[_P<"_])Q&_\"OBS_\
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ML1XHT:=;O0]3_P"$B^+O@S2-#N[.^A+6]U%J<OA76+JREC=EN8(9KB$O$I<
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MW[ /[78 )/\ PHOQUP/;2I"?R )-?SH?\0BOAC_I*K^W5_X,M/\ _E[52_\
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M?\&\_P 1_P!B3X-W/Q.^#O[0_P"T'^V/;0:P&\<Z!\38TU?7_!FA+:$6VO\
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M(?#>E^'?[$TEH+R\"Z;(NF+?N&D4FZGE.S'S'\8/RX_4BBBB@ HHHH ****
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M4=.U6/1M[I+=6VM^#O@E<3E&<11?\)9%>2112WEP'M?!;XG^,/\ @G[\+_\
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M>*/A#X#\'? S]GSP]XUD^'>@_!/2? ^C:=::QI?AGXEWVF>&O"U[8^(;71/
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M>7ZW6F?&9;X.Y5C,9P;FF-Q>#R7AW$Y1X6ULUIXK%9KF=7/,XXXQ.,7U+#/
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M\$!^QLOF*^>6\#<0YIQ:^",-1P?^L"GCZ<J/]HX&OA%/+<!B<RQ2CF."KXK
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MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /Q7^,W_!&KP?\
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M(,'C:.2XJC1IJO@*CBF?!'B[_@GW\*]7_8LG_8P\+:C/X8\.QVMA<Z5XXO\
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M]3/B+P_I'BSP_KOA;Q!9C4=!\2Z-J?A_6]/::XMEOM(UFRGT[4K,W%G-;W<
MN;*YF@,UK/!<1!]\$T4JJZ^4?L]_LW_!?]E;X=Q?"GX"^#!X#\ P:SJGB"/0
M1XA\5>)R-7UDP-J5XVJ^,M<\0ZTYN3;0#R9-2:WA6,+;PQ*2#]YD7&$,BX3S
MS)J.&HULRS/.,GQU">/R?)LYRR&%P&'S"EB(U</G%'&4HXJ4\51="I3P4Y1@
MJR]O2ORU/?P&<QP&4X[!0I0GB<5C,'7IRQ&#P6-PT:5"GB(U%.GC(5H*JY58
M>SE&A)I<_P"\AM+^4S]B'_E7^_X*#_\ 99_&G_J$?LU5S_QY\7>']%^%_P#P
M0ZCUS1O OQ7L?#7P6UWQGK?P&^,WBWPG\-/@QXLTNWM=$:WG\6?$7XC7T'P[
MT:\UR31[_1=.C\56-]I'VNRLK;5([BSU4:7J?]/W@G]@+]D?X<_ #XA?LN>#
M/A(FC? GXJ:SJ'B#Q[X%'CCXD7ZZ]J^J67AS3KV\_P"$EU3QC>^+]+,MGX2\
M/0I#HWB#3K>W&FH]M##+<7;W'YE?ML_L%_&+3?C9^QOXL_9X_9C^&?[4_P"R
MO^S%\-=3\!V7[(7CWX@Z+H%K#JM[)K=G-K]WKWQ<N]3TGQ':2Z-?>%6L&\27
M7BJXMM6\'/<:AHU]]OBF/ZWDWB)PYG'$N9U&J^"IX[B+B;B+"O-L1@,JH5:.
M-X+K9)A<!4Q[S&G2P>/KXMVC/Z]@:-.$HU(YK1JI0?UV#XBR[&9GBIVG0C7S
M',\QI?6ZM#"4Y0K9+/ TL/+$/$QC1Q%2L[*7MZ$(Q:DL7"=D?/?[$/[//A[1
M/V??^"JW[3LWAO\ 9A\-WWQ@^%7Q5B^'?PX^ _Q%^%OQM?X!^#X_AY\4=1UO
MPA!\0_AI=ZUH.C:3XKN=1T.)_#WA_5K33KYO UM=3Z-I\5IIEC9?&UO^R;^S
M_;?\&]MY^TRGPWT!_CO>^)K/Q2WQ/GM(9_%UK<6/[6LOP7AT?3=:FC>^TSPR
M_@B>6*[\.V$]OI=]K+)KE[!<:C;VTT/ZK_L&?\$]_BCI/[27[5G[0?QU_9^^
M&?[+'PE_:#^$.K?!2P_9'^&/C33O$&CVF@>)I_"XU_4]2U;X=W5EX7TZ=]-\
M.7UK%<>%FT>4WGB_7;C2=*\,0PQ1W?ZA_P##$/[+W_#+W_#&/_"L%_X9JV[/
M^%;?\)E\0,8_X6!_PM+/_"7_ /"5_P#">;O^$\_XG^__ (2C?O\ ^)?N_LG_
M $"N+-_$7!Y)GL?99OC<>Y\6<!\09A4R6K0JX2GDF1Y1/#9CPW'%T\XQ5',Z
MU"4L/2YUC,3@<PJTJM?$X[VSE.>&,XCHX+'IQQ=?$.6;Y!F.(E@ITY48X' X
M.5+$98JL<95ABITVZ<.;VU2AB)PG4J5^=MR[/]E;5]3U_P#9?_9OUW6KVXU/
M6-;^ OP?U?5M1NY#+=:AJ>I?#WP[>7][<RGF2XN[J:6>:0\O)(S'K7O5<]X0
M\*:!X#\)^&/ _A/3QI/A;P9X=T7PIX:TI;F\O%TS0/#NFVVD:-IZW>H7%W?W
M0LM.L[:V%S?75S>3B/S;FXFF9Y&Z&OY_QU:GB,;C,11@Z=&OBL16I0<8Q<*=
M6K.<(.,6XQ<8R2<8MQ35DVK,_/J\XU*]:I!.,)U:DX1:2<8RFY132;2:32LF
MTMDV@HHHKE,@HHHH **** "BBB@ HHHH **** "BBB@ HHKQ3XG?%"]T*^L_
M 7@*RB\1?%#Q!$3IVFD[K#P[8L )/$?B25<K:6%JK>;#!(5DO&"@#RV42W"$
MJDE&*UW;>B26\I/912U;9G5JPHP<YNRNDDDW*4F[1A"*UE*3T45JWY#OB?\
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M'/'?A:W\6Z#J&@3>(_!7B$VM\-!\6Z)'J#:GX;UDV5X-+UBUL[XVMP(/*?\
MCIT/]ESX2_LU?\'!W[*7P/\ ^"9>H_$>SA\$?#M?$O[?$<'Q.\:^/M @L4M/
M$CZJGQ2USQ7K&NL_B+Q%H%YX<N-2T"XDCT&S\4^*O!B^&=-T'6YYHK#^NG]H
MC1OC5XB^!7Q:T']G#Q/X4\%_'G6? /B73/A)XN\<17,WA+PUX\O=-GM_#VMZ
M]'::+XDN&T_3;Z2*[D*>'M="M$CR:1J4:O9S?SX?\$R/^"<__!7+_@GUXAM]
M*;_AUIXQ\+?%3XP:!XQ_:L^-NJZ_^V#XT_:P^)WA*Z\5+>^,7T_QAK6A>'/!
MUWXLTOP[J/B)O EAJFBZ;X6_X2B].K^)8KV]U77=5O>?Z*_%^%X'\,O'G,L5
MXI\-Y77X@X.SW@?)/!KB+/ZF39+QEF/%60XG+<;QKQ1AZF%K8/.,%P7EE6K/
MA3*8PQ./QO%V)PTJ=7)L#AL=BL:\PI.KB,'%8:<E"K"K/%0@I2I1IS4E2IM.
M\75E_$EI%4T_C;2C_3I1117\,'K!1110!^)T'_!7?QK=_"[7?C?8_L7>-+WX
M0^!/&:>"OB5X]@^*V@1Z5X;U*[UN'2M,30[6[\(VNJ>*Y[B*_P!%:_$=EI.F
M:/JFM:=H]_JZ->65Y=_;/Q+_ &A/VGK#4_#][\ /V-)/C[\-_$W@WPYXLTOQ
M]-^T+\.?A/,\OB"U>_\ [(E\)>+M*N]8BDLK%[&>2\>403M>&&-%>VES\?:!
M_P $ZOC1I/\ P3T^/'[)<_BKX7R?$7XH_%F/QYX?UN'6/%9\%6>DQ>-?ACXC
M%MK&H/X,37;?46L?!.I1&*R\.ZA;+=W-C&+MH7N+BW^I/$?_  3G_9=^+>F_
M#[5/CU\+[3QS\1/"7PP\"_#N_P!?L/'OQ/T.QFM_!^C16*0V5IX=\4^&;*6T
M2\>^EMKNXTBWOYX9D-T%95BB^5PT>(JE-0JUJGM*F$PE=SJ?4\)['$NKBH8C
M#PG'+,=!I4XX>;C4PTY\TFXUJ<7R'\D\,4/I*9AEJPF9YWF<<RQ_!_!^>3QF
M9/@G@_\ LCB6KFW%F"XEX>PF/H>%7'V$J48Y7A>&\?6PN/X8QN*^L8J=3"9U
ME^'F\%+Z*^ _CGXQ_$#PAJ.L_&_X%?\ #/OBNV\27FF:?X,_X6=X6^*_]I^'
MH=,T>ZM/$_\ PD7A&TLM-LOMNI7NK:5_8L\37UM_8OVZ60P:C;*GX/\ [57@
MOX(^%_V[/VJOBO\ MC_LK_M"_%/X'ZMIOP9MO GQ"\">%_'EEX%T34;'X7^"
M=-\1ZAJ/C#2/&?P]T>YLHKBWDTV5(=5UM[?4=/O[464-[%*K_O!\!_V=?@Y^
MS-X0U'P'\$/!_P#PA/A35O$EYXNU#2O^$@\4^)/M'B&_TS1]&N]0^W>+M;U_
M4HO-TW0-)MOLD%Y'8Q_9/.BMDGGN99OCO]HWX,?\%#?B='\6_A?X%^+W[. ^
M!?Q7@UW0CJ/C/PIXLL/BMX0\"^*])FTK7?!^F1^']*U+PEK$,=E?W^GV^MZJ
M4UZX@\F]34-+O6_<;YMA*^(R["0K4JF*Q5"M[?EC1PN/I5*\</B*4(XB%2E@
M*52E+VVLXX:DH346XPMS'M^+_!W$/$/AIPA@<\RK'\7<5</9TL^>&H9+PKXA
MY5F.?8?AWB3*L'A^(LOS'*_#O*<PRC$2SGWL;A.&,IA@\71PM>>$PL:?UE_:
M?P#USX7^(_@I\+-4^"DZ3?"4^!?#FG?#U4FU&X:S\*Z)IL&B:3I5Q+K$]UJ[
M7NCV^GKI-^NK7-QJ<=[97$>H3S7:S2-ZY7B_[._P4T3]G3X)_#KX*^'M3O=:
MTSP!H*Z4-9U"*.WNM7U"ZO+O5M9U1[2%Y8[*/4-9U"_N[>P6>Y%A;S169N[L
MP&YE]HKW<,JBP^'5:$*=94:2JTZ5E3A44(\\*=FUR1E>,+-KE2U/W_AF&94^
M&^'H9S@<#EF<0R/*89MEN5J"RS+\RC@,.L=@<N5.4X+ X3%*KA\(H3G!8>G3
MY925FROSS^)7[;OCSPU^T!\1/V=_AC^S/XB^,GB_P)X;T/Q6MQHOCW3/#]K?
M:+?^'=.U_5KK4AJ?ANYBT4Z:VK:?I>EV\-UK-YXCU*YBL[*V@O9K6TN/T,KX
MQ\$_LZ>-/#7[;GQD_:5OM5\+S>!_B'\,?#W@O1=(M+S5G\5VNJ:3!X&BN;C5
M+*;18-(AT]SX7O3!+::Y>W#B>U\RUB+2^5^@\"3X3H5.)\7Q9@,%FL<%PKBL
M5D&6X_&YK@</CN(89MDT,-AY5,FQN QE12R^IF<I45BJ4)TXU)*=.M"E5A\%
MXLT_$/$T>!,O\/<VS/()YGQ_E^ XOSO*,LX?S7&Y7P;4X?XEJX[&0H\2Y9F^
M6T>3-Z.1QABG@*]2G6G2A*G5P]3$4:O(^!/VQ_B9\:_@AX+^+_[/_P"S1>_$
M_4-:U[Q#X=\:>#+[XN>$? +^"+[01;,DL'B#Q-I*6OBJTU)+N"6VDL;"QF@C
M<"[MX95>)/9O@M\4/VB_''B+4]-^,/[+G_"C= M=%DOM-\2_\+M\#?$S^U=8
M6^L;>/0_[&\+Z?:7MCYME/>W_P#:<\C6J?8/LK(9;J)E^5_V?O\ @G+X-TK]
MGW0_@[^U%H/A;XDW_AGX@>+?&6A2^$/%WQ!TW2;)/$MCHMBQ-WI[>!=2N+MX
MM*VSV]W:W-I"/+:VE9WD(^J/@M^Q_P#LZ?L\>(M3\6?![X=_\(AK^L:+)X>U
M*_\ ^$M\<^(/M.CRWUCJ4EG]E\4>)M;LH=U[IME-]H@MHKH>3Y:SB*26.3[+
MC#$>$.!AQ7E/#>!CBL53S7-8<.YK#*,^QL/J$LQG4R[DS^IXJ8/!3ITL XT8
M5<3X>XJJH15/$+'8CFS*I^:^&^#^D;FM3P^XAXVS6>7X"MD'#]7C/(*G$?"6
M655F\,EI4<Z57A&EX YEFE.K7S:-3$U</@O&+ 4)5*DJV#EE6#]GDM'YY_X*
M:_"VP\7?LW>/?'FH^+/'=H/AYX9>[TSP9H_B(:7X&UG5=1UW1[&/6?%6C6UD
M+O7K_2K:XGCTA+C5$T^T,\SM8S/-*S^S?![P+%\3/V)O@7X&N/%'C'P;;>(/
MV?O@E;77B'P!K2>'O%EI:V_@WPC?W5MI>LO9W_V"/5K>UDT?4Y(K8W+Z3?W\
M-I/:7,D-W!SW[:/PI_:2^.'@/4OA1\';WX'Z?X&\::#)IOCJ]^)=QX]M/%EO
M=P:O8:CI[^$[CPMIVK:/%;%+(+>-K&G74I=BL$8!WI%\(?!?[9_PW_9Y?X=W
M=Q^S!=_$7P%X<^'G@OX-W5O+\5I_!5SX;\+6^D:'K%Q\3)Y+6QUV;7)O#MC<
M2:9+X6L;.PDUIH7NK6WL2\*:4<=[;PIX4RV'%G#]#.<J\0*N;Y?@,1CH4\3E
M678RAEV"P^)Q%%X65*$:&:0Q688OVOMI0P5\14]I#EI+'$Y3]6^D%X@9U5\/
MN+\7PUG_ (/T>'<YSC!Y55K8+B#.<MQ><9GC,%@\3''PKU)XK(*N RC+O8?5
MH5,S7U.C[&KSUW\S?\$F]-M=&TO]J?1[$3"RTGX]ZEIMF+BXFN[@6MC;W-K;
MB>ZN7EN+F811)YMQ/))-,^Z25W=F8_KK7YB_L6_LT_M8?LY^-O&7_"<:M^SQ
MJGPY^)OBW7/'7C?_ (12_P#B3?>-K37[VPO?[.M_"O\ :^@Z'H5OHZZI+;?;
M8=7^WWHL!/Y%X]P(\_IU7A^-6.P&:^(V=YOEF;X#.\%FE+*\32QV7XB6)IN=
M+*\)@:].O.4(2CB%B,'5G*#3;ISI5.;]Y9?4?1>RO-^'_!;A;AO/N'<WX7S3
M(*^>X'$97G&"A@JJAB,]S#-L)6PM.G5JPJ8*6#S+#TX5(N*5>EB*'(O8W97A
M/[3OQL7]F_\ 9\^+_P =V\-'QB/A5X&UKQF/"RZP/#YUYM(@\Y-,_MLZ7K7]
ME"Y8A&O?[(U(P*2XLYR!&?=J^:_VQ?@WXE_:&_9;^.WP1\&ZAH6E>*OB?\./
M$'A'0-1\37%_:>'[35-4MO+M)M8NM*TW6-1M[!9 !<366E:A<1H2\=I.P"'\
M[R>."GF^5PS)Q673S' QS!RG.G%8*6)I+%.4Z3C4A%4'4O.G*,XJ[@U))G]%
M8-4)8S"QQ+2PTL306(;<HI4'5@JK<HM2BO9\UW%J2W33L?FO\.?^"P_BGQ/X
MV_94A^('[%GQ!^%/P7_; \3Z%X"^$OQCU;XG>&==EU7QIKM]I>B00Q^ -/\
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M)-*\+:1H7PQ\/^&A?^%='BUG5/$,?BLWT^K_ *)_\% ?^"AW_"N?VC+[1/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%-6YI6TE6:T<EI!-PA]J<RBBBL3J"BBB@ HHHH **** "BBB@ HHHH ****
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M?_O+1R4?^?\ _P"4Y?YA[7$?] O_ )7I^7EYO[O,^A**^>_^&??^JW?M"?\
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M\SZ$HKY[_P"&??\ JMW[0G_AR?\ [RT?\,^_]5N_:$_\.3_]Y:.2C_S_ /\
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M_5;OVA/_  Y/_P!Y:.2C_P __P#RG+_,/:XC_H%_\KT_+R\W]WF?0E%?/?\
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M /\ *<O\P]KB/^@7_P KT_+R\W]WF?0E%?/?_#/O_5;OVA/_  Y/_P!Y:/\
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M]WF?0E%?/?\ PS[_ -5N_:$_\.3_ />6C_AGW_JMW[0G_AR?_O+1R4?^?_\
MY3E_F'M<1_T"_P#E>GY>7F_N\SZ$HKY[_P"&??\ JMW[0G_AR?\ [RT?\,^_
M]5N_:$_\.3_]Y:.2C_S_ /\ RG+_ ##VN(_Z!?\ RO3\O+S?W>9]"45\]_\
M#/O_ %6[]H3_ ,.3_P#>6C_AGW_JMW[0G_AR?_O+1R4?^?\ _P"4Y?YA[7$?
M] O_ )7I^7EYO[O,^A**^>_^&??^JW?M"?\ AR?_ +RT?\,^_P#5;OVA/_#D
M_P#WEHY*/_/_ /\ *<O\P]KB/^@7_P KT_+R\W]WF?0E%?/?_#/O_5;OVA/_
M  Y/_P!Y:/\ AGW_ *K=^T)_X<G_ .\M')1_Y_\ _E.7^8>UQ'_0+_Y7I^7E
MYO[O,^A**^>_^&??^JW?M"?^')_^\M'_  S[_P!5N_:$_P##D_\ WEHY*/\
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MW>9]"45\]_\ #/O_ %6[]H3_ ,.3_P#>6C_AGW_JMW[0G_AR?_O+1R4?^?\
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M?_O+1R4?^?\ _P"4Y?YA[7$?] O_ )7I^7EYO[O,^A**^>_^&??^JW?M"?\
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M\SZ$HKY[_P"&??\ JMW[0G_AR?\ [RT?\,^_]5N_:$_\.3_]Y:.2C_S_ /\
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M_5;OVA/_  Y/_P!Y:.2C_P __P#RG+_,/:XC_H%_\KT_+R\W]WF?0E%?/?\
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M /\ *<O\P]KB/^@7_P KT_+R\W]WF?0E%?/?_#/O_5;OVA/_  Y/_P!Y:/\
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2BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>img34756086_4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img34756086_4.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" (_ XP# 2(  A$! Q$!_\0
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M][S_  ?8^A**^>_^,K?^K>__ #(]'_&5O_5O?_F1Z/8_]/:/_@?_   ^L_\
M4/B?_!7I_>\_P?8^A**^>_\ C*W_ *M[_P#,CT?\96_]6]_^9'H]C_T]H_\
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MC_T]H_\ @?\ P ^L_P#4/B?_  5Z?WO/\'V/H2BOGO\ XRM_ZM[_ /,CT?\
M&5O_ %;W_P"9'H]C_P!/:/\ X'_P ^L_]0^)_P#!7I_>\_P?8^A**^>_^,K?
M^K>__,CT?\96_P#5O?\ YD>CV/\ T]H_^!_\ /K/_4/B?_!7I_>\_P 'V/H2
MBOGO_C*W_JWO_P R/1_QE;_U;W_YD>CV/_3VC_X'_P  /K/_ %#XG_P5Z?WO
M/\'V/H2BOGO_ (RM_P"K>_\ S(]'_&5O_5O?_F1Z/8_]/:/_ ('_ , /K/\
MU#XG_P %>G][S_!]CZ$HKY[_ .,K?^K>_P#S(]'_ !E;_P!6]_\ F1Z/8_\
M3VC_ .!_\ /K/_4/B?\ P5Z?WO/\'V/H2BOGO_C*W_JWO_S(]'_&5O\ U;W_
M .9'H]C_ -/:/_@?_ #ZS_U#XG_P5Z?WO/\ !]CZ$HKY[_XRM_ZM[_\ ,CT?
M\96_]6]_^9'H]C_T]H_^!_\  #ZS_P!0^)_\%>G][S_!]CZ$HKY[_P",K?\
MJWO_ ,R/1_QE;_U;W_YD>CV/_3VC_P"!_P# #ZS_ -0^)_\ !7I_>\_P?8^A
M**^>_P#C*W_JWO\ \R/1_P 96_\ 5O?_ )D>CV/_ $]H_P#@?_ #ZS_U#XG_
M ,%>G][S_!]CZ$HKY[_XRM_ZM[_\R/1_QE;_ -6]_P#F1Z/8_P#3VC_X'_P
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M8_\ 3VC_ .!_\ /K/_4/B?\ P5Z?WO/\'V/H2BOGO_C*W_JWO_S(]'_&5O\
MU;W_ .9'H]C_ -/:/_@?_ #ZS_U#XG_P5Z?WO/\ !]CZ$HKY[_XRM_ZM[_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !7GOQ<_P"24_$[_LGOC3_U&]2K
MT*O/?BY_R2GXG?\ 9/?&G_J-ZE5T_P")3_QQ_P#2D9UOX57_ *]S_P#26'PC
M_P"24_#'_LGO@O\ ]1O3:]"KSWX1_P#)*?AC_P!D]\%_^HWIM>A45/XE3_'+
M_P!*8J'\"C_UZI_^D1"BBBH-0HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ KSWXN?\DI^)W_9/?&G_ *C>I5Z%7GOQ<_Y)3\3O^R>^-/\
MU&]2JZ?\2G_CC_Z4C.M_"J_]>Y_^DL/A'_R2GX8_]D]\%_\ J-Z;7H5>>_"/
M_DE/PQ_[)[X+_P#4;TVO0J*G\2I_CE_Z4Q4/X%'_ *]4_P#TB(4445!J%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>>_%S_DE/Q._P"R
M>^-/_4;U*O0J\]^+G_)*?B=_V3WQI_ZC>I5=/^)3_P <?_2D9UOX57_KW/\
M])8?"/\ Y)3\,?\ LGO@O_U&]-KT*O/?A'_R2GX8_P#9/?!?_J-Z;7H5%3^)
M4_QR_P#2F*A_ H_]>J?_ *1$****@U"BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "O/?BY_P DI^)W_9/?&G_J-ZE7H5>>_%S_ ))3\3O^
MR>^-/_4;U*KI_P 2G_CC_P"E(SK?PJO_ %[G_P"DL/A'_P DI^&/_9/?!?\
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M0 4444 %%%% !7GOQ<_Y)3\3O^R>^-/_ %&]2KT*O/?BY_R2GXG?]D]\:?\
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MGA3P7XMLM2UNVL[218;J^@LB8I=0LK:5PD]UIXNH8AEY'6/#F#X]_P#!1_\
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MM/!<36MZ\MMX8\-P:5'*[0S,VGZ0-TF[=(/SF_:*_P"#L./XL_L^_'7X5_\
M#M']J#PU_P +,^#?Q.^'_P#PD>JRC^S/#_\ PF?@G7/#G]MZECP[$?L&E?VE
M]OO,21G[/!)\Z?> !]X_\&;/_*)'Q1_V>%\9/_4%^#M?U@5_)_\ \&;/_*)'
MQ1_V>%\9/_4%^#M?U@4 %%%% !1110 4444 %%%% !1110 4444 %?*/[)^L
M_M$:SIWQ_;]HKP9X>\%WNF_M7?'K1O@W%X>L;:Q3Q-^SOIOBE(?@_P",]8%K
M=W8NO$/B3P^7O-7OIS;W-U< //:0-\M?5U?)G[)7ASXX^&]._:#C^.?Q6T;X
MKW>M?M9_'WQ'\++C1;^TU!? 'P.UGQ3'<?"_X4ZDUI:VHM-9\!Z*'TO4K"X$
M]W:3,(Y[J=L-0!]9T444 %%%% !1110 4444 %%%% !1110 4444 ?*?[<.L
M_M#^'OV3_C;K/[)_@SP]\0OVB=/\)QS?"KP7XKL;;4_#WB#Q$=:TJ-[+5;"\
MNK&VN;<:6^H7 CFNX%\V&-M^5 /U97R=^W/X<^.'B[]DKXX>&_V;/BKHWP/^
M.>K>$H[;X<?%?Q!?VFEZ-X)UT:UI4KZMJ%_?6M[:6T+:='>V0DGM9D,ETB[0
MS!A]8T %%%% !1110 4444 %%%% !1110 4444 %?*G[,.L_M#:OK7[5,?Q\
M\&>'_"&EZ/\ M5^-]&_9[N-!L;:RE\9?L\V_@#X77/A3QGX@:WNKHWWB#4/&
M-YX_TRZOKE;6YEL]'L(GM42".27ZKKY/_9<\.?'#P_K?[5TOQH^*NC?$[3O$
M7[6'CCQ'\$++2+^TOI/A7\#[OX??"NR\-_"K6%M;6V:PUG1/%.G^-?$%Q87;
M75W%:^*+.:2Z>.>*.( ^L**** "BBB@ HHHH **** "BBB@ HHHH **** /E
MOX\:O\?].^+W[(%E\(_"&@^(OAMK7QG\6V/[2>MZMIUM>ZCX)^&$/P-^*5_X
M<UWPY=37=M+I>IWOQ8M/ &@7%Y:P7TTNE:M?V3VZ074MS!]25\K_ ![\/_&G
M5_C#^QYJ7PS^*&D>!/ ?AKXT^+M4^//A'4-0M+.]^+OP^N?@5\5-)T+P;HMM
M<6L\VIWND_$C4/!GC>>TLI;2>.P\,75X\S6]M-#+]44 %%%% !1110 4444
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M7_ZC>FUZ%7GOPC_Y)3\,?^R>^"__ %&]-KT*BI_$J?XY?^E,5#^!1_Z]4_\
MTB(4445!J%%%% !1110 4444 %%%% !1110 4444 ?Q+_P#!8[X&?L<_$O\
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M\+7FJ2^%M9M=?TBUN=2T[_2'T]-6L;.[N+,_N;E[6%90R*5(!_.!^S=J\?\
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M%B@MX8XD4*H%?.'[=O\ R8_^V3_V:I^T-_ZJ+Q?0!_/5_P &;/\ RB1\4?\
M9X7QD_\ 4%^#M?U@5_)__P &;/\ RB1\4?\ 9X7QD_\ 4%^#M?U@4 %%%% !
M1110 4444 %%%% !1110 4444 %?'?[&WC+XT^-=&_:)O/C3\,M)^&,NA?MB
M?M)^#?A;!I6B#0O^$Z^"WA#QY/H/P]^)NIP[B^H:MXULK*[U"\UMPIUD)%?Q
MJ89HF;[$KY._9,T;]H/1=._:"7]H7QWH7CR\U/\ :Q^/FL_!^;0KS3[Q/"?[
M/FI>*8YOA'X$U4Z?!;K;:[X5T$/8ZI9W8FU"VF8)=SRR?-0!]8T444 %%%%
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M?_X*Y_LYZ5^T-\3OBM/H/C=M"\9?##X4^#=.MT313>1ZEX(U[XFZGJLMPAU
M(MO-!XPTM;5DD=C)#=^8JCRL^?\ [97A[0O%O_!7[X%^&/$^E66N^'M>N?A+
MIFLZ-J4*W-AJ5A<QZDL]I=V[_)-!( -T;94X&0:_:S_AB_\ 90_Z-_\ A?\
M^$O8_P#Q%?DM.OQIQ%FV=1RW-<HP>%X>S_$X3"T\7@)U:CE3H5*<)RG3E::]
MAB9Q?,D^>TK:*_\ H1C,K^C-X.>'OAE5XTX"\0^)<]\8/"+)<_SS&9!Q;AL!
M@X4L5FV"QU>A2PV+A?#U'F>1X>M!T7*$:#='[<FN _9._;L^%?[8&K>,-(^'
M6C^)]-G\&:;I>J:C+KT%E'#-!JUS<VMNMLUI=7&YP]J[,'VC805)YK[;K\'_
M /@EMI&E>'_VQ?V_]"T+3[32=$T7QWK.DZ/I5A$(;'3=+T[XF^-;.PL+*$$B
M*TL[2&*WMX@2(X8T4$@9K]X*^QX-S/'YOD-#&9G4I5<;]:S##UJE"FJ-*7U3
M'8C#1<*:;Y4XTEYO=ZG\X?23X'X3\//%C-.&^",+F&"X:_L'@S.<NPF:8UYA
MCJ"XCX2R;/:]+$8MJ/M9PQ&85%HN6*2A%N*391117U)^#!1110 4444 %%%%
M !1110 4444 %>>_%S_DE/Q._P"R>^-/_4;U*O0J\]^+G_)*?B=_V3WQI_ZC
M>I5=/^)3_P <?_2D9UOX57_KW/\ ])8?"/\ Y)3\,?\ LGO@O_U&]-KT*O/?
MA'_R2GX8_P#9/?!?_J-Z;7H5%3^)4_QR_P#2F*A_ H_]>J?_ *1$****@U"B
MBB@ HHHH **** "BBB@ HHHH **** /XYO\ @HY^S3X9_;D_X+KM^S9^VG^U
M[\0OV?/V9]"_8J\,?$;]FOP7X"^*UM\-M-\?>.8_%SZ3\1;/4-3N;Y-,L_&.
MG3W]WJTMO?6CZQJ?AF/P^NFD64=QYGZ7_P#!.C_@C_\ L+?L2?M%)\;/V>OV
MH_C%\7/B$O@3Q1X2'A'QO^T1I7Q,T1M#U^;2)-3U,^&;(^<UU8OIUHL%^08[
M0SMNPTB&OS)_X."_AC_P0N^'O[1-G\9?V\?!O[0OQ=_:K^(WP\T?7(_AC\ _
M%6M?VMIOPL\ VTGARW\=Z[IUO$-&\&^'K==*NK=M7U&]MCJ5QIE]/&NVSFE3
MW_\ X(W?LO?\$8?A5^W!\4K7]BW2OC7X*_:U^$?P5\%ZIKGA'XM^-]=U6VU?
MX0_'_P !?#CXAKXD\*V>H(-/U^UTBXU_1O"^OWEI*TFC:[;,NV2UO[6X8 _J
MAKYX_:Q^/P_9:_9S^+/[0'_"N_&GQ:E^&'A=M>M/AI\.K(:CXV\:ZA+?V6E:
M=X?\.VC!DDO[Z_U"V0,X*0P^;.X*Q$5]#T4 ?R:?\$A?V^O^"B_[3G_!9+]M
M/X2_MKZ7J7P3\-^&OV6/ OQ,\#?LCK>Z?J&E_!RW\5:U\-;_ ,*2ZM=PV_V^
M?QWJ'A#Q-]K\6&ZNB(=2U6YM%L[5;:.&/Y$^.'[6?_!7[]O/XQ_\%6/V@?V'
M?VMM$_9U_9Z_X)7>+_%/@KP5\&K;PU8ZC-\==8^$>D:[JWC]?$>HW>GWOVBZ
MU:'P?X@N[)+R:WLP^L:%H$,4<5M>Z@WWW^Q[HFMV_P#P=)_\%3==N-%UBWT.
M^_8X^!]K8ZW/I5_#HU[=0:3\ O.M[/59;=;"ZGBPX>*"XDD4Q3*5S!,$_&[7
MOVCOB-_P1Y^(?_!=+]BWQ_\ LM_';X@^*/V^_B/\6/B+^Q]XT\$>#[_Q#X-\
M:R_'?1O&^@:6NIZC80R!+/2YO&6ES7<5D9K^*ZTC6='GMH[LVCR ']9?[$7_
M  4T^%WQH_X)?_L[?\%"/VD_&7@7X&:!X\\!:%_PL_7_ !'J\&B>"]!^(L'B
M2Y^'6MP6][=.R66GZ]XVTRXD\/V4\CSQ6NIZ?9RN\ZN3X9^V1_P5X_X)A^,?
MV0OVJO"/A?\ ;H_9OUSQ-XJ_9O\ CCX<\.Z)IWQ'T>YU#6-=USX8^*-,TC2[
M&WC<R3WFH:A=6]I:PH"\L\R(H+,!7CW[)?\ P1]T;XM?\$%?V;?^";'[8!\8
M>"+C5/!?A'QU\3=-\)WUKIOBOPMXIN?B5<?&FR\,2W%W:WUO;W^AW=]I^A>(
M8##*$O;/4((Y,!7K\SOVE?\ @T2_X)P_"#]G+X__ !9\.?$+]HJX\0_"_P""
M?Q5^(FA6^H>+?#\UA/K/@GP+KWB72X;Z%/#L3RV<M]ID"7,22QM)"SHLB$A@
M ?2W_!FS_P HD?%'_9X7QD_]07X.U_6!7\G_ /P9L_\ *)'Q1_V>%\9/_4%^
M#M?U@4 %%%% !1110 4444 %%%% !3#(@=8RZ"1@2J%@'8#J54G<0,') ('>
MLOQ!J%QI.@ZWJMI:M?7>F:1J6H6MDF2]Y<6=E-<PVJ <EKB2-8EQSEQCFOYO
M/!7A;Q#\?OV;?BI^VYXZ_:[\;>#_ (U^&=1\=:[HGAG3/%3:1X;\'S^$I)KK
M0O!=QX:%U;2.=<\JTM=+C2UXM[W3U:._N%N"WS>?<02R>KAL/0P$L?B*^&QV
M.E#ZU0P5.E@LN5!XJI[;$>[4K?[135&A%)S?-*<Z<(.1^V>$_@_1\2,#G6<9
MIQ91X2R;*L[X5X6HXI9#FW$N+QO$O&E7,Z>0X/\ L[)U[?"Y:_[(QL\PS6K)
MQPUJ%'#X7&XG$0H']+5%?FE^SM_P43^!FJ?L]_"/Q3\=OC/X#\+_ !*UOP]]
MF\5Z9=Z@D-Z-8TN^N]+FO[RPM8I/[/.J6]I;ZO(CK'#"+[:A"+Q^B/AKQ-X>
M\9:%IOB;PIK6F^(?#VL6R7FEZSI%W#?:??6SY"RV]S SQN P9'&=T<BM&ZJZ
MLH]'+<XRW-J-&K@<7AZTJN&H8IX>-:C+$T*6(IQJ0^L4(3E.C)*:C*,TK3O&
M[:/C.-O#?C7P]S',,!Q5P[F^64L!G>:Y!3S;$99F%#)<SQV3XNO@\6\HS/$X
M6AALQHN>'G5HU,/.7M*#C545&1N5\.?L+^ OA!X$T/\ :@;X._%R_P#B[9^-
M/VX_VJ?'OQ#GU&999?AU\7]?^(D\?Q(^$<"!W>VL/ &O6$FFZ?#*$9K*2"X1
M/)GB9ON.O@/_ ()_ZO\ L^ZOH_[7+_L]^%O%?A6ST_\ ;\_:PTCXP)XLFDFE
MU_\ :"T[QS##\6_%.@&220Q^%-<UWR[C0(5*1QVB[4C0#%>F?#'WY1110 44
M44 %%%% !1110 4444 >5?'7Q'XI\'_!/XN^*_ ]K]N\9>&OAIXWU[PM:>5Y
MYG\0:3X;U*^TE!!_R\'[=!"PMQS.1Y0Y<5_-F?!/P/\ ^&)A^UL/VC_%B_M?
M?;CXE-V/'KKK;^.CXF>(>"SX9#B_$+:>#,;O/V<1[KS9]@S:5^S/[4?[<VG?
M!#XH:'\"_#7PD\4?&_QUXF\(W7B+4?#7@V:*6]TK2YI+BWCBU*T$$TB)=VD,
MUTSL8U2V>!CDW$.[\ /$?B+X6_'']I_PW\/_ ("_LS>%O@WXU\<OIOPVGTOX
MABZNK'PCXU3Q!J5]K7B<Z)OBB@U)-(CBTP64\<L226[F"REGN(L?BWB%FF7U
M\=3H4*^&Q^*I4<7DL<OKTLRYL+FN-GAI8?'9=5H45A:F98;W:?++$TYTG4A:
MK27M6?Z;?0^X$XPRGA;&YIFF59WPGD.89CP_XFXCC#*\;P8Z>?\ A_PW1SFA
MFW"W&67YMF;S_!\$YUS5\:L30R?&8?&QP>*E+!8]_4DOZL?@5XC\4^+_ (+?
M"CQ5XXM/L/C#Q%\/?".M>)K7RO(\K6]2T.RN]1_<?\L=]S+))Y/_ "RW[,#;
M7JU?DA\"_B;^TO\ L]_M7>!/V1_VA?B#HWQHT3XK>!-8\2^ /&VGZ9'I>L:%
M=>&;'5KVZT_4K:&&W']G-;:'>V<(FB)W_8I89VS<1)^M]?I^0YE#,<"TZ>+H
MXK 5?[.Q]#'1I1Q5+&4*-&<_;.A4K49NK3K4J\:E&K.G*-5--.\5_"_BQP37
MX,XHA.&+R#,LBXNP+XRX3S/A>KC:F18[AS-<RS+#8;ZA#,\%EV9X:& QN7X_
M*JN$S# X7%4*V J1E3E3=.I4^'_^"D_@/X0_$W]A;]I;P-\?/BW?_ CX.Z[\
M.YT^('Q<TN98-1\#Z#8:OI6JR:K8R,\>;J6YL;?3X(5;S+B2\6")7EE1&^X.
MM? W_!4;5OV?="_8!_:>U?\ :J\+>*_&W[/=AX @G^*7A7P/+)!XLUGP^/$V
M@K':Z'-%)%)'>+JC:?/N21"(8I>:^^:]H_,0HHHH **** "BBB@ HHHH *0D
M*"S$*J@EF)   &223P !R2> *6OR[_X*K?$'QCX.^#OPT\.Z%XJU+X?^$?B=
M\7_#G@;XG>/=):6.\\.>#+^WNY[UEN8&CGM(IQ ]S//')'YD6GO9N^RZ8'S,
MYS.&3Y9C,SJ4I5HX2E[3V4)1@ZDI3C3A%U)^Y3BYSCSU9^[2AS5)746?<>&W
M ^+\2>.N&^!\%CL/EM?B',/JGU_$TJV(IX2C2H5L7BJ\<+AT\1C<1#"X>L\+
M@<.O;X[%>QPE%JI6BUN_&3]O_5?#WQ9\2_!K]G[X'^+/VA?%7P^T^'4OB-=^
M&9A%HWAM9HXIQI\=U##<F\U!(I"D@&R+[8)+*,RS6]R(_=/V8?VR/A%^T_X5
ML]3\-ZO:^'?&:3W6FZ_\-]?U"QM_%>BZO8%5O;9;+SA)J%J"P>"\M(W5T$BR
M)%+!,B?@K\:9O&/["?C/XG?##]DGQ_8?%GPW^U1\.H[VV?1-6?Q3\5? LOA_
M3YO[6\1-?:,L[R&XT^^URZLKM]I6VGFNF,-WIH:3 \;6G[%F@?LH_ _Q;^S7
MXKOS^V@^M_#Y[*31=6U23XA77Q NKNT3QK:>)M/DD,-M:PWLNH)IFU%:>Y;2
M[8O=0W<X;\GI\<YWA,RS&6+KX*;R^GC:V99-B:V&P]"$(8JE'!87A['4:,JN
M9XZ6"G2KU?;RY*L\32I^SP]22C#_ $$Q7T6/##/^#.#J'#^4\38:/&&,X8RW
M@GQ*R7+\ZS?,\1B,7D.*J\39[XQ<+YCF6'R_@?A>CQ-A\;E>!_LNC]9P.&R7
M,,9]=S?"TI5:_P#5Y7Q!^QGX$^$/@7Q3^W&WPJ^+=_\ %34O&G[;WC[Q[\8+
M*]F6>'X3?%W7O@_\#(-9^$FFNCNBV.@>%=-\':^8 5:WO?%-Y#*B2HXK[(\/
MOJLF@:')KR1Q:X^D::^LQP_ZF/56LH6U%(L9'EI>&98^3\H%?#W[#6K?L_:K
MXF_;UC^!'A?Q7X:U/2/V^/BAI/Q_F\3S/+!XH_:!@^$GP*N?%7BCPH'DD$/A
M2]\(7?@.QLH8Q&BZCIFJN(PSLS?M,9<T8RLUS14K25I*ZO:2Z-7LUT9_F/5I
MNC5JTG.%1TJDZ;G2ESTYN$G'GIS5E.$K7A*RYHM/J??%%%%49A1110 4444
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MN-)GNH]4NYEE6&^6PB@AMK*$-U'_  47^+GQ ^!O[*?B?XC?##6U\.^,=/\
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M &R?^S5/VAO_ %47B^OJNOE3]NW_ ),?_;)_[-4_:&_]5%XOH _GJ_X,V?\
ME$CXH_[/"^,G_J"_!VOZP*_D_P#^#-G_ )1(^*/^SPOC)_Z@OP=K^L"@ HHH
MH **** "BBB@ HHHH *_GT_8I^&_@;XM_MJ_\%,/ 'Q'\,Z7XN\(:[XS\31:
MGHFKVXGM9C%\9O'$D$\9!66WNK:3]Y;75O)%<0/S'(N2#_077X5_\$X_^4@W
M_!1G_L>/%/\ ZN/QQ7PW%5.G6S[@BE5IPJTJF;9G3J4ZD8SIU(3R7&1E"<))
MQG"46U*,DTTVFFF?U3X"8W&9;X3_ $H\PR[%XG 8_ \ \#8O!8W!UZN&Q>$Q
M6'\3>'*M#$X;$T90K4*]"K"-2E6I3C4ISC&<)*23/H/XZ_L;_LY?LS_L@_M9
M:O\ !SX;:5X7UO6_@CX\M+_7"]Q?ZN]@VD7$ITZ"]O))7M;)I%5I(;<1^>50
M3M*L<87K_P#@DK_R8?\ "#_L)?$K_P!67XLKV_\ ;P_Y,R_:;_[(QXZ_],ES
M7B'_  25_P"3#_A!_P!A+XE?^K+\65A0P6$P''^!PN!PN'P>&AP;CW"AAJ-.
MA1BY9W@G)JG3C&*<GK)VNWJVST\SXEXAXM^B-Q5GG%.>9OQ'G.)^DCPG#$9K
MG>88O-,PK0H>&7$=.C3J8O&U:U>5.C32A2@Y\M."48)+0_2*OB;]B#X=_#GX
M>:)^TR?AM\;KWXXV?CK]MG]J+XB>+KR^N1<-\,/B-XD^(4Z>.?@C;+]LO'MK
M+X7Z[I]QH-I;2"T*Q 2)9PPRQ%_MFO@/]@"Z_9QNM(_:Y;]F^P\8V%E!^WY^
MUA:_&D>,GEDEO/VCK?QS!'\8[_PV9@"O@ZYU\1MX;2/,262[8SM Q^@'\AGW
MY1110 4444 %%%% !1110 45F:IK>C:'%%/K6KZ9I$,T@AAFU2_M-/BEF/2*
M*2[EA220]HT)8]A6BCI(B21NLD<BJ\<B,'1T<!E=&4E65E(*L"00002#5NG4
MC"%24)JG-R4*CC)0FX6YU"37+)QNN9)MQNKVN*ZO:ZOVZ_<?AI_P4?\ ^3]/
M^"=G_91?!O\ ZMOPI7[FU^&7_!1__D_3_@G9_P!E%\&_^K;\*5^YM?#<-?\
M)1\=_P#8VRS_ -4V$/Z@\;?^3-_14_[-YQI_Z\?/C\+/V$/^4GW[?O\ U_\
MC?\ ]6+X<K]TZ_"S]A#_ )2??M^_]?\ XW_]6+X<K]TZ7 '_ "),5_V/^(/_
M %:XDKZ7'_)S\@_[-%X/_P#KO\C/BG_@HU\._AU\6/V(/VD/A]\6_C;>?LX?
M#7Q#\/9X_&?QQT^X%K>_#?1-.U72]7N=?MIS>:>5E#:>ED%2[ADE%V88O,E=
M(G^U@<C/KS7P-_P5&NOV<K+]@']IZ[_:XL?&.I_LX0> ()/BQ8_#]Y8_&5QX
M='B70?*3P_) &F2^75O[-?=&"PA67%??-?;G\O!1110 4444 %%%% !1110
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ME\1/$7PC^"-O??!.R*WEXD-GX?\ #6E^%_%JVX^RM#-XWG62S@E\PO\ :U?
M_P"PS=?LYW/B;]O5?V?;'QA8ZK:_M\?%"U_:*/BUY7M[W]HQ?A)\"YO%U]X.
M$H C\'S>#9OA\E@D.8O[4BUAP2[O7ZT?Y['WQ1110 4444 %%%% !1110!^:
MG_!7'_DQOQI_V6/]DK_UK3X)5^E=?FI_P5Q_Y,<\9_\ 98_V2O\ UK3X)5^E
M=?J><?\ )E/#S_LY_C!_ZRW@B<-/_D98S_L#R_\ ]/9B5[O_ (]+K_KWF_\
M1;5_.]_P0B_Y&#]JC_KT^$?_ *6?$ROZ(;O_ (]+K_KWF_\ 1;5_.]_P0B_Y
M&#]JC_KT^$?_ *6?$ROYKXC_ .2Z\//7BG_U54#^S/!G_E%;Z8O_ %[\!O\
MUO\ ,3]1_P#@I1_R8S^T=_V(\'_J1Z'5+_@F5_R8S\ ?^P-XM_\ 5B^,*N_\
M%*/^3&?VCO\ L1X/_4CT.J7_  3*_P"3&?@#_P!@;Q;_ .K%\85U/_DY$?\
MLB*G_J^IG@Q_Y0NJ_P#:4%#_ -=1B#H?VF? GP\\4?'']A'Q3XS^--S\,O$?
MPY_:&\9:[\,O D$H6/X]>+]9_9Q^-/A:]^'=U%]K@>6'1/".L>(_B4-MO>K'
M)X(1GBB4^?']G5\)_M63_L]Q?M$?\$[$^,%GXON?B9/^TG\0H_V9KCP[-)%H
MEC\41^RW\=7\2S^-D0;;C09/A(OQ M[.*3Y!XAFT>8?-$,?=E?;G\OA1110
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MO@O_ -1O3:]"KSWX1_\ )*?AC_V3WP7_ .HWIM>A45/XE3_'+_TIBH?P*/\
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M)_@MXKT;XWZ]++862:UKGBI_%MYX?GUFWDU"&>Q\(Z?:&^>:RFMK;[+KY?\
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M-?6E?*G[=O\ R8_^V3_V:I^T-_ZJ+Q?0!_/5_P &;/\ RB1\4?\ 9X7QD_\
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M%+Y=#\5:=%XB^*6F_LUV>E:4?@S:^"?#GC2X\.S_  VO[5IU@37KV.RFCM-
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M?@9_PF%IX*\VW@#^"E\%#X=S:?)";B)M5FUK%P[AT3]:/\]C[UHHHH ****
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MAGPQ!?7,-Y?V6C6-I!?7MO9W>H//=(99 #^U^BO /V6/"7QU\!_L\_"7P?\
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MC2]CR5'45.2DJKFU.5&I&/[NZ<7S**:;^D:_"O\ X)Q_\I!O^"C/_8\>*?\
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M'?B2MD]M<_V#%>&UM)+'7[BQ17MX2LL+7H&GS?9[BYLUF^S/^#43_E%A<?\
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M_P!A7]N#_P!:+\%U_2+_ ,%E/^3+]2_[*1X(_EJ]?S=?\$C_ /E9[_X*4_\
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M\RYK71_H37?_ !Z77_7O-_Z+:OYWO^"$7_(P?M4?]>GPC_\ 2SXF5_1#=_\
M'I=?]>\W_HMJ_G>_X(1?\C!^U1_UZ?"/_P!+/B97_/IQ'_R77AYZ\4_^JJ@?
MZ$^#/_**WTQ?^O?@-_ZW^8GZC_\ !2C_ ),9_:._[$>#_P!2/0ZI?\$RO^3&
M?@#_ -@;Q;_ZL7QA5W_@I1_R8S^T=_V(\'_J1Z'5+_@F5_R8S\ ?^P-XM_\
M5B^,*ZG_ ,G(C_V1%3_U?4SP8_\ *%U7_M*"A_ZZC$'7?M(?#U/%GQJ_8?\
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M2\)4<36XBR7 5X8ZIF,<1E\,#F*C7QF787!8NIEN.IX3$UI4HJI^B]?PP?\
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M#X2:+ID_PX^&GB"SOYM*UFPGU&\E(O%T#4;:]M-2OI9+&Q:>QO4MYWCMI9U
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MAUVN(KF%)HPZGE6".-RGH<BOPU_X)Q_\I!O^"C/_ &/'BG_U<?CBOVW\+_\
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M9>*_A5^V/H-M8^%KZYN ;2T:Z?Q(+^V>]"V-Q<:<EA>2P07;SQ_ZA-?YWO\
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MGX8_]D]\%_\ J-Z;7H5%3^)4_P <O_2F*A_ H_\ 7JG_ .D1"BBBH-0HHHH
M**** "BBB@ HHHH **** "BBB@#^63_@O-^UC_P3-^#OQG^&FD_'W]@"3_@H
M'^UK\)OA3J7QSL]%\/Z*[M\$_@?X?UB^U"7QI\3O$<<Z6<?@U-:TG4M0M=!U
MJTU2SC>.>_FM;>VU$F^^FO\ @FY^T/\ L$>-?^"A_P"V+X7^'/[.VO? G]MG
MXP_#+X&?M%^/?&/C />CXY_"KQI\*OAKKJ7WPUU5BMI:>%O GB/Q)#X<UO1]
M-@BBU37;*Y\0F>\C5(-)^(O^"T7[!/\ P4'TC]HW]J/]K#]A'X4:%^TIX5_;
MK_82UC]B+]H3X67>M0Z1\0/ $SVMQIV@?$;X?FXD@_M/3X],CTUKK1+>8Q3Z
ME;:E_:<(CO[&Y@])_P""1'['W_!0?X@?ME^&OV__ -O[X0>'/V:+3X"_L2^"
M_P!B#]G3X)Z9K-KK?BO4- TJ72+KQ)XX\:W%L9);:6XGTJ\GM[>^D20S>(%L
M[*#[)HQN;@ _J5HHHH *_EK_ ."A_P 8/!&L>(OVA?\ @CO_ ,$I?@W\)8?V
MG/VJ=!U^X_;=^+%I%H?AGX3?LW> _B5IQ\.^,O'/Q8U4%(_$'Q8\2>&]7O;3
M0_#ENMUJT$^HQWD\+ZI<6UNW]2E?S/>+O^#6#]@/QI\2OB5\6]4^+G[7]IXZ
M^+GB_7?''C[6=&^-]SI$^O\ B#Q#K&H:[?7%Z]EH\<MQ%'?ZG>-9PW$LPM(Y
M3'"5&<@'UQXX_94_:O\ V,O^"0_PY_93_P""3.N^$_%'[0GP8\-?#7PK\/\
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M>'HY_C,+%0PV+SJED\(9KB</!0IJ-"OCHUZM**ITTJ<HI0@O=7RM_P &M_\
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M9\*A1117VQ_, 4444 %%%% !1110 4444 %%%% !7GOQ<_Y)3\3O^R>^-/\
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MV_"E?N;7X9?\%'_^3]/^"=G_ &47P;_ZMOPI7[FU_F)PU_R4?'?_ &-LL_\
M5-A#^RO&W_DS?T5/^S><:?\ KQ\^/PL_80_Y2??M^_\ 7_XW_P#5B^'*_=.O
MPL_80_Y2??M^_P#7_P"-_P#U8OAROW3I< ?\B3%?]C_B#_U:XDKZ7'_)S\@_
M[-%X/_\ KO\ (SX,_P""G_Q+^'WP=_8&_:;^)GQ5^#EG^T%\/?"'@&'4_%/P
M:U"4PV7C_3F\2:%:#1KB55<HBW-S;W^0C?-9@8YK[SKY+_;K\0?'/PK^R/\
M'+Q#^S3\,=#^,WQUTOPC'<?#;X8>)-,AUG0_&6NG6M*B?2]2TNXEAAO(%TZ2
M^NQ%)*B^9;(^<J ?K2OMS^7@HHHH *X+XE6'Q&U'PI=VOPJU[PWX:\9-<V36
M6J^+-(NM;T6*U2X5K^*?3[.XM9Y)9K;>ENZS*(I2KL&4$5WM%88FA'%8>OAI
M5*]*->E.E*KAJ]3#8BFIQ<7.AB*,H5:-6*=X5:<HSA)*46FDSFQF&CC<+B,)
M.KB:$,31J495L'B*N$Q5*-2+BYX?%4)0K8>M%.].M2G&I3DE*$DTF? W[-_B
MK]K3XB>)?$^H^._'OPBN/!?P]^+7CKX9>(M(T#P3K-EK6NCP:ZV0U+3=2N=3
MD@L/MEW<6]QY4L$GEPQR1$[F!'WS7R+^R'_R#_VB/^SLOCG_ .GC3J^NJ^6X
M%HU*?#>"K5L=F685\6ZU>M7S/'XG'UN95IT5&G4Q-2I*E24*46J5-Q@IN<^7
MFG)OXKPTH5:?".78G$9CFV9XG'NOB:^)SC,\9FE?GC7J8>,*57&5:LJ-&-.A
M!JC2Y:?M'4J<O/4G)_PO_P#!SY_RDT_X)D_]@?PG_P"M 6=?W05_"_\ \'/G
M_*33_@F3_P!@?PG_ .M 6=?W05_IK]*K_E$_]GQ_V;SQB_\ 7@X$]/(_^1[Q
M7_V%Y?\ ^HDC^&+_ ()'_P#*SW_P4I_["O[<'_K1?@NOZ1?^"RG_ "9?J7_9
M2/!'\M7K^;K_ ()'_P#*SW_P4I_["O[<'_K1?@NOZ1?^"RG_ "9?J7_92/!'
M\M7KY;]JK_R6O"7_ &BGX-_^LQB3]V^AC_R??PF_[.[E?_JWH'O_ /P3B_Y,
M=_9M_P"R>6__ *==4K\K/^"G?_*2+]C7_L%_"+_U>7B.OU3_ ."<7_)CO[-O
M_9/+?_TZZI7Y6?\ !3O_ )21?L:_]@OX1?\ J\O$=?YD\4_\FZX>_P"[2_/"
M']?>!'_*9/C)Z?2#_P#2L_/Z+*^#/V'OB7\/OB+XE_;PM/ ?P<L_A'=?#7]O
M/XG?#3X@7]G*9&^,7Q!T?X2_ S7-5^,=X"B^5>>(-'\1Z!X:DB&X+'X0A;>=
MV!]YU\F_LM>(/CEKNM_M81?&GX9:)\.-.T#]K+QSX?\ @?>:-ID.FR?$SX&V
MOP]^%=YX;^)NMO#+(=3UO6?%5_XVT*YU.81336OAJR@:(+;(S?K1_GL?65%%
M% !1110!_.%_P7\_X_/V5/\ KE\9O_1OPMK]C/VH_P!EGPG^UG\)-'\%^(-8
MU7PMXB\.W^D^+_ /CG1'QK'A+Q;I]H4M-3@!9//@D29XKNW\R)W'ESQ2QSV\
M3#\<_P#@OY_Q^?LJ9('[KXS<G@#][\+>3[5]C:C_ ,%=_@UI&IWQT+X6_%[Q
MG\)/">I6OASQ/\;O#WAXS^"]-O4$-O/<0JY%U>64+[V69"C7$7E2PH4GA+_R
M%0SW@3+/&#Z1.5<?8[ 8?*N(*7AE@GA,:L1/ZY1H\(UZF*JQAA(3Q%&C@5.C
M7KYA'V5/+I.A7GB:$W2F?P?AN)/#7)_'KZ5V2^)V999A<DXIH^#V >!S!8J?
MU^AA^!,56QM:,,%3J8JA0RV-2AB<3FL?84<IE+#XFIB\+-T:A\ ?LZV_Q3F_
MX*Z>%OA;\>/BAJOQOU3X*V_C31_#OB/7D,,-O]F^&.H^(;*[L=-C$<-I=17%
MW!)/,5DEGN[9)GED$<&SZM_X.1/^4-7[7?\ UU^ _P#ZT?\ ".OF/]GWQ5X?
M\<_\%MO$7C+PIJEKK?AKQ/'XHUS0]6LI!):W^F:E\!UNK2YB;@@/%(NY& >-
MPT;JKJRCZ<_X.1/^4-7[7?\ UU^ _P#ZT?\ ".OZR_9=JE_Q,3X:.CB:N-I4
M_IK\)87#8W$8RMF.(Q&!P7&O V%R]U,PQ-6OB,9&G@Z=*%*O6KU92IJ+YY7N
M_JOHQJ@^ /'%X?%ULPH4_&/Q+P6$S#%8^OFN*Q66Y?E61X/*W5S3%UL3BL?&
MG@:5&G1Q%?$5YSI*,O:23N\S_@VI_P"4-?[*W_88_: _]:+^*M?AY_P=L?\
M)T?_  3=_P"P1\0?_5B?#6OW#_X-J?\ E#7^RM_V&/V@/_6B_BK7X>?\';'_
M "='_P $W?\ L$?$'_U8GPUK_9;Z.O\ RMW\3_\ LZOTK/\ U6^)1_0V;?\
M)!8+_L!R+_TY@C^Y>[_X]+K_ *]YO_1;5_.]_P $(O\ D8/VJ/\ KT^$?_I9
M\3*_HAN_^/2Z_P"O>;_T6U?SO?\ !"+_ )&#]JC_ *]/A'_Z6?$RO\,^(_\
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M\YO^"OOP<^%GP^^(_P"REXS\#^ _#?A3Q/X\^)_B=O&&KZ%IT6G7'B!].N?
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MSH?M4_\ *9O]G3_L+_![_P! U.OZ+Z_RYX(_Y&7'?_96XO\ ],T3^ZOI1?\
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M@#^8_P#X*Q?M.WMS^VKX._8D_8F_X)T_L^?MM?MU^*?A/:_%[XI>-_C7X/\
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M_P#Y6>_^"E/_ &%?VX/_ %HOP77](O\ P64_Y,OU+_LI'@C^6KU_-U_P2/\
M^5GO_@I3_P!A7]N#_P!:+\%U_2+_ ,%E/^3+]2_[*1X(_EJ]?+?M5?\ DM>$
MO^T4_!O_ -9C$G[M]#'_ )/OX3?]G=RO_P!6] ]__P""<7_)CO[-O_9/+?\
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M_P 5\"TH9_E.(I9MEV8T(K%O)LMJ4,90ITL7@ZN&YZ-2U2<7_*?^P1\'[KX
M_P#!5K1_@[?:JFM:AX#T3Q5I.I:G$'$%SJDOP4N=1U,6HD D^Q07]]<6UEO
M8VD,)90<@?>O_!R)_P H:OVN_P#KK\!__6C_ (1UX'\*?^4[OQ!_["?C?_U1
M[5[Y_P '(G_*&K]KO_KK\!__ %H_X1U_6'[+3+L)D_T@O#'*<!3=' Y7]-GA
M?+L'2<Y5'2PN"XYX'PV'IN<W*<W"E3A%SFW*35Y-MMGU'T6LJP61>&_C;D>6
MTG0R[)O&;Q1RK+Z,ISJ2HX++LOR7"82E*I4<IU'3H4:<'.<G.;7-)MMLS/\
M@VI_Y0U_LK?]AC]H#_UHOXJU^'G_  =L?\G1_P#!-W_L$?$'_P!6)\-:_</_
M (-J?^4-?[*W_88_: _]:+^*M?AY_P ';'_)T?\ P3=_[!'Q!_\ 5B?#6O\
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MPG_V&8__ -18']!W_!P/_P H>?VVO^Q,^'W_ *NKX:5X#_P; _\ *(;X-_\
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MZN,:?/?2_P#^3U8K_L@O"?\ ]=GPJ%%%%?;'\P!1110 4444 %%%% !1110
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M4,NY#M8!A@@&ORJ_X/*HTBMO^"=D42)'%&W[4\<<<:A(XT2/]G=41$4!415
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M]_R07X)?]DB^&W_J&Z+7\77_  0;_P"5AK_@JG_UZ_MK?^MI?#JO[1?V?O\
MD@OP2_[)%\-O_4-T6OXNO^"#?_*PU_P53_Z]?VUO_6TOAU7^^?T(?^48OIP_
M]HZ\&_\ K1T#^_J7^X^&W_7C+O\ U58<_I>_X+6_\HH_V[_^S?\ Q5_Z.L*_
M.?\ X-1/^46%Q_V<Q\7O_3+\/Z_1C_@M;_RBC_;O_P"S?_%7_HZPK\Y_^#43
M_E%A<?\ 9S'Q>_\ 3+\/Z]7A/_E67XL?]I7\$_\ K H]RO\ \EG@/^Q%B?\
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M7X#_ /K1_P (Z_H']F/_ ,I*< ?]IS9#_P"O X+/+^CE_P D=]('_L^_B_\
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M5U?;G\OA1110 5\8?\%$?^3)?VC_ /LG5[_Z<-/K[/KXP_X*(_\ )DO[1_\
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M^4S?[.G_ &%_@]_Z!J=?T7U_.A^U3_RF;_9T_P"PO\'O_0-3K^B^O\N>"/\
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MQK?>(1\9]"L];T);"Y\0PV%RGA#4HYWBNET>XO&T^Y6584/ZF:!_P18_:_\
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MJQTVRB+F*SL+#XKV=K$9':20QV]OXACB0R2,TCE4&YV9FRQ).<LF<N)*.?\
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M7-&BMI[_ ,:&&=]5L%BE\SXA^'W3RW-QM?<B,PVD\*:_<C_A+/"O_0S>'_\
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MC#%XCT&267X"?&&..--8TYG>1_AYXB5$4"YR69B%4#DD@5^8'_!"C7-#T_\
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M6^NX[2UL$NKR2/Q$KW-PEC96=DDTQ>1;2TM;8,(;>)$^N/YW/[Y_^$L\*_\
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M+D9(W+G\/#_P9]?MP$$'_@J.I!X(,/Q=P1Z'_BI:R-+_ .#-O]L/0S.VB_\
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M;%[BR^+$[V5XL$]LMW:-+XB9K>Z%M<W-N+B$I*(+B>(/Y<LBM:_X@^OVX?\
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M=)CT7X<Z2GA:WTJ^UN#1[W1;O3/#]OI\XE=_$>KW7EV.D6MP9MB[_P"#._\
M;6U"VFLK_P#X*?6E[9W"&.XM+NS^+%S;3QD@E)H)O$3Q2H2 2KHRY ..*\;B
M/*GGW#V>Y'&NL-+.<FS3*EB73=58=YC@:^#5=TE.FZBI.M[1TU4@YJ/+SQOS
M+Y_BS))<3<+<2\-QQ*P<N(.'\YR2.+E2=>.%EFV78G +$NBJE)UE0>(]JZ2J
MTW44>15(7YE_6W_P2G\1^';/]@;X V]UX@T.WG2T^(!>*75].21-WQ6\=,NY
M#<Y7*D, 0"00>A%?&O\ P6BUS0[_ ,0?L4_8M;T:Z\GXG>,C+Y.JZ>_EAY/A
MWM+XN/E!V-@G ^4\U_/98?\ !G7^VEI=I%8:9_P4ZLM.L8-X@L["P^*]G:0B
M21Y9!%;V_B*.&/?*[R/L1=TCN[99B36U+_@S>_;&UDVS:Q_P4PTG56LG:2S;
M4M)^*5\;21]F^2V-UK\I@=_+CW/%L9O+3).U<?G^>^&53.?"+!>%\<XAAZF$
MR+A/)GG+P4JD)RX9KY/6EB/J*Q,)16,_LIQC2^M-T?;INI5]F^?\OXD\'JN?
M^!.7^#,<^IX6K@>&N".'WQ!++I5J=27"&)R'$2Q7]FK&4Y1CC_[%<8T?KK>'
M^L)NI6]DU/\ OR_X2SPK_P!#-X?_ /!SIW_R37\.'_!M-JVDV'_!5;_@IU/?
M:IIMG!+I7Q'2*:YO[2"*5C^T<K@122S*DN44N#&S J-P."#7X1W_ /P1U_:O
ML?\ @L3HG_!(=OVZ?$4GC'6?AS+\0D^+ZZS\2U\-V\$7PHU?XJ'3'T$Z]_:;
MW#6>DMI@F6;RA/,DQ.U62OUFT7_@S%_:N\-WU[JGA[_@HUX6T'4]2#KJ.HZ+
MX;^)&EWU^LDWVB07MW8ZU!<70>X_?N)Y) TW[ULO\U?V]X3^.E/PR\*?I"^&
MD^&YYQ/QTX9X1X>IYO',XX./#;X7XAK9X\5/!O!8EYFL8JOU94HXG!.@X^U=
M2JGR+]:Q^5_7<?E.-]M[/^S*V(J^SY.;VWMZ4:?+S<RY.6U[VE?:RW/Z>_\
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M-X=\:^,/ ?A[7?$.G?96C:T3^T+^QFFNXK-H8S9PWQNHK3;_ *,D63GZ1HH
M155%5$5415"JJ@*JJHPJJHP H      &!Q2T44 %%%% !@>@[_KU_/O1110
M4444 %?R]?\ !LI_P3E_:V_X)X> /VU-$_:N^'EA\/\ 4OB_\:/!_C+P+!8^
M*-%\3#4]%TW1?$MIJ$\DNC7$Z6AMY[^S14N#'),)698U"-7]0M% !1110 44
M44 %%%% !1110 48 Z #@#\!T'T':BB@ HHHH **** /Y?/VB/\ @G'^UGX\
M_P"#E[]C_P#X*&>&?A_8WO[*_P *?@J/!_C3QV_B;1;>]TW73\,?VA_#IMH_
M#DURNLW2C5O'OAJW\VWMGC*WCR[MD$I3^H.BB@ HHHH **** "BBB@ HHHH
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M;7H5%3^)4_QR_P#2F*A_ H_]>J?_ *1$****@U"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O,M4^-'PET/XI>&?@
MCK'Q'\&:9\7_ !GX=UCQ;X4^&M[X@TZW\9^(/#7A^:WM]9UK2M!DG6_N["PE
MN8UEGBA(8)<O&'2SNV@]-K^5S_@J!\-?V%/^"I_[0FB^!?V*OVQO WP^_P""
MS/[)=IK6N_ WQC\.M>OYM21_A_+>:_K7PN\=:UI%M<Z*VB6UU=WY-R]U<+X>
MU#5+VUOH+_3M4U32IP#Z3_X**_\ !4+]J?P=^U1XQ_8=_8$\(? 3_A:/P/\
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M*T\]SJESJOBK5[Z:;5/$4=W#9P);006PL/[!Z "BBB@ HHHH **** "BBB@
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M>(-'\+V?V_Q!J5AIIA1K+2;4X22\N)9XXXS*T<$09IKB6*".21?P _X*'?\
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M[#3-,M8K*PLH%8LRPVMK!%!$"S$)&H))YK2HHH **** "BBB@ HHHH ****
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MQ<RMVCC8T ;%Q*T%O/,D4EP\,,LJP18,LS1HSK%&&(!DD(")D@;F&2!7Y$>
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MBZ1IMM%9Z=I6DZ9:Q66G:;86D"I!:V5C9P0VMK;0HD4$$4<4:JB@  TJ***
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O/?BY_R2GXG
M?]D]\:?^HWJ5>A5Y[\7/^24_$[_LGOC3_P!1O4JNG_$I_P"./_I2,ZW\*K_U
M[G_Z2P^$?_)*?AC_ -D]\%_^HWIM>A5Y[\(_^24_#'_LGO@O_P!1O3:]"HJ?
MQ*G^.7_I3%0_@4?^O5/_ -(B%%%%0:A1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 45E)KNB2ZU<>&X]8TN3Q%9Z;:ZS=Z"E_:MK-
MMI%]<W5G9:K<:8LIO8=.N[NQO;6VO9(%MI[BTN88Y6D@D5?P _;>_P""]'P<
M^ GCO]H7X2^"?V5OVEOVJ_AW^S3:'P]^V7\:O@G8:?9_#;X R:W9M!J^@:MX
MKO[^QDO?$NBZ=>>;JL6C7$,NC7B2V;7,6H0C: >=?\%6?^"SB?!SQ)\<?V:O
MAE^Q+\8OVS/@A\-OAOI.G_MY?%SX57T<'ACX,^ OC;X;OHHM$T36K6PU>RO?
M'"^#;R3799+TP:5H_P!LL/MLJ/!=F'\C?V:O GQ$_P""6$/@/_@H5_P0XMO&
MW[?O_!+W]I[3/#NC?M"?LL&]77OC-\.OB#H^EKHT'B-Y+>S75-.\1Z9K$T]K
MJ"3Z?NT.[O+SPWK5E/H>H:%K<.E^R)X\\5?\$6/B?X9^,'PP\,?%?]K'_@B+
M_P %1]>\*:QH>N>(/!FO^(?CU^SWXX\9:</#OAKP_P#$CPKJMK<>(-;2]T5[
M;08X-5MVM_B%X3L[*YTX)XAL9++4_P"G#]A/_@E'^S[_ ,$^OCE^TY\8_P!G
M'Q#\0O#'@3]IZ[\.:])^SM+JQ7X/?#/7++S[K6]9\&>'7#R6NI:[=7"(C2O$
MVC:5'_847VJRBLA9 'A?_!+/_@G/X1^$/C?7O^"B>O\ P5UO]D3]I7]KSX3Z
M&WQ]_9(\'>-)+WX'> _'5UK]UKNL>)M/\+0V]M:V?C#Q!:PZ)>7^GR((?!>J
M7OBO2M,CB35[V*+]O:** "BBB@ HHHH **** "BBB@ HHK*U;7=$T"&TN-=U
M?3-&@O\ 4]-T2QFU6_M=/BO=9UB[CL-)TFTDNY8EN-2U.]FBM-/L82]S>7,B
M0V\4DC!2 :M?G;_P4:_X*#^'_P!@7X8>$-9TWX6>./VB/CC\7O'FE_"[X%_L
M[_"V&*]\>_$;QKJVE:[KFY82)#I?AK1M%\-ZUJFLZU/"T4<=D+.W$EY<Q*,S
M_@H)_P %,_A1^P(/A;X/O_A[\4/V@OV@_CKJ6J:?\%OV:_@7H<7B/XI^/H/#
MT4-SXFUR"SGF@L]'\.>'[69)+[6=3FBMGG9;2V$T_F"/^6/XS_$?Q]^W+\=+
M_P#X+7?\$LM ^-VD_MI?L!^)X? _[8/_  3_ /VA-/U>5KS0](\.^)O"&NZ7
MX"LX);S0$\6?\(/_ ,)5HFO:+X4F.J_Z1>:O9VD'B)9(-; .,B^%_P ./^"K
MOQ8^,/\ P41_X)V:K\2_V+_^"[W[-?C^Q\=_$K]EGXT:[I[6NO+X1\'V7@'4
M/#?AS0=1TG3PFB>+M!TZ2QGU.=9TDU+5K_0_$\=A9ZS::E'^D_[,_P  /BE_
MP6E^-WPP_:\_;:_8<^(__!.WXR?L6>)/A+<>#OCCX-\4WG@KXH?'?QGX:?6'
M^+GPSUK2;FRBU";X16NIVNBC0-:G:YO[;3M1\0>$S<7MC?W:1_1GP,_9@_9'
M_P""QWB[]BO_ (+2_!*3XS?LC_'?P/XD=/B<OA:P'@WQ/\3K;P>L^D>)_A%\
M2FN;:*T\2Z+9Z]"NCKXSL[>\7Q#X1%[I)#++9/I'](- !1110 4444 %%%%
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MSX'N/BGX[L/AC\/$\2ZI;:4/%OQ U71];U[3/"6CR73QQW.M:AI7AS6KJSM
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M5U<:+XO\.>*O!NK2>?H/B:"R$LL\=I)=V['3=7B2VN+/4K66*"XM[^UE2/\
MG<^+/_!NCX]_9A\;ZM^T!_P16_:R\=?L=?$62>35-0^ ?C#6=2\6_L^^.& 1
MKC1+NROAJ$ME;W]O"-,MXM9L-:A@CG?.I6,69$ /DW]KE?VR?^"G/[-/[!/_
M  7*_P""5VN7+?M1_#;X$?$+X$?&SX1>%#I%YXNTRW\6QZAX>^*L/PWM=9!M
M3XQ\(>*KOQ++I%C<F/4;K1-8\*^)+!)5TZ2.X^GO^"3'[//[2WQ$_:Q_9_\
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M_B7Q?X@\3ZE=7Q\B.#19-$T>.%ET_P ROTXHHH **** "BBB@ HHHH ****
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M-ZU\1O&OQL_X+9_\$8;_ .-H_;3^"WQ^^*E[^VI^Q;^T7X*T*PO]:T+QC?\
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M^24_#'_LGO@O_P!1O3:]"HJ?Q*G^.7_I3%0_@4?^O5/_ -(B%%%%0:A1110
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M+C6/&-]J=U<I>^%=2DMA;_8M4T?[-=?L;^UCHO[#/_!6/1/@-^T'^PM^WO\
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MJYNY/#^G:]9V4LD-G?QZ-#J.ER3SR6TL-TL<L7Z5T44 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>>_%S_DE/Q._P"R
M>^-/_4;U*O0J\]^+G_)*?B=_V3WQI_ZC>I5=/^)3_P <?_2D9UOX57_KW/\
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MZFO^L /_ )T4H _?ZBOP!_XZFO\ K #_ .=%*/\ CJ:_ZP _^=%* /W^HK\
M?^.IK_K #_YT4H_XZFO^L /_ )T4H _?ZBOP!_XZFO\ K #_ .=%*/\ CJ:_
MZP _^=%* /W^HK\ ?^.IK_K #_YT4H_XZFO^L /_ )T4H _?ZBOP!_XZFO\
MK #_ .=%*/\ CJ:_ZP _^=%* /W^HK\ ?^.IK_K #_YT4H_XZFO^L /_ )T4
MH _?ZBOP!_XZFO\ K #_ .=%*/\ CJ:_ZP _^=%* /W^HK\ ?^.IK_K #_YT
M4H_XZFO^L /_ )T4H _?ZBOP!_XZFO\ K #_ .=%*/\ CJ:_ZP _^=%* /W^
MHK\ ?^.IK_K #_YT4H_XZFO^L /_ )T4H _?ZBOP!_XZFO\ K #_ .=%*/\
MCJ:_ZP _^=%* /W^HK\ ?^.IK_K #_YT4H_XZFO^L /_ )T4H _?ZBOP!_XZ
MFO\ K #_ .=%*/\ CJ:_ZP _^=%* /W^HK\ ?^.IK_K #_YT4H_XZFO^L /_
M )T4H _?ZBOP!_XZFO\ K #_ .=%*/\ CJ:_ZP _^=%* /W^HK\ ?^.IK_K
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MZFO^L /_ )T4H _?ZBOP!_XZFO\ K #_ .=%*/\ CJ:_ZP _^=%* /W^HK\
M?^.IK_K #_YT4H_XZFO^L /_ )T4H _?ZBOP!_XZFO\ K #_ .=%*/\ CJ:_
MZP _^=%* /W^HK\ ?^.IK_K #_YT4H_XZFO^L /_ )T4H _?ZBOP!_XZFO\
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MFV(JX4;=1-J4YM;.4FO1MM&E*+A2IQ>\:<(OUC%)_B@HHHJ30**** "BBB@
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M-YI>J:OK !_0'17XF?M9?#;_ (*L_'+]H;XI_P#"#?ML> O^"8/[$_P?\/\
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M (H\(^%O&W@/P[KWB'X>ZKXCC&D:GXXTRPN-!\)7ESIT7C&ZT ZMI7VW]I*
M"BBB@ HHHH ***^7/VGOVV/V4/V,- TCQ)^U%\=_ 'P:T[Q#<3VWAVV\4ZG)
M)K_B*2U3S+QO#_A32+?4_%.N6]@IC&H7>EZ/=VNGO<6D5Y-!)>6J3>OD7#^?
M<4YM@\AX8R3-^(\]S&HZ67Y+D66XS-\VQ]6,)594L'EV7T<1C,54C3A.HX4*
M,Y*$)3:Y8MK.K5I4*<JM:I3HTH*\ZE6<:=.*;LG*<VHQ3;2U:U=CZCHKQ'X
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MQ<>$5T5'U=O$D6J/HPTM'U WOV13*/CS_A[#_P $LAU_X*6?L ?^)D?LZ_\
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M6A^)_P!H7]H/XFR6EQ\#?V"OA5XF2UN]+\6>/;*XN;6'Q]\=O&^AW/VWX-?
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MX)+?LF?\$ZM'TF']B_X?_&[]JC_@H!J^D>&M&\4Z/X)73_V1?&.N?#_PO?\
MA73_ !GY6H7/@W6?VV/CE8^+?#.JZ-%+X1GUSX:ZA<:#Y8M+$Q_K9^T]_P $
MJ_\ @G;^V;\0-*^*W[3O[(WP?^+GQ*TBWT^RB\<:[HEUI_B74K#2=HTO3/$N
MJ^';_1KKQ?I6G1J+>QTOQ5)K.GVEHTEG!;1VLLD+_17@']F']G[X5^-=,^(7
MPU^$_@_P+XJT+X,>$?V=O#MUX6T]M%TOPQ\#_ >LZIX@\(_#'PKX9L98?#'A
M?PGHFL:S?WUOIV@:/IPED>W2Z>XAL+".U /Y!_\ @J7^RE^UM^US_P %2O\
M@I+X'_9<\>:=:6_A#_@GS^R/\3?B5^SU=Z/J$Y_;,TOP'\0_&/B32/V8-4\3
M:+KWAC7?"?A#XD0:;XATWQ!+HFOZ;=^(]1D\.>%[^YMO#VK:Y?6?US_P4K_:
M7_9__:]_X(?_ +(W[17PHT#2]!_8G?\ :E_84N_VGOA3;Z)9)X?^%GP \#?&
MGPYX;^*OP;\?^#_#]K)9:?H_PS\:67ASPWK&@V%M!I_EZ/IUSI7G:/<V#W/]
M*6B_L^_!SP[\<?&_[2>B^!=.L/CA\2/!/A7X<^-_B#'=ZL^J>(/!7@F[O[_P
MKX?NK.;4)-&AM=&O-3U">VEL]-MKMWNI1<7$RD*/C#X_?L57'PW_ &:OVJO"
M_P#P3U^"_P"S!I?Q1_:7\?ZG\5OBK\+/VBM#\5^*/V;_ (]^(_&]QIVF_&6R
M\?>#[75KS2=!U/XH>"H+G1[[5]*\.S:-?:A;:/'XFT/4=-B,EH ?DM_P7Z^)
M7[(/C+_ASCHGA?Q9\*_&?QKU+_@J3^QIK7P$@^'NM^$?$'B&/X1/XJ%KXVU?
M2'T*]N+A?A3?O-X#T^5M*,NE:EXGD\"FVAG6P-Q8_P!3E?QY?L[_ /!%CXL>
M/OVGOV</'GBK_@F'^PM_P3%^&/[/'[2_P\_:J\;>./@Y\7+O]HWX\_&KQG\'
MM3N?$OP^^&?PXU.YT&RTGX-?!W5?&9T[7O'^DVT^DWM]9:'H>G:9:&W@O+"X
M_L-H **** "BBB@ K^-__@H;J_[-G[.__!>.V^/O_!5[X93?$#]BGQY^ROI'
M@[]F7Q1XV^'>J_&;X->!OB'HSZ!_PD5KXC^'UEIGBF+5KFROQ\2KZ71X?#.N
M7FEW_CKPUXK/A>;[3:>)M(_L@KF/%_@GP9\0M#N?"_C[PCX8\<>&KUD>\\.^
M+] TKQ+H=V\6?+:YTG6K2]L)VCW-L:6W<IN.TC)K]V^C[XQ83P9XLXAS7-,G
MSK.,CXQX$XC\/,__ -5>)'P=QEE>4\22P%6MG'!_%#RW.:63Y]@Z^6X>,:F*
MRK'X/'9;6S'*<716'S"I5I^9FN7RS'#TJ<*E.G5P^*HXNE[>C]8P\ZE'F2IX
MBASTW4I24WI&I"4)J%2+O!)_RM_\$$K#P;X^_P""A/\ P4S_ &D_V+_ASXA^
M%G_!-7XB0_#_ ,.?"G2+GPY?>"O!?B;XIZ%'IK:]JW@'PK<"VM=,T?3]03XB
M:I#HMG8VY\':%XZ\,^'KFQT)O+T2T_K+K,T71-%\-Z58:#X=TC2] T/2K:.S
MTO1M%L+32]*TVTB&(K6PTZQB@L[.VC'$<%O#'$@X516G7!X^>+:\:_$?%\;T
MLFQ61X*'#_"'"F5X3-,YJ<2\05LIX)X7RKA3+,QXIXFJX/+ZO$?$^98/*:6-
MSO.9X#!_6L96FH8>G2IP1658#^S<''#.I&K)U<17J2A35&DJF)K5*\X4**E)
M4:,)5'&E3YI<L4KMNX5^*/\ P<6?#WQ[\3/^",'[<>A?#/36U;Q=H/A+X7_%
M*"T6V6\9=#^"?Q[^%/QD\8WRV;VM[%>-I?@WP'K^J+9S6LUO=&S%O<*())'7
M]KJBG@AN89K:YABN+>XBD@G@GC26&>&5#'+#-%(&22*1&9)(W5D=&*L""17X
MP>B?Q#_MO?LB_P#!*CX'?\$Q](_X*6_LK?'?7+C_ (*!V>F?#?XG_L]_MJ>&
M/VB_%_Q!_:8_: _:F\9:IH-I=:+X@\.'Q'KND>.M>^(FHZMKFC?$7X<VOPYM
M++PGX?;Q/87.@>%/#>AZ[:6WVA_P4+^ &E?M<?\ !7'_ ()B_#WXZ_%;XS?L
MYWNJ_L!?M%^+O%GB?]G_ .,5]\#/'6E^,++7?AI/J7ABW\=Z:);J+1)=3OKV
M&_TF-@NHBRM@[E(2&_8?X??\$>/^"7OPI^.%G^T?\.OV&_V?/"/QCTO6$\1:
M'XITGP3;Q67AKQ%#*MQ;>(O"?@^2:7P1X3U^RND6\T_6_#?AS2]4TZ]'VVQN
M[>Z)F/<_M>?\$R_V$_V]==\&^)OVN_V=/"?QOUWX?:1J6A>#=1\2:QXRTV70
M=)UB\AU#4[*UC\,>)="@DCN[RW@GD>ZBN)0T:JDBIE2 ?)/[-W_!+7]FW]G;
MXW> /C+X6_;Z_;X^*/B#P5J5]/I7@'XS?MY>(_BE\-/$MSK.BZGX=%EXH\ :
MHJ6/B2*)-8>\TRUF8&WUJVTV_AS/:1 ^Z?\ !9K_ )1,_P#!1S_LS3]H+_U6
M^OUY7X%_X(#_ /!'[X9^-_!OQ(\"_L.?#;PYXW^'WBKP]XW\&^(;/Q+\49;O
M0?%7A35[/7O#VLVL5YX\N;22XTO5["SOH([JWGMWE@59X98BR-^H?Q7^%?P_
M^./PS\>?!SXK>&K/QE\-/B;X5UOP1X[\)ZA/?6UCXC\*>([";3-;T:[N-,NK
M'4(;;4+"XFMIGL[RVN%CD8Q31MA@ ?#GP?\ VB_A=^R5_P $IOV>/VC?C7J.
MNZ/\*?A1^QS^SCXB\=:QX<\)^)?'&JZ/H4OPW\ :3/JR^&?"&EZSXAO;#3)-
M1BOM9N;+3IXM(T:WO]:U!K?3-/O+F'\8O^"V/A[]@G0_V?/^'I/['GQ \#:+
M_P %+?&OCSX$:E^QM\?/V>_B??ZO\3_VD?'^K^(OAOX!TGX5P>'/"'BBZL?C
M5X(\6_"339O"&N>"=2T;5M"B\(VD]K=VL=@^HV&H_P!1>@?#GP-X8^'6B_"3
M1_"^DQ?#7P_X+T[X=:7X,O+?^UM#C\#Z5H</AJR\,75KJ[7W]IZ2F@P1Z5/;
MZF]Y]MLP\=ZUQYLI?X7^!_\ P2&_X)E_LV?&./\ : ^!O[%/P)^'/Q?M)[FZ
MT7QEHGA3S;CPG=WD$UI<WO@32M2NK[0/ -[-97-U8M>^"M*T&Z%A=W=BLHM+
MJXAD /T+T:74I](TJ;6;>&TUB;3;&75;6V?S+>VU*2VB>^MX)-\N^&&Z,L<3
M^9)N15/F/G<?YM_^",OQ(_9B^''P4_X*B>'_ -I/Q=\)O!7QF\-?\%!/VU-?
M_;A3XQZGX>\.:S?>'-7\9:KJ7ACQ=\0O^$SDL?[6^%NJ_#*>-?#&M^4_@2[L
M8_$$&D.UTNN*W]+5?R@_MJ?\$_?VTOC7^T_\2/'7Q'_X)"_\$LOV\=1O_'FI
M2? K]J3Q+\4O$WP&UC0OA<D%A:_#_P /_M1?"N:UUS5/C3X@\#6<9T[5K^PU
MK4--U?2+"/3]"TO2+9+6U(!^6/PJ;X0C_@WA^"WB232[V7]AC3?^"V7@WQ-\
M:K34;*8:%+^Q8O[9CV5]'XQTO5(VDOO#3PW'@_3KS3[VVNF.LFQAN[=I;>;R
M_P"M3]I/XU?\$SKGXA_L%M\8/$/PT^(7Q2\1_'GPE8_L+1?#9]5\?^,K7XA^
M)= O]/M/%GA*#X02ZEJ.F?"FU\+2S'QSXPUY8_@[I.BOIEQXRO88/[)<7/\
M@G5_P3VT#]D+_@GOX*_8E^,,'PU^,EMJ&F_%&\^-VB6G@32+?X+>*=7^./C7
MQ9X\^(7@?P_\.M1TR/1?^%4:;-XROO!?A[0=0T*SM;_PGIMFU]H6FF[FTJVW
MOV=?^"3?_!./]DOQUX@^)W[./[(GPE^$OQ#\2Z7KVB7WC3PQIVJ#Q)IVC^)T
M,6NZ9X4U;4=5OKSP-8ZC 3:RVW@N70(H[3%I L5L!$ #\F]/8_%S_@E%_P %
M]OVZ+I#./VU_"'_!1OQ!\.=4DQYEW^SK^SG^SQXV_94^ \L.,(=,\0>'_@[J
M_P 1]-DB4VUQ#\07NK*ZU2QGMM8U#X(_X(\:9XU_86_:&_X)O?%3]MW7_"OQ
MI\-?\%,/^";7[,/P:_8Q_:<U'PO<Z!-^R=KGPW^'FD>)O ?["%I+<75]X8\-
MZ%\4?AEXHT36+'Q5:7.@^(OC#\9]!UR+^PM8GO-5U"R_KPTW]F'X":/^S;)^
MR!I7PTT/3_V;)OA)JOP*E^$]K-JD.@R?"?7/#-YX/UCP<UVFH#7#::EX<U"]
MTZ\OSJO]L3?:IKM]1-\YNJX_QS^Q'^RQ\2?V?/AO^ROXT^#VA:S\!O@];?"^
MV^%7@3^T_$VFGX>'X+6>GZ?\++[PAXHTG7+#QGH.L^"K'3+.ST?7M/\ $4&M
MK;+/!<ZA<1WEXMP ?D%^QMXN^&/@#_@NG_P68L_COX@\+>%?CGXN\+_L8Z_\
M!+_XB:MIVCZMK_[+FC_!$6/B6+X13:[=6T;^"= ^)-M*OQ*A\*PPVS^,18W?
MBJ2_U2TAN+3AO^"%VL? 3Q-^W=_P7?\ $_[,$OAB^^!^L?M=?!U_#>K^!H;5
M?!&K>*(?ASXE_P"%H7WA>ZTY%TB_TJ\^)4OBG4+6_P!'>72]0M;ZVU/399M.
MOK.>7H/^"J7[&?[6/[1/QYN-8U3_ ()H?L"?\%-/V=K'PYX2M/@C;?$;XGZ[
M^S3^TQ\"]9M;"0_$#1?%?Q.O1KEE\2OA]XF\11#Q%HVFZ#>^%ULWU)=,U?P]
M>W&E3>(]9^M/^"./_!/?QW^PI\-/C]KOQ7\+_L__  R^)?[3WQMD^+>I_ W]
ME?1+[1_@'\!O"&B^#O#GP_\  'PQ\'76I66E7OBO6;/0O#9\1>._&<FBZ.FN
M^,/$6K+'!JIL7\5>(@#]BZ*** "BBB@#P/\ :B^!]O\ M(? +XE_!6?5CH3^
M-]%MH-/U@Q&>+3]:T76--\2:!<W<"XDGL$UO1M/_ +1AA9)Y; W"0/',T;K^
M3VO_  %_X*8?&_X3^&_V-_BCX7^#7@GX.Z./"&@>)/C;I6MV6K:IXE\)> [J
MRN-&2QT*V\0W.J/J#/HNEW8$WA'PL=1O+6SBO+K1K6;4PW[NT5\[F_#.!SFN
M\17Q&88:57!O+L;#!8F-"GF&7NI.K]2QBE2J2='GJUO>H2H5^6M5A[;EE9?L
MWAUXX\4>&N4PRC*\EX0SNE@.)(\9\,XKB?):N:8S@[C&.#PN!7$W#E2CC\%2
MAF/L,ORUNCFU'-LK=?+,!B'E_MZ"J/#\,Z!8^%/#?A_PMI?FG3?#>B:5H&G^
M>XDG^PZ/8P:?:>=(JHKR^1;Q^8X1 SY(50<#<HHKZ",8PC&$4HQA%1C%;*,5
M9)>2221^/5JU7$UJV(KU)5:]>K4K5JLW>=2K5FYU*DWUE.<G*3ZMMA7S5^V=
MH.N>*?V/?VK_  QX8T;5?$?B3Q'^S5\==!\/>'M!TZ\U?7-=US5_A=XIT_2=
M&T;2=/AN+_5-5U2_N+>QT[3K&WGO+V\GAMK:&6:5$;Z5HJC(_%S]F'X6?$[0
M/^" 7PX^#6O?#GQYHGQ?L?\ @E]<_#^]^%.K^$/$&F_$FS\>-^SIJ.AKX)NO
M UYIT/B>W\7-K3II \-S:6FLG5'73Q9?:V$)_./_ ()]_P#!7+QG^RA^P_\
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MP^"7@_QM^V1KOA/4/VTO!6D?![XP_%?X@:9^R_XHU/QU9Z#\((]>\0^(-/\
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M>%IO!GQ"AA^(5_JOA#XE+8ZQ\2M0\+CQ0(;7^K"OG;]J[]E?X*_MJ_ /Q_\
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MOO5:\T*/\.TZB_Y>M/EB_P#IW%[M?SR5_P"6*LI/#DJ8G6MS4J/2@FE.HO\
MI_*+=HM;T8.W\\Y)N"Q/#OAO0?"6DVNA>&]*L]&TFS!$%E8Q"*(,W,DLAYDG
MN)6&^>YG>6XG?+S2NY+';HHK%MMMMMMZMMW;?=M[G4DHI1BE&*2222226R26
MB2Z)!1112&%%%% !1110 4444 %%%% !1110 4444 ?R!?\ !+CQ1_P77_X)
MK_L)_ S]BG_AQ-_PNC_A2_\ PLW_ (N7_P ///V//AS_ ,)+_P +%^,7Q!^+
M/_(F_9_'?]C_ -C_ /"=_P!@?\C7JO\ :']E?VK_ *#]N_LVS^__ /AX?_P7
M7_Z5U?\ SKE^QY_\Q-?O]10!^ /_  \/_P""Z_\ TKJ_^=<OV//_ )B:/^'A
M_P#P77_Z5U?_ #KE^QY_\Q-?O]10!^ /_#P__@NO_P!*ZO\ YUR_8\_^8FC_
M (>'_P#!=?\ Z5U?_.N7['G_ ,Q-?O\ 44 ?@#_P\/\ ^"Z__2NK_P"=<OV/
M/_F)H_X>'_\ !=?_ *5U?_.N7['G_P Q-?O]10!^ /\ P\/_ ."Z_P#TKJ_^
M=<OV//\ YB:/^'A__!=?_I75_P#.N7['G_S$U^_U% 'X _\ #P__ (+K_P#2
MNK_YUR_8\_\ F)H_X>'_ /!=?_I75_\ .N7['G_S$U^_U% 'X _\/#_^"Z__
M $KJ_P#G7+]CS_YB:/\ AX?_ ,%U_P#I75_\ZY?L>?\ S$U^_P!10!^ /_#P
M_P#X+K_]*ZO_ )UR_8\_^8FC_AX?_P %U_\ I75_\ZY?L>?_ #$U^_U% 'X
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MY_\ ,37[_44 ?@#_ ,/#_P#@NO\ ]*ZO_G7+]CS_ .8FC_AX?_P77_Z5U?\
MSKE^QY_\Q-?O]10!^ /_  \/_P""Z_\ TKJ_^=<OV//_ )B:/^'A_P#P77_Z
M5U?_ #KE^QY_\Q-?O]10!^ /_#P__@NO_P!*ZO\ YUR_8\_^8FC_ (>'_P#!
M=?\ Z5U?_.N7['G_ ,Q-?O\ 44 ?@#_P\/\ ^"Z__2NK_P"=<OV//_F)H_X>
M'_\ !=?_ *5U?_.N7['G_P Q-?O]10!^ /\ P\/_ ."Z_P#TKJ_^=<OV//\
MYB:/^'A__!=?_I75_P#.N7['G_S$U^_U% 'X _\ #P__ (+K_P#2NK_YUR_8
M\_\ F)H_X>'_ /!=?_I75_\ .N7['G_S$U^_U% 'X _\/#_^"Z__ $KJ_P#G
M7+]CS_YB:/\ AX?_ ,%U_P#I75_\ZY?L>?\ S$U^_P!10!^ /_#P_P#X+K_]
M*ZO_ )UR_8\_^8FC_AX?_P %U_\ I75_\ZY?L>?_ #$U^_U% 'X _P##P_\
MX+K_ /2NK_YUR_8\_P#F)H_X>'_\%U_^E=7_ ,ZY?L>?_,37[_44 ?@#_P /
M#_\ @NO_ -*ZO_G7+]CS_P"8FC_AX?\ \%U_^E=7_P ZY?L>?_,37[_44 ?@
M#_P\/_X+K_\ 2NK_ .=<OV//_F)H_P"'A_\ P77_ .E=7_SKE^QY_P#,37[_
M %% 'X _\/#_ /@NO_TKJ_\ G7+]CS_YB:/^'A__  77_P"E=7_SKE^QY_\
M,37[_44 ?@#_ ,/#_P#@NO\ ]*ZO_G7+]CS_ .8FC_AX?_P77_Z5U?\ SKE^
MQY_\Q-?O]10!^ /_  \/_P""Z_\ TKJ_^=<OV//_ )B:/^'A_P#P77_Z5U?_
M #KE^QY_\Q-?O]10!^ /_#P__@NO_P!*ZO\ YUR_8\_^8FC_ (>'_P#!=?\
MZ5U?_.N7['G_ ,Q-?O\ 44 ?@#_P\/\ ^"Z__2NK_P"=<OV//_F)H_X>'_\
M!=?_ *5U?_.N7['G_P Q-?O]10!^ /\ P\/_ ."Z_P#TKJ_^=<OV//\ YB:/
M^'A__!=?_I75_P#.N7['G_S$U^_U% 'X _\ #P__ (+K_P#2NK_YUR_8\_\
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M5]F,2J=!1E[6I)U:S5O:25E!/>%*&JIP[VO.6\YS=FBBBBLS<**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P#0]_\ EK^,_P#YG:/^&J?@+_T/?_EK^,__ )G:^A**.;#_ //JM_X/A_\
M,X<F,_Y_X;_PDJ__ #:?/?\ PU3\!?\ H>__ "U_&?\ \SM'_#5/P%_Z'O\
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M_-I\]_\ #5/P%_Z'O_RU_&?_ ,SM'_#5/P%_Z'O_ ,M?QG_\SM?0E%'-A_\
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M_@^'_P SAR8S_G_AO_"2K_\ -I\]_P##5/P%_P"A[_\ +7\9_P#S.T?\-4_
M7_H>_P#RU_&?_P SM?0E%'-A_P#GU6_\'P_^9PY,9_S_ ,-_X25?_FT^>_\
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M_P"?^&_\)*O_ ,VGSW_PU3\!?^A[_P#+7\9__,[1_P -4_ 7_H>__+7\9_\
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' 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>img34756086_5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img34756086_5.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" )& ]@# 2(  A$! Q$!_\0
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M^%IX;_\ EE1_PMSX4_\ 13OA[_X6GAO_ .65'LZG_/N?_@,O\@]M1_Y^TO\
MP9'_ #\U]YZ%17GO_"W/A3_T4[X>_P#A:>&__EE1_P +<^%/_13OA[_X6GAO
M_P"65'LZG_/N?_@,O\@]M1_Y^TO_  9'_/S7WGH5%>>_\+<^%/\ T4[X>_\
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M+_P9'_/S7WGH5%>>_P#"W/A3_P!%.^'O_A:>&_\ Y94?\+<^%/\ T4[X>_\
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MA[_X6GAO_P"65'LZG_/N?_@,O\@]M1_Y^TO_  9'_/S7WGH5%>>_\+<^%/\
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M_P#13OA[_P"%IX;_ /EE1_PMSX4_]%.^'O\ X6GAO_Y94>SJ?\^Y_P#@,O\
M(/;4?^?M+_P9'_/S7WGH5%>>_P#"W/A3_P!%.^'O_A:>&_\ Y94?\+<^%/\
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M\+<^%/\ T4[X>_\ A:>&_P#Y94?\+<^%/_13OA[_ .%IX;_^65'LZG_/N?\
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M?\_-?>>A45Y[_P +<^%/_13OA[_X6GAO_P"65'_"W/A3_P!%.^'O_A:>&_\
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M_P#EE1[.I_S[G_X#+_(/;4?^?M+_ ,&1_P _-?>>A45Y[_PMSX4_]%.^'O\
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M2_\ !D?\_-?>>A45Y[_PMSX4_P#13OA[_P"%IX;_ /EE1_PMSX4_]%.^'O\
MX6GAO_Y94>SJ?\^Y_P#@,O\ (/;4?^?M+_P9'_/S7WGH5%>>_P#"W/A3_P!%
M.^'O_A:>&_\ Y94?\+<^%/\ T4[X>_\ A:>&_P#Y94>SJ?\ /N?_ (#+_(/;
M4?\ G[2_\&1_S\U]YZ%17GO_  MSX4_]%.^'O_A:>&__ )94?\+<^%/_ $4[
MX>_^%IX;_P#EE1[.I_S[G_X#+_(/;4?^?M+_ ,&1_P _-?>>A45Y[_PMSX4_
M]%.^'O\ X6GAO_Y94?\ "W/A3_T4[X>_^%IX;_\ EE1[.I_S[G_X#+_(/;4?
M^?M+_P &1_S\U]YZ%17"VGQ0^&>H7=K86'Q$\"WU]>W$%G965IXMT"YN[N[N
M95AMK6UMH=0>:XN+B9TB@@B1Y9976.-69@#W52XRC\47&^UTU?[RXSA.[A*,
MDMW&2E;KK9OIJ%%%%(H*KWEG::A:75A?VMO?6-[;SV=[97D$5S:7=I<Q-#<V
MMU;3*\-Q;W$+O%/!*CQ2Q.T<BLK$&Q11ML&^YY[_ ,*C^%/_ $3'X>_^$7X;
M_P#E;1_PJ/X4_P#1,?A[_P"$7X;_ /E;7H5%7[2I_P _)_\ @4O\S+V-'_GU
M2_\ !<?\O)?<>>_\*C^%/_1,?A[_ .$7X;_^5M'_  J/X4_]$Q^'O_A%^&__
M )6UZ%11[2I_S\G_ .!2_P P]C1_Y]4O_!<?\O)?<>>_\*C^%/\ T3'X>_\
MA%^&_P#Y6T?\*C^%/_1,?A[_ .$7X;_^5M>A44>TJ?\ /R?_ (%+_,/8T?\
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MO_A%^&__ )6UZ%11[2I_S\G_ .!2_P P]C1_Y]4O_!<?\O)?<>>_\*C^%/\
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M_P#1,?A[_P"$7X;_ /E;1_PJ/X4_]$Q^'O\ X1?AO_Y6UZ%11[2I_P _)_\
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M\*C^%/\ T3'X>_\ A%^&_P#Y6T?\*C^%/_1,?A[_ .$7X;_^5M>A44>TJ?\
M/R?_ (%+_,/8T?\ GU2_\%Q_R\E]QY[_ ,*C^%/_ $3'X>_^$7X;_P#E;1_P
MJ/X4_P#1,?A[_P"$7X;_ /E;7H5%'M*G_/R?_@4O\P]C1_Y]4O\ P7'_ "\E
M]QY[_P *C^%/_1,?A[_X1?AO_P"5M'_"H_A3_P!$Q^'O_A%^&_\ Y6UZ%11[
M2I_S\G_X%+_,/8T?^?5+_P %Q_R\E]QY[_PJ/X4_]$Q^'O\ X1?AO_Y6T?\
M"H_A3_T3'X>_^$7X;_\ E;7H5%'M*G_/R?\ X%+_ ##V-'_GU2_\%Q_R\E]Q
MY[_PJ/X4_P#1,?A[_P"$7X;_ /E;1_PJ/X4_]$Q^'O\ X1?AO_Y6UZ%11[2I
M_P _)_\ @4O\P]C1_P"?5+_P7'_+R7W'GO\ PJ/X4_\ 1,?A[_X1?AO_ .5M
M'_"H_A3_ -$Q^'O_ (1?AO\ ^5M>A44>TJ?\_)_^!2_S#V-'_GU2_P#!<?\
M+R7W'GO_  J/X4_]$Q^'O_A%^&__ )6T?\*C^%/_ $3'X>_^$7X;_P#E;7H5
M%'M*G_/R?_@4O\P]C1_Y]4O_  7'_+R7W'GO_"H_A3_T3'X>_P#A%^&__E;1
M_P *C^%/_1,?A[_X1?AO_P"5M>A44>TJ?\_)_P#@4O\ ,/8T?^?5+_P7'_+R
M7W'GO_"H_A3_ -$Q^'O_ (1?AO\ ^5M'_"H_A3_T3'X>_P#A%^&__E;7H5%'
MM*G_ #\G_P"!2_S#V-'_ )]4O_!<?\O)?<>>_P#"H_A3_P!$Q^'O_A%^&_\
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M_P#E;1_PJ/X4_P#1,?A[_P"$7X;_ /E;7H5%'M*G_/R?_@4O\P]C1_Y]4O\
MP7'_ "\E]QY[_P *C^%/_1,?A[_X1?AO_P"5M'_"H_A3_P!$Q^'O_A%^&_\
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M-'_GU2_\%Q_R\E]QY[_PJ/X4_P#1,?A[_P"$7X;_ /E;1_PJ/X4_]$Q^'O\
MX1?AO_Y6UZ%11[2I_P _)_\ @4O\P]C1_P"?5+_P7'_+R7W'GO\ PJ/X4_\
M1,?A[_X1?AO_ .5M'_"H_A3_ -$Q^'O_ (1?AO\ ^5M>A44>TJ?\_)_^!2_S
M#V-'_GU2_P#!<?\ +R7W'GO_  J/X4_]$Q^'O_A%^&__ )6T?\*C^%/_ $3'
MX>_^$7X;_P#E;7H5%'M*G_/R?_@4O\P]C1_Y]4O_  7'_+R7W'GO_"H_A3_T
M3'X>_P#A%^&__E;1_P *C^%/_1,?A[_X1?AO_P"5M>A44>TJ?\_)_P#@4O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Y[_:"_YH
MC_V<)\-O_<U7T)7SW^T%_P T1_[.$^&W_N:KZ$K:?\&A_P!Q/_2D<U+_ 'C%
M>M'_ --A1116)TA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% 'SW^T%_P T1_[.$^&W_N:KZ$KY
M[_:"_P":(_\ 9PGPV_\ <U7T)6T_X-#_ +B?^E(YJ7^\8KUH_P#IL****Q.D
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH ^>_V@O\ FB/_ &<)\-O_ '-5]"5\]_M!?\T1_P"S
MA/AM_P"YJOH2MI_P:'_<3_TI'-2_WC%>M'_TV%%%%8G2%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 ?/?[07_-$?\ LX3X;?\ N:KZ$KY[_:"_YHC_ -G"?#;_ -S5?0E;3_@T
M/^XG_I2.:E_O&*]:/_IL****Q.D**** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BOYS_\
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M+VZN=)EUG0-0L)5&NZ-I7B.PO_"^OQZEI7AKQ-X<UVWM[?Q#X8TJWUG0;G5
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ME?"+P*MY)XS^(=UH_P 4_"DZ^%O"\6GZ-XAO9]<U-0T6FV]MHNH27%UY<(@
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M1UZV\$W,VCV%R!=6)-O>:@EO;S 7MF3'(V+JW/[U/5A_P4;_ .#I_ _XTH?
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MO_"OBJQUOX>?$W5;VUEL-4F\*ZUXBT*[T[Q%X>O[F&:WCU*29(9GCGC@F&T
M'P)_P;0_LB_%CXL_&3]I+_@NC^T#\5?@KXN^(G[=OA_Q-X=\,> O@->2SZ!\
M/M+\5>/O#?C;XBZ'XWTYH=GA?Q5X=UWP#X+\*Z3X3N=5\4>)--TW2=2U/QAX
MIUK7-=>]FD_X(::C>_ S_@N9_P %X?V/]!O+N;X9:W\3F_:.T+1FE7^RO"^N
MZOX_U'4+ZSTFT6.".T$^F?%_3=#EDCA:6XTWP7H<-Y<W3V,,\FK_ ,$3_P!@
M3_@H1_P2"_X*'?M5_LI-\)/%WQ0_X)<?&SQ!J7B_X2_M 0^+OAO<VW@?Q9I>
MAPZOX)\1>(_#$OC;2_&EK>ZUX1W_  8^*4NF_#V>XU?X@>%O FOZ3;6?@"SG
MUF6/_@@]H>H_'O\ X+)?\%W_ -N:QLHXOANGQRG_ &9? 6O6DHFTKQ=<>&?&
M^MC6[W3G2[N-\EIX;^'7P[\07LLR1PR)X\L#IY""\M[8 _KXHHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH ^>_V@O^:(_]G"?#;_W-5]"5\]_M!?\
M-$?^SA/AM_[FJ^A*VG_!H?\ <3_TI'-2_P!XQ7K1_P#384445B=(4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MR_LI[6VUK38[^WN["2_TN:5+ZS2]M;FT>X@C6YMYH2\;?&O_  3P_8"^"/\
MP34_9E\.?LP_ F7Q%J_AW2_$'BCQEXF\;^-9],O?'GQ%\;^+]2:]UGQ?XUU'
M1],T;3M0UDV,.D^';.6VTRTCM?#OA_0]-5'%B)7^XJ* "BBB@ HHHH ****
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MXQ_M=^(/&'AG]GKP+X9^%GQ;^).H^/-2^'L'AF^\>W-S=_#3P+XOTGP3X?\
M!.D>+M%\0^+/%GQ U#PKX5\/>%AK/BO5M9M/#?ACQ-JFD 'T_1110 4444 %
M%%% !1110 4444 %%%% !1110 445\@?&']N[]F?X#?M&_ 7]DWXG^*/B!I'
MQY_:>-V/@1X1T+X ?M">/='^(9TFZF@\4C3_ (B_#_X6>*/AGIA\ 642^)OB
MC_PD'C'2/^%5^!;O3/B'\1O^$7\"ZMI?B*[ /K^BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** /GO]H+_FB/_9PGPV_]S5?0E?/?[07_ #1'
M_LX3X;?^YJOH2MI_P:'_ '$_]*1S4O\ >,5ZT?\ TV%%%%8G2%%%% !1110
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M6U+4=%N-3\(^)?$WA>\TCQ!J0!]04444 %%%% !1110 4444 %%%% !1110
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MBBL3I"BBB@ HHHH **** /XS_P#@YX_9#_X*R?M#?%+X5^*OV:-#_:&^-_\
MP3ST#X-:/I/[1/[,7[,7QFM? /Q&\:^,K3QY\0=4\>W<G@7_ (1_Q5J'CN7Q
M/\.+_P "^'/"<\'P\^-B:+J^E:BX^&A6><>(?Y_O@M\;/^".WPT_X*)_\$A(
M?@=^S9\4/V$;SX#_ !X^,LG[>8_;<U:XN]5_M#7/!OPOB^$&O^*?%WB[Q%?Z
M+:>'M$U"S\8QP6[^#_A38^'-0NY]=O/"%@FKIK5[_;-_P4T_X+!_&7_@GY\>
M/"7P:^'G_!,;]K+]M+1?$WPCT'XFW7Q2^!&C^*M0\(:!JFL^,O'OA6?P!J,V
MA_"_QM:+XDTNT\%V7B*\BDU6WN%TSQ5H[OI\43PW-W_.'_P4/_X+X?LE_&SP
MOH_AW_@I1_P;V?&A;+Q+9ZOI'@KQ)\?YKCX6^.T@MHK<:U#\-/B?J?P>\'_$
M'0Y[);^QEU"3P/XHL)[1[BQFN61GMF(!_>[X'\=^!_B;X3T/Q[\-O&7A3XA>
M!O$]G_:/AOQIX'\0Z1XL\)^(=/\ -E@^W:'XCT&\O]'U:S\^&:'[387EQ!YL
M4L>_?&P'55^/O_!!#5?@=KW_  2<_94UW]FWX4?$'X'? _7)?CSK7P]^%?Q0
M\9CXA^,O"6E:K^TQ\9=0N[>[\:?V'X=D\0:-J.L7&I:UX1O+G3&OE\'ZEH-M
M?ZIKU[!<:[J7[!4 ?RN?\%@_^"7G[*,ND?M^_P#!2K_@H]^U#\4/'_AO0_@S
MIJ?L8^!K+Q/XQ^%-C^QQ\3?#_AC6-(\,_P#"FH?"WQ*3P_\ $WXC_$KXA'P'
M<>';'Q/X.LM,3Q7%K-[XCLO$-MKJ7?A;\_?%'Q@_:._:[_8+_P"#:C]A3]JO
MQU\2X(_^"D'COQ=?_M0:]I_B_P 0:3XL^-W[,?[/C6$W@[P=X\\:VM]9^+]6
M/QO^$GC[X=Z_XJUB6ZN-0\1ZQ&WB/5-9N=1$=]?<5_P5ZUO]I']M/_@KMX<\
M$?M9?\$^O^"J?QA_X)._L8ZS<#PE\-?V2OV0/BAX]L?VG?BI::)9#5_&>K^(
M[S4_AWX4E\'ZOX@O]0\-V?C/0O%/B;4+?X8^&;K1/ UEX<U3XM>*_%NC?J9_
MP4&T?XO?M'?#G_@D9_P5@_9A_89_:FTO4?V"/VAO'/B'Q7^PYX_^$%O\+?VM
M]'_9N\1W\7PO^)5KX:^ EOXAU*QE\3KI_P '_"^N_#'P7I-W?:EKG@_Q+X9U
MK2%TVQEU&S4 ^ /#7[0GC7_@DUX;_P"#E/\ 8D^ ?C#QOI?PK_8G^%_P4^+?
M[$&EZIXN\0^.]7_9YN?VJ_AAH\&H:9X.UWQS>ZU=IX:\#^*?B/X \3>'='U&
M^N38ZMH^NZQ>Q^*=9\0ZY?W4W[/GP T__@E9^U7_ ,&^?QJ^"GCKXD+?_P#!
M3SX?:S\._P#@H>GBGXG^/O'.D_M%_%SXA_!WX<^-O!GQ$U71/%VH>((=.UG0
M_B3\0M5O]-U31$T*:PL/#V@6%V\D.N^.;S7?>_AI_P $]?VEO^"C/@/_ (+\
M?M5?$KX#?$/]F+Q3_P %/O!'PU^&'[(7P8_:0TRT^'WQ:TK0OV:_AS%IG@#Q
M'\7= L;W4-0^','CSQKX9^'MA<:'JC_:]%B\-ZYJ5W:^+/#UUX?U?5L7]F'P
M%^VW^WM^U-_P1/\ !_QE_8>_:._94^'W_!'OX:>)KO\ :F^(?[0W@K2_!G@;
MXN?'?1?A5X)^&7PX7]G"[2XU>/XGZ(_BCX>V/BIO$&BR6.CZ-HOB3Q$7NY+K
MP_X2O/%8!^>OQ)^&>I_MM?LN?\%K?^"T6M?$CXLZ#^VM^Q)^WU\3_!/[$7Q
MTKXH^-]#MOV<?@_^S+J'PCUFU\&>$_!NFZX_@DQ^+? 7CG5-)\41WFCW\&J^
M(HI];C%I<:WXBDUK]#?C%J7A/_@MW_P4L_X)Q?LF?M(7'C6__8\U?_@D/X7_
M ."C?C_X+>$_'OC7X<^%?BS\6?CPVCZ7X=_X2U?!VJZ!K>IZ=\-K>]\,^)?!
M,US=:7JFBZW%KUA&(=%USQ%IOB+YK^+G[.O[?O[-/P<_X*R?\$?O@]^PQ^T3
M\6G_ ."D'[;'B_XV?LN_M6^"?"UGJ?[*WA3X1_'[5OAH?B!:?'CXK3ZK=+\+
M=8\#^"?A_)X8^R^);?[=K&N27^I6L=O8MX?N?$OW]^T;^SG\;O\ @EA^W_\
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M^R]X._X)X_&#XZ_LW_M#Z!JEQXQ_;1^&_COP_P#\(M\ /%.A/XKD\0:-\3O
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M!_P17)"*J G_ ()R?\%%,X4 #./C&!G YP!]*=_P_P!/^#IK_I"O_P"<Y/\
M@HI_\^2@#\_-4LO^"T?_  34_P""RO\ P3/_ &/_ -L3_@IM^T!\9_\ A=/Q
M\_8Y\>ZUH?P__;/_ &K?B+\+O$?PN^(/[5'_  J_5/!?C73/BBG@3^U_[8_X
M0CQ+9^(O#EWX9U7P[J'AW5+.WN+R]^VZAI]I_I_U_F :I>_\%H_^"E?_  65
M_P""9_[8'[8G_!,G]H#X,?\ "EOCY^QSX"UK7/A_^QA^U;\.OA=X<^%WP^_:
MH_X6AJGC3QKJ?Q1?QW_9']C_ /";^);SQ%XCN_$VE>'=/\.Z79W%Q9V7V+4-
M0N_]/^@#\Y_^"M'[*%Y^VG_P3R_:?^!'AY+I?B/J'P\O/'7P7O\ 3KZ^TK5M
M*^-_PKN;?XC_  EO=*UC2W34])NYO&_AG1],EO[ M<Q6&HWJ+%<)(]O+\$_M
M*_\ !136_B]_P0@\#?M'_!Z]MD^/O[=WPE^#_P"S3\&],L]233+NW_:@_:BU
M#3/@;K.D:-?6]L2NK?#3Q7JOCO7E>QL7DV^!+N>UL\(L:_T'5_+U^SE^P1^U
M-X=_X*8Z9\#O&OPXU[2O^"<'[''[5_[5W_!0/]G3Q]=S^&9/!/COQ]^U#X)\
M&O\ #7X,Z%I%K.WB*P7]G7XC?&;]JGQ':7]]86#2746@Q27VH6\,5SK8 _\
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M9^)_VQ_^#D_]DOPKJG[2'[6O_!)W]A?XE?LZ>!M#O_&_QE\(_ _4?"5A\3?
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MKQYX'\%?$( _3^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\P/VH/\
M@D-^QM^UY^W!^RA_P4"^,6B_$"Y^//[()T?_ (0.#P[X[OM#\"^,/^$)\6:E
M\1?A,/B+X=CM;B]O1\(/B9K6M?$#PC_PANM^"3XBUC5)]$^*Q^)'@6VTWPC8
M_I_7Y _MA?M@_P#!1SX._P#!1K]@O]G/]G']@K_A>_['7QV.K#]I?]I;^UM4
MC_X5?Y>J7=AKW_$^L+N#PE\&_P#A3GA*#3OBOGXKZ;KP_:H_M[_A1_P0_P"$
M<^(_AS5M6G /U^HHHH **** "BBB@ HHHH **** "BBB@ HHHH \A_:#^-7A
M;]FWX!_&_P#:*\<V'B#5?!/P#^$'Q*^-7C#2_"=KIU]XIU+PM\+/!FM>.?$%
MAX:LM8U70M)O/$%YI.A7=OHUKJFMZ-IUQJ,EM#>ZKIUL\MW#X[^P3^VO\*_^
M"B?[)_PJ_;%^"F@?$#PO\,OB\?'(\-:%\4M*\.:)X[L3\/\ XD>,/A?K/]N:
M9X3\5^-_#]M]IU_P5JMYIGV#Q/J?G:/<:?<77V*]EN=/M/L"N?\ "?A/PKX"
M\+>&O W@7PSX?\%^"?!F@:/X4\'^#O">C:=X<\+>%/"WAW3K?2/#_AKPUX>T
M>VL])T+0-"TFSM-+T?1M+M+73M,TZUM[*RMH+:"*)0#H**** "BBB@ K\M_C
MG^V+^V_\"8=!U37?V&O@YK/A_P 7?&3X;?!;PKJ.E_MLWZ7E]K_Q;^(&D_#O
MP1J6I:7=?LJ)_96F3:MK>G76M;;R^N-*LFN&ABU&6!8Y?U(KX _X**?\DW_9
MW_[/Y_8,_P#6H_AK0![S\#?&O[2_BZX\1K\?O@%\.?@I:6$.EMX8G\#_ +0-
M[\;+CQ%<7+WPU6*_M;CX+_"N/P]#ID<%B\,XN]7?47OWC6WM5LWDF^AJ** "
MBBB@ HHHH **** /S@^&W_!4#X!?%'_@I=^T#_P2N\/^$/C!9_M!_LX?!_1?
MC7XX\8ZQH'@NW^#6J^%==TGX):Q::?X4\0V7Q U#QM?>(([;X]>#X[FUU?X>
M:%IR3Z;XD6+59H[/2Y=8_1^N?MO"?A6S\5:QXZM/#/A^U\;>(O#_ (;\)^(/
M&-MHVG0>*M=\*^#=1\5ZQX/\,ZQXABMEU?4_#_A35_'?CC5/#>C7MY/IVA:C
MXR\5WVEVUK<^(M7EO.@H **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^>_
MV@O^:(_]G"?#;_W-5]"5\]_M!?\ -$?^SA/AM_[FJ^A*VG_!H?\ <3_TI'-2
M_P!XQ7K1_P#384445B=(4444 %%%% !1110!_%__ ,%:/VS])_X)T?\ !Q9^
MSM^UUXZ^!GQR^-'P\TK_ ()9V?PTGL/@EX/MO$FMP>(_%G[0/[1<EJXGUC4=
M$T.)+.UA#W\3ZO'?1VU];/';2QS\]#\6O^#L;]FWQ_\ "OXF>!-+_8$_X*)6
M>I^-?A]XS\(Z==W_ ,*O 2V-K?>)/#FI:-:7%ZUO\1[BX6T@N+V.6Y:"">80
MJYBAD?:C?UC_ !Z^,7A7]G?X&?&C]H'QVM^_@CX%_"?XB_&+QDFE6[7>IOX5
M^&7@_6/&OB%=.M%^:ZOVTC1+P6=NOS3W!CB'+5^*OPM_X*$?\%/?CG_P1M\5
M?\% ?AO^QK\-F_:G\6:Q8_%/]GK]G,^*;?6_"WBK]ER;Q_X+U0:_JVJS_$#P
MIJM_XKO?@0_CS5;&*'4O#_B+7?%EEH^HZ)\-U35=-\!W !L?\&Q>AZWX;_X(
M=?L1Z+XBT?5- UFR_P"&D_MFDZUI]WI>IVGVG]KSX^W=O]IL+Z&"Z@\^UG@N
M8?-B3S;>:*9-T<B,?WJKXG_X)R?MI>&/^"B'[$O[/?[9/A+PY=>#M.^-G@^]
MU+5/"%U=S:BWA/QIX3\3Z]\/_B)X8M=6N-.TB77-,\/^/_"?B72-'\0-I.F#
MQ!I5G9:TFGV27RVT?VQ0 45\^?M._M6?L\?L9?"F_P#C?^T_\5?#GP=^%>FZ
MQHOAZY\7^)EU*:T;7/$-R;31])M+'1K#5-7U&_O9$FD6VT_3[J2&SMKR_N%B
ML;*[N8=G]H+]H[X$_LI?"[7/C3^T=\5?!?P;^%OAR2TM]5\9^.=8@TC2DOM0
MD,.G:59*^^\U?6]3F#1:9H>D6M]J^I2J\=C97#HP ![517SO^SI^UK^S7^UO
M\)8_CK^S=\:/ GQ<^$INM5L+KQMX6U='TW1]1T.*.XUC3/$<&H)8ZEX8U33+
M2:WO[W3/$5EI=_;Z==V>HR6ZV-Y:W$WD/[-'_!3']@7]L?XB^,/A)^R_^U?\
M'?C9\1_ EA=ZOXA\)>"/$J7^I_V%I]_::7?^(]!\^"VMO&'ABQU#4=-L[SQ-
MX0N-<T"UGU32XY]1C.I6/V@ ^YJ*^$?B3_P4]_X)]?!_]H[0OV1OB9^UQ\%?
M!W[1_B'4= T6R^%.K>+(%U^RUWQ7%8W'A;P_XDN;>.?1?!_B'Q-;:KI%WX=T
M#Q9JFBZQKEIK.BW>F65U;:QIDMUW_P"UE^W/^R)^PKX3T#QM^UO\?OA]\"]
M\6:G<:/X4;QCJ4YUCQ5J%BMK)J</AGPQI%KJGB?Q!'H\=_82ZY=:/H]Y::'#
MJ%A-J\]E'>VK2@'U?17!?"[XI?#CXV?#WPC\6?A%XW\,_$CX:>/=%M?$7@WQ
MQX.U>SUWPWXCT:\#>3?:9J=C++;SH)$EM[B+<L]G>07%E=Q07=O/#'WM '\
M?_!C'_SE%_[LF_\ ?N*_O\K^ /\ X,8_^<HO_=DW_OW%?W^4 %%%% !1110
M4444 %%%% !1110 4444 %%%% !7C_Q(_:%^ 7P<\4_#'P-\7?CC\'_A7XV^
M-GB!O"?P9\'?$CXE^"_ _BGXN>*DU'P_H[^&?ACX>\3ZUI>K>/?$"ZMXL\+:
M6VC>%;35M174?$OA^Q-L+G6=.BN?8*^0/VC_ -@K]D[]K?XI_LQ_&K]H3X4_
M\+ ^)G[''Q D^*7[-_B7_A.OB3X4_P"%<^.Y?$7@#Q9)KO\ 8W@CQCX;\/\
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MIX1U:_O?#&D@'W!1110 4444 %? '_!13_DF_P"SO_V?S^P9_P"M1_#6OO\
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M9^)O%GAOP0_B"^\#:!K%LWA^_P#&*Z&/$(ET2._MY_Q@?X??ME_\$R_VTO\
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M?$WA^"#0-;TR"/T;]M[_ (*9_LS_ +!&J_"_P?\ %J/XK>/?BQ\:)=:;X7_
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MB@ HHHH **** "OS _;P\9?\%/\ PU^T;_P3JTS]A#X3_#_X@?LYZW^T!?\
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M_P#A'/\ A1GQ-^W?8O\ A6G]K?VW_;UI]I_MK[!_9$']F_;+_P#G_P#VBO\
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M"_\ ^$A\/_!'X,6NAZ)=7,7_  B^L:?\3]7O]7\6V7C[PIH7PK_3^@ HHHH
M**** "BBB@ HHHH **** "BBB@ KY!_;4_8,_90_X*(?"O0O@G^V)\*O^%P?
M#'PUX^TKXH:)X9_X3GXD_#_[%XZT3P]XI\*Z7KG]L_"[QAX)\07/V70?&GB:
MP_LR[U:?1YO[2^U7&GRWMGI]Q:_7U% 'X _\0N/_  0H_P"C&?\ S9G]L/\
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M"+PU>ZBL(U+4-%^'GA72O"FGZCJ9MT2%]3U"VTJ.]U&9% FO9YY3EG)/M-%
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M9:VF+H@'M]%?F!X*_P""C7Q/^(FM?$_P]X._X)=?M_ZQK'P9\?Q?"[XDV?\
MPF?_  3*T_\ X1OQU-X!\"?$^/0OM&J?\%'+&UUC=X&^)?@G7/[3T&?5-'']
MM?V8VH#6--U?3[#],].NI[W3[&]N=.O-'N;NSMKFXTG47T^74-+GGA2673KZ
M32;[5-*DO+*1VMKE],U/4=/>:)VL[Z[MS'<2 %RBBB@ KY ^,/[ ?[&WQ_\
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M]HK]IOP__P )O_PLSXR>&-'MM!T/QC_:OQ&\7ZWX-^PZ3:>&O"%O:?\ "/\
MP_U+PIX6N?+\.Z=Y]YH=Q<O]K>9KZY^N*\\^$OQ8^''QW^&7@3XR_"#Q?H_C
M[X8?$WPOH_C/P+XRT&6272O$/AO7;..^TW4+<3Q07=L[PRB.[T^_MK34M,O(
M[C3M3L[/4+6YMHO0Z "O@3_@H'_P4A_9Y_X)O> / 'C+XWV7Q.\:^)OC#\0M
M+^%/P3^"OP-\#R_$CXU?&7XB:N8Q:>%/A[X.&HZ+9ZAJ),]K#OU77-'LIM0U
M#2-#M+JYU_7=$TK4?ONO&?C1\,=.\<Z ?%&C?#KX.>-/C?\ #;2/%/B#]GC7
MOC)X3MO$&B>!?BO/HDJ>&=875H+&Y\5^%M+N=<M-%C\3ZEX*NM/\12:-;R+8
MW'VJ&UV 'RY^R?\ \%//V4/VN_V9_BC^U/X1\1^)_A=X&^ -_P#$#1/VDO"O
MQX\,R_#7XE_LX>)/A7HQ\0_$3PY\9/"<UWJL?AW4_"6AJ^HZI+INJ:YI(6&]
MM+;4[C4=-U.SL_G/]BW_ (+F_L;?MP?'+PY\ /!'A+]I7X/^+_BAX1\1?$']
MG#6?VD/@O=_"7P9^UCX!\)?VA-XD\8_LX:]=:[J[^.M(TC3=*U/6[J#4;'PY
MK!T;2]9OH=*E70-?73/YC/#VI^,?A)_P2N_X.;?V?/BQ#J=C_P %&O#_ ,;=
M>^-'[:.I>#KBTU7X,^,=._:C\:6NJZ9XI^ ELNC:5KVE?#76O $?C&^UK3/%
MFF#Q)H=AKMMJ6I7>E0ZA::!X8^[_ -HFRT7PQ\6_^#/*[^'46G6WB.PTC3O"
MGABUTV_\I7^$6L?LS?LY:;\0C9K#>P+J&F6/AIM/(N&FN51;Q852Z75Y[6]
M/U>^/_\ P7^_83_9R_:/\8_L^^,]%_:/\0:#\(O'7A'X8_M%?M0^ O@K?^)O
MV3?V9/B#XX>*'P[X2^./Q=_MNQF\/:M<W5Q;6%POA[PSXJMK'4WN]+N[F'4=
M%U^UTGZ*_;W_ ."K'[.?_!/S5/@WX)\;>#?C]^T!\:OV@HO%6H?!S]GG]DSX
M53_&KXT^.O#?@73K;6/&OB[3/#L>L^'=$M_#GAG1[K^U[NYU+Q)8WNHZ78ZY
M?^'[#6;7PUXDETG^4;X/6>E>)O\ @@=_P<LZQ\2TAF\4:K_P4M_;/U7Q+=:T
M%LM5N/%VCW?[.'B3PH=2A98'AOH?B)-)/8VKPQ;M8FFMDCWEHE^R/V!=;\;^
M+_\ @M__ ,$W-0^+GVF3Q5:?\&T7[.?B.UMM39S'8^,O$7B+1O\ A.+_ $AY
M9[C[=?7>JWWBNPU#4UN]2NKB*WN;.>_N(=-C%N ?U$?L>_M>_ G]NS]GKX?_
M +3O[.'BN3Q=\*_B+97<NEW=Y83Z/KFCZMI-]/I7B'POXGT6ZS<:/XD\.:Q:
M7>EZK9E[BU>6!;W2[W4M(N[#4KOX;_X*M_\ !:O]EC_@CY_PH7_AI?P#^T!X
MX_X:(_X6C_PA7_"B_"OPZ\3?V7_PJ3_A77_"2?\ "4_\)_\ %7X9?8OMO_"S
M=!_L3^R?[;^T_9-7^W_V;]GL_M_Q)_P;/SS0_"__ (*G>'])D$WPZ\,?\%C_
M -L;2?AZT=W)=VEGI?\ 9OPPN)M+TIGN95ATJ&WETO4X(H(8;>2[UB_O0\]Q
M>7#)S?\ P<A?$G]J?X>_\,:?\,T?\$E?V?\ _@J1_:__  T1_P )K_PO3]@W
MXB_MM_\ "C/[/_X49_PC?_"+?\(!?V7_  K+_A9OVW7O[;_M;S?^$T_X5]I'
MV#9_PB=YO /Y ?\ @V]_X+5_LL?\$?/^&R_^&E_ /[0'CC_AHC_AG?\ X0K_
M (47X5^'7B;^R_\ A4G_  O/_A)/^$I_X3_XJ_#+[%]M_P"%FZ#_ &)_9/\
M;?VG[)J_V_\ LW[/9_;_ /5[K_*$^!?_  5#_:G_ &H/^$I_X9H_X-P?^"0'
M[1'_  @_]B?\)K_PHO\ X(__ !%^+?\ PA__  DW]K_\(W_PE/\ P@'Q \0?
M\(__ ,)!_P (_KW]B?VM]D_M7^Q-7^P?:/[-O/)_U>Z "BBB@ HHHH ****
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MX*\*ZWHMAX@MM,U_0=1N-&NKV+48;'6](NY+9;?4K.2;^??_ (=B_P#!2?\
MZ1Z_MQ?^(F_'K_Y@:_T9_P#@I+_P7\_8Y_X)<?M(>!OV7_V@/AK^TQXP\?\
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M*:GJND10Z!8:UKUG=:]=6TUWJ-KI<=S/I^E:I=I%93>P5\V;!1110 5^$O\
MP<)_\$P?CY_P5D_8M^&_[.7[.GB[X0>"_&_@[]ISP5\:-3U7XU:_XS\.>%9_
M"WASX7?&;P1?6%A?>!? 'Q'U>77Y=5^(FB7%I:W&AVNG/I]KJDLVJP7,%I:7
MW[M44 ?YD/\ Q!H_\%<_^CGOV'?_  ]7[37_ -"[1_Q!H_\ !7/_ *.>_8=_
M\/5^TU_]"[7^F]17Z!_Q%CQ3_P"CE^('_B9<1?\ SR\E]QR_4<#_ - >%_\
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M#8G6= NK"QM_BO>Z?::WXO%M?1+"/Z"E5454151$4*B* JJJC"JJ@ *J@
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M^T?\4_VM_P!D[X4_M"?&O]F/X@?L;_$WX@?\)U_PDW[-_P 4I/$<OCOX<_\
M"*?$GQCX(T;^W9/%GP_^%WB!O^$O\/\ AO2O'FF?VAX$T+&C^*-/6U_M.R%M
MK&H?7] !7Y<_\%)/^":LW[=UY^SK\4?AE^T?\0/V1?VI_P!DCQWK7C_]GSX^
M>!_#VD_$'3?#VH^*--M-'\3Z3XY^$GB74=*\*_$G0-5TZQ@MX[#6+^RFLH)M
M9TI+N7PWXJ\8:#XA_4:B@#\:?V4O^"-'PL^#'P1_;:\ ?M&_%_QS^V)\7_\
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M#_E&[,_^RNX4_P#4JN?Z2U%%%?U4?X"A7Y _MA?L??\ !1SXQ?\ !1K]@O\
M:,_9Q_;U_P"%$?L=? DZL?VE_P!FG^R=4D_X6AYFJ7=_KW_$AL+2?PE\9/\
MA<?A*?3OA1CXKZEH(_97_L'_ (7A\$/^$C^(_B/5M)@_7ZOS _:@_P""O/[&
MW[(?[<'[*'_!/WXQ:U\0+;X\_M?'1_\ A Y_#O@2^USP+X/_ .$V\6:E\.OA
M,?B+XBCNK>]LA\7_ (F:+K7P_P#"/_"&Z)XV/AW6-+GUOXK#X;^!;G3?%U\
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M /9A'_!5[_U-OVPZ_P \_P 4?\BSXB_[ 6K_ /ION*_T,/\ @F5_RIQ?$?\
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MHO\ W9-_[]Q7]_E?P!_\&,?_ #E%_P"[)O\ W[BO[_* "BBB@ HHHH ****
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MBS_X*5_]F _MD?\ K.OQ&K_//_X)G?\ )D?P4_[J1_ZMOQ[7Y%XT?\DM@/\
ML?X7_P!5V:G^BG[,O_D_'%O_ &://O\ ULN C[NKRG]@'_E9R_X)O_\ 9"?C
MC_ZS[^VC7JU>4_L _P#*SE_P3?\ ^R$_''_UGW]M&OS+PC_Y+&C_ -B_'?\
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MVG_J7_MQUQ=?S)XT?\E3@/\ L087_P!6.:G^YG[,O_DP_%O_ &=S/O\ UC>
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MOPL'@SPAX0FLIOAOJWB[6-#MO#^CVOAO2-&GUZ[FL;&]NK#139I<+&/Z#Z*
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M\.:3;K::5H'AOP]IUOI.B:-IMJGR6UAIFFVEM96D"?+%;P1QKPHH Z.BBB@
MHHHH ^>_V@O^:(_]G"?#;_W-5]"5\]_M!?\ -$?^SA/AM_[FJ^A*VG_!H?\
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MM0NH+*S@\V5((O.N;F2*&+S9I8X8][KOED2-<NZ@_P">7X_^"&D?MO?L=_\
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M@_\ !X;_ ,I?_P!F;_LP/P#_ .KR_:UK^:VOZ4O^#PW_ )2__LS?]F!^ ?\
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M"OVHO^39OVBO^R%?%S_U /$%?XZY5_R-,M_[#\'_ .I%,_Z=^/\ _DA.-?\
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M0ZHNE>']<M?#Z0V?A'1/"LU]>&(WUE9ZI_4E10!^!_\ P1W_ ."<OC3X=?\
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M;?CVOR+QH_Y); ?]C_"_^J[-3_13]F7_ ,GXXM_[-'GW_K9<!'W=7E/[ /\
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MP!XR^*/Q$\2_V9K&M?\ "/>!? 'AW4?%GB[7/[&\.Z?JWB#5O[)\/Z3J%_\
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M)>)+2*1TE2.2YT;5[V%':.149PS(X!4_PM_LO?\ !/G]E?X'>.OV\_ NI_\
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M\<?_ %GW]M&O5J\I_8!_Y6<O^";_ /V0GXX_^L^_MHU^9>$?_)8T?^Q?CO\
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M ,%6_P#E%Q_P4F_[,%_;%_\ 6>/B+7WU7P+_ ,%6_P#E%Q_P4F_[,%_;%_\
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M(O\ KM^TQ_ZUW\>Z_H$K^Z3_ )3 HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@#Y[_:"_YHC_V<)\-O_<U7T)7SW^T%
M_P T1_[.$^&W_N:KZ$K:?\&A_P!Q/_2D<U+_ 'C%>M'_ --A1116)TA1110
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M$64VT!?RE /\TO\ X/#?^4O_ .S-_P!F!^ ?_5Y?M:U_-;7]*7_!X;_RE_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Y[_:"_P":(_\ 9PGPV_\
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MZ;XV\*:=<^,?#EMH?Q.2^E/B7PSHD_B70Y/"#:KH]A<:M!;V2?FK_P ."_\
M@Z:_Z34?^=&_^"BG_P YNO[SO /@#P-\*O!7A?X;_#/P?X:^'_P^\$:)8>&_
M!W@GP=HNG^'/"WACP_I<"VVG:-H6AZ3;VNG:7IUE BQ6]I9V\4,:CA<DD]=0
M!_ '_P &,?\ SE%_[LF_]^XK^_ROX _^#&/_ )RB_P#=DW_OW%?W^4 %%%%
M!1110 4444 %? '[%7_)9_\ @I]_V?\ Z=_ZP+^PE7W_ %\ ?L5?\EG_ ."G
MW_9_^G?^L"_L)4 ??]?YO?\ P=8_\IZ?^">__9N_[)W_ *V7^T37^D)7^;W_
M ,'6/_*>G_@GO_V;O^R=_P"ME_M$UP9K_P BO,O^P#&?^H]0^N\/_P#DO."?
M^RNX;_\ 5S@CT2O"/VI?^38_VC/^R$?%[_U7WB&O=Z\(_:E_Y-C_ &C/^R$?
M%[_U7WB&OXFRG_D:Y9_V,,%_ZDTC_J$\0/\ D@^-O^R1XD_]4V-/ZN?^#7'_
M )04?L,_]W,_^MA_M!5^_P!7X _\&N/_ "@H_89_[N9_];#_ &@J_?ZO[H/^
M4T*^(/VJ/^">/[,'[9?QD_8W^._QW\*^(->^(?["OQ@O?C7\![W1O&/B#PWI
MUMXJO(-%NQI_BS2])NX+;Q'X?M?&W@OX8?$FVM6%GJ)\4_"_PUI-UJMS\/-=
M^)/@;QY]OU^8'[>'QQ_X*.?"G]HW_@G5X*_8K_9R^'_QJ^ WQQ_: O\ P!^V
M]X^\7:;JE_K'P'^%EG=>!O$:^-?#MYIWQ7^']EX7\WX9Z9\>+R#Q'XH\.>.?
M#EWX[\._#KP#:64GCKQYX'\%?$( _3^BBB@ HHHH *_S(O\ @\QT7_A(O^"L
M_P"SKH_VG[']L_8!^&W^D^3]H\O[/\?OVL+K_4^;!OW^1Y?^M7;NW?-MVG_3
M=K_,_P#^#PS_ )3!?LT?]F _#_\ ]7G^UO7Z_P#1[X6R+CGQ]\#^"N*<#_:G
M#/&'B_X:<+<1Y9]:QF"_M'(N(.-,ERG-\#]=R[$83,,)];R_%XC#_6L#B\+C
M,/[3VN%Q%&O"%2/GYM7JX;*LSQ-"7)6P^7XRO1GRQER5:6'J5*<N6:E"7+.*
M?+*,HNUI)JZ/Y._^%+?]3+_Y1O\ [ZU0U3X1_P!FZ9J.H_\ "0>=]@L+N]\G
M^R?+\W[+;R3^5YG]I2>7YGE[-^Q]N=VQL8/T'6%XH_Y%GQ%_V M7_P#3?<5_
MTV>(7[,[Z$>1\ \<9UE?@I]5S/)^$.)<TR[$_P#$2/%NO]7Q^7Y+C<7A*_L<
M1Q[6P];V.(HTZGLJ]*K1J<O)5IS@Y1?XSA.,N)*N+PM*IF7-"IB*%.<?J> 7
M-"=6,9*\<*FKIM7336Z:9_H8?\$T?^5-SXC_ /9@7_!6'_U.?VQZ_G._X)G?
M\F1_!3_NI'_JV_'M?T8_\$T?^5-SXC_]F!?\%8?_ %.?VQZ_G._X)G?\F1_!
M3_NI'_JV_'M?\:_C1_R2V _['^%_]5V:G^Q7[,O_ )/QQ;_V://O_6RX"/NZ
MO*?V ?\ E9R_X)O_ /9"?CC_ .L^_MHUZM7E/[ /_*SE_P $W_\ LA/QQ_\
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M?]@+5_\ TWW%?Z&'_!,K_E3B^(__ &81_P %7O\ U-OVPZ_SS_%'_(L^(O\
ML!:O_P"F^XK_ $,/^"97_*G%\1_^S"/^"KW_ *FW[8=?R#^V[_Y.EX'_ /9
M<1?^M%3/?\-O]QS+_L+I?^F3^57_ ((X?\FS>//^RZ^)/_4 ^&5?K/7Y,?\
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M/*#B*\*_:B_Y-F_:*_[(5\7/_4 \05[K7A7[47_)LW[17_9"OBY_Z@'B"O\
M'7*O^1IEO_8?@_\ U(IG_3OQ_P#\D)QK_P!DEQ'_ .J?&G]6/_!K;_R@K_8B
M_P"NW[3'_K7?Q[K^@2OY^_\ @UM_Y05_L1?]=OVF/_6N_CW7] E?W2?\I@44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0!\]_M!?\T1_[.$^&W_N:KZ$KY[_ &@O^:(_]G"?#;_W-5]"5M/^#0_[B?\
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M_P#V;O\ LG?^ME_M$U^<'_!NE_RG]_8+_P"P%^TA_P"LE_M*U^C_ /P=8_\
M*>G_ ()[_P#9N_[)W_K9?[1-?X(?3"\..&?"+QV\;/#7@VEC*/"_!V>9GE&2
MTLPQ<\?C88.GEM&M&.(QDXPGB*G/6G>I**;5E;0_?O"/%UL?Q+X=8S$.+KXC
MB;AFI4<(J,7)YUA$[16B6FQZ)7A'[4O_ ";'^T9_V0CXO?\ JOO$->[UX1^U
M+_R;'^T9_P!D(^+W_JOO$-?Y1Y3_ ,C7+/\ L88+_P!2:1_U,^('_)!\;?\
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M;1K\R\(_^2QH_P#8OQW_ *1 _N;]HA_RC=F?_97<*?\ J57/]):BBBOZJ/\
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M-</^4%/[#G^]^TS_ .M@_M 5_*3^U)_R;+^T7_V0GXN_^J_\0U_5M_P:X?\
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MZ590^;Y/G0>9;R12R?Z*O_!5[_E%M_P4H_[,#_;&_P#6=_B-7^=1_P $W/\
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M;7]*7_!X;_RE_P#V9O\ LP/P#_ZO+]K6OYK:_P"U?]BM_P HL\??]G_XI_\
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M_?N*_O\ *_@#_P"#&/\ YRB_]V3?^_<5_?Y0 4444 %? '_!1_\ Y(Q\%?\
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M_BKX>6VE7]W>>$]5M[K3DUFQLI+345COK+\T?^#PS_E,%^S1_P!F _#_ /\
M5Y_M;UL_\$[?^5FG_@G#_P!D0^.G_K/7[9=8W_!X9_RF"_9H_P"S ?A__P"K
MS_:WK_47Z!'%6(XW\;?HB<68K"4<#B,]\;?!C'5<)AYSJ4:$Y^).00=.G.I:
M<HI03O+6[9_<7 ?&F*\1?!W*>-\;@L/EV*XDX3QF8U\#A:E2KA\-.='%TW3I
M5*MJDX)4TTYZW;/YKZPO%'_(L^(O^P%J_P#Z;[BMVL+Q1_R+/B+_ + 6K_\
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MC7[!?_#&W_#/_P#P[HSJW_#:O_"=?V%_PF&/[4N_^$J_X2'^U?\ BO\ '_"
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M_$O_ *C43*_X/#?^4O\ ^S-_V8'X!_\ 5Y?M:U_-;7]*7_!X;_RE_P#V9O\
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M444 %%%% !1110 4444 %%%% !7\T7@V2ZU[_@[.^+"^(XWNHO!7_!&#38_
M+7J2*NFVMU^TO\-);R32&?:LB27OBWQI%*\7F1B34-3C.)8Y"G]+M?C1^W[_
M ,$M_BO^T/\ M-?"_P#;D_8P_:^O_P!A_P#;"\!?"#Q3^SMXB^)!^$'AGXX>
M%OB)\#O%&H7VN0>&M;\$>*=8T73K/Q#X0\4:G>>)_#'B4OJ:_;!;6FH:7,+#
M1[[20#\X/^#?+XF>,/@?_P $I/\ @H[XI^&?PIU7XQZ;^S!^VG_P4$O?V9?@
MMX!EU ZK\7?#'PZ\#^$?B#X-^&/@2;0='\93F^\<^.[K7?!OAN7PMX0U@_;M
M0MGTWPMK=]NAU/SC_B([_P""IO\ TK'_ +?_ /X,?VBO_H :_H<_X)S_ +"G
MP[_X)P_LD?#3]E+X<>(M?\;VG@S^WM=\7?$7Q4D<7B3XC_$3QGK5YXE\;>-=
M5M89KJ+3QJNM7\T6DZ2+S49-&T"STG2;K5]:O+*XUB_^X: /\P3_ ((8_&S_
M (*F_P#!%S_AJ+_C1C^W_P#M)_\ #2?_  I+_FD?[17P=_X0O_A3O_"W/^K7
M?BG_ ,)'_P )'_PM/_J!?V1_87_,4_M3_B7?O]_Q$=_\%3?^E8_]O_\ \&/[
M17_T -?U^T4 ?R!?\1'?_!4W_I6/_;__ /!C^T5_] #1_P 1'?\ P5-_Z5C_
M -O_ /\ !C^T5_\ 0 U_7[10!_EZ_P#!1KXO_P#!4W_@H!_P4/\ @=^WM_PX
MU_;_ /A+_P *9_9_M_@7_P *I_X5!^T5X\_X23R-:^.6K_\ "4_\)U_PR_X,
M_L?=_P +G^S_ -B?\(=JFW_A&_._M<_VQY6E<I_PG'_!4W_I"'^W_P#^&7_:
M*_\ H9Z_U-:*_+^-O!CPU\1<UP^=\9<-_P!L9GA<OI950Q/]L9_E_L\!0Q.+
MQ=*A['*LTP.'ERXC'8JI[6=*5:7M>251PA3C#\;\0_H_^$?BMG6%XBX^X2_M
M[.,%E=#)<-C/[>XFROV>68?%XW'4<-]7R7.LNPL^3%9CC*OMJE">(E[;DG5E
M3ITH0_RD?B=+_P %3?B/\-?B'\//^'*O[?\ HW_">>!O%G@S^V/^%%_M%:C_
M &5_PE&@:AH?]I?V?_PSC8_;OL/V[[5]C^VV?VKRO(^U6^_SD^D_@%_P5E_;
M0_94_P"":-M_P0'\0_\ !'G]I_4OV@_B[^S!^UU\./ MUK-U\5O!?QE\4^%?
MVE-6_:*\27GQ.\)_LM7W[,&J>-O%7A_X>6WB?QB+E='\6S:=K\'PS\37DOB#
MP[';ZHFA_P"FW7\@7[9'_*Y)_P $G?\ LP#XC_\ J#?\%+*]C@?PWX+\-\+C
ML%P7DW]C87,L13Q6-I?VCFN8^VKTJ;HTZG/FN.QU2GRTWR\M*=.#WE%RU/>\
M.?"7P^\)L%F67>'_  __ &!@\WQ5+&YA1_M7.\U^L8FA2="E5]IG>99E5I<M
M)N')0G2IR^*4'+4_A:\-?\$[/^"IOAW1++1_^'6_[?\ >?8_M/\ I/\ PR3^
MT5;^9]HNY[K_ %/_  JF?9L\_P O_6MNV[OEW;1N_P## W_!4W_I%=^W_P#^
M(G_M%?\ SI*_VA:*_P!%N$_VCOTS>!N%>&N"N%O&3^R^&>#^'\FX6X<RS_B'
MGA5C?[.R+A_+L-E.48'Z[F/ V+S#%_5,OPF'P_UK'8O%8S$>S]KBL16KSG4E
M]#7X0X=Q->MB:^7<];$5:E>M/ZWCH\]6K.52I+EAB8PCS3DWRQC&*O:*2LC_
M ",/^"=/PL_X*F_L!_M__ 7]N?\ X<Z?M_\ Q9_X4A8?$BR_X5=_PSM^T5X$
M_P"$G_X6#\)?B7\+O-_X3;_A0?C+^Q?[(_X6)_;NS_A$=6^W_P!C_P!F;[+^
MT/[0L?I#_@JQXO\ ^"IO_!3C]O3]GO\ ;>_X<C?M_P#P1_X4/\._A/X!_P"%
M8_\ "E?VBOB3_P )5_PJ_P",OQ%^+G]K?\)I_P ,T^ ?[#_MS_A/O^$?^P?\
M(GK']F?V3_:WVS4/M_\ 9MG_ *G]%?R;XB<<<4^*_%O$O'7'^:?V_P 5<88R
MMC^(\T^I9=E7]HXNO1A0JU?J.2X3+LNPG/2IPA[/ X/"THVYHPC)N3^IR6K4
MX=KY9B<GE]3K9/B<+B\MG98CZMB,'7AB<-4Y<4J\*WLZU.$^2O&K"=N6I&<&
MXO\ RXO^%G?\%3?^D'G[?_\ X9S]HK_Z&.N#^*>L?\%3?B7\,?B-\./^')_[
M?^B_\)_X#\7^"?[9_P"%'_M%:E_9/_"5>']0T+^T_P"SO^&;K#[?]@^W_:OL
M7VZR^U>5Y'VNW\SSD_U6:*_&:/AKP30JTJ]+)>2K1J0JTY?VCFTN6I3DIPER
MRQ[B[2BG:2<7:S36A_5.8?3=^D_FF QV68_Q.]O@<QP>)P&-H?ZE^'M+VV$Q
ME&>'Q%+VM'A.G6I^THU)P]I2J4ZD+\U.<9)27\ ?_!+C_@JI_P %3?\ @FO^
MPG\#/V*?^(>#]O\ ^-'_  I?_A9O_%R_^$9_:*^'/_"2_P#"Q?C%\0?BS_R)
MO_#%_CO^Q_['_P"$[_L#_D:]5_M#^RO[5_T'[=_9MG]__P#$1W_P5-_Z5C_V
M_P#_ ,&/[17_ - #7]?M%?='\I'\@7_$1W_P5-_Z5C_V_P#_ ,&/[17_ - #
M7@'QA_X+(_M?_M ^._@+\3OC7_P:3_M?_$WQ_P#LO_$"[^*7P!\6>+K']H#5
M=8^&'CN]T>;1I]=\.W,W_!/_ /[!7B"#3-06]T>U\=^$/AU\1[73X?'_ ,,O
MA[XE\,_V^44 ?R!?\1'?_!4W_I6/_;__ /!C^T5_] #7@'[6'_!<C_@J;^U!
M^RS^TK^S3_Q#;_M_^!_^&A_@!\9/@9_PFOV3]HKQ-_PA_P#PMKX=>(_ /_"4
M?\(Y_P ,,>'_ /A(/^$?_P"$@_M;^Q/[>T3^U?LGV#^U]-^T?;(?[?** /\
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M  X(_;_\8?\ "0? #]K#X&?\- ?\*^_:*\/_ &3_ (:@USXR:U_PE'_"JO\
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MY_E_ZUMVW=\N[:/ZII/^5ZQ/^ _^N?C7]_E?VOX*^/7BQ]'?BK,.-?!WBO\
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MR'/@\KP-'V%/$0PT?8>TA1C5JUIU/\J?XI:Q_P %3?B5\,OB+\.?^')W[?\
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M[2OA;_A@;_@J;_TBN_;_ /\ Q$_]HK_YTE?Z0G_!K?\ \H*?V'?]_P#:9_\
M6O\ X_U_0#7][^"OTR_I)_1WX5S#@KP=\2/]3^&<TX@Q7%..RS_4_@+B#V^>
MXW+LJRG%8[Z[Q3PMG>84O:Y?DF5X?ZK1Q=/!P^J^UIX>%>MB*E7]4S+A[)\W
MKPQ&88/ZQ6ITE1A/ZQBJ5J49SJ*/+0KTH.TZDWS.+EK9NR27^+7JG_!/G_@J
M;J6F:CIW_#K/]O\ A^WV%W9>=_PR9^T5)Y7VJWD@\WR_^%31^9Y?F;]F]-V-
MN]<Y']#'[,O[<'_!4W]G/_@CAXD_X)+?\."/V_\ QC_PD'P#_:O^!_\ PO\
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MV;_PMS^U/L?_  @^M?;/^$?^P_:K7^UOM>F_TF?\1'?_  5-_P"E8_\ ;_\
M_!C^T5_] #7]?M%?38# 83*\'A\OP-+V&$PM-4J%'VE6K[.FFVH^TK3J59:M
MN\YR>NY^&<7<6\0<=\2YQQ?Q5F']J\19_BY8[-LP^J8+ _6\5*$*<JOU3+<-
M@\#0O"G!<F&PU&FK74$VV_Y O^(CO_@J;_TK'_M__P#@Q_:*_P#H :/^(CO_
M (*F_P#2L?\ M_\ _@Q_:*_^@!K^OVBNP^</Y O^(CO_ (*F_P#2L?\ M_\
M_@Q_:*_^@!H_XB._^"IO_2L?^W__ .#']HK_ .@!K^OVB@#_ "]O^"COQ@_X
M*F_\% O^"A?P,_;R_P"'&O[?_P )/^%+_ .#X'_\*J_X5!^T5X]_X27R=:^-
MNL?\)/\ \)S_ ,,O^#/[&W?\+C^S_P!B_P#"'ZKC_A'/._M8_P!K^5I?)_\
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MSM^T5X$_X2?_ (3_ .%'Q(^&'F?\)M_PH/QE_8O]D_\ "P?[<V?\(CJWV_\
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M;X',<)B<#C*'^I?A[2]MA<71GA\12]I1X3IUJ?M*-2<.>E4A4A?FA.,DI+^
M#_@EM_P51_X*F_\ !-7]A7X(?L5_\0\/[?\ \:?^%-O\3'_X67_PC/[17PY_
MX2/_ (6+\7O'WQ5Q_P (;_PQ?X[_ +'_ +'_ .$X_L'/_"5:I_:']E_VIBQ^
MV_V=:?H%_P 1'?\ P5-_Z5C_ -O_ /\ !C^T5_\ 0 U_7[17W1_*0U&+(C%2
MA958J>JD@$J<@'*DX.0.G04ZBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** /GO]H+_FB/_9PGPV_]S5?0E?/?[07_ #1'
M_LX3X;?^YJOH2MI_P:'_ '$_]*1S4O\ >,5ZT?\ TV%%%%8G2%%%% !1110
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M44 %%%% !1110 5X ?V3OV6&^.H_:C;]FG]G\_M,C&/VBC\&_AT?CJ,>$/\
MA7PQ\7#X<_X3\8\ _P#%#C'B#CPA_P 4U_R!?]"KT'XI?%/X<?!'X=^,/BU\
M7?&WAOX<_#3P!H=YXD\9^-_%VJ6VC>'O#NBV*@SWVHZA=ND4:EVCM[:!"]S>
MWD]O8V4-Q>7,$$GBG[(G[;O[*7[>?PP?XQ?LC?&SPI\:_A_;ZK-H6IZGX?CU
MG2=7\/:Y!%%<MHWBSP?XKTO0/&?A#5I+.>WO[;3O%'A_2+R[TVZM=2M89K&Z
MM[B0 ^J:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MT[PAX>L;RS\0^)M?TG7K;6)KNYN+:ZM+G3-+6UU( _+#]JK]OGXX_P#!7/\
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M? MGX/U?2OB1;_#,66N^&YA+\-OZG?AUX(L?".BPW=SX9^'VA^._$-AI%_\
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MWC+0/BE/HX!]5?MB_P##77_!-;4]*_:U_:!^#_C[XV?\$EOVV/V=OA)\$/\
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M8?A_^S!\=OV4-!^*NL?&KPW\9_@KXKN[5-6_:!L;'Q-K7BGQ?;VOPHL]>O\
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M &A:YK.I:#\,O DVOR1ZI+X.\ Z;X>T"1].\/6+V3:3X2\):?H?Z(T %%%%
M!1110 4444 %%%% !1110 445^2__!;7XW_M=_LT?\$_OB!^T)^Q//9/\9O@
M[X]^$'C:Y\/W?@+Q/\2V\<> [3XBZ#8^,/ D?A+PEH>MZK=V?BFSU"#3?$M\
MK^'ET;P;)XDU>W\9>#M2LK#Q'IP G_!9_P 7_L(:)^R#HO@G_@H3X8\:^/\
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M?B3X/\"?%.'2O#VL^*/ACX@U&QA\/ZUK_A"?3!J]M;G2M:@\"_&#P'J&D>!
M#X@_9W_X)E?\%,?VY?B!\$? O_!>OPG^S)\6?V:?V'=%\11?"^'P?K>H^(O&
M?[6GQAOM0\(P^%_BY\5-5T?6+&67PCX9\*^'[[3=2T'6-&^'<OQ!O]0NX/B/
M\-_%NGZQ>7=C_5[%%%!%'!#&D,,,:10Q1(L<<44:A(XXT4!41$ 5$4!54
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M7>K:S'X:A\5^'X?#MUX.N/$(\277A+0/%EK=:3HUQ9M\+)_B5\$OB!X+\/\
MA#Z$_P""<%[\=O\ @@E^VKH?_!)SXX>&O'_QS_8<_;0^*5_XC_8%_:J\)^$]
M6\2ZSX5\?ZSI5E;ZO\)?C!I7ANQOH[6SM](T+3KCQ!KNEPVFF>!OL$WQ.O\
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MP=\,?!>A7FH^$?!_VW5+,6E\FD:QXGTSPY:'4_"?PVU30OAY>G0I_P!@J**
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MB^TZAJ%U=ZEJ-T9K[4;NZOKBXN)?1*** "BBB@ HHHH **** "BBB@ HHHH
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MK^Q3\2_CSIGC35?^"@/BOXD^*_$?@#]H/]K#]H[X5^.1\0#H'A+PP8;OP_\
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MMS>?#WXH:9X?\%^#=>\;>(O"L_B+QDVKP.^%7_!9>;_@J1\#-&_8G_X*Z_\
M!.7XG?%SX._M"?$Z]^"?P7_;A_8V^$_Q'U;X7^+OC'H.IZMX>T3QG\+K/Q;H
M37&F^-_#=Q;76K3>(OA]XHUZZ>QN=9L/$7P?TCPE-XA\/3?J=_P=4_L Z]^U
M5^QS\+?VB/A;\-?$7Q3^,G[)'Q3TBZD^'G@:Q\1WOCCXJ?!3XR:MH/@#XF_#
M30;?P;%-XGN[O4M5D\%ZHW]FVNH7=AX=L/%QL+3S=0N&;^C?X!_#_P "_"OX
M)_"GX=_#/X96_P %_ 7A'P#X7T;PM\)[:UT^T'P]TJWTBU,/A.ZBTJ^U.PDU
M+1F9[35KNWU351?ZG'=WSZIJ4MP][. ?G1_P2F_X)<^*/^"</A#XAZ;\2OVR
MOCC^VGXO\:WG@33/#WB#XNW.M6'AGX7?#GX4>&M5\&_#;P=\._ 6J^-O'MGX
M:U#3_"^LW>E>)O$NFZO:OXDM(-*L5TK2[+3!#=?KG110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% 'SW^T%_S1'_LX3X;?^YJOH2OF_P#:#U"P&H? W23>6HU2
M;X[_  ]U*+3O/B^W2:?:S:G;W%\EKN\YK2">ZMX9;@)Y22SQ1LX9P#](5M4_
M@T/^XG_I2.:DT\1BK/9T4_)^S6@4445B=(4444 %%%% !1110 4444 %%%%
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M/\->+?\ @IQXS^,GQ%TJ7PQ^U_\ MB?%G4/AY:6W['?PB^&OQ472O#V@Z/\
M#;Q/\1VLOB/\31/X^C\.>%Y?#%I\$YO$/CN32/%/BK^NW]BS_@F!\$/V;OVM
M/C'^WQ^S[XB^*7P;\+_MB_"WP9JWCS]C>Q.C:)\#]%^)6IO;^)-9^)%QX4@T
M\W-CXT"2)9V6EV$VG67A75-=^)+6\E]I7BS3=$\* 'U)^P#\7_VL/CS^S3X8
M^*_[9O[.VC?LJ_&3QAXC\<ZC;_ [3?$]QXKU3P;\.3XLU6/X9V_C34)HXUA\
M<W'@U=*F\36\(M1->M_:5SH'@C4-0O/ 7A;[1HHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBO._B!\4?"GPXM(7UNZFN=7OP5T3PSI4)O\ Q%KMP6$:0:;IT1\Q
ME>4B,W,QAM4<[&F\TI&]1C*<E&*<I/1)*[_KN]EU)G.%.+G.2A&.\I.R7_!;
MT26K>BNST"66*"*2>>2.&&&-Y9II76.***-2\DDDCD)''&@+.[$*J@LQ !-?
M.FJ_%SQ%X\U&Z\+? K3K?6'MI4M]8^)6JHP\%:#N.)4TXE=_B+4XTPT45JDM
MH"T<VR]M3*\=6+P)X_\ C%-'J7Q9FF\(^!Q,MQIWPKT6]=+O4H,!X7\<:U;/
M%+.Q^5FTFU\I8FVEEL+J&02_1.E:3IFA:=::1HUA::7IEA"L%G86,$=M:V\2
MY(2*&)51<DEF.-SNS.Y9V9CK:G2WM5J=D[TH/^\U_$:[1?)W<M8G->MB/AYL
M/0?VFK5ZJ_NI_P "+U]Z7[UZ6C3?O'F7@#X/:%X,O)O$FJ7EYXR\?7ZM_:?C
M7Q ?M&HN7)+6^E6[O+#HM@@)CBMK,^8(,027$D*1QIZ[1164IRF^:3;>WHNB
M26B2Z)))=$=%.G"E'DIQ48W;LMVWO*3=W*3ZRDVWU;"BBBI+"BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HK \5>*O#?@;PQXB\:^,M=TKPOX1\(Z'JO
MB7Q1XEUV^M],T7P_X>T.QGU/6-:U?4;MXK6PTW3-/MKB]O;NXD2&WMH9)9'5
M$)'P1_P44_X*-?#;]@7]BO5OVPX-!7XZVNM7/P]\._ _P5X+\5Z/IEK\:?&O
MQ;O[&R^'6FZ+XYDAU?1M/\-ZM9WLGBB_\56UGKB6_A'3=2U72=+UV[6RTV]
M/R(_X*X_\%E_VTO^"1W[2'Q-U'XK?L_:!\0/V)?C3^SQ?Z7^Q;\7?!6F7]TO
M@;]L#POX/\8ZM;^"/C_<W-_:M-%XY\3?V?->:393Z5"?AEH^D^(?AY+KFO>'
M?C%8Z?\  _QV\2_MS?\ !-M/#FM?\%C/B'X?_P""P7_!);]MOPGI/A7X\_&#
M3/A?I*ZK^R+X]^)BZ;=-J_@W3O"Z7%U:?"'5KIM#N/"VK>#-0T.QUJZT+1];
M^'^B_#;XD:3X4\,_$/1^/_Q__;+_ &8/B[\0?@3_ ,'#O@/X;_$[_@EA_P %
M3/&NIV&@>)_!_C9_B+HW[#/Q"N;&UU?P5\-$\9Z+\-?A?K5CIO@.TT+09H=6
ML_"YNM-U/PK<?&?P9XW\4>)-$^)DOBC]@/\ @DK^P3^TO^S5\*/VD_V(_P!I
MWX@_"/\ ;2_X)ERC0K7]ASQ)XYEL/B%XW\7? ;Q]H,FJ:[\-OB)HDMMJG@/6
MOA7H-A>Z/I7A.!M\%Q?#Q)<^'+2#X<:EX+T'PN >=?\ !*3_ ()7?M/_ +&/
MQE\-Z_X"_P""F'B'XT?\$H_"_A3QQXN_8[_9QTR#2=8?Q!H7[0=GHWB*SNOB
M/XW31O[/\2>#O!L*6GB3X::AX6UB[M]3U?4;KQ-X?LOASI?BOQ]X9\<?T<U%
M!!#;0PVUM#%;V]O%'!!!!&D4,$,2".*&&*,*D<4:*J1QHJHB*%4  "I: "BB
MB@ HHHH **** "BBB@ HHHH *R/$'B#0?">A:SXI\5:WI'AGPSX<TN_USQ#X
MB\0:E9:-H6@Z)I5K+?:IK&LZOJ,UMI^EZ7IME!->7^H7UQ!:6=K#+<7$T<4;
MN,:U^(7@*^\=ZS\+K+QMX2O/B9X<\,Z%XU\0?#RV\1:1/XWT/P=XHU'6]'\-
M>*]7\*Q7C:YIWASQ!JWAKQ%IFBZW=V,.FZGJ&A:O9V5S-<:==QQ?D3_P<)?!
M#X]_M!_\$E?VI?AY^SEHVK>,/'L=EX"\::G\-M AURXUOXJ> /A[\1?"_C3Q
M]\/-+M?#$]KXGU*\USPSHE],F@>'+F'7/%BV+^$],9[K7(XI #^9#_@K-\$O
M"G_!0S]LGX@_\%"O^"17Q@^ O[6MA\(_A?\ !7Q=^W%^RE\%OC[\2="^./[6
M,?[/_P 7_".M6-G-\.?"#:+>^-O!&A^"_ OP\;3O$/@O7HM9FUKP'X?_ .%<
M6FL?%&S\("Y_1%?V7/@Y_P %F?#'P$_X+!?\$3?CYX:_8"_;W\$6MC\-/BNT
M6AZ)>:$FFP^'H/"GB+X3_'KX=Z/H>LZ-/XR\$>&7M1\.?&-SX.U31?B#\/;;
MPUI6LZ/=:+%\._$'PQ_*#]C3]KKX)_&_]H_]FS]KO]A'X9_LS>#/^"DW[1'Q
MZ^$O[+'PP_8>^"GP(\2R^#_V$/\ @G]\.;S7$^/OQ)^(7C'3O"GPN\!>*?BA
MXW\&W6E6NO?'35=#UV72/A/K,O@+X::%;7.@>(KGX=_WE_ C]C?]E_\ 9C\;
M_'KXC_ /X*>!_A;XX_:=\?0?$[XZ^)/"VG/::A\0?&5M8O9P:AJ+RS31V%C%
M-=:SK<?A_18]-\/)XK\4^-?&"Z4/%'C7Q7JVL &_^RY\*O'OP._9T^"OP@^*
M?QE\4_M#?$CX<_#GPOX2\<?&_P :Q"'Q1\3O$^D:9!;:QXMU6)KG4+I)-3O5
ME>V&J:MKNNFR6V.O^(O$6MF_US4/>:** "BBB@ HHHH **** "BBB@ HHHH
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M?XHOM!\*^$+CP!_8-UJ/]5X  P!@#@ = /2FHB1JJ(JHB*J(B*%5$4 *JJ
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M4M=D\<^.(/#WC_XJV+V^B^,?B_\ T)_ 3X.?\%COVV[KXJ?L:_\ !;K]D_\
M85\7_L0>(_!4KZM\4/AAXFUNV\;>,O%=O=O)X9A\ Z=X=^)FJZQH.NZ%J]OI
MWB.#Q=J7@KX57GAN&V,VB:KKFK7 TRQ /QD_;#T7]HWX#V?[+WP*_P"#A?\
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M_#EG8:!I]EH\$>EO;$:?:P6S,T4:K7H] !1110 4444 %%%% !1110 4444
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M?2=%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 ?S"?\%$/^"3_P"U!\'/VX?A[_P5F_X(Z'PUX=_:
M4U7Q7X7\'_M:_LPZMJ>F^"?A3^T]X \5^+=*M?%7B_5;]XX-+T[67CEMM3^*
M\>H#S=5L-%M/BQX+NM-^+W@^2V^)?].-B]])96<FIV]K::B]K;OJ%K8WDNH6
M5M>M$C75O9W]Q8Z9/?6L,YDCM[R;3=/EN8E2:2RM7<P1VJ* "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***\T^(/Q
M6\+?#N*VM]1DN=5\1:GF/0O".AP-J/B+6;ALB*.VL8-SPPNXVF[N?*@R&6(S
M3!86J,93DHQ3E)[)*[_X9;M[):O0B=2%.+G4DH16[D[+R2[MO1)7;=DDVST6
MXN+>T@FNKN>&UMK>)YKBYN)4A@@AB4O)---(RQQ11H"SR.RHB@LQ !-?.6H_
M%;Q5\1[VY\.? NQBGM()1;ZO\4];MY%\+:41)LN(M MIHBWB/4XUR8]L;V:-
MY;O'-:3+=I%;?#KQS\7+B#6/C+<-H7A1)H;O2_A+H5Z_V=PF'AD\::O (IM3
MN5.UFL+9X[>)U5D:T<W%J_T7IVFZ?I%C:Z9I5E::;IUC"MO9V-C;Q6MI:P)P
MD4%O"J111KSA44#))ZDFM?W=+^6K4[;TH>O_ #]EZ?NT_P"=:'/^_P 1MS8>
MAWVQ%1>2U]A!]W>LUTI/4\U^'WPA\.>!+BXUN6:\\4^-M2,CZOXW\0,+O6[Q
MIL>;#:LY=-+L, 1QV=H0?)6..XGN?*1E]7HHK*4Y3;E)N3?5]NB2V271*R70
MZ*=.%**A3BH171=6]VV]92>[DVY-ZMMA1114EA1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110!^(O[:/_!%[P;^T#^W9^S/_P %'_V<
M?C!K'[('[6GPE^(/A9_C1\1? WAO3O$%O^T+\%M)TTZ)K'@OQ=X;U&>VT6;Q
MY<>%8(/ &C^/M6@UBU7P'>S^'_&'AKQK8^&_ %MX3_;JBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M *>T?_ _^ 'UG_J'Q/\ X*]/[WG^#['T)17SW_QE;_U;W_YD>C_C*W_JWO\
M\R/1['_I[1_\#_X ?6?^H?$_^"O3^]Y_@^Q]"45\]_\ &5O_ %;W_P"9'H_X
MRM_ZM[_\R/1['_I[1_\  _\ @!]9_P"H?$_^"O3^]Y_@^Q]"45\]_P#&5O\
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M?X/L?0E%?/?_ !E;_P!6]_\ F1Z/^,K?^K>__,CT>Q_Z>T?_  /_ ( ?6?\
MJ'Q/_@KT_O>?X/L?0E%?/?\ QE;_ -6]_P#F1Z/^,K?^K>__ #(]'L?^GM'_
M ,#_ . 'UG_J'Q/_ (*]/[WG^#['T)17SW_QE;_U;W_YD>C_ (RM_P"K>_\
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MQ/\ X*]/[WG^#['T)17SW_QE;_U;W_YD>C_C*W_JWO\ \R/1['_I[1_\#_X
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MUG_J'Q/_ (*]/[WG^#['T)17SW_QE;_U;W_YD>C_ (RM_P"K>_\ S(]'L?\
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M^"O3^]Y_@^Q]"45\]_\ &5O_ %;W_P"9'H_XRM_ZM[_\R/1['_I[1_\  _\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
K!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>img34756086_6.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img34756086_6.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &N A$# 2(  A$! Q$!_\0
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MH_X5S\>O^CC_ /S#_@S_ .3JT]E#_H(H_P#@.(_^4&/MZO\ T!8G_P #P?\
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M\H#V]7_H"Q/_ ('@_P#YK/H2BOGO_A7/QZ_Z./\ _,/^#/\ Y.H_X5S\>O\
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M_)U'_"N?CU_T<?\ ^8?\&?\ R=1[*'_011_\!Q'_ ,H#V]7_ * L3_X'@_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MQ>85<NA1A/ 8S&>WC5HX7%RG)2PJAR.$5:;ES723_K]_X?(_\$UO^CGM&_\
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M;'3]/@NM0U+4+IE,=I86%K<75S)\D43'..)_8U 7]DG]F95 51\!_A4 J@
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M4445B=(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M 5\(?\%0O^4=?[:?_9N'Q4_]1:_K[OKX0_X*A?\ *.O]M/\ [-P^*G_J+7]
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M%?\ R:7^SQ_V2?P?_P"FJ"OIZ@ HHHH **** $8X!.,X!./7 SBOXI?VD?\
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M^"?7@I$NKNVMG=?VE-99T6>=(F=%/P657=0^Y49D5B,%USFOY#O^&=?VA_\
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M]\9_#MS=75Q9:;!=,YTBV4K+D'D ]U\$= UO]K']N[]ESXU_!O\ X)Z_$/\
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M .Q%\1_^IWXGK]Q*_#O_ (-OO^4,'[$?_8B^(_\ U._$]?N)0 4444 %%%%
M'P'\$_\ D_G]M;_L2?V<?_4;\15]^5\!_!/_ )/Y_;6_[$G]G'_U&_$5??E
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M\.#QK)I;ZVGA#^V]-_X2=M&CD6%]6&@_:?[4_LQ976(WWV7[+YC!/-W<5TE
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M+_UT?_T(U_5/_P %W/\ DPJY_P"R\_ +_P!6%IU?RL3?ZV7_ *Z/_P"A&O\
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MI8_'/QI>2.)W7S'C1OABJM(J@LBEE4N &(4FOQVCP9XEQK4I2AF7)&K3E/\
MX6J;]Q3BY:?7=?=O_5C_ $CS'Z37T(*N7X^EA\3P5]8JX'%TZ'+X88Z$O;3P
M\X4N6;X67*^=PM*ZLU>ZLS^GC]CZYN;S]E']FV[O+FYO+NY^!OPMGN;N\N)K
MJ[N9Y?!>C/+/<W-P\D]Q/*[,\LTTCRR.S.[,Q)/JWQ(\/>)O%G@7Q1X;\&^,
M+GX?^)]:T>[T_1O&EE86^IWOAN]N(S'%JMG979%K/<VI/F0I.&BW@%T8#%<Y
M\!/ .J_"KX(?"+X9:[=V.H:U\/\ X;>"_!NK7VEF=M-O-1\-^'M/TB\N; W,
M4%P;.:>TDDMC/!#,8F0R1H^5'K5?U*?X+Q5DD]TDG\D?@/\ \$KO@Y#\ OVE
M?^"K/PM3QYX\^)=UHWBOX+ZKK7C_ .).LQZUXO\ $WB+Q!X*^(%YKFKWTUI:
MZ?IUG#<742RVNFZ986=G9(3%$A !'Y9?L>^%];O?AM\0[JT_X(E>&_VK(9OV
MA/CVR?&_4OB9HN@W7CA5^)_BA3,^FZGX$UZXA_L]A_9RE=1DC*VXS&I*X_J%
M^#G[)UA\)/CI^UM\:H?%MYK,W[5.H^ M0OM"FLH8(/"A\$:%XAT1(K2Y1C)>
MB_37FF=I0IB:W55R&-?F]X!_X)D_\%!?@A:>*O"7P#_X*=-\/OAEK'C_ ,;^
M.M"\(:A^S;\/O%-UX??QOXDU/Q+>Z=_;VIW/VV^@@O-4F$;3;> #@<8!GUW\
M2_V>?%7QH_8?\+_#'PG?^*_V%],NO!CZAX]^'?PLN=%O/$GA_P /KH>HR:M\
M,]*\47>D?8]-2>9H8;K6[+14N3 DD=M% TI=?A7]C?\ :B^%'_!.S_@BYHOQ
MC\9-J3^#?A5XD^-/A7PO87EW>ZOJVNZR?CIX[\.>#=*U/5)//N[BZU;4C80:
MGJLBNV^::Z,8'RC]C_@O\-?BYX7^"<?P]^.GQD'QL^(EQINLZ=K7Q-B\(:5X
M)_M*/4[5[6%D\-Z.[Z?:FS61V'EM^]+?-C KS_\ 9R_8\\"_!/\ 9QTO]G#Q
M:FE?%WPM8>)_'/B6X_X2_P /Z=>6%_-XR\?:_P".TAN-(NH[JS;^RKG7/LMO
M(R,S?94G^5VX /YO_P#@GI\<?@KK/_!9+1OB#XA_:W\ _&_XZ?M*?LQZY<^*
MT\,>)+F\\'^&/$5QKVCW_A7X,> -.FC6&V_X1G2#>W%V[-)=W^HW=_')+MMK
M>)?WJ_X*3_M8?%+]F#X3^"-/^ /AWPIXC^/_ ,<_B?X1^#OPEB\?->+X$T;Q
M!XKU2VL[CQ+XK6PN;&[N],T#39+K5#IMM?64NHR6JV8N[?SA(#P[_P $VO@;
MX._;<T+]LGP?X9\#^%K[P_\ "G4_ASI_@K0? 7A_3+.WU#4M1M+P^++;4+2W
MBEMM5AAMGM(VAB5EBG?:ZG%<'_P6 \ :+XV_9/EU&_\  OQY\3ZWX%\>^"?&
MOA'Q5^S39:1JGQ>^%GB30O$.G7NG?$#0M%U36]"?7M/T2:%;C7]"L+FXO=5T
M=+RRBL;LS>2X!\B_#C]LC_@HK\ _VT=6_9N_;6U;]GKXC>!- _9/^(7[0NG^
M._@IX,\2>"M2\6:MX3@EGN?#]SH.O^,O%LNAQ:9-;M##>/<W']IP743"WMG@
M<R];^RY\;_\ @L'\1U^!'[47CK1OV7?%/[,OQ\N;/6]8^!/@[0O$WAWXJ?!?
MX7^);*74/"OBN7XH:GXSUC0?&^L65N]D_B+2H/!>D)(LLWD26KH OQ)_P38^
M WQ]_:8_;M^(W[4/QI\;?M&_&3X2_P##-&K? 2_\=_M%?"33_@'%K4WBHWUO
M=Z'\.OA?'>-JUF;*Q<3>)=?U#1=+BU"[NHVM+B],+E/NSX?_ /!(+XQ^#8_"
M/PPU/_@H7\<_$?[*WPFN[S4O@_\  Y-'L=!U/1G6TNX/#7AWQE\1=.U9O$/C
M7P?X1EN89M+T755EM;@V=OYUO%MP #\W/^"A_CGPUJGP3_:V_;@\4W&IS>&-
M)_;*^!_PF\+WUC;7%W<7'PP^$'B'PWJFJW>AV<+HUU<WOBZ?Q/IQMX6_?&W"
M%B20/OGX<_\ !3;XT>)_V1OV@_\ @H0FD>#I?@GI2VW@+]FW]G^'3M0@^)=K
MXMCO]-T*#4_C7XDGU(P:=J5_J6J:?+<^$;+0=/N-$L5N/.U&Y^U6TD7U_P#$
M'_@FSX>\;_LE_#+]EJ'XAW^DVW@#XK:5\6;[Q?'HUI+>>(]>MOB+J/Q&U-+N
MQ:3R8TU#4=3GLA('9HK2.%0,(%'BO[1O_!/#P?X.TG]N#XAZ+I7Q$^)GPC_:
M;^&^GW_Q)_99^&L&A6&N77Q:\+SPRZ=\6OA9J.LZQHMAI/C)8WN[[4-/%]IL
M6LW%O9>9/+-:P+0!\SZ'^U9_P5R^"'[1/[!G@?\ :JUO]E'Q9\-OVP_%CV_B
M'_A5/P_\7>&/%'PTN[CPT?$B>!O.UKXA^);;7XM/C>+3V\3PVME%=W2O,MC'
M&?*']'E?QC?L=_"#]IW]IS]MK]A?Q)<_$_\ ;-^*/PK_ &0(M2O=<'[4?P/L
MO@;X>^&FE6GA6YTK1- GG74I;WXI_$[>+;P]?>)K.UU;3Y4'VL:W)"OF5_9S
M0 4444 %%%% 'SW^T%_S1'_LX3X;?^YJOH2OGO\ :"_YHC_V<)\-O_<U7T)6
MT_X-#_N)_P"E(YJ7^\8KUH_^FPHHHK$Z0HHHH **** "BBB@ HHHH **** /
MPJ_X+N?LD/\ '?X%_"KX\^&/VQO /["_Q4_9)\=:QXZ\"?'GXJ7EK9?#[3K?
MQKX:O/!7BG0=;N+J8""ZUG1;V2#2IK>QU:[%SOBMM.EEF2:#\]_^":G_  3M
M_95O_B?_ ,$V]7\"_P#!0WP5^T%\._V3?A#X]^-/PM^"GA0MHDOQ>_:$\6>)
M-1TOXB?M.0Z/J%];7=SX=T:ZOWT+3G32=3U%%M;47.J65G+/!-]6_P#!PO\
M!'XE>/?!_P"QG\9K+]G/QI^V1^SO^S5^T)<_$7]IO]E?P"=2O_$7Q)\$7?A>
M[TK1M7M_"NFP7DOBZ'P;K;IJ\^D_8+Y@G[WR4A\Z:/\ "'_@D[X5^*?[5G[5
M?_!-:V^#'[$'QT_9N\/_ +"/Q+_:&\<_&K]I#XC^%?$7PY\+ZG\&O'VM^(M1
M\)?LY>';&ZM-.TW6(R^JV44^E0&_O;6YB9Y;2TT:)KM #_0.K^-+_@L__P $
ME/VG[S]H#1_V\)_^"U7BK]E[]F#X=_$S4OB3'#\:_$/Q*U&Y_9 OM8\,'1;G
M4_V:$T+QC_Q6FM^([L2:/IW@.)_AMJ5II5[=16_BKQ 5333_ &6U_-E_P<A_
M"OQQXB^%_P"Q?\=6^"WBO]I+]G']EO\ :AT[XK_M5_ CP?#=:KJGC'X8C17L
M+;5IO"UNLL7B?3_">I;M4O;&]ADLX8G,]T\%MY\\8!^5W_!)3]F[X.?ML?MJ
M?!/XW:O_ ,'"/Q8_X*7:Q^Q]XIU#XJ>"_P!GOXC_  M^*?PH\26GB2*PETF+
MQ;IMG\9?BUXKU2^\-6JW976)_#/A65;R(0V]QK%G;%UE_N>K^&S]G_XY_LR_
M\%4_^"K_ /P3]^,/_!)_]D'QY\ / '[)VN>+_$O[5WQXF^$GA7X(>%=0\"7>
MCR6EO\'M1M/AWJ^J^'_$M_K\MQ"EM;ZGJ/\ ::>:5CTI]-MY;Q?[DZ "BBB@
M HHHH *^$/\ @J%_RCK_ &T_^S</BI_ZBU_7W?7PA_P5"_Y1U_MI_P#9N'Q4
M_P#46OZ /BK_ (-OO^4,'[$?_8B^(_\ U._$]?N)7X=_\&WW_*&#]B/_ +$7
MQ'_ZG?B>OW$H _.W]H;_ )2"?\$[?^P;^UG_ .JGTROT2K\[?VAO^4@G_!.W
M_L&_M9_^JGTROT2H *_SA(_^0Y\1_P#LMOQ\_P#5U^/:_P!'NO\ .$C_ .0Y
M\1_^RV_'S_U=?CVOXR^FU_R;SA;_ ++.C_ZH\Y/\_OVB/_)K."O^S@T/_6;X
M@+=?7/\ P3V_Y2 ?L<?]E3\0?^J_UZOD:OKG_@GM_P I /V./^RI^(/_ %7^
MO5_$O@1_R>+PY_[*? _E4/\ ._Z-?_)_/"?_ ++'+O\ TBL?V-?MK_\ )GG[
M4W_9OGQ?_P#4"UZO\8&P_P"/&R_Z]+;_ -$I7^S]^VO_ ,F>?M3?]F^?%_\
M]0+7J_Q@;#_CQLO^O2V_]$I7_<C^P[_Y''TBO^Q;X;?^I7&1_N!XE_P\H_QX
MS_TG#ENOZZ?^#/+_ )/0_:T_[-@T#_U:VB5_(M7]=/\ P9Y?\GH?M:?]FP:!
M_P"K6T2O[W_:L_\ *$7BA_V.?#G_ ->#PX?+<#?\E+@O^O>,_P#42L?U)?\
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MM<^.K/P[\1_AYI7AU)]6\+?%:?P$EQ=R:3? LNA6FN66H>'[G4O,2\L9Y/*
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M-9P5_P!G!H?^LWQ 6Z^N?^">W_*0#]CC_LJ?B#_U7^O5\C5]<_\ !/;_ )2
M?L<?]E3\0?\ JO\ 7J_B7P(_Y/%X<_\ 93X'\JA_G?\ 1K_Y/YX3_P#98Y=_
MZ16/[&OVU_\ DSS]J;_LWSXO_P#J!:]7^,#8?\>-E_UZ6W_HE*_V?OVU_P#D
MSS]J;_LWSXO_ /J!:]7^,#8?\>-E_P!>EM_Z)2O^Y']AW_R./I%?]BWPV_\
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MSD</?^J;B4_H:HHHK^H3_",**** "BBB@ HHHH **** "BBB@ HHHH ****
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M(_\ D.?$?_LMOQ\_]77X]K_1[K_.$C_Y#GQ'_P"RV_'S_P!77X]K^,OIM?\
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MQ:7LD?BO4/%6D>'K74= M+)8I8#J-E/;S1BX5$*^84/]:E?S#_ C_@K[\=_
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M?ZIU_P""=W[#"?M -^U0O[*7P-'[0[7PU5OBV/A]H'_"8G5Q&(AK/]H_9/\
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MMHE?WO\ M6?^4(O%#_L<^'/_ *\'AP^6X&_Y*7!?]>\9_P"HE8_J2_X+N?\
M)A5S_P!EY^ 7_JPM.K^5B;_6R_\ 71__ $(U_5/_ ,%W/^3"KG_LO/P"_P#5
MA:=7\K$W^ME_ZZ/_ .A&O^(WQK_Y'F3?]BJI_P"I=0_Z)OV8/_)L/$C_ ++S
M"_\ K/8$CK^B;_@W\_Y%3]L;_LM'@C_U7&GU_.S7]$W_  ;^?\BI^V-_V6CP
M1_ZKC3Z\_P '/^2LK_\ 8FQG_J3@3[#]I/\ \F RG_LY'#W_ *IN)3^AJBBB
MOZA/\(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*+GPF-+4Z9ILMY:^(YXIGTR6/5TO-&AXW]GS_@M)^UG_ ,%)_P!M/X/>"/\
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MC"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** /GO]H+_ )HC_P!G"?#;_P!S5?0E?/?[07_-$?\ LX3X;?\ N:KZ$K:?
M\&A_W$_]*1S4O]XQ7K1_]-A1116)TA1110 4444 %%%% !1110 4444 ?P^?
M\%6?V!/^"\7_  4YTCQ9\+OBC^R/^P%JOA'PQX_\277P+^+UCXTGT+XS>$/"
M$7B.[.@O9:Z^J71MWUSP]%IW_"1:1<V\^GW%TTDALH)U79]]?\$U_#?_  <9
M? K6/V7O@!^TC\+/V.+C]EKX?3:+X-^(_COP]XBL6^*,?PYTJQN+>&YT^P\/
M/I.AW>NVPCL8//AT19+T"2>\66YEEN3^(>O_  ]_:<_;B^&'_!3W_@J7XN_X
M*6?&_P""_P 8_P!E7X\_&;P_^S;\&/ /Q,NO#7@+P[X>^ ^O7<%MI%SX477+
M23RO$-G8PVL$6DVL"7MP]U<ZDNJ-,8%_M=_X)]_M+P_M _L<_LJ_$KQYXZ\'
MZC\4_B=\%O 'B+Q/:6>NZ*NH:CXGU+0;:34Y(]*@NQ.EW=7237$]K%;@Q3/*
M@C0(54 ^Z*_!?_@M-^S/^W!^V1X,_9(\5?\ !,[Q-\ X_BG^SY^T-=_%E?B1
MXZ\26R2^%-1\-:1/I-G:>%-7L-$\5V<OV_4VOM%\;:'=6AAO].0Z=>H"K"+]
MZ*_GM_:3_P"#>GX+^./B-XP^-7[&/[47[4G_  3J^+'Q!\177BWQW<?LX?$S
MQ+9?#CQAXHU&\FO]5\1:W\.7US3H!JNIW4\TMXNE:WIFD2/--*=),LTLC@'.
M?LN6_P#P<RP_M ?![_AK+4/V")_V<8O%^G#XTO\ #N?4CX[N/!2V]P-3?PRC
M^$["WCU=IOL\L(\^"+AXP8T;<G]#^C:_H7B*WN+OP_K>D:[:VE]=:9=7.C:E
M9ZG;VVI6+B.]T^XFLIIXX;ZSD(CNK21EN+=R%FC1CBOYD=!_X-V/C?XZU86O
M[7O_  68_P""@W[0?PUDMY;74/ACH7Q USX8Z1KMO+(K2VNN74/BSQ/;WMG=
M0[[:Z@&CQW!AD=8KV+*[?Z!/V8?V7/@5^QM\&?"OP _9R\!6'PX^%G@Y+DZ1
MX=L;O4M1D>]OY?M&J:MJ>JZS>:AJNJZOJMUNNM0U"_O)YYYFP&2)(XT /H"B
MBB@ HHHH *^$/^"H7_*.O]M/_LW#XJ?^HM?U]WU\(?\ !4+_ )1U_MI_]FX?
M%3_U%K^@#XJ_X-OO^4,'[$?_ &(OB/\ ]3OQ/7\ '_!U;_RF8^.__8D?"C_U
M%8J_O_\ ^#;[_E#!^Q'_ -B+XC_]3OQ/7\ '_!U;_P IF/CO_P!B1\*/_45B
MH _G*KWO]E3_ ).A_9N_[+W\'O\ U8?AVO!*][_94_Y.A_9N_P"R]_![_P!6
M'X=H _W?:_SA(_\ D.?$?_LMOQ\_]77X]K_1[K_.$C_Y#GQ'_P"RV_'S_P!7
M7X]K^,OIM?\ )O.%O^RSH_\ JCSD_P _OVB/_)K."O\ LX-#_P!9OB MU]<_
M\$]O^4@'[''_ &5/Q!_ZK_7J^1J^N?\ @GM_RD _8X_[*GX@_P#5?Z]7\2^!
M'_)XO#G_ +*? _E4/\[_ *-?_)_/"?\ [+'+O_2*Q_8U^VO_ ,F>?M3?]F^?
M%_\ ]0+7J_Q@;#_CQLO^O2V_]$I7^S]^VO\ \F>?M3?]F^?%_P#]0+7J_P 8
M&P_X\;+_ *]+;_T2E?\ <C^P[_Y''TBO^Q;X;?\ J5QD?[@>)?\ #RC_ !XS
M_P!)PY;K^NG_ (,\O^3T/VM/^S8- _\ 5K:)7\BU?UT_\&>7_)Z'[6G_ &;!
MH'_JUM$K^]_VK/\ RA%XH?\ 8Y\.?_7@\.'RW W_ "4N"_Z]XS_U$K']27_!
M=S_DPJY_[+S\ O\ U86G5_*Q-_K9?^NC_P#H1K^J?_@NY_R85<_]EY^ 7_JP
MM.K^5B;_ %LO_71__0C7_$;XU_\ (\R;_L55/_4NH?\ 1-^S!_Y-AXD?]EYA
M?_6>P)'7]$W_  ;^?\BI^V-_V6CP1_ZKC3Z_G9K^B;_@W\_Y%3]L;_LM'@C_
M -5QI]>?X.?\E97_ .Q-C/\ U)P)]A^TG_Y,!E/_ &<CA[_U3<2G]#5%%%?U
M"?X1A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% 'SW^T%_S1'_LX3X;?^YJOH2OGO\ :"_YHC_V<)\-O_<U7T)6T_X-
M#_N)_P"E(YJ7^\8KUH_^FPHHHK$Z0HHHH **** "BBB@ HHHH **** /YN_&
M_P#P:L_\$IOB!XQ\=^-]>T7]H%=7^(_B_P 3^-_%$&F_'7Q1IVE76N>+M9O=
M=UAXM,MXEMHK9[V_G$,!5Q'#LB+,%R?3?V9O^#;7_@FS^R9\<_A3^T+\(K#X
M\6OC_P"#7B:U\6>"X]?^-GB?7?#D&J6=M<VL"W^@W2K9WUFL5U*&M'"Q-D @
MKD']]Z* "BBB@ HHHH **** "BBB@ KX0_X*A?\ *.O]M/\ [-P^*G_J+7]?
M=]?"'_!4+_E'7^VG_P!FX?%3_P!1:_H ^*O^#;[_ )0P?L1_]B+XC_\ 4[\3
MU_ !_P '5O\ RF8^._\ V)'PH_\ 45BK^_\ _P"#;[_E#!^Q'_V(OB/_ -3O
MQ/7\ '_!U;_RF8^._P#V)'PH_P#45BH _G*KWO\ 94_Y.A_9N_[+W\'O_5A^
M':\$KWO]E3_DZ']F[_LO?P>_]6'X=H _W?:_SA(_^0Y\1_\ LMOQ\_\ 5U^/
M:_T>Z_SA(_\ D.?$?_LMOQ\_]77X]K^,OIM?\F\X6_[+.C_ZH\Y/\_OVB/\
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M4N"_Z]XS_P!1*Q_4E_P7<_Y,*N?^R\_ +_U86G5_*Q-_K9?^NC_^A&OZI_\
M@NY_R85<_P#9>?@%_P"K"TZOY6)O];+_ -='_P#0C7_$;XU_\CS)O^Q54_\
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MBB@ HHHH **** "BBB@ HHHH _DG_P""%'_!,_\ ;:_8[_X*=?\ !3C]H/\
M:-^"K_#KX0_M W?B:3X0^+F\??#'Q0OB]-2^-6I^+;1DT3P9XS\0^(]$\SP_
M/#?L/$>D:.R>8+9P+M7@7^MBBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MOA9X@\;>+/AG\/O%'Q*\#V?PR^(?B3P7X8UWQQ\.+#Q0_C:S\!>*]6T:SO\
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M !1110 4444 %%%% !1110!\]_M!?\T1_P"SA/AM_P"YJOH2OGO]H+_FB/\
MV<)\-O\ W-5]"5M/^#0_[B?^E(YJ7^\8KUH_^FPHHHK$Z0HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^ /^"L7_ "BR_P""EG_9
M@'[9'_K.OQ&K[_KQ_P#:%^"GA7]I3X!?'#]G/QUJ'B#2?!/Q^^#_ ,2_@IXQ
MU3PG=:=8^*M-\*_%3P7K7@7Q#J'AF^UC2M>TBS\06>D:[>7&C76J:'K.G6^H
MQVTU]I6HVR2V<P!_#/\ \$X],_:__P""A_A?]A'_ ()8?MT_%+X._LZ?L?\
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MK_A?XE>';:+1OBKX/NOA]'X3\96,=NDVBVDEE82VON6E?L'?"/2?^"@>N_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^
M>_V@O^:(_P#9PGPV_P#<U7T)7SW^T%_S1'_LX3X;?^YJOH2MI_P:'_<3_P!*
M1S4O]XQ7K1_]-A1116)TA1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P#(-'_"QOCU_P!&X?\ F8/!G_R#7T)11[6'_0/1_P# L1_\O#V%7_H-Q/\
MX!@__F0^>_\ A8WQZ_Z-P_\ ,P>#/_D&C_A8WQZ_Z-P_\S!X,_\ D&OH2BCV
ML/\ H'H_^!8C_P"7A["K_P!!N)_\ P?_ ,R'SW_PL;X]?]&X?^9@\&?_ "#1
M_P +&^/7_1N'_F8/!G_R#7T)11[6'_0/1_\  L1_\O#V%7_H-Q/_ (!@_P#Y
MD/GO_A8WQZ_Z-P_\S!X,_P#D&C_A8WQZ_P"C</\ S,'@S_Y!KZ$HH]K#_H'H
M_P#@6(_^7A["K_T&XG_P#!__ #(?/?\ PL;X]?\ 1N'_ )F#P9_\@T?\+&^/
M7_1N'_F8/!G_ ,@U]"44>UA_T#T?_ L1_P#+P]A5_P"@W$_^ 8/_ .9#Y[_X
M6-\>O^C</_,P>#/_ )!H_P"%C?'K_HW#_P S!X,_^0:^A**/:P_Z!Z/_ (%B
M/_EX>PJ_]!N)_P# ,'_\R'SW_P +&^/7_1N'_F8/!G_R#1_PL;X]?]&X?^9@
M\&?_ "#7T)11[6'_ $#T?_ L1_\ +P]A5_Z#<3_X!@__ )D/GO\ X6-\>O\
MHW#_ ,S!X,_^0:/^%C?'K_HW#_S,'@S_ .0:^A**/:P_Z!Z/_@6(_P#EX>PJ
M_P#0;B?_  #!_P#S(?/?_"QOCU_T;A_YF#P9_P#(-'_"QOCU_P!&X?\ F8/!
MG_R#7T)11[6'_0/1_P# L1_\O#V%7_H-Q/\ X!@__F0^>_\ A8WQZ_Z-P_\
M,P>#/_D&C_A8WQZ_Z-P_\S!X,_\ D&OH2BCVL/\ H'H_^!8C_P"7A["K_P!!
MN)_\ P?_ ,R'SW_PL;X]?]&X?^9@\&?_ "#1_P +&^/7_1N'_F8/!G_R#7T)
M11[6'_0/1_\  L1_\O#V%7_H-Q/_ (!@_P#YD/GO_A8WQZ_Z-P_\S!X,_P#D
M&C_A8WQZ_P"C</\ S,'@S_Y!KZ$HH]K#_H'H_P#@6(_^7A["K_T&XG_P#!__
M #(?/?\ PL;X]?\ 1N'_ )F#P9_\@T?\+&^/7_1N'_F8/!G_ ,@U]"44>UA_
MT#T?_ L1_P#+P]A5_P"@W$_^ 8/_ .9#Y[_X6-\>O^C</_,P>#/_ )!H_P"%
MC?'K_HW#_P S!X,_^0:^A**/:P_Z!Z/_ (%B/_EX>PJ_]!N)_P# ,'_\R'SW
M_P +&^/7_1N'_F8/!G_R#1_PL;X]?]&X?^9@\&?_ "#7T)11[6'_ $#T?_ L
M1_\ +P]A5_Z#<3_X!@__ )D/GO\ X6-\>O\ HW#_ ,S!X,_^0:/^%C?'K_HW
M#_S,'@S_ .0:^A**/:P_Z!Z/_@6(_P#EX>PJ_P#0;B?_  #!_P#S(?/?_"QO
MCU_T;A_YF#P9_P#(-'_"QOCU_P!&X?\ F8/!G_R#7T)11[6'_0/1_P# L1_\
MO#V%7_H-Q/\ X!@__F0^>_\ A8WQZ_Z-P_\ ,P>#/_D&C_A8WQZ_Z-P_\S!X
M,_\ D&OH2BCVL/\ H'H_^!8C_P"7A["K_P!!N)_\ P?_ ,R'SW_PL;X]?]&X
M?^9@\&?_ "#1_P +&^/7_1N'_F8/!G_R#7T)11[6'_0/1_\  L1_\O#V%7_H
M-Q/_ (!@_P#YD/GO_A8WQZ_Z-P_\S!X,_P#D&C_A8WQZ_P"C</\ S,'@S_Y!
MKZ$HH]K#_H'H_P#@6(_^7A["K_T&XG_P#!__ #(?/?\ PL;X]?\ 1N'_ )F#
MP9_\@T?\+&^/7_1N'_F8/!G_ ,@U]"44>UA_T#T?_ L1_P#+P]A5_P"@W$_^
M 8/_ .9#Y[_X6-\>O^C</_,P>#/_ )!H_P"%C?'K_HW#_P S!X,_^0:^A**/
M:P_Z!Z/_ (%B/_EX>PJ_]!N)_P# ,'_\R'SW_P +&^/7_1N'_F8/!G_R#1_P
ML;X]?]&X?^9@\&?_ "#7T)11[6'_ $#T?_ L1_\ +P]A5_Z#<3_X!@__ )D/
MGO\ X6-\>O\ HW#_ ,S!X,_^0:TOACX UY-8U'XG_$Q+:;XBZ[&UK:Z=#-'=
MZ?X&\/J[_9O#VD2QO- UPZ-OU2_MY)/M$KR1QSRB6[N;[W*BDZONN,*=.GS:
M2<'4<G'?EO4J3LF[-\MF[)-M:!'#^_&=2M6K\CYH1JJBH1GLIVI4:5Y15^5R
5;4;MI)ZA11161TA1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>img34756086_7.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img34756086_7.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" *B!7(# 2(  A$! Q$!_\0
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MW/A3_P!%.^'O_A:>&_\ Y94?\+<^%/\ T4[X>_\ A:>&_P#Y957LZG_/N?\
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M.I_S[G_X#+_(/;4?^?M+_P &1_S\U]YZ%17GO_"W/A3_ -%.^'O_ (6GAO\
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M\U]YZ%17GO\ PMSX4_\ 13OA[_X6GAO_ .65'_"W/A3_ -%.^'O_ (6GAO\
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M3OA[_P"%IX;_ /EE1[.I_P ^Y_\ @,O\@]M1_P"?M+_P9'_/S7WGH5%>>_\
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MG_X#+_(/;4?^?M+_ ,&1_P _-?>>A45Y[_PMSX4_]%.^'O\ X6GAO_Y94?\
M"W/A3_T4[X>_^%IX;_\ EE1[.I_S[G_X#+_(/;4?^?M+_P &1_S\U]YZ%17G
MO_"W/A3_ -%.^'O_ (6GAO\ ^65'_"W/A3_T4[X>_P#A:>&__EE1[.I_S[G_
M . R_P @]M1_Y^TO_!D?\_-?>>A45Y[_ ,+<^%/_ $4[X>_^%IX;_P#EE1_P
MMSX4_P#13OA[_P"%IX;_ /EE1[.I_P ^Y_\ @,O\@]M1_P"?M+_P9'_/S7WG
MH5%>>_\ "W/A3_T4[X>_^%IX;_\ EE1_PMSX4_\ 13OA[_X6GAO_ .65'LZG
M_/N?_@,O\@]M1_Y^TO\ P9'_ #\U]YZ%17GO_"W/A3_T4[X>_P#A:>&__EE1
M_P +<^%/_13OA[_X6GAO_P"65'LZG_/N?_@,O\@]M1_Y^TO_  9'_/S7WGH5
M%>>_\+<^%/\ T4[X>_\ A:>&_P#Y94?\+<^%/_13OA[_ .%IX;_^65'LZG_/
MN?\ X#+_ "#VU'_G[2_\&1_S\U]YZ%17GO\ PMSX4_\ 13OA[_X6GAO_ .65
M'_"W/A3_ -%.^'O_ (6GAO\ ^65'LZG_ #[G_P" R_R#VU'_ )^TO_!D?\_-
M?>>A45Y[_P +<^%/_13OA[_X6GAO_P"65'_"W/A3_P!%.^'O_A:>&_\ Y94>
MSJ?\^Y_^ R_R#VU'_G[2_P#!D?\ /S7WGH5%>>_\+<^%/_13OA[_ .%IX;_^
M65'_  MSX4_]%.^'O_A:>&__ )94>SJ?\^Y_^ R_R#VU'_G[2_\ !D?\_-?>
M>A45Y[_PMSX4_P#13OA[_P"%IX;_ /EE1_PMSX4_]%.^'O\ X6GAO_Y94>SJ
M?\^Y_P#@,O\ (/;4?^?M+_P9'_/S7WGH5%>>_P#"W/A3_P!%.^'O_A:>&_\
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M .%IX;_^65'_  MSX4_]%.^'O_A:>&__ )94>SJ?\^Y_^ R_R#VU'_G[2_\
M!D?\_-?>>A45Y[_PMSX4_P#13OA[_P"%IX;_ /EE1_PMSX4_]%.^'O\ X6GA
MO_Y94>SJ?\^Y_P#@,O\ (/;4?^?M+_P9'_/S7WGH5%>>_P#"W/A3_P!%.^'O
M_A:>&_\ Y94?\+<^%/\ T4[X>_\ A:>&_P#Y94>SJ?\ /N?_ (#+_(/;4?\
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M .%IX;_^65'LZG_/N?\ X#+_ "#VU'_G[2_\&1_S\U]YZ%17GO\ PMSX4_\
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M^%/_ $4[X>_^%IX;_P#EE1_PMSX4_P#13OA[_P"%IX;_ /EE1[.I_P ^Y_\
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M_P#/JE_X+C_EY+[CSW_A4?PI_P"B8_#W_P (OPW_ /*VC_A4?PI_Z)C\/?\
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M ,(OPW_\K:/^%1_"G_HF/P]_\(OPW_\ *VO0J*/:5/\ GY/_ ,"E_F'L:/\
MSZI?^"X_Y>2^X\]_X5'\*?\ HF/P]_\ "+\-_P#RMH_X5'\*?^B8_#W_ ,(O
MPW_\K:]"HH]I4_Y^3_\  I?YA[&C_P ^J7_@N/\ EY+[CSW_ (5'\*?^B8_#
MW_PB_#?_ ,K:/^%1_"G_ *)C\/?_  B_#?\ \K:]"HH]I4_Y^3_\"E_F'L:/
M_/JE_P""X_Y>2^X\]_X5'\*?^B8_#W_PB_#?_P K:/\ A4?PI_Z)C\/?_"+\
M-_\ RMKT*BCVE3_GY/\ \"E_F'L:/_/JE_X+C_EY+[CSW_A4?PI_Z)C\/?\
MPB_#?_RMH_X5'\*?^B8_#W_PB_#?_P K:]"HH]I4_P"?D_\ P*7^8>QH_P#/
MJE_X+C_EY+[CSW_A4?PI_P"B8_#W_P (OPW_ /*VC_A4?PI_Z)C\/?\ PB_#
M?_RMKT*BCVE3_GY/_P "E_F'L:/_ #ZI?^"X_P"7DON//?\ A4?PI_Z)C\/?
M_"+\-_\ RMH_X5'\*?\ HF/P]_\ "+\-_P#RMKT*BCVE3_GY/_P*7^8>QH_\
M^J7_ (+C_EY+[CSW_A4?PI_Z)C\/?_"+\-__ "MH_P"%1_"G_HF/P]_\(OPW
M_P#*VO0J*/:5/^?D_P#P*7^8>QH_\^J7_@N/^7DON//?^%1_"G_HF/P]_P#"
M+\-__*VC_A4?PI_Z)C\/?_"+\-__ "MKT*BCVE3_ )^3_P# I?YA[&C_ ,^J
M7_@N/^7DON//?^%1_"G_ *)C\/?_  B_#?\ \K:/^%1_"G_HF/P]_P#"+\-_
M_*VO0J*/:5/^?D__  *7^8>QH_\ /JE_X+C_ )>2^X\]_P"%1_"G_HF/P]_\
M(OPW_P#*VC_A4?PI_P"B8_#W_P (OPW_ /*VO0J*/:5/^?D__ I?YA[&C_SZ
MI?\ @N/^7DON//?^%1_"G_HF/P]_\(OPW_\ *VC_ (5'\*?^B8_#W_PB_#?_
M ,K:]"HH]I4_Y^3_ / I?YA[&C_SZI?^"X_Y>2^X\]_X5'\*?^B8_#W_ ,(O
MPW_\K:/^%1_"G_HF/P]_\(OPW_\ *VO0J*/:5/\ GY/_ ,"E_F'L:/\ SZI?
M^"X_Y>2^X\]_X5'\*?\ HF/P]_\ "+\-_P#RMH_X5'\*?^B8_#W_ ,(OPW_\
MK:]"HH]I4_Y^3_\  I?YA[&C_P ^J7_@N/\ EY+[CSW_ (5'\*?^B8_#W_PB
M_#?_ ,K:/^%1_"G_ *)C\/?_  B_#?\ \K:]"HH]I4_Y^3_\"E_F'L:/_/JE
M_P""X_Y>2^X\]_X5'\*?^B8_#W_PB_#?_P K:/\ A4?PI_Z)C\/?_"+\-_\
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M_P#*VC_A4?PI_P"B8_#W_P (OPW_ /*VO0J*/:5/^?D__ I?YA[&C_SZI?\
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MCVE3_GY/_P "E_F'L:/_ #ZI?^"X_P"7DON//?\ A4?PI_Z)C\/?_"+\-_\
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M*?\ HF/P]_\ "+\-_P#RMH_X5'\*?^B8_#W_ ,(OPW_\K:]"HH]I4_Y^3_\
M I?YA[&C_P ^J7_@N/\ EY+[CSW_ (5'\*?^B8_#W_PB_#?_ ,K:/^%1_"G_
M *)C\/?_  B_#?\ \K:]"HH]I4_Y^3_\"E_F'L:/_/JE_P""X_Y>2^X\]_X5
M'\*?^B8_#W_PB_#?_P K:/\ A4?PI_Z)C\/?_"+\-_\ RMKT*BCVE3_GY/\
M\"E_F'L:/_/JE_X+C_EY+[CSW_A4?PI_Z)C\/?\ PB_#?_RMH_X5'\*?^B8_
M#W_PB_#?_P K:]"HH]I4_P"?D_\ P*7^8>QH_P#/JE_X+C_EY+[CSW_A4?PI
M_P"B8_#W_P (OPW_ /*VC_A4?PI_Z)C\/?\ PB_#?_RMKT*BCVE3_GY/_P "
ME_F'L:/_ #ZI?^"X_P"7DON//?\ A4?PI_Z)C\/?_"+\-_\ RMH_X5'\*?\
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M Q\Y! .3D J,X&."Q)<?W4H LT5%A\YRV"0<97*X/W3U!0@<GE\G.1SA&\T
M;0S8(SRBEAGD8P .#UR#Q[B@":BJI6?)^9^O9H]H&>VX%LD8R"<+@E#SBG;9
M2IRS*?[H89.T$8#DL0KGYMWWQQT(Q0!8HJ*(2 'S#DY)&,8 /( ZGCIDDD]?
M:I: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%K<+I$EA::BGK_[3O[*G_#1WQ#_8U\>_\)Y_PAO_  R1^TW#^T9_97_"+_\
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M-#XB^#-)U*+Q1J_A.3RC_@E+_P $C?V:?@#^Q7^QO;_M(?L ?LE:'^V9\*_
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MY'H:_06B@#\^O^%0_P#!2/.?^&TOV=,^O_#&&MYZY_Z.7]0#]1FE_P"%1_\
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M6/\ LF/[?\*Z^(B?CG_A,6_+'>D_L/\ X*8KR?'_ .R7)VV_\('\1(OQW?\
M"5R9Z8Q@9SG(QS^@%% 'P =*_P""F Q_Q6?[) '/+>#_ (CKGVX\2'WZ>G7U
M3^SO^"F*_P#,V?LB,#T9O"_Q)C!QW&-??.?3 _I7Z 8'7'/K10!\ ?8?^"F:
M_P#,Q?LA.3T_XI_XF)GZ9UAL_P"?I2&U_P""FH/RZM^R _\ O:1\3T ^FW4F
M))_ #U-?H!28'H/RH ^ ##_P4X7D7_['DGL;#XI1@>^1=R$_3C\: O\ P4W'
M6;]CQC_UQ^*:C_T:Q^G;GFOT P!T %% 'P!O_P""FX/^J_8Z<>\GQ43ITZ!\
MY[],>^> S?\ !3@'Y;']C=Q_M7OQ73'TQ;/G/OC'OGC[_HH _/\ ^U?\%.5_
MYA/[&LF>G_$V^+$?U'_(/D)_#&/?LO\ :/\ P4W4@'P_^QD3Z'Q!\6U+#U_Y
M!9/M^-??]& .@ H ^ /[3_X*< \>%OV,G]/^*H^+<8_+^Q)#[$Y ]J/[7_X*
M=*?^1-_8N;V;QA\7T)_ >'F[]\CZ"OO^B@#X!&M_\%/!G_B@?V*W]SXZ^,:'
M\AX7?^=!U_\ X*>#C_A7/[%;^X^(7QB3\,'PBWYY[].*^_L =!BB@#\_CXB_
MX*>@X'PU_8I8XZ'XD_&)#[<#P5)Z'DD?3BF'Q)_P5!' ^%_[$Y/H?BE\8T)]
M./\ A 7_ )]>PZU^@E% 'Y]'Q-_P5"'3X3_L5,?7_A;7QB0?3'_"N'(/T./I
MS2?\)/\ \%0O^B0_L5GW_P"%R?&)?T_X5@W\Z_0; ]!10!^?/_"5_P#!4(<?
M\*;_ &+FQW'QF^+P!_!OA=NXZ<_AQ2_\)?\ \%/!PWP7_8V)[E/C1\50OX;_
M (9*WYBOT%HH _/K_A,O^"G8_P":(?L?-[I\:OB<%/TW?#8'\P.<TH\:?\%-
MU^]\"OV1W'_3/XU_$<'K_P!-/ATO;WK]!,#KCGUHH _/H>.?^"F(8Y^ O[*#
M?[*_&[Q]N'U#> ,']/IZ._X3O_@I?W_9^_99/^[\;O&_]? :FOT#HH _/T>/
MO^"E6!G]GG]F$G R1\;_ !AC/MN\#;L?7GUII^(?_!2,$AOV=/V:R1P2OQQ\
M5[2?5<^"<X],X/J >*_02B@#\_?^%B_\%(<<_LW_ +.3#L4^.'B3G\_!P..O
M4 GN :/^%E?\%'E^]^S/^SZX':+XXZX"??\ >>$5_#G/K7Z X'7 SZXI: /S
M]/Q,_P""C"]?V8_@,V>T?QQU;(]B6\+J >>W''%*?BA_P44 P?V7?@@?3;\<
M=0!_$_\ "- _KVK] :3 '0 ?A0!Y-\(-?^*FO>#8=2^,O@S0/ /C=M1OX)O#
M?AGQ*_BO24T^!D&GWD.K/:V#R37D9=IK=H!Y)4#))Y]:'0=>G?K^.>])@'J!
M^5+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !7SW_ ,W6_P#=O?\ [TBOH2OGO_FZ
MW_NWO_WI%;4?^7O_ %YG^AS8G:A_V$T?S9]"4445B=(4444 %%%% !1110 4
M444 %%%% !1110!\B_MT?%WQE^S_ /LD_M"_&OX=SZ=;^-_AM\-/$'BGPV^M
M6!U725U;3Q;FWDOM/,T N[50VV2V$T6]N2X\L[O#?VN_VGOBI\&OV/\ X,_&
MCP5-H4/CCQM\0?V7/#FN3:GI OM*?3?BWXN\,Z+XOCL[%KF$6MP]GJUX=/N&
MDE%A(\,GERB,J?K+]I7X/6?[0'P%^,GP1O;X:3;_ !5\ >)/!4FI[&G73WUS
M39;6'4I(5(>1;*9HIFBC968+MC>.1PP_-KQ!\"OVV_VBO 7P%_9K^-WPG^$_
MPQ^&7PB^(?P?\6^/OC#X5^*Q\<7WQ,TOX&:SI^JZ)IWA+X:/X6TF_P# TOC*
MZT;3;J^?6_$_B-M%M9;JQ1KB8QW*@'LNN?\ !53]F[1O&_C7PC<^'/CG<:+\
M+/CC:?L]?%?XJV/PRFE^$WPS^(VH:AHNF::?%_BMM;BN+#0+Z]U[3TCUNQT;
M4X((GDEO8[5(MS>,Z5_P5T\+^%O&7[:#?';X3_%SP!\//V9OC5\//@MX8UO3
M? PUNY\::[X]N4T71+"WMK77I;BX\0Z[KMU:-86=O EA#HSPWL]ZC3O%#R/Q
M%_X)_P#Q_P#$O[)W_!0_X.Z,O@A/'/[3W[7_ (H^-WPVEE\326NG)X+U77/A
MSJ-DWB#4QIK2Z;JR6_A;5"=.6"Z$+- @N6$I9<+XP?L&_M+>+_B'^U)INA^'
M/ <_@7XQ?M:_LS?M->$/&VH>/5MKY['X9:_I_P#PF/A#5/!?_"/RW%E=6.DV
M\VIZ7JXUF:#5;DQZ>;*T?%Q0!]L^)O\ @H[\+O"T^C:)<?!W]IS5?'$_@T?$
M7QM\--"^%%KJGCOX/^ Y;JZM;'Q+\5]-C\61Z?X:M-7^P7UWI5G8ZKK6M7UC
M87-S%I8C,1DO_$#_ (**?!GPKH'A?Q1X)\$?'G]H#P]XH^&-O\98]9^ ?PON
M?&FFZ1\-[I+N>U\0:YJ.J:MX9T^TDN%T^^C72;6YO]<0V4RW&EP[H3)\8_M8
M_L >*O$W[7'Q0_:4\/\ [-WPU_:QTWXV?##X?>#M4\,^.OCQXV^ FJ?"WQ7\
M+[36M(TC4-.U'PX;W3/&'@WQ/IFM1S:UH<^FVNM6>IV$DMIK:6UY]E3R[XL_
M\$^?VI=2A^'OPUTSX6?"WQK\ -$_9T\'_#[PC\#O"'Q[^(7P/^ 'P!^,0DUZ
MU\5>,[[P)8_VKX_^.&B:3'JUIJ7A^RU#XA:'?306$^DO.IN8;FV /JW0_P#@
MJ1X.\8_M6?!GX<^$_"GBR]_9O^*O[(/B7]JJ/]H*7PZUMX3T_P ,VEIIVNV&
MN:Y>W6J0RZ%X3M= ^VVVI7DFF7%^GBC4-'TH60MY)K^'W+X;?\%'?@#\0O$>
MB:%?Z5\5OA58^-M \3>*OA7XS^,'@&3P9X+^,7AWP98KJGB;4_ASK']K:E-?
M1Z7H4D&OO9ZY8:!J5QHLGVVSL[A8+P6WY@?"+_@F#^TWX9^%G[-_P9\<6'@:
M30A_P3.^*O[ 'QM\3^&_B"T5S\.-3\9:#!9:;X^\*:=J&AW-QX[TMI;"&PCT
M1;W0[O3DO!=M?W"VKQ3;7PF_X)@^)KVW\,_#KQY^R!^S]\(8/"/PK\?>!-4_
M:1T/X]_%3XH^+M;UC6O!K^!M$\0?"?X<:KJ-K8_"Z\UNWO;[4O$K^(=2\6"/
M2VN- TY(9+Q+J( ^AKK_ (*B_P#"R?VK/V(?A'\'?!OQ+\.?#K]H;Q9\5FO_
M !7\4_A9<>'-!^*OP^\%>"]0U32?%_PB\2/K5W(^DS:W!9W8?5]-TK4=2TB\
MLY[73VM[F22W_:*OPI^'W[-/[>FO?&O_ ()V1?%/X9_!+P=\*?V&X_&GASQ'
MXT\+_$^[\2>(?BI;M\-Y/AUX,\7^&O"<OA^Q/@VRO-/M;:\\0^%=5U/6[VVN
M]1+6.LK!8>5-^ZU !1110 5R_CBV\4WO@SQ9:>!M4LM$\:7/AO6X/"6L:EIR
MZOI^E^)9=-N4T2_O]*>>U34;.UU(VTUS9-<P"YA1X3-'OWCJ*:P)5@IVM@X(
M .#C@X/!P>QZT ?BUX1_X*->/A_P30\9?M#>,M#L6_:I^&FO^(OV>_%'@*QL
M1!:WW[4>C>)X_!.C:-::(9V-O8^*+S4=$\26E@MQ*HT35("DKH!*?6_"_P#P
M4=^'GPWTC2/!_P <Y?B!XJ\0?#6T\&^ ?VDOVDO _P ,7MOV:? OQJOM)T@^
M+-"U?Q*-;DN])BTK6]3ABOWT[2-7T[1$N[:#4M2AN8;Z*U\C\0?\$\OB5J/_
M  4.C^*6F:KX63]B7Q+X@\)_M1?$'X<BXN;?Q5/^V1\/=$UGX?:/JEE8(/L5
MYX)\1^$-2\*^(M;BN76:W\7_  ZTFXCWKJ,PB^<-9_X):^+M"^(?QI\-1_LB
M_L^?M$^$/C+\??$_Q;TOX[_%CXY?%#PS#X4T#XJ^*U\7^,=!^(OP&\-7\%I\
M1Y_!>JWVL0>')?#^L^%H=9T9=#T_48#>65Y?78!] _#G_@JYI?A;XQ?M?^!?
MCYX>^(MYX.^!O[5K?!JU^*/@7X5S77PP^%/A#Q"OAVQ\#S?%GQB-<283ZMJV
MKM'+JNF:1J7V13&U_%:1[=_TSJG[>OPE^'>I_'9/$?BSQ[\1-5\$_'70O@IX
M9^&G@[X61R>-+SQYKOAE?$=IX#^']M:ZXQ^(<DNDQ7.LW7B'4)=!LM-MHI$N
M)$7RFE^7?'7[ GQQ\0?LV_\ !33X4:)'X+C\2_M6_M!R?$OX2J_B&:WL?^$6
M76OA]?0Q>);R2PFET74(+?PSJ4:VA2_VL+<&X8R[EY*^_8"_:<\*_&#Q9^TC
MX,L/ /BGQUX+_:[M?CU\.?AKJGC6YT+1/B3X'UCX,6OPL\6:+KGB8:3>CP5X
MGM)XHM3T#4;C3M>LT\FZ6XM7^V1^2 ?0OB;_ (*":CKGQL_8Y\/^"M*\2?#3
MP-\4/'/[0/@WX[>%/C;X$F\'^/O"5Q\)_!_A7Q'91RK=:C/8Z5% -9N-0GU;
M3+_6-,U#3I8/*ND,,@7VKX4?\%%/@7\6?'?@GP98:%\7O"-C\5KS5M/^"/Q'
M^(/P^N/"_P ,?CE<:5;7>IN/AGX@?5+R]U$7NCZ??:[I":[H_A^?4M)MI+BW
MB+KY)^7_ (Q_LO?M:?MB>-/V?O%WQN\'_"OX/Z/X2U']IOPWXF\,^!/'5[XQ
M\2^$OA_\6OAGX<\"^&[V?Q-=:3IND^-O&#7]CJ^HW#:1HGAO2M*T\Z;:&WN9
MTGG;R#]CK_@G;XS^#GCW]GC2?&7[&O[..@K^SU+,+K]IA/CM\5?'VM>,9?#^
MAWGA;0/$_P ./@UJ&I16?PU\6^);*\:\UBXU_6O%&EZ/!<:MIMC8,+BU>W /
MWX4Y)^O(]&QR0>X/IVZU)5>-"K*69V;: 2_? ;&0#@R8/+#(V#&.]6* "BBB
M@#X&_P""H/Q/\=_!K]A3X\_$KX9^)]3\&>./#-GX"DT+Q+HS0KJ6EOJ?Q3\#
MZ+?M:M<0W$(:ZTK4KZQDWPR9ANI H#%2/8/C3^T1X0_9L_9TUCX_?$]]9O/#
MWA'PAX?U2_M="M%O_$7B'6=6BTZQTO1=&LY9;:*YUKQ!KE_9:78QR2PP&YO(
MS-)$@D=,']NS]GCQ'^U=^R?\7_@!X0\5:)X)\3_$+3/#L&B>*/$FDW^NZ#I.
MH>'?&GAOQ=!)JVDZ5?Z7J5[97#:!]CECLM1L[A1<B2.92F#\S^._V5_VN?VF
M_@CX\_9[_:>^(_[-FF^"=>\+:1#X3\2_ /P#\5-$\<>%?'_@[4],UOP;XEN!
M\1_B!XP\/:KIFEZSHMA<:AH[Z<K7\*SVS7*I,S  Y?QI_P %2-3^"<'C#3?V
MB?V5/B)\(_&WASPCX3^*ECX8M?B%X%\=67B/X,ZK\0/"'@+QWX]L/$NB&VT^
MUO/A)#XLA\3>-/"MY;QWZ:'IUU)I][<RM&*ZOQ9_P5,^#_ACQ-^UYX2C\'>,
M=2O/V2O#_P (=3^TP7.BVMC\8]:^,<TFG:'X2^'=W<7.W^U]%UNZT#1M>DU'
MRXK2_P#$FFQY(9L8D?[!_P 7OC?XN^(GC_\ ;7^(_P +?'&N:W^S#\2/V5/"
M'A[X*>"/$_@SP?IO@[XN:?%8^/O$VNKXQ\3^*M;U#Q9K$UIIZ6\>GW]EHVDP
MVR2V-JMPS35\^>#?^"-6N:=8_L47?C;X\P^+?%'P ^(?CSQE^T+JD7AJ[L=/
M_:.T[Q)XG\,?$7POHESI[ZG.-(_X0+XC?#[X?ZKX?N-2?5OLNBZ;K>C(I35?
M-B /IS_@I[\1_B?X9_9@^&&H_#SQWXV^#/B/XD?M%?LV> M;USP)JUE9^--%
M\.?$+QKIFG^)]'TW6[G3M2L(+Z:RNYK%[M;&9,HCPJ-U<SKR_%+]B/\ :0_9
MDTE/V@_C'\<_@A^TCXN\5?"[QYHGQ\\5:5XN\3^ ?$>D^"-=\6^&O'/@KQ+8
M^'_#WV71_M6DKI/B?P_=V4SO:7$FJVET);<6K?2'[>G[-7CK]JCX,>&_ _PP
M\7^"_!/C?P=\8_A-\7]!U3Q_H.O>(?"-U<_##Q5;>)8M%UG2_#>M>']9-IJA
MMOL<LUAJMM/;(PD5LX%>;Z+^RM^T)\7_ (S_  Z^+/[:/Q$^#WB72_@A#XNN
M?A3\,?@!X-\;^#O"K>+O''AG5?!FN>./'>H>/?%WB[7-9U73?#>L:C8^&]/T
MVZT[2=-EN5U26UN-1@AE4 X7PM_P5"@UN^^&7CC7_P!G3XB>%/V4?C5\47^$
M/PG_ &G;OQ=X.OK;Q'XLNYM1T_PG>Z]\*[&3_A,_"GA'QSK6CZIHWA[7[J:^
M_P!*73GU*TL8=2AE35^ '_!333OC[XPUMM'^".O:5\&-)3XBF_\ BQ!\4/AO
MXBUKP;!\.;RZL;R[^+_P<TS44^('PIL_$$VF:P/#%SK$.I/J"Z:SR1017%N\
MGD_A7_@FS\=;'1/@U^SIXT^/'@'6_P!BW]GKXQV?Q@^'&B:+\/=9TW]H;6E\
M*ZEJWB#X8^!_'?CF?Q#<^!+CP]X4\1ZQ)=:MJ7A_P3I>O^(K#2M*L+B[@#ZA
M+<T)_P#@F!\1?B!^T5X6^+7QB\7_ +/6G:/X0E\8V^I>,_@'\(?$GP?^.GQJ
M\(^(K77;/3_ 'QNU#3/&%Q\,-<\.VR>)[VYU.?3? \&L7U]IVCW5I?6!6_6[
M .P^#O\ P5]^%_Q6^(GPJ\.77@:T\*?#W]H'QE=>!?@9X^C^-/PD\;>)_$FM
M-)J!\//XZ^#/A/6[SQU\,+/Q7::7=W.F7&M+?&S+VL.KI8S7*@?L#"23(23R
MP^4_PX7!&02,DY)Y/)ZD8K\@?V9?V /C/^S_ .(OA?X7DU[]D&Y^#GP;U&^A
M\->,/#G[+>DZ?^U%XT\-6+W,?A'1O'GQ!U#4;OPC8:O96,\5OX@\7^"O#6CZ
MUJLEA!=Q26\]U?/<?K] 20X((4,=A("DH22N  #M X4M\S* S<DT 3T444 ?
ME3_P6DN?$D7_  3Y^+5GX1\6:[X&\1:UXB^%/A_2_%WAK4[S1]9T"XUWXG^%
M-)34[._L98KB)[,WGVAE5MLJ1M"ZR)(R'\^/VZOVK_B?\0_^"?5G\)O#'C#7
M_"?QUT(^+8/V@M<T+5FM?$&@:%^SIXI\-:1XEAU74(%M+RTE^(]]KWA%/[0L
MA;RI<ZE<6H4K(<_N3^UC^S9X<_:R^#6K?!7Q5XCUSPKHNM:]X.U^YU;PZFFS
M:HDO@SQ5I'BRRM5AU6VN[.2UOKW2(;2]5X3)]FFE\EXY@CK\J_$#_@EO\%?'
M?CO]L#Q]_P );XZT+6?VQ? WA;P1XM@L9M*N],\$0Z%KUAXCU[6?!-C?64T4
M.I^/=7T;0+OQ2VI&[AE?0[#[+'%L- 'RK=?M[7OP;^*?C[X<>$OA!H?B/XPZ
MSX9_85^&'P^\0:SXY\26UK\0?'?QP^&>IZQI]QX[AFCOK/PWX=\$6&A:E<WE
MYX<LIM:UY#LECEO9(WKTK]B;QA^T;K'_  4;_;I\,?M&P>$],\2>&?A?^SN;
M'2_ACXH\4:[\*KBUU#1;JYBUKPG8>+;>QUG1[J\@:*#78+ZPCF?5(+EHKBZM
M?(F;U?Q[_P $OOA?XY\1_$?QK+\3/B1H/C3QAIW[.<GA+Q-H<?ANWU/X5^,/
MV9_#=YX:\"^-_"RW.DW%OJ-_J-G?WK>(M*\0B_TB[ANIK5+>"W<*/3OV8OV*
MM2^ GQI^-G[0_C?]H'XB?'[XK?'_ $;P1H?C+5_&'ASP/X2T73K7X?6DNG>'
MX_#7AOP/I&E6&C1#3C#;W-LC307$T+7GRSSRE@#XG\$?LT?!W]J/_@H?_P %
M$K;XY:'XB\:1>!+O]G[3?!,2_$/XA:!:>%;76?A?'>:C_8VF>&_%.CZ=:R3W
MRQWDDS6<I>ZQ)(&^;//?!#]L/XW_  S\(:'^R9X,DTOXV?'F\_;!^-7[-'P7
M\:_%_7=5LO"D/PU^$_@W0/BC=^)/BIXB\/65_P"(=8O/#'AGQ);>#;>/1=-E
MU76-7MK6:X-M'#=L/L?Q+^PS\5X/V@OCA\?/@?\ MG?$+X'7/Q_3P4_CCP?8
M_!_X,>/M+AN? WAU/#&GW>@ZOXV\.7VO:;-<6(:65#=S0K=LDZQ;8U2J]_\
M\$U?AKIGPL^#OA7X7?$OXC?##XJ? [XE^(/B[X(_:%M_[ \7?$6[^)7CV&]L
M_B;K_C?3?%.EWOA;QA8_$.ROY[/7=$O]*2P@MX;!=.^RIIELJ@'RW\1_^"I?
MQP^%O@GQMX/\<?"'X=>'OCW\'?VA8?@I\:?&T-U\4/&'[,O@?PKJW@?3OBKX
M-^+\\_@GPKK/Q?E\+>*O!VN:7X=_LR7PM%J&@^.K?4TUF9/#\=OJ4MWXC?\
M!6'7O _P;_9HO8A^SIJ_Q?\ VCM:\51:1XV\)^-OB/\ %+]FC3O!?@_1;KQ5
M=^.FO/ACX(\1?%B23Q!H"6-GHG@FX\+6>O:)KVJ01^*KG3;2TNI!]+Z!_P $
M_/$W@SPEXJN/!O[6_P 9="_: ^(_Q7U'XM?&']H"3PQ\,M7G^+.K7FC6/A.T
M\)^*_A/J?AJ;X:IX \/>!M*T;PSX9\,:5I6G6^E+IYU?SKC5+R[N)N%\+_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQH _/_\ X9:_;%_Z2;_&GG.?^,<_V.N_7_FB7?OZ]Z/^&6OVQ?\ I)O\:?\
MQ'/]CK_YR5?H!YD?_/1/^^E_QH\R/_GHG_?2_P"- 'P!_P ,M_MC?])./C5_
MXCG^QU_\Y*C_ (9;_;&_Z2<?&K_Q'/\ 8Z_^<E7W_P"9'_ST3_OI?\:/,C_Y
MZ)_WTO\ C0!\ ?\ #+7[8O\ TDX^-7_B.?['7_SDJ]-^$OP,_:)\"^+X=?\
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M3_XJC[1;_P#/>'_OZG_Q5 'Y\_\ #N3X??\ 1S'_  4*_P#$^?VH?_GA4?\
M#N3X??\ 1S'_  4*_P#$^?VH?_GA5^@XGA/2:(_21/\ &E\V+_GI'_WVO^-
M'PUX._80\#>"_%6A^*K+]H/]N37+K0[^*_M](\9?MJ_M%>+O"VH2P'<MMK7A
MG7?'5[H^MZ>XR)['4+6XMIA@2(<#/W3]::'0D .A/8!@3^'-.H **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ KY[_YNM_[M[_\ >D5]"5\]_P#-UO\ W;W_ .](K:C_
M ,O?^O,_T.;$[4/^PFC^;/H2BBBL3I"BBB@ HHHH **** "BBB@ HHHH \\\
M?LRVNG[6*YFNLX)&?E3TKS7S)/\ GH__ 'TW^->E>/\ _5:;_OW7_HN.O,J
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M&1V!N.C.Q&/+D[$XQT[5[W7S]X7Y\0Z6?6Y_]D>OH&@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M<?7@5PW_  FFG=/.B![C<,CZU)'XSL"3BYB/TE3VX]__ -7M0!WXMH0 ,+P
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M_P"Q/@WXC^+?PL\'_"SQ-\:/V*?[>_X7I]@\.>(/"7A_X?\ B#PEX?\ &O\
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MU_\ L.?M7_L3:Y^QG8Z]??%7X4?$[P5J.J0>.(-'MK_[)?\ [._Q7O-&\'>
MOCAH&L:OIMSH$'B709].T:QNY=,U?4[JU\):_P"'?$>K?'G[-?\ P78_:Q^.
M<?P"^*^N?\$9OVEK+]CG]I'Q-I^@^ ?VD?V?OC%X,_:\U_P]IFI7BV:^,/BU
M\!?@YX(?QW\*O#&C[Q>>)KKQ5?P7>FV<-VNFV>MZFEMIEY\>_P#!);X0_P#!
M3/1?V5/^"E/A3XW_ +-O[2/[2/[&&O>&E\/_ +"W[%7_  4V^)GA[P/^TQ\3
MO!]V/$<'C+P#XZ\6WGA/Q)-\,H-8\#W6B6%OI?B/PKIW@Z+QR+"S\'IX7T^+
MQ-XF@_'G3?V3OVE_!'Q#^#^L?\$6/^"=7_!:'_@FC^V/J?Q.\.3?&GPE\;-:
MNI/^";FB^&8K?4+77;>?XJ_$& W?QLT;3=3FTF:WN/&NGVVDWOAE=?-AX-U/
M6/[$A@ /Z7_B3\9/V4;+_@Y7_9^^"NK_ +&7]M_M<:O^QOK7B/PO^VS_ ,-$
M_$C3?^$0\!1>'_C;-<?#?_AFZVTM_AGK_P!IM=,\16?_  F&HZK%K4/_  E'
MVA(#)HEB),CQ/_P7[^*?Q,^(_P"TAIO_  3K_P""9'QG_;\^ _[(?B'4?"GQ
MZ_:)\.?&;P/\'?#RZ_H$,UQXFTWX,>#_ !1X5\2>(?CA>Z/!:W<D6D^%9;37
M]3MTL-6L]&;PYK_AS7-7\O\ B5^SW^T-J'_!UA^R_P#M$CX)_%;4O@7H'[!V
ML>$/%/QYT?X8^.)/@AI/C:7PK\?;=_#=Y\2?[*NO!^DZS/>ZSI45IH.H^(O[
M7SJVE0&.66]MC-\;_P#!.S4OVY_^#?;P7^V%^PSK'_!,W]L#]M/1_&7[1'C;
MXW_LB?'O]EOP2WQ.^&'Q"E\7^!O ?@?2-)^.>OV5U;WGP8TVST_X?>$KS6]4
MO]+U;5[?6K_QA9Q:+=Z/I6D>(M6 /T[_ &DO^#BCX%_#3_@E+\-?^"J?[/GP
M?U;]H/P5X^^+GAKX,:K\(_$GCZ+X->+?A_XUU'3?%%WXHT/Q9K5OX(^*=HFM
M^$;OPW'!]DT_2KS2?$6F:QIOB'1M?DTFZLIKW$LO^"_WQ \'?M9_L9_ G]IS
M_@FG\<OV8?@S_P %!?$NA>$/V3_CSXT^+7P^\2^)_&>N>*=;\%^&] _X37X%
M^%M(N=9^%UI-K/Q!\'Q:MI_BSQK#XU\/V/B'2M3U7P9!:O?'3_Y]OC[_ ,$;
M?VT_V6O^#9WPU^S,OP5^)OQ@_:A^+7_!0'PG^U1X^^"7P0\%^(?C-XK^&>FZ
M_P#"BY^'\&@WMA\-]'UZYO&\/Z!X%\*W?C'4[%-1T/2/%/B.\T>VUR_M(;&\
MN?V&_P""\'[.G[0_Q<^)?_! S4?A%\"?C/\ $ZT^#7[6W@/Q-\6K_P"''PP\
M<>-+?X4^'[+7_P!G:>Y\0?$6Z\,:'J47@;1[2+0]9FGU;Q+)I=E;QZ1J<DEP
MBZ?=-" ?UCT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %?/?_ #=;_P!V]_\ O2*^A*^>_P#FZW_NWO\ ]Z16U'_E[_UYG^AS
M8G:A_P!A-'\V?0E%%%8G2?G%_P %)?\ @IQ\&/\ @F#\/_A%X_\ C%\,/V@/
MB[_PN_XQ:/\  SX?>"OV</!7A3Q]\0-7^('B#1=:UK1-.@\.>*?'W@#^T/[6
M_L272=-M-$O-6UJ_UJ]TVPM-(F^TM+%\$ZU_P<3?"7P#IMQXL^.7_!,;_@M+
M^SC\+=)"S>+?C/\ '']@6_\ "GPM\#:>6"G5?%NO:9\2_$%_I^G(Q"M+:Z/?
MS;F 6!B:^:_^#ISQA_PKWX?_ /!*CQ__ ,(MXQ\<?\(/_P %5?@!XP_X0KX=
MZ)_PDWQ \8?\(SHOB[6O^$6\#>'/M5E_PD'C'Q!]B_LGPSHGVRT_M76KNQL/
MM5O]H\U/2_C_ /\ !9'XS?M#_!#XM_ KX _\$0_^"P^K_%3XO_#?QO\ #7PS
M;_M+?LD:3\!O@I!<>./#&J>&&O\ QY\1]<^(OB/2M-T2Q_M1;F]L+VRMH-6M
M8Y[&35=+24WL0!^I/QO_ ."H'[,'P4\*?L+>/H[OQ?\ %SP!_P %#_V@?@O^
MSM^SSXV^#^G^&M>\/3>)/CP"W@?Q?XOG\3>+?!]YI'@6&,;_ !!<Z39:_P"+
M-*??:#PA<WT-Q:Q>P_MI?MM?L[_L!_ OQ'^T#^TEXT3PQX0T8II^@Z#IL<&I
M^/?B5XOO$?\ L3X>_#'PFUW9W?B_QOX@F0PZ=I-M-!:VL"W.LZ[J&C^'M-U7
M6+'^/?\ ;Y^"WBC_ ()'?\$L_P#@W=\"?&BT\0?$7QA^R/\ \%,?@1\8OBAX
M8\!O;>*_$FHZXOBWXJ_M!>+OAGX"<2V=CXCU#0[K7K[X>^#!'<PV.JMIFEK#
M=BUG2X/O/[%'BGQ]^TO_ ,%O=/\ $O\ P6W^$VN?!_\ :8NO@QH/QE_X),_L
MU^+=:TK6?V?/AUX*U'^T=6\<6NAVD8:#Q!^UIX/M-(L=0\27OB)(?$%IK'A[
MQ9JW_"/^'Y/!WPPL_#P!^V_[3/\ P6?^$7[(_P"RO^S+^U-\:_V4/VX=$3]K
M'XD:%\+?A=^SYIGPP^$^L_M,P>*?%NCZYKO@ZT\4?#:U^.?]E:7?>*]/T1!I
M/A:P\7:OX[@U+6=(T/6?"6DZX^H:=IWSMK7_  <3?"7P#IMQXL^.7_!,;_@M
M+^SC\+=)"S>+?C/\<?V!;_PI\+? VGE@IU7Q;KVF?$OQ!?Z?IR,0K2VNCW\V
MY@%@8FOFO_@Z<\8?\*]^'_\ P2H\?_\ "+>,?''_  @__!57X >,/^$*^'>B
M?\)-\0/&'_",Z+XNUK_A%O WAS[59?\ "0>,?$'V+^R?#.B?;+3^U=:N[&P^
MU6_VCS4]+^/_ /P61^,W[0_P0^+?P*^ /_!$/_@L/J_Q4^+_ ,-_&_PU\,V_
M[2W[)&D_ ;X*07'CCPQJGAAK_P >?$?7/B+XCTK3=$L?[46YO;"]LK:#5K6.
M>QDU72TE-[$ ?K'^T!_P4U_8V_9R_9;^'_[8'B_XJ1>*?@_\93X,L_@0/AEI
M.H>._&WQY\0_$2W2Y\$^$/A'X'TJ(:_XK\6:_ [RKHRVUG+H\=M?2^(I-'BT
M^^>W\"^ /_!9C]G[XP?'WP%^S%\5?@)^V=^P_P#&KXP6FK77P.\)_MO_  "/
MP9MOC:V@V0U'6=.^''B;1?%OCSPM>Z[IUF=T_AS7M:\/Z^]RUMIL&FS:IJ&F
MV5YQG_!-C_@DU\/_ ( _L+_\$TOA)^U5X3T[XE?M!_L'KXN^*7@;Q _BOQ#<
M6'PO^,GQ=\0>,?&'B^STD>']8TOPYXRL?!8\=7/@SP_+XBTS7]&MX_#NEZ[H
MD$.H6MAJ<?Q-^T]\3K/_ (+!_P#!2W]B_P#9U_9(L%\:?L\_\$OOVN?!?[7G
M[6W[86EP077PUL/B[\(XQ>^ OV8?A5XUAANK#QMXIUR_U!T^*5AHEVVGZ;IT
MEI="\EN_"M['& ?U!444#^I_GQ0!YY\0"!;Z<"0"9+O SU_=1]/6O'IKM8\@
M<XSD]ACJ3S_GKWKUSXB$"'2B2 !+>9). /W474]*^?\ 67EBBF:-L':>^/\
M@)Z<^@X].>: *^J>)8;3S-TN ,X&1SZ]>@Y'MT^E<1?_ !&T^W S.F<GY?,0
M'C(YYR",=,?C7P_^U#\3_&'@#2[O5-(T^\U&*#S=Z0^8SD#/*J@+8XX..XK\
M-OBS_P %.-1\.)?6NH6&M:;J-K&[H)8;J%3C?P#(B!B"",@XP!CO0!_4'/\
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ML$'\\=\4 0&Z5>1C(Z9(_E562[#' XZ$>V#^HX]_:K#VX/)P0.O4GZ#CW_\
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M_P!H#XC_ ++GQB_XIGQCX9_X0_X[?"3^QO\ A8/@;_BL/#WA_P#X2#_A'_\
MA(-(_P"*F\+?VWX.U7[7_P 23Q#J7V>Z\GW^OP!_X(%_\YJ/^T_W_!1O_P!X
MW0!^_P!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M2WGF?\2_1KO8^W]V**:2<X ]#G&01W&<C!],\4 ?BM_P6$_9(_:$_:F\=_\
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M#M>1CD(A'KG+*3SP!QCKQF@#_/7U;_@BGXQBF:.TUZZ0KR-\!8X).,G"@X
MP.G7O4VA?\$4_%]S,([[7+QDS@B&%E# <==I&<<GGW !P*_O:N_V7;*221OL
MY;GC,<>< #IA.@R1]>.*73?V8;*"4%K-L!LA@D8&#@<C9Z=^WXT ?Q9>"?\
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M+;PY8%XF^S: "BBB@ HHHH **** "BBB@ HHHH *_P 0O_@K1_RE0_X*5_\
M9_7[87_K0GQ#K_;THH _P!Z^^O\ @E)_RE'_ .";/_9_7['7_K0_PZK_ &_J
M* "OY<?CL][H'[6W[47_  2TL(9VL/V\?^"@G[#7[4'A[22BK-#^S?\ $CPA
MJ_Q:_;/-F9$^R3:)KNM?\$Z_CKX?UB66'R+34OCC9Q&*^U2Z+7/]1U?/FO\
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M'^SW_P"'-\,__)U'_#RC]@'_ */#_9[_ /#F^&?_ ).KU?\ 4?C3_HD.*/\
MPP9M_P#,A[?_ !#KQ!_Z(3C+_P 1C.__ )A/MRBOE;X>_MQ_L>?%GQCHOP]^
M&?[2WP:\=^./$<EW%H/A3POX[T+5]=U>2PT^[U:]33].M+N2XN6M=,L+V^G$
M:,8[6UGF;"1L1]4UXV8Y5FF45H8?-LMQ^5XBI25:G0S'!XC!5IT93G3C6A2Q
M-.E.5)SIU(*I&+@YPG%.\9)>!FN29SD6(AA<\RC,\FQ56BL12PV:X#%9=B*F
M'E.I3C7A1Q=*C4G1E4I5::JQBX.=.I!2YH22****X#S HHHH **** "BBB@
MHHHH *^6?$7[:G[,WA37]<\+Z_\ $O[!KOAO5]2T'6K'_A#?B!=?8M6TB\FT
M_4;3[39>%;FSN/L]W;S0^?:7$]M+L\R":6)E=OJ:OY:/VAO^2^_&_P#[*[\2
M/_4QUFM*<%-M.^BZ6_5,#]V?^&]/V3_^BK?^6-\2?_F/K7\/_MK?LR^*=>T3
MPQH/Q+^WZYXCU?3=!T:Q_P"$-^(%K]LU;5[V'3].M/M-YX4M[.W^T7EQ##Y]
MW<06T._S)YHHE=U_FNKUW]G[_DO7P2_[*[\-O_4RT6M71@DW>6B?5?Y ?U-U
M\K_LB_M=?#K]LKX?^-O'7@#P_P".O!-]\,?C7\6OV>OB=\._B=I_AO2_B!\/
MOBM\&?%5SX7\6^&_$UCX0\5>-O#L;W")IOB;0I]-\3:E'J/A7Q#H.IR?9)[V
M6RMOJBOYJ/VTOC%XP_X);_M;_M@>(_A=IMM=2?\ !5+X!^%]8_91\(P8A@U3
M_@JEX#\0_#W]E?1?!>D:3;Q)9)J/QN\*_&;X&?$;6Y)Y(I=;L_@9\4?%$[VK
M:3XCU:]Y@/V[_9@_:M^'_P"UKI/Q>\2_##0/&]GX0^$GQ]^*O[/"^,/%6G^'
MK+P]\2_$_P &=<'A+QUXM^%UQHGB?Q!=Z[\.K/QG;:YX1TWQ'K=EX;NM9UCP
MSK=QIVD3Z&NF:QJ>E^T/^TUX#_9H_P"%&?\ "=Z3XNU;_AH#]HKX9?LR^#?^
M$2L-&O\ ^S/'GQ6_MO\ X1[5O$W]L:_H/V+PC9?V#>?VU?Z5_;6LV_F6WV'0
M-1WR^3_/Y^T;^R_J_P"S_P",?^",O_!-7P_\)O@7^T3^SKHWP:_:/E\1?"O]
MJCXR>)OA'\ ?VGOVJOASX?\ A7K%CJ?Q7OM*_9__ &F+?XD>.+^?QE\=?C_X
M7^%'BOX9)X?\5^,Y-?\ B!8W5OJ?PHT^SM_FGQI\-6\6_"GP1^S/\1?^%*R?
M W0?^#B3]G+X9Z'^S]^SQ\3OC9\2OA9^SMX9UOX<)J7Q?_9*\._%'Q]^S[^S
M+INJ> ]#\>ZKXTO!X"^$WABZ\$_"71OB+J_P)M;W0HO!*>%-! /Z]?'?B36?
M"/A35?$/A_X?^+OBEJ^G_8?LG@3P)>^ ]/\ %>N_:]2L[&X_LJ\^)OC;X=>!
MX?[,M;F;6+[^V_&6C^9INGWD6F_VAJ[V&E7W75_'=^VSX \ ? 'P;_P7X_9O
M^!O@7PE\'O@'X:\"_P#!(GXR^&?@W\-=#LO!GPO\+?$CXM?%/Q%X-^)'B;PC
M\/\ 08['P?X/NO&FB?!'X:_\)+#X5T71K77-6\/MXAU:&\U[4M3U*[^\/A1\
M#/V-OVH?B;_P5=^*_P#P47\-_#?Q!\3/V=?VT=;\'6_Q*^-WBN+P1XX_8_\
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MBW=>(?% !^W]%%% !1110 4444 %%%% !7SW_P W6_\ =O?_ +TBOH2OGO\
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M"0-7U#<HR0\P"CKU^3_)Q0![2/#>@D_\@NW/_ ''ZF3BG'PUH(Y.E6_Y-_\
M'*\4A\2^(B&;^U;L@,?^6P/8=?D^AJ1O$^OKC=JMT 2!E91G)/'.S _'MF@#
MV;_A&]  S_95O@^S?_'*4>&M!/(TNW'H<-_23->+OXDUY"-VKW?(R%:9>G<\
M)V/KCKBE/BC764!=7N=Y(_Y;#ZG^'_Z] 'M!\-:%WTRV/X/_ %DI#X;T$<_V
M7;+[D.?Y29KQ<^(O$HQG5KD9Z?OQ_P#$TT^(_$AQ_P 3>[Z_P3C/?U0__KQ0
M![4/#FA'IIUM_P!\R?\ QR@^&M"[Z9;'_@+_ ,S)C_/M7BK>)_$*KC^U+W<#
MD[I5Y'M\HSU!Q]:8OBGQ$3SJMSN'53*,'\-N.GN#Z4 >V?\ ".:!C/\ 95OC
M_=;_ .+H'AO03]W3+88ZY5_Z2>U>)GQ/XC)W'5;U01@*LJC!R>H9#C@?7UI1
MXGU\YSJVH #TE3OZX3^= 'MC>&=!(^?3+8C/'$G7_OX:1?#6@#.W2[?WP''\
MW%>*MXFU]0"-6U'!XYF7'ZIC_/%)_P )/XA[:M>?\"F0?EA?SS[4 >UMX:T$
MXW:7;>VY7;\L2<5$WA?PZV,Z5:''HD@_]J"O&O\ A)O$?&=4O>>FV>/GWY!X
MZ'MQR:<GB77R3OU>^4#UE0Y//<(?3/;CGIU /94\+>'@#MTJT'K\C_UD-/\
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M^"C?_O&Z /W^HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0!WWA+CQ'I8/4SJ?7/[MZ^B:^;/!\Q;Q/I()SF< <Y_Y92?ET/7D 'U%?2=
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MB[^W]+\2^+_@_P"*+GX':7^UW-XBO/V>]1^*G@9]%BNT:ZT?P'=Q?&#XW?\
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M2'+! 9[WD^JPQ$X^@(//7TXKX(\=?%[2_#,,DUSJ"1!6/+R =1D<9!V@<].
M<\4 ?3;ZQ"F2TR+_ +);##VP,_E_^JJ,FN6V ?M,0#,0/G Y';'MFOR=\=?M
MW^!O#;3+)XGT^.1&<L#>P@ +USE^",'CKUXS7SK?_P#!4'X9PRR1/XTT560%
MP#J-L,')[E\ ]<C/!H _>@^)8(LQ>=">H+;U)'8_7'TY[9X-68]<M7PJ,KC
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M3.-V1Z_=)!Z#&:^//%7[9O@?0))4NO$FF0L&(4MJ$ 8C.&X>0#<!U'4<Y H
M_2XZI8A2_FKM'!RX ZCGK]?7I@<]8TU&V=@8Y$Y!(P^XD'J< DX'Z8YYXK\?
MKC_@H)\.4<QGQ;I1&\#;_:%OGO@X#Y[=?TK0TC]OGX?W,A5/%&F@*Y56:^A
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MCJ2??/X "OT4_P""FO[1]IX$^$?C349M5CMFM=&U$J&D97\P6[@*H&"S%B
M 22<#V_@B^(G[0GC+QO+J5J]V(+"\NII?,&6GDC=F(W/]X94C R2O3 H _HM
ME_X+!0K<>0VK*FUR& N H&3Z'I\W^<5V6D?\%8(KJ,7$.MALC*H+E<G&>2">
MY4YS]*_D@9B[,SLS,W)8G)+'J23R?YU/'>74( AN)HL=/+E=.IR<X;N?P]J
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M$>/O%/PNG_9<_P""7OQG_:0\1O;:0^G:]:?%SXQ/K&D_LT7DEWJ4%QI\5_\
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M\?>!/#^FP:UXC\)-'K_@OQ/X UN"W\/>*IO$MP?#GUU_P1*\*>./!W_!+?\
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M=C)%91I)EF)9A)&H;))')YZC)/7X>O?^"!'P[6X+PZ)<@ LVW;*%VDD@C'3
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M*1M588U &1C)"?PX)QZYXZBOO'X8:!=6XC2YLH[9 !Y;*I4D Y)] ?8>OOD
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M_@GUX"\Y9&\,:?DLV&%G&3G&>2 >N.^/SKL]#_8>\':6H$?A^Q4HP8?Z+'R
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M[<R/(JR.H9"VYB$9E*DKG*DD'D5V_P ./^";_P ./#TUO/!X3LH7@=7#Q:?
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MD?8O$_ADXP4N6!P>>;:7'7T]>?U%?H$.@^@Z]?QH 6BBB@ HHHH _%'XJ_\
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MQO\ V)8-(G7=;1X)[ 93UQGM7L/A?X:>'O#B(]A96MN>3M@B6-?3'"^W7TH
M[;2][*DC A0O49SSZ\=.><^A-="D:L 67()'/4 ?4?7G/2DLK6.-63<OW>HS
MD?AQP3_+M5X)Y2K'P21D'T&1P3ZYSGK_ "H AV0ERB@#'!X&#_CQGT]/2GB"
M$G&%YX^[1Y1'S!TW'KR1UXY.W^G&?:IHU(#9()52<CGH#Z@>W]: ('CACY(7
M(_V>G3K[8/O4L8& R;,=@<#WX4\\Y]LTQ@&SNP?KT_\ K?A4AX50L:C/\6>"
M"<9'R]NI[^V30!([.VW  (.>N/3(Z\__ %JC*DR%B#@KC/4YR#T&>N.34BL
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M>.GOZ=,4 <]/:Y7S%565>,%02<GD8P<]!GIC]11.BVQ<L8XAYJB0;DW'<3R
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MK^M)O#-C(0?)@8  DC 9L>JY&/4?7%6XO#VDQ;2+:#<%P?EY!XSSGUS_ (T
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M"U,RRN-.EB,3B\)C98A8B;A/ 0I^QDJKG3_H/_XALOV&?^BK?M8?^%S\(/\
MYQ5'_$-E^PS_ -%6_:P_\+GX0?\ SBJ_B/HK^W/^(*^,O_22G$'_ (AU#_Z)
MS_1/_B7OQ^_Z2YXH_P#$"PW_ -&!_;A_Q#9?L,_]%6_:P_\ "Y^$'_SBJ/\
MB&R_89_Z*M^UA_X7/P@_^<57\1]%'_$%?&7_ *24X@_\0ZA_]$X?\2]^/W_2
M7/%'_B!8;_Z,#^W#_B&R_89_Z*M^UA_X7/P@_P#G%4?\0V7[#/\ T5;]K#_P
MN?A!_P#.*K^(^BC_ (@KXR_])*<0?^(=0_\ HG#_ (E[\?O^DN>*/_$"PW_T
M8'^AK^Q'_P $COV;_P!@GXKZ_P#&'X/^-OC=XD\3>(_A]JWPVOK'XE>)/ >L
M:%%H>L>(_"GB>YN[6V\+_#7P=J":M'?^#],A@GFU.>S6SGOHY+"6:6WN+7]2
MZ_B-_P"#;/\ Y/G^*?\ V:CXZ_\ 5N_ RO[<J_@WZ07#W$'#'B-B<JXEXNQ7
M&^:0RG*Z\\]QF CEM:I1K4JDJ.&>%AC,<E'#).,9_6&YJ5^6-K'^:/TH^%N)
M^#O%?%Y+Q?QUC?$3.89'DV(GQ+C\LAE.(JX?$4:DJ&#>#AC\RC&&$BG"-3ZT
MW44KN$+691117XB?SJ%%%% !1110 4444 %?S,_'S_@W3_X7C\=/C/\ &G_A
ML/\ X1?_ (6[\5OB%\3O^$:_X9\_MO\ X1[_ (3SQ;J_BG^Q/[9_X7?I/]K?
MV5_:OV'^TO[*TS[=Y'VK^S[/S?L\?],U%?<<#^)'&GAQB\=CN"\Y_L;%9EAZ
M>$QM7^SLJS'VV'I5?;4Z?)FN!QU.GRU/>YZ4*<WM*3CH?HWASXL^('A-C<QS
M'P_S_P#L#&9MA:6"S"M_9629K]8PM&M[>E2]GG>6YE2I<M7W^>A"G4E\,IN.
MA_)__P 0P/\ U?!_YK3_ /C_ *]7^ __  ;G_P#"DOCC\&?C-_PV)_PDW_"H
M_BO\._B=_P (W_PSY_8O_"0?\(#XOT?Q5_8?]L?\+OU;^R?[6_LG[!_:7]EZ
ME]@^T?:O[/O/*^SR?TTT5^@8OZ37C?CL+B<%BN-O:X;&8>MA<12_U;X1A[2A
MB*<J5:GST\@A4ASTYRCS4YQG&]XRC))K]0QWTP?I%YC@L9E^-\1/;8/'X7$8
M+%T?]4N!:?M<-BJ4Z%>G[2EPS3JT_:4JDX\].<*D;\T)QDDT5\;?'K]CW3/B
MO\9OAA^TS\//B7XK^!'[2/PH\'>,?AAI'Q-\):/X5\3V7B[X0>/K_1=<\4?"
M;XE>#?&.E:GI/BGP;)XL\,^&?&^AR6%QX>\4>&O%N@6E[H_B.WTK4O$NBZ]]
MDT5^#G\TGY$^-_\ @D=X(\1?#/X2>&_#_P >OB;HOQ<^''[>&D?\%&/%7[07
MB#P_X!\6>-OC#^TCIOA+QGX,DU3QYX=@T'PUX(MO#"^'O%6F>'-#\,>%="T#
M3?#/@_P1X1\,:1'';:?+<W'V?X#^$W[3?A_Q=HNL>./VMO\ A87A6QGGDUCP
M=_PH7X?^$_[<ADL[B&&#_A(=(U*;4=,^SW<MO>^;:Q.\OV;[,X$4SD?4]% '
MS)\1/V8O#WQ%_:E_9I_:GOO$VM:=XD_9G\"_M%> _#_A>TMK&30_$MC^T6GP
MB37K[6+F9#?VUWX>/P@TDZ0ME(L,XU;41>H_EVQC\3^*W[#7C'Q?XG^.FJ?"
M?]L7]H3]GWPO^TQ:6<?Q=\&>#(?AUXQM=,UN/PQ;>"-8\<? [5?B?X.\87OP
M3\:>*_"%AI>E>(IM$36/";:GI%CXST3P?HGCJXUWQ+K7Z#T4 >1_"#X)?#;]
MG_X(_#_]G_X3>$[71?A7\*/A[H?PU\#^#[F\N]4@@\)^&=$AT/2M*U/4]:DU
M+4-8FN;*V1-6U;6I]1U'5KF:ZU#59[V[N;B67^<&7]BO]HOXC_#W]EG]D#X?
M>%OVX?A'\%O@K^UW\!OBU;?"?XVV7[,3_![]G[X6_ WXV:3\6[_P;?\ Q^\"
MZ[JGCO\ :*\ Z'H?AV\\"?LW^$_#3Z]XE@U77? &K?%W6Y-.\%7VOZ%_4U10
M!^=NK_L%^(M!^(GQ\\9?L[?M6_%_]F?0/VH?$:^//C)X)\"^$O@]XKL[?XIW
M'A71?!.O_%OX2ZK\1O 7BB[^''C_ ,7^&_#?A]/%$E]!XS\(WVNZ)9>*K/PA
MIWB&[U^_UO<\;?L#^#?'G[*O[7'[,&M_$/QG<K^V/!\5K?XF?%.[BTN^\<C_
M (6+X.T[X8Z->[KB'[#JNK>!_A;X9\#^"['4=2CD?6$\)VVI7\4<EW+:Q?>U
M% 'X?_'GX1_$OX1_M->/_'?P(\&_MP> ]4^)'P"^$_PS\:_$;]F?PK^S!\5O
M!?[0DOP[L_$>C>#IKG0OC)J]OJ?P,^/GPLLM7OM!T;XC^(H=-^$^O^$_$FD_
M\).WB5_!UDGA/[&_X)<_LS^./V/?V!?V:?V=OB7);M\0/A_X)O7\8VUMKS>*
MH])\1>+O%&O^.-5\/OXJ:WM!XIN/#EWXEET&Z\2QVMO#K]SITVKP0QPWD:C[
MZHH **** "BBB@ KY[_YNM_[M[_]Z17T)7SW_P W6_\ =O?_ +TBMJ/_ "]_
MZ\S_ $.;$[4/^PFC^;/H2BBBL3I"BBB@ HHHH **** "BBB@ HHHH \R^(]I
M?7L.E)96MQ<F.XN#((8FDVAT0!B%!.,J>?7C!R17E4FA:RR&3^RM2 (+%3:3
M;QWQC9@X'8GZ'T^AM7UW3=#\E]1D:%+DRJA6-G8F)020(U+\@\'/X"N=;XD>
M$8P-]_.I(S@VMWGWX*9'T/- 'B)T;764!=$U7&,#-G(,D<9/!Z>G^15?1O$9
MX_L74ACC_CSEZ#M]T5[HWQ,\&JH9M1G7/;[+>?T3%1_\+2\&#C[?='W%C>D'
M\?+Y^O>@#PAM+\2CY1H6JX4;0?L4F..,X(SS[X)[TS^R/$7_ $ M6_\  *3_
M !KWQ?BAX,89&HS?0VEV#^13KZCJ*:/BGX*)Q_:4X/O:77Y?<H \.70M=88E
MT75<'^[9RY'Z#V]??-1R>'-:<X_L75BG Q]CE!P/PZ\#G/X5[M_PM+P4>1J4
MQ_[=+O\ ^(KCO$?[1_PC\)PFXU[Q#<6, SNE;3=19% SR2L)P./Q[4 >:_\
M"-:]^[_XD^K?+G=_H<O.<=./KQP*5?"FMCDZ)JG4GBTF_EM'Y?AVJZO[;?[-
MK?\ ,_QCV;3]1!..O_+$].]*?VU_V;U7>?'AV^HTS53TZX_<4 9\?A;78V)&
MBZOC.?\ CRESQGVQ^7TYJZOA[70H4:/J.<@?\>LP'7UV_P"?6J<_[=7[,UOQ
M+\0-IQG;_9&K;OR\CK[5UO@[]K/X&^/I?)\+^*KG4)#P ='U6$?]]36Z+C\>
M.Y% &6/#VN@@+I&HCM_Q[R#'ZFK:Z#KV5+:1J!( '_'L_8Y[#^F:]?C^(_A:
M4974'/&?^/*YS^H]^./PJR/'WAEB0M_,2.O^B3\?^0OZT >/'1-8*A1H]X,\
M$_9Y<XSU!*]<=^,]S2)H.L(' TN_PRD#-N_7W_\ K?K7L0\>^&R=HOG)]!9W
M //H2, _7CUJ8>-O#Q&?MDO'7_1Y/_B/Y4 >)MX?ULJ0-+O<D$#]P_7MV]:<
MNA:\RK&^EW9QPI$#]3T)^48YQD^F<8KV<^._#8('VZ4D^EM+Q]?W?Z\CKSBG
M'QQX=4 F]D(/)(MY" ..OR9[\XS0!XG_ &%KB.H;2KSKVMY/Z@>WYT_^PM;^
M8'2[TYQC]Q)^/;^5>S_\)UX9)XOG)[ 6TQ.?;,6<T\^-_#RC)O)@#T)M9@/S
M,?'7OB@#Q0^']8RK?V9?AES_ ,N[X[X[>GMW-,;0=>!W+IEYD=,P2'KP<C:<
M]Z]L_P"$X\.<?Z=)SS_Q[R'N1T$>>WY4B^._#1)_TZ3@][:;!]QB/I^1]NU
M'BC:!K4@&[2K\D>MO(!^?4?ES^)IYT+6@A4Z1>;>.5MY"W7TVC//N,<FO:#X
M\\- X^VR\C.1:S_U3/;TI3XY\.#K>R#W-M,1^.$S^HH \2.@:S_#I&H%NP-K
M* ?YTTZ-KA.'T6_5QT*VTFW X(.,'H..,"O;&\>^&5&3?OC_ &;6X)'X;#_(
MU$OQ!\+L>+^<GIS9S_7M$#C\?SH \8_L36S][1]0(]!:R9_6F?V%KP/RZ/J
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MK_\ UZ]V_P"%@>%@ 1?R#/\ >M;I_P#V7C'?U_"D_P"%A>&/^@@W_@%=?X4
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M'^(G^S+KOP!P.O7/IFK-OX9^()=3)X8\0@# (?3;K=GC)(VD!<].A^G?[?\
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MM1UZ2;_A'=6\11R:F ?WZT444 %%%% !1110 5^ /_! O_G-1_VG^_X*-_\
MO&Z_?ZOP!_X(%_\ .:C_ +3_ '_!1O\ ]XW0!^_U%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% '\^?QI_Y+'\6/^RE>.O_ %)]4KS.O3/C3_R6/XL?
M]E*\=?\ J3ZI7F=>1+=^K_,_YF..?^2VXP_[*GB#_P!6V+"BBBD?+!1110 5
M^EG_  3O_P":P?\ =/\ _P!W:OS3K]+/^"=__-8/^Z?_ /N[5MA_XT/^WO\
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M*& &&QR0=I&.W\([CWII*#8!S\QZ8]..X_IZ=!49.';D+D#DGGJ3CC/K_G-
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M_M/_ (2O9\///_M/S//^Q?\ "-0_8L>7]KN\^8/[.*_F+_X-%?\ E#1\/?\
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M$XZG'J"<8!XY_"B278JJ!@< ]_7^H_\ UU2D?!*!MI/ '/7'<C@]>.:<X;8
M 6;(P!U/7UQVZT 7!(VP]../P./_ *_]*K_,,D-SVR.G\^WM[U&I9>"IR>W'
M7C/TXZ@\C%.:0*0 ?F.<#\.?TS_+K0 ?:#&268$X(P5&,D$>H_48K N]9A@W
M+))%&0QY)YR#TZYR>E6KU&=6(9E/'*D@GDGC'&3]1S7SE\0?"'BK499I](U:
MYM6 )7#O]",@[>GMGKS0![<WBNQAR9+J('H!DG/7D<^WIW_.H?&&FF48O(0,
M$!79>OOV'/3\17PUK?@SXQ&W06OB"5I,-M8]1SSGG/IZ9/UQ7/Z!\.?C%=7(
M;6?$-WY+2'<8RP.<C;U/'&>1[8YQ0!^AEMXIL9I2!<P[AP%7#$@]S@C '3OD
M].M=1!>F:,-&ZD8Z<$D=QP>N.V,=*^'=.^&'CBUU"":VUZ^>!9$\U))7)/(+
M8P1UYX]37UIX=LKZULH89Y&DGCB4R;P06P0&^<\$DE>,9/X4 =FUT%7,F(QZ
M\Y)QZ<<?3OZ<56:^B*Y,@)!.#[XX '7]:RM32X>$[258J2H +$/@D X/7C//
MX\ UYX\?B)6=-S84EE4!NA[Y';&.P ]* /3Y-5C50<@,&Z$J=P(QQSP1DGN.
M,'UIT>H12-AW7E01RH(ZG)/0YZ=!_CX-J<7C%HR;=V4J<@D$<],YR,CZ#/?O
M46FIXO=XVN7+'[A"[LC!!R1SZ\?YR ?0/VI'!,8.1G@D'./3C/TX_"H_M?S8
M;*C!.>"#C'? (QGMS7(:;;ZK$D9G<M]UB.01^9YSSZ$=*TM1FGC@WJ,,<\'!
M[=#@YZ>_7B@ O->M[8$M-Y:_/NZ';MQC/(]21@=![UR%Q\0],M9"K7L1YY4E
M0?7G)X[]3Z5\C?M&>.?%/A/0[[4M)M[JZFB69EAMT=G<H%( 6,$\[L<C\S7X
MR>)_VD_VG-3OKN;0_"&H?9O-=(E>"<2$ @#(9!PP''']* /Z/KCXGZ8X;;=1
M@#A<.@P/P.3ZX[BHX_B9IWR[KV+''#.O/KCDXYZ_7GFOYG[7XV_M@WS!3X1N
MXAN )*2K@')&1@9) QZ#.*[K3O''[8-XJ,ND3PE@&^Y(1G&<,QX!&,#IG^0!
M_1_!X]TV=5/VJ,D\ (RCJ<],<]>H_P#K5MQ:_%,A>-]RD' 8@$^XZ< XSWX/
M(YK\!?AIXJ_:XN_$-I;:WISPZ;YJ!YP68;.-W X7C)^;WZBOU\\&7.L'1;,Z
MDTK7@@19,DD"0QC=UXQDD $\'CGF@#T3Q-XIMK"VEDFG2/((^<@8 !ZGCOV]
MP>>0/G#5OB=HXN)P][;;4)P ZDLV3T/;)XP?KWKR7]JC5O'6G^!]=N_"L<\V
MIVUM(]NB*[EF7<54*@SDG !/IGZ?R^?$']IS]MJPU;4X+;P5K$L%M=2Q)+$D
MZ*Z([;2 NW+8/)QWP3QB@#^K:7XNZ/&547MKNP"$,B@J,X&3CGD?Y[Z]K\7M
M)<1L+VW!RH.)4/IGNO7GM7\-7C_]NW]NO0I"MG\.O$=Q*,X9(;N3@$\ @;>.
M3CJ,C\+'PX_;3_;_ /&,A<^ _$%@ H"BX@N@K-C'=>">>^/Y4 ?W?:;\5='F
ME1$U"V8X'RAT+9[8 .,=O7CFNLNOB!;BV,L<JX\LMN&!DKP>_!R">O6OX]?@
MA\1?^"@7BKQGH<>J:5?Z=H<EQ$UX[1S8$7F+ORS<C*GC!X/05_13X:G\61^"
MK%=8:9KY;-3<M(2S&;8/,'(SU!P#D@8R?4 J?M!?MC>#OAE87#^(->T[3 0R
MQFYN8HF)"\_ZQQGOP!VR#7YL>)_^"IOPJT[S2WC71E7>?F-];$8/0Y$OH1_G
M-?A-_P %Z[+XK-?^'-;L9]='A2WO9HM6;3FNEBAWY\IYS!C;'DJA9L+QDX7B
MOYB9-1OY@?-O[J4D<>9>7,C8ZA<,[#(' '04 ?W]3_\ !6CX1M(J)XVT1WS@
ML-1@'/J!YPY'3@?_ %M^P_X*I_":8HQ\8Z22<9(U"#:<=PPD/;(XR<^E?Y[W
MFRGD3NI[EI9 V<]3@X'X=L4];R]4@"]N57^\MQ,%Z=CN]L=.U '^C-H7_!4W
MX/O<102^-]$A+N,%[^V9NG\1,PYYQGU(/IG[Q^!G[<7@'XBXMM#\1Z9J<F4'
M^C744^T,2%9A%(< _GQG'//^5A!/JUS*$MKG49Y2P5%AENY968] BQ;W))'&
M!D\=Z_H$_P"")_PT^.9^*>I^*[Z'Q5I_@HVEK#;IJ3:G%!>7B2L^^&.Y955!
M&<$[.3C' H _T)#\5[&.P%S/=HB,A9V\T!$ '4!CC:01@<8 X-?-GC#]J/P7
MI-U+%<:U9QR(TI;==0\8+9+8<$<=B.#U'0U\9_'?7/'FG_"36[CPU]J;5XM%
MN4M?+5PYG6U<PG&,Y5AR._7-?P&?'/\ :D_:\'CWQ-8>-?'_ (]\.W=MK6I6
MYL3-?Z;;)&MY*JK WEQB6$* (W5RK*%PQ% '^C5)^VKX!AF")XDT\Y)'%U"P
M!SR!^\!XZ=1SZ\BNSTG]LOP%*4V^(]/<LBDXNHC@D D_ZPGCK^8SQ7^6S)\?
MOC;)+YC_ !2\;;V)8'^W[_H3G@"7H>V1S^=='H_[0_[1BRB+1OB9\1+R4X54
MM-5U.[;=CA0D)E8,!@;<<4 ?ZOG@O]J+P9JTL$4?B&Q9Y-FP&XB"X( SNW=A
MQSSD>U?77A?QS::ND4T4T4L3JI1U<,KAA\K#:.A[8SCL:_RKOV8?&'_!1KQG
M\0/"L/A35OBI=Z2^K:<+RXU5-1335LC<Q-.[R3H@VF,-D]0#\PK_ $6?V+[?
MQU:?#KPW'XU>>;5QIUK]HDG<G,ZB+>?FY(W%@.WMS@ 'ZZ_#J[-QXLT,*0!]
MK8#H>?LTO88/X$FOL < #T KXB^$W/BW07)&Y[QOEY&/]&ER.F/K]*^WNE !
M1110 4444 ?E5_P5L^$7QG^(/PB_9Q^*/[/O@[0/BQ\6/V0_VR_@S^UCX:^
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M*Z3PK]K+_@B+^R-^U)\==4_:E\/>.?VGOV.OVGO$FFV&D>,?V@/V'OCCJ?P
M^(WCC3],^Q):1^+Y;?1_$OAO6KP6NG6-C/K,WAQ-<O+*RT^&\U.?^R]+:R_8
M-E).0[+@$8&,'(QSW)'52",'KD<4*C 8+LQYYZ<'T [CL6W'KG/& #\M_P!B
MK_@D-^RW^Q1\4O$7[0FE>*/V@?VEOVGO%'AL>#-3_:?_ &Q/C#JWQZ^.$7A
MW,EW-X;T;Q)J=AHVC^'=.O)Y'.H2:!X>TW4-0A)L[V^GLF>V;N/VRO\ @EQ^
MR;^V[XM\'?%CXBZ-X_\ AC^T5\-[&;3/AO\ M2_LY?$?Q-\"_P!HSP/ILQG8
M:;I?Q*\%75K=:MI5J]W?2Z9I'BVQ\2:3HT^HZI<:/96$^JZE)=_HD!@ 9)QW
M.23]22<GU/<]ATI"I).&(]!SCJ"<\Y)XP,$ 9.0><@'X;77_  00_9S^(M_I
MZ_M:_M;?\%(_V\/!6F7EAJ%K\(?VLOVO=<U_X/27VEW7V^PN]3^'WPF\*_!_
M1]=FAO1'/,=>74TOXX8+#4TO=+B2Q'5_MM_\$/\ ]GW]MGXR_L[_ !NNOVD/
MVU/V6?$G[*7PMB^$WP T?]C;XM^ O@IX?^%^AF35(=0UGP=+<_"'Q?XI\,>)
M-:\.WVF>"=7N_#OB?2=,N?!OA7PSHD>DP)9WLVH_L^!CN2??G]!BFE6)X<@9
M!P!],@DD\''& ".>3F@#\=?V;?\ @CS_ ,,X?&[P#\;/^'I?_!8[X\_\('?Z
ME?\ _"I/VDOVW?\ A:/P1\9_VCH6JZ%]B\?> O\ A6.A?\)%86']J?VQIMO_
M &K9_9==T[2M0WO]C\F3]C:B,188,D@SUVL5[YXQR,'W.>ARN07A< #+'  R
M2<GW.,#)[X 'M0!Y9\3T#P:2-I8B6[?(XQMB3 . 3M93(&S\O3=U%?.NK:7%
M<QM&X#*5*;0O)'.3D$]#C)]^>#BOHKXG@K;:4P&\&>Y4AQE2NR)BI*;9-IQR
M!(N0<$XKQUH%QE@6Z_>ZD'OD8![9('/4T ?*/C;X-Z3XC#+/8I.#N7]Y$&X/
MIQUP,5\C>,/V)?!>N7+277A^UD$A8-NM("K9+$EB%#,3W)]_7G]6KBT$N#Y?
M"CC&!QQCMS_G%4)=,MY,9BQCW'_UJ /QF;_@G1\,Q=+.WAC3=_#;OL4&0<EN
MZY [>N1CJ*]E\'?L6^"/#K1FTT"TC*,K*R6D2CY?4;1@GCDG'ISS7Z6C1[9C
MAX4(!P"5P<?@WXDX^E2+IMNGW8CUSU/_ ,30!\_>&/A-INBP1)9V<5O'&FUH
MT0*CMP2<=!D\G@_A71ZGX#MKVUDBF@#1JI 5L,2.F,\<8QC'3Z5[4;2-$"H,
M$X;@ 8SU'OTZ\5'+:(P<<@.H![@$#&/3K[?3F@#X,\8?LN>$/$K2->:+9W1D
M&#YMM$_R$D[?NY)R.IZ=_?S6W_8M^']HTA@\-:?$9#^\V6,*AL>N%P!7Z6-I
MD8;:%!)[[N/T!_S^-4AI9,I78%Y.&V9]^QYSVYYH ^(O"O[*G@S2)X[BWT6P
MB>-RZ@6\(;WY5<'!_KQR*^F/#WPZL=&B2.VMHH@C1E#Y:C:$&". /O <=A^!
MKU&UL2K%61&'KLQ@<]?F_K[#VV8X8,?..1GKZ\X[<]OPS[4 95A9)"$39@*
M..,GC![]QGKV_"M@(R'=G<"?3D<]OP'^>:G"J20% Z\Y]..E3# 7:5!Z\_CG
M]/K0!#E>@XSQDC/MU)X'/:A(V!)P'SZ<8S[GMZ5.,[L$KC)R=G8=>AST]*5G
M*_ZL<#DDYX]SQVQG]* (%@4#:R$$OGKUYXSQS3BC1$[1P<Y'TX]N?P'N*G5@
MP'.6Z@D=_<YX^O!]JB8L64,2"3S@;ASSU^GX^M  0W  Y;ISZ_SQ0$ (,H)'
M^R>2!V_R/\1,V<#8N-H!#9[<<XZ_AWJ,LN/G;)P<*!CKQZGZ]#_B 0NT8X'
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MD\\X/'Z26^JBXE7#N<]@$]?H>.O3GTKT[PW=H'!=3T'382>#U&T8/7K_ /J
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M=V%E=7FFO+)IUU<6L$US823Q^5/)93R1M+:O-%^ZE>!XVDC^1RR\5=HH *_
M'_@@7_SFH_[3_?\ !1O_ -XW7[_5^ /_  0+_P"<U'_:?[_@HW_[QN@#]_J*
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** /Y\_C3_R6/XL?]E*\=?\
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M !1110 4444 %%%% !7SW_S=;_W;W_[TBOH2OGO_ )NM_P"[>_\ WI%;4?\
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MYL%E7KR2.P^O>F."A/ 8 X&U@2>P^G/7FOI@^#/#9&/[,B_[[E_^+IH\$^&
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M.6*PMC'=L @^Y YQ^/ITJ"7[4 6:'I]WYMQY_P!W) ],]?KFOKQ? WA5<_\
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M^4ZH<;<9,9R/I\G/'T[XS7Z!#X1_#L# \,VF/^NUY_\ )%3CX5^ !T\-V73
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M)D?U']"[_E)?PU]>,/\ U@>*3]+****](_WM"O\ /@_X+B?\I1?VG?I\%?\
MUGGX35_H/U_GP?\ !<3_ )2B_M._3X*_^L\_":O[ ^A3_P G4S__ +-_FO\
MZT?"A_>'[//_ )/3Q/\ ]FOSK_UJ^"C\GJ***_U /]D HHHH **** /Z#O\
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MO#4%G-#:179NI9XV665X@GE*K @HCYW;CD'&,=:X4?%6](!_L>UY _Y>YO\
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M ?0O_"\-3'+:!IZ@Y _XF%P3D=<_Z-]?TI/^%WZMD@>'M/.,<_VA<8YY&/\
M1O3]<U\[#5+9$=I'B;$N!N8Y =LC !ZJ",'OBHGUBU+ "X1 IR2K9R/0YS]#
M_/N0#Z-7XX:L5=CX=L %Z?\ $PN,GCG/^C\8Y^O&*;'\<]3>-I#X>L!AF ']
MH7'.#@=;8<U\\G7;(*-MS&4;C&[WP>1[Y)SZ''%0G5K-E8)<QXR3\I_$C))S
MSW_2@#Z5_P"%VZB4R-"L-X&64W\^ >X!^SYX]P.:A;XX:J%4CP]8$G/'V^X
MQGU^SG_]=?.!UO3R,F=%=?OA6)#'H<YSQCWR,''%-;7+-O+(GB48X7<>><8)
M).#D=1@],YP* /HY/CIJ;;M_AVR4KGI?SD''N;<=:FC^-^HR8QX?LAZYOI_?
MIBW.1QUX/M7SBNN68D*R75O$F.=O+$XX')/TZ=3FIDUVQYW7,!7^'!VDC'?!
M'/OQ@^HQ0!](1_&;5)&*C0+ <X!^W7!S[_\ 'L.,_ISTJ1OC-?J"3H-F<<'&
MH2<$9!X, /4'K7SO'KNGA,I>1KCL"#W[DDGKW'U/M)%KUFD;I(T$C2DLI/\
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MO/\ _B-6_P""67_1 _V__P#PUG[.O_T55'_$:M_P2R_Z('^W_P#^&L_9U_\
MHJJ /0/^(R3_ ()'_P#0N?M?_P#AFO!/_P ]^C_B,D_X)'_]"Y^U_P#^&:\$
M_P#SWZ_G@_XB%?V+_P#A_O\ \/4?^%8_M/\ _#/G_#,'_"E?^$._X0OX4_\
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MQY8W$[B#_> _W>F<\]:K?;Y6^8R;3G(4,<9 Z<YQG/(Z5Y_)XF@1VD=U0="
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M_P"E[_R>7&_]D_D/_IBJ?XC_ $[?^3_9C_V2_#7_ *C5@HHHK^7S^-PHHHH
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M_O&Z /W^HHHH **** /P!_X.CO\ E!1^W-_W;-_ZV'^S[7^0+7^OU_P='?\
M*"C]N;_NV;_UL/\ 9]K_ "!: "BBB@ HHHH **** /\ 7Z_X-<?^4%'[#/\
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MI'^]H5_GP?\ !<3_ )2B_M._3X*_^L\_":O]!^O\^#_@N)_RE%_:=^GP5_\
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M^.TJQV7AQF) :\U!.#CI%;^Q_KCT-?*EPTS AY,QDDX'!"YR .HX!QZ]>^*
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MUYP,\4 ?#NI? S2VEE=K"/>Y)!V!AR/]D>O'KG'XX3? '3.ILH1NS@-&!T]
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MYR3U_I7Z2KT'T'\J_-;X,7*I\2/",##,LFI'..B_Z'<8R,'GGUYZ\ \?I2.
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M^3RXW_LG\A_],53_ !'^G;_R?[,?^R7X:_\ 4:L%%%%?R^?QN%%%% !1110
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MDG:=Q/RD9!Y/(';D9&?\!3O.+2%9L[5'&6('MGG/<^OIVXYI$U8R(3!*,'/
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MSD=P,=!SG'\L9TFB^)86$@\P;E^;!<Y))_V2?IP!0!Z:^L*QS$3]T!B_&W!
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M/? R2,FLQO#GCJ3( *CD<?*#U^8X;_Z_'?B@#V\:TFTG<IP<'YB,8 [Y]_\
M$U0E\1PB387"J0"!N).<D?>Z]NF.F:\;_P"$4\=*K("3NYSN! Z#J6//%5SX
M)\;YW/,JLO/S8/R]?O$DYY/\Z /:Y_$L(0*)U4 $CGH3UR<Y Z#'U^E8S:[
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MC:P=C_H-RQ]<$G/XY'2OUE'0?_J_3M7Y-_ #PGIUA\4_!UY#&0]KJ;RQR^8
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MKZ\8?^L#Q2?I91117I'^]H5_GP?\%Q/^4HO[3OT^"O\ ZSS\)J_T'Z_SX/\
M@N)_RE%_:=^GP5_]9Y^$U?V!]"G_ ).IG_\ V;_-?_6CX4/[P_9Y_P#)Z>)_
M^S7YU_ZU?!1^3U%%%?Z@'^R 4444 %%%% ']!W_!MG_R?/\ %/\ [-1\=?\
MJW?@97]N5?Q&_P#!MG_R?/\ %/\ [-1\=?\ JW?@97]N5?Y/_2]_Y/+C?^R?
MR'_TQ5/\1_IV_P#)_LQ_[)?AK_U&K!1117\OG\;A1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\]_P#-UO\
MW;W_ .](KZ$KY[_YNM_[M[_]Z16U'_E[_P!>9_H<V)VH?]A-'\V?0E%%%8G2
M%%%% !1110 4444 %%%% !1110!5GMK>X8>=!%,%!VF6-90A.<[0V<$X&<8)
MXJ+^SK%A\VGV#?6VB&?P,)(^A)-8'C.XGMM(\RWFE@D^V6Z;XG:-MKYW#*D'
MG\Z\H_MK5,DMJ-X<_P#3Q)U)_P!X4 >YG2=-/72]-/UM;<_S@J,Z)I!X.C:2
M1Z&RM3_[;UX:^MZH 2-1O/;_ $B0_C]X_P">*!KVK8'_ !,;WH/^6[__ !5
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M_ME'_P#&J\).KZHH)&H7A(Y'^D2G_P!FH.M:J4)_M"\_\")/4<_>Y]/_ -5
M'NWV.V_Y\[3_ +]1_P#QJE^R6_\ SZ6O_?M/_C5>!_VQJO\ T$;S_P ")/\
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MS7@W]L:YVU"^QV_TJ4<?3/'TH_M?7/\ H(7W_@5-_C0![S_9>G?] S3O_ 6
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M 4444 ?T'?\ !MG_ ,GS_%/_ +-1\=?^K=^!E?VY5_$;_P &V?\ R?/\4_\
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MN*_,.7XYSX8&YD)'3]^>#Z]<8]>O'O70>'OC+/<W$:^?* Q7/[TL#GUR2!^
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M\*?^YY_]63XQK&O\"_Q+\F!]?4445R@%?SCU_1Q7\X]?TI]'G_FK_P#NW_\
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M>8N1]W.[!*YSNQDGGVK3_P"'E/Q2TYPPTB><#C!ED'MSCCD<<=SZ5]6W?_!
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M]>M<U+I>NJW[J]E4J<XPP!Q_P'_')[]* /;)-3RP9G4*>I' '4\8X.<C!/\
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M'_8/_9XM_$_B'PS\-_VV?^"KG[%7['O[08\*:_J_A37O$GP"^*NH^/-4\?\
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M_M\T4 ?QA?\ !&?_ (*/_%/_ ()V_P#!-C]G#]CKXU_\$=O^"WWBCXF_!_\
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M?'S_ *1"_P#!9_\ \0#\9_\ S25_>S16OMI^7W ?P3?\-;?'S_I$+_P6?_\
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ME'_#P?XN_P#2'K_@MO\ ^*^_$W_S:5_;#17U_P#Q&WCK_H(RS_PW4_\ Y/\
MJ[\K?.?\0LX3_P"?.._\+9__ ")_"]X__P""K]U\*/\ A"O^%I?\$Q/^"N_P
MU_X63\0/#GPG^'7_  G_ .Q;)X._X3[XI^,?MG_"(_#3P5_PD7Q&T[_A*?B!
MXJ_L[4/^$<\&Z%]O\1:Y]@O/[,TVZ^RS[/0/^'@_Q=_Z0]?\%M__ !7WXF_^
M;2OZ8OV^OV&/^&XQ^Q8/^%H_\*O_ .&0/V_OV<OVYO\ D2?^$U_X6'_PS_\
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M-M<TW9R=V]3\ ?\ A_I_UA7_ ."_W_BN3_\ ')1_P_T_ZPK_ /!?[_Q7)_\
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M_A='_"BOA=_PMG[?YGG?;O\ A8W_  BW_"8?;/-_>_:?[9\[S/GW[N:^E:*
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M5N0@/O\ Y% 'PSXE_9E\-^(+22TO=+MY4D3:?,CB.Y<8P5*D<#@#^AKY\O\
M_@GA\+;FYDG_ .$6THR.VXO]CM5;)')Y3.?USW[U^M@L5'8*>F,=/TIQLU/)
MVD_[H[<>E 'Y!M_P3S^'2@ >'=*';YK:W)'IP$(Z=!GIZ51;_@G9\-YW._PQ
MIC$]6%K;X;CH/W9QC/?G@^HK]ACIT39RJG/M_P#6XSWQU[T@TV$<!5'T&/Y4
M ?C]!_P3;^%:SH\GA/26^<-DV=MD$<Y V#)!_$=J]H\*?L5^ O#8B2UT.PB2
M,@JB6\*@,,_-A4Y/3YCSCZ5^C?V <8C! ^Z<#IC&>G<5,MH !\@!'M_]CZ4
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MI_\ :U,'P^ Z:BX^EL!_[4KT7S[?_GO;_P#?:?\ Q=+]H@_Y^(/^_B?_ !=
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MM/\ M$'_ #U@_"2,_KO'\A0!Y]_PKT?]!3_R37_X]2?\*\7_ *"8_P# -?\
MX]7H'VJW'_+2#_O]"/TW\4?:K?\ YZ0?]_X?_BZ //3\/%Z'46;_ +=1C\!Y
MIQZ4_P#X5X.VJ<=O]#7I_P!_J] ^UP?\]8?^_P##_P#%TGVJW_YZ0?\ ?^'_
M .+H \]/P^&3_P 3%S[BV !^G[VE_P"%?C.?[2DSZ_9N?_1M>B"YAP/WT(]O
M,C./RDH^TV__ #\V_P#W\3_XN@#@;;P*MO/'<C4"QAEB=4,#8_=.2>/.P"_R
MY('IG)P*]&'3U^G3^O\ .JZ3PD[4FA+<G:)5=CGG( <G!SP*L#H/I0 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?C3X@T9O^$CM_B!XJOM-TK6=*\:WFLWOC7Q/JEE=PSMXQFT[4X_@+XO>,?\
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ME!TNYCW##$@,Q&6XX&.G)Y'/QKXL_P"#@/XPVE[<VT'P8\>PA'8!KJRN8RV
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MLK]N>F,AR#Z9SBK>F_L^_M%:G-'%8?#?Q_+*[[8REG=Q,9.GWGD4]^2.3UH
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MQ/\ $ZQ\-Z=IL!^'S?%KP'XG7XBRZ+XB\1^#[/2]$TOQ#X*O=;O+M]-'A_\
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M-X;\7:%:W37VB6D4KZCX;U6%K22XC2!)GCGA /Q8\8_$K]J#_@IG^U#^P?\
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M4OP[\<7?CWQ-K/P9N+W2O&'@[2+GQ1:?#?PW(NC6D?PMU+QKXJT[6_BE<_\
M"<W6@^%K+2O"XU+6?Z4J* /R*_X+C?#[XH_$'_@GKXS'P@^%OCSXU>,/A]\;
M/V5/C))\+_A;H;^*/B3XN\+_  >_:7^%?Q$\9V/@;PO#+#<^)?$L'A7P]JU_
MI^@V<@O=3:T:VLTEN7BAD^'_ !_\>?CW^RM^V[_P\YT__@G;^V_^T)^SA^W5
M^Q)^SOX)U_X??!WX/6?BG]MC]E+XH?"_7/'OBJQ^'WQ1_9NN?$=C?:;H_B?1
M/B5;'Q;>Z5XSN(?"OC7PQJ>F:O#(;;2[C5OZ5:* /QS_ ."2GPZ^/ESJW[='
M[8'Q_P#@AKW[,>I_MR_M.:;\7/AY^S]XTU/3M2^(_@7X6^"/@_\ #[X3>$]9
M^*%OI*KI_ACX@>/!X0O?%&O>"$>]N_"BW5IIVI:E>WXG\GQG_@M%X)_:Q^$G
MB7X$?M]_L$_![QK\:_VDO _@']H/]CGQ-\/OASH,^M^)-:^'?[47@5KGX6>/
MM6CLGBOCX9^ 7[47@+X1^.-:(N+73['PCX@\<ZEJM]I-G;MXAT/]\J* /Y4O
M^"D__!+'XD_#']C_ /X)8>'_ -F]/VNO$/AS_@G!>^(M)^+D7[ 'Q$T7X4_M
MN>)/#WQ&^#E[X.\??%_X%^)-8TU[#6/'NJ_$,7&N>/O"EII2ZYX_\-_$#QKI
M6G)IIO[S4+',_P""1G[+_CB[_:+_ &A_VL)O '_!;)/#$G[&_B3]GGPCX\_X
M+-?'WPEKGQE\6:MXF\?Z=XUU'P-X _9CTOX63^.O#WAOPK=>#(M5TOXD:]\9
M[/2K^[\;:KH_A_X7ZO-K>H>*-%_K HH _E#\6?LU?'9/^#6?X'_L[:1\ ?BT
MGQUTSP=^Q+_;/P+TWX5^,5^+6GZMH/[;GP.\<>.O[3^&-KH(\8VFHZ-HUAK_
M (P\6_:M$CN=.TRRUCQ!K'DVMO>W:>]?M2_L5_'3]J']IK_@N#\-_"?A7Q)X
M3LOVG?\ @FK^RQ\(_@O\3_%.@^(="^%OB_XG:)#^TA-=>$K3QZVE2Z-?+IVI
M:KX;T[QW%HLNKZEX7TCQ';7NH:6_VJTMKO\ I"HH _";]DS_ (*8?M6_$K7?
M@-^S O\ P1V_;8^#/Q"\-OX%\%_M%^/_ (X:;X5^$G[(WPC\(>']/M]*\=^+
M/@Y\=+.7QBO[0LVDQV6WX>>"/"/@CPX/&LMQ8P7?B7PCHZ7FOV?XN?&;_@G]
M^UEXH_9L^'?QET;X=_MX>$KG]F;_ (*U_P#!3_XK^.?!O['.OR_ #]N?5/@3
M^T-X\^(FB>'OBS^S-JWCO1U3Q$MQ"VA3_P!DZ3IUY+\4/AAXN\06/AF^CL[^
M?6+3^WRB@#^6S_@B=^S1XP'[8OQ3_:\U+P1_P6LLO!L'[,9^ 7AOXC?\%H_V
M@O!^J_%SQ'?:_P#%?0O'6L>#? _[--A\+9?&WACPKX/E\$IK-A\3?$7QIL=&
MNY_&FKZ5H7PQU:36M1\4Z)_4G110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 5\]_P#-UO\ W;W_ .](KZ$KY[_YNM_[M[_]Z16U'_E[_P!>9_H<V)VH
M?]A-'\V?0E%%%8G2%?G%_P % O\ @G[_ ,-U>)_V$_$G_"V_^%6_\,4_MP_!
M7]LS[%_P@7_";_\ "R_^%/ZA<7__  K?[1_PF?A#_A#?^$B\_P K_A,/(\5_
MV1L\S_A%M3W;%_1VB@#Y8_;7_9 ^$'[>?[,'Q=_93^..F/?> ?BSX9GT>74;
M2.!M;\(^(;66/4O"?COPQ-<QR0VWB;P7XCM--\1:-)-'+9SW5@+'4[>\TJ[O
MK*Y_./\ 9X_X(>?!SX=_\$D9/^"2WQ]^)VL?'SP#=ZCXWUNY^+WAWPE%\(/&
M>E>)?$7Q1U'XK^%O%_@W3;CQ3\3T\-^*_ /B*YL)=-U&YUO7+#66T^:#6M)N
M-$U?4]!G_;]G"DY.1@9&.F>G..<\TPR?,,,1NQ@8R.GK@GU].E&SUT35TWL]
MM%UOKVZ,3:BN9M)<RC?^\_L^NI^"D'_!&_\ :.^+^N?!KPM^WQ_P4_\ B=^V
M=^R[\ _'_A#XF^"OV=IOV=OA9\%9_'OBSX=79N_A_+^T7\5/"FN:_P"(/C5I
M/A^5+:>\T>31O"5KXDOK8:EKIN[V1Y:V/$'_  2)_:4^&W[47[37[0O[!?\
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M1ULM7V5[^NW3_AKB3NVMI)7<>JC>RD[75GI9WZZV9Y'\84=]-TS9U\Z[]?\
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M*,-/M5.>.@*<\_KBOTE^&7[(GASP'806>F:7';16T4:1)'!'$H0!5'$8 .
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M (#P_P#QV@#R#[&/[H_[Y-1_V='G)4=<]&Q_^JO8_P#A7\'_ $$KC_P'A_\
MCM'_  KVVQ_R$ILXZ_9TZ^N/-H \<^P)_P \!^?_ -:I#:Q(#@#CH>>_I@_Y
M[UZ__P *_@_Z"5Q_X#P__':/^%?P?]!*X_\  >'_ ..T >0"VY&?7U_^RJ"?
M3UE/(&.W)]>><X/''?T)KV;_ (5_!_T$KC_P'A_^.T?\*_@_Z"5Q_P" \/\
M\=H \0_L>'^Z/TI1H\.1\HZCIC/X<5[=_P *_@_Z"5Q_X#P__':/^%?P?]!*
MX_\  >'_ ..T >*'1X0"<-P,\Y[?A47]EP_Y)_PKW#_A7\'_ $$KC_P'A_\
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ME<?^ \/_ ,=I?^$!A_Z"=S_X#Q?_ !V@#RLQ<GY>Y[__ %ZFRH[C\Q7IW_"
MP_\ 03N?_ >+_P".TW_A +<==3G'_;O#_P#': .-\- _V_IIQQ]I SVSY,G%
M>[UPVG>#;?3[V"^6_EE>W?S1$T"@$[#'D_O3@8.20#CIG&*[@< #T _SW_F:
M %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M<^V><=^G/OSZ&OE?XP>!+?Q'"2X7,B,?4_-SD#)QUS@ =Q] #\U]7_X*J?\
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M%J/AS6]8\$?!WQCJ_A*^U;2+I9++49=!U*>:\T]+N&6**6:4M&RNRGY \?\
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MC33OA_HC>(?&NK:3H\*RW7]B^&M*6.75M9NDMM*MKFZT_36O#J6I:?9W/#>
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MVP_X*F?MBZ>01\0(Y_\ KXM)&' P<A+E3[D9'/:@#_5 B_:;\(RX U>WR?\
MIK$ ?<9DX'< \@=:OP_M(^%I.#JT/U\V+_X[SUX_SC_+GT[_ (*]_M@6>U9/
M$&C76T*"9+>\C)&,$G%_QNZ\ 8]*Z)/^"S?[6Z8 O-!)Z#Y=2Y[<XO\ '?CH
M* /]1:S^/GA^\'[K4H#C SOB/49'_+3J1UY]^AK=/Q?T7RC(;L>N?,C Z;O[
MV.1D\_TK_,A^'O\ P7 _:DL-<TJWU*RTK4;:6]MHYHK634%FD#N%954S.3P>
MV<9'M7]&>F_MI_%KQ!\"(/'=MIES#J$NA"^.GNTZL93;%PH8C<,GICG&,<T
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M1@$@D$9! /\ 49?XZ:&T!F_M&V*C))#8S@?,1\P'&>?>N$UG]I?PM8$A]7B
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MWD!P<GH/.R">_I^%<>/^"B/PN9RH\4Z<6;@+]KA!)X;KY_H#ZX]\5_EXZO\
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MYE_B]_P68_:6\7ZWJ(\-7%GHVG?:9D@\XWDMP\:2NH=MEQ$G(  !7(()R>
M#_1*E_:#\$H[!M7LER25W2VYR.F0?,Z9X]N_-6[+X]^"I)%==5M6RP!VRVXZ
M= !YG/'.:_S'KG_@IS^UG<N6?QQ$ 3E0MO<84>@+W3-[\''-:6F_\%2_VM=.
M*A?%]I.JL6Q-!= GV+)>J,#MQ]<\4 ?ZA&F_'?PC(ZJ-3MP>F/,A7/(QU?'K
MCCJ<#T/IVD?%W0;@((;R*0L>"LL7.3TP&)Z=,#GK]/\ +FT__@K]^UQ8-N&L
MZ5+L*L01?@8ZXR+T\\>YYSTK]*/V%O\ @LC\;/'OQ+TCP-XVM8I7OG3[-<64
MER8Q\P7<ZRR2GU+$M@G\J /[^]9^+.CV$327-TB)&&)#21*O?C)8=3QD=_2O
MG?Q5^U#X$T]G$^KV*NC,&0W,)88ZY/F8X].@[]#C^;+_ (*/_P#!03XB_!3X
M-2>)?#:-/JEY!%;6S.9A#!<7?2678RG8KN",L!MK^3[QO_P4._:N\;7MQ=7W
MQ.O]/2:5W^SZ8C0PIN.=JF3SGP,X)+$DYQ@'! /]+6__ &T?AA 2)/$&F(RD
M!A]IMR% P<9,PSUP>#@'VKFKG]NKX5PDC_A)M+4*!S]HMP/?_EMT'UK_ ##+
M_P#:D_:!U L;KXI^*F+'YME\T0.1Z(B@=.<8/KWKG9_CY\9;A=LOQ*\7.".<
MZO=*03G."KC.<GMWYR<T ?Z@\?\ P4 ^$T3X?Q;I28.#NN[<#Z#-QT]?PXKM
MO#/[=OPOU6Y%M:^)=,G:1U*A;VW)(('11.6QP3C\J_RJYOB_\49B#)X_\6,P
MZG^W+_DC'/$P';MUKI?#7[0'QI\-:A:W^A?$7Q;'>1312(DFJ74Z22!@$CVN
MY)5R<!=PSSCF@#_6ZLOVBO#FI6#7EIJ$+P[,_NGC9<8P #YG/.>OH:^4/BW^
MW;\+?!LES#K?B;3;=XRZE)+JV5D*DC'SS@ #OCC@$>W\]W[&WQ6^.FO_ +,^
MF>(_%%Q>7&MWFA"=&=IUDW" M'+(K9==V%/7MS7\J_[5OQE^-?BSXQ>.K/QU
MXG\0VTECK^H6L6F"]O+>WBM8[J5;<QPJ\9<&,*-W0CG(H _OA\0_\%7/V?=-
MF=9/'6C H&3 U"U."O!'$YS^?KS7E=]_P6._9UL6/_%=:+D.P/\ IT8/!]!)
MVP.O![5_GAR:EJ$[EYK^\D))/SW4SG)/3#RDX/?D_C4#7$QR6=VYP2993D]\
M_O#R>2>W- '^@_+_ ,%ROV;],9(Y/'6F$*^"8YE;HV&Y&<].I/)S@XQ7T9\&
M/^"TG[.WQ!UJST+2O&]C/>W;B-(C/;QNV<X"J;C>V<X "Y.,\=_\U N3C<-W
M7[QD_+[PZ'TKZ._98^&GQ!^)WQD\%:+X!M=4-\NNV-S<:A8_:%CL;.&8-</(
MT1PRLN4PS#)/UH _V&OV5OC%I?Q'U_PE<:?.MS%=S^9$Z,FTAK:1DPV\@LR\
MX!R<$C-?J8.@^GKG]>_UK^<__@E5X+\1>#8?AAINNRW,UW#):B=YV9B?+TV=
M22&''/+9;.2.O?\ HP_SZ4 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\]_\ -UO_
M ';W_P"](KZ$KY[_ .;K?^[>_P#WI%;4?^7O_7F?Z'-B=J'_ &$T?S9]"444
M5B=)_-5_P7^\1_&/P=\?/^"+GB[X > ;+XK?%SPM^W=X@\1>$?A??^(-.\)I
M\1SHGPEUK4M<\"67BC6$DTCP[K7BWPU;:SH'A_6]64:9I>NW^G7NH/':0S2+
MY1^V9X\_:"_X+)?$3]A_]G#X4_\ !/+]MW]ES1?@+^VC\$_VK/CM^TM^V+\&
MM/\ @CX<^$WAOX-S>)7U?PU\&-<;Q3XB/Q2^(7B*6_.GZ5>^!GU/PTY?2+FX
MOWT>\U+6_#7[;_M=?L0?\-4?'+]@_P",_P#PL[_A!/\ AB;]H#5_CI_PC?\
MPA?_  E'_"S/[5\"ZMX+_P"$6_MC_A+/#O\ PAGD?VI_:7]M_P!E>*_-\C['
M_9$?F_:H_O,M@X*MR0 0,CGZ9( [E@!Z9H _&;XJ_P#!OC_P2#^-OQT\8_M*
M_$[]D;_A)OC7X_\ B!>?%+Q=XT_X7Y^T[HO]K>.[_51K=WKO_".>'_C3I/A.
MP\W4U%S_ &9IF@V6CQX\F/3TM\Q5^-/[1_P)M=,_X*N?MF_$W_@J%_P3"_;@
M_P""E/PF\6S_  PD_P"">OBGX$_"SQ-^TO\ !+X9?#S3_#4=OXT^'6I_#;1?
M&_AGP3\.=>U3Q3?63WVJ?$G3(;.]U+1/$6MW-_8Z7JB^(/$7]F-% '\8?[#/
M_!/+XQ?%#]H+_@NU\(_&O[$.I_\ !.#X2?M\_L;_  6\$_L[>$?#_@"SA^#O
MP\T5?A;XT^&&F6\WBKX;Z9_PI^Y^*NGW5YX<^(WQB^'?A3Q'J.LVOBGQ%XHC
MN9KV9+_56^G/@]^WI_P4=_9M_8-\!_L$VW_!+?\ ;DUK_@HK\'/@7H?[,WPS
M^*.@?#?PWXX_8SUWQ+X*\*K\-?AG\>];_:AU;Q6/AXOATV.D:)XT\6Z%XL2U
MU)]7%UIFIP0Z3>R:Q;_U044 ?S!?M>Z'^V+^S#^UY_P17_;)^-OP:_:$_;FN
M_P!GO]GS]I_X4_M?^,OV./@@GQ*\96OQD^+OPM\$:=:^(]*^#W@.R\/2Q>!M
M8\86VLVNG:AINE:;I^FZ+I4D^IK:ZI+IVG:OA0? /X\77_!0?_@YR\?Q? [X
MR+X(_:&_8D_9S\.? 7Q7<?"WQW::!\:/$NE?L+:CX5U?PS\*]4N] AM/'WB3
M1_%,T?AC6/#_ (7EU36-)\2.-!U&RMM6S9C^IJB@#\&/V+_@]\6_"W_!NCX2
M^"'B?X6_$;PY\:+;_@G-\7O ]Q\(=>\$>)M(^*%OXTU/X;?$"PTWPA-X U#3
M+?Q7%XHU"^O;.SL?#\FDKJUW=W=M;P6DDT\2/]0_\$4/A]X]^%7_  2D_85^
M'7Q0\$>+_AO\0?"/P'\/Z/XL\"^/O#6L^#_&7AC5H;[5'FTOQ#X8\0V6G:WH
MNHQ))&TMCJ5C;7,:NC/$ RD_J-10!X_\7K87&GZ4I_Y[W8Z$_P#+*/T_SUKX
MB\??#NW\26L]O+ LB2I,D@>$,/FR,'*]23C.<_RK[O\ B6ADM=+ !XFNS],1
MQ<]^#S7B4]@DF4*$#)W'_:R0>?\ (^G- '\^O[37_!,3X6?&:*Z'B+P;I6HO
M(9L236,#.K/U*RJGF(3N/\6<BOQ8^*O_  ;Y?"+4;B:;1]"ETP,9!BQ>>(JY
M=N5(;&!G@\#!X/-?W'W_ (8M+E9 \2L"S <+G'8GC)/&>WOBN.N_AYIMR-KV
M\9Y)P8%XSVSCG'3/.: /\ZWXA?\ !O+JUM-*?"FMZO:1@N55Q)<X&2-N9E9>
MG! ]\=>/)-._X-[/BS=7L23^*KQ;0N0Y73U,@7.1DB/C(P.>G:O](BY^$NDR
MD[K&-N3CY$. "<8XX[<?I5&/X/:0C?)I\:CKDH@_IS],^_;( /XEOV7_ /@W
M_P#"/@K7[#Q+XR_M#Q1J.GR02Q'45=[:*96SN%KM"$*<<E. O.<8K][;/]B_
M1M,\'Q>'8M,A6S2R2U6!;3;$4$&P ($VXZ#;^F>:_9^P^&]A:1XAM(4(.#B%
M1DC')XYZ]<<\\5IR^";61/+:,=,']T.#C&. ,X./K0!_!_\ MO\ _!#"S^(>
MK:EXO^'H;PWK]Q+-*?LEJPMKQB3A9X538@?).0H)['U_$KQM_P $:?VK?#-U
M+%8:=;:O A(0JEQ$S8X&,A@<^PX'.,5_JB:U\*=-U&/R[BS@D!!Y\E22/H
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M-LWES?"?Q.'R0 +.0G(X((/;Z#/'>M+3OV%OVGM18+'\,-<A)Q_Q\0F, ,<
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M!SC!([@]*_=;_@G_ /\ !%V;X-:W;^,_&44^L^)2RM'/=6[I!;*K ^7"NU4
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MM+<KY4$:D=]JYX&1G S_ "/6@#B/V>?AW;>%?$WAH0V\<,=K<$J47:#BVD4
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MLG5.?^G"Z_\ C-?2%% 'S:_A[6#C_B5:GR.?]!NL_C^Y_I^-1_\ "/:U_P!
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MS_8NH<?W=-N\_A^Y_P BD'AO6""?[%U;Y>.=/O._''[GI7U110!\L#PUK#$
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%/\ T3'X>_\ A%^&_P#Y6UI_L_\ T^_\D,?]L_ZAO_*OE_P?P\P_X6Y\*?\
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MM'_"H_A3_P!$Q^'O_A%^&_\ Y6T?[/\ ]/O_ "0/]L_ZAO\ RKY?\'\/,/\
MA;GPI_Z*=\/?_"T\-_\ RRH_X6Y\*?\ HIWP]_\ "T\-_P#RRH_X5'\*?^B8
M_#W_ ,(OPW_\K:/^%1_"G_HF/P]_\(OPW_\ *VC_ &?_ *??^2!_MG_4-_Y5
M\O\ @_AYA_PMSX4_]%.^'O\ X6GAO_Y94?\ "W/A3_T4[X>_^%IX;_\ EE1_
MPJ/X4_\ 1,?A[_X1?AO_ .5M'_"H_A3_ -$Q^'O_ (1?AO\ ^5M'^S_]/O\
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M $4[X>_^%IX;_P#EE1_PMSX4_P#13OA[_P"%IX;_ /EE1_PJ/X4_]$Q^'O\
MX1?AO_Y6T?\ "H_A3_T3'X>_^$7X;_\ E;1_L_\ T^_\D#_;/^H;_P J^7_!
M_#S#_A;GPI_Z*=\/?_"T\-__ "RH_P"%N?"G_HIWP]_\+3PW_P#+*C_A4?PI
M_P"B8_#W_P (OPW_ /*VC_A4?PI_Z)C\/?\ PB_#?_RMH_V?_I]_Y('^V?\
M4-_Y5\O^#^'F'_"W/A3_ -%.^'O_ (6GAO\ ^65'_"W/A3_T4[X>_P#A:>&_
M_EE1_P *C^%/_1,?A[_X1?AO_P"5M'_"H_A3_P!$Q^'O_A%^&_\ Y6T?[/\
M]/O_ "0/]L_ZAO\ RKY?\'\/,/\ A;GPI_Z*=\/?_"T\-_\ RRH_X6Y\*?\
MHIWP]_\ "T\-_P#RRH_X5'\*?^B8_#W_ ,(OPW_\K:/^%1_"G_HF/P]_\(OP
MW_\ *VC_ &?_ *??^2!_MG_4-_Y5\O\ @_AYA_PMSX4_]%.^'O\ X6GAO_Y9
M4?\ "W/A3_T4[X>_^%IX;_\ EE1_PJ/X4_\ 1,?A[_X1?AO_ .5M'_"H_A3_
M -$Q^'O_ (1?AO\ ^5M'^S_]/O\ R0/]L_ZAO_*OE_P?P\P_X6Y\*?\ HIWP
M]_\ "T\-_P#RRH_X6Y\*?^BG?#W_ ,+3PW_\LJ/^%1_"G_HF/P]_\(OPW_\
M*VC_ (5'\*?^B8_#W_PB_#?_ ,K:/]G_ .GW_D@?[9_U#?\ E7R_X/X>8?\
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M_P"%IX;_ /EE1_PJ/X4_]$Q^'O\ X1?AO_Y6T?\ "H_A3_T3'X>_^$7X;_\
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M ,(OPW_\K:/^%1_"G_HF/P]_\(OPW_\ *VC_ &?_ *??^2!_MG_4-_Y5\O\
M@_AYA_PMSX4_]%.^'O\ X6GAO_Y94?\ "W/A3_T4[X>_^%IX;_\ EE1_PJ/X
M4_\ 1,?A[_X1?AO_ .5M'_"H_A3_ -$Q^'O_ (1?AO\ ^5M'^S_]/O\ R0/]
ML_ZAO_*OE_P?P\P_X6Y\*?\ HIWP]_\ "T\-_P#RRH_X6Y\*?^BG?#W_ ,+3
MPW_\LJ/^%1_"G_HF/P]_\(OPW_\ *VC_ (5'\*?^B8_#W_PB_#?_ ,K:/]G_
M .GW_D@?[9_U#?\ E7R_X/X>8?\ "W/A3_T4[X>_^%IX;_\ EE1_PMSX4_\
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M]_\ "T\-_P#RRH_X5'\*?^B8_#W_ ,(OPW_\K:/^%1_"G_HF/P]_\(OPW_\
M*VC_ &?_ *??^2!_MG_4-_Y5\O\ @_AYA_PMSX4_]%.^'O\ X6GAO_Y94?\
M"W/A3_T4[X>_^%IX;_\ EE1_PJ/X4_\ 1,?A[_X1?AO_ .5M'_"H_A3_ -$Q
M^'O_ (1?AO\ ^5M'^S_]/O\ R0/]L_ZAO_*OE_P?P\P_X6Y\*?\ HIWP]_\
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M_HIWP]_\+3PW_P#+*C_A4?PI_P"B8_#W_P (OPW_ /*VC_A4?PI_Z)C\/?\
MPB_#?_RMH_V?_I]_Y('^V?\ 4-_Y5\O^#^'F'_"W/A3_ -%.^'O_ (6GAO\
M^65'_"W/A3_T4[X>_P#A:>&__EE1_P *C^%/_1,?A[_X1?AO_P"5M'_"H_A3
M_P!$Q^'O_A%^&_\ Y6T?[/\ ]/O_ "0/]L_ZAO\ RKY?\'\/,/\ A;GPI_Z*
M=\/?_"T\-_\ RRH_X6Y\*?\ HIWP]_\ "T\-_P#RRH_X5'\*?^B8_#W_ ,(O
MPW_\K:/^%1_"G_HF/P]_\(OPW_\ *VC_ &?_ *??^2!_MG_4-_Y5\O\ @_AY
MA_PMSX4_]%.^'O\ X6GAO_Y94?\ "W/A3_T4[X>_^%IX;_\ EE1_PJ/X4_\
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M]L_ZAO\ RKY?\'\/,/\ A;GPI_Z*=\/?_"T\-_\ RRH_X6Y\*?\ HIWP]_\
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M /EE1_PJ/X4_]$Q^'O\ X1?AO_Y6T?\ "H_A3_T3'X>_^$7X;_\ E;1_L_\
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M_P#EE1_PMSX4_P#13OA[_P"%IX;_ /EE1_PJ/X4_]$Q^'O\ X1?AO_Y6T?\
M"H_A3_T3'X>_^$7X;_\ E;1_L_\ T^_\D#_;/^H;_P J^7_!_#S#_A;GPI_Z
M*=\/?_"T\-__ "RH_P"%N?"G_HIWP]_\+3PW_P#+*C_A4?PI_P"B8_#W_P (
MOPW_ /*VC_A4?PI_Z)C\/?\ PB_#?_RMH_V?_I]_Y('^V?\ 4-_Y5\O^#^'F
M'_"W/A3_ -%.^'O_ (6GAO\ ^65'_"W/A3_T4[X>_P#A:>&__EE1_P *C^%/
M_1,?A[_X1?AO_P"5M'_"H_A3_P!$Q^'O_A%^&_\ Y6T?[/\ ]/O_ "0/]L_Z
MAO\ RKY?\'\/,/\ A;GPI_Z*=\/?_"T\-_\ RRH_X6Y\*?\ HIWP]_\ "T\-
M_P#RRH_X5'\*?^B8_#W_ ,(OPW_\K:/^%1_"G_HF/P]_\(OPW_\ *VC_ &?_
M *??^2!_MG_4-_Y5\O\ @_AYA_PMSX4_]%.^'O\ X6GAO_Y94?\ "W/A3_T4
M[X>_^%IX;_\ EE1_PJ/X4_\ 1,?A[_X1?AO_ .5M'_"H_A3_ -$Q^'O_ (1?
MAO\ ^5M'^S_]/O\ R0/]L_ZAO_*OE_P?P\P_X6Y\*?\ HIWP]_\ "T\-_P#R
MRH_X6Y\*?^BG?#W_ ,+3PW_\LJ/^%1_"G_HF/P]_\(OPW_\ *VC_ (5'\*?^
MB8_#W_PB_#?_ ,K:/]G_ .GW_D@?[9_U#?\ E7R_X/X>8?\ "W/A3_T4[X>_
M^%IX;_\ EE1_PMSX4_\ 13OA[_X6GAO_ .65'_"H_A3_ -$Q^'O_ (1?AO\
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MA[_X1?AO_P"5M'_"H_A3_P!$Q^'O_A%^&_\ Y6T?[/\ ]/O_ "0/]L_ZAO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
%HHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>img34756086_8.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img34756086_8.jpg
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /U3K&D\
M&Z%)(SOI%FSL<EC"O)K9HH%9/<Q/^$)T#_H#V?\ WY6C_A"= _Z ]G_WY6MN
MBG=BY5V,3_A"= _Z ]G_ -^5H_X0G0/^@/9_]^5K;HHNPY5V,3_A"= _Z ]G
M_P!^5H_X0G0/^@/9_P#?E:VZ*+L.5=C$_P"$)T#_ * ]G_WY6C_A"= _Z ]G
M_P!^5K;HHNPY5V,3_A"= _Z ]G_WY6C_ (0G0/\ H#V?_?E:VZ*+L.5=C$_X
M0G0/^@/9_P#?E:/^$)T#_H#V?_?E:VZ*+L.5=C$_X0G0/^@/9_\ ?E:/^$)T
M#_H#V?\ WY6MNBB[#E78Q/\ A"= _P"@/9_]^5H_X0G0/^@/9_\ ?E:VZ*+L
M.5=C$_X0G0/^@/9_]^5H_P"$)T#_ * ]G_WY6MNBB[#E78Q/^$)T#_H#V?\
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MG@W2M:UMX;!]1N&MH8X8W92X9E5>_)VD]J:HS:;2V=OS_P A.M!-)O?7\O\
M,[NBL&+QQHDVEQ:A'>[K:61H4Q$_F,ZY++Y>W=D!6)&. ,U!<?$;PY;>3OU-
M?WULMY'MB=M\3,%##"\\]NHYST-+V51Z*+^X?M:>_,OO.EHK(_X2S2/MTEI]
MNC$T9D5MP(3=&H9UW$;25!!(SD<^AJM%X]T&:WNIEU%1';1QS2%HW7Y)/N,
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M,8SWSGKQSQVU%3+$U)+E8UAJ<7S(\WTOX;ZG9P^#(9[BT9-",ZRF-W!D5TV
MK\O!Y)_3WJ'2_A3>V%O80/=P.FF:?=V5LRE@93,3AG&/E !' SDUZ=15?6JO
M?^M?\V3]5I=OZT_R1P'@SX?ZAX;U[3+ZXGMI(K70TTEEC9BS,LN_>,@<=L4O
MB3P#J&LZQXDNX9K9(M4TH:?&'9MR-DG<<+TY/3TKOJ*GZS4Y^?K_ ,&Y7U:G
MR<G3^D<7X/\ !=[X?\075_<RV[Q3:?:V@6)F+!HEVD\@<'FH+GP/>R>/[[Q
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MZL(5!#*NU2..H4D ]AQ60/AYH2_$1O' LP/$;:8-(-UGK;B0R!<>NXGGT.*
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M:7$DMY=0VD;N(U::0(&8]%&>I/85';:WIUYJ%Q8V]_;3WMO_ *ZVCF5I(O\
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MZ4UP;@Z;:&<S-<&3R5W&5H_*9\X^\8_D)ZE>.E &C165'X5T6%8UCTFR18Q
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M1[7&1(@1FSVX]6&,\XN6/[1WAR2VNY[^UOM,2'PTOBU#((Y1+IYR-RF-V'F
M@ H>[#!/./*_#_BS4_&=O\4M9M?A;XF'B_5]&E/E^*=(-M9/!$HC@L8MS9E+
M!W=A\NX[N@V@5?V</@_/X3\;ZSHL5I>:M\.M8\)VXO/[<LVC>WNW8B2R0NH8
MIAYG:,<*9!GYN3[<L+AXQG*2LU;2_I>WZ7W/-C6JR<5%W3OT^[_@VV/;?!WQ
MX\/>+-)\17LD=SI)T"*WGOH;I0S)'/;K/"5V$[BR.!M'.X$ '@GO=)O)M0TN
MTNI[.2PFFB61[28@R0DC)1MI(W#H<$C(ZFO$[[P%%HL/B=O!6@$P:#;F[AM[
MAI)6UC5X;8+:(S.Q9XH%6( 9P9",8,1)U?V>?&7C/Q8->'BB.:6PMXM-:QO[
MBU%O)+-)91R7<6U54$1S%E^[D$LI)*\<-6A!PE4I:)6WWZ?\/Z>C.FG5ES*$
M]W_7]?\ #'L5%%%><=AR4GQ6\)#QH?"!UZV7Q*6V?V=SYNXIYF.F/N\UY)\.
M=2U-[[X^0/XCN+5[&[DBL]2U*X:1;!1 Y5\L3A$/S8'I7T,5'/8^O>N#TGX+
MZ#I;>,1)->ZA!XL+MJD%U(FQRRE3MVHI7Y6(X/Z\U::,Y)MH\ ^!?B3Q!XHU
MF?0'NI_"WB-?!C1V_FM(T>L2N<PZGEA]X J23ER7;^Z0.V\#Z=XO^&]GJ5CJ
M5X+*[U:QL(K6.>X6=;%K>T5=1U%^2-N[!Y/SOLW8WDUZCX7^$NC^%]9T_55N
M+S4K_3],71[.:^="8+53G8NQ%R3@99LMQUY.=>;P7I]Y=:[/?>9?-K$ LYEF
M/"6P0KY*8QA26=CW)<\X  ;DB(P:1E_#/QGX7\1Z4NG>&[Z2ZCT^VMW*W"R"
M4Q2Q[X96+@%O,7+;NYSGG-=G7#_#CX1:-\,I+N;3IKNZN+BVM;(S7CJS+!;1
M^7#&-JJ.!G)QDD\GH!W%0[7T-8WMJ%%%%(H**** "BBB@#R?XP^"?%/B'Q#I
MVJ^'+F:*ZL='U&#3Y(YD5+34I6@-O<2(QP\86.5&QDA78!3O.(/ /PWUW0O&
M^G7=XNRSTV3Q&[77FJWVL:CJ4=U"% .X;$4A]P7#*NW(Y'K]% 'S[H^BS:!^
MUCH=G)J'BC5$7POK++=:]+');-NN=*8BV*@'C.'W#J%QFOH*O#KBUFC_ &Q=
M&F>QUB"*7PIJVRZO+]9;*?$^D@_9H1*QA*]'S''O)!&_&1[C0 4444 %%%%
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M)_\ L9Y__22TKZ^KY!_X)C?\D/\ $_\ V,\__I):5]?5^0YE_OE7U9^A8/\
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MQ%\_R/K:OP,XZBBBM3SPHHHH Z#]E?\ Y*'\7/\ KYTS_P!)*^CJ^<?V5_\
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MOWER?L]I+/\ )':66X#8IRYWC:@^9L':#M./SHK])?\ @F-_R0_Q/_V,\_\
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M_P#TDM*^9X@_W/YH]O*/]X?H?7U>!?M>?\@SX9_]CC#_ .D%]7OM>!?M>?\
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M_DC7BG_KV'_H:U]N^&?^1;TG_KTB_P#0!2K?PX^K_0Z</NS3HHHKC.P****
M"BBB@#$\;?\ (H:Q_P!>LG\J*/&W_(H:Q_UZR?RHKHI[''7W1MT445SG8<OX
MH^'.C>,+^.[U".0N(/LLR1L MS!YJ2^5(,<KOC!['!89PS ]1110 5S/BKX@
M:9X0USPWI=\)A-KMVUI#(BYCB8(2&D;^$,_EQCU>51ZXZ:O/_'GPCM_B!;ZV
M+S4'@N[N*W2PNX4(?3GA?S8I5&_:[K-^\!(ZA<Y H VM8^(&F:'XUT'PS<B8
M7NLK+Y$JIF)'1&=8W;LSI'.RCN()/2LVS^)PO;K7K%=+DCU32=8ATEK)YEWS
M>:L<B3IQS'Y<A?/7$<G=2*H^)_A"/%:SWEUJGEZ\-0L[^SU*&!A]D-NR,B*A
MD(*DK+D$\B>0=ZW'^'M@_P 18O&/FS+J L!8RP*0(92K,8I2.N]%EN%!S]V=
M@>@P <AX7^)W@+P/_P (WX+TK6["71;73)H8=1.H1O'$;62UA$+MGEV^TH<_
M[+5Z9K6IKHNCWVH-#)<+:0/.88=N]PJEB%W$#)QW(%>8W_P"6_T.+36UQD"Z
M9JVEF06@Y2_N89W;&_@H85 ]B<UZ)=:/=:AH&I:==7RRRW:SQK.( HC1RP5=
MN>=JD#.><9[T <E<?&O2+?["S6T_E266FZA=MD?Z)%?SF"V+?WLR+)G'W5C8
M^@/HE>:R_!#3[A;%);Z1D6PTO3[X",#[7'I\YN+;O\GSO(&Z[E<C@@$>E4 %
M<SI_Q TS4O'VK>$8Q,NI:=:0W;M(N(Y5<D,L9_B*?NBWIYT?J<=*>^.M>=Q_
M"$6NN:!KUKJGD:_ILMV]S>>0S+>I<@F6)D,GR(7$4F%/WH4[#! "X\0Z+XV\
M77\%M:7=WKW@:?[=;6X81+=--;3P!D8\,N3<P\X DB;/2F1_&[3)O".B^(X[
M.5]/U+38[\X<;[=I9(HHH9 ?NNTDNWG !CDS]VI]#^$<'AWQ3H6O6>H/'>V>
MGSV&H$QD_P!I"1DD+OE_E82(S@C/,LG]XU;T+X4Z3X>L/%%G D=[::[=37+V
MFI0BXMXEE)=X1'P#$99)Y-I[S..F* -GPCXL@\6V=\\<+6US87LVGW<#$-LF
MC;!PP^\I!5@>#AAD Y W:P/!'@K3? .@KI>F)B)II;F:1E4-+-*Y>1R%  RS
M'   4 *   *WZ "BBB@ HHHH **** "BBB@#E?BCX3N/&_@/5='M)4BNYA')
M"920C/'(LBHQ )"L4"DX/#'@]*Q=%^& OM'\2P:W/J%J-<UF353%I6J7%C-;
MKMCC1/.MY$?)6)68*VW<S#Y@,GT2B@#RO3_V:?!FDQRQV5UXPLXY9I+B18/&
M^M('D=B[N0+OEF8EB>I))-6?^&??#'_05\;?^%WK?_R97I=% 'BOBW]D?X;^
M.(K:TU\>)-76%FFAAU+Q9JEV%.,%E6:X< \@9 '6N8;]@'X(*SJ="O0R+N8'
M6;K(7G!/[SIP?R-=5XDTSQ(/B=H_CNRL[B:WL[XZ%-IZPR><^FR@"67;]WB=
M8Y]PY,<04?,<41Z;XDL_BWI7C>.SN);#5Y9]#O[%89!);V:@M:SN#QA98G/0
M$"_DSG;733Q->E'EA-I>3,I4J<W>44V>9^+/V$?@[J'@K5/^$7M!'KMY9W$.
MC74VNW#0F\\MO*_C(8!P"1@\ \&MNS_8)^"$DC6C:/<RWT$:-/"FMW)9-P."
M5\S(!*MC/7!]*[+0_ ^O^%I/%>EV]NT6AZ0UYJ7AB: *[^;=HSE%0@X:"1KE
M%!!4I/&,?+6%I&@^-=*\;:=K(N-<N9[C3_#UO?RW$$9$Q^TZ@UY'(!&,")+E
M",8QE>216GUW$_\ /R7WLGZO1_D7W%&;]@+X(6T32S:%>11J,L[ZS= #ZDR5
MTWA7]E?X:^!XY-'T*?Q%H_G,;M[+3O&&J6F\D*AD,<-R@/W5&XC/ &>!75_%
MBTN/&'P?U..UTNZDN[RVBDBL98?WZL71@K+SAE[^A%<Q<>#/$$GQ5EO%BE,,
MGBN#6HKX_<BTY=&^RM#D]S<"3]WU_?[\=2,ZF)K55RU)MKS94:5.#O&*3-S_
M (9]\,?]!7QM_P"%WK?_ ,F5E>(OV4?AYXPLXK37XO$NNVL,HGCM]3\8:O<Q
MI( 5#JKW1 8!F&1SAB.]>P45SIN+NC5ZZ,\ D_86^",:@OX7NT&0N6\0:B.2
M< ?\?'<D"AOV%O@C'MW>%[M=QVC/B#41D^@_TBNS^-7A/5?B-IB^&M-G?3 (
M7U :DT4C)%<QD?9<;>K)+B8#GF%.#FN4\=V_C#XJ>"-*O;72I_#^OZ/80:^E
ME>12#_B;(P=+=64_,JF.2-OO!EN 0#BM?;5?YG]Y'LX=CC_ ?[$7PCL?!.C6
MGBO3%O?%>GZ7;#7;B#Q)?A/M0A7SI,"=0JLX9A\JC!Z#I706_P"Q+\![J<P0
M>'Y9I@BRF./Q)J#,$/1L"YZ'L:ZG7O"VK:UXRTG7=+TR2WTSQ9IB:5XEM;K$
M<MM''F:)W']X(]U;G;DYGB.<)FGZ7\.]7L_B]!J4%X7T&UN+[4))9K<QS&6Y
MCBC%JK[_ -[$-ADSM4+LA4%L':>VJ_S/[P]G#L5O#O[)'PV\'+<KX?M?$6A+
M<E6G&F>+M7MA*0, MY=T-Q /&:V?^&??#'_05\;?^%WK?_R97I=%9.3D[ME+
M31'GFG? OPYI>H6MY#J?C!YK>59D6X\::Q-&64@@/&]T5=<CE6!!'!!%>AT4
M4AA1110 4444 %>)_#*]\13?$*V2]DN79D\0_P!M1R,Q6-EU.)=-&#]W-L9?
M+QC=&"3G@U[910!X7>?"_P")4GQ2L_'%K=>!;;4[?3[S369=,N0]S%/);.#*
MXERS(+50O. ';VKI_L_QD_Y__ W_ ( WG_QZO3:* /'O%?A?XO>+?"^L:'<:
MIX)AM]3LYK*22*QO-Z+(A0D9EQD!N]?)2_\ !+WQ:J@#Q[H_ Q_QX2__ !5?
M=GQ+UB]TOPK/#I5PUIK6H'[%8W"6S7)AE<$F;RE!W^6@>3;W\O'>N$O?BGKW
MBKX+:??^'HQ8>.-1AEMS;&UDN%LKVWW+=))&JEMBS1M#N(X,B$]:[</C<1A4
MU1E:_H<]7#TJ]O:1O8^3_P#AU_XM_P"A]T?_ , )?_BJP=&_X)T^+M7\4>(M
M&_X2_3+?^R#;C[2]A+LN/-CW_+\W\/0U]FZQ\6IK>U\ _$&WN;O_ (0K6+=K
M._TKRD+07,RAK9V^7>)!,C6I3=@O<)D96J7C;QWXO\.:?=^'83'-J6E6>BWU
MYK;WBI)*UW>R1-$D0M]NW-NZDY!"N",L#79_;&/_ .?GX+_(Y_[/PO\ (?+O
M_#K_ ,6_]#[H_P#X 2__ !5;W@+_ ()V^-? 'C;0O$UKXVT*ZNM(O([V*&:P
MFV.R'(#8<''TK[2\ >+W\:: U]/:1Z?=QWM[8S6L<_G*'MKN6V9E8JI*EH20
M2HX(XKS^_P#&VOPZ[K6EK?RM;-XXM=&%UY<8:SLY--MKDHI"X^:5S&&;+#SA
MSD B)9MC9Q<95-'Y+_(J.!PT6I1AJC8^S_&3_G_\#?\ @#>?_'J/L_QD_P"?
M_P #?^ -Y_\ 'JWOA)XBU#Q9\.]&U35/FO9D<-+M"^>JR,BRX' WJJOQQ\W'
M%=?7DG<?*%]^S3\7)O$WB+6;3QKX5LFUN^.H3P#2IW5)#%''A29,XVQ+U[YI
M/^&;_C1_T/\ X5_\$TO_ ,<KZPKRCPC\4+Z^^*FI:7J3F/0-4LFO=!EDMGA7
M%N_EW \U@%D#J\,Z%2?E9_[N:Z/K%3R^Y?Y&/L8-WM^9X/JWP9^-&E^+M T/
M_A,?#<_]K1W4GVI-&EV0>2J'#?/_ !;^/H:W_P#AF_XT?]#_ .%?_!-+_P#'
M*](\,^./$7C?5/&GAI]2GT*_U*Q_M;PQJ'V#RVMK=AY.-DJ8E:*18I')#+_I
M2J.!4.A^.O%?CKP7#KNCK=)=V/V/3=6TM/*#I=)=(NJ!2X&7BC5U4@@$EL D
M+@^L3\ON7^0>QAV_%GD_BK]DGXM^,?#U[HNH>/O#)LKQ/+E\K2)5;&0>#YG'
M2O<M/TOXQ:?86UJFH^!V2")8@S6-YDA0!G_7>U;WP;\1:EXK^']GJFJ>8TL]
MU>"VFE55>>S6ZE6UF8+\N7@6)\KP=V1@'%=M43J2J)*73R7Z%QA&'PGF7V?X
MR?\ /_X&_P# &\_^/5TO@N/QG&UW_P );<:#.N%^S?V+!-&0>=V_S';/\.,8
M[UU%%9%A1110 4444 8GC;_D4-8_Z]9/Y44>-O\ D4-8_P"O63^5%=%/8XZ^
MZ-NBBBN<[ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** *\^GVMU=6US-;0S7%L6,$TD89XBPPQ4D
M97(X..M4['POHVF7C7EGI%C:7;-([7$%LB2%I"#(2P&<L54GUVC/2M2B@#/L
MO#^EZ;8K96FFV=K9K+YXMX8$2,2;]^_:!C=O^;/7//6FWGAG2-2FN);O2K&Z
MEN%C2:2:W1VE6-BT:L2.0K$D ]"<BM*B@#/L/#^EZ7<//9:;9V<[[@TMO B,
M=SEVR0,\N2Q]22>M(WAW2FCO8VTRS*7L@FNE-NF)Y!C#N,?,PVKR>?E'I6C1
M0 R&&.WA2*)%BBC4*D: !54#   Z"GT44 -DC61&1U#HPP589!'H:RKCP?H-
MY;V=O<:)IT]O9QM%;126D;+ C+L94!&%!7Y2!U'%:]% %#^P=,^W6EY_9UI]
MLLXF@MKCR%\R&,XRB-C*J<#('' J232;*:SEM)+.WDM9F9I(&B4HY9MS$KC!
M))).>I.:MT4 ( %  & *6BB@ HHHH **** "BBLC4?$UM9W!M($DU#4,?\>M
MJ-S#W8]$'NQ% KV(_&W_ "*&L?\ 7K)_*BJ[:'?^(%/]LSB"T;_F'6;'##TD
MDZM]!@?6BM8R4=SGJ0=1W1T=%%>)W_Q>UZVOKF%!:[(Y&09B.< D>M9I7-Y2
M4=SVRBO"_P#A<GB#TM/^_1_QH_X7)X@]+3_OT?\ &JY61[1'NE%>%_\ "Y/$
M'I:?]^C_ (T?\+D\0>EI_P!^C_C1RL/:(]THKPO_ (7)X@]+3_OT?\:/^%R>
M(/2T_P"_1_QHY6'M$>Z45X7_ ,+D\0>EI_WZ/^-'_"Y/$'I:?]^C_C1RL/:(
M]THKPO\ X7)X@]+3_OT?\:/^%R>(/2T_[]'_ !HY6'M$>Z45X7_PN3Q!Z6G_
M 'Z/^-'_  N3Q!Z6G_?H_P"-'*P]HCW2BO"_^%R>(/2T_P"_1_QH_P"%R>(/
M2T_[]'_&CE8>T1[I17A?_"Y/$'I:?]^C_C1_PN3Q!Z6G_?H_XT<K#VB/=**\
M+_X7)X@]+3_OT?\ &C_A<GB#TM/^_1_QHY6'M$>Z45X7_P +D\0>EI_WZ/\
MC1_PN3Q!Z6G_ 'Z/^-'*P]HCW2BO"_\ A<GB#TM/^_1_QH_X7)X@]+3_ +]'
M_&CE8>T1[I17A?\ PN3Q!Z6G_?H_XT?\+D\0>EI_WZ/^-'*P]HCW2BO"_P#A
M<GB#TM/^_1_QH_X7)X@]+3_OT?\ &CE8>T1[I17A?_"Y/$'I:?\ ?H_XT?\
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>img34756086_9.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img34756086_9.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !! (<# 2(  A$! Q$!_\0
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M5Y?_ ,,_(/\ FHGQ _\ "@;_ .(KC/C-\+;OP#\*_%/B/3/B)X[.HZ782W4
MN-<9XRZC(W+MY'M6?)3;LI_@5S22NX_D?0@8GHM*&/<<?2OG7PGX9U+XH_%+
MXG1ZAXV\6:9:Z-?V-M9VNCZH;:%$>P@E;*A3DEW8Y]Z[C_AG]#Q_PL3X@?\
MA0-_\33=.$=)3U]!1G*2NH_D>I9']VG"11[?A7E?_#/L?_11/B!_X4#?_$5S
MO_"*W_PY^-GP^L;7QCXHUC3]8CU);NTUK4C<Q'RH$=" 0,$$GFE[.,M(RO\
M\ ?/*.LE^)[S[T4BT5@;C/XA]*\A^ O_ ".GQD_[&QO_ $DMZ]>Z,<^E>+_
M_4+6U\;?&19[F*%O^$K)Q)(%/_'I;^M;TKN%1)=OS,)64HM_UH>VTRHEFA9
MXD7:1D-NXQZYJH-8L,$?;K?/M,O^-<ZN^AMS)/5GA'[1W_(YI_V(/B;_ - M
MJ]G\ _\ (B>&?^P9;?\ HI:\3_:0F1/&41:5$#> O$@#,P )VVW%>Q> -4LU
M\">'%:]M\C3;;(\U>/W2^]=DXOV$78YHNU21UE(U01W$,R*\<JR(> R-D'\J
MCGU"UMF"RW,438SB20#CUYKCU=XI:G3=6O<^8/!__)9-#_[*!XF_](37U77R
M?X(NHIOC-H8CFC<GQ]XF8!6!RIL#@_2OJE9%P3NX7KDUWXO1Q7E^K.7#V7-K
MI_P$3GM7F/[3?_)OOQ _[!%Q_P"@UWW]M6&W/VZW_P"_R_XUYW^TE<0W7[/?
MC]X94F3^R+@;HV##[OJ*Y(Q?,KHWDU*#L8GP)_Y*I\:/^POIO_IKMJ]M'WA7
MA'P;U*TT?XD?&R[OKJ"RM(]6TTO<7$BI&H_LRVY+$X'XUJZO^U]\%M#NFMKW
MXE>'TG4[66.Z$F/^^<\5O*G4J3?)%OT5S"G4A"FN9I'LM>3_ !#_ .2]?"/_
M '=8_P#2:.M_P%\;/ ?Q.9T\*>+]'U^91DQ65VKR >NS.['X5S_Q"_Y+S\(_
M]W6/_2:.HI1E&;C-6=GOZ,NI*,H)Q=]5^:/6!WHH'>BL#=$;KO7%?B5\;KEO
MCE^UUXEL] DF9-<\1KIML8I&PX#+"7P".,*6^E?K=^T-\1E^%/P0\9^*2^V:
MPTZ0V_."9W&R(?\ ?;+7X7:+KVI>']4BU.POI;75%#E;R-L2*65E=@>Q(9N1
MR,U]UPOA)5(UJWE9>O\ 5CYS-ZZBX07J?;W[;G[75M#HZ_![X;7[)H.EPI8:
MMJ]M+GSUC4)]FC<?PC WL#R01TSG6_8-_8KNM6FL/B5\0K686"[9]%T.Z9LR
MGJMS,I/W1CY$/7ACP!GR#]A'X<_#+Q)XPOO$WQ+\2:396NAR1FRT/5;A8DNY
MCDB63=@.BX^[W.,\=?TX'[1'PJAC^7X@^&\*/NKJ47I]:G,JW]GTWEV#B[OX
MI6WOYAA(O$3^M5Y:=$?GK_P5(^(@UKXRZ+X5MI<0^']-\R?:Q_UTY#8/T14_
M[ZJ#X>_\$W_%OQ ^%>C>,8_&UGI,FJ:>M_%I]U!*1&C#<H9P>/EP>G>OFCXT
M^/3\4/BUXN\5W3;HM4U*66++8'DA\1J#V&P+^=>_>//^"DGC?Q-\/Y/!VAZ!
MH_@^PDM!8?:+.22:=( H3:A; 4[>,X. >/6OH?JN-H83#X?!I)_:;M^IY:J4
M*M6I4K7\K'-?L0?$OQ-X(_:4\*:'I^JW+Z5K&H'3;^S\YI+>96# N%)QE2H8
M,/2J_P"W/\1I_B)^T]XJ-K<2/9:5(FC6D<,C;3Y0P^ .YD+?E74?L6^&_#OP
M]U#4/B[XL\1:+8-H.G7$NB:'->QF[O+DQD*YBSN51G"]R6ST'/D_[/4&G^,O
MV@/#MSXMU.TT^P;47U74;S49ECC.T-,0S'J6?"_C6T8T(XVKBXQNJ<4MMY/7
M\"'.?U>%&^LG?]#T;_@G=YR_M>>%XI6?>MKJ&Y9&)*L+9P<^]?97_!1+]I4?
M"?X=_P#"&:'=E/%?B2)D:2)L-:67W9)..C/]Q?JQ[5\+_LB_$;1?AC^TPOC'
M7;M;?2;"VU:X>7/^LS#*41/5F)  ]2*P;O6KS]JW]HC^TO%6LVOA^#6[S=<7
ME[<+'#IUDG1%+'&50;5'=C[URXS+X8K,UB:R_=TXI^KUT-Z.)]CA?8Q?O2;7
MY'E,C7,*QLTUS&I7<H9V&Y<GD<\CC]*_3;X=P6/PJ_X)BWMWJ]SY#:MI-S=C
MSG(>6:YD(BC!/.3\H'M]*^"/VA+S1M=^,_B2W\,>2GABRGCTG3/(<&(6T*+"
MCJWH0I?=W+$U]%_\% /BIHUYX1^%_P .O"6OV.LZ%I&GK-=-ILZRQM-&BPQ!
MBIQD .<?[6:WS.G_ &C]5HQC;G?,_));$8:I]656<I7MHOF>">*/%WCG]JCX
ML7%K8V\LNH^)+V-HM"LI&6V#)$L2LW./EC09D;L#7U+I?_!)75I/"YFOOB!:
MVVO&/<MG;Z<7ME?'">87!(SQD+^=8O\ P3-NO 7@W4?&'B_Q;XBT?1]73R].
MT^/4KM(G$9&^610Q_B^1<C^Z1WK8^/G_  4M\9^%?B]XAT;P(?#6H^%K&1(+
M:ZN+5[AIV" NP=95#+N)Q@=/6N#%XC&RQ;P&6)1C#KM<VHTJ"H^VQ3YF]DCY
M!TWP'\2O ?B:+4=)\.>(;'6]+N<P7=I83@^8C<;6"C*DC\0:_8#5-0O-6^)G
MP)OM1A^S:A<V&I37,.,>7*UE$SKCV)(_"OBOX5_\%(OBGXP^)7AC0]9E\(:7
MHU_?1PWM]-9R0K#!G,C;S-A3M# 9XR17V#JGQ-\*^/OCY\+(?#7B/2]>FMH]
M7DG33KM)C$IMXP"VTG )R*\?.Y8J=:$<3249*+U3O?1G=@(THP?LYMJZW5NJ
M/?U;GZT4+UHKXH^B6Q\(?\%5OB-_8_PY\+^"K>;$^MWS7ER@/_+" <#\7=>/
M;VKS']FS]DN/XL?L4>,KY[95\2ZW?->Z+.Z#<IM05C4-_=D;S5/^][5]G?&O
M]CSP!^T%XGM=>\81ZG/>VML+.);6^:*-8PQ;[H'4ECDUZ3X#^'NE_#7P7I'A
M;083;:3I< M[:-FW,%&3ECW))))]Z^FIYM'#9?##X>ZFI<S?S_X8\B6#E5Q,
MJM2UK61^+_[*OQ0MO@W\=-"U+7;.&719Y3I>KVUW"KB..0[2Y5AP8W"M_P !
M(K],/VU=:\-_"_\ 9K\5ZK9:1I,5]J$ TRQECM(LF2?Y-RD#LA<Y'IFD\9_\
M$[_@[X[\5:MX@U'3-0CO]4G:YN5M+YHHO,;EBJ ?+DY/U)KM_B1^RUX/^+'@
M#PYX.\2R:K>:/H.PVNV_997*Q^6IE?'SD*<9-=.89IA,9B:.(2:M\2[VU_X!
MCAL'6H4ITM-=C\[O^"9OPM@\<?':[UF^M([K3?#>FO*8YD#H9Y?W<8((P<+Y
MA_ 5^JT?@KP_@?\ $BTS'_7E'_\ $UQ/P)_9O\&_LZV6K6G@^VNH8]4E2:Y>
M\N#,[,@*J 3T !/'O7J6#7E9MF+Q^*=6G=16B1VX+"_5Z2C/61\4?\%+M7T+
MP+\ XM)L-*TZSU3Q%J4=JLD-K&D@AC_>R$$#/9%/L]>/_P#!+/X3V?B35/'7
MB_5K&&]M+6"/2;87$2NOF/\ O)6 (ZA0@_X'7VM\=/V6?!7[1%WI,_C"/4)O
M[+61;5+.\:%!O*EB0!R?E'/I70?!GX&^&/@+X/?PSX3MIK?3'N)+I_M,QEE>
M1\ DL>O  %=D,TA1RR6$A?GD[M_/_(YY8.=3%>VE;E2T/PG\0PK;^(M7@C4A
M8]0G1$ R>)6"_CTK]5/V4_V>],_9R_9YUGQ5XNTJTF\47MC)J]_]M@63[)&D
M1>*W&X'&T<MC^)CZ"NQ\/_\ !/GX0^&_&UGXIM]+O[K4K6]_M"-+R^:2#SMQ
M8$IC! 8Y ]0*]R\=^!K#XB>#M6\,:L9CI6JV[6ET+>0QR&-AA@K#IG^M=V:9
M['&TZ="E=1T<GU?D8X7+I4)2J2LY:V/Q7_96\)GXI?M->"+&Y@62&XU7^TKN
M( ;=D9,S#'ID 8]*^CO^"IGPKDT/Q=X2\::9IL5MH5S8MI<[6L*HD4Z2-(FX
M*,9=7(!/]W%?8'P@_8D^&7P-\9Q>*?"]E?IJ\=O);(]W>M*BHXPV%(ZXXS[U
M[#XH\':3XTT6ZT?7M,M=7TJ[4I/9WD8DCD7W![^_445^((QS"GB:*;A%6L_Q
M)I98_JTZ51^\W>Y^2G[%/[4'A3X#W6L:-XZT)=3\/:E(ES%?0VB7$MI,J[2"
MC#)0C'3D$9P<\>S?M6?MG?!_QQ\$]?\ #'@*TWZ]J:1VZ3_V,+=(HMZF3#D#
M!*@J,>M>P^)/^"7?P@UJ^>YL9M?T(.<_9[._#Q+]!(C']:CTG_@EG\']/96N
MKSQ+J>.J3:@B(?P2,$?@:Z*F8936Q"QDG-2T=EM=&5/"XVG2]BE&W<^5_P#@
MF1\.(?&?QTU36-0M8[RPT'2G(2XC$D9FF8(@((QG:'(^E?JQIWA?1=+F%Q9:
M186D^W'FV]LB-@]L@5QGPB_9\\#? FQO+7P5H4>DI>%&N9#,\LDQ0';N9R3Q
MD_F:]&5=J@5\YFF8?VAB75A=1V5SU<%A?JM%0EN+12T5XQZ(4444 %%%% !1
=110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>img34756086_10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img34756086_10.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  O ,(# 2(  A$! Q$!_\0
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M;,3.50H(TP"D2DYX+$G(K]&-)_X*5?LWZJX"?$FVMF+!<7=C=1#/KEHL8]Z
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E8X]K!B5'SN60#G'!KZPHH :J@@';@TH4 Y P:6B@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>img155268912_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img155268912_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !] 4D# 2(  A$! Q$!_\0
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MGF6,G'"O&XW%8M4\)@N:A>FL14G&E*>*>*53V:7/&G2YY2<8QIE?YPW[<?\
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MBQ?!_P#J?FU/W:^,P&&S9.?/>GF6'Q2Q;I2B^7E5"A7R^$E"2?.JETG:<_\
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M_P"4=?QG_P"ST_B+_P"J-_9RK^GFOF^)/^1[F?\ V$R_])B?H' '_)&</?\
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M\CK_ (*2_P#*13]OC_L]/]J;_P!7EXZK_7%K_(Z_X*2_\I%/V^/^ST_VIO\
MU>7CJOO^ /\ ?,P_[!J7_IUGX?XX?\BK(_\ L88G_P!1D?VF?\&GG_*.OXS_
M /9Z?Q%_]4;^SE7]/-?S#?\ !IY_RCK^,_\ V>G\1?\ U1O[.5?T\U\WQ)_R
M/<S_ .PF7_I,3] X _Y(SA[_ +%\/_3E0^2/V_O^3$/VU_\ LTC]I#_U3GC.
MO\AZO]>']O[_ ),0_;7_ .S2/VD/_5.>,Z_R'J^TX _W;,O^O]#_ --S/R+Q
MQ_Y&.0?]@6,_]/TC_57_ ."+/_*+#]B7_LC5E_Z?M<K]0:_S:/V8?^#CS]M_
M]D[X _"W]G/X=?"S]E36O!'PD\,Q>%?#>J>-? _Q=U'Q5>Z=#=W=XLVMWVA?
M'+PYI%S>F6\E5I+#0]-@,:Q@6X8,[>\?\18?_!13_HC'[%G_ (;KXY?_ $1M
M>-C>#LZKXS%UJ<,.X5L37JP;Q$4W"I5G.-U;1V:NNA]9E'BMPC@\IRS!UZV/
M5;"9=@L-64<%.455H8:E2J*,E*THJ<79]5J?Z#]%?Q\?\$H/^#@?]LO]NO\
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M33J4\33LX\JHTYS<I2T<9584W3^)-22B_G>.^..!L^X>KX>A?,LTJ4X+ \V
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MF0_8/M5[^GE%%<V)Q-;%UZN)Q$_:5ZTG.I/EA#FDTE?EA&,%HEI&*7D>AE^
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M:^%Q5&G7P]:%^6I2JQ4X32DE)7BU>,DI1=XRBI)I%%%?G7_P4-_X*>?LP?\
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M6AMKD>%]6^'&B_&F[&KS&:4:AJ/_  FGQ?\ %YBNU2W":2=,L/)9K)KB=O\
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M9?&O5OA-_P %4_A9X5M9/#D&@_M ?#[XK_!KQ==^(6N(Y;33HO"5S\7/#O\
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MZVEM#?CQIX*?6O"W@CXAKXH?4-8\475UX<^(8\5>*=;\7>,M/\&_T<5_CA?
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M$:E*K3E&=.I3G%2A4ISBW&<)Q:E&46XRBTTVFF%?Q9_\'?O_ #CR_P"[M/\
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M5KUIJ.W-4FU3@Y3=.C&G2YYJFI/^8;_@[#_Y1U_!C_L]/X=?^J-_:-K^+/\
MX)M?\I%/V!_^ST_V6?\ U>7@6O\ 2)_X*P_\$X/^'H'[.O@SX!?\+E_X4?\
M\(A\:O#OQ@_X2S_A7G_"R_[0_L#P-\1O!?\ PCO]A?\ "<_#_P"R?:_^%@?V
ME_:W]LW/D?V3]C_LR;[?]JLOQ9_9M_X-8O\ AGK]HKX!_'W_ (;K_P"$O_X4
M?\:OA9\8/^$3_P"&8O[ _P"$H_X5IXYT+QI_PCO]N_\ #0NM?V+_ &U_8O\
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M?V;_ &M_8VD_VE]F^V?V98>=]EB_9#_@DQ_P3,_X=<_!+XB_!S_A=G_"\O\
MA/OBI<_$S_A(_P#A6_\ PK/^R?M'A+POX6_L3^R/^$]^(/V_9_PC?V[^TO[4
ML]WVW[+]@7[-]HG_ $7/L^RK&Y!#!8;%>TQ2C@TZ7L,3"SI<GM/?J484_=L_
MMZ_9N?@O!7!?$V4\;ULWS#+?J^73EFKCB/KF7U;K$NI[#]S0Q56NN?F6])<M
M_?Y=3]4J_FH_X.%O^"23?MD?"B3]K#]G_P &^(O$/[6?P6\.V.E:EX/\*.;^
MZ^-GP;TW4-0U'4?#MEX6FE0:E\1_ 3ZQJGBGP9+X;9?$_C#1QK_P[70_'?B"
M]^&&G^&/Z5Z*^'R_'XC+<71QF&E:I2E=Q;?)5@_CI5$FKPFM&MUI*+4HQ:_8
M\]R7 \0Y7BLJS"'-0Q,&E.*C[7#UE=TL30E)-1K49VE!M.,E>$XRISG"7^+/
M7]//_!IY_P I%/C/_P!F6?$7_P!7E^SE7[!?MK_\&N_P?_:8_:+\>_';X,?M
M(ZA^S9HWQ.U"Y\7>+OAA/\'S\6M#MOB-K>HZAJ/C#Q#X.U>7XL?#V\\->&O$
MUY<PZN/!%Q9ZW:>'M=N-<7PWJFE^#[KP[X+\)?1W_!)[_@A#_P .O_VBO&?Q
M]_X:H_X7A_PE_P %?$7P?_X1/_A1_P#PK3^S_P"W_'/PY\:?\)%_;O\ PM_X
M@?:_LG_"O_[-_LG^QK;S_P"UOMG]IP_8/LM[^CYMQ1D^/R7%T:6)E'%8C#)1
MPTZ&(YHU).+=.514O8MQ=US*IR.UT]3\!X8\..*\EXNRS%XC 0J9;@,Q<IX^
MEC,#[.IAX*I&->&'EBEBTIIQDJ<J"JQO9QT;/Z#Z^+/^"DO_ "CK_;X_[,L_
M:F_]4;XZK[3KQ;]I+X/_ /#0O[.OQ\^ 7_"1?\(A_P +P^"OQ3^#_P#PEG]D
M_P!O_P#"+_\ "R_ VN^"_P#A(O["_M/1?[:_L7^VO[2_LG^V=)_M+[-]C_M.
MP\[[5%^98:<:>)P]2;M"%>E.3LW:,:D92=DFW9)NR3;Z)L_HG,:52OE^.H4H
M\]6M@\32IQO&/-4J4)PA'FDU%7E)*\FHJ]VTM3_'0HK^TS_B$"_ZR&_^:E__
M )3%'_$(%_UD-_\ -2__ ,IBOV7_ %NX>_Z&'_EICO\ YF/Y+_XA;QW_ -"+
+_P R>3?_ #P/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>img155268912_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img155268912_1.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !] 4D# 2(  A$! Q$!_\0
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MGF6,G'"O&XW%8M4\)@N:A>FL14G&E*>*>*53V:7/&G2YY2<8QIE?YPW[<?\
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MBQ?!_P#J?FU/W:^,P&&S9.?/>GF6'Q2Q;I2B^7E5"A7R^$E"2?.JETG:<_\
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M_P"4=?QG_P"ST_B+_P"J-_9RK^GFOF^)/^1[F?\ V$R_])B?H' '_)&</?\
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M\CK_ (*2_P#*13]OC_L]/]J;_P!7EXZK_7%K_(Z_X*2_\I%/V^/^ST_VIO\
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M5;"9=@L-64<%.455H8:E2J*,E*THJ<79]5J?Z#]%?Q\?\$H/^#@?]LO]NO\
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M33J4\33LX\JHTYS<I2T<9584W3^)-22B_G>.^..!L^X>KX>A?,LTJ4X+ \V
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MF0_8/M5[^GE%%<V)Q-;%UZN)Q$_:5ZTG.I/EA#FDTE?EA&,%HEI&*7D>AE^
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M:^%Q5&G7P]:%^6I2JQ4X32DE)7BU>,DI1=XRBI)I%%%?G7_P4-_X*>?LP?\
M!-[X;7'BSXS>)X]=^(VJV=O+\.O@-X2U#2[GXI_$&>^NKNQM=1M]'N;J(>'/
M UE/I^I3>(/B!X@%KX?L(=*O=*TEO$'C2Z\/^#]=>'P]?%5H4,/2G6K5)*,*
M<%>4F_P26\I-J,4G*3239.-QV#RW"UL;C\12PF%P\'.M7K34(0BO-ZRE)VC"
M$5*=2;4(1E*23_12BO\ -P_:N_X.4/\ @HU^T'=>(='^%GB;PQ^RE\-]6MO%
M^AV_A_X1Z-9ZGX_G\,>)&,&FC6_B_P",;35O%%AXV\-Z46M=/\=?".T^#MTN
MHSW&N66E:9?Q:4=*_,G_ (>2_P#!13_H_C]M/_Q*;XY?_-U7V6'X#S*I34J^
M)PN'F_\ EU>=:4?*<H14$_*$IJWVKW2_)<;XU</4*\J>"R_,L=2CH\0U1PM.
M;Z.E"K.59PMUJTZ,DTUR-6D_]<6BO\OS]FO_ (+Z?\%1/V:[G1[>#]HC4?CI
MX/TS4=;U2]\#?M*Z>OQ>MO$-SK6DSZ:D6L?$34;G3_CG#IVC73VFNZ)I&@?%
MC0])M-6TZ!)K*ZT>]UK2=5_M"_X)?_\ !=C]FC_@I'XA7X02^&M:_9]_:371
M-1U^U^%/C#Q!I/B/PYX\LM,OM<FU*#X0?$*VM] N/&VM>'?"6G:9XL\6^&=;
M\%^"/$=C8:AK-YX7TOQGX7\#^,/%NE>9FG"N:973E7E&GBL-!.4ZV&<I.E%/
M>K2G&-2*M[TI052G!?%41]%PWXE\-\1UZ>"A4K9=F%6484L)F$806(J-+W<-
MB*4ZE"I)R:A"G5E0Q%66E.A(_<&BBBOFC]""BOR9_P""Y?Q6^)?P1_X):?M0
M_$_X/^._%7PS^(OAC_A2?_".^-_!.MW_ (=\3Z)_;7[1/PD\/:O_ &9K.F36
M][9_VEH6K:GI%[Y$R?:-/O[NUDW0SR*W^>7_ ,/5_P#@I7_T?9^U1_X>KQU_
M\N*^FR7AC$YUA:F*HXFA1C3Q$\.XU8U')RA3I5')<B:LU52[W3\C\[XN\1<O
MX1S*AEN+R_&8NI7P-/'*IAYT(PC"KB,3AU!JI.,N=2PTY-I6M**3O>W^LU17
MY/\ _!'W_@IGX>_X*:?LQCQYJ&EZ=X0^.GPMU'3/ ?QY\#V.J:;=6J^))='@
MOM)^)'A738;V?7=,^'/Q+BCU2Y\-V_B.RM+K2?$GA_QUX(M-1\6VO@H>,_$'
MZP5X.*PU?!XBKA<1!TZU";A4@VG9K5--74HR34HR3:E%IK1GV^6YCA,VP.%S
M+ 557PF,I1K4*B3BW%W3C*,DI0G"2E"I"24H5(RA))IA17RM^W7XH\1^!_V(
MOVQ_&O@[7-4\,>+O"'[*W[0OBCPMXET.]GTW6O#WB/P_\(_%^K:'KFCZC:O'
M<V&J:3J=I:W^GWMO)'/:W=O#/"ZR1JP_S#O^'J__  4K_P"C[/VJ/_#U>.O_
M )<5[62<.8C.Z5>K1Q%&BJ%2-.2JJ;<G*/-=<B:LEW/C^+^/L#P?B,'AL7@<
M7BY8VC4KPEAI48J$:=14W&2JRBVVW=6T[G^LU17PA_P3 \<^,OB9_P $]?V/
M?B!\0O$^N>-?''B_X#^!==\4^+/$VI76L:_X@UF^TQ);S5-7U2]DFN[Z^NI"
M7GN;B5Y9&Y9B:^[Z\*O2="O6H2:E*C5J4G)7M)TYN#:OK9M75];'VF#Q,<;@
M\)C(1E"&+PU#$PA*W-"->E&K&,K77-%32=G:Z=M HK\NO^"L/_!3?P-_P3!_
M9ZTSXF:EX;L_B/\ %3XA^)&\%?!_X5OXGTOP[-KVIV]A+J?B/QCKGFR7'B ?
M#_P)IXLAXDU'PYH6LS'Q+XD\!^$KV;P\GC2W\2Z5_G2_ME_\%.?VV?V\=<U>
M[_:#^-_B?4?!.H7_ -JTWX*^$;RZ\&_!'PY:VFO:WKWA^RL/AQHUS'I&NWWA
M9M>N=*T?QMX[;Q?\3+C1;32K'Q!XWUQM,M)X_H<DX7QN<P^L*<,+A.9P5>HG
M.4Y1=IJE1BXN:B]'*<Z<'*\8R;4E'X7B_P 1\HX3K?494:V8YI[.-5X.A)4:
M=&$US4WBL5.,U2=5>]"%.E7JJ%ISIPA.FY_ZS]%?XL]?I5^Q+_P5O_;K_8'N
M='T[X*?&/4]:^%^D+<Q)\!?BG)J?CSX*FUO=0UG6[VVTCPG=:K97W@)M0\1:
M]J/B/5M0^%^N>!M8US6)6FUS4M1MYKJUN/<Q' &(A2E+#9E2KU5JJ=7#2P\9
M*SNE4C7KVELDG!1=]912N?&X'QPP-7$0IYAD&(P>&EI+$8;'PQU2FVTDWAYX
M/!<T$FW-QK.:2]RG4;L?ZMU%?!O_  3A_;S\)_\ !1O]F71/VCO"'PV\>?"N
MWN-?U'P9KOA?QQ!!/;KXL\/:9HEUXEF\"^*+1+:V\?> [34]8FT+2O&<>EZ!
M/J.IZ-K5AJ7AO0-7TO4-*M?O*O@J]"KAJU3#UX.G6HSE3J0;3<9Q=FFXMQ=G
MU3:>Z;1^V8/&8;,,+A\;@ZL:^%Q5*%?#UHJ48U*51*4)J,XQG&Z>THQDMFD]
M HK^>7_@Y8_:!^.'[-_["OPH\<? +XL^/_@YXQU7]K/P+X4U+Q/\.?%&K>$]
M<OO#5]\'OCOJ]YH-UJ.CW-K=3Z5=:IH6C:A/922-!)=Z78SLADMHF7^3+]@;
M_@I9_P %!O'G[=7[%G@?QI^V?^TGXI\'>,OVL_V<O"GBSPQKOQ=\9ZEHGB/P
MUXB^,/@W2-=T'6=.NM5DM=0TK5]+O+K3]1LKF.2"ZM+B:"9&CD93]#EW#&)S
M++IYC3Q-"G3A[>].<:CF_8*\K.*<?>Z:^I\)G_B+E^09]2R"OE^,KUZOU.U>
MC.@J*^N24874YJ?N7O*R]+G^G/1117S)^B!17^8Q^WS_ ,%+/^"@W@/]NK]M
M/P/X+_;/_:3\+>#O!O[6?[1OA3PGX8T+XN^,]-T3PYX:\._&'QEI&A:#HVG6
MNJQVNGZ5I&EV=KI^G65M''!:VEO#!"BQQJH_43_@@G_P6_\ B?:_'U_V5/VW
M?BS\5?B_I'[1GB[P=X?^!?Q)\::Q/XXO_AW\7M5N'\.6/@O6KBZL;SQE/X/^
M+=W>^&M$TZ^CUJ_T/P!XRTG3;J3PSI^A^._'WCCPW]?B.#LPH8"6/IUJ.(4:
M,*[H4HU/:NG)1E+EYHJ,I4X-S<4[R49*'-+EB_RS >*^1XS.X9+6PF+P,IXN
MK@HXW$2H/#*O"<J=-5'";G"%>K%4HS<7&$IP=5PI\\X?W1T445\@?J845_"Y
M_P ''O[;_P"V%^SM^W[X8\!? C]IGXV_"'P5<_LW_#OQ'<>%?AY\1?$WA709
MM>U#QG\3K.^UB73-(U"UM7U&[M-,T^VN+MHS-+#96T;L5A0#H_\ @VG_ &U_
MVN_VD/VZOBOX'^/O[2GQI^,?@[2OV3/'7BO3?#'Q&^(7B3Q9HECXEL?C#\"-
M(L]>M=.UB_NK6#5;72]=UG3X+V.-9X[35+Z!7$=S*K?3OA?$K)_[8^LT/8_5
MUB?8VJ>TY6TN6_+R\VO>WF?G4?$;+Y<5?ZJ?V?C?K7U^6 ^M<]#ZO[2,7+GY
M>?VG([/3EYMM.W]P%%%?)G[?/BOQ+X#_ &%?VT_''@O7M5\+>,?!O[)G[1OB
MOPGXGT*]GTW7/#GB7P[\'O&6KZ%KVC:C:O'=:?JND:I9VNH:=>VTD<]K=V\,
M\+K)&K#YRE3=6K2I)I.K4A33>R<Y**;MK97NS[[$UXX7#8C$RBY1P]"K7E&-
MN:4:5.51QC?2[46E?2[U/K.BO\F7_AZO_P %*_\ H^S]JC_P]7CK_P"7%'_#
MU?\ X*5_]'V?M4?^'J\=?_+BON?]0<=_T'83_P !K?\ R)^,_P#$;\E_Z$V:
M?^#,)_\ +/7^GI]V_P#!RG\4?%'C_P#X*P?%[PGKYTXZ3\#_ (=?!/X7>"!9
M6AMKD>%]6^'&B_&F[&KS&:4:AJ/_  FGQ?\ %YBNU2W":2=,L/)9K)KB=O\
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M9?&O5OA-_P %4_A9X5M9/#D&@_M ?#[XK_!KQ==^(6N(Y;33HO"5S\7/#O\
MPC5PFJ:=9VWB?5/B!\*/!OART.I6^LPWNF:YK&CV.F#6=4TS4=/_ -*VOF>*
M<LIY7FU2G0BH8?$4XXJC325J<:DIPG3C:R48U:=3DBDN6FX1UM=_HGAMQ#B.
M(N&,/B,9-U,;@:]3+<56DVY8B>'IT:E*O-RO)U*F&KT?;3;E[2O&K4NN;DC^
M+/\ P<._\H>?VOO^Z ?^M1?!.O\ ,-K_ $\O^#AW_E#S^U]_W0#_ -:B^"=?
MYAM?;\!_\B?$_P#8RK?^HN#/QSQK_P"2JR__ +)_"?\ JQS4^T_^"?G[;OQ'
M_P"">W[4OP__ &E_AU8_\)'_ ,(Y_:.@^._A[=>(-9\.:)\3_AQXCMQ9^)_!
M.N7VCN^S?LL?$GA:]U32_$>C>'/B#X<\'>,+WPMXC_X1R+2+K_5=_9U^/?PY
M_:D^!GPK_:%^$NJKJWP^^+G@S1_&7A]WO-%O-2TH:E !JGA;Q(/#VKZ]I&G^
M,_!FM1:CX1\<:#:ZQJ#^&_&&B:YX?N[AKS3+@+_DE?M0_LV_$[]D'X__ !1_
M9M^,EEIME\1?A/XC.@:X^BWDVH:#JUK=6%EK?AWQ/X>O;JTTZ^N?#GB[PQJN
MC>*?#TNIZ7I.KMHNL6/]KZ/I&I_:]-M?V=_X-_\ _@JX?V$?CE)^S]\7+BV?
M]F#]I7QKX6LM<\0:QXF70M/^!/Q*NMGAK2OBSYFNZK8^#++P5K%K/I&B?&N]
MU/\ LK4+7PMX>\+^,[?Q$;?X<3>#_&5<4Y)#-\'#,\"HU,51HQG%T]5B\(U[
M1*+YE%RA&4JM)I.51-TTI.4.6/#7C"KPOFM7A[.'.AEV+Q<Z,U67(\KS.+5"
M4JBY'.-.K.G##XF,G&%&<85VX1A6<_[N?^"BG_*/O]NK_LSC]IS_ -4GXWK_
M "+J_P!='_@HI_RC[_;J_P"S./VG/_5)^-Z_R+JY. /]SS#_ +":7_IIGJ>.
M'_(TR+_L Q7_ *D1/]7_ /X)$?\ *,7]AK_LW+X=?^FA*_1FOSF_X)$?\HQ?
MV&O^S<OAU_Z:$K]&:_.LQ_Y&&._[#,5_Z?F?O61?\B/)O^Q5EW_J)1/\WS_@
MYM^..O?$_P#X*?\ BWX9WUK-IV@_LW?"SX6?#708$U>\O;'6)_&/A2R^-^L^
M*SI4R166BZO>2_%*S\)WPLA.^H:9X(T&ZNKMV$5I8\)_P09_X)<^"?\ @I%^
MT'X\U/XUW%^_[/?[.^D>$?$'Q"\-:'J\VBZW\0O$WC74]8B\"^ )=2L9K;6=
M%\)ZU9>#_&FH>+_$'AZZM?$%M9Z-::%HM]HFI^)+7Q-H/V?_ ,'4G['>K_#G
M]JGX?_ME>&_#DH^'W[1G@_2?!/Q \0VC>*]42T^.?PNTW^Q;(>([B[TY_"7A
M2+Q?\';/P39> M$TS7$O_$\WPN^)^M2>'K5]'U#6-8_(G_@EE_P4T^(W_!+_
M ./>M_%CPOX17XI>!?'/@V\\%?$SX1WWC/5_!>F>*K6*XCU;PKXAL=5L[#Q#
MI6E^,/!^N6Y&CZ]J_@[Q2UMX8U_QSX;T^UTV3Q=<:Q8_K6#=?$<)X>.334,5
M]0ITJ;4HQDL13<8XI1E*5J=2<HUO9SE*/).<9WBEI_,&;+!X'Q/QM3BRFZV6
MK.J^(Q$73G4@\#6C.IELITX4W.O0HTIX1UZ4*=1U:5*K22J2;YO]&7Q=_P $
MI?\ @FGXV\'ZMX&UG]A/]EFRT76=-72KR]\(_!?P/\/_ !A#:J8B)=)^(?@/
M2/#?C_0=2)A3=K.A^)M.U=P90]\PGF$G\_7Q[_X-2?ACKW[3OPMUW]G_ .,'
MB/P'^RAXE\1^(+[X]>!O$NH1>)/B?\.=,CO-6\0Z/HWP'\07NB/9:YX<URR:
MP^&UC+\4)_$'B[X:RVUE\0-9U7XY_P!I:IX9T;]@_P!E_P#X+N_\$Q_VH](A
MN+#]HOP]\"_%2Z?>ZGJOP_\ VG+C2O@MK>BV]MK\^AVD#^+-=U>Y^$7B/4]7
MB2TU[3]%\"_$OQ9K$6A:E;SZM8:9?6FLZ?I?[!5^;PS'B#):LX3K8W#3FJD'
M3Q2J2A)N/*ZD(5U*$IPO&4*L+IVA=R@^67[]5R#@?B[#4:U+"Y1CZ5*="K'$
M9;*A3JPC&HJBP]:KA'"K&G5Y9TJN'K<K2=5*-.M'GAYE\&?@U\+_ -GKX6^"
M/@K\%O!>C_#WX7?#G0K?P[X.\(Z&D_V+2].@>2>:6>[O9[O4]8UC5;^XN]8\
M1>(];OM2\0^)_$&H:GXA\1:IJFN:GJ&H7/IM%%>'*4IRE.<I3G.3E.<FY2E*
M3;E*4FVY2DVVVVVVVV[GV=.G3HTX4J4(4J5*$:=.G3C&%.G3A%1A"$(I1A"$
M4HQC%*,8I)))'\PW_!V'_P HZ_@Q_P!GI_#K_P!4;^T;7\6?_!-K_E(I^P/_
M -GI_LL_^KR\"U_:9_P=A_\ *.OX,?\ 9Z?PZ_\ 5&_M&U_%G_P3:_Y2*?L#
M_P#9Z?[+/_J\O M?K'"W_)+U_P#NH?\ I#/YB\2?^3CX/_NA_P#IV)_KBT44
M5^2G]0'^1U_P4E_Y2*?M\?\ 9Z?[4W_J\O'5?%E?:?\ P4E_Y2*?M\?]GI_M
M3?\ J\O'5<-8?LF_%[6_V2=3_;,\,^'-2\2_!_PC\9M3^"_Q.U72+);J/X8Z
MR_ASP#KO@G7/%9CNGO;7PYX\O?&=YX8T[7#IB:#I'B?1M+T#6=9MM;\=>#-,
MU;^A,-5ITL'@O:3C#VE'#4H.324JDZ4>2";TYIM<L4W>4FHJ\I)/^%<PP]?$
M9KG'L*4ZKH8K,,155.+E*%"EB9^UJN*N^2DGSU))-4Z:E4G:$)27]XW_  ;W
M_P#!6 _MM?!A?V8?C3K?BC6OVKOV>_!@U'4_&?B>]779OC9\)+37;;0M'\>S
MZVEM#?CQIX*?6O"W@CXAKXH?4-8\475UX<^(8\5>*=;\7>,M/\&_T<5_CA?
M;XY?$W]FGXQ_#KX\_!SQ-?>$?B5\+O$]AXI\+ZU8W%U IN+4O#?Z/JT5I<6K
M:IX8\3:3/J'AKQ=X>N93IGB?PMJ^L>'=7AN=*U2\MIO]5[_@GE^W5\-/^"BG
M[+_@W]I+X;:9>>%WU*\U#PI\0OA[J>IV6LZM\-/B7X=2S;Q+X.O=6T](+?5K
M,6^H:5XC\+:T]CHU[K_@GQ%X9UW5/#GA?5-2O/#>E?EW%V0_V=B/K^%A;!8J
M;YX17NX;$2O)P2OI2J^].FDE&#4J:48JFG_2'A=QM_;V!62YE5YLWRVC'V56
M;;GF&!I\L(U7*WO8C#7A2Q',W4K1=/$-U)RQ$H?Q+?\ !U%_RDJ\(_\ 9JOP
MO_\ 4]^+E=3_ ,&GG_*13XS_ /9EGQ%_]7E^SE7+?\'47_*2KPC_ -FJ_"__
M -3WXN5U/_!IY_RD4^,__9EGQ%_]7E^SE7U,O^2'7_8KA_Z5$_-J?_)XW_V4
M=3_TB1_H/U\6?\%)?^4=?[?'_9EG[4W_ *HWQU7VG7Q9_P %)?\ E'7^WQ_V
M99^U-_ZHWQU7Y9@O]\PG_830_P#3L#^D\V_Y%69_]B_&_P#J-5/\CJBBBOZ'
M/X//]@;]K#]DCX!_MM?!G7/@/^T;X%L_'/@+6+RRUFR!GGTSQ#X2\5:2MPNB
M^,_!/B.Q>+5/#/BG28[R^LX]1T^=8M2T34];\+:_:ZQX3\1>(-"U3^'/]O3_
M (-B/VJ_@--XC\??L?ZU%^U7\)K675M5A\$.-/\ #'[0WA30H!XNUL6L_AV>
M6V\*?%H:#X>TCPYHS:I\/]2TOQ_X_P#&OB 6OA;X$:;I\3/'_<]^T/\ M4?L
M]_LF^'?!WB_]HWXJ>&OA'X5\>_$7PW\*?#/B/Q6U_#HMSXW\6)?S:18:GJ5G
M97EIX<TE+32M2U'6O%OB272?"'A?2;"\U?Q-KND:9;RW:_0%?A>5YUFN2J,\
M/*3PM:<G[&O"4L-6E#E51TW[O+.*<5.5&<9:P52Z44?V=Q)PAPUQ;.I2QT(+
M,\+2IQ>+P5:G3S'"TZO/*A&O%*:G1GRU)488JE.-O:NARMSD?XSOQ%^&GQ'^
M$'C#5OAY\6OA_P"-OA=X_P!!&GMKO@;XB^%-=\$^,-%75M-L]:TMM6\,^);#
M3-:TX:EH^H:?JVGF\LH1>:;?6=_;^9:W,,K_ %_^Q?\ \%,_VTOV"->L+[]G
M?XT^(M)\&Q:FNH:W\&?%4\WC#X*>*X[C6/#NJZ]!JOP[U>>32M'U/Q/#X8T[
M0M7\=^!W\(_$^V\/2:AI?A_QSH:7]Q(_^IO\?OV;_@-^U/\ #W4/A7^T1\)O
M!'Q?\!Z@M^R:)XTT.UU-]%U'4-$U;PY)XD\(ZOMCUSP1XRLM&US5[31/''@[
M4M#\8>'C?SW6@ZWIMX5N%_S0O^"V'[ W@W_@G=^W'KWPB^%]W<2?"#X@> O"
M_P :OA1I&J:Y>>(O$7A/PKXJU+Q'X7U3PEK^JWFCZ4]PVB>//!'C.'PP6N/$
M-^? #^$'\1>)];\5OKUS7Z)D_$6"XB<LOQ>"C"LZ3J.E5Y,1AJRARJ3BYQ4H
MS7-S*$H/EBG:K)K7\&XJX#S?@-4L\RO-ZE7"QQ$*$<3AW5P6/PLZO-*FJJIU
M)0J4I>S5.52%6*G-Q4L/",M/[\_^"5__  4U^&__  4]^ 6J?%+PSX>@^&_Q
M&\">)7\(?%CX0S^+=+\5:IX1O[FW_M'PQXCLKJWMM(UB^\$>-M+%R?#FOZOX
M8T".[\0>'_&_AFR34Y?!NH:G<?IM7^?U_P &FOB3Q%:_MY?'OPA;:]K5OX3U
MS]D;Q-XDUKPQ!JE]#X=UCQ%X5^,GP6TSPQKVJ:+'.NFZAK7AS3?&/B[3]!U2
M[MIK[1['Q5XDM-/GM[?7-3CNO] 6OSSB/+J.5YMB,-A[J@XTZU*+;DZ<:L;N
MFY2;<E"7,HMMR<.7F;E=O]XX!S[%<1\,X+,<=9XU3K87$U8QA"->IAZC@JZA
M!1A!U8.$JD81C!5.?V<8PY8K_/@_X.P_^4BGP8_[,L^'7_J\OVC:/^#3S_E(
MI\9_^S+/B+_ZO+]G*OUG_P"#K/\ 9-\1_$O]F;X+_M:>%4M9K?\ 9B\5:[X4
M^)U@EAHMO?/X!^.6H^"M"T'Q;<^(+[7M.U*[M/"'Q'\/>&?"EGX1TC0_$E]>
M3?%R_P#$H?0=(\,^(+F__D-_X)K?MJ^(OV /VR?@]^TAIDNMW/A+0M:_X1KX
MP^%M$DOI9O&WP8\5M%I?Q!T!=$M_%7@W3/$NM:=IK1^,_A_I7BC7(?"EK\4O
M"G@3Q#K<%Q;Z&J5]]EB>:\'2PN&<77CA:^%<+WM7I3<XTV[)*56#ISCTBJL;
MO1GXCQ#)<->+$,QS!3C@YYC@\RC6Y;*6#Q5*-*I6BKR<H8:LL12ELYRPU3E2
MND?ZU5%>8?!?XT?"S]HGX6>"/C9\$_&^B_$7X6_$718M?\'^,- EF:QU.Q::
M:TNH)[6[AM=3T?6M'U.UOM#\2^&M<L=-\1^%O$>FZKX;\2:5I6O:5J.G6WI]
M?DTHRA*4)QE"<).,X23C*,HMJ491:3C*+3332::::N?T]3J4ZU.G5I5(5:56
M$:E*K3E&=.I3G%2A4ISBW&<)Q:E&46XRBTTVFF%?Q9_\'?O_ #CR_P"[M/\
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M5KUIJ.W-4FU3@Y3=.C&G2YYJFI/^8;_@[#_Y1U_!C_L]/X=?^J-_:-K^+/\
MX)M?\I%/V!_^ST_V6?\ U>7@6O\ 2)_X*P_\$X/^'H'[.O@SX!?\+E_X4?\
M\(A\:O#OQ@_X2S_A7G_"R_[0_L#P-\1O!?\ PCO]A?\ "<_#_P"R?:_^%@?V
ME_:W]LW/D?V3]C_LR;[?]JLOQ9_9M_X-8O\ AGK]HKX!_'W_ (;K_P"$O_X4
M?\:OA9\8/^$3_P"&8O[ _P"$H_X5IXYT+QI_PCO]N_\ #0NM?V+_ &U_8O\
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M?V;_ &M_8VD_VE]F^V?V98>=]EB_9#_@DQ_P3,_X=<_!+XB_!S_A=G_"\O\
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+_P R>3?_ #P/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>img238985936_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img238985936_0.jpg
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M!@4%      4#! 8' 0(("0 3%!A8E]81$A46.'@*(3>WN#9Q<W>V_\0 ' $
M @,! 0$!            !08 ! <#" $"_\0 /1$  @(! P(# @H) P4
M 0(#! 4&$1( $P<A(A0Q%18R-%15E)72TR,S-4%Q='6TM211LS9"@8.V_]H
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M_P#7_P J=;.7O]-9-_<3U]_RSNSY\S_SZ#^BZ;_^=Q74H_J'_G,C_D+71$_
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M4QI+&@.Q>R3[V('ZU'F+XRT\%*U8ABK1K&5AD9%9D0S32$ @$IR968^?&/\
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E6(I>,\,UAF++)(D)C]"I'"(QNBJFP* #?8@@=7Q?GDCK4NO_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>30
<FILENAME>lxeo-20241231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-03-24T06:04:08.8282+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.lexeotx.com/20241231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:lxeo="http://www.lexeotx.com/20241231" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2024" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd" namespace="http://xbrl.sec.gov/ecd-sub/2024"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" namespace="http://fasb.org/srt/2024"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" namespace="http://xbrl.sec.gov/dei/2024"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" namespace="http://fasb.org/us-gaap/2024"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" namespace="http://www.xbrl.org/dtr/type/2022-03-31"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd" namespace="http://xbrl.sec.gov/cyd/2024"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd" namespace="http://xbrl.sec.gov/ecd/2024"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2023/calculation-1.1.xsd" namespace="https://xbrl.org/2023/calculation-1.1"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20241231/taxonomy/role/StatementBalanceSheets" id="StatementBalanceSheets">
        <link:definition>100010 - Statement - Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingEquipmentFinanceLeaseObligationsDetails2" id="DisclosureLeasesReconciliationOfRemainingEquipmentFinanceLeaseObligationsDetails2">
        <link:definition>100020 - Disclosure - Leases - Reconciliation of Remaining Equipment Finance Lease Obligations (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingUndiscountedContractualRentObligationsDetails2" id="DisclosureLeasesReconciliationOfRemainingUndiscountedContractualRentObligationsDetails2">
        <link:definition>100030 - Disclosure - Leases - Reconciliation of Remaining Undiscounted Contractual Rent Obligations (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20241231/taxonomy/role/StatementBalanceSheetsParenthetical" id="StatementBalanceSheetsParenthetical">
        <link:definition>100040 - Statement - Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss" id="StatementStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>100050 - Statement - Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" id="StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit">
        <link:definition>100060 - Statement - Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" id="StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical">
        <link:definition>100070 - Statement - Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfCashFlows" id="StatementStatementsOfCashFlows">
        <link:definition>100080 - Statement - Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCybersecurity" id="DisclosureCybersecurity">
        <link:definition>995455 - Disclosure - Cybersecurity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentation" id="DisclosureDescriptionOfBusinessAndBasisOfPresentation">
        <link:definition>995465 - Disclosure - Description of Business and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" id="DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>995475 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurements" id="DisclosureFairValueMeasurements">
        <link:definition>995485 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities1" id="DisclosureAccruedExpensesAndOtherCurrentLiabilities1">
        <link:definition>995495 - Disclosure - Accrued Expenses and Other Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeases3" id="DisclosureLeases3">
        <link:definition>995505 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertibleSafeNote" id="DisclosureConvertibleSafeNote">
        <link:definition>995515 - Disclosure - Convertible Safe Note</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStock" id="DisclosureConvertiblePreferredStock">
        <link:definition>995525 - Disclosure - Convertible Preferred Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCapitalStock1" id="DisclosureCapitalStock1">
        <link:definition>995535 - Disclosure - Capital Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensation1" id="DisclosureStockbasedCompensation1">
        <link:definition>995545 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureNetLossPerShare" id="DisclosureNetLossPerShare">
        <link:definition>995555 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>995565 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingencies1" id="DisclosureCommitmentsAndContingencies1">
        <link:definition>995575 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreements" id="DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreements">
        <link:definition>995585 - Disclosure - License, Acquisition, Research Collaboration and Sponsored Research Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSegmentInformation1" id="DisclosureSegmentInformation1">
        <link:definition>995595 - Disclosure - Segment Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>995605 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>995615 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" id="DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>995625 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsTables" id="DisclosureFairValueMeasurementsTables">
        <link:definition>995635 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesTables" id="DisclosureLeasesTables">
        <link:definition>995645 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" id="DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables">
        <link:definition>995655 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockTables" id="DisclosureConvertiblePreferredStockTables">
        <link:definition>995665 - Disclosure - Convertible Preferred Stock (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCapitalStockTables" id="DisclosureCapitalStockTables">
        <link:definition>995675 - Disclosure - Capital Stock (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationTables" id="DisclosureStockbasedCompensationTables">
        <link:definition>995685 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureNetLossPerShareTables" id="DisclosureNetLossPerShareTables">
        <link:definition>995695 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
        <link:definition>995705 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSegmentInformationTables" id="DisclosureSegmentInformationTables">
        <link:definition>995715 - Disclosure - Segment Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails" id="DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails">
        <link:definition>995725 - Disclosure - Description of Business and Basis of Presentation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>995735 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentNetDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentNetDetails">
        <link:definition>995745 - Disclosure - Summary of Significant Accounting Policies - Schedule of Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" id="DisclosureFairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails">
        <link:definition>995755 - Disclosure - Fair Value Measurements - Schedule of Fair Value Hierarchy for Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfInvestmentsClassifiedAsAvailableforsaleSecuritiesDetails" id="DisclosureFairValueMeasurementsScheduleOfInvestmentsClassifiedAsAvailableforsaleSecuritiesDetails">
        <link:definition>995765 - Disclosure - Fair Value Measurements - Schedule of Investments Classified as Available-for-Sale Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAggregateFairValuesOfInvestmentsClassifiedAsAvailableforsaleSecuritiesWithUnrealizedLossesAndGains" id="DisclosureFairValueMeasurementsScheduleOfAggregateFairValuesOfInvestmentsClassifiedAsAvailableforsaleSecuritiesWithUnrealizedLossesAndGains">
        <link:definition>995775 - Disclosure - Fair Value Measurements - Schedule of Aggregate Fair Values of Investments Classified as Available-for-Sale Securities With Unrealized Losses and Gains (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfRollforwardOfChangesInFairValueOfFinancialLiabilitiesDetails" id="DisclosureFairValueMeasurementsScheduleOfRollforwardOfChangesInFairValueOfFinancialLiabilitiesDetails">
        <link:definition>995785 - Disclosure - Fair Value Measurements - Schedule of Rollforward of Changes in Fair Value of Financial Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfSignificantUnobservableInputsUsedInTheValuationModelToEstimateFairValueDetails" id="DisclosureFairValueMeasurementsScheduleOfSignificantUnobservableInputsUsedInTheValuationModelToEstimateFairValueDetails">
        <link:definition>995795 - Disclosure - Fair Value Measurements - Schedule of Significant Unobservable Inputs Used In the Valuation Model to Estimate Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" id="DisclosureFairValueMeasurementsAdditionalInformationDetails">
        <link:definition>995805 - Disclosure - Fair Value Measurements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueAssumptionsDetails" id="DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueAssumptionsDetails">
        <link:definition>995815 - Disclosure - Fair Value Measurements - Summary of Estimated Fair Value Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" id="DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails">
        <link:definition>995825 - Disclosure - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" id="DisclosureLeasesAdditionalInformationDetails">
        <link:definition>995835 - Disclosure - Leases - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesComponentsOfOperatingLeaseDetails" id="DisclosureLeasesComponentsOfOperatingLeaseDetails">
        <link:definition>995845 - Disclosure - Leases - Components of Operating Lease (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingUndiscountedContractualRentObligationsDetails" id="DisclosureLeasesReconciliationOfRemainingUndiscountedContractualRentObligationsDetails">
        <link:definition>995855 - Disclosure - Leases - Reconciliation of Remaining Undiscounted Contractual Rent Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesComponentsOfEquipmentFinanceLeasesDetails" id="DisclosureLeasesComponentsOfEquipmentFinanceLeasesDetails">
        <link:definition>995865 - Disclosure - Leases - Components of Equipment Finance Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingEquipmentFinanceLeaseObligationsDetails" id="DisclosureLeasesReconciliationOfRemainingEquipmentFinanceLeaseObligationsDetails">
        <link:definition>995875 - Disclosure - Leases - Reconciliation of Remaining Equipment Finance Lease Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertibleSafeNoteAdditionalInformationDetails" id="DisclosureConvertibleSafeNoteAdditionalInformationDetails">
        <link:definition>995885 - Disclosure - Convertible Safe Note - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails" id="DisclosureConvertiblePreferredStockAdditionalInformationDetails">
        <link:definition>995895 - Disclosure - Convertible Preferred Stock - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockScheduleOfConvertiblePreferredStockDetails" id="DisclosureConvertiblePreferredStockScheduleOfConvertiblePreferredStockDetails">
        <link:definition>995905 - Disclosure - Convertible Preferred Stock - Schedule of Convertible Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails" id="DisclosureCapitalStockAdditionalInformationDetails">
        <link:definition>995915 - Disclosure - Capital Stock - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCapitalStockScheduleOfCommonStockReservedForFutureIssuancesDetails" id="DisclosureCapitalStockScheduleOfCommonStockReservedForFutureIssuancesDetails">
        <link:definition>995925 - Disclosure - Capital Stock - Schedule of Common Stock Reserved for Future Issuances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails" id="DisclosureStockbasedCompensationAdditionalInformationDetails">
        <link:definition>995935 - Disclosure - Stock-Based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails" id="DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails">
        <link:definition>995945 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfFollowingAssumptionsPresentedOnWeightedAverageBasisDetails" id="DisclosureStockbasedCompensationSummaryOfFollowingAssumptionsPresentedOnWeightedAverageBasisDetails">
        <link:definition>995955 - Disclosure - Stock-Based Compensation - Summary of Following Assumptions Presented on Weighted Average Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityDetails" id="DisclosureStockbasedCompensationSummaryOfRsuActivityDetails">
        <link:definition>995965 - Disclosure - Stock-based Compensation - Summary of RSU activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpensesDetails" id="DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpensesDetails">
        <link:definition>995975 - Disclosure - Stock-Based Compensation - Summary of Stock-based Compensation Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureNetLossPerShareScheduleOfNetLossPerShareAttributableToCommonStockholdersDetails" id="DisclosureNetLossPerShareScheduleOfNetLossPerShareAttributableToCommonStockholdersDetails">
        <link:definition>995985 - Disclosure - Net Loss Per Share - Schedule of Net Loss Per Share Attributable to Common Stockholders (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails" id="DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails">
        <link:definition>995995 - Disclosure - Income Taxes - Schedule of Reconciliation of Statutory Income Tax Rate to Effective Income Tax Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" id="DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails">
        <link:definition>996005 - Disclosure - Income Taxes - Schedule of Components of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" id="DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>996015 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" id="DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
        <link:definition>996025 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails" id="DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails">
        <link:definition>996035 - Disclosure - License, Acquisition, Research Collaboration and Sponsored Research Agreements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails" id="DisclosureSegmentInformationAdditionalInformationDetails">
        <link:definition>996045 - Disclosure - Segment Information - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalInformationOnCompanysNetLossIncludingSegmentExpensesDetails3" id="DisclosureSegmentInformationSummaryOfAdditionalInformationOnCompanysNetLossIncludingSegmentExpensesDetails3">
        <link:definition>996055 - Disclosure - Segment Information - Summary of Additional Information On Company's Net loss Including Segment Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" id="DisclosureSubsequentEventsAdditionalInformationDetails">
        <link:definition>996065 - Disclosure - Subsequent Events - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20241231/taxonomy/role/StatementBalanceSheets" xlink:href="lxeo-20241231.xsd#StatementBalanceSheets" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingEquipmentFinanceLeaseObligationsDetails2" xlink:href="lxeo-20241231.xsd#DisclosureLeasesReconciliationOfRemainingEquipmentFinanceLeaseObligationsDetails2" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingUndiscountedContractualRentObligationsDetails2" xlink:href="lxeo-20241231.xsd#DisclosureLeasesReconciliationOfRemainingUndiscountedContractualRentObligationsDetails2" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss" xlink:href="lxeo-20241231.xsd#StatementStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfCashFlows" xlink:href="lxeo-20241231.xsd#StatementStatementsOfCashFlows" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentNetDetails" xlink:href="lxeo-20241231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentNetDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfInvestmentsClassifiedAsAvailableforsaleSecuritiesDetails" xlink:href="lxeo-20241231.xsd#DisclosureFairValueMeasurementsScheduleOfInvestmentsClassifiedAsAvailableforsaleSecuritiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAggregateFairValuesOfInvestmentsClassifiedAsAvailableforsaleSecuritiesWithUnrealizedLossesAndGains" xlink:href="lxeo-20241231.xsd#DisclosureFairValueMeasurementsScheduleOfAggregateFairValuesOfInvestmentsClassifiedAsAvailableforsaleSecuritiesWithUnrealizedLossesAndGains" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="lxeo-20241231.xsd#DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesComponentsOfOperatingLeaseDetails" xlink:href="lxeo-20241231.xsd#DisclosureLeasesComponentsOfOperatingLeaseDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingUndiscountedContractualRentObligationsDetails" xlink:href="lxeo-20241231.xsd#DisclosureLeasesReconciliationOfRemainingUndiscountedContractualRentObligationsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesComponentsOfEquipmentFinanceLeasesDetails" xlink:href="lxeo-20241231.xsd#DisclosureLeasesComponentsOfEquipmentFinanceLeasesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingEquipmentFinanceLeaseObligationsDetails" xlink:href="lxeo-20241231.xsd#DisclosureLeasesReconciliationOfRemainingEquipmentFinanceLeaseObligationsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails" xlink:href="lxeo-20241231.xsd#DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="lxeo-20241231.xsd#DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalInformationOnCompanysNetLossIncludingSegmentExpensesDetails3" xlink:href="lxeo-20241231.xsd#DisclosureSegmentInformationSummaryOfAdditionalInformationOnCompanysNetLossIncludingSegmentExpensesDetails3" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="lxeo-20241231.xsd#DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20241231/taxonomy/role/StatementBalanceSheetsParenthetical" xlink:href="lxeo-20241231.xsd#StatementBalanceSheetsParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:href="lxeo-20241231.xsd#StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:href="lxeo-20241231.xsd#StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCybersecurity" xlink:href="lxeo-20241231.xsd#DisclosureCybersecurity" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentation" xlink:href="lxeo-20241231.xsd#DisclosureDescriptionOfBusinessAndBasisOfPresentation" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="lxeo-20241231.xsd#DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurements" xlink:href="lxeo-20241231.xsd#DisclosureFairValueMeasurements" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities1" xlink:href="lxeo-20241231.xsd#DisclosureAccruedExpensesAndOtherCurrentLiabilities1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeases3" xlink:href="lxeo-20241231.xsd#DisclosureLeases3" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertibleSafeNote" xlink:href="lxeo-20241231.xsd#DisclosureConvertibleSafeNote" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStock" xlink:href="lxeo-20241231.xsd#DisclosureConvertiblePreferredStock" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCapitalStock1" xlink:href="lxeo-20241231.xsd#DisclosureCapitalStock1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensation1" xlink:href="lxeo-20241231.xsd#DisclosureStockbasedCompensation1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureNetLossPerShare" xlink:href="lxeo-20241231.xsd#DisclosureNetLossPerShare" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureIncomeTaxes" xlink:href="lxeo-20241231.xsd#DisclosureIncomeTaxes" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingencies1" xlink:href="lxeo-20241231.xsd#DisclosureCommitmentsAndContingencies1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreements" xlink:href="lxeo-20241231.xsd#DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreements" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSegmentInformation1" xlink:href="lxeo-20241231.xsd#DisclosureSegmentInformation1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSubsequentEvents" xlink:href="lxeo-20241231.xsd#DisclosureSubsequentEvents" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="lxeo-20241231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:href="lxeo-20241231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsTables" xlink:href="lxeo-20241231.xsd#DisclosureFairValueMeasurementsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesTables" xlink:href="lxeo-20241231.xsd#DisclosureLeasesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:href="lxeo-20241231.xsd#DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockTables" xlink:href="lxeo-20241231.xsd#DisclosureConvertiblePreferredStockTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCapitalStockTables" xlink:href="lxeo-20241231.xsd#DisclosureCapitalStockTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationTables" xlink:href="lxeo-20241231.xsd#DisclosureStockbasedCompensationTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureNetLossPerShareTables" xlink:href="lxeo-20241231.xsd#DisclosureNetLossPerShareTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureIncomeTaxesTables" xlink:href="lxeo-20241231.xsd#DisclosureIncomeTaxesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSegmentInformationTables" xlink:href="lxeo-20241231.xsd#DisclosureSegmentInformationTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails" xlink:href="lxeo-20241231.xsd#DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="lxeo-20241231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="lxeo-20241231.xsd#DisclosureFairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfRollforwardOfChangesInFairValueOfFinancialLiabilitiesDetails" xlink:href="lxeo-20241231.xsd#DisclosureFairValueMeasurementsScheduleOfRollforwardOfChangesInFairValueOfFinancialLiabilitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfSignificantUnobservableInputsUsedInTheValuationModelToEstimateFairValueDetails" xlink:href="lxeo-20241231.xsd#DisclosureFairValueMeasurementsScheduleOfSignificantUnobservableInputsUsedInTheValuationModelToEstimateFairValueDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:href="lxeo-20241231.xsd#DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueAssumptionsDetails" xlink:href="lxeo-20241231.xsd#DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueAssumptionsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" xlink:href="lxeo-20241231.xsd#DisclosureLeasesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertibleSafeNoteAdditionalInformationDetails" xlink:href="lxeo-20241231.xsd#DisclosureConvertibleSafeNoteAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails" xlink:href="lxeo-20241231.xsd#DisclosureConvertiblePreferredStockAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockScheduleOfConvertiblePreferredStockDetails" xlink:href="lxeo-20241231.xsd#DisclosureConvertiblePreferredStockScheduleOfConvertiblePreferredStockDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails" xlink:href="lxeo-20241231.xsd#DisclosureCapitalStockAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCapitalStockScheduleOfCommonStockReservedForFutureIssuancesDetails" xlink:href="lxeo-20241231.xsd#DisclosureCapitalStockScheduleOfCommonStockReservedForFutureIssuancesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails" xlink:href="lxeo-20241231.xsd#DisclosureStockbasedCompensationAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails" xlink:href="lxeo-20241231.xsd#DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfFollowingAssumptionsPresentedOnWeightedAverageBasisDetails" xlink:href="lxeo-20241231.xsd#DisclosureStockbasedCompensationSummaryOfFollowingAssumptionsPresentedOnWeightedAverageBasisDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityDetails" xlink:href="lxeo-20241231.xsd#DisclosureStockbasedCompensationSummaryOfRsuActivityDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpensesDetails" xlink:href="lxeo-20241231.xsd#DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpensesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureNetLossPerShareScheduleOfNetLossPerShareAttributableToCommonStockholdersDetails" xlink:href="lxeo-20241231.xsd#DisclosureNetLossPerShareScheduleOfNetLossPerShareAttributableToCommonStockholdersDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="lxeo-20241231.xsd#DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="lxeo-20241231.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails" xlink:href="lxeo-20241231.xsd#DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails" xlink:href="lxeo-20241231.xsd#DisclosureSegmentInformationAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:href="lxeo-20241231.xsd#DisclosureSubsequentEventsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#IndividualsOnly" xlink:type="simple"/>
        <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd#eedm" xlink:type="simple"/>
        <link:roleRef roleURI="http://fasb.org/srt/role/srt-eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd#eedm1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_LicenseAndAcquisitionAndResearchCollaborationAndSponsoredResearchAgreementsDisclosureTextBlock" xlink:label="lxeo_LicenseAndAcquisitionAndResearchCollaborationAndSponsoredResearchAgreementsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="us-gaap_TemporaryEquityLiquidationPreference"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_ThirdPartiesForPharmaceuticalManufacturingAndResearchActivitiesMember" xlink:label="lxeo_ThirdPartiesForPharmaceuticalManufacturingAndResearchActivitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_AgreementExpirationTerm" xlink:label="lxeo_AgreementExpirationTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeAmortizationOfDiscount" xlink:label="us-gaap_InvestmentIncomeAmortizationOfDiscount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_InvestmentCurrent" xlink:label="lxeo_InvestmentCurrent"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="lxeo_SummaryOfSignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_ShareBasedCompensationPaymentDescription" xlink:label="lxeo_ShareBasedCompensationPaymentDescription"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_OfficeFacilityAndLaboratorySpaceMember" xlink:label="lxeo_OfficeFacilityAndLaboratorySpaceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockTextBlock" xlink:label="us-gaap_PreferredStockTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_ThirdUcsdLicenseAgreementMember" xlink:label="lxeo_ThirdUcsdLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="us-gaap_ConvertibleNotesPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_TwoThousandTwentyOneAndTwoThousandTwentyThreeEquityIncentivePlanMember" xlink:label="lxeo_TwoThousandTwentyOneAndTwoThousandTwentyThreeEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_QualifiedIpoMinimumNumberOfDirectorsApprovalRequired" xlink:label="lxeo_QualifiedIpoMinimumNumberOfDirectorsApprovalRequired"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_DevelopmentAndCommercializationMilestonesDue" xlink:label="lxeo_DevelopmentAndCommercializationMilestonesDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_CornellSecondLicenseAgreementsMember" xlink:label="lxeo_CornellSecondLicenseAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorOpinionTextBlock" xlink:label="dei_AuditorOpinionTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_CommonStockSharesIssuedOnEarlyExerciseOfUnvestedStockOptions" xlink:label="lxeo_CommonStockSharesIssuedOnEarlyExerciseOfUnvestedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_SeriesAConvertiblePreferredStockMember" xlink:label="lxeo_SeriesAConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:label="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_ConvertibleSimpleAgreementForFutureEquityNoteMember" xlink:label="lxeo_ConvertibleSimpleAgreementForFutureEquityNoteMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_ThirdPortfolioMember" xlink:label="lxeo_ThirdPortfolioMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="us-gaap_GeneralAndAdministrativeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_ResearchAndDevelopmentExpenseLX2006" xlink:label="lxeo_ResearchAndDevelopmentExpenseLX2006"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdateExtensibleList" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_TaxCreditCarryForwardExpirationYear" xlink:label="lxeo_TaxCreditCarryForwardExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_CommonStockDuringOfferingPeriod" xlink:label="lxeo_CommonStockDuringOfferingPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLocationAxis" xlink:label="us-gaap_OtherComprehensiveIncomeLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_NumberOfFormerEmployees" xlink:label="lxeo_NumberOfFormerEmployees"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_OperatingLeaseEndDate" xlink:label="lxeo_OperatingLeaseEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleSharesIssuable" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="us-gaap_TreasuryStockCommonShares"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue" xlink:label="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_InvestmentNonCurrent" xlink:label="lxeo_InvestmentNonCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice" xlink:label="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtShare" xlink:label="lxeo_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain" xlink:label="srt_ConsolidationItemsDomain"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_GeneralAndAdministrativeExpenseEmployeeCompensationExpenses" xlink:label="lxeo_GeneralAndAdministrativeExpenseEmployeeCompensationExpenses"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_GeneralAndAdministrativeExpensesPolicyPolicyTextBlock" xlink:label="lxeo_GeneralAndAdministrativeExpensesPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_FairValueProbabilityOfMeetingQualifiedEquityFinancingEvent" xlink:label="lxeo_FairValueProbabilityOfMeetingQualifiedEquityFinancingEvent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_LeerinkAtTheMarketSalesAgreementMember" xlink:label="lxeo_LeerinkAtTheMarketSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_LicenseAgreementTerminationNoticePeriod" xlink:label="lxeo_LicenseAgreementTerminationNoticePeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_AnnualLimitationAbilityToUtilize" xlink:label="lxeo_AnnualLimitationAbilityToUtilize"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityTableTextBlock" xlink:label="us-gaap_TemporaryEquityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_PayrollDeductionsAtPrice" xlink:label="lxeo_PayrollDeductionsAtPrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentDescription" xlink:label="us-gaap_DebtInstrumentDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_FairValueOfUnearnedEmployeeStockOwnershipPlans" xlink:label="lxeo_FairValueOfUnearnedEmployeeStockOwnershipPlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_IncreaseDecreaseInFairValueOfSafeInstrument" xlink:label="lxeo_IncreaseDecreaseInFairValueOfSafeInstrument"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="us-gaap_ValuationTechniqueAxis"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_NumberOfMonthlyInstallmentsLease" xlink:label="lxeo_NumberOfMonthlyInstallmentsLease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:label="us-gaap_ResearchAndDevelopmentExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_TwoPortfoliosMember" xlink:label="lxeo_TwoPortfoliosMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_LesseeOperatingAndFinancingLeasesDisclosureTextBlock" xlink:label="lxeo_LesseeOperatingAndFinancingLeasesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_OneTimeUpFrontNonRefundableFees" xlink:label="lxeo_OneTimeUpFrontNonRefundableFees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_BlackScholesModelMember" xlink:label="lxeo_BlackScholesModelMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeFinanceLeaseDiscountRate" xlink:label="us-gaap_LesseeFinanceLeaseDiscountRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_TreasuryStockRepurchase" xlink:label="lxeo_TreasuryStockRepurchase"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_SeriesBConvertiblePreferredStockMember" xlink:label="lxeo_SeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_DevelopmentAndRegulatoryMilestonesDue" xlink:label="lxeo_DevelopmentAndRegulatoryMilestonesDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="us-gaap_LaborAndRelatedExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="lxeo_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_SimpleAgreementForFutureEquityMember" xlink:label="lxeo_SimpleAgreementForFutureEquityMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_FairValueTimeUntilQualifiedEquityFinancingEvent" xlink:label="lxeo_FairValueTimeUntilQualifiedEquityFinancingEvent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonMember" xlink:label="us-gaap_TreasuryStockCommonMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_FairValueTimeUntilPublicOfferingEvent" xlink:label="lxeo_FairValueTimeUntilPublicOfferingEvent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_FairValueTimeUntilChangeInControlEvent" xlink:label="lxeo_FairValueTimeUntilChangeInControlEvent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_TwoThousandTwentyThreeEquityIncentivePlanMember" xlink:label="lxeo_TwoThousandTwentyThreeEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis" xlink:label="srt_ConsolidationItemsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_TwoThousandAndTwentyThreeEquityIncentivePlanMember" xlink:label="lxeo_TwoThousandAndTwentyThreeEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="us-gaap_PaymentsToAcquireInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualTermGrantDate" xlink:label="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualTermGrantDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InternalUseSoftwarePolicy" xlink:label="us-gaap_InternalUseSoftwarePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_PaymentOfRegulatoryMilestones" xlink:label="lxeo_PaymentOfRegulatoryMilestones"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_TemporaryEquityConversionOfStockInInitialPublicOfferingShares" xlink:label="lxeo_TemporaryEquityConversionOfStockInInitialPublicOfferingShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_ReclassificationOfInternalUseSoftwareIntoPrepaidExpenses" xlink:label="lxeo_ReclassificationOfInternalUseSoftwareIntoPrepaidExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeMember" xlink:label="us-gaap_OtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_FinanceLeaseMonthlyInstallmentPaymentAmounts" xlink:label="lxeo_FinanceLeaseMonthlyInstallmentPaymentAmounts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_LossRecognizedFromUninsuredBalances" xlink:label="lxeo_LossRecognizedFromUninsuredBalances"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_PaymentOfAnnualLicenseMaintenanceFees" xlink:label="lxeo_PaymentOfAnnualLicenseMaintenanceFees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_NumberOfSharesAutomaticallyIncreaseInAvailableSharesOfCommonStockUnderPlan" xlink:label="lxeo_NumberOfSharesAutomaticallyIncreaseInAvailableSharesOfCommonStockUnderPlan"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_TwoThousandTwentyOneEquityIncentivePlanMember" xlink:label="lxeo_TwoThousandTwentyOneEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_IncreaseDecreaseInFinanceLeaseLiability" xlink:label="lxeo_IncreaseDecreaseInFinanceLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_TemporaryEquityConversionOfStockInInitialPublicOfferingValue" xlink:label="lxeo_TemporaryEquityConversionOfStockInInitialPublicOfferingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_SteliosTherapeuticsIncMember" xlink:label="lxeo_SteliosTherapeuticsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="us-gaap_DeferredChargesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember" xlink:label="lxeo_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_WeillCornellMedicalCollegeMember" xlink:label="lxeo_WeillCornellMedicalCollegeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_ResearchAgreementsTerm" xlink:label="lxeo_ResearchAgreementsTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_PaymentOfClinicalAndRegulatoryMilestone" xlink:label="lxeo_PaymentOfClinicalAndRegulatoryMilestone"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_FairValueProbabilityOfMeetingPublicOfferingEvent" xlink:label="lxeo_FairValueProbabilityOfMeetingPublicOfferingEvent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_OperatingLeaseWeightedAverageRemainingPaymentTerm" xlink:label="lxeo_OperatingLeaseWeightedAverageRemainingPaymentTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsForeign" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsForeign"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityAbstract" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1" xlink:label="us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversionOfNotesIntoCommonStock" xlink:label="lxeo_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversionOfNotesIntoCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_AccruedResearchAndDevelopmentExpenseCurrent" xlink:label="lxeo_AccruedResearchAndDevelopmentExpenseCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCurrentAndNoncurrent" xlink:label="us-gaap_DeferredCostsCurrentAndNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_UcsdSponsoredResearchAgreementsMember" xlink:label="lxeo_UcsdSponsoredResearchAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember" xlink:label="us-gaap_OperatingSegmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_AccruedGeneralAndAdministrativeExpensesAndOtherProfessionalFeesCurrent" xlink:label="lxeo_AccruedGeneralAndAdministrativeExpensesAndOtherProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsUnvestedStockOptionsSubjectToRepurchaseValue" xlink:label="lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsUnvestedStockOptionsSubjectToRepurchaseValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockAmountIssued1" xlink:label="us-gaap_ConversionOfStockAmountIssued1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageExercisePrice" xlink:label="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOptionsExercisableWeightedAverageGrantDateFairValue" xlink:label="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOptionsExercisableWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_FinanceLeaseExpense" xlink:label="lxeo_FinanceLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:label="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_CornellFirstLicenseAgreementsMember" xlink:label="lxeo_CornellFirstLicenseAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsUnvestedStockOptionsSubjectToRepurchaseShare" xlink:label="lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsUnvestedStockOptionsSubjectToRepurchaseShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsShare" xlink:label="lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityLiquidationPreferencePerShare" xlink:label="us-gaap_TemporaryEquityLiquidationPreferencePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_DeferredTaxAssetsIntangibleAssets" xlink:label="lxeo_DeferredTaxAssetsIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AlternativeInvestmentMeasurementInput" xlink:label="us-gaap_AlternativeInvestmentMeasurementInput"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_NumberOfLicenseAgreements" xlink:label="lxeo_NumberOfLicenseAgreements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance" xlink:label="lxeo_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_ResearchAndDevelopmentExpenseEmployeeCompensationExpenses" xlink:label="lxeo_ResearchAndDevelopmentExpenseEmployeeCompensationExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:label="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_SummaryOfSignificantAccountingPoliciesTable" xlink:label="lxeo_SummaryOfSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DividendsCommonStockCash" xlink:label="us-gaap_DividendsCommonStockCash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_FinanceLeaseRightOfUseAssetsAndFinanceLeaseLiabilitiesRecognized" xlink:label="lxeo_FinanceLeaseRightOfUseAssetsAndFinanceLeaseLiabilitiesRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_ResearchAndDevelopmentExpenseLX1001" xlink:label="lxeo_ResearchAndDevelopmentExpenseLX1001"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalUnitsAuthorized" xlink:label="us-gaap_CapitalUnitsAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_ThirdCornellLicenseAgreementsMember" xlink:label="lxeo_ThirdCornellLicenseAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_ResearchAgreementTerminationNoticePeriod" xlink:label="lxeo_ResearchAgreementTerminationNoticePeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_SpecificClinicalAndRegulatoryMilestonesDue" xlink:label="lxeo_SpecificClinicalAndRegulatoryMilestonesDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLocationDomain" xlink:label="us-gaap_OtherComprehensiveIncomeLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOptionQuantitativeDisclosuresTable" xlink:label="us-gaap_FairValueOptionQuantitativeDisclosuresTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_UpfrontCashPayment" xlink:label="lxeo_UpfrontCashPayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsExercisableWeightedAverageGrantDateFairValue" xlink:label="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsExercisableWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_AggregateDevelopmentAndCommercializationMilestonesDescription" xlink:label="lxeo_AggregateDevelopmentAndCommercializationMilestonesDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_SareptaTherapeuticsIncMember" xlink:label="lxeo_SareptaTherapeuticsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_PaymentStartingAfterPeriodOfExecutionOfAgreement" xlink:label="lxeo_PaymentStartingAfterPeriodOfExecutionOfAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings" xlink:label="us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityAbstract" xlink:label="us-gaap_FinanceLeaseLiabilityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" xlink:label="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriod" xlink:label="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_PercentageOfAutomaticallyIncreaseInAvailableSharesOfCommonStockOnBeginningOfCachCalendarYear" xlink:label="lxeo_PercentageOfAutomaticallyIncreaseInAvailableSharesOfCommonStockOnBeginningOfCachCalendarYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_PaymentOfOneTimeUpFrontNonRefundableFee" xlink:label="lxeo_PaymentOfOneTimeUpFrontNonRefundableFee"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDerivativeAssetsAndLiabilities" xlink:label="us-gaap_IncreaseDecreaseInDerivativeAssetsAndLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_PercentageOfCumulativeOwnershipChange" xlink:label="lxeo_PercentageOfCumulativeOwnershipChange"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_AmountsReclassifiedFromDepositLiabilitiesUponTheVestingOfEarlyExercisedStockOptionsPreviouslySubjectToRepurchaseNetOfProceedsReceivedFromEarlyExerciseOfUnvestedStockOptionsSubjectToRepurchaseAndRecord" xlink:label="lxeo_AmountsReclassifiedFromDepositLiabilitiesUponTheVestingOfEarlyExercisedStockOptionsPreviouslySubjectToRepurchaseNetOfProceedsReceivedFromEarlyExerciseOfUnvestedStockOptionsSubjectToRepurchaseAndRecord"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_SeriesAAndBConvertiblePreferredStockMember" xlink:label="lxeo_SeriesAAndBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_AdverumLicenseAgreementMember" xlink:label="lxeo_AdverumLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_CornellUniversityMember" xlink:label="lxeo_CornellUniversityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:label="lxeo_AccruedLiabilitiesAndOtherLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_OperatingLossCarryForwardsExpirationYear" xlink:label="lxeo_OperatingLossCarryForwardsExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_PercentageOfOutstandingSharesForDeemedLiquidation" xlink:label="lxeo_PercentageOfOutstandingSharesForDeemedLiquidation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesIssued1" xlink:label="us-gaap_NotesIssued1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_StockOfferingValueSharesAuthorizedToBeSold" xlink:label="lxeo_StockOfferingValueSharesAuthorizedToBeSold"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="us-gaap_FinanceLeaseInterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_AntidilutiveSecuritiesMember" xlink:label="lxeo_AntidilutiveSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_DeferredTaxAssetsLeaseLiabilities" xlink:label="lxeo_DeferredTaxAssetsLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" xlink:label="lxeo_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_PaymentOfDevelopmentMilestone" xlink:label="lxeo_PaymentOfDevelopmentMilestone"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConvertibleNoteIssuance" xlink:label="lxeo_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConvertibleNoteIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonValue" xlink:label="us-gaap_TreasuryStockCommonValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_AmountDueUnderAgreement" xlink:label="lxeo_AmountDueUnderAgreement"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalCostsIncurred" xlink:label="lxeo_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalCostsIncurred"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_PaymentTerm" xlink:label="lxeo_PaymentTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="us-gaap_MeasurementInputExercisePriceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_SecondUcsdLicenseAgreementMember" xlink:label="lxeo_SecondUcsdLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_CommissionsAndOfferingCostsMember" xlink:label="lxeo_CommissionsAndOfferingCostsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LetterOfCreditMember" xlink:label="us-gaap_LetterOfCreditMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_FairValueProbabilityOfMeetingChangeInControlEvent" xlink:label="lxeo_FairValueProbabilityOfMeetingChangeInControlEvent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_AmountDueForEachQuarterUnderAgreement" xlink:label="lxeo_AmountDueForEachQuarterUnderAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="us-gaap_SoftwareDevelopmentMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_AmendedFirstUcsdAgreementMember" xlink:label="lxeo_AmendedFirstUcsdAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_NumberOfResearchAgreements" xlink:label="lxeo_NumberOfResearchAgreements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_PaymentOfAnnualDataTransferFee" xlink:label="lxeo_PaymentOfAnnualDataTransferFee"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_LesseeFinanceLeaseCommencementDateRangeStart" xlink:label="lxeo_LesseeFinanceLeaseCommencementDateRangeStart"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_AdverumBiotechnologiesIncMember" xlink:label="lxeo_AdverumBiotechnologiesIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireSoftware" xlink:label="us-gaap_PaymentsToAcquireSoftware"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_RNolanTownsendMember" xlink:label="lxeo_RNolanTownsendMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_MilestoneReceived" xlink:label="lxeo_MilestoneReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:label="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_ScheduleOfSignificantUnobservableInputsUsedInValuationModelToEstimateFairValueTableTextBlock" xlink:label="lxeo_ScheduleOfSignificantUnobservableInputsUsedInValuationModelToEstimateFairValueTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_NetProceedsReceivedFromPrivatePlacement" xlink:label="lxeo_NetProceedsReceivedFromPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:label="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_CapitalExpendituresIncurredButNotYetPaidNetOfPaidAmount" xlink:label="lxeo_CapitalExpendituresIncurredButNotYetPaidNetOfPaidAmount"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_ResearchAndDevelopmentExpenseLX2020" xlink:label="lxeo_ResearchAndDevelopmentExpenseLX2020"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_SeriesAAndSeriesBConvertiblePreferredStockMember" xlink:label="lxeo_SeriesAAndSeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="us-gaap_UnrealizedGainLossOnInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermInvestmentsAndReceivablesNet" xlink:label="us-gaap_LongTermInvestmentsAndReceivablesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_FinanceLeaseAggregateMonthlyInstallmentPaymentAmounts" xlink:label="lxeo_FinanceLeaseAggregateMonthlyInstallmentPaymentAmounts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_StockIssuedDuringPeriodValueNewIssuesAdditionalOfferingCostsIncurred" xlink:label="lxeo_StockIssuedDuringPeriodValueNewIssuesAdditionalOfferingCostsIncurred"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_StockOfferingGrossProceedsPercentage" xlink:label="lxeo_StockOfferingGrossProceedsPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_CommercializationMilestonesDue" xlink:label="lxeo_CommercializationMilestonesDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_FinanceLeaseWeightedAverageRemainingAmortizationTerm" xlink:label="lxeo_FinanceLeaseWeightedAverageRemainingAmortizationTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_SeriesALiquidationPreferenceMember" xlink:label="lxeo_SeriesALiquidationPreferenceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription" xlink:label="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredInPeriodWeightedAverageGrantDateFairValue" xlink:label="lxeo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptions" xlink:label="lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_ComponentsOfEquipmentFinanceLeaseTableTextBlock" xlink:label="lxeo_ComponentsOfEquipmentFinanceLeaseTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_ResearchCollaborationAgreementMember" xlink:label="lxeo_ResearchCollaborationAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueNetAssetLiability" xlink:label="us-gaap_FairValueNetAssetLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_ComponentsOfOperatingLeaseTableTextBlock" xlink:label="lxeo_ComponentsOfOperatingLeaseTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_LesseeFinanceLeaseCommencementDateRangeEnd" xlink:label="lxeo_LesseeFinanceLeaseCommencementDateRangeEnd"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalizedComputerSoftwareGross" xlink:label="us-gaap_CapitalizedComputerSoftwareGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_CornellLicenseAgreementsMember" xlink:label="lxeo_CornellLicenseAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_OperatingLeaseAgreementEnteredDate" xlink:label="lxeo_OperatingLeaseAgreementEnteredDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_ResearchAndDevelopmentExpenseOtherPrograms" xlink:label="lxeo_ResearchAndDevelopmentExpenseOtherPrograms"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_SeriesBLiquidationPreferenceMember" xlink:label="lxeo_SeriesBLiquidationPreferenceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_UnderwritingDiscountsCommissionsAndOfferingCostsMember" xlink:label="lxeo_UnderwritingDiscountsCommissionsAndOfferingCostsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_FirstUcsdLicenseAgreementMember" xlink:label="lxeo_FirstUcsdLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:label="us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_EricAdlerMember" xlink:label="lxeo_EricAdlerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:label="us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_OperatingLeaseCommencementDate" xlink:label="lxeo_OperatingLeaseCommencementDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_PaymentOfLicenseIssueFeeAndInitialDataTransferFee" xlink:label="lxeo_PaymentOfLicenseIssueFeeAndInitialDataTransferFee"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_LicenseAndAcquisitionAndResearchCollaborationAndSponsoredResearchAgreementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License, Acquisition, Research Collaboration and Sponsored Research Agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_LicenseAndAcquisitionAndResearchCollaborationAndSponsoredResearchAgreementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License and Acquisition and Research Collaboration and Sponsored Research Agreements Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_LicenseAndAcquisitionAndResearchCollaborationAndSponsoredResearchAgreementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License and acquisition and research collaboration and sponsored research agreements disclosure.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Board of Directors Oversight [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Liquidation Preference</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, Liquidation Preference</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Liquidation Preference</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ThirdPartiesForPharmaceuticalManufacturingAndResearchActivitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Third Parties for Pharmaceutical Manufacturing and Research Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ThirdPartiesForPharmaceuticalManufacturingAndResearchActivitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Third Parties For Pharmaceutical Manufacturing And Research Activities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ThirdPartiesForPharmaceuticalManufacturingAndResearchActivitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Third parties for pharmaceutical manufacturing and research activities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring and Nonrecurring [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability, to be Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenuesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenuesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenues [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AgreementExpirationTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Agreement expiration term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AgreementExpirationTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Agreement Expiration Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AgreementExpirationTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Agreement expiration term.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operation segment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Operating Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of operating segment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective Income Tax Rate Reconciliation, Tax Credit, Percent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Tax credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Options exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Right-of-Use Asset, Accumulated Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Reverse stock split</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity, Reverse Stock Split</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeAmortizationOfDiscount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income, Amortization of Discount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeAmortizationOfDiscount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accretion of discount on investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset acquisition percentage of outstanding stock acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition, Percentage of Voting Interests Acquired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average grant date fair value, forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_InvestmentCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_InvestmentCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Investment current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_InvestmentCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary of Significant Accounting Policies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Convertible Preferred Stock Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ShareBasedCompensationPaymentDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share based compensation payment description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ShareBasedCompensationPaymentDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Payment Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ShareBasedCompensationPaymentDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation payment description.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_OfficeFacilityAndLaboratorySpaceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office Facility and Laboratory Space</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_OfficeFacilityAndLaboratorySpaceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Office Facility and Laboratory Space [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_OfficeFacilityAndLaboratorySpaceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Office facility and laboratory space.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock, Class of Stock [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Rollforward of Changes in Fair Value of Financial Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ThirdUcsdLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Third UCSD License Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ThirdUcsdLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Third UCSD License Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ThirdUcsdLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Third UCSD License Agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertibleNotesPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible SAFE note, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertibleNotesPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Unamortized discount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertibleNotesPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Notes Payable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting period, percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Repurchased During Period, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Repurchase of shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Treasury stock repurchase</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Treasury stock repurchases, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_TwoThousandTwentyOneAndTwoThousandTwentyThreeEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 Plan and 2023 Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_TwoThousandTwentyOneAndTwoThousandTwentyThreeEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty one and two thousand twenty three equity incentive plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_TwoThousandTwentyOneAndTwoThousandTwentyThreeEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty One And Two Thousand Twenty Three Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_QualifiedIpoMinimumNumberOfDirectorsApprovalRequired_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Qualified IPO minimum number of directors approval required</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_QualifiedIpoMinimumNumberOfDirectorsApprovalRequired_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Qualified IPO Minimum Number of Directors Approval Required</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_QualifiedIpoMinimumNumberOfDirectorsApprovalRequired_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Qualified IPO minimum number of directors approval required.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Stock Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Processes Integrated [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseNonoperating_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseNonoperating_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense, Nonoperating</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseNonoperating_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Interest Expense, Nonoperating, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capital Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_DevelopmentAndCommercializationMilestonesDue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development and commercialization milestones due</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_DevelopmentAndCommercializationMilestonesDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Development and Commercialization Milestones Due</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_DevelopmentAndCommercializationMilestonesDue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Development and commercialization milestones due.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CIK</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_CornellSecondLicenseAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cornell Second License Agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_CornellSecondLicenseAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cornell Second License Agreements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_CornellSecondLicenseAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cornell Second License Agreements.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Forfeited, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Forfeited, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorOpinionTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Opinion [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_CommonStockSharesIssuedOnEarlyExerciseOfUnvestedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock shares issued upon early exercise of unvested stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_CommonStockSharesIssuedOnEarlyExerciseOfUnvestedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock shares issued on early exercise of unvested stock options.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_CommonStockSharesIssuedOnEarlyExerciseOfUnvestedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Issued On Early Exercise of Unvested Stock Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock, Shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_SeriesAConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_SeriesAConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_SeriesAConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A convertible preferred stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Convertible Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of convertible SAFE Note</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Option, Quantitative Disclosures [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input, Expected Dividend Rate [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected Dividend Yield</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ConvertibleSimpleAgreementForFutureEquityNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Simple Agreement For Future Equity Note [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ConvertibleSimpleAgreementForFutureEquityNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible simple agreement for future equity note.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ConvertibleSimpleAgreementForFutureEquityNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible SAFE Note [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability, to be Paid, Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2029</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ThirdPortfolioMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Third Portfolio</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ThirdPortfolioMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Third Portfolio [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ThirdPortfolioMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Third portfolio.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability, to be Paid, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations before income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ResearchAndDevelopmentExpenseLX2006_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">LX2006</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ResearchAndDevelopmentExpenseLX2006_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense LX2006</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ResearchAndDevelopmentExpenseLX2006_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and Development Expense LX2006.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingenciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingencies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_TaxCreditCarryForwardExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax credit carry forward expiration year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_TaxCreditCarryForwardExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carry Forward Expiration Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_TaxCreditCarryForwardExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforward, expiration year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_CommonStockDuringOfferingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock during offering period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_CommonStockDuringOfferingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock During Offering Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_CommonStockDuringOfferingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common Stock During Offering Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Location [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_NumberOfFormerEmployees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Former Employees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_NumberOfFormerEmployees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of former employees.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_NumberOfFormerEmployees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of former employees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_OperatingLeaseEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease end date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_OperatingLeaseEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_OperatingLeaseEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease end date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value, Options exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Aggregate Fair Values of Investments Classified as Available-for-Sale Securities With Unrealized Losses and Gains</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability, to be Paid, after Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payments of issuance costs on convertible SAFE Note</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments of Debt Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock Issuable Upon Conversion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Convertible, Shares Issuable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Converted shares into common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockCommonShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Treasury Stock, Common, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockCommonShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Treasury stock, common shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grant date fair value of option</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award options grant date fair value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement by Share Based Payment Award Options Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_InvestmentNonCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Non Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_InvestmentNonCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Investment non current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_InvestmentNonCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment non-current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss per common share, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share attributable to common stockholders, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option to extend</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Option to Extend</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross Unrealized Gains</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payments on finance leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for amounts included in the measurement of lease liabilities, included in financing cash flows</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Principal Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, vested and exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award options vested weighted average exercise price.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Adjustments to additional paid in capital, equity component of convertible debt share.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of SAFE Note into common stock in connection with initial public offering, Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ConsolidationItemsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation Items [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_GeneralAndAdministrativeExpenseEmployeeCompensationExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee compensation expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_GeneralAndAdministrativeExpenseEmployeeCompensationExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense Employee Compensation Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_GeneralAndAdministrativeExpenseEmployeeCompensationExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">General and administrative expense employee compensation expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_GeneralAndAdministrativeExpensesPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_GeneralAndAdministrativeExpensesPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">General and administrative expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_GeneralAndAdministrativeExpensesPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expenses, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted average effective interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Effective Interest Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Weighted Average Discount Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding principal balance together with accrued interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Long-Term Debt, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_FairValueProbabilityOfMeetingQualifiedEquityFinancingEvent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Probability of meeting qualified equity financing event</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_FairValueProbabilityOfMeetingQualifiedEquityFinancingEvent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Probability of Meeting Qualified Equity Financing Event</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_FairValueProbabilityOfMeetingQualifiedEquityFinancingEvent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair Value probability of meeting qualified equity financing event.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of shares outstanding, ending</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of shares outstanding, beginning</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total shares of common stock reserved for future issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares reserved for issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_LeerinkAtTheMarketSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leerink At The Market Sales Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_LeerinkAtTheMarketSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Leerink at the market sales agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_LeerinkAtTheMarketSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leerink At The Market Sales Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_LicenseAgreementTerminationNoticePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Termination notice period (in days)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_LicenseAgreementTerminationNoticePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License agreement termination notice period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_LicenseAgreementTerminationNoticePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Termination Notice Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_LicenseAgreementTerminationNoticePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement termination notice period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flow from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average grant date fair value, unvested, forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AnnualLimitationAbilityToUtilize_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual limitation ability to utilize</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AnnualLimitationAbilityToUtilize_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Annual Limitation Ability to Utilize</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AnnualLimitationAbilityToUtilize_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Annual Limitation Ability to Utilize</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2028</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Schedule of Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Recurring [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Exercise of Outstanding Stock Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Temporary equity, balance, value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Temporary equity, balance, value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Carrying Amount, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_PayrollDeductionsAtPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payroll Deductions at Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_PayrollDeductionsAtPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payroll Deductions at Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_PayrollDeductionsAtPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payroll deductions at price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_FairValueOfUnearnedEmployeeStockOwnershipPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of unearned employee stock ownership plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_FairValueOfUnearnedEmployeeStockOwnershipPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value of Unearned Employee Stock Ownership Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_FairValueOfUnearnedEmployeeStockOwnershipPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair Value of Unearned Employee Stock Ownership Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_IncreaseDecreaseInFairValueOfSafeInstrument_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in fair value of safe instrument</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_IncreaseDecreaseInFairValueOfSafeInstrument_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Fair Value of SAFE Instrument</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_IncreaseDecreaseInFairValueOfSafeInstrument_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase (decrease) in fair value of safe instrument.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Net Loss Per Share Attributable to Common Stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares, granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationTechniqueAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Approach and Technique [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_NumberOfMonthlyInstallmentsLease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of monthly installments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_NumberOfMonthlyInstallmentsLease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Monthly Installments Lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_NumberOfMonthlyInstallmentsLease_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of monthly installments lease.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other income and expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other income and expense, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted average risk-free interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_TwoPortfoliosMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Two Portfolios</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_TwoPortfoliosMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Portfolios [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_TwoPortfoliosMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two portfolios.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of shares unvested, beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of shares unvested, ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Loss Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_LesseeOperatingAndFinancingLeasesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating And Financing Leases Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_LesseeOperatingAndFinancingLeasesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee Operating And Financing Leases Disclosure.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_LesseeOperatingAndFinancingLeasesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liabilities, operating</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_OneTimeUpFrontNonRefundableFees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">One-time up-front non-refundable fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_OneTimeUpFrontNonRefundableFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">One Time Up Front Non Refundable Fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_OneTimeUpFrontNonRefundableFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">One time up front non refundable fees.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-current portion of lease liabilities - operating</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty payments description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Arrangement, Contract to Perform for Others, Description and Terms</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Tax Jurisdiction [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_BlackScholesModelMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Black-Scholes model.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_BlackScholesModelMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Black-Scholes Model [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_BlackScholesModelMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Black-Scholes Model</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital, Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of shares of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeFinanceLeaseDiscountRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Imputed interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeFinanceLeaseDiscountRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Finance Lease, Discount Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Exercised, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Exercise of stock options, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercised, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares, Options exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_TreasuryStockRepurchase_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Treasury Stock Repurchase</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_TreasuryStockRepurchase_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Treasury stock repurchase.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_TreasuryStockRepurchase_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Treasury stock repurchases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_TreasuryStockRepurchase_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Treasury stock repurchases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_SeriesBConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_SeriesBConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series B Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_SeriesBConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series B convertible preferred stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_DevelopmentAndRegulatoryMilestonesDue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development and regulatory milestones due</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_DevelopmentAndRegulatoryMilestonesDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Development and Regulatory Milestones Due</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_DevelopmentAndRegulatoryMilestonesDue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Development and regulatory milestones due.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LaborAndRelatedExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Labor and Related Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LaborAndRelatedExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lab-related costs and supplies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award options unvested and expected to vest exercisable weighted average remaining contractual term1.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining contractual term, unvested and exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Sharebased Payment Award Options Unvested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Financial Statement Error Correction [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">All other general and administrative expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_SimpleAgreementForFutureEquityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">SAFE</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_SimpleAgreementForFutureEquityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">SAFE [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_SimpleAgreementForFutureEquityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Simple Agreement For Future Equity [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_SimpleAgreementForFutureEquityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Simple Agreement For Future Equity [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_FairValueTimeUntilQualifiedEquityFinancingEvent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Time until qualified equity financing event (in years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_FairValueTimeUntilQualifiedEquityFinancingEvent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Time Until Qualified Equity Financing Event</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_FairValueTimeUntilQualifiedEquityFinancingEvent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value time until qualified equity financing event.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of SAFE Note into common stock in connection with initial public offering, net of issuance costs, value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income (Expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Nonoperating Income (Expense), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income (expense), net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture and Fixtures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Furniture and Fixtures [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockCommonMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Treasury Stock, Common [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockCommonMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Treasury Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Processes Integrated [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_FairValueTimeUntilPublicOfferingEvent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Time until public offering event (in years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_FairValueTimeUntilPublicOfferingEvent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Time Until Public Offering Event</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_FairValueTimeUntilPublicOfferingEvent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value time until public offering event.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for amounts included in the measurement of lease liabilities, included in operating cash flows</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercise of stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Stock Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_FairValueTimeUntilChangeInControlEvent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Time until change in control event (in years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_FairValueTimeUntilChangeInControlEvent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Time Until Change In Control Event</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_FairValueTimeUntilChangeInControlEvent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value time until change in control event.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Incremental borrowing rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Discount Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares, unvested and exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other deferred tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_TwoThousandTwentyThreeEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Three Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_TwoThousandTwentyThreeEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Thousand Twenty Three Equity Incentive Plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_TwoThousandTwentyThreeEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023 Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Short-Term Investments, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ConsolidationItemsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation Items [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating lease expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_TwoThousandAndTwentyThreeEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand and twenty three equity incentive plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_TwoThousandAndTwentyThreeEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand and Twenty Three Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_TwoThousandAndTwentyThreeEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023 Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Restricted cash included in long-term assets at end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Restricted cash included in long-term assets at beginning of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputSharePriceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input, Share Price [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputSharePriceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Net of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total other comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Shares, Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Shares, Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchases of investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Investments, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualTermGrantDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement by Share Based Payment Award Contractual Term Grant Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualTermGrantDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share Based Compensation Arrangement by Share Based Payment Award Contractual Term Grant Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualTermGrantDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contractual term grant date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock, par value per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock at par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Asset, In-Process Research and Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized R&amp;D expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InternalUseSoftwarePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Internal Use Software, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InternalUseSoftwarePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Software Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Due within one year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_PaymentOfRegulatoryMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Regulatory milestone to be paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_PaymentOfRegulatoryMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment of Regulatory Milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_PaymentOfRegulatoryMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment of regulatory milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents and restricted cash at beginning of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, cash equivalents and restricted cash at end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: imputed interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less: imputed interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability, Undiscounted Excess Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_TemporaryEquityConversionOfStockInInitialPublicOfferingShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity, conversion of stock in initial public offering, shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_TemporaryEquityConversionOfStockInInitialPublicOfferingShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Conversion Of Stock In Initial Public Offering, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_TemporaryEquityConversionOfStockInInitialPublicOfferingShares_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Conversion of convertible preferred stock into common stock in connection with initial public offering, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Assets, Fair Value Disclosure, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ReclassificationOfInternalUseSoftwareIntoPrepaidExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reclassification of Internal Use Software into Prepaid Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ReclassificationOfInternalUseSoftwareIntoPrepaidExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Reclassification of internal use software into prepaid expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ReclassificationOfInternalUseSoftwareIntoPrepaidExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reclassification of internal use software into prepaid expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reconciliation of Remaining Undiscounted Contractual Rent Obligations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Comprehensive Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_FinanceLeaseMonthlyInstallmentPaymentAmounts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Monthly installment payment amounts</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_FinanceLeaseMonthlyInstallmentPaymentAmounts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Monthly Installment Payment Amounts</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_FinanceLeaseMonthlyInstallmentPaymentAmounts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Finance lease monthly installment payment amounts</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of RSU activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares available for future grants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average grant date fair value, granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized compensation expense, weighted-average period of recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Private Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross proceeds from private placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from issuance of common stock upon private placement offering, net of commissions and offering costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_LossRecognizedFromUninsuredBalances_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss recognized from uninsured balances</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_LossRecognizedFromUninsuredBalances_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Recognized from Uninsured Balances</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_LossRecognizedFromUninsuredBalances_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Loss recognized from uninsured balances.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax assets (liabilities)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Income Location, Balance [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_PaymentOfAnnualLicenseMaintenanceFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment of Annual License Maintenance Fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_PaymentOfAnnualLicenseMaintenanceFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment of annual license maintenance fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_PaymentOfAnnualLicenseMaintenanceFees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual license maintenance fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term (in years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_NumberOfSharesAutomaticallyIncreaseInAvailableSharesOfCommonStockUnderPlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares automatically increase in available shares of common stock under plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_NumberOfSharesAutomaticallyIncreaseInAvailableSharesOfCommonStockUnderPlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Shares Automatically Increase in Available Shares of Common Stock Under Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_NumberOfSharesAutomaticallyIncreaseInAvailableSharesOfCommonStockUnderPlan_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of Shares Automatically Increase in Available Shares of Common Stock Under Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_TwoThousandTwentyOneEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_TwoThousandTwentyOneEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty One Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_TwoThousandTwentyOneEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty one equity incentive plan member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Long-Term Debt Instruments [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_IncreaseDecreaseInFinanceLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liabilities, finance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_IncreaseDecreaseInFinanceLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Finance Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_IncreaseDecreaseInFinanceLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in finance lease liability.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Total deferred tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recent Accounting Pronouncements Not Yet Adopted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments of Stock Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Underwriting discounts, commissions and offering expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_TemporaryEquityConversionOfStockInInitialPublicOfferingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred stock into common stock in connection with initial public offering, value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_TemporaryEquityConversionOfStockInInitialPublicOfferingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity, conversion of stock in initial public offering, value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_TemporaryEquityConversionOfStockInInitialPublicOfferingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Conversion Of Stock In Initial Public Offering, Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of shares, forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability, to be Paid, Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_SteliosTherapeuticsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stelios Therapeutics Inc</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_SteliosTherapeuticsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stelios Therapeutics Inc [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_SteliosTherapeuticsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stelios Therapeutics Inc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock-Based Compensation Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible safe note, principal amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Face Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining contractual term, vested and exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Numerator:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Charges, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Offering Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Private Placement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Private Placement Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Private Placement Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Expired, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Uncertain tax positions, accrued interest or penalties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023 ESPP</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Three Employee Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">2023 Employee Stock Purchase Plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_WeillCornellMedicalCollegeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weill Cornell Medical College</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_WeillCornellMedicalCollegeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weill Cornell Medical College [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_WeillCornellMedicalCollegeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Weill Cornell medical college.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon offering and subsequent partial exercise of underwriters' option to purchase additional shares, Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ResearchAgreementsTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research agreements term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ResearchAgreementsTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research Agreements Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ResearchAgreementsTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research agreements term.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net of Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_PaymentOfClinicalAndRegulatoryMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Clinical and regulatory milestone paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_PaymentOfClinicalAndRegulatoryMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment Of Clinical And Regulatory Milestone</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_PaymentOfClinicalAndRegulatoryMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment Of Clinical And Regulatory Milestone.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options, value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Stock Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_FairValueProbabilityOfMeetingPublicOfferingEvent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Probability Of Meeting Public Offering Event</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_FairValueProbabilityOfMeetingPublicOfferingEvent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Probability of meeting public offering event</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_FairValueProbabilityOfMeetingPublicOfferingEvent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value probability of meeting public offering event.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_OperatingLeaseWeightedAverageRemainingPaymentTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining lease payment terms</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_OperatingLeaseWeightedAverageRemainingPaymentTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Weighted Average Remaining Payment Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_OperatingLeaseWeightedAverageRemainingPaymentTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease weighted average remaining payment term.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Cash and cash equivalents, including restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, at Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents and restricted cash at beginning of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, cash equivalents and restricted cash at end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsForeign_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal tax credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsForeign_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2029</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management, Strategy, and Governance [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value, exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Intrinsic value of stock options exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and development expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financed research and development expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Included in the balance sheet:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset acquisition date of acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition, Effective Date of Acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversionOfNotesIntoCommonStock_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Conversion of SAFE Note into common stock in connection with initial public offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversionOfNotesIntoCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value measurement with unobservable inputs reconciliation recurring basis liability conversion of notes into common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversionOfNotesIntoCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Conversion of Notes Into Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockDividendRatePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of dividends per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockDividendRatePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Dividend Rate, Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Gross, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Gross, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Gross, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AccruedResearchAndDevelopmentExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued research and development expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AccruedResearchAndDevelopmentExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research And Development Expense Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AccruedResearchAndDevelopmentExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued research and development expense current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCostsCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred offering costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCostsCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Costs, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCostsCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net book values</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease right-of-use assets - finance, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Right-of-Use Asset, after Accumulated Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Finance Lease, Right-of-Use Asset, after Accumulated Amortization, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Leases [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input, Expected Term [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Following Assumptions Presented on Weighted Average Basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Summary of Estimated Fair Value Assumptions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_UcsdSponsoredResearchAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">UCSD Sponsored Research Agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_UcsdSponsoredResearchAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">UCSD Sponsored Research Agreements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_UcsdSponsoredResearchAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">UCSD sponsored research agreements.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingSegmentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Segments [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingSegmentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AccruedGeneralAndAdministrativeExpensesAndOtherProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued general and administrative expenses and other professional fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AccruedGeneralAndAdministrativeExpensesAndOtherProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued General And Administrative Expenses And Other Professional Fees Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AccruedGeneralAndAdministrativeExpensesAndOtherProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued general and administrative expenses and other professional fees current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsUnvestedStockOptionsSubjectToRepurchaseValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Adjustments to additional paid in capital reclassification from deposit liability share based compensation and exercise of stock options unvested stock options subject to repurchase, value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsUnvestedStockOptionsSubjectToRepurchaseValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Reclassification From Deposit Liability Share Based Compensation And Exercise Of Stock Options Unvested Stock Options Subject To Repurchase, Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsUnvestedStockOptionsSubjectToRepurchaseValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amounts reclassified from deposit liabilities upon the vesting of early-exercised stock options previously subject to repurchase, net of proceeds received from early exercise of unvested stock options subject to repurchase and recorded as deposit liabilities, value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockAmountIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion of Stock, Amount Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockAmountIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred stock into common stock in connection with initial public offering, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment to selling shareholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, unvested and exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award options nonvested weighted average exercise price.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOptionsExercisableWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average grant date fair value, vested and exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOptionsExercisableWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested Options Exercisable Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOptionsExercisableWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award options vested options exercisable weighted average grant date fair value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_FinanceLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total finance lease expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_FinanceLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_FinanceLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Finance lease expense.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Repurchase of Common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments for Repurchase of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Reconciliation of Statutory Income Tax Rate to Effective Income Tax Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management, Strategy, and Governance [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment to research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire in Process Research and Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_CornellFirstLicenseAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cornell First License Agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_CornellFirstLicenseAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cornell First License Agreements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_CornellFirstLicenseAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cornell first license agreements.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsUnvestedStockOptionsSubjectToRepurchaseShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Adjustments to additional paid in capital reclassification from deposit liability share based compensation and exercise of stock options unvested stock options subject to repurchase, share.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsUnvestedStockOptionsSubjectToRepurchaseShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Reclassification From Deposit Liability Share Based Compensation And Exercise Of Stock Options Unvested Stock Options Subject To Repurchase, Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsUnvestedStockOptionsSubjectToRepurchaseShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amounts reclassified from deposit liabilities upon the vesting of early-exercised stock options previously subject to repurchase, net of proceeds received from early exercise of unvested stock options subject to repurchase and recorded as deposit liabilities, share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Repurchased During Period, Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares repurchased value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Treasury stock repurchase, Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Treasury stock repurchases, Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditFacilityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Credit Facility [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Reclassification From Deposit Liability Share Based Compensation And Exercise Of Stock Options, Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Adjustments to additional paid in capital reclassification from deposit liability share based compensation and exercise of stock options, share.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amounts reclassified from deposit liabilities upon the vesting of early-exercised stock options previously subject to repurchase. Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation, Depletion and Amortization, Nonproduction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Depletion and Amortization, Nonproduction, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Net [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityLiquidationPreferencePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liquidation preference</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityLiquidationPreferencePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Liquidation Preference Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_DeferredTaxAssetsIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets, intangible assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_DeferredTaxAssetsIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_DeferredTaxAssetsIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangibles</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities and Stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ICFR Auditor Attestation Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AlternativeInvestmentMeasurementInput_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Alternative Investment, Measurement Input</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AlternativeInvestmentMeasurementInput_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement input</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective income tax rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Noncurrent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_NumberOfLicenseAgreements_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of license agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_NumberOfLicenseAgreements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of License Agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_NumberOfLicenseAgreements_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of license agreements.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive securities excluded from Computation of diluted net loss per common share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Due after one year through five years</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase In Common Stock Capital Shares Reserved For Future Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase in common stock capital shares reserved for future issuance.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in aggregate number of shares of common stock reserved for issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Conversion, Converted Instrument, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of SAFE Note into common stock in connection with initial public offering, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Consideration Received on Transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">All other research and development expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income Tax Expense (Benefit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ResearchAndDevelopmentExpenseEmployeeCompensationExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee compensation expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ResearchAndDevelopmentExpenseEmployeeCompensationExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense Employee Compensation Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ResearchAndDevelopmentExpenseEmployeeCompensationExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development expense employee compensation expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary of Significant Accounting Policies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendsCommonStockCash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividends, common stock, cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendsCommonStockCash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Dividends, Common Stock, Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Available-for-sale securities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combinations [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance, value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance, value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Notes with outstanding principal exchanged</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Conversion, Original Debt, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Based Compensation Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units (RSUs) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Units [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Convertible Preferred Stock Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable lease expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management, Strategy, and Governance [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_FinanceLeaseRightOfUseAssetsAndFinanceLeaseLiabilitiesRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance lease right-of use assets and finance lease liabilities recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_FinanceLeaseRightOfUseAssetsAndFinanceLeaseLiabilitiesRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Right-of Use Assets And Finance Lease Liabilities Recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_FinanceLeaseRightOfUseAssetsAndFinanceLeaseLiabilitiesRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Finance lease right-of use assets and finance lease liabilities recognized.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Adopted [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ResearchAndDevelopmentExpenseLX1001_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">LX1001</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ResearchAndDevelopmentExpenseLX1001_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense LX1001</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ResearchAndDevelopmentExpenseLX1001_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development expense LX1001.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalUnitsAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Authorized capital stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalUnitsAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capital Units, Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in estimated fair value since issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SecurityDeposit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security deposit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SecurityDeposit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Deposit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ThirdCornellLicenseAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Third Cornell License Agreements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ThirdCornellLicenseAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Third cornell license agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ThirdCornellLicenseAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cornell Third License Agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ResearchAgreementTerminationNoticePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research agreement termination notice period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ResearchAgreementTerminationNoticePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research Agreement Termination Notice Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ResearchAgreementTerminationNoticePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research agreement termination notice period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_SpecificClinicalAndRegulatoryMilestonesDue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Specific clinical and regulatory milestones due</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_SpecificClinicalAndRegulatoryMilestonesDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Specific Clinical and Regulatory Milestones Due</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_SpecificClinicalAndRegulatoryMilestonesDue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Specific clinical and regulatory milestones due.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Location [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value, vested and exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability, to be Paid, Year Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Gross Unrealized Losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leases [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOptionQuantitativeDisclosuresTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Option, Disclosures [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lab Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Equipment Finance Lease [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_UpfrontCashPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront payment in cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_UpfrontCashPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Cash Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_UpfrontCashPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront cash payment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred stock into common stock in connection with initial public offering, value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsExercisableWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average grant date fair value, Unvested and exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsExercisableWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share based Compensation Arrangement By Share based Payment Award Options Nonvested Options Exercisable Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsExercisableWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award options nonvested options exercisable weighted average grant date fair value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AggregateDevelopmentAndCommercializationMilestonesDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development and commercialization milestones description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AggregateDevelopmentAndCommercializationMilestonesDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate Development And Commercialization Milestones Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AggregateDevelopmentAndCommercializationMilestonesDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">aggregate development and commercialization milestones description.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Leasing Arrangements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Right of use asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected Volatility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input, Price Volatility [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementScenarioAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Expected dividend yield</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yields percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reconciliation of Remaining Equipment Finance Lease Obligations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Investments Classified as Available-for-Sale Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Loss Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Tax Credit Carryforwards, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Credit Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition, Acquiree [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input, Risk Free Interest Rate [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Risk-free Interest Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_SareptaTherapeuticsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sarepta Therapeutics, Inc</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_SareptaTherapeuticsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sarepta Therapeutics, Inc [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_SareptaTherapeuticsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sarepta Therapeutics, Inc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_PaymentStartingAfterPeriodOfExecutionOfAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment starting after period of execution of agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_PaymentStartingAfterPeriodOfExecutionOfAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment Starting After Period of Execution of Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_PaymentStartingAfterPeriodOfExecutionOfAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment starting after period of execution of agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: accumulated depreciation and amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less: accumulated depreciation and amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain (Loss) on Fair Value Hedges Recognized in Earnings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss on fair value adjustment to convertible SAFE Note</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Gain (Loss) on Fair Value Hedges Recognized in Earnings, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Included in the balance sheet:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average grant date fair value, granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted-average grant date fair value of stock options granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating lease right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease right-of-use assets - operating</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average grant date fair value, exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercised In Period Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award options exercised in period weighted average grant date fair value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosures of cash flow information</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares, vested and exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options Vested In Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award equity instruments options vested in period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss per common share, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share attributable to common stockholders, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold Improvements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_PercentageOfAutomaticallyIncreaseInAvailableSharesOfCommonStockOnBeginningOfCachCalendarYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of automatically increase in available shares of common stock on beginning of each calendar year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_PercentageOfAutomaticallyIncreaseInAvailableSharesOfCommonStockOnBeginningOfCachCalendarYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of Automatically Increase in Available Shares of Common Stock on Beginning of Cach Calendar Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_PercentageOfAutomaticallyIncreaseInAvailableSharesOfCommonStockOnBeginningOfCachCalendarYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of automatically increase in available shares of common stock on beginning of each calendar year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_PaymentOfOneTimeUpFrontNonRefundableFee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">One-time up-front non-refundable fee paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_PaymentOfOneTimeUpFrontNonRefundableFee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment of One Time Up Front Non Refundable Fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_PaymentOfOneTimeUpFrontNonRefundableFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment of one time up front non refundable fee.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDerivativeAssetsAndLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Derivative Assets and Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDerivativeAssetsAndLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Change in fair value of convertible SAFE Note liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_PercentageOfCumulativeOwnershipChange_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Cumulative Ownership Change</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_PercentageOfCumulativeOwnershipChange_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of cumulative ownership change.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_PercentageOfCumulativeOwnershipChange_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of cumulative ownership change</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AmountsReclassifiedFromDepositLiabilitiesUponTheVestingOfEarlyExercisedStockOptionsPreviouslySubjectToRepurchaseNetOfProceedsReceivedFromEarlyExerciseOfUnvestedStockOptionsSubjectToRepurchaseAndRecord_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amounts Reclassified From Deposit Liabilities Upon The Vesting Of Early-exercised Stock Options Previously Subject To Repurchase, Net Of Proceeds Received From Early Exercise Of Unvested Stock Options Subject To Repurchase And Recorded As Deposit Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AmountsReclassifiedFromDepositLiabilitiesUponTheVestingOfEarlyExercisedStockOptionsPreviouslySubjectToRepurchaseNetOfProceedsReceivedFromEarlyExerciseOfUnvestedStockOptionsSubjectToRepurchaseAndRecord_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amounts reclassified from deposit liabilities upon the vesting of early-exercised stock options previously subject to repurchase, net of proceeds received from early exercise of unvested stock options subject to repurchase and recorded as deposit liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AmountsReclassifiedFromDepositLiabilitiesUponTheVestingOfEarlyExercisedStockOptionsPreviouslySubjectToRepurchaseNetOfProceedsReceivedFromEarlyExerciseOfUnvestedStockOptionsSubjectToRepurchaseAndRecord_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amounts reclassified from deposit liabilities upon the vesting of early-exercised stock options previously subject to repurchase, net of proceeds received from early exercise of unvested stock options subject to repurchase and recorded as deposit liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioForecastMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scenario Forecast</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioForecastMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Forecast [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of common shares issued and sold</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares purchased at public offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance of common stock upon offering and subsequent partial exercise of underwriters' option to purchase additional shares, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Uncertain tax positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Unrecognized Tax Benefits, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Unrecognized Tax Benefits, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted average grant date fair value, ending</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted average grant date fair value, beginning</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Permanent differences</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Existence of option to extend</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Existence of Option to Extend [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of common shares on conversion of debt instrument</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued on debt exchanged</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Conversion, Converted Instrument, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value, unvested and exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Operating Assets and Liabilities, Net [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Description of Business and Basis of Presentation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income and expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense) [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total grant date fair values of options vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: present value adjustment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Noncash Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-Based Payment Arrangement, Noncash Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GranteeStatusDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Grantee Status [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Aggregate intrinsic value, ending</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Aggregate intrinsic value, beginning</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Aggregate intrinsic value, ending</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value, beginning</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_SeriesAAndBConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A and B Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_SeriesAAndBConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A and B Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_SeriesAAndBConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A and B convertible preferred stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AdverumLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Adverum license agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AdverumLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adverum License Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AdverumLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adverum License Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_CornellUniversityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cornell University</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_CornellUniversityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cornell University [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_CornellUniversityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cornell university.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted average remaining lease payment term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Lease Payment Term (in years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Weighted Average Remaining Lease Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AccruedLiabilitiesAndOtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AccruedLiabilitiesAndOtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total accrued expenses and other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AccruedLiabilitiesAndOtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities And Other Liabilities Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AccruedLiabilitiesAndOtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued liabilities and other liabilities current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Reportable Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of reportable segment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_OperatingLossCarryForwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carry forwards expiration year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_OperatingLossCarryForwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carry forwards Expiration Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_OperatingLossCarryForwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards, expiration year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_PercentageOfOutstandingSharesForDeemedLiquidation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of outstanding shares for deemed liquidation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_PercentageOfOutstandingSharesForDeemedLiquidation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of Outstanding Shares for Deemed Liquidation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_PercentageOfOutstandingSharesForDeemedLiquidation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of outstanding shares for deemed liquidation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted average number of shares outstanding used in computation of net loss per common share, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average common shares outstanding, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingencies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-current portion of lease liabilities - finance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of series A convertible preferred stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Stock Issued During Period, Value, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NotesIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Notes issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NotesIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Notes Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Useful Life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated useful life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Useful Life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GranteeStatusAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Grantee Status [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Gross proceeds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_StockOfferingValueSharesAuthorizedToBeSold_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Offering Value Shares Authorized To Be Sold</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_StockOfferingValueSharesAuthorizedToBeSold_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock offering value shares authorized to be sold.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_StockOfferingValueSharesAuthorizedToBeSold_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock aggregate offering price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest on finance lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Interest Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AntidilutiveSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AntidilutiveSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AntidilutiveSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Antidilutive securities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated by Reference [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_DeferredTaxAssetsLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets lease liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_DeferredTaxAssetsLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Lease Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_DeferredTaxAssetsLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Offering Costs Included In Accounts Payable And Accrued Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred offering costs included in accounts payable and accrued expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred offering costs included in accounts payable and accrued expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance costs related to convertible debt included in accounts payable and accrued expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining contractual term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_PaymentOfDevelopmentMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development milestone paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_PaymentOfDevelopmentMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment of Development Milestone</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_PaymentOfDevelopmentMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment of development milestone.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConvertibleNoteIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Liability, Convertible Note Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConvertibleNoteIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, convertible note issuance.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConvertibleNoteIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Convertible SAFE Note issuance at August 24, 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Role of Management [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockCommonValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Treasury Stock, Common, Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockCommonValue_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Treasury stock, at cost, 3,827 common shares at December 31, 2024 and 0 common shares at December 31, 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Available-for-sale securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Option Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' equity:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AmountDueUnderAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount due under agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AmountDueUnderAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amount Due Under Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AmountDueUnderAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount due under agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalCostsIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional costs incurred for research</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalCostsIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Arrangement, Contract to Perform for Others, Additional Costs Incurred</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalCostsIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development Aarrangement, ontract to perform for others, dditional costs incurred.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosure of non-cash activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_PaymentTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_PaymentTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_PaymentTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment term.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents and Restricted Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputExercisePriceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input, Exercise Price [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputExercisePriceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement Table</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Information</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Property and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities and Other Liabilities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Information</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net change in cash, cash equivalents and restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_SecondUcsdLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Second UCSD License Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_SecondUcsdLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Second UCSD License Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_SecondUcsdLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Second UCSD license agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_CommissionsAndOfferingCostsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commissions and Offering Costs [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_CommissionsAndOfferingCostsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commissions and offering costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_CommissionsAndOfferingCostsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commissions and Offering Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State Taxes, net of federal benefit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement of Financial Position</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">IPO</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">IPO [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Initial Public Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedBonusesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued bonuses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedBonusesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Bonuses, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedBonusesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accrued bonus expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Offering price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LetterOfCreditMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Letter of Credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LetterOfCreditMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Letter of Credit [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_FairValueProbabilityOfMeetingChangeInControlEvent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Probability of meeting change in control event</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_FairValueProbabilityOfMeetingChangeInControlEvent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Probability Of Meeting Change In Control Event</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_FairValueProbabilityOfMeetingChangeInControlEvent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value probability of meeting change in control event.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Estimated Fair Value Assumptions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AmountDueForEachQuarterUnderAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount due for each quarter under agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AmountDueForEachQuarterUnderAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amount Due for Each Quarter Under Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AmountDueForEachQuarterUnderAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount due for each quarter under agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining contractual term, Options exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability, to be Paid, Year Four</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2028</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds Received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate total net proceeds raised with issuance of convertible preferred stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Accrued Expenses and Other Current Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SoftwareDevelopmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Internal Use Software</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SoftwareDevelopmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Software Development [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AmendedFirstUcsdAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amended First UCSD Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AmendedFirstUcsdAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amended First UCSD Agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AmendedFirstUcsdAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amended First UCSD Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_NumberOfResearchAgreements_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of research agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_NumberOfResearchAgreements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Research Agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_NumberOfResearchAgreements_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of research agreements.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, and Short-Term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, and Short-Term Investments, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents, including restricted cash and investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other General and Administrative Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">All other general and administrative expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_PaymentOfAnnualDataTransferFee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual data transfer fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_PaymentOfAnnualDataTransferFee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment of Annual Data Transfer Fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_PaymentOfAnnualDataTransferFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment of annual data transfer fee.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capital Expenditures Incurred but Not yet Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">(Property and equipment purchased in the prior period and paid in the current period), net of property and equipment purchased in the current period included in accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Long-Term Investments, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance Initial Public Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock upon initial public offering, net of underwriters' discounts, commissions and other offering costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforward</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_LesseeFinanceLeaseCommencementDateRangeStart_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance lease, commencement date range, start</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_LesseeFinanceLeaseCommencementDateRangeStart_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Finance Lease, Commencement Date Range, Start</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_LesseeFinanceLeaseCommencementDateRangeStart_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee, finance lease, commencement date range, start.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal statutory rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AdverumBiotechnologiesIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adverum Biotechnologies Inc</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AdverumBiotechnologiesIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adverum Biotechnologies Inc [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AdverumBiotechnologiesIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Adverum Biotechnologies Inc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares issued during the period upon conversion of convertible securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Conversion of convertible preferred stock into common stock in connection with initial public offering, share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireSoftware_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of internal use software</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireSoftware_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Software</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_RNolanTownsendMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">R Nolan Townsend [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_RNolanTownsendMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">R Nolan Townsend.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_RNolanTownsendMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">R. Nolan Townsend</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_MilestoneReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_MilestoneReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Classification of Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note, Redeemable Preferred Stock, Issue, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Jurisdiction [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Issuance Costs, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Issuance Costs, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortized Cost Basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Components of Deferred Tax Assets and Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current portion of lease liabilities - operating</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Jurisdiction [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Interest Rate, Stated Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Over-Allotment Option</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Over-Allotment Option [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ScheduleOfSignificantUnobservableInputsUsedInValuationModelToEstimateFairValueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Significant Unobservable Inputs Used in Valuation Model to Estimate Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ScheduleOfSignificantUnobservableInputsUsedInValuationModelToEstimateFairValueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Significant Unobservable Inputs Used In Valuation Model To Estimate Fair Value [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ScheduleOfSignificantUnobservableInputsUsedInValuationModelToEstimateFairValueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of significant unobservable inputs used in valuation model to estimate fair value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_NetProceedsReceivedFromPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds from private placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_NetProceedsReceivedFromPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Proceeds Received from Private Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_NetProceedsReceivedFromPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Net proceeds received from Private Placement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationTechniqueDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Approach and Technique [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_CapitalExpendituresIncurredButNotYetPaidNetOfPaidAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">(Property and equipment purchased in the prior period and paid in the current period), net of property and equipment purchased in the current period included in accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_CapitalExpendituresIncurredButNotYetPaidNetOfPaidAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capital Expenditures Incurred But Not Yet Paid, Net of Paid Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_CapitalExpendituresIncurredButNotYetPaidNetOfPaidAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Capital expenditures incurred but not yet paid, net of paid amount.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_CapitalExpendituresIncurredButNotYetPaidNetOfPaidAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">(Property and equipment purchased in the prior period and paid in the current period), net of property and equipment purchased in the current period included in accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ResearchAndDevelopmentExpenseLX2020_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">LX2020</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ResearchAndDevelopmentExpenseLX2020_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense LX2020</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ResearchAndDevelopmentExpenseLX2020_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development expense LX2020.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentrations of Credit Risk</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_SeriesAAndSeriesBConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A and series B convertible preferred stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_SeriesAAndSeriesBConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A And Series B Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_SeriesAAndSeriesBConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A and Series B Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrealizedGainLossOnInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrealized Gain (Loss) on Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrealizedGainLossOnInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized loss on investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrealizedGainLossOnInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Unrealized comprehensive loss on investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockholdersEquityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Common Stock Reserved for Future Issuances</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockholdersEquityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Stockholders Equity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermInvestmentsAndReceivablesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Investments and Receivables, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermInvestmentsAndReceivablesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Long-Term Investments and Receivables, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermInvestmentsAndReceivablesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Costs incurred for research</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted-average grant date fair value, unvested, beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted-average grant date fair value, unvested, ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset, Periodic Reduction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reduction in the carrying amount of ROU assets, operating</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well-known Seasoned Issuer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_FinanceLeaseAggregateMonthlyInstallmentPaymentAmounts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total aggregate monthly installment payment amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_FinanceLeaseAggregateMonthlyInstallmentPaymentAmounts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Aggregate Monthly Installment Payment Amounts</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_FinanceLeaseAggregateMonthlyInstallmentPaymentAmounts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Finance lease aggregate monthly installment payment amounts.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Income Location, Balance [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_StockIssuedDuringPeriodValueNewIssuesAdditionalOfferingCostsIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value New Issues Additional Offering Costs Incurred</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_StockIssuedDuringPeriodValueNewIssuesAdditionalOfferingCostsIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period value new issues additional offering costs incurred.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_StockIssuedDuringPeriodValueNewIssuesAdditionalOfferingCostsIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional issuance costs incurred for SAFE Note</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_StockIssuedDuringPeriodValueNewIssuesAdditionalOfferingCostsIncurred_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Additional issuance costs incurred for SAFE Note</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_StockOfferingGrossProceedsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross proceeds percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_StockOfferingGrossProceedsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Offering Gross Proceeds Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_StockOfferingGrossProceedsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock offering gross proceeds percentage.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_CommercializationMilestonesDue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercialization milestones due</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_CommercializationMilestonesDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commercialization Milestones Due</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_CommercializationMilestonesDue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commercialization milestones due.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_FinanceLeaseWeightedAverageRemainingAmortizationTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted average remaining amortization term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_FinanceLeaseWeightedAverageRemainingAmortizationTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Amortization Term (in years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_FinanceLeaseWeightedAverageRemainingAmortizationTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Weighted Average Remaining Amortization Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_FinanceLeaseWeightedAverageRemainingAmortizationTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Finance lease weighted average remaining amortization term.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_SeriesALiquidationPreferenceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A Liquidation Preference</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_SeriesALiquidationPreferenceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A Liquidation Preference [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_SeriesALiquidationPreferenceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A liquidation preference.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Expense Information Used by CODM, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current portion of lease liabilities - finance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Right-of-Use Asset, before Accumulated Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average grant date fair value, expired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">ShareBased Compensation Arrangement By ShareBased Payment Award Options Expired In Period Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ShareBased Compensation Arrangement By ShareBased Payment Award Options Expired In Period Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock, $0.0001 par value, 18,125,051 shares authorized, 1,660,650 shares issued and 1,633,206 shares outstanding, actual; 18,125,051 shares authorized, 15,220,250 shares issued and 15,192,806 shares outstanding, pro forma</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.0001 par value, 500,000,000 shares authorized as of December 31, 2024; 33,079,209 shares issued and 33,071,261 shares outstanding as of December 31, 2024; 500,000,000 shares authorized as of December 31, 2023; 26,668,485 shares issued and 26,646,378 shares outstanding as of December 31, 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income, Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Right-of-Use Asset, Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance lease amortization of right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Reduction in the carrying amount of ROU assets, finance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Reclassification From Deposit Liability Share Based Compensation And Exercise Of Stock Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Adjustments to additional paid in capital reclassification from deposit liability share based compensation and exercise of stock options.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amounts reclassified from deposit liabilities upon the vesting of early-exercised stock options previously subject to repurchase, Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ComponentsOfEquipmentFinanceLeaseTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Components of Equipment Finance Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ComponentsOfEquipmentFinanceLeaseTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Components of Equipment Finance Lease [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ComponentsOfEquipmentFinanceLeaseTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Components of equipment Finance lease.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Fair Value Hierarchy for Assets and Liabilities Measured at Fair Value on Recurring Basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ResearchCollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research Collaboration Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ResearchCollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research Collaboration Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ResearchCollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research collaboration agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current portion of lease liabilities - operating</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Operating Loss Carryforwards, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (Note 12)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-employee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonemployee [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income taxes paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueNetAssetLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Net Asset (Liability)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueNetAssetLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Fair Value, Net Asset (Liability), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueNetAssetLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value Disclosure, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted average number of shares outstanding used in computation of net loss per common share, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average common shares outstanding, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ComponentsOfOperatingLeaseTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Components of Operating Lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ComponentsOfOperatingLeaseTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Components of Operating Lease [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ComponentsOfOperatingLeaseTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Components of operating lease.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_LesseeFinanceLeaseCommencementDateRangeEnd_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance lease, commencement date range, end</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_LesseeFinanceLeaseCommencementDateRangeEnd_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Finance Lease, Commencement Date Range, End</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_LesseeFinanceLeaseCommencementDateRangeEnd_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee, finance lease, commencement date range, end.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Additional Information On Company's Net loss Including Segment Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalizedComputerSoftwareGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred software costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalizedComputerSoftwareGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capitalized Computer Software, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Renewal term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Renewal Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Third Party Engaged [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Denominator:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_CornellLicenseAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cornell License Agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_CornellLicenseAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cornell License Agreements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_CornellLicenseAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cornell license agreements.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_OperatingLeaseAgreementEnteredDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease agreement entered date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_OperatingLeaseAgreementEnteredDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Agreement Entered Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_OperatingLeaseAgreementEnteredDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease agreement entered date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total finance lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Information [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Safe Note</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Treasury Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Treasury Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total Investment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Investments, Fair Value Disclosure, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ResearchAndDevelopmentExpenseOtherPrograms_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense Other Programs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ResearchAndDevelopmentExpenseOtherPrograms_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development expense other programs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_ResearchAndDevelopmentExpenseOtherPrograms_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other programs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditFacilityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Credit Facility [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_SeriesBLiquidationPreferenceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B Liquidation Preference</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_SeriesBLiquidationPreferenceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series B Liquidation Preference [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_SeriesBLiquidationPreferenceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series B liquidation preference.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Expired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accretion of discount on investments, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accretion of discount on investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_UnderwritingDiscountsCommissionsAndOfferingCostsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Underwriting discounts, commissions and offering costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_UnderwritingDiscountsCommissionsAndOfferingCostsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Underwriting Discounts, Commissions and Offering Costs [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_UnderwritingDiscountsCommissionsAndOfferingCostsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwriting Discounts, Commissions and Offering Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted average exercise price, beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted average exercise price, ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Expenses and Other Current Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_FirstUcsdLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">First UCSD License Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_FirstUcsdLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">First UCSD License Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_FirstUcsdLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">First UCSD license agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer, Product and Service [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">State and Local Jurisdiction [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State and Local</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_EricAdlerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Eric Adler [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_EricAdlerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Eric Adler.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_EricAdlerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Eric Adler</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Recognized Amount [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Convertible Preferred Stock Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Temporary equity, balance, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Temporary equity, balance, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_OperatingLeaseCommencementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease commencement date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_OperatingLeaseCommencementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Commencement Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_OperatingLeaseCommencementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease commencement date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 3 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 3 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining lease terms</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Remaining Lease Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromNotesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Notes Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromNotesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_PaymentOfLicenseIssueFeeAndInitialDataTransferFee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment of License Issue Fee and Initial Data Transfer Fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_PaymentOfLicenseIssueFeeAndInitialDataTransferFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment of license issue fee and initial data transfer fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lxeo_PaymentOfLicenseIssueFeeAndInitialDataTransferFee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License fee and initial data transfer fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Liabilities, Fair Value Disclosure, Total</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_LicenseAndAcquisitionAndResearchCollaborationAndSponsoredResearchAgreementsDisclosureTextBlock" xlink:to="lxeo_LicenseAndAcquisitionAndResearchCollaborationAndSponsoredResearchAgreementsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLiquidationPreference" xlink:to="us-gaap_TemporaryEquityLiquidationPreference_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_ThirdPartiesForPharmaceuticalManufacturingAndResearchActivitiesMember" xlink:to="lxeo_ThirdPartiesForPharmaceuticalManufacturingAndResearchActivitiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_AgreementExpirationTerm" xlink:to="lxeo_AgreementExpirationTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeAmortizationOfDiscount" xlink:to="us-gaap_InvestmentIncomeAmortizationOfDiscount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_InvestmentCurrent" xlink:to="lxeo_InvestmentCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lxeo_SummaryOfSignificantAccountingPoliciesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_ShareBasedCompensationPaymentDescription" xlink:to="lxeo_ShareBasedCompensationPaymentDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_OfficeFacilityAndLaboratorySpaceMember" xlink:to="lxeo_OfficeFacilityAndLaboratorySpaceMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockTextBlock" xlink:to="us-gaap_PreferredStockTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_ThirdUcsdLicenseAgreementMember" xlink:to="lxeo_ThirdUcsdLicenseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableCurrent" xlink:to="us-gaap_ConvertibleNotesPayableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_TwoThousandTwentyOneAndTwoThousandTwentyThreeEquityIncentivePlanMember" xlink:to="lxeo_TwoThousandTwentyOneAndTwoThousandTwentyThreeEquityIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_QualifiedIpoMinimumNumberOfDirectorsApprovalRequired" xlink:to="lxeo_QualifiedIpoMinimumNumberOfDirectorsApprovalRequired_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseNonoperating" xlink:to="us-gaap_InterestExpenseNonoperating_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_DevelopmentAndCommercializationMilestonesDue" xlink:to="lxeo_DevelopmentAndCommercializationMilestonesDue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_CornellSecondLicenseAgreementsMember" xlink:to="lxeo_CornellSecondLicenseAgreementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorOpinionTextBlock" xlink:to="dei_AuditorOpinionTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_CommonStockSharesIssuedOnEarlyExerciseOfUnvestedStockOptions" xlink:to="lxeo_CommonStockSharesIssuedOnEarlyExerciseOfUnvestedStockOptions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_SeriesAConvertiblePreferredStockMember" xlink:to="lxeo_SeriesAConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:to="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_ConvertibleSimpleAgreementForFutureEquityNoteMember" xlink:to="lxeo_ConvertibleSimpleAgreementForFutureEquityNoteMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_ThirdPortfolioMember" xlink:to="lxeo_ThirdPortfolioMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpenseAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_ResearchAndDevelopmentExpenseLX2006" xlink:to="lxeo_ResearchAndDevelopmentExpenseLX2006_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdateExtensibleList" xlink:to="us-gaap_AccountingStandardsUpdateExtensibleList_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_TaxCreditCarryForwardExpirationYear" xlink:to="lxeo_TaxCreditCarryForwardExpirationYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_CommonStockDuringOfferingPeriod" xlink:to="lxeo_CommonStockDuringOfferingPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLocationAxis" xlink:to="us-gaap_OtherComprehensiveIncomeLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_NumberOfFormerEmployees" xlink:to="lxeo_NumberOfFormerEmployees_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_OperatingLeaseEndDate" xlink:to="lxeo_OperatingLeaseEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleSharesIssuable" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonShares" xlink:to="us-gaap_TreasuryStockCommonShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue" xlink:to="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_InvestmentNonCurrent" xlink:to="lxeo_InvestmentNonCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice" xlink:to="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtShare" xlink:to="lxeo_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidationItemsDomain" xlink:to="srt_ConsolidationItemsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_GeneralAndAdministrativeExpenseEmployeeCompensationExpenses" xlink:to="lxeo_GeneralAndAdministrativeExpenseEmployeeCompensationExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_GeneralAndAdministrativeExpensesPolicyPolicyTextBlock" xlink:to="lxeo_GeneralAndAdministrativeExpensesPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_FairValueProbabilityOfMeetingQualifiedEquityFinancingEvent" xlink:to="lxeo_FairValueProbabilityOfMeetingQualifiedEquityFinancingEvent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_LeerinkAtTheMarketSalesAgreementMember" xlink:to="lxeo_LeerinkAtTheMarketSalesAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_LicenseAgreementTerminationNoticePeriod" xlink:to="lxeo_LicenseAgreementTerminationNoticePeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_AnnualLimitationAbilityToUtilize" xlink:to="lxeo_AnnualLimitationAbilityToUtilize_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityTableTextBlock" xlink:to="us-gaap_TemporaryEquityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_PayrollDeductionsAtPrice" xlink:to="lxeo_PayrollDeductionsAtPrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentDescription" xlink:to="us-gaap_DebtInstrumentDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_FairValueOfUnearnedEmployeeStockOwnershipPlans" xlink:to="lxeo_FairValueOfUnearnedEmployeeStockOwnershipPlans_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_IncreaseDecreaseInFairValueOfSafeInstrument" xlink:to="lxeo_IncreaseDecreaseInFairValueOfSafeInstrument_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_NumberOfMonthlyInstallmentsLease" xlink:to="lxeo_NumberOfMonthlyInstallmentsLease_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpenseAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_TwoPortfoliosMember" xlink:to="lxeo_TwoPortfoliosMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_LesseeOperatingAndFinancingLeasesDisclosureTextBlock" xlink:to="lxeo_LesseeOperatingAndFinancingLeasesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_OneTimeUpFrontNonRefundableFees" xlink:to="lxeo_OneTimeUpFrontNonRefundableFees_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_BlackScholesModelMember" xlink:to="lxeo_BlackScholesModelMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeFinanceLeaseDiscountRate" xlink:to="us-gaap_LesseeFinanceLeaseDiscountRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_TreasuryStockRepurchase" xlink:to="lxeo_TreasuryStockRepurchase_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_SeriesBConvertiblePreferredStockMember" xlink:to="lxeo_SeriesBConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_DevelopmentAndRegulatoryMilestonesDue" xlink:to="lxeo_DevelopmentAndRegulatoryMilestonesDue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LaborAndRelatedExpense" xlink:to="us-gaap_LaborAndRelatedExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lxeo_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_SimpleAgreementForFutureEquityMember" xlink:to="lxeo_SimpleAgreementForFutureEquityMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_FairValueTimeUntilQualifiedEquityFinancingEvent" xlink:to="lxeo_FairValueTimeUntilQualifiedEquityFinancingEvent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonMember" xlink:to="us-gaap_TreasuryStockCommonMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_FairValueTimeUntilPublicOfferingEvent" xlink:to="lxeo_FairValueTimeUntilPublicOfferingEvent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_FairValueTimeUntilChangeInControlEvent" xlink:to="lxeo_FairValueTimeUntilChangeInControlEvent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesOther" xlink:to="us-gaap_DeferredTaxLiabilitiesOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_TwoThousandTwentyThreeEquityIncentivePlanMember" xlink:to="lxeo_TwoThousandTwentyThreeEquityIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_TwoThousandAndTwentyThreeEquityIncentivePlanMember" xlink:to="lxeo_TwoThousandAndTwentyThreeEquityIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputSharePriceMember" xlink:to="us-gaap_MeasurementInputSharePriceMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireInvestments" xlink:to="us-gaap_PaymentsToAcquireInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualTermGrantDate" xlink:to="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualTermGrantDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InternalUseSoftwarePolicy" xlink:to="us-gaap_InternalUseSoftwarePolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_PaymentOfRegulatoryMilestones" xlink:to="lxeo_PaymentOfRegulatoryMilestones_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_TemporaryEquityConversionOfStockInInitialPublicOfferingShares" xlink:to="lxeo_TemporaryEquityConversionOfStockInInitialPublicOfferingShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_ReclassificationOfInternalUseSoftwareIntoPrepaidExpenses" xlink:to="lxeo_ReclassificationOfInternalUseSoftwareIntoPrepaidExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeMember" xlink:to="us-gaap_OtherComprehensiveIncomeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_FinanceLeaseMonthlyInstallmentPaymentAmounts" xlink:to="lxeo_FinanceLeaseMonthlyInstallmentPaymentAmounts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_LossRecognizedFromUninsuredBalances" xlink:to="lxeo_LossRecognizedFromUninsuredBalances_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_PaymentOfAnnualLicenseMaintenanceFees" xlink:to="lxeo_PaymentOfAnnualLicenseMaintenanceFees_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_NumberOfSharesAutomaticallyIncreaseInAvailableSharesOfCommonStockUnderPlan" xlink:to="lxeo_NumberOfSharesAutomaticallyIncreaseInAvailableSharesOfCommonStockUnderPlan_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_TwoThousandTwentyOneEquityIncentivePlanMember" xlink:to="lxeo_TwoThousandTwentyOneEquityIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_IncreaseDecreaseInFinanceLeaseLiability" xlink:to="lxeo_IncreaseDecreaseInFinanceLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_TemporaryEquityConversionOfStockInInitialPublicOfferingValue" xlink:to="lxeo_TemporaryEquityConversionOfStockInInitialPublicOfferingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_SteliosTherapeuticsIncMember" xlink:to="lxeo_SteliosTherapeuticsIncMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLossAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredChargesPolicyTextBlock" xlink:to="us-gaap_DeferredChargesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:to="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember" xlink:to="lxeo_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_WeillCornellMedicalCollegeMember" xlink:to="lxeo_WeillCornellMedicalCollegeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_ResearchAgreementsTerm" xlink:to="lxeo_ResearchAgreementsTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_PaymentOfClinicalAndRegulatoryMilestone" xlink:to="lxeo_PaymentOfClinicalAndRegulatoryMilestone_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_FairValueProbabilityOfMeetingPublicOfferingEvent" xlink:to="lxeo_FairValueProbabilityOfMeetingPublicOfferingEvent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_OperatingLeaseWeightedAverageRemainingPaymentTerm" xlink:to="lxeo_OperatingLeaseWeightedAverageRemainingPaymentTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsForeign" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsForeign_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1" xlink:to="us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversionOfNotesIntoCommonStock" xlink:to="lxeo_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversionOfNotesIntoCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendRatePercentage" xlink:to="us-gaap_PreferredStockDividendRatePercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_AccruedResearchAndDevelopmentExpenseCurrent" xlink:to="lxeo_AccruedResearchAndDevelopmentExpenseCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCurrentAndNoncurrent" xlink:to="us-gaap_DeferredCostsCurrentAndNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_UcsdSponsoredResearchAgreementsMember" xlink:to="lxeo_UcsdSponsoredResearchAgreementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingSegmentsMember" xlink:to="us-gaap_OperatingSegmentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_AccruedGeneralAndAdministrativeExpensesAndOtherProfessionalFeesCurrent" xlink:to="lxeo_AccruedGeneralAndAdministrativeExpensesAndOtherProfessionalFeesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsUnvestedStockOptionsSubjectToRepurchaseValue" xlink:to="lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsUnvestedStockOptionsSubjectToRepurchaseValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountIssued1" xlink:to="us-gaap_ConversionOfStockAmountIssued1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageExercisePrice" xlink:to="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOptionsExercisableWeightedAverageGrantDateFairValue" xlink:to="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOptionsExercisableWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_FinanceLeaseExpense" xlink:to="lxeo_FinanceLeaseExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:to="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_CornellFirstLicenseAgreementsMember" xlink:to="lxeo_CornellFirstLicenseAgreementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsUnvestedStockOptionsSubjectToRepurchaseShare" xlink:to="lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsUnvestedStockOptionsSubjectToRepurchaseShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_CreditFacilityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsShare" xlink:to="lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLiquidationPreferencePerShare" xlink:to="us-gaap_TemporaryEquityLiquidationPreferencePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_DeferredTaxAssetsIntangibleAssets" xlink:to="lxeo_DeferredTaxAssetsIntangibleAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AlternativeInvestmentMeasurementInput" xlink:to="us-gaap_AlternativeInvestmentMeasurementInput_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_NumberOfLicenseAgreements" xlink:to="lxeo_NumberOfLicenseAgreements_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lxeo_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_ResearchAndDevelopmentExpenseEmployeeCompensationExpenses" xlink:to="lxeo_ResearchAndDevelopmentExpenseEmployeeCompensationExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:to="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_SummaryOfSignificantAccountingPoliciesTable" xlink:to="lxeo_SummaryOfSignificantAccountingPoliciesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsCommonStockCash" xlink:to="us-gaap_DividendsCommonStockCash_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionOriginalDebtAmount1" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesAuthorized" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_FinanceLeaseRightOfUseAssetsAndFinanceLeaseLiabilitiesRecognized" xlink:to="lxeo_FinanceLeaseRightOfUseAssetsAndFinanceLeaseLiabilitiesRecognized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_ResearchAndDevelopmentExpenseLX1001" xlink:to="lxeo_ResearchAndDevelopmentExpenseLX1001_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalUnitsAuthorized" xlink:to="us-gaap_CapitalUnitsAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_ThirdCornellLicenseAgreementsMember" xlink:to="lxeo_ThirdCornellLicenseAgreementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_ResearchAgreementTerminationNoticePeriod" xlink:to="lxeo_ResearchAgreementTerminationNoticePeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_SpecificClinicalAndRegulatoryMilestonesDue" xlink:to="lxeo_SpecificClinicalAndRegulatoryMilestonesDue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLocationDomain" xlink:to="us-gaap_OtherComprehensiveIncomeLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresTable" xlink:to="us-gaap_FairValueOptionQuantitativeDisclosuresTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_UpfrontCashPayment" xlink:to="lxeo_UpfrontCashPayment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsExercisableWeightedAverageGrantDateFairValue" xlink:to="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsExercisableWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_AggregateDevelopmentAndCommercializationMilestonesDescription" xlink:to="lxeo_AggregateDevelopmentAndCommercializationMilestonesDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_SareptaTherapeuticsIncMember" xlink:to="lxeo_SareptaTherapeuticsIncMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_PaymentStartingAfterPeriodOfExecutionOfAgreement" xlink:to="lxeo_PaymentStartingAfterPeriodOfExecutionOfAgreement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings" xlink:to="us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriod" xlink:to="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_PercentageOfAutomaticallyIncreaseInAvailableSharesOfCommonStockOnBeginningOfCachCalendarYear" xlink:to="lxeo_PercentageOfAutomaticallyIncreaseInAvailableSharesOfCommonStockOnBeginningOfCachCalendarYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_PaymentOfOneTimeUpFrontNonRefundableFee" xlink:to="lxeo_PaymentOfOneTimeUpFrontNonRefundableFee_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDerivativeAssetsAndLiabilities" xlink:to="us-gaap_IncreaseDecreaseInDerivativeAssetsAndLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_PercentageOfCumulativeOwnershipChange" xlink:to="lxeo_PercentageOfCumulativeOwnershipChange_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_AmountsReclassifiedFromDepositLiabilitiesUponTheVestingOfEarlyExercisedStockOptionsPreviouslySubjectToRepurchaseNetOfProceedsReceivedFromEarlyExerciseOfUnvestedStockOptionsSubjectToRepurchaseAndRecord" xlink:to="lxeo_AmountsReclassifiedFromDepositLiabilitiesUponTheVestingOfEarlyExercisedStockOptionsPreviouslySubjectToRepurchaseNetOfProceedsReceivedFromEarlyExerciseOfUnvestedStockOptionsSubjectToRepurchaseAndRecord_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_GranteeStatusDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_SeriesAAndBConvertiblePreferredStockMember" xlink:to="lxeo_SeriesAAndBConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_AdverumLicenseAgreementMember" xlink:to="lxeo_AdverumLicenseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_CornellUniversityMember" xlink:to="lxeo_CornellUniversityMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:to="lxeo_AccruedLiabilitiesAndOtherLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_OperatingLossCarryForwardsExpirationYear" xlink:to="lxeo_OperatingLossCarryForwardsExpirationYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_PercentageOfOutstandingSharesForDeemedLiquidation" xlink:to="lxeo_PercentageOfOutstandingSharesForDeemedLiquidation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesIssued1" xlink:to="us-gaap_NotesIssued1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_StockOfferingValueSharesAuthorizedToBeSold" xlink:to="lxeo_StockOfferingValueSharesAuthorizedToBeSold_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestExpense" xlink:to="us-gaap_FinanceLeaseInterestExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_AntidilutiveSecuritiesMember" xlink:to="lxeo_AntidilutiveSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_DeferredTaxAssetsLeaseLiabilities" xlink:to="lxeo_DeferredTaxAssetsLeaseLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" xlink:to="lxeo_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:to="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_PaymentOfDevelopmentMilestone" xlink:to="lxeo_PaymentOfDevelopmentMilestone_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConvertibleNoteIssuance" xlink:to="lxeo_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConvertibleNoteIssuance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonValue" xlink:to="us-gaap_TreasuryStockCommonValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_AmountDueUnderAgreement" xlink:to="lxeo_AmountDueUnderAgreement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalCostsIncurred" xlink:to="lxeo_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalCostsIncurred_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_PaymentTerm" xlink:to="lxeo_PaymentTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExercisePriceMember" xlink:to="us-gaap_MeasurementInputExercisePriceMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_SecondUcsdLicenseAgreementMember" xlink:to="lxeo_SecondUcsdLicenseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_CommissionsAndOfferingCostsMember" xlink:to="lxeo_CommissionsAndOfferingCostsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedBonusesCurrent" xlink:to="us-gaap_AccruedBonusesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LetterOfCreditMember" xlink:to="us-gaap_LetterOfCreditMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_FairValueProbabilityOfMeetingChangeInControlEvent" xlink:to="lxeo_FairValueProbabilityOfMeetingChangeInControlEvent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_AmountDueForEachQuarterUnderAgreement" xlink:to="lxeo_AmountDueForEachQuarterUnderAgreement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SoftwareDevelopmentMember" xlink:to="us-gaap_SoftwareDevelopmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_AmendedFirstUcsdAgreementMember" xlink:to="lxeo_AmendedFirstUcsdAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_NumberOfResearchAgreements" xlink:to="lxeo_NumberOfResearchAgreements_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_PaymentOfAnnualDataTransferFee" xlink:to="lxeo_PaymentOfAnnualDataTransferFee_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermInvestments" xlink:to="us-gaap_LongTermInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_LesseeFinanceLeaseCommencementDateRangeStart" xlink:to="lxeo_LesseeFinanceLeaseCommencementDateRangeStart_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_AdverumBiotechnologiesIncMember" xlink:to="lxeo_AdverumBiotechnologiesIncMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireSoftware" xlink:to="us-gaap_PaymentsToAcquireSoftware_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_RNolanTownsendMember" xlink:to="lxeo_RNolanTownsendMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_MilestoneReceived" xlink:to="lxeo_MilestoneReceived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:to="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsNet" xlink:to="us-gaap_DeferredFinanceCostsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_TemporaryEquityDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_ScheduleOfSignificantUnobservableInputsUsedInValuationModelToEstimateFairValueTableTextBlock" xlink:to="lxeo_ScheduleOfSignificantUnobservableInputsUsedInValuationModelToEstimateFairValueTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_NetProceedsReceivedFromPrivatePlacement" xlink:to="lxeo_NetProceedsReceivedFromPrivatePlacement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="us-gaap_ValuationTechniqueDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:to="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_CapitalExpendituresIncurredButNotYetPaidNetOfPaidAmount" xlink:to="lxeo_CapitalExpendituresIncurredButNotYetPaidNetOfPaidAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_ResearchAndDevelopmentExpenseLX2020" xlink:to="lxeo_ResearchAndDevelopmentExpenseLX2020_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_SeriesAAndSeriesBConvertiblePreferredStockMember" xlink:to="lxeo_SeriesAAndSeriesBConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnInvestments" xlink:to="us-gaap_UnrealizedGainLossOnInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermInvestmentsAndReceivablesNet" xlink:to="us-gaap_LongTermInvestmentsAndReceivablesNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_FinanceLeaseAggregateMonthlyInstallmentPaymentAmounts" xlink:to="lxeo_FinanceLeaseAggregateMonthlyInstallmentPaymentAmounts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_StockIssuedDuringPeriodValueNewIssuesAdditionalOfferingCostsIncurred" xlink:to="lxeo_StockIssuedDuringPeriodValueNewIssuesAdditionalOfferingCostsIncurred_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_StockOfferingGrossProceedsPercentage" xlink:to="lxeo_StockOfferingGrossProceedsPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_CommercializationMilestonesDue" xlink:to="lxeo_CommercializationMilestonesDue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_FinanceLeaseWeightedAverageRemainingAmortizationTerm" xlink:to="lxeo_FinanceLeaseWeightedAverageRemainingAmortizationTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_SeriesALiquidationPreferenceMember" xlink:to="lxeo_SeriesALiquidationPreferenceMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription" xlink:to="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredInPeriodWeightedAverageGrantDateFairValue" xlink:to="lxeo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptions" xlink:to="lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_ComponentsOfEquipmentFinanceLeaseTableTextBlock" xlink:to="lxeo_ComponentsOfEquipmentFinanceLeaseTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_ResearchCollaborationAgreementMember" xlink:to="lxeo_ResearchCollaborationAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetAssetLiability" xlink:to="us-gaap_FairValueNetAssetLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_ComponentsOfOperatingLeaseTableTextBlock" xlink:to="lxeo_ComponentsOfOperatingLeaseTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_LesseeFinanceLeaseCommencementDateRangeEnd" xlink:to="lxeo_LesseeFinanceLeaseCommencementDateRangeEnd_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedComputerSoftwareGross" xlink:to="us-gaap_CapitalizedComputerSoftwareGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_CornellLicenseAgreementsMember" xlink:to="lxeo_CornellLicenseAgreementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_OperatingLeaseAgreementEnteredDate" xlink:to="lxeo_OperatingLeaseAgreementEnteredDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingInformationLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsFairValueDisclosure" xlink:to="us-gaap_InvestmentsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_ResearchAndDevelopmentExpenseOtherPrograms" xlink:to="lxeo_ResearchAndDevelopmentExpenseOtherPrograms_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_SeriesBLiquidationPreferenceMember" xlink:to="lxeo_SeriesBLiquidationPreferenceMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_UnderwritingDiscountsCommissionsAndOfferingCostsMember" xlink:to="lxeo_UnderwritingDiscountsCommissionsAndOfferingCostsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_FirstUcsdLicenseAgreementMember" xlink:to="lxeo_FirstUcsdLicenseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:to="us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_EricAdlerMember" xlink:to="lxeo_EricAdlerMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:to="us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_OperatingLeaseCommencementDate" xlink:to="lxeo_OperatingLeaseCommencementDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromNotesPayable" xlink:to="us-gaap_ProceedsFromNotesPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lxeo_PaymentOfLicenseIssueFeeAndInitialDataTransferFee" xlink:to="lxeo_PaymentOfLicenseIssueFeeAndInitialDataTransferFee_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorOpinionTextBlock" xlink:label="dei_AuditorOpinionTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="73.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="74.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="75.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" order="76.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="77.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="78.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="79.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="80.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="81.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="82.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="83.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="84.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="85.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName" order="86.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation" order="87.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId" order="88.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorOpinionTextBlock" order="89.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/StatementBalanceSheets" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_SeriesAConvertiblePreferredStockMember" xlink:label="lxeo_SeriesAConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_SeriesBConvertiblePreferredStockMember" xlink:label="lxeo_SeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:label="lxeo_AccruedLiabilitiesAndOtherLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonValue" xlink:label="us-gaap_TreasuryStockCommonValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermInvestmentsAndReceivablesNet" xlink:label="us-gaap_LongTermInvestmentsAndReceivablesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lxeo_SeriesAConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ShortTermInvestments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lxeo_SeriesBConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="lxeo_AccruedLiabilitiesAndOtherLiabilitiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_TreasuryStockCommonValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_LongTermInvestmentsAndReceivablesNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_LongTermInvestments" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/StatementBalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_SeriesAConvertiblePreferredStockMember" xlink:label="lxeo_SeriesAConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_SeriesBConvertiblePreferredStockMember" xlink:label="lxeo_SeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="us-gaap_TemporaryEquityLiquidationPreference"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="us-gaap_TreasuryStockCommonShares"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lxeo_SeriesAConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lxeo_SeriesBConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityLiquidationPreference" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockCommonShares" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings" xlink:label="us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:label="us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeAmortizationOfDiscount" xlink:label="us-gaap_InvestmentIncomeAmortizationOfDiscount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="us-gaap_UnrealizedGainLossOnInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_RevenuesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpenseNonoperating" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeAmortizationOfDiscount" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_UnrealizedGainLossOnInvestments" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLocationAxis" xlink:label="us-gaap_OtherComprehensiveIncomeLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLocationDomain" xlink:label="us-gaap_OtherComprehensiveIncomeLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeMember" xlink:label="us-gaap_OtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonMember" xlink:label="us-gaap_TreasuryStockCommonMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsShare" xlink:label="lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsShare"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptions" xlink:label="lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsUnvestedStockOptionsSubjectToRepurchaseShare" xlink:label="lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsUnvestedStockOptionsSubjectToRepurchaseShare"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsUnvestedStockOptionsSubjectToRepurchaseValue" xlink:label="lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsUnvestedStockOptionsSubjectToRepurchaseValue"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtShare" xlink:label="lxeo_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_TemporaryEquityConversionOfStockInInitialPublicOfferingShares" xlink:label="lxeo_TemporaryEquityConversionOfStockInInitialPublicOfferingShares"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_TemporaryEquityConversionOfStockInInitialPublicOfferingValue" xlink:label="lxeo_TemporaryEquityConversionOfStockInInitialPublicOfferingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_StockIssuedDuringPeriodValueNewIssuesAdditionalOfferingCostsIncurred" xlink:label="lxeo_StockIssuedDuringPeriodValueNewIssuesAdditionalOfferingCostsIncurred"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="us-gaap_UnrealizedGainLossOnInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_23"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_24"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_27"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_28"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLocationAxis" xlink:to="us-gaap_OtherComprehensiveIncomeLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLocationDomain" xlink:to="us-gaap_OtherComprehensiveIncomeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_TreasuryStockCommonMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_OtherComprehensiveIncomeLocationAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsShare" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptions" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsUnvestedStockOptionsSubjectToRepurchaseShare" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsUnvestedStockOptionsSubjectToRepurchaseValue" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="lxeo_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtShare" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="lxeo_TemporaryEquityConversionOfStockInInitialPublicOfferingShares" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="lxeo_TemporaryEquityConversionOfStockInInitialPublicOfferingValue" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="lxeo_StockIssuedDuringPeriodValueNewIssuesAdditionalOfferingCostsIncurred" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrealizedGainLossOnInvestments" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_23" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_24" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_27" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_28" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_SimpleAgreementForFutureEquityMember" xlink:label="lxeo_SimpleAgreementForFutureEquityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_UnderwritingDiscountsCommissionsAndOfferingCostsMember" xlink:label="lxeo_UnderwritingDiscountsCommissionsAndOfferingCostsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_CommissionsAndOfferingCostsMember" xlink:label="lxeo_CommissionsAndOfferingCostsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="lxeo_SimpleAgreementForFutureEquityMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="lxeo_UnderwritingDiscountsCommissionsAndOfferingCostsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="lxeo_CommissionsAndOfferingCostsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfCashFlows" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireSoftware" xlink:label="us-gaap_PaymentsToAcquireSoftware"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" xlink:label="lxeo_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="us-gaap_UnrealizedGainLossOnInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="us-gaap_PaymentsToAcquireInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_ReclassificationOfInternalUseSoftwareIntoPrepaidExpenses" xlink:label="lxeo_ReclassificationOfInternalUseSoftwareIntoPrepaidExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_TreasuryStockRepurchase" xlink:label="lxeo_TreasuryStockRepurchase"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_IncreaseDecreaseInFinanceLeaseLiability" xlink:label="lxeo_IncreaseDecreaseInFinanceLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDerivativeAssetsAndLiabilities" xlink:label="us-gaap_IncreaseDecreaseInDerivativeAssetsAndLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_CapitalExpendituresIncurredButNotYetPaidNetOfPaidAmount" xlink:label="lxeo_CapitalExpendituresIncurredButNotYetPaidNetOfPaidAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_FinanceLeaseRightOfUseAssetsAndFinanceLeaseLiabilitiesRecognized" xlink:label="lxeo_FinanceLeaseRightOfUseAssetsAndFinanceLeaseLiabilitiesRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockAmountIssued1" xlink:label="us-gaap_ConversionOfStockAmountIssued1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_AmountsReclassifiedFromDepositLiabilitiesUponTheVestingOfEarlyExercisedStockOptionsPreviouslySubjectToRepurchaseNetOfProceedsReceivedFromEarlyExerciseOfUnvestedStockOptionsSubjectToRepurchaseAndRecord" xlink:label="lxeo_AmountsReclassifiedFromDepositLiabilitiesUponTheVestingOfEarlyExercisedStockOptionsPreviouslySubjectToRepurchaseNetOfProceedsReceivedFromEarlyExerciseOfUnvestedStockOptionsSubjectToRepurchaseAndRecord"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireSoftware" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lxeo_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaid" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_UnrealizedGainLossOnInvestments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireInvestments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lxeo_ReclassificationOfInternalUseSoftwareIntoPrepaidExpenses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lxeo_TreasuryStockRepurchase" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:to="lxeo_IncreaseDecreaseInFinanceLeaseLiability" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInDerivativeAssetsAndLiabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lxeo_CapitalExpendituresIncurredButNotYetPaidNetOfPaidAmount" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lxeo_FinanceLeaseRightOfUseAssetsAndFinanceLeaseLiabilitiesRecognized" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_ConversionOfStockAmountIssued1" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lxeo_AmountsReclassifiedFromDepositLiabilitiesUponTheVestingOfEarlyExercisedStockOptionsPreviouslySubjectToRepurchaseNetOfProceedsReceivedFromEarlyExerciseOfUnvestedStockOptionsSubjectToRepurchaseAndRecord" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="ecd_AllIndividualsMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_RNolanTownsendMember" xlink:label="lxeo_RNolanTownsendMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_EricAdlerMember" xlink:label="lxeo_EricAdlerMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllIndividualsMember" xlink:to="lxeo_RNolanTownsendMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllIndividualsMember" xlink:to="lxeo_EricAdlerMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCybersecurity" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeases3" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_LesseeOperatingAndFinancingLeasesDisclosureTextBlock" xlink:label="lxeo_LesseeOperatingAndFinancingLeasesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="lxeo_LesseeOperatingAndFinancingLeasesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertibleSafeNote" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStock" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockTextBlock" xlink:label="us-gaap_PreferredStockTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_PreferredStockTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCapitalStock1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensation1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureNetLossPerShare" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureIncomeTaxes" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingencies1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_LicenseAndAcquisitionAndResearchCollaborationAndSponsoredResearchAgreementsDisclosureTextBlock" xlink:label="lxeo_LicenseAndAcquisitionAndResearchCollaborationAndSponsoredResearchAgreementsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="lxeo_LicenseAndAcquisitionAndResearchCollaborationAndSponsoredResearchAgreementsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSegmentInformation1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSubsequentEvents" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InternalUseSoftwarePolicy" xlink:label="us-gaap_InternalUseSoftwarePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="us-gaap_DeferredChargesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:label="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_GeneralAndAdministrativeExpensesPolicyPolicyTextBlock" xlink:label="lxeo_GeneralAndAdministrativeExpensesPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentPolicyTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InternalUseSoftwarePolicy" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DeferredChargesPolicyTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="lxeo_GeneralAndAdministrativeExpensesPolicyPolicyTextBlock" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:label="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOptionQuantitativeDisclosuresTable" xlink:label="us-gaap_FairValueOptionQuantitativeDisclosuresTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_ScheduleOfSignificantUnobservableInputsUsedInValuationModelToEstimateFairValueTableTextBlock" xlink:label="lxeo_ScheduleOfSignificantUnobservableInputsUsedInValuationModelToEstimateFairValueTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueOptionQuantitativeDisclosuresTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresTable" xlink:to="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:to="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:to="lxeo_ScheduleOfSignificantUnobservableInputsUsedInValuationModelToEstimateFairValueTableTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_ComponentsOfOperatingLeaseTableTextBlock" xlink:label="lxeo_ComponentsOfOperatingLeaseTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_ComponentsOfEquipmentFinanceLeaseTableTextBlock" xlink:label="lxeo_ComponentsOfEquipmentFinanceLeaseTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="lxeo_ComponentsOfOperatingLeaseTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="lxeo_ComponentsOfEquipmentFinanceLeaseTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityTableTextBlock" xlink:label="us-gaap_TemporaryEquityTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_TemporaryEquityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCapitalStockTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureNetLossPerShareTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureIncomeTaxesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSegmentInformationTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_SimpleAgreementForFutureEquityMember" xlink:label="lxeo_SimpleAgreementForFutureEquityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_SeriesAAndSeriesBConvertiblePreferredStockMember" xlink:label="lxeo_SeriesAAndSeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="lxeo_SimpleAgreementForFutureEquityMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lxeo_SeriesAAndSeriesBConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_NetIncomeLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromNotesPayable" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="lxeo_SummaryOfSignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_SimpleAgreementForFutureEquityMember" xlink:label="lxeo_SimpleAgreementForFutureEquityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_SeriesAConvertiblePreferredStockMember" xlink:label="lxeo_SeriesAConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_SummaryOfSignificantAccountingPoliciesTable" xlink:label="lxeo_SummaryOfSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_SeriesBConvertiblePreferredStockMember" xlink:label="lxeo_SeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_LossRecognizedFromUninsuredBalances" xlink:label="lxeo_LossRecognizedFromUninsuredBalances"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCurrentAndNoncurrent" xlink:label="us-gaap_DeferredCostsCurrentAndNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdateExtensibleList" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_InvestmentCurrent" xlink:label="lxeo_InvestmentCurrent"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_InvestmentNonCurrent" xlink:label="lxeo_InvestmentNonCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalizedComputerSoftwareGross" xlink:label="us-gaap_CapitalizedComputerSoftwareGross"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lxeo_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="lxeo_SimpleAgreementForFutureEquityMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lxeo_SeriesAConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lxeo_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="lxeo_SummaryOfSignificantAccountingPoliciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lxeo_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lxeo_SeriesBConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lxeo_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lxeo_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lxeo_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_DebtInstrumentAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lxeo_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lxeo_LossRecognizedFromUninsuredBalances" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lxeo_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lxeo_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lxeo_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lxeo_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DeferredCostsCurrentAndNoncurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lxeo_SummaryOfSignificantAccountingPoliciesTable" xlink:to="lxeo_SummaryOfSignificantAccountingPoliciesLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lxeo_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lxeo_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lxeo_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AccountingStandardsUpdateExtensibleList" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lxeo_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lxeo_InvestmentCurrent" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lxeo_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lxeo_InvestmentNonCurrent" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lxeo_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CapitalizedComputerSoftwareGross" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentNetDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="us-gaap_SoftwareDevelopmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareDevelopmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_ConvertibleSimpleAgreementForFutureEquityNoteMember" xlink:label="lxeo_ConvertibleSimpleAgreementForFutureEquityNoteMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueNetAssetLiability" xlink:label="us-gaap_FairValueNetAssetLiability"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_USTreasurySecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_InvestmentsFairValueDisclosure" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lxeo_ConvertibleSimpleAgreementForFutureEquityNoteMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueNetAssetLiability" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfInvestmentsClassifiedAsAvailableforsaleSecuritiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAggregateFairValuesOfInvestmentsClassifiedAsAvailableforsaleSecuritiesWithUnrealizedLossesAndGains" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfRollforwardOfChangesInFairValueOfFinancialLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_ConvertibleSimpleAgreementForFutureEquityNoteMember" xlink:label="lxeo_ConvertibleSimpleAgreementForFutureEquityNoteMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConvertibleNoteIssuance" xlink:label="lxeo_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConvertibleNoteIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:label="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversionOfNotesIntoCommonStock" xlink:label="lxeo_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversionOfNotesIntoCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_5"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lxeo_ConvertibleSimpleAgreementForFutureEquityNoteMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lxeo_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConvertibleNoteIssuance" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lxeo_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversionOfNotesIntoCommonStock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfSignificantUnobservableInputsUsedInTheValuationModelToEstimateFairValueDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_ConvertibleSimpleAgreementForFutureEquityNoteMember" xlink:label="lxeo_ConvertibleSimpleAgreementForFutureEquityNoteMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_FairValueProbabilityOfMeetingQualifiedEquityFinancingEvent" xlink:label="lxeo_FairValueProbabilityOfMeetingQualifiedEquityFinancingEvent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_FairValueProbabilityOfMeetingPublicOfferingEvent" xlink:label="lxeo_FairValueProbabilityOfMeetingPublicOfferingEvent"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_FairValueProbabilityOfMeetingChangeInControlEvent" xlink:label="lxeo_FairValueProbabilityOfMeetingChangeInControlEvent"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_FairValueTimeUntilQualifiedEquityFinancingEvent" xlink:label="lxeo_FairValueTimeUntilQualifiedEquityFinancingEvent"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_FairValueTimeUntilPublicOfferingEvent" xlink:label="lxeo_FairValueTimeUntilPublicOfferingEvent"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_FairValueTimeUntilChangeInControlEvent" xlink:label="lxeo_FairValueTimeUntilChangeInControlEvent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lxeo_ConvertibleSimpleAgreementForFutureEquityNoteMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lxeo_FairValueProbabilityOfMeetingQualifiedEquityFinancingEvent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lxeo_FairValueProbabilityOfMeetingPublicOfferingEvent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lxeo_FairValueProbabilityOfMeetingChangeInControlEvent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lxeo_FairValueTimeUntilQualifiedEquityFinancingEvent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lxeo_FairValueTimeUntilPublicOfferingEvent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lxeo_FairValueTimeUntilChangeInControlEvent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:label="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOptionQuantitativeDisclosuresTable" xlink:label="us-gaap_FairValueOptionQuantitativeDisclosuresTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue" xlink:label="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueOptionQuantitativeDisclosuresTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:to="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresTable" xlink:to="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueAssumptionsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AlternativeInvestmentMeasurementInput" xlink:label="us-gaap_AlternativeInvestmentMeasurementInput"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="us-gaap_ValuationTechniqueAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOptionQuantitativeDisclosuresTable" xlink:label="us-gaap_FairValueOptionQuantitativeDisclosuresTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_BlackScholesModelMember" xlink:label="lxeo_BlackScholesModelMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="us-gaap_MeasurementInputExercisePriceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_AlternativeInvestmentMeasurementInput" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputSharePriceMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueOptionQuantitativeDisclosuresTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="lxeo_BlackScholesModelMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExercisePriceMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresTable" xlink:to="us-gaap_MeasurementInputTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_SharePrice" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresTable" xlink:to="us-gaap_ValuationTechniqueAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_AccruedResearchAndDevelopmentExpenseCurrent" xlink:label="lxeo_AccruedResearchAndDevelopmentExpenseCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_AccruedGeneralAndAdministrativeExpensesAndOtherProfessionalFeesCurrent" xlink:label="lxeo_AccruedGeneralAndAdministrativeExpensesAndOtherProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:label="lxeo_AccruedLiabilitiesAndOtherLiabilitiesCurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="lxeo_AccruedResearchAndDevelopmentExpenseCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccruedBonusesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="lxeo_AccruedGeneralAndAdministrativeExpensesAndOtherProfessionalFeesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="lxeo_AccruedLiabilitiesAndOtherLiabilitiesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_OperatingLeaseAgreementEnteredDate" xlink:label="lxeo_OperatingLeaseAgreementEnteredDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LetterOfCreditMember" xlink:label="us-gaap_LetterOfCreditMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_OfficeFacilityAndLaboratorySpaceMember" xlink:label="lxeo_OfficeFacilityAndLaboratorySpaceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_OperatingLeaseCommencementDate" xlink:label="lxeo_OperatingLeaseCommencementDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_OperatingLeaseEndDate" xlink:label="lxeo_OperatingLeaseEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_NumberOfMonthlyInstallmentsLease" xlink:label="lxeo_NumberOfMonthlyInstallmentsLease"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_LesseeFinanceLeaseCommencementDateRangeStart" xlink:label="lxeo_LesseeFinanceLeaseCommencementDateRangeStart"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_LesseeFinanceLeaseCommencementDateRangeEnd" xlink:label="lxeo_LesseeFinanceLeaseCommencementDateRangeEnd"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeFinanceLeaseDiscountRate" xlink:label="us-gaap_LesseeFinanceLeaseDiscountRate"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_FinanceLeaseMonthlyInstallmentPaymentAmounts" xlink:label="lxeo_FinanceLeaseMonthlyInstallmentPaymentAmounts"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_FinanceLeaseAggregateMonthlyInstallmentPaymentAmounts" xlink:label="lxeo_FinanceLeaseAggregateMonthlyInstallmentPaymentAmounts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_OperatingLeaseWeightedAverageRemainingPaymentTerm" xlink:label="lxeo_OperatingLeaseWeightedAverageRemainingPaymentTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_FinanceLeaseWeightedAverageRemainingAmortizationTerm" xlink:label="lxeo_FinanceLeaseWeightedAverageRemainingAmortizationTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lxeo_OperatingLeaseAgreementEnteredDate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_LetterOfCreditMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lxeo_OfficeFacilityAndLaboratorySpaceMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lxeo_OperatingLeaseCommencementDate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_CreditFacilityAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lxeo_OperatingLeaseEndDate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementScenarioAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_SecurityDeposit" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lxeo_NumberOfMonthlyInstallmentsLease" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lxeo_LesseeFinanceLeaseCommencementDateRangeStart" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lxeo_LesseeFinanceLeaseCommencementDateRangeEnd" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeFinanceLeaseDiscountRate" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lxeo_FinanceLeaseMonthlyInstallmentPaymentAmounts" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lxeo_FinanceLeaseAggregateMonthlyInstallmentPaymentAmounts" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lxeo_OperatingLeaseWeightedAverageRemainingPaymentTerm" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lxeo_FinanceLeaseWeightedAverageRemainingAmortizationTerm" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesComponentsOfOperatingLeaseDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_VariableLeaseCost" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingUndiscountedContractualRentObligationsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityAbstract" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityAbstract" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesComponentsOfEquipmentFinanceLeasesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="us-gaap_FinanceLeaseInterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_FinanceLeaseExpense" xlink:label="lxeo_FinanceLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseInterestExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="lxeo_FinanceLeaseExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingEquipmentFinanceLeaseObligationsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityAbstract" xlink:label="us-gaap_FinanceLeaseLiabilityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilityAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilityAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseLiability" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityAbstract" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertibleSafeNoteAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_SimpleAgreementForFutureEquityMember" xlink:label="lxeo_SimpleAgreementForFutureEquityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_SareptaTherapeuticsIncMember" xlink:label="lxeo_SareptaTherapeuticsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentDescription" xlink:label="us-gaap_DebtInstrumentDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_IncreaseDecreaseInFairValueOfSafeInstrument" xlink:label="lxeo_IncreaseDecreaseInFairValueOfSafeInstrument"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="us-gaap_ConvertibleNotesPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="lxeo_SimpleAgreementForFutureEquityMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lxeo_SareptaTherapeuticsIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_CounterpartyNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentDescription" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DeferredFinanceCostsNet" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="lxeo_IncreaseDecreaseInFairValueOfSafeInstrument" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ConvertibleNotesPayableCurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebt" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_AntidilutiveSecuritiesMember" xlink:label="lxeo_AntidilutiveSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_SeriesAAndBConvertiblePreferredStockMember" xlink:label="lxeo_SeriesAAndBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_SeriesAConvertiblePreferredStockMember" xlink:label="lxeo_SeriesAConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_SeriesBConvertiblePreferredStockMember" xlink:label="lxeo_SeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_SeriesALiquidationPreferenceMember" xlink:label="lxeo_SeriesALiquidationPreferenceMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_PercentageOfOutstandingSharesForDeemedLiquidation" xlink:label="lxeo_PercentageOfOutstandingSharesForDeemedLiquidation"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_SeriesBLiquidationPreferenceMember" xlink:label="lxeo_SeriesBLiquidationPreferenceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityLiquidationPreferencePerShare" xlink:label="us-gaap_TemporaryEquityLiquidationPreferencePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_QualifiedIpoMinimumNumberOfDirectorsApprovalRequired" xlink:label="lxeo_QualifiedIpoMinimumNumberOfDirectorsApprovalRequired"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleSharesIssuable" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lxeo_AntidilutiveSecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lxeo_SeriesAAndBConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lxeo_SeriesAConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lxeo_SeriesBConvertiblePreferredStockMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockDividendRatePercentage" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lxeo_SeriesALiquidationPreferenceMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="lxeo_PercentageOfOutstandingSharesForDeemedLiquidation" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lxeo_SeriesBLiquidationPreferenceMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquityLiquidationPreferencePerShare" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="lxeo_QualifiedIpoMinimumNumberOfDirectorsApprovalRequired" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockScheduleOfConvertiblePreferredStockDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_SeriesAConvertiblePreferredStockMember" xlink:label="lxeo_SeriesAConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_SeriesBConvertiblePreferredStockMember" xlink:label="lxeo_SeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="us-gaap_TemporaryEquityLiquidationPreference"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleSharesIssuable" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lxeo_SeriesAConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lxeo_SeriesBConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquityLiquidationPreference" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_AntidilutiveSecuritiesMember" xlink:label="lxeo_AntidilutiveSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_SimpleAgreementForFutureEquityMember" xlink:label="lxeo_SimpleAgreementForFutureEquityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_SeriesAConvertiblePreferredStockMember" xlink:label="lxeo_SeriesAConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalUnitsAuthorized" xlink:label="us-gaap_CapitalUnitsAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_SeriesBConvertiblePreferredStockMember" xlink:label="lxeo_SeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_CommonStockSharesIssuedOnEarlyExerciseOfUnvestedStockOptions" xlink:label="lxeo_CommonStockSharesIssuedOnEarlyExerciseOfUnvestedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DividendsCommonStockCash" xlink:label="us-gaap_DividendsCommonStockCash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_NetProceedsReceivedFromPrivatePlacement" xlink:label="lxeo_NetProceedsReceivedFromPrivatePlacement"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lxeo_AntidilutiveSecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="lxeo_SimpleAgreementForFutureEquityMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lxeo_SeriesAConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CapitalUnitsAuthorized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lxeo_SeriesBConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_DebtInstrumentAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="lxeo_CommonStockSharesIssuedOnEarlyExerciseOfUnvestedStockOptions" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DividendsCommonStockCash" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="lxeo_NetProceedsReceivedFromPrivatePlacement" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCapitalStockScheduleOfCommonStockReservedForFutureIssuancesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_TwoThousandTwentyOneAndTwoThousandTwentyThreeEquityIncentivePlanMember" xlink:label="lxeo_TwoThousandTwentyOneAndTwoThousandTwentyThreeEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_SeriesAConvertiblePreferredStockMember" xlink:label="lxeo_SeriesAConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember" xlink:label="lxeo_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_SeriesBConvertiblePreferredStockMember" xlink:label="lxeo_SeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_TwoThousandTwentyThreeEquityIncentivePlanMember" xlink:label="lxeo_TwoThousandTwentyThreeEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lxeo_TwoThousandTwentyOneAndTwoThousandTwentyThreeEquityIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lxeo_SeriesAConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lxeo_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lxeo_SeriesBConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lxeo_TwoThousandTwentyThreeEquityIncentivePlanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_TwoThousandTwentyOneEquityIncentivePlanMember" xlink:label="lxeo_TwoThousandTwentyOneEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:label="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_TwoThousandAndTwentyThreeEquityIncentivePlanMember" xlink:label="lxeo_TwoThousandAndTwentyThreeEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember" xlink:label="lxeo_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_ShareBasedCompensationPaymentDescription" xlink:label="lxeo_ShareBasedCompensationPaymentDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_NumberOfSharesAutomaticallyIncreaseInAvailableSharesOfCommonStockUnderPlan" xlink:label="lxeo_NumberOfSharesAutomaticallyIncreaseInAvailableSharesOfCommonStockUnderPlan"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance" xlink:label="lxeo_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_PercentageOfAutomaticallyIncreaseInAvailableSharesOfCommonStockOnBeginningOfCachCalendarYear" xlink:label="lxeo_PercentageOfAutomaticallyIncreaseInAvailableSharesOfCommonStockOnBeginningOfCachCalendarYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualTermGrantDate" xlink:label="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualTermGrantDate"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_PayrollDeductionsAtPrice" xlink:label="lxeo_PayrollDeductionsAtPrice"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_CommonStockDuringOfferingPeriod" xlink:label="lxeo_CommonStockDuringOfferingPeriod"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_FairValueOfUnearnedEmployeeStockOwnershipPlans" xlink:label="lxeo_FairValueOfUnearnedEmployeeStockOwnershipPlans"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="lxeo_TwoThousandTwentyOneEquityIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:to="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="lxeo_TwoThousandAndTwentyThreeEquityIncentivePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="lxeo_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_GranteeStatusAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lxeo_ShareBasedCompensationPaymentDescription" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lxeo_NumberOfSharesAutomaticallyIncreaseInAvailableSharesOfCommonStockUnderPlan" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lxeo_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lxeo_PercentageOfAutomaticallyIncreaseInAvailableSharesOfCommonStockOnBeginningOfCachCalendarYear" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualTermGrantDate" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lxeo_PayrollDeductionsAtPrice" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lxeo_CommonStockDuringOfferingPeriod" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lxeo_FairValueOfUnearnedEmployeeStockOwnershipPlans" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_TwoThousandTwentyOneAndTwoThousandTwentyThreeEquityIncentivePlanMember" xlink:label="lxeo_TwoThousandTwentyOneAndTwoThousandTwentyThreeEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:label="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriod" xlink:label="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_14"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice" xlink:label="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageExercisePrice" xlink:label="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" xlink:label="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredInPeriodWeightedAverageGrantDateFairValue" xlink:label="lxeo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_22"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOptionsExercisableWeightedAverageGrantDateFairValue" xlink:label="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOptionsExercisableWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsExercisableWeightedAverageGrantDateFairValue" xlink:label="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsExercisableWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="lxeo_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_31"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="lxeo_TwoThousandTwentyOneAndTwoThousandTwentyThreeEquityIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:to="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriod" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_14" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageExercisePrice" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lxeo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredInPeriodWeightedAverageGrantDateFairValue" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_22" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOptionsExercisableWeightedAverageGrantDateFairValue" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsExercisableWeightedAverageGrantDateFairValue" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lxeo_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_31" order="31" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="32" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" order="33" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" order="34" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfFollowingAssumptionsPresentedOnWeightedAverageBasisDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:label="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:to="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_TwoThousandAndTwentyThreeEquityIncentivePlanMember" xlink:label="lxeo_TwoThousandAndTwentyThreeEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="lxeo_TwoThousandAndTwentyThreeEquityIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpensesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:label="us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureNetLossPerShareScheduleOfNetLossPerShareAttributableToCommonStockholdersDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLossAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_DeferredTaxAssetsIntangibleAssets" xlink:label="lxeo_DeferredTaxAssetsIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_DeferredTaxAssetsLeaseLiabilities" xlink:label="lxeo_DeferredTaxAssetsLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesOther" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="lxeo_DeferredTaxAssetsIntangibleAssets" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="lxeo_DeferredTaxAssetsLeaseLiabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_OperatingLossCarryForwardsExpirationYear" xlink:label="lxeo_OperatingLossCarryForwardsExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_TaxCreditCarryForwardExpirationYear" xlink:label="lxeo_TaxCreditCarryForwardExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_PercentageOfCumulativeOwnershipChange" xlink:label="lxeo_PercentageOfCumulativeOwnershipChange"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_AnnualLimitationAbilityToUtilize" xlink:label="lxeo_AnnualLimitationAbilityToUtilize"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsForeign" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsForeign"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_OperatingLossCarryforwardsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lxeo_OperatingLossCarryForwardsExpirationYear" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lxeo_TaxCreditCarryForwardExpirationYear" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lxeo_PercentageOfCumulativeOwnershipChange" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lxeo_AnnualLimitationAbilityToUtilize" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsForeign" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_ThirdPartiesForPharmaceuticalManufacturingAndResearchActivitiesMember" xlink:label="lxeo_ThirdPartiesForPharmaceuticalManufacturingAndResearchActivitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_LicenseAgreementTerminationNoticePeriod" xlink:label="lxeo_LicenseAgreementTerminationNoticePeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_NumberOfFormerEmployees" xlink:label="lxeo_NumberOfFormerEmployees"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_CounterpartyNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lxeo_ThirdPartiesForPharmaceuticalManufacturingAndResearchActivitiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="lxeo_LicenseAgreementTerminationNoticePeriod" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LossContingenciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="lxeo_NumberOfFormerEmployees" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_AdverumLicenseAgreementMember" xlink:label="lxeo_AdverumLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_SeriesAConvertiblePreferredStockMember" xlink:label="lxeo_SeriesAConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_AdverumBiotechnologiesIncMember" xlink:label="lxeo_AdverumBiotechnologiesIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_SteliosTherapeuticsIncMember" xlink:label="lxeo_SteliosTherapeuticsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_TwoPortfoliosMember" xlink:label="lxeo_TwoPortfoliosMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_PaymentOfOneTimeUpFrontNonRefundableFee" xlink:label="lxeo_PaymentOfOneTimeUpFrontNonRefundableFee"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_CornellLicenseAgreementsMember" xlink:label="lxeo_CornellLicenseAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_CornellUniversityMember" xlink:label="lxeo_CornellUniversityMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_ThirdPortfolioMember" xlink:label="lxeo_ThirdPortfolioMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_DevelopmentAndRegulatoryMilestonesDue" xlink:label="lxeo_DevelopmentAndRegulatoryMilestonesDue"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_CornellFirstLicenseAgreementsMember" xlink:label="lxeo_CornellFirstLicenseAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_WeillCornellMedicalCollegeMember" xlink:label="lxeo_WeillCornellMedicalCollegeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_PaymentOfDevelopmentMilestone" xlink:label="lxeo_PaymentOfDevelopmentMilestone"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_CornellSecondLicenseAgreementsMember" xlink:label="lxeo_CornellSecondLicenseAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_CommercializationMilestonesDue" xlink:label="lxeo_CommercializationMilestonesDue"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_ThirdCornellLicenseAgreementsMember" xlink:label="lxeo_ThirdCornellLicenseAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_FirstUcsdLicenseAgreementMember" xlink:label="lxeo_FirstUcsdLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_SecondUcsdLicenseAgreementMember" xlink:label="lxeo_SecondUcsdLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_LicenseAgreementTerminationNoticePeriod" xlink:label="lxeo_LicenseAgreementTerminationNoticePeriod"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_ThirdUcsdLicenseAgreementMember" xlink:label="lxeo_ThirdUcsdLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_NumberOfLicenseAgreements" xlink:label="lxeo_NumberOfLicenseAgreements"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_UcsdSponsoredResearchAgreementsMember" xlink:label="lxeo_UcsdSponsoredResearchAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_UpfrontCashPayment" xlink:label="lxeo_UpfrontCashPayment"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_AmendedFirstUcsdAgreementMember" xlink:label="lxeo_AmendedFirstUcsdAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesIssued1" xlink:label="us-gaap_NotesIssued1"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_ResearchCollaborationAgreementMember" xlink:label="lxeo_ResearchCollaborationAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleSharesIssuable" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_SpecificClinicalAndRegulatoryMilestonesDue" xlink:label="lxeo_SpecificClinicalAndRegulatoryMilestonesDue"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_PaymentOfClinicalAndRegulatoryMilestone" xlink:label="lxeo_PaymentOfClinicalAndRegulatoryMilestone"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_PaymentOfLicenseIssueFeeAndInitialDataTransferFee" xlink:label="lxeo_PaymentOfLicenseIssueFeeAndInitialDataTransferFee"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_PaymentOfAnnualDataTransferFee" xlink:label="lxeo_PaymentOfAnnualDataTransferFee"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_PaymentOfAnnualLicenseMaintenanceFees" xlink:label="lxeo_PaymentOfAnnualLicenseMaintenanceFees"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_PaymentOfRegulatoryMilestones" xlink:label="lxeo_PaymentOfRegulatoryMilestones"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1" xlink:label="us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_MilestoneReceived" xlink:label="lxeo_MilestoneReceived"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_DevelopmentAndCommercializationMilestonesDue" xlink:label="lxeo_DevelopmentAndCommercializationMilestonesDue"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_AggregateDevelopmentAndCommercializationMilestonesDescription" xlink:label="lxeo_AggregateDevelopmentAndCommercializationMilestonesDescription"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_OneTimeUpFrontNonRefundableFees" xlink:label="lxeo_OneTimeUpFrontNonRefundableFees"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_NumberOfResearchAgreements" xlink:label="lxeo_NumberOfResearchAgreements"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_ResearchAgreementsTerm" xlink:label="lxeo_ResearchAgreementsTerm"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_ResearchAgreementTerminationNoticePeriod" xlink:label="lxeo_ResearchAgreementTerminationNoticePeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:label="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalCostsIncurred" xlink:label="lxeo_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalCostsIncurred"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_AmountDueUnderAgreement" xlink:label="lxeo_AmountDueUnderAgreement"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_PaymentTerm" xlink:label="lxeo_PaymentTerm"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_AmountDueForEachQuarterUnderAgreement" xlink:label="lxeo_AmountDueForEachQuarterUnderAgreement"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_PaymentStartingAfterPeriodOfExecutionOfAgreement" xlink:label="lxeo_PaymentStartingAfterPeriodOfExecutionOfAgreement"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_AgreementExpirationTerm" xlink:label="lxeo_AgreementExpirationTerm"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lxeo_AdverumLicenseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lxeo_SeriesAConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lxeo_AdverumBiotechnologiesIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lxeo_SteliosTherapeuticsIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lxeo_TwoPortfoliosMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_PaymentOfOneTimeUpFrontNonRefundableFee" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lxeo_CornellLicenseAgreementsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lxeo_CornellUniversityMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lxeo_ThirdPortfolioMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_DevelopmentAndRegulatoryMilestonesDue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lxeo_CornellFirstLicenseAgreementsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lxeo_WeillCornellMedicalCollegeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_PaymentOfDevelopmentMilestone" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lxeo_CornellSecondLicenseAgreementsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_CommercializationMilestonesDue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lxeo_ThirdCornellLicenseAgreementsMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lxeo_FirstUcsdLicenseAgreementMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lxeo_SecondUcsdLicenseAgreementMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_LicenseAgreementTerminationNoticePeriod" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lxeo_ThirdUcsdLicenseAgreementMember" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_StatementScenarioAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_NumberOfLicenseAgreements" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lxeo_UcsdSponsoredResearchAgreementsMember" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_UpfrontCashPayment" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lxeo_AmendedFirstUcsdAgreementMember" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_NotesIssued1" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lxeo_ResearchCollaborationAgreementMember" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_SpecificClinicalAndRegulatoryMilestonesDue" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_PaymentOfClinicalAndRegulatoryMilestone" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_PaymentOfLicenseIssueFeeAndInitialDataTransferFee" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_PaymentOfAnnualDataTransferFee" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_PaymentOfAnnualLicenseMaintenanceFees" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_PaymentOfRegulatoryMilestones" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_MilestoneReceived" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_DevelopmentAndCommercializationMilestonesDue" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_AggregateDevelopmentAndCommercializationMilestonesDescription" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_OneTimeUpFrontNonRefundableFees" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_NumberOfResearchAgreements" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_ResearchAgreementsTerm" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_ResearchAgreementTerminationNoticePeriod" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalCostsIncurred" order="31" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_AmountDueUnderAgreement" order="32" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_PaymentTerm" order="33" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_AmountDueForEachQuarterUnderAgreement" order="34" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_PaymentStartingAfterPeriodOfExecutionOfAgreement" order="35" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_AgreementExpirationTerm" order="36" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription" xlink:label="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_NumberOfReportableSegments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_NumberOfOperatingSegments" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingInformationLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalInformationOnCompanysNetLossIncludingSegmentExpensesDetails3" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="us-gaap_GeneralAndAdministrativeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_GeneralAndAdministrativeExpenseEmployeeCompensationExpenses" xlink:label="lxeo_GeneralAndAdministrativeExpenseEmployeeCompensationExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain" xlink:label="srt_ConsolidationItemsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember" xlink:label="us-gaap_OperatingSegmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:label="us-gaap_ResearchAndDevelopmentExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_ResearchAndDevelopmentExpenseLX2020" xlink:label="lxeo_ResearchAndDevelopmentExpenseLX2020"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis" xlink:label="srt_ConsolidationItemsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_ResearchAndDevelopmentExpenseLX2006" xlink:label="lxeo_ResearchAndDevelopmentExpenseLX2006"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_ResearchAndDevelopmentExpenseLX1001" xlink:label="lxeo_ResearchAndDevelopmentExpenseLX1001"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_ResearchAndDevelopmentExpenseOtherPrograms" xlink:label="lxeo_ResearchAndDevelopmentExpenseOtherPrograms"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_ResearchAndDevelopmentExpenseEmployeeCompensationExpenses" xlink:label="lxeo_ResearchAndDevelopmentExpenseEmployeeCompensationExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="us-gaap_LaborAndRelatedExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:to="lxeo_GeneralAndAdministrativeExpenseEmployeeCompensationExpenses" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidationItemsDomain" xlink:to="us-gaap_OperatingSegmentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="lxeo_ResearchAndDevelopmentExpenseLX2020" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="srt_ConsolidationItemsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpenseAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="lxeo_ResearchAndDevelopmentExpenseLX2006" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_SegmentReportingInformationLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpenseAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="lxeo_ResearchAndDevelopmentExpenseLX1001" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_NonoperatingIncomeExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="lxeo_ResearchAndDevelopmentExpenseOtherPrograms" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_NetIncomeLoss" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="lxeo_ResearchAndDevelopmentExpenseEmployeeCompensationExpenses" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_LaborAndRelatedExpense" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_StockOfferingValueSharesAuthorizedToBeSold" xlink:label="lxeo_StockOfferingValueSharesAuthorizedToBeSold"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_LeerinkAtTheMarketSalesAgreementMember" xlink:label="lxeo_LeerinkAtTheMarketSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_StockOfferingGrossProceedsPercentage" xlink:label="lxeo_StockOfferingGrossProceedsPercentage"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="lxeo_StockOfferingValueSharesAuthorizedToBeSold" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lxeo_LeerinkAtTheMarketSalesAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="lxeo_StockOfferingGrossProceedsPercentage" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/StatementBalanceSheets">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_SeriesAConvertiblePreferredStockMember" xlink:label="lxeo_SeriesAConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_SeriesBConvertiblePreferredStockMember" xlink:label="lxeo_SeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:label="lxeo_AccruedLiabilitiesAndOtherLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonValue" xlink:label="us-gaap_TreasuryStockCommonValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermInvestmentsAndReceivablesNet" xlink:label="us-gaap_LongTermInvestmentsAndReceivablesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lxeo_SeriesAConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ShortTermInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lxeo_SeriesBConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="lxeo_AccruedLiabilitiesAndOtherLiabilitiesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_TreasuryStockCommonValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_LongTermInvestmentsAndReceivablesNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_LongTermInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/StatementBalanceSheetsParenthetical">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_SeriesAConvertiblePreferredStockMember" xlink:label="lxeo_SeriesAConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_SeriesBConvertiblePreferredStockMember" xlink:label="lxeo_SeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="us-gaap_TemporaryEquityLiquidationPreference"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="us-gaap_TreasuryStockCommonShares"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lxeo_SeriesAConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lxeo_SeriesBConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityLiquidationPreference" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockCommonShares" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLocationAxis" xlink:label="us-gaap_OtherComprehensiveIncomeLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLocationDomain" xlink:label="us-gaap_OtherComprehensiveIncomeLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLocationDomain" xlink:label="us-gaap_OtherComprehensiveIncomeLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeMember" xlink:label="us-gaap_OtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonMember" xlink:label="us-gaap_TreasuryStockCommonMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsShare" xlink:label="lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsShare"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptions" xlink:label="lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsUnvestedStockOptionsSubjectToRepurchaseShare" xlink:label="lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsUnvestedStockOptionsSubjectToRepurchaseShare"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsUnvestedStockOptionsSubjectToRepurchaseValue" xlink:label="lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsUnvestedStockOptionsSubjectToRepurchaseValue"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtShare" xlink:label="lxeo_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_TemporaryEquityConversionOfStockInInitialPublicOfferingShares" xlink:label="lxeo_TemporaryEquityConversionOfStockInInitialPublicOfferingShares"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_TemporaryEquityConversionOfStockInInitialPublicOfferingValue" xlink:label="lxeo_TemporaryEquityConversionOfStockInInitialPublicOfferingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_StockIssuedDuringPeriodValueNewIssuesAdditionalOfferingCostsIncurred" xlink:label="lxeo_StockIssuedDuringPeriodValueNewIssuesAdditionalOfferingCostsIncurred"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="us-gaap_UnrealizedGainLossOnInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_OtherComprehensiveIncomeLocationAxis" xlink:to="us-gaap_OtherComprehensiveIncomeLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_OtherComprehensiveIncomeLocationAxis" xlink:to="us-gaap_OtherComprehensiveIncomeLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLocationDomain" xlink:to="us-gaap_OtherComprehensiveIncomeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_TreasuryStockCommonMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_OtherComprehensiveIncomeLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsUnvestedStockOptionsSubjectToRepurchaseShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsUnvestedStockOptionsSubjectToRepurchaseValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="lxeo_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="lxeo_TemporaryEquityConversionOfStockInInitialPublicOfferingShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="lxeo_TemporaryEquityConversionOfStockInInitialPublicOfferingValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="lxeo_StockIssuedDuringPeriodValueNewIssuesAdditionalOfferingCostsIncurred" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrealizedGainLossOnInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_SimpleAgreementForFutureEquityMember" xlink:label="lxeo_SimpleAgreementForFutureEquityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_UnderwritingDiscountsCommissionsAndOfferingCostsMember" xlink:label="lxeo_UnderwritingDiscountsCommissionsAndOfferingCostsMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_CommissionsAndOfferingCostsMember" xlink:label="lxeo_CommissionsAndOfferingCostsMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="lxeo_SimpleAgreementForFutureEquityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="lxeo_UnderwritingDiscountsCommissionsAndOfferingCostsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="lxeo_CommissionsAndOfferingCostsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="ecd_AllIndividualsMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_RNolanTownsendMember" xlink:label="lxeo_RNolanTownsendMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_EricAdlerMember" xlink:label="lxeo_EricAdlerMember"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllIndividualsMember" xlink:to="lxeo_RNolanTownsendMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllIndividualsMember" xlink:to="lxeo_EricAdlerMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCybersecurity">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsTables">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:label="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOptionQuantitativeDisclosuresTable" xlink:label="us-gaap_FairValueOptionQuantitativeDisclosuresTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_ScheduleOfSignificantUnobservableInputsUsedInValuationModelToEstimateFairValueTableTextBlock" xlink:label="lxeo_ScheduleOfSignificantUnobservableInputsUsedInValuationModelToEstimateFairValueTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:to="us-gaap_FairValueOptionQuantitativeDisclosuresTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:to="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:to="lxeo_ScheduleOfSignificantUnobservableInputsUsedInValuationModelToEstimateFairValueTableTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_SimpleAgreementForFutureEquityMember" xlink:label="lxeo_SimpleAgreementForFutureEquityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_SeriesAAndSeriesBConvertiblePreferredStockMember" xlink:label="lxeo_SeriesAAndSeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="lxeo_SimpleAgreementForFutureEquityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lxeo_SeriesAAndSeriesBConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromNotesPayable" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="lxeo_SummaryOfSignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_SummaryOfSignificantAccountingPoliciesTable" xlink:label="lxeo_SummaryOfSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_SimpleAgreementForFutureEquityMember" xlink:label="lxeo_SimpleAgreementForFutureEquityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_SeriesAConvertiblePreferredStockMember" xlink:label="lxeo_SeriesAConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_SeriesBConvertiblePreferredStockMember" xlink:label="lxeo_SeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_LossRecognizedFromUninsuredBalances" xlink:label="lxeo_LossRecognizedFromUninsuredBalances"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCurrentAndNoncurrent" xlink:label="us-gaap_DeferredCostsCurrentAndNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdateExtensibleList" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_InvestmentCurrent" xlink:label="lxeo_InvestmentCurrent"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_InvestmentNonCurrent" xlink:label="lxeo_InvestmentNonCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalizedComputerSoftwareGross" xlink:label="us-gaap_CapitalizedComputerSoftwareGross"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lxeo_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lxeo_SummaryOfSignificantAccountingPoliciesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lxeo_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="lxeo_SimpleAgreementForFutureEquityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lxeo_SeriesAConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lxeo_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lxeo_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lxeo_SeriesBConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lxeo_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lxeo_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lxeo_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lxeo_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lxeo_LossRecognizedFromUninsuredBalances" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lxeo_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lxeo_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lxeo_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lxeo_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DeferredCostsCurrentAndNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lxeo_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lxeo_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lxeo_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AccountingStandardsUpdateExtensibleList" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lxeo_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lxeo_InvestmentCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lxeo_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lxeo_InvestmentNonCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lxeo_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CapitalizedComputerSoftwareGross" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentNetDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="us-gaap_SoftwareDevelopmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareDevelopmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_ConvertibleSimpleAgreementForFutureEquityNoteMember" xlink:label="lxeo_ConvertibleSimpleAgreementForFutureEquityNoteMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueNetAssetLiability" xlink:label="us-gaap_FairValueNetAssetLiability"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_InvestmentsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lxeo_ConvertibleSimpleAgreementForFutureEquityNoteMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueNetAssetLiability" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfInvestmentsClassifiedAsAvailableforsaleSecuritiesDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfRollforwardOfChangesInFairValueOfFinancialLiabilitiesDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_ConvertibleSimpleAgreementForFutureEquityNoteMember" xlink:label="lxeo_ConvertibleSimpleAgreementForFutureEquityNoteMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConvertibleNoteIssuance" xlink:label="lxeo_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConvertibleNoteIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:label="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversionOfNotesIntoCommonStock" xlink:label="lxeo_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversionOfNotesIntoCommonStock"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lxeo_ConvertibleSimpleAgreementForFutureEquityNoteMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lxeo_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConvertibleNoteIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lxeo_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversionOfNotesIntoCommonStock" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfSignificantUnobservableInputsUsedInTheValuationModelToEstimateFairValueDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_ConvertibleSimpleAgreementForFutureEquityNoteMember" xlink:label="lxeo_ConvertibleSimpleAgreementForFutureEquityNoteMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_FairValueProbabilityOfMeetingQualifiedEquityFinancingEvent" xlink:label="lxeo_FairValueProbabilityOfMeetingQualifiedEquityFinancingEvent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_FairValueProbabilityOfMeetingPublicOfferingEvent" xlink:label="lxeo_FairValueProbabilityOfMeetingPublicOfferingEvent"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_FairValueProbabilityOfMeetingChangeInControlEvent" xlink:label="lxeo_FairValueProbabilityOfMeetingChangeInControlEvent"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_FairValueTimeUntilQualifiedEquityFinancingEvent" xlink:label="lxeo_FairValueTimeUntilQualifiedEquityFinancingEvent"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_FairValueTimeUntilPublicOfferingEvent" xlink:label="lxeo_FairValueTimeUntilPublicOfferingEvent"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_FairValueTimeUntilChangeInControlEvent" xlink:label="lxeo_FairValueTimeUntilChangeInControlEvent"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lxeo_ConvertibleSimpleAgreementForFutureEquityNoteMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lxeo_FairValueProbabilityOfMeetingQualifiedEquityFinancingEvent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lxeo_FairValueProbabilityOfMeetingPublicOfferingEvent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lxeo_FairValueProbabilityOfMeetingChangeInControlEvent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lxeo_FairValueTimeUntilQualifiedEquityFinancingEvent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lxeo_FairValueTimeUntilPublicOfferingEvent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lxeo_FairValueTimeUntilChangeInControlEvent" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:label="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOptionQuantitativeDisclosuresTable" xlink:label="us-gaap_FairValueOptionQuantitativeDisclosuresTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue" xlink:label="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:to="us-gaap_FairValueOptionQuantitativeDisclosuresTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:to="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueAssumptionsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOptionQuantitativeDisclosuresTable" xlink:label="us-gaap_FairValueOptionQuantitativeDisclosuresTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AlternativeInvestmentMeasurementInput" xlink:label="us-gaap_AlternativeInvestmentMeasurementInput"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="us-gaap_ValuationTechniqueAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_BlackScholesModelMember" xlink:label="lxeo_BlackScholesModelMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="us-gaap_MeasurementInputExercisePriceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueOptionQuantitativeDisclosuresTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_AlternativeInvestmentMeasurementInput" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputSharePriceMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="lxeo_BlackScholesModelMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExercisePriceMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresTable" xlink:to="us-gaap_MeasurementInputTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_SharePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresTable" xlink:to="us-gaap_ValuationTechniqueAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_OperatingLeaseAgreementEnteredDate" xlink:label="lxeo_OperatingLeaseAgreementEnteredDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LetterOfCreditMember" xlink:label="us-gaap_LetterOfCreditMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_OfficeFacilityAndLaboratorySpaceMember" xlink:label="lxeo_OfficeFacilityAndLaboratorySpaceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_OperatingLeaseCommencementDate" xlink:label="lxeo_OperatingLeaseCommencementDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_OperatingLeaseEndDate" xlink:label="lxeo_OperatingLeaseEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_NumberOfMonthlyInstallmentsLease" xlink:label="lxeo_NumberOfMonthlyInstallmentsLease"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_LesseeFinanceLeaseCommencementDateRangeStart" xlink:label="lxeo_LesseeFinanceLeaseCommencementDateRangeStart"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_LesseeFinanceLeaseCommencementDateRangeEnd" xlink:label="lxeo_LesseeFinanceLeaseCommencementDateRangeEnd"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeFinanceLeaseDiscountRate" xlink:label="us-gaap_LesseeFinanceLeaseDiscountRate"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_FinanceLeaseMonthlyInstallmentPaymentAmounts" xlink:label="lxeo_FinanceLeaseMonthlyInstallmentPaymentAmounts"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_FinanceLeaseAggregateMonthlyInstallmentPaymentAmounts" xlink:label="lxeo_FinanceLeaseAggregateMonthlyInstallmentPaymentAmounts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_OperatingLeaseWeightedAverageRemainingPaymentTerm" xlink:label="lxeo_OperatingLeaseWeightedAverageRemainingPaymentTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_FinanceLeaseWeightedAverageRemainingAmortizationTerm" xlink:label="lxeo_FinanceLeaseWeightedAverageRemainingAmortizationTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lxeo_OperatingLeaseAgreementEnteredDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_LetterOfCreditMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lxeo_OfficeFacilityAndLaboratorySpaceMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lxeo_OperatingLeaseCommencementDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_CreditFacilityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lxeo_OperatingLeaseEndDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementScenarioAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_SecurityDeposit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lxeo_NumberOfMonthlyInstallmentsLease" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lxeo_LesseeFinanceLeaseCommencementDateRangeStart" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lxeo_LesseeFinanceLeaseCommencementDateRangeEnd" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeFinanceLeaseDiscountRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lxeo_FinanceLeaseMonthlyInstallmentPaymentAmounts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lxeo_FinanceLeaseAggregateMonthlyInstallmentPaymentAmounts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lxeo_OperatingLeaseWeightedAverageRemainingPaymentTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lxeo_FinanceLeaseWeightedAverageRemainingAmortizationTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertibleSafeNoteAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_SimpleAgreementForFutureEquityMember" xlink:label="lxeo_SimpleAgreementForFutureEquityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_SareptaTherapeuticsIncMember" xlink:label="lxeo_SareptaTherapeuticsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentDescription" xlink:label="us-gaap_DebtInstrumentDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_IncreaseDecreaseInFairValueOfSafeInstrument" xlink:label="lxeo_IncreaseDecreaseInFairValueOfSafeInstrument"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="us-gaap_ConvertibleNotesPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="lxeo_SimpleAgreementForFutureEquityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lxeo_SareptaTherapeuticsIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DeferredFinanceCostsNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="lxeo_IncreaseDecreaseInFairValueOfSafeInstrument" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ConvertibleNotesPayableCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_AntidilutiveSecuritiesMember" xlink:label="lxeo_AntidilutiveSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_SeriesAAndBConvertiblePreferredStockMember" xlink:label="lxeo_SeriesAAndBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_SeriesAConvertiblePreferredStockMember" xlink:label="lxeo_SeriesAConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_SeriesBConvertiblePreferredStockMember" xlink:label="lxeo_SeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_SeriesALiquidationPreferenceMember" xlink:label="lxeo_SeriesALiquidationPreferenceMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_PercentageOfOutstandingSharesForDeemedLiquidation" xlink:label="lxeo_PercentageOfOutstandingSharesForDeemedLiquidation"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_SeriesBLiquidationPreferenceMember" xlink:label="lxeo_SeriesBLiquidationPreferenceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityLiquidationPreferencePerShare" xlink:label="us-gaap_TemporaryEquityLiquidationPreferencePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_QualifiedIpoMinimumNumberOfDirectorsApprovalRequired" xlink:label="lxeo_QualifiedIpoMinimumNumberOfDirectorsApprovalRequired"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleSharesIssuable" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lxeo_AntidilutiveSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lxeo_SeriesAAndBConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lxeo_SeriesAConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lxeo_SeriesBConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockDividendRatePercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lxeo_SeriesALiquidationPreferenceMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="lxeo_PercentageOfOutstandingSharesForDeemedLiquidation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lxeo_SeriesBLiquidationPreferenceMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquityLiquidationPreferencePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="lxeo_QualifiedIpoMinimumNumberOfDirectorsApprovalRequired" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockScheduleOfConvertiblePreferredStockDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_SeriesAConvertiblePreferredStockMember" xlink:label="lxeo_SeriesAConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_SeriesBConvertiblePreferredStockMember" xlink:label="lxeo_SeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="us-gaap_TemporaryEquityLiquidationPreference"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleSharesIssuable" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lxeo_SeriesAConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lxeo_SeriesBConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquityLiquidationPreference" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_AntidilutiveSecuritiesMember" xlink:label="lxeo_AntidilutiveSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_SimpleAgreementForFutureEquityMember" xlink:label="lxeo_SimpleAgreementForFutureEquityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_SeriesAConvertiblePreferredStockMember" xlink:label="lxeo_SeriesAConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalUnitsAuthorized" xlink:label="us-gaap_CapitalUnitsAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_SeriesBConvertiblePreferredStockMember" xlink:label="lxeo_SeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_CommonStockSharesIssuedOnEarlyExerciseOfUnvestedStockOptions" xlink:label="lxeo_CommonStockSharesIssuedOnEarlyExerciseOfUnvestedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DividendsCommonStockCash" xlink:label="us-gaap_DividendsCommonStockCash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_NetProceedsReceivedFromPrivatePlacement" xlink:label="lxeo_NetProceedsReceivedFromPrivatePlacement"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lxeo_AntidilutiveSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="lxeo_SimpleAgreementForFutureEquityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lxeo_SeriesAConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CapitalUnitsAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lxeo_SeriesBConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="lxeo_CommonStockSharesIssuedOnEarlyExerciseOfUnvestedStockOptions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DividendsCommonStockCash" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="lxeo_NetProceedsReceivedFromPrivatePlacement" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCapitalStockScheduleOfCommonStockReservedForFutureIssuancesDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_TwoThousandTwentyOneAndTwoThousandTwentyThreeEquityIncentivePlanMember" xlink:label="lxeo_TwoThousandTwentyOneAndTwoThousandTwentyThreeEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_SeriesAConvertiblePreferredStockMember" xlink:label="lxeo_SeriesAConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember" xlink:label="lxeo_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_SeriesBConvertiblePreferredStockMember" xlink:label="lxeo_SeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_TwoThousandTwentyThreeEquityIncentivePlanMember" xlink:label="lxeo_TwoThousandTwentyThreeEquityIncentivePlanMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lxeo_TwoThousandTwentyOneAndTwoThousandTwentyThreeEquityIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lxeo_SeriesAConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lxeo_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lxeo_SeriesBConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lxeo_TwoThousandTwentyThreeEquityIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_TwoThousandTwentyOneEquityIncentivePlanMember" xlink:label="lxeo_TwoThousandTwentyOneEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:label="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:label="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_TwoThousandAndTwentyThreeEquityIncentivePlanMember" xlink:label="lxeo_TwoThousandAndTwentyThreeEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember" xlink:label="lxeo_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_ShareBasedCompensationPaymentDescription" xlink:label="lxeo_ShareBasedCompensationPaymentDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_NumberOfSharesAutomaticallyIncreaseInAvailableSharesOfCommonStockUnderPlan" xlink:label="lxeo_NumberOfSharesAutomaticallyIncreaseInAvailableSharesOfCommonStockUnderPlan"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance" xlink:label="lxeo_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_PercentageOfAutomaticallyIncreaseInAvailableSharesOfCommonStockOnBeginningOfCachCalendarYear" xlink:label="lxeo_PercentageOfAutomaticallyIncreaseInAvailableSharesOfCommonStockOnBeginningOfCachCalendarYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualTermGrantDate" xlink:label="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualTermGrantDate"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_PayrollDeductionsAtPrice" xlink:label="lxeo_PayrollDeductionsAtPrice"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_CommonStockDuringOfferingPeriod" xlink:label="lxeo_CommonStockDuringOfferingPeriod"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_FairValueOfUnearnedEmployeeStockOwnershipPlans" xlink:label="lxeo_FairValueOfUnearnedEmployeeStockOwnershipPlans"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="lxeo_TwoThousandTwentyOneEquityIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:to="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:to="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="lxeo_TwoThousandAndTwentyThreeEquityIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="lxeo_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_GranteeStatusAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lxeo_ShareBasedCompensationPaymentDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lxeo_NumberOfSharesAutomaticallyIncreaseInAvailableSharesOfCommonStockUnderPlan" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lxeo_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lxeo_PercentageOfAutomaticallyIncreaseInAvailableSharesOfCommonStockOnBeginningOfCachCalendarYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualTermGrantDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lxeo_PayrollDeductionsAtPrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lxeo_CommonStockDuringOfferingPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lxeo_FairValueOfUnearnedEmployeeStockOwnershipPlans" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_TwoThousandTwentyOneAndTwoThousandTwentyThreeEquityIncentivePlanMember" xlink:label="lxeo_TwoThousandTwentyOneAndTwoThousandTwentyThreeEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:label="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriod" xlink:label="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice" xlink:label="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageExercisePrice" xlink:label="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" xlink:label="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredInPeriodWeightedAverageGrantDateFairValue" xlink:label="lxeo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOptionsExercisableWeightedAverageGrantDateFairValue" xlink:label="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOptionsExercisableWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsExercisableWeightedAverageGrantDateFairValue" xlink:label="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsExercisableWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="lxeo_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="lxeo_TwoThousandTwentyOneAndTwoThousandTwentyThreeEquityIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:to="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lxeo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOptionsExercisableWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsExercisableWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="28" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lxeo_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="29" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="30" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="32" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="33" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="34" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfFollowingAssumptionsPresentedOnWeightedAverageBasisDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:label="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:to="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_TwoThousandAndTwentyThreeEquityIncentivePlanMember" xlink:label="lxeo_TwoThousandAndTwentyThreeEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="lxeo_TwoThousandAndTwentyThreeEquityIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpensesDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_OperatingLossCarryForwardsExpirationYear" xlink:label="lxeo_OperatingLossCarryForwardsExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_TaxCreditCarryForwardExpirationYear" xlink:label="lxeo_TaxCreditCarryForwardExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_PercentageOfCumulativeOwnershipChange" xlink:label="lxeo_PercentageOfCumulativeOwnershipChange"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_AnnualLimitationAbilityToUtilize" xlink:label="lxeo_AnnualLimitationAbilityToUtilize"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsForeign" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsForeign"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lxeo_OperatingLossCarryForwardsExpirationYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lxeo_TaxCreditCarryForwardExpirationYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lxeo_PercentageOfCumulativeOwnershipChange" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lxeo_AnnualLimitationAbilityToUtilize" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsForeign" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_ThirdPartiesForPharmaceuticalManufacturingAndResearchActivitiesMember" xlink:label="lxeo_ThirdPartiesForPharmaceuticalManufacturingAndResearchActivitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_LicenseAgreementTerminationNoticePeriod" xlink:label="lxeo_LicenseAgreementTerminationNoticePeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_NumberOfFormerEmployees" xlink:label="lxeo_NumberOfFormerEmployees"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lxeo_ThirdPartiesForPharmaceuticalManufacturingAndResearchActivitiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="lxeo_LicenseAgreementTerminationNoticePeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="lxeo_NumberOfFormerEmployees" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_AdverumLicenseAgreementMember" xlink:label="lxeo_AdverumLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_SeriesAConvertiblePreferredStockMember" xlink:label="lxeo_SeriesAConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_AdverumBiotechnologiesIncMember" xlink:label="lxeo_AdverumBiotechnologiesIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_SteliosTherapeuticsIncMember" xlink:label="lxeo_SteliosTherapeuticsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_TwoPortfoliosMember" xlink:label="lxeo_TwoPortfoliosMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_PaymentOfOneTimeUpFrontNonRefundableFee" xlink:label="lxeo_PaymentOfOneTimeUpFrontNonRefundableFee"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_CornellLicenseAgreementsMember" xlink:label="lxeo_CornellLicenseAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_CornellUniversityMember" xlink:label="lxeo_CornellUniversityMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_ThirdPortfolioMember" xlink:label="lxeo_ThirdPortfolioMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_DevelopmentAndRegulatoryMilestonesDue" xlink:label="lxeo_DevelopmentAndRegulatoryMilestonesDue"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_CornellFirstLicenseAgreementsMember" xlink:label="lxeo_CornellFirstLicenseAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_WeillCornellMedicalCollegeMember" xlink:label="lxeo_WeillCornellMedicalCollegeMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_PaymentOfDevelopmentMilestone" xlink:label="lxeo_PaymentOfDevelopmentMilestone"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_CornellSecondLicenseAgreementsMember" xlink:label="lxeo_CornellSecondLicenseAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_CommercializationMilestonesDue" xlink:label="lxeo_CommercializationMilestonesDue"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_ThirdCornellLicenseAgreementsMember" xlink:label="lxeo_ThirdCornellLicenseAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_FirstUcsdLicenseAgreementMember" xlink:label="lxeo_FirstUcsdLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_SecondUcsdLicenseAgreementMember" xlink:label="lxeo_SecondUcsdLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_LicenseAgreementTerminationNoticePeriod" xlink:label="lxeo_LicenseAgreementTerminationNoticePeriod"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_ThirdUcsdLicenseAgreementMember" xlink:label="lxeo_ThirdUcsdLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_NumberOfLicenseAgreements" xlink:label="lxeo_NumberOfLicenseAgreements"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_UcsdSponsoredResearchAgreementsMember" xlink:label="lxeo_UcsdSponsoredResearchAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_UpfrontCashPayment" xlink:label="lxeo_UpfrontCashPayment"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_AmendedFirstUcsdAgreementMember" xlink:label="lxeo_AmendedFirstUcsdAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesIssued1" xlink:label="us-gaap_NotesIssued1"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_ResearchCollaborationAgreementMember" xlink:label="lxeo_ResearchCollaborationAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleSharesIssuable" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_SpecificClinicalAndRegulatoryMilestonesDue" xlink:label="lxeo_SpecificClinicalAndRegulatoryMilestonesDue"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_PaymentOfClinicalAndRegulatoryMilestone" xlink:label="lxeo_PaymentOfClinicalAndRegulatoryMilestone"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_PaymentOfLicenseIssueFeeAndInitialDataTransferFee" xlink:label="lxeo_PaymentOfLicenseIssueFeeAndInitialDataTransferFee"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_PaymentOfAnnualDataTransferFee" xlink:label="lxeo_PaymentOfAnnualDataTransferFee"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_PaymentOfAnnualLicenseMaintenanceFees" xlink:label="lxeo_PaymentOfAnnualLicenseMaintenanceFees"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_PaymentOfRegulatoryMilestones" xlink:label="lxeo_PaymentOfRegulatoryMilestones"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1" xlink:label="us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_MilestoneReceived" xlink:label="lxeo_MilestoneReceived"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_DevelopmentAndCommercializationMilestonesDue" xlink:label="lxeo_DevelopmentAndCommercializationMilestonesDue"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_AggregateDevelopmentAndCommercializationMilestonesDescription" xlink:label="lxeo_AggregateDevelopmentAndCommercializationMilestonesDescription"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_OneTimeUpFrontNonRefundableFees" xlink:label="lxeo_OneTimeUpFrontNonRefundableFees"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_NumberOfResearchAgreements" xlink:label="lxeo_NumberOfResearchAgreements"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_ResearchAgreementsTerm" xlink:label="lxeo_ResearchAgreementsTerm"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_ResearchAgreementTerminationNoticePeriod" xlink:label="lxeo_ResearchAgreementTerminationNoticePeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:label="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalCostsIncurred" xlink:label="lxeo_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalCostsIncurred"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_AmountDueUnderAgreement" xlink:label="lxeo_AmountDueUnderAgreement"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_PaymentTerm" xlink:label="lxeo_PaymentTerm"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_AmountDueForEachQuarterUnderAgreement" xlink:label="lxeo_AmountDueForEachQuarterUnderAgreement"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_PaymentStartingAfterPeriodOfExecutionOfAgreement" xlink:label="lxeo_PaymentStartingAfterPeriodOfExecutionOfAgreement"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_AgreementExpirationTerm" xlink:label="lxeo_AgreementExpirationTerm"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lxeo_AdverumLicenseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lxeo_SeriesAConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lxeo_AdverumBiotechnologiesIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lxeo_SteliosTherapeuticsIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lxeo_TwoPortfoliosMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_PaymentOfOneTimeUpFrontNonRefundableFee" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lxeo_CornellLicenseAgreementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lxeo_CornellUniversityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lxeo_ThirdPortfolioMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_DevelopmentAndRegulatoryMilestonesDue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lxeo_CornellFirstLicenseAgreementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lxeo_WeillCornellMedicalCollegeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_PaymentOfDevelopmentMilestone" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lxeo_CornellSecondLicenseAgreementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_CommercializationMilestonesDue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lxeo_ThirdCornellLicenseAgreementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lxeo_FirstUcsdLicenseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lxeo_SecondUcsdLicenseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_LicenseAgreementTerminationNoticePeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lxeo_ThirdUcsdLicenseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_StatementScenarioAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_NumberOfLicenseAgreements" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lxeo_UcsdSponsoredResearchAgreementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_UpfrontCashPayment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lxeo_AmendedFirstUcsdAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_NotesIssued1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lxeo_ResearchCollaborationAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_SpecificClinicalAndRegulatoryMilestonesDue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_PaymentOfClinicalAndRegulatoryMilestone" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_PaymentOfLicenseIssueFeeAndInitialDataTransferFee" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_PaymentOfAnnualDataTransferFee" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_PaymentOfAnnualLicenseMaintenanceFees" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_PaymentOfRegulatoryMilestones" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_MilestoneReceived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_DevelopmentAndCommercializationMilestonesDue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_AggregateDevelopmentAndCommercializationMilestonesDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_OneTimeUpFrontNonRefundableFees" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_NumberOfResearchAgreements" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_ResearchAgreementsTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="28" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_ResearchAgreementTerminationNoticePeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="29" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="30" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="31" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalCostsIncurred" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="32" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_AmountDueUnderAgreement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="33" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_PaymentTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="34" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_AmountDueForEachQuarterUnderAgreement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="35" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_PaymentStartingAfterPeriodOfExecutionOfAgreement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="36" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lxeo_AgreementExpirationTerm" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalInformationOnCompanysNetLossIncludingSegmentExpensesDetails3">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="us-gaap_GeneralAndAdministrativeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_GeneralAndAdministrativeExpenseEmployeeCompensationExpenses" xlink:label="lxeo_GeneralAndAdministrativeExpenseEmployeeCompensationExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain" xlink:label="srt_ConsolidationItemsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember" xlink:label="us-gaap_OperatingSegmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:label="us-gaap_ResearchAndDevelopmentExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_ResearchAndDevelopmentExpenseLX2020" xlink:label="lxeo_ResearchAndDevelopmentExpenseLX2020"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis" xlink:label="srt_ConsolidationItemsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain" xlink:label="srt_ConsolidationItemsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_ResearchAndDevelopmentExpenseLX2006" xlink:label="lxeo_ResearchAndDevelopmentExpenseLX2006"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_ResearchAndDevelopmentExpenseLX1001" xlink:label="lxeo_ResearchAndDevelopmentExpenseLX1001"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_ResearchAndDevelopmentExpenseOtherPrograms" xlink:label="lxeo_ResearchAndDevelopmentExpenseOtherPrograms"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_ResearchAndDevelopmentExpenseEmployeeCompensationExpenses" xlink:label="lxeo_ResearchAndDevelopmentExpenseEmployeeCompensationExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="us-gaap_LaborAndRelatedExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:to="lxeo_GeneralAndAdministrativeExpenseEmployeeCompensationExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidationItemsDomain" xlink:to="us-gaap_OperatingSegmentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="lxeo_ResearchAndDevelopmentExpenseLX2020" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="srt_ConsolidationItemsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpenseAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="lxeo_ResearchAndDevelopmentExpenseLX2006" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpenseAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="lxeo_ResearchAndDevelopmentExpenseLX1001" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_NonoperatingIncomeExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="lxeo_ResearchAndDevelopmentExpenseOtherPrograms" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="lxeo_ResearchAndDevelopmentExpenseEmployeeCompensationExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_LaborAndRelatedExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_StockOfferingValueSharesAuthorizedToBeSold" xlink:label="lxeo_StockOfferingValueSharesAuthorizedToBeSold"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_LeerinkAtTheMarketSalesAgreementMember" xlink:label="lxeo_LeerinkAtTheMarketSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_StockOfferingGrossProceedsPercentage" xlink:label="lxeo_StockOfferingGrossProceedsPercentage"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="lxeo_StockOfferingValueSharesAuthorizedToBeSold" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lxeo_LeerinkAtTheMarketSalesAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="lxeo_StockOfferingGrossProceedsPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings" xlink:label="us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdate202307Member" xlink:label="us-gaap_AccountingStandardsUpdate202307Member"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/srt/role/srt-eedm/ExtensibleEnumerationLists">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefExecutiveOfficerMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/StatementBalanceSheets">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCashNoncurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_LongTermInvestmentsAndReceivablesNet" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_TreasuryStockCommonValue" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_ShortTermInvestments" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_LongTermInvestments" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="lxeo_AccruedLiabilitiesAndOtherLiabilitiesCurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="7" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermInvestmentsAndReceivablesNet" xlink:label="us-gaap_LongTermInvestmentsAndReceivablesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonValue" xlink:label="us-gaap_TreasuryStockCommonValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:label="lxeo_AccruedLiabilitiesAndOtherLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingEquipmentFinanceLeaseObligationsDetails2">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiability" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingUndiscountedContractualRentObligationsDetails2">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_UnrealizedGainLossOnInvestments" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpenseNonoperating" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeInterest" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeAmortizationOfDiscount" order="5" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings" xlink:label="us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="us-gaap_UnrealizedGainLossOnInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeAmortizationOfDiscount" xlink:label="us-gaap_InvestmentIncomeAmortizationOfDiscount"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfCashFlows">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireSoftware" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireInvestments" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="3" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationAndAmortization" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lxeo_TreasuryStockRepurchase" order="4" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="6" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts" order="6" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="7" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDerivativeAssetsAndLiabilities" order="8" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="9" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="9" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="11" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="13" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="16" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lxeo_IncreaseDecreaseInFinanceLeaseLiability" order="17" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireSoftware" xlink:label="us-gaap_PaymentsToAcquireSoftware"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="us-gaap_PaymentsToAcquireInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_TreasuryStockRepurchase" xlink:label="lxeo_TreasuryStockRepurchase"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDerivativeAssetsAndLiabilities" xlink:label="us-gaap_IncreaseDecreaseInDerivativeAssetsAndLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_IncreaseDecreaseInFinanceLeaseLiability" xlink:label="lxeo_IncreaseDecreaseInFinanceLeaseLiability"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentNetDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfInvestmentsClassifiedAsAvailableforsaleSecuritiesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAggregateFairValuesOfInvestmentsClassifiedAsAvailableforsaleSecuritiesWithUnrealizedLossesAndGains">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="lxeo_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:to="lxeo_AccruedResearchAndDevelopmentExpenseCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="lxeo_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:to="us-gaap_AccruedBonusesCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="lxeo_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:to="lxeo_AccruedGeneralAndAdministrativeExpensesAndOtherProfessionalFeesCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="lxeo_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="6" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:label="lxeo_AccruedLiabilitiesAndOtherLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_AccruedResearchAndDevelopmentExpenseCurrent" xlink:label="lxeo_AccruedResearchAndDevelopmentExpenseCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_AccruedGeneralAndAdministrativeExpensesAndOtherProfessionalFeesCurrent" xlink:label="lxeo_AccruedGeneralAndAdministrativeExpensesAndOtherProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesComponentsOfOperatingLeaseDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseCost" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_VariableLeaseCost" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingUndiscountedContractualRentObligationsDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="6" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesComponentsOfEquipmentFinanceLeasesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="lxeo_FinanceLeaseExpense" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="lxeo_FinanceLeaseExpense" xlink:to="us-gaap_FinanceLeaseInterestExpense" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_FinanceLeaseExpense" xlink:label="lxeo_FinanceLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="us-gaap_FinanceLeaseInterestExpense"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingEquipmentFinanceLeaseObligationsDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" order="6" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="5" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesOther" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="lxeo_DeferredTaxAssetsIntangibleAssets" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="lxeo_DeferredTaxAssetsLeaseLiabilities" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" order="6" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_DeferredTaxAssetsIntangibleAssets" xlink:label="lxeo_DeferredTaxAssetsIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_DeferredTaxAssetsLeaseLiabilities" xlink:label="lxeo_DeferredTaxAssetsLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalInformationOnCompanysNetLossIncludingSegmentExpensesDetails3">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="lxeo_ResearchAndDevelopmentExpenseLX2020" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="lxeo_ResearchAndDevelopmentExpenseLX2006" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="lxeo_ResearchAndDevelopmentExpenseLX1001" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="lxeo_ResearchAndDevelopmentExpenseOtherPrograms" order="3" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="lxeo_ResearchAndDevelopmentExpenseEmployeeCompensationExpenses" order="4" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_LaborAndRelatedExpense" order="5" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" order="6" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="lxeo_GeneralAndAdministrativeExpenseEmployeeCompensationExpenses" order="7" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense" order="8" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense" order="9" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_ResearchAndDevelopmentExpenseLX2020" xlink:label="lxeo_ResearchAndDevelopmentExpenseLX2020"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_ResearchAndDevelopmentExpenseLX2006" xlink:label="lxeo_ResearchAndDevelopmentExpenseLX2006"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_ResearchAndDevelopmentExpenseLX1001" xlink:label="lxeo_ResearchAndDevelopmentExpenseLX1001"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_ResearchAndDevelopmentExpenseOtherPrograms" xlink:label="lxeo_ResearchAndDevelopmentExpenseOtherPrograms"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_ResearchAndDevelopmentExpenseEmployeeCompensationExpenses" xlink:label="lxeo_ResearchAndDevelopmentExpenseEmployeeCompensationExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="us-gaap_LaborAndRelatedExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="lxeo-20241231.xsd#lxeo_GeneralAndAdministrativeExpenseEmployeeCompensationExpenses" xlink:label="lxeo_GeneralAndAdministrativeExpenseEmployeeCompensationExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
        </link:calculationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="lxeo_LeerinkAtTheMarketSalesAgreementMember" name="LeerinkAtTheMarketSalesAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lxeo_SeriesAAndSeriesBConvertiblePreferredStockMember" name="SeriesAAndSeriesBConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lxeo_ThirdCornellLicenseAgreementsMember" name="ThirdCornellLicenseAgreementsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lxeo_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember" name="TwoThousandTwentyThreeEmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lxeo_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" name="ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_NumberOfLicenseAgreements" name="NumberOfLicenseAgreements" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_CornellSecondLicenseAgreementsMember" name="CornellSecondLicenseAgreementsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lxeo_DeferredTaxAssetsLeaseLiabilities" name="DeferredTaxAssetsLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lxeo_CornellUniversityMember" name="CornellUniversityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lxeo_PaymentOfAnnualDataTransferFee" name="PaymentOfAnnualDataTransferFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lxeo_StockOfferingGrossProceedsPercentage" name="StockOfferingGrossProceedsPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_EricAdlerMember" name="EricAdlerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lxeo_QualifiedIpoMinimumNumberOfDirectorsApprovalRequired" name="QualifiedIpoMinimumNumberOfDirectorsApprovalRequired" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_ReclassificationOfInternalUseSoftwareIntoPrepaidExpenses" name="ReclassificationOfInternalUseSoftwareIntoPrepaidExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lxeo_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalCostsIncurred" name="ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalCostsIncurred" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lxeo_PaymentOfAnnualLicenseMaintenanceFees" name="PaymentOfAnnualLicenseMaintenanceFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lxeo_ComponentsOfOperatingLeaseTableTextBlock" name="ComponentsOfOperatingLeaseTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_NumberOfMonthlyInstallmentsLease" name="NumberOfMonthlyInstallmentsLease" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_CapitalExpendituresIncurredButNotYetPaidNetOfPaidAmount" name="CapitalExpendituresIncurredButNotYetPaidNetOfPaidAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lxeo_SeriesAAndBConvertiblePreferredStockMember" name="SeriesAAndBConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lxeo_LicenseAndAcquisitionAndResearchCollaborationAndSponsoredResearchAgreementsDisclosureTextBlock" name="LicenseAndAcquisitionAndResearchCollaborationAndSponsoredResearchAgreementsDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" name="DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lxeo_OperatingLossCarryForwardsExpirationYear" name="OperatingLossCarryForwardsExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_SimpleAgreementForFutureEquityMember" name="SimpleAgreementForFutureEquityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsUnvestedStockOptionsSubjectToRepurchaseShare" name="AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsUnvestedStockOptionsSubjectToRepurchaseShare" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_OneTimeUpFrontNonRefundableFees" name="OneTimeUpFrontNonRefundableFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_TwoThousandTwentyOneEquityIncentivePlanMember" name="TwoThousandTwentyOneEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lxeo_NumberOfResearchAgreements" name="NumberOfResearchAgreements" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_AggregateDevelopmentAndCommercializationMilestonesDescription" name="AggregateDevelopmentAndCommercializationMilestonesDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_AdverumLicenseAgreementMember" name="AdverumLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lxeo_InvestmentNonCurrent" name="InvestmentNonCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lxeo_TaxCreditCarryForwardExpirationYear" name="TaxCreditCarryForwardExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_SareptaTherapeuticsIncMember" name="SareptaTherapeuticsIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lxeo_StockOfferingValueSharesAuthorizedToBeSold" name="StockOfferingValueSharesAuthorizedToBeSold" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lxeo_PercentageOfAutomaticallyIncreaseInAvailableSharesOfCommonStockOnBeginningOfCachCalendarYear" name="PercentageOfAutomaticallyIncreaseInAvailableSharesOfCommonStockOnBeginningOfCachCalendarYear" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_SpecificClinicalAndRegulatoryMilestonesDue" name="SpecificClinicalAndRegulatoryMilestonesDue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lxeo_SeriesALiquidationPreferenceMember" name="SeriesALiquidationPreferenceMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lxeo_ResearchAgreementTerminationNoticePeriod" name="ResearchAgreementTerminationNoticePeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_DeferredTaxAssetsIntangibleAssets" name="DeferredTaxAssetsIntangibleAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lxeo_AmendedFirstUcsdAgreementMember" name="AmendedFirstUcsdAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lxeo_ResearchAndDevelopmentExpenseLX1001" name="ResearchAndDevelopmentExpenseLX1001" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_OperatingLeaseWeightedAverageRemainingPaymentTerm" name="OperatingLeaseWeightedAverageRemainingPaymentTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_SecondUcsdLicenseAgreementMember" name="SecondUcsdLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lxeo_FinanceLeaseRightOfUseAssetsAndFinanceLeaseLiabilitiesRecognized" name="FinanceLeaseRightOfUseAssetsAndFinanceLeaseLiabilitiesRecognized" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lxeo_ThirdPartiesForPharmaceuticalManufacturingAndResearchActivitiesMember" name="ThirdPartiesForPharmaceuticalManufacturingAndResearchActivitiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lxeo_CornellFirstLicenseAgreementsMember" name="CornellFirstLicenseAgreementsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lxeo_IncreaseDecreaseInFairValueOfSafeInstrument" name="IncreaseDecreaseInFairValueOfSafeInstrument" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lxeo_MilestoneReceived" name="MilestoneReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lxeo_PaymentOfOneTimeUpFrontNonRefundableFee" name="PaymentOfOneTimeUpFrontNonRefundableFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lxeo_ResearchAndDevelopmentExpenseLX2006" name="ResearchAndDevelopmentExpenseLX2006" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lxeo_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConvertibleNoteIssuance" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConvertibleNoteIssuance" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lxeo_PaymentOfLicenseIssueFeeAndInitialDataTransferFee" name="PaymentOfLicenseIssueFeeAndInitialDataTransferFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lxeo_FinanceLeaseAggregateMonthlyInstallmentPaymentAmounts" name="FinanceLeaseAggregateMonthlyInstallmentPaymentAmounts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lxeo_ShareBasedCompensationPaymentDescription" name="ShareBasedCompensationPaymentDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_SummaryOfSignificantAccountingPoliciesTable" name="SummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lxeo_PaymentStartingAfterPeriodOfExecutionOfAgreement" name="PaymentStartingAfterPeriodOfExecutionOfAgreement" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_GeneralAndAdministrativeExpensesPolicyPolicyTextBlock" name="GeneralAndAdministrativeExpensesPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_ResearchAgreementsTerm" name="ResearchAgreementsTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_AccruedGeneralAndAdministrativeExpensesAndOtherProfessionalFeesCurrent" name="AccruedGeneralAndAdministrativeExpensesAndOtherProfessionalFeesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsShare" name="AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsShare" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_ScheduleOfSignificantUnobservableInputsUsedInValuationModelToEstimateFairValueTableTextBlock" name="ScheduleOfSignificantUnobservableInputsUsedInValuationModelToEstimateFairValueTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_FairValueTimeUntilPublicOfferingEvent" name="FairValueTimeUntilPublicOfferingEvent" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_FinanceLeaseWeightedAverageRemainingAmortizationTerm" name="FinanceLeaseWeightedAverageRemainingAmortizationTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_CommonStockDuringOfferingPeriod" name="CommonStockDuringOfferingPeriod" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_AmountsReclassifiedFromDepositLiabilitiesUponTheVestingOfEarlyExercisedStockOptionsPreviouslySubjectToRepurchaseNetOfProceedsReceivedFromEarlyExerciseOfUnvestedStockOptionsSubjectToRepurchaseAndRecord" name="AmountsReclassifiedFromDepositLiabilitiesUponTheVestingOfEarlyExercisedStockOptionsPreviouslySubjectToRepurchaseNetOfProceedsReceivedFromEarlyExerciseOfUnvestedStockOptionsSubjectToRepurchaseAndRecord" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lxeo_FinanceLeaseMonthlyInstallmentPaymentAmounts" name="FinanceLeaseMonthlyInstallmentPaymentAmounts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lxeo_AgreementExpirationTerm" name="AgreementExpirationTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_TwoThousandAndTwentyThreeEquityIncentivePlanMember" name="TwoThousandAndTwentyThreeEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lxeo_NumberOfSharesAutomaticallyIncreaseInAvailableSharesOfCommonStockUnderPlan" name="NumberOfSharesAutomaticallyIncreaseInAvailableSharesOfCommonStockUnderPlan" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_PaymentTerm" name="PaymentTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_IncreaseDecreaseInFinanceLeaseLiability" name="IncreaseDecreaseInFinanceLeaseLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lxeo_AmountDueForEachQuarterUnderAgreement" name="AmountDueForEachQuarterUnderAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lxeo_NetProceedsReceivedFromPrivatePlacement" name="NetProceedsReceivedFromPrivatePlacement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lxeo_FairValueProbabilityOfMeetingQualifiedEquityFinancingEvent" name="FairValueProbabilityOfMeetingQualifiedEquityFinancingEvent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriod" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_AccruedLiabilitiesAndOtherLiabilitiesCurrent" name="AccruedLiabilitiesAndOtherLiabilitiesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lxeo_ResearchAndDevelopmentExpenseLX2020" name="ResearchAndDevelopmentExpenseLX2020" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptions" name="AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lxeo_TwoThousandTwentyOneAndTwoThousandTwentyThreeEquityIncentivePlanMember" name="TwoThousandTwentyOneAndTwoThousandTwentyThreeEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lxeo_LesseeFinanceLeaseCommencementDateRangeEnd" name="LesseeFinanceLeaseCommencementDateRangeEnd" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_OperatingLeaseEndDate" name="OperatingLeaseEndDate" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lxeo_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtShare" name="AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtShare" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_ResearchCollaborationAgreementMember" name="ResearchCollaborationAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lxeo_AccruedResearchAndDevelopmentExpenseCurrent" name="AccruedResearchAndDevelopmentExpenseCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lxeo_FairValueProbabilityOfMeetingPublicOfferingEvent" name="FairValueProbabilityOfMeetingPublicOfferingEvent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_TwoPortfoliosMember" name="TwoPortfoliosMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lxeo_TemporaryEquityConversionOfStockInInitialPublicOfferingShares" name="TemporaryEquityConversionOfStockInInitialPublicOfferingShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_CommissionsAndOfferingCostsMember" name="CommissionsAndOfferingCostsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lxeo_ResearchAndDevelopmentExpenseEmployeeCompensationExpenses" name="ResearchAndDevelopmentExpenseEmployeeCompensationExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lxeo_AmountDueUnderAgreement" name="AmountDueUnderAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lxeo_PayrollDeductionsAtPrice" name="PayrollDeductionsAtPrice" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_CommonStockSharesIssuedOnEarlyExerciseOfUnvestedStockOptions" name="CommonStockSharesIssuedOnEarlyExerciseOfUnvestedStockOptions" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_DevelopmentAndRegulatoryMilestonesDue" name="DevelopmentAndRegulatoryMilestonesDue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lxeo_PercentageOfCumulativeOwnershipChange" name="PercentageOfCumulativeOwnershipChange" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_ThirdPortfolioMember" name="ThirdPortfolioMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lxeo_AntidilutiveSecuritiesMember" name="AntidilutiveSecuritiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lxeo_CornellLicenseAgreementsMember" name="CornellLicenseAgreementsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lxeo_PaymentOfClinicalAndRegulatoryMilestone" name="PaymentOfClinicalAndRegulatoryMilestone" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lxeo_UnderwritingDiscountsCommissionsAndOfferingCostsMember" name="UnderwritingDiscountsCommissionsAndOfferingCostsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lxeo_TwoThousandTwentyThreeEquityIncentivePlanMember" name="TwoThousandTwentyThreeEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lxeo_FairValueTimeUntilQualifiedEquityFinancingEvent" name="FairValueTimeUntilQualifiedEquityFinancingEvent" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_ResearchAndDevelopmentExpenseOtherPrograms" name="ResearchAndDevelopmentExpenseOtherPrograms" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lxeo_AdverumBiotechnologiesIncMember" name="AdverumBiotechnologiesIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lxeo_WeillCornellMedicalCollegeMember" name="WeillCornellMedicalCollegeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lxeo_PaymentOfRegulatoryMilestones" name="PaymentOfRegulatoryMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lxeo_SummaryOfSignificantAccountingPoliciesLineItems" name="SummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lxeo_PercentageOfOutstandingSharesForDeemedLiquidation" name="PercentageOfOutstandingSharesForDeemedLiquidation" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_LicenseAgreementTerminationNoticePeriod" name="LicenseAgreementTerminationNoticePeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_LossRecognizedFromUninsuredBalances" name="LossRecognizedFromUninsuredBalances" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lxeo_SeriesBConvertiblePreferredStockMember" name="SeriesBConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lxeo_SteliosTherapeuticsIncMember" name="SteliosTherapeuticsIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lxeo_TemporaryEquityConversionOfStockInInitialPublicOfferingValue" name="TemporaryEquityConversionOfStockInInitialPublicOfferingValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lxeo_GeneralAndAdministrativeExpenseEmployeeCompensationExpenses" name="GeneralAndAdministrativeExpenseEmployeeCompensationExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lxeo_SeriesAConvertiblePreferredStockMember" name="SeriesAConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lxeo_ConvertibleSimpleAgreementForFutureEquityNoteMember" name="ConvertibleSimpleAgreementForFutureEquityNoteMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lxeo_LesseeFinanceLeaseCommencementDateRangeStart" name="LesseeFinanceLeaseCommencementDateRangeStart" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_FairValueOfUnearnedEmployeeStockOwnershipPlans" name="FairValueOfUnearnedEmployeeStockOwnershipPlans" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualTermGrantDate" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualTermGrantDate" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_CommercializationMilestonesDue" name="CommercializationMilestonesDue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lxeo_ComponentsOfEquipmentFinanceLeaseTableTextBlock" name="ComponentsOfEquipmentFinanceLeaseTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredInPeriodWeightedAverageGrantDateFairValue" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredInPeriodWeightedAverageGrantDateFairValue" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_FairValueProbabilityOfMeetingChangeInControlEvent" name="FairValueProbabilityOfMeetingChangeInControlEvent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance" name="IncreaseInCommonStockCapitalSharesReservedForFutureIssuance" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversionOfNotesIntoCommonStock" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversionOfNotesIntoCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lxeo_AnnualLimitationAbilityToUtilize" name="AnnualLimitationAbilityToUtilize" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lxeo_DevelopmentAndCommercializationMilestonesDue" name="DevelopmentAndCommercializationMilestonesDue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lxeo_RNolanTownsendMember" name="RNolanTownsendMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lxeo_LesseeOperatingAndFinancingLeasesDisclosureTextBlock" name="LesseeOperatingAndFinancingLeasesDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_UpfrontCashPayment" name="UpfrontCashPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lxeo_TreasuryStockRepurchase" name="TreasuryStockRepurchase" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOptionsExercisableWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOptionsExercisableWeightedAverageGrantDateFairValue" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsUnvestedStockOptionsSubjectToRepurchaseValue" name="AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsUnvestedStockOptionsSubjectToRepurchaseValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lxeo_SeriesBLiquidationPreferenceMember" name="SeriesBLiquidationPreferenceMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lxeo_OperatingLeaseCommencementDate" name="OperatingLeaseCommencementDate" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_PaymentOfDevelopmentMilestone" name="PaymentOfDevelopmentMilestone" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lxeo_FirstUcsdLicenseAgreementMember" name="FirstUcsdLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lxeo_OperatingLeaseAgreementEnteredDate" name="OperatingLeaseAgreementEnteredDate" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_UcsdSponsoredResearchAgreementsMember" name="UcsdSponsoredResearchAgreementsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lxeo_FinanceLeaseExpense" name="FinanceLeaseExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lxeo_StockIssuedDuringPeriodValueNewIssuesAdditionalOfferingCostsIncurred" name="StockIssuedDuringPeriodValueNewIssuesAdditionalOfferingCostsIncurred" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsExercisableWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsExercisableWeightedAverageGrantDateFairValue" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_BlackScholesModelMember" name="BlackScholesModelMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lxeo_InvestmentCurrent" name="InvestmentCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lxeo_FairValueTimeUntilChangeInControlEvent" name="FairValueTimeUntilChangeInControlEvent" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_NumberOfFormerEmployees" name="NumberOfFormerEmployees" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lxeo_ThirdUcsdLicenseAgreementMember" name="ThirdUcsdLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lxeo_OfficeFacilityAndLaboratorySpaceMember" name="OfficeFacilityAndLaboratorySpaceMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Mar. 21, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">LEXEO THERAPEUTICS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text"> 0001907108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-41855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">85-4012572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">345 Park Avenue South<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Floor 6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New York<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">547-9879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LXEO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,196,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference [Text Block]</a></td>
<td class="text"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Portions of the Registrant&#8217;s definitive Proxy Statement relating to the 2025 Annual Meeting of Stockholders are incorporated herein by reference in Part III of this Annual Report on Form 10-K to the extent stated herein. Such proxy statement will be filed with the Securities and Exchange Commission within 120 days of the registrant&#8217;s fiscal year ended December 31, 2024.</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 527.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">KPMG LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">New York, NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorOpinionTextBlock', window );">Auditor Opinion [Text Block]</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Opinion on the Financial Statements</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have audited the accompanying balance sheets of Lexeo Therapeutics, Inc. (the Company) as of December 31, 2024 and 2023, the related statements of operations and comprehensive loss, convertible preferred stock and stockholders&#8217; equity (deficit), and cash flows for the years then ended, and the related notes (collectively, the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for the years then ended, in conformity with U.S. generally accepted accounting principles.</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorOpinionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X<br> -Number 210<br> -Section 2<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorOpinionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 35,014<span></span>
</td>
<td class="nump">$ 121,466<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Investments</a></td>
<td class="nump">86,504<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">4,603<span></span>
</td>
<td class="nump">2,828<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">126,121<span></span>
</td>
<td class="nump">124,294<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">3,252<span></span>
</td>
<td class="nump">3,252<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Investments</a></td>
<td class="nump">7,012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,028<span></span>
</td>
<td class="nump">1,056<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Lease right-of-use assets - finance, net</a></td>
<td class="nump">1,460<span></span>
</td>
<td class="nump">1,763<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Lease right-of-use assets - operating</a></td>
<td class="nump">8,069<span></span>
</td>
<td class="nump">9,442<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">146,942<span></span>
</td>
<td class="nump">139,807<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">6,417<span></span>
</td>
<td class="nump">3,794<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_AccruedLiabilitiesAndOtherLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">13,759<span></span>
</td>
<td class="nump">10,840<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Current portion of lease liabilities - finance</a></td>
<td class="nump">570<span></span>
</td>
<td class="nump">518<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of lease liabilities - operating</a></td>
<td class="nump">2,100<span></span>
</td>
<td class="nump">2,087<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">22,846<span></span>
</td>
<td class="nump">17,239<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Non-current portion of lease liabilities - finance</a></td>
<td class="nump">817<span></span>
</td>
<td class="nump">1,247<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current portion of lease liabilities - operating</a></td>
<td class="nump">6,437<span></span>
</td>
<td class="nump">7,786<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">30,100<span></span>
</td>
<td class="nump">26,272<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 12)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value, 500,000,000 shares authorized as of December 31, 2024; 33,079,209 shares issued and 33,071,261 shares outstanding as of December 31, 2024; 500,000,000 shares authorized as of December 31, 2023; 26,668,485 shares issued and 26,646,378 shares outstanding as of December 31, 2023</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonValue', window );">Treasury stock, at cost, 3,827 common shares at December 31, 2024 and 0 common shares at December 31, 2023</a></td>
<td class="num">(17)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">397,132<span></span>
</td>
<td class="nump">295,372<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(103)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(280,173)<span></span>
</td>
<td class="num">(181,840)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">116,842<span></span>
</td>
<td class="nump">113,535<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 146,942<span></span>
</td>
<td class="nump">$ 139,807<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_AccruedLiabilitiesAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued liabilities and other liabilities current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_AccruedLiabilitiesAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value per share</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, Authorized</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares issued</a></td>
<td class="nump">33,079,209<span></span>
</td>
<td class="nump">26,668,485<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, Outstanding</a></td>
<td class="nump">33,071,261<span></span>
</td>
<td class="nump">26,646,378<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock, common shares</a></td>
<td class="nump">3,827<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">$ 74,091<span></span>
</td>
<td class="nump">$ 53,130<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">31,675<span></span>
</td>
<td class="nump">15,383<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">105,766<span></span>
</td>
<td class="nump">68,513<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(105,766)<span></span>
</td>
<td class="num">(68,513)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income and expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings', window );">Loss on fair value adjustment to convertible SAFE Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(530)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="num">(9)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="num">(137)<span></span>
</td>
<td class="num">(205)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">7,556<span></span>
</td>
<td class="nump">2,867<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeAmortizationOfDiscount', window );">Accretion of discount on investments</a></td>
<td class="nump">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income and expense</a></td>
<td class="nump">7,433<span></span>
</td>
<td class="nump">2,119<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss from operations before income taxes</a></td>
<td class="num">(98,333)<span></span>
</td>
<td class="num">(66,394)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(98,333)<span></span>
</td>
<td class="num">(66,394)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized comprehensive loss on investments</a></td>
<td class="num">(103)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive loss</a></td>
<td class="num">(103)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (98,436)<span></span>
</td>
<td class="num">$ (66,394)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share, basic</a></td>
<td class="num">$ (3.09)<span></span>
</td>
<td class="num">$ (12.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share, diluted</a></td>
<td class="num">$ (3.09)<span></span>
</td>
<td class="num">$ (12.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of shares outstanding used in computation of net loss per common share, basic</a></td>
<td class="nump">31,787,491<span></span>
</td>
<td class="nump">5,354,368<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of shares outstanding used in computation of net loss per common share, diluted</a></td>
<td class="nump">31,787,491<span></span>
</td>
<td class="nump">5,354,368<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total amount of gain (loss) derived from fair value hedges recognized in earnings in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeAmortizationOfDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accretion of purchase discount on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeAmortizationOfDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Convertible Preferred Stock</div></th>
<th class="th"><div>Initial Public Offering</div></th>
<th class="th"><div>Private Placement Offering</div></th>
<th class="th"><div>Other Comprehensive Loss</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th">
<div>Common Stock </div>
<div>Initial Public Offering</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>Private Placement Offering</div>
</th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>Initial Public Offering</div>
</th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>Private Placement Offering</div>
</th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, balance, shares at Dec. 31, 2022</a></td>
<td class="nump">143,653,545<span></span>
</td>
<td class="nump">143,653,545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary equity, balance, value at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 185,033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,607,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, value at Dec. 31, 2022</a></td>
<td class="num">$ (112,954)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,492<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (115,446)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options, value</a></td>
<td class="nump">51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsShare', window );">Amounts reclassified from deposit liabilities upon the vesting of early-exercised stock options previously subject to repurchase. Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,442<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptions', window );">Amounts reclassified from deposit liabilities upon the vesting of early-exercised stock options previously subject to repurchase, Value</a></td>
<td class="nump">87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtShare', window );">Conversion of SAFE Note into common stock in connection with initial public offering, Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">411,815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt', window );">Conversion of SAFE Note into common stock in connection with initial public offering, net of issuance costs, value</a></td>
<td class="nump">4,417<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,417<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock upon offering and subsequent partial exercise of underwriters' option to purchase additional shares, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,139,656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock upon offering and subsequent partial exercise of underwriters' option to purchase additional shares, Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_TemporaryEquityConversionOfStockInInitialPublicOfferingShares', window );">Conversion of convertible preferred stock into common stock in connection with initial public offering, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(143,653,545)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_TemporaryEquityConversionOfStockInInitialPublicOfferingValue', window );">Conversion of convertible preferred stock into common stock in connection with initial public offering, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (185,033)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of convertible preferred stock into common stock in connection with initial public offering, share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,456,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of convertible preferred stock into common stock in connection with initial public offering, value</a></td>
<td class="nump">185,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">185,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">3,043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(66,394)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(66,394)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,646,378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, value at Dec. 31, 2023</a></td>
<td class="nump">113,535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">295,372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(181,840)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">135,646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options, value</a></td>
<td class="nump">491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsShare', window );">Amounts reclassified from deposit liabilities upon the vesting of early-exercised stock options previously subject to repurchase. Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptions', window );">Amounts reclassified from deposit liabilities upon the vesting of early-exercised stock options previously subject to repurchase, Value</a></td>
<td class="nump">59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock upon offering and subsequent partial exercise of underwriters' option to purchase additional shares, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,278,905<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock upon offering and subsequent partial exercise of underwriters' option to purchase additional shares, Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 88,712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 88,712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_StockIssuedDuringPeriodValueNewIssuesAdditionalOfferingCostsIncurred', window );">Additional issuance costs incurred for SAFE Note</a></td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Treasury stock repurchases, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,827)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Treasury stock repurchases, Value</a></td>
<td class="num">(17)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (17)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized comprehensive loss on investments</a></td>
<td class="num">(103)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (103)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">12,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(98,333)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(98,333)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,071,261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, value at Dec. 31, 2024</a></td>
<td class="nump">$ 116,842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (103)<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (17)<span></span>
</td>
<td class="nump">$ 397,132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (280,173)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments to additional paid in capital, equity component of convertible debt share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments to additional paid in capital reclassification from deposit liability share based compensation and exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments to additional paid in capital reclassification from deposit liability share based compensation and exercise of stock options, share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_StockIssuedDuringPeriodValueNewIssuesAdditionalOfferingCostsIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value new issues additional offering costs incurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_StockIssuedDuringPeriodValueNewIssuesAdditionalOfferingCostsIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_TemporaryEquityConversionOfStockInInitialPublicOfferingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary equity, conversion of stock in initial public offering, shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_TemporaryEquityConversionOfStockInInitialPublicOfferingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_TemporaryEquityConversionOfStockInInitialPublicOfferingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary equity, conversion of stock in initial public offering, value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_TemporaryEquityConversionOfStockInInitialPublicOfferingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481284/470-20-25-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.E.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO | Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 519<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO | SAFE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">113<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO | Underwriting Discounts, Commissions and Offering Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,285<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement Offering | Commissions and Offering Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Net of issuance costs</a></td>
<td class="nump">$ 6,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lxeo_SimpleAgreementForFutureEquityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lxeo_SimpleAgreementForFutureEquityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lxeo_UnderwritingDiscountsCommissionsAndOfferingCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lxeo_UnderwritingDiscountsCommissionsAndOfferingCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lxeo_CommissionsAndOfferingCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lxeo_CommissionsAndOfferingCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (98,333)<span></span>
</td>
<td class="num">$ (66,394)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Reduction in the carrying amount of ROU assets, operating</a></td>
<td class="nump">1,373<span></span>
</td>
<td class="nump">1,266<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Reduction in the carrying amount of ROU assets, finance</a></td>
<td class="nump">325<span></span>
</td>
<td class="nump">306<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation expense</a></td>
<td class="nump">12,474<span></span>
</td>
<td class="nump">3,043<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">304<span></span>
</td>
<td class="nump">271<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDerivativeAssetsAndLiabilities', window );">Change in fair value of convertible SAFE Note liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">530<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Accretion of discount on investments</a></td>
<td class="num">(23)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(1,690)<span></span>
</td>
<td class="nump">990<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">2,378<span></span>
</td>
<td class="num">(180)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">3,367<span></span>
</td>
<td class="nump">2,091<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Lease liabilities, operating</a></td>
<td class="num">(1,336)<span></span>
</td>
<td class="num">(1,414)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_IncreaseDecreaseInFinanceLeaseLiability', window );">Lease liabilities, finance</a></td>
<td class="nump">10<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(81,151)<span></span>
</td>
<td class="num">(59,496)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireSoftware', window );">Purchase of internal use software</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(50)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(481)<span></span>
</td>
<td class="num">(115)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of investments</a></td>
<td class="num">(93,596)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(94,077)<span></span>
</td>
<td class="num">(165)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">491<span></span>
</td>
<td class="nump">51<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payments on finance leases</a></td>
<td class="num">(410)<span></span>
</td>
<td class="num">(425)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_TreasuryStockRepurchase', window );">Treasury stock repurchases</a></td>
<td class="num">(17)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments of issuance costs on convertible SAFE Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(86)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of convertible SAFE Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from issuance of common stock upon private placement offering, net of commissions and offering costs</a></td>
<td class="nump">88,712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from issuance of common stock upon initial public offering, net of underwriters' discounts, commissions and other offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,251<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">88,776<span></span>
</td>
<td class="nump">103,791<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash, cash equivalents and restricted cash</a></td>
<td class="num">(86,452)<span></span>
</td>
<td class="nump">44,130<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">124,718<span></span>
</td>
<td class="nump">80,588<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">38,266<span></span>
</td>
<td class="nump">124,718<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">127<span></span>
</td>
<td class="nump">176<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses', window );">Deferred offering costs included in accounts payable and accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,105<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized loss on investments</a></td>
<td class="num">(103)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_ReclassificationOfInternalUseSoftwareIntoPrepaidExpenses', window );">Reclassification of internal use software into prepaid expenses</a></td>
<td class="nump">98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction', window );">Issuance costs related to convertible debt included in accounts payable and accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_CapitalExpendituresIncurredButNotYetPaidNetOfPaidAmount', window );">(Property and equipment purchased in the prior period and paid in the current period), net of property and equipment purchased in the current period included in accounts payable</a></td>
<td class="num">(120)<span></span>
</td>
<td class="nump">141<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_FinanceLeaseRightOfUseAssetsAndFinanceLeaseLiabilitiesRecognized', window );">Finance lease right-of use assets and finance lease liabilities recognized</a></td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountIssued1', window );">Conversion of convertible preferred stock into common stock in connection with initial public offering, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">185,032<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Conversion of SAFE Note into common stock in connection with initial public offering, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,417<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_AmountsReclassifiedFromDepositLiabilitiesUponTheVestingOfEarlyExercisedStockOptionsPreviouslySubjectToRepurchaseNetOfProceedsReceivedFromEarlyExerciseOfUnvestedStockOptionsSubjectToRepurchaseAndRecord', window );">Amounts reclassified from deposit liabilities upon the vesting of early-exercised stock options previously subject to repurchase, net of proceeds received from early exercise of unvested stock options subject to repurchase and recorded as deposit liabilities</a></td>
<td class="nump">$ 59<span></span>
</td>
<td class="nump">$ 87<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_AmountsReclassifiedFromDepositLiabilitiesUponTheVestingOfEarlyExercisedStockOptionsPreviouslySubjectToRepurchaseNetOfProceedsReceivedFromEarlyExerciseOfUnvestedStockOptionsSubjectToRepurchaseAndRecord">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amounts reclassified from deposit liabilities upon the vesting of early-exercised stock options previously subject to repurchase, net of proceeds received from early exercise of unvested stock options subject to repurchase and recorded as deposit liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_AmountsReclassifiedFromDepositLiabilitiesUponTheVestingOfEarlyExercisedStockOptionsPreviouslySubjectToRepurchaseNetOfProceedsReceivedFromEarlyExerciseOfUnvestedStockOptionsSubjectToRepurchaseAndRecord</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_CapitalExpendituresIncurredButNotYetPaidNetOfPaidAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Capital expenditures incurred but not yet paid, net of paid amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_CapitalExpendituresIncurredButNotYetPaidNetOfPaidAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred offering costs included in accounts payable and accrued expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_FinanceLeaseRightOfUseAssetsAndFinanceLeaseLiabilitiesRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance lease right-of use assets and finance lease liabilities recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_FinanceLeaseRightOfUseAssetsAndFinanceLeaseLiabilitiesRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_IncreaseDecreaseInFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_IncreaseDecreaseInFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_ReclassificationOfInternalUseSoftwareIntoPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reclassification of internal use software into prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_ReclassificationOfInternalUseSoftwareIntoPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_TreasuryStockRepurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Treasury stock repurchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_TreasuryStockRepurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDerivativeAssetsAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the net carrying value of derivative instruments reported as assets and liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDerivativeAssetsAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireSoftware">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition from vendors of software programs or applications for internal use (that is, not to be sold, leased or otherwise marketed to others) that qualify for capitalization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireSoftware</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (98,333)<span></span>
</td>
<td class="num">$ (66,394)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><p id="item_1c_cybersecurity" style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">em 1C.    Cybersecurity</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risk Management and Strategy</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have established policies and processes for assessing, identifying, and managing risk from cybersecurity threats. We periodically assess risks from cybersecurity threats, including any potential unauthorized occurrence on or conducted through our information systems that may result in adverse effects on the confidentiality, integrity, or availability of our information systems or any information residing therein. Following these risk assessments, we evaluate how to reasonably address any identified gaps in existing safeguards and monitor the effectiveness of our safeguards. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We devote resources and designate high-level personnel, including our Chief Legal Officer, who reports to our Chief Executive Officer, to manage the risk assessment and mitigation process in a manner that is consistent and </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">integrated</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> with our overall risk management processes. </span></span><span style="font-size:10pt;font-family:Times New Roman;"></span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As part of our overall risk management system, we monitor and test our safeguards and train our employees on these safeguards, including our cybersecurity safeguards, in collaboration with human resources, IT, and management. Personnel at all levels and departments receive periodic trainings on cybersecurity best practices and threats. For example, we conduct e-mail phishing campaigns with our employees and contractors which send phishing-style e-mails, monitor user responses, and automatically assign further training, as needed, and also provide convenient solutions for our employees to report suspicious messages.</span></p></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">engage</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> specialized third parties in connection with our risk assessment processes. These </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">third parties assist </span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">us in designing and implementing our cybersecurity policies and procedures, as well as in monitoring and testing our safeguards.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also conduct IT security assessments on our key third-party service providers and require them to implement and maintain reasonable security measures in connection with their work with us, and to promptly report any suspected breach of their security measures that may affect our company.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have not previously experienced any cybersecurity risk or cybersecurity incident which has been determined to be </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">material</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. For additional information regarding whether any risks from cybersecurity threats are reasonably likely to materially affect our company, including our business strategy, results of operations, or financial condition, please refer to Item 1A, &#8220;Risk Factors&#8221; in this Annual Report on Form 10-K, including the risk factor entitled &#8220;Our business and operations would suffer in the event of system failures, cyberattacks or a deficiency in our or our CMOs&#8217;, CROs&#8217;, manufacturers&#8217;, contractors&#8217;, consultants&#8217; or collaborators&#8217; cybersecurity&#8221;.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Governance</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">One of the key functions of our board of directors is informed oversight of our risk management process, including risks from cybersecurity threats. Our board of directors is responsible for monitoring and assessing strategic risk exposure, and our executive officers are responsible for the day-to-day management of the material risks we face. Our board of directors administers its cybersecurity risk oversight function directly as a whole, as well as through our audit committee.</span></p><div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Chief Legal Officer and our security governance steering committee, which includes our Vice President and Corporate Controller, Vice President of Human Resources, Senior Vice President of Development Operations, and Director of Information Technology and Cybersecurity, are primarily responsible for assessing and managing our risks from cybersecurity threats. Our Chief Legal Officer has more than a decade of operational experience overseeing and advising on risk management in the highly regulated biopharmaceutical industry, and leads a wide range of business functions, including IT/IS. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Director of Information Technology and Cybersecurity has nearly 20 years of experience with IT, having had leadership roles in strategic technology development and information security, and holds several industry-recognized certifications such as the Certified Information Security Manager (CISM) and CompTIA Network+. They and other members of our security governance steering committee engage in training and education relating to cybersecurity risk.</span></span></p></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Chief Legal Officer and our security governance steering committee oversee our cybersecurity policies and processes, including those described in &#8220;Risk Management and Strategy&#8221; above.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Chief Legal Officer and our management committee</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> on cybersecurity are informed about and monitor the prevention, detection, mitigation, and remediation of cybersecurity incidents through their work overseeing, working with, and delegating daily operations to the IT/IS team, as well as their work developing and implementing information security policies, consistent with the IT/IS processes.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> These policies are reviewed at least annually with updates authorized and approved by the security governance steering committee.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Chief Legal Officer and representatives from our security governance steering committee provide quarterly briefings to the audit committee regarding our company&#8217;s cybersecurity risks and activities, including any recent cybersecurity incidents and related responses, cybersecurity systems testing, activities of third parties</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and the like. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our audit committee provides regular updates to the board of directors on such reports</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In addition, our Chief Legal Officer and representatives from our security governance steering committee provide annual briefings to the board of directors on cybersecurity risks and activities.</span></p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We devote resources and designate high-level personnel, including our Chief Legal Officer, who reports to our Chief Executive Officer, to manage the risk assessment and mitigation process in a manner that is consistent and </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">integrated</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> with our overall risk management processes. </span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag', window );">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">One of the key functions of our board of directors is informed oversight of our risk management process, including risks from cybersecurity threats. Our board of directors is responsible for monitoring and assessing strategic risk exposure, and our executive officers are responsible for the day-to-day management of the material risks we face. Our board of directors administers its cybersecurity risk oversight function directly as a whole, as well as through our audit committee.</span></p><div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Chief Legal Officer and our security governance steering committee, which includes our Vice President and Corporate Controller, Vice President of Human Resources, Senior Vice President of Development Operations, and Director of Information Technology and Cybersecurity, are primarily responsible for assessing and managing our risks from cybersecurity threats. Our Chief Legal Officer has more than a decade of operational experience overseeing and advising on risk management in the highly regulated biopharmaceutical industry, and leads a wide range of business functions, including IT/IS. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Director of Information Technology and Cybersecurity has nearly 20 years of experience with IT, having had leadership roles in strategic technology development and information security, and holds several industry-recognized certifications such as the Certified Information Security Manager (CISM) and CompTIA Network+. They and other members of our security governance steering committee engage in training and education relating to cybersecurity risk.</span></span></p></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Chief Legal Officer and our security governance steering committee oversee our cybersecurity policies and processes, including those described in &#8220;Risk Management and Strategy&#8221; above.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Chief Legal Officer and our management committee</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> on cybersecurity are informed about and monitor the prevention, detection, mitigation, and remediation of cybersecurity incidents through their work overseeing, working with, and delegating daily operations to the IT/IS team, as well as their work developing and implementing information security policies, consistent with the IT/IS processes.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> These policies are reviewed at least annually with updates authorized and approved by the security governance steering committee.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Chief Legal Officer and representatives from our security governance steering committee provide quarterly briefings to the audit committee regarding our company&#8217;s cybersecurity risks and activities, including any recent cybersecurity incidents and related responses, cybersecurity systems testing, activities of third parties</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and the like. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our audit committee provides regular updates to the board of directors on such reports</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In addition, our Chief Legal Officer and representatives from our security governance steering committee provide annual briefings to the board of directors on cybersecurity risks and activities.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Chief Legal Officer and our security governance steering committee, which includes our Vice President and Corporate Controller, Vice President of Human Resources, Senior Vice President of Development Operations, and Director of Information Technology and Cybersecurity, are primarily responsible for assessing and managing our risks from cybersecurity threats. Our Chief Legal Officer has more than a decade of operational experience overseeing and advising on risk management in the highly regulated biopharmaceutical industry, and leads a wide range of business functions, including IT/IS. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Director of Information Technology and Cybersecurity has nearly 20 years of experience with IT, having had leadership roles in strategic technology development and information security, and holds several industry-recognized certifications such as the Certified Information Security Manager (CISM) and CompTIA Network+. They and other members of our security governance steering committee engage in training and education relating to cybersecurity risk.</span></span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Chief Legal Officer and our security governance steering committee oversee our cybersecurity policies and processes, including those described in &#8220;Risk Management and Strategy&#8221; above.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskRoleOfManagementTextBlock', window );">Cybersecurity Risk Role of Management [Text Block]</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have established policies and processes for assessing, identifying, and managing risk from cybersecurity threats. We periodically assess risks from cybersecurity threats, including any potential unauthorized occurrence on or conducted through our information systems that may result in adverse effects on the confidentiality, integrity, or availability of our information systems or any information residing therein. Following these risk assessments, we evaluate how to reasonably address any identified gaps in existing safeguards and monitor the effectiveness of our safeguards. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We devote resources and designate high-level personnel, including our Chief Legal Officer, who reports to our Chief Executive Officer, to manage the risk assessment and mitigation process in a manner that is consistent and </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">integrated</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> with our overall risk management processes. </span></span><span style="font-size:10pt;font-family:Times New Roman;"></span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As part of our overall risk management system, we monitor and test our safeguards and train our employees on these safeguards, including our cybersecurity safeguards, in collaboration with human resources, IT, and management. Personnel at all levels and departments receive periodic trainings on cybersecurity best practices and threats. For example, we conduct e-mail phishing campaigns with our employees and contractors which send phishing-style e-mails, monitor user responses, and automatically assign further training, as needed, and also provide convenient solutions for our employees to report suspicious messages.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</a></td>
<td class="text"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Chief Legal Officer and our management committee</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> on cybersecurity are informed about and monitor the prevention, detection, mitigation, and remediation of cybersecurity incidents through their work overseeing, working with, and delegating daily operations to the IT/IS team, as well as their work developing and implementing information security policies, consistent with the IT/IS processes.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock', window );">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Director of Information Technology and Cybersecurity has nearly 20 years of experience with IT, having had leadership roles in strategic technology development and information security, and holds several industry-recognized certifications such as the Certified Information Security Manager (CISM) and CompTIA Network+. They and other members of our security governance steering committee engage in training and education relating to cybersecurity risk.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Chief Legal Officer and representatives from our security governance steering committee provide quarterly briefings to the audit committee regarding our company&#8217;s cybersecurity risks and activities, including any recent cybersecurity incidents and related responses, cybersecurity systems testing, activities of third parties</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskRoleOfManagementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskRoleOfManagementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Description of Business and Basis of Presentation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1. Description of Business and Basis of Presentation</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Description of Business</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Lexeo Therapeutics, Inc. (the &#8220;Company&#8221;) is a clinical stage genetic medicine company with a focus on hereditary and acquired diseases of high unmet need. The Company&#8217;s investigational therapies have the potential to offer gene therapy-based treatments to address many diseases that have eluded today&#8217;s existing drug delivery platforms. The Company utilizes adeno-associated viruses (&#8220;AAV&#8221;) that have been engineered to transfer genes to patients. The Company&#8217;s therapeutic investigational treatments include gene therapies primarily in the early clinical and late pre-clinical stages of research and development.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is located in New York, NY and was first formed on February 17, 2017, as an LLC under the laws of the State of Delaware under the legal name Lexeo Therapeutics, LLC. The Company filed and executed a certificate of conversion to corporation on November 20, 2020, to convert the LLC to Lexeo Therapeutics, Inc, a Delaware corporation. All of the Company&#8217;s tangible assets are held in the United States (&#8220;U.S.&#8221;).</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basis of Presentation and Principles of Consolidation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;The accompanying financial statements and these notes reflect the operations of the Company that have been prepared in conformity with generally accepted accounting principles in the United States of America (&#8220;GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;). The Company has no unconsolidated subsidiaries. Certain prior period balances have been reclassified to conform to the current period presentation.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10.594230-for-1</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> reverse share split of the Company&#8217;s series A convertible preferred stock, series B convertible preferred stock, common stock, and options to purchase common stock under the Company&#8217;s 2021 Equity Incentive Plan (the "2021 Plan"), as well as corresponding adjustments in the respective conversion prices of the series A convertible preferred stock and series B convertible preferred stock, was effected on October 13, 2023 as approved by the Company&#8217;s board of directors (the "Board of Directors") and its shareholders (the &#8220;Stock Split&#8221;). The Stock Split reduced the number of shares of the Company&#8217;s authorized, issued and outstanding common stock, as well as the numbers of shares reserved and available for future issuance and underlying outstanding options to purchase common stock under its 2021 Equity Incentive Plan, on a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10.594230-for-1</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> basis. As such, all references to series A convertible preferred stock and series B convertible preferred stock conversion ratios, conversion share and per share amounts, and post- conversion share and per share amounts, as well as common stock option, option per common share, common share and common per share amounts, in these financial statements and accompanying notes have been retroactively restated to reflect the Stock Split and the Stock Split&#8217;s effect on the respective series A convertible preferred stock and series B convertible preferred stock conversion ratios for each series of convertible preferred stock. The Stock Split did not affect the par values per share.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Need for Additional Capital</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Since inception, the Company has incurred net losses and negative cash flows from operations, including net losses of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">66.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million during the years ended December 31, 2024 and December 31, 2023, respectively. As of December 31, 2024, the Company had cash, cash equivalents, and investments of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">128.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and an accumulated deficit of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">280.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and expects to incur substantial operating losses and negative cash flows from operations for the foreseeable future. During the years ended December 31, 2021 and December 31, 2020, the Company raised aggregate total net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">185.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in connection with the issuance of series A and series B convertible preferred stock. During the year ended December 31, 2023 the Company raised $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of total net proceeds in connection with the closing of its initial public offering ("IPO") on November 7, 2023 and subsequent partial exercise of the underwriters' option to purchase additional shares, as well $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of net proceeds from the issuance of a convertible Simple Agreement for Future Equity (&#8220;SAFE&#8221;) note (the "convertible SAFE Note") in August 2023. During the year ended December 31, 2024, the Company received total net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">88.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million after deducting underwriting commissions and offering expenses in a private placement offering of its common stock (see Note 8). Management estimates that the Company's current cash, cash equivalents, and investments balances are sufficient to fund its operations for at least 12 months from the issuance date of these financial statements.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the Company is unable to obtain additional funding before achieving sufficient profitability and positive cash flows from operations, if ever, the Company will be forced to delay, reduce or eliminate some or all of its research and development programs, which could adversely affect its business prospects, or the Company may be unable to continue operations. Although management continues to pursue plans to obtain additional funding before achieving sufficient profitability and positive cash flows from operations, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations, if at all.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks and Uncertainties</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;The Company is subject to risks and uncertainties common to early-stage companies in the biopharmaceutical industry, including, but not limited to, successful discovery and development of its product candidates, development by competitors of new technological innovations, dependence on key personnel, the ability to attract and retain qualified employees, protection of proprietary technology, compliance with governmental regulations, the ability to secure additional capital to fund operations, and commercial success of its product candidates. Any of the Company&#8217;s current product candidates and future product candidates that it may develop will require extensive non-clinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel, infrastructure, and extensive compliance- reporting capabilities. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2. Summary of Significant Accounting Policies</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;The preparation of the financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of income and expense during the reporting period. The most significant estimates relate to the accruals of research and development costs, including accruals of research contract costs, and assumptions used to estimate the fair value of the Company&#8217;s stock option awards and, prior to its IPO, to determine the fair value of its common stock. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when facts and circumstances dictate. These estimates are based on information available as of the date of the financial statements; therefore, actual results could differ from those estimates.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash and Cash Equivalents and Restricted Cash</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;The Company considers all highly liquid investments with a remaining maturity when purchased of three months or less to be cash equivalents. Cash equivalents are reported at carrying values, which approximated their fair values and are based on quoted prices in active markets for identical securities. At December 31, 2024 and December 31, 2023, the Company&#8217;s cash equivalents were held in a money market fund. As of December 31, 2024 and 2023, cash consists of cash on deposit with U.S. banks denominated in U.S. dollars, and restricted cash consists of cash on deposit with U.S. banks denominated in U.S. dollars for which its use is restricted and is classified as non-current in the Company&#8217;s balance sheet according to the timing of maturity, and is associated with collateral for letters of credit issued in connection with its operating lease right-of-use and finance lease right-of-use assets and corresponding lease liabilities. Cash is stated at its historical carrying amount, which approximates fair value due to its short-term nature. Restricted cash is stated at its historical carrying amount, which approximates fair value. The Company regularly maintains cash and cash equivalents and restricted cash balances with financial institutions that exceed Federal Deposit Insurance Corporation insurance limits.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investments</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Investments consist primarily of U.S. Treasury securities. Management determines the appropriate classification of these securities at the time they are acquired and evaluates the appropriateness of such classifications at each balance sheet date, including the determination of current and non-current classifications based on the contractual maturity dates of the underlying investments. Investments may be sold by the Company prior to contractual maturity. The Company classifies its investments as available-for-sale pursuant to ASC Topic 320, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Investments&#8212;Debt and Equity Securities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Investments are recorded at fair value, with unrealized gains and losses included as a component of accumulated other comprehensive income (loss) in stockholders&#8217; equity and a component of total comprehensive loss in the statements of comprehensive loss, until realized. The Company's current and non-current investments are presented net of discounts of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">55,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively, at December 31, 2024.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deferred Software Costs</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;We capitalize certain costs related to hosting arrangements that are service contracts (cloud computing arrangements). Capitalized costs are included in Other Current Assets and are amortized on a straight-line basis over the estimated useful life. For the year ended December 31, 2024, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of deferred software costs were capitalized related to cloud computing arrangements.</span></p></div><div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net Loss per Share&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Company follows the two-class method when computing net income (loss) per common share as the Company has issued shares that meet the definition of participating securities. The two-class method determines net income (loss) per common share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income (loss) available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed. The Company also considers the shares issued upon the early exercise of stock options that are subject to repurchase to be participating securities because holders of such shares have non-forfeitable dividend rights in the event a dividend is paid on common stock. There is no allocation required under the two-class method during periods of loss since the participating securities do not have a contractual obligation to share in the losses of the Company.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic net income (loss) per common share is computed by dividing the net income (loss) per common share by the weighted-average number of common shares outstanding for the period. Diluted net income (loss) per common share is computed by adjusting net income (loss) to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net loss per common share is computed by dividing the diluted net loss by the weighted-average number of common shares outstanding for the period, including potential dilutive common shares.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In periods in which the Company reported a net loss, diluted net loss per common share was the same as basic net loss per common share since dilutive common shares were not assumed to have been issued if their effect was anti-dilutive. During (i) the year ended December 31, 2023, potential common shares related to the conversion of the convertible SAFE Note, which converted into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">411,815</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> common shares in connection with the Company&#8217;s IPO on November 2, 2023 (see Note 6), and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,070,027</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> potential common shares related to the conversion of series A convertible preferred stock and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,489,573</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> potential common shares related to the conversion of series B convertible preferred stock, which converted into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,070,027</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> common shares and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,386,337</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> common shares, respectively, in connection with the Company&#8217;s IPO on November 7, 2023 (see Note 7), and (ii) the years ended December 31, 2024 and December 31, 2023, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,724,218</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,415,740</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> potential common shares, respectively, related to the exercise of outstanding stock options and settlement of outstanding Restricted Stock Units ("RSUs") (see Note 9), were excluded from the computation of diluted net loss per common share because including them would have had an anti-dilutive effect as the Company reported net losses for those periods.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deferred Offering Costs</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;The Company capitalizes certain legal, accounting and other third-party fees that are directly associated with equity financings as deferred offering costs until such financings are consummated. After consummation of the equity financing, these costs are recorded as a reduction of the proceeds from the offering, either as a reduction of the carrying value of preferred stock or in stockholders&#8217; equity (deficit) as a reduction of additional capital generated as a result of the offering. Should the equity financing be abandoned, the deferred offering costs would be expensed immediately as a charge to operating expenses in the statement of operations and comprehensive loss. The Company had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> deferred offering costs recorded as of December 31, 2024 or December 31, 2023.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and Development</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred to discover, research, and develop drug candidates, including personnel expenses, allocated facility-related and depreciation expenses, and third-party license fees. Costs incurred to obtain technology licenses are charged immediately to research and development expense if the technology licensed has not reached technological feasibility and has no alternative future use.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General and Administrative&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General and administrative expenses consist primarily of the cost of employees to engage in corporate functions, such as finance and accounting, information technology, human resources, and legal and executive management. General and administrative expenses also include rent occupancy costs, office expenses, depreciation and amortization, other general overhead costs, insurance premiums, professional service fees, and costs related to regulatory and litigation matters.</span></p></div><div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock Based Compensation Expense&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for stock-based payment awards granted to employees and non-employees, as well as shares issued to its employees under the Company's 2023 Employee Stock Purchase Plan (the "2023 ESPP"), as stock-based compensation expense at fair value. The Company issues stock-based awards to employees and non-employees in the form of stock options and also issues stock-based awards to employees in the form of restricted stock units (&#8220;RSUs&#8221;). The measurement date for employee stock option and RSU awards is the date of grant, and stock-based compensation costs are recognized as expense over the employees&#8217; requisite service period, which is the vesting period, on an accelerated basis. The measurement date for non-employee awards is the date of grant without changes in the fair value of the award. The measurement date for shares issued under the 2023 ESPP is the first date of each employee stock purchase plan offering period, and stock-based compensation costs are recognized as expense over the offering period on a straight-line basis. Stock-based compensation costs for non-employees are recognized as expense over the vesting period on an accelerated basis. Stock-based compensation expense is classified in the accompanying statement of operations based on the function to which the related services are provided. As the Company is permitted to repurchase shares legally issued for unvested stock options exercised at their exercise price under the 2021 Plan, (i) cash received for unvested stock options exercised under the 2021 Plan is recorded as a deposit liability as a reclassification from additional paid-in capital in the Company&#8217;s balance sheet, which is relieved to additional paid-in capital as such awards vest, (ii) stock based compensation expense is recognized over the requisite service period for each such award, and (iii) the amount and number of shares of common stock outstanding in the Company&#8217;s balance sheet and statement of convertible preferred stock and stockholders&#8217; equity (deficit) are reduced until such awards vest. Forfeitures are recorded as they occur.</span></p></div><div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value of each stock option grant and shares issued under the 2023 ESPP are estimated on the date of grant or on the first date of each employee stock purchase plan offering period, respectively, using the Black-Scholes option-pricing model, while the fair value of each RSU granted is equal to the closing price of the Company's common stock on the date of the grant. Prior to its IPO on November 3, 2023, the Company was a private company and lacked company-specific historical and implied volatility information for stock options granted. Therefore, the Company estimated its expected stock volatility entirely based on the historical volatility of a publicly traded set of peer companies for stock options granted prior to its IPO, and estimates its expected stock price volatility primarily based on the historical volatility of a publicly traded set of peer companies for stock options granted since its IPO, each for a period equal to the expected life of the stock options granted, and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. The expected term of the Company&#8217;s stock options granted has been determined utilizing the &#8220;simplified&#8221; method for awards that qualify as &#8220;plain-vanilla&#8221; options and expects to continue to do so until such time as it has adequate historical data regarding the expected term of its own stock options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The expected dividend yield is zero as the Company has never paid cash dividends on its common stock and does not expect to pay any cash dividends in the foreseeable future.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Prior to November 20, 2020, the Company was an LLC entity and elected to be treated under the Partnership provisions of the Internal Revenue Code. Accordingly, the LLC entity was not viewed as a tax-paying entity in any jurisdiction and all income and deductions of the LLC entity flowed through to the individual members and therefore no income taxes were recorded by the Company. On November 20, 2020, the Company converted to a C Corporation.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for income taxes under the asset and liability method pursuant to ASC Topic 740, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">("ASC 740"). Under this method, the Company recognizes deferred tax assets and liabilities for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recorded for deferred tax assets if it is more likely than not that some portion or all of the deferred tax assets will not be realized based on all available positive and negative evidence. Under the Tax Cuts and Jobs Act of 2017, the Company is required to capitalize, and subsequently amortize, research and development expenses over five years for research activities conducted in the U.S. and over fifteen years for research activities conducted outside of the U.S commencing in 2022. The capitalization of research and development expenses during the year resulted in a decrease to the Company's operating loss generation during the years ended December 31, 2024 and December 31, 2023 as compared to prior periods (see Note 11). As of December 31, 2024 and December 31, 2023, the Company continues to maintain a full valuation allowance against its deferred tax assets.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognizes a tax benefit only if it is more likely than not the tax position will be sustained on examination by the local taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such positions are then measured based on the largest benefit greater than 50% likelihood of being realized upon settlement with the related tax authority. The changes in recognition or measurement are reflected in the period in which the change in judgment occurs. As of December 31, 2024 and December 31, 2023, the Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t identified any uncertain tax positions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company records interest and penalties related to uncertain tax positions in the provision for income taxes.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fair Value Measurements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The three levels of inputs that may be used to measure fair value are as follows:</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Level 1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Level 2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Level 3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Inputs are unobservable inputs for the asset or liability.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Concentrations of Credit Risk</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, cash equivalents, restricted cash, and investments. The Company&#8217;s cash and restricted cash balances exceed Federal Deposit Insurance Corporation insurance limits. The Company&#8217;s cash equivalents consist of investments in a U.S. government money market fund, and the Company's investments primarily consist of U.S. Treasury securities. The Company&#8217;s cash, cash equivalents, restricted cash, and investments are held with large financial institutions that management believes to be of high credit quality. To date, the Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t recognized any losses caused by uninsured balances.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Segment Information</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;The Company manages its operations as a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_3797e8b8-b7a6-4ad2-8b98-c0c8d90f246c;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">single</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> segment for the purposes of assessing performance and allocating resources. The Company is focused on preclinical and clinical stage gene therapies, and specifically on hereditary and acquired diseases of high unmet need. The Company&#8217;s Chief Operating Decision Maker ("CODM") is its Chief Executive Officer ("CEO") and its senior leadership team. The CODM reviews the Company&#8217;s financial information on an aggregated basis for purposes of assessing performance and allocating resources. All assets are held in the United States. The Company has not earned any product revenue through December 31, 2024.</span></p></div><div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and Equipment</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization are recognized using the straight-line method over the estimated useful life of each asset. Such costs are periodically reviewed for recoverability when impairment indicators are present. Such indicators include, among other factors, unused capacity, market value declines, and obsolescence of technology. Recorded values of asset groups of equipment that are not expected to be recovered through undiscounted future net cash flows are written down to current fair value, which generally is determined from estimated discounted future net cash flows (assets held for use) or net realizable value (assets held for sale).</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Costs for capital assets not yet placed into service are capitalized as construction-in-progress and depreciated once placed into service. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation and amortization are removed from the accounts and any resulting gain or loss is included in loss from operations. Expenditures for repairs and maintenance that do not improve or extend the life of the respective assets are charged to expense in the period incurred. See Note 5 for information regarding the Company&#8217;s capitalized operating and finance lease right-of-use assets.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following is the summary of property and equipment and related accumulated depreciation as of December 31, 2024, and December 31, 2023 (years not stated in thousands):</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:58.884%;box-sizing:content-box;"></td>
          <td style="width:1.421%;box-sizing:content-box;"></td>
          <td style="width:13.085%;box-sizing:content-box;"></td>
          <td style="width:1.421%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:9.884%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.421%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:9.884%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Useful Life</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Internal use software</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3 </span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">years</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">296</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Furniture and fixtures</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5 </span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">years</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">386</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">380</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lab equipment</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7 </span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">years</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">844</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">514</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7 </span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">years</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">272</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">247</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total property and equipment</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,502</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,437</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: accumulated depreciation and amortization</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">474</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">381</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total property and equipment, net</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,028</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,056</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div></div><div></div><div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;In accordance with ASC Topic 842, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">("ASC 842"), the Company determines if an arrangement is or contains a lease at inception. A contract is or contains a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. The Company classifies leases at the lease commencement date as operating or finance leases and records a right-of-use asset and a lease liability on the balance sheet for all leases with an initial lease term of greater than 12 months. Leases with an initial term of 12 months or less are not recorded in the balance sheet, but payments are recognized as expense on a straight-line basis over the lease term. The Company has elected not to recognize leases with terms of 12 months or less.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A lease qualifies as a finance lease if any of the following criteria are met at the inception of the lease: (i) there is a transfer of ownership of the leased asset to the Company by the end of the lease term, (ii) the Company holds an option to purchase the leased asset that it is reasonably certain to exercise, (iii) the lease term is for a major part of the remaining economic life of the leased asset, (iv) the present value of the sum of lease payments equals or exceeds substantially all of the fair value of the leased asset, or (v) the nature of the leased asset is specialized to the point that it is expected to provide the lessor no alternative use at the end of the lease term. All other leases are recorded as operating leases.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company enters into contracts that contain both lease and non-lease components. Non-lease components may include maintenance, utilities, and other operating costs. The Company combines the lease and non-lease components of fixed costs in its lease arrangements as a single lease component. Variable costs, such as utilities or maintenance costs, are not included in the measurement of right-of-use assets and lease liabilities but rather are expensed when the event determining the amount of variable consideration to be paid occurs.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating lease right-of-use assets and lease liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term using the discount rate implicit in the lease. If the implicit rate is not readily determinable, the Company utilizes an estimate of its incremental borrowing rate based upon the available information at the operating lease commencement date. Operating lease right-of-use assets are further adjusted for prepaid or accrued lease payments. Operating lease payments are expensed using the straight-line method as an operating expense over the lease term. The Company&#8217;s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Finance lease right-of-use assets and lease liabilities are recognized upon receipt of the assets based on their fair values and are amortized to depreciation expense using the straight-line method over the estimated useful lives of the related assets. Finance lease liability payments are bifurcated into (i) a portion that is recorded as interest expense and (ii) a portion that reduces the finance liability associated with the lease, according to the interest rates implicit in the leases.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain of the Company&#8217;s leases include options to extend or terminate the lease. The amounts determined for the Company&#8217;s right-of-use assets and lease liabilities generally do not assume that renewal options or early-termination provisions, if any, are exercised, unless it is reasonably certain that the Company will exercise such options.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recent Accounting Pronouncements Adopted</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;In November 2023, the FASB issued ASU No. 2023-07, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Segment Reporting - Improving Reportable Segment Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (Topic 280) ("ASU 2023-07"). </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_73289f60-fe2f-4884-94cc-6b3d31ad5380;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ASU 2023-07</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> requires disclosures to include significant segment expenses that are regularly provided to the CODM, a description of other segment items by reportable segment, and any additional measures of a segment's profit or loss used by the CODM when deciding how to allocate resources. ASU 2023-07 also requires all annual disclosures currently required by Topic 280 to be included in interim periods. This update is effective for fiscal years beginning after December 15, 2023, and is to be applied retrospectively to all periods presented in the financial statements. The Company's </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adoption</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of ASU 2023-07 resulted in a new footnote disclosure for segment reporting.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recent Accounting Pronouncements Not Yet Adopted&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, the FASB issued ASU No. 2023-09, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (Topic 740) ("ASU No. 2023-09"). ASU No. 2023-09 requires disaggregation of the effective tax rate reconciliation into standard categories, enhances disclosure of income taxes paid, and modifies other income tax-related disclosures. ASU No. 2023-09 became effective for the Company on January 1, 2025. The adoption of this guidance will not have a material impact on the Company's financial statements.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the FASB issued ASU No. 2024-03, I</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ncome Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (Subtopic 220-40) ("ASU No. 2024-03"). ASU No. 2024-03 requires disclosure, in the notes to financial statements, of specified information about certain costs and expenses. ASU No. 2024-03 will be effective for the Company starting in annual periods in 2027, with early adoption permitted. The Company is currently assessing the impact of adopting this guidance on its financial statements.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3. Fair Value Measurements</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s cash equivalents consist of investments in a U.S. government money market fund stated at carrying value, which approximates fair value and is based on quoted prices in active markets for identical securities. Cash is stated at carrying value, which approximates fair value due to its short-term nature. The Company classifies its investments, primarily in U.S. Treasury securities as Level 2 assets as these assets are not traded in an active market and have been valued through a third-party pricing service based on quoted prices for similar assets. The carrying values of the Company&#8217;s prepaid expenses, other current assets, accounts payable and accrued expenses approximate their fair values due to their short-term nature.</span></p><div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents information about the Company&#8217;s financial assets, financial liabilities, and investments measured at fair value on a recurring basis and indicates the level of the fair value hierarchy utilized to determine such fair values:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:32.32%;box-sizing:content-box;"></td>
        <td style="width:1.78%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.14%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.78%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.14%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.78%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.14%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.78%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.14%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31, 2024:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Assets:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents (money market)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,636</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,636</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">86,504</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">86,504</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Investments:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,012</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,012</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,636</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">93,516</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">111,152</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div style="font-size:10pt;font-family:Times New Roman;">
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:32.32%;box-sizing:content-box;"></td>
        <td style="width:1.78%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.14%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.78%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.14%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.78%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.14%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.78%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.14%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31, 2023:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Assets:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents (money market)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">102,484</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">102,484</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Investments:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">102,484</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">102,484</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investments, which are classified as available-for-sale securities, consisted of the following as of December 31, 2024 and December 31, 2023:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:23.745%;box-sizing:content-box;"></td>
        <td style="width:1.3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.763%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.763%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.763%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.763%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31, 2024:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized Cost Basis</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross Unrealized Gains</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross Unrealized Losses</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Available-for-sale securities:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">93,619</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">103</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">93,516</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">93,619</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">103</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">93,516</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31, 2023:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized Cost Basis</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross Unrealized Gains</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross Unrealized Losses</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Available-for-sale securities:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All investments classified as available-for-sale securities held as of December 31, 2024 and December 31, 2023 had contractual maturities of less than two years. There have been no material realized gains or losses on investments classified as available-for-sale securities for the periods presented.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Aggregate fair values of investments classified as available-for-sale securities with unrealized losses and gains were as follows as of December 31, 2024 and December 31, 2023:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:38.36%;box-sizing:content-box;"></td>
        <td style="width:2.12%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:26.7%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:2.12%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:26.7%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Available-for-sale securities:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Due within one year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">86,504</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Due after one year through five years</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,012</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">93,516</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth a roll forward of changes in the fair value of financial liabilities, gross of unamortized discount, classified as Level 3 in the fair value hierarchy:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:77.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:53.567%;box-sizing:content-box;"></td>
        <td style="width:4.73%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:39.705%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Convertible<br/>SAFE Note,<br/>gross</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Beginning balance at December 31, 2022</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Convertible SAFE Note issuance at August 24, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,000</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_995b2506-e09a-426b-8450-5340620be7de;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in estimated fair value since issuance</span></span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">530</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Conversion of SAFE Note into common stock in connection with initial public offering</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,530</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ending balance at December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The valuation models used to estimate the fair value of the Company&#8217;s convertible SAFE Note considered the estimated probabilities of each of qualified equity financing, public offering, and change of control events, together with corresponding estimated periods of time from each valuation date until the achievements of each such event. Future values were converted to present value using a discount rate appropriate for probability-adjusted cash flows. </span><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The ranges of the significant unobservable inputs used in the valuation model to estimate the fair value of the Company&#8217;s convertible SAFE Note that was categorized within Level 3 of the fair value hierarchy as of August 24, 2023 (issuance) until November 2, 2023 (settlement) were as follows (not stated in thousands):</span></span></p><div style="font-size:10pt;font-family:Times New Roman;">
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:77.86%;box-sizing:content-box;"></td>
        <td style="width:1.92%;box-sizing:content-box;"></td>
        <td style="width:20.22%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Probability of meeting qualified equity financing event</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.0</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20.0</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Probability of meeting public offering event</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75.0</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85.0</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Probability of meeting change in control event</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Time until qualified equity financing event (in years)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.17</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.27</span></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Time until public offering event (in years)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.08</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.19</span></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Time until change in control event (in years)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.50</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.60</span></span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the closing of the Company&#8217;s IPO on November 7, 2023, the underwriters of the IPO were granted an option for a period of 30 days to purchase up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,363,636</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> additional shares from the Company at the public offering price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.00</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share less the underwriting discount, of which </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,048,746</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares were exercised (see Note 8). </span><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The total grant date fair value of this option of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, or $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.85</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, was recorded as an offset to additional paid-in capital and was estimated using a Black-Scholes model incorporating the following assumptions (not stated in thousands):</span></span></p><div style="font-size:10pt;font-family:Times New Roman;">
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:77.86%;box-sizing:content-box;"></td>
        <td style="width:1.92%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:18.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock price</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.00</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercise price</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.00</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average risk-free interest rate</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.53</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.08</span></span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">65.88</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.00</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>Accrued Liabilities and Other Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4. Accrued Expenses and Other Current Liabilities</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued expenses and other current liabilities consisted of the following</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:88.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:72.793%;box-sizing:content-box;"></td>
        <td style="width:1.274%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.693000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.274%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.965%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued research and development expenses</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,696</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,384</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued bonus expenses</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,718</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,810</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued general and administrative expenses and other professional fees</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,406</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,092</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other current liabilities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">939</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">554</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total accrued expenses and other current liabilities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,759</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,840</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_LesseeOperatingAndFinancingLeasesDisclosureTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5. Leases</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Operating Lease Right-of-Use Asset</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">January 2022</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company entered into a lease agreement for an office facility and laboratory space in New York, New York that commenced in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">April 2022</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and ends in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">July 2029</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> with an </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">additional </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">five-year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">option to extend the lease beyond July 2029 </span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">at the then-prevailing effective market rental rate</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Upon commencement of this lease, the Company recorded operating lease right-of-use assets and operating lease liabilities of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million based on the present value of payments over the lease term using an estimated incremental borrowing rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.53</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% in accordance with the provisions of ASC 842. In connection with the Company&#8217;s lease of office space and laboratory space, the Company provided a security deposit to the landlord in the form of a letter of credit totaling $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The cash collateralizing the letter of credit was included in long-term restricted cash in the Company&#8217;s balance sheets as of December 31, 2024, and December 31, 2023. This lease was classified as an operating lease in accordance with the provisions of ASC 842. The Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t recognize any right-of-use assets and lease liabilities associated with the potential option to renew or extend. The Company&#8217;s operating lease agreement does not contain any significant residual value guarantees or restrictive covenants.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The remaining lease terms and payment terms as of December 31, 2024 and December 31, 2023 were </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4.6</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years and </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.6</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years, respectively. </span><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The components of this operating lease were as follows:</span></span></p><div style="font-size:11pt;font-family:Times New Roman;">
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.64%;box-sizing:content-box;"></td>
        <td style="width:2.08%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:17.099999999999998%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:2.08%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:17.099999999999998%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease expense</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,147</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,147</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Variable lease expense</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">459</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">355</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating lease expense</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,606</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,502</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash paid for amounts included in the measurement of lease liabilities, included in operating cash flows</span></p></td>
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,110</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,294</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><div style="font-size:11pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table provides a reconciliation of the Company&#8217;s remaining undiscounted contractual rent obligations due within each year ended December 31 to the operating lease liabilities recognized as of December 31, 2024:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:73.02%;box-sizing:content-box;"></td>
        <td style="width:2.7%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:22.279999999999998%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Year ended December 31</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Operating<br/>Leases</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,152</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,206</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,261</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,318</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,372</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Thereafter</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total lease payments</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,309</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: present value adjustment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,772</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating lease liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,537</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Included in the balance sheet:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current portion of lease liabilities - operating</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,100</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-current portion of lease liabilities - operating</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,437</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating lease liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,537</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Equipment Finance Leases</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commencing in April 2022, the Company leases certain laboratory equipment under financing arrangements accounted for as finance leases in accordance with the provisions of ASC 842 that are classified in the Company&#8217;s balance sheet as finance lease liabilities with related right-of-use assets recorded and depreciated on a straight-line basis over the estimated useful life of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years. In connection with the Company&#8217;s leases of laboratory equipment, the Company provided a security deposit to the lessor in the form of a letter of credit totaling $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and assigned all rights and interests in the equipment to the lessor. The cash collateralizing the letter of credit is included in long-term restricted cash in the Company&#8217;s balance sheet as of December 31, 2024. The total gross, accumulated amortization, and net book values of equipment finance lease right-of-use assets capitalized under such finance lease arrangements at December 31, 2024 were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively. Under the terms of the equipment finance lease agreements executed through the issuance of these financial statements, the principal balances plus interest for the equipment are to be repaid in full after </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">60</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> monthly installments following lease commencement, with lease commencement dates ranging from </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">April 1, 2022</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">April 1, 2023</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, annual imputed interest rates ranging from </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.90</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.30</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%, and monthly installment payment amounts ranging from $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The total aggregate monthly installment payment amount is $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for the Company's equipment finance lease agreements.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The weighted-average remaining lease payment term, weighted-average remaining amortization term, and weighted-average effective interest rate for the Company's equipment finance lease agreements as of December 30, 2024 were </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.7</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years, </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4.8</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years, and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.59</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%, respectively. The weighted-average remaining lease payment term, weighted-average remaining amortization term, and weighted-average effective interest rate for the Company's equipment finance lease agreements as of December 31, 2023 were </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.7</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years, </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.7</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years, and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.59</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%, respectively. </span><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The components of the equipment finance leases were as follows:</span></span></p><div style="font-size:11pt;font-family:Times New Roman;">
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:62.34%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.860000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.94%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.860000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Reduction in the carrying amount of ROU assets, finance</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">325</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">306</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest on finance lease liabilities</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">127</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">176</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total finance lease expense</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">452</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">482</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash paid for amounts included in the measurement of lease liabilities, included in financing cash flows</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">410</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">425</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><div style="font-size:11pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table provides a reconciliation of the Company&#8217;s remaining equipment finance lease obligations due within each year ending December 31 to the equipment finance lease liabilities recognized at December 31, 2024:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:77.7%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:20.299999999999997%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Year ended December 31</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Equipment Finance Leases</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">587</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">587</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">359</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Thereafter</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total lease payments</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,544</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: imputed interest</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">157</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total finance lease liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,387</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Included in the balance sheet:</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current portion of lease liabilities - finance</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">570</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-current portion of lease liabilities - finance</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">817</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total finance lease liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,387</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_LesseeOperatingAndFinancingLeasesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee Operating And Financing Leases Disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_LesseeOperatingAndFinancingLeasesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Safe Note<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Convertible Safe Note</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6. Convertible SAFE Note</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On August 24, 2023, the Company entered into the convertible SAFE Note with Sarepta Therapeutics, Inc. (the "Investor") in a principal amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million bearing simple interest at an annual rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% to be repaid after one year (the "Cash Out Amount") in the absence of the occurrence of certain settlement events, including upon a qualified preferred stock equity financing, a public offering or a Special Purpose Acquisition Company ("SPAC" transaction, a change of control, or dissolution. The convertible SAFE Note was accounted for as a liability in accordance with the provisions of ASC Topic 480, Distinguishing Liabilities from Equity, which was initially and subsequently measured at fair value with changes in fair value recognized in earnings (see Note 3). </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upon a qualified equity financing event, the convertible SAFE Note would have automatically converted into a number of shares of corresponding preferred stock based on a certain discount to the price of such preferred stock issued to the other investors applied to the then-current Cash-Out Amount. Upon the effective date of an IPO or a direct listing, or immediately prior to the closing of a SPAC transaction, the convertible SAFE Note would have automatically converted, and did automatically convert upon the effectiveness of the Company's IPO registration statement on November 2, 2023, into a number of shares of common stock based on a certain discount to the public offering price of such common stock applied to the then-current Cash-Out Amount (see Note 8). Upon a change of control, the Investor would have been entitled to receive the greater of (i) an amount equal to a certain premium applied to the then-current Cash-Out Amount, or (ii) the amount that would have been payable on the number of shares of the senior-most series of the Company&#8217;s preferred stock after applying a certain discount to the original issue price of such senior-most preferred stock together with a certain premium applied to the then-current Cash-Out Amount (the greater of (i) and (ii), the &#8220;Conversion Amount&#8221;). Upon the one-year maturity of the convertible SAFE Note, or upon dissolution of the Company, the Investor was to be paid an amount equal to the Cash-Out Amount. Upon the event of a change of control or dissolution, the Investor&#8217;s right to receive its Cash-Out Amount or its Conversion Amount would have been junior to payment of outstanding indebtedness and creditor claims, on par with payments for the Company&#8217;s most senior series of preferred stock or other SAFE note holders, if any, and senior to payments for the Company&#8217;s common stock and any other series or class of stock. The convertible SAFE Note did not maintain any voting rights. </span></span><span style="font-size:10pt;font-family:Times New Roman;"></span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the convertible SAFE Note, the Company incurred issuance costs of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million that were recorded as a discount to the liability balance and amortized to interest expense over the term of the convertible SAFE Note. As of November 2, 2023, the estimated fair value of the convertible SAFE Note, gross of unamortized discount, increased by $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million (see Note 3), and the corresponding carrying value was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, net of unamortized discount, which automatically converted into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">411,815</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company&#8217;s common stock upon the declaration of effectiveness of the Company's IPO registration statement on November 2, 2023 (see Note 8).</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityDisclosureAbstract', window );"><strong>Temporary Equity Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockTextBlock', window );">Convertible Preferred Stock</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7. Convertible Preferred Stock</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2022 and until the closing of the Company's IPO on November 7, 2023, the Company&#8217;s certificate of incorporation authorized the Company to issue </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">143,653,546</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of series A and series B convertible preferred stock each with a par value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. Upon the closing of the Company's IPO on November 7, 2023, all </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85,495,722</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> outstanding shares of the Company&#8217;s series A convertible preferred stock and all </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">58,157,823</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> outstanding shares of the Company&#8217;s series B convertible preferred stock converted into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,070,027</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,386,337</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock, respectively, including </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">896,764</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock issued as a result of series B convertible preferred stock antidilution provisions (see Note 8).</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2022 and until the closing of the Company's IPO on November 7, 2023, convertible preferred stock consisted of the following:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:26.9%;box-sizing:content-box;"></td>
        <td style="width:1.1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.6%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.6%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.56%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.440000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.56%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.440000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.6%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Convertible</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Convertible</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Preferred</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Preferred</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Stock</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Common Stock</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Stock</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Issued and</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Proceeds</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Liquidation</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Issuable Upon</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Authorized</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Outstanding</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Received</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Preference</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Conversion</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Series A convertible preferred stock</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85,495,722</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85,495,722</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85,496</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85,496</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,070,027</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Series B convertible preferred stock</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">58,157,824</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">58,157,823</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100,060</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100,060</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,489,573</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">143,653,546</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">143,653,545</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">185,556</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">185,556</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,559,600</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2022 and until the closing of the Company's IPO on November 7, 2023, the rights and privileges of the holders of the convertible preferred stock were as follows:</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Voting</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Holders of preferred stock were to vote together with the holders of common stock as a single class and on an as converted to common stock basis.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Dividends</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;The holders of shares of series B convertible preferred stock were entitled to receive, as declared by the Company&#8217;s Board of Directors, dividends per share at the rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the issue price per share of series B convertible preferred stock, prior and in preference to any declaration or payment of any other dividend (other than dividends on shares of common stock payable in shares of common stock). After payment of dividends to the holders of shares of series B convertible preferred stock, the holders of shares of series A convertible preferred stock were entitled to receive, as declared by the Company&#8217;s Board of Directors, dividends per share at the rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the issue price per share of series A convertible preferred stock, prior and in preference to any declaration or payment of any other dividend (other than dividends on shares of common stock payable in shares of common stock).</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Deemed Liquidation Event</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Each of the following events was to be considered a &#8220;Deemed Liquidation Event&#8221; unless the holders of a majority of the outstanding shares of preferred stock and the holders of at least </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">64</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the outstanding shares of series B convertible preferred stock elected otherwise by written notice to be sent to the Company at least five business days prior to the effective date of any such event; (a) a merger or consolidation in which the Company is a constituent party or a subsidiary of the Company was a constituent party and the Company issued shares of its capital stock pursuant to such merger or consolidation, except: any such merger or consolidation involving the Company or a subsidiary in which the shares of capital stock of the Company outstanding immediately prior to such merger or consolidation continued to represent, or were converted into or exchanged for shares of capital stock that represented, immediately following such merger or consolidation, at least a majority by voting power of the capital stock of (1) the surviving or resulting company; or (2) if the surviving or resulting company was a wholly owned subsidiary of another company immediately following such merger or consolidation, the parent company of such surviving or resulting corporation; (b) (1) the sale, lease, transfer, exclusive license or other disposition, in a single transaction or series of related transactions, by the Company or any subsidiary of the Company of all or substantially all the assets of the Company and its subsidiaries taken as a whole, or (2) the sale or disposition (whether by merger, consolidation or otherwise, and whether in a single transaction or a series of related transactions) of one or more subsidiaries of the Company if substantially all of the assets of the Company and its subsidiaries taken as a whole were held by such subsidiary or subsidiaries, except where such sale, lease, transfer, exclusive license or other disposition was to a wholly owned subsidiary of the Company; or (c) the Corporation&#8217;s completion of (1) a reverse merger into a public shell, or (2) a merger or consolidation with a special purpose acquisition company or its subsidiary in which the common stock (or similar securities) of the surviving or parent entity were publicly traded in a public offering pursuant to an effective registration statement under the 1933 Securities Act, as amended.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Liquidation Preference</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;In the event of any voluntary or involuntary liquidation, dissolution, or winding up of the Company, the holders of shares of series B convertible preferred stock were entitled to be paid out of the assets of the Company or, in the case of a Deemed Liquidation Event, out of the consideration payable to stockholders or the available proceeds, before any payment would be made to the holders of common stock or series A convertible preferred stock, an amount per share equal to the series B convertible preferred stock issue price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18.227267</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share (subject to adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization), plus any dividends declared but unpaid. If upon any such liquidation, dissolution or winding up of the Company or Deemed Liquidation Event, the assets of the Company available for distribution to its stockholders was insufficient to pay the holders of shares of series B convertible preferred stock the full amount to which they were entitled, the holders of shares of series B convertible preferred stock would have shared ratably in any distribution of the assets available for distribution in proportion to the respective amounts which would otherwise be payable in respect of the shares held by them upon such distribution if all amounts payable on or with respect to such shares were paid in full (the &#8220;Series B Liquidation Preference&#8221;).</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the event of any voluntary or involuntary liquidation, dissolution, or winding up of the Company, after payment of the Series B Liquidation Preference, the holders of shares of series A convertible preferred stock were entitled to be paid out of the assets of the Company or, in the case of a Deemed Liquidation Event, out of the consideration payable to stockholders or the available proceeds, before any payment shall be made to the holders of common stock or series A convertible preferred stock, an amount per share equal to the series A convertible preferred stock issue price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.594230</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share (subject to adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization), plus any dividends declared but unpaid. If upon any such liquidation, dissolution or winding up of the Company or Deemed Liquidation Event, the assets of the Company available for distribution to its stockholders was insufficient to pay the holders of shares of series A convertible preferred stock the full amount to which they were entitled, the holders of shares of series A convertible preferred stock would have shared ratably in any distribution of the assets available for distribution in proportion to the respective amounts which would otherwise be payable in respect of the shares held by them upon such distribution if all amounts payable on or with respect to such shares were paid in full (the &#8220;Series A Liquidation Preference&#8221;).</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the event that there were additional assets to be distributed after payment of the Series A Liquidation Preference and the Series B Liquidation Preference, the holders of the series A convertible preferred stock and series B convertible preferred stock would have shared in the distribution along with common stockholders as if the shares of the series A convertible preferred stock and series B convertible preferred stock had converted to common stock immediately prior to the distribution, up to an amount, (a) taken together with the Series A Liquidation Preference, not to exceed $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31.782691</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share with respect to the series A convertible preferred stockholders; and (b) taken together with the Series B Liquidation Preference, not to exceed $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">54.681802</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share with respect to the series B convertible preferred stockholders.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Redemption</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;The preferred stock did not contain a mandatory redemption provision. Upon a deemed liquidation event, the holders would have been paid their preference amounts according to their priority. Remeasurement to redemption value would only have been required if a deemed liquidation event was probable.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Conversion</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Upon either (a) the closing of the sale of shares of common stock to the public at a price of at least $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22.784057</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the common stock), in a firm-commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended, resulting in at least $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of gross proceeds to the Company and in connection with the offering of the common stock listed for trading on the Nasdaq Stock Market&#8217;s National Market, the New York Stock Exchange or another exchange or marketplace approved by the Company&#8217;s Board of Directors, including the approval of at least </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">two</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (2) preferred directors (a &#8220;Qualified IPO&#8221;), which occurred on November 7, 2023, or (b) the date and time, or the occurrence of an event specified by vote or written consent of the Noteholders, then (i) all outstanding shares of convertible preferred stock were to automatically be converted into shares of common stock, at the then effective conversion rate.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Capital Stock</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8. Capital Stock</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024 and December 31, 2023, the Company&#8217;s amended and restated certificate of incorporation provided that the authorized capital stock of the Company was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">510,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares consisting of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">500,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of undesignated preferred stock, both with a par value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. As of December 31, 2024 and December 31, 2023, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,079,209</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,668,485</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares, respectively, of the Company's common stock authorized were issued, including </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,948</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,107</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares, respectively, that were legally issued upon the early exercise of unvested stock options and that are excluded from the number of shares outstanding until the right to repurchase subsequently lapses upon vesting. Until the closing of the Company&#8217;s IPO on November 7, 2023, the voting, dividend and liquidation rights of the holders of the Company&#8217;s common shares were subject to and qualified by the rights, powers and preferences of the holders of the convertible preferred stock set forth in Note 7. The Company repurchased a total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,827</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock issued pursuant to the early exercise of stock options granted under the 2021 Plan for a total of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> during the year ended December 31, 2024, which was recorded to treasury stock in the Company's balance sheet (see Note 9). Each common share entitles the holder to one vote on all matters submitted to a vote of the Company&#8217;s stockholders. Common stockholders are entitled to receive dividends, if any, as may be declared by the Company&#8217;s Board of Directors and were subject to the preferential dividend rights of the convertible preferred stock until the closing of the Company's IPO. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> cash dividends have been declared or paid by the Company.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upon the declaration of effectiveness of the Company&#8217;s IPO registration statement on November 2, 2023, the Company's then outstanding convertible SAFE Note automatically converted into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">411,815</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock (see Note 6). Upon the closing of the Company's IPO on November 7, 2023, the Company issued and sold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,090,910</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of its common stock, and subsequently, the underwriters partially exercised their associated 30-day option to purchase additional shares of common stock with </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,048,746</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> additional shares issued. The net proceeds to the Company from the IPO and subsequent partial exercise of the underwriters&#8217; 30-day option to purchase additional shares were approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million based on the initial offering price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.00</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, after deducting underwriting discounts, commissions and offering expenses totaling $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. Also upon the closing of the Company's IPO on November 7, 2023, all </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85,495,722</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> then outstanding shares of the Company&#8217;s series A convertible preferred stock and all </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">58,157,823</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> then outstanding shares of the Company&#8217;s series B convertible preferred stock converted into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,070,027</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,386,337</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock, respectively, including </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">896,764</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock issued as a result of series B convertible preferred stock antidilution provisions. On March 11, 2024, the Company entered into a common stock purchase agreement to issue and sell an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,278,905</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of its common stock at a price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.13</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, in a private placement that closed on March 13, 2024 (the "Private Placement"). The gross and net proceeds received from the Private Placement were approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">95.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">88.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, after deducting approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of commissions and other offering costs.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company had reserved the following number of shares of common stock for the exercise of outstanding stock options, settlement of outstanding RSUs, and future issuance of stock-based awards:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:86.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:62.12%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.92%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.96%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options to purchase shares of common stock under the 2021 Plan and 2023 Plan</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,457,918</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,415,740</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">RSUs subject to settlement in shares of common stock under the 2023 Plan</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">266,300</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares available for issuance under the 2023 Plan</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,185,328</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,293,816</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares available for issuance under the 2023 ESPP</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">505,284</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">238,600</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total shares of common stock reserved for future issuance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,414,830</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,948,156</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9. Stock-based Compensation</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In February 2021, the Company adopted the 2021 Plan for the issuance of stock options granted to the Company&#8217;s key directors, officers, employees and consultants, as a means to secure the benefits arising from capital stock ownership. In connection with the Company&#8217;s IPO in November 2023, the Company adopted the 2023 Equity Incentive Plan (the &#8220;2023 Plan&#8221;) and the 2023 ESPP (together with the 2021 Plan and 2023 Plan, the &#8220;Plans&#8221;) for the issuance of equity awards granted to the Company's key directors, officers, employees, and consultants, and for the issuance of shares purchased under the 2023 ESPP to the Company's employees, respectively, as a means to secure the benefits arising from capital stock ownership. The purposes of the Plans are to promote the alignment of the interests of key directors, officers, employees, and consultants with the success of the Company and to provide compensation opportunities to attract, retain and motivate directors, officers, employees, and consultants of the Company.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s Board of Directors adopted the 2023 Plan and the 2023 ESPP in October 2023, and the Company&#8217;s stockholders approved the 2023 Plan and the 2023 ESPP in October 2023. In connection with the IPO, the Company&#8217;s 2023 Equity Incentive Plan (the &#8220;2023 Plan&#8221;) and its 2023 Employee Stock Purchase Plan (the &#8220;2023 ESPP&#8221;) became effective. Upon the effectiveness of the 2023 Plan and the 2023 ESPP:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">582,699</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock reserved for future issuance under the 2021 Plan ceased to be available for issuance and were added to, and became available for issuance under, the 2023 Plan, and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> further grants will be made under the 2021 Plan; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,803,980</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock were reserved for future issuance under the 2023 Plan, in addition to the shares of common stock reserved for issuance under the 2021 Plan that were added to the shares reserved under the 2023 Plan; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">238,600</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock were reserved for future issuance under the 2023 ESPP.</span></div></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upon adoption, the maximum number of shares of common stock that may be issued under the 2023 Plan was initially </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,737,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares, which was approximately the sum of (i) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,803,980</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> new shares, plus (ii) the 2021 Plan&#8217;s available reserve, plus (iii) the number of returning shares, if any, upon the cancellation or forfeiture of equity awards that are outstanding under the 2021 Plan. In addition, the number of shares of common stock reserved for issuance under the 2023 Plan will automatically increase on January 1 of each year, beginning on January 1, 2024, and continuing through and including January 1, 2033, by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the total number of shares of common stock outstanding on December 31 of the immediately preceding calendar year, or a lesser number of shares determined by the Company&#8217;s Board of Directors prior to the applicable January 1. Upon adoption, the maximum number of shares of common stock that may be issued under the 2023 ESPP was initially </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">238,600</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares. The number of shares of common stock reserved for issuance under the 2023 ESPP will automatically increase on January 1 of each calendar year, beginning on January 1, 2024 and continuing through and including January 1, 2033, by the lesser of (i) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the total number of shares of capital stock outstanding on December 31 of the preceding calendar year, (ii) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">477,200</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares and (iii) a number of shares determined by the Company&#8217;s Board of Directors. Shares subject to purchase rights granted under the 2023 ESPP that terminate without having been exercised in full will not reduce the number of shares available for issuance under the 2023 ESPP.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On January 1, 2024, the number of shares of common stock reserved for issuance under the 2023 Plan and the 2023 ESPP automatically increased by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,333,424</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">266,684</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares, respectively, to totals of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,070,424</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">505,284</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares, respectively. On January 1, 2025, the number of shares of common stock reserved for issuance under the 2023 Plan and the 2023 ESPP automatically increased by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,653,960</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">330,792</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares, respectively, to totals of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,724,384</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">836,076</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares, respectively. As of December 31, 2024, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,185,328</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">505,284</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares were available for future issuance under the 2023 Plan and 2023 ESPP, respectively. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares have been issued under the 2023 ESPP through December 31, 2024.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock option activity</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock options granted under the 2021 Plan are issued from new shares upon exercise, have a contractual term of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10 years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from grant date, and generally (i) are subject to requisite service requirements, (ii) </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">vest over a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">four-year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> period with </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the options granted vesting after one year and the remainder vesting in equal monthly installments over the following 36 months</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and (iii) allow for early exercise subject to repurchase. Stock options granted under the 2021 Plan to certain of the Company&#8217;s non-employees vest in equal monthly installments over a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">four-year </span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">period or vested upon the achievement of a certain milestone event. The Company repurchased a total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,827</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock issued pursuant to the early exercise of stock options granted under the 2021 Plan for a total of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> during the year ended December 31, 2024, which was recorded to treasury stock in the Company's balance sheet (see Note 8).</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock options granted under the 2023 Plan through December 31, 2024 are issued from new shares upon exercise, have a contractual term of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10 years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from grant date, and generally (i) are subject to requisite service requirements, and (ii) </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">vest over a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">four-year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> period with </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the options granted vesting after one year and the remainder vesting in equal monthly installments over the following 36 months</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Stock options granted under the 2023 Plan to certain of the Company's non-employee directors vest in equal annual installments over a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three-year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> period or over a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">one-year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> period.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the stock option activity under the 2021 Plan and the 2023 Plan for the years ended December 31, 2024 and December 31, 2023 (weighted-average remaining contractual term (in years) is not stated in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:44.791%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.878%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.38%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.298%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.878%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.38%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.398%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>Average<br/>Exercise Price</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate<br/>Intrinsic</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(per share)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in years)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding as of December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,415,740</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.32</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.83</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,689</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,520,330</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.60</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">135,646</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.62</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,288</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">272,276</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.40</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expired</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">70,230</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.94</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding as of December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,457,918</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.37</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.18</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,851</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options exercisable at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,954,937</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.16</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.38</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,851</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The weighted average grant date fair value of options granted during the years ended December 31, 2024 and 2023 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.58</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.89</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, respectively.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#8217;s common stock for those stock options that had exercise prices lower than the fair value of the Company&#8217;s common stock. The total intrinsic value of stock options exercised during the year ended December 31, 2023 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The total grant date fair values of stock options vested during the years ended December 31, 2024 and December 31, 2023 were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company estimated the fair value of options granted using a Black-Scholes option pricing model with the following assumptions presented on a weighted average basis during the year ended December 31, 2024 (not stated in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:61.96%;box-sizing:content-box;"></td>
        <td style="width:1.44%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.58%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.44%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.58%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.14</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.43</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.02</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.78</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85.85</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">67.59</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.00</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.00</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The expected dividend yields are </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.00</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% as the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024 there was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of unrecognized stock-based compensation expense related to stock options estimated to be recognized over a weighted-average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.62</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">RSU activity</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RSUs granted under the 2023 Plan through December 31, 2024 generally (i) are subject to requisite service requirements, and (ii) </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">vest over a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">four-year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> period with </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the RSUs vesting after approximately one year and the remainder vesting in equal quarterly installments over the following 12 quarters</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the RSU activity under the 2023 Plan for the year ended December 31, 2024:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:61.96%;box-sizing:content-box;"></td>
        <td style="width:1.44%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.58%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.9%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.120000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>Average<br/>Grant Date Fair Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(per share)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested as of December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">287,078</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.52</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,778</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.65</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested as of December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">266,300</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.59</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024 there was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of unrecognized stock-based compensation expense related to RSUs estimated to be recognized over a weighted-average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.28 </span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">years.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Employee Stock Purchase Plan</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the 2023 ESPP, eligible employees may purchase shares of the Company's common stock through payroll deductions at a price equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the lower of the fair market values of the stock as of the beginning or the end of six-month offering periods. Employees may not purchase more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company's common stock during any offering period. As of and during the years ended December 31, 2024 and December 31, 2023, stock-based compensation expense and the fair value of unearned employee stock ownership plans related to the 2023 ESPP was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t material.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock-based compensation expense</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-based compensation expense was classified as follows in the Company&#8217;s statements of operations and comprehensive loss:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:62.072%;box-sizing:content-box;"></td>
        <td style="width:1.86%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.103%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.86%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.103%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development expense</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,001</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,751</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative expense</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,473</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,292</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total stock-based compensation expense</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,474</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,043</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10. Net Loss per Share</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic and diluted net loss per common share attributable to common stockholders was calculated as follows:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:63.247%;box-sizing:content-box;"></td>
        <td style="width:1.84%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:14.537%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.84%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:14.537%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Numerator:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss attributable to common stockholders</span></p></td>
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98,333</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">66,394</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Denominator:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average common shares outstanding, basic and diluted</span></p></td>
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31,787,491</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,354,368</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per share attributable to common stockholders, basic and diluted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.09</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.40</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11. Income Taxes</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A reconciliation of the Company's statutory income tax rate to the Company&#8217;s effective income tax rate is as follows for the years ended December 31, 2024, and December 31, 2023:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:91.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.357%;box-sizing:content-box;"></td>
        <td style="width:2.03%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:17.435000000000002%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:2.03%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:17.148%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Federal statutory rate</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.00</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.00</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State Taxes, net of federal benefit</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.72</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.80</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33.98</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36.12</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Permanent differences</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.51</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.36</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax credits</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.73</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.80</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.96</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.12</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Effective income tax rate</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.00</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.00</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The principal components of the Company's deferred tax assets and liabilities at December 31, 2024 and December 31, 2023 are as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.688%;box-sizing:content-box;"></td>
        <td style="width:2.063%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:17.259%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:2.063%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:16.926%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,295</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,904</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax credits</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,743</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,070</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Intangibles</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,918</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,241</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Capitalized R&amp;D expenses</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,338</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,127</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease liabilities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,818</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,244</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other deferred tax assets</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,292</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,753</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98,404</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">65,339</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">95,426</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">61,974</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,978</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,365</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.688%;box-sizing:content-box;"></td>
        <td style="width:2.063%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:17.259%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:2.063%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:16.926%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Right of use asset</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,663</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,102</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other deferred tax liabilities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">315</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">263</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,978</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,365</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net deferred tax assets (liabilities)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024 and 2023, the Company had federal net operating loss ("NOL") carryforwards of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">106.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">70.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, which can be carried forward indefinitely. As of December 31, 2024 and December 31, 2023, the Company had state and local net operating loss carryforwards of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">212.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">139.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, which begin to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2040</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024 and December 31, 2023, the Company had federal tax credits of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, which begin to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2040</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Future realization of the tax benefits of existing temporary differences and net operating loss carryforwards ultimately depends on the existence of sufficient taxable income within the carryforward period. As of December 31, 2024 and December 31, 2023, the Company performed an evaluation to determine whether a valuation allowance was needed. The Company considered all available evidence, both positive and negative, which included the results of operations for the current and preceding years. The Company determined that it was not possible to reasonably quantify future taxable income and determined that it is more likely than not that all of the deferred tax assets will not be realized. Accordingly, the Company maintained a full valuation allowance as of December 31, 2024 and December 31, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The utilization of NOLs and tax credit carryforwards to offset future taxable income may be subject to an annual limitation as a result of ownership changes that have occurred previously or may occur in the future. Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, (the &#8220;IRC&#8221;), a corporation that undergoes an ownership change may be subject to limitations on its ability to utilize its pre-change NOLs and other tax attributes otherwise available to offset future taxable income and/or tax liability. An ownership change is defined as a cumulative change of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% or more in the ownership positions of certain stockholders during a rolling three-year period.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company conducted an ownership analysis under IRC Section 382 as of September 30, 2024 and determined the Company experienced an ownership change associated with the closing of the Company's IPO on November 7, 2023 that limits the Company&#8217;s NOLs and tax credits. As a result of the ownership change, the Company is limited to a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,689,195</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> annual limitation on its ability to utilize its NOLs and tax credits recognized prior to the ownership change. Due to this limitation, no federal NOLs are expected to expire unutilized and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of federal tax credits that had been available to offset future tax liabilities, prior to the date of the ownership change, will expire unutilized. As a result, during the year ended December 31, 2024, the Company reduced its deferred tax assets related to the federal tax credits, which was offset by a corresponding decrease in the valuation allowance.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The calculation of the Company's tax liabilities involves dealing with uncertainties in the application of complex tax laws and regulations for both federal taxes and the many states in which it operates or does business in. ASC 740 states that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, on the basis of the technical merits.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company records uncertain tax positions as liabilities in accordance with ASC 740 and adjusts these liabilities when its judgment changes as a result of the evaluation of new information not previously available. Because of the complexity of some of these uncertainties, the ultimate resolution may result in a payment that is materially different from the Company's current estimate of the unrecognized tax benefit liabilities. These differences will be reflected as increases or decreases to income tax expense in the period in which new information is available. As of December 31, 2024 and December 31, 2023, the Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t recorded any uncertain tax positions in its financial statements.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognizes interest and penalties related to uncertain tax positions on the income tax expense line in the accompanying statements of operations. As of December 31, 2024 and December 31, 2023, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> accrued interest or penalties are included on the related tax liability line in the balance sheet.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company files tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. The resolution of tax matters is not expected to have a material effect on the Company's financial statements.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12. Commitments and Contingencies</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;As of December 31, 2024, the Company had entered into commitments under lease agreements to rent laboratory and office space and finance equipment (see Note 5).</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commitments</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;As of December 31, 2024, the Company had entered into commitments under license, acquisition, research collaboration and sponsored research agreements with third parties (see Note 13). In addition, the Company has entered into services agreements with third parties for pharmaceutical manufacturing and research activities in the normal course of business, which can generally be terminated by the Company with </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">30</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">- to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">60</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-days&#8217; written notice, unless otherwise indicated. Further, certain of the Company&#8217;s manufacturing agreements could require early termination and wind-down payments due from the Company upon either the termination of its clinical trials or if the Company terminates such agreements for convenience.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Contingencies</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of business. The Company recognizes any associated legal fees as incurred and accrues a liability for such contingent liability matters when it is probable that future expenditures will be made, and such expenditures can be reasonably estimated. For all periods presented, the Company was not a party to any pending material litigation or other material legal proceedings, except that on October 12, 2023, Rocket Pharmaceuticals, Inc. (&#8220;Rocket&#8221;) filed a lawsuit in the U.S. District Court for the Southern District of New York against the Company and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">two</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> former employees claiming, among other things, misappropriation of confidential information and trade secrets. The complaint alleges the individual defendants downloaded confidential Rocket company documents and other proprietary materials prior to leaving Rocket in 2021 and that the Company used this information to advance its programs after they became employed at Lexeo. The complaint seeks unspecified damages and asks the court to enjoin the Company from competing and working in the market for gene therapy treatments targeting cardiac diseases. In August 2024, the Company asserted counterclaims against Rocket and Spacecraft Seven LLC, a wholly owned subsidiary of Rocket, for misappropriation of trade secrets, correction of inventorship of certain patents, breach of contract, and tortious interference with contract. </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our counterclaims seek equitable relief, damages, attorneys' fees and costs from Rocket and Spacecraft Seven LLC. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The case is currently in the discovery phase. While it is not possible to predict the outcome with certainty and an estimate of the possible loss cannot be made, the Company currently does not expect the final outcome will have a material adverse effect on its timelines for development of its product candidates.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indemnification Agreements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its Board of Directors and executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. For all periods presented, the Company has not incurred any material costs as a result of such indemnifications.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License, Acquisition, Research Collaboration and Sponsored Research Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_LicenseAndAcquisitionAndResearchCollaborationAndSponsoredResearchAgreementsDisclosureTextBlock', window );">License, Acquisition, Research Collaboration and Sponsored Research Agreements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13. License, Acquisition, Research and Collaboration and Sponsored Research Agreements</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adverum Biotechnologies</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;On January 25, 2021, the Company entered into an exclusive license agreement with Adverum Biotechnologies Inc. (&#8220;Adverum&#8221;) to in-license materials and technology related to the treatment of cardiomyopathy due to Friedreich ataxia ("FA") (the &#8220;Adverum Agreement&#8221;). In connection with the Adverum Agreement, the Company gained access to a portfolio of inventions, patent rights, technology, and licensed methods that the Company continues to develop, and the Company will assume all development and commercialization activities worldwide. Pursuant to the Adverum Agreement, the Company paid a one-time up-front non-refundable fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, and is obligated to pay aggregate development and regulatory milestones of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million including a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million development milestone that was achieved and paid in the first quarter of 2023, and aggregate sales event and commercialization milestones of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is obligated to pay Adverum tiered royalties ranging from high single-digits to sub teens based on annual aggregate worldwide net sales of Products (as defined in the Adverum Agreement).</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> As of December 31, 2024, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> research and development expenses recorded by the Company or payments made to Adverum under the terms of the Adverum Agreement other than the one-time up-front non-refundable fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million development milestone that was achieved and paid in the first quarter of 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Adverum Agreement remains in effect until termination at the date of the last royalty term to expire. The Company can terminate the Adverum Agreement with </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">120</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> days&#8217; written notice. The Adverum Agreement can also be terminated as a result of a patent challenge, material breach of contractual terms, or insolvency by either party.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cornell University</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;On May 28, 2020, the Company entered into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">two</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> exclusive license agreements with Cornell University (&#8220;Cornell&#8221;) (the &#8220;First Cornell License Agreement&#8221; and the &#8220;Second Cornell License Agreement,&#8221; collectively the &#8220;May 2020 Cornell License Agreements&#8221;). The First Cornell License Agreement is for the in-license of technology related to portfolios for APOE-associated Alzheimer&#8217;s disease and Anti-Tau, although the Company&#8217;s license is not restricted by such indications and it includes assignment to the Company of Cornell&#8217;s IND for the use of AAVrh10.hAPOE2 vector to treat APOE4 homozygous patients who are at risk for or have Alzheimer&#8217;s disease to support development of the Company&#8217;s LX1001 program. The Second Cornell License Agreement is for the in-license of technology related to a portfolio for FA although the Company&#8217;s license is not restricted by such indications, and it includes assignment to the Company of Cornell&#8217;s IND for the use of AAVrh.10cUhCLN2 to treat children with CLN2 Batten disease to support development of the Company&#8217;s LX1004 program. Through the May 2020 Cornell License Agreements, the Company gains access to a portfolio of inventions, patent rights, technology, and licensed methods that the Company continues to develop. Under the terms of the May 2020 Cornell License Agreements, the Company has assumed all development and commercialization activities worldwide with respect to the licensed technology.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As initial consideration for the May 2020 Cornell License Agreements, the Company paid Cornell an upfront payment in cash of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and issued $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of notes (the &#8220;Cornell Notes&#8221;). In November 2020, the Cornell Notes with outstanding principal of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million were cancelled in exchange for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,337,610</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of series A convertible preferred stock, which converted into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">126,258</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock upon the closing of the Company's IPO on November 7, 2023. As additional consideration, the Company is required to pay Cornell up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upon the achievement of specific clinical and regulatory milestones under the First Cornell License Agreement and up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in two portfolios and up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for a third portfolio upon the achievement of specific clinical and regulatory milestones under the Second Cornell License Agreement. In the second quarter of 2022, a clinical and regulatory milestone of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million was recognized and paid to Cornell in connection with the Second Cornell License Agreement. The Company is also required to pay Cornell a flat royalty in the mid-single-digits based on net sales of the products covered by the licenses, subject to certain adjustments.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upon expiration of the royalty term of a given licensed product in a country, the respective license becomes non-exclusive and royalty-free. In addition, each of the May 2020 Cornell License Agreements may be terminated by the Company for any reason upon ninety (</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">90</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) days&#8217; advance notice to Cornell and by Cornell upon the Company&#8217;s material uncured breach, and all licenses and rights granted by either party under such agreement will concurrently terminate.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 21, 2024, the Company entered into the Third License Agreement (the &#8220;Third Cornell License Agreement,&#8221; together with the May 2020 Cornell License Agreements, the &#8220;Cornell License Agreements&#8221;) with Cornell. Pursuant to the Third Cornell License Agreement, Cornell has granted the Company an exclusive license to practice under certain patent rights generated in animal studies conducted by Cornell on behalf of the Company and a non-exclusive license to know-how concerning a gene therapy for FA cardiomyopathy and current and future data generated in an ongoing investigator-initiated Phase 1A trial of AAVrh.10hFXN to treat FA cardiomyopathy. Both licenses are worldwide and cover products with human and non-human prophylactic and therapeutic uses. Cornell has also granted the Company a right of reference to Cornell&#8217;s Investigation New Drug application for a gene therapy for FA cardiomyopathy.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Third Cornell License Agreement, the Company paid a license issue fee and an initial data transfer fee to Cornell totaling $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. Additionally, the Company will be paying an annual data transfer fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> until data is no longer being gathered. The Company has agreed to pay annual license maintenance fees ranging from $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,500</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> until such time the Company commercializes a licensed product. In addition, the Company will pay Cornell up to an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in regulatory milestones and up to an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in commercial milestones, plus low single digit royalties on net sales.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Third Cornell License Agreement contains other customary license terms including terms related to sublicensing, development, commercialization, milestones, royalties, intellectual property, and termination. Upon expiration of the applicable royalty term for a product in a given country, the Company shall retain a non-exclusive, royalty free license to the data and know-how, including to continue selling such product in that country.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cornell may terminate the Third Cornell License Agreement if the Company (i) breaches the Third Cornell License Agreement (subject to a cure period), (ii) participates in any proceeding challenging the validity of the licensed patents, (iii) publishes the licensed data without Cornell&#8217;s prior written consent, or (iv) does not reach certain milestones. Cornell may also terminate the Third Cornell License Agreement in part on product-by-product basis if the Company does not diligently develop and sale a product. The Company may terminate the Third Cornell License Agreement, in whole or in part with respect to the right of reference, or the licensed data, know-how, or patent rights, with </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">90</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> days&#8217; prior written notice to Cornell.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2023, the Company incurred and paid $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in connection with the Cornell License Agreements. During the year ended December 31, 2024, the Company incurred and paid $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in connection with the Cornell License Agreements.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stelios Therapeutics, Inc.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Stelios Therapeutics, Inc. (&#8220;Stelios&#8221;) was an early-stage company developing novel adeno-associated AAV-based gene therapies for rare cardiac conditions including arrhythmogenic cardiomyopathy and TNNI3-associated hypertrophic cardiomyopathy. On </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">July 16, 2021</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company acquired </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the outstanding stock of Stelios that was accounted for as an asset acquisition pursuant FASB ASC 805, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Business Combinations</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company is required to pay up to a remaining aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to the selling shareholders of Stelios upon the achievement of certain development milestones, excluding a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million development milestone that was achieved in the third quarter of 2024 and paid in the fourth quarter of 2024. Dr. Eric Adler, the Company's Chief Medical Officer and Head of Research, was a co-founder of Stelios and a selling shareholder. Of the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million development milestone payment, Dr. Adler received approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. Stelios was merged into the Company on December 15, 2022 and ceased to exist.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Regents of the University of California, San Diego</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Stelios entered into exclusive worldwide license agreements on April 23, 2020, and August 6, 2020 (the &#8220;First UCSD Agreement&#8221; and the &#8220;Second UCSD Agreement,&#8221; respectively) with the Regents of UCSD to in-license materials and intellectual property related to gene therapies for arrhythmogenic right ventricular cardiomyopathy and hypertrophic cardiomyopathy, respectively. The First UCSD Agreement and the Second UCSD Agreement relate to the Company&#8217;s development efforts for its LX2021 and LX2022 programs, respectively. In connection with the First UCSD Agreement and the Second UCSD Agreement, the Company gained access to inventions, patent rights, technology, and licensed methods that it continues to develop, and it has assumed all worldwide development and commercialization activities with respect to the licensed technologies. The First UCSD Agreement and Second UCSD Agreement required Stelios to pay one-time up-front non-refundable cash fees of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for each agreement and requires the Company to pay aggregate development and commercialization milestones of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, and low- to mid-single digit royalties and low-single digit royalties, respectively, based on aggregate net sales. The only research and development expenses incurred by Stelios or the Company and payments made to the Regents of UCSD through December 31, 2024 under the terms of the First UCSD Agreement and the Second UCSD Agreement were the one-time up-front non-refundable cash fees of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for each agreement. The Company has the right to terminate the First UCSD Agreement and the Second UCSD Agreement at any time upon sixty (</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">60</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">)-days&#8217; written notice to the Regents of UCSD.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On October 4, 2021, the Company entered into an exclusive worldwide license agreement (the &#8220;Third UCSD Agreement&#8221; and collectively with the First UCSD Agreement and the Second UCSD Agreement, the &#8220;UCSD Agreements&#8221;) with the Regents of UCSD to in-license materials and intellectual property related to LX2020, a gene therapy for arrhythmogenic right ventricular cardiomyopathy. The Third UCSD Agreement relates to the Company&#8217;s development efforts for its LX2020 program. In connection with the Third UCSD Agreement, the Company gained access to inventions, patent rights, technology, and licensed methods that it continues to develop, and it has assumed all worldwide development and commercialization activities with respect to the licensed technology. The Third UCSD Agreement required the Company to pay a one-time up-front non-refundable cash fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and requires </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Company to pay aggregate development and commercialization milestones of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, and low- to mid-single digit royalties based on aggregate net sales.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Research and development expenses incurred by the Company and payments made to the Regents of UCSD under the terms of the Third UCSD Agreement were the one-time up-front non-refundable cash fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> as well as a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million development milestone that was achieved during the third quarter of 2024. The Company has the right to terminate the Third UCSD Agreement at any time upon sixty (</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">60</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">)-days&#8217; written notice to the Regents of UCSD.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On December 3, 2021, the Company entered into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">two</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> sponsored research agreements with the Regents of UCSD (the "First UCSD SRA", the "Second UCSD SRA", and collectively, the &#8220;UCSD SRAs&#8221;) for the Company&#8217;s LX2020, LX2021 and LX2022 programs in connection with the UCSD Agreements. Under the terms of the UCSD SRAs, the Company has the first rights to obtain non-exclusive or exclusive, sublicensable, royalty-bearing, perpetual and transferable worldwide licenses in any resulting inventions owned by the Regents of UCSD or resulting inventions jointly owned between the Company and the Regents of UCSD, and the Company retains the rights to any resulting inventions owned by the Company. The UCSD SRAs each have a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">two-year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> term and may be terminated early by the Company at any time upon the giving of thirty (</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">30</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) days&#8217; written notice to the Regents of UCSD. The total costs to be invoiced to the Company over the terms of the UCSD SRAs are $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, of which the Company incurred $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of research and development expenses during the year ended December 31, 2023. The Company paid $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to the Regents of UCSD in connection with the UCSD SRAs during the year ended December 31, 2023. The Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t incur any research and development expenses in connection with the UCSD SRAs during the year ended December 31, 2024. The Company paid $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to the Regents of UCSD in connection with the UCSD SRAs during the year ended December 31, 2024. The Company has paid a cumulative total of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to the Regents of UCSD as of December 31, 2024, in connection with the UCSD SRAs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 13, 2024, the Company entered into a third sponsored research agreement with the Regents of UCSD (the &#8220;Third UCSD SRA&#8221;) for the Company&#8217;s LX2022 program in connection with the Second UCSD Agreement. Under the terms of the Third UCSD SRA, the Company has the first rights to obtain non-exclusive or exclusive, sublicensable, royalty-bearing, perpetual and transferable worldwide licenses in any resulting inventions owned by the Regents of UCSD or resulting inventions jointly owned between the Company and the Regents of UCSD, and the Company retains the rights to any resulting inventions owned by the Company. The Third UCSD SRA has a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">two-year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> term and may be terminated early by the Company at any time upon the giving of thirty (</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">30</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) days&#8217; written notice to the Regents of UCSD. The costs to be invoiced to the Company over the term of the Third UCSD SRA are $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, and the Company may incur additional costs of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million under the Third UCSD SRA if certain study objectives are met.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 13, 2024, the Company also entered into an amendment to the Second UCSD SRA for the Company&#8217;s LX2022 program that extended the term of the Second UCSD SRA to December 2024. The Company incurred $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of research and development costs during the year ended December 31, 2024, and paid $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million during the year ended December 31, 2024, to the Regents of UCSD in connection with the Third UCSD SRA.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 19, 2024, the Company entered into an amendment to the First UCSD SRA (as amended, the "Amended First UCSD SRA") for the Company&#8217;s LX2021 program in connection with the First UCSD Agreement. The Amended First UCSD SRA extends the term of the First UCSD SRA to December 2026 and provides for additional research and development studies and expenses. The total costs to be invoiced to the Company under the Amended First UCSD SRA are $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The Company incurred $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of research and development costs during the year ended December 31, 2024, and paid $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million during the year ended December 31, 2024 to the Regents of UCSD in connection with the Amended First UCSD SRA.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Weill Cornell Medical College</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;On February 2, 2021, the Company entered into a Research Collaboration Agreement with Weill Cornell Medical College (&#8220;WCM&#8221; and the &#8220;WCM Agreement&#8221;) in connection with the Cornell License Agreements entered on May 28, 2020. The Company committed to fund scientific research at WCM to investigate further and potentially enhance the technology licensed to the Company pursuant to the License Agreements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the terms of the WCM Agreement (as amended on February 1, 2022), each WCM invention, joint invention, and related joint results for which an Improvement, as defined in the WCM Agreement, applies and the Company has made an election to amend the Cornell License Agreements, the Company has the first option to negotiate in good faith with WCM for royalty- bearing, worldwide license, under Cornell patent rights, Cornell rights, and Cornell&#8217;s interest in joint patent rights, to develop, make, have made, use, offer for sale, sell, have sold, and import derived products in the field. During the year ended December 31, 2023 the Company incurred $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of research and development costs and paid $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to Cornell in connection with the WCM Agreement. During the year ended December 31, 2024 the Company incurred $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and paid $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of research and development costs to Cornell in connection with the WCM Agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The WCM Agreement expired in accordance with its terms in February 2024.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_LicenseAndAcquisitionAndResearchCollaborationAndSponsoredResearchAgreementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License and acquisition and research collaboration and sponsored research agreements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_LicenseAndAcquisitionAndResearchCollaborationAndSponsoredResearchAgreementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Information</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14. Segment Information</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company's CODM is its </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_bb5c5ee6-6dc1-4359-ae05-87adfaa76496;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CEO and senior leadership team</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. All of the Company&#8217;s operating results are reviewed by the Company&#8217;s CODM within the same statement of operations and comprehensive loss whether research and development (by program) or general and administrative in nature. Accordingly, the Company has determined that it has a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_e4a8210a-7701-4cf1-bb55-d8e020f66db8;"><span style="-sec-ix-hidden:F_b4f1e989-f912-4b9a-9a96-f56301d549bc;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">single</span></span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> reportable segment and operating segment structure. The Company's CODM regularly reviews total expenses and expenses by significant areas such as departments and programs to make decisions when evaluating the Company's financial performance. The Company does not evaluate performance or allocate resources based on segment asset data and therefore such information is not presented. All long-lived assets are located in the United States.</span></span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table contains additional information on the Company's net loss, including significant segment expenses for the years ended December 31, 2024 and December 31, 2023:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.887%;box-sizing:content-box;"></td>
        <td style="width:1.66%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.897%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.66%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.897%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development expense</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">LX2020</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,451</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,192</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">LX2006</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,256</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,537</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">LX1001</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,501</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,936</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other programs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,424</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,535</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Employee compensation expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,010</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,748</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lab-related costs and supplies</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,356</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,160</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">All other research and development expense</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,093</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,022</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative expense</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Employee compensation expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,158</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,872</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">All other general and administrative expense</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,517</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,511</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income and expense, net</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,433</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,119</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net Loss</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98,333</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">66,394</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15. Subsequent Events</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subsequent events have been evaluated through March 24, 2025, which is the date that these financial statements were issued and were available to be issued.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 24, 2025, the Company entered into a sales agreement with Leerink Partners LLC ("Leerink") to sell shares of the Company's common stock having an aggregate offering price of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million from time to time through an at-the-market equity offering program under which Leerink is acting as the Company's agent. Leerink is entitled to compensation for its services in an amount equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the gross proceeds of any of the shares of the Company's common stock sold under the sales agreement.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;The preparation of the financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of income and expense during the reporting period. The most significant estimates relate to the accruals of research and development costs, including accruals of research contract costs, and assumptions used to estimate the fair value of the Company&#8217;s stock option awards and, prior to its IPO, to determine the fair value of its common stock. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when facts and circumstances dictate. These estimates are based on information available as of the date of the financial statements; therefore, actual results could differ from those estimates.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash and Cash Equivalents and Restricted Cash</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash and Cash Equivalents and Restricted Cash</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;The Company considers all highly liquid investments with a remaining maturity when purchased of three months or less to be cash equivalents. Cash equivalents are reported at carrying values, which approximated their fair values and are based on quoted prices in active markets for identical securities. At December 31, 2024 and December 31, 2023, the Company&#8217;s cash equivalents were held in a money market fund. As of December 31, 2024 and 2023, cash consists of cash on deposit with U.S. banks denominated in U.S. dollars, and restricted cash consists of cash on deposit with U.S. banks denominated in U.S. dollars for which its use is restricted and is classified as non-current in the Company&#8217;s balance sheet according to the timing of maturity, and is associated with collateral for letters of credit issued in connection with its operating lease right-of-use and finance lease right-of-use assets and corresponding lease liabilities. Cash is stated at its historical carrying amount, which approximates fair value due to its short-term nature. Restricted cash is stated at its historical carrying amount, which approximates fair value. The Company regularly maintains cash and cash equivalents and restricted cash balances with financial institutions that exceed Federal Deposit Insurance Corporation insurance limits.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investments</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Investments consist primarily of U.S. Treasury securities. Management determines the appropriate classification of these securities at the time they are acquired and evaluates the appropriateness of such classifications at each balance sheet date, including the determination of current and non-current classifications based on the contractual maturity dates of the underlying investments. Investments may be sold by the Company prior to contractual maturity. The Company classifies its investments as available-for-sale pursuant to ASC Topic 320, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Investments&#8212;Debt and Equity Securities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Investments are recorded at fair value, with unrealized gains and losses included as a component of accumulated other comprehensive income (loss) in stockholders&#8217; equity and a component of total comprehensive loss in the statements of comprehensive loss, until realized. The Company's current and non-current investments are presented net of discounts of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">55,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively, at December 31, 2024.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InternalUseSoftwarePolicy', window );">Deferred Software Costs</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deferred Software Costs</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;We capitalize certain costs related to hosting arrangements that are service contracts (cloud computing arrangements). Capitalized costs are included in Other Current Assets and are amortized on a straight-line basis over the estimated useful life. For the year ended December 31, 2024, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of deferred software costs were capitalized related to cloud computing arrangements.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Share</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net Loss per Share&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Company follows the two-class method when computing net income (loss) per common share as the Company has issued shares that meet the definition of participating securities. The two-class method determines net income (loss) per common share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income (loss) available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed. The Company also considers the shares issued upon the early exercise of stock options that are subject to repurchase to be participating securities because holders of such shares have non-forfeitable dividend rights in the event a dividend is paid on common stock. There is no allocation required under the two-class method during periods of loss since the participating securities do not have a contractual obligation to share in the losses of the Company.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic net income (loss) per common share is computed by dividing the net income (loss) per common share by the weighted-average number of common shares outstanding for the period. Diluted net income (loss) per common share is computed by adjusting net income (loss) to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net loss per common share is computed by dividing the diluted net loss by the weighted-average number of common shares outstanding for the period, including potential dilutive common shares.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In periods in which the Company reported a net loss, diluted net loss per common share was the same as basic net loss per common share since dilutive common shares were not assumed to have been issued if their effect was anti-dilutive. During (i) the year ended December 31, 2023, potential common shares related to the conversion of the convertible SAFE Note, which converted into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">411,815</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> common shares in connection with the Company&#8217;s IPO on November 2, 2023 (see Note 6), and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,070,027</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> potential common shares related to the conversion of series A convertible preferred stock and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,489,573</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> potential common shares related to the conversion of series B convertible preferred stock, which converted into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,070,027</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> common shares and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,386,337</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> common shares, respectively, in connection with the Company&#8217;s IPO on November 7, 2023 (see Note 7), and (ii) the years ended December 31, 2024 and December 31, 2023, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,724,218</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,415,740</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> potential common shares, respectively, related to the exercise of outstanding stock options and settlement of outstanding Restricted Stock Units ("RSUs") (see Note 9), were excluded from the computation of diluted net loss per common share because including them would have had an anti-dilutive effect as the Company reported net losses for those periods.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Deferred Offering Costs</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deferred Offering Costs</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;The Company capitalizes certain legal, accounting and other third-party fees that are directly associated with equity financings as deferred offering costs until such financings are consummated. After consummation of the equity financing, these costs are recorded as a reduction of the proceeds from the offering, either as a reduction of the carrying value of preferred stock or in stockholders&#8217; equity (deficit) as a reduction of additional capital generated as a result of the offering. Should the equity financing be abandoned, the deferred offering costs would be expensed immediately as a charge to operating expenses in the statement of operations and comprehensive loss. The Company had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> deferred offering costs recorded as of December 31, 2024 or December 31, 2023.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and Development</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred to discover, research, and develop drug candidates, including personnel expenses, allocated facility-related and depreciation expenses, and third-party license fees. Costs incurred to obtain technology licenses are charged immediately to research and development expense if the technology licensed has not reached technological feasibility and has no alternative future use.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_GeneralAndAdministrativeExpensesPolicyPolicyTextBlock', window );">General and Administrative</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General and Administrative&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General and administrative expenses consist primarily of the cost of employees to engage in corporate functions, such as finance and accounting, information technology, human resources, and legal and executive management. General and administrative expenses also include rent occupancy costs, office expenses, depreciation and amortization, other general overhead costs, insurance premiums, professional service fees, and costs related to regulatory and litigation matters.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock Based Compensation Expense</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock Based Compensation Expense&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for stock-based payment awards granted to employees and non-employees, as well as shares issued to its employees under the Company's 2023 Employee Stock Purchase Plan (the "2023 ESPP"), as stock-based compensation expense at fair value. The Company issues stock-based awards to employees and non-employees in the form of stock options and also issues stock-based awards to employees in the form of restricted stock units (&#8220;RSUs&#8221;). The measurement date for employee stock option and RSU awards is the date of grant, and stock-based compensation costs are recognized as expense over the employees&#8217; requisite service period, which is the vesting period, on an accelerated basis. The measurement date for non-employee awards is the date of grant without changes in the fair value of the award. The measurement date for shares issued under the 2023 ESPP is the first date of each employee stock purchase plan offering period, and stock-based compensation costs are recognized as expense over the offering period on a straight-line basis. Stock-based compensation costs for non-employees are recognized as expense over the vesting period on an accelerated basis. Stock-based compensation expense is classified in the accompanying statement of operations based on the function to which the related services are provided. As the Company is permitted to repurchase shares legally issued for unvested stock options exercised at their exercise price under the 2021 Plan, (i) cash received for unvested stock options exercised under the 2021 Plan is recorded as a deposit liability as a reclassification from additional paid-in capital in the Company&#8217;s balance sheet, which is relieved to additional paid-in capital as such awards vest, (ii) stock based compensation expense is recognized over the requisite service period for each such award, and (iii) the amount and number of shares of common stock outstanding in the Company&#8217;s balance sheet and statement of convertible preferred stock and stockholders&#8217; equity (deficit) are reduced until such awards vest. Forfeitures are recorded as they occur.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value of each stock option grant and shares issued under the 2023 ESPP are estimated on the date of grant or on the first date of each employee stock purchase plan offering period, respectively, using the Black-Scholes option-pricing model, while the fair value of each RSU granted is equal to the closing price of the Company's common stock on the date of the grant. Prior to its IPO on November 3, 2023, the Company was a private company and lacked company-specific historical and implied volatility information for stock options granted. Therefore, the Company estimated its expected stock volatility entirely based on the historical volatility of a publicly traded set of peer companies for stock options granted prior to its IPO, and estimates its expected stock price volatility primarily based on the historical volatility of a publicly traded set of peer companies for stock options granted since its IPO, each for a period equal to the expected life of the stock options granted, and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. The expected term of the Company&#8217;s stock options granted has been determined utilizing the &#8220;simplified&#8221; method for awards that qualify as &#8220;plain-vanilla&#8221; options and expects to continue to do so until such time as it has adequate historical data regarding the expected term of its own stock options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The expected dividend yield is zero as the Company has never paid cash dividends on its common stock and does not expect to pay any cash dividends in the foreseeable future.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Prior to November 20, 2020, the Company was an LLC entity and elected to be treated under the Partnership provisions of the Internal Revenue Code. Accordingly, the LLC entity was not viewed as a tax-paying entity in any jurisdiction and all income and deductions of the LLC entity flowed through to the individual members and therefore no income taxes were recorded by the Company. On November 20, 2020, the Company converted to a C Corporation.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for income taxes under the asset and liability method pursuant to ASC Topic 740, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">("ASC 740"). Under this method, the Company recognizes deferred tax assets and liabilities for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recorded for deferred tax assets if it is more likely than not that some portion or all of the deferred tax assets will not be realized based on all available positive and negative evidence. Under the Tax Cuts and Jobs Act of 2017, the Company is required to capitalize, and subsequently amortize, research and development expenses over five years for research activities conducted in the U.S. and over fifteen years for research activities conducted outside of the U.S commencing in 2022. The capitalization of research and development expenses during the year resulted in a decrease to the Company's operating loss generation during the years ended December 31, 2024 and December 31, 2023 as compared to prior periods (see Note 11). As of December 31, 2024 and December 31, 2023, the Company continues to maintain a full valuation allowance against its deferred tax assets.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognizes a tax benefit only if it is more likely than not the tax position will be sustained on examination by the local taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such positions are then measured based on the largest benefit greater than 50% likelihood of being realized upon settlement with the related tax authority. The changes in recognition or measurement are reflected in the period in which the change in judgment occurs. As of December 31, 2024 and December 31, 2023, the Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t identified any uncertain tax positions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company records interest and penalties related to uncertain tax positions in the provision for income taxes.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fair Value Measurements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The three levels of inputs that may be used to measure fair value are as follows:</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Level 1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Level 2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Level 3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Inputs are unobservable inputs for the asset or liability.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Concentrations of Credit Risk</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, cash equivalents, restricted cash, and investments. The Company&#8217;s cash and restricted cash balances exceed Federal Deposit Insurance Corporation insurance limits. The Company&#8217;s cash equivalents consist of investments in a U.S. government money market fund, and the Company's investments primarily consist of U.S. Treasury securities. The Company&#8217;s cash, cash equivalents, restricted cash, and investments are held with large financial institutions that management believes to be of high credit quality. To date, the Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t recognized any losses caused by uninsured balances.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Segment Information</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;The Company manages its operations as a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_3797e8b8-b7a6-4ad2-8b98-c0c8d90f246c;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">single</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> segment for the purposes of assessing performance and allocating resources. The Company is focused on preclinical and clinical stage gene therapies, and specifically on hereditary and acquired diseases of high unmet need. The Company&#8217;s Chief Operating Decision Maker ("CODM") is its Chief Executive Officer ("CEO") and its senior leadership team. The CODM reviews the Company&#8217;s financial information on an aggregated basis for purposes of assessing performance and allocating resources. All assets are held in the United States. The Company has not earned any product revenue through December 31, 2024.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and Equipment</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization are recognized using the straight-line method over the estimated useful life of each asset. Such costs are periodically reviewed for recoverability when impairment indicators are present. Such indicators include, among other factors, unused capacity, market value declines, and obsolescence of technology. Recorded values of asset groups of equipment that are not expected to be recovered through undiscounted future net cash flows are written down to current fair value, which generally is determined from estimated discounted future net cash flows (assets held for use) or net realizable value (assets held for sale).</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Costs for capital assets not yet placed into service are capitalized as construction-in-progress and depreciated once placed into service. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation and amortization are removed from the accounts and any resulting gain or loss is included in loss from operations. Expenditures for repairs and maintenance that do not improve or extend the life of the respective assets are charged to expense in the period incurred. See Note 5 for information regarding the Company&#8217;s capitalized operating and finance lease right-of-use assets.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following is the summary of property and equipment and related accumulated depreciation as of December 31, 2024, and December 31, 2023 (years not stated in thousands):</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:58.884%;box-sizing:content-box;"></td>
          <td style="width:1.421%;box-sizing:content-box;"></td>
          <td style="width:13.085%;box-sizing:content-box;"></td>
          <td style="width:1.421%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:9.884%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.421%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:9.884%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Useful Life</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Internal use software</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3 </span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">years</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">296</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Furniture and fixtures</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5 </span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">years</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">386</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">380</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lab equipment</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7 </span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">years</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">844</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">514</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7 </span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">years</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">272</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">247</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total property and equipment</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,502</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,437</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: accumulated depreciation and amortization</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">474</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">381</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total property and equipment, net</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,028</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,056</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;In accordance with ASC Topic 842, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">("ASC 842"), the Company determines if an arrangement is or contains a lease at inception. A contract is or contains a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. The Company classifies leases at the lease commencement date as operating or finance leases and records a right-of-use asset and a lease liability on the balance sheet for all leases with an initial lease term of greater than 12 months. Leases with an initial term of 12 months or less are not recorded in the balance sheet, but payments are recognized as expense on a straight-line basis over the lease term. The Company has elected not to recognize leases with terms of 12 months or less.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A lease qualifies as a finance lease if any of the following criteria are met at the inception of the lease: (i) there is a transfer of ownership of the leased asset to the Company by the end of the lease term, (ii) the Company holds an option to purchase the leased asset that it is reasonably certain to exercise, (iii) the lease term is for a major part of the remaining economic life of the leased asset, (iv) the present value of the sum of lease payments equals or exceeds substantially all of the fair value of the leased asset, or (v) the nature of the leased asset is specialized to the point that it is expected to provide the lessor no alternative use at the end of the lease term. All other leases are recorded as operating leases.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company enters into contracts that contain both lease and non-lease components. Non-lease components may include maintenance, utilities, and other operating costs. The Company combines the lease and non-lease components of fixed costs in its lease arrangements as a single lease component. Variable costs, such as utilities or maintenance costs, are not included in the measurement of right-of-use assets and lease liabilities but rather are expensed when the event determining the amount of variable consideration to be paid occurs.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating lease right-of-use assets and lease liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term using the discount rate implicit in the lease. If the implicit rate is not readily determinable, the Company utilizes an estimate of its incremental borrowing rate based upon the available information at the operating lease commencement date. Operating lease right-of-use assets are further adjusted for prepaid or accrued lease payments. Operating lease payments are expensed using the straight-line method as an operating expense over the lease term. The Company&#8217;s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Finance lease right-of-use assets and lease liabilities are recognized upon receipt of the assets based on their fair values and are amortized to depreciation expense using the straight-line method over the estimated useful lives of the related assets. Finance lease liability payments are bifurcated into (i) a portion that is recorded as interest expense and (ii) a portion that reduces the finance liability associated with the lease, according to the interest rates implicit in the leases.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain of the Company&#8217;s leases include options to extend or terminate the lease. The amounts determined for the Company&#8217;s right-of-use assets and lease liabilities generally do not assume that renewal options or early-termination provisions, if any, are exercised, unless it is reasonably certain that the Company will exercise such options.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements Not Yet Adopted</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recent Accounting Pronouncements Adopted</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;In November 2023, the FASB issued ASU No. 2023-07, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Segment Reporting - Improving Reportable Segment Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (Topic 280) ("ASU 2023-07"). </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_73289f60-fe2f-4884-94cc-6b3d31ad5380;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ASU 2023-07</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> requires disclosures to include significant segment expenses that are regularly provided to the CODM, a description of other segment items by reportable segment, and any additional measures of a segment's profit or loss used by the CODM when deciding how to allocate resources. ASU 2023-07 also requires all annual disclosures currently required by Topic 280 to be included in interim periods. This update is effective for fiscal years beginning after December 15, 2023, and is to be applied retrospectively to all periods presented in the financial statements. The Company's </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adoption</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of ASU 2023-07 resulted in a new footnote disclosure for segment reporting.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recent Accounting Pronouncements Not Yet Adopted&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, the FASB issued ASU No. 2023-09, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (Topic 740) ("ASU No. 2023-09"). ASU No. 2023-09 requires disaggregation of the effective tax rate reconciliation into standard categories, enhances disclosure of income taxes paid, and modifies other income tax-related disclosures. ASU No. 2023-09 became effective for the Company on January 1, 2025. The adoption of this guidance will not have a material impact on the Company's financial statements.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the FASB issued ASU No. 2024-03, I</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ncome Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (Subtopic 220-40) ("ASU No. 2024-03"). ASU No. 2024-03 requires disclosure, in the notes to financial statements, of specified information about certain costs and expenses. ASU No. 2024-03 will be effective for the Company starting in annual periods in 2027, with early adoption permitted. The Company is currently assessing the impact of adopting this guidance on its financial statements.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_GeneralAndAdministrativeExpensesPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>General and administrative expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_GeneralAndAdministrativeExpensesPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredChargesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InternalUseSoftwarePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs incurred when both (1) the software is acquired, internally developed, or modified solely to meet the entity's internal needs, and (2) during the software's development or modification, no substantive plan exists or is being developed to market the software externally.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-40/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InternalUseSoftwarePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 12<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment, Net</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following is the summary of property and equipment and related accumulated depreciation as of December 31, 2024, and December 31, 2023 (years not stated in thousands):</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:58.884%;box-sizing:content-box;"></td>
          <td style="width:1.421%;box-sizing:content-box;"></td>
          <td style="width:13.085%;box-sizing:content-box;"></td>
          <td style="width:1.421%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:9.884%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.421%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:9.884%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Useful Life</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Internal use software</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3 </span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">years</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">296</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Furniture and fixtures</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5 </span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">years</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">386</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">380</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lab equipment</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7 </span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">years</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">844</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">514</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7 </span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">years</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">272</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">247</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total property and equipment</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,502</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,437</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: accumulated depreciation and amortization</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">474</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">381</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total property and equipment, net</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,028</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,056</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems', window );"><strong>Fair Value, Option, Quantitative Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of Fair Value Hierarchy for Assets and Liabilities Measured at Fair Value on Recurring Basis</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents information about the Company&#8217;s financial assets, financial liabilities, and investments measured at fair value on a recurring basis and indicates the level of the fair value hierarchy utilized to determine such fair values:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:32.32%;box-sizing:content-box;"></td>
        <td style="width:1.78%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.14%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.78%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.14%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.78%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.14%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.78%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.14%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31, 2024:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Assets:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents (money market)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,636</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,636</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">86,504</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">86,504</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Investments:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,012</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,012</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,636</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">93,516</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">111,152</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:32.32%;box-sizing:content-box;"></td>
        <td style="width:1.78%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.14%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.78%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.14%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.78%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.14%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.78%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.14%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31, 2023:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Assets:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents (money market)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">102,484</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">102,484</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Investments:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">102,484</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">102,484</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Schedule of Investments Classified as Available-for-Sale Securities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investments, which are classified as available-for-sale securities, consisted of the following as of December 31, 2024 and December 31, 2023:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:23.745%;box-sizing:content-box;"></td>
        <td style="width:1.3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.763%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.763%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.763%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.763%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31, 2024:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized Cost Basis</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross Unrealized Gains</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross Unrealized Losses</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Available-for-sale securities:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">93,619</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">103</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">93,516</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">93,619</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">103</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">93,516</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31, 2023:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized Cost Basis</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross Unrealized Gains</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross Unrealized Losses</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Available-for-sale securities:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Schedule of Aggregate Fair Values of Investments Classified as Available-for-Sale Securities With Unrealized Losses and Gains</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Aggregate fair values of investments classified as available-for-sale securities with unrealized losses and gains were as follows as of December 31, 2024 and December 31, 2023:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:38.36%;box-sizing:content-box;"></td>
        <td style="width:2.12%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:26.7%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:2.12%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:26.7%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Available-for-sale securities:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Due within one year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">86,504</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Due after one year through five years</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,012</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">93,516</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Rollforward of Changes in Fair Value of Financial Liabilities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth a roll forward of changes in the fair value of financial liabilities, gross of unamortized discount, classified as Level 3 in the fair value hierarchy:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:77.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:53.567%;box-sizing:content-box;"></td>
        <td style="width:4.73%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:39.705%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Convertible<br/>SAFE Note,<br/>gross</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Beginning balance at December 31, 2022</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Convertible SAFE Note issuance at August 24, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,000</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_995b2506-e09a-426b-8450-5340620be7de;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in estimated fair value since issuance</span></span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">530</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Conversion of SAFE Note into common stock in connection with initial public offering</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,530</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ending balance at December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_ScheduleOfSignificantUnobservableInputsUsedInValuationModelToEstimateFairValueTableTextBlock', window );">Schedule of Significant Unobservable Inputs Used in Valuation Model to Estimate Fair Value</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The ranges of the significant unobservable inputs used in the valuation model to estimate the fair value of the Company&#8217;s convertible SAFE Note that was categorized within Level 3 of the fair value hierarchy as of August 24, 2023 (issuance) until November 2, 2023 (settlement) were as follows (not stated in thousands):</span>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:77.86%;box-sizing:content-box;"></td>
        <td style="width:1.92%;box-sizing:content-box;"></td>
        <td style="width:20.22%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Probability of meeting qualified equity financing event</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.0</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20.0</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Probability of meeting public offering event</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75.0</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85.0</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Probability of meeting change in control event</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Time until qualified equity financing event (in years)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.17</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.27</span></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Time until public offering event (in years)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.08</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.19</span></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Time until change in control event (in years)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.50</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.60</span></span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems', window );"><strong>Fair Value, Option, Quantitative Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Summary of Estimated Fair Value Assumptions</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The total grant date fair value of this option of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, or $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.85</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, was recorded as an offset to additional paid-in capital and was estimated using a Black-Scholes model incorporating the following assumptions (not stated in thousands):</span>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:77.86%;box-sizing:content-box;"></td>
        <td style="width:1.92%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:18.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock price</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.00</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercise price</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.00</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average risk-free interest rate</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.53</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.08</span></span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">65.88</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.00</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_ScheduleOfSignificantUnobservableInputsUsedInValuationModelToEstimateFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of significant unobservable inputs used in valuation model to estimate fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_ScheduleOfSignificantUnobservableInputsUsedInValuationModelToEstimateFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-30<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-31<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOptionQuantitativeDisclosuresLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_ComponentsOfOperatingLeaseTableTextBlock', window );">Components of Operating Lease</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The components of this operating lease were as follows:</span>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.64%;box-sizing:content-box;"></td>
        <td style="width:2.08%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:17.099999999999998%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:2.08%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:17.099999999999998%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease expense</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,147</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,147</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Variable lease expense</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">459</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">355</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating lease expense</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,606</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,502</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash paid for amounts included in the measurement of lease liabilities, included in operating cash flows</span></p></td>
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,110</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,294</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Reconciliation of Remaining Undiscounted Contractual Rent Obligations</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table provides a reconciliation of the Company&#8217;s remaining undiscounted contractual rent obligations due within each year ended December 31 to the operating lease liabilities recognized as of December 31, 2024:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:73.02%;box-sizing:content-box;"></td>
        <td style="width:2.7%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:22.279999999999998%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Year ended December 31</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Operating<br/>Leases</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,152</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,206</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,261</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,318</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,372</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Thereafter</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total lease payments</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,309</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: present value adjustment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,772</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating lease liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,537</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Included in the balance sheet:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current portion of lease liabilities - operating</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,100</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-current portion of lease liabilities - operating</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,437</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating lease liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,537</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_ComponentsOfEquipmentFinanceLeaseTableTextBlock', window );">Components of Equipment Finance Leases</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The components of the equipment finance leases were as follows:</span>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:62.34%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.860000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.94%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.860000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Reduction in the carrying amount of ROU assets, finance</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">325</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">306</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest on finance lease liabilities</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">127</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">176</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total finance lease expense</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">452</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">482</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash paid for amounts included in the measurement of lease liabilities, included in financing cash flows</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">410</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">425</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock', window );">Reconciliation of Remaining Equipment Finance Lease Obligations</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table provides a reconciliation of the Company&#8217;s remaining equipment finance lease obligations due within each year ending December 31 to the equipment finance lease liabilities recognized at December 31, 2024:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:77.7%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:20.299999999999997%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Year ended December 31</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Equipment Finance Leases</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">587</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">587</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">359</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Thereafter</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total lease payments</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,544</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: imputed interest</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">157</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total finance lease liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,387</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Included in the balance sheet:</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current portion of lease liabilities - finance</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">570</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-current portion of lease liabilities - finance</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">817</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total finance lease liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,387</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_ComponentsOfEquipmentFinanceLeaseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Components of equipment Finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_ComponentsOfEquipmentFinanceLeaseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_ComponentsOfOperatingLeaseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Components of operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_ComponentsOfOperatingLeaseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>Accrued Liabilities and Other Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Summary of Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued expenses and other current liabilities consisted of the following</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:88.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:72.793%;box-sizing:content-box;"></td>
        <td style="width:1.274%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.693000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.274%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.965%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued research and development expenses</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,696</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,384</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued bonus expenses</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,718</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,810</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued general and administrative expenses and other professional fees</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,406</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,092</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other current liabilities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">939</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">554</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total accrued expenses and other current liabilities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,759</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,840</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityDisclosureAbstract', window );"><strong>Temporary Equity Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityTableTextBlock', window );">Schedule of Convertible Preferred Stock</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2022 and until the closing of the Company's IPO on November 7, 2023, convertible preferred stock consisted of the following:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:26.9%;box-sizing:content-box;"></td>
        <td style="width:1.1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.6%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.6%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.56%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.440000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.56%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.440000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.6%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Convertible</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Convertible</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Preferred</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Preferred</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Stock</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Common Stock</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Stock</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Issued and</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Proceeds</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Liquidation</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Issuable Upon</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Authorized</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Outstanding</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Received</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Preference</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Conversion</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Series A convertible preferred stock</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85,495,722</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85,495,722</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85,496</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85,496</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,070,027</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Series B convertible preferred stock</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">58,157,824</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">58,157,823</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100,060</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100,060</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,489,573</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">143,653,546</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">143,653,545</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">185,556</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">185,556</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,559,600</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityTableTextBlock', window );">Schedule of Common Stock Reserved for Future Issuances</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company had reserved the following number of shares of common stock for the exercise of outstanding stock options, settlement of outstanding RSUs, and future issuance of stock-based awards:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:86.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:62.12%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.92%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.96%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options to purchase shares of common stock under the 2021 Plan and 2023 Plan</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,457,918</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,415,740</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">RSUs subject to settlement in shares of common stock under the 2023 Plan</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">266,300</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares available for issuance under the 2023 Plan</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,185,328</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,293,816</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares available for issuance under the 2023 ESPP</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">505,284</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">238,600</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total shares of common stock reserved for future issuance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,414,830</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,948,156</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the stock option activity under the 2021 Plan and the 2023 Plan for the years ended December 31, 2024 and December 31, 2023 (weighted-average remaining contractual term (in years) is not stated in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:44.791%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.878%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.38%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.298%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.878%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.38%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.398%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>Average<br/>Exercise Price</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate<br/>Intrinsic</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(per share)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in years)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding as of December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,415,740</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.32</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.83</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,689</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,520,330</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.60</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">135,646</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.62</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,288</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">272,276</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.40</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expired</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">70,230</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.94</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding as of December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,457,918</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.37</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.18</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,851</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options exercisable at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,954,937</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.16</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.38</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,851</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Following Assumptions Presented on Weighted Average Basis</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company estimated the fair value of options granted using a Black-Scholes option pricing model with the following assumptions presented on a weighted average basis during the year ended December 31, 2024 (not stated in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:61.96%;box-sizing:content-box;"></td>
        <td style="width:1.44%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.58%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.44%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.58%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.14</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.43</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.02</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.78</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85.85</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">67.59</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.00</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.00</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Summary of RSU activity</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the RSU activity under the 2023 Plan for the year ended December 31, 2024:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:61.96%;box-sizing:content-box;"></td>
        <td style="width:1.44%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.58%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.9%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.120000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>Average<br/>Grant Date Fair Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(per share)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested as of December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">287,078</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.52</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,778</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.65</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested as of December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">266,300</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.59</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Summary of Stock-Based Compensation Expenses</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-based compensation expense was classified as follows in the Company&#8217;s statements of operations and comprehensive loss:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:62.072%;box-sizing:content-box;"></td>
        <td style="width:1.86%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.103%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.86%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.103%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development expense</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,001</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,751</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative expense</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,473</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,292</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total stock-based compensation expense</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,474</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,043</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Net Loss Per Share Attributable to Common Stockholders</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic and diluted net loss per common share attributable to common stockholders was calculated as follows:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:63.247%;box-sizing:content-box;"></td>
        <td style="width:1.84%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:14.537%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.84%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:14.537%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Numerator:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss attributable to common stockholders</span></p></td>
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98,333</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">66,394</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Denominator:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average common shares outstanding, basic and diluted</span></p></td>
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31,787,491</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,354,368</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per share attributable to common stockholders, basic and diluted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.09</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.40</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Reconciliation of Statutory Income Tax Rate to Effective Income Tax Rate</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A reconciliation of the Company's statutory income tax rate to the Company&#8217;s effective income tax rate is as follows for the years ended December 31, 2024, and December 31, 2023:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:91.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.357%;box-sizing:content-box;"></td>
        <td style="width:2.03%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:17.435000000000002%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:2.03%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:17.148%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Federal statutory rate</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.00</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.00</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State Taxes, net of federal benefit</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.72</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.80</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33.98</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36.12</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Permanent differences</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.51</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.36</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax credits</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.73</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.80</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.96</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.12</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Effective income tax rate</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.00</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.00</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Components of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The principal components of the Company's deferred tax assets and liabilities at December 31, 2024 and December 31, 2023 are as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.688%;box-sizing:content-box;"></td>
        <td style="width:2.063%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:17.259%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:2.063%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:16.926%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,295</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,904</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax credits</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,743</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,070</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Intangibles</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,918</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,241</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Capitalized R&amp;D expenses</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,338</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,127</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease liabilities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,818</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,244</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other deferred tax assets</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,292</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,753</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98,404</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">65,339</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">95,426</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">61,974</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,978</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,365</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.688%;box-sizing:content-box;"></td>
        <td style="width:2.063%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:17.259%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:2.063%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:16.926%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Right of use asset</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,663</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,102</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other deferred tax liabilities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">315</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">263</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,978</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,365</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net deferred tax assets (liabilities)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Summary Of Additional Information On Company's Net loss Including Segment Expenses</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table contains additional information on the Company's net loss, including significant segment expenses for the years ended December 31, 2024 and December 31, 2023:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.887%;box-sizing:content-box;"></td>
        <td style="width:1.66%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.897%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.66%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.897%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development expense</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">LX2020</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,451</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,192</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">LX2006</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,256</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,537</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">LX1001</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,501</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,936</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other programs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,424</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,535</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Employee compensation expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,010</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,748</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lab-related costs and supplies</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,356</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,160</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">All other research and development expense</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,093</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,022</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative expense</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Employee compensation expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,158</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,872</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">All other general and administrative expense</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,517</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,511</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income and expense, net</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,433</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,119</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net Loss</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98,333</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">66,394</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Basis of Presentation - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">24 Months Ended</th>
<th class="th" colspan="1">27 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 07, 2023</div></th>
<th class="th"><div>Oct. 13, 2023</div></th>
<th class="th"><div>Aug. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Nov. 07, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10.594230-for-1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 98,333<span></span>
</td>
<td class="nump">$ 66,394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash and cash equivalents, including restricted cash and investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(280,173)<span></span>
</td>
<td class="num">$ (181,840)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Aggregate total net proceeds raised with issuance of convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 185,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 185,556<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lxeo_SeriesAAndSeriesBConvertiblePreferredStockMember', window );">Series A and Series B Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Aggregate total net proceeds raised with issuance of convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 185,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds</a></td>
<td class="nump">$ 100,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 88,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=lxeo_SimpleAgreementForFutureEquityMember', window );">SAFE [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lxeo_SeriesAAndSeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lxeo_SeriesAAndSeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lxeo_SimpleAgreementForFutureEquityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lxeo_SimpleAgreementForFutureEquityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">94 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Nov. 07, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 02, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>Segment </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_LossRecognizedFromUninsuredBalances', window );">Loss recognized from uninsured balances | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operation segment | Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCurrentAndNoncurrent', window );">Deferred offering costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Uncertain tax positions | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in Accounting Principle, Accounting Standards Update, Adopted [true false]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingStandardsUpdateExtensibleList', window );">Accounting Standards Update [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">us-gaap:AccountingStandardsUpdate202307Member<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_InvestmentCurrent', window );">Investment current | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_InvestmentNonCurrent', window );">Investment non-current | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedComputerSoftwareGross', window );">Deferred software costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Number of shares issued during the period upon conversion of convertible securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,456,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=lxeo_SimpleAgreementForFutureEquityMember', window );">SAFE | Common Stock | IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Number of common shares on conversion of debt instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">411,815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Exercise of Outstanding Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from Computation of diluted net loss per common share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,724,218<span></span>
</td>
<td class="nump">2,415,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lxeo_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from Computation of diluted net loss per common share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,070,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Number of shares issued during the period upon conversion of convertible securities</a></td>
<td class="nump">8,070,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lxeo_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Number of shares issued during the period upon conversion of convertible securities</a></td>
<td class="nump">8,070,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lxeo_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from Computation of diluted net loss per common share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,489,573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lxeo_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Number of shares issued during the period upon conversion of convertible securities</a></td>
<td class="nump">6,386,337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_InvestmentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_InvestmentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_InvestmentNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment non current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_InvestmentNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_LossRecognizedFromUninsuredBalances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss recognized from uninsured balances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_LossRecognizedFromUninsuredBalances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingStandardsUpdateExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates amendment to accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477123/405-50-65-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 66: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 67: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 68: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 69: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 70: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 71: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 72: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 73: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 74: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 75: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 76: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 77: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 78: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br><br>Reference 79: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br><br>Reference 80: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingStandardsUpdateExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedComputerSoftwareGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of capitalized costs for computer software, including but not limited to, acquired and internally developed computer software.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedComputerSoftwareGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether accounting standards update was adopted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477123/405-50-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 326<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-3<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 326<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of deferred costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lxeo_SimpleAgreementForFutureEquityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lxeo_SimpleAgreementForFutureEquityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lxeo_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lxeo_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lxeo_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lxeo_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 1,502<span></span>
</td>
<td class="nump">$ 1,437<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(474)<span></span>
</td>
<td class="num">(381)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">1,028<span></span>
</td>
<td class="nump">1,056<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember', window );">Internal Use Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">296<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful Life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 386<span></span>
</td>
<td class="nump">380<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful Life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Lab Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 844<span></span>
</td>
<td class="nump">514<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful Life</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 272<span></span>
</td>
<td class="nump">$ 247<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful Life</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Fair Value Hierarchy for Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - Fair Value Recurring [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Fair value Disclosure, Total</a></td>
<td class="nump">$ 111,152<span></span>
</td>
<td class="nump">$ 102,484<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">17,636<span></span>
</td>
<td class="nump">102,484<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">US Treasury Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">86,504<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total Investment</a></td>
<td class="nump">7,012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Fair value Disclosure, Total</a></td>
<td class="nump">17,636<span></span>
</td>
<td class="nump">102,484<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member] | Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">17,636<span></span>
</td>
<td class="nump">$ 102,484<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Fair value Disclosure, Total</a></td>
<td class="nump">93,516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | US Treasury Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">86,504<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total Investment</a></td>
<td class="nump">$ 7,012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetAssetLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of asset after deduction of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetAssetLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Investments Classified as Available-for-Sale Securities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Available-for-sale securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost Basis</a></td>
<td class="nump">$ 93,619<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(103)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">93,516<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Available-for-sale securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost Basis</a></td>
<td class="nump">93,619<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(103)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 93,516<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Aggregate Fair Values of Investments Classified as Available-for-Sale Securities With Unrealized Losses and Gains (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Available-for-sale securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Due within one year</a></td>
<td class="nump">$ 86,504<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Due after one year through five years</a></td>
<td class="nump">7,012<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities</a></td>
<td class="nump">$ 93,516<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Rollforward of Changes in Fair Value of Financial Liabilities (Details) - Fair Value, Inputs, Level 3 [Member] - Convertible SAFE Note [Member]<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConvertibleNoteIssuance', window );">Convertible SAFE Note issuance at August 24, 2023</a></td>
<td class="nump">$ 4,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in estimated fair value since issuance</a></td>
<td class="nump">$ 530<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList', window );">Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Gain (Loss) on Fair Value Hedges Recognized in Earnings<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversionOfNotesIntoCommonStock', window );">Conversion of SAFE Note into common stock in connection with initial public offering</a></td>
<td class="num">$ (4,530)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversionOfNotesIntoCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value measurement with unobservable inputs reconciliation recurring basis liability conversion of notes into common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversionOfNotesIntoCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConvertibleNoteIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, convertible note issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConvertibleNoteIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes gain (loss) from liability measured at fair value using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=lxeo_ConvertibleSimpleAgreementForFutureEquityNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=lxeo_ConvertibleSimpleAgreementForFutureEquityNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Significant Unobservable Inputs Used In the Valuation Model to Estimate Fair Value (Details) - Fair Value, Inputs, Level 3 [Member] - Convertible SAFE Note [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_FairValueProbabilityOfMeetingChangeInControlEvent', window );">Probability of meeting change in control event</a></td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_FairValueProbabilityOfMeetingQualifiedEquityFinancingEvent', window );">Probability of meeting qualified equity financing event</a></td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_FairValueProbabilityOfMeetingPublicOfferingEvent', window );">Probability of meeting public offering event</a></td>
<td class="nump">75.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_FairValueTimeUntilQualifiedEquityFinancingEvent', window );">Time until qualified equity financing event (in years)</a></td>
<td class="text">2 months 1 day<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_FairValueTimeUntilPublicOfferingEvent', window );">Time until public offering event (in years)</a></td>
<td class="text">29 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_FairValueTimeUntilChangeInControlEvent', window );">Time until change in control event (in years)</a></td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_FairValueProbabilityOfMeetingQualifiedEquityFinancingEvent', window );">Probability of meeting qualified equity financing event</a></td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_FairValueProbabilityOfMeetingPublicOfferingEvent', window );">Probability of meeting public offering event</a></td>
<td class="nump">85.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_FairValueTimeUntilQualifiedEquityFinancingEvent', window );">Time until qualified equity financing event (in years)</a></td>
<td class="text">3 months 7 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_FairValueTimeUntilPublicOfferingEvent', window );">Time until public offering event (in years)</a></td>
<td class="text">2 months 8 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_FairValueTimeUntilChangeInControlEvent', window );">Time until change in control event (in years)</a></td>
<td class="text">7 months 6 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_FairValueProbabilityOfMeetingChangeInControlEvent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value probability of meeting change in control event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_FairValueProbabilityOfMeetingChangeInControlEvent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_FairValueProbabilityOfMeetingPublicOfferingEvent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value probability of meeting public offering event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_FairValueProbabilityOfMeetingPublicOfferingEvent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_FairValueProbabilityOfMeetingQualifiedEquityFinancingEvent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value probability of meeting qualified equity financing event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_FairValueProbabilityOfMeetingQualifiedEquityFinancingEvent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_FairValueTimeUntilChangeInControlEvent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value time until change in control event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_FairValueTimeUntilChangeInControlEvent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_FairValueTimeUntilPublicOfferingEvent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value time until public offering event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_FairValueTimeUntilPublicOfferingEvent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_FairValueTimeUntilQualifiedEquityFinancingEvent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value time until qualified equity financing event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_FairValueTimeUntilQualifiedEquityFinancingEvent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=lxeo_ConvertibleSimpleAgreementForFutureEquityNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=lxeo_ConvertibleSimpleAgreementForFutureEquityNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 07, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems', window );"><strong>Fair Value, Option, Quantitative Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue', window );">Grant date fair value of option</a></td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, granted</a></td>
<td class="nump">$ 0.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems', window );"><strong>Fair Value, Option, Quantitative Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares purchased at public offering</a></td>
<td class="nump">9,090,910<span></span>
</td>
<td class="nump">10,139,656<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Offering price per share</a></td>
<td class="nump">$ 11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | IPO | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems', window );"><strong>Fair Value, Option, Quantitative Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares purchased at public offering</a></td>
<td class="nump">1,363,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Over-Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems', window );"><strong>Fair Value, Option, Quantitative Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares purchased at public offering</a></td>
<td class="nump">1,048,746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-30<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-31<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOptionQuantitativeDisclosuresLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Estimated Fair Value Assumptions (Details) - IPO - Black-Scholes Model<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Stock Price</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Measurement input | $</a></td>
<td class="nump">1,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 11<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Weighted Average Risk-free Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Weighted average risk-free interest rate</a></td>
<td class="nump">5.53%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Expected Term</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">29 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Expected Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">65.88%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Expected Dividend Yield</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AlternativeInvestmentMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure alternative investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AlternativeInvestmentMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=lxeo_BlackScholesModelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=lxeo_BlackScholesModelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>Accrued Liabilities and Other Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_AccruedResearchAndDevelopmentExpenseCurrent', window );">Accrued research and development expenses</a></td>
<td class="nump">$ 6,696<span></span>
</td>
<td class="nump">$ 6,384<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedBonusesCurrent', window );">Accrued bonus expenses</a></td>
<td class="nump">3,718<span></span>
</td>
<td class="nump">2,810<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_AccruedGeneralAndAdministrativeExpensesAndOtherProfessionalFeesCurrent', window );">Accrued general and administrative expenses and other professional fees</a></td>
<td class="nump">2,406<span></span>
</td>
<td class="nump">1,092<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">939<span></span>
</td>
<td class="nump">554<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_AccruedLiabilitiesAndOtherLiabilitiesCurrent', window );">Total accrued expenses and other current liabilities</a></td>
<td class="nump">$ 13,759<span></span>
</td>
<td class="nump">$ 10,840<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_AccruedGeneralAndAdministrativeExpensesAndOtherProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued general and administrative expenses and other professional fees current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_AccruedGeneralAndAdministrativeExpensesAndOtherProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_AccruedLiabilitiesAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued liabilities and other liabilities current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_AccruedLiabilitiesAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_AccruedResearchAndDevelopmentExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development expense current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_AccruedResearchAndDevelopmentExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedBonusesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedBonusesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">60 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 01, 2023</div></th>
<th class="th">
<div>Apr. 01, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jul. 31, 2029</div></th>
<th class="th"><div>Apr. 30, 2022</div></th>
<th class="th"><div>Jan. 31, 2022</div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 30, 2024</div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jul. 31, 2034</div></th>
<th class="th">
<div>Aug. 01, 2029 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 11, 2023 </div>
<div>USD ($) </div>
<div>Installment</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_OperatingLeaseCommencementDate', window );">Operating lease commencement date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2022-04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,069,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,442,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,537,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Net book values</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,460,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,763,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Remaining lease terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_OperatingLeaseWeightedAverageRemainingPaymentTerm', window );">Remaining lease payment terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease payment term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 8 months 12 days<span></span>
</td>
<td class="text">3 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_FinanceLeaseWeightedAverageRemainingAmortizationTerm', window );">Weighted average remaining amortization term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 9 months 18 days<span></span>
</td>
<td class="text">5 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Weighted average effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.59%<span></span>
</td>
<td class="nump">8.59%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=lxeo_OfficeFacilityAndLaboratorySpaceMember', window );">Office Facility and Laboratory Space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_OperatingLeaseAgreementEnteredDate', window );">Operating lease agreement entered date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2022-01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_OperatingLeaseEndDate', window );">Operating lease end date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2029-07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Option to extend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">additional five-year option to extend the lease beyond July 2029 at the then-prevailing effective market rental rate<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Existence of option to extend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Incremental borrowing rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.53%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=lxeo_OfficeFacilityAndLaboratorySpaceMember', window );">Office Facility and Laboratory Space | Scenario Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=lxeo_OfficeFacilityAndLaboratorySpaceMember', window );">Office Facility and Laboratory Space | Letter of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization', window );">Total gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Net book values</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_NumberOfMonthlyInstallmentsLease', window );">Number of monthly installments | Installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_LesseeFinanceLeaseCommencementDateRangeStart', window );">Finance lease, commencement date range, start</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr.  01,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_LesseeFinanceLeaseCommencementDateRangeEnd', window );">Finance lease, commencement date range, end</a></td>
<td class="text">Apr.  01,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_FinanceLeaseAggregateMonthlyInstallmentPaymentAmounts', window );">Total aggregate monthly installment payment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory Equipment | Letter of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory Equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseDiscountRate', window );">Imputed interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_FinanceLeaseMonthlyInstallmentPaymentAmounts', window );">Monthly installment payment amounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory Equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseDiscountRate', window );">Imputed interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_FinanceLeaseMonthlyInstallmentPaymentAmounts', window );">Monthly installment payment amounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_FinanceLeaseAggregateMonthlyInstallmentPaymentAmounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance lease aggregate monthly installment payment amounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_FinanceLeaseAggregateMonthlyInstallmentPaymentAmounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_FinanceLeaseMonthlyInstallmentPaymentAmounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance lease monthly installment payment amounts</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_FinanceLeaseMonthlyInstallmentPaymentAmounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_FinanceLeaseWeightedAverageRemainingAmortizationTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance lease weighted average remaining amortization term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_FinanceLeaseWeightedAverageRemainingAmortizationTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_LesseeFinanceLeaseCommencementDateRangeEnd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, finance lease, commencement date range, end.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_LesseeFinanceLeaseCommencementDateRangeEnd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_LesseeFinanceLeaseCommencementDateRangeStart">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, finance lease, commencement date range, start.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_LesseeFinanceLeaseCommencementDateRangeStart</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_NumberOfMonthlyInstallmentsLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of monthly installments lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_NumberOfMonthlyInstallmentsLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_OperatingLeaseAgreementEnteredDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease agreement entered date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_OperatingLeaseAgreementEnteredDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_OperatingLeaseCommencementDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease commencement date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_OperatingLeaseCommencementDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_OperatingLeaseEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease end date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_OperatingLeaseEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_OperatingLeaseWeightedAverageRemainingPaymentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease weighted average remaining payment term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_OperatingLeaseWeightedAverageRemainingPaymentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated amortization of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of finance lease payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to extend operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=lxeo_OfficeFacilityAndLaboratorySpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=lxeo_OfficeFacilityAndLaboratorySpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Components of Operating Lease (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease expense</a></td>
<td class="nump">$ 2,147<span></span>
</td>
<td class="nump">$ 2,147<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease expense</a></td>
<td class="nump">459<span></span>
</td>
<td class="nump">355<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Total operating lease expense</a></td>
<td class="nump">2,606<span></span>
</td>
<td class="nump">2,502<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in the measurement of lease liabilities, included in operating cash flows</a></td>
<td class="nump">$ 2,110<span></span>
</td>
<td class="nump">$ 2,294<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Reconciliation of Remaining Undiscounted Contractual Rent Obligations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 2,152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">2,206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">2,261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2028</a></td>
<td class="nump">2,318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2029</a></td>
<td class="nump">1,372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">10,309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: present value adjustment</a></td>
<td class="num">(1,772)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">8,537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityAbstract', window );"><strong>Included in the balance sheet:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of lease liabilities - operating</a></td>
<td class="nump">2,100<span></span>
</td>
<td class="nump">$ 2,087<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current portion of lease liabilities - operating</a></td>
<td class="nump">$ 6,437<span></span>
</td>
<td class="nump">$ 7,786<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Components of Equipment Finance Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Reduction in the carrying amount of ROU assets, finance</a></td>
<td class="nump">$ 325<span></span>
</td>
<td class="nump">$ 306<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest on finance lease liabilities</a></td>
<td class="nump">127<span></span>
</td>
<td class="nump">176<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_FinanceLeaseExpense', window );">Total finance lease expense</a></td>
<td class="nump">452<span></span>
</td>
<td class="nump">482<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Cash paid for amounts included in the measurement of lease liabilities, included in financing cash flows</a></td>
<td class="nump">$ 410<span></span>
</td>
<td class="nump">$ 425<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_FinanceLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_FinanceLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Reconciliation of Remaining Equipment Finance Lease Obligations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 587<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">587<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour', window );">2028</a></td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive', window );">2029</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">1,544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(157)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Total finance lease liabilities</a></td>
<td class="nump">1,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityAbstract', window );"><strong>Included in the balance sheet:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Current portion of lease liabilities - finance</a></td>
<td class="nump">570<span></span>
</td>
<td class="nump">$ 518<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Non-current portion of lease liabilities - finance</a></td>
<td class="nump">$ 817<span></span>
</td>
<td class="nump">$ 1,247<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Safe Note - Additional Information (Details) - SAFE - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 02, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Aug. 24, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_IncreaseDecreaseInFairValueOfSafeInstrument', window );">Increase in fair value of safe instrument</a></td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">4.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Unamortized discount</a></td>
<td class="nump">$ 4.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=lxeo_SimpleAgreementForFutureEquityMember', window );">Common Stock | IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Number of common shares on conversion of debt instrument</a></td>
<td class="nump">411,815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=lxeo_SimpleAgreementForFutureEquityMember', window );">Sarepta Therapeutics, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Convertible safe note, principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Annual interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescription', window );">Debt Instrument, Description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Upon a qualified equity financing event, the convertible SAFE Note would have automatically converted into a number of shares of corresponding preferred stock based on a certain discount to the price of such preferred stock issued to the other investors applied to the then-current Cash-Out Amount. Upon the effective date of an IPO or a direct listing, or immediately prior to the closing of a SPAC transaction, the convertible SAFE Note would have automatically converted, and did automatically convert upon the effectiveness of the Company's IPO registration statement on November 2, 2023, into a number of shares of common stock based on a certain discount to the public offering price of such common stock applied to the then-current Cash-Out Amount (see Note 8). Upon a change of control, the Investor would have been entitled to receive the greater of (i) an amount equal to a certain premium applied to the then-current Cash-Out Amount, or (ii) the amount that would have been payable on the number of shares of the senior-most series of the Company&#8217;s preferred stock after applying a certain discount to the original issue price of such senior-most preferred stock together with a certain premium applied to the then-current Cash-Out Amount (the greater of (i) and (ii), the &#8220;Conversion Amount&#8221;). Upon the one-year maturity of the convertible SAFE Note, or upon dissolution of the Company, the Investor was to be paid an amount equal to the Cash-Out Amount. Upon the event of a change of control or dissolution, the Investor&#8217;s right to receive its Cash-Out Amount or its Conversion Amount would have been junior to payment of outstanding indebtedness and creditor claims, on par with payments for the Company&#8217;s most senior series of preferred stock or other SAFE note holders, if any, and senior to payments for the Company&#8217;s common stock and any other series or class of stock. The convertible SAFE Note did not maintain any voting rights. <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_IncreaseDecreaseInFairValueOfSafeInstrument">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in fair value of safe instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_IncreaseDecreaseInFairValueOfSafeInstrument</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lxeo_SimpleAgreementForFutureEquityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lxeo_SimpleAgreementForFutureEquityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lxeo_SareptaTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lxeo_SareptaTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1">27 Months Ended</th>
<th class="th" colspan="1">36 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 07, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 07, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 07, 2023 </div>
<div>USD ($) </div>
<div>Director </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized</a></td>
<td class="nump">143,653,546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143,653,546<span></span>
</td>
<td class="nump">143,653,546<span></span>
</td>
<td class="nump">143,653,546<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds | $</a></td>
<td class="nump">$ 100,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_QualifiedIpoMinimumNumberOfDirectorsApprovalRequired', window );">Qualified IPO minimum number of directors approval required | Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding</a></td>
<td class="nump">143,653,545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143,653,545<span></span>
</td>
<td class="nump">143,653,545<span></span>
</td>
<td class="nump">143,653,545<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleSharesIssuable', window );">Converted shares into common stock</a></td>
<td class="nump">13,559,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,559,600<span></span>
</td>
<td class="nump">13,559,600<span></span>
</td>
<td class="nump">13,559,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lxeo_SeriesAAndBConvertiblePreferredStockMember', window );">Series A and B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized</a></td>
<td class="nump">143,653,546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143,653,546<span></span>
</td>
<td class="nump">143,653,546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lxeo_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized</a></td>
<td class="nump">85,495,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,495,722<span></span>
</td>
<td class="nump">85,495,722<span></span>
</td>
<td class="nump">85,495,722<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Percentage of dividends per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreferencePerShare', window );">Liquidation preference | $ / shares</a></td>
<td class="nump">$ 10.59423<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.59423<span></span>
</td>
<td class="nump">$ 10.59423<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding</a></td>
<td class="nump">85,495,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,495,722<span></span>
</td>
<td class="nump">85,495,722<span></span>
</td>
<td class="nump">85,495,722<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleSharesIssuable', window );">Converted shares into common stock</a></td>
<td class="nump">8,070,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,070,027<span></span>
</td>
<td class="nump">8,070,027<span></span>
</td>
<td class="nump">8,070,027<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Number of shares issued during the period upon conversion of convertible securities</a></td>
<td class="nump">8,070,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lxeo_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized</a></td>
<td class="nump">58,157,824<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,157,824<span></span>
</td>
<td class="nump">58,157,824<span></span>
</td>
<td class="nump">58,157,824<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Percentage of dividends per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreferencePerShare', window );">Liquidation preference | $ / shares</a></td>
<td class="nump">$ 18.227267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.227267<span></span>
</td>
<td class="nump">$ 18.227267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding</a></td>
<td class="nump">58,157,823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,157,823<span></span>
</td>
<td class="nump">58,157,823<span></span>
</td>
<td class="nump">58,157,823<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleSharesIssuable', window );">Converted shares into common stock</a></td>
<td class="nump">5,489,573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,489,573<span></span>
</td>
<td class="nump">5,489,573<span></span>
</td>
<td class="nump">5,489,573<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lxeo_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock | Antidilutive Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleSharesIssuable', window );">Converted shares into common stock</a></td>
<td class="nump">6,386,337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,386,337<span></span>
</td>
<td class="nump">6,386,337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Number of shares issued during the period upon conversion of convertible securities</a></td>
<td class="nump">896,764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Number of shares issued during the period upon conversion of convertible securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,456,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Number of shares issued during the period upon conversion of convertible securities</a></td>
<td class="nump">8,070,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Number of shares issued during the period upon conversion of convertible securities</a></td>
<td class="nump">6,386,337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_PercentageOfOutstandingSharesForDeemedLiquidation', window );">Percentage of outstanding shares for deemed liquidation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Series A Liquidation Preference</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreferencePerShare', window );">Liquidation preference | $ / shares</a></td>
<td class="nump">$ 31.782691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31.782691<span></span>
</td>
<td class="nump">$ 31.782691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Series B Liquidation Preference</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreferencePerShare', window );">Liquidation preference | $ / shares</a></td>
<td class="nump">54.681802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54.681802<span></span>
</td>
<td class="nump">54.681802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of shares of common stock | $ / shares</a></td>
<td class="nump">$ 22.784057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.784057<span></span>
</td>
<td class="nump">$ 22.784057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_PercentageOfOutstandingSharesForDeemedLiquidation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of outstanding shares for deemed liquidation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_PercentageOfOutstandingSharesForDeemedLiquidation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_QualifiedIpoMinimumNumberOfDirectorsApprovalRequired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Qualified IPO minimum number of directors approval required.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_QualifiedIpoMinimumNumberOfDirectorsApprovalRequired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleSharesIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common shares issuable upon conversion of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleSharesIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage rate used to calculate dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-12A(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLiquidationPreferencePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The per share liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLiquidationPreferencePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lxeo_SeriesAAndBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lxeo_SeriesAAndBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lxeo_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lxeo_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lxeo_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lxeo_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=lxeo_AntidilutiveSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=lxeo_AntidilutiveSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lxeo_SeriesALiquidationPreferenceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lxeo_SeriesALiquidationPreferenceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lxeo_SeriesBLiquidationPreferenceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lxeo_SeriesBLiquidationPreferenceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock - Schedule of Convertible Preferred Stock (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1">27 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Nov. 07, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible Preferred Stock Authorized</a></td>
<td class="nump">143,653,546<span></span>
</td>
<td class="nump">143,653,546<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible Preferred Stock Issued</a></td>
<td class="nump">143,653,545<span></span>
</td>
<td class="nump">143,653,545<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible Preferred Stock Outstanding</a></td>
<td class="nump">143,653,545<span></span>
</td>
<td class="nump">143,653,545<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds Received</a></td>
<td class="nump">$ 185,556<span></span>
</td>
<td class="nump">$ 185,556<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Liquidation Preference</a></td>
<td class="nump">$ 185,556<span></span>
</td>
<td class="nump">$ 185,556<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleSharesIssuable', window );">Common Stock Issuable Upon Conversion</a></td>
<td class="nump">13,559,600<span></span>
</td>
<td class="nump">13,559,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lxeo_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible Preferred Stock Authorized</a></td>
<td class="nump">85,495,722<span></span>
</td>
<td class="nump">85,495,722<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible Preferred Stock Issued</a></td>
<td class="nump">85,495,722<span></span>
</td>
<td class="nump">85,495,722<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible Preferred Stock Outstanding</a></td>
<td class="nump">85,495,722<span></span>
</td>
<td class="nump">85,495,722<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds Received</a></td>
<td class="nump">$ 85,496<span></span>
</td>
<td class="nump">$ 85,496<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Liquidation Preference</a></td>
<td class="nump">$ 85,496<span></span>
</td>
<td class="nump">$ 85,496<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleSharesIssuable', window );">Common Stock Issuable Upon Conversion</a></td>
<td class="nump">8,070,027<span></span>
</td>
<td class="nump">8,070,027<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lxeo_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible Preferred Stock Authorized</a></td>
<td class="nump">58,157,824<span></span>
</td>
<td class="nump">58,157,824<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible Preferred Stock Issued</a></td>
<td class="nump">58,157,823<span></span>
</td>
<td class="nump">58,157,823<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible Preferred Stock Outstanding</a></td>
<td class="nump">58,157,823<span></span>
</td>
<td class="nump">58,157,823<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds Received</a></td>
<td class="nump">$ 100,060<span></span>
</td>
<td class="nump">$ 100,060<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Liquidation Preference</a></td>
<td class="nump">$ 100,060<span></span>
</td>
<td class="nump">$ 100,060<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleSharesIssuable', window );">Common Stock Issuable Upon Conversion</a></td>
<td class="nump">5,489,573<span></span>
</td>
<td class="nump">5,489,573<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleSharesIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common shares issuable upon conversion of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleSharesIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lxeo_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lxeo_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lxeo_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lxeo_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital Stock - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 11, 2024</div></th>
<th class="th"><div>Nov. 07, 2023</div></th>
<th class="th"><div>Nov. 02, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalUnitsAuthorized', window );">Authorized capital stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">510,000,000<span></span>
</td>
<td class="nump">510,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,079,209<span></span>
</td>
<td class="nump">26,668,485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_CommonStockSharesIssuedOnEarlyExerciseOfUnvestedStockOptions', window );">Common stock shares issued upon early exercise of unvested stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,948<span></span>
</td>
<td class="nump">22,107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Dividends, common stock, cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143,653,545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143,653,545<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Gross proceeds from private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 88,712,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Number of shares issued during the period upon conversion of convertible securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,456,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lxeo_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,495,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,495,722<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Number of shares issued during the period upon conversion of convertible securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,070,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lxeo_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Number of shares issued during the period upon conversion of convertible securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,070,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lxeo_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,157,823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,157,823<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lxeo_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Number of shares issued during the period upon conversion of convertible securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,386,337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lxeo_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock | Antidilutive Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Number of shares issued during the period upon conversion of convertible securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">896,764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO | SAFE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Underwriting discounts, commissions and offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 113,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of common shares issued and sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,090,910<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,139,656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Underwriting discounts, commissions and offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Offering price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO | Common Stock | SAFE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Number of common shares on conversion of debt instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">411,815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of common shares issued and sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,048,746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Underwriting discounts, commissions and offering expenses</a></td>
<td class="nump">$ 6,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Gross proceeds from private placement</a></td>
<td class="nump">95,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_NetProceedsReceivedFromPrivatePlacement', window );">Net proceeds from private placement</a></td>
<td class="nump">$ 88,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement Offering [Member] | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of common shares issued and sold</a></td>
<td class="nump">6,278,905<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,278,905<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Offering price per share</a></td>
<td class="nump">$ 15.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_CommonStockSharesIssuedOnEarlyExerciseOfUnvestedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock shares issued on early exercise of unvested stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_CommonStockSharesIssuedOnEarlyExerciseOfUnvestedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_NetProceedsReceivedFromPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net proceeds received from Private Placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_NetProceedsReceivedFromPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalUnitsAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of authorized capital units or capital shares. This element is relevant to issuers of face-amount certificates and registered investment companies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalUnitsAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lxeo_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lxeo_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lxeo_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lxeo_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=lxeo_AntidilutiveSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=lxeo_AntidilutiveSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lxeo_SimpleAgreementForFutureEquityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lxeo_SimpleAgreementForFutureEquityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Capital Stock - Schedule of Common Stock Reserved for Future Issuances (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of common stock reserved for future issuance</a></td>
<td class="nump">6,414,830<span></span>
</td>
<td class="nump">4,948,156<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=lxeo_TwoThousandTwentyOneAndTwoThousandTwentyThreeEquityIncentivePlanMember', window );">2021 Plan and 2023 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of common stock reserved for future issuance</a></td>
<td class="nump">2,185,328<span></span>
</td>
<td class="nump">2,293,816<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=lxeo_TwoThousandTwentyOneAndTwoThousandTwentyThreeEquityIncentivePlanMember', window );">2021 Plan and 2023 Plan | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of common stock reserved for future issuance</a></td>
<td class="nump">3,457,918<span></span>
</td>
<td class="nump">2,415,740<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=lxeo_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember', window );">2023 ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of common stock reserved for future issuance</a></td>
<td class="nump">505,284<span></span>
</td>
<td class="nump">238,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=lxeo_TwoThousandTwentyThreeEquityIncentivePlanMember', window );">2023 Plan | Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of common stock reserved for future issuance</a></td>
<td class="nump">266,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=lxeo_TwoThousandTwentyOneAndTwoThousandTwentyThreeEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=lxeo_TwoThousandTwentyOneAndTwoThousandTwentyThreeEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=lxeo_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=lxeo_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=lxeo_TwoThousandTwentyThreeEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=lxeo_TwoThousandTwentyThreeEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">14 Months Ended</th>
<th class="th" colspan="1">33 Months Ended</th>
<th class="th" colspan="1">47 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 07, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Nov. 07, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Jan. 01, 2025</div></th>
<th class="th"><div>Jan. 01, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,414,830<span></span>
</td>
<td class="nump">4,948,156<span></span>
</td>
<td class="nump">6,414,830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,414,830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Shares repurchased value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value of stock options granted</a></td>
<td class="nump">$ 0.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense, weighted-average period of recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 3 months 10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,827<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value of stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.58<span></span>
</td>
<td class="nump">$ 9.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of stock options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Total grant date fair values of options vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,100,000<span></span>
</td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yields percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense, weighted-average period of recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 7 months 13 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lxeo_TwoThousandTwentyOneEquityIncentivePlanMember', window );">2021 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, shares reserved for issuance</a></td>
<td class="nump">582,699<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">582,699<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for future grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Shares repurchased value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lxeo_TwoThousandTwentyOneEquityIncentivePlanMember', window );">2021 Plan | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,827<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Shares repurchased value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lxeo_TwoThousandTwentyOneEquityIncentivePlanMember', window );">2021 Plan | Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting period, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualTermGrantDate', window );">Contractual term grant date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lxeo_TwoThousandTwentyOneEquityIncentivePlanMember', window );">2021 Plan | Employee Stock Option | Non-employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_ShareBasedCompensationPaymentDescription', window );">Share based compensation payment description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">vest over a four-year period with 25% of the options granted vesting after one year and the remainder vesting in equal monthly installments over the following 36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lxeo_TwoThousandAndTwentyThreeEquityIncentivePlanMember', window );">2023 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, shares reserved for issuance</a></td>
<td class="nump">1,803,980<span></span>
</td>
<td class="nump">2,185,328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,185,328<span></span>
</td>
<td class="nump">1,803,980<span></span>
</td>
<td class="nump">2,185,328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,070,424<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized</a></td>
<td class="nump">4,737,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,737,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance', window );">Increase in aggregate number of shares of common stock reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,333,424<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_PercentageOfAutomaticallyIncreaseInAvailableSharesOfCommonStockOnBeginningOfCachCalendarYear', window );">Percentage of automatically increase in available shares of common stock on beginning of each calendar year</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lxeo_TwoThousandAndTwentyThreeEquityIncentivePlanMember', window );">2023 Plan | Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting period, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_ShareBasedCompensationPaymentDescription', window );">Share based compensation payment description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">vest over a four-year period with 25% of the RSUs vesting after approximately one year and the remainder vesting in equal quarterly installments over the following 12 quarters<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lxeo_TwoThousandAndTwentyThreeEquityIncentivePlanMember', window );">2023 Plan | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,724,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance', window );">Increase in aggregate number of shares of common stock reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,653,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lxeo_TwoThousandAndTwentyThreeEquityIncentivePlanMember', window );">2023 Plan | Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting period, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_ShareBasedCompensationPaymentDescription', window );">Share based compensation payment description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">vest over a four-year period with 25% of the options granted vesting after one year and the remainder vesting in equal monthly installments over the following 36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualTermGrantDate', window );">Contractual term grant date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lxeo_TwoThousandAndTwentyThreeEquityIncentivePlanMember', window );">2023 Plan | Employee Stock Option | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lxeo_TwoThousandAndTwentyThreeEquityIncentivePlanMember', window );">2023 Plan | Employee Stock Option | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lxeo_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember', window );">2023 ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, shares reserved for issuance</a></td>
<td class="nump">238,600<span></span>
</td>
<td class="nump">505,284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">505,284<span></span>
</td>
<td class="nump">238,600<span></span>
</td>
<td class="nump">505,284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">505,284<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for future grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized</a></td>
<td class="nump">238,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">238,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_NumberOfSharesAutomaticallyIncreaseInAvailableSharesOfCommonStockUnderPlan', window );">Number of shares automatically increase in available shares of common stock under plan</a></td>
<td class="nump">477,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance', window );">Increase in aggregate number of shares of common stock reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">266,684<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lxeo_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember', window );">2023 ESPP | Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_PayrollDeductionsAtPrice', window );">Payroll deductions at price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_FairValueOfUnearnedEmployeeStockOwnershipPlans', window );">Fair value of unearned employee stock ownership plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lxeo_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember', window );">2023 ESPP | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">836,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance', window );">Increase in aggregate number of shares of common stock reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">330,792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lxeo_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember', window );">2023 ESPP | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_PercentageOfAutomaticallyIncreaseInAvailableSharesOfCommonStockOnBeginningOfCachCalendarYear', window );">Percentage of automatically increase in available shares of common stock on beginning of each calendar year</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lxeo_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember', window );">2023 ESPP | Minimum | Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_CommonStockDuringOfferingPeriod', window );">Common stock during offering period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_CommonStockDuringOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock During Offering Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_CommonStockDuringOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_FairValueOfUnearnedEmployeeStockOwnershipPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value of Unearned Employee Stock Ownership Plans</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_FairValueOfUnearnedEmployeeStockOwnershipPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase in common stock capital shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_NumberOfSharesAutomaticallyIncreaseInAvailableSharesOfCommonStockUnderPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Shares Automatically Increase in Available Shares of Common Stock Under Plan</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_NumberOfSharesAutomaticallyIncreaseInAvailableSharesOfCommonStockUnderPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_PayrollDeductionsAtPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payroll Deductions at Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_PayrollDeductionsAtPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_PercentageOfAutomaticallyIncreaseInAvailableSharesOfCommonStockOnBeginningOfCachCalendarYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of automatically increase in available shares of common stock on beginning of each calendar year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_PercentageOfAutomaticallyIncreaseInAvailableSharesOfCommonStockOnBeginningOfCachCalendarYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualTermGrantDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement by Share Based Payment Award Contractual Term Grant Date</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualTermGrantDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_ShareBasedCompensationPaymentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation payment description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_ShareBasedCompensationPaymentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=lxeo_TwoThousandTwentyOneEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=lxeo_TwoThousandTwentyOneEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=lxeo_TwoThousandAndTwentyThreeEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=lxeo_TwoThousandAndTwentyThreeEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=lxeo_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=lxeo_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock Option Activity (Details) - Employee Stock Option [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value, exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=us-gaap_EmployeeStockOptionMember', window );">2021 Plan and 2023 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares outstanding, beginning</a></td>
<td class="nump">2,415,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted, shares</a></td>
<td class="nump">1,520,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised, shares</a></td>
<td class="num">(135,646)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited, shares</a></td>
<td class="num">(272,276)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired, shares</a></td>
<td class="num">(70,230)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares outstanding, ending</a></td>
<td class="nump">3,457,918<span></span>
</td>
<td class="nump">2,415,740<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of shares, Options exercisable</a></td>
<td class="nump">1,954,937<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, beginning balance</a></td>
<td class="nump">$ 8.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, granted</a></td>
<td class="nump">15.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, exercised</a></td>
<td class="nump">3.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, forfeited</a></td>
<td class="nump">11.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Expired</a></td>
<td class="nump">12.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, ending balance</a></td>
<td class="nump">11.37<span></span>
</td>
<td class="nump">$ 8.32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, Options exercisable</a></td>
<td class="nump">$ 8.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual term</a></td>
<td class="text">8 years 2 months 4 days<span></span>
</td>
<td class="text">7 years 9 months 29 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term, Options exercisable</a></td>
<td class="text">7 years 4 months 17 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, beginning</a></td>
<td class="nump">$ 13,689,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value, exercised</a></td>
<td class="nump">1,288,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, ending</a></td>
<td class="nump">2,851,000<span></span>
</td>
<td class="nump">$ 13,689,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value, Options exercisable</a></td>
<td class="nump">$ 2,851,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=lxeo_TwoThousandTwentyOneAndTwoThousandTwentyThreeEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=lxeo_TwoThousandTwentyOneAndTwoThousandTwentyThreeEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Following Assumptions Presented on Weighted Average Basis (Details) - Employee Stock Option<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.14%<span></span>
</td>
<td class="nump">3.43%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 7 days<span></span>
</td>
<td class="text">5 years 9 months 10 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">85.85%<span></span>
</td>
<td class="nump">67.59%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Summary of RSU activity (Details) - Restricted Stock Units [Member] - 2023 Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares, granted | shares</a></td>
<td class="nump">287,078<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of shares, forfeited | shares</a></td>
<td class="num">(20,778)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares unvested, ending balance | shares</a></td>
<td class="nump">266,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, granted | $ / shares</a></td>
<td class="nump">$ 15.52<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, unvested, forfeited | $ / shares</a></td>
<td class="nump">14.65<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value, unvested, ending balance | $ / shares</a></td>
<td class="nump">$ 15.59<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=lxeo_TwoThousandAndTwentyThreeEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=lxeo_TwoThousandAndTwentyThreeEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock-based Compensation Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 12,474<span></span>
</td>
<td class="nump">$ 3,043<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">6,001<span></span>
</td>
<td class="nump">1,751<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 6,473<span></span>
</td>
<td class="nump">$ 1,292<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Schedule of Net Loss Per Share Attributable to Common Stockholders (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (98,333)<span></span>
</td>
<td class="num">$ (66,394)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding, basic</a></td>
<td class="nump">31,787,491<span></span>
</td>
<td class="nump">5,354,368<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding, diluted</a></td>
<td class="nump">31,787,491<span></span>
</td>
<td class="nump">5,354,368<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share attributable to common stockholders, basic</a></td>
<td class="num">$ (3.09)<span></span>
</td>
<td class="num">$ (12.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share attributable to common stockholders, diluted</a></td>
<td class="num">$ (3.09)<span></span>
</td>
<td class="num">$ (12.4)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Reconciliation of Statutory Income Tax Rate to Effective Income Tax Rate (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State Taxes, net of federal benefit</a></td>
<td class="nump">10.72%<span></span>
</td>
<td class="nump">10.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(33.98%)<span></span>
</td>
<td class="num">(36.12%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Permanent differences</a></td>
<td class="num">(0.51%)<span></span>
</td>
<td class="num">(0.36%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Tax credits</a></td>
<td class="nump">3.73%<span></span>
</td>
<td class="nump">4.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent', window );">Other</a></td>
<td class="num">(0.96%)<span></span>
</td>
<td class="num">(0.12%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of reported income tax benefit (expense) from difference to income tax expense (benefit) computed by applying statutory federal (national) income tax rate to pretax income (loss) from continuing operation, attributable to other reconciling items. Excludes state and local income tax expense (benefit), federal tax expense (benefit), statutory income tax expense (benefit) outside of country of domicile, tax credit, nondeductible expense, deduction, income tax settlement, income tax contingency, and cross-border tax law.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Components of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 33,295<span></span>
</td>
<td class="nump">$ 21,904<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credits</a></td>
<td class="nump">10,743<span></span>
</td>
<td class="nump">7,070<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_DeferredTaxAssetsIntangibleAssets', window );">Intangibles</a></td>
<td class="nump">5,918<span></span>
</td>
<td class="nump">4,241<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Capitalized R&amp;D expenses</a></td>
<td class="nump">39,338<span></span>
</td>
<td class="nump">25,127<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_DeferredTaxAssetsLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">2,818<span></span>
</td>
<td class="nump">3,244<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other deferred tax assets</a></td>
<td class="nump">6,292<span></span>
</td>
<td class="nump">3,753<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">98,404<span></span>
</td>
<td class="nump">65,339<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(95,426)<span></span>
</td>
<td class="num">(61,974)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="nump">2,978<span></span>
</td>
<td class="nump">3,365<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Right of use asset</a></td>
<td class="num">(2,663)<span></span>
</td>
<td class="num">(3,102)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other deferred tax liabilities</a></td>
<td class="num">(315)<span></span>
</td>
<td class="num">(263)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(2,978)<span></span>
</td>
<td class="num">(3,365)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets (liabilities)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_DeferredTaxAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets, intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_DeferredTaxAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_DeferredTaxAssetsLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_DeferredTaxAssetsLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_PercentageOfCumulativeOwnershipChange', window );">Percentage of cumulative ownership change</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_AnnualLimitationAbilityToUtilize', window );">Annual limitation ability to utilize</a></td>
<td class="nump">$ 1,689,195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsForeign', window );">Federal tax credits</a></td>
<td class="nump">2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Uncertain tax positions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Uncertain tax positions, accrued interest or penalties</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">106,400,000<span></span>
</td>
<td class="nump">70,200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="nump">$ 10,700,000<span></span>
</td>
<td class="nump">7,100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_TaxCreditCarryForwardExpirationYear', window );">Tax credit carryforward, expiration year</a></td>
<td class="text">2040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 212,700,000<span></span>
</td>
<td class="nump">$ 139,300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_OperatingLossCarryForwardsExpirationYear', window );">Net operating loss carryforwards, expiration year</a></td>
<td class="text">2040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_AnnualLimitationAbilityToUtilize">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual Limitation Ability to Utilize</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_AnnualLimitationAbilityToUtilize</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_OperatingLossCarryForwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating loss carry forwards expiration year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_OperatingLossCarryForwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_PercentageOfCumulativeOwnershipChange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of cumulative ownership change.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_PercentageOfCumulativeOwnershipChange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_TaxCreditCarryForwardExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax credit carry forward expiration year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_TaxCreditCarryForwardExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>Employees</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_NumberOfFormerEmployees', window );">Number of former employees</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lxeo_ThirdPartiesForPharmaceuticalManufacturingAndResearchActivitiesMember', window );">Third Parties for Pharmaceutical Manufacturing and Research Activities | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_LicenseAgreementTerminationNoticePeriod', window );">Termination notice period (in days)</a></td>
<td class="text">30 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lxeo_ThirdPartiesForPharmaceuticalManufacturingAndResearchActivitiesMember', window );">Third Parties for Pharmaceutical Manufacturing and Research Activities | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_LicenseAgreementTerminationNoticePeriod', window );">Termination notice period (in days)</a></td>
<td class="text">60 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_LicenseAgreementTerminationNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License agreement termination notice period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_LicenseAgreementTerminationNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_NumberOfFormerEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of former employees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_NumberOfFormerEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 27<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lxeo_ThirdPartiesForPharmaceuticalManufacturingAndResearchActivitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lxeo_ThirdPartiesForPharmaceuticalManufacturingAndResearchActivitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License, Acquisition, Research Collaboration and Sponsored Research Agreements - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">37 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 21, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 19, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 13, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 03, 2021 </div>
<div>USD ($) </div>
<div>IntegerItem</div>
</th>
<th class="th">
<div>Oct. 04, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 16, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 25, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 06, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 28, 2020 </div>
<div>USD ($) </div>
<div>IntegerItem</div>
</th>
<th class="th">
<div>Apr. 23, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 07, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 74,091,000<span></span>
</td>
<td class="nump">$ 53,130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleSharesIssuable', window );">Converted shares into common stock | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,559,600<span></span>
</td>
<td class="nump">13,559,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lxeo_SteliosTherapeuticsIncMember', window );">Stelios Therapeutics Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_PaymentOfDevelopmentMilestone', window );">Development milestone paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1', window );">Asset acquisition date of acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 16,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Asset acquisition percentage of outstanding stock acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Payment to selling shareholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_MilestoneReceived', window );">Milestone Received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lxeo_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleSharesIssuable', window );">Converted shares into common stock | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,070,027<span></span>
</td>
<td class="nump">8,070,027<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Stelios Therapeutics Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Payment to selling shareholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lxeo_AdverumLicenseAgreementMember', window );">Adverum License Agreement | Adverum Biotechnologies Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_PaymentOfOneTimeUpFrontNonRefundableFee', window );">One-time up-front non-refundable fee paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_PaymentOfDevelopmentMilestone', window );">Development milestone paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms', window );">Royalty payments description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company is obligated to pay Adverum tiered royalties ranging from high single-digits to sub teens based on annual aggregate worldwide net sales of Products (as defined in the Adverum Agreement).<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_LicenseAgreementTerminationNoticePeriod', window );">License agreement termination notice period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">120 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lxeo_AdverumLicenseAgreementMember', window );">Adverum License Agreement | Adverum Biotechnologies Inc | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_DevelopmentAndRegulatoryMilestonesDue', window );">Development and regulatory milestones due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_CommercializationMilestonesDue', window );">Commercialization milestones due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lxeo_CornellLicenseAgreementsMember', window );">Cornell License Agreements | Cornell University</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_LicenseAgreementTerminationNoticePeriod', window );">License agreement termination notice period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_NumberOfLicenseAgreements', window );">Number of license agreements | IntegerItem</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_UpfrontCashPayment', window );">Upfront payment in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesIssued1', window );">Notes issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Notes with outstanding principal exchanged</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lxeo_CornellLicenseAgreementsMember', window );">Cornell License Agreements | Cornell University | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleSharesIssuable', window );">Converted shares into common stock | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126,258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lxeo_CornellLicenseAgreementsMember', window );">Cornell License Agreements | Cornell University | Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Shares issued on debt exchanged | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,337,610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lxeo_CornellFirstLicenseAgreementsMember', window );">Cornell First License Agreements | Cornell University | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_SpecificClinicalAndRegulatoryMilestonesDue', window );">Specific clinical and regulatory milestones due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lxeo_CornellSecondLicenseAgreementsMember', window );">Cornell Second License Agreements | Cornell University</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_PaymentOfClinicalAndRegulatoryMilestone', window );">Clinical and regulatory milestone paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lxeo_CornellSecondLicenseAgreementsMember', window );">Cornell Second License Agreements | Cornell University | Maximum | Two Portfolios</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_SpecificClinicalAndRegulatoryMilestonesDue', window );">Specific clinical and regulatory milestones due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lxeo_CornellSecondLicenseAgreementsMember', window );">Cornell Second License Agreements | Cornell University | Maximum | Third Portfolio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_SpecificClinicalAndRegulatoryMilestonesDue', window );">Specific clinical and regulatory milestones due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lxeo_ThirdCornellLicenseAgreementsMember', window );">Cornell Third License Agreements | Cornell University</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_LicenseAgreementTerminationNoticePeriod', window );">License agreement termination notice period</a></td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_PaymentOfLicenseIssueFeeAndInitialDataTransferFee', window );">License fee and initial data transfer fee</a></td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_PaymentOfAnnualDataTransferFee', window );">Annual data transfer fee</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lxeo_ThirdCornellLicenseAgreementsMember', window );">Cornell Third License Agreements | Cornell University | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_PaymentOfAnnualLicenseMaintenanceFees', window );">Annual license maintenance fees</a></td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lxeo_ThirdCornellLicenseAgreementsMember', window );">Cornell Third License Agreements | Cornell University | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_CommercializationMilestonesDue', window );">Commercialization milestones due</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_PaymentOfAnnualLicenseMaintenanceFees', window );">Annual license maintenance fees</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_PaymentOfRegulatoryMilestones', window );">Regulatory milestone to be paid</a></td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lxeo_FirstUcsdLicenseAgreementMember', window );">First UCSD License Agreement | Stelios Therapeutics Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_PaymentOfOneTimeUpFrontNonRefundableFee', window );">One-time up-front non-refundable fee paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_LicenseAgreementTerminationNoticePeriod', window );">License agreement termination notice period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lxeo_FirstUcsdLicenseAgreementMember', window );">First UCSD License Agreement | Stelios Therapeutics Inc | Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_OneTimeUpFrontNonRefundableFees', window );">One-time up-front non-refundable fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lxeo_FirstUcsdLicenseAgreementMember', window );">First UCSD License Agreement | Maximum | Stelios Therapeutics Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_DevelopmentAndCommercializationMilestonesDue', window );">Development and commercialization milestones due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lxeo_SecondUcsdLicenseAgreementMember', window );">Second UCSD License Agreement | Stelios Therapeutics Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_LicenseAgreementTerminationNoticePeriod', window );">License agreement termination notice period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lxeo_SecondUcsdLicenseAgreementMember', window );">Second UCSD License Agreement | Stelios Therapeutics Inc | Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_OneTimeUpFrontNonRefundableFees', window );">One-time up-front non-refundable fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lxeo_SecondUcsdLicenseAgreementMember', window );">Second UCSD License Agreement | Maximum | Stelios Therapeutics Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_DevelopmentAndCommercializationMilestonesDue', window );">Development and commercialization milestones due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lxeo_ThirdUcsdLicenseAgreementMember', window );">Third UCSD License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_ResearchAgreementsTerm', window );">Research agreements term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_ResearchAgreementTerminationNoticePeriod', window );">Research agreement termination notice period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross', window );">Costs incurred for research</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment', window );">Payment to research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalCostsIncurred', window );">Additional costs incurred for research</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lxeo_ThirdUcsdLicenseAgreementMember', window );">Third UCSD License Agreement | Stelios Therapeutics Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_PaymentOfOneTimeUpFrontNonRefundableFee', window );">One-time up-front non-refundable fee paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_LicenseAgreementTerminationNoticePeriod', window );">License agreement termination notice period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_AggregateDevelopmentAndCommercializationMilestonesDescription', window );">Development and commercialization milestones description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company to pay aggregate development and commercialization milestones of up to $4.0 million, and low- to mid-single digit royalties based on aggregate net sales.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lxeo_ThirdUcsdLicenseAgreementMember', window );">Third UCSD License Agreement | Stelios Therapeutics Inc | Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_PaymentOfDevelopmentMilestone', window );">Development milestone paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_OneTimeUpFrontNonRefundableFees', window );">One-time up-front non-refundable fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lxeo_ThirdUcsdLicenseAgreementMember', window );">Third UCSD License Agreement | Maximum | Stelios Therapeutics Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_DevelopmentAndCommercializationMilestonesDue', window );">Development and commercialization milestones due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lxeo_UcsdSponsoredResearchAgreementsMember', window );">UCSD Sponsored Research Agreements | Stelios Therapeutics Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_NumberOfResearchAgreements', window );">Number of research agreements | IntegerItem</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_ResearchAgreementsTerm', window );">Research agreements term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_ResearchAgreementTerminationNoticePeriod', window );">Research agreement termination notice period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross', window );">Costs incurred for research</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment', window );">Payment to research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lxeo_AmendedFirstUcsdAgreementMember', window );">Amended First UCSD Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross', window );">Costs incurred for research</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment', window );">Payment to research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lxeo_ResearchCollaborationAgreementMember', window );">Research Collaboration Agreement | Weill Cornell Medical College</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment', window );">Payment to research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_AggregateDevelopmentAndCommercializationMilestonesDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>aggregate development and commercialization milestones description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_AggregateDevelopmentAndCommercializationMilestonesDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_CommercializationMilestonesDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commercialization milestones due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_CommercializationMilestonesDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_DevelopmentAndCommercializationMilestonesDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development and commercialization milestones due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_DevelopmentAndCommercializationMilestonesDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_DevelopmentAndRegulatoryMilestonesDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development and regulatory milestones due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_DevelopmentAndRegulatoryMilestonesDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_LicenseAgreementTerminationNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License agreement termination notice period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_LicenseAgreementTerminationNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_MilestoneReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_MilestoneReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_NumberOfLicenseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of license agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_NumberOfLicenseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_NumberOfResearchAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of research agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_NumberOfResearchAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_OneTimeUpFrontNonRefundableFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>One time up front non refundable fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_OneTimeUpFrontNonRefundableFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_PaymentOfAnnualDataTransferFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment of annual data transfer fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_PaymentOfAnnualDataTransferFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_PaymentOfAnnualLicenseMaintenanceFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment of annual license maintenance fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_PaymentOfAnnualLicenseMaintenanceFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_PaymentOfClinicalAndRegulatoryMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment Of Clinical And Regulatory Milestone.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_PaymentOfClinicalAndRegulatoryMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_PaymentOfDevelopmentMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment of development milestone.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_PaymentOfDevelopmentMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_PaymentOfLicenseIssueFeeAndInitialDataTransferFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment of license issue fee and initial data transfer fee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_PaymentOfLicenseIssueFeeAndInitialDataTransferFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_PaymentOfOneTimeUpFrontNonRefundableFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment of one time up front non refundable fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_PaymentOfOneTimeUpFrontNonRefundableFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_PaymentOfRegulatoryMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment of regulatory milestones</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_PaymentOfRegulatoryMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_ResearchAgreementTerminationNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research agreement termination notice period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_ResearchAgreementTerminationNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_ResearchAgreementsTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research agreements term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_ResearchAgreementsTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalCostsIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development Aarrangement, ontract to perform for others, dditional costs incurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalCostsIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_SpecificClinicalAndRegulatoryMilestonesDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Specific clinical and regulatory milestones due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_SpecificClinicalAndRegulatoryMilestonesDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_UpfrontCashPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront cash payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_UpfrontCashPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the acquirer obtains control of the acquiree, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 7<br> -SubTopic 10<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479405/805-10-25-7<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 6<br> -SubTopic 10<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479405/805-10-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479637/805-30-30-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of notes issued in noncash investing and financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleSharesIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common shares issuable upon conversion of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleSharesIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Describes the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lxeo_SteliosTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lxeo_SteliosTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lxeo_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lxeo_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lxeo_AdverumLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lxeo_AdverumLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lxeo_AdverumBiotechnologiesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lxeo_AdverumBiotechnologiesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lxeo_CornellLicenseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lxeo_CornellLicenseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lxeo_CornellUniversityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lxeo_CornellUniversityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lxeo_CornellFirstLicenseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lxeo_CornellFirstLicenseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lxeo_CornellSecondLicenseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lxeo_CornellSecondLicenseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=lxeo_TwoPortfoliosMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=lxeo_TwoPortfoliosMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=lxeo_ThirdPortfolioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=lxeo_ThirdPortfolioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lxeo_ThirdCornellLicenseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lxeo_ThirdCornellLicenseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lxeo_FirstUcsdLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lxeo_FirstUcsdLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lxeo_SecondUcsdLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lxeo_SecondUcsdLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lxeo_ThirdUcsdLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lxeo_ThirdUcsdLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lxeo_UcsdSponsoredResearchAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lxeo_UcsdSponsoredResearchAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lxeo_AmendedFirstUcsdAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lxeo_AmendedFirstUcsdAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lxeo_ResearchCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lxeo_ResearchCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lxeo_WeillCornellMedicalCollegeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lxeo_WeillCornellMedicalCollegeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>Segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription', window );">Segment Reporting, Expense Information Used by CODM, Description</a></td>
<td class="text">The Company's CODM is its CEO and senior leadership team. All of the Company&#8217;s operating results are reviewed by the Company&#8217;s CODM within the same statement of operations and comprehensive loss whether research and development (by program) or general and administrative in nature. Accordingly, the Company has determined that it has a single reportable segment and operating segment structure. The Company's CODM regularly reviews total expenses and expenses by significant areas such as departments and programs to make decisions when evaluating the Company's financial performance. The Company does not evaluate performance or allocate resources based on segment asset data and therefore such information is not presented. All long-lived assets are located in the United States.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration', window );">Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]</a></td>
<td class="text">srt:ChiefExecutiveOfficerMember<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segment</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segment</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates title and position of individual or name of group identified as chief operating decision maker (CODM) for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of nature of expense information used by chief operating decision maker (CODM) to manage operation when segment expense information by category is not disclosed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Summary of Additional Information On Company's Net loss Including Segment Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpenseAbstract', window );"><strong>General and administrative expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income and expense, net</a></td>
<td class="num">$ (7,433)<span></span>
</td>
<td class="num">$ (2,119)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(98,333)<span></span>
</td>
<td class="num">(66,394)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseAbstract', window );"><strong>Research and development expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_ResearchAndDevelopmentExpenseLX2020', window );">LX2020</a></td>
<td class="nump">23,451<span></span>
</td>
<td class="nump">14,192<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_ResearchAndDevelopmentExpenseLX2006', window );">LX2006</a></td>
<td class="nump">14,256<span></span>
</td>
<td class="nump">7,537<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_ResearchAndDevelopmentExpenseLX1001', window );">LX1001</a></td>
<td class="nump">4,501<span></span>
</td>
<td class="nump">9,936<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_ResearchAndDevelopmentExpenseOtherPrograms', window );">Other programs</a></td>
<td class="nump">3,424<span></span>
</td>
<td class="nump">2,535<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_ResearchAndDevelopmentExpenseEmployeeCompensationExpenses', window );">Employee compensation expenses</a></td>
<td class="nump">16,010<span></span>
</td>
<td class="nump">11,748<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LaborAndRelatedExpense', window );">Lab-related costs and supplies</a></td>
<td class="nump">1,356<span></span>
</td>
<td class="nump">1,160<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">All other research and development expense</a></td>
<td class="nump">11,093<span></span>
</td>
<td class="nump">6,022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpenseAbstract', window );"><strong>General and administrative expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_GeneralAndAdministrativeExpenseEmployeeCompensationExpenses', window );">Employee compensation expenses</a></td>
<td class="nump">13,158<span></span>
</td>
<td class="nump">5,872<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherGeneralAndAdministrativeExpense', window );">All other general and administrative expense</a></td>
<td class="nump">18,517<span></span>
</td>
<td class="nump">9,511<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income and expense, net</a></td>
<td class="num">(7,433)<span></span>
</td>
<td class="num">(2,119)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (98,333)<span></span>
</td>
<td class="num">$ (66,394)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_GeneralAndAdministrativeExpenseEmployeeCompensationExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>General and administrative expense employee compensation expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_GeneralAndAdministrativeExpenseEmployeeCompensationExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_ResearchAndDevelopmentExpenseEmployeeCompensationExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development expense employee compensation expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_ResearchAndDevelopmentExpenseEmployeeCompensationExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_ResearchAndDevelopmentExpenseLX1001">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development expense LX1001.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_ResearchAndDevelopmentExpenseLX1001</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_ResearchAndDevelopmentExpenseLX2006">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and Development Expense LX2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_ResearchAndDevelopmentExpenseLX2006</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_ResearchAndDevelopmentExpenseLX2020">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development expense LX2020.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_ResearchAndDevelopmentExpenseLX2020</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_ResearchAndDevelopmentExpenseOtherPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development expense other programs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_ResearchAndDevelopmentExpenseOtherPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LaborAndRelatedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LaborAndRelatedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events - Additional Information (Details) - Leerink At The Market Sales Agreement [Member] - Subsequent Event<br> $ in Millions</strong></div></th>
<th class="th">
<div>Mar. 24, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_StockOfferingGrossProceedsPercentage', window );">Stock Offering Gross Proceeds Percentage</a></td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lxeo_StockOfferingValueSharesAuthorizedToBeSold', window );">Common stock aggregate offering price</a></td>
<td class="nump">$ 75.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_StockOfferingGrossProceedsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock offering gross proceeds percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_StockOfferingGrossProceedsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxeo_StockOfferingValueSharesAuthorizedToBeSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock offering value shares authorized to be sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxeo_StockOfferingValueSharesAuthorizedToBeSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=lxeo_LeerinkAtTheMarketSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=lxeo_LeerinkAtTheMarketSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>103
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( &,X>%I&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( &,X>%HXV6W*\@   "L"   1
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MNIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X8-DOV]:[MR_>X%<R)!%!,!FGK_#
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M"CS<_N\-L,+$CN'MB[\!4$L#!!0    ( &,X>%KANM/O%PH  "4[   8
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M-I<K1@UL:V">+X7I/;H;^_%D^[%L_A]02P,$%     @ 8SAX6K#_NRU\ @
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M-QAIL6@Z9S-1O++-9\65;F5V6.B7#0@3H/?7G*O#Q/2S[O65_@502P,$%
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M:$:7X-*]BH"*5]=1U8MD&WVCLV!2LEP_KBE)*%<&\/N2P1Z^?E$=-)>"L_\
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M@M+LON8QJ=>( \WJHFAU&:F<JY3K>&O</JU>K&[;G5:W'6^?_I\;JGX?#+^
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MC797(SHB]U&:1MOBY89Y:Q;G7\C^_A!%Z?'-..,_1_&7(L?U_P!02P,$%
M  @ 8SAX6BA[D84F P  B0L  !@   !X;"]W;W)K<VAE971S+W-H965T-BYX
M;6RM5EU/VS 4_2M6AC:0&/GH)ZR-!"UH/# B.K9G-[EI+)*XLYT6)'[\KITT
MM*R-Z-27Q'9\CN^Y)[;O8,G%DTP %'G.TEP.K42I^85MRS"!C,HS/H<<O\1<
M9%1A5\QL.1= (P/*4MMSG*Z=499;_L",!<(?\$*E+(= $%ED&14O5Y#RY=!R
MK=7  YLE2@_8_F!.9S !]3@/!/;LFB5B&>22\9P(B(?6I7LQ<AT-,#-^,5C*
MM3;14J:</^G.;32T'!T1I! J34'QM8 1I*EFPCC^5*16O:8&KK=7[#=&/(J9
M4@DCGOYFD4J&5M\B$<2T2-4#7WZ'2E!'\X4\E>9)EM5<QR)A(17/*C!&D+&\
M?-/G*A%K +>[ ^!5 .\]H+T#T*H +2.TC,S(&E-%_8'@2R+T;&33#9,;@T8U
M+-<V3I3 KPQQRI\HJ@!M49+PF(QXO@"AV#0%$F ^00B(R$3Q\(G0O&HE/(U
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MJCG-G]KE+I[-^^;;4E&X'*IX!MB1']G_30!,VA:^ -[(!N8Q G/[UKK$$C1
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M:Z[TD-ICKM<H"!.@[S><J[UA$O2+.?D-4$L#!!0    ( &,X>%HL=6B^0P(
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MN\F+GP6VD2*#>#J#>7P L8BE,@K31:ERG6$+D<5)"+6PPO"%1: )"(&M,"2
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MGL>?.").4Q(N"(X**QY-&\U#LZ)'%,@ORNE+O1RF&GS7_L92E('K.+546-.
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M/W7[J4KI[IXJ M>4N2KT E!JP-4:!2 ^M,=79:25;:HI W.F0H&B"2E9P$F
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MLTZJE=5#=+7\%C!U$;&4KP5IE#T?P/[,P=#V@2]8_SAT_0]02P,$%     @
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M*5(C'^"[Z,(E&0Q[G+.7O6JK"A&W.*J%YPDD']0A_+&:9P90@MPV@:"&L$T
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M80SQBNQ@VY33;CL%\;A54"KIFD)ULN\O:7#(0Y0H&HG&Q6P[1!K>O! B<_@
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M3%[N<B4XLD +\'ZA,%#5-V2@_6)Z_S]02P,$%     @ 8SAX6M;.TIK4#
MJBL  !D   !X;"]W;W)K<VAE971S+W-H965T,3DN>&ULU5I9<]M&$G[7KYA2
MG(U4!5$$P .T;%59N39;%5MEQ4EM;>W#$!B2L\;!X!"M_?7[=0]N@13E>"N[
M+Q(QF.[I[OGZFL&K79)^S#9*Y>)3%,;9Z]--GF]?7EYF_D9%,ALE6Q7CS2I)
M(YGC,5U?9MM4R8")HO#2&8]GEY'4\>GU*QZ[3:]?)44>ZEC=IB(KHDBF#S<J
M3':O3^W3:N"]7F]R&KB\?K65:W6G\@_;VQ1/ES670$<JSG02BU2M7I^^L5_>
M3&@^3_A5JUW6^BU(DV62?*2'GX+7IV,22(7*SXF#Q+][]:T*0V($,7XO>9[6
M2Q)A^W?%_0?6';HL9::^3<+?=)!O7I]ZIR)0*UF$^?MD]U=5ZC,E?GX29OQ7
M[,S<B7LJ_"++DZ@DA@21CLU_^:FT0XO &^\A<$H"A^4V"[&4W\E<7K]*DYU(
M:3:XT0]6E:DAG(YI4^[R%&\UZ/+KNSSQ/U[<0*] ?)M$V.M,DKE>7>;@3G,N
M_9+3C>'D[.%D.^+G),XWF?@^#E3097 )L6K9G$JV&^<@Q^^4/Q*N;0EG[$P.
M\'-K75WFY^[3=2-35>IZ*Q\ K5R\25,9KQ7__L>;99:GP,D_A[0WO"?#O,EW
M7F9;Z:O7IW".3*7WZO3Z+U_9L_'5 <DGM>230]R?M4L'.0W+N1@)L\+RT0KB
MIUC\H)9I 8^E?<!NY!O%4V3\(&20;'.0T!B]%;>AC 5B!8_H+"MD["N1K$1&
M"PC,!M-,K&%UIDO:[/[RE>?8\ZM,?%0/(M I/#=),POD*^TK^J6B;9@\*)4)
M&0?"!RMX'UCAE<28B)0$=W#-E%^DBIDO5:Q6.L?K5&<Z7HM5FD3"EUN=R["2
M:Q>#_T9O1Z0P^,9EU-CI?#,HXD^W[X2.Q=OD7D5+E9+V[D';N.+[WPN=/V !
M'VA#+#+&.J/WQ-897_$T&N5G^^J<U6P8W-W>8GZR5AA*&]D:R]/TFHD1IV1-
M UG-=FB'E!%/[F0:[-NA;X[9&VM@<S PB IRR4QLB]3?,/8*Q(ZTI_$C$5HK
M@7JK.+*'#U\. [^ !#)MDPS"04QBP08$O2+66Y GN>$M0[V..8"4,S4,![ER
M)OT,<S4;FQ6^K[):A!I9<5 *<:\#!=*6OR;;;9+F1:QSK=@*,N>81J;*D:29
M&++K>PGYGRM95Q!CJ+YGW"0 $,W\KF+^V!5JL'9W&N*] T7C3]64_AJ\8YLD
M!%C ?4N6>#[[O;X.W[8&E_U#;DSP,PQ*^YJ@*VY+\._A0Y+7?);*EY$2:K4R
MH!^)#UM(3C3U6-Q"S %KO#2KS*[$U'.LV6)1.2-(@:@(;(U?E&G"./"JR,FG
M:A_N^&L9A'S%K@SL+>$=]U*'<ADJ)J_I2)P=O 30"'BNV>M2OSU$O)C55<S0
MQ0DD2SDJ<N B'PI#6C^2P:"45[7ZMN6-76OAC?<9@.4\W@J57.1K0: 96F4(
M.\;"!TV;;V3>M5N;;\UG0)XKME.EL^-ZUFS\Y30F0)589%^'SF:?4*KJJ(A$
M7'"6;$)^?TG6+)(/M&>TRK 68H<0KRFXR3!\$!-K[LZM<:V()78;[6]X%D<%
M+(XPAYDFFD:T[)D^;^UYC,:A(MZ&18;7>-^Q>NW^#2Q+VS0D)4VC)J)MD<:4
M:BKN>H4M0)(J*H_UR9)A6,;ME.R\4IKM_"@=LWDH^:"QRA"+ ^(\@!".:17L
MK)Y,GP^_ROKD5+) 4P*A?=X"'?LI^;L N[_)F.M$F^67V(@')>&P2[76,=NB
M/<G4]76.R75<T)1\DR;%>F-"9NR'!:O:H7*1&98/8BJ^KN)<GE >?U+3MO$P
MB ;#%&^N7>?N*%*!-IA!@>PKG@M551S(M-0'9I(B1)@%Z:,U X7LCTX-]EP^
M#&:1@02Y33551\:;@=P0UB6<U6K_MYV+\V/7N;HQPN3Z+X,EL]ASL=3;A$.@
M^GQ,D8SESE:AXBB4=2O))V&V%UH<?2;SN>4TT9FD-B%&?AFXH=TSQ%FQ_!>&
MN)BLJI"4SC&:^G^P("<XF66IB*2Z"2J+C;PGC99*Q4)]4JFOJ0Q &EP586CV
M.TYR0"0H?#4<F@XE_GZV>3<02[YPO'M<0@X#EFUO6RY - 'Z6OOFS&;6S)O4
M2:#;KY##$Z98QIDUGH_[]-/QU'+VT ^88/IGFV V15J==:#KNF-KOG".,<'<
MFF,77:]C L\ER\SVF. -$[9<K(*"8]G>U'(=;[\YRTJJ@[DC2KNFRR9[] 5Z
MFU3<X0_*>,.!F%N%ID<:E&<RY9&).;ZD@N!N\"!EJ%B4:1WMN=UM2AU3@U0^
M:AE))4=,ZA4+1#)R;[*L/>;(E!D6O)P(X/4F;Z_1;:2, PJ5M& KI*14PF0:
M$8+ AN;2C*1\VI:5L>X>C;) ]T8I=944Z06M)K8*"3$P'9G3RO-]M8F:8HY<
MY83W6+&P-6BQ%%I>LDPU$=$(,D"_B,XJ&;\(U6'((ADYB'"5A&&R(P)W9J9F
MPFH'8GK->,%RX%*9LJM^%5-'S]@T$*(+YTZ]VVS7\3Q.XHOF'(SM=X16 ]9-
MC%E(D*HD19[5ZEY5IQFREB72R(HY&1BOX[S3^;<T#4!BLB2H7<MSYOLB4 E,
M$)*CY57MTS/GWH/#(=.MN"ZKE^\V "^$;3J%H$A-25!B1=%I]5  :5H)I,TD
MK=HMBG8% FZI1MP[FUK*D..&N5(YR]#FOZ63(N_\*!2X59^W)RK\SSMUZ2/_
M3X[]K(W9YY[?=!VS.5GK>:B,8_HWY*#8=*7Z'EJ^@P7:;XS_-<KDG+_,S9K^
M-QW\4;\[F#\&,T7</SRK#FL-3/;X"-/U1UUQMN.[,!5< (&I7%?;Q>5N'XUG
ML PO<@Y8<WT(P^2F;J2R,L,:V?G+D[=U2?-;Q;WUZ\UZG:HUZ$[*RO8,=C)^
M<=Y>XE<9%NKD7:L^EX/U@XOR86)/K?EDC,CAC5Q'S$>>2U'$13VW./FQQ(AM
M39TQ"K^QL*>CV?CD^[KN/</4J36;S,2Y<$<S!U,=SSOYP33Y/,&9.Y8SIPFV
M/9H0\1:HH3<H!!WPQ MGM)@<(? $T78RG5L+VR,A[9$[A]C\X%C>U#YY5X*[
MC ^,%U3QC_G8UF(ZL1:@)\7M&11W:S8,NVI[1;6]30 1*ZGADV1EDK+O4;W8
M>QA8O T4?EF?J2?J+>77+\1BY"V:P7X=1I+*"A9T)H^E,^TWPG43"\"'@M8O
M0@:?-!X4Z-4*)2+%\Z7*=U3*<9*JTA/:=G./T7>WK':IKD&&\GDG+1J_2[(^
M.VZY-C+HK9T)! !V9QE_QG+&2B9C/FFAIJ4[+H56FS<6[64&L9(]7JVL3)Z%
MF $)J,!_ 0C;5,&$' @9.\YH4HT, :>J;"BY1+*ZNC@,[H(OEJ2X":7_\>+.
MWR0A*6;"+^T6O8Z20(7-34,3P25R>E1RY)M9YDGR/O:WI<P UR,+&7&V/ZC^
MG>CXNOZD37?"=&3 D_<Z^WBQ0EZJ;[5$2GLW&=D39&]W-''%UQ2X8#^R4B^D
MST9C1TQ'<Z^9<I_0B6=(J<B;CCRJ 6;ST7319A-HNMC"1CUH%09B/$+=]G7U
M[Q?VP,&9YGZNG%?Z<+65*$]1+%$VW4H=P-FS34UMW#5(E,E ACN?BDBZ;7OH
MSRZK/C@K-DJ9WI'[QKW]*,V':&4X0SZH\8C914P5YCI&Y@Z,&Y0W\9V;/9(J
MI@,:96(4W7!V';0!*U^]M)B65<2CQ%S5&2LX!%(4[]I(O+_[T-0+>/C<6O7/
M*"19W&[UV&T$GE-+XD\*#D=4D[933<[$4<59Q\9#9FU78/M\>[ L&BB!3C[$
M93S=5^Y< )87=57C>.B5YA[5-%/GY%=#>H$)G>IE;,TQ!S7*9#2;/K7$A(_"
MW#'54\1V<92GN"/WBS@*H^(/^8<[<KS*/PY>X'YX?,AC"17JM284-(T['<?7
MAZY-D]QM*7JG^,;1$)12@$L$=)!:5ALYI#?5B$$N-/1:7F&JA/*!TQBP^!$-
M:I-^FQ)&UL^M,W:C$D5:2M7ZTP4W3_35@.(T9"S5,H[1D,)IK664\.<8,-*L
M=6GWA-9EFJ,HW%NL"K8<N_]0G6 ]#:;A>JZ(L1B=O==]7^];$K'EST9:4'Q\
MY1)C4! P4RW#[J=8@Z(\.8&8^B$J"KW2QB%-,,IZQQ6MSRFP>AG;J+ !^)LJ
MEI9(U88^Q+PG)&79484#,J/$OIO=0=X-DRT?*U5"OF 0V!0.K#D:E!]-LN#Y
M,HC0+M+'>/R!144RLR9SE_JHA7/R2U+?MQPR!;BCDYM/*)988Q0K0U_C7;:^
MGXQ4NN:O1 F&19R;3RGKT?I#U#?F^\MFNOF*]6>9PF50EJL52,>C^?34W*A4
M#WFRY:\QETF>)Q'_W"B)D$$3\'Z5)'GU0 O4G^=>_P=02P,$%     @ 8SAX
M6M]I5K?" @  1@8  !D   !X;"]W;W)K<VAE971S+W-H965T,C N>&ULC55M
M;]I #/[.K["R:5HE1EZAP "I]$6;M%:HU59-TSX<B2%1+W?9W:5T_WZ^"Z1T
MHJA?R/EL/WYLG\UD(]6#SA$-/)5<Z*F7&U.-?5^G.99,]V2%@C0KJ4IF2%1K
M7U<*6>:<2NY'03#P2U8(;S9Q=PLUF\C:\$+@0H&NRY*IOW/D<C/U0F]W<5NL
M<V,O_-FD8FN\0_.]6BB2_!8E*TH4NI "%*ZFWEDXGB?6WAG\*'"C]\Y@,UE*
M^6"%K]G4"RPAY)@:B\#H\XCGR+D%(AI_MIA>&](Z[I]WZ%<N=\IER32>2WY?
M9":?>D,/,ERQFIM;N?F"VWSZ%B^57+M?V#2V<>!!6FLCRZTS,2@+T7S9T[8.
M>P[#UQRBK4/D>#>!',L+9MALHN0&E+4F-'MPJ3IO(E<(VY0[HTA;D)^9W5#?
MOTFM88$*[G*F<.(;PK5:/]UBS!N,Z!6,,()K*4RNX5)DF+T$\(E0RRK:L9I'
M1Q$O,.U!''8A"J+D"%[<9AD[O/@5O$NF1"'6>UG"K[.E-HH>Q>]#"3=PR6$X
M.RAC7;$4IQY-@D;UB-[LP[MP$'P^0C9IR2;'T-_8DN,88="#%J=JDYXS7:3
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M,65-Y520#[%/H& R&<$:NAXEPY1RLP.&-F)8.+QD!S+:VH7'Z?+@!-<4N?&
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M%^#WRB$_Y88/&+[C7?T)4$L#!!0    ( &,X>%II@3VB=A,  #A+   9
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M)%S/B$1B"Z<Y.QY+S /'M55-!8R(,7XM-<!#]I[3V00[[#*./P^_%7=6YW"
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MZC7SE3IC(&WL1+M6A.IPI0L!B3M5&979,0N B$X'$%*-R;H+(!D,%ZB)#A9
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M^^LM^KM8.]6R%!XOK/HFBU#/DY,$"BQ%J\)GNWF/?3U3QLNM\O$)F\XW>YU
MWOI@=1],#+0TW5O\ZONP%W RO"<@ZP.RR+M+%%E>BB 6,V<WX-B;T'@12XW1
M1$X:'LI-<'0J*2XL;MJEQY\MF@!OU_3TLS00+!^F>0]QWD%D]T",,OAH3:@]
MO#4%%G\#I,1G1RK;DCK/#B)>8CZ \>@(LF$V.8 WWA4YCGCCAQ8)W\^6/CCZ
M)'[<56^'-KD;C:_)J6]$CO.$[H%'M\9D\?31Z.7PS0&NDQW7R2'TAPWD,,1H
M.H#_2][;P6ZG%FN$):*A#:%:$;" 4#O;5C5\%"ZO(9O$&4R/8%-+LJ4G!X2"
M7&DA EL>H91&F%P*!3[0D8[H&W1( ;XE5&&*SA9K(958*@JWE+H_'\ G\U]&
M3G1A=2/,+1 @11<@#84)\$*A!U$YC+GHRH0:KA"=-"NX%BX8=!ZNKB[@>=)O
M)R\X(ZD!<:P%C0ULN9_BF8?<:DTZ05<N7W%OI*F(.*6A/!57;,N2L2IHG,S9
MA+9AU,?P:CH8TNU4BH6F=%9#(.7BL^[=-Y71PC%E/28!7)'BTCQDN-T'MI43
M&EJZ2*[O^;8NZCU+&)/R_S G]31AL.])M@R*YVFY+I)P+Z(*DHR#I.GP9TM%
M>&III*5M:R(?&B+%C.')MD&5L]XSLQRQB&WCB?2'#^JEMZKH2XHQ?T]O<->E
M2?<43:.KHFXS++'LQ&VWN_LUG'6*^,>]^Z_0=U5)XT%A2:'#P:MI J[3ZLX(
MMHGZN+2!U#8N:_J]H6,'.B^M#5N#$^Q^F(O?4$L#!!0    ( &,X>%I'(=XH
MVR$  ")Q   9    >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;+T]:W/3R);?
MYU>H<F?O)%6*L9V$!&:&JA#@+K=@H C<6UM;^T&6VG8/LN112PF97[_GU2]9
M5@+,[H<9P):Z3Y\^[Y=_N:V;SV:M5)M\V925^?5@W;;;IX\>F7RM-IF9U%M5
MP3?+NMED+?RS63TRVT9E!;VT*1_-I]/'CS:9K@Z>_4*?O6^>_5)W;:DK];Y)
M3+?99,W=<U76M[\>S [L!Q_T:MWB!X^>_;+-5NI:M9^V[QOXUR.W2J$WJC*Z
MKI)&+7\]N)P]?3Y[@B_0$__2ZM8$?T_P*(NZ_HS_>%W\>C!%B%2I\A:7R."/
M&W6ERA)7 CC^D$4/W)[X8OAWN_HK.CP<9I$9=567_]9%N_[UX.(@*=0RZ\KV
M0WW[GTH.=(;KY75IZ/_)+3][=GJ0Y)UIZXV\#!!L=,5_9E\$$<$+%],]+\SE
MA3G!S1L1E"^R-GOV2U/?)@T^#:OA7^BH]#8 IRN\E>NV@6\UO-<^N^;;2.IE
M<JU7E5[J/*O:Y#+/ZZYJ=;5*WM>ESK4RR:']V]$OCUK8&A=XE,LVSWF;^9YM
M9O/D;5VU:Y.\K I5Q L\ I@=X',+^//YZ(HO5#Y)3F9I,I_.3T?6.W&(.*'U
M3O:L-W3B_[Y<F+8!POF?H1/S>J?#ZR$W/37;+%>_'@"[&-7<J(-G?__;[/'T
MYQ%H3QVTIV.K/_MD%%[92]-JH$QEAN#[NA62O__M8CZ;__QQK1( >)LU&;$-
M/-/"1TM=956NLS(Q+3P.?-F:1"-7Y753P%<*"+==)Y\FUY/D'Y>7[X%E_^@T
MG!RHM0+^QC>2MH9_?5:)<KMF59%D!F3"%G<SL%?6)MER"4Q+^P(D==,J>&B#
MUV,0'GA>M?QJJ;.%+G6K9:E"F[RL3=?0X?*:+A1WWO<.[U( +&,G3>G%??#H
M*J\WBAY17T!< F:+KD%*\F_@O[:JT74Q21#%F]JTB0DXSJ.D426" [C"UP'!
M39>5M!'24=;D:SZJN@&9NB6\YK :  F E%V!6PV^A>A :K:/]W'?&3@7;&M!
M871DNDENLK)S"+JJ-]NLNB-Z.?_9 )KJ_'-2;UG*WF9-07A.@8QTW>""&O#T
M^OV[%/]>J%8U(,B&5L?G )4;6(<6G21O/>TH?(P0A(_MIR $ LBV6M6(")#8
M&D^&?U]K6+4!=)=T3XU62+;X?@VP- !,#M]'>$08\ZYI" # 7[W1>:*J&]W4
M%4+%2$2:!D"*WT%>,V?<KE5%ZS%\N6[R;@/T!!L:(-(<*8L(P43, &2+*J;
M0^B*=2YA]2;39;8H 5ICK^$^FOT9OP$55S<J1>4'Y("D -H*D=R5R"S 9W#L
MIM[ LW4(RF1$1ITY&74V*F&N,L.42G]Y"=( ;I"P@Q]^@+W@+I"5\/LA ?87
M+A]*-Z%?9 >C"]7 "V4)Q+%:EW<@'&"A I!_H]Q=HES+ '=HY"!1 (: O=L[
MON5M![S%EX:7T2AD;E)U0/RE,@:I?@%DA& H#^:$ 5,AX$TH8(!/LZ:YPQV)
M0X P;]<:N7^[;>HO=%$DE'03\)$P1$A)?W0U/@GLB-2GK2D$YV@^HU $$DD
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MDQK\VFMD@!^PLJVKPB\5:&GA%&U8NA%KX.Z!/'><PFIY@%-,J&N*3EF]9-;
M;L>HDY(*L05B^4./'/ZZC5GW6P'4J%4'=%(B!^BJA?^$8P@G.\)A@%"%$$1&
M>2T *[6Z[0*32GW)%;SU2A5TV2^$FE]78"O1#5W5#0@>5C?:?5H"*;6CVN"Q
MTP:/1\7U:R]1AV3]@U^VDCS\2/@5)1S($EV2.T.<^!$\53C+7235 J/"62.&
MC2V\-E@%5:OERCRT@X$P_4K6>@1^(VOFCL1NEI/=R]SMC9;>\A4J!EC3=&B8
M15O1NBK+UST^1X7?MTTL_ Y&*SEP\U"2]+=PRH$L'#$,T41PRJT@L,7  -&L
M@%!QVT U3I+P%C;9'>HY4X-T7]R%@LM;@D,[Q4SAA"';>:$B!N'H#*%C$%?'
M!E@#]:_I,G8N+J^ODH_U%FRTD_DT#:$3JGFA%HP;M!?@D-?^,N/#L"I&P<IL
M[WDX96;K*B"M4O\)7Z^(<\FUJ$&H&;DC%N<96K0@VO 2T'?)P1#L2I(F;'7B
MUXU:8Z #=++X$H>XTA&*73*$UX!3D,NB $@L /"DZ./EV[I%H10MB4M931(X
M;^0?]9]+$_2!T5#DLT5W\Y/92UZZASIR>2L\9*4(,'3,O /GI2/PZH_)Z9-T
M.IW2HC\F9V?TCQ2%W5:1I5*B ALP1<;DTKF32^>CHN6% AL8V?6Z7K:W"/L5
M>D=#,NJ;%K+RZM]H 6YU2WA-<M6@O&=/3#P^\KW #"=]"FHEJU9R5>P4-RA[
MFALPXAP;F>00W-VNH)OL=EX\0LUI]RQD,US'$2B \(ZH\$HN\M)K91)F&_1=
M_V11D248#2$=CH<7WZJ^@=>1MJSS4*"EL^Q*4!Y+T'BO:O[Z#IQ0<)UPUYV+
M3.'>IY-9LM%E*8*LL.@T%IT,/EF0>7"J 'ECN!BCE0M'*Q>C5_P;T/(;Y"8P
M>Y+K-0 U1"9?NX802"0%EV"7U;>L-=K;^IBD8K)1X*85[';X4R*'Q6)CRV*%
M_.@U7:.)Q#&X*]:PH^^%PC:H95BK@"FAK4K99D "N=ZRH1<JTH]#T 4J]0&0
MH=5)NH[78*&T(1^^V+MS;/(6^@:]EP)M<5@%:086#05M;RV,)R,5DU0$S:;1
MJ%IT^"30*+IX^\[F8EKQJ;Q[3BK.!S!$;M,I$;$< 1*'$+S..B?X%JJ]57RG
M]QZ=%7>W9=4-2LF+27LJ6!Y4E\)//&[PRI?DZ0KL/9C6&<(!0 3HB#5S5IHZ
M<)I)G3#U""U9H!"+(-?5%]7DFL.,88PHE&?=XG>*]"'$UI$6].S'@,HS=" L
M<JT5)<"L,S@WZB8XX%*!F,![L7@(+IX O2%EYK\&>;;--$F[.!#U$6,I^'55
MVXOCO(08>V0@#;.KQ (9SP0N:62CT;2C&]AWTJ*&[5H^41;93O6BU"L& ;#%
MK"1G$ALD#M9-DN<@K/.'<*0V(EL4F7&$&FMN/N!UL?QN*1VBBF. O0%K.ZDZ
MDOB>P>6ZZJ[%N!AM$9/D)'FAR\[:$%\'-<?BAJ4C$9MEOCW\']O'V[K%Z @Z
M5H#-7 P:@ U9+!2((<"E%?(/QF[1?_NOPV7H-_C3N#-$RZ A[*@5B(H]VE!_
M^!B5@S7=A7[G[+>BADRV(96T<"0Y_#QSR#"0; <@=U#L5XPG9!028C9LL10A
MJ3BC@!" JZ"/[:)P9<R=A_KH/BOE) U0%P,3V"#B3\%-F2!]PI^T&F71]>6K
ME\EO-3ISC%KYDLPQ6.%T-DLO9F>]+08B,$.AH=?OWR'5_@96&<$^9]"30Z,4
M;9H\/N)HT$4Z/9^FT_GYMYW*8/S<))?1T<#LMU8;"7S<YRP]O7B2GIV??-<^
MS\?VV8-(?\)X/X3J<7IR ?^=]+[K>QW?B/7S':R?"]8/=4!H9I\]O"_&>I*>
M@[$\GUUP.#0]G9VEYZ?3?9CMGZ:'Z%!!AZ(C5M:X$_@$;<D1D]ZS0:SLFE[[
M5*';?GCPX?J3.3@*,/ $,$!,J[Z(\R&)!R42T<4P[I<DU@2(@B&;Y);2&B0%
MT)S)JIC9K13H6<-.FMG]E#78,"4B@G#,?7CBW(<G#_,0WV'>!:'>ZVI^TT*#
M20[G*1GG=)9JE94I&=&2\?8YL':MF^(8+1)P0I0*;+4"[)R\!;NN'T.6:(1$
M'U%Y9L:[;[4%D=TW#B^0O1:^0.Y=1:4A9'=>+ENZ<_DHD*3]W5()RWGGUH=M
M#*5MBBX/%]@V-89"C2<_"V*:@+F(2!A^,<[&D&?4$W>81QF-V!RB9Y7K]FA@
MBZPHR.6BH#)=6K)2%<;7_5$P>V?!L5!/P(LDNA_"#OD9"[C>NE)%:IV[P9MA
MYEDHF\,&(;H!O:HY2,.1+&"^%=GG/O O3^]&F$A2\&-6C.S&FV(/ YFVJO="
M&%[L8(X(\+\C-,<8=S;U53+348[[$&;>7_C,^V ES+<M9;GWPVB2GRC<W5!&
MGBB&;@I*6PR_Z*[(QLG)<#2M?YG=:)-C+"=U!0-IN%)2-!U<!(I]B@Q'%B50
M.FK)TFV5!M[M,LLQD7-W;-4/KPJ4@%($J3]XB\HLO @J=4[U%"B*)B+E0J#K
M!4FT5N7KJB[KE7M#9 H1;$S)9/Z/8TKLQH%E"XJ=H-G98-0"@;#/4#IHJ<"F
MI;P5AV?Y:4 &B#,,T@/9+SO,,F&,;)0T@P*NV2@]_8.$1$G;718;7:$[0UL-
M$N>W+F:C5.$36?3$+IU%^1A6]$Q]:K,MZSM2+S780"MT:LC4XAP4(JDBP0@D
M0;H"T&A3B;2Q4UUI5"?A+RQ-UMTF0P?=U%V36]HBU2>5.N"W21K<IH,F#SH=
MQ4$D@II0T+3.\PX$6'YG*VM <&&8UM-U1.ZT. =6Z8-4=.]*-D<N7*NL\&4]
M-AT'BVQTMS%86U,OE3&L+VQ8&+DD%4G;BRMSKK&MFSNI@6IM_ !0ASG?46*<
M>V*<C](/VX#/R7E&J0['YUU>,BH&2?+[EAP*GPI]L!U'^OB8'?IM=D>,+F5*
M*T"K(,B3I,UMN$]2)+];59;X9QSRDB2R?]G'@7S2A%R!E_*(F,GO;;#K?0E4
M>H@O'/!SU^_?'QS1EB'@>7AR*Z:BO%2L2@F^> DY\_A9K1I'GMH-W!'E$OD_
M;/G>8D'ZFM?MV%G *YQ/?T:7@?XZ^_E(JN0H>RNI6I(+&"ZVF(P+S[#HY_J3
M!4.;J$B*+II98R]68PMR55%V :[!8MLG.NSYK'5'44"C6Y^@L5$7J?Y@8#!%
MYB.!J52J :VJ4LP\RJB,'#V\JK&3DF$.;AHJP&H57,1.,1\M,K)C+\+KJ-O1
MJMU_J1O3.B@HI-^[*!??W2+).]O.8N.ON9O>LGO35A/FP_U[]=']H-WC&]Y_
MP7OW=@9(5!4DMX=2C;B;G?1A.SL*7%HUBESIPWA6+0BQVHQMC3%PKL!J(TF"
MQ]GHUFD2=Y%"'*14RSM+)(BYCO+!WC$2^6$C#H643F!DS@8AJ#PMIK 92<>4
M@G-4[R)IC0?N,; 6%V"%_J&MZ[+U1G?6U^K5?Y"W&/AHF"8X1IM%?+6'E&H%
M\@#N0*L;QNC(JJ@%R/YA7L<#IQQ#XD./DU! K8Y$]\DJGXGS&[J0E<2LN,:)
ME88+0=O8LP]&\W4$0:*'E;$1_P=$?5]@\6%^-C$MN-E$#R[V$."3,M28*.H:
MM1M H+(>M.\:%I*Q!&5\A6J(Q2^!=Z_D)%?.)<V%96,Y#G=B6?E[Y6L<"N2*
M:%SX>9F!++K. 9-XC72,8V1&*G6M"U42V99#!=L$!FI=:T@!T<$5 .':6"XX
M^00$,7><D_K)]"@F1@#^G9:=).][A>11K/5DH "5 _VXZPV5<EFS$"U?.*VP
M#'QTC#A!)@]K^JA6$G"+HO>F!EG)<B%T-)Q=Z<2.8$ RA5QU'4+D+YH,QB]X
M%XZ<@UTPCMN@GQH)\@"ZX%F,&L&U+\ Y1<>VR0J2ZL0]6R6U15FEE=D/\$"5
M/KE'KBA] %R^S0 0[^C]?T'-N2$',A$B/IU9<1:1H8,?2U(L<0TNG+HVCIPS
MZ=Q#PO6B19V [1N($:K\PR!,2YX^G.0/K/8+#P[DC-IDE34NSQ?C@NIH;RN'
M"(]AEC@.=JI1?4 /AD<2PL0Y?5N3 8((=_[3@B*6MR%R1UM#[&^;NR:4BF&/
M@6!$JEZ2CI170=CHZO@&[JLL,_MVZ"_\W^)R!SL6G1%&&).--I^/EUB@KP$]
MZ(PD%&S0)D30 C,"(#NI.43H)ZXEO=-8P XJ@>KU7%8A* ;U\CNPLCFI@%_;
MY&I<!S=,L>&M!\:Z^]Z5+C!4<)8_55,/5?Q4"FT *F\@8\K7AF#);Z_UAD-C
MM>)@%^^&L($#G7!>(5K!.WK**$4E%QSG&@TK^-Z\V6@SW;/7G,#_F'T9;G7[
MBM=MF-7I%)\JG9(FF0YHDBIY\^:*1+/$]:BK5-E*GA8HHXV4_/NL:2NP2]9Z
MRY:UX=XDOL?7%84#R^0#%J!TN%D!W'YIJYI00>-SP::W$G:\T>K6FJYM]N48
M[H.B\/P4-E4 S+]W0.K89>2B3;[LAT.>DG=P$ 4[+<L:=VC73=VMUI8>=467
M376[A"YC6^)8V6&44W9H"<V4ZG.65%P//$G>5??AW>=RT4).KL("]<G^8$\$
M@[\/:C:(NO_NK(@;KA\^/Z7ZX8!N#@_P6_C\X&B2?)*5M:WRB8%WAG>0" .0
M]G4AVEH-"0WCDQA"!8&@J+H_:[E Q9:8<>,6?V=KQ]A&W&D#ZS<HT(VK+UJJ
M3/=W4NX4ER%4J-WYZZ#S S.T] :"S5TCM"F<BC3')'GQ !R@,2P1B$*L4U5E
MS&3P5D.VB)>*-0I/CN;#UX08N7H119Q?#\I7,)D+.$$::NXB%-J42L#1>(%
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MHS(!F.B@ VYHP1ON==XYDKU::[5,WCG_"TQ)-M+>9I]!EQP>7+U[\?;@"$^
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MNJ9Z!WP OD=Q9_^!&[B?17SVOU!+ P04    " !C.'A:/CVG;!D#  #G!@
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MUI8+U-(S")W#N^^-K+ED: B?D<[1O@A\GO9#B5 8Q>7KTR,=$ O<CWM3GS+
M(X-V95$)PIQK+VNJIIOGR-"9%%U1.H_ IXG5%FU_HL/6^O_B!*Z>45@'VA X
M:M&D9CJF<:SOKN>#KPZ+1L&]+/!GU)\!!Q\UH=5"0>,X)E/07EB$!#H_K^%7
M_N+?)H/WC=62&M[SQ KYY.<.Q@?%9#;A+QK<B^U)!J:'W5F:PGB4#NZ1VT=I
M%+.N.&F/Z+5<KQ9/8XC3Z>#!$!-Z(:NCX3B*^9\F4\9S;GXAMVPH*F-)_M,)
MKB"=IG#-8S(;P?5%1T/0_"*\9D]1/.O&\03.W=WPI/E4:'=MBW70UE/7AWII
MW\5ON^;U0[U[ CX)NY/:@<*"3:.;Z3@ V[75;D&F;EO9UA WQG9:\DN$UBOP
M?F$,'1?>0?^VK?X%4$L#!!0    ( &,X>%J_+25WE <  '(7   9    >&PO
M=V]R:W-H965T<R]S:&5E=#(X+GAM;,U86V_;-A1^]Z\@O L2P+$E^9HT">"D
MZ1:@W;(Z71^&/= 2+1&A1)6D['B_?N>0LJRXBI)=, Q%:DGD.?S.X7<NY/E&
MJ@>=,&;(8RHR?=%-C,G/!@,=)BRENB]SEL'(2JJ4&GA5\4#GBM'("J5B$'C>
M9)!2GG4OS^VW.W5Y+@LC>,;N%-%%FE*UO6)";BZZ?G?WX2./$X,?!I?G.8W9
M@IE/^9V"MT&E)>(IRS27&5%L==&=^V=7OA6P,W[E;*-KSP1-64KY@"^WT477
M0T1,L-"@"@H_:W;-A$!-@.-+J;1;K8F"]>>=]G?6>#!F236[EN(SCTQRT9UU
M2<16M!#FH]S\R$J#QJ@OE$+;_\FFG.MU25AH(]-2&!"D/'._]+%TQ&L$@E(@
ML+C=0A;E6VKHY;F2&Z)P-FC#!VNJE09P/,-=61@%HQSDS.4[RA7YE8J"D0^,
MZD(Q<+G1Y.B>+@73Q^<# ZO@W$%8:KQR&H-G-/H!^2 SDVARDT4L>JI@ / J
MC,$.XU70JO$M"_MDZ/=(X 6C%GW#RN:AU3=\T>8>^3E'<O3(+P7-##<4.4+>
M<AT*B<[0Y+?W($UN#4OU[TW.<$N-FI?"F#K3.0W911>"1C.U9MW+[[_Q)]Z;
M%D-&E2&C-NV7"XC1J!",R!6I;>2/G"FJPF1+(&K)7&L&&TJSB+SG=,D%-QSL
M*G<[(M3492%0/K*P4(IG,;FBFNLFHUMA-1M]GS" (R +H&:#[")V%-G&,Y=?
M;)PN(7D0 ].O99K3;/O]-[/ G[[19,4SFH6<"D*M3;W:%[$WK6=MY=F::>/(
MG-9L7:&MZYVM%#++SMHE6EO*1CRD!KR$, 1;,X$NQI>:>%*YN3"P]!^@WTC(
M"(:I%#FCBS"IS==GG;E&-4!GEBZ9JBA]UGEOE_")^PW*WR&YEX:*CMO!L\XU
MU0EA7PH.^ER0IC)C6T@'ZH&98_(M\:>]R7 "#R?EG_O0^=1?],F]LF[8$HTF
M.Q:<D-FD-_9&U4/G=N^WLS:Y:<^#2"]_.[6E3X>]L;_#X/M^SQ\'SU@^_!<M
M]X+>:#:JF^Z^M-E@_[W:8C>[92G2$M+C*J3'KP[I&C!R+8#S?,61Q)K,UY0+
M#*$3B)N3!3B%+"JH30';NFASP-96[Y%-PH',5#$2/@%"GP#1"&3OLQX))91O
M;6#N+GRJ#$";8\'&7P-/G@V=>2J5L<%W+;5Q*8O\H*36Y%,&^^@"\P?H3QH^
MOX=WV-M]_NO,VPQJH8?E_<0_+1EQ!)P8DN,J'#HOC3\;(/\;^T[J?YV#]S;J
M3RKJ3UY-_7D<*Q9#"JYAU_\@)LAG;I(&SR#;K.^:@J85;G/0[''7$C_BKI>C
MOQ!"T T"[F*/6^QQQW;/-PR"$M2XR-)_-:Z^GOC5I)<X\Q9J(<+D&5141K:,
M*J!$65>0*SB!KJ L[L=-HF010WG$=@N_(,/*DM)Y4D-:B#6MB#5]-;$^@IO
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MU_>><S_BD\56J@== ACR5'&AEUYI3#WW?9V54%%]*FL0>%)(55&#6[7Q=:V
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M"<>L01,J<G)M2E#DO%$*A"%?&$T99X;AZ;M[FG+0[Q>^07(+X6<[HG5+%+U
M%$;D2@I3:G(I<LC_!O QZR[U:)_Z.CJ*> '9*1F%0Q(%47P$;]2U8N3P1O]I
M1;_>YV[TK3]6J38*/ZB?A_K0LL2'6>PEF^N:9K#T\!9I4(_@)6_?A)/@PY$:
MXJZ&^!AZ<M?>+2(+\KK)'BKD*-7A0O:DT">5CC3;D?)>(S.)MUL;#,"$T8L4
MDJ-,,+$A\P'.%ZH4(_<S)O]:1H,]GTV JJQT?#D\HMC4E67K$CDAD^%D-G'O
MT33N(E,I&OWL-AJ>A5,2#:=AT+EL0("BW&'3'"\AL].W:G*HSEK) K05+0PI
M ,^B81Q,2#@,9M'@^L5>S$8S,A['@WMI+-?K&GE"0LQ\/+.+8#B- W+H8_)[
M.E&!VC@UM%-HA&DEH[-V@KMJ=>;9O57K*ZHV3&C"H<#0X/1L[!'5*F"[,;)V
MJI-*@QKFEB7^-$!9!SPOI#3[C27H?D/)'U!+ P04    " !C.'A:=TI1X1H#
M  #Q!@  &0   'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q]5=^/VS8,?L]?
M0;C%M@+&^7>2NR4!DKL6.V!M@TN[/11[4&PF%LZ67$F^]/;7EY(=7S;D\F*3
M$OGQ(T51LX-4C[I$-/"CKH2>>Z4QS4T0Z+S$FNDKV:"@G9U4-3.DJGV@&X6L
M<$YU%<1A. YJQH6WF+FUM5K,9&LJ+G"M0+=US=3S"BMYF'N1=UQXX/O2V(5@
M,6O8'C=HOC9K15HPH!2\1J&Y%*!P-_>6T<TJM?;.X"^.!WTB@\UD*^6C5>Z+
MN1=:0EAA;BP"H]\3WF)562"B\;W'](:0UO%4/J)_<+E3+ENF\596?_/"E'-O
MZD&!.]96YD$>_L ^G\SBY;+2[@N'SC8-/<A;;63=.Q.#FHONSW[T=3AQF+[F
M$/<.L>/=!7(L[YAABYF2!U#6FM"LX%)UWD2."WLH&Z-HEY.?6=Q*\83*\&V%
ML*:"H%)8P,;(_!%^^\)H6;^;!88B6?L@[U%7'6K\"FH4PT<I3*GAO2BP^"]
M0!0'GO&1YRJ^B'B'^14DD0]Q&*<7\)(A[\3A):_@?<&ZD8K:$-Y_;[EYACNN
M\TKJ5B%\6VZU4=0O_YS+O,--S^/:.W2C&Y;CW*-+HE$]H;?XY4TT#G^_P#H=
M6*>7T!<;NI-%2T<E=W#AY,[1O@A\GO92VSA4>:RWJ([5CX&) EIA> 6F1+!5
MXV)O3:UZ*^N&B>=?-=RO/P/=NT_RJ?.?./?$A_R$>3,PUZ[G:$]S;4CO\7:R
MHL%! 6Y&)QF/SF8_^G\'$YF:*#AEU"W=:]W2OLUAK62.6&CXDU,/%,R-";MO
MVQZ^-E*,EJTII>+_DL?GUFA#;C;7!ZH)#9.B#XTBQ_X\[+ :;5!QU+"\F.DT
M\]/KS)]004_$MYTR?A&F?C@)_3">'&%7%V&SJ1]E$W\:IR]B E%($.-P^!/T
M]-K/)LDH2A-_G"5^EH[A1<XH?D0$LFQ\(D6TE5W[XS"$<\T<G(RA&M7>#5M-
M;*E9NHDTK [S?-F-L1?S[C'XR-2>"PT5[L@UO)ID'JANP':*D8T;:EMI:$0Z
ML:0W"94UH/V=E.:HV ##*[?X"5!+ P04    " !C.'A:LFKY="D#   Q!P
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M_E,=B*T"V-Y3 -<%\+$%G+J LU/ '>\IX-8%W-T:SO84&-4%1KL%\)X"X[K
MN(Q]%:PRTL27_NPBYX\HUV<KFGY1RE665@&.4MVS%C)7GT:JG)PMJAZ%^!(M
MHE4:+:/ 3R6:!P$O4AFE*W3+XRB(F$!OT3P,(]T?_!C=I%6OUKWC-6'2CV+Q
MR\50JB9I\#"HJR=5]7A/]39&'W@JUP)Y:<C"#@ U \Y< V"H@K&)"'Z.R!4V
M$C_RAW?(FKQ!V,(.$FL_9Z*C7=?'4/ A"C%3" O>(<<N*2ZZ6Q#T^M4O:,%6
MZMZ6^ZG>\51G0]U+H_^AC08=G$W/=$JN\_][YI?WJBRZD2P1?W9<P%55D=M=
MD<[=YR+S W8Y4,E9L/R!#68__V2/K5^[=(>$$4B8!PFC0+"6].Y&>M=$G[WG
M0JAA*^!*]G]8B)8Y3U"11JDH<G5X[\=^&BC=OZ%777(;X7WEAH012)@'":,5
M;%+"]&SD869=#!\Z-!QM-!P9-?Q8)/<LUW>OF@7EU4 AZL3U[3F%=:EGQ/95
M#Q)&*MAH*T;V)D:5))#542!82[WQ1KVQ43W"EBS7]QI?JA<ZV09<R+UWG!'6
M5S-(&!D;^G6EV<$SZ/B%[GONC<DFNA-C=.]4]LK5E"E%TG]"&1?EK&IO=(VP
MOM&%A)')P>@>/(.:SFA%=[J)[M08W>NUGZX84M'=GBNH3AQ$6<S>;+^[D'X:
M^GDHT%T6^E)_&/),JG[_1>8%0TL_%JQS2F%L0E]-(&'$'!Q]65V#"603:-\F
MM&0^V\A\9L089$1?O">I5[_W,5/K@B*I!Z!.)8VU]%42$D;,UU^(MRO?S\Z;
M.&S"4$5!S^ZMR0>FQ^$NR2';2H%@K9Y@6\TBUC+&XB9]8$*6<XN@4.-6.<?H
MS*5F4%^Y06FDIFVG0O?,LG93*FBE]&"E;4FV? 7[6$E2GKX])(L1UEL62!JI
M:=OC_VC4(0MDI?1@I6U9<",+/FYB)_A2/JH5OWEB9Z;UU@621FK:=L^U+:M#
M&,A:Z>%:V\HT=H=M7%+/KGF2J#720O+@:Z<4H"X&*(V TCQ0&H6BM65MK S;
M/96-98,:&Z T DKS0&D4BM;N 8T18A_KA%06*XJ$*%0&#HMR82W7#&5JC<U#
M5&0J 01<C9QY^>1&%:F.9#F3%4R-HFJIV.G27IE;T;MW@#HGH#3/[C!B7'<T
M=L;NSMH2JMZV\HV)8IM=E,6<>FIDW<[LZO#F]E.G?J F"BB-@-(\4!J%HK4U
M;JP<>W*R_ YJ](#2""C- Z51*%J[!S1VDVWV,YK\'E0W>IWF7^3RD-U+%*5"
MYL4^\]M<5>\N,'V1*%W;GMJC=IHDH+5ZH#0*16N+VYA,MMEE\9Y8'D2":?T^
M%5)HBZ6RG'0R_Y25QFVGDJ"^$BB-@-(\4!J%HK6?_3=.$K9.E<XQJ-4$2B.@
M- ^41J%H[1[0&%?8;%S-E<QA%!?Z&T];4V[$GH*X")^?1JLY75;(ZK&F3NVZ
M@/HL91+%^NFUFM&WAH/.#@)J>H'2"'[I/SD3[&)[NN.N=)R(77LT<7>?\T"U
MKRUK8WQAL_&U4$LLI>)<*=>LJ&[S9SMLK^UBQO86"=0! Z5YH#0*16O+W;AI
M^&3?'L*@QALHC8#2/% :A:*U>T!CO&'SEXA.F,=!?3E0&@&E>35M.]E/K8EE
MX<ENLO\>EAMN+#?\0UAN^*41U1F.:W-S>VL*ZJ:!TB@4K2U\X[CA X[;$:/\
MCB/7*2RH%P=*(Z T#Y1&H6AM]1LO#I_,B\.@7APHC8#2/% :A:*U>T#CQ>%C
MO;COF_A?&FM[$C_H5[M :1XHC4+1VL(W/ATV^W1UXK_JO;P#M>E :024YH'2
M*!2MO36DL>F<D]ET#JA-!THCH#0/E$:A:.T>T-ATSH]BTYD;TKN#@-ITH#3/
MZ?C2F3L]&TV<G>4=5+5M[1LOSSG*RS,F^R-F^>9:>@L+:NV!TCQ0&H6BM=7?
MVA=XNHV!L#L#8;<&PNX-A-T<^#VL/:>Q]ARSM7>B6;[STNT:.].QX^S.\LW-
M[2T\J&4'2J-0M$KXX=:^]83EJ_(7!@0J[^-JP_;FW>I7#(A][I6;_7?>G]OG
M\W)/_[#!5#^-\,'/5U$J4,R6"FF]FR@U\^K7!JH#R;-R=_P]EY(GY<LU\T.6
MZQ/4YTO.Y?.!KF#SFP^S?P%02P,$%     @ 8SAX6LPRZ48?!   MQ0  !D
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M-#$N>&ULM59=;]HP%/TK5E9-K33(!]\,(A50NTJK5#6E>YCV8)(+6'5BYNM
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M.:Q8+G'R!>T$\'ZN< "I-LY /4N/_@-02P,$%     @ 8SAX6A[,57#/ P
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M-DGQ)7UTQ7Z!QI4W39-\^W_E<7??\62@3#=YD2[W@\LY6,:KW;_1]_T#\6*
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M@8V-]48UC)M;?- 2=QGZZ>@;8 P4^4RFHB@%!ZX5$2FY?JE8B9>ER0WCE,=
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ML,,,^S=(8X#[J1!Z,S$'M/\(HC]02P,$%     @ 8SAX6F1W""MM P  Q@T
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M<2XUT@@.'HIFX+3R&:1<(%I4M8*M+G)Z/T"JP0(7]-Q<X/CTO>->;JR=HQX
M/V%G=FUM;W9(-P(;W0TH"L.%&_=W*>R]3]WKCO7U4*^QNV!_*C-6;^T.(96#
M[O>8=6C;I<6@K6<MW\^E]MC^0P''[@J^KH4P35O%Q7U/U]M;W:VU^SZ8CK!?
M-)/3=PH>Z CPK)OT&/ZABF-W&?^=EQ?9_S<0]=AFN'>7]B?A292<./"/FFSS
MA?,;$7NJ&U\&.QT67"8Z2Z+Y:&@&BE>V[]YPI;MX>YCK#RT09H*^ON-<W0],
M*]]]NJ7_ E!+ P04    " !C.'A:G!^U4MD&  #,&P  &0   'AL+W=O<FMS
M:&5E=',O<VAE970U,RYX;6RM66UOVS80_BN$5W0)D-B6X[RT20PX=HL%6-.@
M:;8/PS[0TMGB*I$J23GUL!^_.XJ6WV2M7O4AL5YXS]T]=SP>J9L7I;^8&,"R
M;VDBS6TKMC9[V^F8,(:4F[;*0.*;J=(IMWBK9QV3:>"1$TJ33J_;O>BD7,C6
MX,8]>]2#&Y7;1$AXU,SD:<KUX@X2]7+;"EK+!Y_$++;TH#.XR?@,GL ^9X\:
M[SHE2B12D$8HR31,;UO#X.TX."<!-^(W 2]F[9J1*Q.EOM#-?73;ZI)%D$!H
M"8+CSQQ&D"2$A'9\]:"M4B<)KE\OT=\[Y]&9"3<P4LGO(K+Q;>NJQ2*8\CRQ
MG]3++^ =<@:&*C'N/WOQ8[LM%N;&JM0+HP6ID,4O_^:)6!,(^GL$>EZ@MR6P
M5\.9%SC[7@U]+]!WS!2N.![&W/+!C58O3--H1*,+1Z:31O>%I+@_68UO!<K9
MP4C).6@K)@FP)SX%]J LL%,VC")!@>$)NY=%>E&8CL9@N4C,,0YY&KY_AS_/
M3V-V].J8O6)"L@\B27"<N>E8-(Y4=$)OR*@PI+?'D*#'/BAI8\/>R0BB38 .
M>E6ZUENZ=M>K17Q0\S;K]DY8K]L[JS*H7GP,89N=!4Z\7R$^KA<?YK,VZ_6K
MM&]X<U8&ZLSAG>TU9V(Q%,;J'*>=97_\B@/8O874_%EAW5V!UJ]&HVKRUF0\
MA-L6E@L#>@ZMP>N?@HON=15338*-&P+;8+%?LMBO0Q_<&Y-S&0(+E;%567I7
M*W\H;TV"C0NP"P=&Y7P^Z+:#F\Z\@H[SDH[S>CIDB(N% 9JZ4RXTF_,D!Z:F
MS% M$&6Z53%U7F'/>6E/04"M^D,): AL@ZF+DJF+6J8^*XNE,!%\(A(LC%"9
M.P5$T%NCI+]#2:V>0REI"&R#DLN2DLM:2IXE3Q4N'7]#Q")A0I57Y\GE3I[T
MV_TM4FHU'4I*0V ;I%R5I%S5DC)2:8KKY)-5X1?V#[M__%A%22W&H46F2;!Q
M0V ;W+TIN7O3Z!+WIDD6FP0;-P2VP6+07;5TW=H<?,C3"6BJXF&1C2;FJ(?A
M5>C:/=>TX^N("*\O\E[5^?KL#8*K8+NJU9MT*']-H6T2N-83![4$/B%=F>7L
M<PR:9Y!;$9H3S,RPDJ%:K$/3L%&T<5-HFSSV5CSV&IW0'JXI*IM$&S>%MDGE
MJOL/:MOBC7V:Z\TD[M-.6*:%#$6&K0FNQ7O6WWKD@UEM="_@T2[7RTMU2QNL
M6OR@OL<?2IDC(4):0 LLT]Q")2^-MOJ-HHT]&M7!_^[V@U6[']3W^UL3\H2-
MP81:9+2WKZ2HR?Y]]'_0GC,Z'&)?,:)B*K#3A*^YL LV%1+W<4+.&,R=)S8&
MO[KYPPPZG7"'&2\J3R(6\SDPGEM%)QDA3Y+%<CB"8JXHU"++A7.Y8M(2JO$*
MK8A(&1HV!7P0,>,Z/#IRBI@S,40HCONH92O,$)*,PBD:%ENJ/(QW  1N2/'&
MCU7X3Z,U<\Q;I0WC69:(U6O\DZ=ACN((/^(F/OV86S9T,[_-'%4T#*93<,=I
M+,+4)]5<4B?*E$8[(Z'Q+6YEC$6/3NBA2%.(!(Y%4M!<?.(5AHDRY#9!L*?'
MX8A9S:7A[LSNQS@_0:-HWQ!5#V#YCC<2C(L(/<0V.^-R\;-Q?FF8H3>Z.*(R
M%AUQRPW>/*@YN)CZ8Z"3^E 7W=)W1S:?)")$28QHD1SKD=Y .R"0[,B /X:[
M.O9111MB+F=06"FM5DG!_KU/E77")P"2(;"P2:$1XPV4#20PP_V^+1P_$L>4
M&,7"0?,*BZ;C9NDOYFHJ\O00XUTZ'0E$II$>VL;<[AB8\06GG/%1KHH'/3<@
M,1]/4X6%'$N"@.T4>/W352^XO#8[,XM/R4^R?4'!V1]&I<5,T$&GFXM;45S7
MOZW!JAFX"?LB;/QCO+&CRN!$CLLBU.1HKWL]6G7PA:A['EP?KQ4 )>%T 5PS
MG%:YIG+I.:N<K"YF;KHA,T8EN?7;@S66M[.-&_)J@FQQFL&[6>1D]U>HN9N?
MTZK$)FO6#-G47$9;TWG^>G(+:W9(I=)&C[<IVTG&OW+IJQZF9>IM4[G%6E+4
M?2%IKP21JT$4EQ#30! 58<)%BKL#12GM4\&#&#8ET(I<]>GLE*ZR>CN_\&6Q
M(+A04</'8I5$Z J6,2KJBZ*(>J"5]?L5;Q8E2:%;>"5+.YQ+1:5UP]JT#=I3
MYJE\HUV,/C"YU">XN:*%I8B0:;/*]J;1H[S.VN>/%/3,?48B7S'4Q9>0\FGY
MJ6KH/M!T5L.+[UP?N,9:8%@"4Q3MMB_14%U\.BINK,K<QY2)LKAJN<L8.,:$
M!N#[J4)>_ TI*#_@#?X%4$L#!!0    ( &,X>%K7(O $A0D  *M?   9
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MZ @"U315$4>VD*551)@\)3'/XO*=L5(N :NH7 ^&6<N;'&8D+8322$M;'.>
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MOK;>\GVK- 8UB.W^O,D3:0SJ_4)I%$IC*)HJ(^D/VWI_N$UC[Z<.O_78R;J
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MQ+Y.#R-LO8&K 'P^8TRN)VJ#JIGO_P-02P,$%     @ 8SAX6FN682$Q P
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M E=2J7)J<*@6KEXJH$D)RKD;>-[ S2D33C0NYQY4-):%X4S @R*ZR'.J7JZ
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M8Q8O]2PTN0:6%DZ9".,HZH89XS(8#XM[UWH\5 LKN(1K3<PBRYA^N "AEJ.
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M+:&T?L)T=0 S<1W R#TUVP^N5F4A174Y_W,P==". %2344U!-175-%334<U
M-1/5+%2S4<U!-1?5/%3S42U M1#5(E2+42VAM'XT=3T"LZ?MI.^YQ0:M'4 U
M&=445%-134,U'=4,5#-1S4(U&]4<5'-1S4,U']4"5 M1+4*U&-422NMEU7E7
M37!^JIJ@:*Z0VO=FVCRD57O?IZA+:?YTJ;1I+Y6:*Z>G3PWED%@?FT.H)J.:
M@FHJJFFHIJ.:@6HFJEFH9J.:@VHNJGFHYJ-:@&HAJD6H%N^TWGW1Z>7TXKH_
M,9Q0H_83IBL<.!=N$OV)B;HHJ]JW0?@B[<(I_[K,)+_*[K*J?;O 5R?PQ"<R
M.HS0W@%44U!-134-U714,U#-1#4+U6Q4<U#-134/U7Q4"U M1+4(U6)42RBM
M'UG3+K*F[SV!=XZV%*":C&H*JJFHIJ&:CFH&JIFH9J&:C6H.JKFHYJ&:CVH!
MJH6H%J%:C&H)I?6SJNLR.!?O_HYVTW;;Y=KMNZ$OLJ]UM[Q./'N'%AF@FHQJ
M"JJIJ*:AFHYJ!JJ9J&:AFKW3^JO,9U>7D^-U=NBP+JIYJ.:C6H!J(:I%J!:C
M6D)I_7SI>@N:AV^9OE/S:E./F,03O'VI>,31L4-J,JHIJ*:BFH9J.JH9J&:B
MFH5J-JHYJ.:BFH=J/JH%J!:B6H1J,:HEE-;/IJ[WX/SBW>?IT+X$5)-134$U
M%=4T5--1S4 U$]4L5+-1S4$U%]4\5/-1+4"U$-4B5(M1+:&T?E9UK0KGXE:%
M:)W-\[M\+LV;S^3S=#G^34S%(XS.(K1X =445%-134,U'=4,5#//7Q8O7)\/
M%2^@P]JHYJ":BVH>JOFH%J!:B&H1JL6HEE!:/V:ZXH5S<?'"?BXNRN9EDR]_
MXQWGQ .-3ANTA '5%%1344U#-1W5#%0S4<U"-1O5'%1S4<U#-1_5 E0+42U"
MM1C5$DKK1U+7U'!^_>ZS=&AU ZK)J*:@FHIJ&JKIJ&:@FHEJ%JK9J.:@FHMJ
M'JKYJ!:@6HAJ$:K%J)906C^KNNJ&<^%VV\^WIR;GI'6:#W;6B>'1$80V,J":
M@FHJJFFHIJ.:@6HFJEFH9J.:@VHNJGFHYN^T7M??P'QK@(X:HEJ$:C&J)936
M"Y>+KFOAXE37PL_,S75KZ9I'\?=2\LNJOBN7>3FXIEM\#F-S"-5D5%-0344U
M#=5T5#-0S40U"]5L5'-0S44U#]5\5 M0+42U"-5B5$LHK9]676_#Q>2]I^TN
MT,(&5)-134$U%=4T5--1S4 U$]4L5+-1S4$U%]4\5/-1+4"U$-4B5(M1+:&T
M?E9-NZP2;K(E%M>)1QB=16@A ZHIJ*:BFH9J.JH9J&;NM,/%=>>#[VJ$#FNC
MFH-J+JIYJ.:C6H!J(:I%J!:C6D)I_9CINA8NQ%T+Q 3>0UXMNBF\P21"6QE0
M348U!=545--034<U ]5,5+-0S48U!]5<5/-0S4>U -5"5(M0+4:UA-+Z<=55
M-S0/WWL&[QS-*E*344U!-175-%334<U -1/5+%2S4<U!-1?5/%3S42U M1#5
M(E2+42VAM'Y6=54.%\+MM\@,'EK5@&HRJBFHIJ*:AFHZJAFH9NZTP]5:EX,3
M>&@) ZHYJ.:BFH=J/JH%J!:B6H1J,:HEE-9/F:Z$X4)<PK"?G'N:A?L;FV/%
MXXS.&K2* =445%-134,U'=4,5#-1S4(U&]4<5'-1S4,U']4"5 M1+4*U&-42
M2NLG4M?7<''U[G-T:)$#JLFHIJ":BFH:JNFH9J":B6H6JMFHYJ":BVH>JOFH
M%J!:B&H1JL6HEE!:/ZNZ(H<+X>;;SV%CIM7\81M-B^Q;MBS7VVC*_EJW%U+#
M^Y'0:@94DU%-0345U314TU'-0#43U2Q4LU'-0347U3Q4\U$M0+5PI_7>-^3E
M)'"$#AJC6D)I_5CI.A<NQ)T+^VFX=#\-)]59M<J+YNJF+*2BK)O/2^NLRLO!
MXH43^LV9M$A_#$73K?C(T6&"EBR@FHIJ&JKIJ&:@FHEJ%JK9J.:@FHMJ'JKY
MJ!:@6HAJ$:K%J)906B]S+KLJADMQ%<,^<^ZR;'LUDQ=YG:?+)BKJ5*JKM-C<
M957[V:'$V=FG;OS>BL]A;+Z@FH)J*JIIJ*:CFH%J)JI9J&:CFH-J+JIYJ.:C
M6H!J(:I%J!:C6D)I_7SIRA,NA1M>/W\IBL<WQ\GDQ17DQ5":H/4&J*:@FHIJ
M&JKIJ&:@FHEJ%JK9J.:@FHMJ'JKYJ!:@6HAJ$:K%J)906C]-IEV:B.L-?FK9
M6KOMM+FL>>4]6,4CCKTM@VHRJBFHIJ*:AFHZJAFH9J*:A6HVJCFHYJ*:AVH^
MJ@6H%J):A&HQJB64UL^FKA/A<O;>"]@NT4($5)-134$U%=4T5--1S4 U$]4L
M5+-1S4$U%]4\5/-1+4"U$-4B5(M1+:&T?E9UA0C-PS?,RBUW%U"K-"_JK$B+
M^?9&T.#RM9UX.#DWO7@Y-R<<=W2FD)J":BJJ::BFHYJ!:B:J6:AFHYJ#:BZJ
M>:CFHUJ :B&J1:@6HUI":?U,Z8H++L7%!3\]-_=4"3>8.6B1 :K)J*:@FHIJ
M&JKIJ&:@FHEJ%JK9J.:@FHMJ'JKYJ!:@6HAJ$:K%J)906C^;NKJ#R\MWGYM#
MBQ!0348U!=545--034<U ]5,5+-0S48U!]5<5/-0S4>U -5"5(M0+4:UA-+Z
M6=45(5P*-Z\V6;5:9=4\3Y?Y?SWM_#G=^+8C7^R]&EH]A]86H)J":BJJ::BF
MHYJ!:B:J6:AFHYJ#:BZJ>:CFHUJ :B&J1:@6HUI":?UDZ6H++L6U!3]SU^?E
MIM[VKL^+4$';"%!-0345U314TU'-0#43U2Q4LU'-0347U3Q4\U$M0+40U2)4
MBU$MH;1^J'2E!9?B6H%PH)E:JDOI:R:MTWRPJ.#RY;N[3X?>WOU6//3H6$%[
M"5!-134-U714,U#-1#4+U6Q4<U#-134/U7Q4"U M1+4(U6)42RBM%RM772_!
ME;B70,VK32TEMY'\<BF!]"\IJK-E7FZD^"&KTG7V6.?SC604\Z&X$8\T]LX,
MJLFHIJ":BFH:JNFH9J":B6H6JMFHYJ":BVH>JOFH%J!:B&H1JL6HEE!:/Y.Z
M+H.KR7NO(K@B=^O>HIJ,:@JJJ:BFH9J.:@:JF:AFH9J-:@ZJN:CFH9J/:@&J
MA:@6H5J,:@FE];-JVF65N"G!*[*/=;[*I,?UQ[NJ;#*I*(N/57;W6"S2K\NG
MPK?7)NC$]N@40CL14$U!-175-%334<W8:;TIW)<3N"8ZJ/6V06UT4 ?57%3S
M4,U'M0#50E2+4"U&M832^KG1M1A<"7>>_MT.:K$^.CG0A@)44U!-134-U714
M,U#-1#7KQ-^-RU<;U&WT/!Q4<U'-0S4?U0)4"U$M0K48U1)*ZV=.UT;0//P?
MN-?3?"K,#MZ(1SYX(Q[EZ8UX!B-*>#*C(XK49%134$U%-0W5=%0S4,U$-0O5
M;%1S4,U%-0_5?%0+4"U$M0C58E1+**T?6UWAP=7%N]\.0@L04$U&-0755%33
M4$U'-0/53%2S4,U&-0?57%3S4,U'M0#50E2+4"U&M832^EG5%2!<"3>MONEV
MT. &(+$[.H'06@-44U!-134-U714,U#-1#5KIYV\8X3V%:":BVH>JOFH%J!:
MB&H1JL6HEE!:/UJZOH(K<5_!B=F[7;W;V#7;Y+[;6U2344U!-175-%334<U
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MRST E<I2W8@9F66"E![6C*JA9:>4\UNXT?U.MK27R<;JE84KZJ8V5#6-C.F
M_J::T=Z4[;U)U\G90Z:^+?1P1-F'FJ,WDB9L6?:726T 4_=Q=9+G?/65LYE(
MJ1G\P0E' [+F.?-,LD>=#4IEJ@-4NLX#E8I--R-_)<GOZ%*MRVF9X)Z[+?3\
M;^=Y1@65A&^:UK5_S+/\9L=![[TLEW>57<-6C]7+R[&;O&R#R; -)EM1D_TV
MF(Q:8++W;G?-UYCTVV"RVP:3P?&;#(YSWWC5B^_&V_76NW4==> WS-#]!;^+
M>)/4F2P85TQ4O3F+8RJ>O6)K>44FG&[KZ^MCFI %5W<U.'2;]D\:LT4:U5?=
MP$145S7M'S \/ZQ_0.E<3,1T2>-QU96S2=ET=$-GK0X@["+7Y6%',([![ A@
M6![, <8Q+"S/_S2>/CH>@V'>^E:DCW+Z*,>P;,BX_&!Y[)Q('_:11E$0A"$V
MH^.QU<$8F[<PA#^[&N8-&%@>R/2ZN<97&Z^0_76 K>F^"L%&BE<B-E)\K@&Q
MSQLPHLB^VE@>8&"K@-4.Y+?G@9JR<X( 5A7SANU@'(DB#(%:M-=H&"*S$\+'
MOC[8+@F"*+(C@-D=! &&P&[$$<P!>,"0("B?@SO/(V_]G/*:?]N/G@!02P,$
M%     @ 8SAX6I>*NQS     $P(   L   !?<F5L<R\N<F5L<YV2N6[#, Q
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M              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @
M8SAX6CC9;<KR    *P(  !$              ( !PP   &1O8U!R;W!S+V-O
M<F4N>&UL4$L! A0#%     @ 8SAX6IE<G",0!@  G"<  !,
M ( !Y $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " !C.'A:X;K3
M[Q<*   E.P  &               @($E"   >&PO=V]R:W-H965T<R]S:&5E
M=#$N>&UL4$L! A0#%     @ 8SAX6E1D65<+!@  .!L  !@
M ("!<A(  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( &,X
M>%JP_[LM? (  ,H&   8              " @;,8  !X;"]W;W)K<VAE971S
M+W-H965T,RYX;6Q02P$"% ,4    " !C.'A:, %SJNH$   @%   &
M        @(%E&P  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%
M  @ 8SAX6LK521D^#   39@  !@              ("!A2   'AL+W=O<FMS
M:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( &,X>%HH>Y&%)@,  (D+   8
M              " @?DL  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"
M% ,4    " !C.'A:6;SLMR<)   0+   &               @(%5,   >&PO
M=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ 8SAX6OE^TEI. @
MI 4  !@              ("!LCD  'AL+W=O<FMS:&5E=',O<VAE970X+GAM
M;%!+ 0(4 Q0    ( &,X>%HL=6B^0P(  (H&   8              " @38\
M  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " !C.'A:GW@E
M*=D+  #C00  &0              @(&O/@  >&PO=V]R:W-H965T<R]S:&5E
M=#$P+GAM;%!+ 0(4 Q0    ( &,X>%H*"#*?W L  !4@   9
M  " @;]*  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @
M8SAX6F48[L39(   ]6@  !D              ("!TE8  'AL+W=O<FMS:&5E
M=',O<VAE970Q,BYX;6Q02P$"% ,4    " !C.'A:0%LB%/H(  #A&   &0
M            @('B=P  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4
M Q0    ( &,X>%JZWY"YN (  + &   9              " @1.!  !X;"]W
M;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ 8SAX6MMQ6OZT"
MFAH  !D              ("! H0  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX
M;6Q02P$"% ,4    " !C.'A:?>S'5]0&   H$@  &0              @('M
MC   >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( &,X>%K$
M&"#8"@P   4M   9              " @?B3  !X;"]W;W)K<VAE971S+W-H
M965T,3<N>&UL4$L! A0#%     @ 8SAX6I3=N[#@!P  /14  !D
M     ("!.:   'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( &,X>%II@3VB=A,  #A+   9              "
M@7#+  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ 8SAX
M6G>-E2JN!   @@H  !D              ("!'=\  'AL+W=O<FMS:&5E=',O
M<VAE970R-"YX;6Q02P$"% ,4    " !C.'A:<+T4/C8#   \!P  &0
M        @($"Y   >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0
M   ( &,X>%I'(=XHVR$  ")Q   9              " @6_G  !X;"]W;W)K
M<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ 8SAX6CX]IVP9 P  YP8
M !D              ("!@0D! 'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q0
M2P$"% ,4    " !C.'A:ORTE=Y0'  !R%P  &0              @('1# $
M>&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( &,X>%K=5TA:
MM00  'T.   9              " @9P4 0!X;"]W;W)K<VAE971S+W-H965T
M,CDN>&UL4$L! A0#%     @ 8SAX6B(0BG/$ @  D@8  !D
M ("!B!D! 'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    " !C
M.'A:=TI1X1H#  #Q!@  &0              @(&#' $ >&PO=V]R:W-H965T
M<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( &,X>%JR:OET*0,  #$'   9
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M970S-BYX;6Q02P$"% ,4    " !C.'A:8<.X94P&  "<.0  &0
M    @('],P$ >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    (
M &,X>%H9XZ;MCP<  /]!   9              " @8 Z 0!X;"]W;W)K<VAE
M971S+W-H965T,S@N>&UL4$L! A0#%     @ 8SAX6LPRZ48?!   MQ0  !D
M             ("!1D(! 'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"
M% ,4    " !C.'A:K>T>_R@$   0&0  &0              @(&<1@$ >&PO
M=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( &,X>%HCF2*BN@(
M "H(   9              " @?M* 0!X;"]W;W)K<VAE971S+W-H965T-#$N
M>&UL4$L! A0#%     @ 8SAX6F*LU^"' @  L@4  !D              ("!
M[$T! 'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"% ,4    " !C.'A:
MN3MX)(@#   T"   &0              @(&J4 $ >&PO=V]R:W-H965T<R]S
M:&5E=#0S+GAM;%!+ 0(4 Q0    ( &,X>%J'[*-6T@,  %</   9
M      " @6E4 0!X;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%
M  @ 8SAX6A[,57#/ P  :A   !D              ("!<E@! 'AL+W=O<FMS
M:&5E=',O<VAE970T-2YX;6Q02P$"% ,4    " !C.'A:#<^K ,4#  #@#P
M&0              @(%X7 $ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+
M 0(4 Q0    ( &,X>%K6&@-+W0(  %\(   9              " @71@ 0!X
M;"]W;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @ 8SAX6A,]A>(*
M#0  ;[@  !D              ("!B&,! 'AL+W=O<FMS:&5E=',O<VAE970T
M."YX;6Q02P$"% ,4    " !C.'A:VL72[^("  #M!P  &0
M@(')< $ >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( &,X
M>%H1%"3@B0,  .<-   9              " @>)S 0!X;"]W;W)K<VAE971S
M+W-H965T-3 N>&UL4$L! A0#%     @ 8SAX6@[,R@(* P  '0@  !D
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M=#4U+GAM;%!+ 0(4 Q0    ( &,X>%I7VE3XA@H  ']Y   9
M  " @=Z3 0!X;"]W;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#%     @
M8SAX6J6B;XYH P  >A   !D              ("!FYX! 'AL+W=O<FMS:&5E
M=',O<VAE970U-RYX;6Q02P$"% ,4    " !C.'A:E<E%2581   +\@  &0
M            @($ZH@$ >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4
M Q0    ( &,X>%KNEDR.+P4  +,9   9              " @<>S 0!X;"]W
M;W)K<VAE971S+W-H965T-3DN>&UL4$L! A0#%     @ 8SAX6N[$*Y$6 P
M7P@  !D              ("!+;D! 'AL+W=O<FMS:&5E=',O<VAE970V,"YX
M;6Q02P$"% ,4    " !C.'A:!"C^N0X#  !G"   &0              @(%Z
MO $ >&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0    ( &,X>%JP
M51(Q+P,  -@+   9              " @;^_ 0!X;"]W;W)K<VAE971S+W-H
M965T-C(N>&UL4$L! A0#%     @ 8SAX6FN682$Q P  ^0D  !D
M     ("!)<,! 'AL+W=O<FMS:&5E=',O<VAE970V,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( &,X>%HUN!589B<  -$M P 9              "
M@3W5 0!X;"]W;W)K<VAE971S+W-H965T-C@N>&UL4$L! A0#%     @ 8SAX
M6IU$,Q\@!   ] D  !D              ("!VOP! 'AL+W=O<FMS:&5E=',O
M<VAE970V.2YX;6Q02P$"% ,4    " !C.'A:$'L HT $  #'$   &0
M        @($Q 0( >&PO=V]R:W-H965T<R]S:&5E=#<P+GAM;%!+ 0(4 Q0
M   ( &,X>%H)AOUYB@(  &$&   9              " @:@% @!X;"]W;W)K
M<VAE971S+W-H965T-S$N>&UL4$L! A0#%     @ 8SAX6A0+%AMI P  PQ<
M  T              ( !:0@" 'AL+W-T>6QE<RYX;6Q02P$"% ,4    " !C
M.'A:EXJ[',     3 @  "P              @ ']"P( 7W)E;',O+G)E;'-0
M2P$"% ,4    " !C.'A:-6OH_'4%  #X+@  #P              @ 'F# (
M>&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ 8SAX6K % +TV @  '"H  !H
M             ( !B!(" 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L!
M A0#%     @ 8SAX6N'+1LC] 0  /2D  !,              ( !]A0" %M#
G;VYT96YT7U1Y<&5S72YX;6Q02P4&     $\ 3P"@%0  )!<"

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>239</ContextCount>
  <ElementCount>449</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>81</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="lxeo-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="lxeo-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20241231/taxonomy/role/StatementBalanceSheets</Role>
      <ShortName>Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="lxeo-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100040 - Statement - Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20241231/taxonomy/role/StatementBalanceSheetsParenthetical</Role>
      <ShortName>Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="lxeo-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100050 - Statement - Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="lxeo-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100060 - Statement - Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit</Role>
      <ShortName>Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="lxeo-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100070 - Statement - Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical</Role>
      <ShortName>Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="lxeo-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100080 - Statement - Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfCashFlows</Role>
      <ShortName>Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="lxeo-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="lxeo-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="lxeo-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995455 - Disclosure - Cybersecurity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCybersecurity</Role>
      <ShortName>Cybersecurity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="lxeo-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995465 - Disclosure - Description of Business and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentation</Role>
      <ShortName>Description of Business and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="lxeo-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995475 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="lxeo-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995485 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="lxeo-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995495 - Disclosure - Accrued Expenses and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20241231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities1</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="lxeo-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995505 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeases3</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="lxeo-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995515 - Disclosure - Convertible Safe Note</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertibleSafeNote</Role>
      <ShortName>Convertible Safe Note</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="lxeo-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995525 - Disclosure - Convertible Preferred Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStock</Role>
      <ShortName>Convertible Preferred Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="lxeo-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995535 - Disclosure - Capital Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCapitalStock1</Role>
      <ShortName>Capital Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="lxeo-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995545 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensation1</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="lxeo-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995555 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20241231/taxonomy/role/DisclosureNetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="lxeo-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995565 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20241231/taxonomy/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="lxeo-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995575 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingencies1</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="lxeo-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995585 - Disclosure - License, Acquisition, Research Collaboration and Sponsored Research Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreements</Role>
      <ShortName>License, Acquisition, Research Collaboration and Sponsored Research Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="lxeo-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995595 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSegmentInformation1</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="lxeo-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995605 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="lxeo-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995615 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="lxeo-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995625 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="lxeo-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995635 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurements</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="lxeo-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995645 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeases3</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="lxeo-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995655 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20241231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lexeotx.com/20241231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities1</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="lxeo-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995665 - Disclosure - Convertible Preferred Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockTables</Role>
      <ShortName>Convertible Preferred Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStock</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="lxeo-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>995675 - Disclosure - Capital Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCapitalStockTables</Role>
      <ShortName>Capital Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCapitalStock1</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="lxeo-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>995685 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensation1</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="lxeo-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>995695 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20241231/taxonomy/role/DisclosureNetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lexeotx.com/20241231/taxonomy/role/DisclosureNetLossPerShare</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="lxeo-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>995705 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20241231/taxonomy/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lexeotx.com/20241231/taxonomy/role/DisclosureIncomeTaxes</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="lxeo-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>995715 - Disclosure - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSegmentInformationTables</Role>
      <ShortName>Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSegmentInformation1</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="lxeo-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>995725 - Disclosure - Description of Business and Basis of Presentation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails</Role>
      <ShortName>Description of Business and Basis of Presentation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="lxeo-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>995735 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="lxeo-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>995745 - Disclosure - Summary of Significant Accounting Policies - Schedule of Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentNetDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="lxeo-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>995755 - Disclosure - Fair Value Measurements - Schedule of Fair Value Hierarchy for Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Fair Value Hierarchy for Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="lxeo-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>995765 - Disclosure - Fair Value Measurements - Schedule of Investments Classified as Available-for-Sale Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfInvestmentsClassifiedAsAvailableforsaleSecuritiesDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Investments Classified as Available-for-Sale Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="lxeo-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>995775 - Disclosure - Fair Value Measurements - Schedule of Aggregate Fair Values of Investments Classified as Available-for-Sale Securities With Unrealized Losses and Gains (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAggregateFairValuesOfInvestmentsClassifiedAsAvailableforsaleSecuritiesWithUnrealizedLossesAndGains</Role>
      <ShortName>Fair Value Measurements - Schedule of Aggregate Fair Values of Investments Classified as Available-for-Sale Securities With Unrealized Losses and Gains (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="lxeo-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>995785 - Disclosure - Fair Value Measurements - Schedule of Rollforward of Changes in Fair Value of Financial Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfRollforwardOfChangesInFairValueOfFinancialLiabilitiesDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Rollforward of Changes in Fair Value of Financial Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="lxeo-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>995795 - Disclosure - Fair Value Measurements - Schedule of Significant Unobservable Inputs Used In the Valuation Model to Estimate Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfSignificantUnobservableInputsUsedInTheValuationModelToEstimateFairValueDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Significant Unobservable Inputs Used In the Valuation Model to Estimate Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="lxeo-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>995805 - Disclosure - Fair Value Measurements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails</Role>
      <ShortName>Fair Value Measurements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="lxeo-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>995815 - Disclosure - Fair Value Measurements - Summary of Estimated Fair Value Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueAssumptionsDetails</Role>
      <ShortName>Fair Value Measurements - Summary of Estimated Fair Value Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="lxeo-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>995825 - Disclosure - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20241231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="lxeo-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>995835 - Disclosure - Leases - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails</Role>
      <ShortName>Leases - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="lxeo-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>995845 - Disclosure - Leases - Components of Operating Lease (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesComponentsOfOperatingLeaseDetails</Role>
      <ShortName>Leases - Components of Operating Lease (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="lxeo-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>995855 - Disclosure - Leases - Reconciliation of Remaining Undiscounted Contractual Rent Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingUndiscountedContractualRentObligationsDetails</Role>
      <ShortName>Leases - Reconciliation of Remaining Undiscounted Contractual Rent Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="lxeo-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>995865 - Disclosure - Leases - Components of Equipment Finance Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesComponentsOfEquipmentFinanceLeasesDetails</Role>
      <ShortName>Leases - Components of Equipment Finance Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="lxeo-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>995875 - Disclosure - Leases - Reconciliation of Remaining Equipment Finance Lease Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingEquipmentFinanceLeaseObligationsDetails</Role>
      <ShortName>Leases - Reconciliation of Remaining Equipment Finance Lease Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="lxeo-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>995885 - Disclosure - Convertible Safe Note - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertibleSafeNoteAdditionalInformationDetails</Role>
      <ShortName>Convertible Safe Note - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="lxeo-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>995895 - Disclosure - Convertible Preferred Stock - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails</Role>
      <ShortName>Convertible Preferred Stock - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="lxeo-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>995905 - Disclosure - Convertible Preferred Stock - Schedule of Convertible Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockScheduleOfConvertiblePreferredStockDetails</Role>
      <ShortName>Convertible Preferred Stock - Schedule of Convertible Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="lxeo-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>995915 - Disclosure - Capital Stock - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails</Role>
      <ShortName>Capital Stock - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="lxeo-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>995925 - Disclosure - Capital Stock - Schedule of Common Stock Reserved for Future Issuances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCapitalStockScheduleOfCommonStockReservedForFutureIssuancesDetails</Role>
      <ShortName>Capital Stock - Schedule of Common Stock Reserved for Future Issuances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="lxeo-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>995935 - Disclosure - Stock-Based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="lxeo-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>995945 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="lxeo-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>995955 - Disclosure - Stock-Based Compensation - Summary of Following Assumptions Presented on Weighted Average Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfFollowingAssumptionsPresentedOnWeightedAverageBasisDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Following Assumptions Presented on Weighted Average Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="lxeo-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>995965 - Disclosure - Stock-based Compensation - Summary of RSU activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityDetails</Role>
      <ShortName>Stock-based Compensation - Summary of RSU activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="lxeo-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>995975 - Disclosure - Stock-Based Compensation - Summary of Stock-based Compensation Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpensesDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock-based Compensation Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="lxeo-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>995985 - Disclosure - Net Loss Per Share - Schedule of Net Loss Per Share Attributable to Common Stockholders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20241231/taxonomy/role/DisclosureNetLossPerShareScheduleOfNetLossPerShareAttributableToCommonStockholdersDetails</Role>
      <ShortName>Net Loss Per Share - Schedule of Net Loss Per Share Attributable to Common Stockholders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="lxeo-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>995995 - Disclosure - Income Taxes - Schedule of Reconciliation of Statutory Income Tax Rate to Effective Income Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails</Role>
      <ShortName>Income Taxes - Schedule of Reconciliation of Statutory Income Tax Rate to Effective Income Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="lxeo-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>996005 - Disclosure - Income Taxes - Schedule of Components of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Schedule of Components of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="lxeo-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>996015 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20241231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="lxeo-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>996025 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="lxeo-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>996035 - Disclosure - License, Acquisition, Research Collaboration and Sponsored Research Agreements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails</Role>
      <ShortName>License, Acquisition, Research Collaboration and Sponsored Research Agreements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="lxeo-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>996045 - Disclosure - Segment Information - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails</Role>
      <ShortName>Segment Information - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="lxeo-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>996055 - Disclosure - Segment Information - Summary of Additional Information On Company's Net loss Including Segment Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalInformationOnCompanysNetLossIncludingSegmentExpensesDetails3</Role>
      <ShortName>Segment Information - Summary of Additional Information On Company's Net loss Including Segment Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="lxeo-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>996065 - Disclosure - Subsequent Events - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails</Role>
      <ShortName>Subsequent Events - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="lxeo-20241231.htm">lxeo-20241231.htm</File>
    <File>lxeo-20241231.xsd</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img34756086_0.jpg</File>
    <File>img34756086_1.jpg</File>
    <File>img34756086_10.jpg</File>
    <File>img34756086_2.jpg</File>
    <File>img34756086_3.jpg</File>
    <File>img34756086_4.jpg</File>
    <File>img34756086_5.jpg</File>
    <File>img34756086_6.jpg</File>
    <File>img34756086_7.jpg</File>
    <File>img34756086_8.jpg</File>
    <File>img34756086_9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="652">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="15">http://xbrl.sec.gov/cyd/2024</BaseTaxonomy>
    <BaseTaxonomy items="41">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>110
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "lxeo-20241231.htm": {
   "nsprefix": "lxeo",
   "nsuri": "http://www.lexeotx.com/20241231",
   "dts": {
    "inline": {
     "local": [
      "lxeo-20241231.htm"
     ]
    },
    "schema": {
     "local": [
      "lxeo-20241231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    }
   },
   "keyStandard": 355,
   "keyCustom": 94,
   "axisStandard": 28,
   "axisCustom": 0,
   "memberStandard": 39,
   "memberCustom": 38,
   "hidden": {
    "total": 11,
    "http://fasb.org/us-gaap/2024": 8,
    "http://xbrl.sec.gov/dei/2024": 3
   },
   "contextCount": 239,
   "entityCount": 1,
   "segmentCount": 81,
   "elementCount": 802,
   "unitCount": 9,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 652,
    "http://xbrl.sec.gov/dei/2024": 41,
    "http://xbrl.sec.gov/cyd/2024": 15,
    "http://xbrl.sec.gov/ecd/2024": 4
   },
   "report": {
    "R1": {
     "role": "http://www.lexeotx.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_61a2446f-5269-4a91-8e68-185d4038b801",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_61a2446f-5269-4a91-8e68-185d4038b801",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.lexeotx.com/20241231/taxonomy/role/StatementBalanceSheets",
     "longName": "100010 - Statement - Balance Sheets",
     "shortName": "Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "C_1b2d6a36-1a01-47ee-b773-2a16d5242136",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1b2d6a36-1a01-47ee-b773-2a16d5242136",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.lexeotx.com/20241231/taxonomy/role/StatementBalanceSheetsParenthetical",
     "longName": "100040 - Statement - Balance Sheets (Parenthetical)",
     "shortName": "Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "C_1b2d6a36-1a01-47ee-b773-2a16d5242136",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1b2d6a36-1a01-47ee-b773-2a16d5242136",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss",
     "longName": "100050 - Statement - Statements of Operations and Comprehensive Loss",
     "shortName": "Statements of Operations and Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "C_61a2446f-5269-4a91-8e68-185d4038b801",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_61a2446f-5269-4a91-8e68-185d4038b801",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
     "longName": "100060 - Statement - Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)",
     "shortName": "Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "C_e83f79f6-f924-4728-9c7c-5f1eb49397fe",
      "name": "us-gaap:TemporaryEquitySharesOutstanding",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:TemporaryEquitySharesOutstanding",
       "us-gaap:TemporaryEquitySharesIssued",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:TemporaryEquityTableTextBlock",
       "div",
       "us-gaap:PreferredStockTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b8ce5a83-8a3f-4019-b952-412e72e2157f",
      "name": "us-gaap:TemporaryEquitySharesOutstanding",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical",
     "longName": "100070 - Statement - Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)",
     "shortName": "Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "C_f579df17-1e2e-4b2c-ab33-2703e6c475a7",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f579df17-1e2e-4b2c-ab33-2703e6c475a7",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfCashFlows",
     "longName": "100080 - Statement - Statements of Cash Flows",
     "shortName": "Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "C_61a2446f-5269-4a91-8e68-185d4038b801",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_61a2446f-5269-4a91-8e68-185d4038b801",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "C_61a2446f-5269-4a91-8e68-185d4038b801",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R9": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "C_72ef9daf-8437-4cbb-9e5d-f507601fa64a",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_72ef9daf-8437-4cbb-9e5d-f507601fa64a",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCybersecurity",
     "longName": "995455 - Disclosure - Cybersecurity",
     "shortName": "Cybersecurity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "C_61a2446f-5269-4a91-8e68-185d4038b801",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_61a2446f-5269-4a91-8e68-185d4038b801",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentation",
     "longName": "995465 - Disclosure - Description of Business and Basis of Presentation",
     "shortName": "Description of Business and Basis of Presentation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "C_61a2446f-5269-4a91-8e68-185d4038b801",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_61a2446f-5269-4a91-8e68-185d4038b801",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies",
     "longName": "995475 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "C_61a2446f-5269-4a91-8e68-185d4038b801",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_61a2446f-5269-4a91-8e68-185d4038b801",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurements",
     "longName": "995485 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "C_61a2446f-5269-4a91-8e68-185d4038b801",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_61a2446f-5269-4a91-8e68-185d4038b801",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities1",
     "longName": "995495 - Disclosure - Accrued Expenses and Other Current Liabilities",
     "shortName": "Accrued Expenses and Other Current Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "C_61a2446f-5269-4a91-8e68-185d4038b801",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_61a2446f-5269-4a91-8e68-185d4038b801",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeases3",
     "longName": "995505 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "C_61a2446f-5269-4a91-8e68-185d4038b801",
      "name": "lxeo:LesseeOperatingAndFinancingLeasesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_61a2446f-5269-4a91-8e68-185d4038b801",
      "name": "lxeo:LesseeOperatingAndFinancingLeasesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertibleSafeNote",
     "longName": "995515 - Disclosure - Convertible Safe Note",
     "shortName": "Convertible Safe Note",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "C_61a2446f-5269-4a91-8e68-185d4038b801",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_61a2446f-5269-4a91-8e68-185d4038b801",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStock",
     "longName": "995525 - Disclosure - Convertible Preferred Stock",
     "shortName": "Convertible Preferred Stock",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "C_61a2446f-5269-4a91-8e68-185d4038b801",
      "name": "us-gaap:PreferredStockTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_61a2446f-5269-4a91-8e68-185d4038b801",
      "name": "us-gaap:PreferredStockTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCapitalStock1",
     "longName": "995535 - Disclosure - Capital Stock",
     "shortName": "Capital Stock",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "C_61a2446f-5269-4a91-8e68-185d4038b801",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_61a2446f-5269-4a91-8e68-185d4038b801",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensation1",
     "longName": "995545 - Disclosure - Stock-Based Compensation",
     "shortName": "Stock-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "C_61a2446f-5269-4a91-8e68-185d4038b801",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_61a2446f-5269-4a91-8e68-185d4038b801",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureNetLossPerShare",
     "longName": "995555 - Disclosure - Net Loss Per Share",
     "shortName": "Net Loss Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "C_61a2446f-5269-4a91-8e68-185d4038b801",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_61a2446f-5269-4a91-8e68-185d4038b801",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureIncomeTaxes",
     "longName": "995565 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "C_61a2446f-5269-4a91-8e68-185d4038b801",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_61a2446f-5269-4a91-8e68-185d4038b801",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingencies1",
     "longName": "995575 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "C_61a2446f-5269-4a91-8e68-185d4038b801",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_61a2446f-5269-4a91-8e68-185d4038b801",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreements",
     "longName": "995585 - Disclosure - License, Acquisition, Research Collaboration and Sponsored Research Agreements",
     "shortName": "License, Acquisition, Research Collaboration and Sponsored Research Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "C_61a2446f-5269-4a91-8e68-185d4038b801",
      "name": "lxeo:LicenseAndAcquisitionAndResearchCollaborationAndSponsoredResearchAgreementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_61a2446f-5269-4a91-8e68-185d4038b801",
      "name": "lxeo:LicenseAndAcquisitionAndResearchCollaborationAndSponsoredResearchAgreementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSegmentInformation1",
     "longName": "995595 - Disclosure - Segment Information",
     "shortName": "Segment Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "C_61a2446f-5269-4a91-8e68-185d4038b801",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_61a2446f-5269-4a91-8e68-185d4038b801",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSubsequentEvents",
     "longName": "995605 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "C_61a2446f-5269-4a91-8e68-185d4038b801",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_61a2446f-5269-4a91-8e68-185d4038b801",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "995615 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "26",
     "firstAnchor": {
      "contextRef": "C_61a2446f-5269-4a91-8e68-185d4038b801",
      "name": "us-gaap:UseOfEstimates",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_61a2446f-5269-4a91-8e68-185d4038b801",
      "name": "us-gaap:UseOfEstimates",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables",
     "longName": "995625 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "C_61a2446f-5269-4a91-8e68-185d4038b801",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_61a2446f-5269-4a91-8e68-185d4038b801",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsTables",
     "longName": "995635 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "C_61a2446f-5269-4a91-8e68-185d4038b801",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_61a2446f-5269-4a91-8e68-185d4038b801",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesTables",
     "longName": "995645 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "C_61a2446f-5269-4a91-8e68-185d4038b801",
      "name": "lxeo:ComponentsOfOperatingLeaseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_61a2446f-5269-4a91-8e68-185d4038b801",
      "name": "lxeo:ComponentsOfOperatingLeaseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables",
     "longName": "995655 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)",
     "shortName": "Accrued Expenses and Other Current Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "C_61a2446f-5269-4a91-8e68-185d4038b801",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_61a2446f-5269-4a91-8e68-185d4038b801",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockTables",
     "longName": "995665 - Disclosure - Convertible Preferred Stock (Tables)",
     "shortName": "Convertible Preferred Stock (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "C_61a2446f-5269-4a91-8e68-185d4038b801",
      "name": "us-gaap:TemporaryEquityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PreferredStockTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_61a2446f-5269-4a91-8e68-185d4038b801",
      "name": "us-gaap:TemporaryEquityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PreferredStockTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCapitalStockTables",
     "longName": "995675 - Disclosure - Capital Stock (Tables)",
     "shortName": "Capital Stock (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "C_61a2446f-5269-4a91-8e68-185d4038b801",
      "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_61a2446f-5269-4a91-8e68-185d4038b801",
      "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationTables",
     "longName": "995685 - Disclosure - Stock-Based Compensation (Tables)",
     "shortName": "Stock-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "C_61a2446f-5269-4a91-8e68-185d4038b801",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_61a2446f-5269-4a91-8e68-185d4038b801",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureNetLossPerShareTables",
     "longName": "995695 - Disclosure - Net Loss Per Share (Tables)",
     "shortName": "Net Loss Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "C_61a2446f-5269-4a91-8e68-185d4038b801",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_61a2446f-5269-4a91-8e68-185d4038b801",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureIncomeTaxesTables",
     "longName": "995705 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "C_61a2446f-5269-4a91-8e68-185d4038b801",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_61a2446f-5269-4a91-8e68-185d4038b801",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSegmentInformationTables",
     "longName": "995715 - Disclosure - Segment Information (Tables)",
     "shortName": "Segment Information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "C_61a2446f-5269-4a91-8e68-185d4038b801",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_61a2446f-5269-4a91-8e68-185d4038b801",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
     "longName": "995725 - Disclosure - Description of Business and Basis of Presentation - Additional Information (Details)",
     "shortName": "Description of Business and Basis of Presentation - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "C_240d6e00-2133-41ba-92ce-0078e7bbcbca",
      "name": "us-gaap:StockholdersEquityReverseStockSplit",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_240d6e00-2133-41ba-92ce-0078e7bbcbca",
      "name": "us-gaap:StockholdersEquityReverseStockSplit",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
     "longName": "995735 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "C_8d26cf86-cfdb-467b-8eab-522b18243eda",
      "name": "lxeo:LossRecognizedFromUninsuredBalances",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:ConcentrationRiskCreditRisk",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_8d26cf86-cfdb-467b-8eab-522b18243eda",
      "name": "lxeo:LossRecognizedFromUninsuredBalances",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:ConcentrationRiskCreditRisk",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentNetDetails",
     "longName": "995745 - Disclosure - Summary of Significant Accounting Policies - Schedule of Property and Equipment, Net (Details)",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Property and Equipment, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "C_1b2d6a36-1a01-47ee-b773-2a16d5242136",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1b2d6a36-1a01-47ee-b773-2a16d5242136",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
     "longName": "995755 - Disclosure - Fair Value Measurements - Schedule of Fair Value Hierarchy for Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "shortName": "Fair Value Measurements - Schedule of Fair Value Hierarchy for Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "C_6ef7a0b8-9327-4be8-b39d-869ac79fb879",
      "name": "us-gaap:FairValueNetAssetLiability",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6ef7a0b8-9327-4be8-b39d-869ac79fb879",
      "name": "us-gaap:FairValueNetAssetLiability",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfInvestmentsClassifiedAsAvailableforsaleSecuritiesDetails",
     "longName": "995765 - Disclosure - Fair Value Measurements - Schedule of Investments Classified as Available-for-Sale Securities (Details)",
     "shortName": "Fair Value Measurements - Schedule of Investments Classified as Available-for-Sale Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "C_1b2d6a36-1a01-47ee-b773-2a16d5242136",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1b2d6a36-1a01-47ee-b773-2a16d5242136",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAggregateFairValuesOfInvestmentsClassifiedAsAvailableforsaleSecuritiesWithUnrealizedLossesAndGains",
     "longName": "995775 - Disclosure - Fair Value Measurements - Schedule of Aggregate Fair Values of Investments Classified as Available-for-Sale Securities With Unrealized Losses and Gains (Details)",
     "shortName": "Fair Value Measurements - Schedule of Aggregate Fair Values of Investments Classified as Available-for-Sale Securities With Unrealized Losses and Gains (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "C_1b2d6a36-1a01-47ee-b773-2a16d5242136",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1b2d6a36-1a01-47ee-b773-2a16d5242136",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfRollforwardOfChangesInFairValueOfFinancialLiabilitiesDetails",
     "longName": "995785 - Disclosure - Fair Value Measurements - Schedule of Rollforward of Changes in Fair Value of Financial Liabilities (Details)",
     "shortName": "Fair Value Measurements - Schedule of Rollforward of Changes in Fair Value of Financial Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "C_ff8a14ec-2414-4dce-963c-ac378e45b5e3",
      "name": "lxeo:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConvertibleNoteIssuance",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ff8a14ec-2414-4dce-963c-ac378e45b5e3",
      "name": "lxeo:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConvertibleNoteIssuance",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfSignificantUnobservableInputsUsedInTheValuationModelToEstimateFairValueDetails",
     "longName": "995795 - Disclosure - Fair Value Measurements - Schedule of Significant Unobservable Inputs Used In the Valuation Model to Estimate Fair Value (Details)",
     "shortName": "Fair Value Measurements - Schedule of Significant Unobservable Inputs Used In the Valuation Model to Estimate Fair Value (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "C_5d7d637d-2f7f-4be3-acba-58d6df49a889",
      "name": "lxeo:FairValueProbabilityOfMeetingChangeInControlEvent",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5d7d637d-2f7f-4be3-acba-58d6df49a889",
      "name": "lxeo:FairValueProbabilityOfMeetingChangeInControlEvent",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
     "longName": "995805 - Disclosure - Fair Value Measurements - Additional Information (Details)",
     "shortName": "Fair Value Measurements - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "C_47a049b7-455a-448b-84ea-5e98846bad51",
      "name": "lxeo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_47a049b7-455a-448b-84ea-5e98846bad51",
      "name": "lxeo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueAssumptionsDetails",
     "longName": "995815 - Disclosure - Fair Value Measurements - Summary of Estimated Fair Value Assumptions (Details)",
     "shortName": "Fair Value Measurements - Summary of Estimated Fair Value Assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "C_4591c456-caa6-4a3e-acb5-b25d3fb9ee55",
      "name": "us-gaap:AlternativeInvestmentMeasurementInput",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4591c456-caa6-4a3e-acb5-b25d3fb9ee55",
      "name": "us-gaap:AlternativeInvestmentMeasurementInput",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails",
     "longName": "995825 - Disclosure - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details)",
     "shortName": "Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "C_1b2d6a36-1a01-47ee-b773-2a16d5242136",
      "name": "lxeo:AccruedResearchAndDevelopmentExpenseCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1b2d6a36-1a01-47ee-b773-2a16d5242136",
      "name": "lxeo:AccruedResearchAndDevelopmentExpenseCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
     "longName": "995835 - Disclosure - Leases - Additional Information (Details)",
     "shortName": "Leases - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "C_3bc3fa7e-440b-44ad-b57d-4fc9f9165d8a",
      "name": "lxeo:OperatingLeaseCommencementDate",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "lxeo:LesseeOperatingAndFinancingLeasesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3bc3fa7e-440b-44ad-b57d-4fc9f9165d8a",
      "name": "lxeo:OperatingLeaseCommencementDate",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "lxeo:LesseeOperatingAndFinancingLeasesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesComponentsOfOperatingLeaseDetails",
     "longName": "995845 - Disclosure - Leases - Components of Operating Lease (Details)",
     "shortName": "Leases - Components of Operating Lease (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "C_61a2446f-5269-4a91-8e68-185d4038b801",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_61a2446f-5269-4a91-8e68-185d4038b801",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingUndiscountedContractualRentObligationsDetails",
     "longName": "995855 - Disclosure - Leases - Reconciliation of Remaining Undiscounted Contractual Rent Obligations (Details)",
     "shortName": "Leases - Reconciliation of Remaining Undiscounted Contractual Rent Obligations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "C_1b2d6a36-1a01-47ee-b773-2a16d5242136",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1b2d6a36-1a01-47ee-b773-2a16d5242136",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesComponentsOfEquipmentFinanceLeasesDetails",
     "longName": "995865 - Disclosure - Leases - Components of Equipment Finance Leases (Details)",
     "shortName": "Leases - Components of Equipment Finance Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "C_61a2446f-5269-4a91-8e68-185d4038b801",
      "name": "us-gaap:FinanceLeaseRightOfUseAssetAmortization",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_61a2446f-5269-4a91-8e68-185d4038b801",
      "name": "us-gaap:FinanceLeaseInterestExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingEquipmentFinanceLeaseObligationsDetails",
     "longName": "995875 - Disclosure - Leases - Reconciliation of Remaining Equipment Finance Lease Obligations (Details)",
     "shortName": "Leases - Reconciliation of Remaining Equipment Finance Lease Obligations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "C_1b2d6a36-1a01-47ee-b773-2a16d5242136",
      "name": "us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1b2d6a36-1a01-47ee-b773-2a16d5242136",
      "name": "us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertibleSafeNoteAdditionalInformationDetails",
     "longName": "995885 - Disclosure - Convertible Safe Note - Additional Information (Details)",
     "shortName": "Convertible Safe Note - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "C_9a32dff6-03c5-465f-846c-9b718f20e0b9",
      "name": "us-gaap:DeferredFinanceCostsNet",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_9a32dff6-03c5-465f-846c-9b718f20e0b9",
      "name": "us-gaap:DeferredFinanceCostsNet",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
     "longName": "995895 - Disclosure - Convertible Preferred Stock - Additional Information (Details)",
     "shortName": "Convertible Preferred Stock - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "C_47a049b7-455a-448b-84ea-5e98846bad51",
      "name": "us-gaap:TemporaryEquitySharesAuthorized",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:TemporaryEquityTableTextBlock",
       "div",
       "us-gaap:PreferredStockTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_d6e454da-2fb0-4d82-ae44-abd1e7e3c994",
      "name": "lxeo:QualifiedIpoMinimumNumberOfDirectorsApprovalRequired",
      "unitRef": "U_Director",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockScheduleOfConvertiblePreferredStockDetails",
     "longName": "995905 - Disclosure - Convertible Preferred Stock - Schedule of Convertible Preferred Stock (Details)",
     "shortName": "Convertible Preferred Stock - Schedule of Convertible Preferred Stock (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "C_e83f79f6-f924-4728-9c7c-5f1eb49397fe",
      "name": "us-gaap:TemporaryEquitySharesAuthorized",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:TemporaryEquitySharesAuthorized",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:TemporaryEquityTableTextBlock",
       "div",
       "us-gaap:PreferredStockTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e83f79f6-f924-4728-9c7c-5f1eb49397fe",
      "name": "us-gaap:TemporaryEquitySharesIssued",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:TemporaryEquitySharesOutstanding",
       "us-gaap:TemporaryEquitySharesOutstanding",
       "us-gaap:TemporaryEquitySharesIssued",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:TemporaryEquityTableTextBlock",
       "div",
       "us-gaap:PreferredStockTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails",
     "longName": "995915 - Disclosure - Capital Stock - Additional Information (Details)",
     "shortName": "Capital Stock - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "C_1b2d6a36-1a01-47ee-b773-2a16d5242136",
      "name": "us-gaap:CapitalUnitsAuthorized",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1b2d6a36-1a01-47ee-b773-2a16d5242136",
      "name": "us-gaap:CapitalUnitsAuthorized",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCapitalStockScheduleOfCommonStockReservedForFutureIssuancesDetails",
     "longName": "995925 - Disclosure - Capital Stock - Schedule of Common Stock Reserved for Future Issuances (Details)",
     "shortName": "Capital Stock - Schedule of Common Stock Reserved for Future Issuances (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "C_1b2d6a36-1a01-47ee-b773-2a16d5242136",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_19581a58-f4b4-41e4-85f3-1dff41c48718",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
     "longName": "995935 - Disclosure - Stock-Based Compensation - Additional Information (Details)",
     "shortName": "Stock-Based Compensation - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "C_1b2d6a36-1a01-47ee-b773-2a16d5242136",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_465c4136-b851-42be-84ee-27ed04fe8539",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails",
     "longName": "995945 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)",
     "shortName": "Stock-Based Compensation - Summary of Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "C_d4ba692f-b7d0-4af9-9603-697859726ab1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_8ca9fee4-3e70-406e-b516-57586deaa558",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfFollowingAssumptionsPresentedOnWeightedAverageBasisDetails",
     "longName": "995955 - Disclosure - Stock-Based Compensation - Summary of Following Assumptions Presented on Weighted Average Basis (Details)",
     "shortName": "Stock-Based Compensation - Summary of Following Assumptions Presented on Weighted Average Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "C_d210b17b-f2c2-4a07-9b34-0371db6164dd",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_d210b17b-f2c2-4a07-9b34-0371db6164dd",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityDetails",
     "longName": "995965 - Disclosure - Stock-based Compensation - Summary of RSU activity (Details)",
     "shortName": "Stock-based Compensation - Summary of RSU activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "C_afe980af-4f26-4fd3-8f3e-e44a3e233ab1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_afe980af-4f26-4fd3-8f3e-e44a3e233ab1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpensesDetails",
     "longName": "995975 - Disclosure - Stock-Based Compensation - Summary of Stock-based Compensation Expenses (Details)",
     "shortName": "Stock-Based Compensation - Summary of Stock-based Compensation Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "C_61a2446f-5269-4a91-8e68-185d4038b801",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_61a2446f-5269-4a91-8e68-185d4038b801",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureNetLossPerShareScheduleOfNetLossPerShareAttributableToCommonStockholdersDetails",
     "longName": "995985 - Disclosure - Net Loss Per Share - Schedule of Net Loss Per Share Attributable to Common Stockholders (Details)",
     "shortName": "Net Loss Per Share - Schedule of Net Loss Per Share Attributable to Common Stockholders (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "C_61a2446f-5269-4a91-8e68-185d4038b801",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R64": {
     "role": "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails",
     "longName": "995995 - Disclosure - Income Taxes - Schedule of Reconciliation of Statutory Income Tax Rate to Effective Income Tax Rate (Details)",
     "shortName": "Income Taxes - Schedule of Reconciliation of Statutory Income Tax Rate to Effective Income Tax Rate (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "C_61a2446f-5269-4a91-8e68-185d4038b801",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_61a2446f-5269-4a91-8e68-185d4038b801",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails",
     "longName": "996005 - Disclosure - Income Taxes - Schedule of Components of Deferred Tax Assets and Liabilities (Details)",
     "shortName": "Income Taxes - Schedule of Components of Deferred Tax Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "C_1b2d6a36-1a01-47ee-b773-2a16d5242136",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1b2d6a36-1a01-47ee-b773-2a16d5242136",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
     "longName": "996015 - Disclosure - Income Taxes - Additional Information (Details)",
     "shortName": "Income Taxes - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "C_61a2446f-5269-4a91-8e68-185d4038b801",
      "name": "lxeo:PercentageOfCumulativeOwnershipChange",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_61a2446f-5269-4a91-8e68-185d4038b801",
      "name": "lxeo:PercentageOfCumulativeOwnershipChange",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
     "longName": "996025 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "C_61a2446f-5269-4a91-8e68-185d4038b801",
      "name": "lxeo:NumberOfFormerEmployees",
      "unitRef": "U_Employees",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_61a2446f-5269-4a91-8e68-185d4038b801",
      "name": "lxeo:NumberOfFormerEmployees",
      "unitRef": "U_Employees",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails",
     "longName": "996035 - Disclosure - License, Acquisition, Research Collaboration and Sponsored Research Agreements - Additional Information (Details)",
     "shortName": "License, Acquisition, Research Collaboration and Sponsored Research Agreements - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "C_61a2446f-5269-4a91-8e68-185d4038b801",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f5b88d17-128c-461e-aaa6-463ec8135b2a",
      "name": "lxeo:PaymentOfDevelopmentMilestone",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails",
     "longName": "996045 - Disclosure - Segment Information - Additional Information (Details)",
     "shortName": "Segment Information - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "C_61a2446f-5269-4a91-8e68-185d4038b801",
      "name": "us-gaap:SegmentReportingExpenseInformationUsedByCodmDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_61a2446f-5269-4a91-8e68-185d4038b801",
      "name": "us-gaap:SegmentReportingExpenseInformationUsedByCodmDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R70": {
     "role": "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalInformationOnCompanysNetLossIncludingSegmentExpensesDetails3",
     "longName": "996055 - Disclosure - Segment Information - Summary of Additional Information On Company's Net loss Including Segment Expenses (Details)",
     "shortName": "Segment Information - Summary of Additional Information On Company's Net loss Including Segment Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "C_61a2446f-5269-4a91-8e68-185d4038b801",
      "name": "us-gaap:NonoperatingIncomeExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_637f42f6-8969-4386-b873-8c291d47795a",
      "name": "lxeo:ResearchAndDevelopmentExpenseLX2020",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "unique": true
     }
    },
    "R71": {
     "role": "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
     "longName": "996065 - Disclosure - Subsequent Events - Additional Information (Details)",
     "shortName": "Subsequent Events - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "C_ef41b0f5-e670-47fb-a4ba-1fb722c72adf",
      "name": "lxeo:StockOfferingGrossProceedsPercentage",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ef41b0f5-e670-47fb-a4ba-1fb722c72adf",
      "name": "lxeo:StockOfferingGrossProceedsPercentage",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxeo-20241231.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingStandardsUpdateExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingStandardsUpdateExtensibleList",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update [Extensible Enumeration]",
        "documentation": "Indicates amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r192",
      "r193",
      "r194",
      "r258",
      "r259",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r319",
      "r320",
      "r328",
      "r488",
      "r489",
      "r490",
      "r491",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r524",
      "r525",
      "r526",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r568",
      "r569",
      "r584",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r1018"
     ]
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued Expenses and Other Current Liabilities",
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r453"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "totalLabel": "Accounts Payable, Current, Total",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r854"
     ]
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "terseLabel": "Accretion of discount on investments, net",
        "negatedLabel": "Accretion of discount on investments",
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "us-gaap_AccruedBonusesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedBonusesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "lxeo_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued bonuses",
        "label": "Accrued Bonuses, Current",
        "verboseLabel": "Accrued bonus expenses",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "lxeo_AccruedGeneralAndAdministrativeExpensesAndOtherProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "AccruedGeneralAndAdministrativeExpensesAndOtherProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "lxeo_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued general and administrative expenses and other professional fees",
        "label": "Accrued General And Administrative Expenses And Other Professional Fees Current",
        "documentation": "Accrued general and administrative expenses and other professional fees current."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesAndOtherLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities and Other Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_AccruedLiabilitiesAndOtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "AccruedLiabilitiesAndOtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other current liabilities",
        "totalLabel": "Total accrued expenses and other current liabilities",
        "label": "Accrued Liabilities And Other Liabilities Current",
        "documentation": "Accrued liabilities and other liabilities current."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_AccruedResearchAndDevelopmentExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "AccruedResearchAndDevelopmentExpenseCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "lxeo_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued research and development expenses",
        "label": "Accrued Research And Development Expense Current",
        "documentation": "Accrued research and development expense current."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: accumulated depreciation and amortization",
        "terseLabel": "Less: accumulated depreciation and amortization",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance",
        "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance",
        "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r153",
      "r668"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive loss",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r20",
      "r84",
      "r159",
      "r664",
      "r691",
      "r695"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r918"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital, Common Stock",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-in Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r711",
      "r1015",
      "r1016",
      "r1017",
      "r1020",
      "r1086",
      "r1117"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r931"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r931"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r931"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r931"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt",
        "terseLabel": "Conversion of SAFE Note into common stock in connection with initial public offering, net of issuance costs, value",
        "documentation": "Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "lxeo_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtShare": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtShare",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to additional paid in capital, equity component of convertible debt share.",
        "label": "Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt Share",
        "terseLabel": "Conversion of SAFE Note into common stock in connection with initial public offering, Share"
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptions",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments To Additional Paid In Capital Reclassification From Deposit Liability Share Based Compensation And Exercise Of Stock Options",
        "documentation": "Adjustments to additional paid in capital reclassification from deposit liability share based compensation and exercise of stock options.",
        "terseLabel": "Amounts reclassified from deposit liabilities upon the vesting of early-exercised stock options previously subject to repurchase, Value"
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsShare": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsShare",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments To Additional Paid In Capital Reclassification From Deposit Liability Share Based Compensation And Exercise Of Stock Options, Share",
        "documentation": "Adjustments to additional paid in capital reclassification from deposit liability share based compensation and exercise of stock options, share.",
        "terseLabel": "Amounts reclassified from deposit liabilities upon the vesting of early-exercised stock options previously subject to repurchase. Shares"
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsUnvestedStockOptionsSubjectToRepurchaseShare": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsUnvestedStockOptionsSubjectToRepurchaseShare",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to additional paid in capital reclassification from deposit liability share based compensation and exercise of stock options unvested stock options subject to repurchase, share.",
        "label": "Adjustments To Additional Paid In Capital Reclassification From Deposit Liability Share Based Compensation And Exercise Of Stock Options Unvested Stock Options Subject To Repurchase, Share",
        "terseLabel": "Amounts reclassified from deposit liabilities upon the vesting of early-exercised stock options previously subject to repurchase, net of proceeds received from early exercise of unvested stock options subject to repurchase and recorded as deposit liabilities, share"
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsUnvestedStockOptionsSubjectToRepurchaseValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsUnvestedStockOptionsSubjectToRepurchaseValue",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to additional paid in capital reclassification from deposit liability share based compensation and exercise of stock options unvested stock options subject to repurchase, value.",
        "label": "Adjustments To Additional Paid In Capital Reclassification From Deposit Liability Share Based Compensation And Exercise Of Stock Options Unvested Stock Options Subject To Repurchase, Value",
        "terseLabel": "Amounts reclassified from deposit liabilities upon the vesting of early-exercised stock options previously subject to repurchase, net of proceeds received from early exercise of unvested stock options subject to repurchase and recorded as deposit liabilities, value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_AdverumBiotechnologiesIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "AdverumBiotechnologiesIncMember",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adverum Biotechnologies Inc",
        "label": "Adverum Biotechnologies Inc [Member]",
        "documentation": "Adverum Biotechnologies Inc."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_AdverumLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "AdverumLicenseAgreementMember",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adverum license agreement.",
        "terseLabel": "Adverum License Agreement",
        "label": "Adverum License Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_AggregateDevelopmentAndCommercializationMilestonesDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "AggregateDevelopmentAndCommercializationMilestonesDescription",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Development and commercialization milestones description",
        "label": "Aggregate Development And Commercialization Milestones Description",
        "documentation": "aggregate development and commercialization milestones description."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r976"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r889",
      "r900",
      "r910",
      "r943"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r892",
      "r903",
      "r913",
      "r946"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r977"
     ]
    },
    "lxeo_AgreementExpirationTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "AgreementExpirationTerm",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Agreement expiration term",
        "label": "Agreement Expiration Term",
        "documentation": "Agreement expiration term."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r931"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r938"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r893",
      "r904",
      "r914",
      "r938",
      "r947",
      "r951",
      "r959"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r957"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r441",
      "r451"
     ]
    },
    "us-gaap_AlternativeInvestmentMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AlternativeInvestmentMeasurementInput",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alternative Investment, Measurement Input",
        "terseLabel": "Measurement input",
        "documentation": "Value of input used to measure alternative investment."
       }
      }
     },
     "auth_ref": [
      "r844",
      "r1090",
      "r1091",
      "r1092"
     ]
    },
    "lxeo_AmendedFirstUcsdAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "AmendedFirstUcsdAgreementMember",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amended First UCSD Agreement [Member]",
        "documentation": "Amended First UCSD Agreement.",
        "terseLabel": "Amended First UCSD Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_AmountDueForEachQuarterUnderAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "AmountDueForEachQuarterUnderAgreement",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount due for each quarter under agreement",
        "label": "Amount Due for Each Quarter Under Agreement",
        "documentation": "Amount due for each quarter under agreement."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_AmountDueUnderAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "AmountDueUnderAgreement",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount due under agreement",
        "label": "Amount Due Under Agreement",
        "documentation": "Amount due under agreement."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_AmountsReclassifiedFromDepositLiabilitiesUponTheVestingOfEarlyExercisedStockOptionsPreviouslySubjectToRepurchaseNetOfProceedsReceivedFromEarlyExerciseOfUnvestedStockOptionsSubjectToRepurchaseAndRecord": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "AmountsReclassifiedFromDepositLiabilitiesUponTheVestingOfEarlyExercisedStockOptionsPreviouslySubjectToRepurchaseNetOfProceedsReceivedFromEarlyExerciseOfUnvestedStockOptionsSubjectToRepurchaseAndRecord",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amounts Reclassified From Deposit Liabilities Upon The Vesting Of Early-exercised Stock Options Previously Subject To Repurchase, Net Of Proceeds Received From Early Exercise Of Unvested Stock Options Subject To Repurchase And Recorded As Deposit Liabilities",
        "documentation": "Amounts reclassified from deposit liabilities upon the vesting of early-exercised stock options previously subject to repurchase, net of proceeds received from early exercise of unvested stock options subject to repurchase and recorded as deposit liabilities.",
        "terseLabel": "Amounts reclassified from deposit liabilities upon the vesting of early-exercised stock options previously subject to repurchase, net of proceeds received from early exercise of unvested stock options subject to repurchase and recorded as deposit liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_AnnualLimitationAbilityToUtilize": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "AnnualLimitationAbilityToUtilize",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual limitation ability to utilize",
        "label": "Annual Limitation Ability to Utilize",
        "documentation": "Annual Limitation Ability to Utilize"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive securities excluded from Computation of diluted net loss per common share",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r214"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "lxeo_AntidilutiveSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "AntidilutiveSecuritiesMember",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities",
        "label": "Antidilutive Securities [Member]",
        "documentation": "Antidilutive securities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r516"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r127",
      "r155",
      "r183",
      "r219",
      "r228",
      "r246",
      "r250",
      "r291",
      "r340",
      "r341",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r349",
      "r350",
      "r518",
      "r522",
      "r570",
      "r660",
      "r745",
      "r812",
      "r813",
      "r854",
      "r867",
      "r1045",
      "r1046",
      "r1103"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r160",
      "r183",
      "r291",
      "r340",
      "r341",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r349",
      "r350",
      "r518",
      "r522",
      "r570",
      "r854",
      "r1045",
      "r1046",
      "r1103"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total assets",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Assets, Fair Value Disclosure, Total",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r547",
      "r548",
      "r841"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r872",
      "r873",
      "r896"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r872",
      "r873",
      "r896"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r872",
      "r873",
      "r896"
     ]
    },
    "dei_AuditorOpinionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorOpinionTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Opinion [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r980"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfInvestmentsClassifiedAsAvailableforsaleSecuritiesDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfInvestmentsClassifiedAsAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross Unrealized Gains",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r265"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfInvestmentsClassifiedAsAvailableforsaleSecuritiesDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfInvestmentsClassifiedAsAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross Unrealized Losses",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r266"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfInvestmentsClassifiedAsAvailableforsaleSecuritiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfInvestmentsClassifiedAsAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Amortized Cost Basis",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r262",
      "r308",
      "r659"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesAbstract",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAggregateFairValuesOfInvestmentsClassifiedAsAvailableforsaleSecuritiesWithUnrealizedLossesAndGains",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfInvestmentsClassifiedAsAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Abstract]",
        "terseLabel": "Available-for-sale securities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAggregateFairValuesOfInvestmentsClassifiedAsAvailableforsaleSecuritiesWithUnrealizedLossesAndGains": {
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAggregateFairValuesOfInvestmentsClassifiedAsAvailableforsaleSecuritiesWithUnrealizedLossesAndGains"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "Due after one year through five years",
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r270",
      "r656"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAggregateFairValuesOfInvestmentsClassifiedAsAvailableforsaleSecuritiesWithUnrealizedLossesAndGains": {
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAggregateFairValuesOfInvestmentsClassifiedAsAvailableforsaleSecuritiesWithUnrealizedLossesAndGains"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Due within one year",
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r269",
      "r655"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfInvestmentsClassifiedAsAvailableforsaleSecuritiesDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAggregateFairValuesOfInvestmentsClassifiedAsAvailableforsaleSecuritiesWithUnrealizedLossesAndGains": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAggregateFairValuesOfInvestmentsClassifiedAsAvailableforsaleSecuritiesWithUnrealizedLossesAndGains",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfInvestmentsClassifiedAsAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Fair Value",
        "totalLabel": "Available-for-sale securities",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r263",
      "r308",
      "r547",
      "r650",
      "r841",
      "r844",
      "r1029",
      "r1090",
      "r1091",
      "r1092"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r954"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r955"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r950"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r950"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r950"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r950"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r950"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r950"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCapitalStockScheduleOfCommonStockReservedForFutureIssuancesDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r412",
      "r413",
      "r414",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r953"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r952"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r951"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r951"
     ]
    },
    "lxeo_BlackScholesModelMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "BlackScholesModelMember",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Black-Scholes model.",
        "label": "Black-Scholes Model [Member]",
        "terseLabel": "Black-Scholes Model"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition, Acquiree [Domain]",
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "auth_ref": [
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r507",
      "r832",
      "r833"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r58",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r507",
      "r832",
      "r833"
     ]
    },
    "us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionEffectiveDateOfAcquisition1",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset acquisition date of acquisition",
        "label": "Business Acquisition, Effective Date of Acquisition",
        "documentation": "Date when the acquirer obtains control of the acquiree, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r2",
      "r11"
     ]
    },
    "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset acquisition percentage of outstanding stock acquisition",
        "label": "Business Acquisition, Percentage of Voting Interests Acquired",
        "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment to selling shareholders",
        "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable",
        "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r4"
     ]
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "(Property and equipment purchased in the prior period and paid in the current period), net of property and equipment purchased in the current period included in accounts payable",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r30",
      "r31"
     ]
    },
    "lxeo_CapitalExpendituresIncurredButNotYetPaidNetOfPaidAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "CapitalExpendituresIncurredButNotYetPaidNetOfPaidAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "(Property and equipment purchased in the prior period and paid in the current period), net of property and equipment purchased in the current period included in accounts payable",
        "label": "Capital Expenditures Incurred But Not Yet Paid, Net of Paid Amount",
        "documentation": "Capital expenditures incurred but not yet paid, net of paid amount.",
        "negatedLabel": "(Property and equipment purchased in the prior period and paid in the current period), net of property and equipment purchased in the current period included in accounts payable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalUnitsAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CapitalUnitsAuthorized",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Authorized capital stock",
        "label": "Capital Units, Authorized",
        "documentation": "Number of authorized capital units or capital shares. This element is relevant to issuers of face-amount certificates and registered investment companies."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalizedComputerSoftwareGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CapitalizedComputerSoftwareGross",
     "crdr": "debit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred software costs",
        "label": "Capitalized Computer Software, Gross",
        "documentation": "Amount before accumulated amortization of capitalized costs for computer software, including but not limited to, acquired and internally developed computer software."
       }
      }
     },
     "auth_ref": [
      "r317",
      "r797"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash and cash equivalents, including restricted cash",
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r150",
      "r798"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAxis",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfRollforwardOfChangesInFairValueOfFinancialLiabilitiesDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfSignificantUnobservableInputsUsedInTheValuationModelToEstimateFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Axis]",
        "documentation": "Information by type of cash and cash equivalent balance."
       }
      }
     },
     "auth_ref": [
      "r150"
     ]
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents and Restricted Cash",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r113"
     ]
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "totalLabel": "Cash, Cash Equivalents, and Short-Term Investments, Total",
        "terseLabel": "Cash and cash equivalents, including restricted cash and investments",
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable."
       }
      }
     },
     "auth_ref": [
      "r1000"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "totalLabel": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Total",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r94",
      "r179"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net change in cash, cash equivalents and restricted cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r94"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosure of non-cash activities",
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Accounting Principle, Accounting Standards Update, Adopted [true false]",
        "documentation": "Indicates (true false) whether accounting standards update was adopted."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r138",
      "r146",
      "r191",
      "r258",
      "r292",
      "r293",
      "r294",
      "r299",
      "r300",
      "r319",
      "r328",
      "r489",
      "r498",
      "r499",
      "r508",
      "r509",
      "r511",
      "r524",
      "r525",
      "r535",
      "r536",
      "r568",
      "r569",
      "r584",
      "r603",
      "r604",
      "r647",
      "r648",
      "r684",
      "r685"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r926"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r924"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCapitalStockScheduleOfCommonStockReservedForFutureIssuancesDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockScheduleOfConvertiblePreferredStockDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementBalanceSheets",
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementBalanceSheetsParenthetical",
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r156",
      "r157",
      "r158",
      "r183",
      "r208",
      "r209",
      "r211",
      "r213",
      "r221",
      "r222",
      "r291",
      "r340",
      "r343",
      "r344",
      "r345",
      "r349",
      "r350",
      "r380",
      "r381",
      "r385",
      "r388",
      "r395",
      "r570",
      "r704",
      "r705",
      "r706",
      "r707",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r733",
      "r754",
      "r772",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r983",
      "r1011",
      "r1021"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCapitalStockScheduleOfCommonStockReservedForFutureIssuancesDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockScheduleOfConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r157",
      "r158",
      "r221",
      "r380",
      "r381",
      "r383",
      "r385",
      "r388",
      "r393",
      "r395",
      "r704",
      "r705",
      "r706",
      "r707",
      "r827",
      "r983",
      "r1011"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r516"
     ]
    },
    "lxeo_CommercializationMilestonesDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "CommercializationMilestonesDue",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercialization milestones due",
        "label": "Commercialization Milestones Due",
        "documentation": "Commercialization milestones due."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_CommissionsAndOfferingCostsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "CommissionsAndOfferingCostsMember",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commissions and Offering Costs [Member]",
        "documentation": "Commissions and offering costs.",
        "terseLabel": "Commissions and Offering Costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies (Note 12)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r118",
      "r661",
      "r732"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingencies1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r330",
      "r331",
      "r794",
      "r1035",
      "r1040"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCapitalStockScheduleOfCommonStockReservedForFutureIssuancesDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total shares of common stock reserved for future issuance",
        "terseLabel": "Common stock, shares reserved for issuance",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "lxeo_CommonStockDuringOfferingPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "CommonStockDuringOfferingPeriod",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock during offering period",
        "label": "Common Stock During Offering Period",
        "documentation": "Common Stock During Offering Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCapitalStockScheduleOfCommonStockReservedForFutureIssuancesDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertibleSafeNoteAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r857",
      "r858",
      "r859",
      "r861",
      "r862",
      "r863",
      "r864",
      "r1015",
      "r1016",
      "r1020",
      "r1086",
      "r1115",
      "r1117"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value per share",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, Authorized",
        "verboseLabel": "Common stock shares authorized",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r733"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock, Shares issued",
        "label": "Common Stock, Shares, Issued",
        "verboseLabel": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "lxeo_CommonStockSharesIssuedOnEarlyExerciseOfUnvestedStockOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "CommonStockSharesIssuedOnEarlyExerciseOfUnvestedStockOptions",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock shares issued upon early exercise of unvested stock options",
        "documentation": "Common stock shares issued on early exercise of unvested stock options.",
        "label": "Common Stock Shares Issued On Early Exercise of Unvested Stock Options"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, Outstanding",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance",
        "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r78",
      "r733",
      "r751",
      "r1117",
      "r1118"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock, $0.0001 par value, 18,125,051 shares authorized, 1,660,650 shares issued and 1,633,206 shares outstanding, actual; 18,125,051 shares authorized, 15,220,250 shares issued and 15,192,806 shares outstanding, pro forma",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.0001 par value, 500,000,000 shares authorized as of December 31, 2024; 33,079,209 shares issued and 33,071,261 shares outstanding as of December 31, 2024; 500,000,000 shares authorized as of December 31, 2023; 26,668,485 shares issued and 26,646,378 shares outstanding as of December 31, 2023",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r662",
      "r854"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r935"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r934"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r936"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r933"
     ]
    },
    "lxeo_ComponentsOfEquipmentFinanceLeaseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "ComponentsOfEquipmentFinanceLeaseTableTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Components of Equipment Finance Leases",
        "label": "Components of Equipment Finance Lease [Table Text Block]",
        "documentation": "Components of equipment Finance lease."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_ComponentsOfOperatingLeaseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "ComponentsOfOperatingLeaseTableTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Components of Operating Lease",
        "label": "Components of Operating Lease [Table Text Block]",
        "documentation": "Components of operating lease."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Total",
        "terseLabel": "Comprehensive loss",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r163",
      "r165",
      "r171",
      "r652",
      "r675",
      "r676"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentrations of Credit Risk",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r132"
     ]
    },
    "srt_ConsolidationItemsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ConsolidationItemsAxis",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalInformationOnCompanysNetLossIncludingSegmentExpensesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]"
       }
      }
     },
     "auth_ref": [
      "r125",
      "r187",
      "r219",
      "r230",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r250",
      "r251",
      "r252",
      "r340",
      "r341",
      "r342",
      "r343",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r812",
      "r813",
      "r1045",
      "r1046"
     ]
    },
    "srt_ConsolidationItemsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ConsolidationItemsDomain",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalInformationOnCompanysNetLossIncludingSegmentExpensesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Domain]"
       }
      }
     },
     "auth_ref": [
      "r125",
      "r187",
      "r219",
      "r230",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r250",
      "r251",
      "r252",
      "r340",
      "r341",
      "r342",
      "r343",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r812",
      "r813",
      "r1045",
      "r1046"
     ]
    },
    "us-gaap_ConversionOfStockAmountIssued1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConversionOfStockAmountIssued1",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of Stock, Amount Issued",
        "terseLabel": "Conversion of convertible preferred stock into common stock in connection with initial public offering, net of issuance costs",
        "documentation": "The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r30",
      "r31"
     ]
    },
    "us-gaap_ConvertibleNotesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleNotesPayableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertibleSafeNoteAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible SAFE note, net",
        "verboseLabel": "Unamortized discount",
        "label": "Convertible Notes Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertiblePreferredStockMember",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Preferred Stock",
        "label": "Convertible Preferred Stock [Member]",
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option."
       }
      }
     },
     "auth_ref": [
      "r380",
      "r381",
      "r385",
      "r861",
      "r862",
      "r863",
      "r864"
     ]
    },
    "lxeo_ConvertibleSimpleAgreementForFutureEquityNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "ConvertibleSimpleAgreementForFutureEquityNoteMember",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfRollforwardOfChangesInFairValueOfFinancialLiabilitiesDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfSignificantUnobservableInputsUsedInTheValuationModelToEstimateFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Simple Agreement For Future Equity Note [Member]",
        "documentation": "Convertible simple agreement for future equity note.",
        "terseLabel": "Convertible SAFE Note [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_CornellFirstLicenseAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "CornellFirstLicenseAgreementsMember",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cornell First License Agreements",
        "label": "Cornell First License Agreements [Member]",
        "documentation": "Cornell first license agreements."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_CornellLicenseAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "CornellLicenseAgreementsMember",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cornell License Agreements",
        "label": "Cornell License Agreements [Member]",
        "documentation": "Cornell license agreements."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_CornellSecondLicenseAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "CornellSecondLicenseAgreementsMember",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cornell Second License Agreements",
        "label": "Cornell Second License Agreements [Member]",
        "documentation": "Cornell Second License Agreements."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_CornellUniversityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "CornellUniversityMember",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cornell University",
        "label": "Cornell University [Member]",
        "documentation": "Cornell university."
       }
      }
     },
     "auth_ref": []
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertibleSafeNoteAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r185",
      "r186",
      "r355",
      "r383",
      "r609",
      "r629",
      "r658",
      "r799",
      "r801"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CreditFacilityAxis",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Facility [Axis]",
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r339",
      "r1043"
     ]
    },
    "us-gaap_CreditFacilityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CreditFacilityDomain",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Facility [Domain]",
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r339",
      "r1043",
      "r1044"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCybersecurity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r881",
      "r970"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCybersecurity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r881",
      "r970"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCybersecurity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r883",
      "r972"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCybersecurity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r883",
      "r972"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCybersecurity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r885",
      "r974"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCybersecurity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r883",
      "r972"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCybersecurity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r876",
      "r965"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCybersecurity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r877",
      "r966"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCybersecurity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r877",
      "r966"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r875",
      "r964"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCybersecurity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r875",
      "r964"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCybersecurity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]"
       }
      }
     },
     "auth_ref": [
      "r875",
      "r964"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCybersecurity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r878",
      "r967"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCybersecurity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r880",
      "r969"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCybersecurity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r880",
      "r969"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCybersecurity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r881",
      "r970"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCybersecurity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r884",
      "r973"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCybersecurity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r882",
      "r971"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCybersecurity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r879",
      "r968"
     ]
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Conversion, Converted Instrument, Amount",
        "terseLabel": "Conversion of SAFE Note into common stock in connection with initial public offering, net of issuance costs",
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r31"
     ]
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertibleSafeNoteAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Number of common shares on conversion of debt instrument",
        "terseLabel": "Shares issued on debt exchanged",
        "label": "Debt Conversion, Converted Instrument, Shares Issued",
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r31"
     ]
    },
    "us-gaap_DebtConversionOriginalDebtAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtConversionOriginalDebtAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Notes with outstanding principal exchanged",
        "label": "Debt Conversion, Original Debt, Amount",
        "documentation": "The amount of the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r31"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertibleSafeNote"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Safe Note",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r181",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r338",
      "r339",
      "r351",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r367",
      "r374",
      "r375",
      "r377",
      "r582"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertibleSafeNoteAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r65",
      "r66",
      "r115",
      "r117",
      "r187",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r358",
      "r363",
      "r364",
      "r365",
      "r366",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r851",
      "r1012",
      "r1036",
      "r1037",
      "r1038",
      "r1097",
      "r1098"
     ]
    },
    "us-gaap_DebtInstrumentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentDescription",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertibleSafeNoteAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Description",
        "documentation": "Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r46",
      "r61",
      "r65",
      "r115",
      "r117",
      "r582"
     ]
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertibleSafeNoteAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible safe note, principal amount",
        "label": "Debt Instrument, Face Amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r352",
      "r582",
      "r583",
      "r823",
      "r824",
      "r851"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertibleSafeNoteAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual interest rate",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r353"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertibleSafeNoteAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r358",
      "r363",
      "r364",
      "r365",
      "r366",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r376",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r851",
      "r1012",
      "r1097",
      "r1098"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertibleSafeNoteAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r187",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r358",
      "r363",
      "r364",
      "r365",
      "r366",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r851",
      "r1012",
      "r1036",
      "r1037",
      "r1038",
      "r1097",
      "r1098"
     ]
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertibleSafeNoteAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "Disclosure of information about long-term debt instrument or arrangement."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r46",
      "r49",
      "r60",
      "r105",
      "r106",
      "r187",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r358",
      "r363",
      "r364",
      "r365",
      "r366",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r376",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r851",
      "r1012",
      "r1097",
      "r1098"
     ]
    },
    "us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance costs related to convertible debt included in accounts payable and accrued expenses",
        "label": "Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction",
        "documentation": "The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r30",
      "r31"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfInvestmentsClassifiedAsAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272"
     ]
    },
    "us-gaap_DeferredChargesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredChargesPolicyTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Charges, Policy [Policy Text Block]",
        "terseLabel": "Deferred Offering Costs",
        "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges."
       }
      }
     },
     "auth_ref": [
      "r154"
     ]
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfFollowingAssumptionsPresentedOnWeightedAverageBasisDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation [Axis]",
        "documentation": "Information by type of deferred compensation related to equity-based payment arrangements. Includes, but is not limited to, employment contracts with one or more selected officers or key employees. Excludes broad group equity-based compensation plans, defined benefit pension plans, defined benefit other postretirement benefit plans and other deferred compensation that is not equivalent to a defined benefit pension plan or a defined benefit other postretirement benefit plan."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_DeferredCostsCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredCostsCurrentAndNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred offering costs",
        "totalLabel": "Deferred Costs, Total",
        "label": "Deferred Costs",
        "documentation": "The carrying amount of deferred costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFinanceCostsNet",
     "crdr": "debit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertibleSafeNoteAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance costs",
        "label": "Debt Issuance Costs, Net",
        "totalLabel": "Debt Issuance Costs, Net, Total",
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r1048",
      "r1096",
      "r1097",
      "r1098"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Total deferred tax liabilities",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r73",
      "r116",
      "r479"
     ]
    },
    "lxeo_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Offering Costs Included In Accounts Payable And Accrued Expenses",
        "documentation": "Deferred offering costs included in accounts payable and accrued expenses",
        "terseLabel": "Deferred offering costs included in accounts payable and accrued expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r480"
     ]
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Asset, In-Process Research and Development",
        "terseLabel": "Capitalized R&amp;D expenses",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both."
       }
      }
     },
     "auth_ref": [
      "r1085"
     ]
    },
    "lxeo_DeferredTaxAssetsIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "DeferredTaxAssetsIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets, intangible assets.",
        "label": "Deferred Tax Assets Intangible Assets",
        "terseLabel": "Intangibles"
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_DeferredTaxAssetsLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "DeferredTaxAssetsLeaseLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets lease liabilities.",
        "label": "Deferred Tax Assets Lease Liabilities",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax assets (liabilities)",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r1081"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Net deferred tax assets",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1081"
     ]
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNetAbstract",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1085"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other deferred tax assets",
        "label": "Deferred Tax Assets, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r1085"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred Tax Assets, Tax Credit Carryforwards, Total",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "terseLabel": "Tax credits",
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1085"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r481"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "negatedLabel": "Right of use asset",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements."
       }
      }
     },
     "auth_ref": [
      "r1085"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liabilities:",
        "label": "Deferred Tax Liabilities, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesOther",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Other",
        "negatedLabel": "Other deferred tax liabilities",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other."
       }
      }
     },
     "auth_ref": [
      "r1085"
     ]
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization expense",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "totalLabel": "Depreciation, Depletion and Amortization, Nonproduction, Total",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r40"
     ]
    },
    "lxeo_DevelopmentAndCommercializationMilestonesDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "DevelopmentAndCommercializationMilestonesDue",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Development and commercialization milestones due",
        "label": "Development and Commercialization Milestones Due",
        "documentation": "Development and commercialization milestones due."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_DevelopmentAndRegulatoryMilestonesDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "DevelopmentAndRegulatoryMilestonesDue",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Development and regulatory milestones due",
        "label": "Development and Regulatory Milestones Due",
        "documentation": "Development and regulatory milestones due."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensation1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r408",
      "r411",
      "r442",
      "r443",
      "r445",
      "r835"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DividendsCommonStockCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DividendsCommonStockCash",
     "crdr": "debit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends, common stock, cash",
        "label": "Dividends, Common Stock, Cash",
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash."
       }
      }
     },
     "auth_ref": [
      "r107"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r872",
      "r873",
      "r896"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r872",
      "r873",
      "r896",
      "r939"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r917"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r870"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Domestic Tax Jurisdiction [Member]",
        "terseLabel": "Federal",
        "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r463"
     ]
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r928"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureNetLossPerShareScheduleOfNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net loss per common share, basic",
        "terseLabel": "Net loss per share attributable to common stockholders, basic",
        "label": "Earnings Per Share, Basic",
        "totalLabel": "Earnings Per Share, Basic, Total",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r206",
      "r208",
      "r211",
      "r212",
      "r213",
      "r218",
      "r505",
      "r515",
      "r544",
      "r545",
      "r653",
      "r677",
      "r803"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureNetLossPerShareScheduleOfNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net loss per common share, diluted",
        "terseLabel": "Net loss per share attributable to common stockholders, diluted",
        "label": "Earnings Per Share, Diluted",
        "totalLabel": "Earnings Per Share, Diluted, Total",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r208",
      "r211",
      "r212",
      "r213",
      "r218",
      "r505",
      "r515",
      "r544",
      "r545",
      "r653",
      "r677",
      "r803"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss per Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r33",
      "r215"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureNetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss Per Share",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r205",
      "r214",
      "r216",
      "r217"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective income tax rate",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r463",
      "r838"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal statutory rate",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r184",
      "r463",
      "r492",
      "r838"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r468",
      "r838",
      "r1014",
      "r1078"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent, Total",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent",
        "terseLabel": "Permanent differences",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r469",
      "r470",
      "r1014",
      "r1078"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent",
        "documentation": "Percentage of reported income tax benefit (expense) from difference to income tax expense (benefit) computed by applying statutory federal (national) income tax rate to pretax income (loss) from continuing operation, attributable to other reconciling items. Excludes state and local income tax expense (benefit), federal tax expense (benefit), statutory income tax expense (benefit) outside of country of domicile, tax credit, nondeductible expense, deduction, income tax settlement, income tax contingency, and cross-border tax law."
       }
      }
     },
     "auth_ref": [
      "r1079"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State Taxes, net of federal benefit",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r466",
      "r838",
      "r1014",
      "r1078"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax credits",
        "totalLabel": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent, Total",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent",
        "negatedLabel": "Tax credits",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits."
       }
      }
     },
     "auth_ref": [
      "r467",
      "r470",
      "r1014",
      "r1078"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "totalLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total",
        "terseLabel": "Unrecognized stock-based compensation expense",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r444"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation expense, weighted-average period of recognition",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r444"
     ]
    },
    "us-gaap_EmployeeStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockMember",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock [Member]",
        "terseLabel": "Employee Stock Purchase Plan",
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfFollowingAssumptionsPresentedOnWeightedAverageBasisDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "verboseLabel": "Exercise of Outstanding Stock Options",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CIK",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r869"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r869"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r982"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r869"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r979"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r869"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r869"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r869"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r869"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r981"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r922"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r975"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r975"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r975"
     ]
    },
    "us-gaap_EquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquipmentMember",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Laboratory Equipment",
        "label": "Lab Equipment",
        "verboseLabel": "Equipment Finance Lease [Member]",
        "documentation": "Tangible personal property used to produce goods and services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfFollowingAssumptionsPresentedOnWeightedAverageBasisDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation [Domain]",
        "documentation": "Deferred compensation related to equity-based payment arrangements. Includes, but is not limited to, employment contracts with one or more selected officers or key employees. Excludes broad group equity-based compensation plans, defined benefit pension plans, defined benefit other postretirement benefit plans and other deferred compensation that is not equivalent to a defined benefit pension plan or a defined benefit other postretirement benefit plan."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCapitalStockScheduleOfCommonStockReservedForFutureIssuancesDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertibleSafeNoteAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r143",
      "r167",
      "r168",
      "r169",
      "r188",
      "r189",
      "r190",
      "r193",
      "r199",
      "r201",
      "r203",
      "r220",
      "r296",
      "r302",
      "r320",
      "r396",
      "r487",
      "r488",
      "r501",
      "r502",
      "r503",
      "r506",
      "r514",
      "r515",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r543",
      "r574",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r584",
      "r585",
      "r608",
      "r673",
      "r686",
      "r687",
      "r688",
      "r711",
      "r772"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r932"
     ]
    },
    "lxeo_EricAdlerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "EricAdlerMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Eric Adler [Member]",
        "documentation": "Eric Adler.",
        "terseLabel": "Eric Adler"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r889",
      "r900",
      "r910",
      "r943"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r886",
      "r897",
      "r907",
      "r940"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r938"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfRollforwardOfChangesInFairValueOfFinancialLiabilitiesDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfSignificantUnobservableInputsUsedInTheValuationModelToEstimateFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r547",
      "r548",
      "r560",
      "r841"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfRollforwardOfChangesInFairValueOfFinancialLiabilitiesDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfSignificantUnobservableInputsUsedInTheValuationModelToEstimateFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r547",
      "r548",
      "r560",
      "r841"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r549",
      "r550",
      "r551",
      "r844"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "terseLabel": "Summary of Estimated Fair Value Assumptions",
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r549",
      "r550",
      "r844"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value Hierarchy for Assets and Liabilities Measured at Fair Value on Recurring Basis",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r1088",
      "r1089"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfRollforwardOfChangesInFairValueOfFinancialLiabilitiesDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfSignificantUnobservableInputsUsedInTheValuationModelToEstimateFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r365",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r546",
      "r548",
      "r549",
      "r550",
      "r551",
      "r559",
      "r560",
      "r562",
      "r616",
      "r617",
      "r618",
      "r823",
      "r824",
      "r829",
      "r830",
      "r831",
      "r841",
      "r844"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r547",
      "r548",
      "r549",
      "r551",
      "r841",
      "r1091",
      "r1094"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r555",
      "r557",
      "r558",
      "r559",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r649",
      "r841",
      "r845"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1 [Member]",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r365",
      "r400",
      "r405",
      "r548",
      "r560",
      "r616",
      "r829",
      "r830",
      "r831",
      "r841"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2 [Member]",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r365",
      "r400",
      "r405",
      "r548",
      "r549",
      "r560",
      "r617",
      "r823",
      "r824",
      "r829",
      "r830",
      "r831",
      "r841"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfRollforwardOfChangesInFairValueOfFinancialLiabilitiesDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfSignificantUnobservableInputsUsedInTheValuationModelToEstimateFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 3 [Member]",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r365",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r548",
      "r549",
      "r550",
      "r551",
      "r560",
      "r618",
      "r823",
      "r824",
      "r829",
      "r830",
      "r831",
      "r841",
      "r844"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Rollforward of Changes in Fair Value of Financial Liabilities",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability."
       }
      }
     },
     "auth_ref": [
      "r552",
      "r556",
      "r561"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r547",
      "r548",
      "r549",
      "r551",
      "r841",
      "r1091",
      "r1094"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversionOfNotesIntoCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversionOfNotesIntoCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfRollforwardOfChangesInFairValueOfFinancialLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Conversion of SAFE Note into common stock in connection with initial public offering",
        "documentation": "Fair value measurement with unobservable inputs reconciliation recurring basis liability conversion of notes into common stock.",
        "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Conversion of Notes Into Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConvertibleNoteIssuance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConvertibleNoteIssuance",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfRollforwardOfChangesInFairValueOfFinancialLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Liability, Convertible Note Issuance",
        "documentation": "Fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, convertible note issuance.",
        "verboseLabel": "Convertible SAFE Note issuance at August 24, 2023"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfRollforwardOfChangesInFairValueOfFinancialLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in estimated fair value since issuance",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r553",
      "r561"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfRollforwardOfChangesInFairValueOfFinancialLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r552",
      "r561"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfRollforwardOfChangesInFairValueOfFinancialLiabilitiesDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfSignificantUnobservableInputsUsedInTheValuationModelToEstimateFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r365",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r546",
      "r548",
      "r549",
      "r550",
      "r551",
      "r559",
      "r560",
      "r562",
      "r616",
      "r617",
      "r618",
      "r823",
      "r824",
      "r829",
      "r830",
      "r831",
      "r841",
      "r844"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Recurring [Member]",
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r841",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092",
      "r1094"
     ]
    },
    "us-gaap_FairValueNetAssetLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueNetAssetLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Net Asset (Liability)",
        "totalLabel": "Fair Value, Net Asset (Liability), Total",
        "terseLabel": "Fair value Disclosure, Total",
        "documentation": "Fair value of asset after deduction of liability."
       }
      }
     },
     "auth_ref": [
      "r1088",
      "r1089"
     ]
    },
    "lxeo_FairValueOfUnearnedEmployeeStockOwnershipPlans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "FairValueOfUnearnedEmployeeStockOwnershipPlans",
     "crdr": "debit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of unearned employee stock ownership plans",
        "label": "Fair Value of Unearned Employee Stock Ownership Plans",
        "documentation": "Fair Value of Unearned Employee Stock Ownership Plans"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueOptionQuantitativeDisclosuresLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueOptionQuantitativeDisclosuresLineItems",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Option, Quantitative Disclosures [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r571",
      "r572",
      "r573"
     ]
    },
    "us-gaap_FairValueOptionQuantitativeDisclosuresTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueOptionQuantitativeDisclosuresTable",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueAssumptionsDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Option, Disclosures [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value under fair value option."
       }
      }
     },
     "auth_ref": [
      "r571",
      "r572",
      "r573"
     ]
    },
    "lxeo_FairValueProbabilityOfMeetingChangeInControlEvent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "FairValueProbabilityOfMeetingChangeInControlEvent",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfSignificantUnobservableInputsUsedInTheValuationModelToEstimateFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Probability of meeting change in control event",
        "label": "Fair Value Probability Of Meeting Change In Control Event",
        "documentation": "Fair value probability of meeting change in control event."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_FairValueProbabilityOfMeetingPublicOfferingEvent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "FairValueProbabilityOfMeetingPublicOfferingEvent",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfSignificantUnobservableInputsUsedInTheValuationModelToEstimateFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Probability Of Meeting Public Offering Event",
        "terseLabel": "Probability of meeting public offering event",
        "documentation": "Fair value probability of meeting public offering event."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_FairValueProbabilityOfMeetingQualifiedEquityFinancingEvent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "FairValueProbabilityOfMeetingQualifiedEquityFinancingEvent",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfSignificantUnobservableInputsUsedInTheValuationModelToEstimateFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Probability of meeting qualified equity financing event",
        "label": "Fair Value Probability of Meeting Qualified Equity Financing Event",
        "documentation": "Fair Value probability of meeting qualified equity financing event."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfRollforwardOfChangesInFairValueOfFinancialLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of income or comprehensive income that includes gain (loss) from liability measured at fair value using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r553",
      "r561"
     ]
    },
    "lxeo_FairValueTimeUntilChangeInControlEvent": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "FairValueTimeUntilChangeInControlEvent",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfSignificantUnobservableInputsUsedInTheValuationModelToEstimateFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Time until change in control event (in years)",
        "label": "Fair Value Time Until Change In Control Event",
        "documentation": "Fair value time until change in control event."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_FairValueTimeUntilPublicOfferingEvent": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "FairValueTimeUntilPublicOfferingEvent",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfSignificantUnobservableInputsUsedInTheValuationModelToEstimateFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Time until public offering event (in years)",
        "label": "Fair Value Time Until Public Offering Event",
        "documentation": "Fair value time until public offering event."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_FairValueTimeUntilQualifiedEquityFinancingEvent": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "FairValueTimeUntilQualifiedEquityFinancingEvent",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfSignificantUnobservableInputsUsedInTheValuationModelToEstimateFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Time until qualified equity financing event (in years)",
        "label": "Fair Value Time Until Qualified Equity Financing Event",
        "documentation": "Fair value time until qualified equity financing event."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_FinanceLeaseAggregateMonthlyInstallmentPaymentAmounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "FinanceLeaseAggregateMonthlyInstallmentPaymentAmounts",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total aggregate monthly installment payment amount",
        "label": "Finance Lease Aggregate Monthly Installment Payment Amounts",
        "documentation": "Finance lease aggregate monthly installment payment amounts."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_FinanceLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "FinanceLeaseExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesComponentsOfEquipmentFinanceLeasesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesComponentsOfEquipmentFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total finance lease expense",
        "label": "Finance Lease Expense",
        "documentation": "Finance lease expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseInterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesComponentsOfEquipmentFinanceLeasesDetails": {
       "parentTag": "lxeo_FinanceLeaseExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesComponentsOfEquipmentFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest on finance lease liabilities",
        "label": "Finance Lease, Interest Expense",
        "documentation": "Amount of interest expense on finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r588",
      "r594",
      "r853"
     ]
    },
    "us-gaap_FinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingEquipmentFinanceLeaseObligationsDetails2": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingEquipmentFinanceLeaseObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability",
        "totalLabel": "Total finance lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease."
       }
      }
     },
     "auth_ref": [
      "r587",
      "r600"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityAbstract",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingEquipmentFinanceLeaseObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability [Abstract]",
        "terseLabel": "Included in the balance sheet:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingEquipmentFinanceLeaseObligationsDetails2": {
       "parentTag": "us-gaap_FinanceLeaseLiability",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingEquipmentFinanceLeaseObligationsDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current portion of lease liabilities - finance",
        "label": "Finance Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r587"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of Remaining Equipment Finance Lease Obligations",
        "label": "Finance Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1102"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingEquipmentFinanceLeaseObligationsDetails2": {
       "parentTag": "us-gaap_FinanceLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingEquipmentFinanceLeaseObligationsDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current portion of lease liabilities - finance",
        "label": "Finance Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r587"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingEquipmentFinanceLeaseObligationsDetails2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingEquipmentFinanceLeaseObligationsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingEquipmentFinanceLeaseObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease payments",
        "label": "Finance Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r600"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingEquipmentFinanceLeaseObligationsDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingEquipmentFinanceLeaseObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Finance Lease, Liability, to be Paid, after Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r600"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingEquipmentFinanceLeaseObligationsDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingEquipmentFinanceLeaseObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, to be Paid, Year One",
        "terseLabel": "2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r600"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingEquipmentFinanceLeaseObligationsDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingEquipmentFinanceLeaseObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2029",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r600"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingEquipmentFinanceLeaseObligationsDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingEquipmentFinanceLeaseObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2028",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r600"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingEquipmentFinanceLeaseObligationsDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingEquipmentFinanceLeaseObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r600"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingEquipmentFinanceLeaseObligationsDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingEquipmentFinanceLeaseObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r600"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingEquipmentFinanceLeaseObligationsDetails2": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingEquipmentFinanceLeaseObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: imputed interest",
        "terseLabel": "Less: imputed interest",
        "label": "Finance Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r600"
     ]
    },
    "lxeo_FinanceLeaseMonthlyInstallmentPaymentAmounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "FinanceLeaseMonthlyInstallmentPaymentAmounts",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Monthly installment payment amounts",
        "label": "Finance Lease Monthly Installment Payment Amounts",
        "documentation": "Finance lease monthly installment payment amounts"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeasePrincipalPayments",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesComponentsOfEquipmentFinanceLeasesDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments on finance leases",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities, included in financing cash flows",
        "label": "Finance Lease, Principal Payments",
        "documentation": "Amount of cash outflow for principal payment on finance lease."
       }
      }
     },
     "auth_ref": [
      "r589",
      "r597"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net book values",
        "terseLabel": "Lease right-of-use assets - finance, net",
        "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization",
        "totalLabel": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization, Total",
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r586"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseRightOfUseAssetAccumulatedAmortization",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated amortization",
        "label": "Finance Lease, Right-of-Use Asset, Accumulated Amortization",
        "documentation": "Amount of accumulated amortization of right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r987",
      "r988"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesComponentsOfEquipmentFinanceLeasesDetails": {
       "parentTag": "lxeo_FinanceLeaseExpense",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesComponentsOfEquipmentFinanceLeasesDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "terseLabel": "Finance lease amortization of right-of-use assets",
        "verboseLabel": "Reduction in the carrying amount of ROU assets, finance",
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r588",
      "r594",
      "r853"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization",
     "crdr": "debit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total gross",
        "label": "Finance Lease, Right-of-Use Asset, before Accumulated Amortization",
        "documentation": "Amount, before accumulated amortization, of right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r986"
     ]
    },
    "lxeo_FinanceLeaseRightOfUseAssetsAndFinanceLeaseLiabilitiesRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "FinanceLeaseRightOfUseAssetsAndFinanceLeaseLiabilitiesRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance lease right-of use assets and finance lease liabilities recognized",
        "label": "Finance Lease Right-of Use Assets And Finance Lease Liabilities Recognized",
        "documentation": "Finance lease right-of use assets and finance lease liabilities recognized."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted average effective interest rate",
        "terseLabel": "Weighted Average Effective Interest Rate",
        "label": "Finance Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for finance lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r599",
      "r853"
     ]
    },
    "lxeo_FinanceLeaseWeightedAverageRemainingAmortizationTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "FinanceLeaseWeightedAverageRemainingAmortizationTerm",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted average remaining amortization term",
        "terseLabel": "Weighted Average Remaining Amortization Term (in years)",
        "label": "Finance Lease Weighted Average Remaining Amortization Term",
        "documentation": "Finance lease weighted average remaining amortization term."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted average remaining lease payment term",
        "terseLabel": "Weighted Average Remaining Lease Payment Term (in years)",
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r598",
      "r853"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfInvestmentsClassifiedAsAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r309",
      "r310",
      "r311",
      "r376",
      "r393",
      "r533",
      "r567",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r674",
      "r820",
      "r841",
      "r842",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r855",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1087",
      "r1090",
      "r1091",
      "r1092",
      "r1093",
      "r1094"
     ]
    },
    "lxeo_FirstUcsdLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "FirstUcsdLicenseAgreementMember",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "First UCSD License Agreement",
        "label": "First UCSD License Agreement [Member]",
        "documentation": "First UCSD license agreement."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r893",
      "r904",
      "r914",
      "r947"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r893",
      "r904",
      "r914",
      "r947"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r893",
      "r904",
      "r914",
      "r947"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r893",
      "r904",
      "r914",
      "r947"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r893",
      "r904",
      "r914",
      "r947"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r927"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Furniture and Fixtures",
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnFairValueHedgesRecognizedInEarnings",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain (Loss) on Fair Value Hedges Recognized in Earnings",
        "terseLabel": "Loss on fair value adjustment to convertible SAFE Note",
        "totalLabel": "Gain (Loss) on Fair Value Hedges Recognized in Earnings, Total",
        "documentation": "Total amount of gain (loss) derived from fair value hedges recognized in earnings in the period."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense",
        "totalLabel": "General and Administrative Expense, Total",
        "verboseLabel": "All other general and administrative expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r756"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseAbstract",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalInformationOnCompanysNetLossIncludingSegmentExpensesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Abstract]",
        "terseLabel": "General and administrative expense"
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_GeneralAndAdministrativeExpenseEmployeeCompensationExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "GeneralAndAdministrativeExpenseEmployeeCompensationExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalInformationOnCompanysNetLossIncludingSegmentExpensesDetails3": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalInformationOnCompanysNetLossIncludingSegmentExpensesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee compensation expenses",
        "label": "General and Administrative Expense Employee Compensation Expenses",
        "documentation": "General and administrative expense employee compensation expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative expense",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "lxeo_GeneralAndAdministrativeExpensesPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "GeneralAndAdministrativeExpensesPolicyPolicyTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and Administrative",
        "documentation": "General and administrative expenses.",
        "label": "General and Administrative Expenses, Policy [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GranteeStatusAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GranteeStatusAxis",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grantee Status [Axis]",
        "documentation": "Information by status of recipient to whom award is granted."
       }
      }
     },
     "auth_ref": [
      "r409",
      "r410",
      "r412",
      "r413",
      "r414",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440"
     ]
    },
    "us-gaap_GranteeStatusDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GranteeStatusDomain",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grantee Status [Domain]",
        "documentation": "Status of recipient to whom award is granted."
       }
      }
     },
     "auth_ref": [
      "r409",
      "r410",
      "r412",
      "r413",
      "r414",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440"
     ]
    },
    "us-gaap_IPOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IPOMember",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertibleSafeNoteAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueAssumptionsDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsTables",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "IPO",
        "label": "IPO [Member]",
        "verboseLabel": "Initial Public Offering",
        "documentation": "First sale of stock by a private company to the public."
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r872",
      "r873",
      "r896"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations before income taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r122",
      "r126",
      "r654",
      "r670",
      "r805",
      "r812",
      "r1023",
      "r1025",
      "r1026",
      "r1027",
      "r1028"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r321",
      "r327",
      "r329",
      "r553",
      "r556",
      "r561",
      "r681",
      "r683",
      "r757",
      "r797",
      "r843",
      "r1114"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r327",
      "r329",
      "r553",
      "r556",
      "r561",
      "r681",
      "r683",
      "r757",
      "r797",
      "r843",
      "r1114"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority",
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r463",
      "r464",
      "r475",
      "r484",
      "r838",
      "r1084"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority",
        "label": "Income Tax Jurisdiction [Domain]",
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r463",
      "r464",
      "r475",
      "r484",
      "r838",
      "r1084"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r184",
      "r458",
      "r463",
      "r471",
      "r472",
      "r473",
      "r477",
      "r483",
      "r493",
      "r495",
      "r496",
      "r497",
      "r709",
      "r838"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income taxes",
        "label": "Income Tax Expense (Benefit)",
        "totalLabel": "Income Tax Expense (Benefit), Total",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r139",
      "r202",
      "r203",
      "r219",
      "r233",
      "r250",
      "r462",
      "r463",
      "r494",
      "r679",
      "r838"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r166",
      "r460",
      "r461",
      "r477",
      "r478",
      "r482",
      "r486",
      "r703"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationTaxCreditsForeign",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal tax credits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign tax credit."
       }
      }
     },
     "auth_ref": [
      "r1078",
      "r1080"
     ]
    },
    "us-gaap_IncomeTaxesPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxesPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes Paid",
        "terseLabel": "Income taxes paid",
        "documentation": "Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r96",
      "r1009",
      "r1082",
      "r1083"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "totalLabel": "Increase (Decrease) in Accounts Payable, Total",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other current liabilities",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other."
       }
      }
     },
     "auth_ref": [
      "r1007"
     ]
    },
    "us-gaap_IncreaseDecreaseInDerivativeAssetsAndLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInDerivativeAssetsAndLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Derivative Assets and Liabilities",
        "negatedLabel": "Change in fair value of convertible SAFE Note liability",
        "documentation": "The increase (decrease) during the period in the net carrying value of derivative instruments reported as assets and liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer)."
       }
      }
     },
     "auth_ref": [
      "r1007"
     ]
    },
    "lxeo_IncreaseDecreaseInFairValueOfSafeInstrument": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "IncreaseDecreaseInFairValueOfSafeInstrument",
     "crdr": "debit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertibleSafeNoteAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in fair value of safe instrument",
        "label": "Increase (Decrease) in Fair Value of SAFE Instrument",
        "documentation": "Increase (decrease) in fair value of safe instrument."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_IncreaseDecreaseInFinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "IncreaseDecreaseInFinanceLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities, finance",
        "label": "Increase Decrease In Finance Lease Liability",
        "documentation": "Increase decrease in finance lease liability."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Lease liabilities, operating",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r989",
      "r1007"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "lxeo_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "IncreaseInCommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase In Common Stock Capital Shares Reserved For Future Issuance",
        "documentation": "Increase in common stock capital shares reserved for future issuance.",
        "terseLabel": "Increase in aggregate number of shares of common stock reserved for issuance"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r893",
      "r904",
      "r914",
      "r938",
      "r947",
      "r951",
      "r959"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r957"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r874",
      "r963"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r874",
      "r963"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r874",
      "r963"
     ]
    },
    "us-gaap_InterestExpenseNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseNonoperating",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense",
        "label": "Interest Expense, Nonoperating",
        "totalLabel": "Interest Expense, Nonoperating, Total",
        "documentation": "Amount of interest expense classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r232",
      "r1006"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest paid",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r173",
      "r176",
      "r177"
     ]
    },
    "us-gaap_InternalUseSoftwarePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InternalUseSoftwarePolicy",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Internal Use Software, Policy [Policy Text Block]",
        "terseLabel": "Deferred Software Costs",
        "documentation": "Disclosure of accounting policy for costs incurred when both (1) the software is acquired, internally developed, or modified solely to meet the entity's internal needs, and (2) during the software's development or modification, no substantive plan exists or is being developed to market the software externally."
       }
      }
     },
     "auth_ref": [
      "r318"
     ]
    },
    "lxeo_InvestmentCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "InvestmentCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Current",
        "documentation": "Investment current.",
        "terseLabel": "Investment current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentIncomeAmortizationOfDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentIncomeAmortizationOfDiscount",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Income, Amortization of Discount",
        "terseLabel": "Accretion of discount on investments",
        "documentation": "Amount of accretion of purchase discount on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income",
        "label": "Investment Income, Interest",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r219",
      "r231",
      "r250",
      "r812",
      "r1005"
     ]
    },
    "lxeo_InvestmentNonCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "InvestmentNonCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Non Current",
        "documentation": "Investment non current.",
        "terseLabel": "Investment non-current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentPolicyTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments",
        "label": "Investment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for investment in financial asset."
       }
      }
     },
     "auth_ref": [
      "r678",
      "r699",
      "r700",
      "r701",
      "r702",
      "r779",
      "r780"
     ]
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "terseLabel": "Schedule of Aggregate Fair Values of Investments Classified as Available-for-Sale Securities With Unrealized Losses and Gains",
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Investment",
        "label": "Investments, Fair Value Disclosure",
        "totalLabel": "Investments, Fair Value Disclosure, Total",
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method."
       }
      }
     },
     "auth_ref": [
      "r1088",
      "r1089",
      "r1093"
     ]
    },
    "us-gaap_LaborAndRelatedExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LaborAndRelatedExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalInformationOnCompanysNetLossIncludingSegmentExpensesDetails3": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalInformationOnCompanysNetLossIncludingSegmentExpensesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Labor and Related Expense",
        "terseLabel": "Lab-related costs and supplies",
        "documentation": "Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit."
       }
      }
     },
     "auth_ref": [
      "r1004"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold Improvements",
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r601"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_LeerinkAtTheMarketSalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "LeerinkAtTheMarketSalesAgreementMember",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leerink At The Market Sales Agreement [Member]",
        "documentation": "Leerink at the market sales agreement.",
        "terseLabel": "Leerink At The Market Sales Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_LesseeFinanceLeaseCommencementDateRangeEnd": {
     "xbrltype": "dateItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "LesseeFinanceLeaseCommencementDateRangeEnd",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance lease, commencement date range, end",
        "label": "Lessee, Finance Lease, Commencement Date Range, End",
        "documentation": "Lessee, finance lease, commencement date range, end."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_LesseeFinanceLeaseCommencementDateRangeStart": {
     "xbrltype": "dateItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "LesseeFinanceLeaseCommencementDateRangeStart",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance lease, commencement date range, start",
        "label": "Lessee, Finance Lease, Commencement Date Range, Start",
        "documentation": "Lessee, finance lease, commencement date range, start."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeFinanceLeaseDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeFinanceLeaseDiscountRate",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Imputed interest rate",
        "label": "Lessee, Finance Lease, Discount Rate",
        "documentation": "Discount rate used by lessee to determine present value of finance lease payments."
       }
      }
     },
     "auth_ref": [
      "r1101"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r592",
      "r602"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r592",
      "r602"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r591"
     ]
    },
    "lxeo_LesseeOperatingAndFinancingLeasesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "LesseeOperatingAndFinancingLeasesDisclosureTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeases3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee Operating And Financing Leases Disclosure [Text Block]",
        "documentation": "Lessee Operating And Financing Leases Disclosure.",
        "terseLabel": "Leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseDiscountRate",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Incremental borrowing rate",
        "label": "Lessee, Operating Lease, Discount Rate",
        "documentation": "Discount rate used by lessee to determine present value of operating lease payments."
       }
      }
     },
     "auth_ref": [
      "r852"
     ]
    },
    "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Existence of option to extend",
        "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]",
        "documentation": "Indicates (true false) whether lessee has option to extend operating lease."
       }
      }
     },
     "auth_ref": [
      "r593"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of Remaining Undiscounted Contractual Rent Obligations",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1102"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingUndiscountedContractualRentObligationsDetails2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingUndiscountedContractualRentObligationsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingUndiscountedContractualRentObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r600"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingUndiscountedContractualRentObligationsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingUndiscountedContractualRentObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r600"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingUndiscountedContractualRentObligationsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingUndiscountedContractualRentObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r600"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingUndiscountedContractualRentObligationsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingUndiscountedContractualRentObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2029",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r600"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingUndiscountedContractualRentObligationsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingUndiscountedContractualRentObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2028",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r600"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingUndiscountedContractualRentObligationsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingUndiscountedContractualRentObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r600"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingUndiscountedContractualRentObligationsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingUndiscountedContractualRentObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r600"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingUndiscountedContractualRentObligationsDetails2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingUndiscountedContractualRentObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: present value adjustment",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r600"
     ]
    },
    "us-gaap_LesseeOperatingLeaseOptionToExtend": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseOptionToExtend",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option to extend",
        "label": "Lessee, Operating Lease, Option to Extend",
        "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability."
       }
      }
     },
     "auth_ref": [
      "r593"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Renewal term",
        "label": "Lessee, Operating Lease, Renewal Term",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1100"
     ]
    },
    "us-gaap_LetterOfCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LetterOfCreditMember",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Letter of Credit",
        "label": "Letter of Credit [Member]",
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r65",
      "r66",
      "r67",
      "r69",
      "r70",
      "r71",
      "r74",
      "r183",
      "r291",
      "r340",
      "r341",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r349",
      "r350",
      "r519",
      "r522",
      "r523",
      "r570",
      "r731",
      "r804",
      "r867",
      "r1045",
      "r1103",
      "r1104"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r119",
      "r666",
      "r854",
      "r1013",
      "r1034",
      "r1095"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders' equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r149",
      "r183",
      "r291",
      "r340",
      "r341",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r349",
      "r350",
      "r519",
      "r522",
      "r523",
      "r570",
      "r854",
      "r1045",
      "r1103",
      "r1104"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertibleSafeNoteAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total liabilities",
        "label": "Liabilities, Fair Value Disclosure",
        "totalLabel": "Liabilities, Fair Value Disclosure, Total",
        "documentation": "Fair value of financial and nonfinancial obligations."
       }
      }
     },
     "auth_ref": [
      "r548",
      "r1088"
     ]
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current liabilities",
        "label": "Liabilities, Noncurrent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_LicenseAgreementTerminationNoticePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "LicenseAgreementTerminationNoticePeriod",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Termination notice period (in days)",
        "terseLabel": "License agreement termination notice period",
        "label": "License Agreement Termination Notice Period",
        "documentation": "License agreement termination notice period."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_LicenseAndAcquisitionAndResearchCollaborationAndSponsoredResearchAgreementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "LicenseAndAcquisitionAndResearchCollaborationAndSponsoredResearchAgreementsDisclosureTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License, Acquisition, Research Collaboration and Sponsored Research Agreements",
        "label": "License and Acquisition and Research Collaboration and Sponsored Research Agreements Disclosure [Text Block]",
        "documentation": "License and acquisition and research collaboration and sponsored research agreements disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertibleSafeNoteAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding principal balance together with accrued interest",
        "label": "Long-Term Debt",
        "totalLabel": "Long-Term Debt, Total",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r117",
      "r364",
      "r378",
      "r823",
      "r824",
      "r851",
      "r1113"
     ]
    },
    "us-gaap_LongTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Long-Term Investments, Total",
        "label": "Long-Term Investments",
        "terseLabel": "Investments",
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle)."
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "us-gaap_LongTermInvestmentsAndReceivablesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermInvestmentsAndReceivablesNet",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Investments and Receivables, Net",
        "totalLabel": "Long-Term Investments and Receivables, Net, Total",
        "terseLabel": "Investments, net",
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle) and amount due to the Entity from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such investments and receivables to an amount that approximates their net realizable value."
       }
      }
     },
     "auth_ref": [
      "r998"
     ]
    },
    "us-gaap_LossContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingenciesLineItems",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingencies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r332",
      "r333",
      "r334",
      "r337",
      "r452",
      "r821",
      "r1041",
      "r1042"
     ]
    },
    "us-gaap_LossContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingenciesTable",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingencies [Table]",
        "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation."
       }
      }
     },
     "auth_ref": [
      "r332",
      "r333",
      "r334",
      "r337",
      "r452",
      "r821",
      "r1041",
      "r1042"
     ]
    },
    "lxeo_LossRecognizedFromUninsuredBalances": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "LossRecognizedFromUninsuredBalances",
     "crdr": "debit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss recognized from uninsured balances",
        "label": "Loss Recognized from Uninsured Balances",
        "documentation": "Loss recognized from uninsured balances."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfSignificantUnobservableInputsUsedInTheValuationModelToEstimateFairValueDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "verboseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r333",
      "r334",
      "r335",
      "r336",
      "r406",
      "r452",
      "r551",
      "r645",
      "r680",
      "r682",
      "r696",
      "r723",
      "r724",
      "r777",
      "r781",
      "r784",
      "r785",
      "r786",
      "r795",
      "r796",
      "r819",
      "r827",
      "r834",
      "r844",
      "r845",
      "r849",
      "r850",
      "r856",
      "r1047",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "us-gaap_MeasurementInputExercisePriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputExercisePriceMember",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Exercise Price [Member]",
        "terseLabel": "Exercise Price",
        "documentation": "Measurement input using agreed upon price for exchange of underlying asset."
       }
      }
     },
     "auth_ref": [
      "r1090",
      "r1091",
      "r1092"
     ]
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputExpectedDividendRateMember",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Expected Dividend Rate [Member]",
        "terseLabel": "Expected Dividend Yield",
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year."
       }
      }
     },
     "auth_ref": [
      "r1090",
      "r1091",
      "r1092"
     ]
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputExpectedTermMember",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Expected Term [Member]",
        "terseLabel": "Expected Term",
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date."
       }
      }
     },
     "auth_ref": [
      "r1090",
      "r1091",
      "r1092"
     ]
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputPriceVolatilityMember",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected Volatility",
        "label": "Measurement Input, Price Volatility [Member]",
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r844",
      "r1090",
      "r1091",
      "r1092"
     ]
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "terseLabel": "Weighted Average Risk-free Interest Rate",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r1090",
      "r1091",
      "r1092"
     ]
    },
    "us-gaap_MeasurementInputSharePriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputSharePriceMember",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Share Price [Member]",
        "terseLabel": "Stock Price",
        "documentation": "Measurement input using share price of saleable stock."
       }
      }
     },
     "auth_ref": [
      "r1090",
      "r1091",
      "r1092"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r549",
      "r550",
      "r551",
      "r844"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Domain]",
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r549",
      "r550",
      "r551",
      "r844"
     ]
    },
    "lxeo_MilestoneReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "MilestoneReceived",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Milestone Received",
        "documentation": "Milestone received"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfSignificantUnobservableInputsUsedInTheValuationModelToEstimateFairValueDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "verboseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r333",
      "r334",
      "r335",
      "r336",
      "r406",
      "r452",
      "r551",
      "r645",
      "r680",
      "r682",
      "r696",
      "r723",
      "r724",
      "r777",
      "r781",
      "r784",
      "r785",
      "r786",
      "r795",
      "r796",
      "r819",
      "r827",
      "r834",
      "r844",
      "r845",
      "r849",
      "r856",
      "r1047",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r950"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r1049"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r958"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r931"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r175"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities:",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r175"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from investing activities:",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "terseLabel": "Cash flow from operations",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r95",
      "r97"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from operating activities:",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalInformationOnCompanysNetLossIncludingSegmentExpensesDetails3": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureNetLossPerShareScheduleOfNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalInformationOnCompanysNetLossIncludingSegmentExpensesDetails3",
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "verboseLabel": "Net loss",
        "negatedLabel": "Net Loss",
        "totalLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r97",
      "r123",
      "r147",
      "r161",
      "r164",
      "r169",
      "r183",
      "r192",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r202",
      "r203",
      "r210",
      "r291",
      "r340",
      "r341",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r349",
      "r350",
      "r505",
      "r515",
      "r545",
      "r570",
      "r672",
      "r753",
      "r770",
      "r771",
      "r865",
      "r1045"
     ]
    },
    "us-gaap_NetIncomeLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAbstract",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureNetLossPerShareScheduleOfNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Numerator:",
        "label": "Net Income (Loss) Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_NetProceedsReceivedFromPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "NetProceedsReceivedFromPrivatePlacement",
     "crdr": "debit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds from private placement",
        "label": "Net Proceeds Received from Private Placement",
        "documentation": "Net proceeds received from Private Placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recent Accounting Pronouncements Not Yet Adopted",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r893",
      "r904",
      "r914",
      "r938",
      "r947"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r921"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r920"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r938"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r958"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r958"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalInformationOnCompanysNetLossIncludingSegmentExpensesDetails3": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalInformationOnCompanysNetLossIncludingSegmentExpensesDetails3",
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income and expense",
        "negatedLabel": "Other income and expense, net",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income and expense",
        "label": "Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NotesIssued1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NotesIssued1",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Notes issued",
        "label": "Notes Issued",
        "documentation": "The fair value of notes issued in noncash investing and financing activities."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r30",
      "r31"
     ]
    },
    "lxeo_NumberOfFormerEmployees": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "NumberOfFormerEmployees",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Former Employees",
        "documentation": "Number of former employees.",
        "terseLabel": "Number of former employees"
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_NumberOfLicenseAgreements": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "NumberOfLicenseAgreements",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of license agreements",
        "label": "Number of License Agreements",
        "documentation": "Number of license agreements."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_NumberOfMonthlyInstallmentsLease": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "NumberOfMonthlyInstallmentsLease",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of monthly installments",
        "label": "Number Of Monthly Installments Lease",
        "documentation": "Number of monthly installments lease."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operation segment",
        "label": "Number of Operating Segments",
        "verboseLabel": "Number of operating segment",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r813",
      "r1024"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segment",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r806",
      "r817",
      "r1024"
     ]
    },
    "lxeo_NumberOfResearchAgreements": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "NumberOfResearchAgreements",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of research agreements",
        "label": "Number of Research Agreements",
        "documentation": "Number of research agreements."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_NumberOfSharesAutomaticallyIncreaseInAvailableSharesOfCommonStockUnderPlan": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "NumberOfSharesAutomaticallyIncreaseInAvailableSharesOfCommonStockUnderPlan",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares automatically increase in available shares of common stock under plan",
        "label": "Number of Shares Automatically Increase in Available Shares of Common Stock Under Plan",
        "documentation": "Number of Shares Automatically Increase in Available Shares of Common Stock Under Plan"
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_OfficeFacilityAndLaboratorySpaceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "OfficeFacilityAndLaboratorySpaceMember",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office Facility and Laboratory Space",
        "label": "Office Facility and Laboratory Space [Member]",
        "documentation": "Office facility and laboratory space."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_OneTimeUpFrontNonRefundableFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "OneTimeUpFrontNonRefundableFees",
     "crdr": "debit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "One-time up-front non-refundable fees",
        "label": "One Time Up Front Non Refundable Fees",
        "documentation": "One time up front non refundable fees."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating loss",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r805",
      "r1023",
      "r1025",
      "r1026",
      "r1027",
      "r1028"
     ]
    },
    "lxeo_OperatingLeaseAgreementEnteredDate": {
     "xbrltype": "gYearMonthItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "OperatingLeaseAgreementEnteredDate",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease agreement entered date",
        "label": "Operating Lease Agreement Entered Date",
        "documentation": "Operating lease agreement entered date."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_OperatingLeaseCommencementDate": {
     "xbrltype": "gYearMonthItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "OperatingLeaseCommencementDate",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease commencement date",
        "label": "Operating Lease Commencement Date",
        "documentation": "Operating lease commencement date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesComponentsOfOperatingLeaseDetails": {
       "parentTag": "us-gaap_OperatingLeaseExpense",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesComponentsOfOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease expense",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r595",
      "r853"
     ]
    },
    "lxeo_OperatingLeaseEndDate": {
     "xbrltype": "gYearMonthItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "OperatingLeaseEndDate",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease end date",
        "label": "Operating Lease End Date",
        "documentation": "Operating lease end date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesComponentsOfOperatingLeaseDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesComponentsOfOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating lease expense",
        "label": "Operating Lease, Expense",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r1099"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingUndiscountedContractualRentObligationsDetails2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingUndiscountedContractualRentObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating lease liabilities",
        "verboseLabel": "Operating lease liabilities",
        "terseLabel": "Current portion of lease liabilities - operating",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r587"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityAbstract",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingUndiscountedContractualRentObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability [Abstract]",
        "terseLabel": "Included in the balance sheet:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingUndiscountedContractualRentObligationsDetails2": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingUndiscountedContractualRentObligationsDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current portion of lease liabilities - operating",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r587"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingUndiscountedContractualRentObligationsDetails2": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesReconciliationOfRemainingUndiscountedContractualRentObligationsDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current portion of lease liabilities - operating",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r587"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesComponentsOfOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities, included in operating cash flows",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r590",
      "r597"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Operating lease right-of-use assets",
        "terseLabel": "Lease right-of-use assets - operating",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r586"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction",
        "terseLabel": "Reduction in the carrying amount of ROU assets, operating",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r1008"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining lease terms",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r598",
      "r853"
     ]
    },
    "lxeo_OperatingLeaseWeightedAverageRemainingPaymentTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "OperatingLeaseWeightedAverageRemainingPaymentTerm",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining lease payment terms",
        "label": "Operating Lease Weighted Average Remaining Payment Term",
        "documentation": "Operating lease weighted average remaining payment term."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_OperatingLossCarryForwardsExpirationYear": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "OperatingLossCarryForwardsExpirationYear",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carry forwards expiration year.",
        "label": "Operating Loss Carry forwards Expiration Year",
        "terseLabel": "Net operating loss carryforwards, expiration year"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r485"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwardsLineItems",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Operating Loss Carryforwards",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r485"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwardsTable",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Table]",
        "terseLabel": "Operating Loss Carryforwards",
        "documentation": "Disclosure of information about operating loss carryforward. Includes, but is not limited to, tax authority, amount and expiration date of operating loss carryforward, and likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r485"
     ]
    },
    "us-gaap_OperatingSegmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingSegmentsMember",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalInformationOnCompanysNetLossIncludingSegmentExpensesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Segments [Member]",
        "terseLabel": "Operating Segments",
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r251",
      "r812",
      "r813"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Description of Business and Basis of Presentation",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r112",
      "r697",
      "r698"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "lxeo_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current liabilities",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLocationAxis",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income Location [Axis]",
        "documentation": "Information by location in other comprehensive income."
       }
      }
     },
     "auth_ref": [
      "r554",
      "r556",
      "r561"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLocationDomain",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income Location [Domain]",
        "documentation": "Location in other comprehensive income."
       }
      }
     },
     "auth_ref": [
      "r554",
      "r556",
      "r561"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Total other comprehensive loss",
        "totalLabel": "Total other comprehensive loss",
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r16",
      "r162",
      "r165",
      "r170",
      "r199",
      "r574",
      "r575",
      "r580",
      "r651",
      "r673",
      "r1001",
      "r1002"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss) [Member]",
        "terseLabel": "Other Comprehensive Loss",
        "documentation": "Primary financial statement caption in which reported facts about other comprehensive income have been included."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_OtherGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalInformationOnCompanysNetLossIncludingSegmentExpensesDetails3": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalInformationOnCompanysNetLossIncludingSegmentExpensesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other General and Administrative Expense",
        "terseLabel": "All other general and administrative expense",
        "documentation": "Amount of general and administrative expense classified as other."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r1116"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Income (Expense)",
        "totalLabel": "Other Nonoperating Income (Expense), Total",
        "terseLabel": "Other income (expense), net",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "us-gaap_OtherResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalInformationOnCompanysNetLossIncludingSegmentExpensesDetails3": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalInformationOnCompanysNetLossIncludingSegmentExpensesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Research and Development Expense",
        "terseLabel": "All other research and development expense",
        "documentation": "Amount of other research and development expense."
       }
      }
     },
     "auth_ref": [
      "r1076"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r891",
      "r902",
      "r912",
      "r945"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r894",
      "r905",
      "r915",
      "r948"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r894",
      "r905",
      "r915",
      "r948"
     ]
    },
    "us-gaap_OverAllotmentOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OverAllotmentOptionMember",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Over-Allotment Option",
        "label": "Over-Allotment Option [Member]",
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r919"
     ]
    },
    "lxeo_PaymentOfAnnualDataTransferFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "PaymentOfAnnualDataTransferFee",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual data transfer fee",
        "label": "Payment of Annual Data Transfer Fee",
        "documentation": "Payment of annual data transfer fee."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_PaymentOfAnnualLicenseMaintenanceFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "PaymentOfAnnualLicenseMaintenanceFees",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment of Annual License Maintenance Fees",
        "documentation": "Payment of annual license maintenance fees",
        "terseLabel": "Annual license maintenance fees"
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_PaymentOfClinicalAndRegulatoryMilestone": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "PaymentOfClinicalAndRegulatoryMilestone",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Clinical and regulatory milestone paid",
        "label": "Payment Of Clinical And Regulatory Milestone",
        "documentation": "Payment Of Clinical And Regulatory Milestone."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_PaymentOfDevelopmentMilestone": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "PaymentOfDevelopmentMilestone",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Development milestone paid",
        "label": "Payment of Development Milestone",
        "documentation": "Payment of development milestone."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_PaymentOfLicenseIssueFeeAndInitialDataTransferFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "PaymentOfLicenseIssueFeeAndInitialDataTransferFee",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment of License Issue Fee and Initial Data Transfer Fee",
        "documentation": "Payment of license issue fee and initial data transfer fee",
        "terseLabel": "License fee and initial data transfer fee"
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_PaymentOfOneTimeUpFrontNonRefundableFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "PaymentOfOneTimeUpFrontNonRefundableFee",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "One-time up-front non-refundable fee paid",
        "label": "Payment of One Time Up Front Non Refundable Fee",
        "documentation": "Payment of one time up front non refundable fee."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_PaymentOfRegulatoryMilestones": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "PaymentOfRegulatoryMilestones",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Regulatory milestone to be paid",
        "label": "Payment of Regulatory Milestones",
        "documentation": "Payment of regulatory milestones"
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_PaymentStartingAfterPeriodOfExecutionOfAgreement": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "PaymentStartingAfterPeriodOfExecutionOfAgreement",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment starting after period of execution of agreement",
        "label": "Payment Starting After Period of Execution of Agreement",
        "documentation": "Payment starting after period of execution of agreement."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_PaymentTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "PaymentTerm",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment term",
        "label": "Payment Term",
        "documentation": "Payment term."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repurchase of Common stock",
        "label": "Payments for Repurchase of Common Stock",
        "documentation": "The cash outflow to reacquire common stock during the period."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfDebtIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments of issuance costs on convertible SAFE Note",
        "label": "Payments of Debt Issuance Costs",
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of Stock Issuance Costs",
        "terseLabel": "Net of issuance costs",
        "verboseLabel": "Underwriting discounts, commissions and offering expenses",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireInProcessResearchAndDevelopment",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment to research and development",
        "label": "Payments to Acquire in Process Research and Development",
        "documentation": "The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchases of investments",
        "negatedLabel": "Purchases of investments",
        "label": "Payments to Acquire Investments",
        "totalLabel": "Payments to Acquire Investments, Total",
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "us-gaap_PaymentsToAcquireSoftware": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireSoftware",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of internal use software",
        "label": "Payments to Acquire Software",
        "documentation": "The cash outflow associated with the acquisition from vendors of software programs or applications for internal use (that is, not to be sold, leased or otherwise marketed to others) that qualify for capitalization."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "lxeo_PayrollDeductionsAtPrice": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "PayrollDeductionsAtPrice",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payroll Deductions at Price",
        "documentation": "Payroll Deductions at Price",
        "terseLabel": "Payroll deductions at price"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r921"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r938"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r931"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r920"
     ]
    },
    "lxeo_PercentageOfAutomaticallyIncreaseInAvailableSharesOfCommonStockOnBeginningOfCachCalendarYear": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "PercentageOfAutomaticallyIncreaseInAvailableSharesOfCommonStockOnBeginningOfCachCalendarYear",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of automatically increase in available shares of common stock on beginning of each calendar year",
        "label": "Percentage of Automatically Increase in Available Shares of Common Stock on Beginning of Cach Calendar Year",
        "documentation": "Percentage of automatically increase in available shares of common stock on beginning of each calendar year."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_PercentageOfCumulativeOwnershipChange": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "PercentageOfCumulativeOwnershipChange",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage Of Cumulative Ownership Change",
        "documentation": "Percentage of cumulative ownership change.",
        "terseLabel": "Percentage of cumulative ownership change"
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_PercentageOfOutstandingSharesForDeemedLiquidation": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "PercentageOfOutstandingSharesForDeemedLiquidation",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of outstanding shares for deemed liquidation",
        "label": "Percentage of Outstanding Shares for Deemed Liquidation",
        "documentation": "Percentage of outstanding shares for deemed liquidation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r922"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r978"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r921"
     ]
    },
    "us-gaap_PreferredStockConvertibleSharesIssuable": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockConvertibleSharesIssuable",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockScheduleOfConvertiblePreferredStockDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock Issuable Upon Conversion",
        "label": "Preferred Stock, Convertible, Shares Issuable",
        "verboseLabel": "Converted shares into common stock",
        "documentation": "Number of common shares issuable upon conversion of preferred stock."
       }
      }
     },
     "auth_ref": [
      "r382"
     ]
    },
    "us-gaap_PreferredStockDividendRatePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockDividendRatePercentage",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of dividends per share",
        "label": "Preferred Stock, Dividend Rate, Percentage",
        "documentation": "The percentage rate used to calculate dividend payments on preferred stock."
       }
      }
     },
     "auth_ref": [
      "r381",
      "r778",
      "r782",
      "r783",
      "r787"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Preferred stock, par value per share",
        "terseLabel": "Preferred stock at par value",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r380"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred Stock Authorized",
        "verboseLabel": "Preferred stock shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r733"
     ]
    },
    "us-gaap_PreferredStockTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStock"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock [Text Block]",
        "terseLabel": "Convertible Preferred Stock",
        "documentation": "The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock."
       }
      }
     },
     "auth_ref": [
      "r104"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1000"
     ]
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement [Member]",
        "terseLabel": "Private Placement Offering [Member]",
        "verboseLabel": "Private Placement Offering",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromConvertibleDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Convertible Debt",
        "terseLabel": "Proceeds from issuance of convertible SAFE Note",
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Proceeds from issuance of common stock upon initial public offering, net of underwriters' discounts, commissions and other offering costs",
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of common stock",
        "verboseLabel": "Gross proceeds",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock",
     "crdr": "debit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockScheduleOfConvertiblePreferredStockDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Proceeds Received",
        "label": "Proceeds from Issuance of Convertible Preferred Stock",
        "terseLabel": "Aggregate total net proceeds raised with issuance of convertible preferred stock",
        "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Private Placement",
        "terseLabel": "Gross proceeds from private placement",
        "verboseLabel": "Proceeds from issuance of common stock upon private placement offering, net of commissions and offering costs",
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_ProceedsFromNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromNotesPayable",
     "crdr": "debit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Notes Payable",
        "terseLabel": "Net proceeds",
        "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from exercise of stock options",
        "label": "Proceeds from Stock Options Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r14"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r161",
      "r164",
      "r174",
      "r183",
      "r192",
      "r199",
      "r202",
      "r203",
      "r291",
      "r340",
      "r341",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r349",
      "r350",
      "r505",
      "r515",
      "r517",
      "r520",
      "r521",
      "r545",
      "r570",
      "r654",
      "r671",
      "r710",
      "r753",
      "r770",
      "r771",
      "r839",
      "r840",
      "r866",
      "r1003",
      "r1045"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r601"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total property and equipment",
        "label": "Property, Plant and Equipment, Gross",
        "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance",
        "totalLabel": "Property, Plant and Equipment, Gross, Total",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r152",
      "r669"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r601"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentNetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentNetDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total property and equipment, net",
        "terseLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "totalLabel": "Total property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r601",
      "r657",
      "r669",
      "r854"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r133",
      "r136",
      "r667"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment, Net",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r601"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Useful Life",
        "terseLabel": "Estimated useful life",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r919"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r919"
     ]
    },
    "lxeo_QualifiedIpoMinimumNumberOfDirectorsApprovalRequired": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "QualifiedIpoMinimumNumberOfDirectorsApprovalRequired",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Qualified IPO minimum number of directors approval required",
        "label": "Qualified IPO Minimum Number of Directors Approval Required",
        "documentation": "Qualified IPO minimum number of directors approval required."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_RNolanTownsendMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "RNolanTownsendMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "R Nolan Townsend [Member]",
        "documentation": "R Nolan Townsend.",
        "terseLabel": "R. Nolan Townsend"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfSignificantUnobservableInputsUsedInTheValuationModelToEstimateFairValueDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r333",
      "r334",
      "r335",
      "r336",
      "r399",
      "r406",
      "r437",
      "r438",
      "r439",
      "r452",
      "r551",
      "r619",
      "r628",
      "r645",
      "r680",
      "r682",
      "r696",
      "r723",
      "r724",
      "r777",
      "r781",
      "r784",
      "r785",
      "r786",
      "r795",
      "r796",
      "r819",
      "r827",
      "r834",
      "r844",
      "r845",
      "r849",
      "r850",
      "r856",
      "r859",
      "r1039",
      "r1047",
      "r1091",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfSignificantUnobservableInputsUsedInTheValuationModelToEstimateFairValueDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r333",
      "r334",
      "r335",
      "r336",
      "r399",
      "r406",
      "r437",
      "r438",
      "r439",
      "r452",
      "r551",
      "r619",
      "r628",
      "r645",
      "r680",
      "r682",
      "r696",
      "r723",
      "r724",
      "r777",
      "r781",
      "r784",
      "r785",
      "r786",
      "r795",
      "r796",
      "r819",
      "r827",
      "r834",
      "r844",
      "r845",
      "r849",
      "r850",
      "r856",
      "r859",
      "r1039",
      "r1047",
      "r1091",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110"
     ]
    },
    "lxeo_ReclassificationOfInternalUseSoftwareIntoPrepaidExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "ReclassificationOfInternalUseSoftwareIntoPrepaidExpenses",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reclassification of Internal Use Software into Prepaid Expenses",
        "documentation": "Reclassification of internal use software into prepaid expenses.",
        "terseLabel": "Reclassification of internal use software into prepaid expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r886",
      "r897",
      "r907",
      "r940"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertibleSafeNoteAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r185",
      "r186",
      "r355",
      "r383",
      "r609",
      "r629",
      "r658",
      "r800",
      "r801"
     ]
    },
    "lxeo_ResearchAgreementTerminationNoticePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "ResearchAgreementTerminationNoticePeriod",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research agreement termination notice period",
        "label": "Research Agreement Termination Notice Period",
        "documentation": "Research agreement termination notice period."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_ResearchAgreementsTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "ResearchAgreementsTerm",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research agreements term",
        "label": "Research Agreements Term",
        "documentation": "Research agreements term."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalCostsIncurred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalCostsIncurred",
     "crdr": "debit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional costs incurred for research",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Additional Costs Incurred",
        "documentation": "Research and development Aarrangement, ontract to perform for others, dditional costs incurred."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "documentation": "Information by form of arrangement related to research and development."
       }
      }
     },
     "auth_ref": [
      "r456",
      "r1077"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross",
     "crdr": "debit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Costs incurred for research",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross",
        "documentation": "The amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others."
       }
      }
     },
     "auth_ref": [
      "r457"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty payments description",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Description and Terms",
        "documentation": "Describes the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others."
       }
      }
     },
     "auth_ref": [
      "r456",
      "r1077"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Research and development",
        "verboseLabel": "Research and development expenses",
        "terseLabel": "Financed research and development expenses",
        "label": "Research and Development Expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r455",
      "r797",
      "r812",
      "r1111"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseAbstract",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalInformationOnCompanysNetLossIncludingSegmentExpensesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development expense",
        "label": "Research and Development Expense [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_ResearchAndDevelopmentExpenseEmployeeCompensationExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "ResearchAndDevelopmentExpenseEmployeeCompensationExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalInformationOnCompanysNetLossIncludingSegmentExpensesDetails3": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalInformationOnCompanysNetLossIncludingSegmentExpensesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee compensation expenses",
        "label": "Research and Development Expense Employee Compensation Expenses",
        "documentation": "Research and development expense employee compensation expenses."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_ResearchAndDevelopmentExpenseLX1001": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "ResearchAndDevelopmentExpenseLX1001",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalInformationOnCompanysNetLossIncludingSegmentExpensesDetails3": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalInformationOnCompanysNetLossIncludingSegmentExpensesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LX1001",
        "label": "Research and Development Expense LX1001",
        "documentation": "Research and development expense LX1001."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_ResearchAndDevelopmentExpenseLX2006": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "ResearchAndDevelopmentExpenseLX2006",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalInformationOnCompanysNetLossIncludingSegmentExpensesDetails3": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalInformationOnCompanysNetLossIncludingSegmentExpensesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LX2006",
        "label": "Research and Development Expense LX2006",
        "documentation": "Research and Development Expense LX2006."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_ResearchAndDevelopmentExpenseLX2020": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "ResearchAndDevelopmentExpenseLX2020",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalInformationOnCompanysNetLossIncludingSegmentExpensesDetails3": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalInformationOnCompanysNetLossIncludingSegmentExpensesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LX2020",
        "label": "Research and Development Expense LX2020",
        "documentation": "Research and development expense LX2020."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Research and Development Expense",
        "terseLabel": "Research and development expense",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_ResearchAndDevelopmentExpenseOtherPrograms": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "ResearchAndDevelopmentExpenseOtherPrograms",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalInformationOnCompanysNetLossIncludingSegmentExpensesDetails3": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalInformationOnCompanysNetLossIncludingSegmentExpensesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense Other Programs",
        "documentation": "Research and development expense other programs.",
        "terseLabel": "Other programs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r454"
     ]
    },
    "lxeo_ResearchCollaborationAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "ResearchCollaborationAgreementMember",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research Collaboration Agreement",
        "label": "Research Collaboration Agreement [Member]",
        "documentation": "Research collaboration agreement."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r887",
      "r898",
      "r908",
      "r941"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r888",
      "r899",
      "r909",
      "r942"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r895",
      "r906",
      "r916",
      "r949"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfRollforwardOfChangesInFairValueOfFinancialLiabilitiesDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfSignificantUnobservableInputsUsedInTheValuationModelToEstimateFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Domain]",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r150"
     ]
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Restricted cash included in long-term assets at end of period",
        "periodStartLabel": "Restricted cash included in long-term assets at beginning of period",
        "terseLabel": "Restricted cash",
        "label": "Restricted Cash, Noncurrent",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r997",
      "r1010"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCapitalStockScheduleOfCommonStockReservedForFutureIssuancesDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r107",
      "r665",
      "r690",
      "r695",
      "r708",
      "r734",
      "r854"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r188",
      "r189",
      "r190",
      "r193",
      "r199",
      "r201",
      "r203",
      "r296",
      "r302",
      "r320",
      "r487",
      "r488",
      "r501",
      "r502",
      "r503",
      "r506",
      "r514",
      "r515",
      "r527",
      "r529",
      "r530",
      "r532",
      "r543",
      "r584",
      "r585",
      "r686",
      "r688",
      "r711",
      "r1117"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total revenue",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r125",
      "r219",
      "r229",
      "r230",
      "r244",
      "r250",
      "r254",
      "r256",
      "r257",
      "r397",
      "r398",
      "r646"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerProductAndServiceExtensibleList",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer, Product and Service [Extensible Enumeration]",
        "documentation": "Indicates product and service for revenue from satisfaction of performance obligation by transferring promised product and service to customer."
       }
      }
     },
     "auth_ref": [
      "r828"
     ]
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenuesAbstract",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue",
        "label": "Revenues [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r958"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r958"
     ]
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Net proceeds",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCapitalStockScheduleOfCommonStockReservedForFutureIssuancesDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertibleSafeNoteAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueAssumptionsDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsTables",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of shares of common stock",
        "label": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_SareptaTherapeuticsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "SareptaTherapeuticsIncMember",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertibleSafeNoteAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sarepta Therapeutics, Inc",
        "label": "Sarepta Therapeutics, Inc [Member]",
        "documentation": "Sarepta Therapeutics, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioForecastMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioForecastMember",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scenario Forecast",
        "label": "Forecast [Member]"
       }
      }
     },
     "auth_ref": [
      "r407",
      "r1019"
     ]
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "auth_ref": [
      "r204",
      "r407",
      "r984",
      "r1019"
     ]
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Accrued Expenses and Other Current Liabilities",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfInvestmentsClassifiedAsAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Investments Classified as Available-for-Sale Securities",
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r516"
     ]
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Stock-Based Compensation Expenses",
        "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]",
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Components of Deferred Tax Assets and Liabilities",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1081"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureNetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Net Loss Per Share Attributable to Common Stockholders",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1022"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of Statutory Income Tax Rate to Effective Income Tax Rate",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r465",
      "r838",
      "r1078"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r601"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalInformationOnCompanysNetLossIncludingSegmentExpensesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r38",
      "r39"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Summary Of Additional Information On Company's Net loss Including Segment Expenses",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r38",
      "r39"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfFollowingAssumptionsPresentedOnWeightedAverageBasisDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r409",
      "r410",
      "r412",
      "r413",
      "r414",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Stock Option Activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r13",
      "r109"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Following Assumptions Presented on Weighted Average Basis",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "verboseLabel": "Summary of Estimated Fair Value Assumptions",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Summary of RSU activity",
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_ScheduleOfSignificantUnobservableInputsUsedInValuationModelToEstimateFairValueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "ScheduleOfSignificantUnobservableInputsUsedInValuationModelToEstimateFairValueTableTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Significant Unobservable Inputs Used in Valuation Model to Estimate Fair Value",
        "label": "Schedule of Significant Unobservable Inputs Used In Valuation Model To Estimate Fair Value [Table Text Block]",
        "documentation": "Schedule of significant unobservable inputs used in valuation model to estimate fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCapitalStockScheduleOfCommonStockReservedForFutureIssuancesDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockScheduleOfConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r45",
      "r46",
      "r47",
      "r48",
      "r49",
      "r103",
      "r105",
      "r106",
      "r107",
      "r156",
      "r157",
      "r158",
      "r221",
      "r380",
      "r381",
      "r383",
      "r385",
      "r388",
      "r393",
      "r395",
      "r704",
      "r705",
      "r706",
      "r707",
      "r827",
      "r983",
      "r1011"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockholdersEquityTableTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCapitalStockTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Common Stock Reserved for Future Issuances",
        "label": "Schedule of Stockholders Equity [Table Text Block]",
        "documentation": "Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "lxeo_SecondUcsdLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "SecondUcsdLicenseAgreementMember",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Second UCSD License Agreement",
        "label": "Second UCSD License Agreement [Member]",
        "documentation": "Second UCSD license agreement."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "us-gaap_SecurityDeposit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SecurityDeposit",
     "crdr": "debit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security deposit",
        "label": "Security Deposit",
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease."
       }
      }
     },
     "auth_ref": [
      "r997"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r871"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]",
        "documentation": "Indicates title and position of individual or name of group identified as chief operating decision maker (CODM) for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r227",
      "r811",
      "r818"
     ]
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSegmentInformation1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segment Information",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r219",
      "r223",
      "r224",
      "r225",
      "r226",
      "r228",
      "r234",
      "r235",
      "r236",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r254",
      "r255",
      "r257",
      "r806",
      "r809",
      "r810",
      "r812",
      "r814",
      "r816",
      "r817"
     ]
    },
    "us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingExpenseInformationUsedByCodmDescription",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Expense Information Used by CODM, Description",
        "documentation": "Description of nature of expense information used by chief operating decision maker (CODM) to manage operation when segment expense information by category is not disclosed."
       }
      }
     },
     "auth_ref": [
      "r219",
      "r236",
      "r250"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalInformationOnCompanysNetLossIncludingSegmentExpensesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r253",
      "r256",
      "r807",
      "r808",
      "r815"
     ]
    },
    "lxeo_SeriesAAndBConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "SeriesAAndBConvertiblePreferredStockMember",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A and B Convertible Preferred Stock",
        "label": "Series A and B Convertible Preferred Stock [Member]",
        "documentation": "Series A and B convertible preferred stock."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_SeriesAAndSeriesBConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "SeriesAAndSeriesBConvertiblePreferredStockMember",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A and series B convertible preferred stock.",
        "label": "Series A And Series B Convertible Preferred Stock [Member]",
        "terseLabel": "Series A and Series B Convertible Preferred Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_SeriesAConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "SeriesAConvertiblePreferredStockMember",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCapitalStockScheduleOfCommonStockReservedForFutureIssuancesDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockScheduleOfConvertiblePreferredStockDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementBalanceSheets",
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A Convertible Preferred Stock",
        "label": "Series A Convertible Preferred Stock [Member]",
        "documentation": "Series A convertible preferred stock."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_SeriesALiquidationPreferenceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "SeriesALiquidationPreferenceMember",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A Liquidation Preference",
        "label": "Series A Liquidation Preference [Member]",
        "documentation": "Series A liquidation preference."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_SeriesBConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "SeriesBConvertiblePreferredStockMember",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCapitalStockScheduleOfCommonStockReservedForFutureIssuancesDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockScheduleOfConvertiblePreferredStockDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementBalanceSheets",
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series B Convertible Preferred Stock",
        "label": "Series B Convertible Preferred Stock [Member]",
        "documentation": "Series B convertible preferred stock."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_SeriesBLiquidationPreferenceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "SeriesBLiquidationPreferenceMember",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series B Liquidation Preference",
        "label": "Series B Liquidation Preference [Member]",
        "documentation": "Series B liquidation preference."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "verboseLabel": "Stock based compensation expense",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "totalLabel": "Share-Based Payment Arrangement, Noncash Expense, Total",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Recognized Amount [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r835"
     ]
    },
    "lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualTermGrantDate": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualTermGrantDate",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement by Share Based Payment Award Contractual Term Grant Date",
        "documentation": "Share Based Compensation Arrangement by Share Based Payment Award Contractual Term Grant Date",
        "terseLabel": "Contractual term grant date"
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriod",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares, vested and exercisable",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options Vested In Period",
        "documentation": "Share based compensation arrangement by share based payment award equity instruments options vested in period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of shares, forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r429"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value, unvested, forfeited",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r429"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Number of shares, granted",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average grant date fair value, granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodStartLabel": "Number of shares unvested, beginning balance",
        "periodEndLabel": "Number of shares unvested, ending balance",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r424",
      "r425"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodStartLabel": "Weighted-average grant date fair value, unvested, beginning balance",
        "periodEndLabel": "Weighted-average grant date fair value, unvested, ending balance",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r424",
      "r425"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price",
        "terseLabel": "Exercise price",
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueAssumptionsDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfFollowingAssumptionsPresentedOnWeightedAverageBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Expected dividend yield",
        "terseLabel": "Expected dividend yields percentage",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r438"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueAssumptionsDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfFollowingAssumptionsPresentedOnWeightedAverageBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r437"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueAssumptionsDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfFollowingAssumptionsPresentedOnWeightedAverageBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "verboseLabel": "Weighted average risk-free interest rate",
        "terseLabel": "Risk-free interest rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r439"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfFollowingAssumptionsPresentedOnWeightedAverageBasisDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r409",
      "r410",
      "r412",
      "r413",
      "r414",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares authorized",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r836"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares available for future grants",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares, Options exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r418"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Options exercisable",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r418"
     ]
    },
    "lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average grant date fair value, exercised",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercised In Period Weighted Average Grant Date Fair Value",
        "documentation": "Share based compensation arrangement by share based payment award options exercised in period weighted average grant date fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, exercised",
        "verboseLabel": "Intrinsic value of stock options exercised",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r431"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expired",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "negatedLabel": "Expired, shares",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r423"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited, shares",
        "terseLabel": "Forfeited, shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r422"
     ]
    },
    "lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grant date fair value of option",
        "documentation": "Share based compensation arrangement by share based payment award options grant date fair value.",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award Options Grant Date Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted, shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r420"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average grant date fair value, granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Weighted-average grant date fair value of stock options granted",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r430"
     ]
    },
    "lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsExercisableWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsExercisableWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average grant date fair value, Unvested and exercisable",
        "label": "Share based Compensation Arrangement By Share based Payment Award Options Nonvested Options Exercisable Weighted Average Grant Date Fair Value",
        "documentation": "Share based compensation arrangement by share based payment award options nonvested options exercisable weighted average grant date fair value."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageExercisePrice",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price, unvested and exercisable",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Weighted Average Exercise Price",
        "documentation": "Share based compensation arrangement by share based payment award options nonvested weighted average exercise price."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Aggregate intrinsic value, ending",
        "periodStartLabel": "Aggregate intrinsic value, beginning",
        "verboseLabel": "Aggregate intrinsic value, ending",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, beginning",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Number of shares outstanding, ending",
        "periodStartLabel": "Number of shares outstanding, beginning",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r416",
      "r417"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted average exercise price, beginning balance",
        "periodEndLabel": "Weighted average exercise price, ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r416",
      "r417"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value, vested and exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r433"
     ]
    },
    "lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOptionsExercisableWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOptionsExercisableWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average grant date fair value, vested and exercisable",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested Options Exercisable Weighted Average Grant Date Fair Value",
        "documentation": "Share based compensation arrangement by share based payment award options vested options exercisable weighted average grant date fair value."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price, vested and exercisable",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Exercise Price",
        "documentation": "Share based compensation arrangement by share based payment award options vested weighted average exercise price."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options unvested and expected to vest exercisable weighted average remaining contractual term1.",
        "terseLabel": "Weighted average remaining contractual term, unvested and exercisable",
        "label": "Share Based Compensation Arrangement By Sharebased Payment Award Options Unvested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCapitalStockScheduleOfCommonStockReservedForFutureIssuancesDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r412",
      "r413",
      "r414",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price, exercised",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r421"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price, Expired",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired."
       }
      }
     },
     "auth_ref": [
      "r423"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price, forfeited",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r422"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price, granted",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r420"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Based Compensation Expense",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r408",
      "r415",
      "r434",
      "r435",
      "r436",
      "r437",
      "r440",
      "r446",
      "r447",
      "r448",
      "r449"
     ]
    },
    "lxeo_ShareBasedCompensationPaymentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "ShareBasedCompensationPaymentDescription",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share based compensation payment description",
        "label": "Share Based Compensation Payment Description",
        "documentation": "Share based compensation payment description."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedPaymentArrangementNonemployeeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedPaymentArrangementNonemployeeMember",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-employee",
        "label": "Share-Based Payment Arrangement, Nonemployee [Member]",
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor does not exercise nor has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Excludes nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires."
       }
      }
     },
     "auth_ref": [
      "r409",
      "r412",
      "r413",
      "r414",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharePrice",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Price",
        "terseLabel": "Stock price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting period, percentage",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "documentation": "Percentage of vesting of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1050"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested",
     "crdr": "debit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value, unvested and exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested",
        "documentation": "Intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueAssumptionsDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfFollowingAssumptionsPresentedOnWeightedAverageBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r436"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value, Options exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual term, Options exercisable",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "lxeo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average grant date fair value, expired",
        "documentation": "ShareBased Compensation Arrangement By ShareBased Payment Award Options Expired In Period Weighted Average Grant Date Fair Value",
        "label": "ShareBased Compensation Arrangement By ShareBased Payment Award Options Expired In Period Weighted Average Grant Date Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares, unvested and exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares",
        "periodEndLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares, Ending Balance",
        "periodStartLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares, Beginning Balance",
        "documentation": "Number of non-vested options outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average grant date fair value, forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average grant-date fair value of non-vested options forfeited."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Weighted average grant date fair value, ending",
        "periodStartLabel": "Weighted average grant date fair value, beginning",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price",
        "documentation": "Weighted average grant-date fair value of non-vested options outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining contractual term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining contractual term, vested and exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r433"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total grant date fair values of options vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value",
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock."
       }
      }
     },
     "auth_ref": [
      "r431"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offering price per share",
        "label": "Shares Issued, Price Per Share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Balance, shares",
        "periodStartLabel": "Balance, shares",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Investments",
        "totalLabel": "Short-Term Investments, Total",
        "terseLabel": "Investments",
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r121",
      "r999"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Significant Accounting Policies",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r180"
     ]
    },
    "lxeo_SimpleAgreementForFutureEquityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "SimpleAgreementForFutureEquityMember",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertibleSafeNoteAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "SAFE",
        "terseLabel": "SAFE [Member]",
        "label": "Simple Agreement For Future Equity [Member]",
        "documentation": "Simple Agreement For Future Equity [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SoftwareDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SoftwareDevelopmentMember",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Internal Use Software",
        "label": "Software Development [Member]",
        "documentation": "Internally developed software for sale, licensing or long-term internal use."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_SpecificClinicalAndRegulatoryMilestonesDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "SpecificClinicalAndRegulatoryMilestonesDue",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Specific clinical and regulatory milestones due",
        "label": "Specific Clinical and Regulatory Milestones Due",
        "documentation": "Specific clinical and regulatory milestones due."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State and Local",
        "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax."
       }
      }
     },
     "auth_ref": [
      "r463"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCapitalStockScheduleOfCommonStockReservedForFutureIssuancesDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockScheduleOfConvertiblePreferredStockDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementBalanceSheets",
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementBalanceSheetsParenthetical",
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r156",
      "r157",
      "r158",
      "r183",
      "r208",
      "r209",
      "r211",
      "r213",
      "r221",
      "r222",
      "r291",
      "r340",
      "r343",
      "r344",
      "r345",
      "r349",
      "r350",
      "r380",
      "r381",
      "r385",
      "r388",
      "r395",
      "r570",
      "r704",
      "r705",
      "r706",
      "r707",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r733",
      "r754",
      "r772",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r983",
      "r1011",
      "r1021"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCapitalStockScheduleOfCommonStockReservedForFutureIssuancesDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertibleSafeNoteAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r78",
      "r81",
      "r82",
      "r143",
      "r167",
      "r168",
      "r169",
      "r188",
      "r189",
      "r190",
      "r193",
      "r199",
      "r201",
      "r203",
      "r220",
      "r296",
      "r302",
      "r320",
      "r396",
      "r487",
      "r488",
      "r501",
      "r502",
      "r503",
      "r506",
      "r514",
      "r515",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r543",
      "r574",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r584",
      "r585",
      "r608",
      "r673",
      "r686",
      "r687",
      "r688",
      "r711",
      "r772"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementBalanceSheets",
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementBalanceSheetsParenthetical",
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r188",
      "r189",
      "r190",
      "r220",
      "r585",
      "r646",
      "r699",
      "r722",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r733",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r752",
      "r755",
      "r756",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r772",
      "r860"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position",
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": [
      "r204",
      "r407",
      "r984",
      "r985",
      "r1019"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementBalanceSheets",
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementBalanceSheetsParenthetical",
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement Table",
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r188",
      "r189",
      "r190",
      "r220",
      "r260",
      "r585",
      "r646",
      "r699",
      "r722",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r733",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r752",
      "r755",
      "r756",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r772",
      "r860"
     ]
    },
    "lxeo_SteliosTherapeuticsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "SteliosTherapeuticsIncMember",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stelios Therapeutics Inc",
        "label": "Stelios Therapeutics Inc [Member]",
        "documentation": "Stelios Therapeutics Inc."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r890",
      "r901",
      "r911",
      "r944"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares issued during the period upon conversion of convertible securities",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "verboseLabel": "Conversion of convertible preferred stock into common stock in connection with initial public offering, share",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r46",
      "r78",
      "r81",
      "r107",
      "r368"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of common shares issued and sold",
        "verboseLabel": "Shares purchased at public offering",
        "label": "Issuance of common stock upon offering and subsequent partial exercise of underwriters' option to purchase additional shares, Shares",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r77",
      "r78",
      "r107",
      "r704",
      "r772",
      "r789"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Exercised, shares",
        "verboseLabel": "Exercise of stock options, shares",
        "terseLabel": "Exercised, shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r77",
      "r78",
      "r107",
      "r421"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Conversion of convertible preferred stock into common stock in connection with initial public offering, value",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r78",
      "r81",
      "r82",
      "r107"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock upon offering and subsequent partial exercise of underwriters' option to purchase additional shares, Value",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r77",
      "r78",
      "r107",
      "r711",
      "r772",
      "r789",
      "r866"
     ]
    },
    "lxeo_StockIssuedDuringPeriodValueNewIssuesAdditionalOfferingCostsIncurred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "StockIssuedDuringPeriodValueNewIssuesAdditionalOfferingCostsIncurred",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period Value New Issues Additional Offering Costs Incurred",
        "documentation": "Stock issued during period value new issues additional offering costs incurred.",
        "terseLabel": "Additional issuance costs incurred for SAFE Note",
        "negatedLabel": "Additional issuance costs incurred for SAFE Note"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "totalLabel": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture, Total",
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r77",
      "r78",
      "r107"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of stock options, value",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r78",
      "r81",
      "r82",
      "r107"
     ]
    },
    "lxeo_StockOfferingGrossProceedsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "StockOfferingGrossProceedsPercentage",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross proceeds percentage",
        "label": "Stock Offering Gross Proceeds Percentage",
        "documentation": "Stock offering gross proceeds percentage."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_StockOfferingValueSharesAuthorizedToBeSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "StockOfferingValueSharesAuthorizedToBeSold",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Offering Value Shares Authorized To Be Sold",
        "documentation": "Stock offering value shares authorized to be sold.",
        "terseLabel": "Common stock aggregate offering price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockRepurchasedDuringPeriodShares",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Repurchased During Period, Shares",
        "terseLabel": "Repurchase of shares",
        "verboseLabel": "Treasury stock repurchase",
        "negatedLabel": "Treasury stock repurchases, Shares",
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r77",
      "r78",
      "r107",
      "r707",
      "r772",
      "r791"
     ]
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockRepurchasedDuringPeriodValue",
     "crdr": "debit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Repurchased During Period, Value",
        "terseLabel": "Shares repurchased value",
        "verboseLabel": "Treasury stock repurchase, Value",
        "negatedLabel": "Treasury stock repurchases, Value",
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r77",
      "r78",
      "r107",
      "r711",
      "r772",
      "r791",
      "r866"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementBalanceSheets",
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance, value",
        "periodEndLabel": "Balance, value",
        "label": "Equity, Attributable to Parent",
        "totalLabel": "Total stockholders' equity",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r81",
      "r82",
      "r99",
      "r735",
      "r751",
      "r773",
      "r774",
      "r854",
      "r867",
      "r1013",
      "r1034",
      "r1095",
      "r1117"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCapitalStock1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Text Block]",
        "terseLabel": "Capital Stock",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r182",
      "r379",
      "r381",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r394",
      "r396",
      "r534",
      "r775",
      "r776",
      "r793"
     ]
    },
    "us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteRedeemablePreferredStockIssuePolicy",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classification of Convertible Preferred Stock",
        "label": "Stockholders' Equity Note, Redeemable Preferred Stock, Issue, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for redeemable preferred stock issued. This disclosure may include the accounting treatment for the difference, if there is any, between the carrying value and redemption amount. For example, describe whether the issuer accretes changes in the redemption value."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r75",
      "r76"
     ]
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityReverseStockSplit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Reverse stock split",
        "label": "Stockholders' Equity, Reverse Stock Split",
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements."
       }
      }
     },
     "auth_ref": [
      "r108"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r581",
      "r611"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r581",
      "r611"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r581",
      "r611"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r581",
      "r611"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r581",
      "r611"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r610",
      "r612"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCapitalStockScheduleOfCommonStockReservedForFutureIssuancesDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertibleSafeNoteAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueAssumptionsDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsTables",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_SummaryOfSignificantAccountingPoliciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies [Line Items]",
        "documentation": "Summary of significant accounting policies."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_SummaryOfSignificantAccountingPoliciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies [Table]",
        "documentation": "Summary of significant accounting policies."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosures of cash flow information"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r937"
     ]
    },
    "lxeo_TaxCreditCarryForwardExpirationYear": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "TaxCreditCarryForwardExpirationYear",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax credit carry forward expiration year.",
        "label": "Tax Credit Carry Forward Expiration Year",
        "terseLabel": "Tax credit carryforward, expiration year"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforward",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r485"
     ]
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Temporary equity, balance, value",
        "periodEndLabel": "Temporary equity, balance, value",
        "terseLabel": "Convertible preferred stock",
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r340",
      "r343",
      "r344",
      "r345",
      "r349",
      "r350",
      "r450",
      "r663"
     ]
    },
    "lxeo_TemporaryEquityConversionOfStockInInitialPublicOfferingShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "TemporaryEquityConversionOfStockInInitialPublicOfferingShares",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity, conversion of stock in initial public offering, shares.",
        "label": "Temporary Equity, Conversion Of Stock In Initial Public Offering, Shares",
        "negatedLabel": "Conversion of convertible preferred stock into common stock in connection with initial public offering, shares"
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_TemporaryEquityConversionOfStockInInitialPublicOfferingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "TemporaryEquityConversionOfStockInInitialPublicOfferingValue",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of convertible preferred stock into common stock in connection with initial public offering, value",
        "documentation": "Temporary equity, conversion of stock in initial public offering, value.",
        "label": "Temporary Equity, Conversion Of Stock In Initial Public Offering, Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityLiquidationPreference": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityLiquidationPreference",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockScheduleOfConvertiblePreferredStockDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Liquidation Preference",
        "terseLabel": "Convertible preferred stock, Liquidation Preference",
        "label": "Temporary Equity, Liquidation Preference",
        "documentation": "The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityLiquidationPreferencePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityLiquidationPreferencePerShare",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liquidation preference",
        "label": "Temporary Equity, Liquidation Preference Per Share",
        "documentation": "The per share liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityParOrStatedValuePerShare",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible preferred stock, par value",
        "label": "Temporary Equity, Par or Stated Value Per Share",
        "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r43"
     ]
    },
    "us-gaap_TemporaryEquitySharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquitySharesAuthorized",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockScheduleOfConvertiblePreferredStockDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Convertible Preferred Stock Authorized",
        "terseLabel": "Convertible preferred stock, shares authorized",
        "label": "Temporary Equity, Shares Authorized",
        "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquitySharesIssued",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockScheduleOfConvertiblePreferredStockDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Convertible Preferred Stock Issued",
        "terseLabel": "Convertible preferred stock, shares issued",
        "label": "Temporary Equity, Shares Issued",
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquitySharesOutstanding",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockScheduleOfConvertiblePreferredStockDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementBalanceSheetsParenthetical",
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Convertible Preferred Stock Outstanding",
        "periodEndLabel": "Temporary equity, balance, shares",
        "periodStartLabel": "Temporary equity, balance, shares",
        "terseLabel": "Convertible preferred stock, shares outstanding",
        "label": "Temporary Equity, Shares Outstanding",
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of series A convertible preferred stock",
        "label": "Temporary Equity, Stock Issued During Period, Value, New Issues",
        "documentation": "Value of new stock classified as temporary equity issued during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityTableTextBlock",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity [Table Text Block]",
        "terseLabel": "Convertible Preferred Stock",
        "verboseLabel": "Schedule of Convertible Preferred Stock",
        "documentation": "Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r43"
     ]
    },
    "lxeo_ThirdCornellLicenseAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "ThirdCornellLicenseAgreementsMember",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Third Cornell License Agreements [Member]",
        "documentation": "Third cornell license agreements",
        "terseLabel": "Cornell Third License Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_ThirdPartiesForPharmaceuticalManufacturingAndResearchActivitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "ThirdPartiesForPharmaceuticalManufacturingAndResearchActivitiesMember",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Third Parties for Pharmaceutical Manufacturing and Research Activities",
        "label": "Third Parties For Pharmaceutical Manufacturing And Research Activities [Member]",
        "documentation": "Third parties for pharmaceutical manufacturing and research activities."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_ThirdPortfolioMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "ThirdPortfolioMember",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Third Portfolio",
        "label": "Third Portfolio [Member]",
        "documentation": "Third portfolio."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_ThirdUcsdLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "ThirdUcsdLicenseAgreementMember",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Third UCSD License Agreement",
        "label": "Third UCSD License Agreement [Member]",
        "documentation": "Third UCSD License Agreement."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r936"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r957"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r959"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfInvestmentsClassifiedAsAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r376",
      "r393",
      "r533",
      "r567",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r674",
      "r841",
      "r842",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r855",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1087",
      "r1090",
      "r1091",
      "r1092",
      "r1093",
      "r1094"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r960"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r961"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r961"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r959"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r959"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r962"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r960"
     ]
    },
    "us-gaap_TreasuryStockCommonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TreasuryStockCommonMember",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury Stock, Common [Member]",
        "terseLabel": "Treasury Stock",
        "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_TreasuryStockCommonShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TreasuryStockCommonShares",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury Stock, Common, Shares",
        "terseLabel": "Treasury stock, common shares",
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_TreasuryStockCommonValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TreasuryStockCommonValue",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury Stock, Common, Value",
        "negatedLabel": "Treasury stock, at cost, 3,827 common shares at December 31, 2024 and 0 common shares at December 31, 2023",
        "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r51",
      "r81"
     ]
    },
    "lxeo_TreasuryStockRepurchase": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "TreasuryStockRepurchase",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury Stock Repurchase",
        "documentation": "Treasury stock repurchase.",
        "terseLabel": "Treasury stock repurchases",
        "negatedLabel": "Treasury stock repurchases"
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_TwoPortfoliosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "TwoPortfoliosMember",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Two Portfolios",
        "label": "Two Portfolios [Member]",
        "documentation": "Two portfolios."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_TwoThousandAndTwentyThreeEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "TwoThousandAndTwentyThreeEquityIncentivePlanMember",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and twenty three equity incentive plan.",
        "label": "Two Thousand and Twenty Three Equity Incentive Plan [Member]",
        "terseLabel": "2023 Plan"
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_TwoThousandTwentyOneAndTwoThousandTwentyThreeEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "TwoThousandTwentyOneAndTwoThousandTwentyThreeEquityIncentivePlanMember",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCapitalStockScheduleOfCommonStockReservedForFutureIssuancesDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2021 Plan and 2023 Plan",
        "documentation": "Two thousand twenty one and two thousand twenty three equity incentive plan.",
        "label": "Two Thousand Twenty One And Two Thousand Twenty Three Equity Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_TwoThousandTwentyOneEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "TwoThousandTwentyOneEquityIncentivePlanMember",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2021 Plan",
        "label": "Two Thousand Twenty One Equity Incentive Plan [Member]",
        "documentation": "Two thousand twenty one equity incentive plan member."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "TwoThousandTwentyThreeEmployeeStockPurchasePlanMember",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCapitalStockScheduleOfCommonStockReservedForFutureIssuancesDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023 ESPP",
        "label": "Two Thousand Twenty Three Employee Stock Purchase Plan [Member]",
        "documentation": "2023 Employee Stock Purchase Plan."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_TwoThousandTwentyThreeEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "TwoThousandTwentyThreeEquityIncentivePlanMember",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureCapitalStockScheduleOfCommonStockReservedForFutureIssuancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand Twenty Three Equity Incentive Plan [Member]",
        "documentation": "Two Thousand Twenty Three Equity Incentive Plan.",
        "terseLabel": "2023 Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r516"
     ]
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "USTreasurySecuritiesMember",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfInvestmentsClassifiedAsAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. Treasury Securities [Member]",
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)."
       }
      }
     },
     "auth_ref": [
      "r802",
      "r829",
      "r831",
      "r841",
      "r1112"
     ]
    },
    "lxeo_UcsdSponsoredResearchAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "UcsdSponsoredResearchAgreementsMember",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "UCSD Sponsored Research Agreements",
        "label": "UCSD Sponsored Research Agreements [Member]",
        "documentation": "UCSD sponsored research agreements."
       }
      }
     },
     "auth_ref": []
    },
    "lxeo_UnderwritingDiscountsCommissionsAndOfferingCostsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "UnderwritingDiscountsCommissionsAndOfferingCostsMember",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underwriting discounts, commissions and offering costs.",
        "label": "Underwriting Discounts, Commissions and Offering Costs [Member]",
        "terseLabel": "Underwriting Discounts, Commissions and Offering Costs"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r956"
     ]
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrealizedGainLossOnInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfCashFlows",
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrealized Gain (Loss) on Investments",
        "terseLabel": "Unrealized loss on investments",
        "verboseLabel": "Unrealized comprehensive loss on investments",
        "documentation": "Amount of unrealized gain (loss) on investment."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Uncertain tax positions",
        "periodStartLabel": "Unrecognized Tax Benefits, Beginning Balance",
        "periodEndLabel": "Unrecognized Tax Benefits, Ending Balance",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r459",
      "r476",
      "r837"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Uncertain tax positions, accrued interest or penalties",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return."
       }
      }
     },
     "auth_ref": [
      "r474",
      "r837"
     ]
    },
    "lxeo_UpfrontCashPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "UpfrontCashPayment",
     "crdr": "credit",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Upfront payment in cash",
        "label": "Upfront Cash Payment",
        "documentation": "Upfront cash payment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r35",
      "r36",
      "r130",
      "r131",
      "r134",
      "r135"
     ]
    },
    "us-gaap_ValuationTechniqueAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationTechniqueAxis",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Approach and Technique [Axis]",
        "documentation": "Information by valuation approach and technique."
       }
      }
     },
     "auth_ref": [
      "r549",
      "r550",
      "r844",
      "r1092"
     ]
    },
    "us-gaap_ValuationTechniqueDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationTechniqueDomain",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfEstimatedFairValueAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Approach and Technique [Domain]",
        "documentation": "Valuation approach and technique."
       }
      }
     },
     "auth_ref": [
      "r549",
      "r550",
      "r844",
      "r1092"
     ]
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesComponentsOfOperatingLeaseDetails": {
       "parentTag": "us-gaap_OperatingLeaseExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLeasesComponentsOfOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable lease expense",
        "label": "Variable Lease, Cost",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r596",
      "r853"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r925"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureNetLossPerShareScheduleOfNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted average number of shares outstanding used in computation of net loss per common share, diluted",
        "terseLabel": "Weighted-average common shares outstanding, diluted",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r207",
      "r213"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureNetLossPerShareScheduleOfNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Denominator:",
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureNetLossPerShareScheduleOfNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://www.lexeotx.com/20241231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted average number of shares outstanding used in computation of net loss per common share, basic",
        "terseLabel": "Weighted-average common shares outstanding, basic",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r206",
      "r213"
     ]
    },
    "lxeo_WeillCornellMedicalCollegeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lexeotx.com/20241231",
     "localname": "WeillCornellMedicalCollegeMember",
     "presentation": [
      "http://www.lexeotx.com/20241231/taxonomy/role/DisclosureLicenseAcquisitionResearchCollaborationAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weill Cornell Medical College",
        "label": "Weill Cornell Medical College [Member]",
        "documentation": "Weill Cornell medical college."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r923"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481288/505-10-05-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "6",
   "SubTopic": "10",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479405/805-10-25-6"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "7",
   "SubTopic": "10",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479405/805-10-25-7"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "7",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-7"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "8",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-8"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "25",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-22"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "730",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "210",
   "Topic": "954",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-5"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "326",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-3"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "326",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-3"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-7"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-2"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-40/tableOfContent"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477123/405-50-65-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.E.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-30"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-31"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-32"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "12",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-12"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r949": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r950": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r951": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r952": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r953": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r954": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r955": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r956": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r957": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r958": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r959": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r960": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r961": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r962": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r963": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r964": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r965": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r966": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r967": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r968": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r969": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r970": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r971": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r972": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r973": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r974": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r975": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r976": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r977": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r978": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r979": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r980": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-X",
   "Number": "210",
   "Section": "2",
   "Subsection": "2"
  },
  "r981": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r982": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r983": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r984": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r985": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>111
<FILENAME>0000950170-25-043486-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-25-043486-xbrl.zip
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M_Q5&M]QF^D-_P&-OTR,OVEG!P\D7G'LFR\YS$#:,GT]8KJ'%PU5)_4[X%%H
MR;[[:<M+).JNSP8P5:_C<JGDVCF]%N_?W;2%8M0MI%><,]@17KPEI!M[8+<(
M%<JQ0 ZQKP']O2+:]NQ$,.'%8!W8QJ #/S*UED8-UH*B0C*>G&"I\"'8.A2T
M^I/79::H:D@6S))UI*SRLO0 J;6RM2UE?F4:#'D-.P#[HTZ!/03B6'#&.N40
M?K=UFRAJ*]:K<$F3.?Z^G:7:3W6[#MX4R=B ,PQ*#<>TN.K[Q[L*DYDX[U;@
MYL,($Z?I4VWO.VJ?;VUZ\B+?+P<X:_Y1_FCX?=!(J4OA1&_M9JE\"6+),$C=
M/YA><.ST@$:5R[> ;S5QWYZ-5G]J@7D,5/L'.]%(T=?(+Q:R>YV>?5UQ*3G/
M..Y0:W)6IRG4OUSTK -VL]QQM>BJ0&FR<GX[351DN;T62T*?F]SBVC,QPAC$
M6A%N"CV;L-O%#-&%K;NZ[B2T[9S#U4Y[]"YZ3'M1.<7('S_1?Q8OQMS]0OD7
M.57G'.3ABW=>K\^7,\ Y%]<76ZU/N\T-^)<Z]D::>IZ/42"[:=E>?=.W8R2=
ME)L1XOKH1=ZPU>9_3>LY_7NMJ//_-ZGY7Q';ECI0'GI"("Z."OR[]Z4/,Y1I
MQ),>%WPXN6RMN5!,3/;]!0Q@K='5N,?EQ=AJ['FNMNX&#"P*,2Z<IC2AY"@W
M^)"_R.68SS]AX9U\2 Y&\]TW3/Q2;,2M[4MP=@BH7K\Z7=I>#>IN>%8T5<ZM
M=N1/<D^AM1(WC':RWK45YOV4F?Y^#O@Y*6FEEK_OK)GRQD.+5&FS?&.'SV%X
M.RMJJ;9#CN&X53<!>BMW0K3BQ5;"P[-UJ;AFZRPHPIK85(1,J_08P;M8Z[N[
MJ6ZXJ,D>G*H8*QF*_*]DK^J.@+U]V0CGBHOQ@C1Q@G"8GID'W=SXD,<Y9:>)
MI7S(O\;[/Z;DPFU!$-EMO(."1!H(F>KS4'X4H)[(AYR%7G& 7Q((ZG\)^'_,
MR;_?Q9'_58+_H01//V\PMG^- ]4+N5(S['M@.,>":[)['^.G>S"(I[9+0&&4
ML\XU,6WCANS&;W%545:(B*J@#IV\BN ?1X/.KCY</@/+X)HSQ:1CYY2!K131
MEG>M;IB@SO:1#LQ43?<\X$/$XJ!H2=C&!9; TW[,/=,38V$G0()L8O,6=MJT
MC7Y)]<OE\=(YABB.&I[HV;541EB+0-SN6)8 W\].TR7W;^=^&A!:^I).\F<,
M367PCMA-F,2POGBW?2 IL:#VH]@D+H:9IYSS?,65?'$7]WUH'^C[-?0*>V&]
M=5JGA&FK*JBRC#5';Y7DAK;2S9_-''==F:&=SG&R*M?H0S1,.*CC"PVZ+VAZ
M*&?S>#.@FE>#;+H\V@*3G_7N5AGO:DNJU=5E=+!4:.P/ Q&'C4W<&FWV.5Y+
M'RX_LSN:'I#,4$Q,TLLL3GJ%T2^G/15-?M_PDQ>0*^!W2\BG X;EJ047%G\F
MX>6G,&P#EPL.^)1\=;_% 3=I.X>[A4OM6B%?IBH2'M\\MAF26)7'TD9UBN33
MOT&KZ)5TP.5TK5ZOWXT2$S=VTM-\JPDG%Z='IZVU?3"&\X!=>#I%G P3T-WN
M.]P]G-]XPW#I)3":\9%KP_ YV6NJSK+/1!_'].0 X6DG=FNBX)(A<Q!@=Q./
MB:@P?[;L>:ZPLOL9TO?B\5@^Y.!$GC\"$A]O;D^$T9]BQ/^9-A^->,(4(YH<
M+&30;$%M?0./\F;)D<!Q#!#)+$QDC))LF5Z[0I?M#R*@(@K76&[9WV=-)Z^G
MC_B?NEO8&F,T75]>^Z1N?5.1^A,O8.3#?,C#>-Z17_F0ET:9E.]8]B"Q& 7C
M0S2FP"^\]_6C?(@346AR^=B/PWZ13V<NO"%D]@7\-/7K5Y9<='_:IHW/9P!?
MLP.[/YI[*0B/#X0P$?Z(2.<H'V-6CW5TL+UD$FTLXI&ID];[D #P<.=9]S@Y
M$E6$ZAV169[9Y]PW7ETJEJH9;V)2?MC'6)\Z5'#H>8F1C\73XQ9=<E46\%'7
M.@%!%83A0=@R^MP(67D5TQ)S;X-K6U-?].'6""H\FK&F.OY'"G-Z'L["$Y(#
M@<#DK>-6"[9V_;0B7E[L\T_"H8:I6F'/BN1X@HY_T,Q5VBWFG>1]@+\42C<]
MQ_M8>GRWF'N9@/IM_ 1HQ? 18^1DH8];LKP\6ECA5,V!5U$8"=""83"?$C?8
MM81GE.C I,%LA1GA/R9#EU+FKC;73'.K=MMA_F)3>0PC[M$MM@O83X<G^4H-
MDW7 8O/=8I-8)C1=_&,Y^,UK@JS+O9A(,S5H'D=91U0%*RL7\;YGG:3&1-H^
M7W;P\CJ7'Q!Z1^T5#L,[)%T%#X&)P>B?1.%.[;G?',=1QX %Q[%PE9FE63@\
M"-/@,C[[KEC:[5TITT,EH;JF/5OJ\"'6J_ '=Q1E8JFQ1.% $YO[[IE#.<@0
M*!QJ?[(F8^>])?58BN[:^4.1 RRD\?EKMTYJ2%<R*V\T'"6X^O9UR0\G1R\O
M<:V*;NBMS^\O%6189:0;($<F$Y(+ @X=R@YXRC@=K^A<H)%R H\R**JRPQ]Z
MI&Y]VW<DWSK,&??]#><:[Q.N$;L>+9,RWXSMPQU!&7:RM/2]EXU/L4U/LF!I
MVS::L>2A<_@0!FQ_$/D42Q_A\.GF5(OKB)L=Q]HJG%UN<.?$-[2\($GI/)H@
M>+)UO)$BM0UINI7I(3!<P.3(G0O:5]<\]R+0JEVMS:1&8'$RI67WY#76G9 ?
MK86M/USCSGQ0<.QL^[;4UII[T:8U\2>W$8CIP>3P(4"$?3]L/V]R&H;E>CU#
MQK\&W%%R@! M0\2+#Q%:FU[*H]NGM"F+?< P%%G[^JTG:L-11K7@?%]KG/-$
M44E* U.H\+J/GH?.X;]V!1BT7U<PF^G%F ;8.GY!%/H:VF3?3<RT6B!.NU'=
MXBC=X2)(COL(:@\C/*M#]OY6?>TV'Z(8-"?,DL)VLZ>-$NMD]($9ZQ9@J83I
M/.%0__WOC:UMI>NH7. ;5GV2OHZ=8J4$TDA6!;?9L9[UKHU!?Z[M+3'RK)<4
MV5Z\$K7&>%GMX)&BIJ!UJN%,;JFR>$=.)Z]EZ1L>MX3Z>4!$[>W9)_5>=G*3
MCVW.(#.[-&X3??P2GN<;CT_G]3A2-58SGR^X.C85KL1TZX(:? A7<H&=!F)?
M<-5!*XX5& -G\2C1;*6]U)VA)/(II'C+QF^U@S+%9:OPHR;'&*%0M[%-%-9+
MV\AN3"><^.*L>6"X25-/+CH>Y0#.LW!V?$AB"B90[($G1J"3SL$.1&\]B%LJ
MJT>I-+,H::$\^1#Y3-A^M,G:7ZMQN/LWQO*HLM-//<D9Y:MG5XV,O=NJ8O K
MW[08M1OO,(F4ULDD]'FNP6X9YH:H)1.W/L41YPW(?^9=&#&D[%OA0QHRC2V*
MZT+DS=LR>/*KGJY$EJT!5 %L?+_SPSJDTQ6PSY"8L0M-V"0Y:1GM#+9D=:Q@
M&F&RE,6;.5,AO+\M4S';@L&<S[Y.UU%B#!&7+ER*:\^&EX(.3 N]?!.J;/X7
M7>&L-\NCU&KP5K\VU0]PJ5^UB")8I%>EU!QZR!XII'[[RD3-G-NIEX1:RUUS
M]>A7/(Y]"C2?;<>T49>D53Q&ZI+Z7&M2"0&RQ_JB%36O.* '+9F[[P#B1B''
M )QA9[)PZT\8.>DRGK@-(8!C5>PE&#G=C"TYC\$*Q,2'Y4E9/7.F#1\BY@G"
M7%ZU)M+DKTW*HW.82F;7'V@6QH8ZA(:+4D9;@,E[Z,/H;D^C#1P+QJ10I]#2
M-IS0-5_Y(FCZN3BWWIJ22*9M3DI]&?!.5G::TH,P":GT !U%:N)U17I-VT/I
M@R>82$*S57A)M(?Y_*<6+JODP]M*UVY+]?*GPWB3&MVZ#(]9$T/CT7?!'QS[
MQKNU]!P*7!QKE@:^N&Y_N4QP:0]&$PN=^\8(:<C5)PE6_4KIA,N+(S7&$3U7
MRMV1-WQN3O=;R-\H%YNUP(\;_.7PGU&RV#/.L[LO"$IU;^STR3\HAM9W6PM:
MMNHG)@5 5;=>-5+*G1NIK?(*\2K("@M9B_\Z_7:RL^W#([<AS'_D<O]B&O[O
MJ56BZ?]BE_]1X'RA_ >'_S4DV=XP[JX AQ\<%WBX9TBP+9Q<.%>SA@]Y9_F?
M9<%-B9X#05HR^C=T(\I ?2M>W\@F>?] ]2?/78K3&&K@)Q>#"-3BH6OB$VYW
MUJV'^G_-#4A&U:W)Q3PLJ8YZ07CC6/[HCR\(ATPGZTDWEPK!UM^^B6XXF@]#
M6*1GKEJ4,%*??GXZF[=8(%.$B/XQO%TGY>"NY&<N=7W/_ZM+>@EWA&> 4@(I
M:NDG0%N6/X/0*XP2KX.E<!%0*D4)].H;09K1')H'5!.92<!$357K_3J+B<E#
M.[ZUVKH/GSTV@- XB"MW,@ER5CV*I*\.86>6[N88Y#;'EC[L=(O3MKJ3_NC&
MHK3Z?*XV7OU.S4"^4>R=.I^\QO'20G,IYT=2#M=RKS*S%O-'3C^WR+4Z%7!U
M(4NJJ;/S:&7JLR;]H]7/<G^3@NQH#I*/H0) &(MX=2Q:,(WATF0%E->'Y@3/
M!"'7"?(QY%H/[]*(0=>=Z=.$]N$6)9N>CHJ:P( :+VK$OM&527WS6"DG\U-_
M55]-[E*MOEURX;QS4M5[G9$DYL+IKO6%4T5W)YVO!1SKM9/(7%!!OM6VUHZQ
M/5?TW>^_;= <\O_D0OW@F H*+HP/:4H"\_B05YX[$N3X71QFJ0TSU8.RXD,^
M:2<(>]V 9<$X,7R(5=I@(A]R%[^BNZMSV5S*5>VJ@[D4Q,$W:%[>] B!!O(.
M4GIS4M)8I:%28*YNDNT"1427]A-E?"+V?1?TGEVUB>O.Z0?JJL;/5U1IY@IO
MOJQ;G!Q9Q0M3"TLEL";.C$%9Y2!K;E/6R%)F[89*U/KZF\QRG3 /"^_&B$)-
M^P(;Y-O!:>O5E=6.9\_3-:P/G7Y^[Y\%,S41M.N^25"$CIG!]L';EAX*Z* 3
MRI_555 36 5&7F<)I:B"(3>GA[#-Q,/SOH@B ^7#+:S?8^P)" =22.R"PMK5
MS?KZ12];7$#ZY);8T:#6TE,?HBE'5D6-W4-V+/#/Y[J:7L1H(JJG;/WO3'RU
M4JQ27#N\>2,FW=GCER8+NK3Q=S?"X\ +%2%N0O"S_6Z]XP. ^[7._8[->04*
M>^_;^IT9*[(>6U;]*=GI%MHZU9\D."QW0YUQ9NPET'M#D\D2KZBMN1&A;;Q-
MJ"&M-K>79IC_F9.)\<-]#&2H<24Y#+544U&4/$N(9B^!]*?AQ TQ:44I92Q]
M-V"NB5A!J07#>WQE.EI:.H"V))("P?)%/P%I9)T[-V>K$=+26;3C$8Y/=_^U
M%5Q@EPLFC!2/"F^Q[]65X-Y@[</(F,HAY_LZZOHH"S:X)%\=@)U3@2RG&0UI
M=91V50;-Z0'P[.8U6R?75WD;1<T[BO+6P<;W\AP[TFVO?+O>3MK-?][EK2;/
MNKGW0E_$ 1'8NY?M[V^\: !WI&>-/_:J"9]G.CL2/$W&&"K'NGNMQ7.MK?13
M*$<^(Y]2Q/)OZ)%4;E&$![9O:5M;1P&;1E8CH>VC=Q_E1>2&Z46$5@S__ E
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MHI/KY(:F^Z36"SNJVYP*O(?9N8\V!M6- %DJ!E13>SV?S(<T%VZH<!R"E%5
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MU9)S6=.(\//><?>KBSV"T2_A1<)IFSOT2Z('6Q T$3QN)\ZN? 5!D+#(>J_
M=X2BO62M+ZS V4&3.F4K04U:QYXFUNJ>:)PCB[&O_AGG3)=G7\&>BN#R3+?>
MR5U$V44-K?'=9,\(:2OR7P/PKUKXFS@DN,'? >[T%J:9$N:TD8DQR0.$%(\
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M<7IWQWT1 E_A$]&>4+@,/&@--&K/)O(*A+DB*W@O/+["E9N5S=<*I5M/4-1
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M9/F09#._K/<H_=6(<)Z/P7<3@,O4V5). "D*B!7M.]X@&D"V9&4R"=*HDMT
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MY\QS(CJZ(#6W(#2"2)P1?L1"F^&B8]G=5-$M<3PF;4&$"5N0KSSX=8+ 'II
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M=KV7"N2#R<[C N]:;V0Z5 DL[;6,2AYEN'"'TVX?&NB9C-$N(K3Z*))O&OP
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MBC:5#(@DEOJ]O/425%-6HS-)$N,U/T->A4P"ZF4LJ-].4LEG)G>LQ=N&Q(+
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MOY-@+($^D8K9--D[@"%Z<;O(V\'D&A@7#/UQ:]CHT#_3$K:X:"0]Q(1-;/-
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MAF@+KL3'X"S#*S$/IKD;MVWNB*N?:!^Y]C#?"%Z$<834CJ5 :C;:*DEYS")
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M&8""N@B^XDENQK@9<!PC4OKB:^O5051A25@].+9$H'H!:32C)$]7K9TEIRD
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M5;,8$4]**7MPTMPM;>HX=E'5Z8_\MP,?WQPGCJ8/>!(?.<DY/D9+V(O?Z;,
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MSY5[C'(1SMN=3S[,'O[ <-;@.=>I-!%"GR*+<UOK @UJ'E6]"XZ,SZ$?OF]
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M6L3*CPG? ]86R:IIUEK&',CN90^?Y[6N"B-V_FV_\@N+H=,_%%Z#>M09=5D
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M4IX2CKY((O27S\;1$+)E;V 2H-R Q<U[]2M%/EOY>UT)X$VVVPSY$-;Z><E
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MWJ_/AFAF#C_G4Q6<]/O#?N5_:7"V--E3>LZ^^1G%C&PM<ETU;3"19PD2N/=
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M"N"K'(JIMZ;VU#*/QAQ3SCWD:YE9SK53E7TXO/\16_<"4U(2_Q^WJ"9298%
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MGWRO6%D2#2O3:M/A>;IZ:Y"Y,18ADWP,-X50$$GAO.1B'Y&25 Y8L8A+P?H
M;*?B-SR>*JT,,J&/-24&(E9-+' E?_4FU$=NQ7ZM,0Z[<ZEP<&68(6/OU4;J
MF/PJA#^+-\&'7_L:EO7FN/0#TZ&E(Q\Q[^FZ(]^EO0/27C>_&)7>A;VL6'BH
M:5\N^K;3KD<3U#>5U=(XB*!(:7\=>'/9,RE,WNW4VO]GWL[_X0-Z4]B/Z$#3
M$.\J64>F8BIC6>@4G%87*4]$C#(,>[JC_!E6S4V4)T:C'Y XV,32V#MT\]W(
M\]I<ET;R^%+9""\4-.4\8,X,+:8%JX$$H)5VDZP%Q&4TGN'&W84:?GKSR=+@
M:UZ#W[$3R_$+1=:K0:[GNCS+IF/^3LM@%;I^)Q+GQL!#QD/KCA2UV)/X%.0G
M_A]H3:$Y+$.%@X7^%?4AZ%#B'RSO.8Y.>QW2S;>6YU+82DS_<_G8J>BH:P]<
MY@@@_N7&SW(JXAQ4# S(- LWY;CNRAXQ"\WLC-OQ(YNNE%WK*EX4;2<.V4^O
MO#WXYI7^3Q 36*2P?[C)I.I9F%F!Q8T^GY?XP'PWVTC\W=O_;V6/P-$J?PRG
ML-?(Y]NKNE?,<@G;A)K]57O]ECF19./$XT+SX=V7BMQ>E'AW%!_Y@#SH;"A>
MH.''1%I$?HZJ]F#-7Y6MN@6#IF%A>J@YA,K]D5JP5^GL^XN^>=R#*1LWJ[Y9
M;(OU_R-][W2CW)@3<@.H9RR.J6UT4:+0X<\OW^@PUIL#<V?<KPJ'B=0H.=*/
M\NZ1F-[/<D^?9NHZ_V^3POXO)8;YL(?X"AY"2;<0WD'0PC4%+TG24]T68Y@.
M,GP>77P9L'@*Z*86C1C9#*KT-F09]Q0+WMHA)"**QHW<7Y7&N=^).CXAI19F
M4MC ,Q1;,M3DP#*_->UA6DJWS))1?J<- ]_V+UUK1K):]0=[0N#U8:"N\Q1M
M)CJ_H=(QQZ(SLRUB\A=/*+DM)KH?LSRF>D$3;@0NUO,/@=74<6D:*M^#J@H,
M$ZI^B<]IE>##JH)/4U]QWK2&&^&O]-Q^35:<(*"/4%E2(\A-_(>*1Z*_K!/[
M7K]VN'SQNE_&J]^E_SZ4.0=,QJH*$.?)4Z2 N49[SRF8(4G-Z7QOF5/]'(\W
MN_#I&_?KI\NWF@R;FC3O)V1\O'G?+^C#S<L7G2T&VA<_=$,W\'?*9*[-W,&J
MIC*S,_44<HEK'*QMN5>U"N;U3V-NI/$Q!?<;,4=C8+KF5__P++545_E9>L7K
MBK?>7C=;^;R9W_E_D#5MH:3!$O3=D%!21JDO0V1M8]X)[&'7%#?^/_?.D$^
M"+9?[$?.%JB<[R"]N!\K:Y*A==]29<> ?MRW>9,J]S,M"8<ZX!HB_V[-6_/B
M'<31%\S!;G;Y7!8W"FQYPM<%O)+XL.F+G!GJ&"1PQ?HXQ_I1+27+V.!D_UOL
M:4[,5N-B,O_D@7B3W"V7ZCKKZCJPYJN9@8%QCN3^O.]!MCXF'1]]?N 0 'X/
M8UM,^\.B739/ _BNS/26&FS23?OSXO/70SJIKJZI&+L<K*&<V>C'DLO#N=%.
ML-QH\\O[:)]\'<=I[/IQW\ 164?Y4$D,9EQX;ULL9 S4TR<;"#IQQJ9#1 6D
M4 F4Y9V9#X8E#^4:.QG J%!)U3YNW,V%G<\G-V*#@GK@%<O"OP&L1T39B1=^
MZF,^G/QBZR?!$Z--&1]$,JM\EL+]$U#BRR>PRKK9$(8I-W%2N!.4I-N#W<"A
M"716V9_6NR:-B7*KIL?]00]OCG07(R*NB"+Q0]6I$L4\,]E$DK%WM9:?B74]
M_GK%6PYOF>_V>I/<'C?S3=C3#3V5LV7ZH3,P7&%ZZ>J1-SU6?=%Y?WP\(%7R
ML0>>UF]YDG"/)VV(* OY[*6;?R+REJ;NHP.KIPB6AC"E#(]4BU8:;%6/^PVT
M!^2X*YR%T@9,EE"2R3L.RC$[4IBY\)W8(W02/-7B4\'38*>K+2O%PL:ZCG6E
MIX1TOE.M(_V,,=(HR-Q(\'? LK?BM=O/@E;PAOB^$]MB2-?95>XI\ 7O/&X(
M+B\\CG$=@._B(UG*!GP9SO!X5*,U%%-ROH7^E6_:9"RL)J#4-2<V<_0&MG8-
MEFJ5U)%;;SWQ<ZX(ZHMN&A%47UCGK[G9FW2T]\;&_\('!Y&^7]\6JSRCP9P.
M97HGLK1B2Z\Y![:*)[\Z_AHF<RUNSPSS]0CL=?-L$\2J[Y.YB9N-6N[KT$PJ
M0LER@FS %K9DUF:5!MHBO>%U>;/+E*4R"N"8*,?.&X1+"V?*I 35/6%L9_V(
MLAU W)U8XJ[5A2,=X_H?R[TG>M2.8Z!!' O5]5"?U%<]]NS$(*P>\\L3>MMW
MQ13">[M#DUB(4**%=P6[%TP"4-P*03X>M9'>%4=MX?T#5K+"L_7YL0V(  S^
MGR*ATI[T:;(YO=%XA'<K!B85Z6_8BH)E;"KWV,1R57GKD4YG:1-^C=4SWPFV
MDMZD^\^75RGLCA5D^M;1#X\&?08V,CMG,COSLL%NM?Y?.<&61%>MEY=_6>O=
MF>&'XM^!TG\AG/3Z)_H7Z@9/,3_K]WG76A3HS'C6TX55U@>PIP69\*4'\-:B
M(7/K?;A):PG!,]Q);*!7$M5I2<:&6MRQ=?5!:,,[4'',LPW(R^@)J@;C3@-5
MPD-3QHM[5[8ZT@T,28(9189MVAR\U8CT#0)J$==M>4;8,X),ZR.XE^5M8S0!
M=.G+%)YYM!THS^3;U/ECT+;= #'[Z\'I8I2KW.H;[(F0W_UR)A($YY&,J<'2
MJ+IWP<AML8L=DS(UW8>A;V+E;QA-9[[R7XP5\A0RMHY]>%1C3YML_7J"]9B=
MTUF9V7DCYQCNX"0A/^3$8ZW$/O#6$GBQ!E%T 9!_GFTMI=OG,\!$+DTK!DZV
M=!:XD!0.Z/9OB[G<QP8*[N*7'B%:((.N=^#B<&2Y-&ZR7)EL9L\"UT@0L?<8
MM-=XVV@ C2R?U >@3*<75&:P 14@ZC1 +KP;"9W=&LHT3D31_$><%:K$79"L
M<<K#KB-5\^NS>AJ;%!E+6#_F9F<)-,!Z%$/, .EFN;<&+)T?NX\ G0TC2O9[
MFA]:>%XS]U82+UHZZJM__!J5>6TS2L*K;G+*U+%@'\65LE0,!5RVQ62%<WC9
MJFFLJSKAB7!,N'/28%N,:<VQJC=H7$PWWGNP*^VE]?[.NR?QJ!7%YP9O&FMM
M=@)@@D-,V<V\\Y-MOE?Y-[C[!.E\/ ^-1;0#\+2<Z:0EJQUK703:1CH\E&=;
MGF(D<5E'C?2DX&E[+\>Z<]P9Q11H5LN<L(VK=2F?[0KBB\)@'%0<!^%;@5(
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M:O=3W] P!?T^](FRG@)5NF;F-%N9^J*P\-(3 -]>MWD8N"LOZI0ULVURB[4
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M^PG$6(S4/):?HX8*H"KR!@07)&4^8\M0*J8>#,&+CBX-^Y;5QQ(0^U X>-,
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M<'"0,2>2M%K!!74)G+#&$4JVMXAML77%K"Y.WC@'W#^EQ@4=#.6IH,MO.Q'
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M6$Y"6"J1[D[OY8(*%,'T;%\N:-VL,80+BA**Q;(8:@W_M;2-^ 7Q"^)_#43
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M2O!S'IQ#D[P1"8Z41E_85F$=(&>&F!2EFP&],_E'OSS6?CW1&$84U%8;D3I
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M:V',;[ _O#"C'LRS:*0G%?,(:@-)([A^('Y]/* O/%R&OYX2>#]"[Q/G&-\
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M].H@]]( MEF4A[[<F]2K9YI+>+% )L<.^R>SDBO]4A=)_U):$>RK (0R\Q'
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MGG?!.59 S(!%?OH>\?!ZL=(,]L#*N=A!F5_[H('P%-/.F 29/F7=0NM]4,*
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M_VAFEV.(>I;[[CG=N1P'D@J.4G<2S:QJ;I_6-]H'V6B^:YI;\DM\]VW^6%^
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M^IQZ @*@Y"R?],J,<N11L=XLY;*-#[59D7V:4_U.1;:1R$H+Y^EO722S9?'
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M'_,WP^<?;C1NR5#2<EE#UJ>X6+YR%A=VK$1NW&PNU1R ;CBFV>R)LZ8H?J.
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M/N^=]NIW"KCQY[2I25_7ZID>OY9_/\.-AAK'>GDH*9W2/%E7\Y%THKQ6VI/
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M'VLDE4!](:+PA:E<U-+!XXZHEX2J_WV Z_^H(:<HS?I;Z2QU=C>0(Q3'E3F
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MDF=^(>02 8SN\!S?$,K3B.(3LUKU+G$[O,Q==D-6O"ETS,O/QB]YW7PU)R]
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M^)88V?6F#C"0,S:]\/>6$M]D434LT,_!CO][<2'JOY*^_HL1V]^8W6B!A"!
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M'BUT?^:V+9,=NDE]5#P+!)5B9[1H1A9LL8%NS_X^<P[#M#./,=2FO42P4XT
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M%)\B+^1J_3HO+2D5V^,5K >C;F77S3PPY-FTKK(7]DS#V#V,:WF$=G[^[%*
M#3)@^$8$R+ 25].I,@-S856"_(.2?(WH;I%!JRWA7F40X/GOM3OA& 2?Q<J\
MI >/NRJ67.GU<=0G_5:1>&F!>WMSX_C/VO*4N0$2*>I201*]A'$#!J5KE!+)
M LD  2T!@1^ABR9/M/S"00+;1S =FS,W[D2&DSH\'!.Z*A2_GIW/7_1]'6DE
M]CK><$+#]5HN?[J24$RWSZ5V0YY!-2A3RWD@W+^J-<S56RPE[<G:I2DTOUFU
M >70V? \,"0F__-H+_GC)8,1R03BM)/7MV!\'4]XU7^G^XJE<DX_-UUJ,5Y3
M.B(07MJE@"MK")KEI:533P%Y6D;AEP*<D;@>-0& "-W^Y[(CA>CL#HWZ,O;,
MQGI"M<#5!2%@8B"Q]);V!IIN(;?^:Y>_\>,W6A/D3"0KAPV4[]GVB*V'&70V
MT>.CRDQQ\W[C6YW2YJ9ANG<[7V"E":Q:V"W9-/#YQEU-9\SZ 7_Q*]RL2GYN
M2+:.;LVXZG.T)3K@C>."1MB/T>P2YYHQ#'0<K3L@(G^ME-O8*LM"TWI$W7[K
MGL\?EQQ%.\ADRK<;Z;8_OA>6N./O5B\)5PX+QCMGF@EOB!L':H[]H:6PI%@?
M09XE%'EBJT<:6_(V^9CK(E3-=-S:(ZE8EFJ29"!Y3=\27071MTPL<?%WML@I
M?U5K(;5X\,<E5K0(4W8]U&\OG.<V=+5KE_ 8-9>^1U0B_X!?@,0:1]]B6-E'
M@XGVK:.?]D]_":+?^XEOAEG*WWC=_>4'^:#@T&AA@,=!3BA9_8$/3P)0/%<P
M'7#1.LR_W5XN01H^5^ ZX<V3(X1\YC1>M8/:,RQRM@DQ*POJCR'7Q$K]0UR_
M,11L>V,F'W_C=[&:2"+1EO9[;KU$P:ZZ$+)O6>3Q^)@K<@=C74DNM=;Y$Y"B
M@ L^.KGK,2M#:YJ"G]B^2??M&7.' 'CPJ9_GT@O1M:I,M8C@SZ8XOYN9IFE9
M!/LQ&V[8/POSIR:$6/*'AT;384%"/^:"DF"&54[;$G)UOGSL=U4S#YI$\QKS
M>*2OE^1PG[H0/!!,;?;[U_:-N,F^BT< ^RL WUE/$7/*( +E,G\YTNUJW,],
MA*VIA$20HMH23EA$W4[+?/"DZ*@Q\ZWYOV?69^3>HS9![T((ITRTD _FKU=<
M\@E.Y60:X=++L,?X;/ODQV/.AACTH-K2\Z]L[S[FQ<M36AI/RPL]WW6K.J89
M6*>%4%.FK)QE4TW]:+5YRH3(07D6]ZB3OFA;*11E/ Z[0]HU&W$<U4K5#?H]
M9-GMW=S0T=#\D&IQOO+^W[$)-HE(HLG5LJ0!+0S%__]M<3:<3V% ,%M>W"@D
M*ZWTVJK"@.I8VH>="0[JQOPQAD8I"E77%#ZD</W?'1L'[V0M3+HATF]$R[*@
M,>MZ>T^:-$")9&E1JC(&0_S;A'&M'BRLS]VL<L$OO 6KDQ4FD_6^1LK]5L6$
M@?+449D^S HR+>CA;*Z3?;161>E/(ENHSH+6UOV"GM1/Y0-(36/RS<=<N2(=
M%KL BPBV?Q!"=<YE>#V8H.5VS)6$A;NXS-K,S<T=TCNVEY;V%*SN"2/_?RW9
M;F'XRP*O3ST.O*KP""Q #[A_0'IF'VCF% X059Z[FQ?%E:]R\4H,32E$IL"!
M>FI?.&/7$_U#Z<S2K1)RM+O#Y)7\K[\!_"9!'VKF:S49E0<"POCU*A4"\U.B
M0XJ+Y'TYSI#W2A8JF&UV*F@V +2>/L4*PQ_-)#-MF^B+NT%_#FVBMB'SI"D:
MPZ#O0-C*VI$S<*[_K\-A \$4F69;53'N(Z;[N\$L=P0/YK<1X=8QUTHM81\)
MGKO#[@0*(K9^T>W,7$ F?P"E4+UC+OG4;C6&OCL L>V4C:K^KW 4]?7_M0)\
M2."_RN<,QCWFLP;ZQ5KX-^>(?Y39\C 9ZD_T:C2 +);"-*V"(MPI]\CSFS==
M;I-F'C=,A!F&FE(-'B[-T)ON4\\41 :&!/JB4\/!OV,0YMN_;&A,ZMG>(40_
MZI/#SCBEC3Q<3Y$;IV708U=W=?I0(C#U]9%>?>-4RFJ7?-]#>@0Q_W/FV3%\
MANBWS,TC6&Z3]G1>!,79J0;GK<7"=[]H[)C>J"##"U9V.=:8+'<O;4#IW[>N
MEB?Y>O32Y85ZH*XO0#(E66M,K4(O:$RM=Y[WR/:[8FEQOO,#8*4/U0C_(9._
MK)$!CBG9%>OV2]>/N6(6;P>=4F?JL%[M74NX]"'SYSJ#7+W@9N!7>:B!K<@(
M#!3UGQ'W=H% (,$[W9>NI"E#CB(IG4')8@!^IG@(-6&\VQX@[$NA%:AE*,/.
M'!46\]=3E7.WCHJ:$CV<BK=M K6YOZ8+189'R ]\=G-];_HO.U@3-3M/2Z7*
MY3#@+OX>%"N!>8'[5,1.+-DB8+J;YGS,U:]V&7FK!RXQ#KM@ "G?ZE2]WWX;
M$EY>D12XHX5QX3/N=JSQ="2WWW#M]0_. [2CZE I?U-Q.Z4,0V@CGV]?YY5C
MKKA8DDZLECG2EZS:"7-83=UF8*5G#_0,+,@^^+J@"P'^E:QJ\?"$^H; >S+F
MY4UQ UZVJ*C#R>4/X*/HO<VC1"3S5I[W[)F3DKF('OW*2M_(%V( 59Z5X;])
M:?92&X4W[R1_0M22-0K[Q>Z(Q'Y3KWD2HNOLJ!^!=!;)<<YFI7G:;+Y4^%#)
M?LRC@'MSS 5!S!7<9A7 Q#KG=UX2>C(NWM9TYZ<L##MK]M'+J*+XR^#+7TLV
MQTY\T(*63ZH9.;J8"O(.#DJWGSDK\N[QCT?!MF@7H:3\>%V3O>PR6KSN/;V)
M0NREVWJF9>D+;:I]/LT+0(]_2A7I-1;W+'-T6?N%:PW7QU-"JZSMTZZ(FUE<
MB^S?[6!X.#&Y*3N=9R@6NQTCO01!1]3??5_5Z?+WVTS NXP??6L2#8.H'3[@
MHY-Z[,E6D_H8R>@[?Y;:VEH);2V=G<WY/VDT,J1ML.V=-"05@WDG 4E-7G_=
MD#FD6;MO+E-OD/[MF[D@Q*:G4W8:YH7;6E*@ JLBL9"CW=]SZ9AJCV^_%MT6
MA^>+_HV0/Q?[]&%/P>.F5S(QPNF71L7X">50KP1*N\X_CB_M,:G808-G2KEC
M6#N5*])U)68_-4LVK@\N%Q:PZTBJ(EV41K?+6JK.S7-;(C?IPRYF'4\:XM3V
M3 2,]Y$2@0<YIJHO,WD4/G2^/GK/B>>31]=9S01O%( ]_I7R"9QXM!S3\(4I
MT:D9;086V7*>S'>K2.Z/<P%'WVP "T"V]3_\T/%9J] NN=M8?C+X6M[7/UDT
M&U8BGF.FCKFD#A#",(]V2FU)*>S:Z.^]B_[3K5H':^NO0LC1]DM;ZWV1&U.:
M'=+K,B05_2FW9WLC=?&!>S_#>)OE\S4+@E:1(I2WED)#E$C-?457$TM=\8<X
M(U4]_?2KA3=UDQUJ)[W?:2],FDWDK/[LPTY]3/ZSQ!L;VLY_SR:QDGI/86V?
M2+[Q/>3+Q$U-4FK/X,6DD-IZ^X4*"?RFW.I/8YSZ88G0H0,MDM40"-1F?R<(
MPR]!\8&U\,LP8W,6B!2?4"*JTIN;ZAWJ&5ZV-#_D?SX=%OY>I0\?'@3?>HK;
MG;\?9SG]9K4;* SO?FG$G@9J40!IM=;;I#WB%\UC+ND?K;9C][2FD08ZM0%"
M:@F:#+SR3AB#-Q52I-,K."AA&@G,I]7=D6K$\BUX9&LZ&)'$'VUDL'N^K65_
M[U]KAO&9W>QF('P]SI=:7CH*=<R_C%]+L$%;?[?.,<OJT2^>Q(35\N2>B<PX
M(N0/RA+7G>PEU3!&ET U^HYI:BH*/IK5RO: O(O*BD42N3'9U9/%2G,,=Q>$
M$0B_O+/!,&=_CW@!%Z($);-%Z28K[*3<P KZLVUWJEMN:6V *%5N_ICK@HL_
M_$S[QY1ERZ#?@9+&C1WMGQKN&[_?-UP8[?<D 3X.UWW@N$>=?M2L/!E.(#'X
MGA\ZML1:=#1.%(4A$0\#U<'\]+P'8T%:MP*UT.T,"?\(Y_":*=KAX1O5$G82
M\O&V1UJ#O3!4N^%YP*RTC%:I@62\GB<Z?F U#G='W RO/]IG5TUM3DPN1%M4
MU^7'YA=85?$[*OSZON),_8*AT.1U2PS.5XWEBCH:?-!5-@9(&7<H4OLY/Z'G
MI5;IV034!"CH]04:E^D]*F5T,$#LD2.Q'6F@/-.=WD\5ZM8)7O##<>P^3]'U
M6NP!+^NB:NF47%/ZH+6Y?P55FA!1[E]W^[V_B5W"PLP[2VRXY)>ISO^*@;/H
M.J21-.!->BS#BCXE:7''L9&>A1/@A[J-Z37LRO3,)=53W?:2?IX:V O52J:>
M[L EFIM(.+EV15;FY!])<BLC+BM@%2G%^IT [?#0K0S-X2OQ1+*&!/2<-=)
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M0'0 ZGR@ 02[]>*%QE*9<VY.J:MYT'--ND^".O,HU]=%87";#/'">-5%_G1
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M5VP>!::CT)NT7-J+A\8$('L$1 F*S]N58JBSOQ0K31&>H3+R=79V5_=B":>
MMSAVI5YRLQZR='G,()HJ1B(DP,"K'2:?7V(WTE5@5TBFX9 A+^N8;G90O/-2
M787S<)U[@/YG(\!$:?&CZ)@ATCN'KQ01W2:QE+!-$L8VU],H5^RT8G- '7%Q
M'%KKH&?\(:RE6D=GY%S3QN1 "'QV+?/SV+>Z8%*-MI1E^&;7(PSX8@K2X)Z>
M_:=\XG*F*I_M6DR:4-R_>5(,"Z8GZUVG#KN'0#$I ,^?)8%WSS+<X>/N:O3
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M>A7U+'FY3R!%^@K5L(DH]K&C?KQ=#R/Y%J;A7TO$1&*"2!#>MZLQ QP5;9>
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M&MAM90LPDA_1NF/436>6E':[KG:2V2HU34-^6'0AH$[.#.W?$#E TE@FF+S
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MZ*MRXS"V)_,Z6@]\0J6 N@?+2XW%*/G^?)?&JB6T(E!>4>,>:'C/L+>8MA-
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M^P[ @NC/8)9/[+;FPB9QX#E!5G[[CN013\ 6TP:[[G.B3GY9B33.Q_+D#G\
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M'(9N]ID@NVO^/^R]=UA3V=HWG#/.B(B(2 <AHW00HM($@8P@(" @'4&(B)2
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M3Y:\4. - ="X_]-JN<Y^>16?3Y4^.^_;+@X^O9IPKZO&%OC.TTUNF6:+PSC
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M4"5'?*L-_/9_5Q#1814Q"78G'>P_B!X7?(@ ;@?W2_LSU/1. ?>7L$\7*;/
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M&,;:R* E)M;^_6F8'K2CB Z"7:2#BH23&**J??@C&R8JGTV8J\N,$OAUDLF
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MT$'9#E[R6RS"=FX5VN7U%6^L<06Y@0/WXP[N)W1+Y!>^^R^WU_3")MTZ9B2
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MHMU1?E6?.=W>3$\"+4!]C7 !A\.JQ]HAW!0_8(LX"]P,Y01XCIEHY]%<B <
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M^_>G98?@_"3@YSP.Q( D'90Y(TH'+?V*P-^=1QX)(1;E&#1T*>"_D$+G'X6
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M_O+@ZJ9G856V<7TKIH';8O3=K<_-0@Z!J(Y>/QSB!SK(#1:>=X7\0]%F%.G
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M6\*3^PY" OMFAU40=FZ"'5>):4KJ@Q*5IQ7JCA+.+^;O=Z9=8,.T?<;;<UU
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MT/EVD+QC-:6K5?H_6V#WP%1L_2ULMPEXN<(!SIZQGC' =9HG^>1 +S=V17=
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M:/L[_;&G^2!9E2F*D\3&(/R';1^']*^V./$7&2[5>GT[AZ^MC;$%OYB"%J9
M/AMD.0 :^ZIXV&4H@6S+P' </F6SR0AR(0D1XO0JAW'[DX'/$[*44>^B9*=K
ML]FI;#Q"?[TO(BG)*V'[ =K,_^&/,]7_!&"DWV<]B:^V*KNBQW7CC/5ZGU52
M+2@PL7>\Q_TR,[%:([S3K\EFO='SK%G9\Z[07+;OQTKUW$N3JQWLGSRD56R7
M;C_<4_;0U&G-UR_8$0_Y/J.VJF0L7X,MXA;ZK4 ASKF!YW"L,^FT=/K+L>]N
M PY ')MLT(%#"K>'I;[U@SG=7C6!Y>;4/0W)V8V)V?=<*D4HQNV9[0<^\?,C
M%5Y<U=PEC-=)OXO9\_\VMEO D(,]EVZ"/=/.,S$TG[XCCE0XEZ'&QI)PA\\R
M+]<2(&%+=5D\,[[3<:,(I6L[07 U)<&RHW+[Q/.W+"E2MZ[W3K N?.,;YH2=
M$1\KSO\>?MGE1EP!KV:_]ZN,'^]79Z.O;+Z-/>XX&_$DN")8T</77#.Z8O!*
MH]\-"7,Z1-(AV$TO3UA"X]T 2#6 ![7Y*.N*WNWROI[IM2*'*X]2_B8\N1E"
MM#^<0^8LII.K!1QITIV1I[*+ *S%I$ZGCVV;1]/<X_12F"6V?,GE2JS7L_&1
MLS7R]ZIN!]5Q/$\$HN@W#UOWX'.V].O8>2@%].S>84&7X!?=7B(?X@4JNS\(
MR(_K28L+7ZPKYHW'7&B-(V&D_$]9NJ"PCEU''-$!UV\X6#C_K>95/T5XN7_.
MR?EWU6$&&%$[AR.#H]G:M09,-0?/Z5(,&VAAO<031,^TN0$XH+!R:+7N,$WX
MO$;-)KD:6;F>&G">5FB?!I$P<M0CCD0T>$7C#*+MYWN#RZJA-\35;IL^*=OX
ML(FY3L/VYONPSB;\$3^'^4P%ACYKDBB.]08E8$Y2B2E8)&-I5H,L$F^HA&JW
MINJ2S!JK;>:7OYH5NVV$&V9AY('-S54F/*AF*UQJN"N7_#M .VZZA#4U#O^$
M5A'G)N/M2QWL:8"&>QI.E_/1X&HVI6X?>1=G<S<:[^%^YE:F_@QF+JV^;,=Z
MF*8NDWD?/XZSR4/<HYDW\938E36<67GX63\$;\67-Z4LD%=J$U+-J"P81RY8
MPQO@_&Q?5(..0^D*0!Q;9@XY0!AV:'G B"9+8IT 7IU,+M &;E;Z7OW5EAVE
MAK:N1-#AYPTEU!NJX2C('> IV?7)'N'3=N,"U+*SU9=I=G\N<G%TDI<'B#*A
M!<;M:0BA'K/4H"26_%CCZ'E?6&G;X%L_V-4&KU/%I4L]#9=L5:%9NI==3.K[
M)(LN65^4/5X,O#]\;JCBRY)G1SA;,74'H46..#AS*7'_:)<"$PP+M,W$/D02
MX)GIZ3HS/C_ DJ1*I[QA7G3>W9%(0FHD8WF_,Y6\=),[3IRL02L%4C1.?D"4
MNPWAC86:]Q78@_.;@65>-MTV.L331W<@P'V-63S#@F$TPL#.'W&0[P :.X4!
M#,B!Z;SAV%HD;@?4];/Y-[%CP>4:'1(SI#AE)^.@15K;?YNW7UF9J4RNO'?9
ML9(3=S%&.OQ*/AR3J8RF5690OL@&=!1J]7INVH9Z6=VMSAKOU1LOVYC N8EV
M6$GCXZYGNL'J4JZ;E&P^:O/O,3-;VII3?--E=_!_/K?NO^W'$4<*4;A#A2JR
M_*N/-P6CVV(1>!:M1!5)[,#6-EA*\D-P -2X8UJNKA%QC-]/_WFC*_A.T^VL
MB.%;F]/CBV(U\HD*Y;="%3A#*.OZ+Y)ESN ';7.MDVTVO\Z9A=T?"<*)63VR
MCI95&H$8B_;I*NF.7<K%F)9;P]]#MB6*F$Z'[/@%?8Z@-P-#^*WZ/Z>+)U#7
M^RP55J;R?_^[@1$&YE=&)>%HV&%AEH2_A7A*=,YNK,%-,IP3H1^2?MW1H$O9
MSCC!XVD7NQO/%M"&5&S?;G(AU6PTFLC7>)\&)M7&%S9U9L>B$61D[K#)X #\
MT[X%MX!55UU;KD5[75?22'UG1[-SK@4^HD6V-7?[9^^X)MC,-JX(HM.S+'S#
MGN3A2ZFL"I4$Z]N\J[(+"B&;.,8K#>:CI6 A\[66]CAE^\/WD]9N4@:;MD-;
M*]+<$[4F3>+I/7:U@SO)*)_8"OW*Y#S!;Y2*R1R[,K+>9$EKGF3AWMD_G\DV
M*KR#1/W9"&@74#1E"OC<9G< ;8EG*M$@.P*T)HTX;"/O]CYY-'Y1GN83S72G
M7OEYE_K%4(F=A^+1QRB'V-X7&_Q A%&ZRZ3V#N;4Q YLB[1N,W'/'V[<U6&8
M38&<!I)8G$MLA_(>5K).H"V!YS10S]+;F6U5 [%E-2A9@10HL@C(@U-!XFAG
M9(6+7TY<VGX^CV.HJY$1M:\_BG+#4$W^VK3%J;>?:K3G.^57[&G'_00.H\QZ
MLC0]<5SUJ+-K0IHZ;S&C0N;Y!AY#4SK/8N6KE.VJ$S-DXH+Z&,K/'^5MVMBM
MO3GB:%)6LB,97/)*2[TBJGBW-&&=-)E');J$2BO;*0T*;KA/KCKG<FW>LK9.
MEE\_=<11;*[R^_%A%]%=XQRV6\Y0R!FS1*1:5D,I&MW.:<\PUP!L**UXV0DH
M6ED21<L")"JQMT!ES$"N F$H.V: K$'E.K6TLA:G]K1ND/R:'0X",B.JD/JA
M-?GX#7U#?-D^G J]#YR@_:+7L%VN8$K;!E"LX2,.H0 B8E< -3XQT"67W8T1
M3B?E-)/2GK;1HQ3B]\?POJ?_1D;@AX02R83K8K*M+^>J7KM\X"(872!1-N_A
M8@:F\4_[2-J=/D^3@S*0JXYG/;?<UY\Y?IC(-&_,E[M)$B>#D6&*+7J<34'.
MO%QVFJ+Z(304PHM>NM]$)2"\]5J6-Z"Q2N1B'<[0&SB"34^%Z>RL?$D)UF(/
MNCJP[<\ L?%*D27"M.X TAC\W\#'Y0'<:^#1$8?%9"@V!BY.X$V -3TGUY[_
M<+)S<U/\+I! :;=043-!.MYS'JHVO'IE8'7^BTJV[3*6$,;D:Z=?H,4]8Y/@
M-/:3[,Q><!DH%7Y*TZ#DQPU 0.Q\__5@O7L%-[LE??DVU2K7LWQ#FF.L T16
MK/9H&-]+@??H]XH'QC6V.[M?R_GB-L-UV0G9=^A6HZM99%EI'5WI)<AJ4"9X
M(2TX&PP=QQ.#LAL=$^QR,HMN-M;.JCI<<S\D&*AS5DV4KXIZ:]$Y\R[F3X7]
MLY9I9NC[(^),M],U>[-V#'D,_AQ$O77$D8 59ZFR.Z_==0(@KC3A:U!)O?U8
MB6\829IIPMJD.M., N= !?<=-"61;T!@79/%SM7FOOZJ:^.JH69R[9$0DPGM
MH=^[ 34!"AFL]AEA\%G54]?%GN:1;5 &E@^T*VV)EU9-2BI:30Y*O@3Z5,YN
MIN9)R^M]E)<0.3/(U_NIU.UR89^0 U].<G4QPGP&=F,Z665E"5"$,U]"=JJ/
M.+R+&3>/.#;+::Z1,7!IMIULD[_V8/T#&3J@.=XC#GO3Q"UB+/NW-^_!VZ&9
MV,W0$X5Z1QS/K1!''![;@:QB>_#'4XF*M?LO6:+_3WO?_/]J<]2E!(.;RT<<
MYWW9G+NLN1(([&5)3#T('>4%HHR(K>/[^0).X]\].R8(EAK6#2\DVB48$BT>
M+82VYJQKKW.T7^@ZW$4*)[XRT4HNTNM_F.?B<U9.<?"*I?F5)':S+,M!E$TX
MB >HF:OU6R/ZS1HGK#;*")8W;&%EV% V[)D% BH0-C]]L,O[&2T$3&%+48'T
M$NIB1I^D6E-V,?K!6&.[I]Q, E,3*1H[/M#O</7?SO7D#@GOYSV?!H(IM9SS
MZO^TC:0L[WX1/^)0+N0&TGNE>6FG$BBCG,CPVE@FA-SI,.#"YE7QVM<9^1I.
M8SKYZFO7AZ_;C>]+7)-IKR/6M<>J)#GCGWCFG"TVDPWU.D5LA0.7FIE".+8R
M:0J+VS;D9/H1QSMT&3:H0'./5.%YB[&NJ[YSKG4OMGI9HH1D(X3GBHK$WVX_
M^]VX&_XF^WJVTJ Q_MG_<?4QH8;1XI+=>(8N9,DFHIRYE;X&9U2N/?$2;;50
MR,A9ZW5_7:OD]2(]X"$4=6J7M<[:81QQ'*-1/F:JYEZK+'[9IXPRN#]G(?W"
M7-NO,TM3(Q9RQ_R(@RVK^P^[WR2J_'YW>.]_MMAJ68K'Z(VQ)% *O07Z,QT3
M;!=:OF!1%#FTOGSHO-!0'P56+#B@(R/TG-ZG>.7#3!Q)EZ=C.#]7[CW\'/X(
M#^=SR.<4?%VK3Z@<ML59G:O"73/1='4VL=^R(5E7Q]?::)??+;4A^#4\CM&W
M>[UN4U+X=P_?H_1OZ=>559;3:<WTVE8@3*$?KQ&[Q$D!,"&_#2Q.Q]34,NTU
MTKY2G_UG9JM:;1)ZWC<MX,!7).B]FLUWYR#Z^[WTP$ON7;E4W?[:XZC1;FE.
M6LG<VG/R2V90R69.078I*@HVH:J1S]1O..+HL3]9^>6+<[X)F.=&]<1FV..Z
ME]7;%)$9%?]SS*XU3Y)8C:LQ-*>'LC$@ CWFM/JY3>]7S(!UL8&QB_Q%O2>6
M/56^$WC;5THV&;[3015R5@ZT*RSYP9^<73V\0M$5JFH&H4(OR<A[#@HG8=7Z
M@C3')QZR9T;R\/;%D,R6J>0MF^2*OLF4PX#$K]KL('([-M7H;]$;#DTUD*E
M19CP2WFZ33 MWBSZSMU-,/A@55KI[/;!TT,V;?W?!<CYV[]SSPV;NM- Y+4*
M_-PW<9\T ['RK9FFL44GWRQIQ4_?]R/:S?S[OD =VOP[][*SA<?G^$(E:;=H
M-UH%5$1'-G](GQ/OK*:^+-V^EH\D;[)6;VGF+<"#?Z&?9WBI1SSJMTZO1Q2T
M]2\OU3=I<!TV:]01PB%S/S_T2P\M':X;%"L.O&".)YGO:#\.[69:486R>X\X
M.(#B=_JI19&E,%2NY=4K?OI!-T-]-PQT'7Y4FOV G&EICG>=:S!ISHJ-L%4U
M#,O)-C"F\;Z3/M_V;*BOX!H5&[,;8'V_J9$FDM#HRK])N>J1=$GX('.GL;[X
M2CV^/[DTH_S:7_;51OU=W.-J>_A.:%^7Z(2:SJ=UH[9)G1WEP24GOFYZ!4^F
MSO 7ZTT9M?C68-^)D__\'HYG^<UP0S1[IKM7+D]JVFV9-&J*BH^11ERF'H[;
M%]ND:<MQUJ0_*]_&";[YDJWL[9CS"B.?JG$ZH3JVPMRN-*Y_+!^E#G-\V78%
MYZ1486MO=YC3GA1@9KQ0O KG8GW(627&&XK[L47%E4W,C3'#\U\^+P "I(<H
ME=O4$EA(F^V\16GI]U(O;+GK9A!LV//^#CV3<1O_H"[IY4J8+3T&36.+ZNQE
M8O0^F]W[:@$DTVGH@*[NIYLUJ @XM::4O,MCY*E3W3IIX%31'*]VQ%&OO57Q
M73YV9$>FW:QT(O2VC/AP-]WR>K\AW]0^9/N&0I^;Q)1.[7:N/Y8!LIK1'EJP
M97#N^Q>,PEBC36U9NPSY'8T'<_/6/S #^@OSVK9Z!1=971&&\@,#IY-'WK;$
MCX=H:G6WK+:@B;SBFGU3!PM_DZF.#W0X QP_V&5=K-HP*35OL*U0"NZ'?/@@
M0T*)>5!?&<I'5S+0!D%^3BEHS$7[TNC2??-'O9Z:>HE3@@^#<)(W].PS]4-6
M/EAIKF9 38V#GC--@(BKV=*M(NR054]2?]LEE>28UB<NL?$(]?2=4I%IN1JM
M,=*]^V1(W\O%MQ?B>8QAG]"ARX5"KHN?49[]AD(T*7J.KM]5&&]\2(K']^ZP
M^%]N\XA?V0*PM,O1'S=$%V\=4DZB;+H]93@S%:)[^P5S4YP&8QQ[,M*M_4KR
M^*-L,FQM$&7C"\7SJ5IGK]E&!SDBK"JM,F3=,DJMM;_FZU7H:E-RK93*TB/D
M0[6A_0?@';,CCC-Q/<C:>+B$;8\*'B2VZ28UH0V*9LE2B8E>DP^J3^7\E55(
M<X;/+< 1.VBO:;(E3 )_SDSUNWK(D-;#YT1$-=-O*A0DS!2'Q+:ED;BQ[]P,
M)PGG-/C]VN*2]T[.['QM2+/,W-OEVMB@)(E,[B==(AI//FB<U^!WA7VQ"#RY
MD)EH)OA+>A* ZN$<'N:+6Q=QOHH175D(Q\Y.X;U:$!YU=N6>&MN5H[,#62^2
M#O>AVQN+YN:&!GK%"A56_#%^J8T5R\I#)[9]]@^T&R3O7&[QRWR;16\D[\B7
MVG_ K!7N*C_JZR.6*M;H.@ IU%__F:)06>TKQ%/?VO;Z^7@2\*CBVQ.$)Y;O
M'/XQ+EN$&SV1R7<5E_JW\/*5C"^BW@/QZ+#EM#/#"'_*J!@*2A(1CV.BG(&X
M7GV3)!VZ2[_A!^'2)_YR(RZ"AX/$$<Y]2H?]LWZS\>2'+U\9W)8R/WNW<L$O
M")JQ(7=N\AFLU2A'R6]VV\";7[FJ-)%DHBU?,1/0>:E\Q&HLQF'5+SA]S.2Q
M_[?,D<K$P4G"@H#)N,_,?J2/^7BCBJ]L6^LT0>W6^(!9,R'C35^P87&HMD/0
M35D+T52$O..7]T\=LUV8K@PEM!<MK>\<1(3Y'^ IS;G'O]CY0V4_1E*]D-PI
MO=(M?'=AX\=&UX7VZ8L%:NZ-N?BPR0>"6XG4QG_E>L.C?SRIZ_YVK]X@X+KJ
MQY^P@'P#=:CM69/:QEBYR=KX_L$27S)U,%:Z4<K9)J]2_V>1^=F)I(H=%9MH
M0//5(N_)5UZMKL8V92I:L<H$#1_5*S@CWJ@4!6>^^- ZP?L5S3"^LO);G; 4
MNPP$0]_>A[>UO,:4A#UO<'I%J<:_0V8E\ Q021D!7_W.RZ8B)C/RA*3P@367
MOC*W!0.^W1#+'Y4U=/L1QQ/2F30)\O=VK%>I;\%U:D!=Q:99A'P^#N&F.*9S
MCK$WD7-_4GIP9/P F53R-N+)^/[KU)M^G^XTO/QH)?+,4?6^E./0V<3D<F/S
M1J^XRGS1%O,WF7;+^7IM#_,F\M.CY2[]]IC;3=4]K6-^MX]<*CX>5*PX4RKG
M8!X4E2)?-F6F-'+>3\0O.-FMWNSW$E-)YX@C]ND11\S.$<=9%1_6>2)P&TL6
M9@V(+A#!<^!Y[-R3^895A@C=*@S-YFD#']QVC(4</V(T0/OPZFDZT:;[TSOW
MSL&'=,<[8-VZ8D:+46%Z@=NAE=\+8N<U)]C#EUSRI[? ]J7;7:U)U6F]C'V%
M'4U4*MP?^BN]4 %\*?+]HXF4SL\FWU<%K5U\'*%?CSB8(DFLNX<,5^S,S+O"
M0P3\F?U!]_^E5OZQ[1&';%X::\ )RL)97ZL[XOBA.DS<MG_)YN)RMO0>-J-^
M;ECROW<B9=W'^FH "NM, 16ZF0D5UZ\!*$%WDJA:EC35G.]X=VJNV>&;CBMO
MN\M0N7;$28(1CJE#'>B.#(0U4]>*ROU@3R/:.Y4M+$V>U')/[>S,N_W]Q6?[
M%T,4VZV,]17;Z>)%'_]3'8^9"]_OA;F/A:3%"A]Q-'K'+<=VCO-_<>Y*(]>>
M1M4N0V--".Y2);%*(<,GK#IC5> Z]Y^ZI[H2S;'="F!OC6>@QH%8C!;F"[81
M0B*>87H?OL:HL\9 HFJUM2RY;VWPY"J6U+<N4=JQ3R'8,T $*7PA^< DZFJA
M5V#\]_Y7TGB>-,-<G+,EHLQ("A_YIQ!0[L^: FN0=>,PR_ JVN032Q!M )C1
M I=W25@QM!L028L@C\9H@X\!S226'.#SV@T8M61]FF9J^A>[;,)N?,PY7]<:
MYY#U0TU=I2+454TMU (9D<%*ZPWR'/J9V7,M3H2&'W%/+LI>^5DI^$AL512]
M]BA&/%,FT^[=T.4!]\LO$]-Q!K8?OU%H@F3]O7(%O?'LKR'UX&JO(X[YECM1
M<0XNU'U-E$M3]9UQO8-6M,?FK2L#1OQO7SXP]KN;O&*T:>]KDU=L7NI0K)RT
M%[%LVEW+B1D%G6*),WFH.B/-$63>F(+S8TPQ\M8HO^L<?.M7>$#2@Z9/KDB1
M'$QAR6<7/]UC=V9LG! YD469\]OTQY^B$VYX=SD?QF-44$DKV=M8AC;3A1:[
M1@M,ZSJ'-J2=3E1WK&7>,3 .)L^+[G<ZV5^,N9CF.$EIF[K8;#?O+T7Y3_T=
M67[B9"; $V@A9G1U6'%-Z$:38:IG2FEJ]?#H3E &3<<]H6+4:WA'16DH9RCG
M5WWK0>IQ5/A+2:$[EVX4")<)<!OH7'_TPWW=A+^8Q_7)$T1+_\QCPC-VM.IM
M<2K60 >D]:AQ),AI()MR.HUI7 *8=KOQCM5VW*1@^;>R@SYOZ*NGE;V;$<F>
M:;YROD+26F8N41I1HO07WY#!\_X9JWQS@HQYAH)#M5-_/CNK*TU6V#RRCI8Y
M@U,:>>2GF6R;43)NUG1G5=3$-J_XS"UUV[RY9$_1LE4EL\9BT9)Y_Y(7_NV2
MIW?.,?[#5#O,[N)##:WX]&OPPP"?;NES$W*=[3E.%_5CZ\H%@TH!)&G:QD)@
M<_'2S/<I[4,)BZ<=0_A6NW:C0,E?YX\X\L*8@N?H.T ^(Y(9-L5202VLC:'E
MRB*+;P-0ZJ9$6:X%%13%OVGFK_JCZ"*1)EUFO@04N_E.NT)LL/(+_B$14@J6
M;P].L#C;V5&L2_OS-@KY+77[H#D.[,,;%QZS0.QA<[)1U:S=F@6E%],K%-.D
M!S,>0Q3+@"_UB,?0X_;4F@0-NFN1\]9"^"\[YJO:W:6_.F3C3M[S[!7;.0-)
M;! 73E$J'[[_4K]"-[IL'^Y6+1$9W@AO(<XJ6<SV=]! 0QC9H"\M:?P_.NI+
MBE^X*[N.Z"9]K#O_F/YS:]\OX(C#H6SGXQ$'UCI8/^B-M;'0(0<&)G0HB.VN
M9R,1!BQ,W!YC/CGBP*<ORV'U]P]DV,:.'':QX_Y9"#."!N[_QA(RI3TU@% +
MX8!S$#F,UH Z6>TQS71:Q@JK$WA:N@1H+Y^H^5#O7/7NWO-OYO/C?Z^^C.*[
M#Q3R_4@> "\'R'WXD0>>;I DJ57$=9,/JSFEYQHJK,REYP5L4CC#K#'[L+=Q
M3V2_M5B H@>!=(6/FE.1L0+GDF-<C-W,,R/S=<04-'Q,A)0'AZMESEK4^Z2S
MEOYK>-/ 8?[ CNP?R_M##T]BNSN)W#J@V?7E]1U3]E"<!%HI.Y[=H&-%5/]?
M,=N-C]&^71H$(#*$=9$&2?V^-]T8D6^^V_.KKO D2CCRROIP^]0^$>1;MHA\
M?ESW(YP/NTP U0WTQG>$EB/A5)/1V:RM_L4;:;V_<IK3"/X1Y-0&2D2:(% :
MB"/2,+@J"X;:/#*GIO-J=:0Z(:+"K&I^LWDNRBSD( _Z(I?P&_??%3P"MH=^
MF, 2P_0LG2;Z?"/Z8*,73TKS--"XWC+O0N*S"ZZ/&? %TCM5S"<OII.)SU(+
M9EA74F<&"BY,LJ;*-_4'XK?5Y+-\G^\?P_[^'IQ-FQ%Y6 ;M%@+  J06 U=T
MNAJ%:UXDC[IFJ'W%X"_$] "T^U.WMVC.Z)_BMAA557O.5,-QF_12+P<P--NC
MQ4=FA)9G"@$7YWHHVGP,>N)V*A:>2W:],\2_RJ5C8'S'A#]%YU:>BET^(N)O
MW/L,N_FOV$HB-4BDIQJRLOONS]EF]#W FI)OT8_]2]5 S>?-$N+?W_[%W\05
M^K(GT,;+2_'TK)Z3;?7IO<V6[LN[(A);65</8IK_V0,>['S'-A9 ^L" +(19
M,D\W/^*H6^D%']0PO=RF&$K8;KCS,GS;<F7WL^>*PO;NZ1TQ:G/?O\",V:<:
M]2[E#]3O6SV&PK3A=E<__9,=E]'ZM.1?PV5 S;H-+38*3ZK8@&4]K]SD:GKQ
M9A8Q#G,^?(9=QH./@SVPL9AS5!:.'> [@"DM;47C&3M/"VR%A^V(15*PIP$(
MY5':>3C< HGTJ7%A<M)PB2&CVY'*!ZZ<BTBXJ%"ZU1+78_K;H4NG#6HOKF D
MJ;\26H0+N:=&A3A;1TQ)HA^O^CR_U]7Y[[KC@YX0+:X[07J;TOU=\(3J;5JC
MBDF*WY)C"76(3]Q^2Z7?&WTM-\C-HG=B1"9;_]^A!M5U7N?3KRB&U3E>4V^?
MXZ/??"-7_ASOL\8-QU98V2M-T+7L\Q7T[4:-CCBBTL"K,G0L/?"(@QN\]VLE
MA['.XGD\7HLVIOZB"P)IQ8Z[5*_JT?Y\97\3[MCQ\5\#,(7NG8B>:67/XUKT
M0Y5NEDS!TKTSGA-RRIK)&!1F"4YUK(TJ;#;MT9!"@>^RHS2"J445Z0<+?09T
MS3\=<?@REJ10\(%" 0.Q$@#2/Z>16#:^E^\1^%1:F :A8VK+/B.EQ5X,SO2'
M^U=WIB7H7!.7:/%JJ6MGAS<<4%]K6 ;/#O04-K#E#T..>>6PCBFP+'&#UY2*
M9EVCG<HOUO_F)I0Z!SXS!^!-:;JDPD38Z8300,Z^@*P<C?@+$R$60%5UXQ$'
MX5RGS=R6/?%'_7>QE0X>)[*#/P]_1@.6QR=W5>]C;$W8"Y,N9+;W[ZL"QZ#:
MW9Z(%3^OR4RE_BKWF#X/!$6R(EBO,CBY="%I!.4CD+*"YFKX7'5:>.!8:E&.
MD=I'+\B)I'?>0G67NST>3I!((KHVZOR9?MJE9B:/U]:3+/9_,L*, 0@[;OZ@
MHK]&[[DA;DF_(PX)L(<:U(HPZ9/(5SGKP@P=8ZF<*7+^!Z\4R+$1GM6I[Q]B
M:3BRZ;W =6>?FL:4.EWB=Y[Y\#!+9\-_(:3:@@Q)U4Y2:6#51!K=IH6F?,<%
MX!CTIL4+XUY8XXZT::+*$<=R,9QJATT&4>\>.G<?N!')*2+D/Q^4Q?GKS#S#
M"*#@MAU35?>FU:O>O"WL-92;QA'&W]"$F_WO-R!R)-_ZPM1BGQ8ON#ENM(4$
M;\*&Z14')ZA;+!Z!21Q@2]U]!R; MUVI>'H-#4H2"T$N<:.-:)!$[4[^;UN+
M$L^N1_+VS^B?CF<)HRT:&VE[Y[C"1 H4J3OTIW)]O[.^#X[>0=Q!]J53>24?
M]GN1OB"-+A;E>8^/H":T1O5\>/.\ %B+8M =)=.S$.Y7*PH6Q^*S>#_CDH-R
MUS(R'K*FU2;C3,")>H'7NM<ZKD&U*K*79;.IWWE51Y17@4IJKX5<1L'%T+<A
ML@;V<O#\*OT@![/!VDO59R.OLY&];#R@Z\_RM0QV.:>0DVGW"=%UC;I#?">E
M8/.IP)K>V$95V.[#HX+[U 2M^!$7QD-33"$-K=F#UH+9T_@+)J\$/[-GD1-X
M[8#X_3/Q%QE)#61Q\OWY\PGH8U_/ \7%J"V*56$QRK2GZ^S$OIH$N9:$Y;$(
M#2L&3.],?:_^3D#B\ZT8_HNM%->@*NV2&4)_\T3UKNW?$S+UX]KMSG]7QVWK
M]A0">LAE\+O2Z9GE0B8_G@SJ7J&$CL<EC/:,)A;P I%L)2/SJ?^UMB<[,?0H
M,30W_/'_K6!!;@Y8L,8CRMZR)B<Q'\=RYXO57XW^%=0).N-'=1"((Q)^+EX:
M\/CY8!IU9T:Q9_F'P>V6I&/YMCTC3U*U.&E=TS'Z&8+4@"JEF6+KP8",\LD*
ML3 ^ZA?@AZ0Q7.<@UBG#W??>0^O:IP/3O=YVQ1F41QL.; 4=OL6]O6FN(XDL
M-P_!\3A65#Z/^\$PCOS-",?,%/Z%1?ICR=.U5"C],F#/D'1":9C.["U$F *N
MNM&K3;3AZ=H(G*OC9O@ \V+A.8S(?-6!ZE6H<%,ALGZJ3'-IM'YSX5@"ZT3M
MMRJ\4$K_*O# P3-S^D,=P5,7KEJ;V..I3';Q&SF?3-/C)% S7<V#8NY_F\I)
M]E,TJ^BWAJ>OE+M3/U<V/GPY]R16FD>YX$JF.! >.A'MI2"N5QF")[T(L)NK
M.-.TO"K1UU=/:)0Z!Z.9-)>@D*1PAZ(:(*Y7/#\UI>A;FV7)S$%9+=XO3'-V
MXR @W^O!"Q?7Q<6%8:%.0H=F1X/E19-$IW^J2AT>VQG[/+Y767E.2TM2N3+Y
M1>^_'!POK$[K'+(QJ)L'O)Q^GGF&2H]AW,.,N4D><23-4SI5W9@*5*M:@0#
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M74,+Z!NRXH?.KGSHQ)*BZ:W27V/F35$GF;;L'+F*[;RB#P-I-F"&#E,,S\@
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M[$GM4!OG=3<H7:X)S['[<W>#KD%1Z"*FNDFB.#!W0"]@GSH5[<8:LT5Q86X
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MV1E')[)H8W6#E<%1JQZIOWX\'#K%^C"@Y'Z^!:[E8G=&AM?N=)-VK(JMN)F
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M&R82K.7L045W\(S#K;S@&<= SQ=K'8K@4\J"D.-=8:.GYK3+1C3S!ME3<=>
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MX2I3L_^LJ#1-?E)I<E7<]&:EJ%M.+<$ZJ43MOE*^5YZ[GX<_U2>V>VK /[!
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M;Y\#:Q7+G_TU4XC1_G0YI_U&8/S!3-NG@%D"3SI. -N] XHFXE"4C[?64RJ
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M%: G;$@X^X1K_C0<X^CE<EL\I*RQJ?'^)S6CX1KRY-K@MC/_W7,R\RYJ+D\
M$SOD3'29?;^$/+;3Q@B.$_< %MO]5=<,I29=4")(!/.M -9A"\;[MK;>/-9
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M<P2P-RL"V(FW)/XOR.8'A#<U IAAY4U"[.#.;-!JKBST3LC'0MM;2R&T_\8
MS83D<M'E/UG:U*/PB>AO&4+Z_GQILW: GXC^%G=N8)N.^;3Q+W<GLRH0]<5"
M 'MU0U,8/N!U5]%?= 2P@64U],P&(?;!MKHUWE0(AF+"BC83\#;D.7ZO0DZ&
M\!]6XART!;#22?Z5)RC>7W%A1M\_4>>C+WSFKQ=NTX:F='3!5KZ*L&QO89:Z
MVT=@8P0PZ''9?[+T;\?5N>*=OR/&^+Q%S/^*8\XLX/M<T.D,8!&]U1_+DW,0
MP*0)0A0F(O[CBFL_X:.P87^M.@M@&@B?5XR/'@)8_I@5X\4"?_TDUSZ%%RZ
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M3Y/67K#6_T#N'C->0<,A4:XW&-L[A/CH$[\T\02[W<4W!]^C)?"B4)C+Y +
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MX>8$1GZP/YESLU1^R%6&.M2_@KI<OJPINR5JC?<+90 N,^(]S/U6#E$L=*(
MAL#OPV:RY5?)8#;W[LX#VDWP=GO #Z,\2]"HE[5^YR@H(8RA25]F='N1EN--
MQ6&=9;Y"9DLFL)2@)RRX:!];8H_S6K%<;Y?%KL('$7R5[YVH-X%/?>8+(S >
M!G4#*VS&]__Y<H _Z:.90=? &0-J%!8Z34FTD[0G^%POZ8"5XIRA".X*4-\:
MM2>? S^(O<S?8.5WB3.G)KMNT7/9,V*J%IR.Z1L/MR;2"6^GB)HG'V5[7+'K
M+#&(O6;7?R+3K"G=_&RY3O6U*+*%QQ77@URW>?3T7\A 69>FI><I?G4V [F5
M?0.Y'6YI+)UKH<>+0MTB"A>%I7M]I/XMX<:=AK)9:&G^>,"A<5[@[WPQ* Y8
MX>\KJX.D!OGPI8"C+<,FI&E*+_(80,Q8%XW_G:[#.PV*]&.+%]]<R9CTAN:I
M9X"/[PP:R93T?$<&,)1V^O,B7TP36)[LY6L"A3R%G5+GNSSQ;6NAX'F#Z[UN
MK$SB8YP:@.D>4L)F=N*E@,2DJINQX%EF[S21V+Q^$#O4ON6 I72BX)L[\IWY
M>,UA-E@\F33-ZG*S*E-6CASUB)N.O"91WE:!V)><9NCAYEK)22]U=",:SWM_
MMC&BJ;R/TM.%*I96C'-&PC][=KGD,&XL#NP&QJ\N&ES4"2MQ%:+HHZHLFZ L
MVDL<^:(.'68S[Q+@GN)KMB[@UTRD*?9<#_I@4QN\8^M&^FUCTRWY/W!'0=$Y
M:(Q*W70+,2ACJX:Q6XE"/ML?/"'?H)'(#BNV0:UF6'*-(":;-'V.&P"=!%_T
MT!'#-!.VT O+6)0\"60]V!3/W+?L-K5<D)&.2+52UJB5K+22YM2$F\*5("/]
ML[>W_[8R9$MHB*?[7LPR'<>8(^M0-7$A]D55U8_+3E6A0IQBCOJX?\M.\2PH
M]:CWMNNVMD@1(YLA21@$9C-6L>IY5)6B\3--I6LYH9%-[VBJH2$;UAH?QE2*
M-,J^K,E^*]Z6P;_CF^Z4\[5X/P&]&3@3EC,<>[)'[< +:'W[6)B::N/X6C,\
M&=%()G635'G'\OW Z.G\9)-"!Z9,+5T5D,]4)YUI'&["\O3!U/:)^]-^?N_\
M0LWJ@4F>S/K+ %W(# CC5&1OF^'';=O134$9N%T <TZVK3>1#Q?&TQ2Z(93(
M@B.P98Y-(]^/<!5_MD[3+@LQ8\";$>)A>",HSTIB+H<V_L59.01Y=)PO2:>"
M9K;+53E7EB9JK(==B^7M3\Y7.><Z-6F>&DTC:U4-ZGB,<40U18GU\\'#165#
M^P=$+:*7J^MLJJNTM,_B7LN0]_9?.Y%6].N,CY-4;DYNJ%]KS!'24ISL-Q@#
MN#"DP#. YK<#*#V(!!+"Q#F>L4^>>V6R^?P7N#A/^D733J[52="2A4@P82CT
M@6Y^CZ',BB'.LR_K<F'/6\K8MU'QTY-K/U1!L4X M[%J">AE"<WT;)@ YK>"
M:/G:42S%['T<@"6P%<'8/PBAB!_Y?69H23<[@ T)76$A:+38+@U)>P";B;VI
M^E\J /EDGC)G1I,=0TJ)&0PZ=Q&O]A8;?['M23-CN+ZI0&?^U/*U O=<#\]B
ML?NYBCWEX0%Y:K7N!;&I"1'1LK;''A;[1+KF6N0L_T+YBZ5!N9512+%XG!/:
M<R%WR;W.\>F,C[U3HI>(W(=OFO(*KZ43\#V/&&(F#$AK?>UP/4YIDG]H%B<!
MW0?P*R])@"N&B&@<[.YY4(I3 ,E#Z7A9RMKW)V") 0;0N4!6)AQW"1IF2SAS
MK'OOE-,!9LIFW"Z;89PV@7T;C %2N[_N?AMPCHNG"F B"E ,*U,4.^ /YK<[
M3^MVX$\!\%[G)'3CY#W^7G_(E[683-?UA;8YZD1B#"K)=4E[#I6"-(!BV9EP
M;,M0M\6YBZ$ELE!BG=WNS_[>S*GI@(LS[7*YD;]T%&=1G&J+0RY<+_4I]K81
M]H!YK,A/Y8GQKXOR6AWE'+%ZJ1R91XKUDK&T14<=EUJR9ZY]2(=]38-K2JB]
M<:A#GIW]A32RR*F>:ZA2&:^%9A)/YAWKVYB5\Q4V8FJ42P'\4/N1>EC=N=[>
M.G17@!3D$O&0]R-([:I#=VQY=7X 7S>R"&FSQYZ >;EL+"^(51SJ[S!GQ5#(
M;N<C)KX4^[)5\/#6">/,5F[ 26&(3L2=!(*2<=<;<+K0$AN>0!#C:W]DBM!U
M\2-J:L#Z'0WAFV>=C:RJ^>@C\BFUQB>4(66<F19P:)2F70\5GAVF!;&'8+AC
M8&8\S:1RUM\WU((77HK-WD9HYEX5LT=Y9D?:]8Q2U#4-@_H4^AQ[/'2JQP)M
MBGRK F0K7Z<%B37-ZZ.:KCN:W\:6%Q=SC-GY*&.RO*Q61R'%U2343LLE5^=Q
MC99]T1C^ZR.&U2A?[,2< S-]5@HR>X@3VRFULJW ,KG)X/IJ&XN1;BI'VAW-
M3/!BRN&EEGSX5##(R0A;QB$2Z1IG*G"G6P!"^L,QDWUTQ5+0J6QN#>, 8<(Y
M<6>^I(:[85BM/!EY5FQ7&^%E2PM!$G\""GJ)5OP=J8[F#Q$4:1X5.(MXUM#:
MCR3QIAGG+I_W*+C>%]2] @&L:T;)/ZS]EGPR+6YN$JH#%EEUU!2>(FO-[>)(
M_=7NW+8/ [J]/5:?._MLI[;1&859B35F6.UGVF1BE[E;V+3-J5N?<Z3*/-I[
MC[?W^U73?!>YA/TC"SLCGMDIJ:DQ'[4&D7868U<4S3S%T-AA="%!0@";*Z?_
M"+U@98JL;*$Z4)D$L29".N('Y!%<)"3.8:0&[(4($:S,9)^@3L+^8+4CH&=^
M"(NQ!Q<\QD-?J@^6FSW61&\9X=V$=YZ&LS5RR6$6E$Z"2AA=32Y _>D$T+JV
M61;*/PC]C#,'2)R@-3@'+85_Q10CA*!3C\YY=3)$0NR FI<,&2N4&IE%.  U
MOJ2?A!9C:]Z%J9TN= "[O][E[^-I@H0U<3#  2$2UF+JR=>)8A6CNS?U* A1
M=1U)H[1GOY&U*GM&JAPWQA>XQ^=K[*/5%<?2)@Y;J- GW\M$J:AD1=26EV>G
MNF1G/T]@ESG-3OB-+9]MB(A/?;1#-6O\FOEF69?#G$9S2%VD/9"P)?*KVT)[
M"X3B G<>Q6!49I;PQE Q.8Q_" H#AEB,#E7#GR?I&M@!/X"4:"* [1-:S9+#
M]ZUL600QK.%+X5L!4"TIJ\46;ZZA>[8"BED/FHKQMTDI E@3O'UH[]1%G ?D
M7,,?14N;&$IC4_3W\WOY(JW M?O5T*[S(\8S'C1O]HPN-P'JK< JLZXV7ZI<
MEL)Z&NYVWCZ+W>A"6MP.,Y2!E&;YEB1YH;F><!#Q=/\XME!.3G8M5G*M+'6-
MOF210T$7X)HNV9N$>,0OUBBE3KW&#TT9!@>#[N/VC^<KQ^7*/,M_G=\[GG/8
MU;A.>2S7SJW**2RKJ'2]<F/;]N^X6&O</A8*TL)THN[ACT+*+$P"0@QIR?,9
MXUOQ%(')WK4]:#%LU$L?TP=S0L:<7K^G"514U>-^'J<?X=D!IB36]KIHV'4R
M*=GJ=&!$+9;HFA63^G(Z*.V:_N9>/1["7\@5?V"SV9@>TENT V0XQTA3DX2.
M@N^X?T*9<U-(/:BU@R1> 45LG^&9 ZAV:L;DAMU<:B%:#MO)1L5';Y-4H),=
M?!V@;3V==A1([0HP!P:KQFD:5F=8+FP3(O8WZ)M]1*ZL[=1HG2=^.B(^I<SA
MH*?+]1=5:YHJ!D>G.K,+ OIKFRCVM:RT#3T5=[]0"]JFMEMF0UIY88UKNHFZ
MKE:D-5OKV4#!L,>AYF+[B/R58MEOC4 O7TPTD+W^(T\N_B<H#/3EID,#X)4.
MY@%<G "VU[8=0V1*XN5G@QEPG 0H[0,1HC@$F2G<U1UR.71[KEC)\4;_0*>/
M8_I0+TD*F]^]U3K=[ C_Z6Z_1) 3,%Z%FJM B#6G.B=F">G39-L6=VV<KL^3
M 8F]Q?!.M"1/<2[.T.^-E3*PTC5!EX 2*=![(9+R@5%[@)I"4V:G$@$^N92Y
M_&PL9B!HV,HDJG[%S"<P<>NFTVFG"ULOKIVLVF>F=<9VZGF_*ZDI1]U>XM)*
MOW2=4FA$F4</_S6N[NHI,X6A=[KVQ[/L[!TWJAUMK%+LRR=;RLE*UZX9D$UT
MHWH$L+(<KX7OIGJ.@A*S0C^\"+VPA72W[3/W0@-SFEV9T[ISE.1FQ(^0K@.1
M^P?@W.%_\MPX+HK,,QK&\(^UL^M.=N=Y3N^D/9=\  9U"IVEGE7$KP36(4"#
MRD:+SX0\GQ? "!P2I.6UNCEWZL@8)A L892^QP_.BNU0ZF+6]T*WF%VFL;.2
MT!/.S"X6J1V^+X0K5_ 8W%,*2G,RTTVFHM%)2NIYJ<C,&K]@I:UE_I$W!=-]
M,?MN>EZF*&'V>;]VO>YB9[=1==MLSZ.9:IVJX>B9BAJ;:+^X6LV](Z^.NZ86
M=(U^L+/K:Y7M9U>4U^>REYI=[ *0_2XUA""MOIT^:_QM+)$O=A+@L#[%@WG;
M',WVS&GYN<E4NF@P2=SJ$IN:2-<#%CLQLM"&'R#: U?M!-YU($\#^TFB2!V>
M"X!*;S(!D\>^Q%UQ&+8*0:5]&1B4Y _R=/5W9N-#:KG(@SLM39G2@Z!OIT_F
MZL:V ]:0+8!UM,%9L2G*<V;W<-K ^@6HC#,DS@N9V$2)\4Q VSL((8'R@H!/
MA/VAL_IO-M<EL92N #WH#DM?GJ7Z^D[]L@"FA*&K8GW/,R;G\O.NE(FZO,&E
MN&1:%&ONBZJ6-$K(>1_JUJ(K.6-_S9U=,Q*9M9@^W<M2R?$(?#5&TDVT5N];
MNUEVZFG5V=A2;YTHEZ)BG903N*S6=S)>'X:Z,9"V<ZIQVU'6*D.,<!65>BLS
MW8T[#)!6R\!>EE=ZYLL!C"I6W'7"2K\,FCXM[_2\>8=L3"5^G=4 OR;B/%AM
M0:S\U.A,5>P+UO.7!8.,]$U#.-KWW72?@YV0)>Y@6UF3O=1WEG;"B#G$26H&
M8EF:/8@I4F<8&PZ'?.=XLZH[?]$,P4)NW$Y)3&HJYIY2.B73F""#^VD*1+$1
M*<U4F3Z@@,GY1)VK.R+>=L[5PO;N)YSDUM#/D;_@'GXH=7C@&G/%^=U(C([U
MY>MO+U;:G,R=]ZS022V-59A,RW^2:^=4%)0Z>#W4WFI<?^VHDQO71.:PYMF6
MP\_Z73S=66<?U?TV;V.W?;'C1%'IUJ(U#A.W?1VG\;@!O)C]$Q2OF8+3WO;"
MQG+-\UD??-!)Q/3FS!2ZWKB54#;V<BEE4X/LM]&7YOP=7N(UFZ!>^623]*CS
M+S)9X1EU-4/EUM2+)(D^KO7-S>N;E5K/F^8='>FVN@9A-E+7+%;DE?X,=9C)
MPJ_<N+%*\<GUW3;OP;4LS$_F?;(?:J+NTY1?UPW-'>_79:7'<E#=:"G^)$..
M?I!W?)QV4IZ("J).6=I B6Q]^6[IZ>!9!="YUS"#K@ZV43LD-'OQV@)80E17
M@ 'P-9YWE,6XRU<?WPRW?3GQNR>SEQ0R7D<[%U,><LL8<9)GN%/%"![*5!)=
MNS]'):*5OY]:GA;),X3$2[$4EN9:R+865N.S86*!;2_F0/#L:3HA?OH3D4-*
M031I)O (== 5_L&AO5!^ESX+K7B>BSP EA1>8NMK=J@=FL2AHF<>]S^1CJ]<
M=KF;:*4?6O2YLBW7ZK>EGK1J$WN73.,PU^JR5XL6'H;V)IIBCXG&C6(G"NXF
M>C]S/NBDD@*?=I90M'AR-T:&'.)6Y3B0GR=[:*>VJN="C@"&_D@=(J2B6YP8
M9 &LW7B=< V3>,LVJ1R4J]DVA4YR2 E-</EWH19#276&O$ 6$Q[V))A_J/%-
M,Q.^G/_GDF.=W96XL$#J4O[EA6&VV?7GIVIW?+EYT.#V<5X X'P7];NA+$X*
M)':LI_!%H$8AM?%"H#/ *%NT?0&*8:/N!.P;Y^M@OPH94 JO"KU@]_8RU@CB
MH0QQ8__;W4JBF3@SS@S*]?$$3;<2ZW4!BHW;TTB!"OHOY5VF*#:5KEWRDK>^
MM&Z(<<4J12^SQXT?+;7:Y)X?[!Y+JU97MS<Y]LQ6+VYOOWPD-Y)"K%Q11P3N
M92_J8(-,/U2TU<ZQ"Q+*)%3MSAHL?NR6_3;! %P9"3Z:B5:!''@J2AQOB=L[
MPCN]?3J4T6R8$$[7"D9(+DP@#7'R;Y!=]$.@:.>@)HO1)8 EQ^8I,8GD29JL
MY(LY3,I!GBG8\^>L%3"6SU>[.XV0&F)]HG:C6E7P>T>0$GULZE0L-V^4%@X*
M8&RU%T+Z-.MH.R& !<&5L /=MY+N 8MN4#$B.=\;$%V39S,2IVWC8\)%?YZX
MW +N>08J.Q)ML^W;)JS0\"0<0@HJGI_'?AB)UH\UD5MV<:E:77K>[&]^V\GG
M29FCN5>NF=:;1@\_]8=\1D+S3GV_@4,6F35DXE10=-/\X?(@V?ZD2Z[O;$'6
MV'9%"@^ 0H0)[A 4#NKZ 6HEI-V,$/AN[.T>II*5[;;Q#+3=2Y< -.ZSG'?C
M1Y RF3VB_I ^^T7X2?:U5HYN6T#_1KM/7A+^"*3<$6 ,R6JFU(=;'2+)*7?+
M;4W<+_\=PO#%#@*C7;/JP,\W!#!QI+EP-U&^)N[7YY $,,K-'^.AYK3X^[$K
M[&@W;+SCDY'H..0HVW&]YYV$:)?:,:#E!<M00NA)NQA[OB"(!<SD\-J'3T#W
M/"4!C&@BX2^, ^U]#A+&+'GMVV]F+%+OFUC:-W(]_(*MGX^DFSL=CW!,B-JO
MDN,7UEUEJ:_9^FF'^PRC%#8]ZE1;YV@?D5J0?7Y[.H4'0I>$/3@,!8(H;^CB
MGSC%G4<\>6";@^HB2/-4H%B0TAL !TP? $-^$)7E"?X2BQ?MR09U_:$[0:95
MJ'@K85X>DO.'Q!#$6WP*9; \A'ZBT#/#5XNW,8=8:P;EAKAFD!M(8(MV8#*$
M+IB2OIDISKL,,C)C,/%T..12YO,1?Q"* *6["XR?UU.KL)P>QFZ^4K&3_I%>
MQX81')RE[^L)I;.U5M=-XE#M6[G%>4]JSCAK]=H81967JOOD2MJ-)?RVZ'&9
MV<5LR&S,DVRVJ":?=Y(U_Y7]#M?0J'>L/"?4G&)/#L!VA&NY80,!\AK"HMNU
MV&RO_4FB\;,L>P&LVMCK0Z(PMYGVC')K0&?BEQV';F'V4^$Y[/R%ND)*%L :
M)ML11+P<D$.21AZ%.CD5;>"&ZV0S9G^FE!]DBOU=M),IBL5TJYT<%\*!^1,4
M!TQVS"J-T<[5AY8H)&Y:%J[[C*$PZ:(OA\ ?#:4@7S:B6]6'R>70=E+YJMAS
M+%3'COA94'8RXQI?,@0A:V52&C"#I7(JZAY"\4XT+\8H%6D8ND7L<)8(R?>I
MB\>VOIP5!3")/&M0;8&2S6%IM0]?<RVSIUU^EGV]1LPM9*/'JI[4?*%*.W+4
MX[#GP:(9<V];HPX[<YV\M%!WLG;P2*ZYDYF3@=][7M&;M)L5+"U[EY0BS):N
M-1:]*H"!ZT)R:D(D\&S9$M^?:$"WJ5@$6SZ5+\L["T6!1X8Z\^@F@&8&3_ZF
MS*V,U%KG.:HTQ'FYU621=#^N%**<FZ I<YQE@BU(1-RY<K_>:O4-]-($TAM,
MY<#3] 2P,.<I,VXT8/.\0)6184Q-1RGA]1TEDC)O5Z%YQR';4NSM3@NOQ/#Y
M2>,U&PD+9C=:&JD%(=<OC!DG/P2EEI#2XWI?UFSM,[;8GYY=2:C3V3R^IA.C
M[4;UI%A^=3_^)2@@W%[,WMY]B1&D-6NB4CJ@4?Z ]L0X5\'+\76QW3!%5+8F
M]];CLMT< R\YBG$%.>3LR()==]GJ+=W/G)>DEL4NPS1FRSSU)7/W$E)A1"AJ
MAK(\[9U'SG?H^F<"*_UYYT%J%V%JO0>USTJ:XZR&A5]@T&F #&-?N)4#Z. )
MH)*8;L"UM@@V6@YW'$3<6]L49^P*G55S]%HR?(OAR*?PS?FOA)X^!!3COG.!
M'I3-0.LL=+>^S4C'Z'FB)_0 <!!Z%SX<N]YU\.,-R_!H+2L7-GK7,E*S8?AA
MAI;Q&LJ[J;7UGG[>01^VT7LGN90Z[[/:.P& Z[5R?,,3OY0(^^$<]7BJV..<
MG*6QE(1'Q6O%^V\@#GJ,E,]K% >^X@0[O(WS[^MNO6GCTNV::WZ,<\I,JZ66
M.='DM1"[>G_[.G: P^RE)N-W@_E$VM%'O.-@RQV.\SW4D]X48V7'JP,7A;FC
M5>C$" JX_5!A%=3@'Q9 ;V&,?1B/%C(30HIVU/1.V<?K0\ ZNR7%Y+2IY9I!
MV#L!["2D*62:O2 C7@"[XCP%YX@*,T4"09E_*HRD$FU(5))[ IYD!5)668%A
M53@7*)?S(G,W%-OQ&&<AU"">+OCZ"5N\:G;(D]8(!0&M719.A:P<!B@RWF5Z
M2S.9Y##M;6HA76RFA)^0/3[61FI.\%M,(2=7*8SFO _I=Y^5:U9Z[+:8CGWN
MDC:O^'E194A<JP<W+FM^MLV)$*11)B:K=:8_(B6'HUAKK=,T/]#_L<\]ITQ>
MF4\?1F>C]S PI(-+Z -\(\B,8W@';P25=7@R6A?O"6"!0E+'A0_3$,"D,^0(
M?!+FU/A.I QD!BQV15)2<(:@M'_^!5#CR:521AH-!:SW/O<LK(:H9T=Y@1Q=
M\=:G1*>M/4/<KU!0'"@VU&DJ@,'Q!F:=J@Z<YJ'5/C)^I-<9PB)%0QFJM9\,
MC<UYNRXI0%EXHU=EO5LWRH!ZA))9^Q<H*A:4>^TH.=HC/3T05N5G[4=1M7?-
M;/"0^94RY!1Q/2LB;>S(N]28HM_*'W.YGS/;E"(3RY=+KB14*?2Y7X\D:1[C
MJ!M_X@P>R[;/'2\.VY8UC!FT7XH3)IY@2)<O)D^9Q3K/J5)XNLZI)%6Z-O[-
M].2:\Y4Y!!RG"H7/(8AA<:*K[>#5Q9>S!JF^31!YVRXT0!(PNOBQ<7HVA'\8
M1/48#],P&O<J'</D$ZS0["%1G-:S9>3WS]1L\0=YH1/\@^^6&/OYEI!T.UKE
M"UK1'W<2:@1MV_FR .$/$Z8LSQ0H@QALK\["9'1O_BQR&.<X%V[F"$:;\0]-
MT"0N">$0&_ #F%#R W2/O6,ZX#1FXF%5@Q!Q=89KBCDUY&2GC"2L=)3G'.-X
MOG_KYZ4_1U9/ZCI54>GY(>+5\<CK*;4YU3JX)R%MH3UI#XL>D<7?'20N-$VG
M4JU-V^J0F#>ANAOK'23 )3.1KDZTF:#R97$Q@-<?_$,\,X@"A@G3+T'A(UJR
MEG=BVQJ29IDFEQA,F!"2? (R090ON$Z<!S7_J&B%XN?\3W*"[O(/AN*U@-\;
M0EM:[O==JIY^:SMGF$%2$\!"25+X5X0#^/TX2Z@*T.2&C2V B&[XO8 34&<9
M3R[>19B#V)R7>7G"\(R391F*AM#-H7CP:$=9SZP66$Q)=TXV:=O%6J!0/B+V
MQX2%I9+CNP-4&D&CFU<-"HIJ>A2P9T]>(]_Z,TV%)3;"/1$1&475?E-SQO5N
M#B= BNQR]@))]^*JU3,/;:>F12UUL0LY%67FK@$C=I65KFEA;M7+=I7/73T.
M?2"K8=ZDZ,X/385QR4)Z##,4\>5= +PZT"G";.[&5C7J]1-:JJ.]7]&B^>>@
MFE)T0.B->S58MY\!^>XA!';C3,9,]$<AEM=3U.#0S7J?BK*0,(,<$X<XM/,(
M_Q2TLXU?^8H\#*$?XD0!=/<[N,A[/I/T(R%P78H_G,XB)$[WMA.49_K H+-
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MXV54)1BQS%5<?RI1E@+M=BX&K>C)1^3"[K5+4" [.&*PA0Y9]#W] [M<1SX
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MV-TOYD0O2?G$2M!Y*_)-=;U6IN#]G4ZGHO*Z+>])CYKT.]>PCHV,.]7?]T-
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M?B*=DT_2PD-QF=UU^F;WV1IOW_<KA8_O^M[*T/.P/'Q1(?@4(\?ET[-G]/K
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M\WF1Z=A(SQ_A_TSA?(#I+2IG)%'84+[*#^SC[H>*..%ZK E?=Q"1AS83G=W
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M]_QDDF!$L^=+VZ'$RE_I$RWR,P4QKJX'*ZJC!P_3Z2,+Y>[4OS#*4EB+@ ]
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M@@#F2M"F4&87(9NR[2CZ1_*0@V+LR=:DF[(RN3VQ%(TA]VTR>KZ"\E)HB&=
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MU%<Q:Q'27^$N 6+&D&-\$BY(!KGB!&A+:57VG'0.0G##"7/7GI5@X * OF,
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M,/=:;]182,,%ZNHQ-,W85MW[*]:4W6?BJI8F7H1T.5QM8V:UFRH$>G(J5XZ
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MGDJ$]J*YH63%,EOB2=_IA0F,]F!R"3%%3\"D87J+Y#2?Y7%YCR.DZ"5R?!%
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M@Y(_SW*7)8^"QP9O# J.#1VY#UE.*>M=&,^JVFE/K ]3?^?C&.(1>*8YRV#
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M*^%'.;8V !']6B*]['OSZ972&LR V*_2'YFE PXURS:E-:>SD;/4O,JN\;Q
M\5*8Q;X//??!%'H%. "!JOV(Q<-'Q)QB6)C5OI>7:7^^9NH -X^)V^2JKMO6
M4,4.R#U1U&8OS!'5V:+/EUYB+BTSUN?4S3L102P0B,?]N%4\N& [:;Q.%2[L
MX3/S$AIO0'A&)-3_H0$XP8FN&PV7^W:/;J6+9CQK=005'GR<N6&@]&3@41W_
MIH8[\L&M/NPJ_]/#F"J"HEGE3%/7\-/0F@US'F/;G[7Z&,.?P<V9N\?E-6YJ
MXHWV'FIE>256=09V[H%S<]S#%V];!U<^CW$4O>N0D'!4LZ(P*,P^S\S",Z I
M.,<TPM7!HF SK7RV<5RH,#*R=&8APRE))TXQ^F^=3<[(E_ \DD-H#^0L#> %
M8C7 *B2U *_*PQ5\L7E:O9GM#)%P!]7HII$5D/&LW\ISF\J#C&&\1#W+7":4
MJZ[6W1/YO#%E:WK4U5E:$TKY&[0>#ZEGV%>M6R8FKU^,)HCJS4(UC+%0;CL#
MG$*,!54B+D2WA^!.<,6CN@M=OI72Q9FG?5=O_[N51_MOY8L2-* 9=IDP'XNW
MOT;[E.E$T$.,U>+3$53OXQ5F&;E%OI&U^3.?\?DM/C2OQ8;@19=4W,YTOH.:
MY6/)2RY*U08L$1$$/W/YFH]>OH.RAE*FA0\L=;GWS#-$O)&,&-NJ?"&';:9W
MGMIW'W6I(!7\?]9!9V0.>6$&CSO;IE$*G+! \(SL@?;!9N1Q2YFUO;454#:^
M(\<FOF([;";VN0CNJ5YR%G#B5YV?'"I/Y.?XQ).F6;^E:A;M=TJD/8\]J_W#
M_ <]W.-;-ZP%REXEL3T+E#5^<[YRZ!NZ'TT44=C7(GC@6@XX")F#&30 #XJ5
MGSKS.K2R!&Z=2W[<F3](TIGUDO,"ZGZ5.V*Y385>WLF .+:T3,O^CJ^&O903
M29J[<'6 :>CPYS^SK/,D21ZN1'FGA"4 [Q--\<E]:BT1G:Q!'V"DIU-DGU(W
M?HQ]V8>^@;^UCY$'*AX[3DUS#F$L%H9Y(CF&'4U_J^N7N67 G'3E1\I3?0)Y
M'1O=6Y>C\MVB1N^(RHS@>370'*F]:/;G>%B[H,=[BZ'G#;E_9D9>);#82ES)
M#TR?CO*,&WKQ/ALI550YP;\-<HON&V12MA6\I9B[>6?&/<&))RHLP=VD:=?P
MD5'N6F."N_@!<'%.6!,O4>V7H09)A(M70O08#=19V;Z?9!IQI5N6=G5]2[UY
M^7M)Q!WG)T'/6+5#*BS=,J;LW2V:LT-R_VIJH;=OC(U.5<W^BWSL1BQ VUG\
M/:!J%'8^>1"T&$V])$"O7A+E[U )2[(54;R(;#G9"7$\UK9"(6,Y8$F#L!J4
M@*$)KP1]LV+C=+SV/[@9ELPU?'Y3K)_8@=!"N+,NJF,1![[K),09LE4GH0AF
MKP[B=#O)AD20'YV>YQ](CF\22+[BWHSIA[SHC/KC./W#V5/%/%9>:6E0U3Q5
M][KGY,!B8-2"YHW2B'4O:=P^#1!NIR%:FT]0N+B9J]C/5BFU)G3)>\MN4-#P
M;9JK$;[W"X'_='@SSRQR*^T:_M?@H_ ,Z2CA#)&?*&FZ1BV9(MK4:MSCDSD4
MWX?(C^0$_K"&)I)Y:CX37*D*^.YJ67NKE'NJD"EH28+AM3B1'8] &<F<&VQ#
MK2P_K\9G7#,;T^JG\D\I.$S[0ZY^?^U<[ ,5W^R**JRVM+*?<+N:-N+/4CO6
M;SH"O1KF*[8C\#",S^ F6S?H.LAI@GB-!M@_1Q*&C3PAG/2P,.#*DG$ACX38
M5X/'H#CG0AROB1"#72.!I4C;L<)2N> 0NN\Y,&)PN>Z9N4U R[M.S!$B<0VO
M5[#(<QQ&*>TT)EF2M<!Q@1 >N,VZ+W[#N+6>&.F7S]^(A^?S@YG!):[V C-*
M!X^&[B?M]MCO;OY&-^K+U_H&5W)SK*[PA=AN2.%?)7,X$VVCDUI)-[%,@O<L
MN-YM6Y5'6\F;%3C;/JDT\6N #UWK)<;F/&NHR3<KM0)K%!=LO:^8+F5^D62V
M5,RYZWPE\:Y9GX-#C'^:^W24?.FC)X6!K_^NEA6_:U1:,ROYB*T#T3D-F<H!
M7G55R\_/;LZIW>&/2A<K.S^S[R\CTW5OB_W2XQM!YZ=LE(J>B]R*98Z]E)"X
M;/Z(2/I46R$D#O? 2LR:XVQTIGGZ7]^=X=X]B_-P=%9@^=P:,70M@P.8Q9?8
M5[&P0,S!\I Y%(XA1"&2+%THU1_VY0"%Z5\N^;%R[N4K3B:L*G=W$9RBT#BA
M!X<F,UX;A,O'FZ6F]PX^-<=M3?DWF0HL[;>&\6T0E["29($>>J[O$L4)1B,;
MNF_]#A._$+C'#Y^@H5=AX;C50EP6\E#9)4C9H$O?_T"::+\*&1-+7;'_'+HD
M.Z5_O75%MF..1PH?X*_QX'1;D'# %.3>CV3.8[W28/T+MZ.[M_84[C:&$^+%
M:[A7!06V)!E3.]44>.*>I)N%E\M:26>%61K9JG"U_:2\)K;'.E"O0*L1#: :
MS)'<@69MJ"4-H+A)^9*_M3K'T]:6+Q ,FU'*Y!C^NX\_!>"2H?/43.P-\\WS
M?S.(6=QRW#@\Z^Z+:L[9@#"Z\]P0&#T^UA2=_+&M5RS=\&CR?I!8/+]B54<Z
M4VD:.R/?.E4%SHA'#"'/6Q+/#5HGQS51+@Y931TAB:7^Z'V;CD6_]_*>Z_4S
MWU1: DZC4F^OJ*_LS)LWW%>:M!F+2%F5@ R#WB+P4!"9(_K8ET 9ZE^+$N8G
MMI01FT,X++^:_S(A5E;M-G^TVDNQT0\6LPX92U[ ^!P_M=3N-UW2J?O3$L#6
M% IFWEP5?/[32+K?)YF3X*7;?^?Q!>E<GG0\#4"O<>UTE[;4*.7Y7H(P-&GC
MBE _?O4*UXU-0FGBR,\D\6H3WAK;S;!R62%IV A2XX7[5\O7G-*3:9C^F>J8
M/+ZI2*R;<;G@/2=KP[NKBI7:DKQUSB7+" ]E(!LQ6#=CD 5B-]G4=J3S8OKZ
MC+^! )\_CRGOB_JD+5C^0=K(5:<6]JLODD6W;<L*<. KNW.9%J?FZ*+= )7;
MG3PM[:'5CD%N+AKN=?@5VR6PF,K/HG;%(9GBJO:4#S<E?VT?__-.KV7H" 3%
M,)0<"6H*'% @6K4 V;N9B>83O4#6;Y/D(!]';*VD 2K[-+!5DZM]^HB%Z\CF
M5^A.I;L/IL\WB L5IM>WKS*HOM:()+,?'IM0,JB,<'/B&7R.'@&5_$;S-ERK
M@UBZH3P'=PJJ\5#8D!D1X@&GD QGG)ICY>1,6!B,?O[^(N>E]/.+5,:JY:;K
MKL]=1+0W-@:'SS4>L$RZ&11@86XE[L4ZXKUXV??18K.'[MT>1 T;;E]'>;V!
MG))DD/3)&;@@/*\T6K^89 -1&,;_\0+>'LW.EYO;3&=B9IU0/N 6\4**1 C=
M#5:HKOAE5%S)V(?!7$V0*#<>?Q*]/*]Y#Z^<1W*S"%7"Y]55- R=<VO1%)E<
M1UMM77*(K-GLM'DK6Z0WZO.^K]5/NOS5=KGBIVNJ$JZ1'^/'52\^O'HIX/#7
MX]+.>NZ)@M&5%NA8KB\D,@"(]T*2.?+[-IC@KTD\0YY:N!1BT<8@*\X3NL%=
M7C>BV>8WS2?9BIK]W3%BA=/;\@AV%8\L;FK1$T5=I>2? ^Y-)'4S$DV'Z!0Q
MT1-B84(PRL%JE;KRJR[!U6N;DW$*'XD!'HRU(FHEW*,)F8Y&<4M/(VOYYZCC
M'M56'WZZO. 9S J,YKVLHPONH\K@QL7[GM^NN6<OTD^PN+C9*6HJ.UZJ*FC.
M+-V[F>LPL*<\(M4CG:8H:R0I,V#QRF\[X\DW,VE9)4*JF;UT))/<4_<$U^>2
M,::ET  S<0U-X.)81_FE01^;RL;V!@(RW%^F(Q%D1(!&00\/1%KS=X='[*?J
MZ@X*F^ZT9^,PS&T243*. _TI(B62% ?KC@IB<A_F'JIT"XET;3?+(]?W./I7
M[&:HJ,RG#I<614T%9^'B<%:<W$EW[%9FV#^\S2;;$Q'T"B/1];Y&-R_9LYOR
MH?-Z*=Q].E1L-[L\_LC3Y!B4P/^-W[S<=^.]_QVR]L7"8BMKC)7=3N8K]WD>
MR"*'J)NG#Q>RP$WCZA^6WT,'"O^\\T')0'A<)VD@!PZ)5O-NI)N#X5BGYO"-
MO5H>PY;.V*:Y>+/YWY;[DI/**^;B4^M1 DNURB_B,#8=L-X^7Q&+VJP7U"LF
M.(U4EC2?-: CS(+M'9BC_VZS W;0(-,E",*NRYB0>SL!*=9'C,UZ]@M>5*>6
M?^[*KU$=__3G%=CZ.S608R'W]VJPQR\>E#W[/I/^6)Y;>=:,_RDVH5+-M'B,
M<]>HNO?!TUVIMI%%:7^194>@>UIN\>EUQYKOI[FJ%OQ>U66[W,>F8Q[!]Q*/
M:I=5,LV_-X ]_>4Z&\0[\3K??VG)B+T3K5:K>&:D3 ,D:["4VHJ756Z F-Q:
M3+19^@/FJ2*3^S^$F=-9H;>U?(($$[EZKW[]7&5B=OW=^ZL>..3B/)6QG*1(
M'3FF 9I""OIXNT5R%##E%BT$AH$<5C:ZO)SUVTM\Q3E7G&F.GRNX',!MSXM&
M&WJ]F)6<OJ95,>!8TA,@WC)=BP5RPO:H+/-T@O$EZQ/K)0<G^!;(?O.:(IJH
M$H]Z]Q,TK__=@Y<_FGA0(=Q30_H%!ID&J"DE5$-SU)!.W(Q;QAQ!KM-\A/6+
MCG8J43T&)SC/TI\;.-3FPOSDLW=K;H[*,/SN%]^7>S=QUN\UNLL4I$9OVX)C
MLNPY9+[@%T[;RKB3@K34QGPL:U18&1*#A(7+U.I8SYM5OJ</J8+RW/XK%OQ-
MNX[2IN5,TJ;&E4SO>I^F/TH)B\A3-6)+*)4BZ4M5&ISH",0'QYALK<)<6MYI
M?-Z.>IK!QU&0)Z[SXL4Z>;C?.ZB&&<$/4_OUU.[*]$ ^?_M<7AZ';LN\7]N1
M+@SK$<OF1ZS+/LA6]PM:>2A6(S7U\5)I-*,''MR; ;D 6=?.*,;% QD*&.UA
MM^6,^JS5 N,]E3H6RF-_O$0M,7LXNE0]:&RTL5_"##[WUV%KOG(X?!>TO@8E
M2I:@@2]I +>H::IJ'R%@8L :G*"#+H>_F&_2*Y]MBO&4,Y9H^EKK-V"H21T<
M\SNP'IXS<$7),,>/V"1.KHP#^]<[T7W+(2]Q&H@!0=,^):EO"[N+7/8\Z^2.
M^*J-UK!<_(C\)^<T16%YK-1FFY$$QX !5[:#QQ:L1JS")%*CFK-ZV,^O?X+G
M GBW2<K<J\3,S(9-0RU2,C1H.DW*PK>B)LUM^&9"W5*EL T(8W#(!D,\GD8T
M^\OYZDXWA0P78%HP>>EE.5W+10I+=9))\[ZM4M5;F[E<@+^U]<L]LN7K3HS=
MU+HSJ_2=OC%__GWP8.KH@&68SS-RRL90QH92).YV[=>#H(K2C>4/V>0_E!+T
M.GV0:C@\L,%K80/W3PB^5&[/^3YHA+UT*R$STN_P"NST5U\@C]KRE+W!^7PQ
MM9"4!5C4$CCE-$AISTX7G"%C=4N*Y<:[-8-C?WJ>.H6.HAL9!H'Q"$%-/H7^
MMQN0).'STU0ALDZT'6&3<AB%RF-^9'=;2&4+=,72QLW:/Z/#P:UTR-&ISD8G
M.[(T;ZN<I>ECXH-O[7V;5.!(E%/\@(\NQR3NL,J%ZWK*5^SE[NZ'A"9%P:0,
MW8A\A*9LWP8W\/9P-4%8]=;@D$C:SYH NS2GWS>M2@7G>=YO:N4K+$D-1C)$
M;Y7E6<1D5P]CS6932H\"N;'&Q@FB!R:Y+B9>3[P3)$\N%F\D7W ]..M.O8GO
MSCBYI33WI8(8KE_O$6/B)K?JRKWU0U16W^?R1Z5W4=K9-T3$U&XGOP$Y)O-X
MY(M3BD#N1 6R;G#=#O?K[ECYA)1="1K J"7,$SK@(YOM9B76;"G1'+8@LP24
MU]N("1L^@\S4O$/GXLXUO-$:1G)H"*<[8 ?:B.K"W=FO:1J[YTCLJ[%VXY?/
M*N],M7'#J"0+Y\_QAV1BRMO0;6&\S:N[JIGMD8<8!:A7><X1SSK#?@\^\]AC
MTGF2RN]F03 (="S?R8YJJ5F3HZ(J=DYU"RCI="G;U968JE7.G!.)^OGRNG=*
MP^>?@([@QGU0]%T$LS>YU33N3HLZ+G?^?/E@EK-OSQ\HZXNVBVHI?4]+PSXK
MYDKRNBQT2_3,5%OP,+4N!X#[TJ_A8=;UGYZ>SA2'9X/YU(Y"NO@Y*QZ8]STM
MC\ES3W_V([=J*D,XS75X6"7!W=S^=^;M3=LU6;K/#JA$F[_H6>(6.F\]&%VU
M:RU1ZX#O=MM'V0E3]Q[/U)3RS_W=[5E*2?MH9V. RH)_=M;%C*H^>P<9GR=S
M%!]W$"M)M^AFU-!>2 #Y"2&C"P>.X;?H73M#AA)%3C,:J]RILAV3"%<#@P+
MDBW&;A>3N#F37 [+-(K#]6+F(*G[F>PUH2^C;E'D$3W@[JMP;>(?TGGJ-(B!
MRDY\11^RM EK?8N_(4RP5P('JH:9YC-+3Z>]N&<54,$=+"H+[S^DDT<Z6D4$
MO"%BYX@L!#"548!D NO L9+9Y[;_PML=14=T2N(;L<GAB)<JFJ+X?OT/Z%XD
MUQ".!F!ULU[)?=U]R&[9(U%:M["D$DVIJC<$O?]N'!%^.O%].P\&AO3 I]]V
M:H\336\$#<6A6O-+?L&-K'25"]^L)PEAZZ0*'^7T&]UIOR,OD03.Q2>Q&\<7
M)XTINCZKT&F^09+\YIQ&B!<2U.'.<_OY;!:X4MEZ][GT;-&QD?S3-JR]G>,E
M7W4Y\!CTS>O,P;4HT,=H,G?PIU E8N7&"G0(PD VQ6_WO()%0?E@^39++(X/
M"0?CB34312O+[HWV;C<"?3Q!64*Y!"^=2YMO/E%8""YD]E0<SR>%A2C6)>2Q
M-Z6#!O"X)[H1&$YEHT]E?)E:A)8DI4-VF,31AVDY_R[P@W POW;>E);$=MPB
M2F#E@43LX\ GRPQ.FI$$$)411;*V)^I2F7V*8+KKJ&]#Q[7$@1(8>EV\"%;<
M,YDLO'-(N'C2GUU[5&T+"U.:=+2L*VGG/B6YF43X</HT)O#L\:N2>7*.HRDY
M<B"'ZK5%CG7T_@Y]K+##R[_#HR'$B5JRP;1_3@>$P=IZ:2<[=<2AR&-5JMV
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M_0AW@F2MX8,"R47%GPJ. ^CY2 ,<,1!+(64@O-<AN3#X^")=41I4(79[".F
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M^SGE.>OU$1#@<8SVA7PSTG>DVQ "*S6$,,QSC,S4#NUY$EV#Q6?MAFKA#A?
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MVB_#2\,[E5P:FW<4;VD'NZJGWS0I02I0TA]3N4%%(3*#=B.B#W62Y>AGYD-
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M-U5K$QDW0%7#D_'5S]\CH6!5%5C1T^RL"72E 7,#]I@$+1[WDN*JL"6)0Z9
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M.>3;=OLXFH,3%+)<HXR3&YZ-EUZ(6S9^W>"<83+S.J/6^-&95QVM]4WM0\0
M^III+OE"_Y<*X8[#/ 706;C#6D2QSH*+P-!;<J,'7XG'+1ALO 'X+C&!L;,M
M6K+UGQN# ]V3^CO5;U2A8V_T67Y%54Q6RTVY&*?F,S%+^L.S1=R$?T7RBQRY
M#!HL+S%YVOQ84)D'QX:2.:>*9^!TJ:/@(Q9Z>\B\^I8%NDQ.-E!(69O+L0N.
M9VF\NZS"HNSYC+5]Z1:QI[$5^2B]M-G;]X%[PMC2>]Y)K*;@%4P"U.&F@Y*L
M< Z^,S>]@%X\?8?O8/4HL?3]"_OG2)O4V[B^BJ@K$].!.V/=3;A?)9G'6'NT
MDW*JC\)%.B<9#W@0Z3'<D$$RTI1.Y7Y-5#TEJ(:C\7=]"6H=VA@-:J'<9"04
M4EV[8IP0T/CY[KU&#J4R:!J3QTUHMY+J;4W4&I0Q=U%T.?*@2\2K[!LO:MU1
M-_C?=-+WOWMA:\ 9K?BZ;32^DCYWZQC^$L\C![I#A ^]Q8&L0BI"F<:!S"CS
MYJ=DLX3R*"?NCQ_]5S6[6T4C.HH0(?]%^\T4Y[4!1F<1/6'8%6((VO/$^0&C
M;:HLE^L$9=":J5)\_CE(<#++./?Z;@1==RWGH>[[ ^G]2$MJP-=MYD?WNC#R
M#@\>]N68"F7_%B#QH*Y/6:S$.:XHN2C^R6(3WD.>(P^M'_1L"J/I7@1DD2L.
MW&R0 "S/./,5\FD$):$:V'H4S "6NZ8;RG-91Z#=)4IOU+]G5<[[--W<.SO)
M;AA_7O^@S@V9UM:,\?G9S2[/7)A28^19_ITR+=#>I=^M2/E$,@HZ%&=3H%*N
MY;TGO2(])S#CNOZQZT55ZI]?ENX_4SYRHL^14JF+K=#L5_6X#7XHWURNG6-#
MV'%5&HA]E5<E[6T4=/#NQ5<K!X:>C41<V.-_[&R8R\NZ%\_F218/5Z!+_JQU
M,04,C^LA(+2%L00!,\$<>#IL)^;"NEC@J$F7]J(G&;DW)["*H'WH6>2W7[3'
M+,OP>^8=%R^%_EG![<!3;/&,5U#@I!OQ%J%^[*T?'$6\+<[B5C!S)4$MVMLA
MS+- ]P"TRD*S>V3%#Z.Q A_NC=55:]\#@=I!D\>2XL]87?GX1A J*(<CX>-D
MKA4@2^"X<9^!5,9R$@(2BU#\@C$_Q0G/7K[T:M"$[_4R<JVVJN+'5?=M[;V/
M%MMM'4:6M1UV>LFD4%6W'35,KLBJ[+0SM,./JMA@#]_OUU@A1W'P@07^*1A"
MC<UT!R8W>HXM("XG$JT;5VM--I785&P&@D_V+R+H7DS8KI+S*ZO^,QWM1@1Q
M(\28EH[@*:N]M7(E#;$Z-4&@\_BT 27?+G(#A*^4QE44--JYLR#;<;U0$K03
MD3UE!#3ER[83,7$4V&[KFSV$TJ @C1,KUJ]:FQM>EWP,NBT]%/!\_O+RSM=F
M\76%%,%S/./%ANU,[O@6UGZLKJ"<C(3>(6\3ZKYGLDV[(QG+&DC5 O5>3$Q
MB7#"=61T9[1)J%7<T/S-.Z</%5Y-\'?8SPC_T5\- Y^U^3)4V9J (;<<#"_#
M7A04"_>!MJ*8=@JB9CP;A["1C!J?(U[.)<LG6@MZO1KN#SL?J9E]\-%T%[?Y
MBOV5K'J$4;?1&3CEEZ@P7\,S[G_&%'B(?\5-XQMFFS/.CP52S>>M87JM3273
MP;F>-F>+$JG]Y<[;VNY';:HISXL\(_'0_]N#"SY7-JV1'#'--%.Z*2-N:0AX
MY >R.=.LN!2<&E8+  <T_, TEMN,:FJT5U=1<4[ND_=[5Y['V;-&2$<\/!KJ
M"Y3R#C]OO5,5C1KY[;$D NMM9S94,FZ4('\.=.8=$DF7[3 3OEO+X/)*E<<V
MT*L+;=*:4!Z)U%BPMK(J;"JXM+IT]5V#ATR5^Y5[DB;2(2?/O+L%Q0_\OUC0
M___4W.-.W/]V?_30C$^\[@V)](U=,68[7KZ4,C?;=%3WWC9G= PZ;D=00)!#
M[-9'31YHHYAC/+_2Z#RKBZC:ZIK40^?.,I+V!8>,^9+8HY/LB;.&5?0%[N6Q
MT0_O6]$7Z:V_CP][.IJE8(-Y,<*W^ 8T7\F+:7(?0' ? Y]J6*;;(T*L/MLE
MEEFGK52V':[U7[RY-4\I<SJ@*17YPF+2AQ[9R+[\"6*P8(/MOSQ(^]4B*#TM
M$N;7=:W&Y((DPC!Z!]QW=>YC7:AWV)/]Z&+=J_V<)LV=<F_5Q;J&L/K,/L/.
M@A#QAH$EU<Z;N&3Q5.,_:L9/"]V%E*97P0>/F 2ZR%&,G];9HW05G ;>RU^,
MW=\%[6&["676-JX&G@:SSKQN!I9[^B!,W!N66IL7$==7H@6N<C1."!['UEQB
M"59<OG6 D>B7?R//FSQ;%T,FJO1Z-PY<V_9R?C'TD1<OW%$,>YL%_X+D8CE0
MFL=X&C<)ICEL8:J.>Z>ERB$GXR0B0]2&M0?:-)Y@XFA":#+5YCLAGOG%J,CV
MR[-!8V:RNV1,M-&D76=]GOTP![V$ D)[""2/%'(TZO)T5PWG$65=;',;DF<;
ML:K2,G>?^128H=&%!)8[3J,&LH2>6]3W&D(5]7KQ+B06;3%"A.=_-()5B;#'
M6L3,DTX+N^.@==\0K_HS8%I1)0=!J3!6=DS/FB4AG>\F&L6=H4RR&K)D'YES
MG^.<BHT4T: +R #9YC+DVMW5 $?N(^.V LZVQM<\[RIWI=?D!E6^@C7WJ*#
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M60J0U(:%&T6^=)/0H8FS[EI'COT<I!^O3_WUG6F$8D=WJ0S@[H[UX^L)2Y-
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MAXW:S&8T3WV0O'R]7;5+@0Y[XK4TFM=W_;V4\*,OQYPEBO)VP=.V.)XQ]B!
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M?\P+1+N,_+8[YC""-XJ\^3)+Z;94?B3&8)H4:F*A:H?(-6A^4^Y?N21S\@R
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M 4'NR !$D-GFU;=S+77,22KH^IZWN1=6CL9N*?OYAZ7)EX<Z@"LB17JU&E0
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MKQ'_TPY&>]A;."?]Q;T/8Y1H8'K4)#9Q%BK<UL^")1+__?O^3#14=Q$'^!@
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MWZL?>[B^8*"UK_%^\C*B,-V.>(%85Y(D MNBV[ N:$PFN0HN0I5[>7#0.;H
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M=$)1SC?E9AHTI=,[P#X\1+YJ/%AN2PRM(\BRIFJ@V[G4HCLX%.>J=2-[-D2
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M'  =#NJ:V;/Z8[)]*C+&AVLJ#@4_KR+*+L3K&*]&N)_\8-9W!T8-<_XE8#-
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M7-L4\TX!C.#Y@(^$JBG"[62>"K$=^<,W[1<+U4%.:-42-"']41(?KO&0*;Y
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MNRP=UE4__D#Q89O%YH?H=TKMHJ[U%DI\$\&&&1C-)D_8<K5 8QX4OTV0AM#
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MH7@J3Y[8;BG'NB.H%.Z8%W6V+XADB^/-F>YTNH@TI!84H;>")AT'X!2\:6E
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MK_:0&LAN],.[%5NAHV(@AEV)::0/.KI"R3@.*=:;E#Z[L@#*E-I,M-)UK\T
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MV+Y7O:@E.D>[G*]]XV>1.,LBPQI?(_WK26?K+[^\=3!J9:?RAV@2=#Q.R!2
M9QG0UO1)@5!M&-"AH" O,)M#!Q$..[1EV#FK_QPH%A#=,[+Z[]AA2J6[HW+"
MVM3WF1SXG2/1X)QOO R_F0_[']^RP[Z'V4@=1HB%I]E^>'5]A,A03\2?G##A
M^FFU1.!?RM+%@XIH.1$S\!W68B?!.SIQ!"Q-UF #NM\'G\K$"RA982<0R%_M
M1;:?$_<EB@8;U,D!7A#M>IZ_XD1WV(1\6I6C))W^"?,6I] 6R$80JO1<L;@H
M%0<9+";>73S*605:RV[5OH1HUHEA)'UXP!VO/H-=3NUIV/A:^<A>DR>/A'"B
M?JX+W@WZ,X-N0*H[+\5P<G4A;"'E6(^=<0%TQ%FZEDT2RG,.V7D5W01 3_Y0
M/[PZ'\2VL"M5XZCK*!;068F9Z=&.!D.XGZX3MH#ZC;YN 15,6MRUZ<I2WJLR
MP!A0>Q$'U)C%JU/L$ Z-;P8J5!/S^BD;A 88U!O[<FF$>%M&$7!-L*;.3?8:
MZ0*-^ KSE.JWNP@#=)-.3T4NUA$$C[C1_/<K\^VBY7N@"5F;LLP.)\2FYUH@
M=WR#<@7J!WU.]M9I2190:RUEOX^J]"FBGD D7E%H@R&[<S8[&B-FW"XKZ* X
MFTW5?XVS]39]*QAN@U>5RQT6RS_C+KNEXZOYDXNR/1?I\26BX;474%<9M'E&
M2XAM$[MJ>LKA&=PI6%X74@B=<?8[>P[TKP<_^T. J-X\Q+%%]^:W+S6Z^=<M
M?U3U,D(NZ8=\B-!L5@H4&_$@&];#M[I!6PJ;W"!/NG:#)M#4@@R1..:/"+JX
M;-"YA0W>IOB!6!D_3LQ$GE"VB)^*JYS%0\?L_/(CZ83.*L;D\/3+D;P;T5E^
MM6YU.(4!0VY+[I,?92H+@5 V9(J>J@7Y3GW,>NIG(6XJ7!XZ@=%L4",GG^YD
ME,Z:V;AIDL\>!G$QL^K'3*.&?2*;]T[T%6U.=/]I[/5QU7'2Y _Y.7(@#W@Y
MC421 ,HO?74Z(.XP5"BWH.A"WZ7+3DD+DRSXJ\FFHK^1 &ZO3P[@Z=>G%8O3
MM3^,V=S,+@C*K)D<(M?WENUN_4NG\-N'AYBME+7('=8KMBL9["! 76&@3*2N
MH?RB+(2UAR&:3R>,A0?]C<!\7LQBO;DX\$O6L>+K6[VQS8R-1_+;I$!SIK<R
MCD$K#4,"K>NS@%]8@N&,T<VONBYH\L4 >&X:,EX&"Z@'(!4I4337BE.#3,\K
M']59KHT58@<S)1%-Q?@40;E>RKW6S^<R. H2Z-J&!V.\@N\.C)\F4P\!KO1S
M\6W<(=?[!2VBVH1KG6X%<!N.F:G0#A 5-B^@XG$5_*ED)&0+P(@XRN;B'[DZ
M(&/J-,*>)ERD]$FZZ,M,]++S/;M+Z]S ^ZU[H ")*@>C=JVCV[EKNLH4K4'8
MLH#R[;!(R#IHW[_[)\Q*Q0HH4OXSP FRWTH=PC"I;#F9.H0O7T U\F-P59@6
M/!(6#T(7Y8:(>A6MO1U5H%!YW3FC)$GF6@HK.ZO"H3>1$OZ&$?\2(TVI#@>4
MW<_S#(8W#D=<FP^9ROSBIE@'R!C0&[D+_ ZC56<H/T&.X;8"3/:DA]Q=$:V,
M@P\I?NJ:*394<X7N2P2#\F9=J]\IAYF=,TT6<A.I]9TZ!]&CV1N%>3;AO,0+
M_8$O6<PJ\I09O)CY3H5<Z0"%@,7PZF5R<_)GKRX[2X0TGD4^28'[:6(,K:KX
MBT7.F7[1=)KB GM=G:K4>\*-?6_G;HJ*Q 5]OL=<82O>N?6^$[NBL^SKTX:@
MSH2BQ?A'V O110R%=K'L6:>W#R,>$>$XA0Y/-@2-@<Y^APU.2M,YPP*],6\]
MFEU WMM+J87,7KNC^1#;S:OS[YCSG<_(294GF$LF!*"[6]H"RG V/1T#NB'T
M+7VR5WJV!;/$+ASQ8Q3"9*G?Q>F(XJ%)!]C-Z7<$E?1)B="4E(#7HG%KE<=L
MD[$K$9P2KP[6M=<'T]-"2ZJ6/'$*+':\>'6H_5/V#:+(:"43FD(LH6RQ/A6U
ME5VI6R3WIW8OH*H$DP RAA;(Y^%6!-4 "$@9"22!+>S;&":)@UXUAE_';(_X
M&2I_09AW3*["TMB:=6:'YN(S.=\=G@]\H6Y.BW:/2B9&=&]Q+817GR[U4B"P
M&=.*8!$:(*"-\(11#&19',RN!B;+Q3@#HH=3_A>J#O1(RA#*[MX B4X-O:%)
M VK3";E;025R@V%$V\0IK_R*^ESK/UL^FGLHM'\?P^LCL8\.'F'?]E];YQ?%
MPZC4.<L]J+TXW9EZHT]#4>QX]NHP(-Y_8P?%0)R^P>>VQ;P[8B$8'\Q*Z-?(
MBVI%P3=9[D2SXC:B+2H2TTBBT9F."MU8L>/4$[GCQ **19O*EV,4:R!C^6G%
M>>5](( >CRGO;WEEK_%%KX;4Z).#<>N#<13OJ$,&'OB4S%P[:4[O.$>$7>>+
M01-LCL8S1.VLF_R"T<'(?(9"ITW& MT6'X.D9+ZL2K28VXMSG+J4.IJ[ WDT
MAX](C21'N\($ZF2^[%XY1']*UG. VC%QI4]JND+++D$18A^2GDN^#Z'?QJA<
MDJ-Z2I-P_8N6GY>/DH1,X&KIU5B$:2+/157F*WU?F4<FBAF3A8N)VI0,=#,.
M3?3H(-CD,[@"0XA#-2:CQ55]=&#K&4](K37+J/BY'Q31?,9I^WW@RC._D:.4
MSF?K('2$J*UM&MH.+.[K5EG?$6)I&"B,1W2BZIY@''AJ>@U1/SSN:Q%!3!\,
MX+"9YK'"0HB6;TXGF$V,K9L88B?F]X2;1D5-!%DPU'W]?EQOS=SW\Y+Y8?E9
MRN;%+'_)HWI*.A":B@@42SF1VINKTF5OK]"'KLC#%,;*$OM=7HHS$$G"CUM
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M.K23*-0,$4CC]8CL&(XSV,R@-E'O_8!RCX.7<=D3#:3?S&TU<"D>=\3L$WU
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MR 77J8,A"_R0K/DQ4>K'K*O8S>JE53]'PM(!.GSF(?@1'H6L)#4!*\H:Z3$
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M^;:B&J0/216O50=1>:2VLUUYDE&XX/>R4+*XB08>='GV9Y-;U-G/KGZ+UIE
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M3IS;TM1Y/S_D/+>^.#&M)1!#Y'7G1HSS *%9!K0G)&_*-@U7#9ZR-\<<%_H
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M9QQDB/TM C$P9EE =/2^56FI&,NKKP6R&:ZN%FO])'D&W7$;P$$TWAO(<-/
MRLY-ZX08XQ<!#1SV+ONT$NJ@NX<[;G3&=/@.-\_!U/-QG&2+3W3<:+<MB&3I
MF#*_S=WYP3P^3^KLL,^(&7&TR?W<<0#YW?J;E-)YX29#O29:'#_[ F]<F?[_
MG.VE+M@VR\:(O'TG&=8L4WLF)?:RWP9,8B,GPC SOI&=FG\$F1[QAZ[\8AM
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ME:ZY77JM6:)^..D\VFB1#P(TH!MGX-XV:9 F;-<P5:(;<Q5'GWO![$SP*P?
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MYPC)]JD26?JVX:OCQ?X9*W'.RD5#'U6T&8RFX.VV9,[O '@_&KC/=N/&PA^
MD_%,!S@ULGM/I8^4ZGF(#XI+*)];FY>E7((YUC@#S>R57F-%BC8V#G^T75:Z
M6(^9\&QG6.2K\=FV48Z"FEM B#FW*@(:7&RVU\]V$1!'/*8/WESSF4C@?2(I
M<M194#<F]\_Q<.QQK ]0W-6I11SCC;)U)Z:Z.N$C:'5&58V<?%D\=<6Y<?2;
M]J#+MXUS[]XG[8A*O5OI\=:/5[BGQG7J>*@LU^%ZZM-%+Y;$!VL'_X', MB=
M\NX3^01(R'"&E0ZJSU6C?%G/X',</-@B6[E#+;PXML8U->1%FJO_F]2OIB4E
M9<5*GXH_95J/!=AOK*G_%&B-9R&8,3Y(6B<84.OG2$V1(3+&NFA+%J0+'VN
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MO[^U_^5&$J8>8;=EXOF@KFW2SZM?+=172( __G?2MA$?M%2W".?Y^/)!\16
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M>UYSA"'D8J]WSW1L&<6EKWY<;/_^-(2)X)S)W+^%]@*@ L<]-*_#+12XD5N
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MC=9H^G0!FH1G9O-!OZY"3AK+<W3'VI%^?- QG_1V&X%[=N!-O66N;/@Q.N3
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M,DCQR-,P+89R$W/SI?A7:EA4;2:!FO*J:5_=M^_/M.H;]?Z?IPB"V7SFC;[
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MSQ57_RC3.I]K^ J_W=LB.2WM#>]RJ6&'I9--0:G+)"4^R L+G O>B/O[O]K
M3#4G"M!G@-,P:JQ: ETLN"LJIJ47+@FH(T?:H:6H6#N!US)=(3?/RP'A"YL6
M&HX+8_=&%SLGP@-=,F^WC6O,*$9_U*PBG&.<D49F.14G.WKC!M<9(:\E%T^@
M;HJG=3EV.Z29([\0+(I+DSV\;3VT1^.#,^_5OXXS>!=I]2OKY5O@(?5*7FJI
MF6@*(8EP4=WXR6>1,@4V03G7#Y\.D6H78OHLX@46L!:MRJW1'CZ.BJ7+Q!J?
M1*F; Q#F?O^@%X3,??Q]>,$FEF/S!F6S+V^7;73><0S1.W\!P-5, Y$?HQ5L
M>@RBG(<(\X2"0"-(*N2X\1&.0#+$IO)!]_@@$5ZO'"0.?9C:'[^] LPQ^2"Z
M4.WK,I09N:VS.)#E8\WJS NEUQSN?P,\L,3'&V"RJE"QY&O-UZ1SPT*FU]>]
M3Q27RU;MXMC?_W9!O'XLTU8,<9WET[=YM$]1'L#1YU31<"_633HR4> &CZ/&
ML"=,0D(B@_\,..HZ@K:G%T3:-+QO:VVE(%V8<^RB4N+0N&O@3BEQZ8O$,J8;
MPC3#3P_RA-<95HA^TI%MN!R*Q(@@E+E_-6?I,E82M>LD@4;3D2T/13[(@KGA
M"DZ *='3A'3 :GK!.V*ZY$<!B&Q_:DQ?A3+>J+=Z[@_&G68]$4?CQE<Q]W).
M6)Y] F_ C:LY9<G:HE:=V&MG,A^S*;'DML]O6HPR]+U?W"]-K0![/0M3\WDQ
M-/E@S7+]Y:K:VZJ=VV-L]R^L)?9=?+/#2P@YE 5GRU&^$8,!51Q'9LNRP21C
MUXZ)V#Q H)I^KJ_.011>8^D0V[33'<\[9=^R^W:CW/#5[\+E A$<"S_5J8B"
M\X[-[D>3&<-G #/RJ:\D"6/86EL;*J''U3HU;,ZP%]L8V8T# _>^,]=T([J/
MP4QJ5PT*4][ XDPK*J>_^+$]P[\\4.,]@_O@ !5$%V0&SR[BEL(#; X .8SX
M*A:$73H>+F;#.)+&& KMGN*)C!+&.5;0Y&^976U!+Q8Z1-TI]$!KN\0V@0B\
MM>I;=3+ST]Q5] 4:,PC*D;"S26N!GR8PAWM=ME-J,$AQR-.AQ=ECG:(FD1I?
MQ^4&%*[,=H^@?H9I/9)%W, FXDHU2M((HL@-ED*E0?[U# 8]G7S/?_'B:(UE
M0H!ME9FH""4+72PJYYP/J_A,E(($0".R$"I"/OKJ2K*53Z[YQ1>>ZA!!N1+]
MQC]7C!,0XFJ/TBX-GEP;K2:(.)[IR$546)F]GC/5W!R #[=LD/D@M6X^J$O
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M*B>N?H>4)F2&CD7^4\3KF2_*W "<.ZW5AB<#I8MNPKA*O./\E.Y()BK3##Z
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M*@/R&UIR^O>)%=]4K.[LIM&"D0IMGX2*Y]3^3S4,WR/O0CMTZM&QT4^B7_G
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MYSRO3'[WRA5#*_3-M9MYXHEKGAU_C07&1,3>YVP9O\EY.Z6-L>2,_[K5(!C
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MJS%?NW;74/KI($(S-NHQ0=3NW'EG=*5\>9SY2$FO2KRC3,_X1RW.*)X%H2#
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M!@<D#B(]4XWQLN^""CD<LS/H/">V38IY*"/!^IO#U&;YY&:;'P,T3GQA&4Q
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M*!F$5?>5^HP]RD8E-_@5KP]:2+.K"DR$+Y;C[1N+JHHWC/M:BE7^,4^UQ=:
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MGRM;58=./OY4\HQZ5C?QU"VB<Y&E_L&3$W.$@\[YGQ\YVCH5!@;D4G^6113
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M^4 ;YX.:PJB +]NI+YH8%S^3OS"P.2VJ.OV!&I \-_SMUJV4<NXV$\<[N%>
M?HS[G'<*&%FR[%N<J8!(H:R!)!(F%.CIO8[R K9H.5/Z?HBP@!_#)8 E'9U
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M 2&VB PJ<0!!Q*35 S0@1&8$(6TC,HD1$0D0LKM%B#*EE:E5(#+$,!H5 HI
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MM\WPKY/ND5':OI-NLI\E:$*F8.;D+/Y^9'EG'5C/:THE(A :ZMK<XFW1M(Y
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M9[*T]I0;&MA$FQ^/9377:+WTRQ(XCSFZ3%1$N6KEGA&G'7:-'"P*_.1G>;A
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M_1E.G UOEYNTR?N?#VX?."M_+;%>Z@\)?CO^GG@9Z/P) !VY*PY,Z2C :5+
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M=WWR#+SXN,KBJ3)SE(=@JX@HB"5^!+E+UDJ/036EA !H'%Q-\]<>VF#THO6
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M]6$HM-F\<J]6^UM5;C-?KN7-.)J[_Q)N>86FHN_R]#"[RSLO=&O#\MT/%.2
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ML,T:?U"<*"L!(BE0 %K))I21[JA4(:3K:-Y)^9L0+;F29%S'=-R=SU::%:)
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M>%CD+"Z3Y1&-.!&!Q'PPB*\BC)2<F%' 5@_*3 $FZ5UP;;RLKUT!6RO]4>2
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MSBI@"ZC1K^L4,)4:X)4W<8T"-O8K88\"-I(AJZY9_HZ^9QX].BO?D:-,B-I
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MKU8QQ/&*6=U34?;QW#'ZV::6)HEC<>?!1+VKX!D6LZ=D*]7?4>X\NW)'5J*
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MF69_CC+V&4%"705,MC;P\6"\G4,VQKVU40%S>4+J_4KX3.A)W%& $5QF!C?
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M[_KR-2#F@_2;3 FB9<8FLGK4+BR$8RE@JG+M2";\RGQZE4@O4(1-14>T8OA
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M^Y/IOE=ZH8"GFR2".-",F*L3C7=-6(NX0@L>@A,>+,NUIG"2>6TD 8+$?>R
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M:J[;<%\9]-=9%>?O\*FE+/('HQCLC(63DLV7"9BS2PIN5A-M"R584+D%?M5
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MI<C=UL&NDY$^LN/5^BMMO9RKB\,"Z^J<O1)#7H><:C+V?^BW$/U(&:D4 '<
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MIS[[P[9@Y9@;_ @:XW/LX9$:F/XXB)B9*$)'<[38H) _X/VL>_.%H9Y*:^5
MW5_HZ0FE6ENXE)0%M 8LA$*LJ=YTMLH"M(U<E0M<5MT<CA!!5(=%4KLN=*9R
M$_B4T3K6#:RB F-4IX@FQ!S2F.X2ZE-D_5,5=+XH X^!TVIFPLS A*N?/%S$
M/3>D%2M(0[8/D?TSM'V*VUPRZ]4CY5JBRD0#BGR.+>*D^#O>%MFC^ %D6PCB
M'6,T/64?PQ#_$V51O(CLF7X<3,P.LI/I,27"";(L&U2VJ&9:1*;M&PNAC_(Y
M*&#)+M)KH_1DG)2/+3%U9QEM(_"*9=1*5;0NFE-=?#OW6PE6$2[\Y?GJQ:__
M%J;_YX(Y@#@OHPJ^RNV646]4!'-X3P_GVG\QY?Q':.L(BDLERIH ASI WTB5
MW'>ICL9M^2^#DRZL(B,K'RN*5-Q^/U&1QSU;1DPKS:!S]E--%0^ 4X0U\%[^
M]7V&TYF+'&-DWQ@WBIM>:0I7-9P=WUXRWJK02E3':D8*)2(#%7ZN5;#26TN&
MID?.?7%@'[5>1EU6S=ZW0ED!' SAE*]$]Y.ZIN% :&\P7"5W5YDL )CZNZB5
M,?]-,K!?+,QE8]?, BOQ*SZ04"R..>*:(ZE-SX@78]9%$GY)(%XEZ2!V$CB1
ML3XRJ"?MPKA>Q6EF")>/7>4BV2L+5VD@>"KN$%2I]*HCJUN8=9UD0/O1W>XL
M8:J>P18*2 91@";U="V%Z*DHY>RBVBK^^@TD"@R4%J%GS\/[PU2HHZ>?D;>,
M6FM#U B,##/ACMJ^.65%/CAL\RB9@:+T832748%%QU>+T8BN4-:@TE, =-FK
M I9H/%PF!K&"Q9>I$NQ5VGHXM2L)KPF;2H0ON=)G99)ZQ!+:*V5<4>K"R<Z0
M7<\!C'+M^E+G>@E:;<;X0,LPFZ$=":SZHK%?,)Z?<6$GU71J+N:460+P9A;Y
M:1F56LU]MQ+39J>8L%/>Q\S+2=SA?P=G_T/Y[^TS&_.?'S\ZW.5^I'#EJU3'
MW[KU_X,; Z8#%N)4+O@,-I>'(J[$W,MM?'0>Z1>\Q2P)A43+S2ARR>K'A/6P
M$:]R.UPOMZ8>&0V',#F<%?#DYUY DV-2R[V&[3A4$%T:D8G30J?B=U!\?!\-
M8W$8J0C=7Q=V8QGE=/8O])-E% ;H,@14--8HNO1O0V?@6E J/K:,4N>>X5X5
MZ1$BR!D<4_!=21=YW$0,S"<WWFJ1V\"'I0<86;B-$GJFW47"VAKB?*,E*T.T
M7FD<1=L)/GHB1F<&3&+!UGN1&O,$T/__8>_-PYK(UGWA."(@1F52$.*$J""(
M@BA"TFH+ D(4A"A36FUE:J01D"@AI3*#D%8F98H*B(@8D4D!*2% 6FE%Q@@(
MF41FJ2B$DB25K^C>>Y]]]]'SW7/O/>>YW_-\?U1\S I5JVJ]Z_?^?N]ZUUO&
M7P]F2-7*D#\6B'^78[I#X20RP'F!^U;##PK2E6'(T;F7,'3(,648&6I9TSFT
M-1SN-/3=IJGOC% PS41D57BU5E] U.2.Y&[L?B@UN3.:.=U-YTVJ^'N9B,X6
M+TOS-AO/#(N1;N&W;+/Q$ND^HSS.BC"V;C<\5Z%B_?E00,"=BQN/_J"CI_ZU
M%!V/1;;P:E^A X[_FE-/[LO%ZE(B&Y -HLIX_FK@9&!OA)F,U(!?WE6[[0ZE
ML/&"A2]\SNB<:<2"$R)VY-1KUUE3'\-)JGV>^Q]C>M)YR"0<*.PG",*NFF)U
M1MRPR98F)P7:X8F)$0H"FRM2(L1MGO6IK*ON^!!+AHC7ROMQC=4JK!;?C=W0
MZ*70LO[C+?[WW2]6DBYTO)KW_G_1?/]?F75W)WX/P,FV0?*Z]I0"#;&R*!XX
MO>/*/Z^;4P^(3B-*FA)3J@%\Y2%5M[+;$M410E*L] I3JB/+H:E1?X1%H@6L
M9L$??BOT$\I1G8+H<$):%>RZM^D,1S;-UD7O*;M^KO%LS\^W=NO8($K^4$9#
M@ADN 3>/$,"-TEU!#ZJ#KP@G>Q8(S:7KW'8477%U"'.!8JX(^I(T!FRRMWKY
MN6IT_]2TTZIA8SB=NN-A<_[)W3^5;CN6D*8WGE_@NL.V^=CM]ISCK\;2.JZE
MUK5XKRE;NG1-GJ'+0KZ^%KWW8'-V2EF2[2:A0].(GKFF;B7!9C/3''80Q?*]
MV?3Y/ES5.A6*'-, JEK.$RQ,*Z=K4/8>+^\N#R_:]F%[?Z]94WYR0*BR8E=)
MA<X.4<"TBL6(;O=L[P!?UVPJ09"M[WB^T&EE%%]_=4-04+:>IJ_UT1N..XC6
MF0Y66A9YF]^89.NM;K"UVY'H=.UN5V?>QE[?$F>'>Q7[#JH=2_TW9_--A\F9
MG*;-E6@_(,<,6L@QT#FF;+!%CCG^I=YTGD3V_QTI]C<_?9D A81);^>)/\HQ
M->CYNEDRAO_,+(@!>,.37_?93*"7O8 >);$2/'KK_^:.717B:YWYK8M'5/T'
MMG:73RRPKKJQY&QGA?W-B8#3Z1]=8@9V&D;-__QJ-"[/T%9_U4+Z=G(OD:=]
M2&3<!"XH+UVXH[EZL.B&R=K3JT-4GBV(/A5]>:EZY=#BYY:ZMMD?30O(QJ]V
M6H8N>=V1]HON O6$@M5-!U^M+-J?RKN7RGOOD6(75#V3!IOLN7?BZOW[PIUK
M%J]\>+=0ZWCV6=UH&X4_4E.W=D9ENU\KV?CPZQGOO*JJHRX31B7,D@#FP\*$
MT3>?![2+[6_JG+DJZ!6892KRKRN>6)^I;[LA5,]SU8X;2XK5/Y8+WO^<?4:C
M\VZ'@^EX!_%81UOA ^_SOOGH?S-]^TVG'<SR'/PRWV^^FW#@>_7*_Z>.?^^W
M(A3)5D@7X?,^ZD4YYCR(W*/IE#R68R;5"&/3QC(C_5W_B9+I2O""/PNM;7[R
M5Z&UR[0>W.P;<$7QY.QW6NZCEGW548YY90CR,@'Q3[A2$"ECLC(E2-UW6[YS
M9PL$J)/1%R^"=83/P_B!S6!?K/@'F" R;Y!C>AA0"M4"+I#84S5A0 BB9"5@
M>!:(*P^<X"Z!RYJK;>),Z1, =G36M>8>X.,KEF,"VZ:M",X57WYA!A1FC,W*
M,6O)L,7>N8IKP4!_&3"F2VLMGX=$YJ(\[FH64+_K$\#+9Y0-)9> O-O<TD7L
MJR'D=Y'B)BBW3+B*X"?'7&Z'2;8B4CQBB33,LF-J=Q;!,03<KNLG!=CE([HK
M1%Y%=X8YI.M^%I4Y?/IR[G%W#W>?ZM1*+@ 3$:4 U!OVB283:G?RR//GWC(!
MGL)J4?J:<]>VU>KS)A4H1#$35A$0U"EE35X;.@/* 2S%FX77;9-&7"P>&UC+
M"0UOL3*V;BNOV5MB<ZSS7,G#7P(*G^5NSI+N*9Y$5?#&26F!.:)8B+)4=(:C
MI'CL('7/;:SXZW\LZF %1"E)$BS'L%"E<I*8#%0RI5LG84\<5,!F[43)8@>B
M&@B3R- -%%B;8!8DX1.DR60H#IZ4X"0X1!6<D&.^JH>2)[#CS''F%*X*\#UQ
M&=4ZS<R^,+&Q+,ORZ&D>O== 7".[B9\'=QQ[.R$EWJ,<$)+8W&B"LN71^_"Y
MSY(C'=LL#YR^31EJRM0H";O3[^?F6%S8-]HMOG&<&''/3^.ZAZF89,*.A8H1
M)47)(NH%T9OK$(L7._%,LI[Z,YPF6#*])007RU "?0F1Y.72X)*F/-^,S&ZF
MT76^\1*X@\29WCQ5HDT$NRKTGW1\=-?9T?P9&6[R#S MDI+\N! U3'POK6B$
M 8UC-TALB,\??T$E5$4M5W\BO=W]:QU)NN,8S3OC8V#/QTW2@(%G[RT!\<\H
M<T4QCI\MQYR=[)D1A\LQL8%  TK/E/1YL0WT2 #* %BHC&FP0E4626J F^^#
M1_EZ%%VR %D=Z/'GOH)&I -A([W=A#):E]AXPN' 2XG'"]QPST':#T"].H%7
M#$ PH<>;/;>H(MU,GDN"W5='@ MYWM)U9*@<Y*-6Y0<TF$%C?#(=Y&^>.SVB
MSF$9ET94(1K>8J)87ZS"[0%+\5P9DR#.>#=.( __5TAZ[!^,."[D$@CKVXS+
M,:*] F,665MZM%.Z3K1AO\@T'5CQL)S< XKCNI$.0:*VLH[54*>E Z\U\E)S
MI,#_J6F?)[[!RK7U1-<IB4Y!238I1ONXD/X!&T^&2+AY4G]9$? 3,QI7JMD,
MJ/KW:B8C^/?#N/(+](L2 G4_]+HR#Q*,L<9['<I[4<.C1UEH^QZ:[3Q_=K+^
M4D5,>=2\T%\K'UY&7E/#Z(V?T1Z]]UH*-]VFM0YLCM ^ERC*:-+5>DL].?=B
M]IF83YQS50\HWDU:K;%3*F?[6KC>8@>B6T?)'QF^:Y^NW.C#3?#2DMT'_7$]
M$O$;&1TE'*WB21CUHHOF0]@)6P&PAJ+96*<!AT-A?&X#%R<UQ.M 96.5N.6&
M??S"Y-J0C.I%)6UTR07R\I<!_K(<_PC_,WY&@UJ/;DU?]%Q:M<*QY-)QNXJ@
MU.TW6TZ*GD4]<'HX\M-6NP)*PQHK0U.75<'==^SJSECG^SE%N5AWZA%R_S X
M?;^SP/K>IAQ+,P]'S9EW'EJ%3IFY.U)/6CNE!VM]#CWC%_K Z4579*&30Y.1
M#Y/KN>%@FY1PJOIL9/Y(YJ;,#/.9^,(1#8WJ@(0!OZH9MT=%(97I00?.55FD
M%X5?+"*_V;!R@-S?[^5AF:&Y\O?9D*/DK7T!E7T!_57% 9_Z1GNF%#?>L-V8
M=L-M8_I+HWB4'APZ^7<>0D9YPA$4'!Q!J7:Q'',1M:%N2\B!)L>0>%BI&@$%
M8CEF\:@<,^ !3M,M57_ @9W_!2%/ZHQ(&['GC'/EF-!(.>9(B]9<Q!-&-8G>
MF#A0CJFNEV/NGTF*4'1W@;>C#O4C>?:ZQ\<[4H] 610+_3UTY>_:;QY$2*Y=
MC0ZU*IPCPC9UYZZ".= &L3N\,V]L9R]%"P51@O(D@J?ZB+I_BS^GZ2XR&TH.
M!9=(=\. .'9GQ;WX0@J)3=K5A^T+];]BZJ^00/T!FIRX!0%-!!6IF8)43<+W
M*A&9"RX4/?+E*N/5:6^Y3V98.0065R,46-;G-J8%QI9+T$E.6P='"-V-Q_LW
MG=YUYV+>>[^J=''*OMUEWC;I=BA66 #U1#QN#*=*T_.58RHFQQ4@?S&EW4QV
MX,C;T, D<)FEYSW<8LH.R7%[G$H?99)M7F?69KF]^D;6:\)AQA'O)^6UG9_6
MQ_136^*NUUG!!W@ ZA?($Y&2K50WT:14;2^BV":QZ:6QD<VBJD8U"#N>5W3P
M/OS&@<#.5<<O[WP4>BBD=0U<>^#GJN4C#@&AX8%G K3909J,C65WF9R3F\T/
M"O3C7Z8O2]8J+]#:XQ%DYN)S\HR%J9]KXYE0<GEQ7,C)$ZWJE*TI:7OJ-_=]
M%*D'N!R-7MHF>,"Y=W=4.+@_J\#PQPVN#[<<9=>?[\B;T+,]@)VT4W3<<<Z#
M6P,N9M:9^!&665H%BV98=1BHJBE-*X>9&,*,KMO(L23Q-'/9)/!)QS2P=!31
M>VMIQE392VX/& _]?>JUN[V[3+UB<;O1)V;ADQN? H_<3?BZYZ5C<&:4;Y&=
MTY'8'5%J6=3'3JGY>=J]6YU2GI "1B/4U@M7-;UR#KIV:FAO\,O\#--GQTZ_
M-O!RO>;2]\3^A[L)6^W^3F\(WZ''?RJ#-N[GJ_2^+&0"Q6%WK#B"R1W%P)%-
M#,@Y$-[$O5SK(@B<#X\A2BJ2Y13CY@%ET>(R/F$5O+>)40&\"%Q&*6Z@;84^
MY@7GP;$L_"9(7"H<LR+O$RV.+NX9\+WT)NG!B=Y1"Z\\_^#3$0&+_EC96"O'
M2*T2$464^ML:RBX31#L(WF2$TB45P#C$.K W>.X-6(B2,PK[BV3W#-[ZAUJ/
MX /: 6PHC0?8$)0!WAW"8V,V3F>8K$Q3HKTG/%%HQL;7;490P1_ES><T<'O=
M>6 C5@=.E*C:=%H>?(BR"XI- \VL2[H/!8.?*<"AKM!^HH1 ?"I93+_GIY7#
M23MS)MB23.9\MH?T$2<5E"^A&JGL-HQ^/AJ4U?C/]CX<TK4]/S"K'^X.9&&8
M:E"@-)V;Q! OA.WEF'MRC":I@I- ,4?L YM;)?.I>G),!Y!8W/=2COE ;B*+
MUZ&S>8S(BKU^"ZB#Y!A9TA@P&KO7ZE'"9N;"Z89OQ*7_4\>_+J+\Z4?_)>CT
M"T'2A)V5H;VUCW^- E P2J??F0$RLYW_'!PW^$"_)L=4T<?#)7CX!G:A]+CL
M=AV.$L[.6':?@35]O7^L&5CQV[/X4^&,V('%92+]:^/\I[[7 PIKWO)C!F=*
M:F^8.D7UQNC6;:*UJNRO7%^0_3Q'*;@8[U(S6+C:KJ6XXGJ.6Z>/36Z%6\C)
MD&>C;TR%84\^9ME-WJTK[)XB#0TP4(0[*KO\:-ISKTTGZ,/%4C8-N5:[;[,8
M$Q1&XS=0<6U&CW*=5[)P<<A6RM[Z =Q2CU_)S@??N3H,N.=5#60Z,O/'9L_$
M5-WQNW2A(L^O\C?RR*6ZE/" (M_,M*1._VT5$]&R[#(W+S>/'UL,-7=]?KFT
M[4GMN5?[S,@*B0V?9?[*<:Q@;DK?VV*;S+[/DD/LS/Z \YL%O[Y+#CP9=X><
M_GZ@N<0BNZHOZX93Q:P7QQ25,T/F_S?(EV_IBPH$=$%^ .?T<B'Y'WK94L;P
M60 MKI/__0K.P-P5 #D&O40YB94)S_]^&_I]8.9_)!"E\^>"JL"?0=4.,:H&
MNAMDC.(9,8@!></</P%H2G8+]72/0>]1]&QK[>;0J6,,68KJRM03THBY'=)P
M@1SS<$QB0)J6D7_'2E>C2+"Y#$9]C[=,A-KO"8[8E3DV^Z_*5& NS6#V@,B8
M G(GW6Q*[]_[WMY8MO'LES@YIO-2X2[CN22HQ]F:R+TC^*B["0:J^>A@8J1\
M6;X9ME=XI*MN@W2/R'C<!4H4OY*EU5Y4B4YF\$$%J0<Z?2_3-KD/>WG=#/54
M%9A'TLQW)4)#S8:SSRNZF2?O#^L2H/ZGC\-UC,9LPEOVA.Z58WY#%HY8@/6R
M,!?TC'DHN*Q%B:R)2,O=M2V+C3<7#8V70#'=[6^F#CUQJ[I&M1*0X\#EA%(C
M+9--I;Y\G/+HXW[VHJJ^D^E'?\).M"92W?F,>13W1IJYZ%Y- 4QNT%W^=IJX
M$LYKS.S_8$&CWQ[6TDOM32XI'@WC+/VM]_B(>->7?D^BP<+D53GQ@KH#\(JY
M0)$L#?#)T>9[54$2=D8Z)/U5-$.GZ5#7E8K"8BL 190;+3=KC4'4T/Z9=<<6
M^'6+O&SR]*,SN<<[)J</E0OO[XLHM F<]Q0L3R #RM>:(NP>^@P>+8F.-339
M6>B\*T8W7VCG?+[)B75ZY.2@^?ZHH5U%]9\[TFSOW>T1<E@GN[=F/SB[+.=B
ML-TUOP-&.3[6+AO4[A]C1N7XU+L4KSJXIW6@:)7UZ[QAPM65U) L_ILD\PF=
M0.A!J^"/+Z/.8]V$Q?JB,T.7326VS*$,ZX[R/CE&BQW(' W+I*6**]WJBH.\
M"]W]JE,U+9*2TPK</)H*W6:[U$BQ3K3V8(;ANM8M]C<R!Z/VH#XU,>!^LSBA
MYHFM9V[YAI=+6)G.@PETR_XA X-@VWRF?LT%4L3RHP?5%_TC#/6=<)J91/8=
MUHE!:>>_A51_I1G#0?Q)[?<]_?X6=+IA0>E5>PJI :>.UY?B*RD?4OXX6UL&
M:29*S;SO.VI'/0.O?OR(BJM0M2+-EYZKCO/UW4R:NQM/0A/VN8\TE8FKW;8=
M?+KY;7'BBP8[IR<IE)N[FY[I[4KUVAU_:H,=4=DNR8]#WV9Y\"*_R/3#L^QB
M9]:I(8V\,+7[]IFV!Y\6_E'SRF 0[!'RD;1@'C$6P7=:VHB<CXM,9T,X53O]
MN=IX$SCR4,W3B\R'+5XPV4W4CUKNY)$?K'\WFO*]G?!S\L?=[1\W?R07&=3L
M?7'R?&V+9L;)(,JUTR\$)JL.'_2#+2AZT]F[UI<H/;BV11@TT!XI]CM2[!3B
M9W^KZ$CLMD%VJM!D=8R"2A(S-B_Z>+5ID.F6MB:BFBQF?9+%VU!O2R/5&P^&
M@G)V6S_4W.KW\%G)2M1?;IRZ^K_I+['_$[J3><? #UR,0VK1P74RR.XD)*(^
M\_%-8%1W^3]B6)9[Q3<<3A&OXJT<%HAI;:@<CO!\&,(MI<[G3#/GP^&'X&M"
MK_9KF:&?RD1&6VI53F4>6T]<88VLC2_YP+!)4/Z%W.+#$H7QB>,%DOU4%UDM
MX6=NKQ81U@]K:(4WL2\#9[.(B3.Y>[LMM47F/'*BU%/4A%\+FR,K(I1?,/.I
MB\K+.C@_M@5N?-;I72,*]_CJ.IM>+$O]Y=-5=A'M.O4'%,0!*D%DW$A0I[K"
M9T15XKNR6[47A?U.*L'L7OH+XVO!(S1=T:-G\Y0R.7%X;:GMV[I-4J,LEUT/
M#+V0UGI7DO%9RWN_5;5Z!:-(OO 3G%C2^]X7U !X>6 5H]%J)>_K^6$+A61D
MM52[['E9VO[^$Z.7N THVUTC^N/Z^[4FJ@4PRUIY8<HZFXL:QY&4>8D-/*CB
MCOWJ_3L:CY;8Y9>NHK:.F0H369:[-JGYG!2=;]E:H'CLV.BIGSY^3>66I9[4
M\M+=J1+7R"G8>M.O/4DK]<%^4W^>ANYY%N=X@FJQ6Z76[MG W.W!,;IV&HG1
MA:MM.V7F=VM;>$/UK;$X#&T-',8W;R!C"=&U\_@_=FKN?_NA6[I/L&6;NVN7
M<>ASUXO33+71Z@&PR,OOTIN"^W[52>+"!W-;2\TY81D[6X*"#.DC%5_*CCAG
M%FYQS$Q-U=N]-3A5E?HD9_>;AR<W/1Q<Y'0WL=KYAD=K;V+*-8_.T^9J0ZM>
MOC%)R]AQ[?U/@VJ?4K/7?GCX_E3_];]'Z8'MW I4?)+$]7 XBL#'.'4+*'N%
M*LF14 <+5V$C54WAA5U!- I9 &8,*&M-1+1I[75JG-I]DH,><[OYRI.X4=.>
M83SRA'GAZ\ :<0AL:XZRBIB!3:*/Z;0U7A02+Z,YCK8NL91+721#O;@?5P?I
M!!<B:\?(:NL[ZS!S%4F<Y)@^)J(X*<<LY0;SR+'I6IJL5@7D=:X"W/J(N@4N
MY0.ZOC3-2,&].Z*=;AS\_-$RJ75D4RY>A+UL'$)<8Y3(#UP( T>A*;P^*%L$
MQZ*642ACU&VDO1TP@+\6423"RMA[5%NX%5(6)\#/(666UW8HC?X"3&2L <\:
M."BU\JH: U<?]X(7.,&,TV'\4*@P\E.%L1*L+6!$UNG"'&<H_<H#>*@>V=A9
MHE?]]#UD+E55%@.0PH1)@,3.%[\%KJ&9$J_A4#GL \Z7+NVFVO#=F5?(RP@^
M0*\VJPJO#K\6Y=7W6H%7QI%U; %SC4]F8?S*"(5&W,K:?9!P?U<M6="J1B&]
MZ-5,F.Y['7"9D-,*[\$BRCO1FWD'HZ)\H4CV7([A,<!EH"\6/@3ZEVP0*+ F
MHZMC&X@PRD=TR^EE\"0O;,(? IW@@CM 0_@CJ5$'?C7*3Y8\ST#9OB915JAP
M;;!M&ARG&[.J8YAFR"V=27$X^3LK&)<)UP(7R#&_OY8XSNW#1%V,'3#- \N;
M+JE<G+F"RHBSLD+"^%P#KX P"Y%[3SU?7','LI&:2'_3YLX'!M=RH<.@Q )[
M#9S]1.ZK!$L>(+:TA2B)VP?R;@'B$-QJ8/H]6!4 N+N\=A?2XK ?#'ALJ88"
MHI0E"N/--- 3<5 J\D)7%T5X!L1Y 2Y' 8_ IX,^)>X2+*)*5AZA;438<T7T
M8R-'&+U #WJ<0MXB;SJ0G@\1A>.NN=[7<;[^J&5KS*W?^V96E@AR4)U6NI"V
M5?2C10 SX9$QJK[H=/-<W:<5T&?/ _PF"(D/E%STG4V/#UJHE9QO]JS"> 6<
M;.5&*KW1T+??WE8 2CMEU\ /K> 9G&07> 68+99N(]N19E-8@ UWB?^OXOG/
M'5=\+,[^^82W^!I8!>=$>/>RY]UL[4\.R;/)TH[)<Y]12GMFE5FQQ6ZE'$/8
M":ZFVA9F"T8.Q&\C&KXN1<&=+L;OE\66I1LO4/%R'71ZYS;M2_O:"9KO?7ZH
MV7]JK]@+O9F;"-?+1%8*_MQZE: US>A9T(A.'] '%T]>B=>EW*)I(&_(6OA5
ME$EK5(*2Q)ZRV\A>G][F: %=@_:.O$J*KT'M+MBNK<**< 0RF^R=BCA]9%=5
M=>BX*\= ID<2=4BVHP-U$.7Z!/%YAA8PW<^HV@:<ZI):35WA+]/AT5<$[=%4
M'I1C>FZY6!8:-+*4IVLO[.H2F19N[1!_C='7C*=^3J ^*HL*\+'>C#R" N-W
M/C+@/=A3!R3-(B<MV=OO&-IT/;[IWGYGMW6J5;I2C-;508='9VSM2#/YJ/ID
M-M*[OI4<]=\O0.L4V_!;:7]PL;4;)+[2 [);B#;E@ ?,A6X(A>1KB)ET&Q0;
M75*K(\I@RS'JU W> AW* 8'[:E,?*?DA/>%2;LJ:W'FBG*88YAU*E4-7B(S4
MP''+R3+TGZF@Z<^9KG;=0NH^$3&.MD'_16"?0<,.Y$WO)%VJ8RQ5"^>97ZU5
M*1@F*#RJT_6_1(^A;;-"\HI@,9?-4*U;)MTMVG1%D*0O&(J=)D9Y6<)!>JW1
MEOO*#G4!905=#R,\BK'3F2D%FSDA@^//^BT23/.[#FYV8CJ\6OFPV%2XY"BC
M>WU'D77:Q0,]^*41@2>7''.\D3DTZ!R9]F-VP-;40E_KE'N9J06N^&:[M\5.
MJ6<FU,@8,("L2:7"+(C)H],14Q03+,!?Z!CJI5+1>0J++\>,@W?@H>,B\_KG
M.%8N1J20'&#I++)W$#$;L?%:9G(,:Z1V'_^Y-K^_%T9=C(K45HY1Y"13]?32
MDS;N\/*]1!I#?\.,&<# !WG]FGQ.P^1B.!@][V7I[JHV.+Q^8$7[+U/&*L._
MCKKE?"H+#\SWF:4>.3[27>9W*6EBJ"=@7<S 'J.-*PYJG;3Y'5P@#1!Y\PL;
M6PB1Y/+ !H=Y4G]A7XX=00'I9"RTQ.HQ&R:32&Y&D0_@>P@N0<NAJ).Z#W(7
M1&4Z)I;X<2P"$XPK@%C:QIJJ3,)BRLATEH2HL&\FVK(WW_/X_FB] ]BM1^[G
MV558I)KL<'YX)^&:C],=6UOGC,=E>4IO0^X56ZOG'-_24O32.77L6*A_T2N5
MSL+=+G<TM1R/:1<[E=AH[I;X/WA2J.=DE)*FYW@8%7POK9;_M1 AW8#.\+@Y
M3E]K#]'%O[<33D\N0SIH"V7)4YX*8IR(.Q$I!)+QAO#!8-$#46@+,^$"5[%N
MV; 6/=K+(%''@%>7$H8^M'AD%SPM>%HR/JUCP*I6B"UQ9G.5UW42X\S68OM?
M?2\X(!H2/T6_*D4ZR,JUOBAX+A/%-DS&XY31AR-!%+=!P8ABD[ UP6O%7+V'
M\'#Z4J1[5HZ9 ()#!=P$<RT@,31P)27E!$IV[ E1N!X+>GV<)5;@^<O(P+;N
M$F:MKQ"K,YS.<5LB82#*6,DYI E1ED6#O'R@C'$-\ =[(AN <IVA\7T21XIC
M*X\87X>7;GE+V]%/*6:#96&)YVJ5^5F!,5J%B=NH 80X2]\  0'K02%:)QX(
ML&G\U;_:M->JXL.E@D3'>5-RS/^QO!S2U_E_A29S@+^%)H]_$4<PIV>9GQ?]
ME;>%JJ^_$K=*A\8E/^ NF\W\=7FGK+]=0_[71>[6K>&\4/]^XUL%";7M/TJ
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MK-T;P/2S.#,4IZ&C-3 KP+UL?8<3QHXS'E']9 Q+/6@,43XJ<47>TM8_LS?
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M#](49AGQ4+#S:&P*A:DE>0(CYT_J\N#+7J@'>2.%>O-)BY3T)S,+.WU$U]C
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M^P9D6SG*4YLG<TTO%!'06[F:.'AJ0BDL,*9D>RK?F(:%YP0'R#*B K),*?D
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MN:'HC]B]C99UAE';;V4<M5'LT]8K&BA899ZQXXE=(3 BD1S[D7_B'VDG^IU
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M':[]>NY8BT?T?C0,=_%A%).[<0?8N*D!P1I*)TX94>CP]^2(,=(DL#'%!#=
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M"-TFZ3>EB3%1(49T[&2-]Y=AD[('+C+)41..YVI7K"GU2JCW_K+-1K%LL/;
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MIX&?V_U;D27<-U0.;GB5T( 9 +2DF&ADCO'D1;7!(AL9JM+(V93A=>.9:KW
MF7M$.3A6*Z]KIB7K JM=TZFJLVO7AP'OGM-UC\(SRUW1VS<-UNN2]7,F1K=P
ME9H8PS*'(>1Z/G'2]>/3$C0<0"<R\!9=P1&[^]VF"4Y]E48S0V=D=AD=[WEX
M/W,6069) 0&[/%/8[)/L^+<4N8%VL"H0#=_3[I+PS>V1A.]8?S[])B7F[:'H
M/S_$GG)+?W4*^/V,>@MV^54KN:F]RIGGGA?;<#\6QR4KO:S8K(R_7+XXLHW_
MTYACN7<TV2"YV<>E3F;XY>FR@"Y>Q45AF4"W+\^/Y.T8%/&T0M1+$_&<%ZW
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MGH\PS=A'E'B1( (<%O$Y'<)TLKXH=C]1I'=\_KLEZR(KU 0^$O_N QE# .J
M"+P0VFPG;88QB![;3D,=O>#@1M1K/GS?,4Y=]_^Q]Z9A3:3;VG!LFT9 C3:3
MHI!6&Q$0<4*4(:6M2 M"!$0$A#@SB5$!00TI%1D$,4Y(.T $1"8Q(I,#4C*W
M R*33$I($)%)*@BA()7B>XKN?<[9>\-YSWFO;U_O>;^O?]CME8)8]=1ZUKKO
MM=9S+UAPK$HJESE&2;DT>=MZYP'F%^!4?C@!8B,@%%XL,K4;P1P%9/R143!
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M!<%L-/;,6B9F[DK8'4"I9+94Z %B=9\C\[,"LVMX\JSMN!SOA'W \"4#F-^
M:[2/9Q+"X*^?83*3X*E'D1'_Q^1!<(5_%C4%,7[BO&WPN"KS+5*5V8)493['
M_4R[VX]'/&82Y8T"V<;S@\DGJ;U@&^BJ_JU+#/<DN\2(#S&=]5^@;'7\KM,?
M^0-],?BO6XOTF--0X$5XP!/[1I0ZPH.RJ2/MQ?#(6I)5[#O)'/5.DT4U_%.*
M=8QR#'";&=!T^/=<8;]T2A<TNH'%3" -Q22>-!0$&(KG9]@7&$H',!1'EFQE
M]*N)$X_+AF2;X*)$>.!:?Z1 LALB6[#@_1IC% ;B;8S?2?DS=8!B;#;S>X"L
M&-?A#_T &WF,;G(*91^M@[TRZ:]+*H!/@U_PU+I7?F1R5?D5M/.T670MYYW.
M/^\0-/D*.U'U8O[Y;]T-3JMRVQ W*W,U_25W\M;TIYK797B(!*@#0RTHXP43
MM1%@2PPO%BB)F+."#,M;E601,+!CM2#3<KKR^P#:S*",8HX>VOD"UNK1TA(;
MAA5L3/K0U#VJ'K':P/UM[?;JW+AE PUV-4/S7'UZYOVV;'>DXQA%BX&=4L=5
MC8DKSE)@5J+]G&HF+LX@-C $W*$L4M++LPI; E5D9.YSKJ?+$^6%\U##,^!3
M"#"2J?@I.D^Z$?>M*W#M8,_%DC+P->*&"/:">[LXE6M.TE.TA>\"#)R*CVN\
MS4XT0$_-\]W;:;'R@[7OZ&6FL%(H  $>4,$B27,,[QS2=@=0'$ H^XQXLWR(
MI?5];%.I$WZBVB"7J1K$=WS2P+83N5G-6%7Q/HL9%%)Z\V/?YRQ^C['ULJ3[
MWOF!)F%)?GZ!9MG0\+HQR@\^G/=0+M0'(GL2C-:0XME]4Z2;X.*9T'Y#[!=$
M>)*]'XL2LXA98Q1L"Z-O R"K-'RA .5AW%(:26*+P4?3B!!9ONRJA-''[+59
MU >>F:C,'E@/Y3?_ZV9OCYA*NF1Q\R2YLLL<<\[;:JR(/>6H&'H1>]*">V&Q
MTRE-9?M:_GWVAGN[?!3F7[;6"?]<MSK*AS&[3.7\TINJY4GS+=\<D!_H%*H(
M<L8H?0>D+L3+0A-9*K&0**?-](>;@,^K>"H(-X.DYIQW&H&E DU.-:QLYM.F
M:?W"P7N'R5Z#\RCWC,'J_.<-APL@\X+FOC=.*=;7FSVU;_:LEW82BK?0]G)$
M'6[CP;FT$BC<!=CCEG:6!ML\:B/:'T[,:VKVUC)XSW]08'WG:G)S8VOW2?/G
M[Z\&?V?#$J6Z;@L5%%_QV?O]$][K7-ZW;,EJ-+](T[3=H^A6M"DQS4UL*'$2
M?\Q]Q<7<U>.G8\>(N=B>#.Y,[]D";\NR'4]'L7N?B]D?OEP?3?IRV=L8:;;;
M<LIGRLU@GG,,?>LM=;OM*;KE]_8H+O]4]+21P3J38*WLOK*T_6'MM:,Y^Q_V
M.92(DAG=7_WK]$T.,TU_>W"H=L;,+>4_ABDZ:E>>E^SD';B09A^MJS?'"K4O
MKK=]Y)<9[B!Y930_37=@C/(+ .SL&X/_+A;!81+UM/P&X,N:-HJ&S_45!$IU
MO1YR7L4O)C5..6]=6'T*&9SJ^!DUQ(*@'A&U3_^^"\:T0C!3J<F75JH8T*I(
M7!M]7682S[N'V_)$EJ55(?35-BNKRMQUL< V9@1G/MI[,BRS& =Q[VPF0$R2
M.)1;'(HI+[N!3A6%]UE(K8@RGB+L>8IU_F&/1G\$Y(DT>930EX@AKG^_"IO&
MF-+8$F0MY)U/P$Z)%VW&_-J?&4:ZZS6P-V1BYK><4?DPMFFFE];"QY21?F+F
MQ3]!^/ A 8A&V7U_5IDGRFO_I4_RS_HDJ_#5)"E;6!4.]\K=A;L*6_-]E$#@
M'5B*!1(O7"R)6WT]QY%>7C$+8!4-N EI$\@\5M9^RA+T/ZZ2*I;"75V\.@:N
MH4TV%V%\L@]6G$W./I&LYP^&\[\%C5%"-B$=NH@J.3":O@;NL>#\KDI< L!O
M"9([CW#@5QA*R^'1S@(ZY-_&&UF\LDH:1U+#I62#S!1ZZM]R@@3XIK:'R,!)
MZ*'E^#@&%>/Q<0S*Q_Z8U##)I0=/H>^&=JM..KH:FS')O&L[9B_<(I!ZTB)A
MU*%_Q(I52B7G63TCGXU0U&?J.M4CDUP831L$T>VJ;A$\#+!2CRN/ULD%6, ?
M2R&^\$;?'IC"K*G ?_0C[/;]J1LZ1781&HHKG-_PC3'I)2%L8SB2APR#9>A/
MY^0.[AJCW.PD^G@RC-$.MD&<[ 'DPSR#H/:&H85RV%RI$P?\^E2V<H!T%JXM
M/M 94JC(>2>8PYF-[9"6N>17<)NYEG6X=6K0*:'@ FY\EXF=':/\B@K"!Y]E
M'AQX&[S9UW13S7WW3RT[72W4OT&IG%9>_@-^FJ?)>[XTD&@9+<P56K^NM"R^
M^39#RB2J;U[G"]VL[6KX_@:6=FAYVBGQ,H#J9W9K7 Q-\W912PA.VN7LQO2\
M>3WIKIOULC@XT-?XZS"N"8B"[E:,02;K48=QLRGD=[Q'6I"F[#;C,P7.@VO0
MP"@LI8BKN#8V:A4;.M^XM25R;4C)@UEO@Z)6%;\N+81^UPY[XW>_0J?T\\X/
M9H^6;-3V/[KV9DZKPYR.!Y!#9"*RJ7U^[:J$TG5A6F'[N$F_W"JRBE/<66!A
MLCRV#LT]D6"KNF@:XOW1NEQ7:EDE]@YF\N&B7T'T?>^BEGO"E^S*EB&B)SDU
M ?-NG8"$>9!7PT#GV;=>>X.OL!V"!/LC,G/K+V>%[;#?0)K^NV Y.(P7"7UR
M%JO+3N?",N,/3M+KAAL&::^0M[06!6%L6.O<H,MM7^5+8.IC6DFOFD?17(GA
MRB+44N&3F4[HFZ/;_;K]/45'&]GA4TXG197:)W[4"\B:E6:OTG)N?U*"1(O6
M?O2W#VI[S X:*D==6[&]76&O3SU_B47-LPMNSI5EQAE;[K8F5ENH$N:T._]2
MB1MX%2GCSB[4D0$4V98!Y<F74IM.27[!4L3[)):RAP7[I-]C"P6B\")I__P@
M1@4SNZ%DC-)LW38]7N-=H7Z7B^#",B.:<FL3%EOA5&CN&KS(&6T([<,#$S&_
MTAU:<Q[Q;*_K5W5%(BO-@L%6\"5Q-WN;N"&:KHU]DSBB^1$%?F+ELOA%XH8+
M^(:C[;3(-?D:_9&XZWUW'V+A>YV\6MS/:P]K34I&MWKLHZ)]7CX>2F^K6UQ+
M%._Z?-T?]"9?WJWNS8+(H]&'5'>:&:S=?CLAO+0\;Q%UV2%WY2MSTNTDMG</
M&,_0[OUX^=/GQX>.ZUT)4]RN[)^U_5.6\K4%<]\G=E7SM7;1%\4'G<BWVU"N
M=\JO?)A^3)90.(U3P51 #G,QG<#>"F$5IM/0JW"JS;!90&BT$&IT?B;Q"E(Z
MS&8FPB D0HGL]2B,+U"7:-C>2O)"FEW>)IOGGX?S<Z@_!F=O_36AAFRHC.G?
M+[N"P6BGL+^8-:V+1B54,>4B9#HN=R<8D<H7T:BX86+0JF(3'<F#E%.9W;PF
M+0VTX^+?OC"U&["Z?8_"^V[&R?ID%3<" LP>L1FH,:%@ Q96*KM%UPUBMCL5
M49N>E<1/P1+:D#X$VVSFND?$CW@:TWJ51)CA ;!"C[OC]>?MFDY6M_H(K88
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ME0A_AW^'F5F<X;[-'W[;%;RU_)I*W8DKDJ&#R?K?UJY^N@O0P!&'+_\^=Q$
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M%\>'LC0%$;C276?OXN&2DR&,Q _>:][[[@DVRDOVP "8GQ4*%^T:HWS)AXM
ME$$[.+5,V0Q5XMHUIP;,>3!:7%&T%#%Z5;!$K']^[3S#M^)K?M-;%"XWE-0D
M<\N%7V3N80N?9H8_^&CE#P6HJZN^3MHZO*)IL_,-V]OB1I.U:351H>L<;1Z7
MY2Z.N5F=>QR^*<!_(5D  .:)'X$]M(]12F*D-O#@:J?>?ER912B 6"8/,'K1
M,HY24'N;TPLJ^/$B-3932*/AN]]SC'I,N.4&@9)/8OF(O@+'3(PJ;"AY_1S:
M^@QU.D.G>5W"..;JPNLA 2R?@+ONW;KI;MW?7J97>AT]<&"/+*3:+7Y)L X[
M6)SR4Q&:'QFO>]1R'BJ9NK:D$S-+,>6'9826=*[=I;8G=L\WC:-)84G:$<EG
M*OWFK_[YDRA-U*.CUNQ]Q'F98ZQC#'OF#V$:]].>VJ?9;-E2>RW!6/Z$^?RT
M8L9;_;=@=ZCCJE,)!0 7Y $=+G(NG!*T4>(G2S)C@B?>@S+/LM7%(>NQAN1N
MGAP A"TA)?%ZC\5.X6;JXJDO\DPX"<'M_/ QRNS!\VQHV64Q;=?CI[GY[_H"
MU.M\_=,2ZG?GG1UX*T7#B9_2_F@GKV;+3D-H%U'-E"GF$CQ_)Z%\*OR;#KX!
MA"TY&[#2(U(*+*PESS"K^HS296>1O3QL'8U0:)'JL'5E%PL5R7+")IH*>R4&
M8(U" [[(I+_,P$DR\!X/#!ZC*$T5,2YP='V@EJ>\<[AN&X_Z07:K5&M-_:'!
MJMXQRG2O>%LN*Z7E8W">1#_NE_[1YXFG(0K<GL8??4$E_.VY6+</\1#PG3@5
MOJ![O+/"!(#.^Q3@!2STO^E;@:=P@(N*;YH/7\Q58LV%BS2T6!'0'+HQ[O-^
M!SR;TQ*MRH\LI+/WBJO*!7.\1ETJT&Z=\))15B3QDX\)')9YN'78+AL=RKOA
ME>[]]&WRC/>9IV0WJFVVE'TT-3]-K(.$C1!Z9%@V0X!NIN(TX@.$OW!$%,"K
M606WB2!Y]EYLKOC95K$'/OL8K$I4M9J)C4NA'[J&1X?[*@S#<\U]RIARG*6X
M0ITOF^'%:M-WLQJV#B^&YN",U*8-R=[-!A\XB[+>L72>/ZXU")A!VTZ4+KG7
MN>;^I^;=Y/3:"@?FT&D:_B69LW%<?0H C:+@0A5\#1:,/BLI- <?0>X8+,P_
M@^NT:<[\YB)F]"4<O>_VA9CY[I"9Z;U=W0UJD.)@C^[0NMZ<+]K(S2K&P]SK
M71VG3IGNO/$3HZ\Y<M1V;ONR)6W-V'TGI<Z='V)G1R<ISDE_K/O+2O[FV[*[
MNE7QRK8K> 7WKR(.155!^WX2G5Q[<B[A&%JY1.AME:<5K[?RFM?VVR>TUQY[
M9;#.XMBSO)N3.]%#0<J$ J#=\M-Q<ZP:-6V_%]5.Q19I-T1Q*%A[*4%'C\>E
M!X5(!+=*;E[/$B$A-%7.#]YK6A?GY&"G#J2U@AUJ#4CC^8!Y2_R?,S<_Y9;N
M,%'],!QK<B"7N P,>O^@T[O/K<NPF/@#C05)QNWSVVG7V[M,YKS1/'DM;KZ%
M6EV<2>3JO1]<(T\:9;4?:)V'+G.(+CGHS)K>\7CK\9F)F6&E-2EVCDEVBZ^U
M?=Q\[8JO6\JSKW_W%F#=]S348QA711A9V0_#V\-QY1L)63GYV>>3L5CIUM69
MJCFZTWT7Z?2^B=B_Y/23[19+MSC:G89J"B-[T>SR?C6S']^LVM50?-&D:NV\
MY57+_8_A+>J7ZY.L'IC*A3\0KUX^]-%;M3;%]EG WL3$D7Q?SV!;4X,7![>E
M3#^N=EU/Y6ZGK9&#]X_>E1E&&2[0(OS]&$4TBX_I\V1J_9@.C9C/;P;+G)!8
M^ V8A1]<] /<]@Q@,!:W\"=9$OT[W!)\O"7H63GQ,[9!Q#V;W\PLZU<G&IN'
M0_>B_"BV!]I>87(]P6M?6U5(ZY3Z=O'W&ODE,[YK+>_V/19L8F[R;6=8L-[G
MSZ)7_0RBUY-?T"Y([JQQ+9NI7!FD7DJ=@Y5$/K8T&^5*"C?<W'LD9CE@7KUO
M7LO=WFU>H+M'UT;FM.KUPYW-NW(7>3>>]/WH1M^U;,/5W1FU97M6XN;3+9:Q
M/';,OG)[G5#/+_N83^NY9/5[-<%5GZ,DYS!]8#!KB1H>A5C+>1MO4@>UG3-Q
M.LNAXS]AL:A3N4G*N:](VYWC=+U:MK[8H>ADPQGVQM0@;^G.FMR/"ZM*U4YN
M?A9X-,G-^Z96=HIK]XH6F^!D[S4O#6X+7E,G=G,R^A=^Y]1&Z(WRQ&YR5 9\
M\5UP00\N"H;:N.'M+V4WQT5]SH@K\-66N%X_9@,+3P9E2*K$QA(FKL?$=B+H
M1;@8;-]I\L7\,.9>*0M?6GE*RI*Z2EE]T/X:>I'LUB?W8$0:_/<.$($+<_XN
M@2PO5A>IG4=;2A[U/$5N^1U=FK$OT3-OWYNZ(=E>=F9\3,KZ]($MJP?VO;F\
M+R#_G-F;S%R[#WL[M.?<^_3QBFO>R]OMMBMO?TJ:=J]#YY'U:,OQ09=X+[':
M)HB&>"P)28A1%O5RY^S>O_UJT?N,>8\\CMV-5DF_L'[ZODNZVO-H&QO"V$O1
M'[+4DH+%&T4KR_S$BTK?Z6FGT@_PSOJKO6[&]OUJ7[/TV.;H.-NNN?%>;RZ?
MWV\0Z!?\-2#9B?:QV/!6D\.G8Z[KUKV]^^34W<Y7/%<WS^JPN3;IN1[J5):C
MXP5:V1R][6D6C)R[:7Z/9?&'G=+W  YC.3&'$0ND2ZONV4B/$V^UY$[X2P4M
MS"(>Z@IV@\Y%NKG7=<8A^E)/6K9Z)%T)][EE)6:6FFY:[K,&^I[M)OP(2W;G
M8J?N]ZS)PG0<(QFAA30TH$)R0>.':TACZ'97)97GL?;6^A9U!_,OUOAN\$UP
M;<I<$'AEGM?ALPJ?\B.W_'QEK?M&#=-GZ6$'?YXZ$@T,(853!J%,!K8DMMBP
M.5QBDD>>5+JDI2Z[S%G.7A]"S#(_'NPDJ:J&/'MHH3PJL<:3IE+X(\"S;FD5
M0L8\]LH\[(S?@3:>0A-N092CY2G"EP\>F%FPA+RLC<MNI;H 1HH'@'"_<\H8
MY6VD4_^0RA3\H!<3M6)A:QTL"\7O$WS;#;%%&RO%\NWRY6.4Z).OJD2&+4<3
M<\5.%547W-=A+>TS(.N=A.8F%(-MP&K,\&"@]9DMK=UK.%IYM09&-D[.=0E/
MZ_G')PIX3A)C"Y>TU??O]N:LAS4) +'.'@2!J)0S$RM#5[4?OR&JPA9^(O1E
MO((3(E8$9T9M_U!_RT4FU?MD0V2A(NZ,*:<V8_$U@A<[GL9\C:6>XZS >':/
M0JSJ<UP?XY;[[K0R3AV]Y]*M04\;!=1>TP9^3X&_)<9(91;6OL_R S_+BY71
MU\0TLN-)@CF@+<+AXOZ9V# Q378*,(JP5GF4=]K?M-*G#,H++<\*3,),-SQ$
MO][PR]BU$]>OO9]2U_FH]LYUPL><7OS>-26FK[=O[_XSIO D80KV&'3J7@MK
MX#N*WR6$EHC?!EI3PY)L0Q7M,BROQVDLCS;9WG[28*!X]@7'EN/6#FWZ0<["
MSPMS788>,_327'*WO,^PW][]S39YR[JWQW*W\W6-=9(?"([#\^C?@X5S@8M*
M("IG-7LFUI6(E1#37@:(!*?I:\66W +-%._XGV3YG]'/R?>#LMLJREAG;D;G
MG\\TH&LU>0?>W$__$2L2N6U^I6GH5/T@2:QZ,330O./M#=]4+PU>E^7?6XBJ
M>/Z&TAO]J@=75F)1JTH_-UWKLD]8>G"978R7W9W;7@Z'5YSMN'?+KC9MR'F-
MY354HKCNL/7IA-C=^^R3/84/N^WNI3MZU<4EZ]*]<FX%?H%OAH;C<X'?DSM<
M>_]0#D9?"Q>M:YTWS]IGK0OS/)Q38E7M4GQI<\U*SIO?PWZ)4(K99%\:XSCG
MN\DA^ZB]';-V;F MO^O$M0YL/M] _.TB>H+C'%+<@4W7GN\N9U_<]G"[E_#A
MXY-;VERW?]F6;'M-V3>U;'%KYC=&V$K%J]<Z8_8<6/?RK?W1F Y=TY?(J>-#
M'/XSZ!P(A<;X+!]"B4QOE&-2$:UY59MA*8S]'!M5X"MBAA!+,-W@9-Q=#/=%
M\X-V&"IB^>6\&7A FK?:=?ITS+Q-TQV:M2$#-WQGT/O@7H-.;5(MWRC"H^;!
MX<-+^:O'*/50LWI;"CZ_76K%_@X32M=A/=O BYW515? 9"@L8A8QYG3'*S\E
M3T\W8ADV*+^,(=?C+B>>F2"\U;?/JB$G"IKEW*71UU$>'9#N>?)M'"NUPM=(
M$I/:\G.>'VQ=Y_2M4PL0P;E!"64W^)I!9TK7A:L>/7YBB-;''J.LCC/Y#8<E
M!UU#7J):K?YI-2&C#YQCP5(]V3//KJ36=L"6\;Y8> 334T$?6RU/"$^N[.W:
M8#3'[ZVCMD^>K.NM_<FO3<1NGEB.02H-1W7V H,)9T@B 8US3)J<%E3$R:,
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MIM^AWDV,K)EE)$F/\ [^W^+9LC!;0#BBT92%!B1@CYCI9S2QDD 28X,KN4^
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MM)5.Y7"6QWW(S[;DAM*AX))B)9FO(_\/9F/!-?#C'Q4L61&5?U  RV+A++*
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MKG<T^X#UH9-AOAZE*J,%T@/',IDN$@V^MN$J?6'+)P8VTQ &$4BO;Z0AS+2
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M^$%IAVY&T"#4^W&/6["3P32N-(+]-Z3!)#RA- HG\W]5P$9T48YT[(=\V#Y
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M>5ZC\J>)WV#]6>5FBNUM=QL* LM[4##\1"%P#3$;Q#8!XA.0@;04&GEDW5'
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MCL=9D+".W8T[%O%<S_*5@F.??%Y/:8N&GPMZ6QWYO3:DUN3YIW>,NNUO5=H
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M<K6HNU=&O_^H\/U"-UV;M"YL23[@2GU!>=$Y\B5JCPLQ>Q*RLC@T-4'*ZG<
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M<B+Z78%,6J\E5:4.':B;&W4K+8TQ'-IVPX&O==2/\'G>2-/D1F2+L:QA>$E
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MW&!YZEG'HPF'F9M.J$\'VB86#WM7_X@VWU+[[E&P:%E3PU_;^F$(*.Q9"@=
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M8Q&>,:P"?//5I)V92&#Y#3A94T50*CR(U@%.,_-.+=! $L(3@/N;5F\[N_:
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M3E1&.A5DHX$0,258WLQ=GN;X=:Y]UAX,?99CM1G./=&_(!,[= "@.;SDM*7
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M>H4BF7=\2XP]WIA63WZ0R\J<W=1_@2Z>B 7[QT**SS 6#&1_?+1DAUL49I_
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MUS]O8:/B1)'8WS@ &%=C]0MQ9[MPMA#R*V0;1[?&$"__4%Z9JLAV%H8ASU;
M[PDQ(/-Q. Y  ^*_CT1^GC/B "2Y\Z+K-P[@N4QO_,LVE[M9M/M%66[WNB,W
MEP]@U3@UD/:+GEXY[XZ Z5:7A4B;_&OUM[LO([[]\XV9]%'\80>&^?;@JX((
MJX.E7\8!_('L$Y_!;,H+<P"/'X"ZU^B]ZS@D-1=S $-^?_J% TBKYP!J8SF
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M^_NI. IBM-+#ZYO/H<(S#M?(;M/#-1?9^91=$;_>FOG],KO<G-=41QN@$1E
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MY?G[507-LZ/FPD:,J>_9KI'%1'G7@(,:93<+FS3RV&]7,%=/W&2H2/9)WF]
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MDALDNKD!J<[;@+Q!<@8E;K1*@T;!+TD $D01-R!?'-!>9!%($IGV$7[^^L8
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M:/"Z(1[_6'B"T'V:$,E(^_>O6=IMY..);$(LZD\2X E-0;;JIUG((KD1(E,
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ME\K@0J6;D(YL^R-Z&QW5.N=38CK6]OA&PT+^HY%6+R O5XH<CJ@I_(!D1S<
M%5@!,?<HN,O@*I?!_@G+[3( KC_D;^E!6!&[8-BC?F R/_S4,V"-V.G"WQ($
MY&;4!4:P^S-:D^V\Z2,_)G_@3O)0NX,C=T<A< K)^M\GECX!+8(!,(V[0+A]
M73K3V0W(Y'-I45KH=S-DP:27%4?YR#[H%IP52 3B>9[@Q8DS?-MGA/C9J<*N
MYRW#JX%VB;4N0-=:#YLN>6CZHG5]UOKY[=\1)IG9CQYEO7H\LKZVNZ=V_X!1
M]]/A\J!]5_WH=H<\NM\I5\T/R*3UHJ$&1HW0))7D>9OI*I8SFHT](_8\6(ZP
M?!-GY*V#VLWW"_?=/FYTI&[,FO=8_99O]HM2*N8YGBIYM896I1'"9XB^I'UX
M0YPI.,77FY] /QW#FXC44HS1Z=/((3W^Y1?ZMT6.7"$F3-7RUPQ6L=,<=W+7
M@Y$(/O@PL6#H1_/*X\AX.,=QR2I9K1\&'G,1&(#!M&/%/826M6XMES[!3?\C
M*@0-1\X&) NIN+AZIO-#MI/U*!=,-OEZ:%XPO>^T_VQ'[$=\):'[#T8H*7/F
M$6/1A4.[3="P<0_G0;4I&:+ 65<7EV&+8_0\**@!5YGNCI=):55P\(L>_SK^
M<FJ@,>H:NZ<-RG/%!-^2C:%J: [DO8%-!8SBWS* J_TBI0D!<?R\ZO1F<15>
M>P:G1/+JL&^EE_:O(9)RN]0<(U4K/]NX6A3,*$KV!/US7[5\]KEEG@6=SE*R
M^QRVNW+G\MW("Q@/5GL!?^>1^0\WXZK=Z([$AEF3$P;3YJ./YMM;TJP&U.=D
M_LD_8=+G'59XB7Y8F7+2I%^WPK(PZGXCXJI@9<2[P66Z;BP<5>&Y5M;\]5ES
M7@<A)F\/?D(#UKMT,F$&-$(OQO]+$. ?N!/5@\#\3/^T/!@\"\N<MAR3,+\L
M3-@>0N7=_'&;FVQU)I^5LLYT[ 2\)MZ4>)=7=C[.]U8;@'^&IB,Y#23 /3:;
M!#@/LN_,^J;8&F!1*'$EX>(,6ZF[PS>K"X[=\I*AT&E?C0L$C:FZ[](:7ML8
M\Y [%KH4VA'7:0V!V.;97FV5H01T&Q9M_Z1H>,HUQX(R)A8*BJ3 G?SO>D7*
MOV8'E\(H$B9L"X-3LP&1PYN#.F>&\%H1#,TN ]$)X&L:@/1O [ZE)UA?'A>I
M\ .2/?J#'[\W6PEV>372"MTU3R5413DE56/PBA/-<.K$I%3(WB,!KLA<V%;;
MK?\^@(O?C/^ W(DSY!!V28:G+2<27 \,_/MT7*KH)$<<_Q+_!T#*P!UNB*K8
M-;*B$.XQ:F/U=V#M$Q*0'1EBV *LW5TT#6T1.A2'Q5V91M<[^&O+ZU?>I9F0
M#E'MA% 5M\S*@H9?+[ F@[((KX\M.T]7G[J6KB.TO_8ZTJ?26?$.)J4I_DI(
M6$".P5>LD;=/-+'<,?!PPL4Q/4#]KE=)[J[L,!^C!'S-[VJUQ4:O@IHJ,&\*
M(Y$C"?^#83S1%RDI2JT!5#-R&BJF(#E_V^H#IID+AT%T=]<A#?661\,B&!]F
MAY('VT_RW;*B82+39=5(A-_8YY%+EB5)Z:O?302O#K:K6DLQ-5;*ZK,S+,;4
M&B]\T14H%7#%%02IXM_)N+P!D9GLY<L("L"E2MS!<8N93(;2@5;@FX!&%.ER
M"5D=Z?<X*Y/U"_G^.?JN1<.\*=1[&WO>T<8@N[BJ",POI&A/GD1647A#=%!,
M[Y(#!P1]@'=7EA03$0"C-PW<BV7L[MJ'K78:%Z%XC#W8]-FS$A:P=D=TH1E+
M<B:>&Q/=X,$R-B^P.MQR!#=:HX^B&&>6,_VLAAFM!)&2H^!/T$4*XLK@6V$H
M3D><P0A'@@;2;8UEZY]I[>#[OB3E!LST2 \RB;N<\RD!MD2-[;FYW)=L[ &T
M5:PATG,2;UUH^,".RF_+XIFBF,4=1D[DN9+>"<<GW&P]2S\YE6M-GM7%7]6;
MS"Q1\'*YIV\N7Y"]\&@,,PM/*0_2"W0[3$;M139Z4CWHPPU#*?6DBU<?]WFG
MAQ*]XQZ8V.KL*+)4J;]P]:FAT>K<<,]/WNQ.'\2UPO_!WIL&-95^^\)I;45$
MC,@D8UH1D4D<F 1,6FA 0(C,R)0&1&8B A(@)JW,8UIE:$&(BA 10I11$1(A
M!%H1D1E"0TA0D4GV%HE;2,(-_[?N6^>>>\[Y<N];==^J^V$EE4KRC&OZK>=9
M:]MQ VO>%6A//#^2'S$S)I G\\E@_Y+2UBFB(Y97S$3(BH903V.])G!:_#\A
M=!4.[@N@6*B]N#M=[$\WN/V9)>II:G7MP*I/OB>0WI!47'(M;Q.V:_G='1HN
MMF^ VO3S<Q.U%H%LQ2Q"H*C(?P)%W2>,J!^!J!N&WOC](/;5)BPS"<[$2N.^
MGP5$N27?6>C=8<7JRL!<-R9+1BRUV[M:/3.,L&J?2_JF&94X;+>RYB.%6_\8
MDX'U7MNHDXE"BJ_P%C$,D84 G#9ADR^Y[THW8(2_-V'/YECH_&F% 4.#-,;V
M3=CE7D9Z$B;+ AW%_1$X_$O*K&)7V<ZQCDW8GOAV_\&OFS#/E$[/$W[SZ]&%
MTM/U+?IAPH=:+Y:0:@3Q3QJI_8)]#R?YLNU^YESLLE8R$,%25R([MH,VY.3*
M\?#O8A#21%,E=NI6XV@=2>DMCYK(V7@34^ =Y7H5)KPUN"UIZHV?L&Y0]Z]+
M'[H"KY[C@@[P]-?'UY[=%2E*:GNDPQ%Z>[<U^YP-!''Q&>1#3*:2<J&&GD6E
M94&EF=NCTA<C-ND1.N,)WO0([W(5K2[>_DH+C[VFM7X6\9B:@,6-T%BS0:;]
M\?!&]_#L$]4N^D=(;S=A[#G1;MV-:$*'C-BZ,;0$\I[\WX2M6@SH014./0M?
M(@%CW)57:LK?.]AGIHL?X[*3IPQ\@&,M3P07R;]&G-FV^NL=EO(W=55EA28:
M+G)J(D+_R=DHQ<^<Y9$-']$8\J!8+_Z)W_ZOZT)B$*AL@=@X3.M"I)H0%2W0
MX":L&R-M80":^X_.;6!R;_=VHO8*5&;',%*X/QZI2Y9,>PTL-^D*+3=A7N>:
MI$_C]1:?$ X)+HE;<R)V_"K2(71S=FW"0F@[B!VZJ,O]8EB[#[DGG*X^W!8!
MCEE!O0#""UK<L%UHO7:W%N?M4P!:)*W50!&="0 N&ZN$8W;2#< 1@>(Z/ZW"
M#^<_9.N([&>2OBD*Y&:YB"Q4-!S2CVI9X@"#G!E*MS[Q%;&>7RB125 6C9F-
ML4@9G)\%.Q)B^ 8J#3B#+M1VBU@N-IM^"+S<4@75="8U&*0%[3_,+ELKKRNA
M9#3Z>6/@ZS4[;GMT!:B&%+I7I[T"Y7W]M> 9KQ==*I7A._:\5,IZ-:,I+#7M
MF1PNW!7X$1%&#/:O?2;WP[-LK7:T3-6R(%;Y2E?0R7,!GSVH=X>J7=SI]>"X
M]X$V7T*[A$'0KM%R90.QJ=B?9SI8@IU@!"&@H\7+U!F#K<P/%Z0%81319'-+
M#,B1PC\>C-'EH)!72$7(&LCI\)>!*D"4,]A8HGA#=/"S&*D3U'">S/7E_#RC
MN;1HO'DL]T=C>X*3F6?7 8&UYN0T+NF-%*-TS0#2X2S/SW F2)V(ECPQQB#R
MCT W>/JV+&4DC4>"CC3?N2^03F&UFC#[DEDG/AL753\)$_V"4J> ^O<2C(O9
M<^D/;8<%!MS7%%"A@K80,Z_<U.;?NZ$TV;%A#R%$NR7%%M]L1+1=] [3T)+5
MI@'T.H-Z1 54<)0M3S%;)!,^?7H ;S>CDFS.D5]@R!B)1X[[WL5^I'Z0#O@8
MC;;P)O.NKEJ*?=XL <JH+)>M]WL8_B=A#BJ*E(*0:#NQ80Z11;O$///S##0&
M;N_@QT()CL*G2 THAQ\WC#?@J1Q^\=+,GP%*=+A"'JNS6CE-NJ&7FT@NP[SA
M.$=7KY;&Z?7XRJ650[+YCK8RN44:VPL&ZT#<[EN='A<5%,KPMQ.O:]LTJXU=
M8;H4'7M)]6Y[>JHHP.Y=P<'3G;L73KY=>-_YY,#;[K@B%27)0.VV21FST[4Q
M]2Z4BRZN76Y>23IE.LXLUN]/C@X75"@Y-@GM\.)Q50HPD"O0PQO-P.I7Y8"V
MW)6;HD.?^7=Z55?9\P1C8+J4YX><#GNX3;ORYI!KNK9FYJX/\2&_RMW ='LN
M83:PHM><9PGBC1))V<5N>$04RX22Y1BAF%Q_5:#EICY!'7>'I]_?5=-^BI\"
ML8XT<,_%476M1BR0M_W8"\W7%A5SXZ7AUO0-S)]8+STNJ@FS*[27RY'$89CS
ME;@$2T<I9NN1W!)$JIY-,5=?*:[])/MU'$UJ_N'1G67<*=-?]0T=9'X^-'0^
MG?V/]0'2[UNIDC<Q_T\"XD>Q)=E2$I7X&(@%?$5("HX+*^BG< TL\D[\N?(3
M "I3I=MLYS.0S"/EUJZ\R^'2]D<H?\]HN \5V[ZX/<8R\\]*5FUQC(S*Y7^7
M5/S[ ZZ6 4_A!6<QZJGIG3H'O(*TN3%&/T[I&&DXI8471*PZW7.I=NY,LS.[
M4NI+[B(-?!K'1T5Z6.DH\ MJ>'Z1OSUMZ+I0T7^C6F*KDA5)+^0(=X?.^^Q[
M#\EG7FC^D-S81^PX33B&]Q8/V9;881<$DCJGB%QJ1C=M_SQ'A1A,RR!H/AN)
M;-I0LYVI+&J9E3;;L!EL.A#8EC[4/>JIP-GS+<^;-WHZ_N4N[+&GZ\GC4XR7
MN&31;LM1,3**NE;)T^ 9H10-\_;.\B4S?X"].*/D'XJ_#A5>OEOU/.5"H[ $
M:YOYH.V2(H:=%'F;;:'WS-]:F.0)8AZ*91U.C'3 3O(P:=^)</U9\0"#398+
M4*$CHPRN!711,P4*L6D>-3H#MR3NW(1U.AMT6<7'/L08=.9T(??L>_[GPHOF
MP>$%AY7@'Z,29VI(-67NS-\?I+X%\&?3*UQJ7:A[-'>D=WW\5NE>[5&366&U
M^\>A]LJD6_>&9:.GG4QT6!\-@;BOK?&@2]?,B=-&24^K)BOU'$/\TXT?A5&4
MW3Z/U&1^__C%);5"\4@1W4^\Z;*0+0\U$2229(GE\(;PCT<OAO$G@C=^@WI\
MH3Q0I"*YQ[-EVN3%L.C HDD2DEJ60[#0K19$E7</3L=%H!MQIRSO5=]!-Q40
M+[=*+$T!4DRB5)L6X.D$F0-L=!I!HG%@&7]JQL^AHUQ]1'"ZBGZSJ*8J7*HJ
M/.GZ2&WKVY,3D]-V5$>YDLKN^V2V[-1K7-\)@4"\9AU;6;SQ-.@H\15&<IXA
MC?<,F"&3B#];^*"Z$"GKTPV:??2TQ]/_3+"BJ)"M%Z,A>V'..L/'V,RX@K+(
MYYL,AK5R,KXUEG VS%8N%*%. !++8CV\HW<XCBB)MP Q MFA&8F,MH@PXSN5
M4 L_%_1<-I^A6G&O4:.BHZ*:L+(^>&5@9T4LN+/ST[I1Z_#^SC'?T*#G!6?W
MED9L>[3];3>OLNRC4N3GH*<X?/ >0DQVWU'>B>'CIXHT5++S#^4?*Z&YW.EZ
M_)[0D0R/\"9K'0ZXO,Q)>Z!*.=G=W2PK[R/M(UG$_;K>>*7P68S;E><)-G7*
M%15.E*?1U$54>/4@V;RT<)1!):M:V-5"IV9HXKTY@+LV'XD_RT6G<?99V#W
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MK%G'4^[#;2& "I,(CR>E$/9 )AM:@HAA0TYF$BK;MHN1LZZX[ !ZV@ [ZC*
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M>M]O]\/Y?I[]//M7SG/VWJI2,\81$.:DJC@[/9.G5P=H(^6 .U>^K4&$_($
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MY-.K.,G/@,A'Y7O]M]?//;0O[5&Y'\T1DOS\2DB>7>X\4.J1V7 YMO6#_!O
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MX8_#@@ESWTE@U1A8-DV$K[MR'E6_/&0*.X&6Q#Y#*?E)]WL3DBULZ;@3_4^
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ML-!8-.84#R,R#%"V5R=LNHS.&H$EJ*)!'%C.9C#NRDQD))V]%::$'G;(&UA
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MOL>>[&_FM[YWNM\/-?_0>6@E7Z,N4B^H?&EQ8TY#VNMW6;'R9<2[ ]!Z-^L
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MV%6X2<;F8J7U>;]P?^=9 X%1#>AX()4AF;-H-%8U:@0_$M;$Z ;G]1V]C[[
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M[%"='=JG#"A["GR&%-IJW&7S6J+9FE( U5/O<]E_W44?J*:O<%]0X1"F&,4
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MKDK;0NY)L5O+64VFLJ#@ZS5"@4MO[NE44ODJ'Z]RRZ<96TM+)L<U(3]0A.J
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MX"G9EJ<RRKQNFHV+YO9BL09HINX.1JV@YN;Z(7&G[&7*XZ;RKG8L)2"R&U0
M34H^=%_ZN&EGJ??/MR.Y.LZ@\JE.]/$]N3HN19X6!0Y?330]T;?2\LU/M#I<
M^IRG>)5#HLDDYB4S^_/,F4HV,5HZI-E3@<_?%\07*"26?MO!]38H/_HNYRI;
M\_@]O2X[3'=1&SJ%(4O'0[K?F)B1*UV+ZL+F[9 ;R&5ET/DFT\M9E&X5P=U
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M640(^_X3'VBAF+(F\UI!TNB#DP4-5/M4YPC#B^?.WYDKG\NPONO^.7B9@&>
M<;)L4F?,#^D=+0X5L:W??KNBC?/CVJ[4?R1QBCN>%#M?7O+5,;I2^ U]I<@
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M;577X&EX=<M3UO6I6SVW4Z@1ED5<!/J,7MPP9"S\WK\:T)H 0WMF@_D.E(^
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MW? R)FV<1& N75^HBJD;_!X29!'A]>GP2T4U&T^_QH3]B9M7!6NK>P"7+ZV
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M_W&[^5]S.KM,MWPP(OHW9^S()Q6DO#BI<<?&8M=WM:-.LP0!G7%F M+3:L5
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M\C\*'S/ > A!B%<+7P$5@/76?MB-36SI2<++7<!=H(V(.S.@4+"KL]FBJL\
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M7 E^9X3GC>C!=+_'2+SO2\HI"2_U_-AC2O6?I4R/G7ZRJW)V$T*]!CV05H]
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M@ID8>L2WSAXY$H%-G=-$9F4#Y,*C?&-1,GU-*KXV%5$^4&7)?L60+$X1*@R
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M66S\]G>AJV.^TQ-N*4592L&4<K>07;;Y[<W\]N4]85MZ;J(R4F?9_]\DP*G
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MGB^K1U6DT:Q^.:3"H"O4X[W=XO 4/SR#MO3SMQ?9<N2*#RUMAWJ?P;:\BR]
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M;01/IQ;:%KH.3KCW3HPQ#M;Q-U6%4M\'7RIQ9:YUX*TY(C&>W)^\4(:(CG
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MDD8WO\NOPWID;8YM@2^40N;H5N4M]2;YDSK@D!.#ES@':O-0:!O20NWG#<E
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M01;MM)R! [>E2IQV(%Y +8H4O=M(/)3SAOI1;#C32A140FKIT< :@F^L*B\
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MY\+:_#_D:#6TQ&0H=#Z-:V:#95G';&+8"L\?GS&\<E]=9N^CC"VIP &@_B?
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M;>5@6^MTA9LNWQ?>)^"4@7"I+7D88)\#/E?;@[2AX='VAE6%O??;D^MCW 3
MLHVZGV@.OA(3U1/9RO'$*W$NG$UG)M\:;I;5P0FF!R:YL/^AK_(AR@JB;312
MDI$N7JF_KB]=5\DLB."OW8^OMNZ,0 0\>(QZN<L39^I>L?-B9_3;%@$[E WE
M!2LQ=WEHD"S\,03=!$-"&8T*E40;5%^(J9J]$'&(DU_K(256+E%L5QL<\&HZ
M[43/FI>"M;1A.+IXP(ISQ(MUT8K^]\ZL'IV7U)_#*V?5W\:T^+3]6*+_);@V
MHYIMUOJZ+\PW*:<H5/Z9JX?B.16+J-Y,-%D!+[G+4U'#F84"NF.[/']CH2D$
M$30U6WH^'D+M@/! J'F&Z+:M97@LX\>"Q'NYP 6A:N;-']W1:0NA,LZC;$$F
MKCNX?"J("4NX6$:$X9**XVIM(S@/6[>Q"_MOQ(N$,R6Z?'B85A(%WV7="N@A
M"W\Z[ 7-9>[W4-[[J5-+/5RWLY7OU-?2RCVCU)WLU+%2$W4_)ZJ60R(C$;CU
M>PQ2SZV[#D7,5J=,;-'7<1]1P9Q^/5E+CW1L85]S(^CSU,?A#O+U!9]*S^;'
MY=)3,9/UC(WJV'M]Z)_/6=JHP;)C.P5F1Q%0ZE;"R[+M24N6Z_.Z7]$AU3%T
MT/&E7,UM?%.D=,%EY%_Q<[%>=Y1"]5E>Y_X=^KH*?X\&M ^&H8/1]S-//$3N
M"XX_.P@.K!4JO3<Y /E/R7424KN7)T$"+:S4L(UY0 V]G(^=G;%4:.N8H#)6
M*B,.7O@4;WRS<T(Y5Y749'PIX-^O#5*G*:C3")>D!7LA-2 JUX_Q1>\^<?RC
M8N' ]:HL$NU,D;9"DJ>[.XVB(FA2[?BL6CVW_FO%#O>K!&^F!:C%,WF)GCXG
M&"OG^+K^AO'CA*PTJF7Q+WV3WE,1T6+).'/>HYH13TSSG,I3LL1<W<NBE)?&
M-U_?_L[IO7/,,J5\_QG+_*K]PO]:/#V9X-G"OBL,Z#L1E_9S>9/3YB)_C9AS
MB&<X?\W^FOL&7P[]R\,3SOU6^\_\ $<)[LT]EK3Z\4@/"YJO%'OG7<Z78-+G
ML2J[K:^)IV(]V8T.[UI:EF.]=_[96TWRTB\S <Z=OO+F.P.7ZNO?:V;7%.0K
M!9DU<MSJ'=2;[M2@$MBBF 5X=J?-"TA6LR4#'J\4:[/LYD;H:&;9]N1R+BW+
MY\%"(\!KUV9G^ARGKXA+/KM]LR@UE<Q-<DO<#(PC88-I>1[<SRI%3=]K+O@P
M,H-_>4=CJ\TJ=.5A"P6G<8DK;,ZIBQV=/WMPS9/$$3S!Z*C90Q072%C^Y1'_
MK,.558<N_2-V_ 2LW=EEGXLSSS,>GOV$RC^0"LSQ\*J4(HF#C!Z7Q*X%W4[E
M@$3RC_;IIAZ7W!Y_&)TQ\>?W:?^4RD1LDGOQ0[B89I1)G_[+ZB[+?PMI?]L>
MO#$Z'E$?VAVSZ9]&ID4 3X44DAT2JV0U18FT(-HOQUZ_&[^<R8[D6/[;-D(-
MD8G7+K_I+];-V3Q>-3437"#N&?K43^.\V>AT#^74Z#G89<>Y([VO+:1?;;L=
M8";06HN8:!HF$R^SM&;0@LG0#U[_UGG)0Y[(T/5>G(ZW_')N:KXK],ZK"$+?
MS*.GDW]97'/]T-0'T2"&K?"4!)VP_( *!51[E[.8.N1YX:A=GF33\SD);"^Z
MB3Y6P"&C%W.\TX!:\C$,=R<TFG5135/+X",.FPC5+!1G=JO^F4W=7MNTV9/[
MS81IG4V/G:>0($$8AS^&%0I$>P"S#!V:57>IUS^C+26QI7J7QO&G !ES9L!*
M7I7WM5\$6%FOW9N)BN:6XA];?[KXK^BL2M7^G>?-Z;E^%O >XTNMM@(E=(_T
MTAH=@B<J,TF4;(4LQ!OEIS3/XZ^>YMG9.&] 0LA4QM0G><5]:>7\[6!7Z7H1
MO+S-5M29B6KK+$\MC=B\2K4+%90<&Q :Z;F3@C=#GFIBBK^I1P3HL-5H4U_?
M=##M\F."(RIECD>(=4JH()ES%P.#:?NEM)#DZ+.YW0*8"6% 20@CV/9^5=I'
MTT);!W5JL.F#';*[95@_(,W*>-_!0<3*[WO%;,VWW$&XB)1YY=GOC][E.62S
MTXZ[5<\C.GUM+MC-L(G'?)]6Y_1,]\FC!WA^OC]VY"L_C@O_71C.@1%J;*@B
MAS^)%1KL.J12O+E]:]H@4UA[&._?#:OKEKG2?&C.N77X</A9Z+!LQ'K:(/LB
M]:C]D8C#]@G)_EYG^YDV1OTAXT3:CY3W[<YW&J7BH'4FD[77K,NK;40M,R44
MLN69W]%9#$Q\$?1P1):0TL>FJ\X,_0;W+^?ZSX[34K'20(NJ^N.(YEEY3_UJ
M@T/\S>J4O!^WZ\>70;_3\;+<4"J,GV\07K[+<WJ7AYC!G#PP8_T0\V&_+=KT
M/XN,":XC /H279[8?$I)-=<\1TCHCHT=/FD9=X?%PBK_Z?LS=Q7>UM'23JF(
MITN\GS\QTAGZ(-\81S;V,LD1BC 2BCC*6)60S3C?I\<E90X.!<HF/KXIO6 P
MS-C9N33@PIB+G&FZD/>@:)L&)Y'&'C51CLL-='S!/-NGAVS3+Y W$%-SRSX@
M8R[^LZ<VR<)VPME;S(KOE4FDL34%S46LKI;T?M9YU/#7S,"%P\F\-.HO;XZ'
MV'/N;-T"*EE6J"'(H99NX!LS=C,&P%+AZ7.:X^OV*80#&SKW_WQ9FBY-JEA]
MI34[E!H65?1\[#OC;O[YE&FPN>R9+_CJJ "Q%X??Q6$.!4'^0PGPSPP%T]"
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MU4Z/V>5!H8[]ASH_W,W29TLQT;_G6:*<+SZ&@/88HIPF?)\MQ]#;1#*VLFX
MT<_8HJ-(X?)@2G%/(0V3%CT=F-RI%>M/E[DF^A[-U"];<(#S C737AIB(_ZQ
M_?--&+;X.1IDV0$'>-D"YUC*J+DR!<90FMG)G[L\@CB\NB>;ES&'8Y2\WUZI
MC2RWBHI<V.6117C1T:EWN'\0C)(=V]C1(<NK% ?]Z!P%GX\4KU7*?&@;IKSM
MQ>&K9K@0 E>GG#8#@,!(F.!+7#"C_PK3/NU4^OD<4+K9*9N]BQWK"O^4NN;M
MOH17ZA@K<SN8WW3IXJG+$VA= G4:_?<L-'VO5@5JKUS3>88"_F6R?P]T^HO
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MJ]:X(_'NGO_>_G:[X(ET/LPWB((-,!V)<G9\G66:>[L2Y#X:[@AWTR"<W&L
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MI!MW (Z9&Q95(G(\A[N7NU<3-J[HOZ(S3S=X>]GZ;1D9.MKH&^[RE,@?V&E
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MN77%DDOXXVJU[DB0^<,X$60D_2JX40IET84(M'_PAR#"E 3O\O38'P*<#+J
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M<O$@[?@4$>!4P)AO-P?W=M8B;^V5^3ETFOL>S>6L>P=\>;FCZ8IE60Y5(R\
M.]6(K:M,'VP=8$2U2ZN[)K,#?4\B^6@R!@IRZ (8(80H_4NK9V_:,MBF7!E7
M'M30FA8!FCGU9N=173N.-'B:VIES/Y)SLC*!2$->H=792S &Q27[HIJD&!M"
M)P> D +_)]>?O7NYO\"WZ(9'7K]+X$ &\5_W5TIV$6_LWIDV88\8SO*GYUO!
MK$J)!B9^VW]Z(K[_GN4F"%RR(;\J+FN7)\Q^>@K5 SI\"Z4-X@&E'6;UFJK$
M3Y)(W>9==+VZQ>+-RIV**#A@!79H]]).]F6='-OWY$L*Z^I%A=?^:60'XK^U
M:63[SR/EO*9YWQZ_\6M#-F16Z5SN;AN1!XDPE6V(4D(P,MLBBS/XX<]5.6^2
M?F\<5")CNUXDW:X26GL]R"\B_V\8(3J%1*G5:3H<]PCZ$=)KG\ EXP;"P+FW
MFWI KR]CK#>:P'<',C79+:W<PC2<)':,<PZ,1L5PCG,F-L,7BW/2%YI"108Y
M7@->-LW9@['C;V"EUCVGQ'^]BM[E<<-+4]S(*-EA\,76[R-1LZ+6%->)2E&#
MUTL%QZ "=Y^<ONATY*EEP/&>TQJ="H%!,U@G1^LKL_K%<6-N]BOGTUV")ROM
M6M0B1[%V8L&# Y%.U6+&UJ/6-L5:Y_2+WQ5?57V1?O/!_R0N?X=80:AY;B;\
M@#=@1">< BP@Y)(<,80KJ]O)QVHA@F8QIJ4)7_D]=Z(->@11NFK=[1L=$Z%W
M)4"N4[73^FB.Q BCBB]"6.:'OG%LLNXNSS)X7M3FN$^VZ"^$K$B^II(4_:PH
MXFFO:"+Q@E,EG_6$1G??EP;'$@>T&)TW%2E'@Q^EMY.RUW)^F\EU^9UQOVIW
M_35[3#^<?%.R& &64Z6^OB7D_\0EJE',UVZ]H451X,U$>)64+5)MEX?W/'OO
M^6XW%%",7A:C8I)]^)EN9)#D$DH/.&!62H,?#C+%I"$OQ EAF(3WA5M_IH.E
M+5IF=\AW75W79F?!_YIVA1YMZG,U_IRRB&:+PLTIG6>Y/&!M)QEL1+=5=!P&
MFS]#?< TO<RJ_^G9_70;A2T/V0XDVO-Y+)GZ5/G>?O3%(T1<(GP %@,#!QN\
M(SM:*-0^/T#1)TR#NJ0+?].$E\\2/C!@2'T,W6"@9/:]-G:@+$]K>2O9XA/Q
MB#(%NP&+81M)*]3,_CK2X*69')2/=]W)15.?3:);=-+,3B%N((\3&);/J9A]
M%@MOC_@SB<#+7^2'L^=Q4_I3H25=<S*LH].9$IMZG[WYX OY82<DQT.CU\/+
MY",*C#3HWM^3KSBQC!+/PO:1$>E3G03^/U_\R59\FN!7?HUW(B2+'S>*)H$O
M=HV2-8V:J\#FE?P/'W?>(O5 !74_;<4;PR2Z3T!:V5;]E24,'V&!PA^2&Z7?
M:GG!1,D/?@U2*!7>^/)4HF.MV^$U34O!A7?YG@@#'ZSZPYQ%+;&U'[\GF1F]
M4)G. VCZ+D\JY&#G-8:H9S/3KNK9#&#4DQNB&]*V'9"5G!<-IQNC6Y &-)OQ
M1GS[N/9OA2OZ#S%!H_7%,K5/BF01D.5&E@O V@QE0GXOOD"H7&*@<*',V-[H
M.1GF:;S::PI.I7%,LT68=QH^/)A7_[-Q!GH%E+I2LBS!7'+]R?@'U=/_7>-'
M </HV/>GGH"BH!4OIT%M8;$O9S/[,/ZXO=9[OTA-QVS_>%SZ>XH#D:9A;"_L
M@S494(\HR1N[M=:-$OP /N>CYA]A4KB-48\Y[XG _/8>XWO25Q;[]/IM,-[I
M8R18^X !R?HEY"S)LE+31U38,U_-NGGQE144__-%.K"V?K_BY+$+//%'3F;&
M"Q\\ACB9_:(=E"&O06" B$-I/B:CSYHZ)L!25&$I!,ZV=5PD6%-;AWV.-FOC
MWA2_?2YX.4Q^$)9AO/#&)K8DIE@\*AWA79?!5&&+3&[B@3P6'-6WB9$U4__I
MP\O8RKC)#85,L)HVAL&RFVS&">TDD'Y<-72JQ*2RK]#?78&?]EH\--9:S_C@
M(*UZ4LKIE\/'B(D_WF%H._U=GJ8_[+L".F3;<>L:\L*B'\QW7,VK^-]PHFMD
M\=T$!WOZN5/Q9/M#T#/I.1.,C9^^2S9%:C7MJ>.E!I(K8\Y5,5JE;S&I($:8
M%1&2,2^$#LT!M"AM3!T:+@<L_!S1MMF$[P0B:Q"]Q(Z>!Y5  BF%7MCKU5S2
M-7FOM+2EA9-Z:Z6Y))_3&]W .M]3>E+&4Q;M90"XL%307=;H8,*T/8>OBV7)
MF2#M-6SJ*636TJ#DY<@N,X&1J#B?'[2JKK=9.M;#9B*PEUQ>-'<2R&%Z$L>N
M%A\!1^.:"PLQQ]@ZE;/OLA_=R/6PUWS]A?,8"=IY$9JW>0VP9_9O/F>VO<<D
M>>(RV!KE(3X:DW=RTCC'=WF2C Z_K36/BCZ$2S([>0UXZ\D8Q 5$^=^:='T=
M/'>&>:CNA0:A86F[$MLV<V-C;5!TZ'7-5/M-W?+4'E^]PH>NI)$>*ZGL,E-)
M:T3+[Y\6_<?=COX<3U2;S(PKJ2F59(T$_>[]YI$M71F0\3ADLC(K!DF37L(K
MN"Q8BKEIBD:IV.1&9(8H]0\@M%QR:H-P:7@EU&?,?J0YPW]AY3D+S!G%[&?'
M,6W>8_9QM) 6#$X18Y6>0H*F=FSF1U)W>0XO%6?EI%8R!O/K8-C(EXN>[T<'
MQI:D0WL>!Q3/4?Z>MJE,MB\C4$OFVP*3.:J<7DA3=/HN3PAD^AQ-$]*LTAW)
ME#8<8WO1AY)V>820'@L2(QQ]]C\,:(IE!M76S%Z ='OA\LB=+%VQ8:19_#;"
MU4,\]E=:96%I>%GT3D[:H%)"+3_">X@O?[S+7C@CVV]IX8PQFUBF;!R8_&W[
MJ6K Q(3G:*V495AQELF%P?!^EJ+<ANF37LL0_4;G\-?/U:,*5,I:CEHJ&(CI
M!,+]JFDUD;8?#51D+%Y^ TTLJ;[ !ZW][WNL:/1PE-G_%I(D#.4%&5'QB!(Z
M/'6X/N69Y>>VL="9VX14L+EZ@[CI^2?".JL^*IUG32V9)+GN3V)'K&\[I+]%
MG\Z=:)U+4^+*\M1JQQ,O?AC=J,NU_O.X[%&F7\OCBO5,Q]!WQR'DH;0?1,<]
M%;Z-9G.9E CX,A:4 C80"/"]* 7UFCSMZN#[PB,TYF:!AX*1O'.:[",+N8&)
M)HX44M=,T#0G#6Q5;92&5P"*7.U%@;+K$6UJ"D$=^K=J-^6$/I9GG8S7SU@^
M?"0@5[4\G4(9V>4YBI<D41&K&^]@_\)%D1>8I[QRQ(#6Q4B#3U4P[:+*6E5#
M:;E'SMG3E-.I5Q72/<JS_%I:FC;NC49F^BV.14/#[C:]FK28<+(/6E5^4XE]
M'%%E%W6ZULTUEY*OM6!A .NOJ#6HJ*R)#SLQ^[12]_^DY?C_W7J<"5TP8A^O
MY4:G!('ZK(-WN5>GYTJSG/18[SP?7@FHHMY#&J4XCG(=BI!(,;4HP$1"TF=Z
MQ0WOWNT8&6[^VQ*D#1:L^:CG_6LN@#R$'=*TW>G<.Y3*$=II)P1C#G.&M]!2
M]7CIF> Y"49*DID"0F22]I/I#!'A(A<?P!65[E<JF <0OT@I%SK&]6/?0H5L
MOP?=VZ@[\W/;];E8XYMDQ HDY!4NDXR([9JJ,PM.(M]X7//O8&30_V#L/:.:
MVJ*NX5P5D1KI4B1749 .TB&2JUQ B!#IG8A(%Q%I04)RE=ZO5*4JO2.$)D(B
M))"+"$@74$*"@/1$*4<)X8O/\^?[\[[C'2-[Y$^RQ\G9:ZTY9\[>:ZZ^R=%)
M)I,W],J]].H1FNI612+#]@UT(-*::&97)VX57&<%_X64^^5Q=.D1+^5)R&89
MB4GD*$#Y4;<0W)UR8KPIL>O=>?^L?^RC5CSKTOHNT8E^[Y]^$E2S\K-'"A-I
MXH1!VN=Z<7=*7?K6KCM^Z6;IW^FZ8Y[INI,731)/E%Z\PEU=>Z*V^H^_0" .
M#!K;JW4,NO.)L%@,.=%M1[=73;9&N[)%6 EM@, P9L+EGN:]*_$,#.K#<-)+
MOZ64J28S/5=3;G:+B"SYR]DE?C:K-CO3W.'B%4FXX=M4UI1S1UTO'9D__6HT
MX_VWI>H[BH?.8_O"N,OQCI^BKMBF<1?/WJ%OY+?I9U9M'H/"%-![>@2Q]\!!
MRE5W?AH+-*3A$T]5@7[0==&B?:A:=PH+VKJ/Y4#HUQ%U$S)(=]974*J;@PS^
M8%6O/,^'V<$98FR5(LR @^-LN:^4]IS\^K^=2SG9R]A(H1M1P-A>&\.+: C0
M4(49D\C8W%@JB2_F8J@2TT)L<0!2C%3-#%AL\+F=93.A&>^(O\#4Z1[C?Q9<
MCQJ0C&>OKUO+5'VW3;#_K[#,WH>_,G8X1'[)Q14K D\6JR2\%BZ@/$E:NLB4
M[_6&GK&]WJ^'OA?."?2M?)+X^< CH2G7IY-WXLK &.D.0\MCD]')^[>?[3XJ
M7Z%8-HY[DD[RJ*;5F*=?E![/+G3)T"S=$:T0K> R,:OL,G-S,ZB<^$&)+>'M
M5J6[4)'$H)B%,ZTN8$ZT(AT2BS\/. ][)JOB &QO/E]"0FCBES]OT@13SNN?
M5$\3<;;>>=+5PYVL2%7O_.#NF=J_<HYI[.IN $EJ2AVX6S<\V9343ZL=P<L(
M.)>W%3E/5>GGR.YE?YV?*KA4FGTWT\KL4KN9XJ7NS(]LGKYRSB&!-8[E6#IZ
MQ>)@F@&*<HDE?7 &SU^L?NE+%O)A V-?X8<&0./(OW/I_VJ=<KK_[%([:Z+9
M3R9\/D0(-+4M;!_F=Z--(=N?G%_D'%)AK1.\$G>S<T0GQ=HAQ9_AUS"!L!D=
M;ND^'9FSXJ3B9[3AY!V<MW2UF\R];E_:K,M+Y+/A2GVYX;%NW02?]]BPK=JZ
M8E?A+/5YLO:&_U5D 0R7MQE\:,T:?<;4HJ<1MD;9*:G3BTW(.WN#PDV@OL"<
M_T:9-Y1VJ4L9:N!D";V 6C6@FBP/;0]L8/LOW_3@8\(_C;RKQ=M2Z/ 2"90*
MA5;RA"U&*?,\9,@I%@?ZSJ06SXXH4Z8#"'J)ZNSE;Q"<6]>/2$#[1-"N01SH
M>^5SCTW+7K3.Z[8I-@@NS%M,J^ZA2KVS]K:3?Q2;Y>G;5G>%+7-#WZ?D&D 4
MLCWT@ROT;6N[X766L6L#:D5G+*PRDU<J-S&>L!/=6C4YRY'77#L2 Q9;;M)\
MO[8TT<")88R?ACR2>;??LV6I7<$TK69E-MPX=>AU)UI:X\_>)=^OG;6:?K4
M=[I\R2G46Q;7 ;W)X2A%[B@5JEP]2LW@)P=XA%2@V"38K)UQNB=PB0<A<)T6
MD"&^;O_PRS?Y6G_GG%]NS@O715A%$KX'365S\,"JWJ!36&TDMO<BTR#J4.8;
M 7<;& T62]Y%IG8<@R0N @.&$%%\GNOD+F%3\E"6WLF8LWS]^=MKO]SO;A Q
M,T6DG[9^C,DMLP>$9EN;NDROL/PPM8?AO?4GK(H<KU O_BPS5X]=.O>=$%]J
M7A^>.OYQ0H>NV'?_>[G"BJOX/W4*KF)PXISZJY3AAYJ^#^.XAP02WOO>?N=)
MG[P"5;:MB/O@9Q,?$ ?/ J=7@4/IB-F$1>UGAU>97$ 4W<AX*B-1&<U7N3#_
M&?6DE33V=2;,PL5Q,FS+TS[K%OP+?-/DP&9*I0)N/QF4OR D#/%_;B)U^$78
MX95YCKYPS>T*$6Y;O[Z<*[)S<?K!MV-M MO+A#,#.RH;<+N%)?)#+;Q5BO^U
MH)74G"SA>7=:ZG&<EG9RO++(/(\:JAK*U[)UW;[0U^/;1'F5?85YB]5*C=[P
MFZO=0OO%@#3,#_P$KPNHH"W1DNSH?$ZG,&UCC-F5->%0$XCH_\69W,LBLZ8_
MLCZIC,0JG6%-MGWG&'MSVA/\3+5GS+W2)M^S!3JA/-+2=0RR^_ ]E<B9[_6I
MQ,N$,,68Q5PL5N5"?J+)3Q.G]W63-=>C%'9KQVJ&!NT+%Y?%,L[>TW,0_JI'
MX?7YA&CZBC;-]G;B#WFR#Q3JS%RMIW"XJ'YX6.+4.TVDT=D8UDM3M-H'7(UY
M+52POQ.V.77I)_'PQF_3<DUD!I*#X$.)0S!D$3P;,!!3M0QE0AR@T..(#1V)
MH0%@;M]BJ<F[)4;L7U5@&JW59E#"O^;<:A V!-1+Z&W=<H@/#A.K9#H<I>UF
M)#[NV,P(>84:#SKC6](2E-2M5_^M2VGA? :RH%\?$:\"Y?\5GJ)=)MWVRK04
MOH\\-3\W6&-:Y9]4,/-"<UET@Y?@.X9T POK;A<IE<9J_,*3+Y*"I145*I1$
MG?11MTQ%Q_NM:-S)&KUF]K_VH ]4U-,OV,5ST11&5=-%0Q[!].H68;%3&PQ1
MA2I.ZH)<,ATM] ^-FSZL,1>&XY5+0*421'IWW<PCRR_'LP8;<KQ:"NE!8!O-
M=!XP0K?8L$CW'; %NU=@<XC<0+;94=(\>]JGF2 T5S"=MM3W;/#^F.$SC[+A
M2%CB\LQR^OH"2NE+Q02$:-XHI]XS?Q&BL0S %I]+X)]1*8DP;J;\H35P0(2!
MT%'U%" =&[M?#!Z7R^7S:'!6ED*B\!;!JFWGI4=0FED-?J*/O9.+Y5K&E;;V
M)!.;[N"FE A.5QJ^'X-$=8]!BK:>,:,>YSR^=Z?(O3+'(YYY7AGK?4C:L*7^
MM"Y+'5(7KEGZGO\\^4?ORL>GPWZ6]15[TU]&;BU]VZ/RHQD:'SHMR]>7-+85
M:;?<T*J"P=XN2?W>Z# XCU$*-9&T_&*;O^=^5:+OXNMLG*%TC;4KS#WGS/7E
M9/DJ*@47U/OD\!I:D"[7VTLSHE$7ZRR<YUF",N78.\<@OR('DCX>?X_UGT0E
M;O_"'U,6U8@M X+:7[(J\0@%6#!;GZ9.7!U8U<OU+/2VP^.>KW1NNGMED*+T
M;:/Q.N<3:Y+[[?=U'X=66^^WK4^6X,K,BZZ$/)JH.G.E'U/U[]<72-ZOD3I\
M7U'(ZJ_=L!RO65FKI_N?4A%35[NK.$W_R*-BFE/J$OMG?N&%P"9Y[?T.#8EU
M@Z/.#>:9V5\=LIDHX Y!$L^)]@;4YF;IXTPWP(8A1(U!I852ZW429L@+9Z>A
M5\*:RR6WE/P3S"4ZY@<*PZ[I(L\9?@AJ@%):3=<G'0RE>UR5'Y_+%]H/HT_5
MS)09.@YE-H@/5.A]'S877"ZT6<[V$@LPTPJ-$EZWS+EI5_G3WZ;0_X8](O=A
M9K9;OM^<F8'FQ'J^(>3H!<'STE$1S&-8=5_MM_OS@KJ%02]6E/DGA2T$J0+2
MTG[L-W]4 =E=)OKZ;P](+NW."RRBH5: 9JNA;,'AWWZE(2'W'GS0IIQC?Y)N
M&MI\#'H:LH%]#6%J&KV?&^T_A[^<D8*DU\3>G:7-:*8A#R599U4!IP?>)AGF
MAW+S[-DU$Q,Z#Q&?WO?O^V$#OC65OQKXC(COO\O(UC"\96F0J,:T2:[;@^+=
M9Z[U39-H5SS?R,7FZ#ZR[Z?)[3D'Q_-C)G)1D29G4Z,5(A?\S!O\/_8_FFIZ
M;C/L/_2)2C$TS%Z?K$+FVA8Z*&W8YK4DVWH-^]GXJ\-_WC@BM#:!F+\[^CUE
M#<U%D(]!29!6Y&8'W8<*V4QZR;S2?-2(_V-HZ3QG/UYOLK4@,-S 0LY\DJE8
MBIIA"2CR!!K93P9"KU>NS>DDMKU-#.,*U+H:F@8WF=S=L3N*0<,.K[/F,*>/
M"*R37]!AP$_&R7TEQFK<)3IX\_#P!F:LZ_Q!,C12NZE>0ZFK,7]N[R!!BR#J
M-_:M7C4L$+KN[%7H&\J5K\KC[]SV)>889"'L,#7-T ^[RBOKA)!].JSF"'W+
M$S\<?*Y>5@,<2_+ZV;3?&N+*?Z+=:J]>V\L=5Z30Z-1S_Y2O;9$$ZHRU?V&T
M'^/OBKRQ/O*I7(4XJ6L*CK4YOM-5)I40L;VVE%<)Q>"Y<=)(1&Q3:A$'E[G
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MF/^8L0@PR/#XO^Q"APAAY(P6$S<U+<00_WON.0#+C3*?PFE]J'K47E6KWU+
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M^N&1<\[KSVYQPVOW?DXCB6]4196JKE5D>OQ0>N"2,4!?P>:L=.IKJ64>#4?
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M$"[&U$(P_Z30GZ-A']&F^Z. &Y(>2\'V61R#N"#[&?NKL\Q/QZ!FUNS1B_T
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M6;91C%\6NO*,!6\SI+MW66_6M=K3;0Y0'S?G3 VM7\-)4U) )E[6.C[WQ7B
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M^4YE"L%' E.SX?O!*B0?'XB(77BNAN+A^T2_]>$O]7;)C^++\F^TMI08C?(
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MKL7T.15_.QLP_X9??XI6*A4G _[OL\YHVFW2=V-UDZ2'[',5^"?<"XBG9W1
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MJKJ1M'&[(1P3EL4^R8+P8VQ)U;_?)8;JZ6/A&+'<4W%2_%*<WM!EP")R17F
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MO;%3XUDI8&=7;DE-(\$K@_RGMCT(+@:EAER6A"U1XY)X,4G]I]?_M=[\GKE
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M3M=N&#;>N?UV_(;?J$[&1_L.\_7H<?(DFIL)$CEV8+X#G,_,UQA0\<'',$6
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MN4]9VOG& !-><H1E(+ON-NOF[]Z6^$-C'K;*O!C4:V+OX)0V^]?_&P0@TD1
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MR\!;$B/%<WS'!K#9N*W[-&?,#A_>?[:F^6V>I3\N4I5R?O@;ZN/C_V3^TNF
M.WDD?7)XT6:"/EHSB5TH-T[&T0.71FHF;U*XO>SA>(*OSF$PA"-YL\0AWQGX
M]FGX7-ZU.?N()X&_;P4U!K)?9ZG,2YO+?FM=Y5OYZ'+[^GFWFX#<(FQ-4@50
M<X;[>JBR&)KA3)6EX@A&XRCYX<L_M0.;]+*#-SF'E%P96MHCW[KEC<SN:5.A
M=@MDV$LPXVHFXMN2N#%;D88?(UZGG"0XVT:]#I"^_6E9</7"@ZE1H=:%W* I
MI?H+Y$[_F/A'[)3U^J,E;4./O9TJ'<B'VQS;)^;9\Z=?/'8\<O/1HKNM;*9M
MY-/QM*=:)_4SA6/MD9HJ90*^ "DLQDP\Q32P!')VO,O"&GHXZ6](4IAMH41D
M,-'I!P"QOU<<I#53"9Y<E4Z:;G] 'S6@D*M4M4@PV]7'G.M</*URL>YEVL=!
MO:>#N/WIZQ'4+A2HV=NQ-$;FY7RN74JG*P4(']R@)TI-(K-0R%7D#H%%+7>-
MVQ5"$2=J@+UL>UI96&S5R4*MV<)GU1.SJZE[[L)NYF&LI+IPKZKK7%3<4I]#
MFDFZR:1736)-4T,;M+L%[W_WXH17<D*3?F7!Y=>>=Z[=U]O3&ZG3?RC)^%C[
M]+$JWT(7CGGOL4^_SH8;'_VDY4HEDU\QA!X&!_NF/OSX4I;T\%9D^U#>T>>,
M08;?Q5V$4Z6G[^UURBO,-'&ZZ'MN9X;OYGN[)[MOPLZ;IDELN17-((_)_GD'
M)\B8(=%M^OM=/E'F;7++;(FU8?.28%_UUR?JP9=YA_8I7/W>F!.FT=IX^.,9
MZN=" 1;\S7<5A ,. KG>B>$%X2,\=8$B07#_5V"<X X _0M>7]NIG7'"9\]X
M=C%ZP[UX/T*G5IA$=43V(/\$]J.J&5:S,IUS9LK-=B1X)?+C2DW08%CGKOO/
M;PA+;[E6N@Q,J5W,SMQU@U7CV@AE<'.TN2@]]M*6D(AI4GZ NX\_^Z9K%B!"
M(&^7G=MUW6)'>7J[M5BNW]>C"YO*,TJ\78IF'*M\C97:S:_T72 SZ#7DA; R
MJ)>D+$($8C*,B/ION)LI:@2;<C!I\F2^G9U)D_DZ.:V.*AM7J-);]]7FULOZ
M5[QX&_7$A[XR+[^.68\YKUW@(XE]6'G:86B 7A_=1E<%4^9H.T&GR<SH,X!%
M7N@")VQ?:S\'F;9B%R@UV-RD[[5V*_Q!4+C/]85IS&%VE^PZU1-H#JVB.2D7
M6"A7*6Q9_=2AE7GUZ] ^1<&IB,C&"O?E0<;SNCUO%A[OO^<+H+4[O1JSEJD[
M0WS-K7M>'H/E44]IHG!57Y4FQT[*<TIEJSZ0;@,]G=Y-?>:-J&95;1)+R6[S
M<?[WG&-E2D[4G-P%JSAQ$/C_S0JX]C2+R9\D96*N+HW2.92.I63*5G-?_DFP
M]YWRZ8+R0.Q6P:8:2&9)]2L6))_^HEG]I>G]E)-A8EY99*77!KFLT-JNN\H&
M#R[^3;Q$:K&F3V1$L^J&%V4GEL:P/*RPPD*#R*#4:]X1B*/:=MMQ<&WOU0=N
MD%"@///GSR7[/G//DKKVBN-#]YF)GRY@I]>U&^WBM(:FWQGE^D<A/]!@W$D(
M7L'NQ&OSL@?IP;UC.;R_03[?'AJ Y !<&P8%??X45AL7VX81:S*;)$OB^QD4
M20(R0'=JX*:' P,#GKI1*=&N$+F-8RK)S"K E<:8)O[RP4>G8"9FD$Q,*UVV
M:2_@R<  IT4()MT6K)G\MN\W0PT)1D?^ZXF2GU_?\?"F 7_Q>I=5^NGL7WPU
M)IA^+.I82=I[[ZL;CN6Z6X]A 7LTJ(<EBQ XUABR$_L*E4ZZ1,V DR>%I@B*
MG>=2&;M#.'IE(?16?8D*.ZS4K$='^H'$1 $&R#VS'C]KS$T-.Q!GY.\:]NYO
MY%=J/%:,L 6N7BC0'T"SP_^Y@4[&;&N28E.2B[?W>3A%&.8GFQ]ZRORQ[N'M
M?;3$>[RY[HE]'/X'-3IF_V^]QU.^/H__A%D/"HX*/]:HTZ08^08I#;,+$X!-
MP.R$]OV0"F2Z9IK[ DMM<$*FP-:O9M2CY<K ZFZCV/3:ZH,4ORSN3YD1K1=:
M:0AJR8]'6ZWDKG6J'NZX:RFS_X*5C$Y$NVKP+O5,N2VGK#9<D-OBC$ @-M)<
MA8VD[YVP(:7P#1V8*B*$LT+Z_-S;-2?>H@B1@Q*^(BT,8@)QPHL^Z$?(F0I(
M<E2$N'<&+(%Z)28UH4=TL9#U=]3O(L1_^\%_#5@ZQ6&DC$V_3=.%F'3 "8D@
M6 ,]^9RE;2$T?:Z!1W%JQ5CJXM4CA*M<QC\.2EO\&][6Y_S.&W99MHK8]$LU
M/1NYHH!-) 'G,&MGC 5R 5 G64Z$F)ODMA.,=SF5>5I,I#D'M59J%=0'G"LU
MO9LQ.W!GV>N*OWBK3<>U>YZ.&3E_7EZB#%IL](LHP-V!D\R\3:^=<TU1@$0
M1N@MF2W#%4GM["-N)%G\]4K)<RJRI\]7GFS>_C+3UKG\G.&AGB-%^Y_F6"2
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M%%,4,^ =!6E^@=O)D^8Z9$ &7P5'N:@V"E.EPV.I#;WQQ$$WZ#B>[BXL(AJ
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MGU-OL_GMIAGGQ6QJS6([_MH@+".U[(=E[P5&BC11A=U*4Q<$P3<C<S"M6*3
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MGU>!;^T#&*8]Z:$F S4Z">WXTY4XF/B)(FVA[2W )K/%WI&2%1H@8^X+$E)
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M"%H8MO5FB;! L(9=*2<(%,:2G2K)P5GLH(?@$.\&-_8EF[AF]P^7XMDUE?Y
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MFL9E2GWJ&"&#ZU/*QE?/*;+ 0GM3X_CF BMA$1GA?R*(>S:Y\X\+G,"KUUF
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MF_D.FF+]B]H7];<>/JMK;,BQMZB8T_UJGGC1^WBZIE3^K3-WKG_+@+U64"B
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M].:JC]I"F%*RR$#3NG%TW BOAM5MW^I2F5H+8%Y'AGB&EA[Z,.W8V)$4D&G
MZV/H%1RP'%PP-W06Y5-_6G20QAE-V]GT>"7B+9)H)@C(DJSO@QB)$)XO1V'C
M)87D3T>;FXXDMK,.!ZMU59&=<IO2Q.UO0*FIZPYV'3S#P!//+)@H,;X^3SFE
MN\>0XD,UUZF([_#<X]#M$Y^?5IQ8$1,K(Y7857*N]+%-G7-'S&Y'*RFS=_>_
M\RFN#N5L$?7(M)DJ=L^P*PLK4##@G8?\5^>FN /,1,H&Z <K.*T2'] C1C)H
MOU:9#,OX*E[-9<]2IEN6)^8J0G7;*^CQDB4*L3X.OM[9/8Y9EC4W+F:U.=7[
M\]N1OD88_&UL/WVF@*2ZY+<(62 W%A$^6\1*4<;P"O1S7GQ12@^QJJ.0'1R'
MEPZC)PS2)6J5PZVAZ^@46!$::J5L?PY2$X+#/IO:O^";W ,X$C;&%?O<DB(C
MNTY^5CVP,Y3?\$]/@</AOE,:TN<%Q#_8>5JM%P9";11!?-P"%!(NPS4QZU#R
MXL@3$SNX*L%_<.:T>IX%A2TD.QI5;&X_/QQH=/C3FPI)E=?5U\)^Z+B5LX6&
M/_4S%/-PI*,NT26/';F$'=2G#T\\P:"C[X1\-+K,>%_H,J JRY[U(;48U6E=
M;MWS:]7R%01WYV=&D0R]@#B^36,AQ1%HL5E!3:@1JRJ%-V I8&J!JTPI^;=5
MYX*O'.J2@1O"NJ]F34;CGY W(E3\-?=VWW=1A,'Z3/YT)DI0V@'Y<U A!S^:
MVH&]:81NE0&IO GH-ICM;FKZM+$J:URG$=-:><-C)WY;W=?GO3];@$I2#-DA
M;ULCO3[*;M"5(/JQ+;M@?OV?KE%=1"REVR5N%@N4PWW3_!.^'LI]AY+0(W$=
MUX"97AASHU4LC##\"+M&<#"G9;DR/B5EH(O T12$X-OB]T[275UYU75]O:X.
M,3O2B7\3D\?^G?!1@L[Z0E@R=9I%?JD[91W"Z<T%JI6?LO_%'.L#2@)]X0[S
M!)./-Y$"IH$_51PC5XLW,.'VN_-"LU**!=""0'=6%;$:,R..6%B9,(6&)I]\
MSNUIPR=GLZ ?G'LT!<$NL)"9TF3+[MG4S3<GG]&'=W"/RY\W>S3Z^5%.A9%X
M'/_,1'EPF)+_IH*T)6381#?!PP *"*I46:VE:41Y-[8_K9TB2:^#LO+],L,=
M>WWSU!#3U#'9(<!&F3(\M-\_"8G(]Y>O^N3Z;F?N*2?]FI9P7YWWEI4>R,NN
MM^1F=01#ZI3;Q931L9W"1).=\ "PENZ?%JNR TR[T>0+!IO6<;')M.VD'/90
M>[ "R=0-K/OD=*E+Y18Z<:\ K_NN-#5PZ'1?;,R1VA^Z3PH#\ BH"R8,#XV'
M,^@CV]EILX;<-)8 7Y-+G6W@,CG!'<&Q2/K@_Q801HCSV)3&P<;LKKIMWVN[
MJZ%7LAYGMK6ZVC72-[O'*G7!RM_?OTR;1&=62@@V@'%QM/NX4(Z^?7S'>XY1
MTQG.N\@[(2E$*1+!L(ML-BZY_XW E+(+"KD.3J^)+6YSPR:"M#-556T7[KX]
M$^$8L4'S@NR#FOM5?8(:A>P+<J1@\9LE6QNU8M=FG#)JX6CVB,4Q^EN$A&VX
M\Q,S_IU*=]Q\.[3&!BX;S!0!Y87_^WKDA;B_TR,7C/W?TR-O*)X]RG7$HP04
MX1\X)<2@:K'QL]PT7@)W_D8^MZ/".R3LL4 R$,.[ 'T>KQEG2O9(YD;*Q197
MI"&DH?7%LV?/&WLY4=@. ]YTF$YU8<$**G#H+7/[_ KJXC0A"5,=UM 2A?V-
M!KD^%A"Y9QIFK<++CGKN+2P0:*2Q*MM>5&[V(%VV>A$?%+BH2=M_%)QZ\]5=
M7SNGJ'<N^%'Z[MITCL/R!=HGF/AW.\X1M[)6\,CKXXT('^%4Q].VD7XT ]4]
M;<21TO%6H*XG7K 9>\X?N#F$KQ41-.R;;JB7JAU<=LN*]T[55 Z<F_^]/O7D
M$_==UU=00T'T&U3(((E=R5A!):U6E2="6DQ&6J*))/@KK4F,DR8IL*SBBD8+
MSA2.3"NJEP4 OEN'':<ZY@QW'3#=(>/JML,JR7E HSY3\Y8:<3&4%PPE70>S
M&)@BG_CG>;9$XV:P80/)-J6-M2_LZ;. -_LJ.B*>B%S89J*A'-/! H>_6N/<
M0I/3I!):!_--#9I9I?T(OAX'FSRC,XV5&7=/.CA,$*72$N_<*938][/PM=W^
M.]Y:9V2C<L^6J']_8Q%$1DQ!! "S9KS =1T:+43P)#U^"%:#_+D87AB=,(IN
MI:)Q9TI)\^R*XNA#3&72+G[+-68\]HGWL[K:@2=UKP[EY'3<&@G4_\'?,?HR
M?]I^Q$IX#HGW3_$+\<$W 9X=;(B86=?@=/KJ;![,H%;C9P#$#J\):;N%V28H
M@1%T))R3)B+ 60-V8%[*A-]R;J/@$A1H-$PH&^N.*'F2I^ZIV??H16I[0>HV
ME<\%L>HV#; $TO%W3%?A:W46MP?!G!X-Q,"?U[FWU;DYO)#3;P]8A!1YQ[+F
M$5O:?,G=8Q]70SGSJ\E.;H>J.+LH/,_J".>3AT-Q=*:&.,&DD#'LCJWXJO?X
MB[.ZLPW-J.(XVXJJV57J_<F-[33UGI2<3MOI"8;<WW?76R=0T>--M%_DX.V"
MJ>X%)!&J]TLSJ?\-4;'X/XJ*WV,+%02WB&98OCE-!7&MS-__I7*8^*^*0Q#C
MF O6#+CCWB3\9']Q3Q1RYR^+Y^@S-T JDG:HFV)D;8D!P+Z_.LI>)&*^O6=I
M-UZ&/I,']:V@;%]:OMS4](LS*4BG)C!Y!++O"NKQ6*$3 4*01R=&J+EM$)8C
M+O_""W?'M>*1AIL!I"%VM:'^:D,V!FD8BT<:*JPVS/&(,2-PD)"A1/]9I(5I
MSD>H/0(&ODLA/OB@_[]RV__DN#\8\"8:O69UO]L1NJ^W\*D>.O&:T\PG\G[V
M=:[5:4A#^(BR9]27"%;A,,+T,1GX34,CC6]%RN%+&Z^@M,9.(B:!.<T_*4\+
M1;]?[AX\%(AI,PH<2ZG\;A3T/)_YJ#VJT%]>OS$O)T+QY&VU\*L&503_2TDZ
M(6]*#MF4J5UD;3BS8YU@DH(3($9ZT]/$A)3$?E?"%><X">04K =QXJ 3PE.:
M"9M&2 "!2XEM3+L!BY#6'8="V=O+7AA>B8SK;[(PB+MB+":P*FU652PJ_664
MG/G^2)<N)0/Y2:)S>%9,*.7S A(KUO_DSL^R.801E2ZV:-O&)U?H(_)1%&+<
M8)YD^CACL@T;H3QWVR=X TTME<'?&>1M_CL6]_CST,0T$(Q)7D&MH;.RF:!;
M"IZ7*6S$^V!FJ1\K.XA5E"QPGA< W6/1;RR')Y.W@UX<L^+$+_WP;O-2R-_T
M@XN8P)EC?%NO;JP2)S.=Z2(:3SZBG&1R=V\OLVSU8 QR&!3.#UT%_31]^"/U
MJ7ES=S";.F-6#'<T$EOIR7CINN#8*L'A]Q0]<@!1T<5?16SHBH1DU(%>*]WP
M4^\+^FO]2P*M7T[,W7XXYN&_[U;4N5X4X'%H5;TN,/B/DUF"L:,81WP#1B#S
M@[=Z JSC-*:VN(V(L>:*M^!!&VHR<P,L;_T$,C\)TE-G4N)BFR[A?,)5\I]<
MS-/^,-D  @ESP4VZH05,C-0W)Q65@=G,/IM8#F'N6")*L ]:Q47-_2LH7S2T
M*VUF OF$N-*-/Z=-C@SB3E$E33 $[H5@2:CK%9=VKPRR[RCN'),$7W8F!0?4
M5=:Y0R:M&$G(WBF#_4(!_W%HBUG8KIG&X"[\2"0L@9CY#7N!FC";?C$X<4SV
M-@_QB>AB=E8S,PF_I4E/6,@-MV[JHS<(%%C*0%LVGA?S"-+:T%@-?^@+I T$
MU+3ZW'P;;[4M<)R_O3(#'\1<VK^"&M6 N^UY"( 9,.,LH^!K=%8W=>EX6B)^
M!J0= *;$P:OT\DTP 0D&?_'_O_,<P6IEBP[@S0%\ )&_VV<%91>,=OH>1KF(
M=+H7?F(;IAXK3*]!TKM!7-G/1OJ9=_@OKT@1*R@?IPZ"\#Q9[##BZJ^Z$+?]
MW3 <+KAP_:\KYE&FG-C$O]0>OKMOO8+:C5Z[@OHXOG^U=)D._ 0TA4\Q>QO@
M[AX1!/N^8??]C.,AE/?V 6'1"FHFF32-Q, L/0X&M" N[4,Z$\.3AA W*<.V
M9\RNH/Z]^;]")]A&'PV_>AL./WEJVHR@H&TA&&$!%;&#Z3K.:DDZ/6$2K$B-
M7<;.*G9QAVFX%NXZWAMA$66W*[.^S*3<1#Y-AOS;L\1IEN6AY=@'(]<$ZOU7
M1ID2RIH2=^2Q,IT;J/Y2OS&]G9H!D" \R+O<=P@8F0!\T%)095NF$[-A?M:K
M1.!SN_UJC<OK?,J'!II1+"'90^G]^L'Z6&#3Q;$=4J,7#6R3XGWJNLS"C 0#
MO,D%[M_7I0/$Z>!1^M)9?W@3 K,\Z/4-<'T6HQ3^5B;X1#_7,SK$+A;(E,'B
M&DB7.T/37/1O7$P*=K%2&A[";X:W"7!@RC-J&WX+19U4S'L%1LU=9T<=^>RB
M??1(9EP9T>WSR>JMLS/G3^Y\UIB^46T%94&[X:;9YA;&QO0!-R$KS7:?^U9M
M% GPB7WZQ&$]T?A.KRJW<P\M[W@[7OG6>V,PK$INRH[!?MQ:I"KEF+$I3,M\
M_-FCETKZ^%CDBQ,9BH8I?AE:5A=;#^T=RPK\:6OQQN9#8F !X(L'79A+9IA9
MA&)<6$%Q*H7*GL3["#[RTQ \:AV'WWEQ?L'W*)BA#J"A6" /M!.EZ5X](^.\
M4\):P&L^@5JET!Z,Q+D:?,HB_8]T:.Z+GXDRE%Y/" P5WI1CU]6F=Q*?59E%
MDBR[Q#VN%W?S(I-R]')F>B ]&=C6,P0Q[/U<A)"<HJ.GO_V8W_1LLI4P_)IS
MP:S3V4RI0>Z>4!T2-WZSG[1Y: ]G\VVC-]K@"56QS9V[.9*8S@L1ZH'1J0=%
MDUL<R_[H'#I+#I*1B:Z<F?Y08F-HU^D9(B#>+(MY/+GU_+/2,ZI:89H.Q;;G
MO#0VW2D[)J?9E6F;;G>CR7N;=M&]G\!?5_F#O)&!Q"!^\!,QZ*O L!D8#%?0
M-SG-!0)_*OU3 <"!_],% )$[L!ZLH"32VN<_ON#%0P@\$1^@7[@H,&>)1S^#
M?F:7C^R$/'V*_%R":B(YQ%G70%/+9]5G*PY]G_4X&R;NN\G]T,49MQ.(GX95
M7@=8CY=]9KZ7P\V86MX]OBLIK=U#6G@_&+=F/2"/,V<E.5>2G0J@2Z2LHZ2Y
M*U:ND5;?BU[  ]9&NZI&;,9.I=>_7<N8+^6'+I'^([ U,<8Q'?@X^AH*QI\N
M VM,OX<B6TU44F7"KW[K^_3IL_NI3)Y14(Z/O ^]OW+N_$E=W1WV:M7Z-A\_
M?(ZHNOM6W3VZ;9P+96_5D=P4X^:(54@LV[0U0%\Q>K==W;7%TL-]A989A]^$
M:=E8[D\,K+WU^NZ%K4IEZY+?_L!=V([MJA;HD2\8*R=7$"2B6]C[^B=<I1+:
M.%IO9!^_S[>4+G&LL#BQ)=JMH->\^ .1"J#HK ( !1\1_-8';QUV@;J:3;!<
MB:8&BD05%XY=5E/9WQ!KZ!/V?F[$/-:_H3YA;D?M.96O:EFO?-62'PK75VK'
MD?+CGC6LT^F*_9$L&7J]V(/D<C=9PMOQ4-6A<;%W,1>''?+/V)?8/(HY>\RN
MT"[W;+%-P6ZL3,SAKAC2N&Y>2*LAS[UM6R#.^I2RFZ-[?,K%]^V]*489^S[&
M1]9=6AS0JBW3.O/0YG*^2\K%8LL*PZ[5Q8^;5/R$.AT\1>6O@Y LX[+V';UQ
M$XQD =9DSY(%$G8TX&989@4U^$=-Y=P->B^^T$GPZ&^*W9J(<06X24DLTWP%
MI3JFO;H;BH[@0#5@,\(A5E!+SO/P)@3%>1)'$;-SP;:$"7?]8PT#P.#?OI3<
M,'MF!94^%$V?E14@L'_02YHR^Q/),[?GV0;"W$^5B&G_1".8[48(\#H5[J;S
M"+HKJ)_3I4X3/@+9>=C.C*^(^!26K0!78J6&IJC_9C'(MWF:R#/"&,Q?OA22
MZ3*_.6WI%'7;$9,_@65'"F"6P>V<N0U^$AARL;.9/=P/-#W".)+4MW<PI8MZ
MB6>H#OBU"FUT,5B\Q1_441N)6?[N^^#L=T?:(6NMSP$[KY.O:< ]-UQ+SN?,
M7(,PO&U]>!]W@S9F0PW< ^_B.L7KN1-6CZHN@3_L@_(&_2^2C?EFUF :ZY2*
M#C@?DSQ8_VBZM3YO<ST4%>4=)NY^;#DVOW379^,.;OOR!S@20_Y/-7F'2]IL
M#:L;V^YH(O8".LHWKTS4<[7VLNT]% T95[Q\5U'X34'^:B.M^'>1#HWJZAS;
MOD'G.ZRH^H_CTIOX^K3CW-=X<(19 [[N%&CBT]S.C^>&LCU(WS]23-\[O>8&
M:1QN];P\M73"TWR=T?-WUID<.?+Z_1]*K RZP6U7BN6T?BIKW;U&2JS3''YS
M,"<Q>R*%RN .8DV:6=5--F;9[(77@ST+F_-EJ[:YX][H/9Y\/N=TYTV!+/>P
MSXDBZ4RM.I>KH2F6J9L*W':,8TNO!%J$Y:I:#0SVG.[+.M-77B?7M^AO_G0@
MP)$W8GS+I^3LJU.9X;Q66XF)LG3>+S&U4U8[*]O2($,9^/0 WQT)F<0_5E#+
M"%C:./U+_5_,T$W1']FE+]L*%?LG>O3&Z=%:]A.V7]/'QS!V65J!YO<^+Q3U
MOGP2M>%RL5+<H10+OD6G9H=FO^UI^^Q6!SOJ+N2*,;>2NNW#!EX'88E5,9$>
M_(;)VRI\@%]\!&L-L2<%RE4K* W$<=9_1OS&O TC/$N5\/^V@H+4" *Y+MX>
MQ(Z!O\WU>1'B .6F\">?!:>X.E1,'9\8AY$D:Y="OSH4@^-<>6E0N>J0X&CA
MM\>3IGU[SR7.<3K<CYTLH"6^8\]RKFR:74*(AJ@"91!8@P\DQ!/!4]A4:DU6
MF@XN"OSEU@?O/BNLWOBU:N!*X+DNCD(KC_:>;/'(0\<E,Z9B6 >LZZ "Z^WB
MOR:>?7OK9"K03U^+T^0>5!,^Q@5S;(*;<:Z9ES8 G,G>8HET;JKQSK=//QG>
M&RS)A/)G/&]V^WNRH\NK\&?:HQQ#REXG+M>K3O66S6@MD"]XI[:<837I2^9I
MHW%G=#8<G_(<=Y2N6%_Z>]"$M8EWT,4?OG,_]OJ[8[Y9(X.BDD5<G#> D_S@
M<#HKFKBPCS* 6?P.IJV@K$S4G7Z:_B\O$2R'8 19'BK7N 2X]#'F&^$F?B&1
M>0HAL2P#N&$I81FY3F3/ZJR8,)\^8XY$(+LCDB5 RP'ZEPX*"HD9V]OIRU5D
M3R?@?UUE5!L9[->OTH2WY/"+4:= KQ74'G<GN/=&'-R8?'2(THM!V[=3%>F>
M*RCY+BX=E@L -@,7T0JDZ[@-8?XI.,I[!:/)F1_<VZU;!/I\6<68@FM]%TN>
M='/W!SRI"#N,@-YHI:FU(YHS[*8&_@::C+#LROPP[P<O?A5&N).)0X(S!0*K
M/KPO(=X)7V.3\\"Y)S0?2N-$TZN9G:X$:=^\_7G:SN-//^C",H1QH6,OA^-_
MN&"H_$J.V;V)9ZEBE)F_W[LOB(.ZN)&\8N$#P)\>CZFFSO1QUQV%=!\)I,'8
MZQR\"FG:H<_)?E OA=AVU<BFQ-.[V-5"Y#7<G:I\X=V'P>TA_(]SDWDLS;H8
M81Q/3/B(ID.V[J<8DR6AA2M15ASFS/BX,5%\.D\;_'E.5[7=R*,H3*TO./EB
MF>RUZ,N^"D3?A4&L_K:*;"O27GG.;L'07JZI^MMG#R\-X&IP^592.3X1&US;
MMB:KJQC*^U,O31@MAC:5B3IN;;S[<;#%7"S%DJ:]+J[UG,_U=H:$1WE))W5!
MJ;@C"-,-O</M--?@X(XH.4:TN6'OA-AHKXN)DYATLVIU"-%[EK2[V2G6J,A+
MZ01QL^2Y?.*V+,]+9QOO!1GER<BX.#PJI20-@2TKJ W="-5PI+.*Z;R-T*T5
M5,5.92!T4; /:*D!%C(J(<UYX0T3-6#ZI#EQ*OR#%6SKRKL!#->!.2LH5X$S
MSWE>D$8BP PDA2TGK5N61%+Q]174!!I?/R1,H*+IBV'D0Y4(<KOY.S"QA;D!
MH4N%@M#5#4X50S0D.3:_K4"B!TE8G_@G ][2$\?8<>. B1[YT*M7E6O_JE'?
M&^3F3FZV""]N0&CK]+T"AQ74E[J'"&C[3!">S?_O3&+M)?W#)%8C[?_MC/]'
M=>9&81&\L8=O3A:#DD"[(4YP&^:F$P776UZN VL(M ;LCW.1<0H^-.M_:DA7
MCRCI9Z=VBW$IZ-"SV;V<#$7MET9?%]Z=VLV0FOMY6O1''*?R8Q(L'@SB3:E'
M(4_^>?@='K0-CLGL*Y@&TWA<2*_(5V5?/^?ZC;/.[5S1UOJA1G7^5MD]30.U
MG=G.BA:?7C3&T^J$-P _YNBZL] ]?_X^N(\*6GT.YN%2NUKSU+CZ][BN;(-X
MP?9QS/#5Y1_'&WLY)LJ]BVC)EB+B=T7XN9P@BR??<,VEX,.P^PGO\&1C"A*-
M6GY'!O$Q40FQ!#JD29S556+6%E#7"=;Q59 O<4&T'? [S-J)DP_ZZ'Z$$07>
MC=[%REBC$R\CE-]4"M36L:_6<?C!TB[.Q_O,?<+!CX<N!60Y9QH30=/Y>'J]
M:#, [8ECS ]O'S>?C1P'1GH(PGSD>;DJBL)JBB&$[W0IH.T8H'O34\=V#%VQ
M^HB3'JH\\FGY>!9%96AVQ\O>N9&6(J.\O/G"D=>^:_Y<QS?^C[&!O?%^"!SH
MXX4)J31#00!D#T[R/(0%=-_*]?!;CQU9K?1:GTYT=/;>>WA&6FS>CAIZCN5@
M@$9_\.Y=W"L2)T9X?7:T3*OM\GD=B[J3I-G"W-_P17]Y],&3:9ZO\!%%GC*(
ML!<YN!<OHM?)Q;3.)YM(]35YL27L_)T#@B5B?MV3:X\M]L3/UPJ]S/MW-/7J
MI9BXO?8J/?MYY+F7E%<K_)F^@&22>H(PNWA68@55FM3^<XU@$6C)P2\D8&2!
M83;Y_ JJ7X$U"YR5$U"1GO^++_[+SL(>8IW/K#;(YQT14DW4*;U4N5V#7R$
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M<:6M%1JN:!?9Z6-R)6<>VCGT:_>66=I'TT6#PX!D?$/EK 1?D^A+KR$FT=9
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MD[$<S#0,OF,]FZ;RS?M>\E0(?E/\N$+/4&?\#H[CVL+VY-GG"+W[3VMIJPD
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M7Z2,A5X"(7AQB&F".S0O7@F,K*/>Q0C2&^$O*M=<)ES(%6;$,V>Y)C#!]="
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MPSJC]]"=WKCF+YGO R,&NH-ND5?VZ^[( PJHM_\#8Q-QA[Y^@:@U2V)/Y/M
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M219G4[XAGUP96OIK\=S[ Q(7.SE/]K]@$#*I6\QWXEM>KL/JYO,AA9K/96'
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MZ75%<8%_9GII4$E7+L_!SOEJ]9MTZX<!DK-)=SMM_1*WAS;I6773NJ.03Q'
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M: ?*3W<86Y:6OHW.,L\ZF/]WW=U]_33[)KPO:42!N[&4] G?HD"].LC/C-3
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M@O/G WJ3UV=C[O[C_M=W?&D1 )XF79> A^<P<:S%<"/4*O!W@^[QA4#2K)<
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MMB2_@#&N"!+6D;U-Z<:2(5\_MX)(!6#2T#LA;D[GG'OD,S!8[$X'M/IEFCN
M] GI14T:GT[]AC5(TB7:@EG2FG2M=0C?$%G\D$$[WBT1Z$. +^V&HHTL<\PJ
M&);X^B+V??9+.AYL*$AQ=9L1S)[/.G]W%?T^J3@%TXX"@<W>YS5=E1YVE,[I
M.HJ]SVCMZ7O5G',7-F:3D^,;<A\?&Q+\]9Z\]?/?E[GW[<N/#$:==_Y/0?0L
M,]3+\*6)I!=.B/%"49CZ*/(CR8QI#N&:2/I3]0Z*7+*4D+3-GK^2Z0W39>.T
MMM-$H])/E\3#J%8^ /RIE^MT,'W8= RRCB/?=?F%O$=GTL]X@9:1/9D#!FB7
M.:D=&%%:77/4V=2@TW64>5!SGXO2&Q>!6:)R@7H?JY.$_:&[ ,;+"(L9=UV&
MJ2W7:H3Z>W7K#\BQ:Q@)KG83Q4]$3WT?#8U0/SG'L'. I6P-AK>*L6Y(EB6@
M)G+T)[[J-?BTRV9NU&^0IOJ=/.;"_6I#U_UDQHI;DG]M*"=R^$]/O<L_1SF>
MO_-.T5<7N?]$\^E3KUKO'=.SO/_CDC.*6[]E1_YSS,;-Z[KS@6 9US%_WJ5@
M%O1T38]3F_"(291<A!CO4RWJ(86T&S.\5(406[D!?3P>^GBQR/&XIKQMF@?U
M%J4".2%I#O.\I2%:H3$7S&%,D+4RVY--GSU"\IO#I*Y6PKQOP/IC#4]RHXT]
MO^\>Y>WHWK:^Y[7KHWG/OP]H/ 4$8(=<FH$J[L1ER$5.3^'_0+= W&!]G-)"
MWOX-PTN -V$:J5W;08G<WAF?:HO8_2"^-US 3IV:WO2XAWAHYL6@[>1]14BE
MQI],\XTAG>X&BE%P[E<US!?N"V4G<O1XZQ%]N%'*MX0!^<S-*>(Y*:/$(6<I
M<5_QJ,_63$?>AB],.]NF<5/GQ/BOYNHP)Z$X0E7LEOSTB"WWF\#5_#OMQJP6
MD@E)>AOGMD13!TCO9K/3YC!T+KS176GP@$$[I"F:P_RD'RULAQ)F6EB&4,5&
MSAQ&C_PZPX-F6U83\RS-Y]#47V&;+TZKU<5I1LV>_2S+NFP_[,R^?P5ZK-<V
M45\$B3P"5$)X-3@E)\751T$Z@JQ^E@$<KI 8^TN"J14?V,)BLKZ7R,T(I,;/
M++4W'WK3YVIU.GWRX\G,IK[?0[:?/;Q&[])K2YEZ)=#XG78-2X"O!)2#T+BL
M,*W>PY&MIB&>G6Z;WB,; F/;7P,K'%Q<G2?'A3AGDUN[[$*U&R @B4@I\J/B
MU^VT][;WL-SI'3&'V<$_^A_XT^8QIZ(GHS.SMVZW7\HTC?+B+B[Q<.@9I2W*
MJ'3LX+9M_;STCWV&2->A/^(RJ(U3+>WP5HYROI[+:EA'1EFE;7%SZ6#AM*CC
MQ?*E#ZZ]JU 3M$*^7DNQG')KQ 6V =L;:U@&4 -'B7\8&BLXXK?^#(.G;JX1
M!S.F&_;VT886?R8P2862PJ\HWUJ,F<^!@CAH;GZ5Q%.73;",F;Z:0E(()]VF
MU!_9HLGF??/I.4UB@+C+II8_  P8U? PV93S@!%PI'5_I.N!II&S@O"PP#6?
MA[XO0N*9]K!3*?,@Q$5OVI:#&"3,813!FDJM'I,%%T6K0UG-_$IJ;*6-GH:V
M%T+-0/4QG;<,-J/HCSJ*W5Y<E:6&[5 U[0>1\;+0;^PWE!+W%8K%8Z_QG5AD
M9:MV6:YL#B-FJTB\3B!TBEV]DC7(7X#XRBDKM#T\'/SB\2<2:I92OR!?Z%U1
MF(RVOG.R[$(IETB@Z8]P9'Y._D/+VYYYORD(O22(6>;0+J96LA$CO"Q+B5,S
MM<U4\!@5]B >EN*3YS#EMH5ITZ\4X/78A1"M:61]^3VFJXQ@/+:5+)(IE\UA
M3D,'FM^N;+8;FZ4G1UK8CBQ]G,( =O#6_*N:N32'!)YM<Y+J(";[1'.8BJEF
M3AS+&2J(?PGSP2=C86197P[DZPVZ59F1'R,G.Q^55]+-/UUQV]1YCH8W\8ZY
M41^8/ZK2CUH;D4(#1I^M^K$FP89A\&/"TD<)JWK.!:1LT#7;-/$TQ1B[>],W
M1_YW:/M_:^KN=6]\#K.&M0+VE6?%LI:B:CPH=IJ4*C&TCXD66BZ$Z45P'*42
M2DRUIRXW#^R/M,7NSPZLYU5WI_7XTYI7;S.5OMY@FG40?XK[9[MV61__N0YB
M3%.U@>VHNLQ0)5?/%\)9'*G))5H\9%(T&?S@&-PQ-@7\,(>Y153S#;V1);70
MO?CWU3XM^9'8C#+R@\5W9SQB]L(#S0#1>3+QR@(28FJGF,,@1N':937%0T"C
M-4)0!S#,913E/2F!G8?M=S-GDOLC !-2;#T."FJ<CXE(04QD4_@0HS.?6B&'
M2MIP@*"Z^K+$14S+.'#.1.C4U=+Z!8\8T;7+[C\"&@WK]>53\ :4I77+2&SB
M0BA<6I@<Z8>R&2$I@8>'$H5J@GA\#\Q1_'UQ2.B_RO.N5J5NCC)[PNM/T\\1
MT*X6[K.M[,OT7]==9>.-!*@6P7KJ==H123D_G21-!FKX3:WT02_MLC2U UPA
MQ]YBDB W/Q=*%RH_IUK$HI3(]E5BA 62TF('_9 ]]2]?]CO"=8*I(C\Q(TYP
M24QS/BE:Z.L?/(?IYB)&%:K]\!Q&RAD424=NH$.[M1;>H"9KNSD5<Y@DQ*,
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M&-1:>CPAEW@SKLS.4I<P<EK,3M<.UQLT,TF_4LS@&NW2<6@.HUTZ!6;)VIL
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M?!GTQC%-;FL9]"5L<MU;IV/W2PBR5\]?O:RYO3 5[>0.TV"^ &%(^T" XJ.
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M+3,Q7$Y?P4A1[.VJ+#7SU5N*(?D$<W^;#V@42U27-<FL%>, GA1*3[4TAUW
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MOC,B7P[LW5S3L*+C8*])X\I0Z_(/?E=*JCXH2N6;$6W%8RM04(U:*>XM%.7
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MBS]\^!))WPK'A80\'/-?!&<)00.?L4OI&>43O*5M['/'W<K>4WRVE!5ZMSU
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M9W,)MGQ5>*_H%R-JTGG^2M="RGPX/VG6T'&7,$:>2\6'\C[-,@<!R)W#(\M
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MLJ::)_!XAF>RM!JS"N^_0(XK_F+HTP^] P27R9I$#0I?DWZQD$ZN7!A!/(X
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MG#7N4J6KU]75^WIK\_W@HC)G3LNEY0')!=U:XD"IZ>.DO7L>/[QU\,(!3]&
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M&T&%:1F+Q%C;,JP@B]LXI 7H\70]8?Z'?%K3C$QMK 3-@]*4]L[EY,4CO=/
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MXWS8&+6LUYP7(B,*8!&RB[0HL!C=HPWLN] 0E:B@FP=5C"37UCGU8VN9RY&
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M/15WP-1JI2WV?*^]UW=0;;%O1T7 +=:8,,*P^X_L[\\UL)<<#!9\]*H%D4!
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M5;P9+4>R]Z+6>2+E.V"!U"VP3.9]NC>@D,DB++'LB,@#!>'1]L<;"GQ7/:6
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M>;W&[,.3QO]76@P%JMX"_IU-O"2I!00^BB0D@"P$3R0;;">-_0\ Z9<K,JN
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M9[W&R:^*_@7R-D-CHDPF9Z?.^ZST,=#Z::+.%,>+L( T)#,B9K3?(VH .SJ
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M#G\BW-W76IN^_,RCN36Y'?SIU\'=A?[?%^VY=&U%DW?@L\W'N_/&.<8D4#5
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MS, 38#($-_+@%@J\A=&CWZUX5<LG$L$L8CA\C$KO=I=35<1<C-=H -PB!',
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MSRFSQB]$?HMD7,XF"F!)8W)X(8T7_L#7K7CJ*ZL;69+J/3L,O_VF/S<&P/[
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M=:3?(?R51/V+?I?GVX^:@*ZO@8RQ"8TE]-&*I<&)K$EDH>$JN ACB,!O=H<
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MO7I(3/[CV &!H?F-3_MMAI9M3UIC<*7 QS+I8?Z2%^W\K>8[KYUR"W6:1K9
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MY"&-H_'XE-3I;,LB;!W,O%SC*5__$V#,XHJJW--JF#)H!B,0_17O:O /NWV
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M=[H 2_U,U9/JH+[5Z_J%1O?Q&?B] @6,[Y7SOOVS ,/3+N%L[6V UT/P;/I
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MV$_"?Y7" W>K4%))G80=T#!5T\$L3\A,OU"EY'HNI03AGZ.M N[;W-/F#N>
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MN^=#2Y_BT7VQQ=J]EQZ,<)<^G3Y8M_=2^/Z^G3FN_KEK]Q:F<AZ=N:D*GU?
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MQQ<>'9(.)6HLVJ.";%_N8WB-%*F-@R3/B$O***0HSJ%(+:AVD:1GJ9 &LQX
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M4UE]4V][9TY[=5UHH_OEJG)Y$O_50I_V)[-3L,)>$<H2859[,V^&+(_$ETO
M\\8IU2:'_"/QQ4%*(\MD=<[AF9_Y"+:Y?CB=<PG9]>7-F2>MRQAU-?VUFGUC
MS@%A%G'QD.R<%)4).T=IU1#Z&U^+R"&UQVKI@S@5!<+7T7X1VM@AK9X11,4Q
M+P[Z1T=W!R0'U\3<5W/[.=A6:OO5.N)X-QS* _3Z>2-</YB C=+,R-_))81%
MOI]PN2KU--*Z0!([B+NSSRG@YK=3Y /9VVUYR8F5&]7.UK^_X_'="BKG>'8H
M>MAW] ZLO!'P*6W:WDTI.Z?T-M3>&Z6Q8X)O)ULH<UH^7 E\GM;7?+OYPH7$
M=3ELZ(\G:@>,FJO;0)PKF=8GG8C(7U$,M)*N1&;T^MM3,WRQAX#VL59SE'0Z
M%K22?$$A>HRV@N7TC((3)2=,<] _J--9F&?9CO>0@/'$I/U#;IJ/R<T@:+>8
MC%T^2MO483U\=!%5&B=\_2Z+134[S:4F";=Z6^\,X:]2"FXUN/N_.KLT;=['
M<P6SC&[6#+GI1"UR^=U/K^(P]/T^\2FXW<_IM^U=QYX? -)HW?'[TLWE*\.O
M!$=Q;>57=BU_FNG![=BQW_ZV4_O+&^=&:=;<8_YS*9?')XX=#/!2BFX28P=8
M $X50BP(T>)UE8G0+$B^AJSWL<3G2-%+F%:7PW&D )$'P!7VO8!4,]JI*8I"
MEQH >RZ%:@GF1E:H<SA*;F$/TA#TGRF.#<=* Q87FS.8I0WJJ>MM[-?&,(*]
MQ?DW4T-<&@IZO2[<>?+JP)%/@FE5KWTKIT=6/JHQ47D'$#F56\F%6_H[%XW<
MU-,:*MY\3?= SM#Z(OWHTKKB^64' NXU!>=L6[&T\^]$1<;?SOD@N^]6=-/?
MZ?W=!=!?BY0^-9698G*Q>0/5]+'TK1ZI:X(N40\"7S$=(SJ0?!VN%2V#<2LQ
MMIE1P!;"@.9$B,\\KL%G@RASA>(YV)(QG@-1/ >8.H,B.A(GS9916NBP#P<(
M>IV:L?1IW%CZ-(6*@=/ZB V[Q;589YE(G[_JY;[AUFG[I.KJH)C:GIT';:'.
M:22G'YVRWS%WFY4Y8*V+' \?4-@^O)W><C#3Q[_UG-?T6>Z+<&XE!$CS28%U
MT!;_65V?)I-O7RW:NFUZJOYI\JUBC[A]YT.^O\,,-_TA?LJRVGOY[ZIV.3XO
MZ<C44<Q1/IKCO;FGX23T+%3]&RJD$A G,&87=!)"/\# T\LA-(4.W.$76"ZB
M% NL@33:53Z,>.2=(6"M7Z\38B6G30I:^UM:T>]J40&I>:9Q1KP$+Y _M<,^
M, SA&- .7[C8[*_*<5WTCJ!*SC@H9.#$-W684,&,$RP'>JB"U0-/%=C0#87M
MCN3+Y=W"3Y#\>Y1>!6/KJA.<671\]MM)=9#<FFRIL]OFJ33ECD2UHMH1P/R;
MP%-V,HB#2]AU^U@T5!2WU=MBMNQUEH:QH&J74;@/QA7OVAI74--:$; H.52S
MIW7:V4JW5/KQ\D;UQAQ36[6?ZF;6\G.B)MYA>8H6YGE.\?#HL0.L_NDBL\O>
MK_8[0LH%4COUHPL6.B=*6RJ)P.4U'QQOA<L/],]@!KH7+U*IG569ILE6K^#G
M-;& [(L 59GX\<(1"%_>!7"V6#/K$0183NP:XOH=7%*P31)! IV[7K/T<"?4
M\D#YI,1/:2;]:^V@CKF.U'TR)#*0]6^_D_N;RNX:JY(TS%A'*&YPKXG\=3XY
MJSMFB[2_/S%NL'^IY_GM@B<7T:7,156$)[,\ ("/3\T.U9;GI*1#L7]LIJ1/
MX>@:M]^+FBG!AU1&(=[_8Z;D=>^Z"U,OECLW)/'OG]XA_O5<'H!+(,C0'$#9
M-%H"*3*.JIL23DVAJ0+)*3&B2E\.!:;H*VD!^S@D!Y9]$ABT6Z4PUCP(GRM%
MK^([B40B"8AV;4UX$/[#\B(P2GE0OL-6 @'"!0AY;)ZX&J8RS5\!MDS"##5'
M@1&<'L,7<"LTTV5<#0J11FZX%;/#N@9&D_8TDPXA" KN60Z&?<)3F;1_#_CY
MW2!T'Y9/;*:$9G<JD0L_<'[*)'ZZ)7XGFORP,9[/49RUZH(,EC"'XN)YG0;Q
M5?M==@XY?^=)9'%,XLX:&GCV'C8W65"Z_>E-<]NLVA3YOM]B'LFGOGP$%<C]
M)#/*EA71NZ_8<C1+[.1[&A>\RIO.SLLX,Q(;E-2U^\.T0Y9MNZ:H>'QVL^K\
M?&^UXW/'TS_N907Y)_MXG)]#^G'0?(2BMM&2L?G9"=UC&9P:/\LJ$"%U4U76
M<E$E)XZ#OAL [Z\"[=:4IB]$V>H:?!Y5Q&\3286=G(J1V!@@@X'W3>@, "9U
M+PI1<G9H(D0=Q6(+Y2$-_FZ4YI5@K>KP-]VW0;>@S^/9X9#Z;-V"]X SKKN0
MN6Q^N5]>S<,G:RR#YZ;E-OHP&MOC&B-[5ES>;OMHEU/E /?XBWT7KTQ<'#>2
M(E<RPV*JZM,9!NLZ-LF71V1KUMI;3CSB-<O#Y,/)KMDWD&-T;$X1;N3VIXII
M)F($WPNJ8!6=2M.KLL@IG?AZ&-L*HZ=!?)@(RRU @$Q4':V1&E&#P\5M8<#U
M[X_]DSN291)\CD^6.D[-4=]<(.@DTH)'QO^GD]KL-XSGKIL2?[#UB$G>DMU[
MX]C:*\<.W)"]FY@V?OG_KH,*_ZT76]@'46<X&. [49%RFH)Q7*H]).V@E_HS
M'J&BXP*G4$C?V>0V?R?*B>'.5-G?Z8[E6ZI<-*M$U6^GHT1ST1GG0&YXQNZ1
M]^EISN8+5':+.^V.J&\5;8,J)?'2B243>-I5G"FD#=95+M4O,<,8OXC\57%G
M^6%W@\GI:%'LE\0=\3:D^$Y(?N>6]I]VGK/F%;<G?UIX\T3+FYV/TJ>*WG/;
M@#;;I-$32&L5E<1O4# K;I1F.D376K-(%11WT//N;G-FO<T/33<;3'P>HYS3
M7V!]K+#8-O)6:4M'4.+,^EWHJUS_M]N8WL6QGUK6''-1_&=]+R'G\RVQK:J:
MTLL#Y=(S,'5RS'9LIT+8+\'6E,S@>Z#<.,%,GF$EI^UQM4AA\W\1]^Y139QO
MVVBL!T2$@" H*%%141%3*P?ED&A141&CHB @I$H5@6)J$8D0,BIR%E*URD^H
M1$5$!(Q 8A1"1D@@;5$YRB$H.541(6:F2IP?F0S?I-^[U]I[?V_?]7W[_6,#
M VME90V39^[[NJ_KF?O@9$AIH:SM20:(.%,9I"SI/EV3LAOK[/E(::Z.*V97
M)+R-'HRDV4!"%:Y7SHMG=(KM43LD#L<_I2DDXW(C#H<)3VA,Q<A@;<)??E:Z
M&!OJ\R3:)% 'HFV@TI*[3& GU@_/JGDPUL#5L[D,O3$FI-?3E^>EU[\[RSZ"
MP#A$K3:>!XX3\[!%R$+#M^Q^ZE=L:U8$O-O+P2?VO"A)\X:TK<_]AXF#US[?
M#)"R68KOH3,E5;.78[_WBJ*2;@]\^&'^#R?7+>ST'OJ:9OG\Z]=#P?-;FZ3[
M.ABG9N2NW2!98[ZL>&&,^Z+:79=XBW*>%UY:N'.&(^%ZWO^])N__49^7@93!
M 2I=,S6;XHTTPC&M<O(YL2.Z$7K)TY 6,=NE8=]V;(=&LCZ[;6((_/=,)O*6
M[G!7,]8-#Z_6D5U/U*RM^;AN),N<X =AOROJFDVM7"RW \>Y@RC6$U"AM6-;
MHCB-S1RGJCGXG[-3A!5).)-!#I'^6@*T6DX17,S07-SG=T\1?G,PSFG"0 KP
M'0=90QO?@B_5^DZ_Y(>8#%R8*%X6#/6$/NX6):ENADG$*R!J@9]?<9'<Z=N^
MCZBK9K';]KY[4$?.'<'31%OIF3-"G^!7+^[=OMN>S*@9C7AXX]BDY3]W'_R1
M9,>V1=<B&F5PBBJEC9=52D":H?96TF"&%'>*58BW!+3V,U<OO3/F".2</O40
M"6PM/EFC,M(-KG3<B)+^5R,B ?2Y+#I.6/[%;N820-P-@#IB&TV>K>)(=')O
M]:_V(4QOU3WP?KQ-U$NY0&HO)M7#Q!SWSV.<V0CI(!SUXD43F.'!6,3,D!0+
M"U;><('*KS_2YA$FN2I&"R,3F,XROXVN0U9#/:J_F^!E12_ >BB.2#(D;!8O
M0@ EC;B8<:C7+Z#Z)K&%8MMSFF,JLI9CN&46<P<\#(!PS+'T=N6;LT)AT8;?
MW_]7S1F9TXQ7P6-9R =JO)>Q&(C]9-A]*4:?1YV%+285ECGC2BR3M1[^$4G"
M;&$.#K2M5NO55GY+IPAV_>AYH+.JD[V:%8*<@@)-4Q_<65&P, M;A'I L[+/
MJFD+$46KO/QQ@4IG]?[QFKE?Y(6WSXS:Q4>5"1^?MW@]/$QCQ!RS;'W[W'JG
MFEOGJFTTK&8/ W-)&H?Q KB^A>N(D88^U)^(**U0(1,W7<,@_=,9^PX_+E!W
MF"&\H$Z_6)5E1- FK4[+U]DQ@1VBQIZ3-<ENAX[7-@B?_#S]0_&J_V@3^O_Q
MH*09;X'O<G T:6%Y31%>OTHWI_^_^UC65*".I"\XQ=T5Z$G^<BFLAF3TLMNW
M[>CIS/^3#IFLMX;H49#_N-;P-9K40XWA6B.N+5R!Y1<)UR82M8&)TN -!GJ+
M3VSAL*DO4O#]P=_4OZ][,P,ZD9I5FU"%I.WH?]L]P9C'3)'*9UXO5QGW9%\"
M?J -CCVC"ZC-INY34HPB?&2\@_D@TV6 +641T]Q#N^=C5$@+E>BXM.:#8U9Y
M0L*ZDCN>ZL":G?AB)Y1L><B9@Y0N]G_;T/U"I,BC"WEM'4,I^B;<ZF\. <VK
MP!CZD.T.4W%Q./J-\:H63*#B*[4H$5M\0C&?LHIUJ$_ <XI$ K8@1Y0\BX3B
MD:SO>D1+56-.[51KI(3>G3R6>#2AL20_H2KHYH:@R*@=T_^2Z!\8Q:8FX,V'
M<5 NHEM3YKYAS6CJ I1E(+2'+'=14MMH0U]PPJE>;/]NA?$NCN .L/T]/X;#
M!3\RC@JR/+8#\VI$NJV,L@8*O;JN3-TQ>YAYE&3>3,[_ 0V&VJ4D6[\0S%QE
MB$9B]*5& 7B<)C?3+Q8BD6HJLHJFS39L1?U+]'(H4*(;S&]M,&O1#5A@YIE0
MI738#5E\F[6['R7=9MHA7]K$BZ"3U\H1GL8NM/AZ$^S:5IR=C2Y5&@.>%1]E
M[I=)P;N@D#3>KNH8HNFU\!V@>1/[:R:H"D/MVS'S "5I\,(4H8WKA"T;O<S<
MH!)JM^%1*+?8LNT6-@.I(F=]?N^>W&X 9OP>4X-DTWM8%K%*(WT7<ID!/0]/
M$#O]*P@:FKR))"OS2;/?/WKS&HE5Z;,UH/5 G,,48=X$-3MZ0;8D@IS+BEV,
M"]?$^)]EKC>KHPY1JDY5!MU=#.Q[Y1F9YG2M\..D^FU%\5[BEO\\"/\I2M-T
MS&*Y0]1+E!7H=MBK0 D26%3HY5/3&&!0&M8Y6DS,1%>K;GJ-'.J?,,;N??+]
MA?;=W:<;?:O&AFX<6NX%[1BYMVIZ#6\D4J\R60Z[%X2".I!5PDQT&WX3&-M@
M$CK/37\5#[<24TH&D?(UZ@==ZTV5C5?"5;M]^,-+7K$]%-F]$U3KBD*&YZ:/
MR80B>\< EB^DRQ80LU/-X>SSF.LHYF^HTN,\[$(1ZHVDX*3S@:ET8>8FX\UC
M/6)/INT>Q(+<"EQ<N2,YV#L(7E?Q\+"<F=32A[GVC.33^OGY44ZM#>4"82$_
M,H?_!M@1[':X^W@4]:" X?K7RM6>W'/X51-Q2_D-_P^#[*$('6J7I@\WUK+-
M6<2^=>)9Z&K$6W63J)))5F/>KR.CMY6S5L"!&1-IB6&1_/Q(."5#!5%;G=(#
M5)?8CAS)8VQ9#S\9WMVP_-$Y]EPT]17%DNFJ_V1*IC]*0U:_XCT#+M)QGIE(
MDNM:06%!!VHGD3G/ZA=_S?H6Z3',"Y?=07C*E'&%80V2+5%8L6B)RJ"FF(#N
MDZ<3R+D8"?890+[UY>0 EBR7Q!KF<\1>)J4.DE&;Z6I&&_42Z9'K!;^S,%6E
MR!+;,>?@=ECJC;/6[SNR,0>(PH/>R22*6MY%1J+?4H.OS/6B** R(7KI(P?,
MIK.P\NZ;L8:7O,HQBI.X<Z)2X#8P,;L"^!7WUVMT*(AQB5I'*8(!?;SQKN@(
ME*!_;KR 8\V0I-2TV7P2)V8+6*0*ID$CE"1.;W5D-<CR^/Y)!F KMZ5T?I=H
M@U^QUPW5[ZQ5E2N?U@2HJ?-'&V+/\1='!D.)V9^_>G#_00[^/?_@YH,']V4>
MW'?.CF#Z>J8^9_^?DI_5^<M_T#G^5K \DB4-W0_KG*ZF7@CWYKD]L91<OKQY
M[M,G%UX.IS56[K=(.'3LR9/24(M%7V\N6-O]FRQSAR8T)>;9WIVC=$D_:N>B
M?VALHBJ%=.(4(:&Q UG.X5!LT(/&<\#WC8J+Q0[2O^?G1$$D+ARF'X&/YU<S
M 4U*GNVN;K]PU0KX5])<U#])E4B2.-(N\&L 5=9M^&'[;B1?A=!E]JE]G%OM
MAF!#'+N+[H2K6MW B)2[$%!F@@)\Q41A<)&>9KSS9Q.<?>ZSD^6& YULZC#+
ML5?G L>.3SR,;T"ZR?P"E[8Y:]%@57#2+E%&"\GA\^S3VI42::6*YAC)[ E$
M/8V<"9(SU@OR<6JAK*9"V]*G2Q2SP?C@-/67##%.TYJ/X3?P.F"+1L5"AF=U
MAQ%.Q),ZF"%;>*NQL.- 5XW[A"=,RJOQB[O+]#T ;]/E)OH%\^)*B:\H2T?I
MCF)[YOCT]SH"Z@#AJH\J!>NYJ'T0-KL(=E6-C.\SI+ H,#F+/8\]1)WN=ZSB
MM>N%"87%X?@(R@V-(IM+0J>I5IW.ACTF[0O*VRN9*2%1;I)/K' HZZK*\&(#
M'7*5@M.0@ ,00T\YWW+_IVK5 =]EOX2R+%OWUE_;_]/!H*?[SH7G_ YQ,J8(
M=5_&=08J4J%Q+<#FL!R1= AL5?!="_]$2N JJ;,EI+U>4(D#V6M]RS!@C>2I
MY1X)^3?>)KS9SUQJK]^ 9$?"WKEO!0P;9H4T]5ZESN,_UVKACKH<#Y+%:(KC
M2*Z@R472X'[W^N6H^,F/Y<?NQIWI5@Q'CO:M?QWO>+%/__/O:?>CY /RY5?=
M#D<?'I*W.)\MVPYS<T&!Z_@$E*+F-M/.3Q%LQ5\C3L\4#L )(YW>23%C6DA]
M'D2.31&L)QASW_<DI$I]/*] CR(B6A?S4U(O3J87WGY(?X\MZ'GXD;7SX7MY
M%&36;&I)0T96LW,-=LR@9S@$BJV0#!4CEZJ\-440X+#@C*XS<MAFK&V]$_G!
M#E+*.EP;)#0#9N.B%,T-OEMX>;??3*4VH&W_V*>'9<!M\!)=$B'.O$W/>M3/
M^$Q[YZOD/ .SJ?Q^[09#&M!,!I1-I!GLA>@FW$[S,3EE4P_;A_T2?,R]*/*]
M-1B'>0@[Q0X(654DT5GAK]MZVCWJL^(J[T'+)[]<9#LW#72C\7*AE)L][-G%
M!VW"7ZBT>W3::ZJ.'- !C'-/P*,DCN"W8 6ZC+10%(-K%X43H"S@0F%<"X2^
M'4D_4L8LDT:\>%Q9CBY^]:Z3D3CKO.HNO.$$97ZOG]D4P7RMXQ0A&PTTNU!=
M +^!R.I-1H4IL^ 8^=(40>@]/@I12,@ZTO@U94VL_KZIO>@)8Q)FU]^:*]IY
M)-VA+11A/O;R(<K^=1HT.QQWO%W"WM!T8= 3G,DL=8"*I#4QS]@DA'M*^<:7
MU@0-Y]\AI%/Q1<]%<%TPTQ$7?YYCP'2<N0S[0.36#D>6,Y)?@U(1$EPA:=!B
M3S6T?&":AZ^[%WD64Z(N;U7SKR!U.QT--$&OY\ZPMHC"W)@CKIRR7E:D?;FZ
MPPZK[/J'VH[+:DO@6Z@THP:I:'5\6:12S$42=O3BX&'#S#@,"KH_1UE\VU7]
MKC<Y/3:L5W?L0ON>[L\O*'+UE[U@8[%3I.^.E4^>7-]8EC*?D^^WMB$+O"O,
M95$:>)D>[9:,5I\C?:=5]YD)VU^%[+\:]&K"X)*DOTG:W5O6)<A=2YY8H*UA
MV.[J+1X.MV][WXK@GW_F/&,5$$\O4-21)/2A1FQV+7P5#_Q:3R4PJ%#K\OVV
MP>W*P(LL_QC-["E"/">[=/:37C\GV$75=Z,J2MOO4M*BOSPV^5:8Z;?I[LT4
MM5<1< <!56\P0>4AIMD>^)R9AHS:]>M18QVHO$NRQ'"^;+PDMF;9&*MQ",NG
MUCEH_0W^0V@Z5)YY':Q$XXSW$['9.Z%8_4VD_A2@U-F=>'RT7\G^Q2\ OZZ9
M2-E6Q\7OJHN/WWR U(?6@9UE?6J(]TKQ%?5[ \\!ZP+K2:B]!68)P44MW%E8
MAT*P7:@$9Y@V^FLQ,.68DG=1&&U]P0#DBVA)2IIE1THYDZ@AMPPPDC<^%*U7
M)3 ]HVS;?AI"."T_(ODMT?X(IXS9\XZ(K#Q V0"-:(D01S^).Q")>82]',=A
M"O4DD.\#G*,J;^.4-S&VE6(/-2G&-\#'/YH_9 7"+A)2W#4/WEQF4//D#T)L
M!:3GEL=U13(Y+;EE*+63/U;@T$:W5"%'C SV'_1:L_%:@_4)<)[(W^#.<H84
M+98DM4ZJLT'I\$>N:J3WF/"5*$%]=O[#/P7!N_03IVG$N)^7IP)9+-)M2^\6
M]OP>VW%GYR[^4.RUY81)?NRB"5WAC?^#_;/_7_?4@(4X(M(9^71H'YA!Y=M?
M-IPR3?<5;V(=@UW'&U7 H)Z8H1!^#]:7EN% S,Z$W (0?_@E:4$\MK(.NBZL
M9M:Y;] 0]60IQSK@(9(=BJ3-[[B 6M[YT%\,YL@NU/A]SUHR[4NL-@[N:%%
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MA /0<#FN@HJD8?*7C:JH>6.JQ ?Q,!K&:1ZV[Q&=D/.R1/[J*G]J.-1:4U@
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MF%:(!E0@(3L?=R<*:+8)#$M^F$_!\] _WEE8^%-W]-S^B__"(;CG=(FOFQ/
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MS1Z%X'VFY9C3S8%&^^<Z\WS-N]TLRA?7HA<GXEML)^)9S[U==4U_UZ#A_X-
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M[V,'WX%)6H8(8%T4W!4!6<DBX"N6V0Z?RH(5VEMI*P=$@* 1WB@"?DYW#UK
M83M% /- ,GS:?6Y:!'0H:HL L7H1\,=I8;O"'X9 AYJ,7[@E I:C!<HBX',/
MI>$]M"@"K-$BX"]*/560;ET:+5QC+P(^WD(+7II_P*^L;D(F)&)A7TS$J[H0
M!*4_=P9.PHJ /2(@'+MLF@PY8#7HDQSD,U"0H0AX_(9W6@2\C,-"FS1%P!/Q
MJ@(1<-B1*D")BX!OGAU/'-HI8#'9G-+9*@+&T:"G"-!&/F[#!*=?J$:!+XN
M=93?@1I?T LRUB)@51/E]SW>(F524DX$W&<BZRY<D8U;GO\'=.P_K/-O;:$Q
M2A.NND(!S1"8QM2C]GAS$? /X/^P3<A.2H<E6B N(P*^B WW(J!T<;!X.++L
MLLD3.A/T?P#_=XSC@5I9GR4"[K&QRX=#[M(7UL8BI@4I@KY0"4O2TC]PH_]A
MFME,$7!$G@*J(=;8B2(XP/=*L) &2@2DMF?N_(_1POP)=G);,BP6(P+&5OTG
M*_Z3%?_)BO]DQ7^RXO\/K'C*SH;Z0<X%R#<X7^ M B)J;+G6S=AUD.&9+@00
MA#OR1]>X("V6@.8?'9[KEZP>;;%U?:M7V\:C8G3>9"B@%HOL3I#B]$[))<Q[
M;@KXT'\M]<46$2 9G'*BJB)PVU1/]NX;N^WS9H>74O9Y=^6=T7/A?UY>*V_O
ME(8\'?[_<J#-X0[\GV.4619&E?++IR[B;WY[&2R_PO)N4J7H2\;XHQ>Z82D4
M'S%7MF9J"K]%IR\93MNP\U6)Z=&XG2]7_W\X4/]8*D+I<B5!)YI_ !?%X*?2
M,G409ZZ+%B*1T_7PFZV0HS"#<-DN4M[>,7VKI?SI5?^O#TTU'9F>U=9,'<%;
M.@$/':#!&[K!L[Q.82Y&7H 1OA8!I209)BX!HP=.1)9'@PX1Q5%/7TU5A8U^
M;SD46UYF5M(0^V )I=N<'G^\$0 H>8L*\!$*5VY>H.@))\5A!5MJD4#Y4MW3
M06=.8"'=;-[[5X/M_-,M':X^0X'E4R)@/3H"('K61NTZ_3#GZCKK+0\_S7T#
M*+2U"FQ\F4-\X+P&W(X5JR6P"YI[S.S8"-<9*($M6W(Q=HO+B*<+6/?\S;2#
M[<9+6D=#:F(]9%ZN3ZM\ VQ8QL(;BD"'5K0RW9T00P<+S(ZP#:1(%R!/'BX>
MO2D0+36]M&+YHVX':%%9X)?K:IS0J?H-L^SN]:LP5_:(Z1N'H_O6BT_.*4":
M?#RY+W5^SIZ_ ?XT*@LIYTW?56I*AG:2:\")^A5?8M#94!,7L"HZM9?DPKW<
M-RV[E.KW/9$U(N[2/1[::;?FCZ7,4XUSEQO@+BSHT$88U&$7M<_Z\\V)6"8]
M"<US ,7#KF-TH11>O/#U%L@@."1W8/*.8A]9 PI5GP@77 [DS*O99EEXY[DI
MS_N=7%)J&[]QQ_NBV,K.5_04;!RC:B*); YWBP#0#CUDR#."?&FDRST8$X$,
M-._WBJ39B]DR0I1L4*'$Z1)J5Z_<A^+9\MV!=J;==N#R#OF^<5#05<6+6#UZ
MB%!>$3)+!4_7M ^),0-NPAWTLI,94A +U.;-0\I\4X$CY)Y)<NKY"2Y%DT+9
M!IN)I_B-&49@?V* *]8BK1FC&M;JV!V8W:T_JUG1P[E06BUK81@'P.&3M$:\
M!J7^%-TW-(3MV>*2/(CF*:'+4;/#_#W0 LD8ZN3*SK";W&2A2#9:8<#9NSHZ
MMIP63MF4'!$8Q'T!*W4'^NT;YW_M*TH87Y&W5Y1$KZX2 6%A1&N>'1?)X_)I
MO%(HQLPUF(4VY%U-^TC?1,+ENTY6/2/O@+)96*DI6!TLSB*0AM*I86.NGFZE
MX4U_ZMU-IVH,]'>$L3*'/J*[S!6@R_PU(J#^$H'NC1O:U,;#0X,LU'VR I3.
M,1"?9DC#ZM/8LOY6/B$Y0[H:Y#U4.\N8U-C;NPT,BDB.%'BZ;P274R\K%=PR
M--M[_>HRW7\2>!6W\]\.L0GZD"3LE2Q\H=U($'YSZ'CZAS&W5@086</?Y5A5
M\'C!Y(DA2CU2R6]A%U[[GQ$!Q.:[G2*@^[*E_ 7MX_:6\L!_;)!&^)<%'ERE
MV7F^#MR!52=MSYFL;HV%Y4@[N=3D '6#IEMXW,MI%5JTD6^ZU?=^A^B3==W&
M$@'+.9%GQG0K5'6>Q;R-&U?:^E&\R\AA B>0]>?50;'\8,0Z6+HG?JB&77>?
M2=](.@R]9Z7C'+D[8L'?;1>[:]4]@B^SS=VM+#MF239LE/S,G;ZN([F6.I84
MVO3MV(R3N+?Y!I,5@+R]Y;\9YW_=F-/MO%I3755AY9>_9&B]VM#]T/ELC[4E
MWU=]/W1Z;9R.N7'H;H?C63T+RUH/[JMYAUS_]7-A??RN:]J5'?Y#Y3O_1S.O
MVBQ;*'[F-2I/ ;XH JH( E47$;#V%C3&]X"[T4H8-+F]6C&728A!*PE<V 0)
MGS*$UZZ7=^1E^@1=87^!!D:A2M49K/'%O*H/89)/KE[A;M&A+BJ_NH?]- QO
M=4!XUR$".M\1_44 "MU @*_[GK5 "K8CA5GVS'0T,00[.\9J#NN^T%WL28$N
M8B6&K^YQ;=2E59#<WU>^VCMTK\Q=\C-ML>+5/3,'W@V03 ?Y/!*DR<0I.%N[
MLPGK!+M 5)39$0]Y<,32NW"2O+G;:.3$T*&TH&>2$5&_AAS[O*X^VK4ZVMIC
M"_5*34557<7[TNK8'94U8;Z^,5=/?]:5:^FT5<W[M'ORZVN-E[T(Z[@&/&-D
MT9=(UD(JQ7=>7>  Q7((:XEE3-0]?<Q6'%\-DK3R\R)&LU[3E19'3)RXWUIC
M,VN[]0(RS2,KGU0;1']/"PTM;3Q+WW19O(TB+2S ,A^C58Q10W1V^YPVWUAP
M0'@?-G:"._I,T0)=[ 9X6 1L6D3),(ABS<YZB<7)J/@Z==\AD_MFOD&AA/W/
M<Z=F;K&*[!?FC']M>?Y]OOP0>C(I#A#$04CA6P-#B&N2Z"6X9LD1?^9K4X?9
M)3">38G :$WAI4A2X@USXN>XE.3B6O5;"OV-\ZN)OM:5X'A:YK!!M'8<V^5Q
M#N,BJK1FZ-E&N>9B+/,OM'H:7I@;2*SU %N_0.T($39"8GPGR,VDFKLE!!6-
M")YMH(KOBF)%HG0A>=<'C%(=_#7NZX^I!.U*OMW"FK8Q>!Y1'!&FU%E;Y,W[
M( 6N"8<1C;U"2**4T9&W>Q*&?-FA$\U%0<Y0F2]'F;Q7L(E+B2G_AK;B)O8W
M%DBI-ICV1PE<"'F.7J;V744DF^*I$N_^"UUM*DV>GH6H!#QH;:!.N@5JSWDS
M<1H"9[ _UH!L<)'<KK$;(G#:%;V#W#3IO>2M HFW8&_W#%:IUCC4'?/XC=?H
M'JYVM-A,JGG"4).LMVGBCQV[3FVE,(80CQ^")40 7X+<A5^'T6_F&G#Z&_#0
MCHD&6Q2*Z#S1Z.R6QE<G*22U-M?MZ?F9>$E#M[^6PL9&PU+]M;M+8_K&*1LA
MLNV(?C#"-)>V8_Y\]W^FF57_S%W+\[PPI.% A+NG!(APP/_\PG8_+!.)EG?4
ME3,'\RBU5SYXB8"IMZ_B=.1>[WP5!_Q'A@X+!>U6$F31>$B%*[L)Y8F -Q7"
M4 9^/:7^-'U,G5))%:9%-^.$EK1),38-VL^'3]?S$=D]$,_&"D\)</AW3Z$@
M1%(Q*%\V8Z]@^3(D1$_E,6)GEF3O(9KPOPTN(X$"8*3)'::G'F>2+H-6Z9QT
MS:,]JN>["HT/)5JIAM@=8>V?"XC/'1U,>=!P,OC!NPVG.O;Y#KQYB6IF0$BO
M-.O--[++@SM@O126VU.#&%B9/,Q0-<*MFO[C4Z>9\:?1%!LUW)"8Z>T<\'AF
MW_7NA9S4.Z7E#VS6[&#?S*NT4N!;XJEX$$=;%H<'\#PRMMSZ#QA)#NOXAV3#
M4ZDR6&8^^BVZ@:I"#&?-)R&JDK%I2L, K)B9JH:?^K+P,:F"NW<RT2O#!XUQ
MFXA8A\ZQ]]')ICHARQGJG\<C1M\+@<?"B]1?)G"8K^!/G4Z9-3>%4VIUPD!@
M@(^]FN_AL.//*2W6S7VXLS\R@HTA:A)9EUV[A55+,V^X^H[T.SCJEEJIXW6K
M_3GKY#-U=VC+SEAEZV*V?[?I.'WZ9IR/W1]O]^7A*4U.E,G')-G/[U+$&@?<
M-/-2)\#/N1'-XPJW)^TCP,U?/:L2G0]<O)B[77=WM&;$^9RQ;P&/83J%]1L+
MVA%6#LZIB@"I^184'%2.](%K'R!9S+?L%6J(<FSMB"92'E&P@=7]]+#B92V(
M5-)2$[/VIX?E=Z=[X_2$Y'VXY4D1L-1-2;SF>_MX@)VCTA6IA'MA36&2K0^.
M?-K2_QN6FZIYP;[E>/$0R->-:[KB=?KVQ2-Q-W97.)Z];<LW<-"XUM7%L[6=
M$A#"A:]JC\2V7-[3!5;M"&MBOQT(,FX^T,<LZ,NU^:S]Z/6/X&&;BI#M@:'8
MSI1&-ZT.@3MK!-6<H=Q3M)B\B9ABT[TX(GFAX@_F6YZW2E&A0W7H(CWUX>>?
M(\[?Y#N7'V;-W7JO4"J>00J"N""-YPTYL!F):!4S!V]F>W3&AN[LGHJ1&].2
M-:W'.59><]<#A!C)(HLS/?K/3]YYIJA8I>2PC_3P6.L!-L7]M!+/1OC\Z>'S
MZ%6P I / *@UD^^ C8#XI75K _#E=VI U0;T>I(+)WG(WDP>(T/4:*YU8/O2
MT(.(W(HN=.]LO&@1M#TG_Y'SMV#Y<$6;DFSOP6-$;4VAE,^WXN^M*Z][TUS3
MDQ]A/;#0;OIL"?\BQ#\'.3!ID#,>!6]W@GPX+7<=PLC&) .N9\-(4'.=;/E>
MR2)*PVDHM:%/_7;7P$67#TV*2!!['5%KT^KSBM?4_OX;D11!6 _?1(=FYZ H
M,HK<7W>H#$R.J[5@CE@TN4D(,VK/LM%2([[DS;WZY:%N>H8.Y0^&&18$BJ?9
M-J_2PM-)Z[=XDM9TU.G (_3RB2@Z,Q,K4X?&"^0A<9#":D]80 ]BZS6TN]DE
M4 E7'ZWB]%<%-@YSL*KF?J"!)-'MS_$DEL"<I;RU_/T[T_3*S.#M_0-=9[DX
M@=P,DR%0T&FFBYFY%L+MC$KJ1VP46O(&Q0LUM(JDQZ0IDU ]9I=IDWNUFPF*
M>CTF*S_OCCU1LKL5,C'2\F X9UN@P\$C3S17E$#JW%ZPL0F]ZCH6R7TR#!_T
MACI55^)M@CS^(LFE3$.L-T!JWZBR]M/ N4-.J;N,^/5J)V6_C13O>'S]].M'
MU9D<,S$^@?R-(8/U:$L>-K""[OMZ\@^Y>)/U^O'L=26>P;F#==',$?SYS@I7
M9U63R$6)(L_JSE\,N^-SSM,KBO<SJ_1V9_LSY$7 -;R4P%_XO!RA1W]E'1H:
M8Z/6$7UPTM"S>9QK4,/H!JYU4KDKZC1^[CE)+\=7VB+X]?.<X%<@_&XEXR^M
M]7^&OG*MVK@$@5R6 X1BB@!H>U7TKSKL9W#^,+0]FSC/:4Z.<>>.529Z@_,G
M.YG0(G=U7TN[?7G/-E?9_N.5YZ+6ZV5'ZK(B98T3W4^_%&/0K]*@W8S9=+Z[
MX.A[R ED+[%Q$;5!^K'8N%J=EZ2+D#L'%16$EJ[5],,._C+#,6U(N!RG86*X
M;62JLI;TR93.>G^_F[PKRIP[PEVT"33[9\8!"$GM:SV$L9@=@K/0?9#!NP?A
MN=\)\H+=PJ>U8LR1_6T-F"U"JA%6QCM#H^<JM[F\VJ-=X."F6%?1?7V.MB-5
M)U[UP+-.IHO[EF#,!R3?- O.0"E,1AA]/5E%@(&>%PDVO16^A,T%)M A#CW1
M3<-7QX_PT6TCUSI&5R_P3N>BJ]70KU:KW@I^$ 4UX.-_N,O9U6=/FT_G#ZT;
M -9MDC:6TC"ZF3LQJX<L5)MKW8"*$@$5T2TB(!FS&ER:17%=V*.)8!F;D:S)
M'9L/)_EG.[M^]J2-C%CZ$=Y,G_8M\B3X^RI6;&>&.1:WO-![^?C2%.4J/2R%
MK PY\;<CX71,@$C4M=90H@<7S;'DQ;+;XZH)30P-KZ&J>E2<+'&HP?>#.^*^
M"%C#3CTGC?7!VJKZ+Z?)Z$;N\/2SQTXB(">X\Y<L0&XC$1#\X>3O]+*E1&/&
M*D@$./1G]9L9F0'&]-ET6=<3;;@TMELMK 9F5S3WG,G?_FW\==K5B$2P:4KG
M7J'.W%_:2>S-V@F"%!EKHV#FDX>*E@<6ASX^'*(_I T'G>4FO>>CD.:DHC*2
M&<UU2((-808:A6N@;G3%6^:VTXA85E!" 'X-1&B@Y7U2/!0B2=\,.3C5FDA%
MHD)UHH"-=U'A(L 'E9B*FCW/)Y%[W$R@1#8B/,FC&;)]"^@(A@)&U3?U23]F
MM?!)@!W^?$E7@&1R=)W4\9==VAW?4_SSIN^X'>S=VF<06)"X_7G%NK O1_:(
M+YZWI.P09])B1<!5[% C++$?7B.LPWH1$E8(<X;LJWWD71":;=(LB568Q,N,
M]Y@A.DM";10#"A,_)&;_2GLY,FUH]M:+5U85[5>^X*@WIVBICRU<^9>8^?<D
M$FF)?X3R#1$L91&0GPAXG[\B6TD%O2@_<,)=:CWTT;UNY92% 7M+A=BN_[YS
M^I\/!3!:H" )V_?S$4D]^(YT3@3T.,-U\[0(+/,-_G<2?1@'?VMDY\*O^A=6
M<1T$JJ$B8.<E80PB82RY:#B7K$W[<4)P".EJ"/2QC>@2M#"F#EESSWS3(C_V
MO]N+DPHZWOGS8=^!3J>1D;!7V\*<TO^*/']:XIH6L$J+71(=6[O_5K*T5_2!
M%F,7L1<++?H'VWV6^;P^+7(KO6+7FC"L9WO\3^F;1Q Z2KK]E/ED#.NGDM,O
M\R1E>#JGUZ:_!5R:@-5K@-#1!GHE'$4_FK1MQ?W*.[YDH\#_$7CNG22J<2#A
MY)^$ O7GK7N2I<]]F^I*7!O6=#K 37G,,%#]5*#]A60# \WQY;JM[!-FYFJZ
M^2R?*^3RF9WY@9J;<%?SJLA7Y[_-&544$0R%X70F=>57[+HT/MYLZ/MC61P_
M".Y$2=9E7\W;EPQ9Q'J]:*\\+)9S0G;=V/=].@L[VB]T58@39XW-,2O'>\P>
M#HZZ7*S>>LBBNE&S-.^&V!X@8]4W2G3<5.KM";_$U%]7OE6.RCPCU+:NW]<J
MIO7[UF?:3!N\<39,DC*,Y55)6\AOPPV&-]9=BE7< ^.;_=!M^O)2S6:#^Q6_
M,_;R./Z>O/G7_;.U'%R6=?@+&\XF?W:5)-=*+'IO\#K98MMG-V&_>RU7LJD3
M[\G6)P*XCH4>SD:<Z+R_K&7L3[QXP3IU.C%[^_;QJS_\HK[[;S@8:B9U5ZY(
MI?2\]H4766B/$X'.MQ+.!ITN[;?Z1<GTD'=HQ9?/)V-]DZ/WWYU/P*PG8IGH
M6,%:%GZM#[RC7XGM$%L;^(J8XR)4'&+#XZUV\8W5EO"SONZAP\?D?IQ(*DLO
MS?FJ(@+TDJLPS:_JE(6/,;OA?H:R$5Z,9 V]9R8/\I$@-PMDQN,5'!N9*'EH
MR85;]'2\@*#>\CQWQ(+F-41. %N2[!:;SLI]B5%(F@W]]B^ZK0+"4%L29*:E
MR'(".R0]R0A4N1--.#7BC"4TP\77W\DXP+4J8,_0I)R:W?.=IH8J*[F?\R1U
MWL_K>2C>KMV[V6\(]6/M[N(O ^@:>8=(ZLW63=Q3*L\D8_>=+#-O.%U<8G1S
ML'A3U/Y(W:,1>?D=N6YR$3X[3]T\:YOV[(Q#F><WKHDX2%.Y-.DA<&E\CY6]
M=',@,KZ195A(E_J+-<E^>K#+,2Z@Q&CZJ,+YW4]W_7F=_?F@%>\Z'$)GHRE1
MZ 5_NI(( ,]FBX#?7<\-!*IC8#Y[E]XOK#<M07;XU*M#,2DGNS6]+^L6<F.5
MSHTHWWPW^O+I]\.?:)-GXI:]B$=8'@=;;H)+X:P#)PPCLAYX?+%_XGSKB7-F
M )NCF-IK[,]F,:W#>B8V/!'H,@^<RSWP72YYH\?NTR^TLB4L"XU[LG;F_'U5
M)(1GJANP'!HIJP2&G?HWYHTHT; T,FU 3<V2+/[B%*S651209C.OI8SRUU5\
M6/MUD\K1EMHL7I'P,2Q)'L*+5]#NH]&UV"!V<M3HUNJRFMYR%_,3?GJ_QM[>
M";FY)*VS-]'IL]?@"?I1G2D5G07WQ? _6-YMQ%FV\"=T:6O3B &[O\%/FZV>
M&V\4BN';EB!D:=)S=^O,*NW1'7O[+K(\_K7+!7L_PU;ICS)7%905."H,@30!
MEI@J@J*;8"V,-/3TM1NQIBFU/SXPS4Z,3:YY[8TK)D;!H;@+-57=<P\L"+R"
MF><3@:=,/K6:]<]^D%_%9*RF>Z*B\&6T^AG4?>HF/>._!&*Y+M,7WCK/K/3V
MU>35JI2[V4WC\EWOF]5SOA2S?E_E%)T'VV=+0,T&$2!6@1^L&V;Q$O-)BOUG
MFSMFR&+]3#L7J]XB06"A3^I\[!R-F7XX50IWIB]0XO7)7?8'UW^\YSMINE/L
M3S_O$@+=F=Q$+44ETV!M@1QD[OZ:.!URJ$C'FJM810EDJ\Z+>YF42MRH/<BL
MZG$^PAK9%*RX/T1G[^,QJS69#N)!\ 9CT(!M/:? WT.L8E$:L='4-1C=Z:'F
M7XG[LT$&Y_>T(BS.O99X.=_9C>'86#SE[%9%827+6$O5_""&N%5UT5QPO5GE
M+UH4)%$U7B]1$SA8 FF(U[S@$F9% /\XL8V7"V6"OBSM66@HN5$)LG])TH*"
MN9)-%.7%4'\[^J.?,\[T9'@;1&T@;WC&Z_0;[6MM7%&H2[ZE_K3\K(3^S6G4
M"%D2@6E"J3<CHTGG>C$&T%GFIOAL*'4E](X(L.T^P_N%VT"T<.;J??A67,5&
MKR-Z#TS!Z'X#YH?J))<9CRNO@LW>=6NBWQB=%F_#: L3Z)[M2@)5T/.CJW^]
M_0_!/A 5LT!7A'R/V.8FSY*W=)D=P<;I!6J_V.KMZ7=GG&.?_OQ(:O#K:UM*
M:/NA/_S-Q+/X=Q"#&\UL#R=K-/*M21<@4X9$A6]R3*7A-%X*LV52L=2ECII%
ML@&%A?L2SZSW8[\K+>]I,G2=F@JYM:T9LW1V*51^E:"0W(0&K;"Q&'EA4=T:
MN ,O2[_&&)SGG>^D>VH6C!XA@/'L]O@Z U^T=$7-W([I%BF=QDXH^6.&1"7D
M#[);S[Q3R4ZZ[[>_0.MT2^7AN4,S*[G_9F_C_X <(".UM-Z%PD22C+0(8%(Q
MBM!:%O4>O2PCFV\/=U$KE)J5,8AE(0="8?M+[Y24H3M_!:;[G^D-U'$Y-%SE
MHH?U'78Z^JSDZ\DRUVGGT(J:KV1GX5]80C*DCVM*'E)B&=RC>%$@K=8PS :!
M#-<ZOJB<&DM76)A/X%4+Y^\)C+<7_4A162Q.UB@YY+//PE^A?/7(MI2;+]Z>
M4;HY0V=6T\NJYCC<QU;"!W4[R!^=3>IU\''T,NV6#PX<=493>X*&5E<MHHTW
MK+0T-A*NT >KD]YOZ=+J)%FK]3M[QA<N2OJFA:3OW(TN0R_\56O VRS,05#6
MX57K#@CT4]AUT0BOA[@IL_5^'!=7;0XU >M)C5]Q:$+)3]Y=[3PB^><U"D6D
M.9:%N[J45^EXFIT\^OSLY],F.\47VBT5!%/D#C1X4\6:BVZFB%.8&>BW2G.^
MB)I6Y%+N"5P*(/%6-W/(GXE3@)28VA$"CY>C-CF^=6@J.ZJ .7);1WCV<._6
MU-9S23.V'0$.J89"*OO0N[3OIU&3E7&PFQ$%TF<(Y U8Y,Q<!KF? A[%#NO4
MXZ5^Z>NK.G+G/\;'8DQ\W#9W%[4X_T)\:*H=*7B?B?M@/)K-04L-:YWHLN E
M1*+K**4.<[Z@">\'A&8A_N %<XV7XC!JQ!P_:UP4YP((5[%<_:W[%PX]OLPV
MV B%'^:N?1J5A2Q3HZ?+U?!\Y5Z[ZRD/CNOI_V(.'KH7NNM?6TK_W$Z;^;4"
M6< ;(A%M.",L1[3A#\QNRK0>Y3!:@5)?Q?@=A1I(AIOP"%6G@]AWA4VT1OJ_
MM_OVY+]N&08O-:NKLO7IS"*\+72>XZK-FD_2/R9FS76K8GG5>N9Z9WM<>-'.
MFEJ4TC\TOU^Z\XWO0&TEDCSW[W^ .O**OM4,1?E[^Y9+F1/GMC(3J!5!#2XZ
MA/ 5=*/YM7ZW9-[UDF<3KAAL]Z+Z4?;H=*> ^':P^$6EQL5]AW^7P]>N2E;2
M70+>T>861DRE+OS6LS@7U=*E=P*6O.PIM2BXP\T>^[G_BHWE:P<32:W.88FK
MTIHQ$4ERMX#E1EZ_"'AL)LRCSS(P!@C6M30'Z., I34Q17C7A3+YA,8C"RM$
MP,]VK ^!;](>+P)6[OOVPGOVH[D<#Q'@]HRQLEU'."V,IOP^L&))&:AJ) A/
M<#1_S\N*@.@GE&1E$?":U18H#$"<GH'_?1==D2M,6W=?!!2X'*/]=*874R'#
M-AAGP4-<4':I [OHZ_54.,^_0!E;7WM:!)2T1V-70.+-Y1OK1,"CE+7()W*I
M*[&.(N#H76[[D"9\7+N%PM\^:HKH=]\S-'>:FO 5]F<8R5,$E+IR:$*KBMTB
MX"%G*2M"&(>@Z$)R43)?"T:)@.YS"@N+I$:^@@CXG VWHWDV C32'K[1F9K^
M5P:S.K"&@_SVBQV@L5-X#Y&.H1S>1EHG?(G9*U H$4:2MK+CL9%T:=(19AI>
MQI7<D5KWT+^H\=5%R<">W"XV9/FF.??S[:"]%4GPW!57.OW*<?10F[!/!"#6
MT,3_5.=3!&L@;C[Y![J"G)TMD(+:\J;ZZ6J"6[<\WW@S)$G^H>Y!:U*FN>V^
M0=Z9=H1;:V*^<-ODDU7SUCHF^?(9O!#H$!.;B-G-Q6T2;KD%G:R)O UOH*6.
M/2TAN6ILRM4=5ZYTB<I=SQF+:] ]EJ%8MU7HD.%@TS.VI%_G$F^XL5O_8T?1
M4ZNS-+.3EXW5L'WHLIN/H7,>7]X_"9T)#L2^8D )9>P@H2:G'@L]JD:(<M"Y
M#/&Y^"/!R>H/I14$2+L_[*%^\5Q1>C_O29]3IV?Z-D]+[-JGKCV8,:NK%S37
M]A^D_3P$*_?SD,2518'&1$!4/!NQO6$%Q4:83O>Z7.!]#&X7 6KW5#(R< )G
M;(SZVA]:BR H=O^1#;#)IIE2'-S:8<#S8I4F=,N%LQ,>.=9B7))HD7'<[T^M
M=2W5])R?R.8*RY>'"]8[*Y+:K=)'X'4I\MR$_+,);WK'GOQ=)R2*0HKM<7C/
M01J]1P1XX,+1TE>A$C">%=TL45[>,09%,]$24)^=RJ$R<NI9*,VBM$_UE&U?
M6&]QW]=1U<#W^_O&+V]^T"CC%S[&@'9.S-W*@YL9I1,)9 /(\UBWF07G\XWR
M>0F!>5?%3&<.=!NO3(RZ4-XYP=5XZ<\SE^V[/('_&O=[?<KZ7*UD#^'#Z_-&
M2,^*Y]UZVZ/[:X'/QX:A)><(NH2YG+(/9=7A]:EF9X==ARYJ^0]?K-]=[G]D
MGU;)\<)'NTL?8/01!=)&_HP4/LIU@X&T9LHF\F:BOQVW/<'L(#M94F#U%@K*
M'VW-=2)9Q-?W)[_Y 1VDY60,C4H$_G6_,GK.L/GZK^'M-]=?$ '/CU>RTT9>
M,XJ2!]N?42Y1AX9YI=SY.<E\$I:+FPOF;R,/U:W2V,!=5\$]+-@"\MZ#N:WX
M56:![@3UWO2HR)>^2G<7L'("\5NWQJ<LG$IKNS)V>92___W@D!79%=K+MR0/
M4\KW1W-H,0Y4T($RB.,%*XH )?(NR-H.LF=3PTQWE!5!#I8@)3&0CIK:,WWW
MZ5(+9=./$=>+3MYO70W3MPV>:'L0#"SAUP1($7@EPAJZ1WLB!8E_9@8=J?J7
MV\7);?!Z[EQ5\[PR-,/*B0;CYEOV^-;)U('CCT%<X]"IM-PI62+#LJR/=GVQ
M+-]I&#^Y1WWUJ(LWRS,\J!5?QDOG:PAV@A--!'&X!PM:&20@ZZO3IR9158P_
M^+)5X68'JLPVKMOS8L$Q[HZ\ESX7W'0?UYN4^MS9Y]5_Q^9&>_#-[-7RN^_=
MN$2QP$MC#@J"A!E8=XH4U-CHO"Z;'RP([#$Z,+L@Y<+23\PF6C?4&?7^TKU!
MV\:->J-/LBAR(?K6W[DY;/P],] SE'9QC81"[;[R[.YO6 _*D /O(\1!JGQO
M/*<RG4F/'C40T@)C8-VI:H>PE'/5G1@U%XC12)46N+#LM$^D.2H&.3SR4D'S
M7 N53,.FN#]\3@]]OEWYK C[%-V#+VM-,-/A:O/LW]9"WJ!+"WIUK;92V")#
MBFC+0L4+) /!>5?P6V+48_.*J!14^(WKY<L!!5;["B_LYPXV*]<[]L=!,SS#
M;KHW?E $P!+/#Q'EF#708TY_1*TM]T]3!AHRYX3$UF[W9]\*YJ:T5O.>YQ2-
M_*PFOGW?'Q!?X+T0_"L[J@]?,7S\UY6;CF*-2/0QAM)XO:#)7#<+-:C*BX X
MH"JO^#T4"<XWC9I"\1Z@0X,LI-.$+IV(#7#H5$%O@AX9LG&RC<60#^CS:' (
M/Z*N=/I1B$2.RM4KKN$\25Z4, LC!7^A;Q!8<K,X]$2DBJP2F(%?7/0S"QG6
M_OY:2U5+>QVG[IY*N^PNU?PK*W]Z*++Y0Q35PT^R=BE(1G-S1WF\8%FP*[H5
M7Y$BD!?GW826^5A*/1;>0VXT[;]7,7>V"5U9U<S0(.YC,!<HBN5I-;8AJLF1
M2UPGR]=VW%?C?B=ZB_U(-K<4Z1Z>[FIR1P)];@Q_%0)(M#:2]G#G$\@H@1(4
MRT2O:^5>^\,TF5L%#K/["D#+0"G]_G-07A:1@"]YUV.$VS@P8R(],$/>75+E
M9$Q!38YY5M?UZOI=*JU*G6(?735-+0L2*"3S]@CSR=O0$2) TLR/?0#>-@P9
M.D+AA41<BQNJMQ9=0 QI<-ZM6Z724D4HB$FL*&HN*^I]\C;MK_'P[:/:UHFW
M,')((;Y"OT1+Q*LBQKJO(085O1DE)C>I\+)8^+7$LC/@LYK7I/W0?7;Z5L]0
MZ\;1#=PB8;DSN21O>'M%6Z37G%^QHA)_^]?9TR:<_DC,'B*=-XF +2=VN: &
MH]D3L\UO?"@@#A^'1BW4B( D#;G''\GF7'(9K?6-LU.ZA65M5/O%,A!.]-]9
MTCV_N+-K*+C?WI3TVUK.;]%@L(TSWZHNR4R>9?'EI_&@C0A ,T@7A,_]RC_H
M-+OI0/',1 SZ7@8JA=7W_)94?S,ZBGP@A((T>C)0?).5^'OPIX9"CWY%37S;
MN)QNAF\$L"+'^R3\( *\:-&C^Z'!?-*VGEIS=W"89= \/\AG.M=EOT)>M*5P
MZ.K$\./ON=]J1B1GKN+>0K@FYXMO\\[^/.GT@EJ-/1& '2[CW>X5V' +&NTA
M1F#N+(.5YDKA$)H4R_:2C,'KOUV>YW9NY[K;\4*M\6$')IZ%FMB$\3\["JK2
MVA]MSA8<%^93W$5  E4>260IMDP&= RSLY7KR8L7THS:XQCRE\&B9[F^7-7&
MU O9W*.A*NUN9Z\_G'9V'7\*_D'ZN&ZWXY=36XR3OQ(3M#:J4@>M.?0&RJ )
MK_WOTP_6S)ET_,=1M>Z Y"1\F4%+NT*]>70D;$"\C9/V,J4B#1[I''>1&WZ"
MRKY[T7&*MRN(+67-QS7%4VXN*9G<\DZX# C-_SZIN39/>!]C3K*!0L 4UGP3
M01['28XW_;J";W0U< 4UZ*PF;D6"?6TG1&U<<J[=W\$@7OFEM6_(9WT#VS'F
M:6%6PB]:[PI\6(#CGX5R>;'"*BPS$1;KHURF):++])8:VN5^3/6/[H!*F 44
M2>^PB2-0P(K=4ABLZ&JTMYV-DQP0)KG4A/I:AB1O^C&Y5=]O?)#?*"3_Z]ZP
M^#^.$_[CU!%"ZG +F$V9.CZ>#7/C%K,04=<0M[/PU(/_X23-?SFTM!R"7/XB
MT.4:Y,N7@G0XGG&UP4S*@':K"*AP>YA)'L;L!%5]I#_[,8V[!/,;'*%',R><
M#(H$)J%LV0M0\\:FPFN.62%_;7$6?!=2S?8BF7L60F3D6H148:&3>/ H-2:5
M&K/0'F.*2S::'_:LIZ!([AR:!FD[+DS15-75@FV@Z 9]_[5PA$TT1N\8;UB?
M^SZNA7NE.DG/T-XK"'X/=^/!<XQ$S Y(@BW4::6 %K0A/"\>K(I!W&0+B;'1
M8<Z5L=C8.3,G)GJMR^@/;ZKB?("Y+6M'B3N"1/FSIZSW7H;WC)=6ADEYG[&B
M]#(#T<KUB*NONU"BZ>4&]\AR J6_]\+K]L/UF,T0E]V&W@#Q.7/4>WZU.BSZ
M)F];A;%9YZJ$0%]LA(I\_XIBFIG+MI+W_46Z<]GOURG&QC@ <)D.5Q66W,KW
MA'L1X8V-HG@8A%'?*C72HN\NS1GPW04!U9 E^%L$L!7^P@.0??FW312%F=2D
M(@^"<03*?/'M7\VWS&CJ-=N_M3GYR.USH<]]HV#1H(O!/;PL_08^BE'V(7F6
MR@^&OR)= BJF;CW<8>)VL!>SA?BG16,S_[J&,9B3) + Y"F,/'=[@FE. 4L$
M*!!#SK@4%!%L2NE=GC7=;BZNUU3;%$),@'$1<,U<!][D',T+AXXAGB;$T2_5
MS _6FWE<(1L."0YV!1ZH)6##+#_T\R+(BL_\]NUL>=./]9 V2]ZP3':7Q;#@
M&#_=ZX6RQV>OSUW/2@V^D9/4-:H3\&S\RL9^6=V=<7].'-YWXF/- \F]V^C/
MZ ,B@#4O4"38"',QZ]Q(@0@U1N%F.AK>-$B<.4F)P:\52&21MH:WT&4%Q@H5
M72.0>^.2J74C7\IKNBKYY]='CCX7@B(^_@[-77WL\4K&2]1CNA]C6))%G]W*
MWR\X+,R&=TUIZ'/14;52! \%>F2M1-;G8F)5LS-,"WBFHA0=8+NE\V/5W?2%
MAXV\FL&YV2+-/]KO_EJS7@1DT$O;!8IAK1SQ.6,F8? 0[ZGP09T1N0FK0-XK
MV$.'Z.!>LBZ4]=%-%UQJ8JSU-@WBM>3IWFT/#Y2X GXO\43D=79E8I%5RM6H
M*LINIJ[?BCK?C]R'%:-?,1C,8GO.Z?$M\(V^2+9M>60LF29&\ O.(SZ^F"Y(
M1D$NC3RE8]:AM)FAQY8>.<,)3ST?L;@;94M%@"X6Q*$V"/P0.[V&N^NPR-^W
MY%Z\'%F>*.;2BUE%N@0Y(($V(4PVV\L5:U"A)9.46!05(MZM(Y.;\8'%U\/S
MG:6N^3I]^RIA)ED\;=K\L3?75>YD5WG!KL-82R0)AR? ,MA$/\$IA*R4N56H
MV8.!?(MV_IY&_MVV()8Q=(XA5[1XF37E6KM9OSWQ;(,O[6$.5;9V6T]*W/F8
M\CS)D.BY("3(2SK( -S!D*5<F[]'+;5N$0'#N!8J0)8=)-T0OJXP"$^=O[_@
M)\;LOQ>XLWDD(J6?O*-'$2]#C O=8Y,G AH.Y1R1&JCZ'6:C:59G_5N=V:X&
M62!+"O<MI%\]1%.;#$)7'*74'R\F:WP&KS#.A]M#50:)5Z#/'H&[/S/?:%.;
MBK0ZG7],1RW/#@T=?G2-F[-)9V&)%\#-C<2ZTZ%=#@*EM$9&A4-3J!@KYP.'
M/C#_D;P?=,OF:I_OKM73;D))#0BT2CINS-<:&1\"C0O>& >&FGD[D_J=G] V
M/MI>DG30>0]JIHV'$^;""N1!>EE[ V/(G5F<A\D#)]BM47YF-IFJ/Z.D'$YY
MVUI07LW<>8#S5W]6EL6P-(_*\MGQP-I,UW[4Q)JP&7%@)N4+DG;\L'P35!QU
M)1[?_P>1@VO&A ^Q!%0"&O0+:C (QY<&M:A;\YR%KS%;H-(9MDDC-6:%EECK
M#U9SCD-!;TA6*2Y>9YM$P*;R=FEBV:DJKN)]M3:"5.6+SX'JGZ+F+D?&H[_2
MAM+@]5-(DZHE,!&FU1U ,AE6H%!/"@6I#>B-)!>:P (\+"RD^[1+F\23MN9Z
MGVTO]A([UE^GYC29^KRG4-'7WSU_U,7Q1X&1X=<W$UO0W4O_BS<0T:L$B-9Z
MO"RLH,_:"%]0%E6Y"J'+^'_WOX?1>\E#(N"W)[4"6?5$LP@0'JZ8%@&;55$0
M%PD)FBU!*/OT[Y,:=,'SB3D[)($M<RDBX+3>77K+ND;8[#I]IFM8!!S+IGS
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M8]XK8?YB.[13>]:2[^ &]U'DR%N(C? &5[XMN<,9A70)5]5]FTQ38LQ6,47
M0']#0;X+),D>?<Q*"^ZV!;\,^#@[577.?U7L:W*VP:1[Z^YS-:;8X$$7>@R]
M[ A$X!N3D?@L%Y_-]N2[^^ KDN?6LA@ 49QU?@2FO527]KJ)J>$08O?#.AT[
M2OH6=)+7$&T(B\:N!@Y=^L8'+H0<)+RJ-%PGH GO8YFY^++D6"P3:18WD-19
M6&A'?QAF(_G[RF@%5Y('"&/H?N;KQ@(3/<_3(:Q::E066#>,\_5^"?(2BY>5
M#-M"LB\VFW_*,.E9]/.[]@) S6+H3PB0CO;L5D1;W14F8J_%'Z_3^SN=*),/
M^3)4*#X$1=))R()_2* )17-:H(?<+-YSZ&FVSUXHS%RF<-%I/K/+P;:VIH9>
M5?&V=V[!Y4X2YU3'C6OKXX47^SE! @4^SYH;-'<P"V[#[(36\BU)QL)TNA]N
M\ _'H[6),:AS!LH.S<5&"8(X.\#9%7R<8".L4O-B%$I<Q$M^WD.83=1Q^M#%
M9MSI\Y6L[;Q'0204>)(6A06MU25Y5(0/023+:%ABB?N'AX.&N>T7H?M%I/7<
MH+@Z0X$U5P3<(RES^:P=56\@\@23$4]8'$9+#(X2^^!F@WD]HZK.7]I5'V*<
M?(;TPC97;(!G?9=7(W.2D79W!Y;Y,D,)$@'\W1 -WN"!S,6[ \XW$ ;=.;AF
M7"*^+/<C/:*_;1.=J\2+@-*#WDQ796CU&'\X(;6;_;O=VNXH'(*6&JC+-G1&
ME]KDMJI\#L7WSP%$I'G@&PO6"?-KU],W4KSHD>1-4#.X'%ADV.3>H'&PZW+?
M@L'<-^515YUSOI()#?VII$>'ADY^<5:Z<[7^(.T%&46IUZ$STREE2XA(9R_5
M$P;FF0Z-N-@ZQ9 \LT,<B@11TZZ+9)'U.43,>:0B*?-&O.XZ]LB0\AUJQKYS
M7#P%49G;14#C.K@%"];AY@YCKZ'#W'EAWG4]#,761L8FE(HQKX,ZY%<0CSY8
M<>7>KEZ<X.1Q,1.M^PXPEMR$+]6>LR^$\$WX<OSL&!C.V?^!^?X"7G(&+VTF
MDPG%G^NL/+'#T8\P7Z3UGK_E^;%7WVVNEO_!^&]BVZP\BP/:NP(2=0YW+0CE
M++JO!X2JVI15=I=_T#E9$=9ZJKM0E^VH=[VP<.[1H1 7%R_[;6'KW8^S$\_+
M'+VGP_[?_<Y#9?5KDR65:UGKG@9K4//MW(,4TRC&I:,6'A0MV>WI/_H2/E79
MN_S8//[H1[7$0Q7SJ9J;@A/_$[6.3J9*&XL :&?0?:P78;";Z0YW,];16- ?
M=V[<.%XZ>?";YCMPEB$IV$I@Q^^\7(:65E1]5_%<7_'++R=UMRYC[Y<V:A&T
M'FSDBG63G62]Z?[G7(<64VPR*?#&XT1"LPHJZFR#RH5LS7;-PWYFF)25OTH<
MB[[>VB>L]M?,.NYX8PBC)\RDCVVA@J<8_'5(NEK)6_@BE'VY^I7A48EU7O?5
MI*^>#)\,SO,5M!L3PJGK:VTXJ+B[$S%D!<'!_L /MIR4UO<5ZNY.("ZJPN[L
MZ>=D0VA:(94'\^TRIJ?/1^UD.^UX.G@E45H]'Q \;D$I(LW$^GVZ5>9?;R=<
M\[?=]XWSI"%*4L8"=>:IS24NL=G9GZ9L==J^X81:R<4?W?&#AB!#@W2KS4R<
M54B--;P8C:9V?OLS</4<.$C604446!7^%MRY5"*7L6-?1-Z;2YYV+3IIJ:_=
M/E-'#>JMC_!)Y*&?U8"9'/_ K^W]8^U1@F/K?A$_<U[XMSKSISQBDQ2/#V3<
M=[7!WCM(^[,?7;;T\=)7#I/:<'@6N(;>9*:F'+:PD3$PN.7.YP-S>*27J3<B
M*PKV@9X">6O>H5X!&IS_."K?^QIZRCZTRQ@K!>&.="Q*Z(Z!FZI_.YN//[_L
M>Y/799KU6>SXE:!CUXY^62^@A,$I9MB6%PX/;N:HAO]YH:B)^>HUUE,2^&>C
MPHD#P7WC%2>>3'6??>'>5GBE.ZA#@&YDY%I+0N$M@KWU!TZM;O\]BY,;[]F7
MOWGVE'?*A<S(/%>;_(J\,[DJCR."56Z%CQ/\C+$5^&$\?/(/+P?A-@FB(]Q6
M_(#GB%T6 1K[\8M3"(Q79^B#_/_'^^XKV?_C/?45SR8Z:PS-::%,';@]0G'%
M@IXI@HSH.6^D&ZQ_29GNZ]195J3-Y,(;?R-S=PB+L+,#1BBA\]!V2@C<2UT^
M:B"/G?5GM<.U&FH8E_OTG]GUE/Y:3_C5!6R> :0_(?CK?+LPA7H/O_*V?!J^
ML$,$N!@( RC"]?V+.!&P]@<RZ8;W(J#T#R@I BXHIN._-#%F$,%;G"P",E5$
M0 P#>?H9_)@RD)\+9_=@)]/^/AWV^2U7$V[[:@"7#<B:PK%T)J-]60%[G<#7
MTU@O GIOY?;_*<-WF@A4ET7 MMRY1!'@D56/7BDV6ODC4!,!CTKIPM@2ZLKC
M^YA&WF-DNGM?*+,_;R[!>>^>P%%O7L7!F=B&/7]_,;+XN+5FF$(,ABFK(^#!
M!YR^<:C)U/)-']@?**TJ=85D8V@"IX0'2^"MWB6M'A[Z&7IZETHZ!?:YWKR.
MP]MOJ=WA/=RRD?A9"P&C(_7ER]T]FG\VT\90[ F!C 6/W5.G3SK/U6[$JY#;
M[N:&D7RY8DT:1AT37'HLO-MK=%>4>O#<2&&%'_8H1,F?LK?SY7F<[@M:DGEW
M)>BG__)$S/*%T#2/ Z9JF!*4 DXM_[PCZ=S-1SQ,RVN7IS87LKYI!*&#GM?,
M^*%F<9E!:*(M:S[FHF4J1#^[._<!&SI3+&D03$?UL7>CC()S\,X;,F237)^?
M>(HOZ"KN#;*2L#RAT3U:)K 5 1%RAT4 E:XJ EB]4($(^%;AZ0-+=A89%1W]
M-20"6O=>=!Y69CXE[R:=^WJ[5<M#[08W:V/>S]7KM2Z%[4/-&@@.(IV0B0BP
M4)I%&!O):*'#=Q3<YN'UH0@#E.@5&5\(<N26FXUWPB2RDUNQ*F['V4'XO1PK
MZ$I^U^ZP3]E/;>]MCMQ!5\^JS]C>4K'KA'**ED_W$V0U/FE+\NRQW/[ )8+0
M400<_X-^W=\15HQ/SHYN AWZ=C-O!4S>ABXG17PH!_]$ZCO5*5ZDI3=T59<Y
M5)=A<Y,'5L;'__#LA6DWYO5O$/1_D=<)]#+&?_UF^Q;4/!\#W1)^M_O[W_R-
MNV56_/7W-Z-DW:2OO[XV/9YFR)J9LPF*1*5F#560D*!/1D-4Y\Y?"T+5EF<7
M%%?2YZ/F;VCN;<X?''1]Z&O^+0]S==<!KZI[KILW.AP$Y3Z:TAIH8>CU=<J^
M57=,HRI !$A5F$"U .]][4XWP1@M!87@N@STKTM]/7U1]6!N^2-;=S/IKU>N
M[ON_V'OSJ":RM5\X-BH"0F16$.(("F*Z54 14ZV(B#1&1$% 2-N*3$)$1:*$
ME(J(@)!&%%I0XHR*$)D58P*$045%YDG(I#)&*@BA))7*+<[ZWG77]Q[N>\Y=
MZ[S?^NZZYX^PPE39M?>S?\/>SWYJ!_.Z>2FE-1<F&AY)[UW!>D,XAVF=7:-Q
M?R(_*1^ PCQ R[,^QQ'.C+I'8PNY>?F8)!?O+C8O%:MP^K3D&G--^/R9@M#)
M%E_?P:FHF_;&'FO**B)N' H*.G*Q5F_!+$(&I7 T?N*EX))@P;=\0)@88*K,
M6YJ-:1?Y&QEO+WSC[H!]P,;],$L<OYZ4_1C6#WB>H-B2(#]QO?7(E?SG[T)W
M2:;BX4T*RP/T%?"@PH\>FE!;GO5.4+K[GM!FFV);UMN%2Z [T(YXL9GNLI(7
M.]8%)(]W9 6%;/LKJW?_B84=7R?/@<(; +2'<L$HQPK*K 3@U2UT$ASX%+N1
M.M3A(V?I(\9['I[C&26:Q.:(+:#7-RCHZ;[5V$.]?>'[OK]VM(0+U<[7S6+Y
M(V[*'&QJW9,3(!Z?H"& V7+CEK6<A5,)3(89LN9%$]715:3"X0L2'KW)HZ]O
MYGA$WX]ENKM^#3Y4T3Y2LN_%SRO2>IS5=ODS#)48>H02XPG0[D9XV==D&;/.
M_3$0QS"DI4O(\73BH3/1,7E#W=^*& ZT47Z.=G/IEKUDTC?QL%=KRD63G+QE
M+ZE98?<6$E8IF3 1ZA#WQZ,:]="D)+=NJZQ8O+(N^^E@=T=-)V?I YJE8M>6
MW6W20T>@OM31W.YLV[3.,^&*9H'=S]:-*EP0L?-[)6\V]L:,*#\N"PVA&--M
M#HG!Q7"&!-7#[F6P(\/X.ZVA'IN2J<VF*<N&-N?9H6]?=) :J,N7KX^];OG#
M_SD.I4ZG/+ 6,S2' <C'QE2,OPR&@3B$B@W8+L:[LU\:DUKXYBM><"#PDJ-S
M)#MX$C6$?Q%J.P2WFU+A':?B8B)/CS3["X;LHV5OUO:$T3(G\U!-LN( ?:_R
M+Y(^O)P,JXD$FC0FYL3J@414%]X,91 )MF)8?X=,/6G"+6PS4P_./[;V6,2W
M\?=J[E>']SF$ETY<J[B2D7=TK101+7'</)V0")L*1WM.;E,6T0DBEAKLJ^!C
M?B8*2'  +Y009M' WXK+6VUM=C1#<%'/GI+R)+]PKX7A.<UVEU8&)D5W#T4>
M)"!&:I4FQ!3>D1]1&'+]A)R1D<J%%'/8LHZK*_,>:0F\'\HRYAK1TK?)=&[%
MY-)__5CB[^GWD170,NYZQR\%W/;LQ?-7;:=.<8J2ZD;>?WZN_IJG QQCPJO8
ME4"/BY<RFQ<>[B<_"Z<(W=4P9Q&OV#:(;H97"QOU:-9[94?S11M7YO3S)QUT
M>!*B4<.=VH?N$1_YM$E[0O=Q_^W5?5W"DT0_Q=J_'1FJ0EPHYPFEQJDEU*[H
M6J"86-^0O85Z -872K5J^LS@QQ!%!"8>>]#J:"U^P5@5REC?OH%@.FSD-7H$
M7=9\&PKX\^J:XC-ZOA4XGAY894=2H\<J'P(1@LN"4GP=RY31Q%M$PB*$OR%4
M,(N(1&,6:T4+.JLVWUU\+Y8:?0=Q@"EFDM#VHV]K:_I6=DQH&[LE[WE9D9*_
MEOC;6L]OC0D8RNPD7F%H,ZN!^;8 O(I2#^BB;P4:!:.VQ#@53BW=I?!CU)9%
M[<W?\-JTZ#J*[BFI#\=)0E&'=_C]=;1YW']_8.ESN]-H%,?O. ZP!X1WT$U0
M^V.(+"]3/G?TC'S\7I1B*7\+$Z#LZLEVNP[C:&/"?-("6@+_[,.\Z#M=U0,=
MWO;<M:R:J<CR>!X]O-IHQ9^D'_!)C#[LX"8QV&4JQYIQX:)%FG"0H3'H%BXD
M=I7+P83=K4O@S#!QY^AXKZ8V64))M&R]8G+Z ?@X-(M>3M(M^GA*D:)7&^$H
MW=$O]6IVGIA>P8 M&A,X5,5*9)TRXPZ< -[OH:F)RZ[+CBIJ90/M5_MHS( R
M./D1LJ.U^5OM_;'#[DX>K?U%>NI'DYHW[IN_Q$/,*Z$B^OPJ5*<9C,!?/KOV
MNDQ?'%0-=%-%7!8HLY3[P&%SXP\5^--](0[4D$OWA7T>#3O4)1^Z#[\Y'/-2
MZD0V[C[F^[[V5>8-QV+?RI)9WTD)"B^PZB!W'J,)>!9T'H.C?*K<0Q;$I_;@
M:YE4,0'>#^ 1?Q'3@+[AY7.H2;:,9OJAG;L4SNBA))-3Q"T]-5!WEW/T*?:Z
MSOI%8PGC9RAU]B/14)S\EC(7"&=W4FHR 7T5[I@@"=!4X8[,*[7N/<YH!=5&
MN'/A&-'#ZR$BOUO6VS]:WHI:366L1G;WV7"VQ(K#-OO[D:^K=]>5K[#^ZBT_
M^=]6;0A?S<:4Y,B?*IP9.@>Q@K^+F#VFE< S7BVYR[+>MSZ5HR'K%S_XDI_)
MESH(ZK@F',@[Z919A'CH]R45[:?\NI8T/RPO;"NH_0#GEPP&WK"(^RY -3"'
M.%NJO$Y%+3$38#<!8K:^RHENJ-A*WZQ,9RR )R7D:L&%' .;NVZR&/E%65"B
MK1E1;"G=I,-\1/'S_P1'[ZC@Q6KM/M4<M<79J+WUX%"&UXG&V0(O[#K5V+49
M*VF352I<(:LNC-C56,<J<QD95=@R/F8"NF (KXM2:;F7)S.N8<WVAP-&=S65
MQH":@\\"W,0#=-/\BM#O@\#OW-]9K\;V$AR",7L%"M.YAG"NPHO1!D+N8=0X
M0J%Z/;GK)0:+SY@UO&Y33#?Q0O"744.9,9^E-03.Y<3FP\D>4.;(%U&/:9[[
M9O?VY<0G7<ZDZ[-XKTI?).;XN;F;6+S\%3^NPY:XH5H UN1KRMQ1(%B;((=8
MJ-9^,;LK1OX['"U;OQ=.7PR8($XR:X\7RC^)I<SY9D;]GLHL_6TR)N*5);C\
MK2:+=$NXD24J>Q#R(*#7F2IF+S!TWX#)[E*D"ZQZ#6HBD6)B/-8;8+T7;"/F
M=;O)(Y496"2;;1;SI-[0\BJH-[0B]PIC88KAB$UI",<FHJA6' M4G\V0[I77
MR1>M$26^FR3/*6<Y_DZX+H!<L5L7]DL+%:%T?;@W;[K+ 2- ^*"[?B16?,M)
MG'L!XTG>915."XO75;*5N8G+GF6Z)M=6A+/J*,D!UFU$CFUH>6!4(K)>Y.,U
MME3[55UAT#'_0+0_#SZF9*&;T'<\:#\ 6ZEPB/ZD!(_H@?*MLOY*/([QIKL_
M&7%3>--IV2++>,8\FO<>:&4?<^4#7I5T1XNHC_T$!FO*IY#R!0]*N;F/5+B0
MW"RO+:O'>\Y0C17I_S.PN0MFVL+LG9CQ(.(YDM7,:PV4!! *GT3NQ,FQ'Q4:
MUX!3M^ <7N0JM>_E\DLJW+4+8-5F<,14X8/9P=P6Z_%=O,U@,/7'3DM$OQRM
MXI6RT">QZWC;'^'8WR\R42>6K@HW4H;0,1/5(<&$A$N%"K=Q)^; -LD(: .U
MOE'IS]C"EA ?=B#9'XPPW_:!B3[ZGHZ@RKO 6-A&:_2#-EYY%#Y73CF(C<D6
MWI<EA,)ZY75@ 3C$Z\C['#K5CVI(5;C5.&4J,/(8QE![/_J*4L.=#;X10_WH
M6SK^RQX5;C.: HZ!CMC$+*I?J\(U6Q,Z.Z1L%<[BC,(3[.+2*=C=:P6P9>>?
MJ7!,4^+4>)D*U[2:,J)4A&%F+H?1*I!36<8JW,1/'7G([\< 25T#^LJ&-[[+
M6_D:Y?-^+(Y=QAOQ$Y6C#R+34"$M$W&\A] :E98Z?C,[W65M,Z>:CX+=Q2K<
M*F=Q@C*5ODF%ZXCC)S0<MT>N/2=.35[!&KFK?F+E/W:Y* 9%PI>LL4/>@#R
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M'2*,NRM^!C]WTC!U'_@5PSZ?$0TS<+L HO8C2:PR>V4&<S8X]+QE^$?7S F
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MH]LXZVTS50#%PNR" 3C]+()P=N<HJHFQY)R-RMN8<A!<8$/#(KQ4+5H<0EH
MO^#$0O6U6N+Q5JYM*,.FY$B3XR()L !F;O_N"#C:CSBZW \>R?F][/C:-B%E
M^(]_0L?^@Y?:W\GFOQ^C;K#JC@H7"8S?/[E7A:/5GFU2X5HPP>YEN?.?'WR:
MNO2PK 5=!,H/*!_P0D#8F2?"R/92M)*%KJ.?PJ:>M8**ZK+@WP#17KJ#C( Y
M3I$1]F.F8GD- <*^J]ZJPLW#-#A9+I#KE"NORWGE*MR14$J08G$E)IJ<0:Q[
M9V.R4$BY<@+VDT?" D4X6$7DKF:\IA1.2GUB(8$;[*KPA3WE27"8PIUNW_*-
MM-: @)\@)Y\EQCM:"\E&R$JHKBPPGK!/MC:C^\'%8KZV(*'9]2?FIQBPVT]*
M*(V:',$DL:::_$;<"*"9+LY%-J345[.MY1X<P1.?01 J6,/X686CVG>3K-@]
M0 FEF@"E/NQ=VSXVJMC^P]P/%[O>V? '=C-S\,H2QFI,D.J!PIM<'3CR-JSN
MVP*$"7K*1?4C53(KT#2$L:R5/0[@8#Z?9-,>M852.3808 7U<K/%\-H2TXTC
MU D%13^XT._-B4QS0D6:.&,!OB5I%?L6$"CH;I0SE"6DA:ZR3'D(-LN1-:Q+
M'V%>;<Y/Z34@E 1W5/70?83A'N,4@T%*)TJ"!/&E$F7FXQUR083_FL'RY]]+
MAAM>GEBYA.#<1,D!RURD7X'#^%2@T/B"8PS$5K@)@Z2QLB>3\E,=0/!")&+J
M(&4.Z1=:W%;6'MCZ]G#?O,RJS';&DB:&35B&+S/!N 8O$<P'JU=;L$X^^A12
M4:.YC'0>ZX39RF)D$39JB/)/=!W:UF?[L<#QL#'?7?,=S5/TE?5D+?,ILAM.
M%H<'\*L%>,;B@7*)>_LW&R+'7]Q[>%?S5U[QQRC%+=/?TO=T@(6V&S>\D![!
M*=8E";E&M+BZOC5P$*2H)>AQ\$%0@YB0Z&@L2HFN)^BL<=R#VA5#QDD3X28?
M5#@*=,K\9Q!/<^?LSC%I_;;V%"@=A7><,FPS>==G<?U(^AJ-OH^SG V_,T>4
M"C^T$2RU>RSKV0'KRM10_7PW>3 LD5"Z>)+P<F19CCU4CRREF)#,/KF$20AS
MS_2M@P0)^8B+DAFY!I/(U<ZBU5&CFJ&FY8-GI6-S?Y\U'F78SS+B+@6K<^'#
MDM%$'A2'.,&96* 3XFUYAF U%W83L>'?N):T1H5171C6,&2.B%PVR(/2:&RO
M,4;]70P=J<6*6.19C_*AC:(NJ%*0Q((XI 5T!Q@C-$V)N+P:#Q_(,6Q&/+%O
M^9+,.&QB41 *9"^_28I&EK-TZ8;*>WE@]7IQ/J#T>GP?#!'$7J6F2_6B;N.]
M[O)685.JB%=.KN7!E@DC42&*;71#:)3/TH<_@*F"V8R%I!LREYTRNU+1^=OT
M7;)KYN8=5*.&:L9::/<3VV2WU;[^%L)A]\ Y'_%G<@6U?^&'OOQO56[X[ZO@
M,.,+5D,U:U6X54488F> 7><8782I#SS=O-$I;!9U&PMSX\$0\CG*8B (, LU
M7]),UY<IA)B(X%W(^:7-T3(J]P"<YPZQ:\ESA@/FR'3NB+*EAW=UE"0#"WP&
M3:1?ZE*BG@2?_7"+^J@^W%9^_5'/BK*3.'#^])F/+>OE/.Q#$V"*'+O+"P<8
MO8 !5P?]P)J6H=,%')SD+V&-Z<)\]GRJ(>$R =I#OD#16;.&XWH/WMTO(:;0
MJ4\&3=0OH\8T)AGZS#)%M@A'-8--%&X/ H9(>LWWH1)=6C.A=UC031!/Q@-"
MR72-:.VCLLE:4 _1@>P1W<T></\A!2D$M9.MK.<W"!+/$J6_"!OFRH[&0WVQ
M>^!UA$23W(3NT>IVKI7[LBV1X\IM_JLG\,\.NFO%WA'CX171([U/D3G*!))&
M2, &N%>8$H-J],0(M01=H/PRY)U(UWZ ?N3J4]2"3Z.+N,U1H$$ ?6,K8LB&
M*6+OA/"[35PKF#0L&F?HRZY?.3UHEQRR\OK%,NZ7!XPJP;QQ%KS*'(OI.<L2
M:@1ZN?"@F-"U5R#?RH/>?V"+/*&G=/MR./TN?:\_0["M' KG)4EDGW*6?@RW
M.=*:73=&BU8L\\NC(40S"1_$J7]78L!3!QLJJ&#5#O!H+Q[5K)<08.MZJ1/4
M($FH"_<3$Y-10[HF["\&- ^B5;S9IXCJL 0S]<WH(KJW\B;B]#"T JA1V)
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M%4@7U#C2HB#0,JL 38813$7G78?.-OBT3H"7O0.T"V649$>J8B=RJ*+M&#'
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MK&7VU23SIO%DLNY0NZ_%=8M7$?3_T=ZUA35U9>$#=D"+&+F)0DO&T<@E*%7
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M]>G358:7:6FWWV=4S;/61B&RY.JTX=D*\M3B;-KL+TY)W"^#"[SX?;0@OB/
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MU*#05V=B?>1WBTN\34/V_/W3L0X\]"M02P,$%     @ 8SAX6J>(:[R$@0(
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MT$.>?S*R4-8&]DL(B!%^;(QR86#?O^^*:_$C)4#L5P+1;Y&87D\EP"SA0"=
M7E-4_WU/7^P^K3 A6:$_&L^!O:FA2B!M'_A?#9N_RT/D3%25\ T7XHK26Y1
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MMI,TO<QJ'!<TT5/Q+NQ2YP)>IZE_P<9!]TUX)@AA\X#@ 6<\$BQFH8M2*I3
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M=KZ#2**1HTZ-<?MTH/CX"7?Y$<WWH<A6D9G_@<1=A2WC1XS?'0K)JNBHWEQ
MZ0[\9>WK56M,,E[]T?+39=>=^-YB&56*EQR16R(46$6(FQ^0J2$EU5FOYSX+
MR%PN798*%@PX[+HOY!M30^N;W9X$.NQ';S[R[3Z\X9+,WJ^H[?17_</7+&[O
M.(KPQ)QNBJQ"D8O.AL=D%Q5Y; NT*3WT<OBH5N \F%S' 1!5Z=Z?I(VQ-% @
M(>_L0$Q$/I>D>)%ZDI,SUH>^Q5E=AX.,'0??=$)/94WG'JU? WQ& K'6V=Z&
M:M2(Y]C)KBE^)RZF64C+XYTLA*2$-.*"4CA60#$[1&4(WCV1JM::SY#R&:>=
MW+-,0H@=8\(EQ%7Q=7TV4/[GZHC!^X.=>P(GR]>5'*_D&( U>XDXV*^.7]I_
M)1N*2 JWXG5;<;$9*)Q44A.6U=.%^'6PUS8MNWL?=A=^_%C_CB^),O2I;+8)
MB?1P?9O0@BG ]-,7%F4LN(YBQ&O(MH.K1)8,)1 "7E4"6K2S!<%@,:Z.T;VW
MUMP<7B%@Z,'K:Z9#8]BK Z4'87E=SQ#<6(>N[)C &03K>0<.AIHSP9/9@6MZ
MEY1M>/)SDRUM2L"'+0Y4Y!U$ZPWI&^ Q7"+-$U(5X1E.)^5;AJY3@[XVDA79
M):.Z5"87KT,C9!T>''WTSH8!;V);T(@P^!BFB_=$^8Q4KL[('WB58TO9L!"7
M1Q+D<7102]A?=A0^]A!QDO*3V=HP0^0JF2_?0-7RZ732>'+H$-RZ%>JO(Q@/
MIH/7QJ/L?"I:2ZUF$W*+JM+KOW8TG'AC49L='N;P#=FCP$(-Q'6GNI%[<&)\
M(^DROH216+T?JFI,MVSDS0_T72TE1=-<'\ 61Z2A<=5A I9N%PQR^2??H^T/
M"E)%(.YC]\[1P+/+G@2>7UIND#\>+QF4VU*'90_AM4*.*K)&"EY&],286/"#
M/:3@YG8G\-YPWR(HN9W'Q<WWH:99&QYJ0>SRJ>"A#>GWR^2FQ0>#REI[+33F
M%U_R#<U"W_!+++%M* EK8O8JM(>D0\11;[K#BW")!71]9"VL(N";P(ZU^:)1
M4ZK_?NA4A9AA-F3N+(U(+&WRW]]*LWL:M(%HTCK>F^_HUGJRXL@>'Y_D;;-/
M[IYK6,N']BVWK1J-\]W8J03\R5<S]16_T6UIGN 5$C8?!/9R#*D.T[UU]%55
M&9ZMB.5%%LVJ,!75(VE271L=.AB/ _K,.[_FLI7 CB/V$U;N"\*7G_2@1..A
MO1Z.XM$DV[+WZ.SA'J^:Y*7$Q1E*('$>;3<<*K(.KGE&LZ^N+*RN@CE0V,ZV
MO2+UV@S2/(_<8%6NH4.=0^J05F[Q:WV=PS[5F60A!5[&:_0QTQ-TC@R*R0QS
M%6QT/<[O'A:;,1MP\<;+$J')0ZU@0$@@S>I14-]"V$\ FL%?P'D?8%TQMT]?
M:EZXM"/_$16L<?#EB*SF6.UX]KPJFGC?NDGC^QOD>!WZ0OI[7P.X5)J(@5S<
M<3<;WD)9T#ODNQY6A^+KF.JH RT(8ES-#^]U)F%:M'3.^@9#O+8M;VZOY;71
M,^'VXWS5FJ<42F"/<WO.Q"6?B2I@A#A7"=10Z(;( ?@:](1[TW=6"93'Y?>H
M-WCYSH2-Q .H#;)$6GX-<<NW2;\$C<'# MZ5B2J>&6U-L?1([LV(L-S#P>ZT
MTV][N$]RDCI7JH]H+TE=M.0;]S.)&UMCI):4>N."4^:#XYR%X"E*EZJ8A$W?
M(D(L:ICJJ_CU#'TNS:0M]#[4F>1D+[<>=  E6\7D.0=?_$'7>5]]0:J^N^T,
M8G'L2?=!WGS.52>*@#4G8+KCR=(KAF?=0IW;QS[0.9O<YLY>Y&)V)?K!_24%
M "!1C;4>6Q?=]-I&Q1E3D_C?29"W.U-WJQ)0FX)+_85X@V#V+*E!*>8"$=^"
M'!'F[QIS[3BOE1PA F-M?FL;&1TYF2"R++9C!IP\T+MR6W/EJQOK\#Q&[Q,9
M"V9*<:C&A#^4P35?TXE82CNW$*UC9)<[;:P/Y=,VWPN@%.<ET&P?4-/,O'9?
M"B%8+X4942SJ5E+)JMCJ1V&/#GO'6BWB?25+_+#6#Y,5P;9/:/.E7E<G>)H#
ME1TO!!)Z_P%H*+ XZ!HAQFG_ VK1F_9C[2$%(Y]*V2]:%I6\\+KR6A:8\\W7
M_K(#@C$OJA$*>372'17/G**4@$9H2HFUOZP>LHNMUA%UK3K54C#.4W.Y']QA
M;M%9RE3KXA_RT'=@,L*C3#952=V#MGTUHK@\DZ\Z>]I&Y5M^IT1R$0H5,1EL
M4ZJ[<%:\B)3DP(L#CU'B\+CJS4_A_KJT#LX\6H24*\S,>QHX:>X8%S#Z%+$3
M\M4.!GC_WO2Y/WY5;D?I)\>E*3[=%I'CK*Z,!GS)F4)L)S%15-+6RK?5")W7
MUV4:P12Y8X890<A(</(L0%8^+VVS\7ERJY2ET44MZVL\]/XK:V' O<ZC[&<I
M_NT+*P(*5N?3KF6T(Q>Q_+%ABIBI@[A*GW+TB$L"B#;2N+MR^]="@E[ 6?@,
M?R_L)<9U,[D1F<80(1E95>[@4<_.!A]V\_O*KY:PYB4J%G\U>92_IT\K0M/9
M479<D5!*B&8:TS?0FU$[Q3WZ8AH=SI<J@6W0MGBQ-:7!W!0B72DYXM IG'A0
M&1$OACKC$-R#P /&-BZ[UO1^Z+7PF%G77-K_UNE;&@ S:_#%KC7\'@:JB<=B
MUBV#/]^'$QNN4W5'9?16FIXNX@+'WO.F'N@\!%/,OF0KDG.QO=V!>#=XR>1;
MLT^IMG=ROA8NN<0^/<97(YTF)6/"#5ET'WV=J9WJ#G=+OXS):N!VN0W-4,JJ
M5T3L+X(>D.;0]6"[37!VA(B<D+D8FOA="5P-3^1I4_WKTOKFE#.VMIYL#T_V
M[>D(C@DQM3M-;)021M9+?7$]6N+X1MXE)5 644>XU$G"M]:0Q0SU+@0/KQ5+
M5ILP5:GA3FOS/@XX<)*K[:-8@<6'#\:E[;,+VU)^.O6IC]^^QY/8".1!B:OT
MK^7%8$/T$2E!9,?%)3!5V4OA&-'H95* #SB",Z1MK8)_%W>%GD:7#:-VK;2]
M.7VP3X,!:=X(J[^X\[R[8L6JA>5Q->='BW)OGWZL\HU?!\(K*8VX6+:&M#P&
M.0O%"SOCV<Z(F>+^,7B%-*^A^2-MMS1^Y*T U!SJ4V]EKX3M1,@8;%E;R:N?
MHEF+6.K!Z91XL'@I5.(=%R-^$N5A>SN5*^T=VO,1QA"=>:RS&@>%R@)>7*6_
M2^=@#-KCZ"W=Y^V:7&TI#L4V5GW.J63'&CKN_9GJ_1'BW&J,GADZM(,WR/,"
M-/S\LZC+Q+4=D;)KK*!?745/[FYH:1G:/,[&@%1#I'8Q3DM%3QBS4(SPC<X3
M>E1%I/HH5U%G [YG!EF;MJZ]'RY^XAO00=0K@9@)J-X0W3A#^)BJRNV;U5*"
M*6M_KO&!W_-\!MWS[E+>/6\GK/ZZ3$@C8*9S(%<N7YUJ/"R,:.#@:1L4]ZIG
M2H,;2<;G1WL,N>9Z\-D3D[ZKX.R :<LZ#\W0F-UP.%'7&W&66L8].&),F!E(
M-R]J'8^(ZSW8NBQFW]7#S]39: V_M"-/?IAF)SU3)<)K6L8[[8>&&QT8EVP_
M[G5I02+R: Y2;J^/RT4_,2&.);7@$G6DR8VQX3Z!Z?HQOLTC$XYSMO2(M!AK
MS2U)O_PD;[MQX</F!1:!9EZ_KB_/W;9YPE:@!%39^C!72(ZS-<&9(J%PC+2_
MOK*O(JQ@F+X6OJ0>?[[.T&YY8>YM(4.+2M[10B,)\7-[MAHO.!^R^F.VGI%E
MX-LW+R]6JZ]-N:.[9GVCL[WE^,;Q>QH!60D @@TUEQOA5 K$0/3B97>EAG'A
M'N"VCA*FQD'?@T-$8_;SUHFN$QX1[LN<UPVU?&D1K?BRZ>AFL[IMVV[=#U=+
MG\+)>(HBFIM4,[2KN&::])+02Q!<#*:41XQ<\WM(?2LB<YL(+WUU.>\+Z"O@
M<%LSO?T=-N#5R/:VPN!?ZI^^N[DT]N-=^8Z0,V_J&ERFZ^7>]'?>.,E)""^R
M&U&(.+K!F?K0:%W(,M[.-ELE,*?^&+$TUS7DX>:'&J?OMUM_?;ID7>GC+7WA
M5;_F0'9JBSF8#+2%(V176^FX0=_%4B)'V,761LYAXJO?+<,EQB,]Q.\@O%ET
M=WV]P[9K3\QV]7RQ>3\1G+_!ZLC^D3I#_HDTEV";]<>W D@3["G_A>8N_:4P
MCS9;D4&<2UN-\1KM)\5]3N!;?;Q.=;CX+2.V!W^9J!'TC)7@!(K<,[0PFK-S
MP,1.Z%<;A>5VJ#->P-CQK(UU);4I.(=KU?G:?)FBE',:JS1QXPB!%,<V0C!G
MI=Q:3IFAI%%N']RG5@%GB+58,0XYF":. [5&[TO+D\*M+=SB?=O'NTEE#ZI;
M2ZR<S?MW%Z5--^WYZ8;SYL8V)6"J!/PDP;)3'-A/3(HVIDA((H;Y5FFYF%.7
M!_="+ER.)G$1M5^8PVG(6,%R<A%X^ GR&$_/\S1IF^"SHA79*;5]:/^AHH[J
M%8^Y><'7K#_^,3.(A^CUHQKU8M+L /QLXGK:!:EEW1Q+43DVR(,]&;)K[VFV
M(@W$&60%;V"6^#($HW,2*0FIAP[FE]UE#5:&Q@C:#-VAIVD]]+30[):?RG_N
MV3:B,HV3ST=;,E<ILA$MJ25JX!5;O5Y(2."KH?:8/%25.KI#NUB/ANFS*Z5>
M7.OS@^>"41R[8Z1$<19Q9AUR\W_8W3O4\>O0@<P3UP\W')P!KN+X\;OZA>J2
M]0)>KZ/(M4Z+<56'=KQ<4<8YG6]8PS<8!Z_QYXW0W 0:-#-I1L,:JH$2X#I$
MPG=I:T.P2>GG9ZV]VPLKFG-;WG3EE#8]Z/A\G7,4]&=V-W+YQ7?XIF>J22+"
M/&HRZH30X5CYYF#I<&'@=3.M(S C/#C\T8"QG2PJO^R\LW/^KP>=Y1Z/UCE&
M90T=:"#:-I,$=RCZU6:&#9S9-&=%%7L=U40PVDA(!.>S5U);A;)$B"6X*?MX
M#6X7-9'KB4[0Z!7V\B/4 Q23@-U'S/SVM)9XG+&Z-M&D:77US,B9K9+J<P!.
M1W$'#&7VI(I#L2FO.U[07S.J35LJ[918B,C=HSYPJS1"1&B8$U9/-(5]V;I0
M:(*$:#+8:;R4>7F\B5*7?C.);D'-G0K-%Q\\WESB;.G:L9I0D)<YNO-2!7D!
M6'.<=M$PAJT;5!G!Y<5RU%BV<D:RN2Y<)=6376EC+QLBJ=&,I&$"U[KK4'D]
M:8X-QY!FB8ECEO67SO!+=M><;$4,0^^!2#RRN-NGTSBGI*-TTC )%&32#5M#
MV5IPHLP7+A3CN^T:P9E$0SY-HQEQ%X3BJ':-!^B+8<)CV[3[=I=I^X64JPX'
M6/>## V(B]Z7,'4&B"M2-I9*\/L\?GHZYA-L>-W\. FVG-,8@\Z'786N-80>
M3&9Q0TQV/9-6D_1",)N\6)(11MC<.HINM6>$.-2$.MF8J0G?%GIX<:^)G2GU
MQIDY%\P+'VSV#PW,\P6/]W9%Q?78 GB'[X/ZY6?4)R]1 AP!,;C&H2\Y<Y#=
M53!>B,,F,/U2T'288\A>B:PHN5EO)?.AJ"+KI)2146BTT=#<ZGF&9XQG.K_!
MH93-N*<$3AY*<P]^TFU1'MI*[K:4?7]O-U?!9)LA8>29\$VAF-KOEC8T5H.N
M:AT=_^B_M>WTZ&J;X5=_&.>DW097,YUDR1$/>&''_,]BXX /STEG1Y,Q @I9
M\#*#FU#H3MC/;N2)?!LVO]ZEA4)*0)B(+)+BDTJP,1$AP0S#.DR_$A\]I%ZG
MU/OJ2-_%7A16F9WAUGN793\=L&/C2UJ/-Q][;FS.#*BT\3S$:.;%]FE4P\$"
MPAPJ8:^T,YFXE#_@0#-(9S"("X<.3)<GTLBT7</YE(.9;QK)10F!7S]F6CF:
M;+0^+?GDXQ[0,ML0,+\S"S!Z!Q@-9CJ(,SG>WIN;SP\XG$><7ZP(^)??:?A?
M[6!E*H$OP^#7/B4P^<"K^?<Q/O(Q5-'+1\<3>AC("R7 6J^8>WI7&VED&>,+
M[_[RK(2ZP;_\>L@*K96*+UJ9MQ?ZC^5.75<"O)^4 /LF$J!:0]\(EXM'KXQ_
M7-PO(-=\?[VT[6NXD;"C9%0/V5T.'YN5FI?SG+HZG_4%XF,"J^13YNCD.>^K
M(4CAF WCAOJ[M](\5',Q@(?J2+,;5?,DP7E^6'4D'@!OLYI)ZTA3 \S)%B60
M;'X"''M/&LU1 L8 @BB!V/>8FILWC(ED%XA!Y$ =Z1&MZ#6O/'T.5$D29)'&
M3WS_/+_4VF84#0^?GOG%50DXZZ'3%&GV'PPTTE(QSA%OPC/CQ:Z(_J8)Q56Z
M#I,E"<R=[L=LL$B^ ?_' L[@<?P5?_1KZRXET+^?<H_^3S><7F&GLD"^.VJC
M,@73;<":G\B4KGBAT2A/$I@7/J$$;GBY(JL9\/*XM7]W4Q7KL;B2UF=K6QGP
M_B-/QG'_<,7U-AX9)\L'P89H$@G7P(27I^"08[A:EQHQ:MRYJ[^7&1LUS">J
MPV]E"=((V0 \#)%K\>JQJ8?NJE$IHGI.W:BD[CPI2.[5C1"$#2W)&9+]?K*8
ML*1'2:9>S>A_=IK]=T2!C>/.#N8O2/A0[RD7\;*[\F!?.+.#TJT$&BC%=O'5
M1HJ;LRN+X!H![EJFI=0J6&L5,S!MCDL-Z@2]2TN_^-.Q>9MDY',/UEZX-2]X
MB/\O,J50 E<NHIJIW__[/9DNMI$Y2GN5 ',.'F* -7O @3QZ+07VISN"8T)6
M,^'_PD@$9J05-8@8L8AI VOOP!+>$B7P_MC$$H5;-JHS"J_<%:8$M+ U>"QD
M!3^E&X,_BSO<1+]TX4_5.F:A!#*O*8$H MRLWC^*6/"A?7?ZOUM=FHIIDN]F
MF8K#-F"M,Y9[-\S"7;E&)/C:%):TMJ+N<_YM8TP*O)=C5JP$GL0Q8%>.X!%I
M?"_G& %9SS'C3$&= X;_2#?CGR$#=#KFPO>5M_='U(UVD1=L;*P93<G6MC^<
M*HV65IG$V1O-8-^ \?[RK=V#QNGT]^R%L*V(H%-V;VY\&.3/-;>%V,FSKLL"
M:*]L?2A&<':]783#]:HQL]76!?E'?8X_#/GCTAUY_)_7'LW[6R-HK/Y%]UZA
MVH99*@M-?]58J)IR)V9@,\L$Y@HHURCSJM?/2H1XXKQKJ,KP\*/-M+ZU$"N&
M;@*+=U>T"O<4!_3O@.\*P?EP5$C!:S?O;];VMOK=5PMTW/V[:?]LD>_(1?U'
M0F%5U"A4UJ $'MRA!2F!NC!%"F?JM2?6)*7RXTJ@91?1%A39HXU'II5 DRZ+
M@_QG,__@'@$./LGI-4%OG)4^40(Z/!FF8_N7NB+K.B6)K:@Y=M:<";T#"SN5
M@/U*N1+XZW;#MJ(TSFG*M!NG(3.,"3>2NH8YE*FL(_+IR6S4*%B&#8D/,K[O
ML__AI]> ^E^FCZ:"!5 N]P/_X3\%^?00ZW@?12%GT!)OS)%^%[TL]-Q^;'K^
MUR;^,P:8C2>M=%U$6Y%%TQ+!X4K@&KZLO(Z50C=*:?C60U&AWA2JCT@%^>N^
M# EG> ]9%R ;X&!AJ![7.H:Q8>.B]@,MYW8<V6P#6D>=_$L2U*GU^:)MDO4M
M4N_R7/7=V]Y7?=[_;D/2URS!VI1-*=+"E$U%BY\FFUPO/;&]:]WZ['EOS';<
M6-.MEI#Z5V 2U:L5MY1 \-LJN?P)"5[AU7!DP[N+PQ4CXP/?%>K<(3-BR\5K
MR\J?71Z:%#0U??[#P-/!9ZOSA[$C;ZYKK#Z9=B#0^"]32@&G_ED^?^9=2/U[
MLA,BE4 -!I@Y_]L9+-LN;>!KW7^D[L\EYL5'_YJ_O]OA2Y*5@-M&N%T)7.V7
MFX%C-QY@R?-6%)(I\ I. T9AO_S]-*L9]\^<6688(A,,5$Z1?O_8YO=*\@7%
MIS#S%["]:0'V0!C&1(E+F_#06TK9:FPCP-G!K0PR[(^5&7[ZP9-1)>! F!K&
M*V08DG?_9 L4IBF!TZ'3;HT-+,05NUL)W/E]"WB2WSO/D8 XM8K=>JJND8KC
M1R(*B]^[X6?^>N/^N9^]5-BP,VFSTP"G_RDXV8/Y1[AMI 32KKK*A[$P4X6]
MSJZ[FDL2YU .54D-'IW,\_8><IB8R&3F^0;;E4%+O!SN-L5=#PW,.<2[N/)%
M75IE>/Z+WZP7I?0L$.WW[.<LH.L%@D;5EF&"CY0&TGPG'7];2;*T \4ANZ1Y
MM>0%2]).A3S;*AJ=$91.?&' )&32._W,!"455D9W%V2)VY$N3O^#O[ME>7?V
ML(T+VF/YG3LKL?39$_$Z/ F&STS-=]N50.J4XN%%777R58MGXPAY#P?Z2H[G
MCX?AH=TLA,SLB<>H=SX]9@H">0&<41&8;$[#C_40Y##S^ZZ._ZN[__+DGTT0
M[N+^@3X/A",LN:/3]MCN[85:\B0N&.UH,O[J)&?+G]">%>!ZZ#C^D"%&3F-\
MU.PU)$=3_%#-^5C7CLEW*X&QVNR_/,MJ#BW9Y,##*1 RNI)1XH,9IH*C0Z!T
MG\K4&*:0/\%12L#U;^A@Q8QA TY]_TC[7Y[W&MB8J=<2P&C!:-*8LH$P-?BW
MXMJ$GT-UE,V#["XC^^_#C]_*8A05MF_SYZ)6\BB+!DH92S)?-*H5I/LRPKJL
M5'@WHM&KDEB>]_Q59N/NTN=EMXYNCU<EG5<$WF_^5?6^<_11LK#)X?_[;RW_
M3_?M9U6>$_V/LDIZA]7M@N++V^C[QEFV8YA2R61@_&4'=^90E8#B0 :JZ$03
M4ZK?1.._8#+#&8].AV*<G(I&DA3C?/'.K/])SI?\W>O6Y?=FCBT;7?1=.B*!
M?2>88Y@V'LW%RNND/J $UI&G!K#YHA7KPO^7+SG=\!OE4$;M."^V_M//1_';
MID'/W:0^4OPW?8#]IR<B=PCNO!(S1IF>HSMWY0TJMMIW_JQJU.]\MJMYQMM5
M5U8O =D:W/)=D8+Q"9[^IQL[\7TDS/B]R8?7-]PXF[*VT[GQQ?9M%YP-F6^5
M0.<FS6]NE^2-PPK9Y.3#ZM>D_FPEP/= ;9ZRCWY,NC/VSOZ3G/Z[>=.+0B8-
M8ZQ\@/0/6%UO6R+CH'R0TW#;X^3'E+,)P,V_N/9DG:31ODFKZBZ'01[>9$#[
MQPJVIC?<&D>7F$5N%[<V)UPK/UL%#2I6;OC8P&_,F[BG4==RB;&6U_Z!V?Y(
MNR65N6[S^/67"N,GZ!@BR9YD]H< .[ZYEZ R7_ZW#K(GVNYO<T/(N4C R,,:
M*TM_Q>/G?:>X$Z2WWR9X\*GB$VXF]I,C]C6\ I!5$###[L9A1M_;5C3R]1#8
MDWNAZ/S825Y>NA) ]B]*.'WV^AUIBF-X?Q[)^\K6U8(=9R3/+X?UEJTAD6JC
M5]<OJ:;+*-6DST\S^9(#E]U7OY=W7\3ZR O;#2.+MKS*F_D+\VOTID_RU,[>
M64^M?E]E4D!R8C0:#78F76R>>?OPKW5O5Y_EC5+*D=GGIR<:2X_N<E^/(^[&
M-+[SB4\8++[5@D_]^;YI>UZ7&PWSZ&[V@XV4L=[5^U4J]NP*&^41F3?ISRW2
M@=!4Q@LGP:3Y:2;B*7$K-E6_'<]*1] 0>.^UA8(5+QN_3>^]<31O9F38NY]!
M<EX^L'A33?E4\=PPQH:=TT>1KL'&^?=U"U77-8V/G?@$\BDLFB*H:$=.T=GA
MI/%)Q%DZU?[J$X/(GAJ6M$Z!$P,SFM5F*D:R+V'8WOD%B_/1D16_J+[+:*;+
M=N(HHHE&X5[G6A7&FB3_),9-L\U*0)?D_2YMM_O1F#N3D@$B^_GD-.!B_>"<
M[J$O;U+8M)B-YE7Q0H3A??R@ZYU1P<0?8_Z=-TQ,*C_-[1]T__)UBKSYV\1@
M;TM^X[*-C<?X!8[C][0.R%X>O= B[9PLBEJSC@J8D[0S2UFA^#2PXVWT1H58
M/C;)F"+&%8M)/X]/;598[5IA;^9L+VDD@Z'?EJL^AIZFA"LV&IE=>C[PKL[O
M;6KAQL9=[:/A8Y.Q4]*Y:5%G0)DKZ]Z/UT;^SX?36*,2&"KA3W[EC!\._T(E
MQG^S'<S$QHK]N9F]7RLD:('#MV_P$K_[C12T%""Q':<CD(>//\L^OX@"B>RN
M7$5V-^@ %%\?(JW=YOH0J=\=_/"2_1+3.]#:SG+GY?)]% G=!0F8@7Z_9NVI
MVY_K[%K@# 5YK@7"!P>6SVA:]OV"UQAOTO5+$*ZD$>W\1&J()GR*9/RQIQWO
M[&SR#2_>,]4OSQZ[IV6S/W2C'-W"^/XK>M7[_=7BT2E-I^^_@&+WF '08O^5
MNE_MG:8U?R-N7S!T%IN;\C?ALA*V_*PQ?D_]Z#3^S8U;^"7:X=CX,KQW  ,Q
M^'K)V"!2#ZS&7!AX-8&_]?C+9OP?%\\;U=B+'KM=T$WE?#[\[=PZW&$_#O%N
MQ;TY3@S/J81USJY?K#*CO-_O<JH9K7%VCF_#6LE(41A 2K(KTT0?1"]7O7]N
MMB"&Q^JX/EOMDY@Q9#77V?=CBKZVN-.^,5<#"?K#^\J>M6I'@5W;(C]IAUT:
MYI<"P5B\[Y(P\^VXTF5S/WQS%.#^!VUO'@[5&\<-C]!$,:20;12E39)]FTEE
M2TRE$F(JR98D9&+,6+)E2_WB%S%*H<)4MA(SQC:J7T;(A)BMDF5R)HR363S'
M\_[S/M=[O7\\U_4\E^O,F6N<N>=[OO=W^7S.?=_?FX%J2)DZ))Z4=;#N2Z1O
MDGFTJN%CUY7W.\Y(=A>-<A;1=Z <@6(BGHDSP'[YA[RW8C/)3N.R)U(;9&%8
M1< 1TYR'PEXX,$,B'DWQZRW98N?:!X?;T >7%_D'M7QTH^FUJZJ?*2TZD[+Y
MXH#>K>NV,CT)O&I=E^]*@>C;LX_W:AV7H5\S3<Z[[BS#,)<9+SHMU3>;DV[J
MN6<].K(X)YYA:/=HW?S^@;HTP$XT^RNLJLJ>O0[_]PWJ26"SY\@"8Y/,Q-7Q
MONBQYH6JH**\TF5B;M1G\&[?L0,?;*8/K%M@4#47D/?]_:\/.Q88>:(H$MME
MZ2:9P;5R^*]&4V-_E@=UZG#Z40N+=:&+'X_(_2UG!S>#\</'I'M?YG8T/+^^
M5OD'_>1^LX4I"(%?.QI'$YL=513J$TA/;_) AJ=7OJ7I8NP,@]IH)E5SL&CQ
MT),^F'BSI9=7#%LXY!5G<!=NS<[[MB!.\-J^TR_)-'DL&>3I)(;?PFCXJ%@=
M?=IF%9R7JJ.'KG40>UWVWJ-O!-=7+9.\*ILH_27;\"W5OGKQ.Z*O^%*F6N&Q
MI2EIO'<A%K?D^3IWPN\-UP"Y)^*OBXV-87"5_D*=XAP/D\$G!6+;W0S5?CK+
M+$I-&,@T6.(F1L2]TEM+]L3<_9('>80 X@A\;)AR)3*7H/.-.,A'>![[@/!D
MFR+OFQ*L< E1LE[-LLC8H)SJJ=Z](\N3#R<;88DF/\;B>QPRMR #PD[?'NGI
M5^'URS+M%Y>7F7V%+"US!1\B-^BJ(P-UR<?H(;+5TW6&H3.97#S5P,HJMN#E
M[Q-H-MOXJ*0R3J3V1Y&(0[)?<]LHF-\%;V?>R4FWS/#=A#NA?+5E<DO^\OS?
M^7.74'M?Q7K[R*[5_]VK/S]]0($.AU?3'U5]Y'Z4T\YY;A6\Y?R!A//GD2NP
M,[;]\ M";4^V[+<H^@_H[^FVLW[?!5]YZYEEIG3[ZU&+;&^E%9A"9>E@7Z8>
M[UKO\E !V-=^+_O?_(%30AYK!?:%?U 7;+H%V]\*LY%UL/NS.X2]!1E#0$U\
M5P5CI\X=(^RLOW_G[W-'V+7V/.?$>6:SIYE?_\PUMYP-.;$G%7K,RJK(FV3&
M<:=A@K4/>O7/"<H.6+H-,M'W$^6Q#N!1W'?F0LT&M6NF=^V<C/"BX'(>P.C_
M!W;":=/_SB$CUA'OE-QK):[ X-:$48B4F>A*AZF-:#HFC?K*:/:^8/*$I(P"
M)WRBRL6.(P]K1'(^^?FET[M;7@H"DKGDM:-A2UI74X.X&-6PY>;D5B^N?SA6
MX#ZE=>,M9TX)9^(R6$>-0+/O$@%7TBA9JN EX/&P&3&,L7P_D+<"DYMCMEHI
M-=-8(R*N1]X[+B)S8IW ,-BEK5FP20,H0<!Q!^9<SXH/<]H\!SG"PA:CKMP#
M2V[#C?D;0*+OYX42?[,_92:R$&WU6H&Q67-C[L(! 77VK6@M[IU4T4TD+QU9
M@6V.1>?%:Z11E,[ATM&WB1OPL5QC/Y\AC<ZE0JD"8-5MHC&UBU,I4)K,6%2H
M0VT!2SH#]@*4(H[Q=4:75(.Y5;#O'GS*2JP6)\Q9@:7PI:/H3=20%5@VJ8$Q
M.\\Q^8H1>@]35*>7(V<Y@!\W+NUJ(#A2(3[?TE];8V_RW*UZ>C@ *6B-7UOZ
M[.D*+%,<52T^"B96.D5'QU6$!"@#C_T.UXR?3;H)YT-(!*XGCI'\>\7^M""C
MAPJX,G*E"I*[>%/>UU8$O!LY:B2\#5X0[9?V2TU\8DL\U$U40#7A=K"$8RJH
M[X[7>[3C46#U5'SZ@[W%-S^7'!]:_"A9PSK$]"Q9T.!#RH;+@FBAXQ<JN]A,
M;"XIQ$>+/' F4L5 MJX)UZACIDV6WD1%2 U"B['9?)1F -ZZOX&<84M.L7<*
MY)(U<3RI>F5:U5C(*"D/CPA^&D:+,&D,E'L],4I$>A-?&O&=:H@T!VHX-0F[
MD<C.1C>QNAG@[KE,RG8&+S(3VUS4182'E]D!LVC%UJV\2#GP]W1D"DM5?)CK
M?QV3M0+;U.H2R,G%<.I!+W9E%CF<8 K,W5[T/X:K]W,JZNB7?A3[2@K1H1A=
ML?<*+/7(8@EZQ$^8.=2 'LG@N+3[RPIOEYP$Y046QA082.(TD40'IGRSP-ZB
M"34%H"4"V:4G/]QH?&"II^+0N')Z[$<% N-*LZN,2/5_%B"Z2M@M[2'5-[?/
M;21\P0(8I)[80=),#4/FE1F!NB); DVZ'I0 2]P)JF#M_,&W0-M]<G:=U *'
MZ73CZ)IUCN8]Y:$5?PTX/<)%=R\_+:OG$A&^+L'$B-AJ5B@RDZ5&##7)PS9@
MQ#ICD-''DX3_2/+Q1-%&<1C@TH'0G4(9@6X\DTR4+/CN,7:JA9Z.#C4.=A3$
M=;)NK\"4J_3T!(PT,J=XSK7UG>V9U.H0Z:Y^L6-YP%2*Q_YSWPB07=':2:_C
M^ YU> COIEPDTERI0= ;RCY)92,"-*+2_5VZB>K4X!581B%UE+JQU0_@^0D0
MG>3-NI$<8?(5;V^!<FWE1[:2=^=2_+ZT4*[QC026.B[R3#T@;K%,X_K0.P)V
M"1#\#-$-(JT3"1Q=@8WMA'[5"ATQ-U(OO 2& YT] 2HKL%M4R-!H_M@CPPUT
MHA*>0#K%I.SMY-CEJX.1[-HV5J:]1R4NO&-"2P#Y0@-5+=S4,8*+>5U9RFU3
M'-Z/:/B?<RL;FV?O<U9@HW%296T!L1VZ@:HN1CI5#7V9-'IH>5*8,R3=(#X#
MOA.=$7M+WA*VA1+55V!7[/R4@CE+[9\2W%X-$C3 %[X"[W1Q^+,I/5E =W9"
M*YR<];XJK*6I!&I9WB<L_%\6<!W3Q;JU M,F7H;TL@)K(HG5D#W4UY&=U-%\
MNI9&"DH/+#HIJ9$JX=U /N<]WOW9E*UGR0N\G^2N.58Y!*V!4O/]ZA]^ ][5
M$I?+.LILJ DX^S74=[@Y;/2P-!BO+\E%LY\(E[W%NM100(,]26>E4C6HH9C1
MR$[*5DD1'DO&V?5@%3+H)AG#Q,9\?BB7E#4#F-#UC 86C$UZ(KB,E !]RD"#
M/Y8VVOBEK1,4==2&/X="6L?A)UBWOZ4"6>$>L*":P%B! <=*2"-,Z;I@411>
M#<P06>##P*TO"!.L!HT<*0S'\@7;!/G<I[=#X\KV#DOUP&VC&$UQN*"*]E'B
MTAEP0-"] LOBMYIQ6'(X%^\O]D;LH8%';UO[ZQIA"+ZV<!RRI9Z9%9C,"BQ\
M#DIZ-!0Z<+40&0DXCAQS7N((P'H>,4VJ"5:Q5V#)! 70'^ _OLUE>@G(W43M
M7Q,&GQL^710.3'JT-0W\7BAQ,*>1P8NC&!67&K#(>>"J9$FJ #%*^4.KVS3)
MFX/1@N#3@P0M7#/;J&<%-C+(+7L&8(79$I+]S>=3OI.W41K@"NSH/ \WZ#>P
MK:&9B;<B5H=.;/T<TQ:6:.38]F:XU8B;H)V[L3_TU:=8D"YRQAM+JM#L8BH0
MP,@F 6>PZPET:@.)7R\R(8Q@7TO3 '=ZO,ML/CL(K!(TL^=RQ Z/Q0J?+UP&
MCQ45[R,_GRIZ)K('3R[&[OG(MW-RQVJ&=R1>'3L-2.JRJPD?B+3]Z! $N+.(
M;\,AY2$U5F!7,2.=-.SK_$Y) O><< 7VVHKV%F_#92"D_:/$CO5^+!5W29O(
MU:E.?$A R$=F-SJ@YCI\@PH?/ ;#.3\^U3TK!ZEGV@#@,T32-W1?E!$/$VD\
M+2L:656<"/7$=ER",$<0G&DO+T*%LS31(7QM7G->JU&$P^3M5@T@_)2@:M8O
M4(#N+MM2WP@P<O==;77D,.08=>%:%HW4U%8?^^7<TH;C8'! 09%[B]@'J"Q=
M+8<GN4]EEQ,!C ^5/4$="Q=^EE2@3,6')(]:-W,B<R84!=14L5L%+L$;3(SB
M.E@Z>#M]&9YG!\_^QCMQ/K*4/;C.@KS[+W"!765ZG_'[6_)O_\9[<1[$I!>;
M3&M(E9&2>Y1=TB%D,U.LLEZJRABIXL+YJL#J$JW5M:-H#A3$7J&4P'PNJX,!
M%^\56/7D?ZT2)4@UJK[:VW 1"C@BY+B9]MNA5RW(#"$G( HQRF$4G<_V7D)6
M0VCQU=KO*[ CQ+7HBZ2O8\)KS$C[$R)[PGMLO4E[I%J896[5M-XVT!30Y@1W
M\&\LT_XF[/F$;9=NZF]<7^)BW]BPA%@?=_@@LK.*OP<R0F/0#]))%91IBJGL
ME^B&N2XR(CS ZDLLXFL)!]T!!3JT<H-AL38IDZ2)]P"JI H",@[;P1P='1T?
M!;&'M+QOM;J0<1E=<2_[KL1X*$N-=W3Z"72'L\O#J->(-"KRM3H4<>0/@-E<
M+&B"X'\6'.X@-I#Y2"XQ2\\(8-)(J<.(."+;9$0/*Q.NH5[LD49/:WP0N;:
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MWMRQ[< U!*:S6)JQ?:B&%E3XP>-[:<TVZW-EIM-KH^[E\,H6ZY]*TME)A3!
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MG10F IC;4AW\3G"D%OJ7"\4$[UBV"Q\-O/"[Y\?4!RN A)- Y:N(*([2^J.
M1^']%R 5T]8PC$=73WM$U851$>WHJ@_BU?GR\BNPOC T'\T"3E EO-CE?"YQ
M#"TD@FH B]U\&WV%E<N"0?>)V"(^!SB3R(YL:CY2&Z4KWG<'+*,[ GT5@O4=
M4JT6,)F+4&J^C6W7(M\V_V040#J:QY[B5X<>"%,(BW6W*/D3*%6:$ 2GX1,X
M6' O,J]U/3<2 0[24.:0#'-$VL%6'_:<)HCQ&6QUX6#5<=Y=\7$TA\#.B1T
M(S,FH>2300 @??<DP&>ZV++^Z81_Z&AE:6Q$8F"T0X/@:#NR?_'_UORZ_]>A
MD]&%T,-Y<2*3[8,$)G3?BI"R]2"1DYC00]C[91 SM!@:PU(&P]U;ABU*OIKG
M;OQX<G@Q/#L1U7?3>*%6VW/((O%H;-['8R];*67K0]'FZ,LD<"]K=H_HN-@=
M[ ;>M:,U6Y$)7&2ZGKD@(*V\FR-)M(]#=T7*X_:P6;>D9F ^M_+^!?:,[LGY
M3CV55P.M3C7@:;7NJ2=AWA-V #S??FOE6,#,A&[;($_B=]>BT&;;1<XEE]R<
MZVX;DOV/WM/I;W%72W)SVQ93H+TAKT8&J4GXA 0PU)%PX2%!0#TO/RE@';-5
MFTM6Q[E(53&9MMWTKLC,,LAQ7\1(+07_@[=WCX:R__]&+ZDFATQ2.<]4*I7B
M5N001B>BF^EP2U$FR2V$A$R,N90<PR3)'3%*0M(DA,)@'%(WXRS$G"J'(7.%
M<3$SU^SI]WN>O?:S]G>O]?RQ]U[+K,6LY3.?ZWUXO5^O^1S>Z&8#6@*HKMY<
MK]__%"Z$LD3-B &T89&J916)H4,V%_>?K1/\@@M,%*A_7D)GUBN!C0%2X!(Z
M%:M+UB<I"ZBMLZLN^HTI?^B^+' 24EY7)2T0$H5[!<_ )+)-?ZE8B5-G=A*B
M1E\CJT?%_R5PO>?.W9'.F=P*M5*EP)K:XZ:2(XX]M #Q[XY5?>1&L,)H1@&2
M%]X2&+725DYAM@F$-$Z=$6>F,YV[4^Q03#J3NL@)$3M"[PI0,28'M6F;2)9O
M8"_3U_EL4!T/&3D+>D:(8PQ$]57;:\)DEO=X+V$5_1)V"!22X)I7I)NP"YNY
M#@:Y@TG3]9O/B0]!'8/-8$*$\ -TD;P%7JC?^G543*@=K,47GX#<3PL":X*+
M)J6 DBD.6Y5@A*@3W<_UU^JS_5/4;.LB ?K_&#KJ?V-HJ'[KA5'2_];0C$7:
M)<#F"BQ+X55%DCM2X.KL,*Y9"I3',R@I&.6!VB/K8/< 0>?BB<%6VBO2J0%D
MLV_]C@\0)IJ*WE,QQV/%N\4W?9"L8!Z&(#CC&=&/93= <G@Z6=4SY*?N\+<4
M*-T(938QOR@)"; Q],%5DH]@B/N;+8U:F1L(XM-T:+#9HEY/?+3?5 HDED*$
M"]VF=<Y,;FEK,3>R##KH*#@I^'GOJ7AS#RGTO3!'$,DXH'H5I[*WUN*2QP[1
M@?]\ZYP46$>'#>S%!4<015<IX+,@\@3YATE':,+Y9]&X!DR]K%#>.0U^.B5C
MMMDRG"*4#2(5.,9+*1 TM1.@?6_CE8]-8"NK9GZWMJEX$W?SC:069.=1WPS.
M'.+,;'OVJNMW-^/U5EM*Q&Z2\H[':3;M!Q)?\PD"9WIJ/79@^R/LUM[3,,]'
M-4GTU_N](1)[5V:6%)@N$<BW8"MHT>"UM9&<5FH1(E,U2H@V3.5@;]OH.Y00
M'QA(Y#GCR6%R+XGQC.Z)L\O_VFRH5\]\$5[5'^:T6N3>PZ'W!YCD.+;VNO:Q
M/P!()"+O/NJ/>V?6@(.W]S4&B*U%RF#C<5P ;?@3GV'L5AM"'?K0!"K7&D!M
M0I>SORY'*H%*1%=NO'A#$"<\CF3CO:GI?+V2O9?GWP\F2Z("EF65;PF/:\2)
MCKK^OH2Q-$.T>9!E:39-%V 94J""DBP%_.NPG!]4+]$Q\6'8DT.+L3&&_\DJ
M3+A"'ZC7@NW=WD,JMSDU)A:5MT@&?^\U]7]77=T_+U'LO=C'K>R9KKQX>IEA
MUQ/PJNIGO;QX5RV\\(S<FVFS<<[&' [AJ"?9R$^,F2%?H:U1% X^Q<KG=VMU
MF^T"FECO%%^)HT29,5*'E9HBZ,+O [=QB7NDP-OZ1L]7;I.9PQD9;-3K[O^G
MI1<F.!=&7PP"13T&$X[_USL) ^P1#RDP^!B)/Z#OAQ6JV<_Y=#T\=>QR:.Q_
M@&[,+5D)77 +$BT2E@TM?PU0'AP_E7M+@P^[%L&2Z'M.G># 5]J1E'\3@$[C
M!W:H8IJQO*_%N/[!ZU'.ASZV1JK:;OC[G8/E4^M;0-J"3OBXP+K$, HS=E)^
M)#_BNQV12<BTL!A/'N_5F;^%N1L98!5Y_>!?^@_(+Z+-VTE[/?64A^U3]XO*
MDG,E98W?@CN<5L?X!]IG!&A1+^:!^+G)B][:KA+J1RD F<@YCG7K4105GRQN
M5AG+3_MI7E3X;DY/SU]M N41%4\NE#DVJ:>@42AN@[M0#^#L!F'6I^^\@ZG
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MXGJ5FJ)@5B<!V2HKJW=9'IVX*E/Y5'J=!^X7]E<'$/E8@(HYU";66P['E-B
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M(,(M$])L,8E<<$C$-DLIA&/#>$9W"&MJW4.@$&>!'07RX#7+(KE6FX:'#CK
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MX;3TFX1";_T+FV:*^$J<EAX5.FVM_2\"LG9,T)G#IBO*GN226#?_*WQG[KB
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MP:P7?8EK#AYI^9$?5VE_W[O8XG10IF+5DHJ@N9GYH"8,4U"Y0GDY?4H5X0G
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MU-JJ?9=3%V_N.N_AN^4GQT5"Z>[.FZ?TJ)9KX $>\':5_@3W%87#)W'%TWF
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M-]E]$CQ 'Z+HI;9+HCMAZ["ITYV##![@^3&5Z-(]IXX\!RZ2<^Z5[ <?OT)
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MCW7!$\.%@5W"5(\(V?JE3BGKQ!4 =XA;J*[Z78+XG9:DEPO>5#:CUVEW8$Z
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MV:-+0OSSS5DN/IM+/^Z43M>856MHF(E *>CG/&T.OOT!_NO%[*OKTI6?QF/
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MD!_;9"W"3NV6;;$O!P(6Y A;3Y=:_[8Y]2W>%F]G#NTK G^V'W_ /$V%]1#
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M$'YY3XVAQR&>'#33Y273WG#)T<*QRC$*N967U>:1-H;F*V!9]]+&RIAH7H$
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MI\6'[EU>X*0V0@K"-#UT5-S2K?7!;A,3E=#^,S^NN\1AU(NKVS$D\[_[?9,
M!I'55/[ZTK'S!H5-S=BI5$T*96+;.LWS\B6I+X?8[FGU@VP4J1 QB" 92&WQ
MG98M4T-CSR'7%?*KIU.?$2B%M2(4G5G^"RDA7U#/42$MUY"-U;F8(,(HJ>SF
M&597N7Q6\1A#-+F?AZ8D%$-2$&L#Z99=TNXQ/P&VR-3F^J7-MXLG?92164.V
M5Q!X.Z$R82W!OD)]:$+_U2L+[#K'4  (\:3%TVM\?=AK+8[L"*WYKZ[QG1TQ
MSU\T3O[0P;@'K809T[4=^ITL%_+3G@7C+[@94:8FMHE0IJ@?CLNUGXCUK*5N
M^47 XD^PU-Q')DA'7MC*_[E^6ES,MR5?P=XMT0B$@;034P?>'Q5I5_\002-
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M/!.J$=8KI3T]%ZQL;I"_!6 ;6YAX^WQ$)SQ\4A4.&[+"-S6H>]_G&R[JNVE
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M(O*X]P?O<=:#RSL,M2Y[W7U:F7'XE=-M$M=  "3V0Z<SA!T<01$% .M>LZ(
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M&Q>3$'(=$(J_HM _+ZZ#@0]'3[V;"RJ3L=YN[/KKGN46(X<A$Q(T&IKFO;[
M8 T7I#[SO)HH,:<@,I<EU!W\JPMY>9+G<O:>RNJX8FVK+;I<:$+=)]JTLT1'
M\\UK$I"51=_\&+ Y(OLR^_#.)O/H!:S+)+^%EC=WYK-^G[)""2#9UV&LL[8Z
M9)I/.SO^IG?R;+&-F,:T!GQ((@+[*<IDK&Y_;DB?T@U&Z,!1\H16(;3T@,1H
MF8.8J_6GCV$#*Z1\_S C-=DPB]PJW]MWMFFF2,RK:!;\8(MN8OB(TC/HAR&F
MYT[I/O2/"-(Q/VK"#Q(90_OD2EV6'!<QC0\7(:J0*BUU?[8ADE[97R #9 J=
MS=-S7KQ]J/B3KY@L2%FK#6V/_EIY)N3T'3%+5Y*1.0=+6%BV5%U &U]N^A2E
M'V:D"8^Q]X7*;SKDS3KZ#[]?4KZKE';(N$]L6=M5OJ._-W(]-";7R%@M>C(4
MT A3-[C2H^VE>$ K_IY:OD>$.TTH6"VC(@G"B5?:"[N?GCZ5J0PXN^D8B6++
MJE=O7M^P/N.8>:S=Z/K=22,SLLHF/(TR@MG(CY+/>":-I!!CB705QJ*X;;-[
ME$C*J,S+55\\]+%Y(GXXP'*GO'/CGLO]N]Z[:Y/N\Q4BRGM-X/ACZP%F;YT-
M/[^Q%&F]/*7-4#>)TD>\[:2T7+/K5O,Q=YZ>N05JHJ25!IQV(Q]62SV!^3#G
MHU5O1("Y;,Y''=]5Z#@UK_>/6;;:FH2)9Y4M2=-S\\-^[2,A[\;6%6S)$ZGY
M6<OCY3W';,1S6VEB^Y6-%@JF2%-*1Y@'YO?]P'AFBZ4] \_@_?#FD?O^&?AY
M-G WZIGXLVG1)1L=G>@TYTA-W0/@@F_]'6)ZAT?51/+=&GSUSUSUNN7EH )*
MS569T[!'\7^^IARR.R5W?J]_<I1MAXHV@V%1A'+=?GHZ^]#*5E>-? WSL-Z
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MJ@M=AUT6Y9AP3_!J'UJ O= -L';THW>LZWY;^%_KL:)%L1>II[^PTIS?-=)
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MW!4S_)'+9_L/9]KVJX PP<:#2'N.#U*5E4M2UAY%2E5ZFQR>/G/M09BZX5%
M 7!6+X$X#%F;R('KZE;_8LB=R*HC=1_O-(C4!)67I7YRU_9<#,!_KWDKU'K=
M+<ZM/33UV!71NWMF5\81IJTAY'0369(8<5UDEO!CBOF<)C-)OLI*F4V<0D8]
MCWCM:&S<KSP.F%?;&>UMDC%@GN"5FQV/8 Y _A_VWCNJJ>Y;&]T8,"!(1*27
MX N*KTH5*5("^DH1)784D:CH2Y,.T@*;HH *1$! %!)4I(@0"TT%0I,B0A 0
M!!0" 2(]H8:4G;L]YY[?]YUSWF]\=]QQQQWCCG'_V/\D>Z^UYEQSS?D\:^\Y
M5^+(KNRSZ+2(;.?MDG)['?-4'P&$EFC,*P]X%D8EK64HE=ZI_EW#+]1R5B=;
M;T:A7]T2 )7(V\TLK9;W-\_;;=<]\</U2F#RX/*AY1_*G& 9WD/V\)H__^W"
M7*$7.C%*+1:GQ7NC_/89L;9%U$2>SK9Q.8J_BYR#&:B($*FY\OQ6.D;.WGV@
M.ZM:\2'DU/RN;.K/F*6,=G5SL;4\U(HVVXOUT8X59,OQG@CQOQX?]-!VL^YF
MA4O*C%3JP8'07KH((7ZG=>W#(Q+WFOROF;@$V)DOB=53D9LH6A@:<532#$<#
M$Q[O2KBWZ+L8?.-UE=& G$^/@H^$OP_XR$VA2])R?I;T/DJ7=RB])?POO^+@
M["R/^BN6>TWD?\'0R\1\*Q"HF#4?-G9_LSK72G1K?'/VQ';C#<X5H5Z%7T@?
M'_2P3<,)T_1738@$=>GCX1-NQL%JKH#DC^!IEZU&<WDIK]X=>+?IDM;[1^DY
M$QEF(<H2D?L^F?ES%7]<_M-+[O%NS73959/V!6#-+)Q!I*'S=*'O(R(/GNLD
MWASV;_C44ZSY5%[?T)*JS!KH52&F<K&AV,O!%6_[YGVTKS?>OA?LNAS9XS W
MD23](\)Q;*26*QO:B3,,)SZ5'#"US/2+_!#.(EHNNC"XYE$=D!Z3G'BM[Z"W
M V=JS\\+^]\=L][!U!VD _[30]$82] #G>24$ <IA=YO/K_T@',K.RQ4EW9U
M9T6:WYSM_C.334 ]_:F*UX9^/X7V_D/+DV(O3F17 N@?> ,,\1!.M5>[A]M]
M/K'ZI_JV0A\;<].!523W*%N6T2P )'A63VMNU T\<[DX;]KXH=-S;5(IIYI!
M #]3J(5T\AR)%=( RM1<S!MFFYZOJ\BZT*<=-/O$R\,)615&M'P_'/M9^4_&
M<AZJ7^0WAF'?@<-FZ*73P@PMY>8T2?^.MGI62A/OR.^\A;XU_(AROU'.1-B,
M7IH?L+W,F%'(>,PSZK,0QCOU_K'L:X8JLY%'AU[X8K<0>'LBB4ZN<MF7])'I
MF!3$>T+9ZO5@+SW0XLFM'4'4SDD9GG5DI#MB?0K#UI;,RS/BJ7/>?I1XLVQE
MLKZ1V.FGJ@,/YGLHM$)B6Y>;EJ?[75D/V5],/)"J5"*5M#87IB( Q*;>UMQ9
M.^'A+RZ=_';XPYNK?<#78@WB]U4RCGV4:=0*RM?8%_ZR4.Y>O&Y7>->'G/RJ
MV%MXU[=+@3=/?K$RWID2FH>:1T%B=[B!; I]M"F>)9?X+$W\B<?"M2?;VUB+
ML>>3*[-5[DOL44L*L 88&#N>$SRD')XQ&UM\V1W:PY+)N//SW;$"DX6:2E<E
MF3;5O\-HT3:3G?A_JX? YS^\QM[')%DSYVN)VHJ=R3\H1H_6I0NS]U& M!NN
ML0&A$SE_4_X$:<]Q3 ?R/<QVB[W8<<*6CK U^^SKN]5W]#1\N&CWJU!%TEK7
M6"49B,IW@1&_IX5DL1CJ;NF6U-BHO@2-=:0?G6ALKA_8_SZ"RM8B->Z[-H.W
MDP*D4_U0YN$)$ZZ:>6O3N&@G&]YVS?'Y'SO)9)^_RIY&V]\Z)[RF[E$O3!\F
M]N'@9M7J=)KSAUVP^V^G5LS;!YGK YHI^NZ(M9(+L,!,O'YOH>\[3ZT@1+72
MC0#1TY8F)T/K9U<XI*_H[RAH2TA^5%_='L5;L3V/2A^%)75-?HV:OJ;0MH\8
MO6<W):W#EZV!;54H.RV;>>Y\ZK:W@V_,Z)J%GR-H*]/]E'R0K9' DUX\Q<]!
MK:44,RY[R4FJSKC%9'S.,?UC_ARPZ=BZINI@'@KV8VLA?2_ZS#QH@V:=[;NF
MIHPGIOK'8A@%ML@'?MAPOB7Y\^A@Y9"M60CMUW?]_) MENK*3RX1ZZI5$^)(
MX?S3_^.[DHDL:(LI]PHLM HDS"8RUK389')4_U 7F:4#;;$#67%K.;TK!+G?
MV])U\EXD$3-'%GI,LUE\40I_AHE)J3G '#XM .YD,QN%4'<,"&)0%UH$?QXO
M5>S$7A@8UXF;P[PS^S,D2 !LY[FR8P3 9KX'>BO^3!A7)S3N=]?GHKK)WC<*
M>3OY1 -R$IIY 77G]X8/WK=DIE+1(77,U@RDX^"%V*@W!I;;X0=.SSB][)"/
M[[?5HE77/!X1PQ1@V?N0+;Y2>$6V!U?7J)$<31&%+*)Z*3LPWNC;HZ*4ZY=0
M*0$SMT@2=?+X*)9O;-W>$2L6J9F3&>,1.)YL=(*IV5B+&G^"^Q%ZVAXCY3P]
ME+N05?#CXPSJ1A@[K!AL.$ZAT7[JU)/*,<TXN5\"@/D["95WD)\A +R"^ 2,
MAZ]"J&,#6(E*Y#DR_X9F3[$#"YWQ415,0B*T[U>EZI]LTV?3&%DS%7I<45-(
M\'AHC3XGY44)'I.BA;KTM@* FO\?.+4- 3_V3_N]O[=X553^;8OW/65AD/)[
MB]<-CO-J3O]IEU  X,C_N.7[^S1K+P(O[_F:@@#XF"T ^IOX>27KG'^5B?F_
M>F%(F&3,T@5H/SAXC#4 Y7->A.6&N_WWW>&:NSY\W!3XI559 +1[MZ#7SK*0
M4.F;JT=WG+:X\&\*6GD'B8T*@(-QT+0 @!:^;13^US2U4EC(E@1^K0#(;X.>
M<^3 S_9LK]D6-*>>9<>Y>'2'8SY8^_2?4\_XR%D>&T.K)BT]Q V%3#,=!<!%
MQMA!\$KD%G!BQ@U>>+[+.+X[^R3$Y!/!I?!0$M09%2P 2G$BZ/2^4T?!(B17
M[5_[ZU:C3&\2CX3YA.$>1*N ,S_9"KCA#%"*\H\_IPL ^]$-L^I1KN82FJ]W
M5@!(0;F4)? =FKN+[24 3I6([#B%ZV"PJO_OY ;^STEGOXYM+$(^5=#\H@ (
M/^IM \'.=" ;2C#4]$2O2=LLNW4_/'7T6M#OP^;0F>@*39Z4$23FP77'7\.@
M*1Z8042] -A6IT/E/^&7T.UQ._#'F3*,>VC;JJJWO3=8E;G,T5;5;5_-@OV]
MKKJY%;R@)@5U!HR5?[2_K&^GVCBB%,278QHU@0DDB2@TVW?,IHDJPK[4@).H
M41K[B$:R<?4N2E^#^.J-3L@[0;.[>N?*MQXX_"Y6Z]# L=CVHV\'\S?))KU.
M=?Z8.9\MDX(U<U7YP+!XORX<HB*6O]3'4%??:_E+Z%2#?(/%QNYHS Y>).QT
M?H$-,M NGM5'=NXXZ;OIV$34WKJ^KC=AJ-N\8-;S,4;<@LX([6?'?LI6"(VW
M9[8V/9=8?F?>2>+]\>SSQ $;?U^-FVW@R:#%P5::X1VFW"E^%D^/6=4P(LXG
MK6(!]OVQR-9&LM!T,4UG2Q,-)^MAQ-%,7-'2'FZ@/OWA_OQ\[^KEHS[!6HI3
M38[<RQ.<G!#6C._:Y[7./$ _=":TPZV/KKE2('IF9Z)&$HTA+SP1+8= GX3#
M\0Y^#NB&BQ4 ;VT:,$!4%^D=X[;<&.P'J/&*WFNI-!P2;+09)\GDHK!]P:7V
MS4:5]&95HP&\W7@IMJO_8+(UL^.55_AM5F3A',M>Y=5)*[FJ6/GKVVR*U%(D
M4>K=K-4"^0<Y=*2P?RM2.2((F11P8!:+ "1#@<!V>A^G>]/7HSN$QC#*(4]T
M4+=;>9$X-\SJYU&>^;[)RZ<5'B-J91YJ?TW"=_2:P?0=^[GN.7M^;^N-L99K
MEEZ=5L;&TS*4-U#URL&E%TW'ZQ/2]=(<D,+: <",,5*U-F(\VB*"Q8C3.IB1
MZ[,SY3+K]=",I,R[AL^K:))O.)O0"KXC)*P23+MZ;GY^^^&:[=>'$U5^CS2)
M@53E57+OY6/]?]HK3[X^'!N8RC/]N#V"Q784+_J5625>T9AS0%FJ9=Q$13*,
MIS??C6#N&\?.2=-\MUW^T1X\]E,O.ZE:Q_T5\ ,+M.:X/EV<QBF&MD)BKDSZ
M^<>'(=G>&^?VC[(F%6;\&_;U4A"%YB4<\!M/\^J!MHOJ-^-/92#[P*!(I/'Z
MINHGY(0UPL-+MO;&W.9-@/J* # 7 4#=\VBF+7C',4MVR3E4\T0D.7[TAF1C
M7HK_)#V5O61"_H8=)*^=[;;8.BU[*"1AY=()_?YN85NM/VR_G8M(C@Z(3#CM
M8#HPO8L<_>JIVQGAO8<9"X3:;@[KQ[4/N3J-:]WS0G\@4NX)F5V!\?XHO1/
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M8%7)7_E]$ W;:\V6_P0O\AQ_N =#(V+>&<WOXCI$]>+09CI,(QHY=E4 Q D
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MTS110E.I]JBS'$EN-5G2%XG:ZE6GS.J$;3_(?3+KTR@S-^S#YTMU,86O2%O
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MC1/*^U(:F39;[56RQY;#LQ]B^I)$'.S& IVJG746,B573%Y_C7M754XI=S+
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MZ-V#3NB$'-P1H^#;E8;>XZ_1:PSD;XN#.GJ62;#2S0^L[3E .+XA0\,,<UK
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MTWIX2/BQP&38E%]._$OXZ2[U%/6#=_MJ)^E\PS]9-S(STS1CPJAA OQ4Z%1
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MI\^TSQE[#GW]^];+BA/3^U5V(1F^CWU[IC!\9Q3L 8)I)%,6[9PJ 5JE%^N
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M4.[.Q0C*A>ZN@_U"IO@Q8@LK=-NNAG(\(7^1 <(0,M?6[6-3,/ I?D,MNTI
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M%V2)-^'/@2FO\%M 9_$)PA<Y;'WCCC%TJ.P;& #P>:16I([D4 ^Q8DW*,=D
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M=?W^J!?=BX;Y@:_$"816]'(Y+!@);B&U0@+>&"TX+I3#N.9ME%O$*IK$#"[
M *R61?A-](5X2BJKBMJ&O$E<7X_FTIF&W,S'K\=/(E=&L:ZC-H$ON*OJ3W#6
MAAU]P&C+0>EO'-"NSCM7=FIBAGCZ+W?X3(S0GHVF4< MC9"B6MX@+2:HX!7
M.O$EB;4T2PX[=SM"IL07N^,/2O/W6Z/5)%'9S8N%>8!]6Z,^^!6HX91]';DK
MAZE>S.9Z-J>2VAO75W^-% _'8]8%QMU_F,D</O[AW>_1I8[^P1AP.[*)#.[$
M"I9>;)%!ET=M)HRPUA"62?9(;\F4)6&5/1)#87KS"$*:M3\AK(.H,L?*R$UH
MZ"A!Z0=3-64'<-DG$_SL!J[5UB3AT0&E2H<E&Q_DEKR0'NFQ0_Y=(]D]S9R7
MK6X5EHK@X"%>&+A5#A,<%VO@7$08:2E!FS"(KC9NHS =6VI-;Q"TSN#MI&3)
M/FX\50&_79J+/[1E3CI/<U5N0VK.E2%.86Y:'29=?PI1/P=G^JMR8>?T= AV
MVG1I>\A6[$V6NLU2^@EKP' V0@=O]Q[ 2#8,RY3&A28=5W"&+;73MWX".:WD
M%7B?!$R'+UIHX[7VNG@,M1IXD._PF!NV(>A5X.-+!QT%<672I\AZ"B-N&XSR
MTYR30PMC(F5*FX1]H@GP )<$;J4+&L2^8(SHG?1#H[ELB%@AA]&P@Q4<_73A
M\6;M7WGB/S]RO!E@@G#&ITYX,<6XQ97((=]\[0^D2HQ&C)U?[ZY7]R_!#HYG
MC1'T9?U?B:4[MBDNO <_"]5%C=([U%!D*A8X'H9<:CF#0DD@G KTQ,LD!Z4%
M,EO\>NEMEIWT.0I%^(C6D"@)K2$;J?X:;UX:^!:9^D48W$0PQMY\-]:X68A,
MF9IM4'<1(I(I476?:_H<4^6P&H*)]#$Q ,D<%MV57B>RW\IA52>IXDV2"Z _
MEPQNBQ$X0B$<$:*;Y;!!.>PD\%IF(2W:#ZEO<H5Y.WK(GB,KXV%N8E4DB!"*
MSY@VZ]:LZ2KP%8U@ D0.,+Q24_#6CR?B4F\&Y#@G!KV3P_PBW>&C&($24-PQ
M8@0E_"=BLP7*9$AR0.A&!68XI5-UXNC 7,@VO J#!S$I*38*W&D(!8IO@4;R
M:US'+JL$1$NCD= W*X3[:M?*WGF/M_USWZU8;1N9^)B3/4%.U-LLP(.JB/\3
M#!=O)C9W-:*%Q-8PM;&1C<+I#O)0? =Z;116%[0^TU>O)71LE>F#GN*=8W%O
M'G/2!<=Z:6["FNN"^L-/@WRU&;MGE8<_;XLRV>7B\*$V>9')U:2^C5L@BGJD
MV2A=V?>E9ZWM<MC0/NY(%2],16()?BTZA8MIMV*T%CC^T6L3?,Z_%)?J(-RI
M!A(]A.8W)#Z/O;X?$*4%KJ<\!\-.7"\S>G_;P+G0D@.3G!*2(,BGR%8'B-UE
M4*#ATT1V ;7*?"J*PQK$BCX 9(&?V!$?+"V*)"J-$94"!F1J^-T@F5V&Y*"G
M/G,%BMY?STL?VUCSZ.OQAZN=ZF,>,\&+':VM5GN^1NU:QG3._43_[2=J )W%
M+I) L$(<*=DA?8L^2P5WA@GRQ'^ +"Z?9ATV9/69X]@>M@%G+%-R#0%V+/K\
MT2J*J&Z$@(/:BD<!J2EED5]6KS4^"29QIM68P82]C#GHQK:;B[Q$50F!P5*&
M"DS_GCO\=YU8'[\<'&B$K'^*[QQK(X&.U*S?AYSJ$:\G#!.4P(_A/.PUPMZ>
MK: JKPX*(43_<(AD!_%..:>[=PUS;GS@!1<HM^=Z7MLE<6?J/^/&J[YD!IJ-
M.(2=0^Z&DL!%#KM@FHE>26674*M( I>7T!6:8Z),$UG5&U/$5L$$)0:1?8.Z
M;C;>UN_(4NN.E =D>/T)-I'IPO&X,=UN=6W@H$RIU\:'C4U3G-+?4-UG$_,<
M=[Y[(DZB_?H@EKEEO8(D_1+K+4)@#O!D2MGB/7@'\+380M:',@.;Q1;$YE.1
M:'#'QG*QJ>PKM=*\%7.;6D7O"%LUOL@G24RY5- )M>62_G+0>^EG/*RV)*0(
MQR224IO-[6FYLFSNBOY*93EL _B9>_)MI#7QF4P%'RXMDL-"D: ):<I1?/0;
ML=F6>)DTA!'%@1%B$P*4>0@:I!""R->/2:R%[2P2WO6U1.M]0V_].;9@,[]]
M(WFMQ'SSV$"69%=_?3"WS-H;? ;9/:4O RF<X%TF+;QC \1G$*G\-I$IWP;$
M7%(;$C2F9-!:$-<;;<"O/$0J2P?MC\FXBS<%O1]3;Z&,P+H6"(C40.)UHJI-
M@!\[3+EUISEJBW"G_@9 5$8L'3MX5?F[:YDV\\N6#[C'V1PY#"F)!>>AR0Y#
MB5R EBD-B\-DW>2*5,%7L1JA2Z;$D"'Q>J!M )<\["<Z!CX&J&>$T[=>$Y!X
M#VG>&[RC7T+)F,RX![7%&[EQ9-QWW_O4EL8#0$=I21#0&5)9=]M[\<231+3N
MTB] 9)5&U)D)5HVC( DJN.P;#6*S"6*-J<"R1'(&C!6C<7W'^ZI,;\I6@-YL
M$B1L$8WJ.,QI\''8TY?C,DTPB=?,46:M#QY9Y=A0!SSY[A7(?/ LGF#\&Q\@
M4S[,)C-I'.,TPG("B_@6TSRM_4_'>00;R42(+(7FK=.I5FL666D'**G$*HTD
M+SXG@%1U::K0A,<A)V*K-!(;54&>UV8N U,.0"(QXD50#=.UH Z7:B_]#<W_
MOBFX'2U1HW$QK<C!I;\WGX-"-]2 #J:L Z$JWAS/W67,'<6^A;>Y:G P@@]<
M# ("GV4\>QJ)QX(:7%<_U_BU?K1:2IM9^!N<N.5![K')0C3 :D-HCWM=#2R1
MS;B7_[W4Z(?P6691MR2M+A&9+6$P8O/E[%8U0H?,2%J(-^31P9T,&DLIF*R%
M/_T*ET=;C+D=A53$*8K\>F4;,3P* A?64N.[)OU$K\PHF*4U-?M*3-4)JD6G
MRC0F9H+C4F_MQTXNNP63N4M.BP_@HS'@ 3*;."5X"LF22K)>)!U.:*,.HY?-
MLJX3S+#I7H2R(MDP6;$^G$<1H&\<K%TEO%U27'QI0%L.R[#Q%I6I61=8'WTW
M8'/H=>S!ZOF:P&ELE>F4)U1@'TM+J.SWZ+428PY6#>?V650 K2U(]AFY"M(B
M&*%;"E=/F1.6+C.^=$?6J^Z#.])'*WOF4HS=7? BJ%&GKSYF8_INR@L<UDFH
M5_7K\3,JLVS7&SGL*90*D%0]"EWK(>$K5:V*E<BJ6 :1B!XUA)2"7E=_4+8"
MP HT>')8IG;8=8(:H9.U2K*)(T6QC@A9Z2@5?&1%3H>)^(\O3VG^-1Q^LHTA
MFZ2"T/X<[K>"E88W+'[VDQH ?A#FR92DXM.X8M%E,$:8XP#&B'&X(WS116A<
M2,@U8V0F(+^96MY%-6U"#)/_ M7%]K@9[M8TSG0ZNN)@&:]![WB;2[CRI>,0
MX8U;18U2UZ,T<75M&U%:C9E=LH3S?6(\!*D'='!SS%0/3T%\7G)<2CE@NIS8
M'+RS7@<^U4%0P(5QS24;2:)D@/!*&-$6PX2J5H(RS8N6@D>(]P_B=^5TC&@"
ME)0?P)'@@TAU_&%A"<VACMR1VWC_,=[LZ].!*N3Z,7)_P?^B]P?^Y]\A6("*
M[8JE1OP$B%.C<&21NM!8LHL*GJ "[>@:1#-V>-\4%D@BMH3)8<JFLO6RQ^%$
M.6PU2X $'H'VLG4LT*E>#C.1J2,,VXE#.C9T\'"5[;#&;/0MV(*?B"&]@UI'
M&"%6P-M90QA>YL/Y$06P@O-H-C9*QXD=$M:"VE3UP-:EA6 -M#',/JZM2:O7
MX%J[FK=Y[<]VW)4_?W(9[7A-?>^;Z==OB!9R6  )W,1O7G*1SEIH]ET6DF <
MC$3:*,8\!UG>'\ &#DOI,)#2$>>9!@7<T0.D<,(T0'/7]T),VRS NB51Y)KD
M*45^=^![,W8>>-#W,\6K-W2_*_9X=X"4&K#:S<UAI8-50*D%WZ9O#7E/JVJ=
MIF;G^&1R0H*51P7CSZ]]\;:5/F&4T S7YV\N]I[Y9"Z;$:-JR<EWB,TZ$!],
MIR_RFRG*!!82@("5QJJ.F:H#$#39.C"/31EBA@T-<P*:3TOBN?14SXO3' FU
M$MN.61T,J;*;J .!*.3]7:7U/:,]]5N"N2Z3YUX$E_P2.3ZHMCD$"<4TZ3.4
M#J$?6\D0*(N7WNQUJ?<3Z^."19W">V@U:&S$M3C^5#M0*KK;^PNU19H4.<G2
MQ>\2:K0A5"\=D]A\#;OKX[88G^!H+WQ#WEW\W&&W('0VQ/#/GD@(+H<#SMVY
MNM?A"MQ^5F\["[J9UI<66%\07_<OEM;^CJZM_7U9XB3-1+/3(,*'W#3I)AGP
M</7KD,/T)"'BO_![EC;H 34XJ==EEJ I+R>5UR 4O:+@CD.*:UW]/J%QVU)N
MN.JT#9R,$U#:TUFW" <&\EJ]3%NI*X; U=;?S>V!*NZXU=:"-=C]DV3@$(49
M<$I:4#4]^">Q&4NP-9:HC]=O?X7;UXR&_:(&R&'7<] ;*A&K#I^K:&*MQ6/$
M1YE@BJLP-8. P!T_?J,]"JEP&O1K\6PT J)>X5&D]CA$JM?WG1 [L4:(!96$
M&8F@"+%<FMT(Q;'5%**\"LQ4#U33,1)C)-#U3X/!9FH2$8#NRWEB"Z2UE%(E
M.S"IOKH 7+(%#602@\$4F2KD2YW0'*1L0-8F&X&2[ETC0X00)+A,R6&7\U@3
M*Z_6U9AI&EPI8B]&HAG5MH'XGHP 8ZTNL\Q]XRDT-(GCZ+T+ZQ^_*.B3:7/=
M!&5/[W^+>S[RR8UQ,NXTZTUU0);DG&."^=$A1E?=G!Q6Z#''%F+ST'J0,SS>
M/><28OO#)>ULE@&NXK?3^;.E85J;WD\=^DCI(Z9Y)#SI.^)^]2@CQ1:N:FR#
MP'8U1@W4[ULKN>"\[JR#$LTX7S2&*5^,+ K\[G-YSG%A!EKLGU1V(;*:WDY/
MFV=.)S<:!HE0^@]..XJ.T(EA&P5_-P\)WJC#-9>'-'_L_$)P"\("SMCAZ&,M
M\VV>.8X1)AJ- _[+DYTM9RHJ\PNES;0#LB>%!N"!)T&^@3E':\[_FCI==-(H
MN^#;5><)C->,"V6(WKHW%$J/735&V;(,2R.R_30Y=&GCG[^W0II03WQ!Z>!&
M<SUB+'_B&L4.MS>;\=S6BA'+(8&;J0+OU_M#8MYLN7:7O."O__17J=&=OP-\
M$Z01S0+9?4/11:#5BCR5=U9%2=^.77@%E;_F;/[/6AWD$*\U.GNEZXY^7NFB
M16<374\<%R6YI+@ 02)YZ5UY,\(!PA?FCZY7/(36I-=8OW%-Y-O<X*KRJE/]
M:X:;?EN;V8P^@/$T*>,!QX'=#>;7G[YU)-,?,"Y=7D=3SGQ$-U"+%TV83#7H
M<'RS2F'GWU4?@^FN44WJHQZ=7>Z7?['N)."?EX2\ U=,RAK4!WD4CAV2AA6D
MB5?A"<(W%:]\0&\:RK"7^_";ZH8Z>M.63(TU*V%:2-X7PAK))6B&EPG?<T.^
M]8UAUTE<7MM=7:/V'<O,5W/22B(__^6@H'N>VH?T 3V>3AC.#T3SPT?O*/$T
M/UK8S'VT+;_U6^HI"@7:)\GF1ZH-X<CW>@MSEKID2M@1F!RV,^2X:)64>HSW
MZ2Y"C65&[VHT^)K8B2H\+;*4P^88@ZQW-(E:C>BK$)T^N\NEO=%$J'&CLBYX
MTON%X!RU_]?/]^X3(]XYE_I?=*A<L1H]RR8^,9;LC4G1M]_4$Q)!\PZG1\AB
M)Z=]DSCDH<E6*Y/7#YC^E9H=J\ZH9@"HT%4\H>2Y(C=L\#.[)@VE#6K\"<C*
M8^,3;)]5-=2=.9.2LUWSH]%=9P/]4DLC_N;&+T)LRS!Q_5!9 [-6<,;?^9?5
M(@G_V[*94E2)AI\.S%H(_T,C[(]X/TW;185!87OHMW'A9H7"8GAFT6A$YQQ?
MPE:<F99I93OMY%R[%OO(\OPAG22>I:2I(Q@U*3H)2+IT_QPUM=AIM\79AG<7
MH:6GXIH@ATG)(0(Y#$\6/D=B:KZ9=2%*J4B[!+3]H"+G.?JBZ1K2=M^/5]?K
M.T\IP0O?0_5P?#]YB-PBJE']5.V>XZS:7V.XZ9T2JBV*MD'D*(IZ,:M74;/(
MOQ4972VLY9?\$ Q;C"(I-3P[38(2D%"2%+"AZFF@FH''3=FT6ZKA<&GIAHEE
M;:XJM#$8//-*G I.<PHW?>M5R?++._U6E^:KJ%C0N59D.<Q]W)!TB5Z*)K_X
MA9'#7B9:]CUI3FE%AEK*HHZ%(;S/W#BNVA'1]UC/.HJG>#=>[7#T>K\8S2ZB
M-%*A?1AWOM=V\.:-Y3--<%;HJC'',$)5@%A_Q. (K69U>'[T\DB:!9Q1-*L;
M1? 4HRF0=B"92,D,.8QBIW_B#1BTRVVHV.".\!W_(G#HVYY#AI9Z%:SA#0M2
M89C(  P1FK@'3Z_#!;6(?AZ\J$8/5#\8-_-SI4(J!;Q(/6Z4YMP\YHCQD,4M
M?M6J'-S:Y1GMYD2;$\U+;+<I"E'3,B4:4&5PZBP0_6"SI9:W]3G:>Z8=C^H[
M2-GW%7(E#ZBK3+__S&OV\JLPWS0K=H1;3BQ+R;J[C\YK)XBJTQ21#]:9W;VB
M(*GH7RRT"L]-J]39>_#A2E[&W96XR8X$ZFJ81*4/S;Y/AE_^X8E=/KZC%6YX
MM'KY583[TT)<,V_#'*F%/$AN1JIH;]]?L.Q3E\,.<_O+=^Z8F_"V%?GM0&M+
M4?K(2OAF7>1\G#3VY^N2+(66FS<\C8?UT(ITBAZJ"+DUB B?FIY=V#G"W/PL
M>LII_D?TG:M[;,TF^P8:M84LB7H-)S4]*OZVYU] 9I[M5*\-R:8ZJ\)RYQ5G
MDSN$I^ID+^ECJ\M'WO]V]"U^P=,%;'=DU.Y?.[/?,'N<-4%$'H%)$(T0+6 E
M._/WDI0";Y'-KE:'9U<**T>CZ=2J*S54P'GZ&D.MH%"M[[2ET<$"Q43,F5!=
M_4?\K%G*V!WPZI?:UD4$O__K2>!KH=LF/;>KQ8OG$]&%M_?)E'8!A)%?UJD
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MV#LT[)O*AS%;HL>".WQI3Z1D/-[RWH]ZL]*-QL8' YOGC%3>C_+FRAH,1<O
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M]>[+>NP,9BT7/>QT,>ESZ8(-.W^6XT[\NIAK/,/=NTU)&SF-^)%HP7V?PFO
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M?C]F,Q@!&_:DV8+M10SS(<8!7\R/&FTG_.\SLU\K8ZK3G@HW1'YO(,IGB^O
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M-/CASWBWQ ;BW.Y4]3;SQ97A^\3:\>&BNI-7AE5>GGXLE(-COD\-9@/*<]T
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M*J440/&Q@6HVP-C]!3^I6%H2A"7-(H07-L2[#],/O!/T[% AN49?N<WW]83
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M9T,-N&EN%&/>^#!7COD(ZX$2KRO%?.E^.*SC9==0X_:SVLP_]3YO")%UC56
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MU3TN-0C7<7_X W,$V144\75AXQFYA$'/XABLJHX:YJ-]J$USX21?YI/\-YY
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M[NZZL6QL<\F9,W//O3-WK?O>^^^MJ=75J[I+/NOZZO=U=3_-/ZT#./+2<M(
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M,_X3Y_[O^9SJI2\ZA*W<95.]=H82KOB03^=K.>M2NL^U0VU]'9[4@$0H4M0
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M7^5*5= Q6% :$0RU\ G8;A%E? (&N2 >CX'LH"N%.24QG$66 QNT%3GRQE=
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M?9X.(,K=68[/WR/9[M]L17SFP/%#<=Q^/L,1B*;F>D8R@&FI JVC@@QP_1J
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M<6E8>YQ0"L"=LL[/3;Q+!DQF,,?<-\U.)$+JQ_*06VJ+1[P&\&SHQ,J7=*>
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M432S3].H'(XA)*X_YVIVF=$@",ILD@'.@OQ\U:N'J>X7!G>-Q'K0LQFUC&1
M&413X@53,H!/VMB=5*6WU$+5HVQ\H+GQ=HE]47$OJ2\9G&9@O'>*M<6#+?<O
MAS=$LPM:%"7P\9K!AN:OA<O"_G%H6:^ ,^CETSG<^_[4/(?GU4KI;GY^KKS(
MU#*G:P,=XWHW=6-^[0.TF2=%]D4P^#ZV46/#<O3F R/XQHQZ35ST?4NKMV\Y
M'%_N-0->16M%8AB0'F(T4^_MC?]*ZI/C0I6,3[8ARD0.LS_J78_PR54!_N1
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M,GI&T@5^>LP)DG<PW4&+RR3*2S2(?H<,L)&4 D&4_%NM_0HW<)',L.FG^)S
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M=XB!&#G[&O:^?X!TPH_/)+&+!"N*0S;[R !7X7.U,K5J75-V,D 7^XLO/OT
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M&D7,?2Y2P()>NLB]*Q'].F[*86R:+0^;-<G;GY<FHS@HJV;W(-;V*(Y'I5\
ML>Z_B02O8!.C,DDYV$1C8!,M]<@ZSW+9E9BHL4ZXWIX:].;T9SE&L*48["FG
MD0FY1('!%JRIE,^*>;0Z,I&6K]+>=6M^=(8R&_,;;-;);[;^/8[>CX>ALWCO
MN<.DWZ+-!0E;E;"._QK'H3^YYB1I;FAS6B;EL5@_EAD=.0/#QRF)>,(8)#LP
M-57,,Q-HE*FW_I*E!'MTX _E"_M#SPV]#QA;3F,*(1>] JN,&Y8/ORQ&RBB&
M@=VC5[WUA[ZI8RA'IXF0YW;M8QR-<N&4R9C.U+''D:1)S]/'O=A<""Z9Q(BR
MZ!$742!G34 Q2F4<,8J3M=J^'(?L\NS1QWFX:J6P.CF+7*ZMR%52R"H#4"6C
M<RQX9U)OPPL?LZOWSD&*'5FY*SABNH+:%XJ1Z]!*LM(Y;ZE#N4(< "_'R$EB
MD*>1:LT4-JIWCKD%X&\)%7?Z8SW)P)W-V;(R9Y4$#E#%(UC8#'ZGUCD:^EL7
MZ?EI-@HGXP)%,&>'N,<!.9PL$DR !1.BC[2WMN[#:S;/.V9Z.5DL5@.8,R*1
MS$5SP8[F0(M@BF&=RT2J% CM;6&\'^W+[D%9AYQ^=LNSBH4?WD-7*FE=J7P1
M)>'"T'LI"<9'T ,4,CI7Y&+>(R/!6),".Y>HR8DX?:6@6SEA/D;0!0ZJ0?AP
M>%17WQZ&SSO3"XQ/(L'MDFRSHW- *),")6NH#X "@?<WB'!=R6*RA]:DQ#%&
M- D%NET@H.4!D402@]9.2,E[5P7O8;T1-P9,?!V&6'^ORUS&.'?NR=I$<_=B
M+!WX6U<0?VIM4BX7C><2 V(3YY&ES"- "!XD(3**WJ8^K0^CSV^E4PECD>._
M0CX!@5UT4D9$A58Z)N^%[YWKO(]J?*LNKBC_<44@D%L"Q*SNX^Q4)Q:,4 ,2
M!3.J)4E41-Y_I_J/TT0 S!\RLV!)!EI(S("6!E*>14!LT*RM=!A%R2/3+$C%
M>JM>3]IE[-KCK?'HH*HO'9"U^YB]-Y6W@_\>UV432K^ N[@_6G644EL=4? !
MF$@GB8Q7 ?E@C#-<!&5ZNSF/^3A@[;3_ 4VF:#2V8.0EFE6"P)!. !V YY9%
MRIAUO4TE76<7]46Q=$0$"LHCBBDG'1(1LW]'(*$HV M8:JI[:R,L.>EP<6J&
M-PGEH&U+M)-CJ\#LC,V[8S\8YP)9=76807,\:C%S.\T"]3['>@*W)U??8#X>
M^\H!CT6U<<0:&7)Q'MZ6;@ :R]W:D$B$A6R\,-)??T8?XSKZG_K4X4FGXTH(
M*0P*+N:.<)8C0T@^JTX\BF2,E;W5O99P>-")&7Q:M&_Y&1X72P!Q1-DB,N["
MT'O).&ZT<8X@%FCV@UF;^Z8&Y +%/H>58=S;8)Z, FUD[^C=-_CGLLYT8<"3
MU97FP$5TUW#&"8HUYQXH3>>>0!A$D^4)2<VD]@$[&WH;6=S]<4G74G$KA!;S
M[."S+<.'X1M[5([LX&DJTLHFB;U#SN:<L^! 0B7#D>:*1:PCF&6]\]"NYM F
MYR.TJO!N3IDL ;OF0.97(-7?=_Q!-0#]M@KQ)F)9^*ES"1!M5:W+2'IQQ+OC
MHYAMT=U8/\UB5$XS$(!)(2*90MP*BQQV*N=*1D$PEACW5K-Z7P[MT)>Y+_CY
MX[_9@*\[NW6[H2</9#!UJ?)J'X7-#:PLRU*)&.2,H+GD1%0T4B)4_PVFRT;Y
MF;&T"E\][7)_(F$)-,A(<JLQ+$-N5P :JU-*$L.3L[UEG)ZDKMVY#B)9PF1Z
MG4?7):Y8;DW@&H&RPG)W<(R,)Q*YZ+U.E&H0 7VK(I(]ZXC@141CA_D?SEGI
M&(E(3$IW@?%H;"!(@;A,1&#B^ULU]O::SI>R^1T(']AL%.O8C+[8^Q?V? *Z
MY2/5ZCR/1.>8,06<PY.52'OM@(<25BHPINGCS@QX@&39Y=0O=TE9DIA%GF*!
MN,@EC#EH>9;:H$A&8M?_4(P'S0)XJ(S#Y9Q[>"J2L,!_"GL0MU[D$Q"2$+:8
M<4^,D:&W?L<><F*'BI 71F!J"&@^P']<&(><QA&1A%U*+FD=>UO)K]>^M]7$
MN'FI3 )F0]Y+FU,3%-*4*A0IUMF9@17MK>_MZ8?GW"-8=^$9_ 46;)3?S8[&
M%QCATIK-K>XGX)SILBP]9R<WR94/;,8 .QA+(T4QN@@X)PTP1F1(<J:L])$R
M^9BS09YJBT,O RB$02)!.$9<T8"<\!I1P[$%99Z&1ZXXK"BYMP?6F0<+C&J3
MD$I1@75&#+*>P]92RS%SFEG>6^ML68'U"YD"#YE)\)"MLB[2)$=T09H\-_1>
M-&DD-CIG!Q%!IKG!T49D,;$F.!63<WVER47<V7<X"EKX^<_0B^R-,U8SC[06
M G&B+4@GJU$ :"-<!$[[5XMZ17+<24E2(D@PDL^)3'NVZL!,R>YV&87O7]/0
MIQJZMO##)\DLIU9VSEFY;$Q]B4W,IU8 /6_SJ535JC@Y8@"F]"2#Z+PW6"I.
M4+2YDFJ4 6G#&8H"S(I@95"FMSII;^JJ7\0DO7@11MT5)J68N! 2*<%3/@,D
MR#"%D1?$&T6(I\NOC7W;E:*+HS?M#KT#QEXYL):3EJ"J<YE5=6KS>;^@1%)E
MW=*C,&XKY+&<:Z-P'R$?B+<21X.8RHUI:#Y/BB( '6(3HM0<N]ZZU'K>C&HU
M)]J!$NP(*!^)>HJXS85<' .*88H$)XGD_8UT[;&/]'%Z(=K:<88FY%3 0 S)
M(+ !&9)&:6$4E3W.'7S"Q+ :*R4('CSS(#DX!SD7!<NU)4#',U&[:!W00V^C
MV18Y>;A7P<<;9_+,"N,&H;TPWB$3')"(EA%9 !.D&2;:<2IY["UR=![#<#^7
M3(<!J4%&#EQL$4VY/5C0%-G(.;(ND*@B\\;T3JG'F2CI@ZM!1HI$P/RA6@/]
M)DF1B;G9O(\Z*66U]KWU==ZQU.WR3ET[3>/OC7\S.!YD/ITA*I?02SPBC9D#
M$B'"!PNV,^UMF%;OG5<KTG?!P''6&.25SRJ.L<@:P$?CO:84&PU6;E^WM#=M
M@'JQCTI0Y2+"(:.WYP%IZ@,R"NL4>(JQ?XD7J^H@V*L^?Q<=(/.=_GY<O_;<
MT'O13HS&,R,1T(]&7$E0CT@T*$2FH@)P=[2W1>Y[6808JP4#FBX,O=<F)JJB
M ;;G K=-PP##38J(!1*XI$0&UKLRUC< 0!LY\1DN -N_K^K/![8^M+[=1COX
MS0['R?K1.!\0@[P^%=T>=+E.#K)79K^N2((DF[!5"5G%.$B0P+,;E"&KB:+6
MBR3,8R.@YU,/'Z-LJ9VMZ7V4_.2(#2$B%WP$(%$$::$HPEZI1"T1G/4_ OS'
M93$??4G,2+,C.K.IS+7)G$VP6TXB3@#MK:"4B=[:ZK?*G]BIT@A,Z3AGC2T_
MIZD;8SDR[*P#ME3>\QS/R'(3(0!L0KP.V,2$>VM9_0C?=B*\YW-K+(';B(2%
M=+H+0^\CDB,7P-^1HQ1#-NJ41#K&ML6GTX0##?'^0W%/DG&6Q.3"2!.9RZU7
M4TZ7TLBZW$N&>2<X29J9WG51[K'2U(:P+25(>@7YDAWJ9%&SI$R2*!E0^;FB
M.E=9]KE.9'3<,*/2TG7SE1WA1 W"TY)<&I.#91M@&;0R B5!M%748Q9[ZYY8
M3GS=?5E\!S2JHY%=N@@]A[D@%2GOA!XL)RH0A5108*!PDY"A&B-ML67.2P$7
M^TH//4P>[E(:.LP#\Q89FT D!J/@-]@C)UPTP1K)0F^3ZIY:*[6%G]W[@['5
M-'6+GD5/G$-2YSY!&L2YH4#05GKLM2:8ZMZYPWI=FGEUC<K87)62&Q+'YH?>
MBWI""CA0T%1RRCVGAB'ML$?1&"TH:"U6]Q8)5Z2SK+.;]V),BA K$3&Y(Y%V
M!M1\T'D%C\JH(*@1O0LM[[$U.?%4/8 C_F)*!E\X)>-<5L*]2"=QXG 2*$J5
M$^-!_VJC#TERBE(/@!/Z6QCSANBMCS&W(_Q]:P0:T*3V8A[7=*Z%=5Q1_+Z$
M)+(XH@OI/1>&WH>0$N;.)2$1*/(:))>BR(J44,PF.(9GF1Z7XGK0BGI]\W#V
M0( EP@C!+H#2' WB7B>DI0G(LZ2QQ2(FTH<$Z$O1D9TDAB5*M/$ZU[YUP#DB
M1*2-8$@Q26FD41O:V\J8:XMAU>$7B=)@@$H0L7I:5]4%"G04@'&LL"FDWA[I
M+N1"^$L<QMH.MH9A*QR6PQ(,#)O#KI]R=&T2RH1$%")Y9[FC'MD<4T,59E%Z
MKH3M_P%>]^7*U[;@(J3CM,Y>;D)U[E--(K*Y8B:7+'I-F'#]S3WKX0'^BOA?
M.N*]<XB27.<T)\H;;RRBV+-(J35.]ZZFU>,+RGRH E0K(:" %0L).2Y:%" Y
M'M,AT+&9<=B8M/Q*"W=%@74KTZMDR2H:XB8MB9&@5BJ60 U1.;^':XK 8N%)
M@$T&E_M&1:OR*UY]TC7G9P2E!S17/]JM/L<Z5?4AH.#V"(19<ZF.XP0KJWJ4
M*I!XO?=\W@E\'U<@3=)>X*3A=C%0Q)E*R&!OD&9,)F&DBOT[U9MPPK !&@JM
M7?4!]/(+AODV+ )<&^[O3&Z[;"?WBG1BKVF*V2VIX/$\A("L9!1VCP1) \;6
M]B[:KLL./[0K"'F&M1F3=X0H9@%+F$#<FX ,\1@QHZ7&2>'8W_3V5KQDGUP=
M#_*U;W'B<;G:T7+=Z*>I( >*(R$&)1,!T#V.R*B\P89QQS4.B?46$OIA)L^Q
MVX5TQ'NQ6Z26$!H1$SDOA2H+EF\B*$I,O1!.Q-0[E?.\.W/7'F^-1P=5G4MP
MGV.PMW"U@?UHU=-Z"<40EX2 T7&9*]5)36!+(J7(<K E.65$A9@P%;T]V?N1
MSIL#\W:.LH)4QS./0V=*;[^XM0^0F[22U@ND0O"(<V!M9S5&/K#D13 RR-Y*
MTB470%QX'EOP)J$<C+/;X:ST]KMC/QB'&-[7U6$6X.-1*]ZWTZQT!5B<D[IM
M)U??8+Z P94#'L2]\="5MX @+>'1(\H)![/ @PX@F4?6,Z4CS\*FMP>O79@%
MK"NJ_%')^*E[X90O?AP,^*FZL4_BXS1!,:8V1I>0)AQ,4)EB]AT  G*NK8E!
ML/ZVO^QY]=?5U#+&V!%,94">.# ;G-'(Q4A0(M92)G%TRR\0=]<-O54VR4>P
MWN-!-0@?P#*LOCU 48(.=5=,;%3>&V3 < "-%0MD2=*P7]Y0(<&(Q[WSVZUS
MP'JBL&(6L!0<;%&M:%98.3),>A2\3$GX3$B/,A-_9NN\J0:#28.H;)-T%15[
M _W\+9:#P?2XX;<8\NEOGD?<?Z)R7W IK'6(QI0S<$%6: Y0Q*+U+G^&=6_]
M&<M(;>L "8##%VK5<6'H_791)=@[C)C-H76:@*5 E ?9[[E@W,0>>PL?3?LX
MLW#WCEQD7W7%H(HIZ9Q%$50" 'F/D?,<_C0Z]T"UE-C>@OPJTC]75MUL->7Q
ML'%*,% ;(XLX-W=QR%$KD<  W0+;9!]!UXX^!F=O@ZVX-1A4HSS!!^H%L HG
M$XZ!2D8Q2A@$!A<@/ZRQ'LB3.B.)2YCUM@I%WS)5EF0C)LZE# &9:'/R"<ME
M3&U$- 50\VWP*O96 JR^6T-_DN#FJ$.<U_7O0QT$!\^-9RBEW#G8L(2<(" %
M(M4^$,P8Z6V7MDYCTKY7IQ%ICZ[][#H$K@-&(-9Z)B6B.0:&*\5 418"*6-X
MH#&:$!Z[('NJ:6KG&]K-UZJX%T$H*V'7'<(4_N',"V08F'!:"FN,XSSXWJK&
M/6YYU:GLWQ[&-G2]FS8FO5'9B"9!1IK#.$5;M6#:,RGRJ &)E">RMUZU6QV^
MO!_7PS+[]F'@^_(X__9HSEZ(EIXZ F+"9*<9!0U;N\!1@LUAACG&^]OUI7]'
MGLNID4ATQ(EX@D+,/8@=_.:$CX@9I:CC+)#^AD#TO@#9:DX<B!&:6*%1XHXC
M3B)'6B1X %BSG'BN57\-EEOWXWJJ\LW1("V3B-B<L*!B1"XKW-02&03EE+"E
MEP%;W<M[C14'D1X4,8CG8IW:6H9DU(;)$()GO<U=G$MU: .M+DOTBR- ^_?Q
M?ZH!8->@;]70%GY:CBQKP7<W=UPJ_S6>5TI_!</F]QU_4 U =ZE"7'8)F]4$
M"Y!(K29,(4E#1-RJG%Z4, I$@%A5 ,B\M]5E>],0;3GE94D41KCH $$DRU6P
M#3():"19P!4;F(;E[-O6K,I#MN1.* O/HQ^=<B[T<B"+XDH[M)L"?20%G)A0
MR-/<.Q-@!KF@,1+8>BPDH:R_<8;K[(NK#[(!V?!"(2P7AMZ'CN!NFNGDD,]M
MZ3GW#%F?R<HYCK&A0&>]+2ET>ZWJW7&L?=G$5KM:ZU3]L6QRG(^AD2"#0[9.
M60#+!@@R:F*4U<'+_CD<^GA:U<;?W5$0+O3"*SBL:@/V:#=D1FFB/ JD=.[U
M$)1"6G&-M!."I*0I9[VM@K74'*^[GTL\3F\89=&DX%-N^I'SO!E&SG !E,8Y
MQ9)@)7M[2/6HO6$=VF^4@WZBE =L2 9,Z^"039+F+*J0! [&Q]X6Q>]5^8X?
MY>G-QGS=V:U;9>IDX>S/NRS&<RD? K0;9,08:)>!VDV<18;ZB#!6.BKGO/-]
MJ&Q\,5 2+QAC?V'HO9!:$N(4ETA0)8'+*6B&1'O$0%M,WEFM^M>)O@]]>'ZD
M);9]\9;1@&AUX4R@(;).&%/*)#R8'\$H$"J*@'(HB$=:6\YS40N_KKK=@ZC_
MUI-&\8)8U%70-E56AI@"HLDHQ)DAR%$P)$")=%PH'@"I>DL<3[,K1G])=#7]
M-J@FG#N9NQD"G7+# ])9Q5#".N\5$U@L_5!C=1:!(20P[L"\IP1>7@ODF(Y(
M*!5R"UW&:&]#]M=.\<ND<<'/?3_2L%I*P9"0,B).-1B+!OY1B8$-F8(*IO]A
MRMV7SG^DWAOC4F Q(8FE1=SAF)L*6:2=E4G##A/>.\N_C][B%9V8KB82@UI*
M9>[V+(2WN;<Z1HXGF$L4).@<?9IZ1S0/EL]U;P]]5WE5U!$PMP*&7<)9Q0X<
M69MK;7BIK0=[/_K>Q<OTD;7O<Q#4 7_/']C<6(R!=L/?7O(<_( 2CAR$0JY*
M+UA"3,$5[8F4_:TCV+LN ^?U\WG[^5[,[7UDE$NPW!5 <+ 2.24,BLEC9A4V
M'/>N?\G2G"N/5(H&1A25#@GM/'"9$*!UZ0#6*_7828H?P'&]#!-KA85K5K*+
M3MI(<M^.H!''DB!-82*2.:\9)R&0WD:/]0XK>U!-@D;%M(JY(XL-TW:].$0D
M? 2=B5MJ<6]CX[LX"B7KH\B["^7$B)-@1P-%YL-SFK(=39!GQ#KNM*:\M[2S
M#$1?^.']<)?U0)HPJIDGS"(6<V]!9@0R 3OD4[(NP04F>F>S];T7QG)XG3$#
M>G8.>/,<=BIPD/L*-  2HM,Q&&M%[[2W&ZSKK0!6]?CPU[(:Y8#8:E#ME_&A
M#M*G#W\6.B/CT3 A0+W@.6\[1UJY7 ^)@-G&@G."R-YR^9+35^['WQWF;;/<
M(-A8C:)R"7$O [(>2Y1S)RE),;#86Q](+TK7W[D?Z,*O^:B*XJ\(:835,GEX
MLLW])2/SR,@8D0:H45$PQEGO$O/6!99[1D,R*&5!)TW9R\B)#TA;)Y 423&I
MA*:AMW%<B\3C_E8-X\DD3N?]>!C6L;CW$)I:>B9DKE65JP;%))%S7B$FN"(4
M$$>ZWH8&]/%@L ?^,&:)BX1()+SDB LED4V@M4IOG"-)VLAZ6PBJUT7I;DYD
M?*0$X[@G 9C>! P$DTOQ ^,;9'0DV&,K(^]M0Y"%"A[])0Y!E1Z 6-D*AZ#1
M-J.L?GR+3[GD$7.>)9L3_3@&=.<V("<4&+#)FV2(%$'W+LF"Y@/Q1;L6P=!N
MJ@DPSWQ*U""E<Q]KK@ERW"@P(SE+(3IC^MO2I&_5J/N@_'H7<0P$T<1RM]3H
MD<9Y(HQ:8;3F0/U]W<Y;U4$\O;CD;;PM5^)NMC'(:+W2R.0>0SQBC9S/'C>6
M*.4RU_EXE';PI);R(SN:N?'9J\M]T@AWTF29A22DB0Y4'^L!-KA"-NK<C!#0
M(SGOI>EM>LMRNJ)UH\S2Q959V@EN1$=E[B<)^^DG:4I&PV].6,HY)=+U+X:R
M9[Z/=23""M)W6 +EQ B"4LC>&&)9)EF#0N2$12&#\$_Z]&)-.W>G'8X)"QQ4
M7L]SORXE!;*YP:<%,\]XK@1VCS**Y5FE?O7 9\ )H<PIBI+1H'/G8R<C0!&*
MACHOI'.:]?;<H-\EY+MD=JIP<" 9O%48-DECI,%&0A(390(AD3[ZHJJGU5:R
M#W;BZWTLYRF<$TD-L4AKHW.0$48N$8D\Q<!<FA#Y.(]OGZ;9^FC*YE\P=']<
M9_7<T'O) \ZH2+G8A.,Y.E9@9%@$P>2QQ#YJPG!O/:/]Z@)WP\G2N3D\3=6"
MA\",D8AP%Q'70*9.:((D8*+B/'*S_'IEC^,TCO/$.)-Z6MS828Y,)"!+8I0"
MV-$1T]^^RCT\D5].-A\7)O>Y!L%N<XB-91%,+B>0HR*PY$R,HK>[]+ U>V]?
MJ+@MV=EIE>*G63>82QP4-QBEE&-W?$[ZU8DCARDA7I!@=&\S2I]^L[G[)N/=
M.(V5%7>:P*A>1"YV>*X+ZJ?GA$GDM""(4U C-,A$1%4,F*>H17_#FK:^VSI<
M!CZP*$8 <Z-IH/W783EJONQ\?9+'\EQ9S(U3B MA<Y2%R]MGD8CY3%XZ&Y:?
M)[4Z;<%2IXA0B#"=&R8KBVP.LU("AV EH:Z_CK6[-!HXBIFHWV;X!IKY8F^,
MU>^I[K)JO:$/?!M(,IY&8(9<\T!'C9S,T:0X6"6H-ECV]FRACSV<.DQXXL$P
M:[.W!ZQKL$&P1=K&[/^QG+.4K(R]2VB\!1\OOP?T1?::[P)]0^&>^:'W82^!
ML0U<Y^T+(!FH,$@';I$GPNG</YJ;WN[AQ&NZ:X^WQJ.#JH:IG=_ MW"U&96^
M3<RIEQUNLAIX!&5&\L0IDHP;T&T<058+BHS!GB1LG"&][:7PU H(],IB.E_)
M,Q?I[@+RA8A*J-S],]B43V@=<LPD1+%DEG(LF.AME-JM6W>LUE/8E93.Y^:P
M+1+AA"/BV$10H"Q'7GFGJ,>$Q-Z>U]Z$\*V"M34,^<!L\-_CNFP"F+/+[YNS
M(JQ7%*O(0$(3YQ#WF0U!0".79)3:4R[[6V'Y&49% 4XR$H@ &YX+P$KXQQ$-
MC,>I%=1J(_JK6O4FHO>2/X1VLC4V"<N40<3ZD%,408Q9+9&7/!+@*2)Y;[>F
M']%BRSE1$ Y8@R2%O,D]'GRPR 1)$ LD,9I(U*2WIUJ+G#UN#Q^\@FBGNZ.8
MLD$A$6GNFZ0",CX8X)H@390X:-M;36*A\+QVT[93 I/CO?5M[_>L7$S*152@
M-Q[9&\\$[ZM:&! 7"ZH6[=".5 OGK2+2(-8JB2)A9*E0N28EP<(QDGQO58MG
M9T8^FJ@QOC@MPU#343ZM"+GAB,J-@E0.8(FYJ[*S2.@@0^+&:MW;@[I>U&%:
M5TM:G-8BX<3X"-8TR>ZWX)#!C +!R61,BJ#'/.KR)2M06#H\]A11444Y09*$
MK.:WN7@ 20 0-$6&67"]4_/[V,]@1:T,VCYSB[%T.[0C\1&3Y<;P7& 1 ]'8
MB)PA\*<DC&$AA>YO*X.^E6-8SKDC[)!GEDADL0/0]0*L=V[!7HP*0)>9'!C>
M^QWZ83',7S^6L(&A5><FQ3#C\/[1B"LZ?N@0T"7)2=0R(4%E[CH-@*ZCU(AH
M$3AFVFG<AR">'B@FDE&LK7&(6&-RMP^*-/ -PK!" ?[/G.PMCZP^=6+YE4A[
MEI2Q*B)5B=,DD3:9G9G.P96*(>VI(8$K9?I:$7O85(,I/G\ /+\@7[=A$>#:
M<']G<MNGV=--LJACRNV9!09%R7H+VC6%?<16,BV82/VM6]6[/B;+\=A*3C6G
MSB'/!>A'&FQ4HY@&&Q74)&P,I?V-T.IQA'Y_]E?:$'.B;\0Z-U95"IE\MA^T
M]-0"&T;<6U=7C\[VE[0Y1@LB@T)> TCRA $?K=((/B*&2T) QO5U<_J4*-\'
M46>5U1$@U.=H*AZD1*":<,2"\@;$H'&ZMSZ!E4=)+B>Z(I>-I@+4#0"\G'PF
M0'>422$7;<K=U2CL6%^WI,>BK5,C[:&\Q^<0(L>((+)0J8(N$2(P0UP4H&2)
M+(DQ [#G E$-X$^55![WMH;Q@CZINS9HN9.U_2")A#F+$!&\"*ETF& O@R=
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M*Y,/B&"+<W/2" !@$Q@LC!D7P5:A]VY.^L&G>BN_655OG>WO^X'=7T/ $X*
M5#1G)4Z N&_;\^=:<3Z/(F?<VS:QG90DJ2[)^TD3O$FUP,G7IH5,TJ"M;P(?
M^:JNIS.I)EI&7>?2)E5FSF]E-6X&)S/>O.JI#\.?B>/$M!6()\%R8%) EDB&
MF$K8$QY2X/*^_/FV\N/\2N_+X<[H</0NK\.;T]59\^D3X],?,UE6<%M^JD _
MGK#$&:?,^'J.]UIQ=EH.(LMS7[6U+D!L#TZ:<B*-A[FX,XAGY&Q6F;-2'8?-
M1,[GDA1PJ:V?=/KT>6X^E?L7V\W6S7QMBQH4_&^9^4^G,%7CY\%G6BJ#XPV"
MWR(""'0U'_>3AM?$^L,*+&W*?7,0!X.9B5C\=$7EV&L3RW]>USOLL&I%YZIJ
MH(H9JY!CTH$\S"7>(Y=(L"!(<%;:T)&MNI-)Z"IO.KSY<0SP$H/FKJT_'K;"
MWWV%WM/P(FVU0NB_Q\-8,/RRH)CRERWS#W(-NV!_)',.JZ:5*' GT =;;U#,
M7B10@JIAU@P;#VKAO\8VETV:W-7N[\.-,FH=MC7YIWU;IL_X5K6V8+9V<[&/
MZ9]^TNPER]'120'TUXK#MAI(RLHKW.TJ/3?78K)'1W5U7 *-1ICA_[YOY:5.
M#X2FC/R^K:0$[S?M3A(-B9EUG1<4C,XDD?$L(!$9%=IX[_FEH+N L0?KE*&D
MI4+ TP993RWB6 I*)%76I<N<_+FUP=\/*CMZ 59^.;G;U[VO.V]?%'GG8#3H
MSR%Z6+]!\^<72)QG^.'X$(5JA*8C7OPBJ-HP,\::O5?/JB[!]P<PJSO427DJ
M>D-NCS%IB)Z9ICD M;695DZ[R.!^KLU248U'K>>VY=#V&[_9VA\4E+2P(5J&
M>P0<AAD6$8.8U%Q)D)7<(V>\0(1+;IPTCII+;AW%25"81N K [*2)(RL)A(I
MI33U'$?/Z15E,]OEV\FKM],N\_;9$IYCN<DFS//:AT_O;V VQEX2(U\:H_K-
M<1N]FLT=.D[HN_-]!ZVVNWSYM]MOOO[V[M/N3O'ATYOM+Y^WOVSMOGM;_/J/
MXLN[]^^^O/OTYMV%Y0GEMVN*#1JBJ7 &><.!(5A22 NA41#6:V.8T<YTY7MI
M/@S!S#ZJVB2L7T_@;K&.8#7OPJU_'0!SO2@BR*LC^-JH'L?%HF2>"II_SF[Z
M:>&R\R;?*8K/RIM]B\5GT(9.BIV9BR+[!6RK8X'YG[_=XOC6<#C.39-B;"_!
MC5L(.Z@&(;L5LINCG-L1T,CJ"/8CZ&3U;&NR/?D9U+[BPX</IT4WI_?]<GJJ
M\1[PK2 8_77V^/:\<31Q),[NNU'LY.J91^W,3YTKQ7>0XV?EI=OSQPN5I+,6
M>6K!9B@NFR9+@3RVS"[627WF'^BW4P7V)-JZF)R#O@5EMY6<;"+T^,:Y0_B+
M)D5FGQZ>P#]4ZZAI ;66W39H;FT:*E ZX^OY, TRF\S*EZ5]]A+7!:AATNDZ
MQZGL1W2^'AW,-0^83O7?J 2".]Y$['4:Q&,4RJF;,9>3&Q\.7X>R.1K8D\U\
M]5),RX8HA^W<IJ&NDP_^.6Y&93J93;/]*@*Z?GU43<Z>-R=P\"W.%U4[[5![
MO(KXPQ5NV81]SYCXX#2 >/H.Y7!0#F%R(P"Z21G \Q=@:2<?3W:[#26V"12"
M33OX#L@SK5$WO^WGXI?:39LCA$L;NMZWZ_=MV; [4^U:?0C$XU[>Y#LJ!5<W
M6NMPC7:W?OWXKMA^7[S9OH\VOO1Y?MK-VFF_2Y@N6TH\TAJF>.,.%3PUW=#T
M]E]3&_C&DJDW)'XXZW_?KZOQ,* I]4^:U'>8$;*!R>4(U,,RA#D%:"X(=?91
M/07X]MO/*K?ZR@6[ON7N>L%NN6"G&L%426PU\J8:E*&83?_*-;UB 9:XQO?S
MF5P248L9T2"[;YD]UHJ!5:'(-7'LM^"(7AQFW7&SMK[L%A_NSRA/9!%7CRLW
M@<891R]S#=NG/_PB]@8BVJ7(MB)8]G)#9P]C1P0_KX1.[SS_,/Q0[IM.-_/#
M*!X69.-)PH@M#NKL<O\#K-#A'MESL\HJUZ[G=?38WCQ$GSV]V='0!H-GY\9$
M;[C%>L^JNYPNN%V#T7WHEZW!Z*F!T=:S0".[5Y?-[WO)^E'UH_ZYRX>D+S"/
MXOUD'FM8Z@B6U!J7GAHN_?HL<,GMC8=U! SY%L->,[(I[>7PIQQ_L$J0^GHZ
MJ7QLGU)[DITGM4:L;FC<Z#5B/37$>O,L$,OO^1,7ZVEFX<DJ4>K-_$36R+1&
MIC4R78E,]#D $]T[JJNC/.FX4M7I\^DLUHC4$2*9-2(],41BSP&1V-X@[MM!
MQB4?8Y[42H'I8YY,CL6>36:-3]U0-,%X#5!/#*#X<P HO@=K$/<:F^+H9"^4
MC1]4S;A>K?[T)3:Q_A;#&IV>!SIUSC3RL0!-!^$Q/8286P+'4X@FZHKBGGLP
MT:,E[J7%&SZK@,.G#!&/2&'H-T:LC9G;&S/B.1@S8F]O4MQG+U7UWEE>=;,W
MJ2>R%_^U2K/FMTGAH5S ^HID^4G-CN)=6VSH)8P8M+GH<QGPQ6^Y$F\]23#_
MD(M@UL7G<>T/;#,II#+Y[EPJ^MJ ZLJ (FM$?&*(*)\#(DI P8DO9>W/6</1
M&H[Z"T?J.<"1VCMK'-"TWN9Q6QIG;U:7>"^M5D&[U-7@[>D<6ZUK:ZY^\OO3
M^N-OJF&8]"C)8P#MQH-) ?3MHSB9U%H3ZPSZZ!KZGAKT/8O\$V77NMA3!"2R
MUL6>&B#IYX!'>N^T@<K>6>L(T,3"7C,^.AK$PU7"U)ERM7/6UB)K5SN3N<'?
MMCXIWMJ172-95TBV5JV>&I*9YX!D9F]2:[79*X<M?H%A:??K.$6T7'9UI2DJ
MD\GERK09P-[.3Z[X6ZX?NS7I1F?;MEG#V9_EM"'!&12^/0W/6F->1YC'U]K;
MD\.\9V%.&KLW[: YT=G:"/.PZLC--],IM<#U^71*:[A:P]4:KJZ!JV=1Y<"X
MO2IWAP,5;=)<!'!FE4"UW;:J^W VF35$=051:RORR4'4LRAK8/Q<_DN.'K-U
MGEF.)0-"72E:G1E^.7)L,J_<Q"3/J_CO<5TVH9QTFFH[OWZNXS?X(L!;<S3M
M$;N&M^<!;^M4FJ<%4<\P3GZIJ33W7+4K>GX\>03HA;)RKPR:=0K-$X&&Y2H*
M3Q\;UL;/'6JZX>=@_!"\-^GT5M7-7CR.?IS;>NU5*94^UJV+>;4&T'1N+XMW
ML\D5V]/)M<[F-[.VD,5?*EC\?&2V/B7KS.A9%_U^<K#V/%H0D#DP\]7A41PV
M*_<]GR'8F[D9K<%J#59KL+H&K)Y%^4I"]V:5;/>J[T/0; [*(U#!]D#)&=ER
MI9@US2D^*;9G$\OY+6\F$RM^C<,(NEB.49I<;U6RLW2::5[,M1G-:^Q;8]\:
M^Z[!OJ=>*'.*;GN37M+5,(/+)*:IGB#&7BZ4T-B5QC5-@>[+_!S/H=IN.\?)
M8=O+::#GQ&8M/L!C0<T#0ER;I&ND6R/=M4CWU"MN'M7ET)='=K!G3T.\]U*,
MTZR;6'\K_0]:N3]$X?+I!.=CT-_#!">I-Y,)KK6U9X)AZUB"IX5#S_# <!U+
MT"\$Z(5&<I]8@O]9(\/30(9U*,':P'EP ^>I5^&,QP>E*Z=5!*XH+[#7^(,8
MQH/5GKY-YOBRN*+&0+$SF>#:R.G.R.&+XM@:NSK#KJ7)GT>/53U<I4<)$DO7
M<."G=8/8_MH?PCA[]H\>=X]UR*\;RF^%']BFR=2S'V':-4B[=CYP0YAK'C"=
MZK];;#G>1.QU&L1C-(GBRR(2,'1\.'P=RN9H8$\V\]5+-+8A@*#RW*8ZY.2#
M?XZ;49E.9M-LOXKB,+P^JIJVSN'FY*SF6WSMJN.\)OD]I[.$3Q8D2$)O6,8?
M[-H9Y=]%<G6]B^4Y0H;=F?Z;-_.@OB <RF'66Q H1?5HTXY'U>OS%V"A)Q]/
M]KZ5;3;!VV[:P7=[TKQ^\>J42J[$F+R%<V1Q:7N[W<6GPGAG.[;,E[X?W5[R
M7'2]*CN?W[WYL/6Q^+2]^Z[X\NXO6U_>?OCTE^+]]I>_P:_HX_;V7_/?.[M;
MN^]^>_=I=^<"<BW"]3?-=DEF6M=+M7M0-L76<#@&^^%+/*KJ4:[=\[ZJ<\@X
M^NO+HJK/7WY9Y"_;<MCD%@#?+:BO@ZKZ/1^QG-5?FR1PEL-OU>!;+.JR^7UR
M]C(>3H_)<UG_C>)OL3BTOX/Q,_8'/[K;T;ANQA;LFE$%=X;Q-L7BP-; Y<51
M77TK<V7;ME1MOOJY+K_E".JS!@+%1_BQWYI<\!8Y6;[8\J,\GA@CVIFU:?U%
MBH :\*K-V5<']CO,=&LPF)_09#2\Y/#<IZF U1Q5==:*BF0]?#9=K!ARX:31
MI<5^"1_[P3A<>.'3M-VB&L.LQJ.<,UN?5>2M3BORMI,_M5&+&2B^+-RX@<<V
M39$;-(SB_LG+(L1O<5 =M18B"--\PI]_Y,D!D7F [7;BS0CF,STL._UP5,/M
MX0N7YW)I2#S.Z;IPTUPHU-:PM?E.\P_W59,M5WC+,4!W59_,37)4'I;3DE&#
M\O<X* ^J*N3G )%X>)^7A6V*[Q'V WZV;S'9/_?/K#!\F[20.*O/W/:IF$[Z
M;-7@)O#W]12W47R G:T.8^%S5XJ7Q4DUAE^'19D-(% J?D2M[J0 <#QL)F0-
ML\QEF"D&1#AYV?Y*7L\^^EX.!A<_:PZJ\2!<_'2RJ!<_S>]_\3/@DS*??H[B
MQ2O^JAN7&0DN?0I2?3]>?EQ=_?.*6430LPZO>)Z#W8-=7W0XT&#._[[T<96A
M"DAK]CELZ.D+Y;/=<9R[D@%@&/=;A6 *"$V<[@=<GC!N S0VL'6F5*#1"7A,
MU@&H%C#F=)?G=M6Z:CQJ;S^AIHT,DM>1P U</V7Z^++(5=WR?0<PHY&=<.[%
MAV[.I%,?Y$5QO9*?HS_1   0Q4EIRW8:P',OKO(KL W&V'^>U^LORM<K-?A6
MXWS=2E*4']EL.N#1K'->DKEG+S%]6F^$,-O@7!EB"!<$2V;4?\Y[@GZ/\0BF
M.3A=G:E.W2[2#Q8EZX/ "?)4(9Q3KB?/)1C_YX6[]D43R:PU ?^76:CO9\YL
MH7U>[HWK1475V? JC$'8 WJ',@!G-3?*W+.9Y)O 70%]3NOBY_2+06S_S$)I
M.H&,/)/'3F8\B::#J1[9>B+A8'M_?]G>&CBB!)$60,. )\ "@Y3(G\^]9SN#
MR?VRB"A<]%D8V6\6<,L-XD3DP=M=*V+;%;2'S9EM<-Z>6_/MFF^[YMM3EILJ
ME:#_9UD_4;R!,8=P]U"/]UNCXL.GMR#JQNZPG C@E_.,!C>:W>0B6V="/WO<
MJ:YY.FS&15GO^_AWBK%LOY)_I1@>D@J@[0$,!39Z><I'4_5_HB=>AHS7Q9J-
MUFST4&R421>$7"R/)BDGP A5MIQ;8 >B!Y*T1:JKP]O(P[4@6%/P0PH".SR9
M@_?\22IAMOO-E+Q/37^@L+KZ!G3:?FD"Q];!V-%)ML4JUZ8LY"N'V7&4_[CB
MV_. _W**]E/F.9FB^Q6PON:)-4\LG2?*0WA0"]Q'8P>:1W$0[6!T4/BZ;*98
M/2%0&[[%NHG%_J!RP ^@\P^K0QCO9XVYVKKJK;IRWO_76A4S-TD!*U&/CUH]
MJO4^Q(O#3UV#K:51P@Z!E0+<!J\VSEY+T(%RB8JV,'.>^:F14=7[=EC^>^9#
M X9[\V4[_S+QJDP"ZR<>V=#>8F(P#<!FJ5HSJ&D='F#S@.SZ?^R]>W/;5K(O
M^E50<R9GVW5)C9YVG-2^58H<3SR3.#Z6D\R]_^P""9!$# (,'I*93W_ZU]WK
M 1"D'I8<R$+5GAV+)!;6HU>_^]>7,2\,-]),:%"SA@MYSQ>R)5VLIV]%1,UN
M "907!J:?\PMB2O:+9@8D_56AP)?PCR(LX*(W8V%ZS<H7P-=?R9!,W'UZ]-%
M"-8=DXBIDBE1*$)F:,@= VTHG*Z-W* )Q37]!%_$TVJ'VVR@X8&&[Y^&#6^^
MH;.7F&\4+TDKX3BB4CO_TA+\#G^P4\$D?GIAG;$#T0]$?_\*B7@Q54-OQB'P
M.A,14+V"B'15IT8)I\/_$%=!.)W&JPIP<4+-*\09ZPQ7"89QX\X0OV_>L8X(
MR4PM:])[\/PT7R[C@D5+7<;#K1ANQ?W?"F>.XC),PY7(!B,"7,J("^?QC2$2
M-U)$ W:&="^2EGAIOF(95XL\DM&Y$5%9#FK/0.N?@]8+.D=FWMS\("F( %LN
M&1 H/F-<*E)W. Z]%G.UI'--H.9DE?&-LBCA+TF3@73!,\W1/-X_4/E Y7^Q
MGC/-5[&)&UC5(R&-9"HAX0[W/NLU6[W[ TD/)/U9?8F:H#JK4^++3NM@!?YJ
M-7L@UX%</RNYIO%%7(3SV*3L5)P7[_O$O9RR':DQ ]T.='O_FH/FC%O_-%2)
MC%/S\VR>0XM(\Y+_MA4*%W%6QR,8CDG%B6%_U$EA$JLUT2"+U<&1=R8=1!)W
M135'G;&N,D'Y2,S!2]H946CPQ#S.8G8]0B/1=TN.CKDR99@.MV6X+9^9R]/%
M"2=$30C>NP0:%Y.7K(+">%.2:5!L@(."I&VBI029.%]:DIRA?<=5/E#V0-E_
M2>@>=633HDXJ3;UG O\0KY%G7^99%J<#:0ZD^1E=>/6*,Z^J.$V)9:+JBU0
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M8FE0Z]A=DY;Q)0*IVVCMNYB(_.J=33(,DE7IVE_6%@#.D4 <TEJ%A*8 &JG
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MO(%F0<3CD?0D2!+^#F_?X)$Y/1/"G2I4@>(?A)K51?\]MDJ[(X_.04V1A7N
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MDD:<S8-,7I1,S 74<VO_"ZF# @@LW3=ZQL#D&D\\/=.,R2$?)?R8+*$P-KL
MYW<$!?;9;F*/0T&?)7YGC.DA?O?9F=PGH.U9Y71])P<XX.Q]UEXN]PIABR?B
M(F"SQN+FA5,,*'F>+83>4:-092ODK5@ZV^!N1[?'NXV++8BW'!]N[8Q%K@:V
M=R:N=+'#4LGFTIW"0!NIF!(J@TGFU;ZBLT98H.T1+#>%@&]7QC;*?J3?I&D
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M36$ [OCXL]Q\#&LF3(<:RP>A2W/#X7"Z'I3JGBO5)B-#<MQP([ODHKNRXBA
M RCQ!:V=WAVDL>W/U' LM/LY&-^"=2W$T89'H<-U,&I *D9.J>((FDL%9*M
M)+;&)YRVU6\Z[)T@,:VI34 2^I6%,%-A<LD8[SZ@6I6W.W_@(<9U&P/L9)$O
M\S_7<R"L#>=QL\P$V Y/2-N$ZY:38UW T2?\IRH\XVG!"!ZH1+N,4[KG.(22
MFP&96^O<^9Q.AL"B.ZKA?&YT/@OBH(6A;7-8W!]<#^N*0^+=WW5&K&0-]L7-
M#\:Q'+$*634=!0>'>DQE\C%8AJDF5>*O6<Q_/[59-_,BKU?"[DP!*1^@S55N
M@SL&3^X98?!D;__PY(M&P!L%]PPA>,=;>-3'+<R+X&$18B]W40QCM&G37K(-
M%2?DK.MQFL]=&'82D]"-E7N ,3SE]BBH!K=^HCG-&\W7)G&:7XZ8H> ;3UB/
M6F]Z(9UPF6VQ)JZ8CT"+7R 9B#G8R=?;?O6P2*&'/$EXO#-[R$**]H*S/ -
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MK.0&\:M;(BE-$8[O;F#.4P* 3P8KI0R4Y]K ^#L]_74LSM&&QF7<!$;L:,X
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ML_;8Y7 ^-SL?Y!U.6GWL8)%/%[+AR.-K*W8VGT]EW,,QT.\=Z>3GNC))?F?
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MM)OS(E\V+M!<PH,"]NI6N+>E]/D,2\%:XOY;<5WD4:R@-% <U0M=DD8XY=8
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MN\V$J^WSM_PRR<H\O2#US:8UB9DA)=?N;V&/XM\N.Y*S3+9B(UR/;*WRSJK
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M#@BOVT GL]M+< > +IAG].+FC%P\C]Y$+')YFX#>]NC6;D9Z#6QD'D!*2H>
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M&1]L04#8,85A?HUT"^W6@6/T@(K"=(+)"$?S^BCCT-.JE);%F*$5 DVS^\*
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M1W6*VX2/PK%AS C:\6"LN6CN3AC4%4I.\/NW<E>_(.Z0&;%NI@K"<MM8H[$
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MG6R@7\6<A$[&BJT^W 7R_&J)ET+2F %R7<)URY^<61FC7KY(I6_ (U\B$VH
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ML-L[[[>1("3X.B_TS2P"@ADHV8O<<D4_PZ_C6Y:?Z8TQ_IF-3_B%T.%>TJI
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M8F1,B;C&-05Z=,BV1^/O#OG9\>8O(2!/#G[LV<T1,I^)ZI<E=/_6,EM-3=X
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M-CB@S&30")3X_7_59;2].;,OLIC T44Q-D5<<'@'0CV5KPDP'$F8!H?<>DB
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M5P\B?FYDPH_6443.!(M1&+>:466:(N_,2Y0GF7N%3,<MVQ,@1MZ<QQAO68)
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M*V.#O,OLY*2D%;1*(@<*=(63R9(U[]-5U^;LSF[)+G9O^&!!/5&-%^@VTR!
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M[UD\7CH^N.#LZ\TI J]081YAJJV -K+6.I8CX!)*9VSWVV+=,\9*R-29([:
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M:[3\+TW\>D.WYPRR0%[N.L[KAJ:E:)<]O>SICP#35(8#*# Q<7JJ,CPJE'B
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MD(!]5PJ!V:0A*6E[G4=YGZC#F9/;F&,;1F792M6Z6[&H72=$:R5G8*)]8N\
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MB8JA#DA_:5 (  >&.@6L1=XQ,DC03M!%JX^G8.^_(3C-3PU+YA01N,?]EK?
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M3<<F:M?X?70B,WZR6_=E'>Q%IL>,IINF].JA+>5VMLDQN<5LQZ]C(TDZLK/
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MAT9*AO7Z _VCW["]^!#7\&[^-8>-GCX)T>.4'V"Z(GX;D_@/^M<_^B0:Y[-
M1H+YK,?GMC4\PH\43\V3-=S"NNF[(KM^V%KGQ)1HZ20'%W^<<S-,93,2\I 6
MS'D#V(B<2UNBO)!DV]A\(76R10JP:[(TI6@^G0G;PBMM]\5VB:$>C-MA1-/"
M-,)<>LD:8)DJIS_#89:LZ)#JB<Q&FB*ZD\E)6^2/G #J64U+U1CNNN%.,,O>
MH<487:&G)5FD)Q1:).SO*SE?-KFAVV+?_^>31X^^RO#_)X\D=\H@^E,D 5"_
MX0FM(!Y-$=-RM-Z/1_].2Q*W+-W0Z7ZJ'#-:@[_STMX)_<G<XD.>U^W":.V#
M](?F5<T$>[<S'!%)?_]P.%22;H:Y[\LN,+>OAY(E/3R*6%FT0\"=K/MFZ#7#
M,/5.E6WLIIB7Z@%:.>%U]-F-D-,PUF$-ZQT_IG)L)W#G,!M1)\BEO\V93;['
M&U9F%1];6([OUP[\,37S82DER^@DTVC0.N U)61ZH._FE4%+YECDG$SVU')7
M17Y=5E *<J@T)OJ^TUXU_;2?*=PVU58X25!K'5FG#A.+Z=QBCX$=:H/*63,B
MU+O.V[*A^'GAU%OP);]2?(EX6#A2$_Y^2 G*#IV)OGPG9=^\*S?BIX:_KLLF
M2:WYH(W%B?<(APHNF.<;;+$M"V39QT"XR1^"O2KD@%.%^$R!6W_Z_M5=T(5+
MF\.#:'-XO+0Y+&T.RP'T&SR &-TK!4.5HVS'.1(&N" .D3.!BS9 #.V;;:'4
MEW2+28*0F^HDCR>H!X6HJV#1;-*C#=KCXN>N]V77Z2F8IUE%ZYK^=K6 ?)<]
M\&%[H$ YGCN-7_[E>=*2'T6O7SR_T!C]D$MICS,)] K3STM&H*J:FZ JEJ0:
M3\E=M!.%D(58=EGXGWKA![F"3:!3B:GS2)P9D^A>W@8<AD&![(XEHL5<+ZOV
MPU=M")2+NFVJ*I#&IG'SI#H98V8)83=_>G:G&'99D,N"O-5_L.9??]0S"/XT
M8YM574[ G,X$F^FT)MOH"KCZ0GH#Y5)6&I7;.;+@J!C!RDSF>-D6R[;XP&V!
MU7607BTK)(]Q(>IAQ_1BLA:'_JH1N.VR')?E^('+L<J'6BKG<WQ448P\053<
M7!5P@?.*+LUA&O3P/!)>N.?Y0\LB71;IARY2%4/47GH.L=9%7=!G))J"A%MR
MIB=N[9X6:[,5S3,N\P" ;1*90"$P+#BN[O61>0A9KJZ3%D@3L>0=,M2E=@!Z
ME^20'U&)90^#OE&V$?M0UEO+@RP[8=D)'R$Q37> ]N)&P$" 2$AKDS736$MV
M!(EJD^RMWN^R/)?E^9'K)AGW.2OI)8#6?7Y9J/ 8<QGO"C6F6G2715RA)0ZI
M9]'$*UWPIG66$2EF'G7UK#=K6>#+ O_4_)BRQHI3Z01N"4W\:J:M7U;AL@H_
MU!_N&2WL5,&X9;<V_UA(M,EU;?-MP<D%<5?Y)V[5;:7#K%?Q<E%_#-F%XAVY
MS1U3TQ]OJ;+%,HAVH<GEU/)J<YL*Z,T3=',]>]=49;-LAV4[?.!V&*U_U#O0
M6&O,,$Z<R4F(66LVRX@LOL&R##^M5?;I NCKDB<L#4=;6I0"E"_W:V[9Q27>
M8WPM0\'S]?CK;X$1IQ&B 8L=DQPM'V?-[NS0;+@96#N]\G5GG(18_W<8RD(:
MN&R/CV^E<S"]E?7 H:'D][C0(3$A.2]-1>M2/>TD0J0-L2NK2<:/-@P#C'P9
MY?P4K.(WU)43VX=!81=! F,V.<WD,XE>9';1%I.9OL>$<\RXPFYO2D8 3Y>Z
MI1<T[7Z>LWU>X5FC?]QZU,^<-#U;$[5VK)T6T(A9AJGJ<W+C6<XV6\\CIJNE
M/^W!])3_;9)(JNEXK-#+IJFHF:7AVM?><IM(G_)G*FNF$">!\HJS7W*(-WSC
M_\_>^_>X;23KPE]%N'@/D 4X<VUG3_9'@ M,G&0W]ZY/#-M[<OZEI-:(L41J
M27'&RJ=_ZW=7DTW-.':R,S:!@[.Q1B*;S>KJZJJGGH<R [&G;&QZ#@T\=^D_
M&L^+_9 "7]6WRSU\W?F61=X<V?#8YD)_1+8@=%+E:DO,8&@7Q0)"-SBEP]C2
MWML>>2Y_"6*V;5EWR!%#C;K+X$I=6394=-/?]7A,IV['-O@?,B\.?-=DFD?0
MW)Z(BJZN_KO=/GURN;C:';?$EN'6$*9SXT49%TF#V?8PQ7FP+S8(?_E$^T";
M&MO#,J.!^UXLB1,UMV:[W"0L3PIE?M">>NX>>VS=8\_F[K%/J'OL,]JY?B(:
M3HENA?:8=Q:,;,6UGW&S2;R.O>MYRI=,NP<WBM2G,^Q+O+E1B^^VZB*QY$W
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M4)JCW)U^"8/%FH>02S7?\PVS:1[:BF59<ES#D5/8<06/2%4]BIC*P93:AS]
M2$Z3:13%$LVSE#U,37]HZA$&PY\@_)-0*T>2?BDF7Y]S-$D^NL3L-WD?2^B0
MD(YF?",Q;'2AM,?LPG75[2+,!0?%O+.Q%CXX[[RG?SY-]$)(9@J_)@:5E,1W
M6#DH^?!N0NM#!^YG9J4J/JI+C QYUSP8W@XB#H1]3R"Y8@0/%'&R*:=423&I
MF0 ]2!DB*X023=]EULW76(D&M_ Z]:A4P?"FH4PX-X%W-H.9#'^E2UJ/EWXG
M?M"'K\\H^!M5+2D9JKK6$CA080+_?-TV_0'Q[QW$$4OL^%HVLE5J%MB=NL$H
M*-3:][MK-'VT!<3!')&GZ9B]L6S;Q4!3'O8F5*B;$OF:CDXI0]N2D\4UXYV=
MX'U(]L=*6[1UNF'I,<E@>:&%&Q]5 Y@3O RS(_1-(DV478@<=]G&/:4XI,-*
M!0$[,"&] X6GT66:I#7YHRN.'IPFYMA=<*:;-Z=)G&8QI72&>S3Z+9<D\NL_
M8S52Y4H2.K&0X+-+W.:U*:L=1:0-R5^>T?E=<.QCE<IA%\9DQ&_[M)L+BBF[
M@:"<4H^R.U.'7:K9TN,.0T]-/?KX$>X9Z19NY3APPV$GGJ%0$9UQ8RDDDAKN
MV)#7;!ZXC*J!TQV.@/;75GQS- _M6[F?6J1$Q[A<I#K,^U8=KFD3@ _SF-%)
M@/!P;;R/:.MXUYZA98\16O;R?HSJ= "R,UE!;_Z"7 ]<F"36$]Q*1Y(%-:&8
MN7E=_/8-@C5Q%44X6=,?P0B#"X/$PT#DTO2$ W"G6:?(ZY"5]UY%,X[KT41$
M5[O=.0'2-@QS8XA/*5N"8^5$1NWPB4=BN#!N:[T<F.&]<@HCJX*6\YLI)_;9
M<<9;IS\:G9L&A)L)0RSO_(4'EUF*@\_- MGT6Z$[<,&!HN[!T^,W&)'$J]*E
MIK+=B[QLM6T!UV-;<9V_M2H2?,]7O2;%'K]A7=2S8,U..3^'_+D:0$Q.-?L-
M+/RMPYZZ5KCNR.+BO%&?+.EE*K \@_Z]X^/H^QF^>NO:F3!)6%1;2M9IJDXD
M7[A-@DPV4,L"K,%PU,0#G5N1R@1=:$DY+<Z]GKF3,P3WFB%<4?B'"QD54I).
M#">%3G(UT>C V,+&3Z0F^@<$DBAY!&6E5B?_6$>B:4V?"]XYZ0B/DY2C]X05
M9V-+@15Z@;GPOKL08EICJ:@8BV492NEI@1$=; YJ!KLDWX-1SE')PWCTY\.%
M5G4^M, XE_*]>USNU*"<1+'DD3IO_Q9+'$_4!B(P].N^;"%H"*XM9KB<]4 E
ML*! >K#=:AO6_8X2Y%I2@76E"4#I)L*Q#+X>X]_84BZY8X*:-&V2\M16CXW(
MIM.3L7(Z>("><H9T*$F91ES?W3KS4)9N%$E[XO[$'\D0\&SSO6Q].-6L#2SS
M0\#Z-6]/F9ROG&<$/EN)!$5]W:B[G)"7*MO@QVQSZ9L&AJV1[$\T&RR]ATZV
M+2F(L)>MG8IPQFM&,FGV4C 42]2[1&^DT<G+QPG14VZ#<Q0%H\)1S&J/NA]G
MQ_0P'CU)'@<Q<7K9SH[S"]%;\L#O.'"ZBKE-U ;)R"VWY2HEG52AU@W'DE04
ML;+O$*P3Y><9;'5N/41J)T(2P?_%, 2>[]CV'+L,5S1FYZ@F)@M(%7QI::+N
M;V9CYC:'M,NAH91ZTW$FG]-9-,[C;4,4FY+Z*6)TP+VBNQV]..QK#6M+,DJ@
MW?(,N)G/*.I-%6BI.P,L(DEOA7<8BF*K'Q9,);=2*>N%N$O'K,Q=BQ8%O8![
M8M!=Q!<:*;J(MXE]CV6.,.2N0])<H5FW=8 #-0;E-B-+](.3Q:"3OT$N2V7-
MZ*-^#MK'<!;IJ'&,]JQ/(05AMSQHKX+7W7%/Y$DKSO=; 1OGAZ?5.*=RD!1$
MK)-4K8G*14ZA6%IC8FU^ ]CKYLS/)1VCQ;N1Q;*LAS3\!CF'&=\VX]M2?-L?
M9WS;C&][C.&5-.B/>_/Q3"]]&9IV83<\<5Q"-TMUN0DNUTA-B* @ZTG)4%[H
M ?":]ENAD]-L">TNG,O&  ]\7=M7 D(?$&K(;W&'6X:IXZ$Q//+Y2=M1/6F
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MIEN-BPQ, 6Q#*(;A@B4"XA>;  L!+#:BE%WBD('GG7H!#A/DY0LE"?[I85N
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MD*!5.^%F!BSKMLUMC:-B8\.L'R>C.U?7W9;(.AU:E"59R5B4U]SROR?I+HB
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MU4Q]-,*][+DWWW%+$1<=&Z[&;S %/X3\338V4-BQ!Y.]284 Q:;I.IQH'#Q
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M0?Z^FB%_,^3O,7K^GT+:J);-F QP'F<8#J::D0:1+1^;TYM@R(PQ!#QSS_U
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M<ZHBR5PDC"U,'CSY5:%)WIZZ6&&WKSH$-FX@A@/1?97.VLV:40TW50LA3^1
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M(C[V?X4>#@O@ZH*_GWSAROP01N:W(X-]V:+TS@OTU40L:U=]T\/U,G>DTTC
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M*VR6HRX[^P/84JB-DQ)C+8KR<$_BA60WXY6I)&&<[RO7S2$=?Y%P7,KU5MG
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MEJU1'XIW&ZVU/7J1\4KC^3,W4K:2"Z.(F1[W8GFZH/] ;D%48_D18GOZP%)
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M-=0.C76I?WZ#^$;3=(=V7VV&/9QK29\QC"O\8%"&F;L4JJ)&M":1C3$8MDH
MD-FN\V-?GW7Z*!HI8G]+3 )/[#Y? ]2QN:JR# 'L@<JLLS_/,2 HL-Q:4&#Y
M1G M+T@OK(9))3O-0QO6_>)S1$++N2=P(>S%,6?P^HR;5H2Z8'9@42/V>VY6
MCCAY(OZ&@>J2M.1>@4W7]GT4SDM;M5U!M0BGV5V%LP=1E![.ZIQ%7B'1GC>,
MVF5]DZO5OTQQ/EUGTF.C:.9\N93QX>FH\*<!+SZ@@)CD6O>0-3EY<IX(H<7V
MMU!NZJ0*=^(RF/;ZW%O>,W=UA(&X#]Q$1XZ3+S:,1#R[8PSHB+/"?\$9QQ:@
MW-ZRPYE:FFUXG+)I)>2F!OA8=0]Q;L,H4&T]9Q\O>N.*"Q+4Y'<4ZX?_.91I
M,$H5W-3)9]S$H@S<AJ%K%%QTH@[[X'N?N0^"/M]K_&]RY+0I$L(,_2!W?TE?
MQMGD4[.083JKX@1Z; L]M)\-QE.6LX/(8L?GU]>+.MP5H;&"CZ9M'QH>K%&8
MFBAD8#_UEA3IRT/&.6:H2IBY3SPYV9ZE7!6B3(_C1J+\$_Q4[/@PV1><*Z+U
M/D]0;]&!F='U-=JEHZKQ;+Z@1Y^QJJ:'RP RN5+QI%[3*V^K259UF*_P%6VX
M@>,:7).NJ<Z&U-A5Y*M;UX'Q@L)E)<.E8]=((K*IO**#D8M*65U0. &D(7#H
M[[%6>5NGLU7S1JK(!'&[0]K%L_K4431J;)'6\K?R/F;0D.3!=L3*UE?!'"AD
MT=</$XB@<J4HB'"NO6@Z5O\%D*&\QA/J%I<(^7EQH]GR)HN2&F\^;6A9B!"U
MT2YI[YNX 7;.9,P7[EW<PU?G]BFSW,2-O]J!4R?!>+PM"=XDW]TD-]Y"@O<4
MPZ/O8!-Z=C"0IV/"&'%M=56"P23?7CG(2E29R1:W(P34%"9.DR'00[]U!7_J
MH"_B1G-VHA"N41O'G7!*WFJK6.SG%JM/G"PG;N6_6KU.=GC*V^9\@7[H):5>
M2=^X!(;$SSMF#4.&D+<(<[8':])(DMZI6"C@P#U/^.PU\@;([851;2@O]:]'
M6HOQ""=>EUIT3IE 'UC2)MPD[Q0SM?&,Y_Y0G\8N@$0M2 \]#Z+J!<+PW" ,
M?UH@# N$X3?:D/$]AR2"FJ:83.M3J8P0=<.YI, F]?NU=]CX2SA%&(X/!AKB
M2-]65%[BT*4!$0J=@!P#D6H3!T%((5+0QVYMM7U$[+!T=3P;A_![!2W20JEO
MZVV(KZB7O>5D!H6Y-3?1RQJC,%M\BQ3(V^(7&937.+]3-2V)] J#?""BNNMJ
M\MR<"FLA2<?]7IVXZ97.X?_VMD;[*25Z--GK_=!L#;]IVKL7-^U=!/7*WJN[
MX&9V;Z2]U>=:YW>B%.]^ZD8,\1-%7B?8@C1$>YN-F<V1Y4&H)F"_GY4BLMX(
M[6V<>=P'7DZ"RP8 96@Q<,]'Q5ARIW!FV>>OG(\]R=Y%L8KK#B8  X],FS,9
M]W,]E("PP/>7/%4:[/COLNUUI=I<G,9'XN%Y]+G&5"LAI-H.E0VU9POMVM 1
M7!0<O_3RRAPCE<4$!2=])#O?5<?A%-U_GNL=KY^KU1<)GVNS^B;\GK!%+S\L
M5A]^\.%'13 *&ZHD,,HZ<GRXEBID?N_:[-52%HAFB#$0AY:"1'W/W,LZ08<U
MNSIQ#W]N,+,KPBR*?02IW4O$H]8H4II2?]9=LV_+;;X)Y '9VA!5V68X6.?#
M."#5=$<OO*QAFO<5=_+(E<):"5/W,@%XL]P2<M_NJ4ASD'/N6K6[[DH"^P%
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M'^UJ]3EX*[@EE5EF/<F.TB3L@4BAX 1=RT+52G+I_:0[1>G,-]6X\:A 7S@
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MAW 28?N) HV>#5]\]JJ8 43JK9V-J[F/@3%+6SX%^(_X$U +MLRN5J\ESYL
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MW]S679OF(@#TLRJJKS>ONG8]"!PV#)4X45!-%]6?K(?O0!6U$!/D^L/TM\C
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M#XQH7-2NPR[;N&(]1U2KLJ0AV+D@VEZB.NY%_R7&V"HIMYXI(RT)V<LU*Z"
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M2^))9>E8&VDY@$F0N%3KY>(-2L+"ANP?#9YUH0@-Q%I,));W#LZ&(XO!J#2
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M'W:=R/MHD=:/ZX*_@OAZWL,V6K7(%[8S=RXXP0"A#+W)+356!:\*6SX\KB[
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MJ9M0D,=&JKLII"ULN*^#HD6[;3NW-G)I*.5+MBBD21]?2YT DA- ,@9(/IH
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M,3@$RG)Q-DOPB2PH'5\6>0_! [*9]-VD)3=9W&>R.+">8FV((1)L*.*?.!;
M^,'' W\3=8\K$[C\D-T2KN#)WZY^X%&?#PY^4HV"1[\YWR+QQ[0 I@7P"18
M6SM&LYG(Q,N2T$HCS:!UKH%+P7$DI,I*$X>M:9Y^)@:J-8Z.X\JX@==+G&E2
M QTW]\FX)^/^0XT[HY:NQT>0KR;B/BPS_*L'AX^82@I^JW?GGNTP]YQ V)/Y
M_H[!B:(A>68Y#.CH:!E"([.B0<*.1==84HHO%SQ-)&547VKQ^=[ZWAGM;N@9
MF%9-4UW$U<F&EU'R03*"A=8ZE<=2GOS3MTQ2C_.[1\EW3%.)P+(T>26*'J>G
MOG05A(0OL=A+AR**1^EMQMX("UA:(698/7H?+1%C!QX+N\1Q,SBRU+>.:%2+
M("6XC\.;6LE!B!1%#BT'I#YM='YZ$IV ;N@T9)!(+E,34A^O&+XF@8/PKCGY
M%/:*UWW9%9LR/F[@>D64;-9I0%RUX"!%A((E)5!HI2^I-#??&M <7W%,[DK?
MSU7Z\3>&XIYG=+<>^4&E^G?4Y^FM(DU<>>-Q'8@?12+*>/$/=[&=Q"1^Z4I)
M%*4L]MWZV"T7M!^]T54M'$%\=7ZAM 3(7&9"Z4>A7HI#>V:VPT-!X)R$Y<,P
MDD#@C75@U!<0A+D0\1+H$=&9\(S!8="+$>S*\'F%*R($(UTU^L.,.'<1M4HK
M&JD#&:YZ4US7C<R0T/.,8U7F?*4%KFO:HWSWG=E3;7ZH00E'(@,?"106JSF'
M<4;A&FS;>L'DC]0B"89"]RVF@(@'>I"CRZJA:1$TOZK& _8-D5MX2S:WI78J
MSX.\6L9&PZ^# +2[ISIH=,$7M;?QV,Y>NXT1MX5GYV5K6]:-@?L.UZW?SE(_
M'O3.\W"O,/(0@24S= I'?,.@4\A13D?0X]8T%#^P@Y@&32_?2+1(9$1APE<1
MW[G#K6J:HV.]2?I;?&2:F-*U<XN+$'%'")YV!7]RW]-34-6'[U8\;E-4AM<#
M"5<K[]Y* J4C\W( ^>.M,]6I;G:_T2,1GHI?QQZ/E%* XFGSN:7<(GJ5O//$
MBGI_01,OPMKWF$ V3(?<Z@TBOB$)Z<,8\Z"Y"O\1@Q &<[!1V"!EN 9LIH\6
MZUPYO\E/(.!@![<P(#=7_G@-5)&P8[WI*)0<?IFAA!"$<96K<>OZ1C!U$I@'
MYM\)BW!OML<1(WV7._7<IU25'.P1R"59XBP"-4C%I!(<7, -TMBNV78D-62]
M"*9\B:DL.0ZWAH@GU50F;'UVB(!&T!3 X.=^")E-1!QTZMN"IEX5GPT7O"XD
M]V!,*BQ1YXGIS49NF/!Y/^\\CRAORV$TB<XVYZDQ20$WF><2%S@N@9'H9.,L
MK12O8G+GX!K;5O>5.Q"P1M-,.M=,KX^82. [?N?&D@D<?8//50,)V#/K@D?4
M:!#5K>>$.EH*U;(N]Z1SV5HCH$'$LVQZ(F9PD5%@+><3^1K\/KA'O$B4>X@=
MW++>?^#![>P^DJ/D<D0997B7?YG0)5-)\[?Y7@Q@A5N:30;<+B:8NXN3,EMR
M+L0C#=X*A[7"4*?Y9*=DOCI:B//JQ"I1T* 9#UY&)0KGB%)KJM%/!OV1-7H:
M#V2.J6Y5-W#X/*EZ]+.[ELJ9&>__.<\'HKH.C1;B?W5?P)U1W;=DLKLK9#+>
MR7@_TGA#+"?J3CYPC"((K!M*0!)LF>?.)\N<+//SQ@D1S\4@N,68=%.W1.R
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M+G9^$5_Y(175*!$%ZR407D4SA'Y$UGH@N)E5!==XO97JX;+)V WC5Z0<*SX
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M\X/.>%Z$!SJE9@<:7'R'Y1NB(\?Z"_PW5;WGN5L@&W)1D0 /801&-%E$3%.
M;D1MG#7(F]PW3&QL9SR.DN=5\GS1U1@,GIRF&!">I7#-"PR<D:(=-6]0409B
M$:]/=?3J" )22 R*19=<P?$Z#^BE_!!N,_P=SJA)CQ>,^<&]=34'.K<U52"=
MI0<AH4DN.:]KK(DS PGRF;1$M!P4B;7K:)C<HL:>\,SDU*UJ7,=\!JQ^@G/
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M:T<0;&Q<()\Y$1HOY_J>;MO7<L^<^>0H  4)8Q#@8)',^?5O9E9AHZC%%!=
M+,=,2R*Q5&5E/KE45J9H8R0#P:!+>,XYA:##LI 5:E88.;[2 DGWNK"LSY;8
MB;HE9>W(,J6;4=%ZBM%C?X FV28L$YFU@X\7K](XRY(JB3HOEZ*8&98*:PZQ
M43OA*)&->#D(<WI3W,X>N[5C=]Z\I:I7V#HL+TH7IM3C6?(6G?U:U6E"&!:N
M<N<P< >3DN'1.ZH24:80WASP)3ZO7-+9O];6G R0CJH\N$W%XC96BJO(WNY:
MW11&*^D;L8\H'E(7W  <I>JZ^>TP[5W3P"W4@(-_ W3BU\!%*I[;4U3\(DXO
M7;!8Z!SLF%KKR<8E>ZW]*7:T95J#LHMZ"NY?R0(B?"?? ^S_LKVD>;70>;VV
M]9X_M36OB[UN:"E/1V-D.N5:U<@Y%HT$?T/D,=2G>"_>O<%+A)UFFF2G.?NW
M2BAZ/!01O#\84IT EI$3A.#S$*@<D?ZI[UTCJ=@.[D:6D0@B=-S=,T!FQLOU
MF*W24EXB!FH:QMCXM;J>2F,N<WZ68Y<>>']%]8PH1/>]P-?#^^NP-M:'$GW]
MSJK[Y45P55!'=NEUP!IS^]=VO%E2202<?[OC-G.+6R9C=SX]R*NLL>ML,\(M
M;@'R'6A2![IE,K:GSVQ"^V&[__BMR-8E3^[JN !4'O._@\T+UK,N82^D?YMA
M[P;$7>PLG8G])?Q@@]!V]Y4,,TK6#QT).+ZULXB[3/*C3.X\T=T;$'N#;G!W
MO-FR([7P.*RG7F:=?:4B: @++\=O_O+">K$+(M>[==6&[I)ZA46!5LWO1)?A
M*YWZ^EB'<BY$S.4EN+9_)E&1OZH5Z]UKM=_U$?)IV/U=H;O79-L=UAU3=R/E
M-E-JBJ0_PK;U+BBE,.,PF'&.]1\OL0@LE8)E0)$EH =!1XT<KQ1<*+A0<*'@
MXF=,#(R;?)8]?S_39FV\PN8<8*]CIYW/,4NH'\9G>?! 88S"&(4Q"F/^\P_V
M(UJ4BPIE$%O.FVUO[2W&VS+M;RPN^:O-&$0I(W^PE?8/7FA_Y2U,^K/.2%'X
M<W3\^>GPC@^$"OVG1'(>4U-F)T"WJR5Y2HS_<0E>U=E-L8N!>[_51[;\; O)
M: \J20=)Y0-HV#UPXT9IWB/EZ.5[95!=L=]PV._P=#J6=:Q83"&<0KC38S^%
M< ,BW3!93"&<8C^%< KAGB^+*813[+=]&+#*\E)AP-WQ;WT LQ4'; YE&BH0
MJ"#VV! [MZ>* 8_(@'!YCXFD;,BA\]?) YPSGL\4!PZ' Q7(#8ATPV2QYP=R
MRE$>$/LIA!L0Z8;)8@KA%/NIC, ^A0+?<O]6*+#^[$@Y@5LF2P]3"O;*L4]/
M.U<PO6L6OC\'7#%Q7V%WB,:J0E*%I I)%1,K)%5(VA<F5$BJD'3P3-P3.BDD
M/64F5$BJD+27@5J5L[E['J=B+$?E<VML(:,':8F%6158'XB6SP^N#Y_;>2_Q
MGR-D]R(#=+_U?W;*DH*2+\UMBM^=",)VZ?UXTOZBH/:(6:8C8W;<[5L%ML_"
MEAU^I*'7X-I[-E28VI-H@\)3A:<*3P?/A@I/%9X>.GX+/[%)TMY;P#^YF9B[
ML\94X-%C=\:,+^NJL$USTELM3ZF4++5>;341B[!KE6AC2+5D.<O@4_Z#9WXD
M&LKQQ3).5YS+IZ1+T;$Q2K U8<*I&V'33ZQ]IVB 6(U-(UX3;_)YGK.JTV+.
MLVNLV ^_^L#EV%12WER]^CAM4ILF]M-OV#XSN^;!ENM^F%[UT['VI==M_R01
MUQ8SB*XU/V9YCEAXR?5N\S.@.%X@I_)O/4H"_N-,MU^',?^ABXZ6P$C8NZQ<
M)*^#*%_&;'6&W]Z"Q_$$4 X')_=WQ ?_+/,B"E?5..E6G2?!ZV6:4VO.,VHF
M&EWS=H^G&F=_W(&;MQC2VIXAGU:[>M?+:!IF!XAA?>1_<3FOZETT.:$HB:,$
M1E:P3/:@ZWX!I!8?B]6GO306PGS/6'S#5KELH=5F@Z[.Q$5L,<:M!=[M.A[(
M4-[UHFU0H-6*[7_2#93.OL$-L,[4W?8;MK L\QS6YAM\&J_R*/\6]AIC9V/M
MCWH"V"[<G+W.M;?U/$3_1SD7U&.]!N3W=1_B-U4?8IK EZ9M\:>Z;?&36@2K
MEK);B38]^0S;0D?^3Q#C'VD)EF!:Q@$88"R0/<#C.+V!6[6@RZVLQ:UH=6UH
M3DW7;>QEK17I):?VM+4)V-P/D%\(29</$#VYD[3@:$#Z<1G GSS.^0UUQ:5N
MY3"0\R3!=M=K'6Q-0__OL?85+VC- "<-)F../<YO6!;H<9I^QUFV7NZ1:2PL
M3]D=E__ CMG5'- RCI+K-+Y&,S7_+L:+W5W('L4VKV/M$]"F:<1-I* VVE$8
MPO2QH4,&DP;K.<S2!3PS!9NWZ<\>R%[L.;]OI S^)Y^.=+YF&=KI34]Q032\
M23Q?$D(\'>'(,EX33IGG8 S"3+3WXE;ZSGQ-\T(#FY9L"1J9UO,AJJM^P)T^
M ]?HL?";GZ?*\9S.'4X?/$[LJ,; :(\2C$D@ U]R[9(G'+A=6_  >#[AZ'W"
M<+'1/'Q (E"DR-Q7;(D<?,6QI1+\-P;@\%8:6R[C%7ZQ!*'D($PH&G[$00KQ
MQK!, H920C(&+F4"[[Q*;S0?9"E*KQE( G93 9'@U*P9!UD _,&+QUHUZ. :
ML0F>S#1D<P#%*!42 (BVY"5.P <AB0*&($7(4+#O<&>TT/!W +@2.Z^(H59S
M]EDI^T/7F-F1UO?G<IB+50IH<+4::9__^[,%8\JN5L75 D TH<=TKT%I%:(:
M<)@@XI7 ;S%#@MPKX'88TH(7&E M.(JKW _&1(!>I'DA5QGX;8TUEED:E'[1
M+/!(^_U_+,.8(B33TA*_()/A4FY8-(!)J4& !SV.JP$+$Y<5P%_\^?'+AXMW
M^OOS$>G2-+E,\:+/% $Q?[,:H2E06U1XS,  RQ(>QZB&./BCEPQ0&WP:8"4A
M.7CU6/N0:/^WA%?CN>61=H.AG/0Z0BT*Y(_0200VK5]1+L4D80G\JT;AHCJ,
M24"O6 ;J 6Z"-_IYI;A@H&8E.:0C2(61>O*S-,\%I6Y26&_@;BZ4);R)-0^8
M=^^[N4JU*T;&B'^%@RVT&%BXT*;Z I;OBB1'&"AZN40M2"*)\@;<@$H?]2:]
M LR:&Z3U F<NM280\#M?B<5BON;!BK$,6"9O22 RJG8-EV>18(8%R_%[<!I'
M&MHE&1#L!K %E:'_/>%Y+N0/Y4O/>8(^Y#6V?B^R%"P)>.>'L78>"&%'3$)Y
M;PI-TG'S&PK. <[@"HKPFY9Z(@HB5LS/4)3QSA L*O8#?H&)%<!9:*( 6)*1
M(TP'@9B25B6J;S!,</[T:*0O(=-EBDO;T&*9XQJ]]-,KU.NF]C+YB_EJI,F_
M+?S;?O4*B;Z L909<LA*^_W-'Q>".Q>+,DG!0"A26+L%_,Q6XTIN@*U!#'A"
M0)@1,M\ %P.LQ&@AXBP%RP!V7 DF1I,1EQ*6]1,,= 5STLC=UP+PTY-+$!SX
MN,4^ N868!)%RYBT2IIY$=)=LA[3:'39BB@3EWH< 6#GJ\42X"K':&>.\9-
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M#W[?(7?)8"8NI'3N5VW''AQ]8!8N?)EKCC$R=-U!:0.GC8@M1,P25H.VIED
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MJY0"I6.,M"CQXQ+)H87,C^*H4'D9P])OJKZ0JB^T>QTY,J:JO-" 6;G'C*I
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MLT+J28!)GW, ?2 TC]#%)R\/1_/A\R<:&04K )! 2>#PI>\+0,,S/Q)(@Y?
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MMA4=D,6?#>/7M:?V1;;(*$L '9GH^9+[($DC ;@\!X$0@C>2C9BEUJC:*E8
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M.(./ 6?@LLN,JO]D!7:.*:YXSK4P2ECB1[2%RPJ^@$?EXS6:!M&UYL<LSU%
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M@0-\^[58MLV:[%F,Z5&K(P-JR:7&?RQYDO.[BX7N&(IZO(7?>_6H:'>0X,:
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M>-LUTKMZQF\LM(M."X,YLH+X_"P>9W?N*0J.1Q5,B-CTLEG)S>=_U>'/DTJ
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MQUJW5TC_.V@A%+(.^A4]!E! 0GL#)>UH+TAE@Q*/6(E/VD$7H,1C"6Y'I+@
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M/[TP M,RX"-JAK@P#CF-(R()NY1<TCJJ.]+/_['35?P^^[Q_U[P@P#]';)4
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M)&**J2D%O#U&LQA/J, 0TX[8' 'Q1R2Z<:H8Q+2@?H!P@'"'JV* <*!^@'"
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M9TU[Y,DL;%CZ^[3-W=O#'][HS"=$&"#M$/8-54J'Y'<A[ /U@[ /M.ZHM Y
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MM YE;W:7S^&$HF -"Y1IK<W.%NL?[$4+=FLXVLCW99%&3Z D)U1KP*4C"#B
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M-#K!,+ AJ':-*<CN=P*=SW;7VGVF0*%N?+>$K2QN^QS7H^F ^D!@,'3D.=;
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M/#%"]S*)<R<<^+#&M@]3.UN>S,+K#;SU%!]PO?=6LH'8_W@:Q08B,/ UX&O
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M( Y(_:"<MF^.<U5.2U7=-*NVGN;G35=@R\>UHG'36'T\>?.Z>C=?PIYBX*?
M3X&? O6#2!P0;L0J!NF=IUDW[TA(25EDB N("^:0Y=@AP[P66AB)=SO''S+?
M_'UZ%=WR[3J6>UE"N9ZR/'KO\T<'8N]0YQG6&^AU?=<E"\J,"/@/1 <0'0#_
M ?4#_@,(=V J-@S^\^1\)$>/Q!H:D=,<(TY#YA:E?NP-BR9*&:0B?:]O>GD5
M1Q5RTE?CV20+"2@)5&..@HF<G<UGZTZTU7G^Z_FB_FR7L3J?YA\KS#\?EN(B
M_\:DFL7EYJ1\D;*JL-TL>'- 5^ !'@->'KS\@7IYGITT49@@IFG9P==B9)(4
M*'@:M, :![>SBOFA\RHV.<?WZ4.'31\VT-17 E)/%*'@\4=LCH#X(Q+=.%4,
M,E>@?E!=&26GJ7.44-MI=;YRT]KO$IK\GN+BRR+?SZ+Y]RK4C<^O;ME,=IG.
M\C0N@.^,T_N-9@CZX/TC[-D'>_8=K@K#[C6@J*-0U#ZP]L#R4T1RCC$3B 0G
M$1=8(".M1%%HG5A2@=K>I^QM\E-ONRCS0QMDOE_'B'VMA,1X0O<_<N^HS'H/
M=:OCVYST<?:,/5_O\E2YBUNWF(%]8R'N&#] 0=PQF+@C1<TX"0'IR!SBCB:D
M>1!(2DI3\DP3OC-XJ<=]7-]L,.X^N]A]MS:F]MZ@#V8-O!?\#R@J^)]O^!^#
M.64)$Z1TT(C+[%6T(02)B#-UM-Y$U@OO?7+_0S";J/UO*G)4=@W%S4$0V5,[
M^Q2K>M92VDE';.,_5_7G;$9EM$8I2"YBLUS4?IFI;OD>:I$CB1,&(KK!1P$#
M]O$'O\*<..DXSB26!HL13S&4%>84"1*8#CC'"P[WP6E+0%'^]_H*VWZ[A+7R
MQ<DL7/]@Z\@/<5'/<P3BRR#"^"IV_\W_GJZ*XKS^VL'H;W897Z<4_0_TC-YM
M=W<M)UQ \^AM-G%W!80YA>"[P'<=,#_%5E/KJ$#>"9Y]2?[#:A41,S(PX7T@
MU/7!3X?J2_Y\P2&?$ 8K#D==N1T_C>H5!5[>F;)6=EFYF&^T7+0TXYZW5@A,
M=B31P%%EQB#C/9B(PC,E,8XY.A \,TUJ$S(\4>13$%%HGD,'>C.BH)IP[J1"
M*J2 N.$!:<(84L(Z[Q436.A>(XJ^DN"43Q31^XX0P-2A"@L^"105?-*W9G)B
MAADS"25"$^)*%/]"0_F;\R9%)IF]Z9.B9DF9)%$R-#-C134R7GDD$HF.&V94
MBD/T21I/A :7-&A:"W79O=+:V,[& 4([YN"!/J,%4\)\58:U#@Q4[EMN^<N>
MXX@?$.J11A**N,2P)4C0J!%/UB.G T.><<FQD678WLU(@C@:I&42$8M)CB1B
M1$XIAJ@E,@C**6%RB)$$TQ,J!]9B/&BS'QEKN"%+(+A'I:S@HP[51S&".?.:
M(!QQ9JY,6*1U9$CP[+28ULIJ#1G88[7[O=9Q;U/W![#@47&NNUK^ETZ0;CX-
M/P %'U?GY]-V^**=MI.2IO-FE;EO.WBI\-XTG7^IZEEG3=E$[F$AHQ+WXX8/
M^666;_[S)_K3W07V2"U)CSJ69U]1&(AN3Z(#2P5U TOM2710&=AW9>!MT:E,
M0JIS6T.N?RQYE(&(;CPY$LA_;,W"QT$E'SC"4E'$<;3(&9Z0DS+9J'G42?:Q
M/FH#+1\RLKR+?36=$ZKVG<T8B/4-/IT^$#D!P / 'Q7 LWPUAD-$F"F5P=I3
M9&49[T2QTLD29L+. MC[+%IZ)(#?_]BF@5@?I*(' 7M/E(HNF>A\'NJZL!XR
M\G%4LH;LUK!3-)#=&J;HP%)!W<!2(0\]_"CI3N_F54QQL8@W-V6MZG:*0?Z\
MGN6@J-O?J#JW%[:TCI3^]?SA8I6_CU_/XZRY5[PT_E<!*0Y(<<#>1*/60\CF
M M0!U$$V=R>;ZWPD3%B+J+$$<9D<LEQX1+PI25G"(HD/R>9.O\;Y\TWXM=G^
MYV4)OMZN8Z^WLY-UY/6A"[Q.9N&D"[M>KZ.NOG*_$X(%9'_WG_T%7M.33?\Q
MR_*;YEL.U73>-%6[J^OGV"Q+_A?("GAP\.!/[<$/?@"R5RX:@3."F]+@(\J"
M6A(TTHE)FC#C@H4^&GRNL.V_;3W[-</;^]G;*W#K>V(QP0Q"@P?! (PK!I<#
M+@?R8V/40RCS# ( 'JB\OT4_M4U3I_SX;<0R3YD/9;.<V6FU:F+5S-/RBUV4
M_6.6\RK_0EF7 ,4=<%[@O(XFX\FEBMIAC[0/#G%),#*>$J0\":(L4"!\9T3N
MC_"7-N-Y$XG>I[=K'/JCB1_7*)0_FG_H,*CG3*?9^TR&@9@HU+W "X 7  IS
M!'H(%9U! ,!#5TPWS<K.?%PWJ"WBU);AJ9FMY&-:L936M!#=$IK7P+.!9P//
M=OAZ"$$\0!U ':1R=E(Y1HB4J,.(Q6@1=P$C%ZA$,9B )7=8*-''4N17.=S:
M!&:;WK55:6A[M2KM;._FL[*L\OWB@\TOT4[7__Y]86=-=[\]I74$;(<(Y9H!
MX>0#C?KG#XOY>7[ZBY:ME*TCSDMK1W6^6OA3VW3,9GD:J_-%/5^L=XQHCVW+
M-NLO6TLL9[5?_W52S>*RW6#BCA>_?OZ?LBH@4!!50%0!#76]M^#'9&A$*9;B
M$L<).>X2BDP:Y1637I,'%Z1>VO-Z::=MG2G4RS*<>!/$_+):OILO_S=N)JV\
M3^4O)V<%^GH;JP61"S37@?L9AZZ!^]FG.Q!*:LJM1%:Y3&HCBTCC_+>@!(DF
M<*/5SB9'/[PBZ]'=P1V;KCD!OP#5N^& Y ,M^DT]:XMWTY@99M4^&<I4M+0>
MVJ:)ZTT1T[6CIK5U];2=QE4MHI]_FI4U#T UP=>#KS]T7T\T$=R5S8T-SS3.
M"XU<$!A1I04FCGE!=U9?_S#U6X/2KP5M?BN/_3[]T<23%H].9F'[ZU^OL.BW
M2RCJB0-2"JX>RIG@#< ;0.?&L>@AU.D& 0 /5-Z7;>=ALUY0M=V'F"^V'JS7
M+.?^']VR*C\_.YO/+C\I)\QB%_5\J9>G^:.Z5,FK\Y6;UOYR)-]EX:Z^U@()
M1 A<'[@^<'UCTT.(\@'J .H@Y[.[_I1$+1R-R$B3$ ^2(Q,91=':9*1U7!G?
M1]/B5=3V/GTLL5A7PBE]C#&0O@K[6DPP@\P.%'$&A(2]TIV/)V]>5^_FRPCD
M!CS^OD5W)!X?R,W ]1#(#4 =0!V0FQURHZ5V0DN+;,H<A5N;R0W.#$='IH33
MBM+8VXJLJSBM^]NRS!)OEHM56>?1D9V^: Z?< (; T--9T"(^$#S[>RC[3A;
M#ZJ*H4J+^5DVB_-Y4R^O]:6MSN?=8JDR?C=?NS"9:!?3"Q2_QH6OF\L*T/R\
MF$93*D.?Z_FJF5Y4S<K]/5.D,L-B$3?+K[:7:?D80WLGL?Z\N8OVZM7FZN7
M53O[=^>';KUZVV97FND69267;6Y[*.!>$)! 0'+P 8E/U,>DD<6*(>X30;K,
M+;=)<69L\,P\?-K?&DQ_V\+2-QG$7G6@L]54]T?&T=]/X_]T*/H^O2XH]WH#
MH6V6]GV':Q\N\?-C!W"_SW^[A+>N*W\-G+^M<;/\XK7KO4]_K"%S^\*W7.YD
M%GYKL;*O9>H&0B6@R>"5P"N!5[K=*T7J<"),H,QK,N5U2F7_)"+"@0EC")5,
MJ@>O\0*O=,TK:2#P_1/X_-\R&*/]ZQW,5FZ6YS\M(V[O13T3W_GU[MARZ>=E
M<63M?\#.L_VTXT+.\NU=%(8\FR_SQ<NL>3MKA]!_6I2RH%VTK#=SZ<Q2NX5@
MI5S8+.TRMOO:/-L2=Y%JJ#]7K0$7=?P4LVPRIUVTCYE_)@ND'+"6Q[]0/0OQ
MZW/$7J1I_(I"O>AJD\^SI%9GLQ>A;LZG]N)Y^79'0Y^)K([E^=:9F.Z#OZ\R
M*J2+S:.VIZ(X"R]:%"G7;F=49EM_X>9?BZB+K-9WF3^Y(Z 3>G_5N/(<]U:.
M]G:^JQMWT@12,H5;%I/?S_K/\CI/+_-=ZP>J9]-ZEN]LF37CN5TMYR^N?Y%%
MW7W<O?TVZV53?M[G=OK%7C0O?OJ/2SVY%;;*2]Q2C)T7W.][?**XL.^7=@O2
M;=[84S_T7?7V2_<2W7P:MF7R/8B]NTQ^C3F*J#*PY9^,J^SBFDGU=N9O M3C
MRZ<-FEH\_=MR_K=\@Z&,LPWE;\U\6H<R(?=O&4N'*LAWMXV9&<S=M7YJ.:_>
M7#JCCY?.Z,E?]:-#^#W=^\^_=U.5UUGS=G18CH/M+&2CB%]]/%]6S6GG[4,9
M);;Y5W?"7W>=^H89O%N=Q47M-^DJHZBC5*"8/$,\6(6TBP9AJ@-A@5D37!^;
MZ[U??+*S^E_MWA0O+\TH_R-'W3G(;_)3K_>MN%2+*ZUX53=^.F]6B_A[OHM?
MICF,_ZF*.2@_S[^P7*S62U;KV2J&D^5='^MOY(Z1PO?>\]/B[??BEA\(')Y5
MK[(4%_7Y9N^B7U9-#@&:;FK +[:IF_+I]OO9]ECCDUU__OL;@GL(\/8?8FA*
MZ(MO>=7JYU)?*P=1_.)EQR/:?Y$7?ZWRB[>9!=2SPC,+6?@4JT]Q%O/IU5D,
M=:8"I:.P/:GK0[29#/M5NR-P_JE\2(XO+]93X?^YJLN2K4P&RIKO5J=.\_O)
M-/LL+JM9IN_/R@U66W=!U(MFO;5P_:G5O'P?R_8A2GWPU'Z.W:3&>7G:XD2R
M1VF;']O[7!]Z@5P[>7&9H]AN%\]R6(Y6%T7)S\K-7][4\M0NN^O&;A[C<A[L
MU;W$KW57B0R+5?XC3G/@FA\PLYMER0(TUYZ@RG(N.XEF*>;088XRFYIG2"O%
MQ,_U8E5^[N>UY$]._N=2ZE>WX&*<57&632,689:[7I;IKIOG:Y_C/,NE97"W
M"F]Y]<9W!7DEC_7XR6VI%0&?+^ILFED!-U,KN_KHI4J4%UMV"BAU5W1=4=KW
M6R##+OQI>V"(G^-TWH[#?#82 .G;&+>5(QM7=F&M-F3AEJO][WSQCTGU[G];
M:7VQ32;JBV;9II?R0=FDWD2W6!6#(FI245S^M 6EJU]_?9G-*%.F]B5-[9=F
MS?:[H*K\XU6F6>T>=%O'Q4_Y;14/7=T&#_FBU]4YU=/8#4+-1_M5N?,,#R4-
MU>XW%:^6:;9=S&W;\N)\OEAOBI<?<OXYGKG\ZQ27^R]_7NTPT=Y2>9#\T3?0
M*C_NU7-L7?M9=3*=;IYXQP)L-J VBEJ/PLGGGL;IY2#6/V9U>9)64%<&^<>S
MC\\V%CD6;7UT=W=K+- JQ(=%1I#Z?-J9_;70;H#.<"=K=EM&K'VN+F'6)=46
M,4W;EH]\=IGQ:[M.D.MJ=Q.]V\T>%YV-Y_LHMEPOU\ZR@.W"3C.@YIO)H7P,
MF]&_Y9[.KT1ZJZ;FWSUI8WA[J;3_?7+RX5)IJY-\-^U"Z5@:_[MK7#Y,<8#G
MYYF-M 3CTRJ_K/:H[ ^CG:W[6HJ?*3ZGB&N5F<>B7K:IFJK\4(&>5)JE-K=W
M<G7O^19GP2Y"D\42KO;%O/1V'U]>>KLBY5O/_.,\7+/(DX]_7)ZTEOD5=[SU
M"K_,\W\NSW]S\O&7*^%LX]II?I+9/ /C-K,O'3Y-'>KL_F+VK2\S0MEZ=GTF
MM+/3(K5FZWU?:VSJP*V\\XT8;TQ]/M^RH[&@3-\V>5+]^3C<[_[43[=S6DZ"
M24PZ)+T/B M,D9:1(<.C(2DJ&5*ZR6DIQT%&C!$E+!-&XBPRU$>$L=)1.>?=
M;D]H6T\ZS9B;W=[K'.,N+WZ+Q07&]HN/V<:6 Y$TP<^$X91AE%42D4M]NR:]
M_QH27F=S:D6Y3FLT19C?\O--+)9:G?S9I(C)YJA?_ORH[>56DQ:B-GU_)>#>
M=/M=6Y1U%5;=O+$<Z)"JTXP2Q!2BDM'B0X:.CGS]U!Y0_OW37]N [DO,T4S^
M;XYP,CZ<SV<EK9XY1*F);,+U]I?*MZ72\CENQUT9HGR\]$MW$4O[A'>33 E+
M8R98?MF%I._]<EXB.L+:B(ZU >GY^6)>6BK=Q:T"<2TNY_OK"D7S1;,6Q"^;
M+UYMOOBI<Q!U?N96!=9V=HVUMG96M89V'=^WOLBB"BL?6X=>S59M$)I_I[WF
M31=^>9]KG_>O&";M KIU\#M?+9OB8\I+N:$H5^_NZG>:K1\J<+_XO+Z._6SK
M:>M^LSE6:57&H5XMU"M'M#HU;2.4[1^]HRX6H7U;]R;E[=E'PEX;K?4Z1:1I
M:1I0S"$M'$>416HY)MAX#=@[<.QU)=K/861I=O:G6;NS9E_&DZWV]8HMVQ#6
MQM;-9/NC/TES=PA]/F^6Z.YG;,/LENETMC59_[<]<_-]N<#DVK_:BZ\_N.4W
M+D/N;]*+6TKWVZ'D<C&W+;Q/2R3?GAO6D?DE$]D&N35CJ6X@8I>Y:D&[FN]X
MCD=^B2VX1>M/-^?_^2RG7>0.=2BBJ6SW &VZSRZJSW:Z*AFJC=C'$CX_.DE_
M%\MBABSTDQ#J=:9O/7=[2/"RIN(?ZXZ<%O[;&M[R!C&KU_/!VX4;TWE3LJ9%
M&V?Q4\=%RYY759K.OS3=$HXK:CY9IS5;X[HZ.RO@7Q[H]IYB>PX6@I4A.\ZD
M).):8624,(@8:IGAF<H(V4=)[EU<YL!@?A9_S=+Y9L^;O-;S)NXZ:-WH9^R;
M[6]#T,(JGS_=)+%&H!5:,!^B%<A;34L'9UGHR"3"5C(>>4@\\3X6.CZJ5DCY
MC(]#*T*[T5Z+21?1YE ^SDI-Z%7T71Z;D9;U\%9];GZ:&=&5FYU>M)%4FXB_
M<?)-S LMI$TZ8"L[B&57%R_#G*Z(TX40XT R3+S-(7]$,69HXM%IY!A.*!#O
MM);46KZST1!Q-$B;%9OD4S.!B!$YI1BBEL@@*,\<0>Y,'LKR*O][?26RDUGX
MF"G<\O>X.'M[);B[*_1WMA?2S\0X%+D--MN=Y59GJVYO[Q!3[;MTR@B4R 7.
M>9(6<1]U=FT<(QNY1]S$Q#1S2N*=[4GNHT2_Q9+FC>&U;6^U.;F2V*M.8'VC
M(=7XV;<G60U.B\JN[KZKH+>A69LG7]JN^KZ.O3)D_EBDUL:K!07S?S-ABEU6
MI,V(/*M>W0V$R:T@C*^CZ\*VBX;MIT^+<E<Q/\:RU$!S='BY(G@<!L&TB0(;
MELW <\1#2;$0BI$GF*JHC=3$[,2'P1-C.4->\;)QK3/(<LUS?!@,%E8:X>A-
M@]BLK"@K*C:;T;Y/+Z\8W(<-@6M)6U_0JL6S;^_=-BBCN&4:5]&XRT1>R?YM
M*/9=:?2.TG]#Y]EMRCT"Y55!2<\=1UZZ@'C6/>2(S)!.\T]*82R-._V&.ED>
M&<OGB)25EP>#M,NJKZ5TF,<<802^DQ_,JK<>0UAJTG58 \YFF=#[V5UV2_Y!
MU<5X+*2GY+UW\>\;"EUZ+]<S&.JV!''KQ+GJYY_>?GC_TU^OM7NH36U@UI55
M<U#;%D&[?:NOC5LHO]2FK[\LLC@6S;]O,G';R6Y[E=GH$NM7^;P1*']4.> U
M6>59PIFE)Z>0*?3>>Z^2#X;BM(/<WALL%2<H%E+/HPQ(FPSD47 A2YY &?UG
MR%TF"38?NNV$>])S]NS;ZZV'IN77]+N-/6Y"M+T&QQ_KL_/\GY,<);39VC8^
M>=-5:-;5E$U;01G4>-F74%*XZUK6M<MMACEFN\C6=;+ZM&J6K4G<%>AOD,3+
MH26C#5\LLTPIK%#45F6%#A19' 6R1A/I!+<9VV\:@34^B40H2C(5(LDUTDR*
M_!2&^F"U#WPGGM^'!]#ZV;<7?0[*--H57?G1PLJW4?LE\FYJF]E$VOB\K7MN
M(+Y0@%G3]2794F[^W+: 3O.-M\9R>>#:55PKL/R<P_MNL*G^Z[/J_[4S^ZD[
MJ[2FGK4=/VT+U9:Z_WMSV3=SU\S(96=.VS:P2H6YQ:ZM*:W6!>4;]"/_9MD9
M;UD16N7;79[>AA1AW>9XMX64CU"': \?:"?/V^N=<'63]:EE<J4IV[7M4UN>
MN[R'HB0N%M)767]:Q\_E@ZW7E4$M_T2W8OQB4^6KOY_V3U4I U_'S"]9Y_./
ME7?MNS):B%-[,5FW!E2E3#6M\[.55]S,S]I/;-=76B^;;_8REYO\M+!G^7>S
MJ//W?KZ:9HH9VD)T:>[K"E?E&FZSLB*?TV8&\TGS:UTCU9F]*'=Y);G-FI:M
M)RS]KF4AT*?3TKV^,:#-@9O&@&;5&F77*/"D\B\-Y&TOX6Q>NFY7B]9V;IKU
MY1MI5CZ;:I-6TX(HW9W>N)'-S99 ,"[.FG7'Y$9&UQHPUR:^%D?7,'%--_)M
MY/=ZS5!WZO";99BP#GITZZ UK(,^H'706X+]X;ZD-038[0+:X2X)[.]U_%8W
M_^ABOC]FOFM\WAY=. 0SW^KDWXHWMJ<R7C[#:OL9-L%H/J*;)-FM:NO:<.JK
M7GM7S\]/;0[R?;O^Q!;7%#(6+RZVN@HFV:$OV^:4$CATS3F3;7>6 =_/VQ5B
M-X.&=5"1'6R)O;,WS?ZM[7>?7#O,7;2W%I=UVR;94MDOV07ZTUD6_*?UC<WF
MGS?N+<2RM7K;\9^?\A_QHG3(-"6=,^W"H8TS+PL ELO"3M93*]OXX)^KK)YM
M[WK,#'A^$<L-Y9M<KK-!W>3,'/+'=F'?Y8U<M(U1Y].Z]?3=ZH;RX+/R%+;T
MC7TJ193+\&#[-IKH"Z_>"DU\UZYRZ<JW_?>FY:JDC$K@W0G[V_+LUD%\H\/S
MLAU_Y[1NQ^R.\=_R;1O+U,LV6EN_KRZ<6<1VF6/F2%E1FQ(H935&UQ;,7?YC
MN9YJVLF_%="\J$K;/EM2:^U:@_7N#]WSKM=.MUU2F8#$E&.W-C;M?K54G-KE
M%OF9-HO&2W)C1[23LB0QO^S"VZ[THYZEA2VCC'UY[LFZWK-YD*L7C,K,T_S#
M+4NTYY<3G9Y5KS_'60FQ;A/V1HS;^KUY@(ZF;>QF4D3;TH>UY>;(.L[^+*[/
M?KFLM+PF@-([7N+F-CS=_'B3&6.S$_IM.XKKON?V_E;%7,3*2<0XU=F+*(],
M# 8)X3'A6*<@<1_-.1^O'N=JA<N'^;1$Q<U=5\'?Y69'ZO+Z6P5/GU4?5V=G
M!=3*[BM;:K2UM&@C^6WU>4A\LKMF!<LD$_/(*B(0%SPAIP)!0@7+F.;6QITJ
M]WWTZH\R$.WU)N%R0W_&J C]!19_='6(2^$,-.CIUA7:C5-N:^>W=1G7;=-'
MIA%7CKDL;>U6\*W=1K.=1<CNYLS^(VZEX]K>D<SBSS;+#HKOV^K&[7Q!J:IO
M>9SU6MNR/GQKH'<;!5V.\5BW A?3*K_\K7.Z7]G*O-WZI)/+[N?;[J=NF]DN
M&QAF^25O]79=>;-N75[7A'PV;Y;7',J52%JN=IEYR )>Y+CI3U>\=QLO;7>D
MWGI6$4<;DZT/ORG[5=.EKC:WTHG#UNM^Z&^NC=KJ;:_*\NG0RGER%6*4X.GM
MA_>3+B]6<BSU[+:KW\SG7D_AEL-: 97#OJU!;2M)_O/3O$U M:N*5VUQ\;3.
M5UVTT5%Y3SG.W*R%F9>D4KZ9=EG0MARWEU7&++_Y68;3./M<+^9M]-D)L>AT
M<VT-50DIVNMU]^?KA5^=E4Z6DC8.M2^:=1EG73U*5MMNFD1;^N_J *U4+U?S
MV,L%1=_3V1==IJSDW_)=YJ"KC92;U;05<LDBAKH=9K%.1,^W;^7[^:M^?1-1
MVF/! _)!.\23D<@([)'G1-'(<(B[&PC>QS>5%KZ36;C1R?=;?NY\+]FL;_^^
M=<T73^#)^DS /[HS*T)JM;O]RY:XV@^O9-I^/U!/MXGS_;I\U[1)^3(Y9GJ1
M'45^INNEG_4<FD4\6Z>1L[5DJ"^+[HO%;YH(0F>8BQ@WU9X,A--")3,"NKA3
M8WK6R3!NRW"Q[6P*/UPLVI4\W=J433V@Y7-?6Z-M'52]V,+4-3ANH\H_5_-R
MY'H99^O VXQ[UL-_% =9BE59$+,N+=&RYS7[.EG>O37Y5CI\\PF_Q*UA&;8(
M*EZL[Z-EYM_L:6Y_M?NA]J+MRVLZ7]Q^4)JKUYMC7 4ESL[^43;-*!@^VTQ&
M:;\)\^G4+M8.<7&EMWU>O!5L]\J*^\JNMG#0K1]KBXQ-M;7 OQT<D.G]VOVL
M<T<[ZUV[8F35G,8LMRX<:SU7%SXL2]&I+99N-'6R^:FMB4'M@_ARI\LR-**]
MV6E<+M<+3'T[;&FS3/6V'2*O*IZE/;-,.ZK:B<!HGM!JO7=)YZ3BK5]?16?7
MUR5WQVY%;&M+*>FX;L6:[8I?6[[]TE*Z$.T62VFVXXZPBIL8I2GMW*C$)]EM
M=/VAO]U0A_Y^^/J8B"Y%4^8?%60I:8FUQ;0RV0&'6Q3ULBK=OI&KB"!?:5DO
M5UOA=9GME\]Z$T/[LM?#LZNWLTTQ[>769)WZ\M,V#?GDD4%@_S][;]K<QI$E
MBGZ_OZ)"=WS'BF"R*Y?:Y)F.D"6[0S?<EI\ES\3]U)$K66,08*, 2NQ?_\[)
MK"H4%BXB0;) IKLED4 MF2?/OBKX/R\)HQJM5BJ($AI$/2@%59JQBO&]>$-6
M&?Q!VE_E 'GQ8G]0ZC!"H3Y87<>Z!XW&@)=YIOQY#GQE.;]<$W #6Z,W4D*M
MO:=@> IJW!V#UD/S&)M(]$_JC$I@O=[(N0P=L[L6==Y,[&V9C<=/6W<S%D5O
MO,H_U]>ZKK-\M ,V399N_?T:.R'B4^8'0F7S%;V>X V?UEY$RZ'7<TS7'ZA/
MI@P]! 9:TG$R/(4VYZ !A-SHV3#T06^_:9T_]G*Q:1-$5R_ IA"=?>0+X-$-
M&W(4VF9#;S^]2S[/SH&G<,S9?R2TO6-;U@'L6IS&P8#^Y-KLP$\]JHV) -=/
M/:BOW;"RQ4#N'04!M9RV;G63G'AIYUTSH;"C;1CH52#I0P/PXA#7&A89!:L=
MOY[;TS:.T/IBOL<G^7S(9M#%H56:O"AM4TXV'A]2'M<?B8_JM*^!\\O[ES:O
M.TK0F]N'#-:;3@Y2S3;IL-X 7=N[J:U,]MU,&KUR@*TT"F!J!Y"06:5"&R$R
M8FGAB%"I(253BJ0T+5C)=5IMUQM_2X&5GPVR0K]W :K;&9>K/,OTINF8U1%
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M3F^"^ZH$$GU2R;OA#) ';I\Q=EMD9UQI#?@K1/2#;-:F#%YV,G[W0()"',!
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MYHW&0PRF<%4:S@PE+,4Y8TQDI,(I&\)B>,$ZS5.WR7I+PW+MRIQH9Q0.Y5#
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MV_?8_?66V.K+5IXDW7??9TXW1H2% ^Z.\[37%]L-U=-)/865+>2\+?)8_P)
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M3$G)<DI4R0J7FE3K<BL;>K^2^ %/LWR:TWR8!)@H?Q]'_NJ^=&C-?QTE<)3
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M\Y03(; 7ELX*HI42:5HQZC!"LB<_T]#5WODI.E[E8W&/X5**2L"HE(!8&/!
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M4&,T*S.BL(6=H#8'^TUA5:PM%!=,%^G6G.2[1ND>56BD1Z5X^BS&D5+K0]B
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MK_9R_O;5G]9\LC>S+B]B@S%:"WS8=7RDM.)#+]J>/+N& !:%VY3/5<S#*I7
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MMBOF/]#E.)))4$_O9CQK>7RRW85FGU7QL":O5_5S%<^BG6O5GVW;88F5D+T
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MP&@?[>S#K,K<*G[9QS@KO+>-HN'7;+S@JOF']*Z84/OC= QF?EY??1=>Q&=
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MV%'%(C#VJBG074>V/9"SX^K$$VE*L%8)?YV"Y&02_;BB:EL'K*5TF\5A73[
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M8-SP6<DKL)RY!@2A) *6\(",4AXIH4UV;FMC^&/PYSE;8F"%*_#L5Q&G-KH
M2,-\!/6;,# ADXX(!T:Q"=+KL-4+]#[ ,]Q>H /BE4W$.1UM*5VB*EU?9F,<
MK;:)Y$'+(H#\E !@C'-$#1><!2D(W_+W.VZT<2ZGRE(#K&\M,@0'Y +%GAC%
M,=:#D9_D1 IV8N3QF)##9YJ4%-54."0L QPC &8V:8,,#8'88+RA6TR#$^=2
M!I"IT9H\'X$C2VQ$-($*)VSP*@Y'4V<,GRA#CX%ECESI<I1'B0DH4)&" A6
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MZ@S%O5PZ#-5C8D(3#8+$@)G#\Z0\C:-!1'/KF8I!J"U=Z#Y4?[3!4_Z51WX
ML5I!LUNTY+!K$X>R<&FVG*,,W<<@8CH%IPQT&+[V3D-P,2B%F'? L1P@PFB1
M4,#4!,V( N5^;QS[D+*#=8[]->N2#?!M]L"",GE7L_RVV8STYG3"(;#47_I1
M?$56?6QI,;)ID9'LXF(^^UR4<)!#<)5V\D<_/1#$C1T7H=:?!D8XR"$[&<&_
MYG %.&L\;4!QF!3!U.+CYB 20ON#FR/8@!O:77[._--XVDZXZ?R(_\]H5,;Z
M^(EMFNRH_1#1YB23KS;F_OP392)^_A:Q[](D?D8!Y'CADSR%9'D^_2Z,FXN)
MO?PV_[KENST5XVEYW"X%IOWB'TM8D'39/WDY%<5I^.YBUA2E_]MB=HT_QO7!
M%ZM6=9_OZ/HM<W4>J*<]KM_?OA>6,+JQM,4AO%K.LU6B4?="X^ED/(4G6P#G
MMA-E-G\ 4K=?MZM?LHW*GOK63C[9RZ:;*[+.!IL._;R(:XRQM<#[7<<G"F/N
M>]%VA/'6-^!#-:_U/=U),A8$,YP;I )8_SR1!$:\H2A%ZPFW3G K_B_]:L_S
MO(B('$>"<XI%3K$T#&6G-[*4:R>L)&K;W;"'>5Y;DO17@'=XJC*Y>.;_?#,-
MU[[)8XV;-YVM5Z=[70NT7 F[;MS5\AQ> &[4]()W92?O-!+;L;M?'KMUP.%:
M!-?I6@.<KF6>^@T)Q6O_//0Z YJTM0T9+Z#3_1&W ']%U-IS@^_!4.ZP[;I!
M.\HR;Y8J)]9]6_?MT>S;_^KCM/_+S?_Z'V_:8&WY_)]E:OS;/#4^I\N,2KY,
MY=<C&JY4E:@*QB\#C!\XJ./EP75Q C6'9M2!#ORI6_\8J/6@K0^_U'W_!;I_
M?0'&59,W_T-[^#Z:X*]LY]<6:(,J9_^C2ZC,>>H[<J<?.BKL95"Z5B?6ZL07
M4YV(*B,>(2-6U#LZ^CVTGO-?A\-U%?Y>%$<^K^Z^GU94Y15S<MAT\2U83X?&
MVO7<$='GVG2WQ]?S9HY"T__/MB9C."!31=O1T>]X]:@7*-%N*$"PR2C!!!*$
M2<0]B\A&@1$E6GOF'#,L7D^@M"D:C6U"/%$X)P6&=((3(^>YKQ5C^VPW\L/_
M+,>+RW?39C%?EA3Y][D\^_<S.WW?5L$6H&K>3=MZFHV:A.*I:]9+$=[]_.-M
MQ0A:G> \U*!V'#G^;5QEQM'1[WB9[=7(#*LT%81D<:$%XM)[I+6F"%/+/2?<
M>;_5%'_(,J-/ONG2;LJ/.>%FU9YFLT4%?,Q)_7! \SZ]*=4(]FW.UYXWY7%6
M57#X/D5P.4&:5JDS%"MT/Q&D:H4^$H#^7J)-P\'XJE <'?VJ0C$@A:*Z58^1
M$2OJ'1W]CI?9*NI51JS!I)>EQO\XFZ<XKIK\<<JTO:;_'@78')0='TC.%R@7
MOWY,XZ)'.#"3Q=1+3U"43B$>E4<&4XZ(\8$[14VP>-@.S!6@[B_NA4_4,,)>
M>TY^'V3RUD/+!ZH@K(*P"L(7)PAO& 7#8V2":.2CSJW=&4>.,(] 1I'$DV0.
M;PT1&Z286H(T&D:0C9_*0<RN/B89]Q("<2]#;CYE*1>O&LK1:RCTE&9@";-E
M;G-7=91'ZRCW(.BKT5*(I59K3)"CT2$N\I1S96WN26T)3D18O-7"VNC@'#88
M:9G;=NI(D4G$($(H 1V%^<CHTVDIJS$A;?>LQYO24IZP80RM^R+[OEA-HXJH
M*J)>86U>E56W5CM03$0B%B67\H 0 A:UI1H%$XR)A(*1O-4N>J"R:ACVM#@5
MILJY(5C43SZY=<@]Q5_$9$>G4G19DTY)8L0=S6GVCB :+%&*24J=N Y6FFAK
MA#1($&409XPBYZ-$1F%,D]4A2'%LDQW9*1OT?)B]#'8LLV4&.,]1*Z9PY 3Y
MA$'ZX<B0]2R@%*PDFLJ0U-8X<BZ%Y[F<T&E!$*<N(LUC1%3%@'F*6C!3YSE^
MB:78*=6K!1WPL)\ZSW&#'#T3C\K(C]$OR[D_ QXN,RI>'I'NZ&7>F-;QPV^_
M_'(RBO"8XZR:Q8Y@S>C<7HXN>GJU3I=^[%8W"_O?FPRBY[-IBZNKP9 7]G(.
MBBQ(E+#T[5Q<NP"HO)CGJ8_ML"V T^'+>^65MU(HI 18*%QSB2P3(/FQHI(9
MY[G;RDK1FA(?/46$IH!X LEO,0>@5CIYRRBETF_,C/REI=;;%;'>+'[)A-K7
M+#=])+/<)K-/I4]^.VLM-]:&#?5G7(P^9MMIQ7LMJ]G5WR["ILNW&7439^*T
M"-]F_!D!:R[.X(\$, T'M)*Y.1W]L,'D>53[BM'/9Z".+L"Z.P+VC#%I[%Q"
MP(<>F))09$'^(QFD\<X'+\+VJ"5&,2BD#A%K0!T-EB(M8D)88Q+@?\Q)ML&>
MWY<=7N#S[3*3\7U'SCUE.<D3_ 7'[! X]&[@%PIQ1O#+=88[';7&3QY!V!W5
M3T9J;AJ-5 [>ZN5X<KL"V\\Y+!NH[)Q6"8:;3>&<'MZ[AYY]FL9Y<S:^&%V
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MA68/27VO KBR;!7 SRN $S8T:HX1YC(B3@)')CJ!(K;>:V&"25MMU1\2&QF
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M3KLG9PV%3V\N1!@29YR,YK&YB/" 'P$^3D;P!/X,0&8Z<K%@S3B&44><4?8
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M;LPT!.S)!W1O\L^2/O;Y6\2^2Y/X&060D$7 YWF$R_/I=V'<7$SLY;?YUZT
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M+S^-<W_<E9ITVXK!Q?XZFV^4M.8@V(Y7 $6DQ,FR=I#7SR_/ERU^]4< #8_
MKQ"H$XF+W"/4(BY%1%HDAY312AOO) YFRZ] +.5<)B2H!-/4&H)TE!H1+0+'
M3#N--]W5O\1YEI$@0-ZG[U=T>M^3]/M"KPWWP@6LS<J_@.BZ@X'>XE\0>-#N
MA;^4_3IK70=Y0UUQ5B\)BT;IXSPKG_"X,__GV6P"VPDX;CG/^C>@Q6PR*1;4
MV3Q&E/7QWG!YO0;H-3LI+/VB-<&N*&P!Z"X;V+H%GD8 8CTVMM!8*/];O%AT
M:CM>4^8WC)&K.\7/F?#9] H[H0XTYYD?V_PHV>1LK2HP://J=1#<7>K?F]&[
M7]YG]/MY]K%] -6:#2VD%HALUL_("$S4=\TN4=44$W9=KFPR6_MXFQ8/$*;<
M)+\BR*IC\(LR1;#V(L-0 G5&.(VLB@X9[0./7C%CMEH>WQN_WA21_=-*1+UI
M!</OLS]:N;3M&;V"JW<__WB;K_Q$:G-"S,W%7$/873OTEB_+Z5T\"=SH9Q^F
MV? &.3[.DG:VDR]/1V^7L?VQ9\IRSQ.PWU<!GO8.\UCVH.^XMO/++J?=LX1C
M\? 3ER1GG"/&22EAX,A929"A4E-/M<%R.XOD'IS<>_A7)8F_PEI,/1"I4';E
M"FY^!.$$V+ZOG))3,VR^[@-!@)"[(H>=[AU 7XW36S3)]38H)YL,'G(>U(T@
M7#Q36YR[@> GO?#/5R@"OVCEVYZG34B'MUAFT91?99=/K!C=[<XI=L,V!7JO
MX:<B'<L;N\M6Y<\!$A"T^:E@O;-O;Z75['"5O7+5!#:/+YKOE6/\2O!?8QZ@
MXL?9Y&/,:V:+HE=TA^6TTPJ[8\I%[,7%9.Q7UX7-?3&)G]LKVD\M!,_CA^[6
MK6NW^(C7UKKSNN?+G6>N*6E[Y0Z=Q[CWQF>S:CX*V:YS2]!A8I./ D;][?N1
MXK@_L?7&KCO^1VD^.\\*TNH=RJ^]RMM;A&ORX=-9G-[J\<U/O+I&V47%K&PZ
MO^T2V!/V%2S?M!,?K>\[4Q28=S99KO3M=K.TFP%("F0OKYK7XT-+W(OYS,/[
MYJW=A1J<S;ID'^6(_FR:RP!&V84*^M?K9O<K ,KN]>:&=6^RSKW)^"-;'/)M
M&"1S?<];F4-MR/[@H@0W<>/$CEV:T3^6X4/N-[[RGMAM-7@M* /?3.$5Q]-6
MBN6O2M#BRK^RPOS3T=^BMWG@3G>9;J]EY2?'FK(#H?VEB9M[M<7D/F:UQGJ%
M[[MGRZ\^NK"7Y>';> >P/AP_'P.&7L7(NKVT"2!]H"8VW3VZ1UQ.U[;4^GY<
MHUV)Y, CKP?A^KTTCVG2ZE8V+TX+\BT(Q/X/D!V=^R3?("MCTRM!T)JE5U!R
MG=CPCFL$?E3J3W,$_A8>H\$E Y3J[(/EH. 93Y#C7G'-M*1\R]_RD.+6/];6
M'52[OW7AU_M8*JB)/NMSN5E!$Z<WO1'VF#&3D_@I$_!TWB#C&$>",&^YC%@Q
MLH_ZL$.\T72V0S<=L+*ZZ."T6#67-V+JN$7"!%(/%'R02$4LER$,52JMI%)A
MI4PL0%B S3;&':=V4N3)FF)\$YD[+6 ']N7(V4H_\[Z]:58ZKA9B,^!^;^0;
M/M))A0D'$$"<49&SSS ">U0C&KUPF"=)U5:9SQZ1;F7F_M(OZ9MI>->M]1OO
MY\L8#H"&VB@N= 0\2UPCGCU3SN<WP"(J(HW5=@O?]XB&!W_K8T/,O/WR2U]M
M\]E\;9?;XH?OTF&Z_;S:^>M!H(TM[>RDJ*?-68R+X>9TO%YX3^-);(WJ>5PL
MYZV9 ;=O_'SL8&G=Y2HQK=C(G;+\C^5\W(2Q7TG1+>OW=/2N98%IWB,3V,C+
M>6L/].;PED=]+<BY9HGF1^@-\ SQ;:'<Q@-DQPNP;&_@%_WX][,-ZR$_-[P#
M[-9%#@^-VX2K=7=HB1K;E1DQBJ#BP\-TK'YE/]RJ*_SU6CK!9H;"[AQ6IXF-
M.#)DC;:(.T6S7]XB*V5BS 89S%8.ZT-<FO :Y^-%>6: N^_+4WX .P9V^-MQ
MDZ,MRWG\'>[QM\G,__D5&$G>7L#Y"T"&]O[P5C&\6=SUH>^:(/$LK;(^M=DU
M;C8)ZSOMM@2G>V08T=/1&LD+_VX0_; @=&A"[0^2?BKV\9#D0XD8TN]N4#:W
M:VE*9ELK/6?9W;%:\S: .BDN7_MA'CNEMJ1X3A> JBZG@\SFEVU^1L["!7F9
MW[!\T<)-',7_68XOBL/CZR;&T<\S $'QS8&-E.-AH+5=]I*Y"'@#K*83T-6
M'5KKJE1?1#O/=>JS2<=.?;U.CCHTLWS%U4%K/-B%V<<YF=O.BYIWQ5R$?5-D
M>$Y1;.]SW8>T\;!-G'\<EZ3T+UX_^]0OSBRH!#XN%ZT3V$Z7"13B+F-CNOZL
MN:9DO.[#_X(V<56K#^":U85)<92WN0A%3^V4F?X=RN,=IB9%Q(B%L1$QDR@8
M*KEQJB,):49B5)8ROEV$E*0CWCN'*/%@"W(0ZL8;"P:19Y%2:YSV&\'VGUIN
M>-,3_/?N36&Q8 7AQU^*1W';3 G+>;"7 ]%&V3%4JZ",UX=A%2DLID2 )>N3
M0CQW=#?,<T2X(R0Q*IS?8I60J(K9^N4"9_;"'!F3@-L""5Q2(@.++Y!5Y%&P
M"M"KZ?*-1I_F8S X2J!DG$M.EM-)#@1>)5R.IR&')',(^\?E/']]LDIHVXQ]
MKE*8KN'E%=P"*$XR>()HR*D>=IZ#@%<+7:#U$]P0A=FG:1\_R:ER<2M.TL4#
MQVVVZ%G<N X\5W::>C#T"X OLKU4(AWCC2>^@MYLVVV*GBP'@&8?X[1DA&T9
M4+7"XF%*VM J+$2ML*@5%C=56.S3@?""+9L=_H(A;.[.MOFQB([Q>9N$"/^]
M7AMXV;K6>JGF^_?9B*QWB3#S\54\O-0:YI+7;65_LZ)R+425_US+(Y[$#R"?
M4FQS&\;3KB2DY$<4;W=.>+CR7&>A5 35CF>\7/D.U])M+N8SU^:XY:?OTMM*
M: ML)OA\E1UP;D,VV[))EF^P<4S77FRMXK//3<A: 3Q3KM9LLP-:WVS&^+!)
MYKZ$U!9+Z[*MH,D%MFW2V<JKN9:E Q=NJT&N?BSD*MD[I7P5C*KXV<>++LD"
MSGGO%[-LP1+:A]=^G?D_XV+TRX9-!R>^F_K3T===#4Q[4%\&4YS.N50T>Y27
MXT6_X'^<_G8Z>CMN0)_P"W@ST(=6Y;6_S9;Y6:=7O^>Z(^#:_Y[-_P3% CBK
M66Q0)--Z^+$_+K4*R4LDG>%9DR?(4>)03)8I0GABTCTZ*QLT*5BT]^G'7&L]
M_^'\8C*[C-?&:ZQ]>X\@U^+3KBC7<#"J/#SP:^S?+NN/8SCZ VS&\UFN+.A4
MW);=S\=-::IW,1^OY0E.4RX97^0MLIZ04Q(!Y["Q1TW.\%ETL%1RG7(Z4]ZW
ML:U*:Q7]C^.P[.8!3H,MNC=HXI.9S3&UC=MTN\KW->,SO[SR(+>/W#YE7&2$
M['=P<Y5*.XGV8][YW95@B\%^)5WRHMW<*LNFE&J,FXW7RQ 2/A;G8UM--OLP
MM^?P"%GCRN=G]XH'+NNI"UMZ,?HI L==)T03XY_9AY6[A(Q3[J$8[+G]T"53
MVN;/ILL2RUL^AW^F_YB--P(OK862KQ@7O9L(N/#/_+D[$@1\?M.,&-D!E+\#
MO@(H!&#MO&A K _M^=Z"=+%^!%9 <3T75]>;Y0?0\'>XYG(*\'Q1%FF9]>O"
M1,T*=CH:YV?Z+3.UGP.-1K_E,L'13S]]G\O^/IW-LC\J)S1G$>":,=Q^7K+A
MVK-/RH/OXK\-%CMILXG]RA#+)M1BUB9)KQ5#7=B\ ^#PK"6#P&GY>)'W:"N&
MX)Q%3MMKP[U=-EOK$NL//-V)G]U6IHPD^I1;^?UR?HW\F:N*7[PT6<[1Z'%,
M)SUKG>0*Q]E\&B^;?^]4@&E>P)P469CIEE7[XML_4UYT4ZHINPQ&8*>.\X&)
M_>QC!':Z.(-C3D?_=3;.E9J+/LZYWECB(B>K^Q8 0*BN6GSTK+-H16=NR'$M
M0W)UE:[+R+3K$-'J-NO[Y>H)2P+T5:BU39T?YRK:JWN#=G,]^ K $[/.=Q6$
M+14&0+YL"+;N@P K-9FU,9'.)0$[)Q>SY6<+XU#"T#5 TC+0.S!ZSZ< OET"
M_,H5.$2;XMVM%L"VD0%KGSN[E*Z\ZR\*)WV$:Y2<,C^[:*-JV3-58G"PV0.@
MY\DH^^7*AU6V?E:D<_G)NLSMHAAEOW1-K_)5>M1=I1?TN?/Y<HO"_U?E@B=E
M_Y24FG%;W+@L#'R%U->=9<#L!;$R5$]RDO&R5=/!)EAD$$C9$QC;5.X6&O.6
M;,,=:\&7^X1SKE/Q>E3GO$2RFG[C_6V6.P+E&%=QL\TZJH$NX)>ETKN-:\X[
M.Z_L^=Y1N?8<NY6RM<<I 9SSE>#MZ;YE2&:&:(U)=]D95AV*C><E;V-9J-H%
MK;)Q&%8/GNVB[FE;/>;<?AZ?+\\!_Q:=>F9+F[=2"-7:?"MGZ@8*%G]LL>S*
MFY8TDW/[9^RB>6WZ^Q<H/6YR&49;:)+!ORD.Y):1[FP9GG66X9KU>Z4P=O+P
M6N)_X;]KS_7X'!=LDC2:<I1(#G0$)9#)<0^E)!=)<$?C5J/[>YLZ?:!C&MY<
MA4CAKU^[D.+WZR%2^/ZW/D#:'W"%B_=/B+G+&QZI/VN/.3'L=/13'\=^LQ['
M_G45]BUI,M=CV:NENCIP6XB]=C'_)BM.@%5_&\]*F14\UX=A^@W?3T?_GP7X
M /%.1?$FD4W@VI!'61W]#$*UR<*D2X.X@LJN_&GWNV^ZHKJ#5KZH(EQ0?\4K
M0[K5$KJK7%ZO_ES9E,6PRK;D[/QR!D;7V66)I\%A/^99 ?.8<Q+L B2('7W]
MU8]OOOIFHSE,_\@K1NZ?J\AJH-FT,_56'1&VSM@DVH>N#9O/!7AM;X(+L/32
M;#*>7=F+;=)D:R..RKBD+&97;]M:B!U- LCZQ5D6,%M^@Q[^FK9A7U''3U;U
MD5=I%KG_7M,L<]>8R61#;V]-LG,0$SFCLF\IM);V 3;^)  7@5'S"^B N1->
MOP:W4.+"CK./$3@1%>_T\@*!$C7-VM@4S6,"&5S,1C -CZ3I<1!!)48#<CP7
M"TB6<_ZC02(%J1G'@<NM)-'@E*#*182#SB-$<L8\]0$9A74*'%[>;C8Z_:75
M9-ZG]].8W_&/BQ\SU7Z>37]=T>S'N*.1PP-;W Z\E\.JQ6WFU%S"ZB;9?]XB
MP476,C\ ^^5OMOBZ*R7.F7WG.<MZ,<N6*[#:\B*?? 0,1ZG1)%B)?(H<<<<P
M<I$R9+ J37<)5EL,9ZRW.FF/ B$YIF<D<HXFI#'5202-8\ ;#/?VBFQ%3^N)
M]K]7-'N[O".[W:&#R+$PW%KY]5%TEP&M5P(.,:12Q(@G8Y")U"#,O.)*4R:P
MWU+N(\N: $/11X>X8!Q9QP42GEG#A)%8N-W8M,8S*S;9$R*Q8V&0=;A9X4MG
M7F=[SI^-X8@VV%ED8=_P;CP'R_E_0/'*;GR HS:.5WQ^*RQK;"X+R:[0FV3T
MD4*:B=Q:;2E*6+L\!( AEYE52NRCX-$JMY5M=V](^_XZM0Z"9=R<#KN!6\^J
MNSWIC\^<=-)[@!N/I,CI(S9G3@H%UG>T@0-^6!>VAD P9IA57"/MN0<3G1.D
M5="(A.AT#,9:L34R:.4:F(9U836?V\[K]GT7,/E]]DO;T/K'V?Q]=F$U;TLA
MU47G;,A9E\U 4K/6$RAVZ36]=@U:>$D?GUWVY;[PUEDL%8_D&=@.H^S$G$04
MQA_&;6%#LW1@38#QD/M^M.6"74^L*X19*?:E@WF+-P DO[0>_&;TM;UJ&]DA
MUY;"OU;^,-Q\T)OJE8NU,@="Y'\-'S@9"'@B$T$^3QCG)'D$0,H05I'HJ)/B
MV[,(-9@G3.1]1F-N>)"3G%6>T>!2($P([VVZVV;[H2T7WW]![H#X9+[N_EJ7
M[EVM?'/5TN!:(4.NJ>@=T,7S#WNPWRPK5W,7\^AB>5M[:>5SMUWLY>78S4HX
M*T(V>H6BB#,)9HR+"=G(G"6*@2$L]J>;5KOY^M"@S$Y'P"8BF=*%!3'@%H L
M8Y$-*2+!G3:.*4?T=BI6-6&&8L*\INX">XM''$*KW!8M\Y@GA)0:OBZA8SE=
MC">;Q2F+K>Z/$PNKW"J>;2W)5=?2:[->LLSJ:TUN$&\'+/;CDDM+P#YD.>+'
MJ033D,.?*8!E 2J.)D0^VB_[,BJX"#V&$J[1S25<+>-MLU=F04#GV;6*TVN!
M==O'7/Q9S@TM'4U7H?CM3+UL,16M[:045TV;W.ERZB^S_M?59I5L[YKDM*J5
MF$_C9#+Z8SK.^6/CQ>60V.HJ\/F_P<"FNMB!^ M!S^'K3$SJ9+TD2%(#.A-F
M%+FH([+)!N.((U)N-14/R29L%>C?"M0E[@//;? 8LIHH:KU(PL2=Z>O7(7 S
M@3WW;OH0Y^\6\?QEI;!_(>[=)6-ML_TJW-W]M IWKP>??RQJ5']R1]VM4/1*
MA>_.^BTWPPXWGW;2GY>[$?1#(=<O4)@?&/_F2S174?",MK<\9W9?]64B:Z'\
MK$3LC-^OXN'M:6]^>?\#6JL9>C/YYUF$U9JO"FZ['/%"B#>@N*#?[?($T'YQ
M-EM^.-M9H]L_1)=_F]MIY:*5UG3OTZOZS*HVMKCHVVOE=*P&H+;M;CK;M/33
M:&U%RZW>_?QV]?I=Q]4W;_X^/R/X]"R_&QU]+(EMY5(Y;:&\,1^=S<YG_[S\
MD%/ 02B-6VXZFY5&7S9G!31_ENO"_Y?LW)OI4CQ^%YFLUW-R=Y'FI_]#,"9]
M.4&[PK?QU'V7>#WI(9_WXYL]+M?)8=;KE&#_Q]GW/_U,KU8*#*!)F,<N_:/\
M]C=;M)%'T)ZOTWZ^HLD=MN5VJDGSC)DF_<RF+=_6O=\DITBV"2KA$1DJ6UG!
MQ8;I7^WJG6NM^PNM=9>UUOUEU;K?5+=^QSS?!Z4'TV&G!^\]7S5[A<:+-A6]
MG=C;4KH7D?<&\^(H[ _.8Q0NVO!%WR\^EZ#;YNQ(8A=:89>(B8ARF[OD4HFT
MU0Z%J(A3D0<IME.P./9>R8B,S<VG9)3(46H1%A;^/V$IW6:^PA\MB;X'LG3^
MZ3UYHO$I&[9MM1ZF&(,&$(]B !)3F"O! \(*S&A.B$!.$ SV=VZ#S*4QVXWD
M[\,4?2PV]X%KWA6RD#UQ!#D6CLC3+O+K;UC,/:P4PFRD:J\&T:V[=-8.;I7#
MV7(! K]MR7 Q!_MA?&$G1X)$.(K E;)(^YP,JH&!#.>@FEA'N%>$!;_EY191
M444Y09*$W*S,$&0T5BBH0%-DF 6WE6WS-KJ<4%,<&;/I>[ 9<KEH_O9-J;IZ
M=9Q8$D1\KL.?3-IDF/BY&YF8A>3P.<=)X6S.&PZ4&9!A7B$C(D%><FNX<890
MM=7?/@HC7'0(@(HAKJA!)F$";Z&MM8%I@K<ZO6]R3OL);/AW4[#F2_N$W\[L
M?#>@->67^TXC9$R=2#+P)+SVU4I97QZ_V8S>M(W7YHM2RPUW[V:=E?FIJS::
M/?6.Q1-M!$]6)< CP7$.PH%\(S@A!>*-$:Z%Y%LRT2J<C L4V1*]]S@@AY-%
M@@GF&2QTI%OP]$M/K]\RN;Z_HN05<^54C\=S%Y4G5.ACX:WL(IEU,WC;YH&+
M!XQO;>?X=17*UTV"K7[QZV6U.66Q%[A'DXSL+*'>!(.2*O45T2*GJ492$6YM
M3E3U6SP+N"A-9,"N"><QKD8C$, 22>:!\TG2S(@-Y?ZWMN>*_[YKUWCX(@M]
MRH?-MKUD7?%IEVG2NTZ[-C7^JL7ES?4\5_EUMX4I\C6.AC59P):SE!#5+N6N
MM 98,X(9*H3V@5'*M_M2$1P\-YZAE#($&Y:R6>)RS1"<0S!C1#\S:_)C4?IR
MIM.GC5C54;&/EDY@JS%*+ "R*0V*OP.[DPHOHW#4L>TRBZ0E,5(KI!B(<:XX
M!P-#4Y0HX4DD8N'G9V8??"J/@WVR86#[[A^KJ,Q^\>ZVH-UJ DS3'KB9KT=S
M5ZQ;[W<DMG$(V 0/QHVG2B%N\ZQ"#!@8> C!<$=!T&\)\I@4 :9&Q$0/]K3+
M[=XY18)'9500U.06\;M21[_,[WMSW9'C8/6<*;HVN7.5*PI V;/F>'<I_>T,
M?*U(IB1XW:1UVE&:V*M\Q;XIW3B@S?J854G,1MU+Z:_5U[Z49EY7:?Y=#+$Y
M69^0U+>^:>>\/L7$PL'&$/YH9Q=?C.<;,Z,W,D=+\MV'<>[MM@K)]MW"RCC9
MTEIN?GG2#38K0=SUG!L7<[>RIE1!7&7D%-QJ[X,2L,VU%DM]0M\= QG];.>;
M1U847)^N6AH50 <"Q9SQ<YCD5B,8F!8!(R4H*'52)( VL%%P< !MR@AEMNI^
M[AV >!G)K>88<EN_V4AN[1M\MLFMZYB9.=NMV]2;@]#6IA%TZ:O+W%\J<VQ)
M8^T*BB>3%7JU>Z5D@(P^S.VTX^[U/-9.N=AL?];V#X$7N&HJN-H?KQ7QWD]'
M;R[FX\F([IPDM)%$FG_XO2B"VR;I>FRC/>;VM+[%[$,L2[:2HW<.T5Z+HMR<
M][>1UKC=^>6V1UW]E!-[>E[;[ V](ZNR],;,FH[O&[1M-E-=,6^9+M2Z1N%*
M65T"?EB&[%O-"L6R3QSKGR+/,(QG=I*N^<':+7)-HJP]S9_3V2=T-OM4F+]E
MBRS$UGO;=LEMUSH0E9RE;LQYF2'6-JD+=F&O/ST\W(=9VT3W8^[W^2$KDZ@-
MR>>#?LD-14?D33OD8SU9[>S'__/S5:;:UD.<COXV@S6\VOWS]9K?-JOJ8]O&
MN%5ZRI*?+<]M&XW-5&G_RHT.SRXG967Z9%1X^=)J/&?0-:<;ZUV4M)V+WBY@
M?H?BPRT-;Z\0[RI!;T6)K$SD[?EVOOS0#Y=<7)E7MZ_$:\6GJ\2\6[?JCI9-
M5]F8S;*M,^T:TO:9(H61%[#$#2QC.6!-<"UF"R (</01V(TB11>P8BA@+D!1
M<KKULAFMN$U,>;==F4H=$20K9$)@L#6S?\5:'A'S4EOOG8V>_/_MO6MSVTB2
M-OK]_ I$[_:N/<NB<+](>S9"+<LSGG;;?BW/9>/$"4<!51 Q30(< )3$^?5O
M9@'@7=:-%X#*B9BV2.)2]5165F8^59F;_<8:?<5_O9=2U3M6@+X#/+_5<&[O
MC&I7@B5][7S&. RG*V45ZO(-X.A56<>;1 ;K(MB12$4@N&T' 1-XOM4V#9<%
M+OPE?=OP3=MWO'@M">?S)>Y<@?6@>,V%2G] IAR]!]"T6ZRJLXU*0-1^<FT(
M:RP(22A1A&!9P;0/8CFXH!8N5(KSO&*5G,T3$V+RWZH4J$IFOI2&HP."YP@]
M"- )##TS9K:T(O )N<O,P#4<US!CW5OCNB)/6*8?Q)A4RJM("![9/H/'V+H5
M^A:WHQ\)7JWP?IMC]WZU[,43Y<_L.6T7OVX0!)&+F0Q]BWF^[3+;UW7&7<=B
MTG%]SXUUZ7KQJCAXD6/HKADRR\?=1*9CL"!P0@;_#T"=Q8YCRSV+@],5=:1\
MZJI*T]*QBOG!AKH6TG)L[ <IP]72N$Z[XQ(Y2_+3C351"L_SI.,P;F,>*3TR
M66B(D(66(?38BETW6,M=]WQ9W$11;<GB,KL2LP?7<S.[-"<Y.RA'1F3*P HD
MB$,,.DTBZ6GJG#E@Y ?"XIX1K1V&-743ED6)?!$2I88E8('400_Z1N!Q7T0N
M)D7?<FXYYCZT^:CM2FU!D.8Z;$&0>MIX."G \KJMLY-IBGU92&.V2,!0ZI 6
M]/O;P]$"-7?4J<,J654T@=$>80;Q6=1,G0.<YTZM/B^<#"TF876M*LZQ<-"O
MMW[*K[<D4#/1Z6VNP]&;%1:IF8N^=@\Q54>25,VB18ZJBBHML5(58[7$337K
M;X$I)*!K%0NX'$7LS1Z,I-1B3+'.L<)58YL 8V\1L6QV;$DKH)>J;@H:#POM
M4L<SZT;1W&E!OYL9@_SA<B*<AV;42L7F-\G;FL"IR]8]=/^;!4J:8]!9UO5(
MWO;@8? T57L&SSG@(0@5<IXN5)B<)4)1H@?ONP%P!28P:'( S0S2IJ 9/!4?
MB_.X:%HYNTJ)-D:2L:;.:F"WJHW7Y'/!O:5JWL-W;Y*;M_-2554>EEE-GYD.
MF,>957D9C#,_$>Q4P8%K3SV;6#AES<0*>8$5^)8'9-8HD8#45?17K;6J:J*P
M?LV5QG)0X<G2H*K-8*4Z6>6;J5J[Z5CS>B1=X;@V%KT%':.R%"Z= ]]A3J8H
M-J4I8I\%//*9+;C) K#(F(@<W]4-;MGN6KCAR7$NHJT/DY)I>2*O<=>T)+6@
MW^\F>:/3IY+GFDPQ<>EJ%EQK95/_8H5FQ09UP.T+8R_P7--ECATX=2@K<!WF
MZ[9GAX%I1QM.GH1>K.N.SPQ#@*L88S34=7%[M>_Y,HXB)S*WEAGWH2B6T8&@
M^CU;^.[?2M#7'B>!]A%(H"NE%7JP4CEA9#+;CC@+9,"9B&,KE+KE<F^=1@S"
M6%@R9J[N8E)[73+NQ)SY(7=CWW%=PW9?*('/9 V]=DOB4NCA21+9D95@YUGZ
MKL![QA,-W^;[..J"\6T:Z#I;W_V-G>58JR^9;UY",@\<?YX/IYC@Y5K."WE7
MTP;U4IK!GQH7,LV6TH^=_Y556X07MI=@P JC SE71X&KTM6XURBI$H@M%(O)
M\\&T'(PRN!LW]*]O#/KVZ=,':_&-@RG&+W"3S=H-?>USNB,#/78Y]UPC8KIN
M24R "FWR!*R PO"$X-S2G;7B#4+*(+("EWDAF/*VYX*!;L@ E(?E2<^,C-!<
MRV'P2UW.=:'2X*7*09O<R'?0_\_QPB_&LG+"9+1L!$T8X#,9F* ,5Q*&:0-;
M(:-_GH [:+A5];P.6/$K5=6C>B=]^U=8S[(#X0<&XT* :^B8 0O!L&.6Y\"<
M-T-8-/VU\TS"U*5A!"P.I(FGBR4+/,O!@W%V"&:BB"WG$=(*/B0FN@(M\CG^
M:X;%ZS^H[9U%65T% "XMO>-)+F=K+S.?>.JXY7;@STU<:#&31G7H&'YH=/5"
M!O&J8KRH8JM*+8/FPZKO<X"U<;.]]/WYU2_:^=6%YNM.;U_EW]633Q/<M!8]
M 8E&4G VA770H55E/M=.SZP>G*EYOCH[N%J\.D;X"<\+S$B"J\==Q?KA]CT'
MW#_=ML&1BRPS#%:U@NY9G@OZ@LDP"M!6UUD8V? Q\%TOB+EI<'&?5E@8ZHO%
MD_'-YBH ]Q(P+J<S#5'ENL"=?IOR$KRDD)[9E2(#=<1RQF5@RH(!V+9U]?)&
M9]QW-K() V^L50"6H.)<NE2GSS1$"/)F6)BP68B ^1$'D172\\PXB(U@O?Z9
M<#PKUBT0;FXPVY(6"S!-@=3M*'!"TQ+^6IJ,O8OL@XZEVY%J:8^NBE&?,*P.
M^2X?KK772V9DDQP\U)7+^MJ[O*]=HE5^+H8R7[+/_A/6%GA5K/TFA3JD^SF.
MP:G-U;/_)+G IS0A@5[5-I <!J]2V[\7)E=UT&'#% 0'(^Y,?1BIQZ%MN"R.
ML8P0!\LN","!X=('TS"V)#?6M'WLA+X/'@TS3#]BMFM(QCEW5?'>R#<LF#WW
ME-_=87V8CL^$.I%C3\FN$EL\_RL352EF/,ZSNP0/I8%GU &A,F0(VE6)!:9S
MB84+;C X%M)U?6$ZAN>X:[FQ'!X[W/("9O (LZIY(0NY[V(^+6GXD6.X]K)0
MS03H:XW3*TNAUI\I(E12X!9?+QZ.F^7J3N?!8:.J2&]6!Y6DBL>HXC-)4:[E
M;U[,$$L9G+N<P=FC#,Z4P7DA%?.S,CA;[<[@O//P_E=YK9(9U)&:A:(D6 T!
M.@!K2IKPGG8%C7^7R.NL36O&2MA_Z2CU_)3N_"3KAIHLV>QTMM64^%&E0R;7
MH)&U*EJK;ZC$\I>+JW>/+;^R?.WL</8\<<5P^G9.2BT,B;H1^K)01J,YPE\7
M(MFTN7%Q"^4&7F*%=:AV!V'Y!_ L)D.>;^(A?D []);ZL5@$9KG;,VPV@E*W
M>:4DQ[QZR6*%U1AZ459]P1PM'_^. 77U>/6GV93,*%:;]F$S"_CTUJ[7UD!S
M=E9<X\75-))R8Q&-63&3U1H8<PE_6C6,1]7 2' SW0]'];X1K4.(LTAO%4I\
ML%BMROBNSLUU([)H1Y'EZ#Q@OFUR3/7(F1]$#N.1[EBQ&W+#63N2$MJ>X[A.
MP 0FDH3[;%B<C! \B]B63AP$W+W'UWQJR=K';RVYATT)8S,P=8NYE@,M]<&!
M"7S+9KIN>'X4.8[NKP6A/#O@CHAC9@3H]!BQRT+?\YCE2#N&*0TK\CT';G;7
M._.^C3-M]HE0QZD-KGQIPM53JUA20\U9U%E<_F%=L'"8!Z9:=Q(6&F8<<LMG
MNA]BJ?+09J$;1"STN AU1P>G>JW.@NG"]/)LESFFYS*;FX*%J@RH*8TX I?<
M6ZGAN1#3.4_%-D[R/";C9<MS""^68.B H#@B,BQ'.,R7/FXL=GT6.J;)=$_W
M/,<5MFZO'?*RA LSSO-98'LVLZ4.]T1<,L.*,9$JZ'37/[B@F!W)VKML@=4F
M3W;+4-',L^VMG?=J+MO\\^I#9TGZYJIO?EI,62Y9.D2KN(I^JZ<O&935GKAB
MOI\PG,Z,EGJC_&(6H#JFB>FTQ,QB7;/:ZVIM:UL8%Y)R+A5">X;-K(H-*(+]
MV$PJ,((BX>I8B\+W, &!Q0*)?X5.S.-0-[FY-G&CT'6-.#:88QD&L_7 @U4!
MK)4HBOS8=*43><LG GYL:[SHK/D]AB*/?-\/H86>#>K(<0W&===F$0]T#CVU
M[/7,H[9MN&9@@$GI!ZC";)V%L>&RR-0-P\1JU9:_KUX=B0FUGLUC?DJF7#TF
M](QIR4MU<*J>D)AH']#<6<['T T]X=H1XX8-]GF@@X $3LQT/#9C6;9C1VND
MQ).]CY<?GME8BUT7H>?"RTVLP&Z+T&3<M4T6^\(.HD@XNKU6I49:>LC!R&->
M%-F89L2"5L-";1A&Y L]D+$NCO#<CWO_N9_V[B!\R^ZOS7[/NMF5?=<[2!+Y
M.2HS-!3L:H?H#[)$+F5$_$%T<T/*R/O#EDL5H%\<&ZM?NOS32LK(K0<[5?@/
M [CKV?Z>&/2LEHA-D-7O*YX=J=3G%7WOB4=N>NVKBCC^&/YF8^*&T,?C#>&.
MV,&Z)W33Y2:3?@PKI!>HW0,>\TS#!3<U@#5\+:$S]R-36EAEA@L3+&98'#D8
MTTSW9> '7BP,LSW!M_8L5LN!M1V=H_ #,_)-AX&M#T-CA"X# RADAANXPM<%
M-\*UG>EF;,%U+F>ZB?>X9HS'O@P6608/[=#W33M>&L[SQ@M^?&!"%E&>C/'+
MEBR'KS.NZ;HF=RVT: /<7R3#F'$S$LP$FUR/ B'XAOU%#IC,,1C-KF4'X%."
M=\E]QV1!H$=&K*N"?0</5]D=V<3VZ #5#T-.'3C;,]L*^KA@V+,B8/?$N3:N
MZD^/9'5D 7=#PS%=6V>FP!,$?F0PW(#*7,/R/"/BPC?6N$$9ZK:P\%PPCT-P
MBP,/_O*P6&(H P&+OB7<@X=\6B3+8)K>JBH(13>V]4OIV8[!=>;[/IXP4V7"
M(X_!,N\91A1%MK^NYL.(>V F,"O6):CY6(>EP?% ZX>&[H26$4=B[WN3.U-V
MZ+&[],4\"\'&G?I/BAQN5'3[C0W&L6?HH:LSF\<&GL'UP-X,7.9$7AR Q!AA
MN%88\,GNP]$'V-HCT!10>TI ;4Z]/1A1:_^B$1J6ZX!?P$+7\6%:<LG\P(A9
M)$+3#(7I1'(M![,9&(:P[)!Y(#"PT,!J$UJ^9([G"2Q!:UGF\J(!,@]X8=K;
M.G?(+'*WM&+@\:]KF7\HY>A'?H":Y+!HW&:Y*/ 8?GF;M7N]*$ C%QE*Q9PL
MGF\5O3=HJ<*L/RV$2J^^GO]42=M/BS'2ZNO58.MZP!2NFX=*XV4&>A9H;(*=
M]V]_O"_KR4I0MJ_]9;.E/FO+\L1IEKU8];>NLP-S* O5V<NEW)9(GR\DNIPE
M]$33=);WDH4 M4KQ.9;Y6*KPK@HQU\<.E=V_%N:>)2B$H9H,RZ8L3A4%U;+;
M=.ZZK(X7)N?8=-,_LD3E[*MOEN6ME.F:\[/AB;W9#\V%5:K/!?N@J/(D/Z:Y
M]3,J8V,V"!6).>!8R&Y7X2EA&E9@F,P)?:P)'(4LU U,G&#[AL^%Y:WK&"/&
MM-M@B49F'#/;D"8+!=SMZ+C]T35,*["7=,RZ;D&#8:-U,%,<K= .H+U41I$.
MV E5BEJ4R?4BA2K3S9I3OVJ6XH_7R<VL'GR2[\Y*-3V3>SXXN$$$_[&EH;/
MMSF+N!E&MA5%PESSD5\N=MTT4ZU.F*G:T\U4I>Q4.2@8Z:)2ER"XH",SN$NL
MT&V:*D=V_XJE*IAU(!3@A;'!?4MGNF6%S+9-DP62>PQ/DX:V)^W(?Y'H_S@9
MW'F.A6G4;+B 5V#3OF4P#7 &O,_RSTB@%A<X&A_J8. ?\ZS85@$$IR,EIWHH
M7?#::+ D@;/X: ?$+-(]B]NQPQS7 4? ]EUP'H3-3->U#3WV@\!9*R1EZX8E
M;&&PR,;(I>?B@0;XBQNN$T2VY^AA?(B<@UTYQUPE7'XHRBX>EWEU.?#4E527
MPC4D-^.(Z6ZLDC" SPH"QSP16*X;@@O*U[3;<\2NCG46W[(ZR=:'] MF+2^*
MS0*YM?!G-S9AWT?0_,@]5(OHLX13)%W($1<'?F :IL\L&6"NCP@94U-GAJO'
M3LSMP)9KD=%8AK8K'<%<W\"2,;!8<]N 9=NT#$_(6#>=1RZ\3].([H^C*FF[
M@RIEM5(VON^#K.-69-+NIL*, AG[N--'EW:,B?!U%J)U:(,A'4:^$3O15J3R
M8 JS(^F"=ZLP-]!(=3'=:#*:5-DA:E>H&R0W+,NAY4F'Q;CSQ';B@/DJ\8(?
M>(X(/>E':_NX/>D%MA^'S+ \4,"Z [:![04LE+YM<0F>4+"6'O9 8MN5W2OW
MB2U7?V[(I?Z0/+<JQ?-KK<WPN4E085B;<N O;PRO:>L?\1@/T!CKN\5!$AY'
M1LR8A_L$:^-^\7OIA^4F$ =Q. YB>22JO> [HB!T6 U<+@,6&3&6]PQ=YLM
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M$MA%#P]%;S;!*J5KONU5YZOQIMF>J%ZU&VOQBRI)8)5QM/JQVDM5^5C5*3%
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M"1,)$Y&)+7)L6^/,=C)40&0BQ9$.KK9?;<R1X"%X"!Z"A^ A> B>(X+GB(Q
M(A-W$T<B&O'@\_'@-.(3\K+ZAV82[\F"^F>>3G@^U8PJ':O9T\I,95=](O,X
M5>3BHU*YWL] /A&<QW>>DJ^VW-+H5.27.$X2)>(X2:+:*%%HF_I'#!8)$W&<
MK79VB.,DCK,U>)!P4"B4X"%X"!Z"A^ A> @>@N<(C4#B.'<31R*.\^#S\> <
MYV,)SJ"M!.=D.-7L%7+S:2E:7\1MJJ^7VV8NM<UX ?&JO?EAJ<O'/G*5!'Y+
M=&F[C99.!9&)+B51(KJ4)*J-$H5F;G#$8)$P$5W::K^)Z%*B2UN#!PD'154)
M'H*'X"%X"!Z"A^ A>([0""2Z=#=Q)*)+#SX?NT*7FGJ[Z-(9);D0P_(/2)H^
MCM=\H$6+U"]1FBTW+#H5Z"5*DT2)*$V2J#9*%)BBIG[$8)$P$:79:M^&*$VB
M-%N#!PD'13X)'H*'X"%X"!Z"A^ A>([0""1*<S=Q)"J9V1Y7]>#<YN/3W9KF
MH>G-A\\Z5O$L8UXU\US  $U&VB])5LIHD$)SKQ.Y2%3>QV+VM&6Z<LY-SHC+
MYO7O99BK]S?T*N6^/=X%MA7X$/-)HM1&42+FDR1J^Q:K><1@D3 1\]EJYX>8
MSPZYD\>.!PD'!4@)'H*'X"%X"!Z"A^ A>%X%/,2%[B2R]-+ -_EG;1*5+9SK
MM/5 -RWK1'A.X.E617P:AR8^EX]*6FN\HU'EF[6W<ZQ3WLGLD,<Z-V77?>1C
MUD^Z'OR,:$<7' H?MXXH)4DZ&DFJ>%+?<5T2*!*HEABS)$LD2\K:'.?)4*L(
M4IMDBAC3+GF@Y)&3<) V(G@('H*'X"%X"!Z"A^!YA? 08[J;O?C_10X:4:9(
MF>J!HQN>CI2IHSO>R?!.9@SYTN\'/RAZ.1H/LZEB#]<HPBJZ9>@-8[K"?B+)
M>)&-H.75]W_."JG]QM.)'&J?07]EQ">V>K7J4J#5T-G_H96=1&D+HJ3K!K,-
MWW%(GDB>MF3JD2B1*&V#3IQ<3XI2,TPB%(E0[)Y_1OXJ"0=I(X*'X"%X"!Z"
MA^ A> B>5P@/$8H[B3)953I:\M*(5?PQJV@=FE7\-DARH=U[]K B%DWC'F)Q
MP\E)_'F!;R1FL=7+5I=BKL0LDB@1LTCRU$)Y IMO1UDW291>F2@1LTC,8H=]
M-/)923A(&Q$\! _!0_ 0/ 0/P4/PO$)XB%G<";-H_]<?R$,[0E9QX:"A?6A.
M\$<G#=_)J,I%:OB//&SX*W1 ^\J+D$<#8@-IJ2%X"!Z"A^ A> @>@H?@(2:O
MG7X1^8DD' 0&@4%@$!@$!H%!8! 8;0'CU7D]Q)R]F#ES*,GG,1)G6ZZ+Z+>9
M?)O51K0>R;U=YDFDG8NAS'O:;_UW?>+?6KU@=>F<PH'K!NX8JA:+4M?7XG:4
M"7R]\M,*?+9MW?E'C!7)TCZ/WU&=P*TXK_ O#X=2_2F2&RT:\J) Q*XE-#,'
MZUB]'=X$+<,+ZH;]BR5@.M^=,NLL'LH[)I)<1LJDAF&>C-(SD13C(9^>XJ]K
MZ/8=P!<;7?O+U1?_F!1E$D^;]JM;F4S%V3@K$O7L7 [!;K^19V%VA_ C '4K
MX9M'BK5APN>#2/:\.3]Z_1,4JKU\,![&I_XO#N=@%I6H.Y2DZ.FPHN1Y><HG
M97:V_ - 77U=C;X*3_ 8^GO*A[=\6IS]=#*3DTTS2PWB@F"L#?!VQW%/COJV
M!VW#G&Q&3$W%E4'#QE:CLCP=L4MX.8-)EDWJ2ZKW&;K>UW]NK@?A'/)Q(4\+
M.>;@]LH&FER-C+KOI]4XUDU2)&$R3,KI:7/_AB!5]3K_Y\5AK#M:C>/)/;<8
M?=U\^EVV^XPW/?V6_;S%>,8]S\#,VT]G['[P'#%XZ!;:6$(;2UJ#!PD'@4%@
M$!@$!H%!8! 8!$;; YH=C\W1QI*M;BQQ:6/),1&?.]I8$G1B8XGYR(TE5_"?
M1+N24OO&$]I;TH$UJTLD'.TM.6X52WM+CE1^6H'/M@V\X(BQ(EFBO26=D2EB
M[8BU:PT>)!P$!H%!8! 8! :!06 0&&UW%8_(ZR'6[L6LG4=YE(\II+PAC[)W
M:,:MJJUZ-<[2(LNET+[*0O(\&MQ79M5X[+%N_/Q57L,#"BV+%ZNOPJ<+ ";.
MH'F\AS2=]BZ1UQF1<[0T$3P$#\%#\! \! _!0_ 0T]9.1XH<2Q(. H/ (# (
M# *#P" P"(RV@/'JO!YBVE[,M/G$M!TYTW;PI,GG(YD*=;3M4];'0VR;:;4R
M4]39MT^?/E@_8.-F-4ZK&XW>C(C[>/GWR\_:MX&$YLL)C$G1TSZD47\3*X<?
M[V?F>*%Q;+041,W16D;P$#P$#\%#\! \! _!TU5J[D"I=(F;:]D,?*72\1KU
M$<%#\! \! _!0_ 0/ 3/:X&'R,*=D(4!D87'Y*%M( L/G@CS/K)P<CTI2LTR
M%.EGS=C"\Z]_O2"RL-O*FN A> @>@H?@(7@('H+GM<#3:K+PV#TO\D1). @,
M H/ (# (# *#P" PV@+&J_-ZB)I[*35GZ43-'3<U9^GMHN:LE7-\P<HY/F+F
MNJ^K"1Z"A^ A> @>@H?@(7A>"SS$S!$SUQH\2#@(# *#P" P" P"@\ @,,CK
M(6:N.\R<0<S<D3-S1KN8.;OAV*[DN*Q(-M.KV#DBYXY'71,\! _!0_ 0/ 0/
MP4/PO!9XB)PC<JXU>)!P$!@$!H%!8! 8! :!06 0&$3%M96*,XF*.W(JSCPT
M%7?%A]"--4:-*T;L-T6WX2$Y4S>=GA9.%6\V(]<D=.0^<NVCE'F2_JY]X7F9
MRKS0/GZ\(.:, FP$#\%#\! \! _!0_ 0/,2<M=-5(M>1A(.T$<%#\! \! _!
M0_ 0/ 3/*X2'N+WM<WMVW]BS>_9:RV7OF=H;E.6X.#TYN;V][1<RZE]G-R?G
M>31(;F1Q(L4UST\$+_F)$>B>H?LG*$V!HQN>;MJZZ0>V<=*P@_;W@Y_3N\B$
M1![PLAPD47%H]FYK@W:DZ\N.\=GR[@;VZQ%C1;*T1UG2=8/9AN\X1PP8"=0^
ME=/+S;,V8T6RM$=9JK90&54=8+O3-BYQ?L=.ZQ#GUSGA4*^V^[JI+_[/@;:T
M ZNC#HT1/ 0/P4/P$#P$#\%#\+341B0"L'4$8-#?>YK-;L8#.B,KJX?[@L/3
M=Q_2(H%[M6\Y1U#4L;R_):G(;K4O,D\RH7V!)T;30Q-[KW:1('@('H*'X"%X
M"!Z"YXC@.7+OKS4>7R<1)4*.IANI9H*'X"%X"!Z"A^ A> @>,@*)<=LAXV9:
MQ+@=-^-F6H=GW"ZRM("_\,S<KU]^^Z/V\>.7GI; X\98.0Y^R.5U4H!>E4(;
M3\)A$FD\BK))6B(_%R?YJ']H,HX.'Q ^A _A0_@0/H0/X7,\^!R3D4ZL'+%R
MK<&#A(."=P0/P4/P$#P$#\%#\! \1V@$$BNW"U:.:MP=5?1CA91S6L7)_2T9
M%EFJ7<$W29IH?\PRD2?10/L//AJ?01\+>%=/^]*_Z&MODC0:3H046I)JEW>#
M)$Q*S>D;;P_-S[W:E83@(7@('H*'X"%X")XC@N>(S'2BY8B6:PT>)!RDF@D>
M@H?@(7@('H*'X"%XCM ()%IN^[2<38?ECI27^[=Q=BOS[UG\G</%>2JGA^3F
MOF!CD)D[KQNCO<$?.3Q+$6_E )X)W>#E))?:F%]+K<S@VZ30SM-TPH?:5SG.
M\E++4NU]EH\TK"OVEL[0M7S9)7P('\*'\"%\"!_"ITOX')/M3F0=D76MP8.$
M@\ @, @, H/ (# (# *#P"!RK(WDF&40.79DX8:50VN6T8)3:XA/# CA<Y A
M^Y(G:92,^5"[O)/1I$QNI/8YABMDKGV9Y,6$IR628U\G0^B^87%FV&_X6U7T
MS7!$_4DU2-%J5_"0/"D3N/CR+AKP]%IJYY$Z)F<$EMW3>*&=BVQ<2K'T?+A/
M-<G23;Q6/8KG(4]EP3[?#>6T>8JIZR8Q<13))'P('\*'\"%\"!_"IVNF,3%Q
MG?3[B8FCH!"!06 0& 0&@4%@$!@$!H'1-A^'F+B7,G&4/?*HH@WK1)S98B+N
M?9)R^!/^>LU$',T3 H/ (# (# *#P" P" SBN]HL7N3QD7 0& 0&@4%@$!@$
M!H%!8! 8Q'=U@.\R^\8?_HV.GATSXV5V^.B9X6M_Z5]A];2&FS(L1W^0P IT
MMX4$%LD]H4%H$!J$!J%!:! :A 8Q62V3+V*R2#@(# *#P" P" P"@\ @, @,
M8K(ZP629>V>R.BE\G9&5=2*KNT>WCHK((K$G, @, H/ (# (# *#P"#^JAWB
M10X<"0>!06 0& 0&@4%@$!@$!H%!_%7[^:O ZQMT#NL8Z:M!68Z+TY.3V]O;
M?B&C_G5V<W*>1X/D1A8G4ESS_$3PDI\8@>X9NG^"TA0XNN'IIJV;?F ;)S4#
M%GB'/\KU!:Z/IMI7.80GI=<J+2$\%Y"?(A]UF>=P=S8IAE/M_);G0@KM(AN-
M95JH-].9JU=4ZV2K"M+0V:^=U@<D.0>2'%TWF&WXCD/B0^)S$,N,).=52LYO
M',P\S3!ZF@FV',D046<MGI5$G9%P$!@$!H%!8! 8! :!06 0&#OS<>!?'@ZE
M^E,D-UHTY$6!^%Q+:&0N9*[>#F^"EN$%=</^Q9)4R+M39IW%0WG'1))79T5.
MP76=C-(SD13C(9^>XJ]K6/8=0!,;7;-UU1?_F!1E$D^;]JM;F4S%V3@K$O7L
M7(7[;^19F-TA^ A W4KXYI%.J&'"YX-XZ_/F_.CU3XA%V^[2V,+XU/_%X1S,
MG->Z0TF*5 LK2IZ7IWQ29F?+/P#4U=?5Z"N/EL?0WU,^O.73XNRGDYF<;)I'
M:A 7!&-M@+<[CGN::-L>M USLADQ-157!@T;6XW*\G3$+N'E#"99-JDOJ=YG
MZ'I?_[FY'H1SR,>%/"WDF.>\E TTN1H9==]/J^&.FZ1(PF28E-/3YOX-<8WJ
M=?[/B\-8=[0:QY-[;C'ZNOGTNVSW&6]Z^BW[>8OQC'N>@9FWG\[8_> Y8O#0
M+;3!8P?\I='_\.F*]G@<TQZ/G4G+!V49:'__Y>M'[4,*ED,:2>U=%DU&.%/Q
M//#:MYK(H/EI5FI\/)8\UY)4JRX$2X)'*L?N.UYR[7T"BUTH(SXIZC>4_+K0
M>"XU.0JEP#T;MTDYF-T_;XJHW]4_FE$C&28T" U"@] @- @-0J.S:-#F"=H\
MT1H\2#@(# *#P" P" P"@\ @, B,'?DX1$N]F):ZNO@3T5+'&G#8&2WUC=]E
M:3:::I=W\&N!Z6JOHH$<\1DC=308DD01&H0&H4%H$!J$!J'1632()"*2J#5X
MD' 0& 0&@4%@$!@$!H%!8! 81!*U,>R/)-'%^4<BB8XUX+!/DNB"#Z/)L*J@
M^#%)?P]Y(8DR.F[Y(C0(#4*#T" T" U"HU-H$&5$E%%K\"#A(# (# *#P" P
M" P"@\ @,(@R:B,)@)31N\OW1!D=:\!AGY31.QDG:4*,T2L2+T*#T" T" U"
M@] @-#J%!C%&Q!BU!@\2#@*#P" P" P"@\ @, @, H,8HS9R ,@8?3S_A1BC
M8PTX[),Q^LA#.22RZ)5(%J%!:! :A :A06@0&IU"@\@B(HM:@P<)!X%!8! 8
M! :!06 0& 0&@4%D41O#_T@6??EZ2631L08<]DD6?<EE 1=22KK7)&"$!J%!
M:! :A :A06AT"@WBC(@S:@T>)!P$!H%!8! 8! :!06 0& 0&<49M9 $,W2:^
MZ%B##5N5E(L,^JE]X==2^P#?Y3PJDQNIO>,EU]XG0ZF]B;-\Q,M2"HT76K)
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M?G#\L.M!G6!"#4>Z:HMM=Z3ES)7V29^S#DR@G O$V*!W-V7D_6,8^&.XCX*
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M[;T&.*9PEH'4V:FF8LV=,I"H=Q!=2\$S0WD/NE,=-M/!(R^]ESE!L@R#4CY
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M^HY#WS:OT6H398D3>JM7LHS[90@Q+Y5?KP@5S 3]ZQ#.D_^"(1ZAYE(:AO+
M_/XE<P):UN=Z%WWQ0W^;;86S00:&+':[.'J!$B-:^\GA=.PY+[:[(-IC9C"M
M_<9T+6T%.'QQ0H=]W'=QY&(HK@3FJ.>8QNIU"65H2<FZ@Y&GGI";+1*>KP9G
MHZ['C$S\\("W%[S;]Q_X5K@ I3_:\>H,(/^#GPBJ>C&0!C\@2QV%6.-N[][?
MWO8X4O('6]-RK;R9M8%G+3I:#"9(TMAWH3B4DVQ@]<E_X/"0BQ<$!?UO:^_
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M@$QK^-II.)X9E;NVRZS\,<8 \2@SR:"=R<P@!*7>B-7<?BX(B:W"9.K['(&
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MT;07/[8!,X.,OJ!%'7VB@.T"G/^*:%VA!Y7B'W<>V:6%%^U2XSW2AZ(]?Y<
M?Z9I:5C_<LD<(FI^22@P4KG<TVV4_AVGQM,R_GA3&DUN_O;IX\>RV-FZF_W+
M"^83IS1Z+_^E4D_"%#4_&%F+Z)?40T(EED;)P-#8OB%K&+0?85LB\BCU'5Z'
MPEG89,L:?7R+U138P>9QL"8YI=1J:,!_J&;$0_\[) NTZ38V8#M >G!S![FA
M?1H:5ZU'TJWO; !/&K1;8_.AC;,[[()1M1Z@'?QE6MML^]YV'6SPXL=X U9N
M$4US$[%(]=IP_Y:=9V9GZ)J/7%<G<?%,/JEG(EY. IQY^'QF@2ME+&(+M5%,
M#V'K_K-Q#I02'%PWVV:TNAHU)D+E(R< Z08>Y#.\CF)LSGX=AK;%R 6 U6J*
M=RLVLB_SL:_M+YD#\=PT?E(I/51G5.E"P9X>*NP[M7;'<BM[M<= Q[E,4G]+
MCKE)'B@U&AJU:[>.HY#%-K.;1_?::UK-LG"+B@[$ [M 8\QOE3H_U<$T9P9[
M(NT>,T$^Z36?H1,LA0RAF%6@%$6TW<*DX(&AW"D2;%[S1K<X_0C.P7.H6%3A
MM8)<!J5*>Z=D+5U_>S8:R$KE$9 W#36.]&UGHS'2<+0?(R(,41&Q$TJFON^P
MK"5QJK!%_I6S1/Z15Y5X<''HD(M5H_V:VQV?AJ6/+&1:C0H</4U$HV;<>6E,
M/)I^WPIII0N%B>LV7;ZYU'<#I4DU04C:9C-PL9K#N'H!X1Q(=M*+*<>DD-;#
M<_"PX7@'1>!AA[0VHFY][2/7@L9,BVL1I9GZPIK>PS8]YR"[,!>Q+*U5F&G;
M,"A#;^M1@DK-"0XV5 ^\WMS/_D$TA(2;V\U&! ,7Y1592H$5"N]H)SFLAL#0
M^B.1#7:IL]J0Q=SA+/5=\(V9'3ZU[0>>&Q=7B*1'JW[33!RF:R_71"]T,Y9N
M**]4W7P[TYA?B&-C%84V/>U7F%/5ICI<4&-[>W;MW+JL@MR0GP.L0;LQ;H?)
MM#T4>6L+)+SJRU!J%?^%O6<UZJK1T=^-QKR4D@:[?GT?^V9^U23?I%'5]IE]
M8FB3DZT[G>,S.&@KLW6U]=J:Q<R*(2J,"DS>541X(8K!EJBR-"P@:7R_AZ$]
MEZ)/M8*NONVD>OP7Y\W?9OKJ0=6_SP$P18OE9+K!FKK9U^LZE-:J[S,S5YK(
M!_<.O51MS<+BS;$C,BYPX 3@+KX*HM?K$"XXQG1#_>F6O>=R3$3]$%E=I1#,
M)+9KT#/1<DA[(1@EI* + !DR!_(;6MN-ZH'K]7J[BZ.7FF#9-CV&MI[(2J/+
M]2)+(_@J7"<(]CF,CS2[LP2T0LF$97B&G_TPI&6#SAUW<^X$&/)(0/;56EK&
M'&]2D,O+-XIV0ZVBVH^RMND<)(9FX6 D6]UR#?A6_A8_[JX@".@6(O'7&=E'
M<.Y4]*Y.7>TKRHJ9-@?M^B^?O*M$>J\'!.]&8T80PQ?D5+_0R#V98M=\T#J3
ML6?;H[.IQX,NMID;+*FFJI"!CPX$1GR+SIFQDYR$Y6M(])*-OV-IC$V/BKGC
MT'%?%*HAR;'J&<9A":>>+-/C+@I7&_PC6SX*?!CLI0"N@M3?Q?C%C[(DV&LJ
M-9!]H=G'+L9>(B#78,0"/:+XM"O\0+,KW"C6BI)?#6_3!B7Q&*.K*,:ND^AM
M'#4-YQ;_RN2O6_Q*_]0QT+7<V5Y$=!A+W\#*>>-09L;0:$-KNQ;<IV:M[JEC
MF<5NQMMI)C S<.5B5!'A@SR'F4M#M>O1% \F-^L%$# "E7"7O#!X$$2O&ES8
ML48Y/K<*_1_^6K)[TH01->@0LW*Y7;[YY#H@^T=T.7I%K"**&6@RZ'2C,:D-
MX,H/<'P.,"E17+:UFUK-!*U, U+,GNSZ8MD=B1S?LUDUAH(+;45N)?Z>&7)&
MY3,W]#/:?T(SLA/0N<M/6:?D-U?UZ4O5GF\K?G9"'I\# -I1P.OUD+D2]2@!
M%98%FLDJZS+.*6E?(G7P8>S9,J(P$KLJP&6IH-146;FQWT2O!+<&79%%=0(P
M49NKVQB;VC=HZCXH;J#TECF&"FE %CXN0:K41X4/.\;\HC(9AF+3%]NZ^_$]
MIUI7HMSU6N%WC.%F)0C+F+''T".?/4WU\"[?H/9O;:&5PVC-!?SRSHF7,7UP
M6#)TMRIWQMXSTP4[:7468W+!"(,Q+&B6U+JF="UGMN;MPU^669H WB&5#R9
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M%&?MDVML;L\<3J48&A^NHI-=AY[_XGL9($JPX+)D16:1BZIJ,%LMRP,.,-\
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MOXNC%]^#>CG,MBB/6([NV)3I.<900Z=L*Z&2B^?G&#^3>^$+N=,W ;U:G"
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M;<9P$6_ O/)][<5<UV,FP8:F?"T6V5%3^;0S&7N79:F28&.0@;']+&IH0;T
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MQ;]432R*Q[],Y310%"-U(DB9"5J3/TY[TU(A1 8[^S0 [V[CQ%O'Q5GJNTY
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MGM<\,),&G/>,#^.$X:#+>$\7Z$*.C)6HSR%X+<7J*DS2=&=!%%&JT]8"42.
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MZ^\?BK?3H=!/_+\3A@!S8%WLZ145/L5>D3K@+V"O^*E&S9BHWN X?*H::PL
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MS#\H3]UF?LL*;W=1[,1[IND/ NXO:0J+R?3(_8.R9:I<7X)^/BJ>BM*&6G#
M(H?MC:J#Q(A(.)F"\;A@)1\]<F1\E@^W)T\)LR1LA%]R;*#D'L"[(&6]OZ]6
MB3R45$=WS8[)7%#FZ\0"8TK$R)T3+V-:;MQCH:4<:7&XT)B=(]"[)4SF$?(7
M%%CC,3"$.!1I9^1%X+  EAP=&Y-GD=.Y,*O^84>R^*1(#"'RI*CI9*P6!/<>
MC,6;N_?^<;Y_@K-$\?_V]W[R\Q<G=)BWXRY*?!9^">;;K9^FF(8Y[2)6Q[:O
M %08&L'8*!\<R=%AS_/QD3(!(C%9DY6H<09>'HK>ME" :%<1.:@'1(%7HW=S
M"9&%>9^(W,(3]HE_)2SG4=Q?/<,F&7DG)<AI*H.,S:=!Q3E!8BC$QCI!BQ*$
M,QMO[ 501(SK<)>E*]*I%_B.0A!1B@A(3H._<^?LR52""Z*;4%RC9)'V <[C
MY%!.#P(4Q\>X&XJ-DH_BV-DI6(4Y+UZ!E]V8O,C8")"ZM@R^B^A'5Z 0]LWY
M$R2I/@U*%Z4Z@3[%T+<R2,4G\G*Z[YE[J9*:,@=S$::^YP<9@$?D$,XP@5YW
MF4JV  W-6!OY2M.[S2]PXL8^%8>'<9R?((7DY(GT-$ZA%_0$#73PJHGTQ\&*
MW!,-Q@$E.-EU5@(G3'I< V5(QF2*&N[2:K)</X;8B2%COJ"JOH;DV&S\'7B^
M>GF1KPJ%P3(^6 ZOQC*2(C$>VL& 1\Q[Q78$;(MQ<K0]KJE+MN^.G&US,K)]
M]@&<]Y*\3NE^X7FD3<+_<^.'!Y>G9O00IW0B?D! $RW#<87$Z]"%"H3X K/_
M7H?*YCXX:YP_6/W\?XP\!8HO?,8)&8/\5@QRK,P&)3Z_%6/\!E@NGF&*#WM]
M]"Q7:F\)UCV5]=K='A\F@#O,EFMM::%%Z%V G G2Q!A%P<&90V.XI)6X8FY0
M+<R\8M17LBA!=3V,Y9AHW H?U8(;>KRX>QI=GUR'O1+!ILN)8-.%[W;<O+*Y
M+WPA>+$$87'"<AK&2UC0>D7NXL@E4L%5%%^'ZP@2XY[/(K(0TC&QC!^R)U?\
M2W%2D"Y+BD[^O$E'\)CPB=%$<#DU1.>6>TVHVTR97L&) CWE#"=UJ< [2$_<
M"KN;T/\EZV.$D<308K>+(\?=T%M-DIY"&6-G=;G^$H7I)J#?AQ,$] .A@6G#
M? =;1IT^Y(+\4;$5%#A:KA$GC%3*+,#PJ/@JB63U.\8*.HTN@AD#7V]Z)J+4
MQO1.DI:2(P4F1"MU-R YX1<<1'0*'"QYB! H,0#ET<N'F IU>A0& PUO"G59
M5L!:86APH/5X#RIUH9E#;A+#_&T4RC YEG[6#QE<I2?SV3C)T8$X!V.F&C?/
MDC-]QA"K6C;)!]6?)6VIPJ6!G4D2 0Z6Y:5%8I$DV9:)[R!:7L48"T1R@.>V
MISTI]AMECB=, (9I3HN</KN5;H#4C\D0IVM8IDDA]6>W3(4G?=HUH>+FZC6Z
MB^)T'05^E/0/UB7D4$YO[C,/=).>!O9I@-F7)'O@8B=)SA=MM=%,<QMQ( C;
ML)HM#61ROE-!;LYVZ5M@O>8@'Q+H5<13_LJ7K08W.%\T!AH\]HKE+LT?HR C
M-TR\O_(#<LWW<V=*8HA1&W/Z"[)1'FS65> \]X*!$(1F.]N@-%$$1.R! E!/
MS0@P!]P'-+J>/#!GA0 I"R@.'%&SD)"\"#T)#D^-B@G4/ HBB!;NZPY@0ZE)
M:43GS"'RV7 H'V\2X_YDBU !4^VV&&/CJHZ_ $6456?$(I]Y<G<YG,&0>#]L
M_$8)="#''#A:?BM;AP).B@;:2N/4J&=T&>*5O\6/NZLX"E,B6-WC=19Z</->
MX7Z DX3T:4IHHVQ'M&Q"'851>!I+^FB-1RY).S!S@>0+ 5GTN$.4,&@D*">-
MKHZ,K](E"OSQ?4-RWU!IWT;7=PT?&6'696C_O?RHY"!R,E2'YU7#@_)7B$['
M_PQ'8[@JXU706G+B=MQ7BC)X3@X:>)A6T1V.(80!8B9 [TN4&'W2&Y"/>UU+
M]]'>"8AVM..X,,B;+@? [BHT>?L*=6;%3&@^'IL+BQ*ALRED3O 8"S*CT1,/
MHBU1S'V7)MO$^UY62$&+YAW\KRSV$\^G^52380(,PDTA.A][4"!ZU+?G+'#<
MGQ_<#1D[^1)Y.!C$F$JIGG*R: MTQY7-!V*#GZ7B]"F]:<S: [&A'B(-+].F
M>?7.7:MD>4V:L[;P/(I9X 2 @G8=\JHM"D!&+_.8I$X>,-\[)9J1RP8X/KZ"
M"DM &90]3OND$)H]NKW:@7AL!F$2LY(*O7%9@*9:>:U8NNE8. J*S @HEI@7
MOY@&?(594]2*Y6J)\EZ9,=L=#7J?U#,^+#L%8^ )*I5<+U18GP"F*\?V[A?%
M +D;4^"T'S9E;?B/2#>9YY0-%5"F6&-V--E!SU6'/LX+<=C%(5<4DHE<%_0B
MA))KV+O( $Z,93JP^FP*2%0B$)[:)T%H#Y<D(ZK?'3&#C4A8/)58>/V_%H;5
MA^<KW$\A*@Q89%7,Y1ARHHK+!Y?082$*]<E/?!2$\V&^^A49[V#!G,8.)6(Q
M:#$%B-K3#^T>[TB[S>&9,X(:S[[/Z1T##^58.L&+J&@KZ(YK!!J(F4) IHF3
MD8,S>W*B%3>FYZ55LLL0D)M-&2]'R.#1)"OULK0VIRI-879](%((3LX4]$8)
M_TV_P/X[R$9 9S8PQD=D,6C/W3'O9.EYD^RZ9KC/<5\ZU=L8>O?X&6JE1?'^
MBQ]@,GR(H3Q&G_.J?HKP:<9R"+258R!O//C6\=@,]!SFU%%.'ET<(X>EX]IZ
M+T</ B&'*XHIG[2T7[\$2DJ,;QVK%#C18S\,%X5P,>?I-.9,N%&2)I2M)-OM
M@@F*VY;@\GKYZLIX>:.[Z0#V\QXTQ7X/&'PKX+MW J3"_DZ"]=M6%W\RZ.*/
M/+T!D #(670!9BCZD?Q*48A+%6KO,;#EA\\B+"1S HCXZ RX5GX9*2 3G2BM
MSRK5>:>HSB=*.QZX@QQ@21@(9<Z&S+D%MB!X!7ZM6DK0:R4W4C '[[/@CI8^
M_S3NJWS,&UE;<=B\HB?EC1K=@G7T*ZU:OE"#Y>N,6[Z>JH8O:344O-#@>,$-
M6D4(^%&-8M6*W)(GI#!%0[\^C9FN<\$OC2L_?$BWZ64<1_%Y1&1G&J_5(X='
M$!8Y H29')":#H/R<=!/,-+H3J4?< A!7&1S%MZ6+#8 ;P *\P!B R=-OSRG
M0/S(F JJ_!3I3B7:#;U9BF.VF;F):E</S&/1$+<(! +(L_%PCFVU8B^$O]T%
M>/$<8_KU7T7Q5982L8X)J$/8' %S].A8*-BD #1U&JO,")R(9Y221I(V(L01
MHRYK,!XKBV7A>B:L2BP/FK02IG[P%R(V^&L?\U1OF19'09IZN5]HW@H,@7X1
M8_ Z0F@M\P QQ8+ZU@_1'CMQ,AIZTA3<\V.MP..PW"2Z!G(DL=]Y+B0=[)@9
MUV&4,Y#CM/TA&-V"M?#^F?&JNZO($$);LJ<LUXHU&F*9#XZKE4.#'EP79ENQ
MPI2*F\(LOL:5JI;B2G@J&'WK;J.48@-%A:A=6#FBUH9<*WCUTPWY%9DNQ&1G
M3X'O$@)K#.$U%/0+R/E)DM&(3&JMFZB2&4W5&1J&CB&R6 6C&Y8O5>9NP=Q$
M0O? /%:JQG" NF^Q9&M$>#I#C4DR*_+-!/L%^5K !K&,[[&3D(_^*=C?^#_C
M8+^*RJWN\3/5"\(Q<)3SP9"8$Z FY[-";%IPG5;:HGQJDP(H7V4QN7R(3$?Q
M!=[@IP& Q215JH\)NL?#2U#'QF09?H6P');+T@\YK1#S)=-CCHX=;<34J#$-
M365N&8(Z3@!;\!GR/[P>9L6&HK9B+)0/-I%MD0R]]M.#4@;4@-2)4@8.GVV0
M3U2\WT"&O'+DGT%&,;WN>-Y_N1H(Y,2#<3L* O;^LZ2@^3);SN88BN.1)1V#
MCGA')>@E%Z"'- B49'/;5H !&*W5_1E]) :PHO /P&,K-5^[M1-#E'!G6Z^;
ME19 A;Q>"K7@T/+(D/8 7S!-4$1$>$=;)>! AUIR4NB1JS(N4%]#>=7C6!FA
M<98!3 2]":YD%V,ON8JC[>"Y/X(X0.QLA1^\FOAT=#P&.O9X@4#N@):T)[Z-
MSC?@)[\.S]EC-^3;XE+2W#($Q&V_+D/P6ON\L &(L(#X$%8>F"'8;/7"&#9X
M_ C((H;@L'GO@&Q'.0_04Q3'T2M<LM,EOP_'%3^I(B.X\F),F@"?!^ <%FM4
M0C=>KEEZYK IA%-'8<UL<80S>,!LP@HL.74C3)/6.X]%+>-J3[2Z)^B2H72?
M38AK/I?55L'?)UOO,PDE/]&2*P7G;W(]9["J\S>J[C1)Z?DA&*HI/^0)[E+"
MG:(9CEUB8[6)LH2\**M7<J;VJTV,L0#S=\EO_!<,=>)Z%P\1PR V#J(#Y>4C
M^%"T)MUDU47&9%U3>:3#$HR<0STNZZH4\_GCY^\I1^/?\%&<0E3S-;T$^Q@O
M**E3H(448L? @&I6UG,QD2M\$&8*:L_H^P!)1D0E3:+ ]^A'2XM@]BAD6"#&
M2FI.5,:PJ*0-5_5/JFC,?#E18OH@W)CLDA/%G-_%&$S$HO1GZ-$W?T%4WS0Y
M[P45S2G+7'IX7YA P:B?H/-IT*)'8+%H>V5\\D/'LB=9%+I !7?H6-91=9(&
M6)VK*%YC&N @ZZR7TI"$L96B-0Z:Y"5MUCL@?0(N"YC+>&;=8UFU#L:%I*T^
MIDPYA\$ZJ69H200U.O.I)+_%9')O*N1>^/^4R;XIE7UY@*\O9=_=E++O2"N@
M4WIFJOB,M )6%(![(B"2[X=\6."1/;P$0]DBEM-ESEC53QM$X?,II,CRMP<Y
M*92? [O+;A+0NV&95@U37=G.2Q4>'?,E%":5[6-A(:C,'NA-62QD11HMU\HS
MV4MS"@+ WV"9A*HEE"96*O]6:HT6.TVC:)T'Y /@:-V](#4H(8G3/1GNO0*#
M<1WNLI1*-50*Z?7TJ>@:E.X)DY<X_/A4H:]#<U?(JZ3[-*K 5D@K &$TQALB
MCY+3G:-(W^)TN5XY;[T20PJTRZ&(MRP9AHQQC'P60C^8$8.IC 66IPB,'86[
MJHG&$G<:QGH>S9:'\J02&7OG3/'<#<BPNHL]N9[(NCLD\X5L/@O'5A1"87[2
M998FJ4-=TSTYD:F')T@A>DP,!05>>/:*<"<?*4]EY:Z1N:D#%89G5E7J6K [
M>9R B Q>10OWE\R/\4 NHSL!?$QS>:?SXPW"CS9.X*@Y*GDM1"%'2')G1*?T
MM0YZYI3GNX&MB9YG&7*K*$!W4>"[>_:_?;-PE>!B9803Q*BCG_A_I\RG'8OC
M0GJMENUQXW,.+N%0 K#[ 5*<+PZ/TFT%9"?<(DCC%JF SR$Z)70Q8G#O/%90
MBY[YOI(]X^#/2QB5Z)DN@C=!K'@1;)PH7LN8 A!Z]&XXM%Y?$7?LK@@T?H)V
MCDAP(%(=BP@_3CY+/GV52W C2#Z/D[N@S)BHNTC8BF(&5.GQ1V2R*HQ*X"H+
MQ[@.>3[[O;;FPQ#AN70@2&0^Y4.A>T,5B&/GOI@+2B&/_'^15;C_?YSM[O^[
MD $KHV,QA:GO^4$&[H\'AF/@X^3RC;GM(%<0KNV,O4/+]:43@Y:7B)-^MM<3
MZ.'&40FBG.+(OADM:@3?\:LHO@ZA+#KA/$=W6()==NNG*<9P)G91F  XU0A@
M->);@$QA.1$59X*"UXJY(&4RD\+34#2!T D>$_P0K=-7<)M0.?K E1#T$"&(
M!$6;^L)@#!;+:8@[GY,D6YF,IQ\ R/(E^<(@8H-,@\A"Y#,C8I73+YZ0D40*
M39 LG:FB"!<OCA^ 49M\JE"[.+\V "ONBY/R?_W53S=^N SQW\D5+M6_@U^N
MIU2YH$Z0G,4I^49/81XG*%?_3A"?QYZT#,B!=412W@/YG,FW*OY,9?(3!%-$
M9*I?U]H5CCX19UXI512%F&9/CZJ*<.UBN=854^D7_E$MFP+&G"=,(1Z.AZFB
MG0T,AMK:-\?#4$F-5AC3EKH9W4[O)!OX?XB9(_H*&(**L3RT=HSZ"Z7EH0(%
M#>FA>",*L1-4B?IA]7(*OU1[?%5K4_">#K1 4[E1IUPGC3.(+@4-[L,Y75X]
MJAC\9R>^S\+Z*)[!3JLS:= GPV!F==E%)NK^,?0X8 )4JP(M8T&AB/JYG "=
MX4_(![V1AGY.@ZLV#H.ZFEQ?'WO"1\/&$&E.<I@3I Z$V$B(#35Z^:X>M@1C
M\2X+"76@UO5"\YU#'MTA3 3E^?/3!;3&35G VUT4._%>@(D+V&\>>WL=7C,P
M[R)XW6$@#>4,%C$VSU8YX15!!>JXQ!<WXHDS_):1TUJF7"%^#O*5N>0KH^"Q
M+T4L\W6(^-!E>$,1@?(5+(SV\2RBT]?4D>V)5Y], EC#C.?27 #P3$$$]W#_
MF-QI$C<'8T"8MWE^K1(7D-,\&F94_:F6HRF@9>^Q"XD0_IJ\\\Q-H;'4DE]%
MQ63C0R^P\G#PF6IMU>P#+:5:CWMO3;44I==.MR2^6)*,+$E26))=*2M[W$=N
MJC4I6@1[+8@-5#XI[ L[],KIX\XJK484NH2X7(N\O&1!L5#C,^YIIA9YM)Z=
M2?!1)UB3(-<?M>"%BK[%K,=0$B?W&Z"?Z/!3NKQ,^2>]$KT:\X<FR_4:EKUJ
M[94BCS<CYB8PU%3%1/"%?$J;8'\=)N3Y#6AH(P^N8EC3?9CCM,G=)8GGM9H9
M^:/E4V<)08)A990\O.[(&2Z#XG+&F9%A:V^G)0:(N\%>%F".GEB!8\QMN50S
M*UAWZ6\>B0:4+, I/=0%KH7QR",:"ZX#ILZ67 ?LES"Q$R1F9N%VG]/2%M)D
ML^T6# 0@*#P\(H</8!UMQA2J6H3W5!WJ-&IU2#Q?Y CJ-!QHS6I\TC!6^QA&
M$ZV/YBL\$ 2U#'B:AW#0U:6SF^VJ"N 5\D72"YR!BJXV3LBQA.CT3;A',IYZ
MD%"."F14'EB-UA)F_83]>@:X47-=T^&.MH0*DJRHL!<2;8KQ4PLTE2<**":>
ML7?P<KL+HCW&#SA^\5VLWU )74QY3JBE2?T[>!ANH_3O. 4-]#F$"%O&)KEZ
M^*^@W:<^1_\QC"5QFD,O-PN+XNVO?$E/Q=?!/+XL#$7.XM>]I&U%*SE!<=!A
M1E"_%>TQ5&84DSKA!YI>Y/?3K;):9N6:UX)=KN]B_X5\0'>!X^(>P?+%6BN"
M/)PC/@"2(QPGG^J']4-,]&6T*["\XVSNCIO-<MJ.RJ*O[&K!N9/MR(^5!:A6
M((9.A @MP$/A+D6M+'?,P&*JIX*%(_\$8<V(AA""'\#C>>&][ Y 'BFW+5VO
M3(R GO@0Q\9BH'!W7^).$A>)]4?'7<F^T'(/1R^W4TGP4=#Y;_%PV4P)16 Y
M,F[*A28+508X>M^W2K6!T0N!ZY.NN*>F?Q*&K2RS$=@*ZCD2;DB[>31@8Z=9
MC3"EFXCYR'K&><DJB=R5(,B>B)MS*G0_%F):"BSM@VM(HT7#:L#QR P5H_$7
M89B1.X$H#N3T?'' F4D-Q5=XB#0#1AUQ\DBACV" XV/1G'C@,%8#SNI6875]
ME*RJ%^G"#G/%^);^@'A3AA;UBB.:;04L:0$C\\RVHM+H#H/K . <>IE<!"&&
MX3!^Y<WYK<9P=D(E:DN9'"MQ0=<8YC?JI53R#F1IM'5HR#8X.=T8_)#7H33,
M<WRSM0)Y]AAZ. :P\&$=+>I$ ,B:S@0LI;D+AC>M:.HP(8I*_Y4N7%!>,^$^
M*:S9M;)FN6/E0:Z9BBN'Z%Q&A7RWO&8EB> (UZY2 &P9CH;^_^G(V>%?B*Z
M&QEF)H4<AF>[KHX'K^$!N=':"AYH2X><P/+SE.9N,1JU<.CSR^,GX(.\@>H&
M%%B+X@*H?C<6V#'NKHK[X@*+2TR;+]8O[0WNHT"MH+EF8QPC9WP+Y3TKR$/F
M23'X2PYQC&R6/DC)KH?S]V5="/D2&[R?S 3+##;% JF#%WNEWJ2CX*B8%;2J
M**=3EWP5S-WBUX5+([7]\/DNCD+R(_-!)8.C9MYCE^HH<CQ4') Z?/^.20LO
MVDT04#(V[T*@QJ]FGFV8;'.XH(7GD3;).?EQ&:^BUT-U!HX4Q,F=(" ( %9
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M"J?$,\RZ[ A6Z[P Z*99<\WL=EIP?"4:CJ&*7^@O_?Q"=;>0IEA5OQR<,3@
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M.BRURMF1H/4K5;/9'(#Z(_+4^$BMGS":-PE=1ZK="DTW@Q"5=#<54EZ4O4^
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M&U2*&Q+)_9$=4W&MK6=E>26".V1 %6692MS>9/ 9IGC2\C+YLSY(:=4*G_6
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M6C]E%&,A1@.F_7$GV-'\Y'V2-3L>=X*=>@,)O<2\?]N)YEM.,%>#\6HH>7H
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M$G(<-;"N';/WI=GO&.$2NV)2]R((!K1TA&M[SHFUT<NG&E^@\-X&JQ(HBCW
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MCMX=&Q9&%ZA06E]@[3C1@,>YS8ISR+X,^5SF+ *+YY4'>P7^N&H>)78%LIP
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M_\6UXT1UVR14O[&J BR]%B6ODZ(=6 EY1,Y=$=:D4\=T6>R PW%EKATPL2@
MG@O1SH/)+A"+OR_73E^C)'D> X"*C&>K$NU)KK,J@#-0SN>6ORA>NE9DU6.S
M,#Z5:>U90?DX&=D((36RW%!.Q7WH&$[:6V7P@1YD=V5PLGA%%OA5$)&1X- 9
M$L8>K"*'X-(Y$LGGWXI\BP)JS)!9J4!H>>=L7-B%%>D1!:BK!;$*:)9'5F."
M6E1D1310PYL$("U 1DG:1&,/)18]_2$P2G(Q;KL@$+RC)*GCM@%J8GVL2"JY
M^,TJ72B5I+9<ZVYQAOPH28&Y,$SE1@HI28FY4$1Y0XR4I,!<C=9"T'Y_L$3]
M)?/!B3%3%8YR-#YSJ\^H0[)W,=NL^LF*\:JP7'LR_>D<40!,ZY4Q.;%H%9PV
MJTLB<6S54YH<A66I%XQ D%P%F!QM9.F \=9=^;+V[/MRXEI0K%X-F8)'W.MP
M@30V*O:O1E&J!K)@%,?$)%88KKMT&1]^^ )<7Z3J$XOE:]A R1HCJ7K"TH_@
M("ZSADFJ!D"&:<GE50K^_@Y2WT60E!!OM5:4)6EVSN5VU=>'$[H@U[D(TZ=V
MV6JLR%S4 FJLH/>&VS!)XPP1!4*0BC:QN>R\-_[Q%(#=6PSRDW83Q3=9FL6@
M8#984/G[;14NM@H76X6+K<+%Y,M78X4$ M]\@2)4_!V9KL.WJA)X@B*K_ 09
MN1,HNW7LLF1..G(D0RXR"B%A&DK>A%%X&PRMTEH(QBJ#=-':CA!K$Q/;&(<2
M2X1N'M"XA%I+D@%M.4A&,*PM!\F6@\2X*,_U@K,E?U!X&XY55;;,$$1]9^UY
M(,@Z'AF9-@6N/VJ?^_3Q'S1+?-"W3! J(]37GPEB3("UVE %4]Z1G>3])HB^
M-R=J$<_!]R!%,W^(HP\?SN/B_)( [S;<GT#L()%E!\7 C]Q%F/%H,&(@C1;M
MZ."GE/S@K0;ZS9$MVN)_N!EVT9F0'4<9A7NF!!*C#:3=8^$YVKG_SOP8/$6'
M]/NP=!B[O<:GJ],IR,G)"2IRN@T/47PL;AX&+7+VUN>U$$(I#1(.BEF$E$7R
M7>BUTCA=%Z41!%>@^%_(6E'2O(:_)@E(D9!;!1C[*&PP9>S2U%$-@N,A!B>X
M25>E,'']B1Q( 9+ZT8J*A7"CP#68/E^%\CS=1Z$+_]DPP-"[\4,G=#O,$%D=
M@BC)8L @ALG#2GY@K-#OA]@$F8?X_LXMC"F0=2*A%,X2_B7.ZMW"EGJ;/*89
MQ1D?@0LWR0] QQWX.9(CRRGYE#;@ZDG=H;/]Z+^]0_D(SC<_Q;MC%*?^'_F=
M5.XQ 13A84P3N#!G>)S 11M(ITSO N E*-6&2%ER=C]S9$@X5TB$Z?DA<,(4
M90J!?SVA)KQ")7D G1<Y9"G/SB=(D(Q%OJ$[K0R2.WI7!K>(T>^WE:^3LYR"
M.P$6ER8LB[>W$<M[@!*,ZY]0WI4S;:_H?<SA;VRJHW8QBRD@J;&E-56Z0R-&
M-+^)\ R1827+X_VL5OM#KAV'3@"/2&6O@'^*2NV))H>/'DMOL3[N@HERBR*2
M2D6W"PLTX>(XO$E-31-2,1K$9(.S7D4=_1^2LSZ< '&I1\BN8M]-(67 '^#Q
M[?ZAU;((C!TR :2KPO5=?\(=#-_ HY.":ZC-4M7Z&2=A&D5AS,.3[<LF735=
MO;1.+\AO\"/TU^OBWG9#KK*J%/'BI75J'S\X,4JS5/YWRVF)YA$_:5R-D)QB
MX/I5AD@..9;60[O MS\,]H(A[^%Z+).KJV#2LN6*(9-H:Q D%B/45>/F%<DI
MD3SI^<@OO>8#%UEZ'Z7_!5**(8*[NT$WQ!7(?37]#X![SN&^*!C#&&'Y&Z08
M9=K\^CTVKE*U_/:3](@QSL,#!;'] ?VCR*V#XS-CA]+W? -5=Y#?QJVK&%YK
ME4LPW FHZA[][)BPS2 C!S/BB%:7.-R6G@LYQVFE=)9,JQ1#8%(_B'9O-<@%
MT6/96XBLHCBBG3RF41N(37,JL(?X_IH3 +02N18<HTA5]0.)P=([F:8+8U[N
M)C_]Z544FPTH+W(TR]IU/M\,TMYQ=Y?,68IAD\8""CQ,?0"([,LI"I_?P6^%
M]6%_N';BX%R_2[8?*R&S__"C+ G.F)( Q158'D#X50 EN/R+G?$@*^*K,)"+
M#&X48SG<:M9FAMOU>._<;JA6X^YJ6R IT76VEU-/&&8K@!SONHM+,8#QA96*
MHL%);,5<:3MI!OINJE80GB1OURZ0XSQ&+2%163ZE=>C==.]-*RA=I5MGI\2Z
ML!>D%?"/]Y7L25@LYT.;T10D535'PJZ ^FF2+U7 LP)(19(OQ8-7*JSFRAF3
M1.&>J[ 5E#B+*#QP8K8"6IDR+[<WM17(SB75<CM[6Y*62(XXR_ QM^2FDB/,
M3F;?=N6GF2:W4NG<"B 5R:W86EHK/_]S"5Y"@2)6$+%T6^3XR!4K\)Y+6F/5
M]]J$,PJ(](@?2WBR')E,)/9(10ZS-$J=P"181<6ON>.:K-@$.:*;2!24%;#.
M(L81@["40&R:_*#"CB8A"LP*[.>2W:@A:%8@+>FIF!8#)Q5'<Z6X6<6-&E4%
M%9CA0N+4)&0E7G9BD8 J,#:. ZBXY_CC$:V >*[K3#Q*4BK\YO)F^0Y1@YA,
M*PAYUCONVT\UJC^MOLBY=.OPZ+!4J9";RQ+FXLEC0V0MV0;YG)D6BJN"G1AH
MDQ=ET]SN:R5^_UCU)2>=%4^/NK8"=W6L@!#4;06J8T2V:=1?POK/5<.J1&MF
M!.M; :P<+B"2*D )K*8]&*EZS>!+55!"_/.J*5>ZW+":O /5_O^B?O\E%D[+
MOYD ]R]OT<=?@>L5GX74#3E*_!P[Z%U_%\?H6;^3UFC^&FGM218I1EROR2P"
M_^/;+@AN0P^2GI<Y05TELABP3'5!;"8[X?)]%#CA<_0]A/!XV*F0VTF>RW7L
MNSLO #%Y&OTF>GD-:R\;YT LRFH*7AK#B;G1&>Q[]48Y!S#SUW9L[IK+\RN:
MDYO%K527^AB6>RX9%OQ'P[#@?WSK3/313WZ_B)S80W:S&%XS49SL<[$#*M//
M<&87\)._]T[OV%&D9'X:N\"\M&^: K"/X8WJ5O_U"!)XQ2?HM>$FBB<L?>SX
MND#YZH3.6UF6-(:*[-L92A6_1A_(S1G93)JRK&P N,?2O]A<"$L2D,#=0'8B
M*/V%;[<>_,4_G N1,F\,__D,O^VDB1 IR/F0?IBP^T@H_S1I*$.7^HRIS3-^
M'/V+K*D1!3*\H8EZ-X'33[\X<A!=RROG P]885*'1TDUJY?]22,I8RK'PXVD
M:Z&/4$K;'YI)"JV-W%G_OCV_^[&'O%G/U^$;_-N(\XP?0O_2'I 1!ID^]G%]
MKI+V41+G7#PCZEIXLPTU@X!W2"DJE!%HC33!N7;Q0<W?][%\B7M8?1! ?=9W
M@N"\RR-8@+>/'X&30,WX-3C?^;^#X/P<]5L]@C<?25%ARG\@)'Q'/YT@SYLX
MS0VFS1^GTPG_L$NE$T%@9'W,(/FPV5@9/&;:!_0?)!9G? 2G*$Z?HUS$E7_K
M#H?7:^2<:!U#-E %]B<5F0 # TS*4JQ21,PE67PV\,GF'P[L:;852Z&58( 4
M(?J^O<<JU"7P;NDV)A69Q8S= &GLG&<G-V3E\^K6#ED*KS9^;2ME2V#:%*.O
MBMQ!QD(Y-Q43;-)682Z!?$4MX2K2*1B+[SPT/<(F;]4NS$KE0_8M-1;86)#G
M8M\R'A^LVABIU"_PFJ$BR-)8D)=!_;;NCAK3BLCSC(H8PS7#/>G91T4DUP!L
MG>[;5R!Q8_]4I!"XR""'@:0)&<N%D_@)BMUIOJG/N7M,U=M]_.:$97*$2[C!
M4>![55:V]JKVAS*4R@GJP-9!(&#Y[B=W;&T%@2=-OR$=TI.QLL^8$90GE; Z
MI>>D;XN*1P]2<@J=3.PI.QZ=^+P_//EO8:ZGAFE9J@=>K@\02+=5PGL9_&LX
M?P93HG30QFFH^\'B'YR=S> *[.WJI$?AQ&6^:H@ZC^^-X\>_.4$&ON99VW7'
MOHXA]'H)S:I8YY7:1=N)Q<V*=5#I?<PXGSP;U*GM1,?!CH/9*S5<E5RY1#G?
MPG:Z@!^6=5K)U63:?V)>MP)C:#O/_?K1/+-N!?<6.\UB )(_8@;'&$4DO3Q]
M4J&W@^?D2<N2'Y?%4(I),SA&KY'DQ!-WR%(,FE22K10QQ8?9BOOX<<PXL?A=
MJ%,TC$/(CE/72C[\Y!S ?92"99U E#F*G "I=Q()C;5=TMWYL&Y;4FLS#B%]
M(_K)OK8CAX[<0[64//_5L@[>,SB>HMB)SRC/=GKF/H/L?MJ.8W<[6,>1U-J,
MX\B]/=V,IP0 +#F91:+S?/$+TVR+768<O5XC?=9A!/![%$":2HHY(;F#_R+D
M[V_&6<1O3L<NS(^('4<Q!^2U7PIU88>R6<[^T%[&(PB0PWM>U"JO^9HOM*I\
MQ9)AIPVJ3];EG?=%>]Y,F7CBJ&8P"#F$TI&QIZ)M!YNY!RDJS_$ XAR,9;&7
M:R<._?"MGCWK]B<UU\82^C-B'79R>S..,6M#V@>4LG8[CEY1'.?9^5R:@T8]
M<6Z5E]9#V^'#3(IU_JA=S#B"')O3*W-' <&.@UBXQ!8210@E@]PG!83N\IYW
M*2OA/JMB8V@[O5S39)UGP4',..&C-KE;&T4,.CNXP)WO(E^/G?OOS"^\Y1_A
M5^"VO%]& :2;**Y<4I^0VWP$5UHUV+W%8(F^6Y77.R2(5S_,9\E2OJE=9#_L
MECL2>JU-*:I<BNX+[Q.PVB^:P3]X=KUY.E:\!W;PEB?PAB!HU0%<F&!1+J"(
M$T(N!'0N06RNS^+>FY& K9VCIQD'F[5)'7L[#QZ6',[L-0'_SE!@[L?R[O#^
M[%DGD]1<W\GLS8AY'HGM#3F%C WI%HLEKMV6L\<3O[3%,6D[G2\H2\%UDOI0
M; ']TC"$1OIL D[RCC1:^#_H#?G#"4!>\P^"Z*- ?_SO.=AGPM(F#:G1M%E5
M/R]FPK9KDMIK7$**,M(%D+:>HD/Z'?)=ZD:1VQOSNL.W%ZQ>&GTUBZOF$L[J
MK63*S-4P.AGF@?,(/*BL.@/'Q+QL,)7\QH^G#8):0P^]*_ !@NA4):>!"C]U
ML3P])=N"?@4AB)T V2&\HQ_FN5A2_P-4$5K%5^DT.6$@?71:NRBTG1B*0K$H
M/UGH0N3A]!\")Z3?9&-&TO\VQWM_$9KKCR9M1?;RT*AX?XTO,#G)%*8_E&_F
M$K(W/T7_(CZWD'L88QD2V26^OAK=N2.4:>R,CC3*9H@NIA._5,C=7=L"B\"F
M(H:);TVT'MJ6<0^^MW2_&&K*&3PHQT:3X%N;\#!F&$S$$DCT%=+Y["2+@6B:
M&JPB]?3" :6HTRHR'2\>+:+FKB)C[L+18AH)5.1973AF+$N$BKR<"X=L@KU#
M1=K-A:/)93I1D4%SH;A-,>&4,/Z\P3C)E%/A^,N&(]ML5 O!FUHQQB15P[<I
M$7S&KQJP38\0-:[5T&U*Q0C+78W>IE[PV0AKP#;E8H+AL49Q!J7"?/>FO#SJ
MYMPT_R*(;'+TR\BR;>L\>-CAEXA-S+S$<_KDH,*(N5'GWCG"?S['4">$^P^G
M>Q4='3\DD#A'1WW> 0_[K^#X"F+"W)O?];__%UKY?V;P1/EI;N]HY56^ZY?#
M)7D!<(ZB?[FH6E.:E*?&VX>/J!Y-C&HHH[(JW%X/O,/H7_!JTIY32:RLX#Z!
M2(L1M$89^)X/A;$68]M]^J231VZO;PGN._ R-)G=A^,'3E%Q'$WOJ2CZY*.:
M3FX4NG[@Y_=1CCG3AV7JL 9X.2>7@9,D4, &WL49!32C,Y4YP5<GS:MA73DI
MX )CTI#ZSW KGS:)=[Z$T6L"X@\T]=OPE*6]O>7ET#(_)=E7M*'HEMHUF$SR
MD@#O-D2+R:?S-?) \!Q5KB7U0JETH_Y[^HFJN(NA.D#?<MC@/@KC#@74BWT&
M[GOH_SLK[P%!.4#1M\U0T?@E],[312,"6^$!-5*>QKY?<,NH=B$K6A^&1V!4
M@6!@$'A,L;+SH,%QTM<.V AUHQ\P2\![0X[) :=K$%8XATZD4>&-4@'JRBAW
MFJIGA9.N3 E)JAYIA=/O!/1GT%FM\"&6KR*HTGGG\T_67\]LB8]F!A0U0XZ=
M48CNN_VA+MR5?Y)MC^+NJSENKSNWZJ2=JYN<RU(T9B2%6U6_F!<%UL"('>,9
M0I]1L#6G<1LF,H(9]PJCN![_2;7"G$1&:]+AMT+Q%* T+D9CA=[#)C@AIC6?
MMK*(^M9+%-\L*G+=LNCU:BZCA+W])8CZ X@/:09+F%S >AJL=KA($JMX+I%E
MK+"69V]J7&>?WL>,PSVJKB<##!4G%AZ.U\BT,]NJ[[G$8[JL(I^-27<0?"]X
M$S,',.-H<I3Y%,#$CFL47^=SB8=S*_:)/_S88/U\VXN'BF3GIO['"*8P=F"C
M0"FW;/?=B;WVW.MGE%V29,?B;Z,!FO 14\ :L(@FGU?A!)/79&G_Y27TTTFT
M)?>3!@#97@OB',CY94 C<>R$;T7 UR[(9X1R:Q!.6\Y_+O* .4&$YYR+&=*!
M_!J_,IBL%4;Y>:"?PLJML.\KWP;)EX05[P<J-V76"\>.EXM>P?(E*DJ++UO>
M$'A_;L@#RD59\?P@@X='4"82&\T,]B%2\GPT;G:80EH%T9=XK%=2%KU%I(<#
M0))!LS&/#LH9.B'$>,20!@!1Y9N%T\4YA@IB(#::&5Q.L*K\-!JR0B4;C:@@
M,<ZG6)E58'>)-\CRJ^PVZFAO;JV=N3B7/PJ8(X5&,^. "U7C'8N;'8+A%4C<
MV#\5>O%%6;X<LKT\WF)_>&AOKN?YQ;);R%V!U/&#I3&#+7.7EBE>@5=XC\"S
MFJ&SAA"DHDUL+CNIB7\\!6#W%H/<5'03Q3=9"L]&\7:.!96_G[X:8BB8LR16
M*LR8AK(!!C'R"H1LI?C7!='!C0*VZ!A;/BPY[WH!G&Y4E!/HV%/S^#R7\'.+
M+U(3G"GXD"'<C;+AF(;:)KV/WYS0_Z,T@(=)%/A><=N'7OORWQ\*5W\?N;A!
M-9/'P43.V!J+,$ZFR#M&$DJIGS"HX.\C^$"2;O[#TPEJSZ3CS]%38PIC_P-2
MXT/@% FWJ=(5H;'&NH=I809!+SJ$.7?;:"2?\LRW!1':?4ELKX]5.,E[K^8?
M$E3>H:+Y#.)C*\4&B1'P#Z"QJ#54]4+@50\L.]?-CEG^DGL%#KY+/.4<'77F
M*7<!\)*;.#JBTEPHF@T)(P39DGCZQ4;1=]8:"1/=R+X'RJ(IP 7PCO'V8>MN
M82O!'&,8L;.H(%L59\2QA9WFAIB\3$QE:%(F))9MH4D'PZ7M6_%00C81-&@)
MJ^Y6(+<E)Q0%3)E%H5N]=*B"KQU9J1H\R==.UI:M?3-4V SHM68QJO:<(9>+
M$XE(6KT57M+S<&%V)MG5YN-4??Y[9AVI</Y2P!F"-Z29FT2V9,LZ^?)O:P"5
ML_U?5GOO,&UHG7*I&+'? HCFX7WDC5 1\F$2P*IYGXB1U8KPFGDH6NZVJHBD
ML>D0\!CAK<@*K1IHX8<!*Q)!*]=OQ=XGYLOVO&+,R0\E);Q;)6ED C?%^Y7D
M8\>UB@$A=%SL!(?0]K2W@Q/R4#@?I/BFO,KUIQMD$%A$QRBN-ZOLGH,XPB-:
M$N$=4,[8)CSP;J[-VDF2Z>+,[*9M0=?'4Q"= 6AEFZ#N ;F]?L>BPE+>Y'CF
M<2["]M&W&]W94&D*W]80M]C-Z5^QS^KQ6";GH9[68;LM3J%V=A@?G6!L3,)$
MJ>;BC!^ PDA5?M'BT(Y)TC\N$D.XN_[K?+E^PABUDIDKG]1!ZX5>,+JD<#E!
M+ _53JLN[?P )\AH!KP?*->\P"!*&/WX,#1S@\\6&824(U=L]56&JKW!6\"/
MO(($&BKIF%^;*X$66S)^4,D4A][K46H.R%[_**Z_%WC?Y47O+IP &9>Q)AF>
M;OIB3#)$ZZW23&40/3'>A-A>XW$ISFZ>^ZTLT5*:58O_()X>5C]M2WI!11-+
M@GEV/B] " X^<4](K?6I ^_(@'T;MFX^>'A='RE=]9_@U1YZ3NPE+R</7O([
M+SK!RX.D-TP8T0!)H3>S:V0^3A"SNO,3MMA [RV9R35/\)?8TT-HI&P6\#AR
M3:353F,(65X_ IW#0C&"BE!T2+_#V^K7F!S#Q^RF]PUKRM-$^XU*DL7?CM@$
M$T.%C$.)UV#?QHAB$[?%YYK'I-Z!#&^X7GL<P *BT0RD+NHK1]<G;6#FMH)I
M\0?L;6%Z,YF]V5(*QA-]M7QOBXN4+QA/\#5?'6S\AO2&(8J O%;<9.EAHK9_
M%?%>!@HNW/<R=_C\.N,097 ]I7?ZVN,3MT@ZU1QRZEO6JB.79)Q_2HZ'U8;6
M;>&=RLXM_^OLJL.JI.HC>./@6D/_9-T<E.?T5<>622$]9LH)J=BMB>PX7"!6
M'68WA?S&[8$*.-=$D40/EOGB$1>,WB0'FA+A?VZD2?!#X'7+*8'\>0,2(VYC
M_(1*O'[9CC8;M+9;4V6P6N<[GC2>R'2NJG!<>S$W+BR;Q#(/<02UD?0,!4*D
MU)UR\@/I(JL^56M!!9[3]H(&I-/SL>/HJ#/+-7YN-*=!1B?S%G-Q?H:?I40S
M\/0T;UEH:M201YZ>!A0)(D^3J_0/H[N^!997Q!7X $%T8M8 (;<WP(U\P0%G
MG1Q7\))Q_3+Y"E1IRD3'NR.JZ5@D02:2$WG)<H;7!M!-%H<^\AJ$T[GQ/]&_
M$BJE4CJ8QR6AO"'*'E$7K;D:V,RBW\H\W%\2<,B"._] *9G![*EM67? 20#*
ME'U[/,711Y$QB[HCM!YF/ /R2["]_%Y4$=$*3U !T9(+N[;HME:GL;&"'A>
M;=S7#J"  M!YU"++GU:<63XG3W$JM9;<6*9M25*V)5GIE;#%N\$SX6I]$4=R
M19JRLVKG64528*Y>*?$ZC%(G6 1P=((;Z'-K]S:43&!M/5*%#YB!\0 C*8VJ
ML\[G?JCS@>K&\>/?G" #7R$6\+]S")J;MO[Y?_D@AOOQ?KZ)XEV2@#P;]IWO
MO/I![DA==O=V:=UEC[*(9S'RR;YP$C]9Y"-6O1K:HELK+3RYXL[":59Y>>/K
MLX962[@X#\GE#NE2E(<DSL[Z%]<^'\.94E^5Q,;06&\:*GN^"Z5^5/4%$EJO
M^ O^KU03WZ0AM0'Q-0K!^:L3_P[2FRSTZ$LD--9:&GT(*>4$4CKH/W7-1<5Z
M2*-VT;^0V_"4I4G.T'Z@/Q51>NA?QH1;:B#,*K@)[_0[B!2SQU CZ364V%[_
M;E^<6S?630S^G8'0/?/=YL2>^I>%FYKP!=[O:=2RDOJ4\/$:6E=]B16?GN-\
M7N<F7I.Z'$H'_;O38N=?A"^ +[J7T2KVQ\_:&)TDIR%LQ_=2DSRAFDODA,-C
MAC&*NGX4IJX?=2^C=='S4Q>CD_X]N0=I?KE7$SVSMF38P0SKFG0;2.=Y@=-Z
ML/9'1#$K"A9!/A/%VH&48<9HPTNR!JP=1[8AH5LG=0KJ:\>2QYZ!/=+3.:XU
MT(H8:+%8XTPT5OC]*+'N=%Q=R#81NP!F&U18%_O 8&'C^298;9A"T< J8A?U
M*1;?R:2]=L\JV2(GS?*U=BR5W.=?K')84WZ?LZR!&\I3V2I-^5J[.YPL;CK>
M*KSJG)!*&>V/=D*HBM&R#.,;RM+D5SE;N-:<B[-1/.WU9//(!?M#2_;*$\_Z
M!Q]XNV3WX?@!(O)#%"=..\7Q(MUNF_76"X/W]5-G80,Z(B:\X!E#G\,0<7*L
MU!'LCOH?09?NP(>R7[> [4%.\^SFZ:EM67GE%\@F$0=_ O&'[T+NO#_<^*$3
MNKX3- F_$Q1"D>!_HCI-2?W$YH0TZ30.@:4Y\1%:&\,A>R>K")(M$NKF @8G
MOV0.8^J"F\#A/*,$2M]:Y-K[%1Z5"R0!0/;R.0X%SK$7!PW*.*\*FN[8QD#3
M%@';"Q$6)WK=S=!$1DF(G4=)#KG+KO<A3N<$+I%H[<^2*@0HP2>@=5.E@.#=
ML1^01)VU$R2_&DEC@FS12@GQF9:Y@"$PMQ&4RPC63J4C3[7@9;_V-W(E9YU7
MJ[#B<7=>A'O*B=17'7/S.<G!F*SE;,\%B%^^O<7YUM?MDA%O"/_RT_<NN0)T
MWR'.L+"'A=48IE?Y;$ _W%^=M$6/?K@/P7\!)Z[W9Y1A@SFH\6#L#I KP6D_
MO\=1]O9^XW_D*TADX<(>WU"(UF;R$C74;!8NA9(&FQEMT$Z&EH.U;>J(/%%Y
MAG24!HO*CU$00,GWNQ-[^T-1U2^Y#9MT=HWAIN7SM$COFBVIW9;4;DMJMZBD
M=EO2DRW#G9%VB)6DH-DRW$VZ/0H#8?2:@/@#7=S%UL*51%!@"HK*!DWX;;F2
MTK&;9J-0\RW)3'CL) ES;#%CQ&YODR2#8F<?H3F_O#A2(ZP/V:N1\?HV=(,,
M"N"WX;43A[ 9\\0J_[Y^B+MS'JRPN\#!DIZ@LI/#@UX7H#8V*-!-QU?MQY=P
MWA/88'] QPZ21QI=1L=C%#ZED?O[; >?,@7]Y+G4R^;;3X;8D+8L;G."O&5Q
M6TD0^+K-]UN2MRW)VY*@59FK8/WH*0_:EBNDJ=B7$X!#>5!AB%.3^+#N9#*K
M=9551ONS6GY4[)*!9=P6F.ECM5F8C+TT1MCVMC0Y4C=,L:5PRZ%CW)5$,TZ6
MV_7WE4<K&,L/6=;':H-^DB]&7X?#+3+8P>O)?PO]@^\Z83H$]25!=\;S.T #
MY-/Z&GD@>(ZND]0_M@,H-I<O16_;*ER^DCAMP0/_JX$&_L>W1^3EAW$=Z?ZF
M__5C\T+;O- V+S3E7F@\W ([__ZOLT[KJQ_ZQ^Q(G%CW]\UO;_/;V_SVEN>W
MQW)&>8BCUU+TWQ^^ I#"3_]GY@1Y<&_!-\L AO#M^@.>)*I?B?AH\[(\YY/.
M\CJ_SPGY0_8:^.[^ )6IT4#CQIAS#47PRVT(+^04JECC%H$=1-4JGOTC> E3
M/QA/\9Q#*%^!* %1.RJ?K3"IT'NNQ]8S>(?HJ9O6/#IOGE";)Y3!SR<$O:XZ
ML3W=:JW$AK6%=;C6VA'8/.(VC[@E0KMYQ)GTF#=9)5_U76MB*,+J/-]8 DW7
M<K)6% PXZ5A%WHIT-;J]63>G//G4C#?T;)YU9KJE;LYSTTX KSUYOARS%F%.
MNSCEN!EN2-.L]RH<!A>2.'GG>7ZQP-OP$,7'_).+=/A#"?_VA]Q']]XYPG_F
MA0H<-U\0S:6*HZ.VU_[;ASW51:'Y7;]#PCX_*?#^@ <-4<E'VPHV.*0DEP/.
M4;0M-Z<3%*@$O*L,\:"'(L#N'?*ZY!Y\SW\B5NCDZZQQ<66H0G'Y7T;'4Q0R
MG);H?;0MI3<;*@? M]7G-]9$&U /_[#=YAPXEZ?,JIVO5^/J1[U,N+S[.4;0
MQZVSU\3W?"<^MT08&J<FMM>VA/T'B'=!$.6U.0JLJ2R/W%[?+N27=W&I/\2^
M"^"=GO^-M O$]I)]E_)!H8:$JID=3P"*M(5B%R-.@_"[.#=-'IQS7O0K3P:=
MXYK\"ANF5^U ()R?DX*OZ-W*J6M);L-"JOL7\-_>4^#M(,TZ;X )IZY9F&$)
MX%??VL;$EGYDUT.BF++5*2W'J<"HP-/ % Q<*D\;/X)BL78/ JH^U7FN&FHO
MJSZ:HYZ?5PZ%]4YUHQW!>#26M8/'U&LZUQF'W+!VP$;HNUV)@'H%KAV]<9(G
M17.UR^5E@B1*UIPW"#F.+9E-6N/D)DY\RDPC=GD&B9$L/A1L_5YK$WGCG*8H
MNQQ[QG%<X7V=Q3G-.)^2I^QXA+?2_E!EDO+:;C[9L:#0S<ED<S*9->M%G>?L
M&;COH?_O3, K1=5G]162#B!S#G/6=1M^@"178UJ'. ^2(J#"UU?;TOHS>8;?
MHIY-2@=C%I%?]KF21#VJS&[:%C0\!I27:D)C@R9/)2AB<_W\<W/MV%P[]+%A
MR@J(S25[15P$COO[D_L.Y=@D3WA*3L]':KH\_P2<_'W]"6+73XK;0;8K ON#
MQM!E9UI"ERNNIU[:8.ZE8=@_^LGO-S& 8B24**$@^>@0TF6.&& =IQ2WP#D.
M*_:[QM#-]><)H!PDSR#&._H*=-1+)Z_L_7KE8Z[-PGZ@$8B:#QI#&3F#^RT*
MX-)0-*\0<>#[KH./5-O5+&\N3D+XLC$44\WORO_P/1!ZPG<098!UT4Y[@7-2
M3N>[9CPD;-ZJ<T7W\EAMVQAS&C:MP)]M"6TCQS8Y6@$:W5#9!HQL%5R[R]3F
MWKBY-^IE8R2\:"QO[3@I]R=;+7*L]YW:<8QH/;;B:M0ASZFT>5OA93I-",1:
MQZW ;2(W)5]:UCCGSLTENJ=ZW8ZXTTXU[=W%"O@F'FZ2CFB-8_-2!0#\<YH*
M-UT#0YVG2@+#-[?-:5S :5S9F=E2H"KB.HH>9ZW([#F-V1"><:U ;O&7+.FM
M>;XTJXNE>]ICM!7PK8;XNX_EY=[]8PX)4V<\V,YUXPQX"(0P 6C[]ND[B"_A
M[L!OM;:RCA'C[K'(>+%R=:UE5 ML_XGNB"\VAF1WZ?+CCQ!E>(A1'8HK5%$F
M.N7Y(HI-*_<*YT(MTEU?+%0QR8LHA.<QP:^&WE8-Z+^"$,1. $';>4<_]-$.
M(ZVC?U8>XN@ DB1G(C> M *9(^O+%XEF-3P0]#UC=%*S>?3CRMXBOOYF7-JC
MN%S]IB;$8JQX9QN-)X.CJ7AY,-#.)84<)S-?*^SHDRF5Q="ML#!*(5C."T>)
M"25*G< H/>0.:HI@1<5-[B"+ <6JKD#BQGZ^4[0P5UH/;>(;9)8G$*?GA\"!
M*G28UY@Z%1HV(SR4I^=6_6!0OGLPL>[O6_4#UA$;&(ZXCMG=Y 0?!.5B#P^!
M@ZH3YE^L:]E?Y\^9WM4P,(.WE[YB)W &?GKCN+FAF)I6 =M4([VD$+[]H9@5
M-6((V]0\)LQ,E,+34^-^Y%<^W9;6:S0K_ZO3K#ZY('2@\$7@A?AV\TZU_/)+
MF)R FY>#Q!(&O:ULWG<X^"ZHCC]Z&7!>HQAU/S^='$+LODA/+1#?1#%PG03/
M0"@-#6'8%)$-TW"%A:"X+FJ4$Q^$;GZJ^2[I00^MA=1.11 =Y8KKMU(*YW7(
M*>I4#34+E=U)/8(0?'<"Y Q"%2K)O8Q:3N$5]1Q=YSJRP(IZ'8U:U#7D5BDZ
M?_O#Z/61Q]#W?-(E*904=G]X28K'=M+K";6/(4NI+%UGKD4TK8TB.F2^BK*0
MEN.%V4U?Q@'D@H'4,G"*$I]$3/U6YBE!D+(/67#G'TA;P--37WJ\O%P[P!W5
M"W"(<@>-[)@%*"GO[AC%J?]';O(DK'7T<"8"(&WI2UJT^.IDBV[W&1((]X>O
M49B^!^?;,$F=(,@31>>?QTEQS#Z2YUBPU38H??D[-U!"S3S&OMD+]=<S]^N!
M["+:6_-=V9XC]TU)["1Y$]K?&1)MY3-X1)_OJ\OB_17.???V%H,WY'0Z<1'\
M QDB0?9*)#P"9,*J?J1E51,>1JEJ3/I^"3I&Z1PYB!&7W>A-$QQ$X8DC?;TM
M69!V;=0X)FY<FS4_@-@E^_()#F*&?P?'ZWW;)X;KE7RM*3E8Y32[[]NK=@?<
MRFD*OLW7+E$\S^2K)AV>U_4VR\$_9EL!D8!/$A>3MBGC%/[-O4M8E*MOK? P
M7_LK)DYY9U\K-B.\4!JVSND!L&J^Q>6?T2>POI?!JA%B>RITZM5CK\BU'S].
ME01?N'-UJ:M82D?7D\2*]&?31.ZAPXL5H E>:D07&RO $K2*X+CYVO-M33N$
MM9N4%:%H C<:039?>QXE 6KB]E^S(CY/D%,Q<581@[="0NM[WEF1_4D2=A0'
M1BOR"(V D>$<.6<*GR4#UW+%+"'[YP89SY'M.K64V/V\G=)>LJZ^GVD)U"\;
M4)P/%&T/UTK17+<A< 1ZXQUI*TAM5-['0LH$TT;5=2R8#6IK3V@M:AYANR)7
MR&TZ1ALW,??H"L--P1B!X75+0_M!JJZQ9 1Y/<$KX*1J'$L&;H1S>H7AIGF0
M,!1PDJ_ W+03JLV QX^[>L385!7RBP^7]W\%Y*:@4&1J$8J4JIRL0,P>%]Y0
MH;DI+2*$B8V<J*"4JL68F&Z^\#]%6?NC$&EQZ+&C8U)=9JY'W8FL1@?1748)
M7QJ)O*&V2?_FQ#YZO&7->=C.$)S+),1<4%=M#9EZ*8J0DD81&IO"NEGN[KCC
M8(6O+1L:S*&SQ,U-C&CJLZW$:PN;J7E!Z#3L8S[/(_T2SB-PHQ Y/N:#[P^U
M&/T2>J4 B(H7A3F(F1,\PGGL7P/_+6^_S-(Y!*\"AES$ZF7(+5A/C%&YA-[)
MXERKPNE#"%!6_.0J _>0Y)^_@^"CL.O1,SZ/&,XTTKN'+&4,];7Z&;^G_P6<
M^/E[-'$KJU&6L5SX39'T<?1Q%K'DFR@CI]X6'&89"_8_9&QQ/HSQ"]X=H%@F
M:=7=L8Q?^L35&KK MM!Z_>G"IL5[V9C5$L<R[;85NV,-T<XX97 .9V"["KCQ
MYD48(Y1: : \PFM+N9N]:9SPO.$V5@JW)/)2)G*%,&])7*%4X'+QV)(@.5G
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MZI 89S)8VC8*/RJHJ(JZ'<99WQVV,JH&;J'0$X"2@JMD(<1@3VO\S\@Y/4S
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MAZI,55:<D*F\AID;JT3QIU6C. ^?(;Y&J\!XXQQU4C05\!KT1""+%; SMY5
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MNH2?6^(7\U% ZB<,, ]*6 ^U6HC\#QE2,F(KU+&]^AC\ZK/5M\!R;WGU+4@
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M$B;SY7ZA05JR$"(Z BRT[J@L7"9Y&*C [N?E8,?MEJ "IU_,QXGD!J%$JUO
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M574,@9!#_,!I.WP*A8Q&"[*HR%;K.*J,B J_GQMR3(D*,L,SY&!4&.Q,I!U
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MG_:?O3 OR]2L\FR/><IO:+N)K]!+'&Y;V]2=;8^2Q$4 V40DG&,-E-9NA/>
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M,6C32TFL*?E_Y$P_L.I(3$O9M9<DI[/7R1EP62?%X#6%X)@^>2>B1+IYIBS
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M2TJ;@LEP"%0>T2R<8K&:.=L_P@2!,QC$#6+X-Z3WICO'&BA"+P43$-&,D0N
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M!?A0(;,%BE\SLGW<,6#("JK83:Y""Q,)Y75:R+91IC(O/#D#1:'(E=R?YAB
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M9]0ET[YNQ=45^YUP.-.^=FE7*\:(V_R6;&[0.)-S,,_WVVO9$M H-8(<91#
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MGV0##E0[XMNL*(I1:$4;HW)XG\G\$]9<RC10%NK2=^!VB=Q[.8_DS/N)^_/
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M"59_)'4;F+$N WI')-GP5JT#*YT-K&9403%";J-'Q98$6)%H]41=#%;P+[K
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MG?5UZ[,?#/'Q&!JWK5/'^B,* L>VCNO6P>;ZP=8:_+MMY[/.1Z$G#K\*QQW
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M]_'.*S0%F"9=ID5G,3QKX-&*;G[K#_-1PSC>1#KAD1I7X2)7L\BO+#F?"?Y
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M5UB11"KN0!973>].A*G?DQ:+66,>.7B49;4QW>'$,*FU/.EQGJ#$YJ @&,8
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MOY'HSR=,:/M,U=%E^H!W0&1VYB(R.R3!90EE%_1 :QDG1?)" M^\880O3F1
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MF+D$>*$ KFMF_>A-(MS<3(2W)]'=!'U9J'=GS\&*+ZQ*2H3B:(Q&>"SCQ&%
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M@]JSWS8XWI5_8NWC3\>[ZJ^S_0]02P,$%     @ 8SAX6ADD?G:Y"@  16@
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M]\_>Y_D:!K9\;E?B^/F\:-;+[/I94>*9.L2I;IL_^)(NFV22MOQ*< 3^K?/
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M[RPK/&5F0^ ^S5=9P7\!$_( # NR6)-5WEY4\V2U:3>4.R9TKI@4SCJ3ZUB
MO!/>5399^8'W;X<1] P3V\N-UD2FPE]@7\!D;+%D+H(Z$6Q+"]9B@WX)[]L
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M4\0S5C\6%4S<C--GCXZ3-T<_':5TBO]/5;]/7F#%$%*6IG$_YL!6!C5$6-K
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M3]A++%J5#A/WZJ#>T3:COGES0?(G/?$9+-+:$RU_YR$:^ZL\YR$^@[Q*IV=
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M&W!Y;;EBBO(R!POV7)6C2#E>*3"#.?P#;.MB!?]M-@4I5KF\^%-%B6I1ZO1
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M(ELN>K*G3?$ZSYAFL_?G-9GH<6V _7$D@B3>1+B (XKLX:;=KJFHBK.1<%+
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MT\0D6<AB\T'NW;/L.Y0FQCN7!3@^K[AF.+_ETND70RW;RRTQ\D)]\60*<BG
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M+'X$7;"!Q?'\@>3T^ZPT&J)U+J^Z?3-8#-<3/3(%WQL!4WLK?Y91'&G!H8:
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MN7[NX6SFL#2MK0AVQ&KS#3OO:' ON(\8JP$6U]0! C'>/:>SSS>@<X?K_+*
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M^LU3?D5_@=Q+'=Q(>]O\U^LW9V=IPD.CB2$#;(NA(O!(X3EHA6T?628SRS_
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M3AUNALOM_\SA44S%); #U+MDH[AI",6F!@U&9)N3)U%>05==WRISIW0F-JY
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MCOC]"BVUFN]R5KK\-L3W>7(\/3SY9J!D?#0)'JQ)4-\MD^!U*6"J?3JV'5-
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MV2 CVAR1LBU;WMU8FH)LSL@4@Z37ZW#,AP*Z0+;5Z,;T00K[Z]^\ZN@+I&Y
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M[]X49YWS"N->M1T;OI/8 S>S21JC_.2'.+LINN*6T&^6Y!(9H46?!P^B%QB
M)%!2N_Z.N*TYVS?F7#>$).3,,>?7-])V6"+;JH;V0:=->P#7N@<?>GCZX=T=
M-Y5V6;%3:KLTNY\D.>4TAZ/=< CD].#'@V\/4#"\0.E\^=6335('#EB]F_<%
MR7!.0_M^I[N!DBW@1QK.3XJ"%$$B@7O-<OU\7_\*&R?6?B1Y05PL83SH \FU
M="WE>6/CJ!@ HA<?/O[J'Y&T6P?+J?[*"4;" #3WR[@R*MVSX?6VE_6(\XFN
M4:_#_(\FH>=Y^VXR)'7(KES2MGX!;S';3B*5IUUY>HF#/1RDZ(C:,@I3IFY5
MFBG9]R&UI1,D\=H3.&WJ8>?"9Z)M2;W;)&8/"&,?"F$L 9."C[6'TIRO3 >,
M(5[#C(UFB0?\B2BMZ3QV(4.KAO[9)-<&F[D5K4H%3)X^)5V:<E;P'WW0P:0
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M.3)(EWL,5ADJ4+NI6][E?@-3KU$IXFM5[:ZF+KQ#+I"W['-L3HX=[C0W(!W
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MBZI]O@[5/J':9Y-UF\5VZ38='(X7A(E;@;*3;)C7EF[TN4QO&/W:M6_U,4?
M1.(_GSP9QQ\!%<;=\)PKWW(06P^>I!SW7,4.R*ZK+U!=M=?#TFL1R\WK&%D
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M%Y?1RY<G040&:1"(LGE$"3P8CEL@RN;QX,X&C$*^PL91$?,5SC46Y[PH5^$
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M)PN",5.I&2M4L@K@9)@\2 8@#2X2QG-S@O_.M+L-6>D7P9*C\B59BU5TG8)
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MV/AO9((;A)IJ;$B &: -[+8*RE_U_:7F0&J*=J0%L)G@  :189"[[ZZ.![*
M=;X(=!.27X4\61!!N+0T?#8Q^7A"KQBJ2,.UXBML#IR2PJU" ;.9&.1:9%"S
M2X&1@E2/4/1(' MDLYXBI;R5'(3%3,)')./NIIK+G>UOG39Z(8M9C4 .2<9R
M[%7."<AQTBF $YL^WRFZXU#OB2+!&A'<-%'AV$GNNB;-:H9.4$%/4 VU4V Y
MCO2LW;T*(-_=<=\?W!ZA=O^0A@8$'F ,W/JZ[T\CMP.'*!J=C,%-%44[M,P6
M:8X*1J>^@0NWZ\A$D9D1$Z#CHG3(+6QZEH0,G98*NN/5=MZI'"N@<0J'/=$%
MWO?JQQ7QPH2BV82!,<) VCQ.ZDX9%Y!<K%IW'\.*:X'&!X=Z!4!72;@D GEH
M;G!UD.)NGG %E_D.!OK[!8@\DL/GL5GI_V#ACSIBT!OL5=;Q23__81&?CTV
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MWJ0>'JBKWO63A1WFC<.Q0- @592<QNXSL!<V '3S5ALD@]#./F=4&981WD4
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MXUFP*_LSOL.\)(KQ&"<:N UB#T.TK$UQ#L(,=[/FLUZ#*:\I4G1/M)I;39E
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M3Q*1WX2_%N-.QO6-R$->6O4OD15*6Y[;SH8;-!'#NLM?@<@3&(?!;B<3>3
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M>OY<9+6PG]IH2V^N%D@%->;-#FYZ$0AN;  ""G"/!J0;Z=II9,*X*05=1YF
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MKX%_ZKA_J]2P7!5O+M"\\:T[&YLU$;9=VR$VCD%;$7"9X3X282BAZ)JKQOP
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M-38P.#9?,2YJ<&=02P$"% ,4    " !C.'A:=?>Q@ L-  "N#0  $@
M        @ 'T9@4 :6UG,S0W-38P.#9?,3 N:G!G4$L! A0#%     @ 8SAX
M6L,:%E<QM@( _DH# !$              ( !+W0% &EM9S,T-S4V,#@V7S(N
M:G!G4$L! A0#%     @ 8SAX6N5ZK6#'+ ( ^HT" !$              ( !
MCRH( &EM9S,T-S4V,#@V7S,N:G!G4$L! A0#%     @ 8SAX6H!H-\.0P@$
M]AT" !$              ( !A5<* &EM9S,T-S4V,#@V7S0N:G!G4$L! A0#
M%     @ 8SAX6J,12W4>E@$ _?X! !$              ( !1!H, &EM9S,T
M-S4V,#@V7S4N:G!G4$L! A0#%     @ 8SAX6L"]\*_OB@  !+8  !$
M         ( !D; - &EM9S,T-S4V,#@V7S8N:G!G4$L! A0#%     @ 8SAX
M6J>(:[R$@0( & @# !$              ( !KSL. &EM9S,T-S4V,#@V7S<N
M:G!G4$L! A0#%     @ 8SAX6O]/;Y^B9P  ,70  !$              ( !
M8KT0 &EM9S,T-S4V,#@V7S@N:G!G4$L! A0#%     @ 8SAX6K"!)EZ]$
MA!$  !$              ( !,R41 &EM9S,T-S4V,#@V7SDN:G!G4$L! A0#
M%     @ 8SAX6N[6KSQPV@0 HFLX !$              ( !'S81 &QX96\M
M,C R-#$R,S$N:'1M4$L! A0#%     @ 8SAX6N>:W$7(P $ C*@; !$
M         ( !OA 6 &QX96\M,C R-#$R,S$N>'-D4$L! A0#%     @ 8SAX
M6OXV5)QD/@  :O,! !               ( !M=$7 &QX96\M97@Q,%\R-"YH
M=&U02P$"% ,4    " !C.'A:RQ/4-:HV  #^CP$ $               @ %'
M$!@ ;'AE;RUE>#$P7S(W+FAT;5!+ 0(4 Q0    ( &,X>%H(4(HEF0H  *1M
M   0              "  1]'& !L>&5O+65X,3!?,C@N:'1M4$L! A0#%
M  @ 8SAX6ADD?G:Y"@  16@  !               ( !YE$8 &QX96\M97@Q
M,%\R.2YH=&U02P$"% ,4    " !C.'A:[';UXX$+  "&?@  $
M    @ '-7!@ ;'AE;RUE>#$P7S,P+FAT;5!+ 0(4 Q0    ( &,X>%HYJLW-
M'PL  +IU   0              "  7QH& !L>&5O+65X,3!?,S$N:'1M4$L!
M A0#%     @ 8SAX6FK1KZ6CP   #UD& !               ( !R7,8 &QX
M96\M97@Q,%\S,BYH=&U02P$"% ,4    " !C.'A:9@S8W3 <   GX@  #P
M            @ &:-!D ;'AE;RUE>#$Y7S$N:'1M4$L! A0#%     @ 8SAX
M6H,B2J*T!   &D    \              ( !]U 9 &QX96\M97@R,U\Q+FAT
M;5!+ 0(4 Q0    ( &,X>%J6X;(HU0@  $\\   /              "  =A5
M&0!L>&5O+65X,S%?,2YH=&U02P$"% ,4    " !C.'A:$P<G>. (  !3/
M#P              @ ':7AD ;'AE;RUE>#,Q7S(N:'1M4$L! A0#%     @
M8SAX6EWW(>,9!0  61T   \              ( !YV<9 &QX96\M97@S,E\Q
M+FAT;5!+ 0(4 Q0    ( &,X>%IUQ,LA(P4  , =   /              "
M 2UM&0!L>&5O+65X,S)?,BYH=&U02P$"% ,4    " !C.'A:GJ\-U_(*  #9
M50  #@              @ %]<AD ;'AE;RUE>#5?,2YH=&U02P4&     !L
,&P"0!@  FWT9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>lxeo-20241231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:lxeo="http://www.lexeotx.com/20241231"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="lxeo-20241231.xsd" xlink:type="simple"/>
    <context id="C_818a9569-5179-4332-bce6-97002fa8dd65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_81b19c2d-22eb-4f90-b119-49d130c596ae">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lxeo:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_8821cec2-12fd-4f69-a047-478fca32226c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandTwentyThreeEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_889faa80-3bbf-40d1-b770-591485567a8d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandAndTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-01</instant>
        </period>
    </context>
    <context id="C_8b7e354c-42e5-475d-87f9-4bfd1355ccaf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lxeo:AdverumBiotechnologiesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:AdverumLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_8c6b7b14-2521-4983-80fe-50cd39b26715">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">lxeo:OfficeFacilityAndLaboratorySpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2029-08-01</instant>
        </period>
    </context>
    <context id="C_8ca9fee4-3e70-406e-b516-57586deaa558">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandTwentyOneAndTwoThousandTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_8d26cf86-cfdb-467b-8eab-522b18243eda">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
        </entity>
        <period>
            <startDate>2017-02-17</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_8e099335-d590-43f9-972a-d06c24fef007">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lxeo:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-07</startDate>
            <endDate>2023-11-07</endDate>
        </period>
    </context>
    <context id="C_8e396f66-88d9-4bb5-8412-da93d2388896">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lxeo:CommissionsAndOfferingCostsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_8fa4e334-c5fa-44d9-8bc4-866b04e010d4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-07</startDate>
            <endDate>2023-11-07</endDate>
        </period>
    </context>
    <context id="C_90a370bc-c9ba-46da-a45b-b1abd87d6810">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_90b3b8b5-08ff-4ed8-b03a-36a19e205081">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lxeo:SimpleAgreementForFutureEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-02</startDate>
            <endDate>2023-11-02</endDate>
        </period>
    </context>
    <context id="C_90de349f-5edf-4ccd-81d6-310075c43d96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:AmendedFirstUcsdAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_931de80a-517d-4a40-8171-722f60ac7671">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lxeo:SeriesALiquidationPreferenceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-07</instant>
        </period>
    </context>
    <context id="C_933a22df-2af6-4858-8d9e-d0defe7f6576">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_93e60cc0-c98a-4905-a0ae-b6c3266b5a78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-11</instant>
        </period>
    </context>
    <context id="C_940cc76e-9af2-46e6-b22a-05a05af066b0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lxeo:CornellUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:CornellLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-28</startDate>
            <endDate>2020-05-28</endDate>
        </period>
    </context>
    <context id="C_948b5c1c-c12b-4ae5-a807-364c74cca6f3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_95dc5b03-a8d3-46ba-9c0f-f641f5341cf5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">lxeo:ConvertibleSimpleAgreementForFutureEquityNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_98130704-057d-4280-9bc9-5ebe7b7bf561">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lxeo:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-07</startDate>
            <endDate>2023-11-07</endDate>
        </period>
    </context>
    <context id="C_982e832a-cdf3-4671-8548-8f56b1f3f254">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lxeo:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_98679350-4c2b-4d25-9968-d21e18f72506">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lxeo:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_98dbb090-8617-48e2-9f19-11212333ce32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandAndTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_99fa4607-5a6b-4035-bcda-41e63ec19b9d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_9a05326c-b178-412f-9312-a4d581f2c9d7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandTwentyOneAndTwoThousandTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_9a3288c8-11b0-411a-aef1-05a44eec67ca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-30</endDate>
        </period>
    </context>
    <context id="C_9a32dff6-03c5-465f-846c-9b718f20e0b9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lxeo:SimpleAgreementForFutureEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-24</instant>
        </period>
    </context>
    <context id="C_9aca8f8c-d11a-4b96-bb2f-8028f5d80ed0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lxeo:AdverumBiotechnologiesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:AdverumLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-25</instant>
        </period>
    </context>
    <context id="C_9d082257-9ef3-44bf-b671-47a3b444bcf4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_9d573f03-b8a1-43e3-9828-e04c95b23d8a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lxeo:SteliosTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_9e79f7b3-b991-4a2c-abc3-1a0ef29ab5b5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_a20a05b8-9d12-490a-93f2-114ea8e35fca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_a398e430-4b76-4f00-9eb3-273c39d2e6fd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-04-01</endDate>
        </period>
    </context>
    <context id="C_a42efdd6-1a5f-4930-9ba0-797305fcec72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">lxeo:OfficeFacilityAndLaboratorySpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-01</instant>
        </period>
    </context>
    <context id="C_a5546360-23ec-45e5-ba9d-ee679b197414">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-07</startDate>
            <endDate>2023-11-07</endDate>
        </period>
    </context>
    <context id="C_a65a8fba-bdff-47f7-a790-76ebb3dcb9f8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandAndTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-08</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_a6bbca2b-aa76-4540-b619-c2e288370970">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:TwoThousandTwentyThreeEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_a6d4ba66-86df-4d4a-b4e0-034d42abb2dc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">lxeo:OfficeFacilityAndLaboratorySpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-01</instant>
        </period>
    </context>
    <context id="C_a70f9bd2-aceb-4c0d-b0fa-5353c3dece2a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lxeo:CornellUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:CornellLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-07</instant>
        </period>
    </context>
    <context id="C_a8c2e316-6ad2-4b74-acd6-08e9897fd12e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lxeo:SteliosTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:ThirdUcsdLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-04</startDate>
            <endDate>2021-10-04</endDate>
        </period>
    </context>
    <context id="C_a9ce9707-98f9-43cc-9660-650bbf29c98a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_a9cf5f12-f6ff-4e48-8365-fa92cda8cd46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_aa9ff400-2f57-4dd1-8623-e1ed88b5664f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lxeo:UnderwritingDiscountsCommissionsAndOfferingCostsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_aaf7b4cc-4609-41bc-a23c-cf54d6116e53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_ab7f0058-11d6-4f3c-b66e-25878efcc5c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lxeo:CornellUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:ThirdCornellLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_abb5ce74-a0ec-41a2-a9d1-032861f25e44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lxeo:SeriesAAndBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-07</instant>
        </period>
    </context>
    <context id="C_adf39fa9-e13e-4660-a6b0-e64e383d673a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_ae668a8e-dcdc-48f6-9c7d-cd99b945d79a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandAndTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-08</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_afe980af-4f26-4fd3-8f3e-e44a3e233ab1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandAndTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_b15d25c2-ef2b-415e-98f5-5721bc068283">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">lxeo:AntidilutiveSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lxeo:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-07</instant>
        </period>
    </context>
    <context id="C_b1a96dae-b4d3-465e-8d90-5f13defcc31f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:TwoThousandTwentyOneAndTwoThousandTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_b4755659-dbea-42a4-911b-aaf4e5f99a6a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lxeo:SteliosTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:FirstUcsdLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-23</startDate>
            <endDate>2020-04-23</endDate>
        </period>
    </context>
    <context id="C_b4989bb1-3d29-41aa-910d-bd20c1974008">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandAndTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-01</instant>
        </period>
    </context>
    <context id="C_b520844c-238f-400e-8a4f-68368cd0badd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_b7af60cb-baf3-4dbb-af94-8473e08ee442">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">lxeo:BlackScholesModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_b8320cf7-1637-4a5a-b0b7-b67e5100600a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_b8ce5a83-8a3f-4019-b952-412e72e2157f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_b8e13f0d-e121-406d-b1a0-0b776194fbaa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_ba4a9d48-b7a3-4350-9c16-becc8f228a5a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
        </entity>
        <period>
            <startDate>2021-08-10</startDate>
            <endDate>2023-11-07</endDate>
        </period>
    </context>
    <context id="C_bba6b31e-5617-48b1-9ad1-7cf7f1501cf3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">lxeo:BlackScholesModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_bc4e18d1-8708-4fa6-8c8b-10f077d3382c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-11</instant>
        </period>
    </context>
    <context id="C_bf7a1f3a-c205-45ba-9483-a2ad719c16b4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-07</instant>
        </period>
    </context>
    <context id="C_c25f5aa6-70c3-4c5e-b41f-0a034c1996d8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_c5950291-be83-459b-b80e-1f0bffbf88e7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_c679f25f-cc6a-43c7-8227-e208b67e0722">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-16</startDate>
            <endDate>2023-11-07</endDate>
        </period>
    </context>
    <context id="C_c6a9a2e2-eebe-4569-82e3-6437a6ce2366">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_c6dd71d6-5140-472d-b5c8-2940a8c82dd8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">lxeo:OfficeFacilityAndLaboratorySpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_c7d3289f-7fe7-4f19-ac48-22a403b83a4c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lxeo:CornellUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:ThirdCornellLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-21</startDate>
            <endDate>2024-04-21</endDate>
        </period>
    </context>
    <context id="C_c96098bc-a151-4b74-aeae-a01a9db7efbb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_cb661ff1-5311-4097-b67b-ccc8f26e5c71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lxeo:SteliosTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:FirstUcsdLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-23</startDate>
            <endDate>2020-04-23</endDate>
        </period>
    </context>
    <context id="C_cc906741-ea91-4e6d-8943-e5456da6d798">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lxeo:SimpleAgreementForFutureEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-31</endDate>
        </period>
    </context>
    <context id="C_cfef4556-754f-4351-9370-c51c9711c2f4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_d00c7be3-f867-4469-ac2a-406521627abf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_d1ca60e9-37da-42d1-8e5d-0809de6840b2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lxeo:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-10</startDate>
            <endDate>2023-11-07</endDate>
        </period>
    </context>
    <context id="C_d210b17b-f2c2-4a07-9b34-0371db6164dd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_d4ba692f-b7d0-4af9-9603-697859726ab1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_d54dc3c6-3447-4e53-b661-49e8beab972a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandTwentyThreeEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-07</startDate>
            <endDate>2023-11-07</endDate>
        </period>
    </context>
    <context id="C_d58c59cb-9db1-486e-a4ba-83018b4264e1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_d6e454da-2fb0-4d82-ae44-abd1e7e3c994">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
        </entity>
        <period>
            <startDate>2020-11-20</startDate>
            <endDate>2023-11-07</endDate>
        </period>
    </context>
    <context id="C_d965f156-2881-4f62-9e05-2ce8f77a88cb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:TwoThousandTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_db4d6fe7-17ff-4f4e-803b-2c15cda55624">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_db61ba99-c7c7-4e9a-a944-9cc82209837d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_db7527be-0d81-4c4d-82cd-9708fd4feeaa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lxeo:AdverumBiotechnologiesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:AdverumLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-25</startDate>
            <endDate>2021-01-25</endDate>
        </period>
    </context>
    <context id="C_dee9c396-7be8-4764-a1e9-de37e72c1b20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lxeo:SteliosTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-16</startDate>
            <endDate>2021-07-16</endDate>
        </period>
    </context>
    <context id="C_df27e94d-4502-4904-99fe-3d1d46216d3e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lxeo:ThirdPartiesForPharmaceuticalManufacturingAndResearchActivitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_dfaf0a7f-a734-4cd4-9b33-a8172ac5f59e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lxeo:CornellUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:CornellLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-28</instant>
        </period>
    </context>
    <context id="C_dfb1adde-bdce-4971-8572-0c77f2a15437">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lxeo:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-07</instant>
        </period>
    </context>
    <context id="C_e226ab34-462b-4baf-bdb6-41d1da52235b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_e30bab05-7cc4-4f13-aa74-111c8d09ef0d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lxeo:SteliosTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:SecondUcsdLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-06</startDate>
            <endDate>2020-08-06</endDate>
        </period>
    </context>
    <context id="C_e4562be4-fed1-4c76-8ee0-9ebb81409e47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_e5969e3b-4f0f-4598-ab16-63cb541f8395">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lxeo:CornellUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:CornellFirstLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-28</instant>
        </period>
    </context>
    <context id="C_e83f79f6-f924-4728-9c7c-5f1eb49397fe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_e84f1a1e-8d42-4df6-8795-f518a72c03e0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lxeo:SareptaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lxeo:SimpleAgreementForFutureEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-24</instant>
        </period>
    </context>
    <context id="C_ea417d17-7d7e-449f-9280-8a0a3bc657d1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_eb04d3ca-9afb-4d97-9a7e-b5be9da963d6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lxeo:SteliosTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:ThirdUcsdLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-04</startDate>
            <endDate>2021-10-04</endDate>
        </period>
    </context>
    <context id="C_ec3ec1bb-68cc-4820-9297-a6c0c881028e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-11</startDate>
            <endDate>2024-03-11</endDate>
        </period>
    </context>
    <context id="C_edfd0d26-83c7-4293-8b0c-e99852a72a86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lxeo:SimpleAgreementForFutureEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_eef711a6-19ec-48b9-9c42-54e797d52952">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lxeo:CornellUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:CornellSecondLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_ef41b0f5-e670-47fb-a4ba-1fb722c72adf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:LeerinkAtTheMarketSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-24</startDate>
            <endDate>2025-03-24</endDate>
        </period>
    </context>
    <context id="C_f04bbf56-d3c8-4272-a5ff-e1a1e02029b4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_f13110bd-68e9-4c8f-869d-c3f80a05ef1a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
        </entity>
        <period>
            <instant>2024-12-30</instant>
        </period>
    </context>
    <context id="C_f2189c8d-e1b8-45de-8953-73622e2e8923">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_f22d9e2e-1a87-48b1-bd28-4d0a0a5afdfb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_f579df17-1e2e-4b2c-ab33-2703e6c475a7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_f5b88d17-128c-461e-aaa6-463ec8135b2a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lxeo:SteliosTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_f6b1ccbb-21c3-4469-9c9a-20c3e22a9b8c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lxeo:ThirdPartiesForPharmaceuticalManufacturingAndResearchActivitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_f6d073df-b45c-4611-a81b-0bd39b099fbf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandAndTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-08</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_f8619687-73fe-4744-9482-f214f5f1a619">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lxeo:CornellUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">lxeo:ThirdPortfolioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:CornellSecondLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-28</instant>
        </period>
    </context>
    <context id="C_f8c50f85-2ed2-437f-90c9-8336f5967e8e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_fc82fec8-4701-4ddd-a632-831d62d00aa5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_fcb1173a-0535-4c9d-91c0-398680f70ecb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherComprehensiveIncomeLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_fd20e119-f9e2-4c0e-9735-4934b480df35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lxeo:SteliosTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-16</instant>
        </period>
    </context>
    <context id="C_fe2a112e-35b6-427a-9cf1-e602c55b5ef9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_feb46e5d-6816-4e22-a41b-42317def0254">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lxeo:SteliosTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:UcsdSponsoredResearchAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_ff876ac5-7ddc-447a-ba80-cd3fc5d96d6b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">lxeo:AntidilutiveSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lxeo:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-07</startDate>
            <endDate>2023-11-07</endDate>
        </period>
    </context>
    <context id="C_ff8a14ec-2414-4dce-963c-ac378e45b5e3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">lxeo:ConvertibleSimpleAgreementForFutureEquityNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_002aeebf-8141-46fe-833a-b448a9ed53f3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lxeo:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_00b1026d-c1b5-4b98-bee1-f1aa2360eb94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_01ae7cc9-95ef-4205-a1f8-4bc92563980e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lxeo:SareptaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lxeo:SimpleAgreementForFutureEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_03d0654e-3872-4474-936c-dc6ff5ca1f8d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lxeo:WeillCornellMedicalCollegeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:ResearchCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_05465aab-2ef4-47b5-84ef-3eacb2ef4089">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:ThirdUcsdLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-13</startDate>
            <endDate>2024-04-13</endDate>
        </period>
    </context>
    <context id="C_057f47b0-3a28-481e-917c-c1c45349ef35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">lxeo:OfficeFacilityAndLaboratorySpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2029-08-01</startDate>
            <endDate>2034-07-31</endDate>
        </period>
    </context>
    <context id="C_07376bba-ebc9-44c0-bc4a-e98679fa21ad">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lxeo:SteliosTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-16</startDate>
            <endDate>2021-07-16</endDate>
        </period>
    </context>
    <context id="C_09b75305-e3e0-435b-b2a6-50f4050afab2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-07</startDate>
            <endDate>2023-11-07</endDate>
        </period>
    </context>
    <context id="C_0ed26320-f07c-4528-a9ac-162b961bf030">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_0f4466dd-9ea9-4c34-a1ae-2fdff5adc7ed">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandTwentyThreeEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-01</instant>
        </period>
    </context>
    <context id="C_10dc49c3-ff40-493f-b51b-be28cd103318">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lxeo:CornellUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">lxeo:TwoPortfoliosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:CornellSecondLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-28</instant>
        </period>
    </context>
    <context id="C_11aac366-2c9d-4773-bc55-7994d2ee9dd0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-11</instant>
        </period>
    </context>
    <context id="C_17a6e9db-02db-43c5-9308-865a99b44dc2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandTwentyOneAndTwoThousandTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_181d6e2d-a650-47fe-a4ba-e4e8ee97c169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_186c2b13-b928-42dd-8bd4-f169393b3424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lxeo:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_18e0f1c1-de91-4bc1-b5ce-39772b43d1e3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_19581a58-f4b4-41e4-85f3-1dff41c48718">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:TwoThousandTwentyOneAndTwoThousandTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_1b2d6a36-1a01-47ee-b773-2a16d5242136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_1c8074fe-d719-4d7e-8aa3-6e8936dddc3f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">lxeo:BlackScholesModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_1e2a8137-62de-4a72-83f0-d154bc7a5841">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_1e595beb-6e63-4729-9f01-fa8aaad38108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lxeo:CornellUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lxeo:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:CornellLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="C_1fd0f357-c2ff-41e2-bd80-50ac05612394">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lxeo:SteliosTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:UcsdSponsoredResearchAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-03</startDate>
            <endDate>2021-12-03</endDate>
        </period>
    </context>
    <context id="C_202838fb-c603-44c3-ac57-cbb400921fd7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">lxeo:BlackScholesModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_202992e1-90d4-413d-b703-e8197a8dc6e3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lxeo:CornellUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:ThirdCornellLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-21</instant>
        </period>
    </context>
    <context id="C_222f24e5-787e-4d77-8748-8b551ff8243a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_23e9fdcf-7d72-4c30-b945-044420610762">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:TwoThousandTwentyOneAndTwoThousandTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_2409277c-21f9-4adb-af62-46fdf50d9ce6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_240d6e00-2133-41ba-92ce-0078e7bbcbca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
        </entity>
        <period>
            <startDate>2023-10-13</startDate>
            <endDate>2023-10-13</endDate>
        </period>
    </context>
    <context id="C_2611b746-5276-4a2d-b18c-32e1fcba87aa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lxeo:SteliosTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:FirstUcsdLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-23</instant>
        </period>
    </context>
    <context id="C_266f5c3d-d979-4718-851c-88a44ef02c23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-20</startDate>
            <endDate>2023-11-07</endDate>
        </period>
    </context>
    <context id="C_27a6defd-2f97-4391-b27e-7d7b4574d1b7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:LeerinkAtTheMarketSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-24</startDate>
            <endDate>2025-03-24</endDate>
        </period>
    </context>
    <context id="C_28144b67-7dfd-494d-8133-75abcc735058">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_2911d34b-7821-4985-b38e-577d63cb332d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lxeo:SteliosTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:UcsdSponsoredResearchAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-03</instant>
        </period>
    </context>
    <context id="C_29a86653-566e-428b-a98b-7f3277fd7d90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_29bfd3ef-606a-4b0e-a5fa-8ba6f8566146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lxeo:CornellUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:CornellLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_2a226df6-55ca-4590-b4f4-0e51d8f169f6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandTwentyThreeEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-01</instant>
        </period>
    </context>
    <context id="C_2b151cd0-5507-43d4-aa4e-3c68accbaec1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lxeo:CornellUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:ThirdCornellLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-21</startDate>
            <endDate>2024-04-21</endDate>
        </period>
    </context>
    <context id="C_2c640ac0-f0e4-4b44-953f-372c68c1666b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandAndTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-07</instant>
        </period>
    </context>
    <context id="C_2cce3246-207a-4da6-b759-efc03a70940c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_2d31726b-58bc-4b55-8b8d-242c0b620bca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:ThirdUcsdLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_2db6ae14-94d8-4061-8201-63bc8341dd14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandAndTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-07</startDate>
            <endDate>2023-11-07</endDate>
        </period>
    </context>
    <context id="C_2e7387e7-73ad-47fb-a0de-5ceccb4a2a0f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_2f31b66a-0232-462f-8ba1-c31ab4b8824f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lxeo:SteliosTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:ThirdUcsdLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_3283c13a-3e8c-4395-9d0b-cffabf13a351">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherComprehensiveIncomeLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_3393a748-8c4c-4d41-87d8-1deb8ed9aa5a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lxeo:AdverumBiotechnologiesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:AdverumLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_34e9355d-4428-4f62-b1ae-10943dbb5161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lxeo:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_3579d9a8-e7bf-4c6d-ac06-1c8021fed3eb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">lxeo:ConvertibleSimpleAgreementForFutureEquityNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_35a86fc1-0afe-4e3c-96ee-81097e533438">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lxeo:WeillCornellMedicalCollegeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:ResearchCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_36d77a3a-fda6-41cd-8ab5-65f7367582d3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_386c356b-4350-4ef6-bbc7-35471297e6b0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandTwentyThreeEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-07</startDate>
            <endDate>2023-11-07</endDate>
        </period>
    </context>
    <context id="C_3a1be116-5c64-4576-af28-6c9bb1f6ae39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-07</startDate>
            <endDate>2023-11-07</endDate>
        </period>
    </context>
    <context id="C_3b4c1dc7-9d04-44ef-97e9-98e10c0a6e4e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_3bc3fa7e-440b-44ad-b57d-4fc9f9165d8a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="C_3c3cff29-78d2-4481-b497-e743fdeb998d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_3cbe0ed1-2f36-42ec-8001-032a59884f91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="C_3d6eac78-9474-4e08-bcae-13f2246c0568">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lxeo:SteliosTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:SecondUcsdLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-06</instant>
        </period>
    </context>
    <context id="C_3df569eb-97ac-4247-ae8a-b4800fbcc697">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lxeo:SimpleAgreementForFutureEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-02</startDate>
            <endDate>2023-11-02</endDate>
        </period>
    </context>
    <context id="C_3eb26141-df5c-4391-985c-b5a244216bc1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_3f598951-fd6b-41a3-b5a9-de413e56d5cb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_4013d4d1-c4c9-4765-acc9-a1659c4750bf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lxeo:SteliosTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:UcsdSponsoredResearchAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_41123b72-f984-46ee-9547-e92bc56bb833">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_4270dba9-ca70-4680-8947-60179d11e241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_4416291a-8898-4d40-bf16-c20112811638">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lxeo:SteliosTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:SecondUcsdLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-06</startDate>
            <endDate>2020-08-06</endDate>
        </period>
    </context>
    <context id="C_44325f11-2b42-4650-93e1-0c060ce8130d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandTwentyThreeEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_44dd3996-14be-4820-b581-6281744e49e6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
        </entity>
        <period>
            <startDate>2023-11-07</startDate>
            <endDate>2023-11-07</endDate>
        </period>
    </context>
    <context id="C_44f34368-c2ff-4b64-9e18-4ee6525fb195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandTwentyThreeEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-07</instant>
        </period>
    </context>
    <context id="C_4591c456-caa6-4a3e-acb5-b25d3fb9ee55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">lxeo:BlackScholesModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_460d7490-ff50-4c44-98f4-b0211c51d98c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandAndTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-08</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_465c4136-b851-42be-84ee-27ed04fe8539">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_47a049b7-455a-448b-84ea-5e98846bad51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
        </entity>
        <period>
            <instant>2023-11-07</instant>
        </period>
    </context>
    <context id="C_4a2b7157-1380-497a-a4ef-750dda612b33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">lxeo:BlackScholesModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_4d1f9c2e-11bc-48e8-b628-60da7528906f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_4d93aa08-044d-4a0a-8ae0-08a443ffa6ea">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-11</startDate>
            <endDate>2024-03-11</endDate>
        </period>
    </context>
    <context id="C_500ad48d-4ad0-4259-8d4a-c15b843c549a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_55a64f42-6349-45b1-a852-990c1f09b912">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lxeo:SteliosTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:ThirdUcsdLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-04</instant>
        </period>
    </context>
    <context id="C_55e7577e-8daf-46eb-b39f-2063a2405357">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:TwoThousandTwentyThreeEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_56bb5356-0f0e-409e-b6a4-c7cb72c011e1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_57207e39-81bb-4c7e-8c54-bf6e68c2462d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_57731d15-0745-4645-b184-c42a52a8959a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lxeo:SimpleAgreementForFutureEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-02</instant>
        </period>
    </context>
    <context id="C_5af5a379-1acd-457b-ba86-c64e18c5164a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lxeo:SteliosTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_5b2a51f7-c997-4cda-9d61-3d1f32f1e815">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_5b737ad7-5e23-417d-9cd9-c6d69e60d8a1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">lxeo:OfficeFacilityAndLaboratorySpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2029-07-01</startDate>
            <endDate>2029-07-31</endDate>
        </period>
    </context>
    <context id="C_5bca7169-3f0e-45f0-a257-63b105b31fcd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lxeo:SteliosTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:ThirdUcsdLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="C_5d7d637d-2f7f-4be3-acba-58d6df49a889">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">lxeo:ConvertibleSimpleAgreementForFutureEquityNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_5e1419ce-c719-45db-9032-ac6f99fec990">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-07</instant>
        </period>
    </context>
    <context id="C_5e727241-61dd-4591-9807-d7d2fe303dba">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lxeo:CornellUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:CornellLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="C_5efa4994-b1a0-45ae-b914-b6133056586b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_5efc3a16-a0b9-4c5b-b4a7-4e7f9939e813">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lxeo:SeriesBLiquidationPreferenceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-07</instant>
        </period>
    </context>
    <context id="C_61a2446f-5269-4a91-8e68-185d4038b801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_63208a9b-1a99-4da2-85ef-0801d8013b63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandTwentyThreeEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_637f42f6-8969-4386-b873-8c291d47795a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_63e8ef1c-8500-4aca-9829-40a638535f8d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandAndTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_642842bb-c457-4819-9738-9093909922ea">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_66ade898-e08e-4277-96a4-d86c2aa63e09">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_698516d7-c81c-4f0a-9a78-6d719461191d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_6a7a8e57-c021-4d66-95a4-3d7c93e89b8b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_6c352529-96a0-4c56-b6f7-beafae1427a8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-16</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_6d391be5-485e-4203-9a45-2881c2767c0e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lxeo:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-10</startDate>
            <endDate>2023-11-07</endDate>
        </period>
    </context>
    <context id="C_6dc19a43-c74a-4bb9-a484-18d905a695b2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lxeo:SeriesAAndSeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_6e00ad79-bc53-4f37-aa8a-ea9cb4e9ab24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_6e382123-eceb-4534-ab45-5c3a9359605b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lxeo:AdverumBiotechnologiesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:AdverumLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_6ef7a0b8-9327-4be8-b39d-869ac79fb879">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_7042155d-e81e-427a-88f0-e247950d7a4c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandTwentyOneAndTwoThousandTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_728011d4-41ee-44fe-984c-9acd7fa9e5e1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_72ef9daf-8437-4cbb-9e5d-f507601fa64a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_7381b4b3-de2c-4fd9-b6c4-d8e5a85475c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lxeo:TwoThousandTwentyOneAndTwoThousandTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_73f22931-4674-407c-ac09-c2a140ebf868">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:AmendedFirstUcsdAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-19</startDate>
            <endDate>2024-04-19</endDate>
        </period>
    </context>
    <context id="C_741d702e-ac99-41f0-a816-77782c40ec42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
        </entity>
        <period>
            <instant>2025-03-21</instant>
        </period>
    </context>
    <context id="C_74419331-e290-447a-86d3-c0fb520fc7bc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-07</instant>
        </period>
    </context>
    <context id="C_749a5dff-19cd-41f6-b877-35e4f821f1fe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lxeo:SteliosTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:FirstUcsdLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-06</startDate>
            <endDate>2020-08-06</endDate>
        </period>
    </context>
    <context id="C_754c742e-ae45-493f-9e9c-c876f6b36a1b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">lxeo:OfficeFacilityAndLaboratorySpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="C_75c654f9-7566-4300-8e93-f4d56b98a5b5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-01</instant>
        </period>
    </context>
    <context id="C_78220819-138e-4d2f-ae70-819bfa7f0e94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-11</instant>
        </period>
    </context>
    <context id="C_794eac83-f22b-40f0-ab3d-8bc9174bde90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lxeo:TwoThousandTwentyThreeEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_7be3bda2-4be1-4d70-adee-fffeb575b241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_7c1f486a-7a1e-460e-b332-6ac6ec1ac145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lxeo:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-10</startDate>
            <endDate>2023-11-07</endDate>
        </period>
    </context>
    <context id="C_7c51062b-38dd-4251-995b-95b9d29f554e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lxeo:CornellUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:ThirdCornellLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-21</startDate>
            <endDate>2024-04-21</endDate>
        </period>
    </context>
    <context id="C_7c6c7513-7f64-4c68-bcf5-17a805d1e6fe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lxeo:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-07</startDate>
            <endDate>2023-11-07</endDate>
        </period>
    </context>
    <context id="C_7d2537f3-c638-4060-a3bc-90ab8b609181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_7d455504-a441-4ca1-b057-e166af9463cf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lxeo:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-07</instant>
        </period>
    </context>
    <context id="C_7e7948fb-137c-405e-8479-be843ae42290">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001907108</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lxeo:SteliosTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lxeo:UcsdSponsoredResearchAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-03</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <unit id="U_Segment">
        <measure>lxeo:Segment</measure>
    </unit>
    <unit id="U_Installment">
        <measure>lxeo:Installment</measure>
    </unit>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_Director">
        <measure>lxeo:Director</measure>
    </unit>
    <unit id="U_IntegerItem">
        <measure>lxeo:IntegerItem</measure>
    </unit>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="U_Employees">
        <measure>lxeo:Employees</measure>
    </unit>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_8681bb52-9d5a-4513-8709-0ab847ac8ff1">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_66538079-9108-4dff-a6db-e27e0ebc3aa7">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_97033277-f81a-4c26-b472-4238834ddd37">0001907108</dei:EntityCentralIndexKey>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      id="F_95c520d2-e3a3-4e2b-91f0-f9045a6f3c7f"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_28144b67-7dfd-494d-8133-75abcc735058"
      id="F_9891b892-ff8e-44a6-bc0c-e6f1514a27a8"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      decimals="INF"
      id="F_3797e8b8-b7a6-4ad2-8b98-c0c8d90f246c"
      unitRef="U_Segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:AccountingStandardsUpdateExtensibleList
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_73289f60-fe2f-4884-94cc-6b3d31ad5380">http://fasb.org/us-gaap/2024#AccountingStandardsUpdate202307Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList
      contextRef="C_ff8a14ec-2414-4dce-963c-ac378e45b5e3"
      id="F_995b2506-e09a-426b-8450-5340620be7de">http://fasb.org/us-gaap/2024#GainLossOnFairValueHedgesRecognizedInEarnings</us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList>
    <us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_bb5c5ee6-6dc1-4359-ae05-87adfaa76496">http://fasb.org/srt/2024#ChiefExecutiveOfficerMember</us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration>
    <us-gaap:NumberOfReportableSegments
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      decimals="0"
      id="F_e4a8210a-7701-4cf1-bb55-d8e020f66db8"
      unitRef="U_Segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      decimals="0"
      id="F_b4f1e989-f912-4b9a-9a96-f56301d549bc"
      unitRef="U_Segment">1</us-gaap:NumberOfOperatingSegments>
    <dei:DocumentType
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_b35bdbbd-890f-4c62-ad23-fc07c9751dbb">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_574756b6-363d-418f-ba64-af4f8ada790b">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_b39b7c2f-8bce-42ce-88a6-e197b7115892">2024-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_d9eb8737-354b-46f6-8a9c-6d8497f00b3c">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_ad549a93-a75b-493f-972e-28fa9dfdb3e0">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_e36f4895-364e-4703-b764-ea7bbc6b7842">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_d79642da-96d8-4650-a83d-0148cebb2ffc">001-41855</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_2a146f68-0ac8-4dab-8d8e-107324c8acf3">LEXEO THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_b906f70d-90d8-4775-b5e7-e36f64159ead">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_45fdeeeb-773e-4676-aae2-198c1ae3a2b6">85-4012572</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_8f4a3bfe-7e6b-4212-bee8-735915b6c0fe">345 Park Avenue South</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_ea651cdb-0b11-48f6-9c32-6f66d3e87e63">Floor 6</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_91f05269-01d2-4219-abe6-98c1f2580e3b">New York</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_1e0eafd2-0cec-47b6-ab3a-88ac41d255c8">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_472882ce-0a9c-411d-a5f9-db6d438029f9">10010</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_3961df50-ce7d-4e05-ae66-48b14b7e7f3c">212</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_1f0c2a92-1858-4cc4-85ab-c5e03e73128a">547-9879</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_f57eb837-d73e-4340-8454-c178eeb91403">Common stock, par value $0.0001</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_ec7e391c-73d3-4377-a69b-5375a2fc31e5">LXEO</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_4a1b2303-8431-471b-87e7-6181e110e502">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_57f1d6b0-743d-4268-bf22-afe4100dc782">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_427aa037-5bb8-451c-8339-790e3fe3cde1">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_64f0acc1-7850-4c30-a619-1f962061b760">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_921ba213-762e-498f-a090-6dffc107be87">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_c3d03229-7cba-4676-b4d6-c67984f07555">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_bf44f215-528f-4eab-9d3d-3b68b36367f3">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_f4536b9a-b286-4974-92e5-fd308aa6638e">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_2c2e3877-4966-47a2-a2f9-2a6379772777">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_6bda6fcd-10a0-47be-a2af-92339be66328">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_f40f38a5-4f53-467d-a163-37f0c14dfd46">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_6d2739a7-b36b-4f1b-8e46-53d51dba6ad7">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_d00c7be3-f867-4469-ac2a-406521627abf"
      decimals="-5"
      id="F_ee91ee46-bc52-47f6-9c3d-5e32589ccc43"
      unitRef="U_USD">527900000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_741d702e-ac99-41f0-a816-77782c40ec42"
      decimals="INF"
      id="F_0305e06b-8476-4f4c-b9c5-14649b69b298"
      unitRef="U_shares">33196997</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_991825b9-c949-43f7-8558-d5ac899398b9">&lt;p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Portions of the Registrant&#x2019;s definitive Proxy Statement relating to the 2025 Annual Meeting of Stockholders are incorporated herein by reference in Part III of this Annual Report on Form 10-K to the extent stated herein. Such proxy statement will be filed with the Securities and Exchange Commission within 120 days of the registrant&#x2019;s fiscal year ended December 31, 2024.&lt;/span&gt;&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_22002f0b-3642-4aa8-a282-356a27febc28">&lt;p id="item_1c_cybersecurity" style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;It&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;em 1C.    Cybersecurity&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Risk Management and Strategy&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We have established policies and processes for assessing, identifying, and managing risk from cybersecurity threats. We periodically assess risks from cybersecurity threats, including any potential unauthorized occurrence on or conducted through our information systems that may result in adverse effects on the confidentiality, integrity, or availability of our information systems or any information residing therein. Following these risk assessments, we evaluate how to reasonably address any identified gaps in existing safeguards and monitor the effectiveness of our safeguards. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We devote resources and designate high-level personnel, including our Chief Legal Officer, who reports to our Chief Executive Officer, to manage the risk assessment and mitigation process in a manner that is consistent and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;integrated&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; with our overall risk management processes. &lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As part of our overall risk management system, we monitor and test our safeguards and train our employees on these safeguards, including our cybersecurity safeguards, in collaboration with human resources, IT, and management. Personnel at all levels and departments receive periodic trainings on cybersecurity best practices and threats. For example, we conduct e-mail phishing campaigns with our employees and contractors which send phishing-style e-mails, monitor user responses, and automatically assign further training, as needed, and also provide convenient solutions for our employees to report suspicious messages.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;engage&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; specialized third parties in connection with our risk assessment processes. These &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;third parties assist &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;us in designing and implementing our cybersecurity policies and procedures, as well as in monitoring and testing our safeguards.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We also conduct IT security assessments on our key third-party service providers and require them to implement and maintain reasonable security measures in connection with their work with us, and to promptly report any suspected breach of their security measures that may affect our company.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We have not previously experienced any cybersecurity risk or cybersecurity incident which has been determined to be &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;material&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. For additional information regarding whether any risks from cybersecurity threats are reasonably likely to materially affect our company, including our business strategy, results of operations, or financial condition, please refer to Item 1A, &#x201c;Risk Factors&#x201d; in this Annual Report on Form 10-K, including the risk factor entitled &#x201c;Our business and operations would suffer in the event of system failures, cyberattacks or a deficiency in our or our CMOs&#x2019;, CROs&#x2019;, manufacturers&#x2019;, contractors&#x2019;, consultants&#x2019; or collaborators&#x2019; cybersecurity&#x201d;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Governance&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;One of the key functions of our board of directors is informed oversight of our risk management process, including risks from cybersecurity threats. Our board of directors is responsible for monitoring and assessing strategic risk exposure, and our executive officers are responsible for the day-to-day management of the material risks we face. Our board of directors administers its cybersecurity risk oversight function directly as a whole, as well as through our audit committee.&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our Chief Legal Officer and our security governance steering committee, which includes our Vice President and Corporate Controller, Vice President of Human Resources, Senior Vice President of Development Operations, and Director of Information Technology and Cybersecurity, are primarily responsible for assessing and managing our risks from cybersecurity threats. Our Chief Legal Officer has more than a decade of operational experience overseeing and advising on risk management in the highly regulated biopharmaceutical industry, and leads a wide range of business functions, including IT/IS. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our Director of Information Technology and Cybersecurity has nearly 20 years of experience with IT, having had leadership roles in strategic technology development and information security, and holds several industry-recognized certifications such as the Certified Information Security Manager (CISM) and CompTIA Network+. They and other members of our security governance steering committee engage in training and education relating to cybersecurity risk.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our Chief Legal Officer and our security governance steering committee oversee our cybersecurity policies and processes, including those described in &#x201c;Risk Management and Strategy&#x201d; above.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our Chief Legal Officer and our management committee&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; on cybersecurity are informed about and monitor the prevention, detection, mitigation, and remediation of cybersecurity incidents through their work overseeing, working with, and delegating daily operations to the IT/IS team, as well as their work developing and implementing information security policies, consistent with the IT/IS processes.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; These policies are reviewed at least annually with updates authorized and approved by the security governance steering committee.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our Chief Legal Officer and representatives from our security governance steering committee provide quarterly briefings to the audit committee regarding our company&#x2019;s cybersecurity risks and activities, including any recent cybersecurity incidents and related responses, cybersecurity systems testing, activities of third parties&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, and the like. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our audit committee provides regular updates to the board of directors on such reports&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. In addition, our Chief Legal Officer and representatives from our security governance steering committee provide annual briefings to the board of directors on cybersecurity risks and activities.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskRoleOfManagementTextBlock
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_7bd46ff9-4352-4c7e-99e1-5da34fce3666">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We have established policies and processes for assessing, identifying, and managing risk from cybersecurity threats. We periodically assess risks from cybersecurity threats, including any potential unauthorized occurrence on or conducted through our information systems that may result in adverse effects on the confidentiality, integrity, or availability of our information systems or any information residing therein. Following these risk assessments, we evaluate how to reasonably address any identified gaps in existing safeguards and monitor the effectiveness of our safeguards. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We devote resources and designate high-level personnel, including our Chief Legal Officer, who reports to our Chief Executive Officer, to manage the risk assessment and mitigation process in a manner that is consistent and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;integrated&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; with our overall risk management processes. &lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As part of our overall risk management system, we monitor and test our safeguards and train our employees on these safeguards, including our cybersecurity safeguards, in collaboration with human resources, IT, and management. Personnel at all levels and departments receive periodic trainings on cybersecurity best practices and threats. For example, we conduct e-mail phishing campaigns with our employees and contractors which send phishing-style e-mails, monitor user responses, and automatically assign further training, as needed, and also provide convenient solutions for our employees to report suspicious messages.&lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskRoleOfManagementTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_d523653a-7813-4dae-9be4-3c52144b127e">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We devote resources and designate high-level personnel, including our Chief Legal Officer, who reports to our Chief Executive Officer, to manage the risk assessment and mitigation process in a manner that is consistent and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;integrated&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; with our overall risk management processes. &lt;/span&gt;</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_0e27eed5-5cd6-44e9-8380-2d3a6a848c87">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_4b9391e1-0f5c-485f-90d4-08a3b1a7078c">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_e603fbe3-db09-475d-97cf-1fcd84a100bf">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_f4124969-6bbb-4f48-844a-0b7d2da46760">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_11338233-5dc5-4c6b-84e0-f48f40f846c0">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;One of the key functions of our board of directors is informed oversight of our risk management process, including risks from cybersecurity threats. Our board of directors is responsible for monitoring and assessing strategic risk exposure, and our executive officers are responsible for the day-to-day management of the material risks we face. Our board of directors administers its cybersecurity risk oversight function directly as a whole, as well as through our audit committee.&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our Chief Legal Officer and our security governance steering committee, which includes our Vice President and Corporate Controller, Vice President of Human Resources, Senior Vice President of Development Operations, and Director of Information Technology and Cybersecurity, are primarily responsible for assessing and managing our risks from cybersecurity threats. Our Chief Legal Officer has more than a decade of operational experience overseeing and advising on risk management in the highly regulated biopharmaceutical industry, and leads a wide range of business functions, including IT/IS. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our Director of Information Technology and Cybersecurity has nearly 20 years of experience with IT, having had leadership roles in strategic technology development and information security, and holds several industry-recognized certifications such as the Certified Information Security Manager (CISM) and CompTIA Network+. They and other members of our security governance steering committee engage in training and education relating to cybersecurity risk.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our Chief Legal Officer and our security governance steering committee oversee our cybersecurity policies and processes, including those described in &#x201c;Risk Management and Strategy&#x201d; above.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our Chief Legal Officer and our management committee&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; on cybersecurity are informed about and monitor the prevention, detection, mitigation, and remediation of cybersecurity incidents through their work overseeing, working with, and delegating daily operations to the IT/IS team, as well as their work developing and implementing information security policies, consistent with the IT/IS processes.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; These policies are reviewed at least annually with updates authorized and approved by the security governance steering committee.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our Chief Legal Officer and representatives from our security governance steering committee provide quarterly briefings to the audit committee regarding our company&#x2019;s cybersecurity risks and activities, including any recent cybersecurity incidents and related responses, cybersecurity systems testing, activities of third parties&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, and the like. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our audit committee provides regular updates to the board of directors on such reports&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. In addition, our Chief Legal Officer and representatives from our security governance steering committee provide annual briefings to the board of directors on cybersecurity risks and activities.&lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_db5866f1-9d9e-4bdb-916b-99d74bbcb049">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our Chief Legal Officer and our security governance steering committee, which includes our Vice President and Corporate Controller, Vice President of Human Resources, Senior Vice President of Development Operations, and Director of Information Technology and Cybersecurity, are primarily responsible for assessing and managing our risks from cybersecurity threats. Our Chief Legal Officer has more than a decade of operational experience overseeing and advising on risk management in the highly regulated biopharmaceutical industry, and leads a wide range of business functions, including IT/IS. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our Director of Information Technology and Cybersecurity has nearly 20 years of experience with IT, having had leadership roles in strategic technology development and information security, and holds several industry-recognized certifications such as the Certified Information Security Manager (CISM) and CompTIA Network+. They and other members of our security governance steering committee engage in training and education relating to cybersecurity risk.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_7655f1e6-f7f3-461c-9755-cfed650d67d3">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our Director of Information Technology and Cybersecurity has nearly 20 years of experience with IT, having had leadership roles in strategic technology development and information security, and holds several industry-recognized certifications such as the Certified Information Security Manager (CISM) and CompTIA Network+. They and other members of our security governance steering committee engage in training and education relating to cybersecurity risk.&lt;/span&gt;</cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock>
    <cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_dffd865c-bbff-4607-8887-e43160f40b34">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our Chief Legal Officer and our security governance steering committee oversee our cybersecurity policies and processes, including those described in &#x201c;Risk Management and Strategy&#x201d; above.&lt;/span&gt;</cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_de753e8d-20e9-4b2e-8a7f-5e2caaa68361">&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our Chief Legal Officer and our management committee&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; on cybersecurity are informed about and monitor the prevention, detection, mitigation, and remediation of cybersecurity incidents through their work overseeing, working with, and delegating daily operations to the IT/IS team, as well as their work developing and implementing information security policies, consistent with the IT/IS processes.&lt;/span&gt;</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_41cd2f14-97d4-436c-ac94-a67d34964807">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_b91906aa-5d48-41a7-9cb0-19ca64a6027c">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our Chief Legal Officer and representatives from our security governance steering committee provide quarterly briefings to the audit committee regarding our company&#x2019;s cybersecurity risks and activities, including any recent cybersecurity incidents and related responses, cybersecurity systems testing, activities of third parties&lt;/span&gt;</cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_d3b75bda-5e83-422f-9490-93326f79207e">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag>
    <dei:AuditorName
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_465d32ab-ac34-4768-a849-de577eb44e5e">KPMG LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_c3f1162f-306f-415e-84f1-65edc3f1794f">New York, NY</dei:AuditorLocation>
    <dei:AuditorFirmId
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_83d2b853-29ee-4d78-9d2b-e7273551c317">185</dei:AuditorFirmId>
    <dei:AuditorOpinionTextBlock
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_09d10cbc-df2b-4f9a-8f0a-eefc90cdbf38">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Opinion on the Financial Statements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We have audited the accompanying balance sheets of Lexeo Therapeutics, Inc. (the Company) as of December 31, 2024 and 2023, the related statements of operations and comprehensive loss, convertible preferred stock and stockholders&#x2019; equity (deficit), and cash flows for the years then ended, and the related notes (collectively, the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for the years then ended, in conformity with U.S. generally accepted accounting principles.&lt;/span&gt;&lt;/p&gt;</dei:AuditorOpinionTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="-3"
      id="F_0b4fd9b1-9cac-48b5-b9dc-02e3707053ab"
      unitRef="U_USD">35014000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_28144b67-7dfd-494d-8133-75abcc735058"
      decimals="-3"
      id="F_0d271bfa-3663-4cfc-81dd-7749fb0ff5b9"
      unitRef="U_USD">121466000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="-3"
      id="F_60e85897-3047-4edd-b5a2-41edbe7ba6a0"
      unitRef="U_USD">86504000</us-gaap:ShortTermInvestments>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="-3"
      id="F_328d931b-434c-420c-aa4f-6dd64a9ed771"
      unitRef="U_USD">4603000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_28144b67-7dfd-494d-8133-75abcc735058"
      decimals="-3"
      id="F_8dd292fc-a122-48f4-88ea-61f6ba69bd10"
      unitRef="U_USD">2828000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="-3"
      id="F_7d612836-1b77-444b-b947-a11e2c5234e9"
      unitRef="U_USD">126121000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_28144b67-7dfd-494d-8133-75abcc735058"
      decimals="-3"
      id="F_b9ce66f1-f6c7-43e0-a264-186862eeee67"
      unitRef="U_USD">124294000</us-gaap:AssetsCurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="-3"
      id="F_c1eb0996-db8a-47d8-a7d2-2283579976b7"
      unitRef="U_USD">3252000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_28144b67-7dfd-494d-8133-75abcc735058"
      decimals="-3"
      id="F_e419bfa2-d2d0-48f4-ad7e-e97de2dae10c"
      unitRef="U_USD">3252000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:LongTermInvestments
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="-3"
      id="F_bc1bab9e-14d5-41b4-be80-f3eb49b02cc6"
      unitRef="U_USD">7012000</us-gaap:LongTermInvestments>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="-3"
      id="F_9061a874-1f1e-4ee2-b9fa-b25f3dde1d89"
      unitRef="U_USD">1028000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_28144b67-7dfd-494d-8133-75abcc735058"
      decimals="-3"
      id="F_07f903ea-8a8c-4e47-8fbd-9f91e6354c02"
      unitRef="U_USD">1056000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="-3"
      id="F_4188bab5-5b86-46d2-827f-13bf953cfeeb"
      unitRef="U_USD">1460000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="C_28144b67-7dfd-494d-8133-75abcc735058"
      decimals="-3"
      id="F_d007e499-1c98-4112-9b28-6e24faab6219"
      unitRef="U_USD">1763000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="-3"
      id="F_34bd0bbb-2f69-4253-b79a-93c9c9b29224"
      unitRef="U_USD">8069000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_28144b67-7dfd-494d-8133-75abcc735058"
      decimals="-3"
      id="F_47b3dbac-da52-4cbb-ae52-a4d8045525dd"
      unitRef="U_USD">9442000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Assets
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="-3"
      id="F_821167c4-2e75-4f2f-b60a-b92dd72085f7"
      unitRef="U_USD">146942000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_28144b67-7dfd-494d-8133-75abcc735058"
      decimals="-3"
      id="F_606e7a15-5c9e-4884-9b41-7ba2911c146b"
      unitRef="U_USD">139807000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="-3"
      id="F_0daa4963-8d8c-4c7b-a9ba-98ea3a611982"
      unitRef="U_USD">6417000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_28144b67-7dfd-494d-8133-75abcc735058"
      decimals="-3"
      id="F_43a2966d-d5a2-4b7d-994a-698668d20232"
      unitRef="U_USD">3794000</us-gaap:AccountsPayableCurrent>
    <lxeo:AccruedLiabilitiesAndOtherLiabilitiesCurrent
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="-3"
      id="F_fc6db418-111d-4630-8108-cc524560f54c"
      unitRef="U_USD">13759000</lxeo:AccruedLiabilitiesAndOtherLiabilitiesCurrent>
    <lxeo:AccruedLiabilitiesAndOtherLiabilitiesCurrent
      contextRef="C_28144b67-7dfd-494d-8133-75abcc735058"
      decimals="-3"
      id="F_17963d74-f81f-4663-98cb-1d68364b8042"
      unitRef="U_USD">10840000</lxeo:AccruedLiabilitiesAndOtherLiabilitiesCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="-3"
      id="F_f22f0731-a6ac-4e31-a4c3-85c0c4c28e45"
      unitRef="U_USD">570000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="C_28144b67-7dfd-494d-8133-75abcc735058"
      decimals="-3"
      id="F_b0551b63-6c35-4c8a-af94-b6e51f1e8313"
      unitRef="U_USD">518000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="-3"
      id="F_7fbd935c-acb3-4f99-bcfc-a0f5f09c57f8"
      unitRef="U_USD">2100000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_28144b67-7dfd-494d-8133-75abcc735058"
      decimals="-3"
      id="F_0f879c49-e864-4af5-99a7-3b2af1471f37"
      unitRef="U_USD">2087000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="-3"
      id="F_a9840f44-2f3c-45b0-bfaa-11d5ff37c1df"
      unitRef="U_USD">22846000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_28144b67-7dfd-494d-8133-75abcc735058"
      decimals="-3"
      id="F_c9abf934-dd77-42f9-a5f3-2f6cc2217049"
      unitRef="U_USD">17239000</us-gaap:LiabilitiesCurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="-3"
      id="F_46eb5e8f-9ed0-41ee-90e7-30129acfb39f"
      unitRef="U_USD">817000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="C_28144b67-7dfd-494d-8133-75abcc735058"
      decimals="-3"
      id="F_0363413f-19c0-4e1d-be6a-38a4d645dcda"
      unitRef="U_USD">1247000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="-3"
      id="F_9bec8af9-f732-4d1b-a778-dfa06aefcafe"
      unitRef="U_USD">6437000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_28144b67-7dfd-494d-8133-75abcc735058"
      decimals="-3"
      id="F_ff1a54d2-f560-4735-9799-84a054712629"
      unitRef="U_USD">7786000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="-3"
      id="F_432530a9-d511-425f-b74b-0970c1e8efad"
      unitRef="U_USD">30100000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_28144b67-7dfd-494d-8133-75abcc735058"
      decimals="-3"
      id="F_3010171e-04ca-480e-aac1-5a0e2fa3f43d"
      unitRef="U_USD">26272000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="INF"
      id="F_51d4bbd9-ff2a-417d-ab77-7258c12f4498"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_28144b67-7dfd-494d-8133-75abcc735058"
      decimals="INF"
      id="F_390b56ff-1225-409c-a92d-2d234c739516"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="INF"
      id="F_3428772a-c35b-45b3-890a-18a9475d61ce"
      unitRef="U_shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="INF"
      id="F_0199ce48-7229-4f7b-8474-bb048ebbeda1"
      unitRef="U_shares">33079209</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="INF"
      id="F_65cc649e-1c1b-4391-a0be-57fa430a5d1c"
      unitRef="U_shares">33071261</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_28144b67-7dfd-494d-8133-75abcc735058"
      decimals="INF"
      id="F_7b908d1c-5aef-4ddb-a06a-eb6129cd9225"
      unitRef="U_shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_28144b67-7dfd-494d-8133-75abcc735058"
      decimals="INF"
      id="F_ff8eda1e-58e5-4d2e-b73f-6f330f90fe07"
      unitRef="U_shares">26668485</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_28144b67-7dfd-494d-8133-75abcc735058"
      decimals="INF"
      id="F_36490d19-e9ae-43c0-b9ca-76b6714a2e9b"
      unitRef="U_shares">26646378</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="-3"
      id="F_c61fd279-f2f4-4a97-8f67-97a8802d3e37"
      unitRef="U_USD">3000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_28144b67-7dfd-494d-8133-75abcc735058"
      decimals="-3"
      id="F_5e4a5a03-396e-480e-8e0c-e3c519fa063c"
      unitRef="U_USD">3000</us-gaap:CommonStockValue>
    <us-gaap:TreasuryStockCommonShares
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="INF"
      id="F_37c10cd3-77ba-47ce-9ada-d8f7b90a671f"
      unitRef="U_shares">3827</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares
      contextRef="C_28144b67-7dfd-494d-8133-75abcc735058"
      decimals="INF"
      id="F_4bd0b785-174e-4a16-b048-b3cea1017980"
      unitRef="U_shares">0</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonValue
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="-3"
      id="F_3ad95da6-d400-477a-bed1-68fb666f9557"
      unitRef="U_USD">17000</us-gaap:TreasuryStockCommonValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="-3"
      id="F_98db8bfb-8c7d-41a6-b64a-1b24b0fa7dfe"
      unitRef="U_USD">397132000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_28144b67-7dfd-494d-8133-75abcc735058"
      decimals="-3"
      id="F_317d3fce-63ff-4634-9687-99a1767c102e"
      unitRef="U_USD">295372000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="-3"
      id="F_12a8e2be-e51e-4d0b-aab4-fa5d2bc9e947"
      unitRef="U_USD">-103000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="-3"
      id="F_477b4bff-13a6-4f7c-9914-cd9fdd3ba01c"
      unitRef="U_USD">-280173000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_28144b67-7dfd-494d-8133-75abcc735058"
      decimals="-3"
      id="F_bc488715-a893-4360-a796-6516883a96fd"
      unitRef="U_USD">-181840000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="-3"
      id="F_d3edce55-3c97-4dbb-9894-594854ea163c"
      unitRef="U_USD">116842000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_28144b67-7dfd-494d-8133-75abcc735058"
      decimals="-3"
      id="F_9aef0872-c827-440f-b242-fc7bfa8dccf6"
      unitRef="U_USD">113535000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="-3"
      id="F_5aa44c6d-85d7-4211-af16-a949bdc3eea3"
      unitRef="U_USD">146942000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_28144b67-7dfd-494d-8133-75abcc735058"
      decimals="-3"
      id="F_7c2b41b0-9773-4ce6-86ba-013ee9e2d6d0"
      unitRef="U_USD">139807000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      decimals="-3"
      id="F_73fdcc1f-0f65-48a4-911d-d3c6a6a73021"
      unitRef="U_USD">74091000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca"
      decimals="-3"
      id="F_edd40730-64db-47ea-b463-78df4289093f"
      unitRef="U_USD">53130000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      decimals="-3"
      id="F_428653c4-6d75-4ab0-8db4-bd4361c5c25b"
      unitRef="U_USD">31675000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca"
      decimals="-3"
      id="F_ce40f303-82a4-45a8-b74a-3333748d9749"
      unitRef="U_USD">15383000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      decimals="-3"
      id="F_833fe65b-6e61-4e63-bc41-8776d50acd67"
      unitRef="U_USD">105766000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca"
      decimals="-3"
      id="F_c944e571-be9f-46be-8216-48a8bde71e8f"
      unitRef="U_USD">68513000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      decimals="-3"
      id="F_65df310b-6bdb-4cff-a840-883aa58d0574"
      unitRef="U_USD">-105766000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca"
      decimals="-3"
      id="F_b6fd411a-2aea-4a3d-a390-a73e8876ca2f"
      unitRef="U_USD">-68513000</us-gaap:OperatingIncomeLoss>
    <us-gaap:GainLossOnFairValueHedgesRecognizedInEarnings
      contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca"
      decimals="-3"
      id="F_b203c694-ecc4-4742-a8bf-1c944cd52b46"
      unitRef="U_USD">-530000</us-gaap:GainLossOnFairValueHedgesRecognizedInEarnings>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      decimals="-3"
      id="F_81ccf843-8e1f-425e-ab18-3be920312a3d"
      unitRef="U_USD">-9000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca"
      decimals="-3"
      id="F_8ef508b1-b68b-4127-95eb-12bde16e1064"
      unitRef="U_USD">-13000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:InterestExpenseNonoperating
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      decimals="-3"
      id="F_502ace51-eab6-4984-8c29-09ecdc645c2e"
      unitRef="U_USD">137000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca"
      decimals="-3"
      id="F_e6d9fe84-a948-43d4-b23d-9f99f865304b"
      unitRef="U_USD">205000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      decimals="-3"
      id="F_a6642ae1-909c-41bf-9e26-7e666558c869"
      unitRef="U_USD">7556000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca"
      decimals="-3"
      id="F_f6ea862c-9d63-4cbf-8f83-6cdf202d6fe3"
      unitRef="U_USD">2867000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeAmortizationOfDiscount
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      decimals="-3"
      id="F_9e068a54-af3e-4141-929f-10af7c1ec324"
      unitRef="U_USD">23000</us-gaap:InvestmentIncomeAmortizationOfDiscount>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      decimals="-3"
      id="F_b241ecf7-093d-49dc-8d22-b78b0b271d44"
      unitRef="U_USD">7433000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca"
      decimals="-3"
      id="F_ab97ae53-c7d8-425e-be54-ef92c60473e7"
      unitRef="U_USD">2119000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      decimals="-3"
      id="F_1aaaff0a-d14c-4006-b313-6ea0ca9857bc"
      unitRef="U_USD">-98333000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca"
      decimals="-3"
      id="F_c713e5a8-5515-4aec-bcf5-983e781b948c"
      unitRef="U_USD">-66394000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      decimals="-3"
      id="F_c3229343-28e0-4bfb-86fe-720e1a921905"
      unitRef="U_USD">-98333000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca"
      decimals="-3"
      id="F_113f576b-d848-4485-bb92-1c332306ec7e"
      unitRef="U_USD">-66394000</us-gaap:NetIncomeLoss>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      decimals="-3"
      id="F_42737d83-89e2-4418-81be-bad3d7dbf837"
      unitRef="U_USD">-103000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      decimals="-3"
      id="F_a17953d8-e455-4cad-a2da-e5b0e08d1947"
      unitRef="U_USD">-103000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      decimals="-3"
      id="F_7079d20e-accd-4a19-aa2d-b604f1198c98"
      unitRef="U_USD">-98436000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca"
      decimals="-3"
      id="F_5e3fdc5b-e23b-44ef-ac2e-c96a7e9e01c7"
      unitRef="U_USD">-66394000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      decimals="2"
      id="F_42af735b-0873-4591-8538-5a27299d0eff"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-3.09</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      decimals="2"
      id="F_1eb85904-a51c-4ac0-b5c2-db4e7d9de094"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-3.09</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca"
      decimals="2"
      id="F_6b464957-2b1c-4a23-b8eb-46765dc0933b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-12.4</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca"
      decimals="2"
      id="F_087b04dd-88df-47af-94cb-0508e79609b1"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-12.4</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      decimals="0"
      id="F_988bb475-15a4-45c5-80d7-906c15c21565"
      unitRef="U_shares">31787491</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      decimals="0"
      id="F_50b5c16e-001e-4ded-8a71-c57247f10c43"
      unitRef="U_shares">31787491</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca"
      decimals="0"
      id="F_0090fa9e-fb1a-4c30-9736-a526bcb79679"
      unitRef="U_shares">5354368</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca"
      decimals="0"
      id="F_16ca339d-b270-4fad-bc98-ed61012d7be7"
      unitRef="U_shares">5354368</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_b8ce5a83-8a3f-4019-b952-412e72e2157f"
      decimals="INF"
      id="F_fd401cc6-f10a-4226-b7ea-42ffa8758072"
      unitRef="U_shares">143653545</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_b8ce5a83-8a3f-4019-b952-412e72e2157f"
      decimals="-3"
      id="F_471669fd-d099-4f91-bdeb-4b8b67cd75db"
      unitRef="U_USD">185033000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="C_d58c59cb-9db1-486e-a4ba-83018b4264e1"
      decimals="INF"
      id="F_887f21a4-892b-4670-a426-0639a517d6fe"
      unitRef="U_shares">1607185</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_5efa4994-b1a0-45ae-b914-b6133056586b"
      decimals="-3"
      id="F_9f9a314a-0d43-42f7-b1ed-92608980beaa"
      unitRef="U_USD">2492000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_4d1f9c2e-11bc-48e8-b628-60da7528906f"
      decimals="-3"
      id="F_26c2ea6c-8ce8-47fd-864e-6a0814e1c65c"
      unitRef="U_USD">-115446000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_e83f79f6-f924-4728-9c7c-5f1eb49397fe"
      decimals="-3"
      id="F_ff645ec8-1152-4014-bdf9-7cbde4476bef"
      unitRef="U_USD">-112954000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_728011d4-41ee-44fe-984c-9acd7fa9e5e1"
      decimals="INF"
      id="F_aad99da5-97a2-4050-a394-3ad6b7724d52"
      unitRef="U_shares">11916</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_c5950291-be83-459b-b80e-1f0bffbf88e7"
      decimals="-3"
      id="F_a646cae6-a3e4-4b24-9ccb-34db2398d9c7"
      unitRef="U_USD">51000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca"
      decimals="-3"
      id="F_7e670300-c297-461d-9588-6b8775e19898"
      unitRef="U_USD">51000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <lxeo:AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsShare
      contextRef="C_728011d4-41ee-44fe-984c-9acd7fa9e5e1"
      decimals="INF"
      id="F_39dbc0a4-655e-4f70-a8bc-d293e08ec299"
      unitRef="U_shares">19442</lxeo:AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsShare>
    <lxeo:AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptions
      contextRef="C_c5950291-be83-459b-b80e-1f0bffbf88e7"
      decimals="-3"
      id="F_b2a021fd-05b6-47d5-b115-5c90a1624ff9"
      unitRef="U_USD">87000</lxeo:AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptions>
    <lxeo:AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptions
      contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca"
      decimals="-3"
      id="F_44969d59-6d41-406d-b62b-c1d741232dd4"
      unitRef="U_USD">87000</lxeo:AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptions>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_edfd0d26-83c7-4293-8b0c-e99852a72a86"
      decimals="-3"
      id="F_b7cd95ba-7c93-4966-905a-f6be05d1d804"
      unitRef="U_USD">113000</us-gaap:PaymentsOfStockIssuanceCosts>
    <lxeo:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtShare
      contextRef="C_728011d4-41ee-44fe-984c-9acd7fa9e5e1"
      decimals="INF"
      id="F_3316a44a-f64c-476d-bd6c-e9d2438bf016"
      unitRef="U_shares">411815</lxeo:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtShare>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="C_c5950291-be83-459b-b80e-1f0bffbf88e7"
      decimals="-3"
      id="F_a4c64611-72e4-4821-bd0c-988a73417c93"
      unitRef="U_USD">4417000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca"
      decimals="-3"
      id="F_98f09e82-03fa-4339-ab98-599247dbcbc5"
      unitRef="U_USD">4417000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_aa9ff400-2f57-4dd1-8623-e1ed88b5664f"
      decimals="-3"
      id="F_a353942b-1894-47f1-b28e-7b3d1c6f98b4"
      unitRef="U_USD">11285000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_90a370bc-c9ba-46da-a45b-b1abd87d6810"
      decimals="INF"
      id="F_4781f99c-c9bb-41d2-8de6-edf6c85e0ccd"
      unitRef="U_shares">10139656</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_90a370bc-c9ba-46da-a45b-b1abd87d6810"
      decimals="-3"
      id="F_fa9f0ace-1c51-4cfa-a1d3-9a103309cace"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_f04bbf56-d3c8-4272-a5ff-e1a1e02029b4"
      decimals="-3"
      id="F_25e8db4b-c87c-4c59-928f-248c9ef1a7e7"
      unitRef="U_USD">100250000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_c6a9a2e2-eebe-4569-82e3-6437a6ce2366"
      decimals="-3"
      id="F_77a66d5b-008d-41cb-ae89-dde1c182bef2"
      unitRef="U_USD">100251000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_f579df17-1e2e-4b2c-ab33-2703e6c475a7"
      decimals="-3"
      id="F_6a893262-e988-4939-8384-8e2a53d3fe29"
      unitRef="U_USD">519000</us-gaap:PaymentsOfStockIssuanceCosts>
    <lxeo:TemporaryEquityConversionOfStockInInitialPublicOfferingShares
      contextRef="C_29a86653-566e-428b-a98b-7f3277fd7d90"
      decimals="INF"
      id="F_cda58fa9-f71a-49de-92cd-5712daa75ff8"
      unitRef="U_shares">143653545</lxeo:TemporaryEquityConversionOfStockInInitialPublicOfferingShares>
    <lxeo:TemporaryEquityConversionOfStockInInitialPublicOfferingValue
      contextRef="C_29a86653-566e-428b-a98b-7f3277fd7d90"
      decimals="-3"
      id="F_d35f59fa-e54b-4c46-8f29-9c86520a2f28"
      unitRef="U_USD">-185033000</lxeo:TemporaryEquityConversionOfStockInInitialPublicOfferingValue>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_728011d4-41ee-44fe-984c-9acd7fa9e5e1"
      decimals="INF"
      id="F_bdad7a87-0db1-4e8c-a851-47471e9a5b94"
      unitRef="U_shares">14456364</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="C_728011d4-41ee-44fe-984c-9acd7fa9e5e1"
      decimals="-3"
      id="F_a61169c8-55d6-4a8d-a436-a572e353fff7"
      unitRef="U_USD">2000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="C_c5950291-be83-459b-b80e-1f0bffbf88e7"
      decimals="-3"
      id="F_2b0935d2-9d7e-4d30-8290-59673afe8148"
      unitRef="U_USD">185032000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca"
      decimals="-3"
      id="F_340c19b2-1948-4fad-8d47-38f4512044c8"
      unitRef="U_USD">185034000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_c5950291-be83-459b-b80e-1f0bffbf88e7"
      decimals="-3"
      id="F_febd0f89-18f9-49be-a952-8f89bc2fcacb"
      unitRef="U_USD">3043000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca"
      decimals="-3"
      id="F_61871af4-53fe-4232-8fb3-abd31db1355e"
      unitRef="U_USD">3043000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="C_948b5c1c-c12b-4ae5-a807-364c74cca6f3"
      decimals="-3"
      id="F_84ecb6f3-b7c3-4bf2-8fec-1220ca118d4c"
      unitRef="U_USD">-66394000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca"
      decimals="-3"
      id="F_9b9a9b2e-a205-4f6a-86e7-dcf47816ef4d"
      unitRef="U_USD">-66394000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_933a22df-2af6-4858-8d9e-d0defe7f6576"
      decimals="INF"
      id="F_a4095834-74f9-41ec-98a7-c0b48825c143"
      unitRef="U_shares">26646378</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_933a22df-2af6-4858-8d9e-d0defe7f6576"
      decimals="-3"
      id="F_28e02e59-4bf5-4b40-8adb-ef2be2e7a200"
      unitRef="U_USD">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_e4562be4-fed1-4c76-8ee0-9ebb81409e47"
      decimals="-3"
      id="F_24aad368-7897-4f12-a3f9-86a3f9573083"
      unitRef="U_USD">295372000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_1e2a8137-62de-4a72-83f0-d154bc7a5841"
      decimals="-3"
      id="F_f725909c-c310-48b7-b65d-c63b296e8035"
      unitRef="U_USD">-181840000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_28144b67-7dfd-494d-8133-75abcc735058"
      decimals="-3"
      id="F_e2e9c909-d7c7-4211-b5bb-6bfd04910e69"
      unitRef="U_USD">113535000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_2cce3246-207a-4da6-b759-efc03a70940c"
      decimals="INF"
      id="F_62f4c58e-1e63-4ce0-9079-30febe4cb6d8"
      unitRef="U_shares">135646</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_3c3cff29-78d2-4481-b497-e743fdeb998d"
      decimals="-3"
      id="F_5e4340e1-f52a-49af-9f88-c8d300bb1392"
      unitRef="U_USD">491000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      decimals="-3"
      id="F_6a82ced1-68d2-4b92-a4b1-a119fb298c8a"
      unitRef="U_USD">491000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <lxeo:AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsShare
      contextRef="C_2cce3246-207a-4da6-b759-efc03a70940c"
      decimals="INF"
      id="F_7aa20353-6c8a-4d9c-9b63-6e572dfcad62"
      unitRef="U_shares">14159</lxeo:AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptionsShare>
    <lxeo:AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptions
      contextRef="C_3c3cff29-78d2-4481-b497-e743fdeb998d"
      decimals="-3"
      id="F_6bac568d-68c1-45cc-9961-14cab1e74324"
      unitRef="U_USD">59000</lxeo:AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptions>
    <lxeo:AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptions
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      decimals="-3"
      id="F_18df30b1-86cc-4744-8275-1601b008826c"
      unitRef="U_USD">59000</lxeo:AdjustmentsToAdditionalPaidInCapitalReclassificationFromDepositLiabilityShareBasedCompensationAndExerciseOfStockOptions>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_8e396f66-88d9-4bb5-8412-da93d2388896"
      decimals="-3"
      id="F_814ae46c-a06a-4f55-8b85-0567e42c4ccc"
      unitRef="U_USD">6288000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_f2189c8d-e1b8-45de-8953-73622e2e8923"
      decimals="INF"
      id="F_8b762c6d-f5e0-4276-b020-0f1bcbb6fa96"
      unitRef="U_shares">6278905</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_b520844c-238f-400e-8a4f-68368cd0badd"
      decimals="-3"
      id="F_9bc456e0-aad1-4bd5-b88e-c3a4d99374c5"
      unitRef="U_USD">88712000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_a9cf5f12-f6ff-4e48-8365-fa92cda8cd46"
      decimals="-3"
      id="F_975a5325-d855-4893-907a-17215ed8c061"
      unitRef="U_USD">88712000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <lxeo:StockIssuedDuringPeriodValueNewIssuesAdditionalOfferingCostsIncurred
      contextRef="C_3c3cff29-78d2-4481-b497-e743fdeb998d"
      decimals="-3"
      id="F_e5d6df29-4b9e-4d86-a5f8-357e9032da3a"
      unitRef="U_USD">24000</lxeo:StockIssuedDuringPeriodValueNewIssuesAdditionalOfferingCostsIncurred>
    <lxeo:StockIssuedDuringPeriodValueNewIssuesAdditionalOfferingCostsIncurred
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      decimals="-3"
      id="F_1345e201-38a3-4218-9a05-c3445cc810af"
      unitRef="U_USD">24000</lxeo:StockIssuedDuringPeriodValueNewIssuesAdditionalOfferingCostsIncurred>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="C_2cce3246-207a-4da6-b759-efc03a70940c"
      decimals="INF"
      id="F_c7759e05-6667-4818-9079-3815fb2ac610"
      unitRef="U_shares">3827</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="C_698516d7-c81c-4f0a-9a78-6d719461191d"
      decimals="-3"
      id="F_e4983e1f-7f8d-47be-9dc9-17658ac576ff"
      unitRef="U_USD">17000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      decimals="-3"
      id="F_2ae168f7-0388-41bc-bc72-a016720053bc"
      unitRef="U_USD">17000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="C_fcb1173a-0535-4c9d-91c0-398680f70ecb"
      decimals="-3"
      id="F_95498bb3-1292-40e6-ad1e-042b8e85a72a"
      unitRef="U_USD">-103000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      decimals="-3"
      id="F_d117744d-3dd0-4392-bdf0-e54e9b9efe65"
      unitRef="U_USD">-103000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_3c3cff29-78d2-4481-b497-e743fdeb998d"
      decimals="-3"
      id="F_fb478d66-62b4-44ae-94e4-0cd70d193d5d"
      unitRef="U_USD">12474000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      decimals="-3"
      id="F_e015922e-b69e-4d79-89d4-90dc1f96d932"
      unitRef="U_USD">12474000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="C_db61ba99-c7c7-4e9a-a944-9cc82209837d"
      decimals="-3"
      id="F_91b15811-ffc2-4b87-8b36-e5d136d98f93"
      unitRef="U_USD">-98333000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      decimals="-3"
      id="F_ebe9d4da-b78c-4330-a86c-de1452d80865"
      unitRef="U_USD">-98333000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_7be3bda2-4be1-4d70-adee-fffeb575b241"
      decimals="INF"
      id="F_91cb2c9d-0c95-4d24-b2ee-3fb913e33819"
      unitRef="U_shares">33071261</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_7be3bda2-4be1-4d70-adee-fffeb575b241"
      decimals="-3"
      id="F_fa4fa378-c96c-4f95-b5b8-ea07979de9f4"
      unitRef="U_USD">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_4270dba9-ca70-4680-8947-60179d11e241"
      decimals="-3"
      id="F_dba74b03-a6a9-4332-be80-a1784de5020e"
      unitRef="U_USD">-17000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0ed26320-f07c-4528-a9ac-162b961bf030"
      decimals="-3"
      id="F_a9a197b2-9fac-4605-ac89-eaf0f82bf20a"
      unitRef="U_USD">397132000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_3283c13a-3e8c-4395-9d0b-cffabf13a351"
      decimals="-3"
      id="F_4dbdd29e-de6d-4f03-9998-608d29990fa4"
      unitRef="U_USD">-103000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_9e79f7b3-b991-4a2c-abc3-1a0ef29ab5b5"
      decimals="-3"
      id="F_b3521589-83ee-4ee7-b58d-36bb63845122"
      unitRef="U_USD">-280173000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="-3"
      id="F_f5d46319-3919-4c8c-b75b-9c212975958c"
      unitRef="U_USD">116842000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      decimals="-3"
      id="F_1a4e76cb-875c-46d4-8e7b-11f054ffe169"
      unitRef="U_USD">-98333000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca"
      decimals="-3"
      id="F_40c3b074-cf86-40d4-9251-d61dd6b6b5bb"
      unitRef="U_USD">-66394000</us-gaap:ProfitLoss>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      decimals="-3"
      id="F_8ccc6703-696e-4eba-b4e8-479363e94e94"
      unitRef="U_USD">1373000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca"
      decimals="-3"
      id="F_4e7bbb7b-59b8-4b80-8b2d-dc788e9c64d9"
      unitRef="U_USD">1266000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      decimals="-3"
      id="F_4fba9135-5414-47de-beb6-747be8da0745"
      unitRef="U_USD">325000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca"
      decimals="-3"
      id="F_55d8cfba-e4bc-4b61-b804-359aa954300e"
      unitRef="U_USD">306000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      decimals="-3"
      id="F_a7a1ed63-bf5b-4a5f-b7dc-41f20124ab92"
      unitRef="U_USD">12474000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca"
      decimals="-3"
      id="F_51a9ba6b-5398-4207-8490-d2e0362d05bc"
      unitRef="U_USD">3043000</us-gaap:ShareBasedCompensation>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      decimals="-3"
      id="F_ca148a76-6f36-49bd-a48c-b9a187eaa597"
      unitRef="U_USD">304000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca"
      decimals="-3"
      id="F_c638f5b3-3f95-4b5a-a0e7-e98e426dbfe9"
      unitRef="U_USD">271000</us-gaap:DepreciationAndAmortization>
    <us-gaap:IncreaseDecreaseInDerivativeAssetsAndLiabilities
      contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca"
      decimals="-3"
      id="F_b3b178c5-822e-4c2c-bc43-ce7859ba6b93"
      unitRef="U_USD">-530000</us-gaap:IncreaseDecreaseInDerivativeAssetsAndLiabilities>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      decimals="-3"
      id="F_b7b731e6-b25d-441b-a86c-5e99e9b35a06"
      unitRef="U_USD">23000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      decimals="-3"
      id="F_770600bb-bf13-4c2b-bae0-5b363c66dbaf"
      unitRef="U_USD">1690000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca"
      decimals="-3"
      id="F_10aa9fd6-87cd-4bea-9ba1-7e9a1e486172"
      unitRef="U_USD">-990000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      decimals="-3"
      id="F_25ee229d-f9ef-4834-80de-31d91dc9e782"
      unitRef="U_USD">2378000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca"
      decimals="-3"
      id="F_15f5ea7a-0f51-4099-8b1c-dc238ca5df68"
      unitRef="U_USD">-180000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      decimals="-3"
      id="F_231b63dc-6060-4bdb-bcd8-84e4e66a81c0"
      unitRef="U_USD">3367000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca"
      decimals="-3"
      id="F_dee4aa49-5682-4888-87f5-f5dc93c8c7e7"
      unitRef="U_USD">2091000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      decimals="-3"
      id="F_ef9bd871-7889-4547-9620-b6640c3ec9ee"
      unitRef="U_USD">-1336000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca"
      decimals="-3"
      id="F_083e0d3d-46dc-450f-b314-e61ee75de12a"
      unitRef="U_USD">-1414000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <lxeo:IncreaseDecreaseInFinanceLeaseLiability
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      decimals="-3"
      id="F_be9134ff-5b2b-4509-bf25-5afa9db24b7f"
      unitRef="U_USD">10000</lxeo:IncreaseDecreaseInFinanceLeaseLiability>
    <lxeo:IncreaseDecreaseInFinanceLeaseLiability
      contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca"
      decimals="-3"
      id="F_ba00382f-5238-4ef8-89ab-dbce162cc910"
      unitRef="U_USD">-5000</lxeo:IncreaseDecreaseInFinanceLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      decimals="-3"
      id="F_9c8e7279-40e3-49cf-b0e9-589a2394c43f"
      unitRef="U_USD">-81151000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca"
      decimals="-3"
      id="F_bed0f94f-93ab-4022-a321-2ee7efd26254"
      unitRef="U_USD">-59496000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireSoftware
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      decimals="-3"
      id="F_e1cfd58f-eab6-46fc-bbfa-2eb78dab5fdf"
      unitRef="U_USD">0</us-gaap:PaymentsToAcquireSoftware>
    <us-gaap:PaymentsToAcquireSoftware
      contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca"
      decimals="-3"
      id="F_6fa2fabf-23ab-43e3-9107-2cbd757f35c3"
      unitRef="U_USD">50000</us-gaap:PaymentsToAcquireSoftware>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      decimals="-3"
      id="F_77766342-7ce0-4a4a-8e07-73e8ddc19580"
      unitRef="U_USD">481000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca"
      decimals="-3"
      id="F_9c4887b7-a802-432c-ade7-42e2d34eb238"
      unitRef="U_USD">115000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      decimals="-3"
      id="F_069b134e-7806-4485-9081-277eb2995d38"
      unitRef="U_USD">93596000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      decimals="-3"
      id="F_4f899f37-c584-4710-8a5a-2d2675624acb"
      unitRef="U_USD">-94077000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca"
      decimals="-3"
      id="F_843c72a8-9063-47f5-b34f-7dada7a20e4f"
      unitRef="U_USD">-165000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      decimals="-3"
      id="F_cdfe0d04-9808-4ab7-b687-4d761d36cc3e"
      unitRef="U_USD">491000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca"
      decimals="-3"
      id="F_c5f15e7d-8f11-45bb-8c5f-4c8cde67b0c9"
      unitRef="U_USD">51000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      decimals="-3"
      id="F_0351ec0a-b3b5-4bb2-8dff-a2ef8efe0cc7"
      unitRef="U_USD">410000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca"
      decimals="-3"
      id="F_b89a306d-4414-4687-afe5-56ddba0dadac"
      unitRef="U_USD">425000</us-gaap:FinanceLeasePrincipalPayments>
    <lxeo:TreasuryStockRepurchase
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      decimals="-3"
      id="F_e987d413-40f1-4186-8e9e-961d7637b2f3"
      unitRef="U_USD">17000</lxeo:TreasuryStockRepurchase>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca"
      decimals="-3"
      id="F_8b1dff7a-91bd-453b-a40b-93c85859603e"
      unitRef="U_USD">86000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca"
      decimals="-3"
      id="F_ff01a92e-b840-42da-ba91-c93e9e66d671"
      unitRef="U_USD">4000000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      decimals="-3"
      id="F_44181701-3820-4aa0-9f65-dc2d85080db9"
      unitRef="U_USD">88712000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca"
      decimals="-3"
      id="F_16440035-1db6-4505-96a6-e588f3f7d2a9"
      unitRef="U_USD">100251000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      decimals="-3"
      id="F_fe8341dd-8e3b-4b2f-84d5-6622ffc3814c"
      unitRef="U_USD">88776000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca"
      decimals="-3"
      id="F_90423f01-78d8-466f-8911-5e0100ac9e39"
      unitRef="U_USD">103791000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      decimals="-3"
      id="F_1b6b40d5-2da0-4fed-a402-51d38d018ab0"
      unitRef="U_USD">-86452000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca"
      decimals="-3"
      id="F_0a82ab25-cb54-4f54-a87e-396d35ccd12b"
      unitRef="U_USD">44130000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_28144b67-7dfd-494d-8133-75abcc735058"
      decimals="-3"
      id="F_c37600ec-8549-42af-94f2-cfd5e5849a82"
      unitRef="U_USD">124718000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_e83f79f6-f924-4728-9c7c-5f1eb49397fe"
      decimals="-3"
      id="F_8030339f-f12f-475d-812d-475bc9fe363a"
      unitRef="U_USD">80588000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="-3"
      id="F_71bf30a1-52e8-4fac-b8d3-c3464096f01a"
      unitRef="U_USD">38266000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_28144b67-7dfd-494d-8133-75abcc735058"
      decimals="-3"
      id="F_31043c81-0e04-435a-88e3-5452e3887a88"
      unitRef="U_USD">124718000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      decimals="-3"
      id="F_40d7fcd4-0672-40ea-b94f-b66fae84e8f6"
      unitRef="U_USD">127000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca"
      decimals="-3"
      id="F_3ace30de-0377-4ac2-a63b-42078fa139d0"
      unitRef="U_USD">176000</us-gaap:InterestPaidNet>
    <lxeo:DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses
      contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca"
      decimals="-3"
      id="F_bce135aa-29a1-46fb-a45c-1c942ca13e1e"
      unitRef="U_USD">1105000</lxeo:DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      decimals="-3"
      id="F_c7be950d-b972-45ee-b1d8-8f362f03453d"
      unitRef="U_USD">-103000</us-gaap:UnrealizedGainLossOnInvestments>
    <lxeo:ReclassificationOfInternalUseSoftwareIntoPrepaidExpenses
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      decimals="-3"
      id="F_467e8b0c-8cdb-4610-9c21-7c1d5e84e142"
      unitRef="U_USD">98000</lxeo:ReclassificationOfInternalUseSoftwareIntoPrepaidExpenses>
    <us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
      contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca"
      decimals="-3"
      id="F_955ff2b0-3eea-4bd0-bd26-ed9d064b0575"
      unitRef="U_USD">50000</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <lxeo:CapitalExpendituresIncurredButNotYetPaidNetOfPaidAmount
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      decimals="-3"
      id="F_bceef92e-fe69-440f-b4bf-e3697c736c81"
      unitRef="U_USD">120000</lxeo:CapitalExpendituresIncurredButNotYetPaidNetOfPaidAmount>
    <lxeo:CapitalExpendituresIncurredButNotYetPaidNetOfPaidAmount
      contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca"
      decimals="-3"
      id="F_576824a6-a7ba-4e3e-80ba-d751e9d4987a"
      unitRef="U_USD">-141000</lxeo:CapitalExpendituresIncurredButNotYetPaidNetOfPaidAmount>
    <lxeo:FinanceLeaseRightOfUseAssetsAndFinanceLeaseLiabilitiesRecognized
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      decimals="-3"
      id="F_18154b28-9949-4c58-bd50-278501b3c52e"
      unitRef="U_USD">22000</lxeo:FinanceLeaseRightOfUseAssetsAndFinanceLeaseLiabilitiesRecognized>
    <us-gaap:ConversionOfStockAmountIssued1
      contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca"
      decimals="-3"
      id="F_41e85b2e-969f-4d64-9e32-eaaf96ab479c"
      unitRef="U_USD">185032000</us-gaap:ConversionOfStockAmountIssued1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca"
      decimals="-3"
      id="F_868b586a-af8a-4aa4-9064-8e375b8722e5"
      unitRef="U_USD">4417000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <lxeo:AmountsReclassifiedFromDepositLiabilitiesUponTheVestingOfEarlyExercisedStockOptionsPreviouslySubjectToRepurchaseNetOfProceedsReceivedFromEarlyExerciseOfUnvestedStockOptionsSubjectToRepurchaseAndRecord
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      decimals="-3"
      id="F_8cf2cef8-a073-4cf1-8972-af7439adc392"
      unitRef="U_USD">59000</lxeo:AmountsReclassifiedFromDepositLiabilitiesUponTheVestingOfEarlyExercisedStockOptionsPreviouslySubjectToRepurchaseNetOfProceedsReceivedFromEarlyExerciseOfUnvestedStockOptionsSubjectToRepurchaseAndRecord>
    <lxeo:AmountsReclassifiedFromDepositLiabilitiesUponTheVestingOfEarlyExercisedStockOptionsPreviouslySubjectToRepurchaseNetOfProceedsReceivedFromEarlyExerciseOfUnvestedStockOptionsSubjectToRepurchaseAndRecord
      contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca"
      decimals="-3"
      id="F_e2b0f135-cff5-4b77-a05e-0d3599126367"
      unitRef="U_USD">87000</lxeo:AmountsReclassifiedFromDepositLiabilitiesUponTheVestingOfEarlyExercisedStockOptionsPreviouslySubjectToRepurchaseNetOfProceedsReceivedFromEarlyExerciseOfUnvestedStockOptionsSubjectToRepurchaseAndRecord>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_8972b225-efc3-4da7-8be9-028d13d3a9db">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;1. Description of Business and Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Description of Business&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;Lexeo Therapeutics, Inc. (the &#x201c;Company&#x201d;) is a clinical stage genetic medicine company with a focus on hereditary and acquired diseases of high unmet need. The Company&#x2019;s investigational therapies have the potential to offer gene therapy-based treatments to address many diseases that have eluded today&#x2019;s existing drug delivery platforms. The Company utilizes adeno-associated viruses (&#x201c;AAV&#x201d;) that have been engineered to transfer genes to patients. The Company&#x2019;s therapeutic investigational treatments include gene therapies primarily in the early clinical and late pre-clinical stages of research and development.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is located in New York, NY and was first formed on February 17, 2017, as an LLC under the laws of the State of Delaware under the legal name Lexeo Therapeutics, LLC. The Company filed and executed a certificate of conversion to corporation on November 20, 2020, to convert the LLC to Lexeo Therapeutics, Inc, a Delaware corporation. All of the Company&#x2019;s tangible assets are held in the United States (&#x201c;U.S.&#x201d;).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basis of Presentation and Principles of Consolidation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;The accompanying financial statements and these notes reflect the operations of the Company that have been prepared in conformity with generally accepted accounting principles in the United States of America (&#x201c;GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Updates (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;). The Company has no unconsolidated subsidiaries. Certain prior period balances have been reclassified to conform to the current period presentation.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;10.594230-for-1&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; reverse share split of the Company&#x2019;s series A convertible preferred stock, series B convertible preferred stock, common stock, and options to purchase common stock under the Company&#x2019;s 2021 Equity Incentive Plan (the "2021 Plan"), as well as corresponding adjustments in the respective conversion prices of the series A convertible preferred stock and series B convertible preferred stock, was effected on October 13, 2023 as approved by the Company&#x2019;s board of directors (the "Board of Directors") and its shareholders (the &#x201c;Stock Split&#x201d;). The Stock Split reduced the number of shares of the Company&#x2019;s authorized, issued and outstanding common stock, as well as the numbers of shares reserved and available for future issuance and underlying outstanding options to purchase common stock under its 2021 Equity Incentive Plan, on a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;10.594230-for-1&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; basis. As such, all references to series A convertible preferred stock and series B convertible preferred stock conversion ratios, conversion share and per share amounts, and post- conversion share and per share amounts, as well as common stock option, option per common share, common share and common per share amounts, in these financial statements and accompanying notes have been retroactively restated to reflect the Stock Split and the Stock Split&#x2019;s effect on the respective series A convertible preferred stock and series B convertible preferred stock conversion ratios for each series of convertible preferred stock. The Stock Split did not affect the par values per share.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Need for Additional Capital&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;Since inception, the Company has incurred net losses and negative cash flows from operations, including net losses of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;98.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;66.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million during the years ended December 31, 2024 and December 31, 2023, respectively. As of December 31, 2024, the Company had cash, cash equivalents, and investments of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;128.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and an accumulated deficit of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;280.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and expects to incur substantial operating losses and negative cash flows from operations for the foreseeable future. During the years ended December 31, 2021 and December 31, 2020, the Company raised aggregate total net proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;185.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in connection with the issuance of series A and series B convertible preferred stock. During the year ended December 31, 2023 the Company raised $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of total net proceeds in connection with the closing of its initial public offering ("IPO") on November 7, 2023 and subsequent partial exercise of the underwriters' option to purchase additional shares, as well $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of net proceeds from the issuance of a convertible Simple Agreement for Future Equity (&#x201c;SAFE&#x201d;) note (the "convertible SAFE Note") in August 2023. During the year ended December 31, 2024, the Company received total net proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;88.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million after deducting underwriting commissions and offering expenses in a private placement offering of its common stock (see Note 8). Management estimates that the Company's current cash, cash equivalents, and investments balances are sufficient to fund its operations for at least 12 months from the issuance date of these financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;If the Company is unable to obtain additional funding before achieving sufficient profitability and positive cash flows from operations, if ever, the Company will be forced to delay, reduce or eliminate some or all of its research and development programs, which could adversely affect its business prospects, or the Company may be unable to continue operations. Although management continues to pursue plans to obtain additional funding before achieving sufficient profitability and positive cash flows from operations, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations, if at all.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Risks and Uncertainties&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;The Company is subject to risks and uncertainties common to early-stage companies in the biopharmaceutical industry, including, but not limited to, successful discovery and development of its product candidates, development by competitors of new technological innovations, dependence on key personnel, the ability to attract and retain qualified employees, protection of proprietary technology, compliance with governmental regulations, the ability to secure additional capital to fund operations, and commercial success of its product candidates. Any of the Company&#x2019;s current product candidates and future product candidates that it may develop will require extensive non-clinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel, infrastructure, and extensive compliance- reporting capabilities. Even if the Company&#x2019;s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.&lt;/span&gt;&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:StockholdersEquityReverseStockSplit
      contextRef="C_240d6e00-2133-41ba-92ce-0078e7bbcbca"
      id="F_41d9f36b-6ccd-4502-86e3-94e91fe76dff">10.594230-for-1</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:StockholdersEquityReverseStockSplit
      contextRef="C_240d6e00-2133-41ba-92ce-0078e7bbcbca"
      id="F_aeaac8fe-8255-473b-85b4-23e2a40109c8">10.594230-for-1</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:NetIncomeLoss
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      decimals="-5"
      id="F_b3dda6db-8f76-4870-9759-192a39486e56"
      unitRef="U_USD">-98300000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca"
      decimals="-5"
      id="F_853cdea5-ca82-4b74-9036-0a634e4df4f4"
      unitRef="U_USD">-66400000</us-gaap:NetIncomeLoss>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="-5"
      id="F_01ca010e-ee6f-4eb8-b30f-d1cb8862aa41"
      unitRef="U_USD">128500000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="-5"
      id="F_bd444f6a-4ce8-4a40-ae4c-49ef383b760a"
      unitRef="U_USD">-280200000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="C_6dc19a43-c74a-4bb9-a484-18d905a695b2"
      decimals="-5"
      id="F_389e5093-aec4-4d3b-8120-c1027e896819"
      unitRef="U_USD">185000000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="C_8fa4e334-c5fa-44d9-8bc4-866b04e010d4"
      decimals="-5"
      id="F_7d76c4b4-c6bd-405a-b160-a2000659a2eb"
      unitRef="U_USD">100300000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="C_cc906741-ea91-4e6d-8943-e5456da6d798"
      decimals="-5"
      id="F_e7a4195a-3f09-4fb7-9870-ccc7fcd920f9"
      unitRef="U_USD">3900000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="C_a9cf5f12-f6ff-4e48-8365-fa92cda8cd46"
      decimals="-5"
      id="F_a3a37707-e8a7-4ed2-a0e5-a9816b54a8bc"
      unitRef="U_USD">88700000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_73be07b6-3428-4d7c-9ed9-55c01408fd60">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2. Summary of Significant Accounting Policies&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;The preparation of the financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of income and expense during the reporting period. The most significant estimates relate to the accruals of research and development costs, including accruals of research contract costs, and assumptions used to estimate the fair value of the Company&#x2019;s stock option awards and, prior to its IPO, to determine the fair value of its common stock. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when facts and circumstances dictate. These estimates are based on information available as of the date of the financial statements; therefore, actual results could differ from those estimates.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cash and Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;The Company considers all highly liquid investments with a remaining maturity when purchased of three months or less to be cash equivalents. Cash equivalents are reported at carrying values, which approximated their fair values and are based on quoted prices in active markets for identical securities. At December 31, 2024 and December 31, 2023, the Company&#x2019;s cash equivalents were held in a money market fund. As of December 31, 2024 and 2023, cash consists of cash on deposit with U.S. banks denominated in U.S. dollars, and restricted cash consists of cash on deposit with U.S. banks denominated in U.S. dollars for which its use is restricted and is classified as non-current in the Company&#x2019;s balance sheet according to the timing of maturity, and is associated with collateral for letters of credit issued in connection with its operating lease right-of-use and finance lease right-of-use assets and corresponding lease liabilities. Cash is stated at its historical carrying amount, which approximates fair value due to its short-term nature. Restricted cash is stated at its historical carrying amount, which approximates fair value. The Company regularly maintains cash and cash equivalents and restricted cash balances with financial institutions that exceed Federal Deposit Insurance Corporation insurance limits.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Investments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;Investments consist primarily of U.S. Treasury securities. Management determines the appropriate classification of these securities at the time they are acquired and evaluates the appropriateness of such classifications at each balance sheet date, including the determination of current and non-current classifications based on the contractual maturity dates of the underlying investments. Investments may be sold by the Company prior to contractual maturity. The Company classifies its investments as available-for-sale pursuant to ASC Topic 320, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Investments&#x2014;Debt and Equity Securities&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. Investments are recorded at fair value, with unrealized gains and losses included as a component of accumulated other comprehensive income (loss) in stockholders&#x2019; equity and a component of total comprehensive loss in the statements of comprehensive loss, until realized. The Company's current and non-current investments are presented net of discounts of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;49,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;55,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, respectively, at December 31, 2024.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Deferred Software Costs&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;We capitalize certain costs related to hosting arrangements that are service contracts (cloud computing arrangements). Capitalized costs are included in Other Current Assets and are amortized on a straight-line basis over the estimated useful life. For the year ended December 31, 2024, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of deferred software costs were capitalized related to cloud computing arrangements.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Net Loss per Share&#x2014;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The Company follows the two-class method when computing net income (loss) per common share as the Company has issued shares that meet the definition of participating securities. The two-class method determines net income (loss) per common share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income (loss) available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed. The Company also considers the shares issued upon the early exercise of stock options that are subject to repurchase to be participating securities because holders of such shares have non-forfeitable dividend rights in the event a dividend is paid on common stock. There is no allocation required under the two-class method during periods of loss since the participating securities do not have a contractual obligation to share in the losses of the Company.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basic net income (loss) per common share is computed by dividing the net income (loss) per common share by the weighted-average number of common shares outstanding for the period. Diluted net income (loss) per common share is computed by adjusting net income (loss) to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net loss per common share is computed by dividing the diluted net loss by the weighted-average number of common shares outstanding for the period, including potential dilutive common shares.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In periods in which the Company reported a net loss, diluted net loss per common share was the same as basic net loss per common share since dilutive common shares were not assumed to have been issued if their effect was anti-dilutive. During (i) the year ended December 31, 2023, potential common shares related to the conversion of the convertible SAFE Note, which converted into &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;411,815&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; common shares in connection with the Company&#x2019;s IPO on November 2, 2023 (see Note 6), and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,070,027&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; potential common shares related to the conversion of series A convertible preferred stock and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,489,573&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; potential common shares related to the conversion of series B convertible preferred stock, which converted into &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,070,027&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; common shares and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,386,337&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; common shares, respectively, in connection with the Company&#x2019;s IPO on November 7, 2023 (see Note 7), and (ii) the years ended December 31, 2024 and December 31, 2023, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,724,218&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,415,740&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; potential common shares, respectively, related to the exercise of outstanding stock options and settlement of outstanding Restricted Stock Units ("RSUs") (see Note 9), were excluded from the computation of diluted net loss per common share because including them would have had an anti-dilutive effect as the Company reported net losses for those periods.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Deferred Offering Costs&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;The Company capitalizes certain legal, accounting and other third-party fees that are directly associated with equity financings as deferred offering costs until such financings are consummated. After consummation of the equity financing, these costs are recorded as a reduction of the proceeds from the offering, either as a reduction of the carrying value of preferred stock or in stockholders&#x2019; equity (deficit) as a reduction of additional capital generated as a result of the offering. Should the equity financing be abandoned, the deferred offering costs would be expensed immediately as a charge to operating expenses in the statement of operations and comprehensive loss. The Company had &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; deferred offering costs recorded as of December 31, 2024 or December 31, 2023.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Research and Development&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred to discover, research, and develop drug candidates, including personnel expenses, allocated facility-related and depreciation expenses, and third-party license fees. Costs incurred to obtain technology licenses are charged immediately to research and development expense if the technology licensed has not reached technological feasibility and has no alternative future use.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;General and Administrative&#x2014;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;General and administrative expenses consist primarily of the cost of employees to engage in corporate functions, such as finance and accounting, information technology, human resources, and legal and executive management. General and administrative expenses also include rent occupancy costs, office expenses, depreciation and amortization, other general overhead costs, insurance premiums, professional service fees, and costs related to regulatory and litigation matters.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock Based Compensation Expense&#x2014;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company accounts for stock-based payment awards granted to employees and non-employees, as well as shares issued to its employees under the Company's 2023 Employee Stock Purchase Plan (the "2023 ESPP"), as stock-based compensation expense at fair value. The Company issues stock-based awards to employees and non-employees in the form of stock options and also issues stock-based awards to employees in the form of restricted stock units (&#x201c;RSUs&#x201d;). The measurement date for employee stock option and RSU awards is the date of grant, and stock-based compensation costs are recognized as expense over the employees&#x2019; requisite service period, which is the vesting period, on an accelerated basis. The measurement date for non-employee awards is the date of grant without changes in the fair value of the award. The measurement date for shares issued under the 2023 ESPP is the first date of each employee stock purchase plan offering period, and stock-based compensation costs are recognized as expense over the offering period on a straight-line basis. Stock-based compensation costs for non-employees are recognized as expense over the vesting period on an accelerated basis. Stock-based compensation expense is classified in the accompanying statement of operations based on the function to which the related services are provided. As the Company is permitted to repurchase shares legally issued for unvested stock options exercised at their exercise price under the 2021 Plan, (i) cash received for unvested stock options exercised under the 2021 Plan is recorded as a deposit liability as a reclassification from additional paid-in capital in the Company&#x2019;s balance sheet, which is relieved to additional paid-in capital as such awards vest, (ii) stock based compensation expense is recognized over the requisite service period for each such award, and (iii) the amount and number of shares of common stock outstanding in the Company&#x2019;s balance sheet and statement of convertible preferred stock and stockholders&#x2019; equity (deficit) are reduced until such awards vest. Forfeitures are recorded as they occur.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The fair value of each stock option grant and shares issued under the 2023 ESPP are estimated on the date of grant or on the first date of each employee stock purchase plan offering period, respectively, using the Black-Scholes option-pricing model, while the fair value of each RSU granted is equal to the closing price of the Company's common stock on the date of the grant. Prior to its IPO on November 3, 2023, the Company was a private company and lacked company-specific historical and implied volatility information for stock options granted. Therefore, the Company estimated its expected stock volatility entirely based on the historical volatility of a publicly traded set of peer companies for stock options granted prior to its IPO, and estimates its expected stock price volatility primarily based on the historical volatility of a publicly traded set of peer companies for stock options granted since its IPO, each for a period equal to the expected life of the stock options granted, and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. The expected term of the Company&#x2019;s stock options granted has been determined utilizing the &#x201c;simplified&#x201d; method for awards that qualify as &#x201c;plain-vanilla&#x201d; options and expects to continue to do so until such time as it has adequate historical data regarding the expected term of its own stock options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The expected dividend yield is zero as the Company has never paid cash dividends on its common stock and does not expect to pay any cash dividends in the foreseeable future.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;Prior to November 20, 2020, the Company was an LLC entity and elected to be treated under the Partnership provisions of the Internal Revenue Code. Accordingly, the LLC entity was not viewed as a tax-paying entity in any jurisdiction and all income and deductions of the LLC entity flowed through to the individual members and therefore no income taxes were recorded by the Company. On November 20, 2020, the Company converted to a C Corporation.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company accounts for income taxes under the asset and liability method pursuant to ASC Topic 740, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Taxes &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;("ASC 740"). Under this method, the Company recognizes deferred tax assets and liabilities for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recorded for deferred tax assets if it is more likely than not that some portion or all of the deferred tax assets will not be realized based on all available positive and negative evidence. Under the Tax Cuts and Jobs Act of 2017, the Company is required to capitalize, and subsequently amortize, research and development expenses over five years for research activities conducted in the U.S. and over fifteen years for research activities conducted outside of the U.S commencing in 2022. The capitalization of research and development expenses during the year resulted in a decrease to the Company's operating loss generation during the years ended December 31, 2024 and December 31, 2023 as compared to prior periods (see Note 11). As of December 31, 2024 and December 31, 2023, the Company continues to maintain a full valuation allowance against its deferred tax assets.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company recognizes a tax benefit only if it is more likely than not the tax position will be sustained on examination by the local taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such positions are then measured based on the largest benefit greater than 50% likelihood of being realized upon settlement with the related tax authority. The changes in recognition or measurement are reflected in the period in which the change in judgment occurs. As of December 31, 2024 and December 31, 2023, the Company has &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t identified any uncertain tax positions.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company records interest and penalties related to uncertain tax positions in the provision for income taxes.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Fair Value Measurements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The three levels of inputs that may be used to measure fair value are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;Inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;Inputs are unobservable inputs for the asset or liability.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Concentrations of Credit Risk&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, cash equivalents, restricted cash, and investments. The Company&#x2019;s cash and restricted cash balances exceed Federal Deposit Insurance Corporation insurance limits. The Company&#x2019;s cash equivalents consist of investments in a U.S. government money market fund, and the Company's investments primarily consist of U.S. Treasury securities. The Company&#x2019;s cash, cash equivalents, restricted cash, and investments are held with large financial institutions that management believes to be of high credit quality. To date, the Company has &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t recognized any losses caused by uninsured balances.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Segment Information&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;The Company manages its operations as a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_3797e8b8-b7a6-4ad2-8b98-c0c8d90f246c;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;single&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; segment for the purposes of assessing performance and allocating resources. The Company is focused on preclinical and clinical stage gene therapies, and specifically on hereditary and acquired diseases of high unmet need. The Company&#x2019;s Chief Operating Decision Maker ("CODM") is its Chief Executive Officer ("CEO") and its senior leadership team. The CODM reviews the Company&#x2019;s financial information on an aggregated basis for purposes of assessing performance and allocating resources. All assets are held in the United States. The Company has not earned any product revenue through December 31, 2024.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property and Equipment&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization are recognized using the straight-line method over the estimated useful life of each asset. Such costs are periodically reviewed for recoverability when impairment indicators are present. Such indicators include, among other factors, unused capacity, market value declines, and obsolescence of technology. Recorded values of asset groups of equipment that are not expected to be recovered through undiscounted future net cash flows are written down to current fair value, which generally is determined from estimated discounted future net cash flows (assets held for use) or net realizable value (assets held for sale).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Costs for capital assets not yet placed into service are capitalized as construction-in-progress and depreciated once placed into service. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation and amortization are removed from the accounts and any resulting gain or loss is included in loss from operations. Expenditures for repairs and maintenance that do not improve or extend the life of the respective assets are charged to expense in the period incurred. See Note 5 for information regarding the Company&#x2019;s capitalized operating and finance lease right-of-use assets.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following is the summary of property and equipment and related accumulated depreciation as of December 31, 2024, and December 31, 2023 (years not stated in thousands):&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:58.884%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.421%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:13.085%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.421%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:9.884%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.421%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:9.884%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Useful Life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Internal use software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3 &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5 &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;386&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;380&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Lab equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7 &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;844&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;514&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7 &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;272&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;247&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,502&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,437&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;474&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;381&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,056&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;In accordance with ASC Topic 842, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Leases &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;("ASC 842"), the Company determines if an arrangement is or contains a lease at inception. A contract is or contains a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. The Company classifies leases at the lease commencement date as operating or finance leases and records a right-of-use asset and a lease liability on the balance sheet for all leases with an initial lease term of greater than 12 months. Leases with an initial term of 12 months or less are not recorded in the balance sheet, but payments are recognized as expense on a straight-line basis over the lease term. The Company has elected not to recognize leases with terms of 12 months or less.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A lease qualifies as a finance lease if any of the following criteria are met at the inception of the lease: (i) there is a transfer of ownership of the leased asset to the Company by the end of the lease term, (ii) the Company holds an option to purchase the leased asset that it is reasonably certain to exercise, (iii) the lease term is for a major part of the remaining economic life of the leased asset, (iv) the present value of the sum of lease payments equals or exceeds substantially all of the fair value of the leased asset, or (v) the nature of the leased asset is specialized to the point that it is expected to provide the lessor no alternative use at the end of the lease term. All other leases are recorded as operating leases.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company enters into contracts that contain both lease and non-lease components. Non-lease components may include maintenance, utilities, and other operating costs. The Company combines the lease and non-lease components of fixed costs in its lease arrangements as a single lease component. Variable costs, such as utilities or maintenance costs, are not included in the measurement of right-of-use assets and lease liabilities but rather are expensed when the event determining the amount of variable consideration to be paid occurs.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Operating lease right-of-use assets and lease liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term using the discount rate implicit in the lease. If the implicit rate is not readily determinable, the Company utilizes an estimate of its incremental borrowing rate based upon the available information at the operating lease commencement date. Operating lease right-of-use assets are further adjusted for prepaid or accrued lease payments. Operating lease payments are expensed using the straight-line method as an operating expense over the lease term. The Company&#x2019;s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Finance lease right-of-use assets and lease liabilities are recognized upon receipt of the assets based on their fair values and are amortized to depreciation expense using the straight-line method over the estimated useful lives of the related assets. Finance lease liability payments are bifurcated into (i) a portion that is recorded as interest expense and (ii) a portion that reduces the finance liability associated with the lease, according to the interest rates implicit in the leases.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Certain of the Company&#x2019;s leases include options to extend or terminate the lease. The amounts determined for the Company&#x2019;s right-of-use assets and lease liabilities generally do not assume that renewal options or early-termination provisions, if any, are exercised, unless it is reasonably certain that the Company will exercise such options.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Recent Accounting Pronouncements Adopted&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;In November 2023, the FASB issued ASU No. 2023-07, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Segment Reporting - Improving Reportable Segment Disclosures&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (Topic 280) ("ASU 2023-07"). &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_73289f60-fe2f-4884-94cc-6b3d31ad5380;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ASU 2023-07&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; requires disclosures to include significant segment expenses that are regularly provided to the CODM, a description of other segment items by reportable segment, and any additional measures of a segment's profit or loss used by the CODM when deciding how to allocate resources. ASU 2023-07 also requires all annual disclosures currently required by Topic 280 to be included in interim periods. This update is effective for fiscal years beginning after December 15, 2023, and is to be applied retrospectively to all periods presented in the financial statements. The Company's &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;adoption&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; of ASU 2023-07 resulted in a new footnote disclosure for segment reporting.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Recent Accounting Pronouncements Not Yet Adopted&#x2014;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In December 2023, the FASB issued ASU No. 2023-09, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (Topic 740) ("ASU No. 2023-09"). ASU No. 2023-09 requires disaggregation of the effective tax rate reconciliation into standard categories, enhances disclosure of income taxes paid, and modifies other income tax-related disclosures. ASU No. 2023-09 became effective for the Company on January 1, 2025. The adoption of this guidance will not have a material impact on the Company's financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2024, the FASB issued ASU No. 2024-03, I&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;ncome Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (Subtopic 220-40) ("ASU No. 2024-03"). ASU No. 2024-03 requires disclosure, in the notes to financial statements, of specified information about certain costs and expenses. ASU No. 2024-03 will be effective for the Company starting in annual periods in 2027, with early adoption permitted. The Company is currently assessing the impact of adopting this guidance on its financial statements.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_406f6f3c-a715-454f-b7d1-57da3384aaea">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;The preparation of the financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of income and expense during the reporting period. The most significant estimates relate to the accruals of research and development costs, including accruals of research contract costs, and assumptions used to estimate the fair value of the Company&#x2019;s stock option awards and, prior to its IPO, to determine the fair value of its common stock. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when facts and circumstances dictate. These estimates are based on information available as of the date of the financial statements; therefore, actual results could differ from those estimates.&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_178c054d-cd8b-4f96-950c-c4172e30de9c">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cash and Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;The Company considers all highly liquid investments with a remaining maturity when purchased of three months or less to be cash equivalents. Cash equivalents are reported at carrying values, which approximated their fair values and are based on quoted prices in active markets for identical securities. At December 31, 2024 and December 31, 2023, the Company&#x2019;s cash equivalents were held in a money market fund. As of December 31, 2024 and 2023, cash consists of cash on deposit with U.S. banks denominated in U.S. dollars, and restricted cash consists of cash on deposit with U.S. banks denominated in U.S. dollars for which its use is restricted and is classified as non-current in the Company&#x2019;s balance sheet according to the timing of maturity, and is associated with collateral for letters of credit issued in connection with its operating lease right-of-use and finance lease right-of-use assets and corresponding lease liabilities. Cash is stated at its historical carrying amount, which approximates fair value due to its short-term nature. Restricted cash is stated at its historical carrying amount, which approximates fair value. The Company regularly maintains cash and cash equivalents and restricted cash balances with financial institutions that exceed Federal Deposit Insurance Corporation insurance limits.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_d3bd3b38-21c5-4514-b4c1-830d90529230">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Investments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;Investments consist primarily of U.S. Treasury securities. Management determines the appropriate classification of these securities at the time they are acquired and evaluates the appropriateness of such classifications at each balance sheet date, including the determination of current and non-current classifications based on the contractual maturity dates of the underlying investments. Investments may be sold by the Company prior to contractual maturity. The Company classifies its investments as available-for-sale pursuant to ASC Topic 320, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Investments&#x2014;Debt and Equity Securities&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. Investments are recorded at fair value, with unrealized gains and losses included as a component of accumulated other comprehensive income (loss) in stockholders&#x2019; equity and a component of total comprehensive loss in the statements of comprehensive loss, until realized. The Company's current and non-current investments are presented net of discounts of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;49,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;55,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, respectively, at December 31, 2024.&lt;/span&gt;&lt;/p&gt;</us-gaap:InvestmentPolicyTextBlock>
    <lxeo:InvestmentCurrent
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="0"
      id="F_904cd445-e17f-4b0d-82bb-0107283c0956"
      unitRef="U_USD">49000</lxeo:InvestmentCurrent>
    <lxeo:InvestmentNonCurrent
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="0"
      id="F_896a838a-b928-4fc0-9b43-071e697a7323"
      unitRef="U_USD">55000</lxeo:InvestmentNonCurrent>
    <us-gaap:InternalUseSoftwarePolicy
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_9031150b-5b62-4c0b-84eb-3cb147cbe0da">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Deferred Software Costs&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;We capitalize certain costs related to hosting arrangements that are service contracts (cloud computing arrangements). Capitalized costs are included in Other Current Assets and are amortized on a straight-line basis over the estimated useful life. For the year ended December 31, 2024, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of deferred software costs were capitalized related to cloud computing arrangements.&lt;/span&gt;&lt;/p&gt;</us-gaap:InternalUseSoftwarePolicy>
    <us-gaap:CapitalizedComputerSoftwareGross
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="-5"
      id="F_d5d366ed-d68c-4492-9c4e-9c1ece836a40"
      unitRef="U_USD">100000</us-gaap:CapitalizedComputerSoftwareGross>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_e71c5b31-ae91-4917-a3cc-4509d52a90aa">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Net Loss per Share&#x2014;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The Company follows the two-class method when computing net income (loss) per common share as the Company has issued shares that meet the definition of participating securities. The two-class method determines net income (loss) per common share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income (loss) available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed. The Company also considers the shares issued upon the early exercise of stock options that are subject to repurchase to be participating securities because holders of such shares have non-forfeitable dividend rights in the event a dividend is paid on common stock. There is no allocation required under the two-class method during periods of loss since the participating securities do not have a contractual obligation to share in the losses of the Company.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basic net income (loss) per common share is computed by dividing the net income (loss) per common share by the weighted-average number of common shares outstanding for the period. Diluted net income (loss) per common share is computed by adjusting net income (loss) to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net loss per common share is computed by dividing the diluted net loss by the weighted-average number of common shares outstanding for the period, including potential dilutive common shares.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In periods in which the Company reported a net loss, diluted net loss per common share was the same as basic net loss per common share since dilutive common shares were not assumed to have been issued if their effect was anti-dilutive. During (i) the year ended December 31, 2023, potential common shares related to the conversion of the convertible SAFE Note, which converted into &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;411,815&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; common shares in connection with the Company&#x2019;s IPO on November 2, 2023 (see Note 6), and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,070,027&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; potential common shares related to the conversion of series A convertible preferred stock and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,489,573&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; potential common shares related to the conversion of series B convertible preferred stock, which converted into &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,070,027&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; common shares and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,386,337&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; common shares, respectively, in connection with the Company&#x2019;s IPO on November 7, 2023 (see Note 7), and (ii) the years ended December 31, 2024 and December 31, 2023, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,724,218&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,415,740&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; potential common shares, respectively, related to the exercise of outstanding stock options and settlement of outstanding Restricted Stock Units ("RSUs") (see Note 9), were excluded from the computation of diluted net loss per common share because including them would have had an anti-dilutive effect as the Company reported net losses for those periods.&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="C_90b3b8b5-08ff-4ed8-b03a-36a19e205081"
      decimals="INF"
      id="F_b6ec1366-44d2-4893-bae8-fe76cbf546e6"
      unitRef="U_shares">411815</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_982e832a-cdf3-4671-8548-8f56b1f3f254"
      decimals="INF"
      id="F_dd0b43ea-6fd5-4dd8-a784-90c17d6d8be0"
      unitRef="U_shares">8070027</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_98679350-4c2b-4d25-9968-d21e18f72506"
      decimals="INF"
      id="F_1f9ff97a-7997-4425-940f-3a3f35b43799"
      unitRef="U_shares">5489573</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_98130704-057d-4280-9bc9-5ebe7b7bf561"
      decimals="INF"
      id="F_1793b359-e698-475f-8dd1-dec26a32778b"
      unitRef="U_shares">8070027</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_7c6c7513-7f64-4c68-bcf5-17a805d1e6fe"
      decimals="INF"
      id="F_96df45c5-b0ea-4ab1-bec5-d2e6931c37aa"
      unitRef="U_shares">6386337</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_6e00ad79-bc53-4f37-aa8a-ea9cb4e9ab24"
      decimals="INF"
      id="F_cbf82ba8-fb53-420d-8d43-b1ce8ae3fa54"
      unitRef="U_shares">3724218</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_222f24e5-787e-4d77-8748-8b551ff8243a"
      decimals="INF"
      id="F_10434e37-9303-4f77-a36d-b5e5f3880409"
      unitRef="U_shares">2415740</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:DeferredChargesPolicyTextBlock
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_a7db4365-2d02-4296-a318-c891e50598f3">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Deferred Offering Costs&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;The Company capitalizes certain legal, accounting and other third-party fees that are directly associated with equity financings as deferred offering costs until such financings are consummated. After consummation of the equity financing, these costs are recorded as a reduction of the proceeds from the offering, either as a reduction of the carrying value of preferred stock or in stockholders&#x2019; equity (deficit) as a reduction of additional capital generated as a result of the offering. Should the equity financing be abandoned, the deferred offering costs would be expensed immediately as a charge to operating expenses in the statement of operations and comprehensive loss. The Company had &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; deferred offering costs recorded as of December 31, 2024 or December 31, 2023.&lt;/span&gt;&lt;/p&gt;</us-gaap:DeferredChargesPolicyTextBlock>
    <us-gaap:DeferredCostsCurrentAndNoncurrent
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="INF"
      id="F_d15a925d-9c6e-47e2-800f-f133efad6ff9"
      unitRef="U_USD">0</us-gaap:DeferredCostsCurrentAndNoncurrent>
    <us-gaap:DeferredCostsCurrentAndNoncurrent
      contextRef="C_28144b67-7dfd-494d-8133-75abcc735058"
      decimals="INF"
      id="F_1275f940-de14-4dc3-864f-44597632ffc4"
      unitRef="U_USD">0</us-gaap:DeferredCostsCurrentAndNoncurrent>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_6e919e10-b39a-40b6-9deb-350bf5acf88b">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Research and Development&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred to discover, research, and develop drug candidates, including personnel expenses, allocated facility-related and depreciation expenses, and third-party license fees. Costs incurred to obtain technology licenses are charged immediately to research and development expense if the technology licensed has not reached technological feasibility and has no alternative future use.&lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <lxeo:GeneralAndAdministrativeExpensesPolicyPolicyTextBlock
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_196a168a-718c-492b-af10-27d94d2df755">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;General and Administrative&#x2014;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;General and administrative expenses consist primarily of the cost of employees to engage in corporate functions, such as finance and accounting, information technology, human resources, and legal and executive management. General and administrative expenses also include rent occupancy costs, office expenses, depreciation and amortization, other general overhead costs, insurance premiums, professional service fees, and costs related to regulatory and litigation matters.&lt;/span&gt;&lt;/p&gt;</lxeo:GeneralAndAdministrativeExpensesPolicyPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_f16239d9-394b-4109-9a07-0881b76dad71">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock Based Compensation Expense&#x2014;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company accounts for stock-based payment awards granted to employees and non-employees, as well as shares issued to its employees under the Company's 2023 Employee Stock Purchase Plan (the "2023 ESPP"), as stock-based compensation expense at fair value. The Company issues stock-based awards to employees and non-employees in the form of stock options and also issues stock-based awards to employees in the form of restricted stock units (&#x201c;RSUs&#x201d;). The measurement date for employee stock option and RSU awards is the date of grant, and stock-based compensation costs are recognized as expense over the employees&#x2019; requisite service period, which is the vesting period, on an accelerated basis. The measurement date for non-employee awards is the date of grant without changes in the fair value of the award. The measurement date for shares issued under the 2023 ESPP is the first date of each employee stock purchase plan offering period, and stock-based compensation costs are recognized as expense over the offering period on a straight-line basis. Stock-based compensation costs for non-employees are recognized as expense over the vesting period on an accelerated basis. Stock-based compensation expense is classified in the accompanying statement of operations based on the function to which the related services are provided. As the Company is permitted to repurchase shares legally issued for unvested stock options exercised at their exercise price under the 2021 Plan, (i) cash received for unvested stock options exercised under the 2021 Plan is recorded as a deposit liability as a reclassification from additional paid-in capital in the Company&#x2019;s balance sheet, which is relieved to additional paid-in capital as such awards vest, (ii) stock based compensation expense is recognized over the requisite service period for each such award, and (iii) the amount and number of shares of common stock outstanding in the Company&#x2019;s balance sheet and statement of convertible preferred stock and stockholders&#x2019; equity (deficit) are reduced until such awards vest. Forfeitures are recorded as they occur.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The fair value of each stock option grant and shares issued under the 2023 ESPP are estimated on the date of grant or on the first date of each employee stock purchase plan offering period, respectively, using the Black-Scholes option-pricing model, while the fair value of each RSU granted is equal to the closing price of the Company's common stock on the date of the grant. Prior to its IPO on November 3, 2023, the Company was a private company and lacked company-specific historical and implied volatility information for stock options granted. Therefore, the Company estimated its expected stock volatility entirely based on the historical volatility of a publicly traded set of peer companies for stock options granted prior to its IPO, and estimates its expected stock price volatility primarily based on the historical volatility of a publicly traded set of peer companies for stock options granted since its IPO, each for a period equal to the expected life of the stock options granted, and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. The expected term of the Company&#x2019;s stock options granted has been determined utilizing the &#x201c;simplified&#x201d; method for awards that qualify as &#x201c;plain-vanilla&#x201d; options and expects to continue to do so until such time as it has adequate historical data regarding the expected term of its own stock options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The expected dividend yield is zero as the Company has never paid cash dividends on its common stock and does not expect to pay any cash dividends in the foreseeable future.&lt;/span&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_20006a9e-7b5c-458e-a606-064a289abae4">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;Prior to November 20, 2020, the Company was an LLC entity and elected to be treated under the Partnership provisions of the Internal Revenue Code. Accordingly, the LLC entity was not viewed as a tax-paying entity in any jurisdiction and all income and deductions of the LLC entity flowed through to the individual members and therefore no income taxes were recorded by the Company. On November 20, 2020, the Company converted to a C Corporation.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company accounts for income taxes under the asset and liability method pursuant to ASC Topic 740, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Taxes &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;("ASC 740"). Under this method, the Company recognizes deferred tax assets and liabilities for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recorded for deferred tax assets if it is more likely than not that some portion or all of the deferred tax assets will not be realized based on all available positive and negative evidence. Under the Tax Cuts and Jobs Act of 2017, the Company is required to capitalize, and subsequently amortize, research and development expenses over five years for research activities conducted in the U.S. and over fifteen years for research activities conducted outside of the U.S commencing in 2022. The capitalization of research and development expenses during the year resulted in a decrease to the Company's operating loss generation during the years ended December 31, 2024 and December 31, 2023 as compared to prior periods (see Note 11). As of December 31, 2024 and December 31, 2023, the Company continues to maintain a full valuation allowance against its deferred tax assets.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company recognizes a tax benefit only if it is more likely than not the tax position will be sustained on examination by the local taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such positions are then measured based on the largest benefit greater than 50% likelihood of being realized upon settlement with the related tax authority. The changes in recognition or measurement are reflected in the period in which the change in judgment occurs. As of December 31, 2024 and December 31, 2023, the Company has &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t identified any uncertain tax positions.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company records interest and penalties related to uncertain tax positions in the provision for income taxes.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="INF"
      id="F_107c753c-16cd-40fe-b097-67d0298843a9"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_28144b67-7dfd-494d-8133-75abcc735058"
      decimals="INF"
      id="F_77892856-cefc-430b-9696-ebe34582eb13"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_24afb23b-e7f9-4c67-a91b-be61083bde99">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Fair Value Measurements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The three levels of inputs that may be used to measure fair value are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;Inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;Inputs are unobservable inputs for the asset or liability.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_3b52618b-72cb-4a2a-9f08-868beb746861">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Concentrations of Credit Risk&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, cash equivalents, restricted cash, and investments. The Company&#x2019;s cash and restricted cash balances exceed Federal Deposit Insurance Corporation insurance limits. The Company&#x2019;s cash equivalents consist of investments in a U.S. government money market fund, and the Company's investments primarily consist of U.S. Treasury securities. The Company&#x2019;s cash, cash equivalents, restricted cash, and investments are held with large financial institutions that management believes to be of high credit quality. To date, the Company has &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t recognized any losses caused by uninsured balances.&lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <lxeo:LossRecognizedFromUninsuredBalances
      contextRef="C_8d26cf86-cfdb-467b-8eab-522b18243eda"
      decimals="0"
      id="F_3b8d32d1-2091-4245-9671-4e144befc30f"
      unitRef="U_USD">0</lxeo:LossRecognizedFromUninsuredBalances>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_9bd25b73-9a13-4394-a5cc-065e8069e281">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Segment Information&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;The Company manages its operations as a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_3797e8b8-b7a6-4ad2-8b98-c0c8d90f246c;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;single&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; segment for the purposes of assessing performance and allocating resources. The Company is focused on preclinical and clinical stage gene therapies, and specifically on hereditary and acquired diseases of high unmet need. The Company&#x2019;s Chief Operating Decision Maker ("CODM") is its Chief Executive Officer ("CEO") and its senior leadership team. The CODM reviews the Company&#x2019;s financial information on an aggregated basis for purposes of assessing performance and allocating resources. All assets are held in the United States. The Company has not earned any product revenue through December 31, 2024.&lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_e9f456a2-1309-4d3f-8362-bc858c3d148c">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property and Equipment&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization are recognized using the straight-line method over the estimated useful life of each asset. Such costs are periodically reviewed for recoverability when impairment indicators are present. Such indicators include, among other factors, unused capacity, market value declines, and obsolescence of technology. Recorded values of asset groups of equipment that are not expected to be recovered through undiscounted future net cash flows are written down to current fair value, which generally is determined from estimated discounted future net cash flows (assets held for use) or net realizable value (assets held for sale).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Costs for capital assets not yet placed into service are capitalized as construction-in-progress and depreciated once placed into service. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation and amortization are removed from the accounts and any resulting gain or loss is included in loss from operations. Expenditures for repairs and maintenance that do not improve or extend the life of the respective assets are charged to expense in the period incurred. See Note 5 for information regarding the Company&#x2019;s capitalized operating and finance lease right-of-use assets.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following is the summary of property and equipment and related accumulated depreciation as of December 31, 2024, and December 31, 2023 (years not stated in thousands):&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:58.884%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.421%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:13.085%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.421%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:9.884%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.421%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:9.884%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Useful Life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Internal use software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3 &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5 &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;386&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;380&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Lab equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7 &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;844&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;514&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7 &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;272&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;247&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,502&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,437&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;474&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;381&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,056&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_c82f6d39-f798-4c10-a825-1845407ad04e">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following is the summary of property and equipment and related accumulated depreciation as of December 31, 2024, and December 31, 2023 (years not stated in thousands):&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:58.884%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.421%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:13.085%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.421%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:9.884%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.421%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:9.884%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Useful Life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Internal use software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3 &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5 &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;386&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;380&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Lab equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7 &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;844&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;514&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7 &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;272&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;247&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,502&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,437&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;474&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;381&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,056&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_7d2537f3-c638-4060-a3bc-90ab8b609181"
      id="F_190c6e8b-a80c-4c48-b7f5-9a1cf0b07235">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_7d2537f3-c638-4060-a3bc-90ab8b609181"
      decimals="-3"
      id="F_f22c46ff-017c-4ac9-a184-c719d349c6c7"
      unitRef="U_USD">0</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_e226ab34-462b-4baf-bdb6-41d1da52235b"
      decimals="-3"
      id="F_71d9a6f1-a055-47d0-9d13-df2bf7ba0880"
      unitRef="U_USD">296000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_181d6e2d-a650-47fe-a4ba-e4e8ee97c169"
      id="F_d6df4c2e-6825-4273-bbd9-f8e379e3dec5">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_181d6e2d-a650-47fe-a4ba-e4e8ee97c169"
      decimals="-3"
      id="F_dac06f1b-d823-4855-b8e4-cd7b0038a80d"
      unitRef="U_USD">386000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_41123b72-f984-46ee-9547-e92bc56bb833"
      decimals="-3"
      id="F_fb900f26-51a9-4c36-a2aa-ec470562099d"
      unitRef="U_USD">380000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_c25f5aa6-70c3-4c5e-b41f-0a034c1996d8"
      id="F_2b47fc44-1c6e-4e9b-b3e4-1db79cc78725">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_c25f5aa6-70c3-4c5e-b41f-0a034c1996d8"
      decimals="-3"
      id="F_941f9949-6750-4070-a659-4d058dacbb43"
      unitRef="U_USD">844000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_ea417d17-7d7e-449f-9280-8a0a3bc657d1"
      decimals="-3"
      id="F_f5d16bd9-ec76-4d77-a247-b298a9884d4e"
      unitRef="U_USD">514000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_00b1026d-c1b5-4b98-bee1-f1aa2360eb94"
      id="F_33f33880-b5d6-41bc-8594-7d948c3c4245">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_00b1026d-c1b5-4b98-bee1-f1aa2360eb94"
      decimals="-3"
      id="F_6922291f-129b-46b8-a773-349a8751bd54"
      unitRef="U_USD">272000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_a9ce9707-98f9-43cc-9660-650bbf29c98a"
      decimals="-3"
      id="F_96cf09f2-c852-4073-8f70-6862731ed108"
      unitRef="U_USD">247000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="-3"
      id="F_b0350604-8696-414f-94f1-69fbe543032a"
      unitRef="U_USD">1502000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_28144b67-7dfd-494d-8133-75abcc735058"
      decimals="-3"
      id="F_dfabf5f8-4fdd-4ba8-b0fc-16ce23727751"
      unitRef="U_USD">1437000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="-3"
      id="F_873383da-c3ea-440b-80b5-e39759ac4f9a"
      unitRef="U_USD">474000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_28144b67-7dfd-494d-8133-75abcc735058"
      decimals="-3"
      id="F_b6d7c7cc-6b2b-493e-82ef-b0b60e9ed704"
      unitRef="U_USD">381000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="-3"
      id="F_52e627c0-cfaf-4c6e-881a-3f39b39e1222"
      unitRef="U_USD">1028000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_28144b67-7dfd-494d-8133-75abcc735058"
      decimals="-3"
      id="F_93d9d69b-010c-41f4-b16d-322d9e157175"
      unitRef="U_USD">1056000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_0adc84c5-141d-4eac-8505-52a34478923e">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;In accordance with ASC Topic 842, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Leases &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;("ASC 842"), the Company determines if an arrangement is or contains a lease at inception. A contract is or contains a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. The Company classifies leases at the lease commencement date as operating or finance leases and records a right-of-use asset and a lease liability on the balance sheet for all leases with an initial lease term of greater than 12 months. Leases with an initial term of 12 months or less are not recorded in the balance sheet, but payments are recognized as expense on a straight-line basis over the lease term. The Company has elected not to recognize leases with terms of 12 months or less.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A lease qualifies as a finance lease if any of the following criteria are met at the inception of the lease: (i) there is a transfer of ownership of the leased asset to the Company by the end of the lease term, (ii) the Company holds an option to purchase the leased asset that it is reasonably certain to exercise, (iii) the lease term is for a major part of the remaining economic life of the leased asset, (iv) the present value of the sum of lease payments equals or exceeds substantially all of the fair value of the leased asset, or (v) the nature of the leased asset is specialized to the point that it is expected to provide the lessor no alternative use at the end of the lease term. All other leases are recorded as operating leases.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company enters into contracts that contain both lease and non-lease components. Non-lease components may include maintenance, utilities, and other operating costs. The Company combines the lease and non-lease components of fixed costs in its lease arrangements as a single lease component. Variable costs, such as utilities or maintenance costs, are not included in the measurement of right-of-use assets and lease liabilities but rather are expensed when the event determining the amount of variable consideration to be paid occurs.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Operating lease right-of-use assets and lease liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term using the discount rate implicit in the lease. If the implicit rate is not readily determinable, the Company utilizes an estimate of its incremental borrowing rate based upon the available information at the operating lease commencement date. Operating lease right-of-use assets are further adjusted for prepaid or accrued lease payments. Operating lease payments are expensed using the straight-line method as an operating expense over the lease term. The Company&#x2019;s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Finance lease right-of-use assets and lease liabilities are recognized upon receipt of the assets based on their fair values and are amortized to depreciation expense using the straight-line method over the estimated useful lives of the related assets. Finance lease liability payments are bifurcated into (i) a portion that is recorded as interest expense and (ii) a portion that reduces the finance liability associated with the lease, according to the interest rates implicit in the leases.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Certain of the Company&#x2019;s leases include options to extend or terminate the lease. The amounts determined for the Company&#x2019;s right-of-use assets and lease liabilities generally do not assume that renewal options or early-termination provisions, if any, are exercised, unless it is reasonably certain that the Company will exercise such options.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_c93cf723-5cca-44b0-86ba-0ef99785d98e">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Recent Accounting Pronouncements Adopted&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;In November 2023, the FASB issued ASU No. 2023-07, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Segment Reporting - Improving Reportable Segment Disclosures&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (Topic 280) ("ASU 2023-07"). &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_73289f60-fe2f-4884-94cc-6b3d31ad5380;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ASU 2023-07&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; requires disclosures to include significant segment expenses that are regularly provided to the CODM, a description of other segment items by reportable segment, and any additional measures of a segment's profit or loss used by the CODM when deciding how to allocate resources. ASU 2023-07 also requires all annual disclosures currently required by Topic 280 to be included in interim periods. This update is effective for fiscal years beginning after December 15, 2023, and is to be applied retrospectively to all periods presented in the financial statements. The Company's &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;adoption&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; of ASU 2023-07 resulted in a new footnote disclosure for segment reporting.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Recent Accounting Pronouncements Not Yet Adopted&#x2014;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In December 2023, the FASB issued ASU No. 2023-09, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (Topic 740) ("ASU No. 2023-09"). ASU No. 2023-09 requires disaggregation of the effective tax rate reconciliation into standard categories, enhances disclosure of income taxes paid, and modifies other income tax-related disclosures. ASU No. 2023-09 became effective for the Company on January 1, 2025. The adoption of this guidance will not have a material impact on the Company's financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2024, the FASB issued ASU No. 2024-03, I&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;ncome Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (Subtopic 220-40) ("ASU No. 2024-03"). ASU No. 2024-03 requires disclosure, in the notes to financial statements, of specified information about certain costs and expenses. ASU No. 2024-03 will be effective for the Company starting in annual periods in 2027, with early adoption permitted. The Company is currently assessing the impact of adopting this guidance on its financial statements.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      id="F_981b3ae7-f300-468e-b441-94964a43c71c">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_df15aa06-fcc5-4c7d-b3d0-ed445c3392a4">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;3. Fair Value Measurements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s cash equivalents consist of investments in a U.S. government money market fund stated at carrying value, which approximates fair value and is based on quoted prices in active markets for identical securities. Cash is stated at carrying value, which approximates fair value due to its short-term nature. The Company classifies its investments, primarily in U.S. Treasury securities as Level 2 assets as these assets are not traded in an active market and have been valued through a third-party pricing service based on quoted prices for similar assets. The carrying values of the Company&#x2019;s prepaid expenses, other current assets, accounts payable and accrued expenses approximate their fair values due to their short-term nature.&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table presents information about the Company&#x2019;s financial assets, financial liabilities, and investments measured at fair value on a recurring basis and indicates the level of the fair value hierarchy utilized to determine such fair values:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:32.32%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.78%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.14%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.78%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.14%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.78%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.14%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.78%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.14%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents (money market)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,636&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,636&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;86,504&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;86,504&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Investments:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,012&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,012&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,636&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;93,516&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;111,152&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:32.32%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.78%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.14%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.78%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.14%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.78%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.14%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.78%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.14%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2023:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents (money market)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;102,484&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;102,484&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Investments:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;102,484&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;102,484&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Investments, which are classified as available-for-sale securities, consisted of the following as of December 31, 2024 and December 31, 2023:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:23.745%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.763%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.763%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.763%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.763%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized Cost Basis&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Available-for-sale securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;93,619&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;103&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;93,516&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;93,619&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;103&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;93,516&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2023:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized Cost Basis&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Available-for-sale securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;All investments classified as available-for-sale securities held as of December 31, 2024 and December 31, 2023 had contractual maturities of less than two years. There have been no material realized gains or losses on investments classified as available-for-sale securities for the periods presented.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Aggregate fair values of investments classified as available-for-sale securities with unrealized losses and gains were as follows as of December 31, 2024 and December 31, 2023:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:38.36%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:26.7%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:26.7%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Available-for-sale securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Due within one year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;86,504&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Due after one year through five years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,012&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;93,516&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table sets forth a roll forward of changes in the fair value of financial liabilities, gross of unamortized discount, classified as Level 3 in the fair value hierarchy:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:77.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:53.567%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:4.73%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:39.705%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Convertible&lt;br/&gt;SAFE Note,&lt;br/&gt;gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Beginning balance at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Convertible SAFE Note issuance at August 24, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_995b2506-e09a-426b-8450-5340620be7de;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in estimated fair value since issuance&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;530&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Conversion of SAFE Note into common stock in connection with initial public offering&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,530&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Ending balance at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The valuation models used to estimate the fair value of the Company&#x2019;s convertible SAFE Note considered the estimated probabilities of each of qualified equity financing, public offering, and change of control events, together with corresponding estimated periods of time from each valuation date until the achievements of each such event. Future values were converted to present value using a discount rate appropriate for probability-adjusted cash flows. &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The ranges of the significant unobservable inputs used in the valuation model to estimate the fair value of the Company&#x2019;s convertible SAFE Note that was categorized within Level 3 of the fair value hierarchy as of August 24, 2023 (issuance) until November 2, 2023 (settlement) were as follows (not stated in thousands):&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:77.86%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.92%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:20.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Probability of meeting qualified equity financing event&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Probability of meeting public offering event&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;75.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;85.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Probability of meeting change in control event&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Time until qualified equity financing event (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.17&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.27&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Time until public offering event (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.08&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.19&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Time until change in control event (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.50&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.60&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In connection with the closing of the Company&#x2019;s IPO on November 7, 2023, the underwriters of the IPO were granted an option for a period of 30 days to purchase up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,363,636&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; additional shares from the Company at the public offering price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share less the underwriting discount, of which &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,048,746&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares were exercised (see Note 8). &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The total grant date fair value of this option of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, or $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.85&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share, was recorded as an offset to additional paid-in capital and was estimated using a Black-Scholes model incorporating the following assumptions (not stated in thousands):&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:77.86%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.92%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:18.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercise price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted average risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.53&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.08&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;65.88&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_be1b0fa5-123e-4c74-b57f-1aaaee3ab7a7">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table presents information about the Company&#x2019;s financial assets, financial liabilities, and investments measured at fair value on a recurring basis and indicates the level of the fair value hierarchy utilized to determine such fair values:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:32.32%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.78%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.14%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.78%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.14%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.78%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.14%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.78%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.14%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents (money market)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,636&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,636&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;86,504&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;86,504&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Investments:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,012&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,012&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,636&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;93,516&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;111,152&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:32.32%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.78%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.14%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.78%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.14%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.78%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.14%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.78%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.14%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2023:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents (money market)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;102,484&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;102,484&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Investments:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;102,484&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;102,484&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_b8e13f0d-e121-406d-b1a0-0b776194fbaa"
      decimals="-3"
      id="F_0c6be6ca-fe8a-4988-b85e-10949e233537"
      unitRef="U_USD">17636000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_36d77a3a-fda6-41cd-8ab5-65f7367582d3"
      decimals="-3"
      id="F_b46b969c-f24d-4904-8d18-9f2bf28b356d"
      unitRef="U_USD">17636000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_2409277c-21f9-4adb-af62-46fdf50d9ce6"
      decimals="-3"
      id="F_41a76624-f54e-4ed9-9b86-c8520e5362ca"
      unitRef="U_USD">86504000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_c96098bc-a151-4b74-aeae-a01a9db7efbb"
      decimals="-3"
      id="F_cb27bb2a-4205-4f1a-8f39-3b6084c16032"
      unitRef="U_USD">86504000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_2409277c-21f9-4adb-af62-46fdf50d9ce6"
      decimals="-3"
      id="F_3f827fdf-6b22-430c-82b7-de1de6407a27"
      unitRef="U_USD">7012000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_c96098bc-a151-4b74-aeae-a01a9db7efbb"
      decimals="-3"
      id="F_ca0c0aa8-cf9d-4bb1-b776-9726bb2fa1f5"
      unitRef="U_USD">7012000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:FairValueNetAssetLiability
      contextRef="C_2e7387e7-73ad-47fb-a0de-5ceccb4a2a0f"
      decimals="-3"
      id="F_407980b4-0016-4f5d-9c79-67b88b29e86c"
      unitRef="U_USD">17636000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="C_fc82fec8-4701-4ddd-a632-831d62d00aa5"
      decimals="-3"
      id="F_e6f4ca44-7943-42be-a00a-095d37970529"
      unitRef="U_USD">93516000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="C_6ef7a0b8-9327-4be8-b39d-869ac79fb879"
      decimals="-3"
      id="F_f06b3d04-b279-41e0-b4de-a28fdf1aec58"
      unitRef="U_USD">111152000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_3eb26141-df5c-4391-985c-b5a244216bc1"
      decimals="-3"
      id="F_4ea09a13-d06e-45f7-a7fd-943d17f0bb25"
      unitRef="U_USD">102484000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_a20a05b8-9d12-490a-93f2-114ea8e35fca"
      decimals="-3"
      id="F_1ec5fce6-0f30-4d54-be4d-fceb899cca37"
      unitRef="U_USD">102484000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:FairValueNetAssetLiability
      contextRef="C_3f598951-fd6b-41a3-b5a9-de413e56d5cb"
      decimals="-3"
      id="F_a7925312-7c84-4ecb-9364-277271db83cd"
      unitRef="U_USD">102484000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="C_57207e39-81bb-4c7e-8c54-bf6e68c2462d"
      decimals="-3"
      id="F_d1b38864-aab4-4c96-8b6e-4db24afbee0b"
      unitRef="U_USD">102484000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_28715e2a-7f11-47b4-93a9-afcbfe67d7c4">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Investments, which are classified as available-for-sale securities, consisted of the following as of December 31, 2024 and December 31, 2023:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:23.745%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.763%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.763%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.763%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.763%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized Cost Basis&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Available-for-sale securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;93,619&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;103&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;93,516&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;93,619&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;103&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;93,516&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2023:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized Cost Basis&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Available-for-sale securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_b8320cf7-1637-4a5a-b0b7-b67e5100600a"
      decimals="-3"
      id="F_a487dc7a-ca6e-4457-8ba5-d81ad237e189"
      unitRef="U_USD">93619000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_b8320cf7-1637-4a5a-b0b7-b67e5100600a"
      decimals="-3"
      id="F_8b4aa70c-af86-43dd-9f4b-f5502efc2e73"
      unitRef="U_USD">103000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_b8320cf7-1637-4a5a-b0b7-b67e5100600a"
      decimals="-3"
      id="F_8d483756-0fa0-4067-a12f-f358180702dc"
      unitRef="U_USD">93516000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="-3"
      id="F_601b07f3-ffcf-46f5-b7f6-dd7dc77499a5"
      unitRef="U_USD">93619000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="-3"
      id="F_0239a1e9-d347-48cd-9e89-032e5ee36f83"
      unitRef="U_USD">103000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="-3"
      id="F_26458d95-4a3e-4f7b-bb28-bfaceceb2578"
      unitRef="U_USD">93516000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_2a40baa8-fe06-429f-9646-40ed21ca047d">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Aggregate fair values of investments classified as available-for-sale securities with unrealized losses and gains were as follows as of December 31, 2024 and December 31, 2023:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:38.36%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:26.7%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:26.7%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Available-for-sale securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Due within one year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;86,504&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Due after one year through five years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,012&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;93,516&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="-3"
      id="F_e5d878a0-9a00-423a-83fb-0248a0d1d99d"
      unitRef="U_USD">86504000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="-3"
      id="F_bf9e2d19-464f-4f89-9245-119e4ba5448a"
      unitRef="U_USD">7012000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="-3"
      id="F_1cb9b75c-7454-41b0-87e1-acb378682707"
      unitRef="U_USD">93516000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_8c1b0d59-f757-4466-9145-6c6c01121e4e">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table sets forth a roll forward of changes in the fair value of financial liabilities, gross of unamortized discount, classified as Level 3 in the fair value hierarchy:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:77.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:53.567%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:4.73%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:39.705%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Convertible&lt;br/&gt;SAFE Note,&lt;br/&gt;gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Beginning balance at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Convertible SAFE Note issuance at August 24, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_995b2506-e09a-426b-8450-5340620be7de;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in estimated fair value since issuance&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;530&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Conversion of SAFE Note into common stock in connection with initial public offering&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,530&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Ending balance at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <lxeo:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConvertibleNoteIssuance
      contextRef="C_ff8a14ec-2414-4dce-963c-ac378e45b5e3"
      decimals="-3"
      id="F_6b84ecf6-7871-44d9-b80a-20c6fdfba158"
      unitRef="U_USD">4000000</lxeo:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConvertibleNoteIssuance>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="C_ff8a14ec-2414-4dce-963c-ac378e45b5e3"
      decimals="-3"
      id="F_40b2dcce-b05a-47fa-a363-e2c3754235b3"
      unitRef="U_USD">530000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <lxeo:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversionOfNotesIntoCommonStock
      contextRef="C_ff8a14ec-2414-4dce-963c-ac378e45b5e3"
      decimals="-3"
      id="F_5a36fa4b-5687-4a8b-971b-d58aa95772ae"
      unitRef="U_USD">4530000</lxeo:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversionOfNotesIntoCommonStock>
    <lxeo:ScheduleOfSignificantUnobservableInputsUsedInValuationModelToEstimateFairValueTableTextBlock
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_1d3d22e4-ed62-41a3-95c3-a53335a84607">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The ranges of the significant unobservable inputs used in the valuation model to estimate the fair value of the Company&#x2019;s convertible SAFE Note that was categorized within Level 3 of the fair value hierarchy as of August 24, 2023 (issuance) until November 2, 2023 (settlement) were as follows (not stated in thousands):&lt;/span&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:77.86%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.92%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:20.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Probability of meeting qualified equity financing event&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Probability of meeting public offering event&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;75.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;85.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Probability of meeting change in control event&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Time until qualified equity financing event (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.17&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.27&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Time until public offering event (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.08&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.19&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Time until change in control event (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.50&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.60&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</lxeo:ScheduleOfSignificantUnobservableInputsUsedInValuationModelToEstimateFairValueTableTextBlock>
    <lxeo:FairValueProbabilityOfMeetingQualifiedEquityFinancingEvent
      contextRef="C_3579d9a8-e7bf-4c6d-ac06-1c8021fed3eb"
      decimals="3"
      id="F_a4beffc4-e0a8-484a-9914-4caa743c3c3e"
      unitRef="U_pure">0.10</lxeo:FairValueProbabilityOfMeetingQualifiedEquityFinancingEvent>
    <lxeo:FairValueProbabilityOfMeetingQualifiedEquityFinancingEvent
      contextRef="C_95dc5b03-a8d3-46ba-9c0f-f641f5341cf5"
      decimals="3"
      id="F_a0fcd1eb-0ce5-4422-8f6e-f522640c3890"
      unitRef="U_pure">0.20</lxeo:FairValueProbabilityOfMeetingQualifiedEquityFinancingEvent>
    <lxeo:FairValueProbabilityOfMeetingPublicOfferingEvent
      contextRef="C_3579d9a8-e7bf-4c6d-ac06-1c8021fed3eb"
      decimals="3"
      id="F_6beae816-1b08-44e0-9610-33b6d8ff8b15"
      unitRef="U_pure">0.75</lxeo:FairValueProbabilityOfMeetingPublicOfferingEvent>
    <lxeo:FairValueProbabilityOfMeetingPublicOfferingEvent
      contextRef="C_95dc5b03-a8d3-46ba-9c0f-f641f5341cf5"
      decimals="3"
      id="F_0ff9e128-47a0-4380-8261-b827f0d0cc83"
      unitRef="U_pure">0.85</lxeo:FairValueProbabilityOfMeetingPublicOfferingEvent>
    <lxeo:FairValueProbabilityOfMeetingChangeInControlEvent
      contextRef="C_5d7d637d-2f7f-4be3-acba-58d6df49a889"
      decimals="2"
      id="F_bb7becdf-8b4c-410f-8f5d-fdb7f7f9b872"
      unitRef="U_pure">0.05</lxeo:FairValueProbabilityOfMeetingChangeInControlEvent>
    <lxeo:FairValueTimeUntilQualifiedEquityFinancingEvent
      contextRef="C_3579d9a8-e7bf-4c6d-ac06-1c8021fed3eb"
      id="F_b4fccadb-2146-4447-a662-be938ae79f9f">P0Y2M1D</lxeo:FairValueTimeUntilQualifiedEquityFinancingEvent>
    <lxeo:FairValueTimeUntilQualifiedEquityFinancingEvent
      contextRef="C_95dc5b03-a8d3-46ba-9c0f-f641f5341cf5"
      id="F_a5608f1c-ff36-4f51-b35c-d57ebefbe403">P0Y3M7D</lxeo:FairValueTimeUntilQualifiedEquityFinancingEvent>
    <lxeo:FairValueTimeUntilPublicOfferingEvent
      contextRef="C_3579d9a8-e7bf-4c6d-ac06-1c8021fed3eb"
      id="F_27a502d3-f52d-4c75-879b-c183527a7c7e">P0Y29D</lxeo:FairValueTimeUntilPublicOfferingEvent>
    <lxeo:FairValueTimeUntilPublicOfferingEvent
      contextRef="C_95dc5b03-a8d3-46ba-9c0f-f641f5341cf5"
      id="F_008a2b38-01db-4513-86c8-168f45f33e70">P0Y2M8D</lxeo:FairValueTimeUntilPublicOfferingEvent>
    <lxeo:FairValueTimeUntilChangeInControlEvent
      contextRef="C_3579d9a8-e7bf-4c6d-ac06-1c8021fed3eb"
      id="F_8fd1a4f9-2a18-4c86-b64a-3f68f2d9d436">P0Y6M</lxeo:FairValueTimeUntilChangeInControlEvent>
    <lxeo:FairValueTimeUntilChangeInControlEvent
      contextRef="C_95dc5b03-a8d3-46ba-9c0f-f641f5341cf5"
      id="F_055749cd-66d8-4e3d-97e7-ea47933005f9">P0Y7M6D</lxeo:FairValueTimeUntilChangeInControlEvent>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_a5546360-23ec-45e5-ba9d-ee679b197414"
      decimals="INF"
      id="F_303224c0-cdf9-4d34-8024-1dd25f05d6fa"
      unitRef="U_shares">1363636</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_74419331-e290-447a-86d3-c0fb520fc7bc"
      decimals="INF"
      id="F_0b37db10-0918-4d4f-831a-73a8e98f3691"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">11</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_09b75305-e3e0-435b-b2a6-50f4050afab2"
      decimals="INF"
      id="F_d837c73a-7d3d-41c9-bf75-b25bba3e89d7"
      unitRef="U_shares">1048746</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="C_99fa4607-5a6b-4035-bcda-41e63ec19b9d"
      id="F_e0e68581-61dc-47fc-8674-60dca9d89dcc">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The total grant date fair value of this option of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, or $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.85&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share, was recorded as an offset to additional paid-in capital and was estimated using a Black-Scholes model incorporating the following assumptions (not stated in thousands):&lt;/span&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:77.86%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.92%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:18.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercise price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted average risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.53&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.08&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;65.88&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <lxeo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue
      contextRef="C_47a049b7-455a-448b-84ea-5e98846bad51"
      decimals="-5"
      id="F_e6b39a72-5cf0-4de3-b61e-c0cadb4b9ac7"
      unitRef="U_USD">1200000</lxeo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_44dd3996-14be-4820-b581-6281744e49e6"
      decimals="2"
      id="F_fa3dc1e9-05de-41e9-a399-9a24fd09c7d0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="C_4591c456-caa6-4a3e-acb5-b25d3fb9ee55"
      decimals="0"
      id="F_a5a92941-c788-4617-b56d-a558eba68935"
      unitRef="U_USD">1100</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="C_202838fb-c603-44c3-ac57-cbb400921fd7"
      decimals="2"
      id="F_d3867ff0-f184-4dfc-877b-79be306d55c6"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_bba6b31e-5617-48b1-9ad1-7cf7f1501cf3"
      decimals="4"
      id="F_9be41146-0951-4325-89a3-e3e8b51f4efb"
      unitRef="U_pure">0.0553</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_b7af60cb-baf3-4dbb-af94-8473e08ee442"
      id="F_1d7eee1b-dff7-4aa6-89c7-b8b7bcc0410e">P0Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_1c8074fe-d719-4d7e-8aa3-6e8936dddc3f"
      decimals="4"
      id="F_3232e8aa-44ce-4645-9785-6ff88933975f"
      unitRef="U_pure">0.6588</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_4a2b7157-1380-497a-a4ef-750dda612b33"
      decimals="4"
      id="F_589501c1-c5e5-4fc0-87f4-ab11f76bc6ba"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_5bc4c2ab-890b-4665-8ae1-0691c0378b88">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;4. Accrued Expenses and Other Current Liabilities&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accrued expenses and other current liabilities consisted of the following&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:88.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:72.793%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.274%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.693000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.274%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.965%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,696&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,384&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued bonus expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,718&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,810&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued general and administrative expenses and other professional fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,406&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,092&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;939&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;554&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,759&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,840&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_d66c071d-c4f3-42c6-a49b-2235cc9c5681">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accrued expenses and other current liabilities consisted of the following&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:88.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:72.793%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.274%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.693000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.274%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.965%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,696&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,384&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued bonus expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,718&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,810&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued general and administrative expenses and other professional fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,406&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,092&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;939&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;554&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,759&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,840&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <lxeo:AccruedResearchAndDevelopmentExpenseCurrent
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="-3"
      id="F_0198fafb-6214-498b-866d-99341ac29344"
      unitRef="U_USD">6696000</lxeo:AccruedResearchAndDevelopmentExpenseCurrent>
    <lxeo:AccruedResearchAndDevelopmentExpenseCurrent
      contextRef="C_28144b67-7dfd-494d-8133-75abcc735058"
      decimals="-3"
      id="F_82eae3c2-6db0-4db9-b1e4-502f3f3ac8b1"
      unitRef="U_USD">6384000</lxeo:AccruedResearchAndDevelopmentExpenseCurrent>
    <us-gaap:AccruedBonusesCurrent
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="-3"
      id="F_6470db6b-f670-4e71-8bff-4815ddc49d22"
      unitRef="U_USD">3718000</us-gaap:AccruedBonusesCurrent>
    <us-gaap:AccruedBonusesCurrent
      contextRef="C_28144b67-7dfd-494d-8133-75abcc735058"
      decimals="-3"
      id="F_ec806e56-8785-4cd5-aded-b71f3dca3704"
      unitRef="U_USD">2810000</us-gaap:AccruedBonusesCurrent>
    <lxeo:AccruedGeneralAndAdministrativeExpensesAndOtherProfessionalFeesCurrent
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="-3"
      id="F_6edd41cb-2c6d-473e-b6c8-ef7d563db1e2"
      unitRef="U_USD">2406000</lxeo:AccruedGeneralAndAdministrativeExpensesAndOtherProfessionalFeesCurrent>
    <lxeo:AccruedGeneralAndAdministrativeExpensesAndOtherProfessionalFeesCurrent
      contextRef="C_28144b67-7dfd-494d-8133-75abcc735058"
      decimals="-3"
      id="F_7c9cd471-6bc2-4717-afb7-b6dae104a41d"
      unitRef="U_USD">1092000</lxeo:AccruedGeneralAndAdministrativeExpensesAndOtherProfessionalFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="-3"
      id="F_47024422-60bb-483f-95e5-e448bf77a1ef"
      unitRef="U_USD">939000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_28144b67-7dfd-494d-8133-75abcc735058"
      decimals="-3"
      id="F_853a8532-1926-40a6-ad61-4cd03ca034fd"
      unitRef="U_USD">554000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <lxeo:AccruedLiabilitiesAndOtherLiabilitiesCurrent
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="-3"
      id="F_ca1d07fb-c0c3-4e1c-a388-9e5022433d84"
      unitRef="U_USD">13759000</lxeo:AccruedLiabilitiesAndOtherLiabilitiesCurrent>
    <lxeo:AccruedLiabilitiesAndOtherLiabilitiesCurrent
      contextRef="C_28144b67-7dfd-494d-8133-75abcc735058"
      decimals="-3"
      id="F_71ddc285-be68-41e6-81bb-86e7b342c705"
      unitRef="U_USD">10840000</lxeo:AccruedLiabilitiesAndOtherLiabilitiesCurrent>
    <lxeo:LesseeOperatingAndFinancingLeasesDisclosureTextBlock
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_5a77f444-e834-4995-a369-77f78a6189d3">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;5. Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Operating Lease Right-of-Use Asset&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;January 2022&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company entered into a lease agreement for an office facility and laboratory space in New York, New York that commenced in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;April 2022&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and ends in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;July 2029&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; with an &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;additional &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;five-year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;option to extend the lease beyond July 2029 &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;at the then-prevailing effective market rental rate&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. Upon commencement of this lease, the Company recorded operating lease right-of-use assets and operating lease liabilities of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million based on the present value of payments over the lease term using an estimated incremental borrowing rate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.53&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% in accordance with the provisions of ASC 842. In connection with the Company&#x2019;s lease of office space and laboratory space, the Company provided a security deposit to the landlord in the form of a letter of credit totaling $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. The cash collateralizing the letter of credit was included in long-term restricted cash in the Company&#x2019;s balance sheets as of December 31, 2024, and December 31, 2023. This lease was classified as an operating lease in accordance with the provisions of ASC 842. The Company did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t recognize any right-of-use assets and lease liabilities associated with the potential option to renew or extend. The Company&#x2019;s operating lease agreement does not contain any significant residual value guarantees or restrictive covenants.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The remaining lease terms and payment terms as of December 31, 2024 and December 31, 2023 were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;4.6&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;5.6&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years, respectively. &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The components of this operating lease were as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11pt;font-family:Times New Roman;"&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.64%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:17.099999999999998%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:17.099999999999998%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating lease expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,147&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,147&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Variable lease expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;459&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;355&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total operating lease expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,606&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,502&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash paid for amounts included in the measurement of lease liabilities, included in operating cash flows&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,110&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,294&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:11pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table provides a reconciliation of the Company&#x2019;s remaining undiscounted contractual rent obligations due within each year ended December 31 to the operating lease liabilities recognized as of December 31, 2024:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:73.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.7%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:22.279999999999998%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Year ended December 31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Operating&lt;br/&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,152&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,206&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,261&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,318&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,372&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,309&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: present value adjustment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,772&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,537&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Included in the balance sheet:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Current portion of lease liabilities - operating&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Non-current portion of lease liabilities - operating&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,437&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,537&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Equipment Finance Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Commencing in April 2022, the Company leases certain laboratory equipment under financing arrangements accounted for as finance leases in accordance with the provisions of ASC 842 that are classified in the Company&#x2019;s balance sheet as finance lease liabilities with related right-of-use assets recorded and depreciated on a straight-line basis over the estimated useful life of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years. In connection with the Company&#x2019;s leases of laboratory equipment, the Company provided a security deposit to the lessor in the form of a letter of credit totaling $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and assigned all rights and interests in the equipment to the lessor. The cash collateralizing the letter of credit is included in long-term restricted cash in the Company&#x2019;s balance sheet as of December 31, 2024. The total gross, accumulated amortization, and net book values of equipment finance lease right-of-use assets capitalized under such finance lease arrangements at December 31, 2024 were $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively. Under the terms of the equipment finance lease agreements executed through the issuance of these financial statements, the principal balances plus interest for the equipment are to be repaid in full after &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;60&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; monthly installments following lease commencement, with lease commencement dates ranging from &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;April 1, 2022&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;April 1, 2023&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, annual imputed interest rates ranging from &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.90&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.30&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%, and monthly installment payment amounts ranging from $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The total aggregate monthly installment payment amount is $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;49,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for the Company's equipment finance lease agreements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The weighted-average remaining lease payment term, weighted-average remaining amortization term, and weighted-average effective interest rate for the Company's equipment finance lease agreements as of December 30, 2024 were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2.7&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;4.8&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years, and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.59&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%, respectively. The weighted-average remaining lease payment term, weighted-average remaining amortization term, and weighted-average effective interest rate for the Company's equipment finance lease agreements as of December 31, 2023 were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;3.7&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;5.7&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years, and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.59&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%, respectively. &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The components of the equipment finance leases were as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11pt;font-family:Times New Roman;"&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:62.34%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.860000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.94%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.860000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Reduction in the carrying amount of ROU assets, finance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;325&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;306&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Interest on finance lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;127&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;176&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total finance lease expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;452&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;482&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash paid for amounts included in the measurement of lease liabilities, included in financing cash flows&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;410&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;425&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:11pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table provides a reconciliation of the Company&#x2019;s remaining equipment finance lease obligations due within each year ending December 31 to the equipment finance lease liabilities recognized at December 31, 2024:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:77.7%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:20.299999999999997%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Year ended December 31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Equipment Finance Leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;587&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;587&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;359&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,544&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;157&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total finance lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,387&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Included in the balance sheet:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Current portion of lease liabilities - finance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;570&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Non-current portion of lease liabilities - finance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;817&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total finance lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,387&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</lxeo:LesseeOperatingAndFinancingLeasesDisclosureTextBlock>
    <lxeo:OperatingLeaseAgreementEnteredDate
      contextRef="C_754c742e-ae45-493f-9e9c-c876f6b36a1b"
      id="F_1573e534-5b72-4bf8-8dcf-e90dab0baf7b">2022-01</lxeo:OperatingLeaseAgreementEnteredDate>
    <lxeo:OperatingLeaseCommencementDate
      contextRef="C_3bc3fa7e-440b-44ad-b57d-4fc9f9165d8a"
      id="F_055cfa16-f41e-4f7a-81f6-2a76bc14f01f">2022-04</lxeo:OperatingLeaseCommencementDate>
    <lxeo:OperatingLeaseEndDate
      contextRef="C_5b737ad7-5e23-417d-9cd9-c6d69e60d8a1"
      id="F_19f0992f-1cdb-4691-b887-eb53e7321e56">2029-07</lxeo:OperatingLeaseEndDate>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="C_c6dd71d6-5140-472d-b5c8-2940a8c82dd8"
      id="F_89538aac-eb2c-43ee-89f2-d6ed42e8fb9c">additional five-year option to extend the lease beyond July 2029 at the then-prevailing effective market rental rate</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_8c6b7b14-2521-4983-80fe-50cd39b26715"
      id="F_962c68ad-534d-4100-ba30-d08379faf8b7">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="C_057f47b0-3a28-481e-917c-c1c45349ef35"
      id="F_82f51493-cfe7-4f9d-960a-1c873124a239">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_a6d4ba66-86df-4d4a-b4e0-034d42abb2dc"
      decimals="-5"
      id="F_dc250255-564b-46d7-aca8-0b30a81cf225"
      unitRef="U_USD">11600000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_a6d4ba66-86df-4d4a-b4e0-034d42abb2dc"
      decimals="-5"
      id="F_4f8a0f10-0f5c-45c7-a022-4a10e4e01ecf"
      unitRef="U_USD">11600000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="C_a6d4ba66-86df-4d4a-b4e0-034d42abb2dc"
      decimals="4"
      id="F_d6687662-39db-4e11-8580-755918b04c89"
      unitRef="U_pure">0.0853</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:SecurityDeposit
      contextRef="C_a42efdd6-1a5f-4930-9ba0-797305fcec72"
      decimals="-5"
      id="F_ea717c9b-ae36-4060-8955-2ad60d5e7e07"
      unitRef="U_USD">1200000</us-gaap:SecurityDeposit>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_8c6b7b14-2521-4983-80fe-50cd39b26715"
      decimals="INF"
      id="F_aef2c22c-25e8-411a-8e06-f895954914f1"
      unitRef="U_USD">0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_8c6b7b14-2521-4983-80fe-50cd39b26715"
      decimals="INF"
      id="F_5cbdf731-1688-47f5-b889-191fc1a4e251"
      unitRef="U_USD">0</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      id="F_9e19e77b-02e5-4421-b187-2512a62d8816">P4Y7M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <lxeo:OperatingLeaseWeightedAverageRemainingPaymentTerm
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      id="F_c06f706a-1e62-45d6-a90f-cc040a1d5be4">P4Y7M6D</lxeo:OperatingLeaseWeightedAverageRemainingPaymentTerm>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_28144b67-7dfd-494d-8133-75abcc735058"
      id="F_1ea720f1-922e-46c0-9b7d-a3109bb33e35">P5Y7M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <lxeo:OperatingLeaseWeightedAverageRemainingPaymentTerm
      contextRef="C_28144b67-7dfd-494d-8133-75abcc735058"
      id="F_8c5e47e9-5450-4f21-b811-45e7dfdc23f8">P5Y7M6D</lxeo:OperatingLeaseWeightedAverageRemainingPaymentTerm>
    <lxeo:ComponentsOfOperatingLeaseTableTextBlock
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_487abefb-62c4-4cf5-b938-e3d0d7397523">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The components of this operating lease were as follows:&lt;/span&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.64%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:17.099999999999998%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:17.099999999999998%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating lease expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,147&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,147&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Variable lease expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;459&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;355&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total operating lease expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,606&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,502&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash paid for amounts included in the measurement of lease liabilities, included in operating cash flows&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,110&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,294&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</lxeo:ComponentsOfOperatingLeaseTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      decimals="-3"
      id="F_d60d58cb-c5b9-49a0-b4eb-fe32effd2c5e"
      unitRef="U_USD">2147000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca"
      decimals="-3"
      id="F_be38c6fb-1012-48bb-aa65-8b3fcb35146b"
      unitRef="U_USD">2147000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      decimals="-3"
      id="F_4b9c9aa4-3221-4eee-b774-191d7af32cf3"
      unitRef="U_USD">459000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca"
      decimals="-3"
      id="F_72122d69-55bc-4223-a1bb-e5063c04b544"
      unitRef="U_USD">355000</us-gaap:VariableLeaseCost>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      decimals="-3"
      id="F_22cd6715-48ab-4c0c-ba13-80bb68341015"
      unitRef="U_USD">2606000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca"
      decimals="-3"
      id="F_c3dfacde-b6b2-4a11-9072-4479e083c57a"
      unitRef="U_USD">2502000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeasePayments
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      decimals="-3"
      id="F_d5fe241e-ef44-4ee4-bc4c-1c657ae04bc1"
      unitRef="U_USD">2110000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca"
      decimals="-3"
      id="F_1b3c03a8-e9c8-4c03-b81c-c0b9058dd8da"
      unitRef="U_USD">2294000</us-gaap:OperatingLeasePayments>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_fd7d7985-2638-4f72-8eaf-33ee9984829a">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table provides a reconciliation of the Company&#x2019;s remaining undiscounted contractual rent obligations due within each year ended December 31 to the operating lease liabilities recognized as of December 31, 2024:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:73.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.7%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:22.279999999999998%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Year ended December 31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Operating&lt;br/&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,152&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,206&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,261&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,318&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,372&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,309&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: present value adjustment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,772&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,537&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Included in the balance sheet:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Current portion of lease liabilities - operating&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Non-current portion of lease liabilities - operating&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,437&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,537&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="-3"
      id="F_c44af2fe-ce8b-4d8a-be15-02d640a9f1ae"
      unitRef="U_USD">2152000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="-3"
      id="F_ed99035a-a853-4b88-ba9c-dc9fddd1d5f4"
      unitRef="U_USD">2206000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="-3"
      id="F_e9ec2c35-a81a-4d70-94f6-5a66d7e366d2"
      unitRef="U_USD">2261000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="-3"
      id="F_26ee9081-3326-4da4-9ad4-2c26aa59e3d5"
      unitRef="U_USD">2318000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="-3"
      id="F_f701011d-aa3f-4449-b1d6-8ff14b265228"
      unitRef="U_USD">1372000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="-3"
      id="F_1b31bd74-26a8-4796-aac6-f4b5cf22bbc5"
      unitRef="U_USD">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="-3"
      id="F_731606be-8082-4b2f-a274-468c67bed127"
      unitRef="U_USD">10309000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="-3"
      id="F_19e9a9e0-18a6-467f-834c-6dcef3eed152"
      unitRef="U_USD">1772000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="-3"
      id="F_29c7e4a8-a11e-4e97-ba23-c333a49e0243"
      unitRef="U_USD">8537000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="-3"
      id="F_1045e883-ee9f-4e44-98ac-f8a4fe99dfcb"
      unitRef="U_USD">2100000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="-3"
      id="F_3847e248-f6b7-44eb-b811-0587add57b8e"
      unitRef="U_USD">6437000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="-3"
      id="F_b292e42d-f767-40e7-a5e4-3786eefa0da0"
      unitRef="U_USD">8537000</us-gaap:OperatingLeaseLiability>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_c25f5aa6-70c3-4c5e-b41f-0a034c1996d8"
      id="F_e9236bca-7d4d-467a-a8bf-f23f979320c1">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:SecurityDeposit
      contextRef="C_75c654f9-7566-4300-8e93-f4d56b98a5b5"
      decimals="-5"
      id="F_ae181e96-5086-4363-97e8-4ee20c8cc72e"
      unitRef="U_USD">1900000</us-gaap:SecurityDeposit>
    <us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization
      contextRef="C_c25f5aa6-70c3-4c5e-b41f-0a034c1996d8"
      decimals="-5"
      id="F_c71ab003-697a-4400-9a45-140142e0d07f"
      unitRef="U_USD">2200000</us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization
      contextRef="C_c25f5aa6-70c3-4c5e-b41f-0a034c1996d8"
      decimals="-5"
      id="F_f19b63d3-20d4-4a33-8764-f36a0f5b055a"
      unitRef="U_USD">800000</us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="C_c25f5aa6-70c3-4c5e-b41f-0a034c1996d8"
      decimals="-5"
      id="F_9594ece5-b42b-42c3-8a2b-2450b7f8be1f"
      unitRef="U_USD">1400000</us-gaap:FinanceLeaseRightOfUseAsset>
    <lxeo:NumberOfMonthlyInstallmentsLease
      contextRef="C_bc4e18d1-8708-4fa6-8c8b-10f077d3382c"
      decimals="INF"
      id="F_fdd2ae30-d71c-43f3-9f3b-cb1878fc9520"
      unitRef="U_Installment">60</lxeo:NumberOfMonthlyInstallmentsLease>
    <lxeo:LesseeFinanceLeaseCommencementDateRangeStart
      contextRef="C_3cbe0ed1-2f36-42ec-8001-032a59884f91"
      id="F_799db80f-fb82-4f33-8edb-eed883a2c60c">2022-04-01</lxeo:LesseeFinanceLeaseCommencementDateRangeStart>
    <lxeo:LesseeFinanceLeaseCommencementDateRangeEnd
      contextRef="C_a398e430-4b76-4f00-9eb3-273c39d2e6fd"
      id="F_5802a426-603e-4cfa-bdc4-596e1738138d">2023-04-01</lxeo:LesseeFinanceLeaseCommencementDateRangeEnd>
    <us-gaap:LesseeFinanceLeaseDiscountRate
      contextRef="C_93e60cc0-c98a-4905-a0ae-b6c3266b5a78"
      decimals="4"
      id="F_96a11173-5a31-492a-b8b3-bd37a6174fa9"
      unitRef="U_pure">0.079</us-gaap:LesseeFinanceLeaseDiscountRate>
    <us-gaap:LesseeFinanceLeaseDiscountRate
      contextRef="C_78220819-138e-4d2f-ae70-819bfa7f0e94"
      decimals="4"
      id="F_4447d356-c024-4a73-8637-d6845b6abca5"
      unitRef="U_pure">0.093</us-gaap:LesseeFinanceLeaseDiscountRate>
    <lxeo:FinanceLeaseMonthlyInstallmentPaymentAmounts
      contextRef="C_93e60cc0-c98a-4905-a0ae-b6c3266b5a78"
      decimals="0"
      id="F_9245f3f4-a898-496b-8589-01d876f54199"
      unitRef="U_USD">4000</lxeo:FinanceLeaseMonthlyInstallmentPaymentAmounts>
    <lxeo:FinanceLeaseMonthlyInstallmentPaymentAmounts
      contextRef="C_78220819-138e-4d2f-ae70-819bfa7f0e94"
      decimals="0"
      id="F_e6522759-b249-49e5-9b95-5fda609660f8"
      unitRef="U_USD">18000</lxeo:FinanceLeaseMonthlyInstallmentPaymentAmounts>
    <lxeo:FinanceLeaseAggregateMonthlyInstallmentPaymentAmounts
      contextRef="C_c25f5aa6-70c3-4c5e-b41f-0a034c1996d8"
      decimals="0"
      id="F_07fb4d4d-6880-4337-a1db-7a83b3d78a75"
      unitRef="U_USD">49000</lxeo:FinanceLeaseAggregateMonthlyInstallmentPaymentAmounts>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_f13110bd-68e9-4c8f-869d-c3f80a05ef1a"
      id="F_4dd75619-1d0f-4456-a70a-a353773674b8">P2Y8M12D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <lxeo:FinanceLeaseWeightedAverageRemainingAmortizationTerm
      contextRef="C_9a3288c8-11b0-411a-aef1-05a44eec67ca"
      id="F_82415951-a465-468a-a4ea-08a9c545615e">P4Y9M18D</lxeo:FinanceLeaseWeightedAverageRemainingAmortizationTerm>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="C_f13110bd-68e9-4c8f-869d-c3f80a05ef1a"
      decimals="4"
      id="F_6f3c9632-087a-4951-a69a-cdd7bee162bf"
      unitRef="U_pure">0.0859</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_28144b67-7dfd-494d-8133-75abcc735058"
      id="F_99454693-bc98-408a-a2c1-4414f08938a8">P3Y8M12D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <lxeo:FinanceLeaseWeightedAverageRemainingAmortizationTerm
      contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca"
      id="F_3d7858f2-9c42-43e1-82b1-6a8d700ba31d">P5Y8M12D</lxeo:FinanceLeaseWeightedAverageRemainingAmortizationTerm>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="C_28144b67-7dfd-494d-8133-75abcc735058"
      decimals="4"
      id="F_f29e4845-a201-42c9-9129-7298bd806333"
      unitRef="U_pure">0.0859</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <lxeo:ComponentsOfEquipmentFinanceLeaseTableTextBlock
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_9a8f27e8-b058-40c1-b68f-498fbe01881f">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The components of the equipment finance leases were as follows:&lt;/span&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:62.34%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.860000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.94%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.860000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Reduction in the carrying amount of ROU assets, finance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;325&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;306&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Interest on finance lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;127&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;176&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total finance lease expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;452&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;482&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash paid for amounts included in the measurement of lease liabilities, included in financing cash flows&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;410&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;425&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</lxeo:ComponentsOfEquipmentFinanceLeaseTableTextBlock>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      decimals="-3"
      id="F_77fd4978-0d66-4496-8e89-46cc9073f73c"
      unitRef="U_USD">325000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca"
      decimals="-3"
      id="F_98f2f87a-5910-43fa-a416-33535bacfa98"
      unitRef="U_USD">306000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      decimals="-3"
      id="F_396a4383-5f1d-48ee-83b2-09c9288998e2"
      unitRef="U_USD">127000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca"
      decimals="-3"
      id="F_5b199938-6410-45cb-b982-202244dd2fe1"
      unitRef="U_USD">176000</us-gaap:FinanceLeaseInterestExpense>
    <lxeo:FinanceLeaseExpense
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      decimals="-3"
      id="F_426b5663-fc3e-4eb2-a9f2-ae2b1f1e2c5f"
      unitRef="U_USD">452000</lxeo:FinanceLeaseExpense>
    <lxeo:FinanceLeaseExpense
      contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca"
      decimals="-3"
      id="F_1f4627d2-6826-4865-bf16-7aee36d7f48f"
      unitRef="U_USD">482000</lxeo:FinanceLeaseExpense>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      decimals="-3"
      id="F_e1f26958-4eb2-4a89-91e0-2847b09465f3"
      unitRef="U_USD">410000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca"
      decimals="-3"
      id="F_ed12f960-b37f-48a4-a2b3-53dc51e53822"
      unitRef="U_USD">425000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_c06becc4-0d45-4d75-afcb-4598ea0c592f">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table provides a reconciliation of the Company&#x2019;s remaining equipment finance lease obligations due within each year ending December 31 to the equipment finance lease liabilities recognized at December 31, 2024:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:77.7%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:20.299999999999997%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Year ended December 31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Equipment Finance Leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;587&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;587&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;359&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,544&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;157&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total finance lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,387&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Included in the balance sheet:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Current portion of lease liabilities - finance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;570&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Non-current portion of lease liabilities - finance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;817&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total finance lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,387&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="-3"
      id="F_60078e7b-8f5e-47e0-b6a5-4ad1340e558a"
      unitRef="U_USD">587000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="-3"
      id="F_0e0ee3d0-8e9c-497c-9602-a81752931458"
      unitRef="U_USD">587000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="-3"
      id="F_a2a9e783-03c9-4b58-a227-852d52750e33"
      unitRef="U_USD">359000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="-3"
      id="F_2ef64039-4f2a-445a-b283-a9e18bef2340"
      unitRef="U_USD">11000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="-3"
      id="F_1e0352f6-cacc-4cce-9e8c-0b651afb2d6f"
      unitRef="U_USD">0</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="-3"
      id="F_cc5e8958-b1cf-419d-80a9-27c02915ce58"
      unitRef="U_USD">0</us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="-3"
      id="F_d2ad9ded-4e09-4904-8907-1fc5a21ea28f"
      unitRef="U_USD">1544000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="-3"
      id="F_5c2921b7-08c2-43ef-a368-2e9db0e76edd"
      unitRef="U_USD">157000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiability
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="-3"
      id="F_0c64f65d-a7ad-49a2-9f67-1447c43b1a21"
      unitRef="U_USD">1387000</us-gaap:FinanceLeaseLiability>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="-3"
      id="F_e6a4888e-8978-46bd-bb6d-1fe78677dcf8"
      unitRef="U_USD">570000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="-3"
      id="F_4aee5403-79bd-4ea5-8d88-13e12ba14148"
      unitRef="U_USD">817000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiability
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="-3"
      id="F_3d2bde62-f3bd-4bac-81ea-67f657583d8e"
      unitRef="U_USD">1387000</us-gaap:FinanceLeaseLiability>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_3f7f5262-0a5a-483f-83bf-bcdd6efaa409">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;6. Convertible SAFE Note&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On August 24, 2023, the Company entered into the convertible SAFE Note with Sarepta Therapeutics, Inc. (the "Investor") in a principal amount of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million bearing simple interest at an annual rate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% to be repaid after one year (the "Cash Out Amount") in the absence of the occurrence of certain settlement events, including upon a qualified preferred stock equity financing, a public offering or a Special Purpose Acquisition Company ("SPAC" transaction, a change of control, or dissolution. The convertible SAFE Note was accounted for as a liability in accordance with the provisions of ASC Topic 480, Distinguishing Liabilities from Equity, which was initially and subsequently measured at fair value with changes in fair value recognized in earnings (see Note 3). &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Upon a qualified equity financing event, the convertible SAFE Note would have automatically converted into a number of shares of corresponding preferred stock based on a certain discount to the price of such preferred stock issued to the other investors applied to the then-current Cash-Out Amount. Upon the effective date of an IPO or a direct listing, or immediately prior to the closing of a SPAC transaction, the convertible SAFE Note would have automatically converted, and did automatically convert upon the effectiveness of the Company's IPO registration statement on November 2, 2023, into a number of shares of common stock based on a certain discount to the public offering price of such common stock applied to the then-current Cash-Out Amount (see Note 8). Upon a change of control, the Investor would have been entitled to receive the greater of (i) an amount equal to a certain premium applied to the then-current Cash-Out Amount, or (ii) the amount that would have been payable on the number of shares of the senior-most series of the Company&#x2019;s preferred stock after applying a certain discount to the original issue price of such senior-most preferred stock together with a certain premium applied to the then-current Cash-Out Amount (the greater of (i) and (ii), the &#x201c;Conversion Amount&#x201d;). Upon the one-year maturity of the convertible SAFE Note, or upon dissolution of the Company, the Investor was to be paid an amount equal to the Cash-Out Amount. Upon the event of a change of control or dissolution, the Investor&#x2019;s right to receive its Cash-Out Amount or its Conversion Amount would have been junior to payment of outstanding indebtedness and creditor claims, on par with payments for the Company&#x2019;s most senior series of preferred stock or other SAFE note holders, if any, and senior to payments for the Company&#x2019;s common stock and any other series or class of stock. The convertible SAFE Note did not maintain any voting rights. &lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In connection with the convertible SAFE Note, the Company incurred issuance costs of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million that were recorded as a discount to the liability balance and amortized to interest expense over the term of the convertible SAFE Note. As of November 2, 2023, the estimated fair value of the convertible SAFE Note, gross of unamortized discount, increased by $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million (see Note 3), and the corresponding carrying value was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, net of unamortized discount, which automatically converted into &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;411,815&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of the Company&#x2019;s common stock upon the declaration of effectiveness of the Company's IPO registration statement on November 2, 2023 (see Note 8).&lt;/span&gt;&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_e84f1a1e-8d42-4df6-8795-f518a72c03e0"
      decimals="-5"
      id="F_64d498e3-f0ca-4d61-9590-83339d0c7047"
      unitRef="U_USD">4000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_e84f1a1e-8d42-4df6-8795-f518a72c03e0"
      decimals="2"
      id="F_baa95010-7fb9-4ab9-a2b3-6e855e217f04"
      unitRef="U_pure">0.10</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentDescription
      contextRef="C_01ae7cc9-95ef-4205-a1f8-4bc92563980e"
      id="F_9155180a-d408-4416-b73d-7020f0aa98f6">Upon a qualified equity financing event, the convertible SAFE Note would have automatically converted into a number of shares of corresponding preferred stock based on a certain discount to the price of such preferred stock issued to the other investors applied to the then-current Cash-Out Amount. Upon the effective date of an IPO or a direct listing, or immediately prior to the closing of a SPAC transaction, the convertible SAFE Note would have automatically converted, and did automatically convert upon the effectiveness of the Company's IPO registration statement on November 2, 2023, into a number of shares of common stock based on a certain discount to the public offering price of such common stock applied to the then-current Cash-Out Amount (see Note 8). Upon a change of control, the Investor would have been entitled to receive the greater of (i) an amount equal to a certain premium applied to the then-current Cash-Out Amount, or (ii) the amount that would have been payable on the number of shares of the senior-most series of the Company&#x2019;s preferred stock after applying a certain discount to the original issue price of such senior-most preferred stock together with a certain premium applied to the then-current Cash-Out Amount (the greater of (i) and (ii), the &#x201c;Conversion Amount&#x201d;). Upon the one-year maturity of the convertible SAFE Note, or upon dissolution of the Company, the Investor was to be paid an amount equal to the Cash-Out Amount. Upon the event of a change of control or dissolution, the Investor&#x2019;s right to receive its Cash-Out Amount or its Conversion Amount would have been junior to payment of outstanding indebtedness and creditor claims, on par with payments for the Company&#x2019;s most senior series of preferred stock or other SAFE note holders, if any, and senior to payments for the Company&#x2019;s common stock and any other series or class of stock. The convertible SAFE Note did not maintain any voting rights. </us-gaap:DebtInstrumentDescription>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="C_9a32dff6-03c5-465f-846c-9b718f20e0b9"
      decimals="-5"
      id="F_d3d129ac-aabd-4766-aac1-2c83f9fb0ef8"
      unitRef="U_USD">100000</us-gaap:DeferredFinanceCostsNet>
    <lxeo:IncreaseDecreaseInFairValueOfSafeInstrument
      contextRef="C_3df569eb-97ac-4247-ae8a-b4800fbcc697"
      decimals="-5"
      id="F_50c72b92-9b28-440c-a33e-0c47e69e2659"
      unitRef="U_USD">500000</lxeo:IncreaseDecreaseInFairValueOfSafeInstrument>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_57731d15-0745-4645-b184-c42a52a8959a"
      decimals="-5"
      id="F_fc94790d-62d2-490d-b22a-1732658b79f8"
      unitRef="U_USD">4500000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="C_57731d15-0745-4645-b184-c42a52a8959a"
      decimals="-5"
      id="F_55c00670-3cd9-4908-ae0a-3e9d63aee7ba"
      unitRef="U_USD">4400000</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="C_90b3b8b5-08ff-4ed8-b03a-36a19e205081"
      decimals="0"
      id="F_1481de7a-3825-46d3-a493-aa81a020cfd1"
      unitRef="U_shares">411815</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:PreferredStockTextBlock
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_ef9a575c-8906-4a9f-a622-4c2b7af57840">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;7. Convertible Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2022 and until the closing of the Company's IPO on November 7, 2023, the Company&#x2019;s certificate of incorporation authorized the Company to issue &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;143,653,546&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of series A and series B convertible preferred stock each with a par value of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share. Upon the closing of the Company's IPO on November 7, 2023, all &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;85,495,722&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; outstanding shares of the Company&#x2019;s series A convertible preferred stock and all &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;58,157,823&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; outstanding shares of the Company&#x2019;s series B convertible preferred stock converted into &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,070,027&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,386,337&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock, respectively, including &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;896,764&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock issued as a result of series B convertible preferred stock antidilution provisions (see Note 8).&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2022 and until the closing of the Company's IPO on November 7, 2023, convertible preferred stock consisted of the following:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:26.9%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.6%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.6%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.56%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.440000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.56%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.440000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.6%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Convertible&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Convertible&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Preferred&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Preferred&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Common Stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Issued and&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Proceeds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Liquidation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Issuable Upon&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Authorized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Received&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Preference&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Conversion&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Series A convertible preferred stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;85,495,722&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;85,495,722&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;85,496&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;85,496&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,070,027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Series B convertible preferred stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;58,157,824&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;58,157,823&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100,060&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100,060&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,489,573&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;143,653,546&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;143,653,545&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;185,556&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;185,556&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,559,600&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2022 and until the closing of the Company's IPO on November 7, 2023, the rights and privileges of the holders of the convertible preferred stock were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Voting&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;Holders of preferred stock were to vote together with the holders of common stock as a single class and on an as converted to common stock basis.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Dividends&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;The holders of shares of series B convertible preferred stock were entitled to receive, as declared by the Company&#x2019;s Board of Directors, dividends per share at the rate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the issue price per share of series B convertible preferred stock, prior and in preference to any declaration or payment of any other dividend (other than dividends on shares of common stock payable in shares of common stock). After payment of dividends to the holders of shares of series B convertible preferred stock, the holders of shares of series A convertible preferred stock were entitled to receive, as declared by the Company&#x2019;s Board of Directors, dividends per share at the rate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the issue price per share of series A convertible preferred stock, prior and in preference to any declaration or payment of any other dividend (other than dividends on shares of common stock payable in shares of common stock).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Deemed Liquidation Event&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;Each of the following events was to be considered a &#x201c;Deemed Liquidation Event&#x201d; unless the holders of a majority of the outstanding shares of preferred stock and the holders of at least &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;64&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the outstanding shares of series B convertible preferred stock elected otherwise by written notice to be sent to the Company at least five business days prior to the effective date of any such event; (a) a merger or consolidation in which the Company is a constituent party or a subsidiary of the Company was a constituent party and the Company issued shares of its capital stock pursuant to such merger or consolidation, except: any such merger or consolidation involving the Company or a subsidiary in which the shares of capital stock of the Company outstanding immediately prior to such merger or consolidation continued to represent, or were converted into or exchanged for shares of capital stock that represented, immediately following such merger or consolidation, at least a majority by voting power of the capital stock of (1) the surviving or resulting company; or (2) if the surviving or resulting company was a wholly owned subsidiary of another company immediately following such merger or consolidation, the parent company of such surviving or resulting corporation; (b) (1) the sale, lease, transfer, exclusive license or other disposition, in a single transaction or series of related transactions, by the Company or any subsidiary of the Company of all or substantially all the assets of the Company and its subsidiaries taken as a whole, or (2) the sale or disposition (whether by merger, consolidation or otherwise, and whether in a single transaction or a series of related transactions) of one or more subsidiaries of the Company if substantially all of the assets of the Company and its subsidiaries taken as a whole were held by such subsidiary or subsidiaries, except where such sale, lease, transfer, exclusive license or other disposition was to a wholly owned subsidiary of the Company; or (c) the Corporation&#x2019;s completion of (1) a reverse merger into a public shell, or (2) a merger or consolidation with a special purpose acquisition company or its subsidiary in which the common stock (or similar securities) of the surviving or parent entity were publicly traded in a public offering pursuant to an effective registration statement under the 1933 Securities Act, as amended.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Liquidation Preference&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;In the event of any voluntary or involuntary liquidation, dissolution, or winding up of the Company, the holders of shares of series B convertible preferred stock were entitled to be paid out of the assets of the Company or, in the case of a Deemed Liquidation Event, out of the consideration payable to stockholders or the available proceeds, before any payment would be made to the holders of common stock or series A convertible preferred stock, an amount per share equal to the series B convertible preferred stock issue price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18.227267&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share (subject to adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization), plus any dividends declared but unpaid. If upon any such liquidation, dissolution or winding up of the Company or Deemed Liquidation Event, the assets of the Company available for distribution to its stockholders was insufficient to pay the holders of shares of series B convertible preferred stock the full amount to which they were entitled, the holders of shares of series B convertible preferred stock would have shared ratably in any distribution of the assets available for distribution in proportion to the respective amounts which would otherwise be payable in respect of the shares held by them upon such distribution if all amounts payable on or with respect to such shares were paid in full (the &#x201c;Series B Liquidation Preference&#x201d;).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In the event of any voluntary or involuntary liquidation, dissolution, or winding up of the Company, after payment of the Series B Liquidation Preference, the holders of shares of series A convertible preferred stock were entitled to be paid out of the assets of the Company or, in the case of a Deemed Liquidation Event, out of the consideration payable to stockholders or the available proceeds, before any payment shall be made to the holders of common stock or series A convertible preferred stock, an amount per share equal to the series A convertible preferred stock issue price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.594230&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share (subject to adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization), plus any dividends declared but unpaid. If upon any such liquidation, dissolution or winding up of the Company or Deemed Liquidation Event, the assets of the Company available for distribution to its stockholders was insufficient to pay the holders of shares of series A convertible preferred stock the full amount to which they were entitled, the holders of shares of series A convertible preferred stock would have shared ratably in any distribution of the assets available for distribution in proportion to the respective amounts which would otherwise be payable in respect of the shares held by them upon such distribution if all amounts payable on or with respect to such shares were paid in full (the &#x201c;Series A Liquidation Preference&#x201d;).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In the event that there were additional assets to be distributed after payment of the Series A Liquidation Preference and the Series B Liquidation Preference, the holders of the series A convertible preferred stock and series B convertible preferred stock would have shared in the distribution along with common stockholders as if the shares of the series A convertible preferred stock and series B convertible preferred stock had converted to common stock immediately prior to the distribution, up to an amount, (a) taken together with the Series A Liquidation Preference, not to exceed $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31.782691&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share with respect to the series A convertible preferred stockholders; and (b) taken together with the Series B Liquidation Preference, not to exceed $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;54.681802&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share with respect to the series B convertible preferred stockholders.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Redemption&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;The preferred stock did not contain a mandatory redemption provision. Upon a deemed liquidation event, the holders would have been paid their preference amounts according to their priority. Remeasurement to redemption value would only have been required if a deemed liquidation event was probable.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Conversion&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;Upon either (a) the closing of the sale of shares of common stock to the public at a price of at least $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22.784057&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the common stock), in a firm-commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended, resulting in at least $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;75,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; of gross proceeds to the Company and in connection with the offering of the common stock listed for trading on the Nasdaq Stock Market&#x2019;s National Market, the New York Stock Exchange or another exchange or marketplace approved by the Company&#x2019;s Board of Directors, including the approval of at least &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;two&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (2) preferred directors (a &#x201c;Qualified IPO&#x201d;), which occurred on November 7, 2023, or (b) the date and time, or the occurrence of an event specified by vote or written consent of the Noteholders, then (i) all outstanding shares of convertible preferred stock were to automatically be converted into shares of common stock, at the then effective conversion rate.&lt;/span&gt;&lt;/p&gt;</us-gaap:PreferredStockTextBlock>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_abb5ce74-a0ec-41a2-a9d1-032861f25e44"
      decimals="INF"
      id="F_427d96b3-96a0-4c0c-9643-59fc2923cd92"
      unitRef="U_shares">143653546</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="C_abb5ce74-a0ec-41a2-a9d1-032861f25e44"
      decimals="INF"
      id="F_31dc9345-3c33-496b-b523-255736f0453d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_dfb1adde-bdce-4971-8572-0c77f2a15437"
      decimals="INF"
      id="F_dd31c88a-6abd-46cf-8938-45b714b8af63"
      unitRef="U_shares">85495722</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_7d455504-a441-4ca1-b057-e166af9463cf"
      decimals="INF"
      id="F_9f1b771b-840a-4a93-9075-73a5ebb1e31e"
      unitRef="U_shares">58157823</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:PreferredStockConvertibleSharesIssuable
      contextRef="C_dfb1adde-bdce-4971-8572-0c77f2a15437"
      decimals="INF"
      id="F_237dd7c5-d22d-4a88-9818-192305263372"
      unitRef="U_shares">8070027</us-gaap:PreferredStockConvertibleSharesIssuable>
    <us-gaap:PreferredStockConvertibleSharesIssuable
      contextRef="C_b15d25c2-ef2b-415e-98f5-5721bc068283"
      decimals="INF"
      id="F_ee43b7a7-dbea-408a-ad1a-a2625f72f305"
      unitRef="U_shares">6386337</us-gaap:PreferredStockConvertibleSharesIssuable>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_ff876ac5-7ddc-447a-ba80-cd3fc5d96d6b"
      decimals="INF"
      id="F_87629bf6-e0aa-4b17-891f-ba97bc777fbc"
      unitRef="U_shares">896764</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:TemporaryEquityTableTextBlock
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_e0d8b6bb-0c91-42dc-8ffb-b2d68ecd328b">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2022 and until the closing of the Company's IPO on November 7, 2023, convertible preferred stock consisted of the following:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:26.9%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.6%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.6%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.56%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.440000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.56%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.440000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.6%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Convertible&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Convertible&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Preferred&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Preferred&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Common Stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Issued and&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Proceeds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Liquidation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Issuable Upon&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Authorized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Received&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Preference&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Conversion&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Series A convertible preferred stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;85,495,722&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;85,495,722&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;85,496&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;85,496&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,070,027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Series B convertible preferred stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;58,157,824&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;58,157,823&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100,060&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100,060&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,489,573&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;143,653,546&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;143,653,545&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;185,556&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;185,556&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,559,600&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:TemporaryEquityTableTextBlock>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_dfb1adde-bdce-4971-8572-0c77f2a15437"
      decimals="INF"
      id="F_d0838c56-3adf-4c36-ac2a-cc101ade67cf"
      unitRef="U_shares">85495722</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_34e9355d-4428-4f62-b1ae-10943dbb5161"
      decimals="INF"
      id="F_3432366d-47f3-4c4c-8bee-598ecacb7c6d"
      unitRef="U_shares">85495722</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_dfb1adde-bdce-4971-8572-0c77f2a15437"
      decimals="INF"
      id="F_0f66bd94-e2da-4d2f-bf7d-87b9fe6c5dd9"
      unitRef="U_shares">85495722</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_dfb1adde-bdce-4971-8572-0c77f2a15437"
      decimals="INF"
      id="F_074c2f67-b89e-43b7-89fc-16b264474474"
      unitRef="U_shares">85495722</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_34e9355d-4428-4f62-b1ae-10943dbb5161"
      decimals="INF"
      id="F_760cd3b8-e316-4ec4-9126-05f5d343916c"
      unitRef="U_shares">85495722</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_34e9355d-4428-4f62-b1ae-10943dbb5161"
      decimals="INF"
      id="F_00765210-006f-4308-8056-94c0f6962b3d"
      unitRef="U_shares">85495722</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="C_7c1f486a-7a1e-460e-b332-6ac6ec1ac145"
      decimals="-3"
      id="F_86d37996-91da-4025-8e94-6e4e7a7de7e3"
      unitRef="U_USD">85496000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="C_81b19c2d-22eb-4f90-b119-49d130c596ae"
      decimals="-3"
      id="F_7238fa9a-12ac-436a-a8be-338d0f114e27"
      unitRef="U_USD">85496000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="C_dfb1adde-bdce-4971-8572-0c77f2a15437"
      decimals="-3"
      id="F_7d6a13b2-0490-4131-95c9-103e206bed61"
      unitRef="U_USD">85496000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="C_34e9355d-4428-4f62-b1ae-10943dbb5161"
      decimals="-3"
      id="F_3dc783fa-3723-49ef-826a-f5d6b41f718a"
      unitRef="U_USD">85496000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:PreferredStockConvertibleSharesIssuable
      contextRef="C_dfb1adde-bdce-4971-8572-0c77f2a15437"
      decimals="INF"
      id="F_20f9fc07-be3c-41c1-ad6f-480c8a60be75"
      unitRef="U_shares">8070027</us-gaap:PreferredStockConvertibleSharesIssuable>
    <us-gaap:PreferredStockConvertibleSharesIssuable
      contextRef="C_34e9355d-4428-4f62-b1ae-10943dbb5161"
      decimals="INF"
      id="F_6f6b2ea5-fd77-4882-9873-a5ad326c11ef"
      unitRef="U_shares">8070027</us-gaap:PreferredStockConvertibleSharesIssuable>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_7d455504-a441-4ca1-b057-e166af9463cf"
      decimals="INF"
      id="F_e3ddf0fb-b10d-47f4-b87f-eba7f31fbf33"
      unitRef="U_shares">58157824</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_186c2b13-b928-42dd-8bd4-f169393b3424"
      decimals="INF"
      id="F_d9e38357-fddc-4835-9996-6be9563e2de5"
      unitRef="U_shares">58157824</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_7d455504-a441-4ca1-b057-e166af9463cf"
      decimals="INF"
      id="F_eb34a0fd-a3d7-411d-b089-a233a553bdae"
      unitRef="U_shares">58157823</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_7d455504-a441-4ca1-b057-e166af9463cf"
      decimals="INF"
      id="F_accd0682-45f2-45bc-aed7-524dbeebce6d"
      unitRef="U_shares">58157823</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_186c2b13-b928-42dd-8bd4-f169393b3424"
      decimals="INF"
      id="F_98c214aa-dbbb-44c6-8e80-a11157260fb3"
      unitRef="U_shares">58157823</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_186c2b13-b928-42dd-8bd4-f169393b3424"
      decimals="INF"
      id="F_10848c46-2b23-44f4-8de3-c02e18803086"
      unitRef="U_shares">58157823</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="C_d1ca60e9-37da-42d1-8e5d-0809de6840b2"
      decimals="-3"
      id="F_19ce5292-c883-41c0-9c5f-229ae7c6a749"
      unitRef="U_USD">100060000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="C_002aeebf-8141-46fe-833a-b448a9ed53f3"
      decimals="-3"
      id="F_0a314790-4e22-4467-bb19-fe17cd2ff7c1"
      unitRef="U_USD">100060000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="C_7d455504-a441-4ca1-b057-e166af9463cf"
      decimals="-3"
      id="F_d9ae343f-ecd0-482c-a4ff-3b4a99752550"
      unitRef="U_USD">100060000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="C_186c2b13-b928-42dd-8bd4-f169393b3424"
      decimals="-3"
      id="F_c8cbe552-e5fa-476d-ad1f-cc470753e5f6"
      unitRef="U_USD">100060000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:PreferredStockConvertibleSharesIssuable
      contextRef="C_7d455504-a441-4ca1-b057-e166af9463cf"
      decimals="INF"
      id="F_7bbcbc88-c778-425e-906e-35f2629e3fdb"
      unitRef="U_shares">5489573</us-gaap:PreferredStockConvertibleSharesIssuable>
    <us-gaap:PreferredStockConvertibleSharesIssuable
      contextRef="C_186c2b13-b928-42dd-8bd4-f169393b3424"
      decimals="INF"
      id="F_444d6f5c-ef95-4b84-bf43-bd740721bc15"
      unitRef="U_shares">5489573</us-gaap:PreferredStockConvertibleSharesIssuable>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_47a049b7-455a-448b-84ea-5e98846bad51"
      decimals="INF"
      id="F_5d2f38c1-eec2-47b4-b7a6-666e1ab29f72"
      unitRef="U_shares">143653546</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_e83f79f6-f924-4728-9c7c-5f1eb49397fe"
      decimals="INF"
      id="F_98c7c9ea-9d92-4594-bd45-b41120f86aa5"
      unitRef="U_shares">143653546</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_47a049b7-455a-448b-84ea-5e98846bad51"
      decimals="INF"
      id="F_1d4506ab-2291-4b4a-9857-9fa82590d4fd"
      unitRef="U_shares">143653545</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_47a049b7-455a-448b-84ea-5e98846bad51"
      decimals="INF"
      id="F_9ebeeb2b-4a44-456e-9fb0-856843ad74ae"
      unitRef="U_shares">143653545</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_e83f79f6-f924-4728-9c7c-5f1eb49397fe"
      decimals="INF"
      id="F_4fd8d436-3e07-4a80-87e5-473f6234327d"
      unitRef="U_shares">143653545</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_e83f79f6-f924-4728-9c7c-5f1eb49397fe"
      decimals="INF"
      id="F_524c9c48-0d46-42a3-89f8-25f082fe19d9"
      unitRef="U_shares">143653545</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="C_cfef4556-754f-4351-9370-c51c9711c2f4"
      decimals="-3"
      id="F_9cd1b5b1-2a2e-4baf-8595-ba8a5433554c"
      unitRef="U_USD">185556000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="C_ba4a9d48-b7a3-4350-9c16-becc8f228a5a"
      decimals="-3"
      id="F_3eed4896-30f2-4812-a957-469c3e93a13f"
      unitRef="U_USD">185556000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="C_47a049b7-455a-448b-84ea-5e98846bad51"
      decimals="-3"
      id="F_352ec02c-c16b-4e60-a6a0-a8c90a8fdc76"
      unitRef="U_USD">185556000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="C_e83f79f6-f924-4728-9c7c-5f1eb49397fe"
      decimals="-3"
      id="F_4b9f03c8-c0ec-4f14-94e2-fcfaf68ad4ad"
      unitRef="U_USD">185556000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:PreferredStockConvertibleSharesIssuable
      contextRef="C_47a049b7-455a-448b-84ea-5e98846bad51"
      decimals="INF"
      id="F_03a06c1d-78dd-49bb-a78f-4e1132ccc54f"
      unitRef="U_shares">13559600</us-gaap:PreferredStockConvertibleSharesIssuable>
    <us-gaap:PreferredStockConvertibleSharesIssuable
      contextRef="C_e83f79f6-f924-4728-9c7c-5f1eb49397fe"
      decimals="INF"
      id="F_2050811b-6fae-4757-bfd5-9151f39378fd"
      unitRef="U_shares">13559600</us-gaap:PreferredStockConvertibleSharesIssuable>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="C_d1ca60e9-37da-42d1-8e5d-0809de6840b2"
      decimals="2"
      id="F_d70710e6-df4d-4b33-aac7-b00ad5073c0c"
      unitRef="U_pure">0.08</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="C_7c1f486a-7a1e-460e-b332-6ac6ec1ac145"
      decimals="2"
      id="F_fb5dc939-fa06-4bea-abf1-aea8c9252bcf"
      unitRef="U_pure">0.08</us-gaap:PreferredStockDividendRatePercentage>
    <lxeo:PercentageOfOutstandingSharesForDeemedLiquidation
      contextRef="C_6d391be5-485e-4203-9a45-2881c2767c0e"
      decimals="2"
      id="F_0c359780-11f1-4657-8c03-a5c8c60d1333"
      unitRef="U_pure">0.64</lxeo:PercentageOfOutstandingSharesForDeemedLiquidation>
    <us-gaap:TemporaryEquityLiquidationPreferencePerShare
      contextRef="C_7d455504-a441-4ca1-b057-e166af9463cf"
      decimals="6"
      id="F_c16240dd-70cf-4d3d-a47a-186850086548"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">18.227267</us-gaap:TemporaryEquityLiquidationPreferencePerShare>
    <us-gaap:TemporaryEquityLiquidationPreferencePerShare
      contextRef="C_dfb1adde-bdce-4971-8572-0c77f2a15437"
      decimals="6"
      id="F_618a14ab-9848-47c1-bcab-6adce4ccbf4d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">10.59423</us-gaap:TemporaryEquityLiquidationPreferencePerShare>
    <us-gaap:TemporaryEquityLiquidationPreferencePerShare
      contextRef="C_931de80a-517d-4a40-8171-722f60ac7671"
      decimals="6"
      id="F_5b921a9a-bf5f-4c80-8be0-776000d60a17"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">31.782691</us-gaap:TemporaryEquityLiquidationPreferencePerShare>
    <us-gaap:TemporaryEquityLiquidationPreferencePerShare
      contextRef="C_5efc3a16-a0b9-4c5b-b4a7-4e7f9939e813"
      decimals="6"
      id="F_76b21a89-0f9f-4121-884f-e3fc120a181d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">54.681802</us-gaap:TemporaryEquityLiquidationPreferencePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_bf7a1f3a-c205-45ba-9483-a2ad719c16b4"
      decimals="6"
      id="F_adc6ec09-a3a4-45c4-b28c-ce723566646c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">22.784057</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_266f5c3d-d979-4718-851c-88a44ef02c23"
      decimals="0"
      id="F_f15f5439-cb4e-46ee-92a8-e63cb02b12cb"
      unitRef="U_USD">75000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <lxeo:QualifiedIpoMinimumNumberOfDirectorsApprovalRequired
      contextRef="C_d6e454da-2fb0-4d82-ae44-abd1e7e3c994"
      decimals="INF"
      id="F_2e7b5a7a-428f-4466-9114-b55b02e7b4f3"
      unitRef="U_Director">2</lxeo:QualifiedIpoMinimumNumberOfDirectorsApprovalRequired>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_9b0fadde-3883-4e43-b5ab-b89bca749e5a">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;8. Capital Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024 and December 31, 2023, the Company&#x2019;s amended and restated certificate of incorporation provided that the authorized capital stock of the Company was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;510,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares consisting of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;500,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of undesignated preferred stock, both with a par value of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share. As of December 31, 2024 and December 31, 2023, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33,079,209&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26,668,485&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares, respectively, of the Company's common stock authorized were issued, including &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,948&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,107&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares, respectively, that were legally issued upon the early exercise of unvested stock options and that are excluded from the number of shares outstanding until the right to repurchase subsequently lapses upon vesting. Until the closing of the Company&#x2019;s IPO on November 7, 2023, the voting, dividend and liquidation rights of the holders of the Company&#x2019;s common shares were subject to and qualified by the rights, powers and preferences of the holders of the convertible preferred stock set forth in Note 7. The Company repurchased a total of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,827&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock issued pursuant to the early exercise of stock options granted under the 2021 Plan for a total of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; during the year ended December 31, 2024, which was recorded to treasury stock in the Company's balance sheet (see Note 9). Each common share entitles the holder to one vote on all matters submitted to a vote of the Company&#x2019;s stockholders. Common stockholders are entitled to receive dividends, if any, as may be declared by the Company&#x2019;s Board of Directors and were subject to the preferential dividend rights of the convertible preferred stock until the closing of the Company's IPO. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; cash dividends have been declared or paid by the Company.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Upon the declaration of effectiveness of the Company&#x2019;s IPO registration statement on November 2, 2023, the Company's then outstanding convertible SAFE Note automatically converted into &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;411,815&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock (see Note 6). Upon the closing of the Company's IPO on November 7, 2023, the Company issued and sold &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,090,910&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of its common stock, and subsequently, the underwriters partially exercised their associated 30-day option to purchase additional shares of common stock with &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,048,746&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; additional shares issued. The net proceeds to the Company from the IPO and subsequent partial exercise of the underwriters&#x2019; 30-day option to purchase additional shares were approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million based on the initial offering price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share, after deducting underwriting discounts, commissions and offering expenses totaling $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. Also upon the closing of the Company's IPO on November 7, 2023, all &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;85,495,722&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; then outstanding shares of the Company&#x2019;s series A convertible preferred stock and all &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;58,157,823&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; then outstanding shares of the Company&#x2019;s series B convertible preferred stock converted into &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,070,027&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,386,337&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock, respectively, including &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;896,764&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock issued as a result of series B convertible preferred stock antidilution provisions. On March 11, 2024, the Company entered into a common stock purchase agreement to issue and sell an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,278,905&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of its common stock at a price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.13&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share, in a private placement that closed on March 13, 2024 (the "Private Placement"). The gross and net proceeds received from the Private Placement were approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;95.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;88.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively, after deducting approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of commissions and other offering costs.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company had reserved the following number of shares of common stock for the exercise of outstanding stock options, settlement of outstanding RSUs, and future issuance of stock-based awards:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:86.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:62.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.92%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.96%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options to purchase shares of common stock under the 2021 Plan and 2023 Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,457,918&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,415,740&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;RSUs subject to settlement in shares of common stock under the 2023 Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;266,300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Shares available for issuance under the 2023 Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,185,328&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,293,816&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Shares available for issuance under the 2023 ESPP&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;505,284&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;238,600&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total shares of common stock reserved for future issuance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,414,830&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,948,156&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CapitalUnitsAuthorized
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="INF"
      id="F_2dec0de7-d2c4-4a9f-8b63-e396297c3751"
      unitRef="U_shares">510000000</us-gaap:CapitalUnitsAuthorized>
    <us-gaap:CapitalUnitsAuthorized
      contextRef="C_28144b67-7dfd-494d-8133-75abcc735058"
      decimals="INF"
      id="F_eb8c1b11-09c2-48d9-a08c-088c077df3c1"
      unitRef="U_shares">510000000</us-gaap:CapitalUnitsAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="INF"
      id="F_c9713f8c-ee39-4ec6-b254-6a5c790f338e"
      unitRef="U_shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_28144b67-7dfd-494d-8133-75abcc735058"
      decimals="INF"
      id="F_953153b6-752a-4c11-b9b0-bd87bf57878a"
      unitRef="U_shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="INF"
      id="F_5970e92f-5a91-4827-8d63-b55fa6de1612"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_28144b67-7dfd-494d-8133-75abcc735058"
      decimals="INF"
      id="F_c00257fd-06e2-4829-8f69-fa5c2fafc337"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="4"
      id="F_6c11d0c8-ba3b-4f3e-b58c-a689e4a0c715"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="INF"
      id="F_92a160cd-dc28-4ba3-91fa-1da70d038be1"
      unitRef="U_shares">33079209</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_28144b67-7dfd-494d-8133-75abcc735058"
      decimals="INF"
      id="F_229fa49d-967c-4ce3-adf0-d950dd01bac7"
      unitRef="U_shares">26668485</us-gaap:CommonStockSharesIssued>
    <lxeo:CommonStockSharesIssuedOnEarlyExerciseOfUnvestedStockOptions
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="INF"
      id="F_c7ed91a2-3d34-4835-aef2-c12d81277fd6"
      unitRef="U_shares">7948</lxeo:CommonStockSharesIssuedOnEarlyExerciseOfUnvestedStockOptions>
    <lxeo:CommonStockSharesIssuedOnEarlyExerciseOfUnvestedStockOptions
      contextRef="C_28144b67-7dfd-494d-8133-75abcc735058"
      decimals="INF"
      id="F_fde6dd5c-002c-4cf0-89d9-c6673a642034"
      unitRef="U_shares">22107</lxeo:CommonStockSharesIssuedOnEarlyExerciseOfUnvestedStockOptions>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="C_9d082257-9ef3-44bf-b671-47a3b444bcf4"
      decimals="INF"
      id="F_f4cbd2fe-aa06-4202-978d-933bd4009907"
      unitRef="U_shares">3827</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="C_9d082257-9ef3-44bf-b671-47a3b444bcf4"
      decimals="0"
      id="F_c9ef02d4-64d9-46f0-9a4f-1cad6353e6f7"
      unitRef="U_USD">17000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:DividendsCommonStockCash
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      decimals="INF"
      id="F_42650972-aa78-444a-b9c2-db1fba0de3e0"
      unitRef="U_USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="C_90b3b8b5-08ff-4ed8-b03a-36a19e205081"
      decimals="INF"
      id="F_6c6fb810-f021-4b79-b21e-0c064238c93c"
      unitRef="U_shares">411815</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_3a1be116-5c64-4576-af28-6c9bb1f6ae39"
      decimals="INF"
      id="F_4a61475a-372a-4ac2-8614-fad1fd90e43b"
      unitRef="U_shares">9090910</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_09b75305-e3e0-435b-b2a6-50f4050afab2"
      decimals="INF"
      id="F_0e6f8dff-2d32-44d7-852c-a027d137b6d7"
      unitRef="U_shares">1048746</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_44dd3996-14be-4820-b581-6281744e49e6"
      decimals="-5"
      id="F_8442b192-46e4-4a8e-877a-cfe60e67c19c"
      unitRef="U_USD">100300000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_74419331-e290-447a-86d3-c0fb520fc7bc"
      decimals="INF"
      id="F_a1855e99-1ef9-4ec5-81e3-701e251aa2bb"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">11</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_3a1be116-5c64-4576-af28-6c9bb1f6ae39"
      decimals="-5"
      id="F_0f3a1470-5db7-4679-b2f2-8cc55ee10530"
      unitRef="U_USD">11300000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_dfb1adde-bdce-4971-8572-0c77f2a15437"
      decimals="INF"
      id="F_2552f638-c422-48ca-b867-46ea07c8d410"
      unitRef="U_shares">85495722</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_7d455504-a441-4ca1-b057-e166af9463cf"
      decimals="INF"
      id="F_6d03292c-50d3-4a21-a9df-0d9701422778"
      unitRef="U_shares">58157823</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_8e099335-d590-43f9-972a-d06c24fef007"
      decimals="INF"
      id="F_35266470-1c0b-42a5-a802-8a8032bcb060"
      unitRef="U_shares">8070027</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_7c6c7513-7f64-4c68-bcf5-17a805d1e6fe"
      decimals="0"
      id="F_d71dea99-795c-41db-8d62-d900b90f22ae"
      unitRef="U_shares">6386337</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_ff876ac5-7ddc-447a-ba80-cd3fc5d96d6b"
      decimals="0"
      id="F_ee26de8b-3ec8-4222-bc2e-5bf73e481cec"
      unitRef="U_shares">896764</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_ec3ec1bb-68cc-4820-9297-a6c0c881028e"
      decimals="INF"
      id="F_65f44f6a-db40-4d0c-ab36-3ec12b51ef51"
      unitRef="U_shares">6278905</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_11aac366-2c9d-4773-bc55-7994d2ee9dd0"
      decimals="INF"
      id="F_4557c4da-8455-4557-9de5-7641ba598c2a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">15.13</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="C_4d93aa08-044d-4a0a-8ae0-08a443ffa6ea"
      decimals="-5"
      id="F_4a4cd17a-9958-480f-87c1-d9b410fbd0ee"
      unitRef="U_USD">95000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <lxeo:NetProceedsReceivedFromPrivatePlacement
      contextRef="C_4d93aa08-044d-4a0a-8ae0-08a443ffa6ea"
      decimals="-5"
      id="F_fa3580e7-f8a6-4732-9a0f-14f2b468c832"
      unitRef="U_USD">88700000</lxeo:NetProceedsReceivedFromPrivatePlacement>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_4d93aa08-044d-4a0a-8ae0-08a443ffa6ea"
      decimals="-5"
      id="F_0d4378d6-8adb-46cc-a0e7-804c2333b669"
      unitRef="U_USD">6300000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ScheduleOfStockholdersEquityTableTextBlock
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_6c8156cd-272e-496f-b66b-7579df06cfa4">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company had reserved the following number of shares of common stock for the exercise of outstanding stock options, settlement of outstanding RSUs, and future issuance of stock-based awards:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:86.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:62.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.92%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.96%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options to purchase shares of common stock under the 2021 Plan and 2023 Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,457,918&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,415,740&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;RSUs subject to settlement in shares of common stock under the 2023 Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;266,300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Shares available for issuance under the 2023 Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,185,328&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,293,816&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Shares available for issuance under the 2023 ESPP&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;505,284&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;238,600&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total shares of common stock reserved for future issuance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,414,830&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,948,156&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityTableTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_b1a96dae-b4d3-465e-8d90-5f13defcc31f"
      decimals="INF"
      id="F_7ec077b5-2c43-4e57-824b-ba08636ae120"
      unitRef="U_shares">3457918</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_7381b4b3-de2c-4fd9-b6c4-d8e5a85475c9"
      decimals="INF"
      id="F_242aee94-bf9b-4858-a7e7-7668684341c1"
      unitRef="U_shares">2415740</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_d965f156-2881-4f62-9e05-2ce8f77a88cb"
      decimals="INF"
      id="F_5ad3ce9e-dbcd-4d7f-9b54-b94f8c77ac21"
      unitRef="U_shares">266300</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_19581a58-f4b4-41e4-85f3-1dff41c48718"
      decimals="INF"
      id="F_e5caa94f-a02d-4e5c-8b23-63db21f80ada"
      unitRef="U_shares">2185328</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_23e9fdcf-7d72-4c30-b945-044420610762"
      decimals="INF"
      id="F_1c2b3431-3fb6-4581-846c-ab7b6446b8c9"
      unitRef="U_shares">2293816</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_a6bbca2b-aa76-4540-b619-c2e288370970"
      decimals="INF"
      id="F_4db58a96-b830-4f56-b057-619f4b148c10"
      unitRef="U_shares">505284</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_55e7577e-8daf-46eb-b39f-2063a2405357"
      decimals="INF"
      id="F_5dd4ce48-6dea-4bc2-971e-f00c11b9fca5"
      unitRef="U_shares">238600</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="INF"
      id="F_658c1d6a-3303-4566-a7a6-2eafde94e0e6"
      unitRef="U_shares">6414830</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_28144b67-7dfd-494d-8133-75abcc735058"
      decimals="INF"
      id="F_3bc4d8db-4a86-4fe0-b97c-86ac4a5a2e27"
      unitRef="U_shares">4948156</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_3d539449-7dcc-4f1f-9b92-feac14ab54a5">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;9. Stock-based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In February 2021, the Company adopted the 2021 Plan for the issuance of stock options granted to the Company&#x2019;s key directors, officers, employees and consultants, as a means to secure the benefits arising from capital stock ownership. In connection with the Company&#x2019;s IPO in November 2023, the Company adopted the 2023 Equity Incentive Plan (the &#x201c;2023 Plan&#x201d;) and the 2023 ESPP (together with the 2021 Plan and 2023 Plan, the &#x201c;Plans&#x201d;) for the issuance of equity awards granted to the Company's key directors, officers, employees, and consultants, and for the issuance of shares purchased under the 2023 ESPP to the Company's employees, respectively, as a means to secure the benefits arising from capital stock ownership. The purposes of the Plans are to promote the alignment of the interests of key directors, officers, employees, and consultants with the success of the Company and to provide compensation opportunities to attract, retain and motivate directors, officers, employees, and consultants of the Company.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s Board of Directors adopted the 2023 Plan and the 2023 ESPP in October 2023, and the Company&#x2019;s stockholders approved the 2023 Plan and the 2023 ESPP in October 2023. In connection with the IPO, the Company&#x2019;s 2023 Equity Incentive Plan (the &#x201c;2023 Plan&#x201d;) and its 2023 Employee Stock Purchase Plan (the &#x201c;2023 ESPP&#x201d;) became effective. Upon the effectiveness of the 2023 Plan and the 2023 ESPP:&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;582,699&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock reserved for future issuance under the 2021 Plan ceased to be available for issuance and were added to, and became available for issuance under, the 2023 Plan, and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; further grants will be made under the 2021 Plan; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,803,980&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock were reserved for future issuance under the 2023 Plan, in addition to the shares of common stock reserved for issuance under the 2021 Plan that were added to the shares reserved under the 2023 Plan; and &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;238,600&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock were reserved for future issuance under the 2023 ESPP.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Upon adoption, the maximum number of shares of common stock that may be issued under the 2023 Plan was initially &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,737,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares, which was approximately the sum of (i) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,803,980&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; new shares, plus (ii) the 2021 Plan&#x2019;s available reserve, plus (iii) the number of returning shares, if any, upon the cancellation or forfeiture of equity awards that are outstanding under the 2021 Plan. In addition, the number of shares of common stock reserved for issuance under the 2023 Plan will automatically increase on January 1 of each year, beginning on January 1, 2024, and continuing through and including January 1, 2033, by &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the total number of shares of common stock outstanding on December 31 of the immediately preceding calendar year, or a lesser number of shares determined by the Company&#x2019;s Board of Directors prior to the applicable January 1. Upon adoption, the maximum number of shares of common stock that may be issued under the 2023 ESPP was initially &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;238,600&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares. The number of shares of common stock reserved for issuance under the 2023 ESPP will automatically increase on January 1 of each calendar year, beginning on January 1, 2024 and continuing through and including January 1, 2033, by the lesser of (i) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the total number of shares of capital stock outstanding on December 31 of the preceding calendar year, (ii) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;477,200&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares and (iii) a number of shares determined by the Company&#x2019;s Board of Directors. Shares subject to purchase rights granted under the 2023 ESPP that terminate without having been exercised in full will not reduce the number of shares available for issuance under the 2023 ESPP.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On January 1, 2024, the number of shares of common stock reserved for issuance under the 2023 Plan and the 2023 ESPP automatically increased by &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,333,424&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;266,684&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares, respectively, to totals of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,070,424&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;505,284&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares, respectively. On January 1, 2025, the number of shares of common stock reserved for issuance under the 2023 Plan and the 2023 ESPP automatically increased by &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,653,960&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;330,792&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares, respectively, to totals of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,724,384&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;836,076&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares, respectively. As of December 31, 2024, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,185,328&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;505,284&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares were available for future issuance under the 2023 Plan and 2023 ESPP, respectively. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares have been issued under the 2023 ESPP through December 31, 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Stock option activity&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock options granted under the 2021 Plan are issued from new shares upon exercise, have a contractual term of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;10 years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; from grant date, and generally (i) are subject to requisite service requirements, (ii) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;vest over a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;four-year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; period with &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the options granted vesting after one year and the remainder vesting in equal monthly installments over the following 36 months&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, and (iii) allow for early exercise subject to repurchase. Stock options granted under the 2021 Plan to certain of the Company&#x2019;s non-employees vest in equal monthly installments over a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;four-year &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;period or vested upon the achievement of a certain milestone event. The Company repurchased a total of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,827&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock issued pursuant to the early exercise of stock options granted under the 2021 Plan for a total of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; during the year ended December 31, 2024, which was recorded to treasury stock in the Company's balance sheet (see Note 8).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock options granted under the 2023 Plan through December 31, 2024 are issued from new shares upon exercise, have a contractual term of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;10 years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; from grant date, and generally (i) are subject to requisite service requirements, and (ii) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;vest over a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;four-year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; period with &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the options granted vesting after one year and the remainder vesting in equal monthly installments over the following 36 months&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. Stock options granted under the 2023 Plan to certain of the Company's non-employee directors vest in equal annual installments over a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three-year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; period or over a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;one-year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; period.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the stock option activity under the 2021 Plan and the 2023 Plan for the years ended December 31, 2024 and December 31, 2023 (weighted-average remaining contractual term (in years) is not stated in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:44.791%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.878%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.38%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.298%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.878%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.38%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.398%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(per share)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,415,740&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.32&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.83&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,689&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,520,330&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.60&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;135,646&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.62&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,288&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;272,276&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;70,230&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.94&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding as of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,457,918&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.37&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.18&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,851&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options exercisable at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,954,937&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.16&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.38&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,851&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The weighted average grant date fair value of options granted during the years ended December 31, 2024 and 2023 was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.58&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.89&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#x2019;s common stock for those stock options that had exercise prices lower than the fair value of the Company&#x2019;s common stock. The total intrinsic value of stock options exercised during the year ended December 31, 2023 was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The total grant date fair values of stock options vested during the years ended December 31, 2024 and December 31, 2023 were $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company estimated the fair value of options granted using a Black-Scholes option pricing model with the following assumptions presented on a weighted average basis during the year ended December 31, 2024 (not stated in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:61.96%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.44%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.58%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.44%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.58%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.43&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.02&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.78&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;85.85&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;67.59&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The expected dividend yields are &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% as the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024 there was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of unrecognized stock-based compensation expense related to stock options estimated to be recognized over a weighted-average period of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2.62&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;RSU activity&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;RSUs granted under the 2023 Plan through December 31, 2024 generally (i) are subject to requisite service requirements, and (ii) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;vest over a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;four-year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; period with &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the RSUs vesting after approximately one year and the remainder vesting in equal quarterly installments over the following 12 quarters&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the RSU activity under the 2023 Plan for the year ended December 31, 2024:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:61.96%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.44%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.58%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.9%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.120000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant Date Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(per share)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Unvested as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;287,078&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.52&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,778&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14.65&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Unvested as of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;266,300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.59&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024 there was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of unrecognized stock-based compensation expense related to RSUs estimated to be recognized over a weighted-average period of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;3.28 &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;years.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Under the 2023 ESPP, eligible employees may purchase shares of the Company's common stock through payroll deductions at a price equal to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;85&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the lower of the fair market values of the stock as of the beginning or the end of six-month offering periods. Employees may not purchase more than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of the Company's common stock during any offering period. As of and during the years ended December 31, 2024 and December 31, 2023, stock-based compensation expense and the fair value of unearned employee stock ownership plans related to the 2023 ESPP was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t material.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation expense was classified as follows in the Company&#x2019;s statements of operations and comprehensive loss:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:62.072%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.86%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.103%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.86%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.103%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,001&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,751&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,473&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,292&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,474&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,043&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_5e1419ce-c719-45db-9032-ac6f99fec990"
      decimals="INF"
      id="F_dd7b85bd-5f7e-42ab-a718-da88af99a59b"
      unitRef="U_shares">582699</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_5b2a51f7-c997-4cda-9d61-3d1f32f1e815"
      decimals="INF"
      id="F_a842d8ab-13d5-4927-89c4-1d823abf27bb"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_2c640ac0-f0e4-4b44-953f-372c68c1666b"
      decimals="INF"
      id="F_12052bd2-4d44-483d-a3f3-18621d284711"
      unitRef="U_shares">1803980</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_44f34368-c2ff-4b64-9e18-4ee6525fb195"
      decimals="INF"
      id="F_825fdebb-2d1d-42bc-b02d-5acd19aba4c7"
      unitRef="U_shares">238600</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_2c640ac0-f0e4-4b44-953f-372c68c1666b"
      decimals="INF"
      id="F_7a093fdb-e8bd-431d-835a-745c311c1115"
      unitRef="U_shares">4737000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_2c640ac0-f0e4-4b44-953f-372c68c1666b"
      decimals="INF"
      id="F_e3adfe3c-d6cf-403b-a686-5234b41fa799"
      unitRef="U_shares">1803980</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <lxeo:PercentageOfAutomaticallyIncreaseInAvailableSharesOfCommonStockOnBeginningOfCachCalendarYear
      contextRef="C_2db6ae14-94d8-4061-8201-63bc8341dd14"
      decimals="2"
      id="F_7732807f-5b70-472b-8df2-a2c8f607a982"
      unitRef="U_pure">0.05</lxeo:PercentageOfAutomaticallyIncreaseInAvailableSharesOfCommonStockOnBeginningOfCachCalendarYear>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_44f34368-c2ff-4b64-9e18-4ee6525fb195"
      decimals="INF"
      id="F_c130a77a-c4b6-4b51-8afd-fa8e52575ed9"
      unitRef="U_shares">238600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <lxeo:PercentageOfAutomaticallyIncreaseInAvailableSharesOfCommonStockOnBeginningOfCachCalendarYear
      contextRef="C_d54dc3c6-3447-4e53-b661-49e8beab972a"
      decimals="2"
      id="F_264ad72c-82ab-48a8-b9b6-b4a811c100d1"
      unitRef="U_pure">0.01</lxeo:PercentageOfAutomaticallyIncreaseInAvailableSharesOfCommonStockOnBeginningOfCachCalendarYear>
    <lxeo:NumberOfSharesAutomaticallyIncreaseInAvailableSharesOfCommonStockUnderPlan
      contextRef="C_386c356b-4350-4ef6-bbc7-35471297e6b0"
      decimals="INF"
      id="F_963ad2f4-ece8-47e0-8a91-43f22d167ea9"
      unitRef="U_shares">477200</lxeo:NumberOfSharesAutomaticallyIncreaseInAvailableSharesOfCommonStockUnderPlan>
    <lxeo:IncreaseInCommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_889faa80-3bbf-40d1-b770-591485567a8d"
      decimals="INF"
      id="F_1f3fbf41-c79b-4ae3-93a3-b22d80c9180a"
      unitRef="U_shares">1333424</lxeo:IncreaseInCommonStockCapitalSharesReservedForFutureIssuance>
    <lxeo:IncreaseInCommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_2a226df6-55ca-4590-b4f4-0e51d8f169f6"
      decimals="INF"
      id="F_dff8c546-8c4b-478c-93e3-0e401b8c7be5"
      unitRef="U_shares">266684</lxeo:IncreaseInCommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_889faa80-3bbf-40d1-b770-591485567a8d"
      decimals="INF"
      id="F_c7257481-b21e-404d-977c-758952348994"
      unitRef="U_shares">6070424</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_2a226df6-55ca-4590-b4f4-0e51d8f169f6"
      decimals="INF"
      id="F_92aebde3-3ce1-4138-bf8e-0d3209d6c8d0"
      unitRef="U_shares">505284</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <lxeo:IncreaseInCommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_b4989bb1-3d29-41aa-910d-bd20c1974008"
      decimals="INF"
      id="F_0ea8af13-de5d-4761-b344-294543d65142"
      unitRef="U_shares">1653960</lxeo:IncreaseInCommonStockCapitalSharesReservedForFutureIssuance>
    <lxeo:IncreaseInCommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0f4466dd-9ea9-4c34-a1ae-2fdff5adc7ed"
      decimals="INF"
      id="F_ff72825b-5a3a-41ca-af89-92dd1ad9c922"
      unitRef="U_shares">330792</lxeo:IncreaseInCommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_b4989bb1-3d29-41aa-910d-bd20c1974008"
      decimals="INF"
      id="F_b24e6010-3e2f-4d34-bebe-392b1b416ef1"
      unitRef="U_shares">7724384</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0f4466dd-9ea9-4c34-a1ae-2fdff5adc7ed"
      decimals="INF"
      id="F_976426a3-d244-4bbe-a44f-b6ac207f1635"
      unitRef="U_shares">836076</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_63e8ef1c-8500-4aca-9829-40a638535f8d"
      decimals="INF"
      id="F_67e4def3-c251-4180-ab89-9abdcd47d29e"
      unitRef="U_shares">2185328</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_794eac83-f22b-40f0-ab3d-8bc9174bde90"
      decimals="INF"
      id="F_055ae26e-c672-416b-a509-3824f40bf7de"
      unitRef="U_shares">505284</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_794eac83-f22b-40f0-ab3d-8bc9174bde90"
      decimals="INF"
      id="F_2293e07a-be0c-4327-96aa-103ae647666e"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <lxeo:ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualTermGrantDate
      contextRef="C_6c352529-96a0-4c56-b6f7-beafae1427a8"
      id="F_71ee80bf-ce06-4bb1-9516-1dca932cf4e4">P10Y</lxeo:ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualTermGrantDate>
    <lxeo:ShareBasedCompensationPaymentDescription
      contextRef="C_c679f25f-cc6a-43c7-8227-e208b67e0722"
      id="F_9cb6e0ca-2a11-4d86-89f7-a97b2b6dcb21">vest over a four-year period with 25% of the options granted vesting after one year and the remainder vesting in equal monthly installments over the following 36 months</lxeo:ShareBasedCompensationPaymentDescription>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_6c352529-96a0-4c56-b6f7-beafae1427a8"
      id="F_dbb5911a-0173-49d7-8bbe-72b5e7774fbd">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="C_6c352529-96a0-4c56-b6f7-beafae1427a8"
      decimals="2"
      id="F_a75d0835-2f10-40fe-bcb4-dfbcb9acb87c"
      unitRef="U_pure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_6c352529-96a0-4c56-b6f7-beafae1427a8"
      id="F_e70bfffb-6e57-4d42-ab0c-c483c339deac">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="C_9d082257-9ef3-44bf-b671-47a3b444bcf4"
      decimals="INF"
      id="F_106b2a78-cfbb-448e-9c1d-e91db6f0d62c"
      unitRef="U_shares">3827</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="C_aaf7b4cc-4609-41bc-a23c-cf54d6116e53"
      decimals="0"
      id="F_09f3a5ab-764b-45e8-9482-28475322d14a"
      unitRef="U_USD">17000</us-gaap:StockRepurchasedDuringPeriodValue>
    <lxeo:ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualTermGrantDate
      contextRef="C_ae668a8e-dcdc-48f6-9c7d-cd99b945d79a"
      id="F_22f57384-6a70-451a-9229-c748a7c89c54">P10Y</lxeo:ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualTermGrantDate>
    <lxeo:ShareBasedCompensationPaymentDescription
      contextRef="C_ae668a8e-dcdc-48f6-9c7d-cd99b945d79a"
      id="F_0d22ccb1-03ce-4c77-88f6-ad2437c1549f">vest over a four-year period with 25% of the options granted vesting after one year and the remainder vesting in equal monthly installments over the following 36 months</lxeo:ShareBasedCompensationPaymentDescription>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_ae668a8e-dcdc-48f6-9c7d-cd99b945d79a"
      id="F_3de0020c-2638-4261-a4bd-d1b6140cac8b">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="C_ae668a8e-dcdc-48f6-9c7d-cd99b945d79a"
      decimals="2"
      id="F_eb1de0a8-4ff6-4831-93d5-1bb9f6e973a4"
      unitRef="U_pure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_460d7490-ff50-4c44-98f4-b0211c51d98c"
      id="F_6898b935-4e92-4bac-ba66-32b6283bb499">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_a65a8fba-bdff-47f7-a790-76ebb3dcb9f8"
      id="F_bba13ef2-e359-4987-ad65-602bd0872114">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_6df3d892-aa6b-437c-bd04-1b6669102044">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the stock option activity under the 2021 Plan and the 2023 Plan for the years ended December 31, 2024 and December 31, 2023 (weighted-average remaining contractual term (in years) is not stated in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:44.791%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.878%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.38%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.298%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.878%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.38%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.398%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(per share)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,415,740&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.32&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.83&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,689&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,520,330&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.60&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;135,646&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.62&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,288&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;272,276&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;70,230&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.94&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding as of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,457,918&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.37&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.18&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,851&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options exercisable at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,954,937&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.16&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.38&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,851&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_9a05326c-b178-412f-9312-a4d581f2c9d7"
      decimals="INF"
      id="F_f8becc96-2daa-44cd-93f1-88a5bc4f7c23"
      unitRef="U_shares">2415740</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_9a05326c-b178-412f-9312-a4d581f2c9d7"
      decimals="2"
      id="F_2aee35c7-eba1-49b6-96cc-b970c8582a84"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">8.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_7042155d-e81e-427a-88f0-e247950d7a4c"
      id="F_b5094625-4dd4-4b90-b5b6-d199fbc055dc">P7Y9M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_9a05326c-b178-412f-9312-a4d581f2c9d7"
      decimals="-3"
      id="F_89ceb185-041a-406a-bccc-78e7e3228461"
      unitRef="U_USD">13689000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_8ca9fee4-3e70-406e-b516-57586deaa558"
      decimals="INF"
      id="F_2844795f-14ac-4317-9b87-a9f38679e304"
      unitRef="U_shares">1520330</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_8ca9fee4-3e70-406e-b516-57586deaa558"
      decimals="2"
      id="F_7f49589f-a3cc-4566-8d1d-083a0f26f31f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">15.6</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_8ca9fee4-3e70-406e-b516-57586deaa558"
      decimals="INF"
      id="F_a557552b-a892-4d46-872e-b26be4c94d8e"
      unitRef="U_shares">135646</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_8ca9fee4-3e70-406e-b516-57586deaa558"
      decimals="2"
      id="F_7284f39d-edca-4dfe-8493-f0c642755666"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.62</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_8ca9fee4-3e70-406e-b516-57586deaa558"
      decimals="-3"
      id="F_2f65ab54-a251-4e56-aa1d-22408c345d75"
      unitRef="U_USD">1288000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_8ca9fee4-3e70-406e-b516-57586deaa558"
      decimals="INF"
      id="F_12e588d6-2bf5-4d3b-bbde-b6111b850264"
      unitRef="U_shares">272276</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_8ca9fee4-3e70-406e-b516-57586deaa558"
      decimals="2"
      id="F_92bca7e5-0530-4222-bc5f-733924449d1b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">11.4</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="C_8ca9fee4-3e70-406e-b516-57586deaa558"
      decimals="INF"
      id="F_f3d7e8b6-1aa2-41e4-87a8-efcdc8affc57"
      unitRef="U_shares">70230</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="C_8ca9fee4-3e70-406e-b516-57586deaa558"
      decimals="2"
      id="F_aff59ccf-873a-4024-a4e3-cc58ad3adf96"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">12.94</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_17a6e9db-02db-43c5-9308-865a99b44dc2"
      decimals="INF"
      id="F_cf69608a-2459-490b-bb8b-193d26ef79e8"
      unitRef="U_shares">3457918</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_17a6e9db-02db-43c5-9308-865a99b44dc2"
      decimals="2"
      id="F_accfd193-64e4-45ff-98b7-6fedb2b2e3f0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">11.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_8ca9fee4-3e70-406e-b516-57586deaa558"
      id="F_c993d7d5-91c5-48b1-ba67-c0d96ec34ef5">P8Y2M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_17a6e9db-02db-43c5-9308-865a99b44dc2"
      decimals="-3"
      id="F_3f1fc462-52e9-462c-b83e-bf3b3615b2fa"
      unitRef="U_USD">2851000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_17a6e9db-02db-43c5-9308-865a99b44dc2"
      decimals="INF"
      id="F_ebbc96f4-d827-4cb9-b674-82ff0851dceb"
      unitRef="U_shares">1954937</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_17a6e9db-02db-43c5-9308-865a99b44dc2"
      decimals="2"
      id="F_a3b81aba-9448-493d-abf0-a828b50edb0d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">8.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_8ca9fee4-3e70-406e-b516-57586deaa558"
      id="F_a571cd17-9d3c-4a8c-959c-230832b349ed">P7Y4M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_17a6e9db-02db-43c5-9308-865a99b44dc2"
      decimals="-3"
      id="F_3c6f4f10-763c-4df4-8446-634f67133ca3"
      unitRef="U_USD">2851000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_d210b17b-f2c2-4a07-9b34-0371db6164dd"
      decimals="2"
      id="F_1f4d6fe7-c66e-4256-93d6-4c803bf8f300"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">11.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_d4ba692f-b7d0-4af9-9603-697859726ab1"
      decimals="2"
      id="F_a026973f-ae13-44c0-8b8d-d0817d34a03d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">9.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_d4ba692f-b7d0-4af9-9603-697859726ab1"
      decimals="0"
      id="F_9c062f66-2765-4a69-83c6-95341ffa71cd"
      unitRef="U_USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="C_d210b17b-f2c2-4a07-9b34-0371db6164dd"
      decimals="-5"
      id="F_d26c6341-9dbc-4c01-bcd5-648e6701c0cc"
      unitRef="U_USD">7100000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="C_d4ba692f-b7d0-4af9-9603-697859726ab1"
      decimals="-5"
      id="F_984c6220-cc39-4dae-8b94-94eaf1e663b1"
      unitRef="U_USD">2400000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_02462a73-0e6c-43a3-b078-90557295626d">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company estimated the fair value of options granted using a Black-Scholes option pricing model with the following assumptions presented on a weighted average basis during the year ended December 31, 2024 (not stated in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:61.96%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.44%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.58%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.44%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.58%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.43&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.02&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.78&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;85.85&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;67.59&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_d210b17b-f2c2-4a07-9b34-0371db6164dd"
      decimals="4"
      id="F_dc0b5a8f-e23b-40ca-a1a3-839d2779e259"
      unitRef="U_pure">0.0414</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_d4ba692f-b7d0-4af9-9603-697859726ab1"
      decimals="4"
      id="F_7faf58d3-c847-4ffa-8483-f034171ef31f"
      unitRef="U_pure">0.0343</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_d210b17b-f2c2-4a07-9b34-0371db6164dd"
      id="F_2793de8a-3380-4039-93f0-3873aedbccd0">P6Y7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_d4ba692f-b7d0-4af9-9603-697859726ab1"
      id="F_f0a22b2b-41d4-49d5-aaf2-e9caec59f884">P5Y9M10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_d210b17b-f2c2-4a07-9b34-0371db6164dd"
      decimals="4"
      id="F_77491c10-e5ab-427c-8d31-ef1bada6358b"
      unitRef="U_pure">0.8585</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_d4ba692f-b7d0-4af9-9603-697859726ab1"
      decimals="4"
      id="F_5a8122a2-6d17-423c-843d-b0c8d0f5b82c"
      unitRef="U_pure">0.6759</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_d210b17b-f2c2-4a07-9b34-0371db6164dd"
      decimals="4"
      id="F_d11736e2-55aa-471f-bb7b-d751aa02a3e2"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_d4ba692f-b7d0-4af9-9603-697859726ab1"
      decimals="4"
      id="F_d8f98218-f3b8-4feb-8d8f-d3d89540c18a"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_d210b17b-f2c2-4a07-9b34-0371db6164dd"
      decimals="4"
      id="F_2bbb0485-74a7-4696-916f-f22591aa7c27"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_642842bb-c457-4819-9738-9093909922ea"
      decimals="-5"
      id="F_ee223627-6d22-48cf-8abb-3aa72cdd1e4f"
      unitRef="U_USD">13600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_d210b17b-f2c2-4a07-9b34-0371db6164dd"
      id="F_f22895cc-cead-42d8-aa09-f57b17efacfd">P2Y7M13D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <lxeo:ShareBasedCompensationPaymentDescription
      contextRef="C_f6d073df-b45c-4611-a81b-0bd39b099fbf"
      id="F_9ebb737d-74b3-404f-bc09-2d7063c0db79">vest over a four-year period with 25% of the RSUs vesting after approximately one year and the remainder vesting in equal quarterly installments over the following 12 quarters</lxeo:ShareBasedCompensationPaymentDescription>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_f6d073df-b45c-4611-a81b-0bd39b099fbf"
      id="F_ef35818b-f96f-473f-80e9-184ac37ed57f">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="C_f6d073df-b45c-4611-a81b-0bd39b099fbf"
      decimals="2"
      id="F_2ddbed77-3cbf-4409-985f-d029d8317223"
      unitRef="U_pure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_15e40e10-4717-4293-bbb0-a248b5a617fd">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the RSU activity under the 2023 Plan for the year ended December 31, 2024:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:61.96%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.44%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.58%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.9%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.120000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant Date Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(per share)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Unvested as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;287,078&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.52&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,778&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14.65&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Unvested as of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;266,300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.59&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_afe980af-4f26-4fd3-8f3e-e44a3e233ab1"
      decimals="INF"
      id="F_2af97535-5136-4c3e-ae50-2188c3bb393e"
      unitRef="U_shares">287078</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_afe980af-4f26-4fd3-8f3e-e44a3e233ab1"
      decimals="2"
      id="F_a7825116-4c85-46cc-8882-02a4c414bccb"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">15.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_afe980af-4f26-4fd3-8f3e-e44a3e233ab1"
      decimals="INF"
      id="F_fa02c6c1-e6b7-4e7c-9024-19cd4b729da0"
      unitRef="U_shares">20778</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="C_afe980af-4f26-4fd3-8f3e-e44a3e233ab1"
      decimals="2"
      id="F_d4ee3518-ce82-4834-b13c-d4b1f4f63b02"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">14.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_98dbb090-8617-48e2-9f19-11212333ce32"
      decimals="INF"
      id="F_1a2a8801-b2eb-453c-87aa-a81a10f15a03"
      unitRef="U_shares">266300</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_98dbb090-8617-48e2-9f19-11212333ce32"
      decimals="2"
      id="F_22015f1a-fbff-4714-ba28-d9d99e1244ad"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">15.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_818a9569-5179-4332-bce6-97002fa8dd65"
      decimals="-5"
      id="F_b7feb7aa-ff60-4b2c-88b1-2da1773622b5"
      unitRef="U_USD">3300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_465c4136-b851-42be-84ee-27ed04fe8539"
      id="F_87370e41-cf07-40e3-ac3d-fda61826df7a">P3Y3M10D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <lxeo:PayrollDeductionsAtPrice
      contextRef="C_8821cec2-12fd-4f69-a047-478fca32226c"
      decimals="2"
      id="F_7c7ca657-751a-4846-a350-4072639bc4b0"
      unitRef="U_pure">0.85</lxeo:PayrollDeductionsAtPrice>
    <lxeo:CommonStockDuringOfferingPeriod
      contextRef="C_63208a9b-1a99-4da2-85ef-0801d8013b63"
      decimals="INF"
      id="F_eef80bbf-c4bc-4012-a26d-6d69cbcdc5dd"
      unitRef="U_shares">6000</lxeo:CommonStockDuringOfferingPeriod>
    <lxeo:FairValueOfUnearnedEmployeeStockOwnershipPlans
      contextRef="C_8821cec2-12fd-4f69-a047-478fca32226c"
      decimals="INF"
      id="F_9002bbdd-f7fb-412c-b76b-6690726e5a02"
      unitRef="U_USD">0</lxeo:FairValueOfUnearnedEmployeeStockOwnershipPlans>
    <lxeo:FairValueOfUnearnedEmployeeStockOwnershipPlans
      contextRef="C_44325f11-2b42-4650-93e1-0c060ce8130d"
      decimals="INF"
      id="F_58c2cac4-6fb2-4325-a81a-8889af0ebe0d"
      unitRef="U_USD">0</lxeo:FairValueOfUnearnedEmployeeStockOwnershipPlans>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_f5be0796-0b80-4dd7-bc64-d517c69c3816">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation expense was classified as follows in the Company&#x2019;s statements of operations and comprehensive loss:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:62.072%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.86%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.103%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.86%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.103%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,001&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,751&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,473&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,292&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,474&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,043&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_db4d6fe7-17ff-4f4e-803b-2c15cda55624"
      decimals="-3"
      id="F_c9c3043a-274d-4f48-b758-ab302ccb1219"
      unitRef="U_USD">6001000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_18e0f1c1-de91-4bc1-b5ce-39772b43d1e3"
      decimals="-3"
      id="F_a3ecbc8e-6af7-4e2c-98b4-ee9aaea411b6"
      unitRef="U_USD">1751000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_f22d9e2e-1a87-48b1-bd28-4d0a0a5afdfb"
      decimals="-3"
      id="F_01da58d8-7c4d-49c8-9d51-83c6bbda97ad"
      unitRef="U_USD">6473000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_3b4c1dc7-9d04-44ef-97e9-98e10c0a6e4e"
      decimals="-3"
      id="F_f2ec6d86-5515-4e0b-bf00-565658871f0b"
      unitRef="U_USD">1292000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      decimals="-3"
      id="F_06132283-3e01-47a7-b655-8769d72766be"
      unitRef="U_USD">12474000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca"
      decimals="-3"
      id="F_0634fc32-2a15-4b0e-aa1d-10d662ce84d7"
      unitRef="U_USD">3043000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_001dca8e-608b-4e55-a7d1-03cac0b67b51">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;10. Net Loss per Share&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basic and diluted net loss per common share attributable to common stockholders was calculated as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:63.247%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.84%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.537%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.84%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.537%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Numerator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss attributable to common stockholders&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;98,333&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;66,394&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Denominator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average common shares outstanding, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31,787,491&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,354,368&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss per share attributable to common stockholders, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.09&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_48ea2ae8-d38d-4744-9b07-1774363f928f">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basic and diluted net loss per common share attributable to common stockholders was calculated as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:63.247%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.84%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.537%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.84%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.537%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Numerator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss attributable to common stockholders&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;98,333&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;66,394&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Denominator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average common shares outstanding, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31,787,491&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,354,368&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss per share attributable to common stockholders, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.09&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      decimals="-3"
      id="F_ec1f79cc-f567-49fb-b651-ee525602b4b2"
      unitRef="U_USD">-98333000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca"
      decimals="-3"
      id="F_f623000c-a438-4ab6-a662-b318c655e8f0"
      unitRef="U_USD">-66394000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      decimals="0"
      id="F_bd5b8c5b-9841-4fbc-8336-7b31b2b71b3c"
      unitRef="U_shares">31787491</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      decimals="0"
      id="F_82febfcf-87f2-449b-ab72-e4bd69508291"
      unitRef="U_shares">31787491</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca"
      decimals="0"
      id="F_f092e840-046e-41d4-9eb5-e0acc859d9fb"
      unitRef="U_shares">5354368</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca"
      decimals="0"
      id="F_8c464008-5127-42ef-af30-141ad7a24f46"
      unitRef="U_shares">5354368</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      decimals="2"
      id="F_cac7f9d2-5d06-41d5-859e-fc4c7ac0eb32"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-3.09</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      decimals="2"
      id="F_456675f1-8db4-40f1-babe-9670b7596317"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-3.09</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca"
      decimals="2"
      id="F_ff862a2c-e160-43af-afaa-0b7265449c23"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-12.4</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca"
      decimals="2"
      id="F_15e9be39-3237-40d4-9d00-1de0bc494c9b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-12.4</us-gaap:EarningsPerShareBasic>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_3b6333a7-4e1f-4e36-b65d-7f79e390ba07">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;11. Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A reconciliation of the Company's statutory income tax rate to the Company&#x2019;s effective income tax rate is as follows for the years ended December 31, 2024, and December 31, 2023:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:91.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.03%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:17.435000000000002%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.03%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:17.148%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Federal statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;State Taxes, net of federal benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.72&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.80&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33.98&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36.12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Permanent differences&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.51&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.36&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.73&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.80&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.96&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Effective income tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The principal components of the Company's deferred tax assets and liabilities at December 31, 2024 and December 31, 2023 are as follows:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.688%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.063%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:17.259%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.063%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:16.926%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33,295&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,904&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,743&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,070&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Intangibles&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,918&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,241&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Capitalized R&amp;amp;D expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39,338&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25,127&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,818&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,244&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,292&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,753&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;98,404&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;65,339&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;95,426&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;61,974&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,978&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,365&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.688%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.063%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:17.259%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.063%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:16.926%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Right of use asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,663&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,102&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;315&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;263&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,978&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,365&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net deferred tax assets (liabilities)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024 and 2023, the Company had federal net operating loss ("NOL") carryforwards of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;106.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;70.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively, which can be carried forward indefinitely. As of December 31, 2024 and December 31, 2023, the Company had state and local net operating loss carryforwards of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;212.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;139.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively, which begin to expire in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2040&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024 and December 31, 2023, the Company had federal tax credits of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively, which begin to expire in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2040&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Future realization of the tax benefits of existing temporary differences and net operating loss carryforwards ultimately depends on the existence of sufficient taxable income within the carryforward period. As of December 31, 2024 and December 31, 2023, the Company performed an evaluation to determine whether a valuation allowance was needed. The Company considered all available evidence, both positive and negative, which included the results of operations for the current and preceding years. The Company determined that it was not possible to reasonably quantify future taxable income and determined that it is more likely than not that all of the deferred tax assets will not be realized. Accordingly, the Company maintained a full valuation allowance as of December 31, 2024 and December 31, 2023.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The utilization of NOLs and tax credit carryforwards to offset future taxable income may be subject to an annual limitation as a result of ownership changes that have occurred previously or may occur in the future. Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, (the &#x201c;IRC&#x201d;), a corporation that undergoes an ownership change may be subject to limitations on its ability to utilize its pre-change NOLs and other tax attributes otherwise available to offset future taxable income and/or tax liability. An ownership change is defined as a cumulative change of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% or more in the ownership positions of certain stockholders during a rolling three-year period.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company conducted an ownership analysis under IRC Section 382 as of September 30, 2024 and determined the Company experienced an ownership change associated with the closing of the Company's IPO on November 7, 2023 that limits the Company&#x2019;s NOLs and tax credits. As a result of the ownership change, the Company is limited to a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,689,195&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; annual limitation on its ability to utilize its NOLs and tax credits recognized prior to the ownership change. Due to this limitation, no federal NOLs are expected to expire unutilized and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of federal tax credits that had been available to offset future tax liabilities, prior to the date of the ownership change, will expire unutilized. As a result, during the year ended December 31, 2024, the Company reduced its deferred tax assets related to the federal tax credits, which was offset by a corresponding decrease in the valuation allowance.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The calculation of the Company's tax liabilities involves dealing with uncertainties in the application of complex tax laws and regulations for both federal taxes and the many states in which it operates or does business in. ASC 740 states that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, on the basis of the technical merits.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company records uncertain tax positions as liabilities in accordance with ASC 740 and adjusts these liabilities when its judgment changes as a result of the evaluation of new information not previously available. Because of the complexity of some of these uncertainties, the ultimate resolution may result in a payment that is materially different from the Company's current estimate of the unrecognized tax benefit liabilities. These differences will be reflected as increases or decreases to income tax expense in the period in which new information is available. As of December 31, 2024 and December 31, 2023, the Company has &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t recorded any uncertain tax positions in its financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company recognizes interest and penalties related to uncertain tax positions on the income tax expense line in the accompanying statements of operations. As of December 31, 2024 and December 31, 2023, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; accrued interest or penalties are included on the related tax liability line in the balance sheet.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company files tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. The resolution of tax matters is not expected to have a material effect on the Company's financial statements.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_c332914d-d577-4d7b-b5c1-27928be876b1">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A reconciliation of the Company's statutory income tax rate to the Company&#x2019;s effective income tax rate is as follows for the years ended December 31, 2024, and December 31, 2023:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:91.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.03%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:17.435000000000002%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.03%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:17.148%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Federal statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;State Taxes, net of federal benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.72&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.80&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33.98&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36.12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Permanent differences&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.51&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.36&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.73&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.80&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.96&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Effective income tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      decimals="INF"
      id="F_e398e903-a766-45a1-91ec-d62bd638567c"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca"
      decimals="INF"
      id="F_34d47b1a-6711-4b7a-8204-88817fe7148f"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      decimals="4"
      id="F_e6fec0f5-afe5-4df6-af8f-8b2d6e2eca58"
      unitRef="U_pure">0.1072</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca"
      decimals="4"
      id="F_13a543f5-7cf6-468c-8c54-807f562e9d5b"
      unitRef="U_pure">0.108</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      decimals="4"
      id="F_e0d56f88-7de3-43f4-bb9e-06fb667b4e24"
      unitRef="U_pure">-0.3398</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca"
      decimals="4"
      id="F_6feae12c-fdfc-4f21-b426-8ee205d66d4e"
      unitRef="U_pure">-0.3612</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      decimals="4"
      id="F_0c0591de-981c-4f0b-a892-f48d42514963"
      unitRef="U_pure">-0.0051</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca"
      decimals="4"
      id="F_1e22dfd9-2f03-42ac-88ff-cc54e970d5d5"
      unitRef="U_pure">-0.0036</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      decimals="4"
      id="F_61756e3d-86fc-4e6e-8dc2-53716eaca317"
      unitRef="U_pure">-0.0373</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca"
      decimals="4"
      id="F_03fc9d1e-0120-4ecc-b64d-5b3f09d1e389"
      unitRef="U_pure">-0.048</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      decimals="4"
      id="F_a197c325-65c5-4a89-b9f1-edd8177a5c78"
      unitRef="U_pure">-0.0096</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca"
      decimals="4"
      id="F_eb53aee9-231d-4767-b511-463406bd66ee"
      unitRef="U_pure">-0.0012</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      decimals="4"
      id="F_82d3a3d7-e829-4e60-9ae1-fe1e3f05fb87"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_c9b9a83c-8855-418a-b5a8-d7d3145d42ca"
      decimals="4"
      id="F_6932a1c5-1bfa-4e11-a013-ddd11e6386db"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_895193cc-0f01-47ba-9880-64f51829bdcc">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The principal components of the Company's deferred tax assets and liabilities at December 31, 2024 and December 31, 2023 are as follows:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.688%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.063%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:17.259%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.063%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:16.926%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33,295&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,904&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,743&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,070&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Intangibles&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,918&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,241&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Capitalized R&amp;amp;D expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39,338&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25,127&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,818&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,244&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,292&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,753&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;98,404&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;65,339&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;95,426&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;61,974&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,978&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,365&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.688%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.063%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:17.259%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.063%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:16.926%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Right of use asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,663&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,102&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;315&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;263&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,978&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,365&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net deferred tax assets (liabilities)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="-3"
      id="F_e5a244d0-e0e7-483d-8e51-59ac89a7cc04"
      unitRef="U_USD">33295000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_28144b67-7dfd-494d-8133-75abcc735058"
      decimals="-3"
      id="F_88bdd709-6147-4a06-8960-b3deb80bc13f"
      unitRef="U_USD">21904000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="-3"
      id="F_206b128d-54e1-4f20-b3a8-a27bfe76903e"
      unitRef="U_USD">10743000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="C_28144b67-7dfd-494d-8133-75abcc735058"
      decimals="-3"
      id="F_e161a92c-4972-4b3e-bf70-730d2ab040df"
      unitRef="U_USD">7070000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <lxeo:DeferredTaxAssetsIntangibleAssets
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="-3"
      id="F_39c83b88-3691-4c00-8d66-95afcec5318e"
      unitRef="U_USD">5918000</lxeo:DeferredTaxAssetsIntangibleAssets>
    <lxeo:DeferredTaxAssetsIntangibleAssets
      contextRef="C_28144b67-7dfd-494d-8133-75abcc735058"
      decimals="-3"
      id="F_1b5a2a51-642a-49ef-b261-d353ef15693c"
      unitRef="U_USD">4241000</lxeo:DeferredTaxAssetsIntangibleAssets>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="-3"
      id="F_934ac133-11f2-4fcc-8e56-e17944d58c18"
      unitRef="U_USD">39338000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_28144b67-7dfd-494d-8133-75abcc735058"
      decimals="-3"
      id="F_675be89e-82de-4ab8-86a8-c796688ce8b8"
      unitRef="U_USD">25127000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <lxeo:DeferredTaxAssetsLeaseLiabilities
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="-3"
      id="F_876602ae-c2b8-457f-9854-285d22f9f4f1"
      unitRef="U_USD">2818000</lxeo:DeferredTaxAssetsLeaseLiabilities>
    <lxeo:DeferredTaxAssetsLeaseLiabilities
      contextRef="C_28144b67-7dfd-494d-8133-75abcc735058"
      decimals="-3"
      id="F_298fc5e7-5079-422e-b1b7-d072b5d1bb7f"
      unitRef="U_USD">3244000</lxeo:DeferredTaxAssetsLeaseLiabilities>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="-3"
      id="F_b82852ed-06a9-40ca-94de-5de3e5e47676"
      unitRef="U_USD">6292000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_28144b67-7dfd-494d-8133-75abcc735058"
      decimals="-3"
      id="F_8bd045b9-3aaf-4b8b-a687-5b6027cbdf09"
      unitRef="U_USD">3753000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="-3"
      id="F_39a559f3-4c66-414d-b743-a07838490d62"
      unitRef="U_USD">98404000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_28144b67-7dfd-494d-8133-75abcc735058"
      decimals="-3"
      id="F_52d1eef0-890c-4c51-b8d9-435c0b6a394c"
      unitRef="U_USD">65339000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="-3"
      id="F_f1ce16f8-5d6f-4add-bf18-1539ed97bcf3"
      unitRef="U_USD">95426000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_28144b67-7dfd-494d-8133-75abcc735058"
      decimals="-3"
      id="F_7452e813-3b0d-4188-aa18-0a0670ff1483"
      unitRef="U_USD">61974000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="-3"
      id="F_51970f40-dc1a-418c-b7ff-d21a4971e1b7"
      unitRef="U_USD">2978000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_28144b67-7dfd-494d-8133-75abcc735058"
      decimals="-3"
      id="F_84af31c1-861f-4f2d-903a-5fe339017ce7"
      unitRef="U_USD">3365000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="-3"
      id="F_a64b88fc-86b0-447b-afb0-a167c09a7eee"
      unitRef="U_USD">2663000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="C_28144b67-7dfd-494d-8133-75abcc735058"
      decimals="-3"
      id="F_e7f59281-2810-402b-b6e0-702af78e1c68"
      unitRef="U_USD">3102000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="-3"
      id="F_d894c368-3900-43e2-8069-3a5caedc6f16"
      unitRef="U_USD">315000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="C_28144b67-7dfd-494d-8133-75abcc735058"
      decimals="-3"
      id="F_320f03d0-6679-4d9f-a2f6-5055799c46d0"
      unitRef="U_USD">263000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="-3"
      id="F_554edf10-61c2-466c-9627-221c65ae8514"
      unitRef="U_USD">2978000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_28144b67-7dfd-494d-8133-75abcc735058"
      decimals="-3"
      id="F_7b7df12d-59d9-4f5d-befd-99996d22f6f8"
      unitRef="U_USD">3365000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="-3"
      id="F_bb57bdb7-8e16-40d3-a518-dd46008c2320"
      unitRef="U_USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_28144b67-7dfd-494d-8133-75abcc735058"
      decimals="-3"
      id="F_9a8c4eb4-d82d-4e1e-ba7f-97a0d7694a9f"
      unitRef="U_USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_fe2a112e-35b6-427a-9cf1-e602c55b5ef9"
      decimals="-5"
      id="F_538e21c9-3579-4776-823f-4dba8a6fda93"
      unitRef="U_USD">106400000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_6a7a8e57-c021-4d66-95a4-3d7c93e89b8b"
      decimals="-5"
      id="F_7e1eb0f4-c611-4cce-ab3a-f7d1089e561a"
      unitRef="U_USD">70200000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_66ade898-e08e-4277-96a4-d86c2aa63e09"
      decimals="-5"
      id="F_6014dc24-60bb-49dd-b32e-b810d91c807f"
      unitRef="U_USD">212700000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_adf39fa9-e13e-4660-a6b0-e64e383d673a"
      decimals="-5"
      id="F_43c4cb49-c56f-4334-9a60-1c25f337fc28"
      unitRef="U_USD">139300000</us-gaap:OperatingLossCarryforwards>
    <lxeo:OperatingLossCarryForwardsExpirationYear
      contextRef="C_56bb5356-0f0e-409e-b6a4-c7cb72c011e1"
      id="F_4c662304-38a0-4051-ab64-d5f17f1d552d">2040</lxeo:OperatingLossCarryForwardsExpirationYear>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_fe2a112e-35b6-427a-9cf1-e602c55b5ef9"
      decimals="-5"
      id="F_14f80352-9ca6-4d07-90c3-2bceaaba2d74"
      unitRef="U_USD">10700000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_6a7a8e57-c021-4d66-95a4-3d7c93e89b8b"
      decimals="-5"
      id="F_e4419583-9196-49d8-96a4-e5a80a4df052"
      unitRef="U_USD">7100000</us-gaap:TaxCreditCarryforwardAmount>
    <lxeo:TaxCreditCarryForwardExpirationYear
      contextRef="C_500ad48d-4ad0-4259-8d4a-c15b843c549a"
      id="F_73b1003d-aff9-4917-8fe2-c83f0a154bdd">2040</lxeo:TaxCreditCarryForwardExpirationYear>
    <lxeo:PercentageOfCumulativeOwnershipChange
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      decimals="2"
      id="F_ed2b5f45-a16a-465e-85fb-798789cb60d9"
      unitRef="U_pure">0.50</lxeo:PercentageOfCumulativeOwnershipChange>
    <lxeo:AnnualLimitationAbilityToUtilize
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      decimals="INF"
      id="F_37108c59-4aff-45b8-a7eb-98cd4ec7399e"
      unitRef="U_USD">1689195</lxeo:AnnualLimitationAbilityToUtilize>
    <us-gaap:IncomeTaxReconciliationTaxCreditsForeign
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      decimals="-5"
      id="F_1bf64344-3411-47e4-ba61-92682c28906f"
      unitRef="U_USD">2900000</us-gaap:IncomeTaxReconciliationTaxCreditsForeign>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="INF"
      id="F_4ee90a60-1287-4e41-99c1-b4c748386249"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_28144b67-7dfd-494d-8133-75abcc735058"
      decimals="INF"
      id="F_0c0339ce-a235-47c9-9b34-513ca46e0731"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="C_1b2d6a36-1a01-47ee-b773-2a16d5242136"
      decimals="INF"
      id="F_67014513-4325-4d60-8b88-2ec5b04f627a"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="C_28144b67-7dfd-494d-8133-75abcc735058"
      decimals="INF"
      id="F_897458ed-8f48-4c59-bc73-205e7169a8a9"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_b81ae0e3-a98a-4b72-98ca-a66f33ad6d9d">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;12. Commitments and Contingencies&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;As of December 31, 2024, the Company had entered into commitments under lease agreements to rent laboratory and office space and finance equipment (see Note 5).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Commitments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;As of December 31, 2024, the Company had entered into commitments under license, acquisition, research collaboration and sponsored research agreements with third parties (see Note 13). In addition, the Company has entered into services agreements with third parties for pharmaceutical manufacturing and research activities in the normal course of business, which can generally be terminated by the Company with &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;30&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;- to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;60&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;-days&#x2019; written notice, unless otherwise indicated. Further, certain of the Company&#x2019;s manufacturing agreements could require early termination and wind-down payments due from the Company upon either the termination of its clinical trials or if the Company terminates such agreements for convenience.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Contingencies&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of business. The Company recognizes any associated legal fees as incurred and accrues a liability for such contingent liability matters when it is probable that future expenditures will be made, and such expenditures can be reasonably estimated. For all periods presented, the Company was not a party to any pending material litigation or other material legal proceedings, except that on October 12, 2023, Rocket Pharmaceuticals, Inc. (&#x201c;Rocket&#x201d;) filed a lawsuit in the U.S. District Court for the Southern District of New York against the Company and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;two&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; former employees claiming, among other things, misappropriation of confidential information and trade secrets. The complaint alleges the individual defendants downloaded confidential Rocket company documents and other proprietary materials prior to leaving Rocket in 2021 and that the Company used this information to advance its programs after they became employed at Lexeo. The complaint seeks unspecified damages and asks the court to enjoin the Company from competing and working in the market for gene therapy treatments targeting cardiac diseases. In August 2024, the Company asserted counterclaims against Rocket and Spacecraft Seven LLC, a wholly owned subsidiary of Rocket, for misappropriation of trade secrets, correction of inventorship of certain patents, breach of contract, and tortious interference with contract. &lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our counterclaims seek equitable relief, damages, attorneys' fees and costs from Rocket and Spacecraft Seven LLC. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The case is currently in the discovery phase. While it is not possible to predict the outcome with certainty and an estimate of the possible loss cannot be made, the Company currently does not expect the final outcome will have a material adverse effect on its timelines for development of its product candidates.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Indemnification Agreements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its Board of Directors and executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. For all periods presented, the Company has not incurred any material costs as a result of such indemnifications.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <lxeo:LicenseAgreementTerminationNoticePeriod
      contextRef="C_f6b1ccbb-21c3-4469-9c9a-20c3e22a9b8c"
      id="F_5ee059ae-39f2-49fd-9b1f-831ee7a23452">P30D</lxeo:LicenseAgreementTerminationNoticePeriod>
    <lxeo:LicenseAgreementTerminationNoticePeriod
      contextRef="C_df27e94d-4502-4904-99fe-3d1d46216d3e"
      id="F_65a0215d-8cf7-4f10-93c4-14b11f325bc2">P60D</lxeo:LicenseAgreementTerminationNoticePeriod>
    <lxeo:NumberOfFormerEmployees
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      decimals="INF"
      id="F_4687dfc6-6b94-4901-b21b-efa37114f36b"
      unitRef="U_Employees">2</lxeo:NumberOfFormerEmployees>
    <lxeo:LicenseAndAcquisitionAndResearchCollaborationAndSponsoredResearchAgreementsDisclosureTextBlock
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_09f69824-f1f7-4d75-915d-77645f54b2e3">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;13. License, Acquisition, Research and Collaboration and Sponsored Research Agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Adverum Biotechnologies&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;On January 25, 2021, the Company entered into an exclusive license agreement with Adverum Biotechnologies Inc. (&#x201c;Adverum&#x201d;) to in-license materials and technology related to the treatment of cardiomyopathy due to Friedreich ataxia ("FA") (the &#x201c;Adverum Agreement&#x201d;). In connection with the Adverum Agreement, the Company gained access to a portfolio of inventions, patent rights, technology, and licensed methods that the Company continues to develop, and the Company will assume all development and commercialization activities worldwide. Pursuant to the Adverum Agreement, the Company paid a one-time up-front non-refundable fee of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, and is obligated to pay aggregate development and regulatory milestones of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million including a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million development milestone that was achieved and paid in the first quarter of 2023, and aggregate sales event and commercialization milestones of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;49.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is obligated to pay Adverum tiered royalties ranging from high single-digits to sub teens based on annual aggregate worldwide net sales of Products (as defined in the Adverum Agreement).&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; As of December 31, 2024, there were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; research and development expenses recorded by the Company or payments made to Adverum under the terms of the Adverum Agreement other than the one-time up-front non-refundable fee of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and the $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million development milestone that was achieved and paid in the first quarter of 2023.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Adverum Agreement remains in effect until termination at the date of the last royalty term to expire. The Company can terminate the Adverum Agreement with &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;120&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; days&#x2019; written notice. The Adverum Agreement can also be terminated as a result of a patent challenge, material breach of contractual terms, or insolvency by either party.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cornell University&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;On May 28, 2020, the Company entered into &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;two&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; exclusive license agreements with Cornell University (&#x201c;Cornell&#x201d;) (the &#x201c;First Cornell License Agreement&#x201d; and the &#x201c;Second Cornell License Agreement,&#x201d; collectively the &#x201c;May 2020 Cornell License Agreements&#x201d;). The First Cornell License Agreement is for the in-license of technology related to portfolios for APOE-associated Alzheimer&#x2019;s disease and Anti-Tau, although the Company&#x2019;s license is not restricted by such indications and it includes assignment to the Company of Cornell&#x2019;s IND for the use of AAVrh10.hAPOE2 vector to treat APOE4 homozygous patients who are at risk for or have Alzheimer&#x2019;s disease to support development of the Company&#x2019;s LX1001 program. The Second Cornell License Agreement is for the in-license of technology related to a portfolio for FA although the Company&#x2019;s license is not restricted by such indications, and it includes assignment to the Company of Cornell&#x2019;s IND for the use of AAVrh.10cUhCLN2 to treat children with CLN2 Batten disease to support development of the Company&#x2019;s LX1004 program. Through the May 2020 Cornell License Agreements, the Company gains access to a portfolio of inventions, patent rights, technology, and licensed methods that the Company continues to develop. Under the terms of the May 2020 Cornell License Agreements, the Company has assumed all development and commercialization activities worldwide with respect to the licensed technology.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As initial consideration for the May 2020 Cornell License Agreements, the Company paid Cornell an upfront payment in cash of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and issued $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of notes (the &#x201c;Cornell Notes&#x201d;). In November 2020, the Cornell Notes with outstanding principal of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million were cancelled in exchange for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,337,610&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of series A convertible preferred stock, which converted into &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;126,258&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock upon the closing of the Company's IPO on November 7, 2023. As additional consideration, the Company is required to pay Cornell up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million upon the achievement of specific clinical and regulatory milestones under the First Cornell License Agreement and up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in two portfolios and up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for a third portfolio upon the achievement of specific clinical and regulatory milestones under the Second Cornell License Agreement. In the second quarter of 2022, a clinical and regulatory milestone of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million was recognized and paid to Cornell in connection with the Second Cornell License Agreement. The Company is also required to pay Cornell a flat royalty in the mid-single-digits based on net sales of the products covered by the licenses, subject to certain adjustments.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Upon expiration of the royalty term of a given licensed product in a country, the respective license becomes non-exclusive and royalty-free. In addition, each of the May 2020 Cornell License Agreements may be terminated by the Company for any reason upon ninety (&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;90&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;) days&#x2019; advance notice to Cornell and by Cornell upon the Company&#x2019;s material uncured breach, and all licenses and rights granted by either party under such agreement will concurrently terminate.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On April 21, 2024, the Company entered into the Third License Agreement (the &#x201c;Third Cornell License Agreement,&#x201d; together with the May 2020 Cornell License Agreements, the &#x201c;Cornell License Agreements&#x201d;) with Cornell. Pursuant to the Third Cornell License Agreement, Cornell has granted the Company an exclusive license to practice under certain patent rights generated in animal studies conducted by Cornell on behalf of the Company and a non-exclusive license to know-how concerning a gene therapy for FA cardiomyopathy and current and future data generated in an ongoing investigator-initiated Phase 1A trial of AAVrh.10hFXN to treat FA cardiomyopathy. Both licenses are worldwide and cover products with human and non-human prophylactic and therapeutic uses. Cornell has also granted the Company a right of reference to Cornell&#x2019;s Investigation New Drug application for a gene therapy for FA cardiomyopathy.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Under the Third Cornell License Agreement, the Company paid a license issue fee and an initial data transfer fee to Cornell totaling $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. Additionally, the Company will be paying an annual data transfer fee of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; until data is no longer being gathered. The Company has agreed to pay annual license maintenance fees ranging from $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,500&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; until such time the Company commercializes a licensed product. In addition, the Company will pay Cornell up to an aggregate of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in regulatory milestones and up to an aggregate of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in commercial milestones, plus low single digit royalties on net sales.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Third Cornell License Agreement contains other customary license terms including terms related to sublicensing, development, commercialization, milestones, royalties, intellectual property, and termination. Upon expiration of the applicable royalty term for a product in a given country, the Company shall retain a non-exclusive, royalty free license to the data and know-how, including to continue selling such product in that country.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cornell may terminate the Third Cornell License Agreement if the Company (i) breaches the Third Cornell License Agreement (subject to a cure period), (ii) participates in any proceeding challenging the validity of the licensed patents, (iii) publishes the licensed data without Cornell&#x2019;s prior written consent, or (iv) does not reach certain milestones. Cornell may also terminate the Third Cornell License Agreement in part on product-by-product basis if the Company does not diligently develop and sale a product. The Company may terminate the Third Cornell License Agreement, in whole or in part with respect to the right of reference, or the licensed data, know-how, or patent rights, with &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;90&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; days&#x2019; prior written notice to Cornell.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;During the year ended December 31, 2023, the Company incurred and paid $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; in connection with the Cornell License Agreements. During the year ended December 31, 2024, the Company incurred and paid $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in connection with the Cornell License Agreements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stelios Therapeutics, Inc.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;Stelios Therapeutics, Inc. (&#x201c;Stelios&#x201d;) was an early-stage company developing novel adeno-associated AAV-based gene therapies for rare cardiac conditions including arrhythmogenic cardiomyopathy and TNNI3-associated hypertrophic cardiomyopathy. On &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;July 16, 2021&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company acquired &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the outstanding stock of Stelios that was accounted for as an asset acquisition pursuant FASB ASC 805, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Business Combinations&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The Company is required to pay up to a remaining aggregate of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million to the selling shareholders of Stelios upon the achievement of certain development milestones, excluding a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million development milestone that was achieved in the third quarter of 2024 and paid in the fourth quarter of 2024. Dr. Eric Adler, the Company's Chief Medical Officer and Head of Research, was a co-founder of Stelios and a selling shareholder. Of the $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million development milestone payment, Dr. Adler received approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. Stelios was merged into the Company on December 15, 2022 and ceased to exist.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Regents of the University of California, San Diego&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;Stelios entered into exclusive worldwide license agreements on April 23, 2020, and August 6, 2020 (the &#x201c;First UCSD Agreement&#x201d; and the &#x201c;Second UCSD Agreement,&#x201d; respectively) with the Regents of UCSD to in-license materials and intellectual property related to gene therapies for arrhythmogenic right ventricular cardiomyopathy and hypertrophic cardiomyopathy, respectively. The First UCSD Agreement and the Second UCSD Agreement relate to the Company&#x2019;s development efforts for its LX2021 and LX2022 programs, respectively. In connection with the First UCSD Agreement and the Second UCSD Agreement, the Company gained access to inventions, patent rights, technology, and licensed methods that it continues to develop, and it has assumed all worldwide development and commercialization activities with respect to the licensed technologies. The First UCSD Agreement and Second UCSD Agreement required Stelios to pay one-time up-front non-refundable cash fees of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for each agreement and requires the Company to pay aggregate development and commercialization milestones of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively, and low- to mid-single digit royalties and low-single digit royalties, respectively, based on aggregate net sales. The only research and development expenses incurred by Stelios or the Company and payments made to the Regents of UCSD through December 31, 2024 under the terms of the First UCSD Agreement and the Second UCSD Agreement were the one-time up-front non-refundable cash fees of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for each agreement. The Company has the right to terminate the First UCSD Agreement and the Second UCSD Agreement at any time upon sixty (&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;60&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;)-days&#x2019; written notice to the Regents of UCSD.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On October 4, 2021, the Company entered into an exclusive worldwide license agreement (the &#x201c;Third UCSD Agreement&#x201d; and collectively with the First UCSD Agreement and the Second UCSD Agreement, the &#x201c;UCSD Agreements&#x201d;) with the Regents of UCSD to in-license materials and intellectual property related to LX2020, a gene therapy for arrhythmogenic right ventricular cardiomyopathy. The Third UCSD Agreement relates to the Company&#x2019;s development efforts for its LX2020 program. In connection with the Third UCSD Agreement, the Company gained access to inventions, patent rights, technology, and licensed methods that it continues to develop, and it has assumed all worldwide development and commercialization activities with respect to the licensed technology. The Third UCSD Agreement required the Company to pay a one-time up-front non-refundable cash fee of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and requires &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;the Company to pay aggregate development and commercialization milestones of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, and low- to mid-single digit royalties based on aggregate net sales.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Research and development expenses incurred by the Company and payments made to the Regents of UCSD under the terms of the Third UCSD Agreement were the one-time up-front non-refundable cash fee of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; as well as a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million development milestone that was achieved during the third quarter of 2024. The Company has the right to terminate the Third UCSD Agreement at any time upon sixty (&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;60&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;)-days&#x2019; written notice to the Regents of UCSD.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On December 3, 2021, the Company entered into &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;two&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; sponsored research agreements with the Regents of UCSD (the "First UCSD SRA", the "Second UCSD SRA", and collectively, the &#x201c;UCSD SRAs&#x201d;) for the Company&#x2019;s LX2020, LX2021 and LX2022 programs in connection with the UCSD Agreements. Under the terms of the UCSD SRAs, the Company has the first rights to obtain non-exclusive or exclusive, sublicensable, royalty-bearing, perpetual and transferable worldwide licenses in any resulting inventions owned by the Regents of UCSD or resulting inventions jointly owned between the Company and the Regents of UCSD, and the Company retains the rights to any resulting inventions owned by the Company. The UCSD SRAs each have a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;two-year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; term and may be terminated early by the Company at any time upon the giving of thirty (&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;30&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;) days&#x2019; written notice to the Regents of UCSD. The total costs to be invoiced to the Company over the terms of the UCSD SRAs are $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, of which the Company incurred $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of research and development expenses during the year ended December 31, 2023. The Company paid $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million to the Regents of UCSD in connection with the UCSD SRAs during the year ended December 31, 2023. The Company did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t incur any research and development expenses in connection with the UCSD SRAs during the year ended December 31, 2024. The Company paid $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million to the Regents of UCSD in connection with the UCSD SRAs during the year ended December 31, 2024. The Company has paid a cumulative total of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million to the Regents of UCSD as of December 31, 2024, in connection with the UCSD SRAs.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On April 13, 2024, the Company entered into a third sponsored research agreement with the Regents of UCSD (the &#x201c;Third UCSD SRA&#x201d;) for the Company&#x2019;s LX2022 program in connection with the Second UCSD Agreement. Under the terms of the Third UCSD SRA, the Company has the first rights to obtain non-exclusive or exclusive, sublicensable, royalty-bearing, perpetual and transferable worldwide licenses in any resulting inventions owned by the Regents of UCSD or resulting inventions jointly owned between the Company and the Regents of UCSD, and the Company retains the rights to any resulting inventions owned by the Company. The Third UCSD SRA has a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;two-year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; term and may be terminated early by the Company at any time upon the giving of thirty (&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;30&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;) days&#x2019; written notice to the Regents of UCSD. The costs to be invoiced to the Company over the term of the Third UCSD SRA are $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, and the Company may incur additional costs of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million under the Third UCSD SRA if certain study objectives are met.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On April 13, 2024, the Company also entered into an amendment to the Second UCSD SRA for the Company&#x2019;s LX2022 program that extended the term of the Second UCSD SRA to December 2024. The Company incurred $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of research and development costs during the year ended December 31, 2024, and paid $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million during the year ended December 31, 2024, to the Regents of UCSD in connection with the Third UCSD SRA.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On April 19, 2024, the Company entered into an amendment to the First UCSD SRA (as amended, the "Amended First UCSD SRA") for the Company&#x2019;s LX2021 program in connection with the First UCSD Agreement. The Amended First UCSD SRA extends the term of the First UCSD SRA to December 2026 and provides for additional research and development studies and expenses. The total costs to be invoiced to the Company under the Amended First UCSD SRA are $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. The Company incurred $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of research and development costs during the year ended December 31, 2024, and paid $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million during the year ended December 31, 2024 to the Regents of UCSD in connection with the Amended First UCSD SRA.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Weill Cornell Medical College&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;On February 2, 2021, the Company entered into a Research Collaboration Agreement with Weill Cornell Medical College (&#x201c;WCM&#x201d; and the &#x201c;WCM Agreement&#x201d;) in connection with the Cornell License Agreements entered on May 28, 2020. The Company committed to fund scientific research at WCM to investigate further and potentially enhance the technology licensed to the Company pursuant to the License Agreements.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Under the terms of the WCM Agreement (as amended on February 1, 2022), each WCM invention, joint invention, and related joint results for which an Improvement, as defined in the WCM Agreement, applies and the Company has made an election to amend the Cornell License Agreements, the Company has the first option to negotiate in good faith with WCM for royalty- bearing, worldwide license, under Cornell patent rights, Cornell rights, and Cornell&#x2019;s interest in joint patent rights, to develop, make, have made, use, offer for sale, sell, have sold, and import derived products in the field. During the year ended December 31, 2023 the Company incurred $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of research and development costs and paid $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million to Cornell in connection with the WCM Agreement. During the year ended December 31, 2024 the Company incurred $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and paid $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of research and development costs to Cornell in connection with the WCM Agreement.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The WCM Agreement expired in accordance with its terms in February 2024.&lt;/span&gt;&lt;/p&gt;</lxeo:LicenseAndAcquisitionAndResearchCollaborationAndSponsoredResearchAgreementsDisclosureTextBlock>
    <lxeo:PaymentOfOneTimeUpFrontNonRefundableFee
      contextRef="C_db7527be-0d81-4c4d-82cd-9708fd4feeaa"
      decimals="-5"
      id="F_d5d7f32d-b413-463e-b7e9-5fd68340d46d"
      unitRef="U_USD">7500000</lxeo:PaymentOfOneTimeUpFrontNonRefundableFee>
    <lxeo:DevelopmentAndRegulatoryMilestonesDue
      contextRef="C_9aca8f8c-d11a-4b96-bb2f-8028f5d80ed0"
      decimals="INF"
      id="F_22981da6-cfe4-4b30-be23-90773b10107d"
      unitRef="U_USD">17500000</lxeo:DevelopmentAndRegulatoryMilestonesDue>
    <lxeo:PaymentOfDevelopmentMilestone
      contextRef="C_6e382123-eceb-4534-ab45-5c3a9359605b"
      decimals="-5"
      id="F_82465fd3-7fe0-4f99-9e29-03c74782350c"
      unitRef="U_USD">3500000</lxeo:PaymentOfDevelopmentMilestone>
    <lxeo:CommercializationMilestonesDue
      contextRef="C_9aca8f8c-d11a-4b96-bb2f-8028f5d80ed0"
      decimals="INF"
      id="F_9e4aa8a2-f08b-4273-bf99-660ce54ea7b2"
      unitRef="U_USD">49000000</lxeo:CommercializationMilestonesDue>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms
      contextRef="C_3393a748-8c4c-4d41-87d8-1deb8ed9aa5a"
      id="F_b6cc7fec-658a-4a10-9574-fead4359abd4">The Company is obligated to pay Adverum tiered royalties ranging from high single-digits to sub teens based on annual aggregate worldwide net sales of Products (as defined in the Adverum Agreement).</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_8b7e354c-42e5-475d-87f9-4bfd1355ccaf"
      decimals="INF"
      id="F_324616f1-c518-41fc-aa83-07e18e8f741a"
      unitRef="U_USD">0</us-gaap:ResearchAndDevelopmentExpense>
    <lxeo:PaymentOfOneTimeUpFrontNonRefundableFee
      contextRef="C_6e382123-eceb-4534-ab45-5c3a9359605b"
      decimals="-5"
      id="F_75ba5dcd-9572-4360-bbef-ae3ba1738fd5"
      unitRef="U_USD">7500000</lxeo:PaymentOfOneTimeUpFrontNonRefundableFee>
    <lxeo:PaymentOfDevelopmentMilestone
      contextRef="C_6e382123-eceb-4534-ab45-5c3a9359605b"
      decimals="-5"
      id="F_5f9a46e0-3a5d-429a-adfe-54b89b37b18b"
      unitRef="U_USD">3500000</lxeo:PaymentOfDevelopmentMilestone>
    <lxeo:LicenseAgreementTerminationNoticePeriod
      contextRef="C_db7527be-0d81-4c4d-82cd-9708fd4feeaa"
      id="F_4646a18c-3d75-426f-848c-fd7d8caf8116">P120D</lxeo:LicenseAgreementTerminationNoticePeriod>
    <lxeo:NumberOfLicenseAgreements
      contextRef="C_dfaf0a7f-a734-4cd4-9b33-a8172ac5f59e"
      decimals="INF"
      id="F_368fac61-629d-4032-be8e-afad9b1b166e"
      unitRef="U_IntegerItem">2</lxeo:NumberOfLicenseAgreements>
    <lxeo:UpfrontCashPayment
      contextRef="C_940cc76e-9af2-46e6-b22a-05a05af066b0"
      decimals="-5"
      id="F_870bf19e-24a8-4c26-8a8b-de71b7e4d65d"
      unitRef="U_USD">300000</lxeo:UpfrontCashPayment>
    <us-gaap:NotesIssued1
      contextRef="C_940cc76e-9af2-46e6-b22a-05a05af066b0"
      decimals="-5"
      id="F_3704754d-077f-4115-b510-40abcc469931"
      unitRef="U_USD">1300000</us-gaap:NotesIssued1>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="C_5e727241-61dd-4591-9807-d7d2fe303dba"
      decimals="-5"
      id="F_0e5d477a-8ce4-48e6-944e-bab14c713dc6"
      unitRef="U_USD">1300000</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="C_1e595beb-6e63-4729-9f01-fa8aaad38108"
      decimals="INF"
      id="F_b65bae23-d239-4cc7-95e1-c64a949b9127"
      unitRef="U_shares">1337610</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:PreferredStockConvertibleSharesIssuable
      contextRef="C_a70f9bd2-aceb-4c0d-b0fa-5353c3dece2a"
      decimals="INF"
      id="F_954fa7fe-b540-4266-b10f-7a0531485641"
      unitRef="U_shares">126258</us-gaap:PreferredStockConvertibleSharesIssuable>
    <lxeo:SpecificClinicalAndRegulatoryMilestonesDue
      contextRef="C_e5969e3b-4f0f-4598-ab16-63cb541f8395"
      decimals="INF"
      id="F_ba12c9d9-f7e4-4bea-b828-6714aa93a7c1"
      unitRef="U_USD">8400000</lxeo:SpecificClinicalAndRegulatoryMilestonesDue>
    <lxeo:SpecificClinicalAndRegulatoryMilestonesDue
      contextRef="C_10dc49c3-ff40-493f-b51b-be28cd103318"
      decimals="INF"
      id="F_3d0a43ff-28bf-4f19-b8ee-2558cd32246b"
      unitRef="U_USD">4300000</lxeo:SpecificClinicalAndRegulatoryMilestonesDue>
    <lxeo:SpecificClinicalAndRegulatoryMilestonesDue
      contextRef="C_f8619687-73fe-4744-9482-f214f5f1a619"
      decimals="INF"
      id="F_86b50a80-f3d4-4781-9bf2-25c6e5b2b3b2"
      unitRef="U_USD">600000</lxeo:SpecificClinicalAndRegulatoryMilestonesDue>
    <lxeo:PaymentOfClinicalAndRegulatoryMilestone
      contextRef="C_eef711a6-19ec-48b9-9c42-54e797d52952"
      decimals="-5"
      id="F_dd09dc39-c277-4a41-9040-d4ddd94b2a12"
      unitRef="U_USD">100000</lxeo:PaymentOfClinicalAndRegulatoryMilestone>
    <lxeo:LicenseAgreementTerminationNoticePeriod
      contextRef="C_940cc76e-9af2-46e6-b22a-05a05af066b0"
      id="F_95363cd0-7520-465f-9028-0dbdd979579a">P90D</lxeo:LicenseAgreementTerminationNoticePeriod>
    <lxeo:PaymentOfLicenseIssueFeeAndInitialDataTransferFee
      contextRef="C_2b151cd0-5507-43d4-aa4e-3c68accbaec1"
      decimals="-5"
      id="F_5febd073-d045-46b8-b8ee-9874af37cbd5"
      unitRef="U_USD">600000</lxeo:PaymentOfLicenseIssueFeeAndInitialDataTransferFee>
    <lxeo:PaymentOfAnnualDataTransferFee
      contextRef="C_2b151cd0-5507-43d4-aa4e-3c68accbaec1"
      decimals="0"
      id="F_d9da4499-d29a-4216-969a-e841824857f3"
      unitRef="U_USD">50000</lxeo:PaymentOfAnnualDataTransferFee>
    <lxeo:PaymentOfAnnualLicenseMaintenanceFees
      contextRef="C_c7d3289f-7fe7-4f19-ac48-22a403b83a4c"
      decimals="0"
      id="F_5d09922a-b72f-4e3c-b2a6-29615612f071"
      unitRef="U_USD">2500</lxeo:PaymentOfAnnualLicenseMaintenanceFees>
    <lxeo:PaymentOfAnnualLicenseMaintenanceFees
      contextRef="C_7c51062b-38dd-4251-995b-95b9d29f554e"
      decimals="0"
      id="F_c6f32d83-7846-4800-a653-e56876f0e67f"
      unitRef="U_USD">25000</lxeo:PaymentOfAnnualLicenseMaintenanceFees>
    <lxeo:PaymentOfRegulatoryMilestones
      contextRef="C_7c51062b-38dd-4251-995b-95b9d29f554e"
      decimals="-5"
      id="F_ed777e55-a48a-40c2-b1db-b31d0f3f669c"
      unitRef="U_USD">2100000</lxeo:PaymentOfRegulatoryMilestones>
    <lxeo:CommercializationMilestonesDue
      contextRef="C_202992e1-90d4-413d-b703-e8197a8dc6e3"
      decimals="-6"
      id="F_1c2e939e-42f6-4e81-920a-5ebd9d3a71ce"
      unitRef="U_USD">100000000</lxeo:CommercializationMilestonesDue>
    <lxeo:LicenseAgreementTerminationNoticePeriod
      contextRef="C_2b151cd0-5507-43d4-aa4e-3c68accbaec1"
      id="F_cf2e2df8-9ac8-4da2-94e8-dc58601a3461">P90D</lxeo:LicenseAgreementTerminationNoticePeriod>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_ab7f0058-11d6-4f3c-b66e-25878efcc5c2"
      decimals="0"
      id="F_bf797626-5495-4800-a965-80474b924c41"
      unitRef="U_USD">10000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_29bfd3ef-606a-4b0e-a5fa-8ba6f8566146"
      decimals="-5"
      id="F_6ee3b74e-5bc2-44ca-9e9a-dff3be036a75"
      unitRef="U_USD">700000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:BusinessAcquisitionEffectiveDateOfAcquisition1
      contextRef="C_dee9c396-7be8-4764-a1e9-de37e72c1b20"
      id="F_f6aa761c-003e-4c43-a7de-2d17ddaa3054">2021-07-16</us-gaap:BusinessAcquisitionEffectiveDateOfAcquisition1>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="C_fd20e119-f9e2-4c0e-9735-4934b480df35"
      decimals="INF"
      id="F_7349d891-add7-4529-b24c-3752212bba68"
      unitRef="U_pure">1</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
      contextRef="C_07376bba-ebc9-44c0-bc4a-e98679fa21ad"
      decimals="INF"
      id="F_d7792ce5-8a6e-42f8-b850-a044587c32b9"
      unitRef="U_USD">12500000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
      contextRef="C_9d573f03-b8a1-43e3-9828-e04c95b23d8a"
      decimals="-5"
      id="F_8221db4a-139d-4dd9-8ca0-ade772f9f192"
      unitRef="U_USD">6000000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <lxeo:PaymentOfDevelopmentMilestone
      contextRef="C_f5b88d17-128c-461e-aaa6-463ec8135b2a"
      decimals="-5"
      id="F_5e0fb416-ff72-4a19-991c-ae8d89f3ea19"
      unitRef="U_USD">6000000</lxeo:PaymentOfDevelopmentMilestone>
    <lxeo:MilestoneReceived
      contextRef="C_5af5a379-1acd-457b-ba86-c64e18c5164a"
      decimals="-5"
      id="F_1ebd571e-aa0f-4fd6-a74c-e668d2517567"
      unitRef="U_USD">1300000</lxeo:MilestoneReceived>
    <lxeo:PaymentOfOneTimeUpFrontNonRefundableFee
      contextRef="C_b4755659-dbea-42a4-911b-aaf4e5f99a6a"
      decimals="0"
      id="F_4cc350a9-842a-4f0a-89c5-ac053f6ba15c"
      unitRef="U_USD">20000</lxeo:PaymentOfOneTimeUpFrontNonRefundableFee>
    <lxeo:PaymentOfOneTimeUpFrontNonRefundableFee
      contextRef="C_749a5dff-19cd-41f6-b877-35e4f821f1fe"
      decimals="0"
      id="F_7bf29203-635a-487b-9834-00178cc55082"
      unitRef="U_USD">20000</lxeo:PaymentOfOneTimeUpFrontNonRefundableFee>
    <lxeo:DevelopmentAndCommercializationMilestonesDue
      contextRef="C_2611b746-5276-4a2d-b18c-32e1fcba87aa"
      decimals="INF"
      id="F_812fba38-08b5-47b4-b69c-b7adb050516d"
      unitRef="U_USD">4800000</lxeo:DevelopmentAndCommercializationMilestonesDue>
    <lxeo:DevelopmentAndCommercializationMilestonesDue
      contextRef="C_3d6eac78-9474-4e08-bcae-13f2246c0568"
      decimals="INF"
      id="F_5dc135d5-8e88-4d68-b522-0707756d404e"
      unitRef="U_USD">2400000</lxeo:DevelopmentAndCommercializationMilestonesDue>
    <lxeo:OneTimeUpFrontNonRefundableFees
      contextRef="C_cb661ff1-5311-4097-b67b-ccc8f26e5c71"
      decimals="0"
      id="F_f4ecd601-6187-4e33-9e87-4b5fafb02a2e"
      unitRef="U_USD">20000</lxeo:OneTimeUpFrontNonRefundableFees>
    <lxeo:OneTimeUpFrontNonRefundableFees
      contextRef="C_4416291a-8898-4d40-bf16-c20112811638"
      decimals="0"
      id="F_4ac888b1-5748-4561-a064-ca90a6183412"
      unitRef="U_USD">20000</lxeo:OneTimeUpFrontNonRefundableFees>
    <lxeo:LicenseAgreementTerminationNoticePeriod
      contextRef="C_b4755659-dbea-42a4-911b-aaf4e5f99a6a"
      id="F_b6b7d64c-a14a-4900-b95f-0a34633454c7">P60D</lxeo:LicenseAgreementTerminationNoticePeriod>
    <lxeo:LicenseAgreementTerminationNoticePeriod
      contextRef="C_e30bab05-7cc4-4f13-aa74-111c8d09ef0d"
      id="F_40db76a4-248c-4db2-a642-f8d49ccd5046">P60D</lxeo:LicenseAgreementTerminationNoticePeriod>
    <lxeo:PaymentOfOneTimeUpFrontNonRefundableFee
      contextRef="C_a8c2e316-6ad2-4b74-acd6-08e9897fd12e"
      decimals="0"
      id="F_07d026a2-e8fc-479b-ba87-72166ea9659a"
      unitRef="U_USD">20000</lxeo:PaymentOfOneTimeUpFrontNonRefundableFee>
    <lxeo:AggregateDevelopmentAndCommercializationMilestonesDescription
      contextRef="C_2f31b66a-0232-462f-8ba1-c31ab4b8824f"
      id="F_f892c825-1832-41b6-b76b-1696d80da1b8">the Company to pay aggregate development and commercialization milestones of up to $4.0 million, and low- to mid-single digit royalties based on aggregate net sales.</lxeo:AggregateDevelopmentAndCommercializationMilestonesDescription>
    <lxeo:DevelopmentAndCommercializationMilestonesDue
      contextRef="C_55a64f42-6349-45b1-a852-990c1f09b912"
      decimals="INF"
      id="F_662a6313-a90f-4ebf-a2cd-2e5f0c9dda67"
      unitRef="U_USD">4000000</lxeo:DevelopmentAndCommercializationMilestonesDue>
    <lxeo:OneTimeUpFrontNonRefundableFees
      contextRef="C_eb04d3ca-9afb-4d97-9a7e-b5be9da963d6"
      decimals="0"
      id="F_6b152640-2dc9-48c1-8d89-613771cad81c"
      unitRef="U_USD">20000</lxeo:OneTimeUpFrontNonRefundableFees>
    <lxeo:PaymentOfDevelopmentMilestone
      contextRef="C_5bca7169-3f0e-45f0-a257-63b105b31fcd"
      decimals="-5"
      id="F_ee7451a0-8885-4926-8ac7-1b6711ccc487"
      unitRef="U_USD">100000</lxeo:PaymentOfDevelopmentMilestone>
    <lxeo:LicenseAgreementTerminationNoticePeriod
      contextRef="C_a8c2e316-6ad2-4b74-acd6-08e9897fd12e"
      id="F_ff710b60-4af1-4767-b796-5c7f9fcd1bbb">P60D</lxeo:LicenseAgreementTerminationNoticePeriod>
    <lxeo:NumberOfResearchAgreements
      contextRef="C_2911d34b-7821-4985-b38e-577d63cb332d"
      decimals="INF"
      id="F_b1365a90-b658-4bae-891f-cdb22bd25cef"
      unitRef="U_IntegerItem">2</lxeo:NumberOfResearchAgreements>
    <lxeo:ResearchAgreementsTerm
      contextRef="C_1fd0f357-c2ff-41e2-bd80-50ac05612394"
      id="F_fd213912-5b80-49cb-b01c-374818ad37ef">P2Y</lxeo:ResearchAgreementsTerm>
    <lxeo:ResearchAgreementTerminationNoticePeriod
      contextRef="C_1fd0f357-c2ff-41e2-bd80-50ac05612394"
      id="F_272a787e-9c7e-4e10-984a-ca2bc43ccd2c">P30D</lxeo:ResearchAgreementTerminationNoticePeriod>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross
      contextRef="C_1fd0f357-c2ff-41e2-bd80-50ac05612394"
      decimals="-5"
      id="F_7bf1a830-033b-4422-9ea7-d251b47e4c8c"
      unitRef="U_USD">5600000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_4013d4d1-c4c9-4765-acc9-a1659c4750bf"
      decimals="-5"
      id="F_c073a4f5-5651-4486-89d4-266410f89953"
      unitRef="U_USD">1300000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="C_4013d4d1-c4c9-4765-acc9-a1659c4750bf"
      decimals="-5"
      id="F_d61ea2fc-06f2-4a1e-8641-7d9366b63cac"
      unitRef="U_USD">400000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_feb46e5d-6816-4e22-a41b-42317def0254"
      decimals="-6"
      id="F_f9892128-3e9c-46c2-9920-160f5fa494eb"
      unitRef="U_USD">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="C_feb46e5d-6816-4e22-a41b-42317def0254"
      decimals="-5"
      id="F_c9ef88fc-0e4f-4da0-b830-4217bc81f5cb"
      unitRef="U_USD">700000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="C_7e7948fb-137c-405e-8479-be843ae42290"
      decimals="-5"
      id="F_c47b37e5-f852-45f9-8824-f8975db7e8c6"
      unitRef="U_USD">4000000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <lxeo:ResearchAgreementsTerm
      contextRef="C_05465aab-2ef4-47b5-84ef-3eacb2ef4089"
      id="F_037c6ae9-c1fa-40b6-8e9e-a1c40be08070">P2Y</lxeo:ResearchAgreementsTerm>
    <lxeo:ResearchAgreementTerminationNoticePeriod
      contextRef="C_05465aab-2ef4-47b5-84ef-3eacb2ef4089"
      id="F_442342f2-f01b-4e66-b067-8765709132a2">P30D</lxeo:ResearchAgreementTerminationNoticePeriod>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross
      contextRef="C_05465aab-2ef4-47b5-84ef-3eacb2ef4089"
      decimals="-5"
      id="F_56ab5b59-7024-4204-afc8-b17d1ac9de81"
      unitRef="U_USD">700000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross>
    <lxeo:ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalCostsIncurred
      contextRef="C_05465aab-2ef4-47b5-84ef-3eacb2ef4089"
      decimals="-5"
      id="F_dbc2cfb2-56d7-46e3-b1d6-145c764041ee"
      unitRef="U_USD">600000</lxeo:ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalCostsIncurred>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_2d31726b-58bc-4b55-8b8d-242c0b620bca"
      decimals="-5"
      id="F_113f16eb-ddf3-48bf-8671-d431072d24c9"
      unitRef="U_USD">700000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="C_2d31726b-58bc-4b55-8b8d-242c0b620bca"
      decimals="-5"
      id="F_310dea35-b494-453f-afe8-04f313f4798d"
      unitRef="U_USD">600000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross
      contextRef="C_73f22931-4674-407c-ac09-c2a140ebf868"
      decimals="-5"
      id="F_aaab8794-6396-4d33-9100-126a62489aa4"
      unitRef="U_USD">700000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_90de349f-5edf-4ccd-81d6-310075c43d96"
      decimals="-5"
      id="F_d6096990-d41b-42df-a501-3b7d18dcc2a7"
      unitRef="U_USD">600000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="C_90de349f-5edf-4ccd-81d6-310075c43d96"
      decimals="-5"
      id="F_1d4a9d25-79e0-4ee1-8f79-b421e7deb0de"
      unitRef="U_USD">300000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_03d0654e-3872-4474-936c-dc6ff5ca1f8d"
      decimals="-5"
      id="F_1057e437-c789-49f9-9f6a-39bc661afb3a"
      unitRef="U_USD">1000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="C_03d0654e-3872-4474-936c-dc6ff5ca1f8d"
      decimals="-5"
      id="F_a706fa2f-4799-4c7d-8ee5-89aeab73f96a"
      unitRef="U_USD">2100000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_35a86fc1-0afe-4e3c-96ee-81097e533438"
      decimals="-5"
      id="F_529cfd15-ccef-4aba-ae3b-c4bbd12b6812"
      unitRef="U_USD">400000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="C_35a86fc1-0afe-4e3c-96ee-81097e533438"
      decimals="-5"
      id="F_530c779a-314d-4250-8075-ad853f8aad4a"
      unitRef="U_USD">300000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_b98e6b79-b2f5-4f5a-aac0-a01efaff0cd5">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;14. Segment Information&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company's CODM is its &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_bb5c5ee6-6dc1-4359-ae05-87adfaa76496;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;CEO and senior leadership team&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. All of the Company&#x2019;s operating results are reviewed by the Company&#x2019;s CODM within the same statement of operations and comprehensive loss whether research and development (by program) or general and administrative in nature. Accordingly, the Company has determined that it has a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_e4a8210a-7701-4cf1-bb55-d8e020f66db8;"&gt;&lt;span style="-sec-ix-hidden:F_b4f1e989-f912-4b9a-9a96-f56301d549bc;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;single&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; reportable segment and operating segment structure. The Company's CODM regularly reviews total expenses and expenses by significant areas such as departments and programs to make decisions when evaluating the Company's financial performance. The Company does not evaluate performance or allocate resources based on segment asset data and therefore such information is not presented. All long-lived assets are located in the United States.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table contains additional information on the Company's net loss, including significant segment expenses for the years ended December 31, 2024 and December 31, 2023:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.887%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.897%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.897%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;LX2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,451&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,192&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;LX2006&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,256&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,537&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;LX1001&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,501&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,936&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other programs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,424&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,535&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Employee compensation expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,010&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,748&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Lab-related costs and supplies&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,356&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,160&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;All other research and development expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,093&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Employee compensation expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,158&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,872&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;All other general and administrative expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,517&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,511&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other income and expense, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,433&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,119&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net Loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;98,333&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;66,394&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:SegmentReportingExpenseInformationUsedByCodmDescription
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_b9dddd81-7ad3-4b17-809b-851a9dbf5054">The Company's CODM is its CEO and senior leadership team. All of the Company&#x2019;s operating results are reviewed by the Company&#x2019;s CODM within the same statement of operations and comprehensive loss whether research and development (by program) or general and administrative in nature. Accordingly, the Company has determined that it has a single reportable segment and operating segment structure. The Company's CODM regularly reviews total expenses and expenses by significant areas such as departments and programs to make decisions when evaluating the Company's financial performance. The Company does not evaluate performance or allocate resources based on segment asset data and therefore such information is not presented. All long-lived assets are located in the United States.</us-gaap:SegmentReportingExpenseInformationUsedByCodmDescription>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_4cf0a330-2d6e-4be1-bb41-bcfe2543bad7">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table contains additional information on the Company's net loss, including significant segment expenses for the years ended December 31, 2024 and December 31, 2023:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.887%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.897%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.897%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;LX2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,451&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,192&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;LX2006&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,256&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,537&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;LX1001&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,501&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,936&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other programs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,424&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,535&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Employee compensation expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,010&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,748&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Lab-related costs and supplies&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,356&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,160&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;All other research and development expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,093&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Employee compensation expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,158&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,872&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;All other general and administrative expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,517&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,511&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other income and expense, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,433&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,119&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net Loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;98,333&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;66,394&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <lxeo:ResearchAndDevelopmentExpenseLX2020
      contextRef="C_637f42f6-8969-4386-b873-8c291d47795a"
      decimals="-3"
      id="F_1d686e06-d165-46bf-bea9-31b7b32705c3"
      unitRef="U_USD">23451000</lxeo:ResearchAndDevelopmentExpenseLX2020>
    <lxeo:ResearchAndDevelopmentExpenseLX2020
      contextRef="C_f8c50f85-2ed2-437f-90c9-8336f5967e8e"
      decimals="-3"
      id="F_9b31930d-9359-4d1a-b17e-532dbb3ddfa0"
      unitRef="U_USD">14192000</lxeo:ResearchAndDevelopmentExpenseLX2020>
    <lxeo:ResearchAndDevelopmentExpenseLX2006
      contextRef="C_637f42f6-8969-4386-b873-8c291d47795a"
      decimals="-3"
      id="F_7397ac48-24b9-4f1a-8c05-6f3a709cf018"
      unitRef="U_USD">14256000</lxeo:ResearchAndDevelopmentExpenseLX2006>
    <lxeo:ResearchAndDevelopmentExpenseLX2006
      contextRef="C_f8c50f85-2ed2-437f-90c9-8336f5967e8e"
      decimals="-3"
      id="F_ee61f246-fe92-4988-a22f-ced649cfdd12"
      unitRef="U_USD">7537000</lxeo:ResearchAndDevelopmentExpenseLX2006>
    <lxeo:ResearchAndDevelopmentExpenseLX1001
      contextRef="C_637f42f6-8969-4386-b873-8c291d47795a"
      decimals="-3"
      id="F_5c6c7e62-90fd-4536-a86c-ec6c43435b43"
      unitRef="U_USD">4501000</lxeo:ResearchAndDevelopmentExpenseLX1001>
    <lxeo:ResearchAndDevelopmentExpenseLX1001
      contextRef="C_f8c50f85-2ed2-437f-90c9-8336f5967e8e"
      decimals="-3"
      id="F_49904193-6dad-4fee-bc53-4204ded52638"
      unitRef="U_USD">9936000</lxeo:ResearchAndDevelopmentExpenseLX1001>
    <lxeo:ResearchAndDevelopmentExpenseOtherPrograms
      contextRef="C_637f42f6-8969-4386-b873-8c291d47795a"
      decimals="-3"
      id="F_c2fa02d1-6e73-4c01-bc06-caece2c75da2"
      unitRef="U_USD">3424000</lxeo:ResearchAndDevelopmentExpenseOtherPrograms>
    <lxeo:ResearchAndDevelopmentExpenseOtherPrograms
      contextRef="C_f8c50f85-2ed2-437f-90c9-8336f5967e8e"
      decimals="-3"
      id="F_dffea6f9-dd1b-4f68-bd0b-b9a3604899a7"
      unitRef="U_USD">2535000</lxeo:ResearchAndDevelopmentExpenseOtherPrograms>
    <lxeo:ResearchAndDevelopmentExpenseEmployeeCompensationExpenses
      contextRef="C_637f42f6-8969-4386-b873-8c291d47795a"
      decimals="-3"
      id="F_a7bf18c3-6f49-4cb8-a727-905b6c3bb28a"
      unitRef="U_USD">16010000</lxeo:ResearchAndDevelopmentExpenseEmployeeCompensationExpenses>
    <lxeo:ResearchAndDevelopmentExpenseEmployeeCompensationExpenses
      contextRef="C_f8c50f85-2ed2-437f-90c9-8336f5967e8e"
      decimals="-3"
      id="F_e17c1992-7698-480e-8295-dfa25c281693"
      unitRef="U_USD">11748000</lxeo:ResearchAndDevelopmentExpenseEmployeeCompensationExpenses>
    <us-gaap:LaborAndRelatedExpense
      contextRef="C_637f42f6-8969-4386-b873-8c291d47795a"
      decimals="-3"
      id="F_7ddd0854-90fe-400a-b4e9-c392835d7dce"
      unitRef="U_USD">1356000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="C_f8c50f85-2ed2-437f-90c9-8336f5967e8e"
      decimals="-3"
      id="F_0b4f2103-6a41-4683-961c-017d20de6abc"
      unitRef="U_USD">1160000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="C_637f42f6-8969-4386-b873-8c291d47795a"
      decimals="-3"
      id="F_7fe2ea78-5f84-4892-b355-c9dad1967402"
      unitRef="U_USD">11093000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="C_f8c50f85-2ed2-437f-90c9-8336f5967e8e"
      decimals="-3"
      id="F_78272df8-7416-4e8a-a568-fa2db41d252d"
      unitRef="U_USD">6022000</us-gaap:OtherResearchAndDevelopmentExpense>
    <lxeo:GeneralAndAdministrativeExpenseEmployeeCompensationExpenses
      contextRef="C_637f42f6-8969-4386-b873-8c291d47795a"
      decimals="-3"
      id="F_50692c79-ce7f-4496-b439-b482f71a0d41"
      unitRef="U_USD">13158000</lxeo:GeneralAndAdministrativeExpenseEmployeeCompensationExpenses>
    <lxeo:GeneralAndAdministrativeExpenseEmployeeCompensationExpenses
      contextRef="C_f8c50f85-2ed2-437f-90c9-8336f5967e8e"
      decimals="-3"
      id="F_57b0df72-41a4-4ad2-a02b-4410c95b9b01"
      unitRef="U_USD">5872000</lxeo:GeneralAndAdministrativeExpenseEmployeeCompensationExpenses>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="C_637f42f6-8969-4386-b873-8c291d47795a"
      decimals="-3"
      id="F_54fdbb5b-8751-4f6f-8deb-8b68f8e2a2e6"
      unitRef="U_USD">18517000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="C_f8c50f85-2ed2-437f-90c9-8336f5967e8e"
      decimals="-3"
      id="F_c5140dac-3fc7-4383-b519-aa854abf0ede"
      unitRef="U_USD">9511000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_637f42f6-8969-4386-b873-8c291d47795a"
      decimals="-3"
      id="F_2d83cf76-33e8-4acf-baff-7ab586111022"
      unitRef="U_USD">7433000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_f8c50f85-2ed2-437f-90c9-8336f5967e8e"
      decimals="-3"
      id="F_4ee8c1c3-62d0-4fe9-ba10-14183b48f10d"
      unitRef="U_USD">2119000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="C_637f42f6-8969-4386-b873-8c291d47795a"
      decimals="-3"
      id="F_bccee535-63f3-47ad-8370-51ec556c507f"
      unitRef="U_USD">-98333000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_f8c50f85-2ed2-437f-90c9-8336f5967e8e"
      decimals="-3"
      id="F_39021236-46e0-4067-b322-c0529e1f3e04"
      unitRef="U_USD">-66394000</us-gaap:NetIncomeLoss>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="C_61a2446f-5269-4a91-8e68-185d4038b801"
      id="F_a275bb75-b950-41cf-af87-0d363a051b56">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;15. Subsequent Events&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Subsequent events have been evaluated through March 24, 2025, which is the date that these financial statements were issued and were available to be issued.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On March 24, 2025, the Company entered into a sales agreement with Leerink Partners LLC ("Leerink") to sell shares of the Company's common stock having an aggregate offering price of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;75.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million from time to time through an at-the-market equity offering program under which Leerink is acting as the Company's agent. Leerink is entitled to compensation for its services in an amount equal to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the gross proceeds of any of the shares of the Company's common stock sold under the sales agreement.&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <lxeo:StockOfferingValueSharesAuthorizedToBeSold
      contextRef="C_27a6defd-2f97-4391-b27e-7d7b4574d1b7"
      decimals="-5"
      id="F_ca96207a-576e-4a2b-8ff0-0bc7d0d9ae0d"
      unitRef="U_USD">75000000</lxeo:StockOfferingValueSharesAuthorizedToBeSold>
    <lxeo:StockOfferingGrossProceedsPercentage
      contextRef="C_ef41b0f5-e670-47fb-a4ba-1fb722c72adf"
      decimals="2"
      id="F_591cc955-f4ca-4e62-bb34-02fab867c3d2"
      unitRef="U_pure">0.03</lxeo:StockOfferingGrossProceedsPercentage>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="C_72ef9daf-8437-4cbb-9e5d-f507601fa64a"
      id="F_c18758b8-047d-483d-8b52-ac48fc38a043">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="C_72ef9daf-8437-4cbb-9e5d-f507601fa64a"
      id="F_6ef0a5ea-0f5b-4417-93a3-09fac310e112">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="C_72ef9daf-8437-4cbb-9e5d-f507601fa64a"
      id="F_1d5d7ebf-b412-4756-ab19-a0ef3bb72399">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="C_72ef9daf-8437-4cbb-9e5d-f507601fa64a"
      id="F_b9d81b97-7ed9-450b-81d1-9be662f8566d">false</ecd:NonRule10b51ArrTrmntdFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
